StarDrop ID 1
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 49 51 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 0.0000 0.0000 0
M  V30 2 C 0.0000 0.0000 0.0000 0
M  V30 3 C 0.0000 0.0000 0.0000 0
M  V30 4 C 0.0000 0.0000 0.0000 0
M  V30 5 C 0.0000 0.0000 0.0000 0
M  V30 6 N 0.0000 0.0000 0.0000 0
M  V30 7 C 0.0000 0.0000 0.0000 0
M  V30 8 C 0.0000 0.0000 0.0000 0
M  V30 9 N 0.0000 0.0000 0.0000 0
M  V30 10 C 0.0000 0.0000 0.0000 0
M  V30 11 C 0.0000 0.0000 0.0000 0
M  V30 12 C 0.0000 0.0000 0.0000 0
M  V30 13 C 0.0000 0.0000 0.0000 0
M  V30 14 C 0.0000 0.0000 0.0000 0
M  V30 15 C 0.0000 0.0000 0.0000 0
M  V30 16 O 0.0000 0.0000 0.0000 0
M  V30 17 O 0.0000 0.0000 0.0000 0
M  V30 18 N 0.0000 0.0000 0.0000 0
M  V30 19 O 0.0000 0.0000 0.0000 0
M  V30 20 C 0.0000 0.0000 0.0000 0
M  V30 21 C 0.0000 0.0000 0.0000 0
M  V30 22 C 0.0000 0.0000 0.0000 0
M  V30 23 C 0.0000 0.0000 0.0000 0
M  V30 24 N 0.0000 0.0000 0.0000 0
M  V30 25 O 0.0000 0.0000 0.0000 0
M  V30 26 N 0.0000 0.0000 0.0000 0
M  V30 27 C 0.0000 0.0000 0.0000 0
M  V30 28 C 0.0000 0.0000 0.0000 0
M  V30 29 N 0.0000 0.0000 0.0000 0
M  V30 30 C 0.0000 0.0000 0.0000 0
M  V30 31 C 0.0000 0.0000 0.0000 0
M  V30 32 C 0.0000 0.0000 0.0000 0
M  V30 33 C 0.0000 0.0000 0.0000 0
M  V30 34 C 0.0000 0.0000 0.0000 0
M  V30 35 C 0.0000 0.0000 0.0000 0
M  V30 36 C 0.0000 0.0000 0.0000 0
M  V30 37 C 0.0000 0.0000 0.0000 0
M  V30 38 C 0.0000 0.0000 0.0000 0
M  V30 39 N 0.0000 0.0000 0.0000 0
M  V30 40 O 0.0000 0.0000 0.0000 0
M  V30 41 C 0.0000 0.0000 0.0000 0
M  V30 42 C 0.0000 0.0000 0.0000 0
M  V30 43 C 0.0000 0.0000 0.0000 0
M  V30 44 C 0.0000 0.0000 0.0000 0
M  V30 45 C 0.0000 0.0000 0.0000 0
M  V30 46 C 0.0000 0.0000 0.0000 0
M  V30 47 C 0.0000 0.0000 0.0000 0
M  V30 48 O 0.0000 0.0000 0.0000 0
M  V30 49 C 0.0000 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 9 14
M  V30 15 1 12 15
M  V30 16 1 15 16
M  V30 17 2 15 17
M  V30 18 1 12 18
M  V30 19 2 8 19
M  V30 20 1 7 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 2 5 25
M  V30 26 1 4 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 1 29 30
M  V30 31 1 30 31
M  V30 32 1 31 32
M  V30 33 1 32 33
M  V30 34 2 33 34
M  V30 35 1 34 35
M  V30 36 2 35 36
M  V30 37 1 36 37
M  V30 38 2 37 38
M  V30 39 1 33 38
M  V30 40 1 31 39
M  V30 41 2 30 40
M  V30 42 1 28 41
M  V30 43 1 41 42
M  V30 44 2 42 43
M  V30 45 1 43 44
M  V30 46 2 44 45
M  V30 47 1 45 46
M  V30 48 2 46 47
M  V30 49 1 42 47
M  V30 50 2 27 48
M  V30 51 1 2 49
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
1

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Difelikefalin acetate

>  <Synonyms>
FE 202845 acetate;Difelikefalin acetate(1024828-77-0 free base);CR 845 acetate

>  <CAS>
TP2501

>  <Formula>
C38H57N7O8

>  <MolWt>
739.9

>  <Pathways>
GPCR/G Protein;Neuroscience;Endocrinology/Hormones

>  <Target>
Opioid Receptor

>  <Receptor>
??-opioid receptor

>  <Bioactivity>
Difelikefalin acetate is a peripherally restricted kappa opioid receptor agonist. CR845 exhibit low P450 CYP inhibition and low penetration into the brain.

>  <Reference>
"Shram MJ, Spencer RH, et al. Evaluation of the abuse potential of difelikefalin, a selective kappa-opioid receptor agonist, in recreational polydrug users. Clin Transl Sci. 2022 Feb;15(2):535-547."

>  <ID<1>>
TP2501

$$$$
StarDrop ID 2
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.7512 0.7634 0.0000 0
M  V30 2 C 3.4656 1.1759 0.0000 0
M  V30 3 C 3.4656 2.0009 0.0000 0
M  V30 4 S 4.1801 2.4134 0.0000 0
M  V30 5 O 3.6498 3.0454 0.0000 0
M  V30 6 O 4.7104 3.0454 0.0000 0
M  V30 7 C 4.8946 2.0009 0.0000 0
M  V30 8 C 4.8946 1.1759 0.0000 0
M  V30 9 N 4.1801 0.7634 0.0000 0
M  V30 10 N 4.1801 -0.0616 0.0000 0
M  V30 11 C 3.4656 -0.4741 0.0000 0
M  V30 12 C 3.4656 -1.2991 0.0000 0
M  V30 13 C 4.1331 -1.7840 0.0000 0
M  V30 14 C 3.8781 -2.5687 0.0000 0
M  V30 15 C 3.0531 -2.5687 0.0000 0
M  V30 16 O 2.7982 -1.7840 0.0000 0
M  V30 17 N 2.5682 -3.2361 0.0000 0
M  V30 18 O 2.9038 -3.9898 0.0000 0
M  V30 19 O 1.7477 -3.1499 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 2 4 6
M  V30 6 1 4 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 2 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 12 16
M  V30 18 1 15 17
M  V30 19 2 17 18
M  V30 20 2 17 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
2

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Nifurtimox

>  <Synonyms>
BAY-2502;BAY-A-2502

>  <CAS>
23256-30-6

>  <Formula>
C10H13N3O5S

>  <MolWt>
287.3

>  <Pathways>
Metabolism;Microbiology/Virology

>  <Target>
Dehydrogenase;Parasite

>  <Receptor>
" Taluahu??n:9.91??M, Brener strains of T. cruzi- epimastigotes:10.44 ??M, LQ:12.28??M"

>  <Bioactivity>
"Nifurtimox is an antiprotozoal agent (IC50s = 9.91, 12.28, and 10.44 ??M against Taluahu??n, LQ, and Brener strains of T. cruzi- epimastigotes, respectively)."

>  <Reference>
"Cabanillas Stanchi KM, et al. Nifurtimox reduces N-Myc expression and aerobic glycolysis in neuroblastoma. Cancer Biol Ther. 2015;16(9):1353-63.;Maya JD, et al. Trypanosoma cruzi: effect and mode of action of nitroimidazole and nitrofuran derivatives. Biochem Pharmacol. 2003 Mar 15;65(6):1999-12006."

>  <ID<1>>
T5325

$$$$
StarDrop ID 3
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -0.5408 1.5746 0.0000 0
M  V30 2 C 0.1737 1.1621 0.0000 0
M  V30 3 C 0.1737 0.3371 0.0000 0 CFG=1
M  V30 4 N -0.5408 -0.0754 0.0000 0
M  V30 5 C -0.5408 -0.9004 0.0000 0
M  V30 6 C -1.2553 -1.3129 0.0000 0 CFG=2
M  V30 7 C -2.0089 -0.9774 0.0000 0
M  V30 8 C -2.5610 -1.5905 0.0000 0
M  V30 9 C -2.1485 -2.3049 0.0000 0
M  V30 10 N -1.3415 -2.1334 0.0000 0
M  V30 11 O -2.4840 -3.0586 0.0000 0
M  V30 12 O -0.2052 -1.6541 0.0000 0
M  V30 13 C 0.8882 -0.0754 0.0000 0
M  V30 14 C 0.8882 -0.9004 0.0000 0
M  V30 15 C 1.5556 -1.3854 0.0000 0
M  V30 16 N 1.3007 -2.1700 0.0000 0
M  V30 17 C 0.4757 -2.1700 0.0000 0
M  V30 18 N 0.2207 -1.3854 0.0000 0
M  V30 19 N 0.8882 1.5746 0.0000 0
M  V30 20 C 0.9744 2.3950 0.0000 0 CFG=2
M  V30 21 C 0.3613 2.9471 0.0000 0
M  V30 22 N 0.5328 3.7541 0.0000 0
M  V30 23 O -0.4233 2.6921 0.0000 0
M  V30 24 C 1.7814 2.5666 0.0000 0
M  V30 25 C 2.1939 1.8521 0.0000 0
M  V30 26 C 1.6418 1.2390 0.0000 0
M  V30 27 H -0.6923 0.8371 0.0000 0
M  V30 28 H -1.3075 -0.3143 0.0000 0
M  V30 29 H 0.0408 2.0368 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=3
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 6 10
M  V30 11 2 9 11
M  V30 12 2 5 12
M  V30 13 1 3 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 14 18
M  V30 20 1 2 19
M  V30 21 1 20 19
M  V30 22 1 20 21 CFG=3
M  V30 23 1 21 22
M  V30 24 2 21 23
M  V30 25 1 20 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 19 26
M  V30 29 1 27 3
M  V30 30 1 28 6
M  V30 31 1 29 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
3

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Protirelin Acetate(24305-27-9 free base)

>  <Synonyms>
Lopremone Acetate;TRH Acetate;Thyroliberin Acetate;TRF Acetate;pGlu-His-Pro-NH2 Acetate;Synthetic thyrotropin-releasing hormone Acetate

>  <CAS>
T6956L

>  <Formula>
C18H26N6O6

>  <MolWt>
422.4

>  <Pathways>
Endocrinology/Hormones

>  <Target>
Thyroid hormone receptor(THR)

>  <Receptor>
Thyroid hormone

>  <Bioactivity>
Protirelin Acetate is a tripeptide that stimulates the release of thyrotropin and prolactin.

>  <Reference>
"Noda Y,etal.Hyperthermia induced by thyrotropin-releasing hormone (TRH, protirelin) in the rat.Kurume Med J. 1979;26(2):107-12.;Van Sinay E,etal.Evolutionarily conserved TRH neuropeptide pathway regulates growth in Caenorhabditis elegans.Proc Natl Acad Sci U S A. 2017 May 16;114(20):E4065-E4074."

>  <ID<1>>
T6956L

$$$$
StarDrop ID 4
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 44 48 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.2868 -2.4750 0.0000 0
M  V30 2 N -5.0013 -2.8875 0.0000 0
M  V30 3 C -5.0013 -3.7125 0.0000 0
M  V30 4 C -4.2868 -4.1250 0.0000 0
M  V30 5 N -4.2868 -4.9500 0.0000 0
M  V30 6 C -3.5724 -5.3625 0.0000 0
M  V30 7 C -3.5724 -6.1875 0.0000 0
M  V30 8 C -4.2868 -6.6000 0.0000 0
M  V30 9 C -5.0013 -6.1875 0.0000 0
M  V30 10 C -5.0013 -5.3625 0.0000 0
M  V30 11 O -4.2868 -7.4250 0.0000 0
M  V30 12 C -5.0013 -7.8375 0.0000 0
M  V30 13 O -5.7158 -7.4250 0.0000 0
M  V30 14 N -5.0013 -8.6625 0.0000 0
M  V30 15 C -5.7158 -9.0750 0.0000 0
M  V30 16 C -6.4302 -8.6625 0.0000 0
M  V30 17 C -7.1447 -9.0750 0.0000 0
M  V30 18 C -7.1447 -9.9000 0.0000 0
M  V30 19 C -6.4302 -10.3125 0.0000 0
M  V30 20 C -5.7158 -9.9000 0.0000 0
M  V30 21 C -5.0013 -10.3125 0.0000 0
M  V30 22 C -4.2868 -9.9000 0.0000 0
M  V30 23 C -3.5724 -10.3125 0.0000 0
M  V30 24 C -3.5724 -11.1375 0.0000 0
M  V30 25 C -4.2868 -11.5500 0.0000 0
M  V30 26 C -5.0013 -11.1375 0.0000 0
M  V30 27 C -5.7158 -2.4750 0.0000 0
M  V30 28 O -6.4302 -2.8875 0.0000 0
M  V30 29 C -5.7158 -1.6500 0.0000 0
M  V30 30 C -6.4302 -1.2375 0.0000 0
M  V30 31 C -6.4302 -0.4125 0.0000 0
M  V30 32 C -5.7158 -0.0000 0.0000 0
M  V30 33 C -5.7158 0.8250 0.0000 0
M  V30 34 N -6.4302 1.2375 0.0000 0
M  V30 35 C -7.1447 0.8250 0.0000 0
M  V30 36 C -7.8592 1.2375 0.0000 0
M  V30 37 C -7.8592 2.0625 0.0000 0
M  V30 38 C -7.1447 2.4750 0.0000 0
M  V30 39 C -6.4302 2.0625 0.0000 0
M  V30 40 C -8.5737 2.4750 0.0000 0
M  V30 41 N -9.2881 2.0625 0.0000 0
M  V30 42 O -8.5737 3.3000 0.0000 0
M  V30 43 C -5.0013 -0.4125 0.0000 0
M  V30 44 C -5.0013 -1.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 5 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 15 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 21 26
M  V30 29 1 2 27
M  V30 30 2 27 28
M  V30 31 1 27 29
M  V30 32 2 29 30
M  V30 33 1 30 31
M  V30 34 2 31 32
M  V30 35 1 32 33
M  V30 36 1 33 34
M  V30 37 1 34 35
M  V30 38 1 35 36
M  V30 39 1 36 37
M  V30 40 1 37 38
M  V30 41 1 38 39
M  V30 42 1 34 39
M  V30 43 1 37 40
M  V30 44 1 40 41
M  V30 45 2 40 42
M  V30 46 1 32 43
M  V30 47 2 43 44
M  V30 48 1 29 44
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
4

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Revefenacin

>  <Synonyms>
GSK1160724;TD-4208

>  <CAS>
864750-70-9

>  <Formula>
C35H43N5O4

>  <MolWt>
597.8

>  <Pathways>
Neuroscience

>  <Target>
AChR

>  <Receptor>
 M3 mAChR:0.18 Nm(ki)

>  <Bioactivity>
"Revefenacin is a mAChR antagonist has a high affinity on M3 receptor( Ki : 0.18 nM),and potentially useful for the treatment of respiratory disease."

>  <Reference>
"Pulido-Rios MT, McNamara A, Obedencio GP,et al.In vivo pharmacological characterization of TD-4208, a novel lung-selective inhaled muscarinic antagonist with sustained bronchoprotective effect in experimental animal models[J].J Pharmacol Exp Ther. 2013 Aug;346(2):241-50.;Pudi KK, Barnes CN, Moran EJ,et al.A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease[J].Respir Res. 2017 Nov 2;18(1):182."

>  <ID<1>>
T7392

$$$$
StarDrop ID 5
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 130 135 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.5545 -0.6903 0.0000 0
M  V30 2 C 10.0312 -0.0525 0.0000 0
M  V30 3 C 10.3219 0.7196 0.0000 0
M  V30 4 C 9.7986 1.3574 0.0000 0
M  V30 5 C 10.0894 2.1295 0.0000 0 CFG=2
M  V30 6 N 9.5661 2.7673 0.0000 0
M  V30 7 C 8.7521 2.6330 0.0000 0
M  V30 8 O 8.4614 1.8610 0.0000 0
M  V30 9 C 8.2288 3.2708 0.0000 0 CFG=2
M  V30 10 C 8.5195 4.0429 0.0000 0
M  V30 11 O 9.3335 4.1772 0.0000 0
M  V30 12 N 7.4148 3.1366 0.0000 0
M  V30 13 C 6.8915 3.7744 0.0000 0
M  V30 14 O 7.1822 4.5465 0.0000 0
M  V30 15 C 6.0775 3.6401 0.0000 0 CFG=2
M  V30 16 C 5.5542 4.2779 0.0000 0
M  V30 17 C 4.7402 4.1436 0.0000 0
M  V30 18 C 4.4495 3.3716 0.0000 0
M  V30 19 C 3.6355 3.2373 0.0000 0
M  V30 20 C 3.1122 3.8751 0.0000 0
M  V30 21 O 2.2982 3.7408 0.0000 0
M  V30 22 C 3.4029 4.6472 0.0000 0
M  V30 23 C 4.2169 4.7814 0.0000 0
M  V30 24 N 5.7868 2.8680 0.0000 0
M  V30 25 C 6.3101 2.2302 0.0000 0
M  V30 26 O 7.1241 2.3645 0.0000 0
M  V30 27 C 6.0194 1.4581 0.0000 0 CFG=2
M  V30 28 C 5.2054 1.3239 0.0000 0
M  V30 29 O 4.6821 1.9617 0.0000 0
M  V30 30 N 6.5426 0.8203 0.0000 0
M  V30 31 C 6.2519 0.0482 0.0000 0
M  V30 32 C 6.7752 -0.5896 0.0000 0
M  V30 33 O 5.4379 -0.0860 0.0000 0
M  V30 34 C 10.9034 2.2638 0.0000 0
M  V30 35 O 11.1941 3.0359 0.0000 0
M  V30 36 N 11.4266 1.6260 0.0000 0
M  V30 37 C 12.2406 1.7603 0.0000 0 CFG=1
M  V30 38 C 12.5314 2.5323 0.0000 0
M  V30 39 C 13.3454 2.6666 0.0000 0
M  V30 40 C 13.6361 3.4387 0.0000 0
M  V30 41 O 13.1128 4.0765 0.0000 0
M  V30 42 O 14.4501 3.5730 0.0000 0
M  V30 43 C 12.7639 1.1224 0.0000 0
M  V30 44 O 12.4732 0.3504 0.0000 0
M  V30 45 N 13.5779 1.2567 0.0000 0
M  V30 46 C 14.1012 0.6189 0.0000 0 CFG=1
M  V30 47 C 13.8105 -0.1532 0.0000 0
M  V30 48 C 14.3338 -0.7910 0.0000 0
M  V30 49 C 15.1574 -0.7425 0.0000 0
M  V30 50 N 15.4579 -1.5108 0.0000 0
M  V30 51 C 14.8201 -2.0341 0.0000 0
M  V30 52 N 14.1254 -1.5892 0.0000 0
M  V30 53 C 14.9152 0.7532 0.0000 0
M  V30 54 O 15.2059 1.5253 0.0000 0
M  V30 55 N 15.4385 0.1154 0.0000 0
M  V30 56 C 16.2525 0.2497 0.0000 0 CFG=2
M  V30 57 C 16.2904 1.0738 0.0000 0
M  V30 58 C 17.0231 1.4530 0.0000 0
M  V30 59 C 17.0610 2.2772 0.0000 0
M  V30 60 C 17.7936 2.6564 0.0000 0
M  V30 61 C 18.4884 2.2115 0.0000 0
M  V30 62 C 18.4505 1.3874 0.0000 0
M  V30 63 C 17.7178 1.0081 0.0000 0
M  V30 64 C 16.7758 -0.3881 0.0000 0
M  V30 65 O 16.4851 -1.1602 0.0000 0
M  V30 66 N 17.5898 -0.2539 0.0000 0
M  V30 67 C 18.1131 -0.8917 0.0000 0 CFG=1
M  V30 68 C 17.8223 -1.6638 0.0000 0
M  V30 69 C 17.0083 -1.7980 0.0000 0
M  V30 70 C 16.7176 -2.5701 0.0000 0
M  V30 71 N 15.9036 -2.7044 0.0000 0
M  V30 72 C 15.6129 -3.4765 0.0000 0
M  V30 73 N 16.1362 -4.1143 0.0000 0
M  V30 74 N 14.7989 -3.6107 0.0000 0
M  V30 75 C 18.9271 -0.7574 0.0000 0
M  V30 76 O 18.7084 0.0381 0.0000 0
M  V30 77 N 19.4503 -1.3952 0.0000 0
M  V30 78 C 20.2643 -1.2609 0.0000 0 CFG=1
M  V30 79 C 20.5551 -0.4889 0.0000 0
M  V30 80 C 20.0318 0.1490 0.0000 0
M  V30 81 C 19.2082 0.1005 0.0000 0
M  V30 82 N 18.9076 0.8688 0.0000 0
M  V30 83 C 19.5454 1.3921 0.0000 0
M  V30 84 C 19.5833 2.2162 0.0000 0
M  V30 85 C 20.3160 2.5955 0.0000 0
M  V30 86 C 21.0108 2.1506 0.0000 0
M  V30 87 C 20.9729 1.3264 0.0000 0
M  V30 88 C 20.2402 0.9472 0.0000 0
M  V30 89 C 20.7876 -1.8987 0.0000 0
M  V30 90 O 20.4969 -2.6708 0.0000 0
M  V30 91 N 21.6016 -1.7645 0.0000 0
M  V30 92 C 22.1249 -2.4023 0.0000 0
M  V30 93 C 22.9389 -2.2680 0.0000 0
M  V30 94 O 23.2296 -1.4959 0.0000 0
M  V30 95 N 23.4622 -2.9058 0.0000 0
M  V30 96 C 24.2762 -2.7715 0.0000 0 CFG=1
M  V30 97 C 24.5669 -1.9994 0.0000 0
M  V30 98 C 24.0436 -1.3616 0.0000 0
M  V30 99 C 24.3343 -0.5896 0.0000 0
M  V30 100 C 23.8111 0.0482 0.0000 0
M  V30 101 N 24.1018 0.8203 0.0000 0
M  V30 102 C 24.7995 -3.4093 0.0000 0
M  V30 103 O 24.5088 -4.1814 0.0000 0
M  V30 104 N 25.6135 -3.2751 0.0000 0
M  V30 105 C 25.9833 -2.5376 0.0000 0
M  V30 106 C 26.7990 -2.6614 0.0000 0
M  V30 107 C 26.9332 -3.4754 0.0000 0
M  V30 108 C 26.2006 -3.8547 0.0000 0 CFG=1
M  V30 109 C 26.0767 -4.6703 0.0000 0
M  V30 110 O 26.7212 -5.1854 0.0000 0
M  V30 111 N 25.3084 -4.9709 0.0000 0
M  V30 112 C 25.1846 -5.7866 0.0000 0 CFG=1
M  V30 113 C 24.4163 -6.0871 0.0000 0
M  V30 114 C 24.2925 -6.9028 0.0000 0
M  V30 115 C 23.7719 -5.5721 0.0000 0
M  V30 116 C 25.8291 -6.3016 0.0000 0
M  V30 117 N 26.5974 -6.0011 0.0000 0
M  V30 118 O 25.7052 -7.1173 0.0000 0
M  V30 119 H 11.6063 2.5334 0.0000 0
M  V30 120 H 14.4536 1.5548 0.0000 0
M  V30 121 H 15.5051 0.9140 0.0000 0
M  V30 122 H 9.1027 1.9667 0.0000 0
M  V30 123 H 7.5946 4.0439 0.0000 0
M  V30 124 H 5.0908 3.4773 0.0000 0
M  V30 125 H 5.6669 0.5223 0.0000 0
M  V30 126 H 17.1264 -1.0545 0.0000 0
M  V30 127 H 19.9119 -2.1968 0.0000 0
M  V30 128 H 23.9238 -3.7074 0.0000 0
M  V30 129 H 25.2515 -4.1697 0.0000 0
M  V30 130 H 24.4035 -5.1622 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 9 7
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 9 12 CFG=1
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 15 13
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 20 22
M  V30 22 1 22 23
M  V30 23 2 17 23
M  V30 24 1 15 24 CFG=1
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 27 25
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 1 27 30 CFG=1
M  V30 31 1 30 31
M  V30 32 1 31 32
M  V30 33 2 31 33
M  V30 34 1 5 34
M  V30 35 2 34 35
M  V30 36 1 34 36
M  V30 37 1 37 36 CFG=1
M  V30 38 1 37 38
M  V30 39 1 38 39
M  V30 40 1 39 40
M  V30 41 1 40 41
M  V30 42 2 40 42
M  V30 43 1 37 43
M  V30 44 2 43 44
M  V30 45 1 43 45
M  V30 46 1 46 45 CFG=3
M  V30 47 1 46 47
M  V30 48 1 47 48
M  V30 49 1 48 49
M  V30 50 1 49 50
M  V30 51 2 50 51
M  V30 52 1 51 52
M  V30 53 2 48 52
M  V30 54 1 46 53
M  V30 55 2 53 54
M  V30 56 1 53 55
M  V30 57 1 56 55 CFG=3
M  V30 58 1 56 57
M  V30 59 1 57 58
M  V30 60 2 58 59
M  V30 61 1 59 60
M  V30 62 2 60 61
M  V30 63 1 61 62
M  V30 64 2 62 63
M  V30 65 1 58 63
M  V30 66 1 56 64
M  V30 67 2 64 65
M  V30 68 1 64 66
M  V30 69 1 67 66 CFG=3
M  V30 70 1 67 68
M  V30 71 1 68 69
M  V30 72 1 69 70
M  V30 73 1 70 71
M  V30 74 1 71 72
M  V30 75 1 72 73
M  V30 76 2 72 74
M  V30 77 1 67 75
M  V30 78 2 75 76
M  V30 79 1 75 77
M  V30 80 1 78 77 CFG=1
M  V30 81 1 78 79
M  V30 82 1 79 80
M  V30 83 1 80 81
M  V30 84 1 81 82
M  V30 85 2 82 83
M  V30 86 1 83 84
M  V30 87 2 84 85
M  V30 88 1 85 86
M  V30 89 2 86 87
M  V30 90 1 87 88
M  V30 91 2 80 88
M  V30 92 1 83 88
M  V30 93 1 78 89
M  V30 94 2 89 90
M  V30 95 1 89 91
M  V30 96 1 91 92
M  V30 97 1 92 93
M  V30 98 2 93 94
M  V30 99 1 93 95
M  V30 100 1 96 95 CFG=1
M  V30 101 1 96 97
M  V30 102 1 97 98
M  V30 103 1 98 99
M  V30 104 1 99 100
M  V30 105 1 100 101
M  V30 106 1 96 102
M  V30 107 2 102 103
M  V30 108 1 102 104
M  V30 109 1 104 105
M  V30 110 1 105 106
M  V30 111 1 106 107
M  V30 112 1 108 107
M  V30 113 1 108 104
M  V30 114 1 108 109 CFG=1
M  V30 115 2 109 110
M  V30 116 1 109 111
M  V30 117 1 112 111 CFG=3
M  V30 118 1 112 113
M  V30 119 1 113 114
M  V30 120 1 113 115
M  V30 121 1 112 116
M  V30 122 1 116 117
M  V30 123 2 116 118
M  V30 124 1 119 37
M  V30 125 1 120 46
M  V30 126 1 121 56
M  V30 127 1 122 5
M  V30 128 1 123 9
M  V30 129 1 124 15
M  V30 130 1 125 27
M  V30 131 1 126 67
M  V30 132 1 127 78
M  V30 133 1 128 96
M  V30 134 1 129 108
M  V30 135 1 130 112
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
5

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Afamelanotide acetate

>  <Synonyms>
afamelanotide

>  <CAS>
1566590-77-9

>  <Formula>
C80H115N21O21

>  <MolWt>
1707

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Melanocortin Receptor

>  <Receptor>
melanocortin-1 receptor

>  <Bioactivity>
"Afamelanotide acetate is a synthetic ??-melanocyte stimulating hormone analogue and first-in-class melanocortin-1 receptor agonist, used to for Erythropoietic Protoporphyria."

>  <Reference>
"Langendonk J G , Balwani M , Anderson K E , et al. Afamelanotide for Erythropoietic Protoporphyria[J]. New England Journal of Medicine, 2015, 373(1):48-59.;Kim E S , Garnock-Jones K P . Afamelanotide: A Review in Erythropoietic Protoporphyria[J]. American Journal of Clinical Dermatology, 2016, 17(2):179-185."

>  <ID<1>>
T7589

$$$$
StarDrop ID 6
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 49 53 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.8592 1.2375 0.0000 0
M  V30 2 C 7.1447 0.8250 0.0000 0
M  V30 3 C 6.7322 1.5395 0.0000 0
M  V30 4 C 7.5572 0.1105 0.0000 0
M  V30 5 N 6.4302 0.4125 0.0000 0
M  V30 6 C 6.4302 -0.4125 0.0000 0
M  V30 7 O 7.1447 -0.8250 0.0000 0
M  V30 8 C 5.7158 -0.8250 0.0000 0
M  V30 9 C 5.0013 -0.4125 0.0000 0
M  V30 10 C 4.2868 -0.8250 0.0000 0
M  V30 11 C 3.5724 -0.4125 0.0000 0
M  V30 12 C 2.8579 -0.8250 0.0000 0
M  V30 13 C 2.8579 -1.6500 0.0000 0
M  V30 14 C 3.5724 -2.0625 0.0000 0
M  V30 15 C 4.2868 -1.6500 0.0000 0
M  V30 16 C 5.0013 -2.0625 0.0000 0
M  V30 17 N 5.7158 -1.6500 0.0000 0
M  V30 18 C 6.4302 -2.0625 0.0000 0
M  V30 19 C 7.1447 -1.6500 0.0000 0
M  V30 20 O 7.6296 -0.9826 0.0000 0
M  V30 21 C 7.8592 -2.0625 0.0000 0
M  V30 22 C 7.8592 -2.8875 0.0000 0
M  V30 23 C 7.1447 -3.3000 0.0000 0
M  V30 24 C 7.1447 -4.1250 0.0000 0
M  V30 25 C 6.4302 -4.5375 0.0000 0
M  V30 26 C 5.7158 -4.1250 0.0000 0
M  V30 27 C 5.7158 -3.3000 0.0000 0
M  V30 28 C 6.4302 -2.8875 0.0000 0
M  V30 29 N 8.5737 -1.6500 0.0000 0
M  V30 30 C 9.2881 -2.0625 0.0000 0
M  V30 31 O 9.2881 -2.8875 0.0000 0
M  V30 32 C 10.0026 -1.6500 0.0000 0
M  V30 33 C 10.0026 -0.8250 0.0000 0
M  V30 34 C 9.2881 -0.4125 0.0000 0
M  V30 35 N 8.5737 -0.8250 0.0000 0
M  V30 36 O 9.2881 0.4125 0.0000 0
M  V30 37 N 10.7171 -2.0625 0.0000 0
M  V30 38 C 11.4315 -1.6500 0.0000 0
M  V30 39 O 11.4315 -0.8250 0.0000 0
M  V30 40 C 12.1460 -2.0625 0.0000 0
M  V30 41 C 12.8605 -1.6500 0.0000 0
M  V30 42 C 13.5749 -2.0625 0.0000 0
M  V30 43 C 13.5749 -2.8875 0.0000 0
M  V30 44 C 14.2894 -3.3000 0.0000 0
M  V30 45 C 14.2894 -4.1250 0.0000 0
M  V30 46 C 13.5749 -4.5375 0.0000 0
M  V30 47 C 12.8605 -4.1250 0.0000 0
M  V30 48 C 12.8605 -3.3000 0.0000 0
M  V30 49 N 12.1460 -2.8875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 10 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 8 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 19 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 23 28
M  V30 31 1 21 29
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 1 30 32
M  V30 35 1 32 33
M  V30 36 1 33 34
M  V30 37 1 34 35
M  V30 38 2 34 36
M  V30 39 1 32 37
M  V30 40 1 37 38
M  V30 41 2 38 39
M  V30 42 1 38 40
M  V30 43 2 40 41
M  V30 44 1 41 42
M  V30 45 2 42 43
M  V30 46 1 43 44
M  V30 47 2 44 45
M  V30 48 1 45 46
M  V30 49 2 46 47
M  V30 50 1 47 48
M  V30 51 1 43 48
M  V30 52 2 48 49
M  V30 53 1 40 49
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
6

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Saquinavir

>  <Synonyms>
Ro 31-8959

>  <CAS>
127779-20-8

>  <Formula>
C38H50N6O5

>  <MolWt>
670.9

>  <Pathways>
Microbiology/Virology;Proteases/Proteasome

>  <Target>
HIV Protease;SARS-CoV

>  <Receptor>
HIV; HIV Protease; SARS-CoV

>  <Bioactivity>
"Saquinavir is a potent HIV protease inhibitor, is an antiretroviral drug used together with other medications to treat or prevent HIV/AIDS."

>  <Reference>
"Walmsley S , Avihingsanon A , Slim J , et al. Gemini: A Noninferiority Study of Saquinavir/Ritonavir Versus Lopinavir/Ritonavir as Initial HIV-1 Therapy in Adults[J]. JAIDS Journal of Acquired Immune Deficiency Syndromes, 2009, 50(4):367-374.;Kupferschmidt H H T , Fattinger K E , Ha H R , et al. Grapefruit juice enhances the bioavailability of HIV protease inhibitor saquinavir in man[J]. British Journal of Clinical Pharmacology, 1998, 45(4):355-359."

>  <ID<1>>
T7903

$$$$
StarDrop ID 7
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 105 112 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -9.2139 3.5980 0.0000 0
M  V30 2 C -8.6941 2.9573 0.0000 0
M  V30 3 N -7.8794 3.0871 0.0000 0
M  V30 4 C -7.3597 2.4465 0.0000 0
M  V30 5 C -6.5449 2.5763 0.0000 0 CFG=2
M  V30 6 C -6.1711 3.3117 0.0000 0
M  V30 7 C -5.3561 3.1833 0.0000 0
M  V30 8 C -5.2263 2.3686 0.0000 0
M  V30 9 N -5.9610 1.9934 0.0000 0
M  V30 10 C -6.0894 1.1785 0.0000 0
M  V30 11 C -5.4477 0.6598 0.0000 0 CFG=2
M  V30 12 C -5.5761 -0.1551 0.0000 0
M  V30 13 C -6.3460 -0.4515 0.0000 0
M  V30 14 C -6.4743 -1.2664 0.0000 0
M  V30 15 N -7.2443 -1.5628 0.0000 0
M  V30 16 C -7.3726 -2.3777 0.0000 0
M  V30 17 N -6.7310 -2.8963 0.0000 0
M  V30 18 N -8.1425 -2.6741 0.0000 0
M  V30 19 N -4.6778 0.9562 0.0000 0
M  V30 20 C -4.0362 0.4376 0.0000 0
M  V30 21 C -3.2663 0.7339 0.0000 0 CFG=2
M  V30 22 C -3.1379 1.5489 0.0000 0
M  V30 23 C -3.7796 2.0675 0.0000 0
M  V30 24 C -4.5495 1.7712 0.0000 0
M  V30 25 C -3.6512 2.8825 0.0000 0
M  V30 26 N -2.6246 0.2153 0.0000 0
M  V30 27 C -1.8547 0.5117 0.0000 0
M  V30 28 C -1.2131 -0.0069 0.0000 0 CFG=1
M  V30 29 C -1.3414 -0.8219 0.0000 0
M  V30 30 C -2.1114 -1.1182 0.0000 0
M  V30 31 C -2.3242 -1.9153 0.0000 0
M  V30 32 N -3.1480 -1.9592 0.0000 0
M  V30 33 C -3.4443 -1.1893 0.0000 0
M  V30 34 N -2.8037 -0.6695 0.0000 0
M  V30 35 C -3.5967 -2.6516 0.0000 0
M  V30 36 C -4.4206 -2.6091 0.0000 0
M  V30 37 C -4.8693 -3.3014 0.0000 0
M  V30 38 C -5.6932 -3.2590 0.0000 0
M  V30 39 C -6.0684 -2.5243 0.0000 0
M  V30 40 C -5.6197 -1.8319 0.0000 0
M  V30 41 C -4.7958 -1.8744 0.0000 0
M  V30 42 N -0.4432 0.2894 0.0000 0
M  V30 43 C 0.1985 -0.2292 0.0000 0
M  V30 44 C 0.9684 0.0672 0.0000 0 CFG=2
M  V30 45 C 1.0967 0.8821 0.0000 0
M  V30 46 C 0.4551 1.4007 0.0000 0
M  V30 47 C -0.3148 1.1044 0.0000 0
M  V30 48 C -0.9565 1.6230 0.0000 0
M  V30 49 C -0.8281 2.4379 0.0000 0
M  V30 50 C -0.0582 2.7343 0.0000 0
M  V30 51 C 0.5834 2.2157 0.0000 0
M  V30 52 O -1.4697 2.9566 0.0000 0
M  V30 53 N 1.6100 -0.4515 0.0000 0
M  V30 54 C 2.3799 -0.1551 0.0000 0
M  V30 55 C 3.0216 -0.6737 0.0000 0 CFG=2
M  V30 56 C 2.8932 -1.4887 0.0000 0
M  V30 57 O 2.1233 -1.7850 0.0000 0
M  V30 58 N 3.7915 -0.3774 0.0000 0
M  V30 59 C 4.4331 -0.8960 0.0000 0
M  V30 60 C 5.2030 -0.5996 0.0000 0 CFG=2
M  V30 61 C 5.3314 0.2153 0.0000 0
M  V30 62 C 4.6898 0.7339 0.0000 0
M  V30 63 C 3.8931 0.5197 0.0000 0
M  V30 64 N 3.4431 1.2112 0.0000 0
M  V30 65 C 3.9617 1.8528 0.0000 0
M  V30 66 C 3.8319 2.6675 0.0000 0
M  V30 67 C 4.4726 3.1873 0.0000 0
M  V30 68 C 5.2431 2.8923 0.0000 0
M  V30 69 C 5.3729 2.0776 0.0000 0
M  V30 70 C 4.7322 1.5578 0.0000 0
M  V30 71 N 5.8447 -1.1182 0.0000 0
M  V30 72 C 6.6146 -0.8219 0.0000 0
M  V30 73 C 7.2562 -1.3405 0.0000 0 CFG=2
M  V30 74 C 7.1279 -2.1555 0.0000 0
M  V30 75 C 6.3579 -2.4518 0.0000 0
M  V30 76 C 6.1451 -3.2489 0.0000 0
M  V30 77 N 5.3213 -3.2928 0.0000 0
M  V30 78 C 5.0250 -2.5229 0.0000 0
M  V30 79 N 5.6656 -2.0031 0.0000 0
M  V30 80 N 8.0261 -1.0442 0.0000 0
M  V30 81 C 8.6678 -1.5628 0.0000 0
M  V30 82 C 9.4377 -1.2664 0.0000 0 CFG=2
M  V30 83 C 10.1300 -1.7151 0.0000 0
M  V30 84 C 10.7707 -1.1954 0.0000 0
M  V30 85 C 10.4743 -0.4254 0.0000 0
M  V30 86 N 9.6505 -0.4693 0.0000 0
M  V30 87 O 10.9230 0.2669 0.0000 0
M  V30 88 O 8.5394 -2.3777 0.0000 0
M  V30 89 O 6.7429 -0.0069 0.0000 0
M  V30 90 O 4.3048 -1.7109 0.0000 0
M  V30 91 O 2.5083 0.6598 0.0000 0
M  V30 92 O 0.0701 -1.0442 0.0000 0
M  V30 93 O -1.7264 1.3266 0.0000 0
M  V30 94 O -4.1645 -0.3774 0.0000 0
M  V30 95 O -6.8593 0.8821 0.0000 0
M  V30 96 O -7.6546 1.6760 0.0000 0
M  V30 97 H 0.8129 -0.9206 0.0000 0
M  V30 98 H 3.7992 -1.3025 0.0000 0
M  V30 99 H 6.1363 -0.2405 0.0000 0
M  V30 100 H 7.4117 -0.3527 0.0000 0
M  V30 101 H 9.3341 -2.2610 0.0000 0
M  V30 102 H -7.1336 3.3847 0.0000 0
M  V30 103 H -4.6700 0.0312 0.0000 0
M  V30 104 H -2.3330 1.0931 0.0000 0
M  V30 105 H -1.0576 0.9809 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=3
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 5 9
M  V30 10 1 9 10
M  V30 11 1 11 10
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 16 18
M  V30 19 1 11 19 CFG=1
M  V30 20 1 19 20
M  V30 21 1 21 20
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 23 25
M  V30 26 1 21 26 CFG=3
M  V30 27 1 26 27
M  V30 28 1 28 27
M  V30 29 1 28 29
M  V30 30 1 29 30
M  V30 31 2 30 31
M  V30 32 1 31 32
M  V30 33 1 32 33
M  V30 34 2 33 34
M  V30 35 1 30 34
M  V30 36 1 32 35
M  V30 37 1 35 36
M  V30 38 2 36 37
M  V30 39 1 37 38
M  V30 40 2 38 39
M  V30 41 1 39 40
M  V30 42 2 40 41
M  V30 43 1 36 41
M  V30 44 1 28 42 CFG=3
M  V30 45 1 42 43
M  V30 46 1 44 43
M  V30 47 1 44 45
M  V30 48 1 45 46
M  V30 49 2 46 47
M  V30 50 1 47 48
M  V30 51 2 48 49
M  V30 52 1 49 50
M  V30 53 2 50 51
M  V30 54 1 46 51
M  V30 55 1 49 52
M  V30 56 1 44 53 CFG=3
M  V30 57 1 53 54
M  V30 58 1 55 54
M  V30 59 1 55 56
M  V30 60 1 56 57
M  V30 61 1 55 58 CFG=1
M  V30 62 1 58 59
M  V30 63 1 60 59
M  V30 64 1 60 61
M  V30 65 1 61 62
M  V30 66 2 62 63
M  V30 67 1 63 64
M  V30 68 1 64 65
M  V30 69 2 65 66
M  V30 70 1 66 67
M  V30 71 2 67 68
M  V30 72 1 68 69
M  V30 73 2 69 70
M  V30 74 1 65 70
M  V30 75 1 62 70
M  V30 76 1 60 71 CFG=3
M  V30 77 1 71 72
M  V30 78 1 73 72
M  V30 79 1 73 74
M  V30 80 1 74 75
M  V30 81 2 75 76
M  V30 82 1 76 77
M  V30 83 1 77 78
M  V30 84 2 78 79
M  V30 85 1 75 79
M  V30 86 1 73 80 CFG=1
M  V30 87 1 80 81
M  V30 88 1 82 81 CFG=1
M  V30 89 1 82 83
M  V30 90 1 83 84
M  V30 91 1 84 85
M  V30 92 1 85 86
M  V30 93 1 82 86
M  V30 94 2 85 87
M  V30 95 2 81 88
M  V30 96 2 72 89
M  V30 97 2 59 90
M  V30 98 2 54 91
M  V30 99 2 43 92
M  V30 100 2 27 93
M  V30 101 2 20 94
M  V30 102 2 10 95
M  V30 103 2 4 96
M  V30 104 1 97 44
M  V30 105 1 98 55
M  V30 106 1 99 60
M  V30 107 1 100 73
M  V30 108 1 101 82
M  V30 109 1 102 5
M  V30 110 1 103 11
M  V30 111 1 104 21
M  V30 112 1 105 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
7

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Histrelin acetate

>  <Synonyms>
Histrelin acetate(76712-82-8 free base)

>  <CAS>
220810-26-4

>  <Formula>
C68H90N18O14

>  <MolWt>
1384

>  <Pathways>
GPCR/G Protein

>  <Target>
GNRH Receptor

>  <Receptor>
GNRHR

>  <Bioactivity>
Histrelin acetate is a nonapeptide analog of gonadotropin-releasing hormone (GnRH) with added potency. It acts on particular cells of the pituitary gland called gonadotropes when present in the bloodstream. Histrelin stimulates these cells to release luteinizing hormone and follicle-stimulating hormone. Thus it is considered a gonadotropin-releasing hormone agonist or GnRH agonist.

>  <Reference>
Crawford ED. A review of the use of histrelin acetate in the treatment of prostate cancer. BJU Int. 2009 Mar;103 Suppl 2:14-22.

>  <ID<1>>
TP2107L

$$$$
StarDrop ID 8
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 42 47 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.7145 3.7125 0.0000 0
M  V30 2 C 1.4289 3.3000 0.0000 0
M  V30 3 O 2.1434 3.7125 0.0000 0
M  V30 4 C 1.4289 2.4750 0.0000 0
M  V30 5 C 2.1434 2.0625 0.0000 0
M  V30 6 C 2.1434 1.2375 0.0000 0
M  V30 7 N 1.4289 0.8250 0.0000 0
M  V30 8 C 0.7145 1.2375 0.0000 0
M  V30 9 C 0.7145 2.0625 0.0000 0
M  V30 10 C 1.4289 -0.0000 0.0000 0
M  V30 11 N 2.1434 -0.4125 0.0000 0
M  V30 12 C 2.1434 -1.2375 0.0000 0
M  V30 13 C 1.4289 -1.6500 0.0000 0
M  V30 14 C 0.7145 -1.2375 0.0000 0
M  V30 15 C 0.7145 -0.4125 0.0000 0
M  V30 16 Cl 0.0000 0.0000 0.0000 0
M  V30 17 C 1.4289 -2.4750 0.0000 0
M  V30 18 O 2.1434 -2.8875 0.0000 0
M  V30 19 N 0.7145 -2.8875 0.0000 0
M  V30 20 C 0.7145 -3.7125 0.0000 0
M  V30 21 N 1.3819 -4.1974 0.0000 0
M  V30 22 C 1.1270 -4.9820 0.0000 0
M  V30 23 C 1.6119 -5.6495 0.0000 0
M  V30 24 C 2.4369 -5.6495 0.0000 0
M  V30 25 C 2.6918 -6.4341 0.0000 0
M  V30 26 Cl 3.4765 -6.6890 0.0000 0
M  V30 27 C 2.0244 -6.9190 0.0000 0
M  V30 28 S 1.3570 -6.4341 0.0000 0
M  V30 29 C 0.3020 -4.9820 0.0000 0
M  V30 30 S 0.0470 -4.1974 0.0000 0
M  V30 31 N -0.1830 -5.6495 0.0000 0
M  V30 32 C 0.1526 -6.4032 0.0000 0
M  V30 33 C -0.3323 -7.0706 0.0000 0
M  V30 34 N -1.1528 -6.9844 0.0000 0
M  V30 35 C -1.4884 -6.2307 0.0000 0
M  V30 36 C -1.0034 -5.5632 0.0000 0
M  V30 37 C -1.6377 -7.6518 0.0000 0
M  V30 38 C -1.3022 -8.4055 0.0000 0
M  V30 39 C -1.7871 -9.0729 0.0000 0
M  V30 40 C -2.6076 -8.9867 0.0000 0
M  V30 41 C -2.9431 -8.2330 0.0000 0
M  V30 42 C -2.4582 -7.5656 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 4 9
M  V30 10 1 7 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 10 15
M  V30 17 1 15 16
M  V30 18 1 13 17
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 2 25 27
M  V30 29 1 27 28
M  V30 30 1 23 28
M  V30 31 2 22 29
M  V30 32 1 29 30
M  V30 33 1 20 30
M  V30 34 1 29 31
M  V30 35 1 31 32
M  V30 36 1 32 33
M  V30 37 1 33 34
M  V30 38 1 34 35
M  V30 39 1 35 36
M  V30 40 1 31 36
M  V30 41 1 34 37
M  V30 42 1 37 38
M  V30 43 1 38 39
M  V30 44 1 39 40
M  V30 45 1 40 41
M  V30 46 1 41 42
M  V30 47 1 37 42
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
8

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Avatrombopag

>  <Synonyms>
AKR-501;E5501;YM477

>  <CAS>
570406-98-3

>  <Formula>
C29H34Cl2N6O3S2

>  <MolWt>
649.7

>  <Pathways>
Proteases/Proteasome;Immunology/Inflammation

>  <Target>
Thrombopoietin Receptor;Thrombin

>  <Receptor>
 TPO receptor:3.3 nM (EC50)

>  <Bioactivity>
"Avatrombopag is a new oral thrombopoietin (TPO) receptor agonist, activating TPO receptor and increasing megakaryocytic proliferation/differentiation and platelet production."

>  <Reference>
"Al-Samkari H.Avatrombopag maleate for the treatment of periprocedural thrombocytopenia in patients with chronic liver disease.Drugs Today (Barc). 2018 Nov;54(11):647-655.;Xu H, Cai R.Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease.Expert Rev Clin Pharmacol. 2019 Sep;12(9):859-865"

>  <ID<1>>
T7417

$$$$
StarDrop ID 9
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 128 135 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 21.3015 0.1816 0.0000 0
M  V30 2 C 22.1249 0.1301 0.0000 0 CFG=1
M  V30 3 N 22.4920 -0.6087 0.0000 0
M  V30 4 C 22.0357 -1.2960 0.0000 0
M  V30 5 C 22.4028 -2.0349 0.0000 0 CFG=1
M  V30 6 N 22.0208 -2.7661 0.0000 0
M  V30 7 C 22.5982 -3.3553 0.0000 0
M  V30 8 C 23.3371 -2.9882 0.0000 0
M  V30 9 C 23.2162 -2.1721 0.0000 0
M  V30 10 C 21.2047 -2.8869 0.0000 0
M  V30 11 C 20.6920 -2.2406 0.0000 0 CFG=1
M  V30 12 N 19.8759 -2.3614 0.0000 0
M  V30 13 C 19.3632 -1.7150 0.0000 0
M  V30 14 C 18.5471 -1.8359 0.0000 0 CFG=1
M  V30 15 N 18.0344 -1.1895 0.0000 0
M  V30 16 C 17.2183 -1.3103 0.0000 0
M  V30 17 C 16.7056 -0.6640 0.0000 0 CFG=2
M  V30 18 N 15.8895 -0.7848 0.0000 0
M  V30 19 C 15.3769 -0.1384 0.0000 0
M  V30 20 C 14.5607 -0.2592 0.0000 0 CFG=1
M  V30 21 N 14.0481 0.3871 0.0000 0
M  V30 22 C 13.2320 0.2663 0.0000 0
M  V30 23 C 12.7193 0.9127 0.0000 0 CFG=1
M  V30 24 N 11.9032 0.7918 0.0000 0
M  V30 25 C 11.3905 1.4382 0.0000 0
M  V30 26 C 10.5744 1.3174 0.0000 0 CFG=2
M  V30 27 N 10.0617 1.9637 0.0000 0
M  V30 28 C 9.2456 1.8429 0.0000 0
M  V30 29 C 8.7329 2.4893 0.0000 0 CFG=2
M  V30 30 N 7.9168 2.3685 0.0000 0
M  V30 31 C 7.4041 3.0148 0.0000 0
M  V30 32 C 6.5880 2.8940 0.0000 0 CFG=2
M  V30 33 N 6.2846 2.1268 0.0000 0
M  V30 34 C 6.7973 1.4805 0.0000 0
M  V30 35 C 6.4938 0.7133 0.0000 0
M  V30 36 O 7.6134 1.6013 0.0000 0
M  V30 37 C 6.0753 3.5404 0.0000 0
M  V30 38 C 5.2592 3.4195 0.0000 0
M  V30 39 C 4.9558 2.6524 0.0000 0
M  V30 40 C 4.1397 2.5315 0.0000 0
M  V30 41 C 3.6270 3.1779 0.0000 0
M  V30 42 C 2.8109 3.0571 0.0000 0
M  V30 43 C 2.2982 3.7034 0.0000 0
M  V30 44 C 2.6016 4.4706 0.0000 0
M  V30 45 C 3.4177 4.5914 0.0000 0
M  V30 46 C 3.9304 3.9451 0.0000 0
M  V30 47 C 4.7465 4.0659 0.0000 0
M  V30 48 O 7.7075 3.7820 0.0000 0
M  V30 49 C 9.0363 3.2565 0.0000 0
M  V30 50 C 9.8524 3.3773 0.0000 0
M  V30 51 C 10.1558 4.1445 0.0000 0
M  V30 52 C 10.9720 4.2653 0.0000 0
M  V30 53 C 11.4846 3.6189 0.0000 0
M  V30 54 C 11.1812 2.8517 0.0000 0
M  V30 55 C 10.3651 2.7309 0.0000 0
M  V30 56 Cl 12.3007 3.7397 0.0000 0
M  V30 57 O 8.9422 1.0757 0.0000 0
M  V30 58 C 10.2710 0.5502 0.0000 0
M  V30 59 C 10.7836 -0.0962 0.0000 0
M  V30 60 C 10.4802 -0.8633 0.0000 0
M  V30 61 C 10.9929 -1.5097 0.0000 0
M  V30 62 C 11.8090 -1.3889 0.0000 0
M  V30 63 N 12.1124 -0.6217 0.0000 0
M  V30 64 C 11.5997 0.0247 0.0000 0
M  V30 65 O 11.6939 2.2054 0.0000 0
M  V30 66 C 13.0227 1.6798 0.0000 0
M  V30 67 O 13.8388 1.8007 0.0000 0
M  V30 68 O 12.9285 -0.5009 0.0000 0
M  V30 69 C 14.2573 -1.0264 0.0000 0
M  V30 70 C 14.7700 -1.6728 0.0000 0
M  V30 71 C 15.5861 -1.5520 0.0000 0
M  V30 72 C 16.0988 -2.1983 0.0000 0
M  V30 73 C 15.7954 -2.9655 0.0000 0
M  V30 74 C 14.9793 -3.0863 0.0000 0
M  V30 75 C 14.4666 -2.4400 0.0000 0
M  V30 76 N 16.3081 -3.6118 0.0000 0
M  V30 77 C 16.0046 -4.3790 0.0000 0
M  V30 78 C 16.5173 -5.0254 0.0000 0 CFG=1
M  V30 79 N 17.3334 -4.9046 0.0000 0
M  V30 80 C 16.2139 -5.7926 0.0000 0
M  V30 81 C 16.7266 -6.4389 0.0000 0
M  V30 82 N 17.5427 -6.3181 0.0000 0
M  V30 83 C 17.8461 -5.5509 0.0000 0
M  V30 84 O 18.6622 -5.4301 0.0000 0
M  V30 85 O 16.4232 -7.2061 0.0000 0
M  V30 86 O 15.1885 -4.4998 0.0000 0
M  V30 87 O 15.6803 0.6288 0.0000 0
M  V30 88 C 16.7571 0.1594 0.0000 0
M  V30 89 C 17.4960 0.5265 0.0000 0
M  V30 90 C 17.5475 1.3499 0.0000 0
M  V30 91 C 18.2863 1.7170 0.0000 0
M  V30 92 C 18.9736 1.2607 0.0000 0
M  V30 93 C 18.9221 0.4373 0.0000 0
M  V30 94 C 18.1833 0.0702 0.0000 0
M  V30 95 N 19.7124 1.6278 0.0000 0
M  V30 96 C 19.7639 2.4512 0.0000 0
M  V30 97 N 19.0766 2.9075 0.0000 0
M  V30 98 O 20.5028 2.8183 0.0000 0
M  V30 99 O 16.9149 -2.0775 0.0000 0
M  V30 100 C 18.2437 -2.6030 0.0000 0
M  V30 101 C 18.7564 -3.2494 0.0000 0
M  V30 102 C 19.5725 -3.1286 0.0000 0
M  V30 103 C 18.4530 -4.0166 0.0000 0
M  V30 104 O 19.6666 -0.9479 0.0000 0
M  V30 105 C 20.9954 -1.4734 0.0000 0
M  V30 106 C 20.4827 -0.8270 0.0000 0
M  V30 107 C 20.7862 -0.0599 0.0000 0
M  V30 108 C 20.2735 0.5865 0.0000 0
M  V30 109 N 20.5769 1.3537 0.0000 0
M  V30 110 C 20.2890 2.1268 0.0000 0
M  V30 111 C 19.9220 2.8656 0.0000 0
M  V30 112 C 20.8147 2.7627 0.0000 0
M  V30 113 O 20.9013 -3.6541 0.0000 0
M  V30 114 O 21.2123 -1.2445 0.0000 0
M  V30 115 C 22.5811 0.8175 0.0000 0
M  V30 116 N 22.2141 1.5563 0.0000 0
M  V30 117 O 23.4045 0.7660 0.0000 0
M  V30 118 H 16.8851 -4.0955 0.0000 0
M  V30 119 H 21.6799 1.0256 0.0000 0
M  V30 120 H 22.9985 -1.2317 0.0000 0
M  V30 121 H 20.0706 -1.4571 0.0000 0
M  V30 122 H 17.5579 -1.9822 0.0000 0
M  V30 123 H 15.9693 0.0126 0.0000 0
M  V30 124 H 13.5715 -0.4058 0.0000 0
M  V30 125 H 12.0978 1.6961 0.0000 0
M  V30 126 H 9.5852 1.1709 0.0000 0
M  V30 127 H 8.1115 3.2728 0.0000 0
M  V30 128 H 7.2094 2.1105 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=3
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 5 9
M  V30 10 1 6 10
M  V30 11 1 11 10
M  V30 12 1 11 12 CFG=1
M  V30 13 1 12 13
M  V30 14 1 14 13
M  V30 15 1 14 15 CFG=3
M  V30 16 1 15 16
M  V30 17 1 17 16
M  V30 18 1 17 18 CFG=3
M  V30 19 1 18 19
M  V30 20 1 20 19
M  V30 21 1 20 21 CFG=3
M  V30 22 1 21 22
M  V30 23 1 23 22
M  V30 24 1 23 24 CFG=1
M  V30 25 1 24 25
M  V30 26 1 26 25
M  V30 27 1 26 27 CFG=1
M  V30 28 1 27 28
M  V30 29 1 29 28
M  V30 30 1 29 30 CFG=3
M  V30 31 1 30 31
M  V30 32 1 32 31
M  V30 33 1 32 33 CFG=3
M  V30 34 1 33 34
M  V30 35 1 34 35
M  V30 36 2 34 36
M  V30 37 1 32 37
M  V30 38 1 37 38
M  V30 39 2 38 39
M  V30 40 1 39 40
M  V30 41 2 40 41
M  V30 42 1 41 42
M  V30 43 2 42 43
M  V30 44 1 43 44
M  V30 45 2 44 45
M  V30 46 1 45 46
M  V30 47 1 41 46
M  V30 48 2 46 47
M  V30 49 1 38 47
M  V30 50 2 31 48
M  V30 51 1 29 49
M  V30 52 1 49 50
M  V30 53 2 50 51
M  V30 54 1 51 52
M  V30 55 2 52 53
M  V30 56 1 53 54
M  V30 57 2 54 55
M  V30 58 1 50 55
M  V30 59 1 53 56
M  V30 60 2 28 57
M  V30 61 1 26 58
M  V30 62 1 58 59
M  V30 63 2 59 60
M  V30 64 1 60 61
M  V30 65 2 61 62
M  V30 66 1 62 63
M  V30 67 2 63 64
M  V30 68 1 59 64
M  V30 69 2 25 65
M  V30 70 1 23 66
M  V30 71 1 66 67
M  V30 72 2 22 68
M  V30 73 1 20 69
M  V30 74 1 69 70
M  V30 75 2 70 71
M  V30 76 1 71 72
M  V30 77 2 72 73
M  V30 78 1 73 74
M  V30 79 2 74 75
M  V30 80 1 70 75
M  V30 81 1 73 76
M  V30 82 1 76 77
M  V30 83 1 78 77 CFG=1
M  V30 84 1 78 79
M  V30 85 1 78 80
M  V30 86 1 80 81
M  V30 87 1 81 82
M  V30 88 1 82 83
M  V30 89 1 79 83
M  V30 90 2 83 84
M  V30 91 2 81 85
M  V30 92 2 77 86
M  V30 93 2 19 87
M  V30 94 1 17 88
M  V30 95 1 88 89
M  V30 96 2 89 90
M  V30 97 1 90 91
M  V30 98 2 91 92
M  V30 99 1 92 93
M  V30 100 2 93 94
M  V30 101 1 89 94
M  V30 102 1 92 95
M  V30 103 1 95 96
M  V30 104 1 96 97
M  V30 105 2 96 98
M  V30 106 2 16 99
M  V30 107 1 14 100
M  V30 108 1 100 101
M  V30 109 1 101 102
M  V30 110 1 101 103
M  V30 111 2 13 104
M  V30 112 1 11 105
M  V30 113 1 105 106
M  V30 114 1 106 107
M  V30 115 1 107 108
M  V30 116 1 108 109
M  V30 117 1 109 110
M  V30 118 1 110 111
M  V30 119 1 110 112
M  V30 120 2 10 113
M  V30 121 2 4 114
M  V30 122 1 2 115
M  V30 123 1 115 116
M  V30 124 2 115 117
M  V30 125 1 118 78
M  V30 126 1 119 2
M  V30 127 1 120 5
M  V30 128 1 121 11
M  V30 129 1 122 14
M  V30 130 1 123 17
M  V30 131 1 124 20
M  V30 132 1 125 23
M  V30 133 1 126 26
M  V30 134 1 127 29
M  V30 135 1 128 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
9

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Degarelix acetate(214766-78-6 free base)

>  <Synonyms>
N/A

>  <CAS>
T10988L

>  <Formula>
C84H107ClN18O18

>  <MolWt>
1692

>  <Pathways>
GPCR/G Protein

>  <Target>
GNRH Receptor

>  <Receptor>
GnRHR

>  <Bioactivity>
Degarelix acetate is a competitive and reversible antagonist of gonadotropin-releasing hormone receptor (GnRHR) .

>  <Reference>
"Sonesson A, et al. Metabolite profiles of degarelix, a new gonadotropin-releasing hormone receptor antagonist, in rat, dog, and monkey. Drug Metab Dispos. 2011 Oct;39(10):1895-903.;Sakai M, et al. In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonistdegarelix on human prostate cell growth. PLoS One. 2015 Mar 26;10(3):e0120670.;Rick FG, et al. An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. Onco Targets Ther. 2013 Apr 16;6:391-402.;Broqua P, et al. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormoneantagonist: degarelix. J Pharmacol Exp Ther. 2002 Apr;301(1):95-102."

>  <ID<1>>
T10988L

$$$$
StarDrop ID 10
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 41 45 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H -8.4375 1.2750 0.0000 0
M  V30 2 C -8.1536 2.0518 0.0000 0 CFG=1
M  V30 3 C -7.6232 1.4196 0.0000 0
M  V30 4 C -6.8089 1.5643 0.0000 0
M  V30 5 C -6.5304 2.3411 0.0000 0 CFG=2
M  V30 6 C -7.0607 2.9679 0.0000 0
M  V30 7 C -7.8696 2.8286 0.0000 0
M  V30 8 O -6.0000 2.9679 0.0000 0
M  V30 9 C -6.2786 3.7446 0.0000 0
M  V30 10 C -5.8125 1.9286 0.0000 0
M  V30 11 O -5.1000 2.3411 0.0000 0
M  V30 12 N -5.8125 1.1036 0.0000 0
M  V30 13 C -5.1000 0.6911 0.0000 0 CFG=1
M  V30 14 C -4.3875 1.1036 0.0000 0
M  V30 15 C -5.1000 -0.1339 0.0000 0
M  V30 16 C -4.3875 -0.5464 0.0000 0
M  V30 17 C -4.3875 -1.3714 0.0000 0
M  V30 18 C -5.1000 -1.7839 0.0000 0
M  V30 19 N -5.8125 -1.3714 0.0000 0
M  V30 20 C -5.8125 -0.5464 0.0000 0
M  V30 21 N -5.1000 -2.6089 0.0000 0
M  V30 22 C -5.7696 -3.0964 0.0000 0
M  V30 23 C -5.5125 -3.8786 0.0000 0
M  V30 24 F -5.9946 -4.5482 0.0000 0
M  V30 25 C -4.6875 -3.8786 0.0000 0
M  V30 26 N -4.4304 -3.0964 0.0000 0
M  V30 27 C -8.9679 1.9071 0.0000 0
M  V30 28 N -9.4982 2.5393 0.0000 0
M  V30 29 C -10.3071 2.4000 0.0000 0
M  V30 30 C -10.8375 3.0268 0.0000 0
M  V30 31 C -10.5911 1.6232 0.0000 0
M  V30 32 C -10.0607 0.9911 0.0000 0
M  V30 33 N -10.3446 0.2143 0.0000 0
M  V30 34 C -9.8143 -0.4179 0.0000 0
M  V30 35 C -10.0125 -1.2161 0.0000 0
M  V30 36 C -9.3107 -1.6554 0.0000 0
M  V30 37 C -9.2571 -2.4804 0.0000 0
M  V30 38 N -8.6786 -1.1250 0.0000 0
M  V30 39 N -8.9893 -0.3589 0.0000 0
M  V30 40 N -9.2464 1.1357 0.0000 0
M  V30 41 H -5.1000 1.6911 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8 CFG=3
M  V30 9 1 8 9
M  V30 10 1 5 10 CFG=1
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 13 14 CFG=1
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 15 20
M  V30 22 1 18 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 1 23 25
M  V30 27 2 25 26
M  V30 28 1 21 26
M  V30 29 1 2 27 CFG=3
M  V30 30 2 27 28
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 2 29 31
M  V30 34 1 31 32
M  V30 35 1 32 33
M  V30 36 1 33 34
M  V30 37 1 34 35
M  V30 38 1 35 36
M  V30 39 1 36 37
M  V30 40 2 36 38
M  V30 41 1 38 39
M  V30 42 2 34 39
M  V30 43 2 32 40
M  V30 44 1 27 40
M  V30 45 1 41 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
10

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pralsetinib

>  <Synonyms>
Blu667

>  <CAS>
2097132-94-8

>  <Formula>
C27H32FN9O2

>  <MolWt>
533.6

>  <Pathways>
Apoptosis;Tyrosine Kinase/Adaptors

>  <Target>
c-RET

>  <Receptor>
" RET M918T:0.4 nM, CCDC6-RET:0.4 nM, Wild type RET:0.4 nM, RET V804L:0.3 nM, RET V804M:0.4 nM"

>  <Bioactivity>
"Pralsetinib (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion)."

>  <Reference>
"Subbiah V, et al. Precision Targeted Therapy With BLU-667 for RET-Driven Cancers. American Association for Cancer Research. 10.1158/2159-8290.CD-18-0338."

>  <ID<1>>
TQ0277

$$$$
StarDrop ID 11
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 84 91 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 9.0932 -2.2831 0.0000 0
M  V30 2 C 9.1525 -1.3714 0.0000 0
M  V30 3 N 10.1551 -1.3270 0.0000 0
M  V30 4 C 10.7072 -1.9401 0.0000 0 CFG=1
M  V30 5 C 10.2947 -2.6546 0.0000 0
M  V30 6 C 9.4877 -2.4830 0.0000 0 CFG=1
M  V30 7 O 8.8746 -3.0351 0.0000 0
M  V30 8 C 9.0461 -3.8420 0.0000 0
M  V30 9 N 8.4330 -4.3941 0.0000 0
M  V30 10 C 8.6046 -5.2010 0.0000 0
M  V30 11 C 7.9915 -5.7531 0.0000 0
M  V30 12 N 8.1630 -6.5600 0.0000 0
M  V30 13 O 9.8308 -4.0970 0.0000 0
M  V30 14 C 9.4015 -1.6625 0.0000 0
M  V30 15 C 11.5142 -1.7686 0.0000 0
M  V30 16 O 12.0662 -2.3817 0.0000 0
M  V30 17 N 11.7691 -0.9839 0.0000 0
M  V30 18 C 12.5761 -0.8124 0.0000 0 CFG=2
M  V30 19 C 12.8310 -0.0278 0.0000 0
M  V30 20 O 13.6380 0.1437 0.0000 0
M  V30 21 N 12.2790 0.5853 0.0000 0
M  V30 22 C 12.5339 1.3699 0.0000 0 CFG=2
M  V30 23 C 13.3409 1.5415 0.0000 0
M  V30 24 C 13.5958 2.3261 0.0000 0
M  V30 25 C 14.3804 2.5810 0.0000 0
M  V30 26 C 14.3804 3.4060 0.0000 0
M  V30 27 N 13.5958 3.6610 0.0000 0
M  V30 28 C 13.1109 2.9935 0.0000 0
M  V30 29 C 15.0949 3.8185 0.0000 0
M  V30 30 C 15.8094 3.4060 0.0000 0
M  V30 31 C 15.8094 2.5810 0.0000 0
M  V30 32 C 15.0949 2.1685 0.0000 0
M  V30 33 C 11.9819 1.9830 0.0000 0
M  V30 34 O 12.2368 2.7676 0.0000 0
M  V30 35 N 11.1749 1.8115 0.0000 0
M  V30 36 C 10.6229 2.4246 0.0000 0 CFG=1
M  V30 37 C 10.8778 3.2092 0.0000 0
M  V30 38 C 10.3258 3.8223 0.0000 0
M  V30 39 C 10.5807 4.6069 0.0000 0
M  V30 40 C 10.0287 5.2200 0.0000 0
M  V30 41 N 9.2217 5.0485 0.0000 0
M  V30 42 C 9.8159 2.2531 0.0000 0
M  V30 43 O 9.2639 2.8662 0.0000 0
M  V30 44 N 9.5610 1.4684 0.0000 0
M  V30 45 C 8.7540 1.2969 0.0000 0 CFG=1
M  V30 46 C 8.2020 1.9100 0.0000 0
M  V30 47 C 7.3950 1.7385 0.0000 0
M  V30 48 C 7.1400 0.9539 0.0000 0
M  V30 49 C 6.3331 0.7823 0.0000 0
M  V30 50 C 5.7810 1.3954 0.0000 0
M  V30 51 O 4.9741 1.2239 0.0000 0
M  V30 52 C 4.7191 0.4393 0.0000 0
M  V30 53 C 3.9122 0.2678 0.0000 0
M  V30 54 C 3.6572 -0.5169 0.0000 0
M  V30 55 C 2.8502 -0.6884 0.0000 0
M  V30 56 C 2.2982 -0.0753 0.0000 0
M  V30 57 C 2.5532 0.7093 0.0000 0
M  V30 58 C 3.3601 0.8808 0.0000 0
M  V30 59 C 6.0360 2.1801 0.0000 0
M  V30 60 C 6.8430 2.3516 0.0000 0
M  V30 61 C 8.4990 0.5123 0.0000 0
M  V30 62 O 7.6921 0.3408 0.0000 0
M  V30 63 N 9.0511 -0.1008 0.0000 0
M  V30 64 C 8.7961 -0.8854 0.0000 0 CFG=1
M  V30 65 C 7.9892 -1.0569 0.0000 0
M  V30 66 C 7.7342 -1.8416 0.0000 0
M  V30 67 C 8.2863 -2.4547 0.0000 0
M  V30 68 C 8.0313 -3.2393 0.0000 0
M  V30 69 C 7.2244 -3.4108 0.0000 0
M  V30 70 C 6.6723 -2.7977 0.0000 0
M  V30 71 C 6.9273 -2.0131 0.0000 0
M  V30 72 C 13.1281 -1.4255 0.0000 0
M  V30 73 C 13.9351 -1.2540 0.0000 0
M  V30 74 C 14.4871 -1.8671 0.0000 0
M  V30 75 C 14.2322 -2.6517 0.0000 0
M  V30 76 C 13.4252 -2.8232 0.0000 0
M  V30 77 C 12.8732 -2.2101 0.0000 0
M  V30 78 H 10.9621 -1.1555 0.0000 0
M  V30 79 H 9.7465 -3.4489 0.0000 0
M  V30 80 H 13.5543 -0.6045 0.0000 0
M  V30 81 H 12.8430 2.3209 0.0000 0
M  V30 82 H 9.9537 3.1677 0.0000 0
M  V30 83 H 7.7758 1.0890 0.0000 0
M  V30 84 H 8.2309 -1.7103 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=1
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 8 13
M  V30 13 1 6 14
M  V30 14 1 3 14
M  V30 15 1 4 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 18 17
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 22 21
M  V30 23 1 22 23 CFG=1
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 2 24 28
M  V30 30 2 26 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 31 32
M  V30 34 2 25 32
M  V30 35 1 22 33
M  V30 36 2 33 34
M  V30 37 1 33 35
M  V30 38 1 36 35
M  V30 39 1 36 37 CFG=3
M  V30 40 1 37 38
M  V30 41 1 38 39
M  V30 42 1 39 40
M  V30 43 1 40 41
M  V30 44 1 36 42
M  V30 45 2 42 43
M  V30 46 1 42 44
M  V30 47 1 45 44
M  V30 48 1 45 46 CFG=3
M  V30 49 1 46 47
M  V30 50 2 47 48
M  V30 51 1 48 49
M  V30 52 2 49 50
M  V30 53 1 50 51
M  V30 54 1 51 52
M  V30 55 1 52 53
M  V30 56 2 53 54
M  V30 57 1 54 55
M  V30 58 2 55 56
M  V30 59 1 56 57
M  V30 60 2 57 58
M  V30 61 1 53 58
M  V30 62 1 50 59
M  V30 63 2 59 60
M  V30 64 1 47 60
M  V30 65 1 45 61
M  V30 66 2 61 62
M  V30 67 1 61 63
M  V30 68 1 64 63
M  V30 69 1 64 2
M  V30 70 1 64 65 CFG=3
M  V30 71 1 65 66
M  V30 72 2 66 67
M  V30 73 1 67 68
M  V30 74 2 68 69
M  V30 75 1 69 70
M  V30 76 2 70 71
M  V30 77 1 66 71
M  V30 78 1 18 72 CFG=3
M  V30 79 2 72 73
M  V30 80 1 73 74
M  V30 81 2 74 75
M  V30 82 1 75 76
M  V30 83 2 76 77
M  V30 84 1 72 77
M  V30 85 1 4 78 CFG=1
M  V30 86 1 79 6
M  V30 87 1 80 18
M  V30 88 1 81 22
M  V30 89 1 82 36
M  V30 90 1 83 45
M  V30 91 1 84 64
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
11

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pasireotide Acetate

>  <Synonyms>
N/A

>  <CAS>
396091-76-2

>  <Formula>
C60H70N10O11

>  <MolWt>
1107

>  <Pathways>
GPCR/G Protein

>  <Target>
Somatostatin

>  <Receptor>
Somatostatin Receptor

>  <Bioactivity>
Pasireotide Acetate is a stable cyclohexapeptide somatostatin mimic

>  <Reference>
"Allen P J . Pasireotide for postoperative pancreatic fistula.[J]. New England Journal of Medicine, 2014, 371(9):875.;Coopmans E C , Muhammad A , Van d L A J , et al. How to Position Pasireotide LAR Treatment in Acromegaly[J]. Journal of Clinical Endocrinology & Metabolism, 2019, 104(6):1978-1988."

>  <ID<1>>
TP2207

$$$$
StarDrop ID 12
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 91 95 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.2868 -7.4250 0.0000 0
M  V30 2 O -5.0013 -7.8375 0.0000 0
M  V30 3 C -5.0013 -8.6625 0.0000 0
M  V30 4 O -4.2868 -9.0750 0.0000 0
M  V30 5 C -4.2868 -9.9000 0.0000 0
M  V30 6 C -3.5724 -10.3125 0.0000 0
M  V30 7 O -2.8579 -9.9000 0.0000 0
M  V30 8 S -2.1434 -10.3125 0.0000 0
M  V30 9 O -1.4289 -10.7250 0.0000 0
M  V30 10 O -1.7309 -9.5980 0.0000 0
M  V30 11 O -2.5559 -11.0270 0.0000 0
M  V30 12 C -5.0013 -10.3125 0.0000 0
M  V30 13 O -5.0013 -11.1375 0.0000 0
M  V30 14 C -5.7158 -11.5500 0.0000 0
M  V30 15 O -6.4302 -11.1375 0.0000 0
M  V30 16 C -7.1447 -11.5500 0.0000 0
M  V30 17 C -7.1447 -12.3750 0.0000 0
M  V30 18 O -7.8592 -12.7875 0.0000 0
M  V30 19 C -7.8592 -13.6125 0.0000 0
M  V30 20 O -7.1447 -14.0250 0.0000 0
M  V30 21 C -7.1447 -14.8500 0.0000 0
M  V30 22 C -6.4302 -15.2625 0.0000 0
M  V30 23 O -5.7158 -14.8500 0.0000 0
M  V30 24 S -5.0013 -15.2625 0.0000 0
M  V30 25 O -4.2868 -15.6750 0.0000 0
M  V30 26 O -5.4138 -15.9770 0.0000 0
M  V30 27 O -4.5888 -14.5480 0.0000 0
M  V30 28 C -7.8592 -15.2625 0.0000 0
M  V30 29 O -7.8592 -16.0875 0.0000 0
M  V30 30 C -8.5737 -16.5000 0.0000 0
M  V30 31 O -9.2881 -16.0875 0.0000 0
M  V30 32 C -10.0026 -16.5000 0.0000 0
M  V30 33 C -10.0026 -17.3250 0.0000 0
M  V30 34 O -10.7171 -17.7375 0.0000 0
M  V30 35 C -10.7171 -18.5625 0.0000 0
M  V30 36 O -10.0026 -18.9750 0.0000 0
M  V30 37 C -10.0026 -19.8000 0.0000 0
M  V30 38 C -9.2881 -20.2125 0.0000 0
M  V30 39 O -9.2881 -21.0375 0.0000 0
M  V30 40 S -8.5737 -21.4500 0.0000 0
M  V30 41 O -7.8592 -21.8625 0.0000 0
M  V30 42 O -8.9862 -22.1645 0.0000 0
M  V30 43 O -8.1612 -20.7355 0.0000 0
M  V30 44 C -10.7171 -20.2125 0.0000 0
M  V30 45 O -10.7171 -21.0375 0.0000 0
M  V30 46 C -11.4315 -19.8000 0.0000 0
M  V30 47 O -12.1460 -20.2125 0.0000 0
M  V30 48 C -11.4315 -18.9750 0.0000 0
M  V30 49 N -12.1460 -18.5625 0.0000 0
M  V30 50 S -12.8605 -18.9750 0.0000 0
M  V30 51 O -13.5749 -19.3875 0.0000 0
M  V30 52 O -13.2730 -18.2605 0.0000 0
M  V30 53 O -12.4480 -19.6895 0.0000 0
M  V30 54 C -9.2881 -17.7375 0.0000 0
M  V30 55 O -9.2881 -18.5625 0.0000 0
M  V30 56 C -8.5737 -17.3250 0.0000 0
M  V30 57 O -7.8592 -17.7375 0.0000 0
M  V30 58 C -10.7171 -16.0875 0.0000 0
M  V30 59 O -10.7171 -15.2625 0.0000 0
M  V30 60 O -11.4315 -16.5000 0.0000 0
M  V30 61 C -8.5737 -14.8500 0.0000 0
M  V30 62 O -9.2881 -15.2625 0.0000 0
M  V30 63 S -10.0026 -14.8500 0.0000 0
M  V30 64 O -9.5901 -14.1355 0.0000 0
M  V30 65 O -10.4151 -15.5645 0.0000 0
M  V30 66 O -10.7171 -14.4375 0.0000 0
M  V30 67 C -8.5737 -14.0250 0.0000 0
M  V30 68 N -9.2881 -13.6125 0.0000 0
M  V30 69 S -9.2881 -12.7875 0.0000 0
M  V30 70 O -9.2881 -11.9625 0.0000 0
M  V30 71 O -8.4631 -12.7875 0.0000 0
M  V30 72 O -10.1131 -12.7875 0.0000 0
M  V30 73 C -6.4302 -12.7875 0.0000 0
M  V30 74 O -6.4302 -13.6125 0.0000 0
M  V30 75 C -5.7158 -12.3750 0.0000 0
M  V30 76 O -5.0013 -12.7875 0.0000 0
M  V30 77 S -4.2868 -12.3750 0.0000 0
M  V30 78 O -3.5724 -11.9625 0.0000 0
M  V30 79 O -3.8743 -13.0895 0.0000 0
M  V30 80 O -4.6993 -11.6605 0.0000 0
M  V30 81 C -7.8592 -11.1375 0.0000 0
M  V30 82 O -7.8592 -10.3125 0.0000 0
M  V30 83 O -8.5737 -11.5500 0.0000 0
M  V30 84 C -5.7158 -9.9000 0.0000 0
M  V30 85 O -6.4302 -10.3125 0.0000 0
M  V30 86 C -5.7158 -9.0750 0.0000 0
M  V30 87 N -6.4302 -8.6625 0.0000 0
M  V30 88 S -6.4302 -7.8375 0.0000 0
M  V30 89 O -6.4302 -7.0125 0.0000 0
M  V30 90 O -5.6052 -7.8375 0.0000 0
M  V30 91 O -7.2552 -7.8375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 2 8 11
M  V30 11 1 5 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 2 24 26
M  V30 26 2 24 27
M  V30 27 1 21 28
M  V30 28 1 28 29
M  V30 29 1 29 30
M  V30 30 1 30 31
M  V30 31 1 31 32
M  V30 32 1 32 33
M  V30 33 1 33 34
M  V30 34 1 34 35
M  V30 35 1 35 36
M  V30 36 1 36 37
M  V30 37 1 37 38
M  V30 38 1 38 39
M  V30 39 1 39 40
M  V30 40 1 40 41
M  V30 41 2 40 42
M  V30 42 2 40 43
M  V30 43 1 37 44
M  V30 44 1 44 45
M  V30 45 1 44 46
M  V30 46 1 46 47
M  V30 47 1 46 48
M  V30 48 1 35 48
M  V30 49 1 48 49
M  V30 50 1 49 50
M  V30 51 1 50 51
M  V30 52 2 50 52
M  V30 53 2 50 53
M  V30 54 1 33 54
M  V30 55 1 54 55
M  V30 56 1 54 56
M  V30 57 1 30 56
M  V30 58 1 56 57
M  V30 59 1 32 58
M  V30 60 1 58 59
M  V30 61 2 58 60
M  V30 62 1 28 61
M  V30 63 1 61 62
M  V30 64 1 62 63
M  V30 65 1 63 64
M  V30 66 2 63 65
M  V30 67 2 63 66
M  V30 68 1 61 67
M  V30 69 1 19 67
M  V30 70 1 67 68
M  V30 71 1 68 69
M  V30 72 1 69 70
M  V30 73 2 69 71
M  V30 74 2 69 72
M  V30 75 1 17 73
M  V30 76 1 73 74
M  V30 77 1 73 75
M  V30 78 1 14 75
M  V30 79 1 75 76
M  V30 80 1 76 77
M  V30 81 1 77 78
M  V30 82 2 77 79
M  V30 83 2 77 80
M  V30 84 1 16 81
M  V30 85 1 81 82
M  V30 86 2 81 83
M  V30 87 1 12 84
M  V30 88 1 84 85
M  V30 89 1 84 86
M  V30 90 1 3 86
M  V30 91 1 86 87
M  V30 92 1 87 88
M  V30 93 1 88 89
M  V30 94 2 88 90
M  V30 95 2 88 91
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
12

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fondaparinux sodium

>  <Synonyms>
SR-90107A;Natural heparin pentasaccharide Sodium;Fondaparin sodium;Arixtra

>  <CAS>
114870-03-0

>  <Formula>
C31H43N3Na10O49S8

>  <MolWt>
1728

>  <Pathways>
Metabolism

>  <Target>
Factor Xa

>  <Receptor>
Factor Xa

>  <Bioactivity>
Fondaparinux Sodium is an antithrombin-dependent factor Xa inhibitor with antithrombotic activity.

>  <Reference>
"Bauer KA. et al. Fondaparinux sodium: a selective inhibitor of factor Xa. Am J Health Syst Pharm. 2001 Nov 1;58 Suppl 2:S14-7.;Ben-Hadj-Khalifa S, et al. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation. Blood Coagul Fibrinolysis. 2011 Jul;22(5):369-73."

>  <ID<1>>
T4076

$$$$
StarDrop ID 13
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 83 87 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.4595 -4.9354 0.0000 0
M  V30 2 C 6.7145 -4.1508 0.0000 0 CFG=1
M  V30 3 O 6.1624 -3.5377 0.0000 0
M  V30 4 C 7.5214 -3.9792 0.0000 0 CFG=1
M  V30 5 C 8.0735 -4.5923 0.0000 0
M  V30 6 O 7.8185 -5.3770 0.0000 0
M  V30 7 N 7.7764 -3.1946 0.0000 0
M  V30 8 C 7.2244 -2.5815 0.0000 0 CFG=1
M  V30 9 O 6.4174 -2.7531 0.0000 0
M  V30 10 C 7.4793 -1.7969 0.0000 0
M  V30 11 C 6.6723 -1.9684 0.0000 0
M  V30 12 S 6.1203 -1.3553 0.0000 0
M  V30 13 S 6.3752 -0.5707 0.0000 0
M  V30 14 C 7.1822 -0.3992 0.0000 0
M  V30 15 C 7.4371 0.3854 0.0000 0 CFG=2
M  V30 16 N 6.6302 0.5570 0.0000 0
M  V30 17 C 6.0781 -0.0561 0.0000 0
M  V30 18 O 6.0781 -0.8811 0.0000 0
M  V30 19 C 5.2712 0.1154 0.0000 0 CFG=2
M  V30 20 N 5.0162 0.9000 0.0000 0
M  V30 21 C 4.7191 -0.4977 0.0000 0
M  V30 22 C 3.9122 -0.3262 0.0000 0
M  V30 23 C 3.3601 -0.9393 0.0000 0
M  V30 24 C 2.5532 -0.7677 0.0000 0
M  V30 25 C 2.2982 0.0169 0.0000 0
M  V30 26 C 2.8502 0.6300 0.0000 0
M  V30 27 C 3.6572 0.4584 0.0000 0
M  V30 28 C 8.2441 0.5570 0.0000 0
M  V30 29 O 8.7961 -0.0561 0.0000 0
M  V30 30 N 8.4990 1.3416 0.0000 0
M  V30 31 C 9.3060 1.5131 0.0000 0
M  V30 32 C 8.7540 2.1262 0.0000 0
M  V30 33 C 7.9470 1.9547 0.0000 0
M  V30 34 C 7.6921 1.1700 0.0000 0
M  V30 35 C 6.8851 0.9985 0.0000 0
M  V30 36 C 6.3331 1.6116 0.0000 0
M  V30 37 C 6.5880 2.3962 0.0000 0
M  V30 38 C 7.3950 2.5678 0.0000 0
M  V30 39 C 9.5610 2.2977 0.0000 0
M  V30 40 O 9.0089 2.9108 0.0000 0
M  V30 41 N 10.3679 2.4693 0.0000 0
M  V30 42 C 10.9200 1.8562 0.0000 0 CFG=2
M  V30 43 C 11.7269 2.0277 0.0000 0
M  V30 44 C 11.9819 2.8123 0.0000 0
M  V30 45 C 11.4970 3.4797 0.0000 0
M  V30 46 N 11.9819 4.1472 0.0000 0
M  V30 47 C 12.7665 3.8922 0.0000 0
M  V30 48 C 13.4810 4.3047 0.0000 0
M  V30 49 C 14.1954 3.8922 0.0000 0
M  V30 50 C 14.1954 3.0672 0.0000 0
M  V30 51 C 13.4810 2.6547 0.0000 0
M  V30 52 C 12.7665 3.0672 0.0000 0
M  V30 53 C 10.6650 1.0715 0.0000 0
M  V30 54 O 9.8581 0.9000 0.0000 0
M  V30 55 N 11.2171 0.4584 0.0000 0
M  V30 56 C 10.9621 -0.3262 0.0000 0 CFG=1
M  V30 57 C 11.5142 -0.9393 0.0000 0
M  V30 58 C 12.3211 -0.7677 0.0000 0
M  V30 59 C 12.5761 0.0169 0.0000 0
M  V30 60 C 13.3830 0.1884 0.0000 0
M  V30 61 N 13.9351 -0.4247 0.0000 0
M  V30 62 C 10.1551 -0.4977 0.0000 0
M  V30 63 O 9.6031 0.1154 0.0000 0
M  V30 64 N 9.9002 -1.2823 0.0000 0
M  V30 65 C 9.0932 -1.4539 0.0000 0
M  V30 66 C 9.6453 -2.0670 0.0000 0 CFG=1
M  V30 67 C 9.3903 -2.8516 0.0000 0
M  V30 68 O 10.4522 -1.8954 0.0000 0
M  V30 69 C 8.8383 -2.2385 0.0000 0
M  V30 70 O 8.9245 -3.0590 0.0000 0
M  V30 71 N 8.0313 -2.4100 0.0000 0
M  V30 72 H 11.2289 2.8073 0.0000 0
M  V30 73 H 11.9403 -0.1184 0.0000 0
M  V30 74 H 0.0000 0.0000 0.0000 0
M  V30 75 H 9.9541 -1.1159 0.0000 0
M  V30 76 H 0.0000 0.0000 0.0000 0
M  V30 77 H 7.0233 -3.1997 0.0000 0
M  V30 78 H 8.4996 -3.7714 0.0000 0
M  V30 79 H 6.5711 -0.1146 0.0000 0
M  V30 80 H 5.9402 0.8586 0.0000 0
M  V30 81 H 0.0000 0.0000 0.0000 0
M  V30 82 H 0.0000 0.0000 0.0000 0
M  V30 83 H 0.0000 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3 CFG=1
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 4 7 CFG=3
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10 CFG=1
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 15 14
M  V30 15 1 15 16 CFG=3
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 19 17
M  V30 19 1 19 20 CFG=1
M  V30 20 1 19 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 24 25
M  V30 25 2 25 26
M  V30 26 1 26 27
M  V30 27 2 22 27
M  V30 28 1 15 28
M  V30 29 2 28 29
M  V30 30 1 28 30
M  V30 31 1 30 31 CFG=1
M  V30 32 1 32 31 CFG=3
M  V30 33 1 32 33
M  V30 34 1 33 34
M  V30 35 2 34 35
M  V30 36 1 35 36
M  V30 37 2 36 37
M  V30 38 1 37 38
M  V30 39 2 33 38
M  V30 40 1 31 39
M  V30 41 2 39 40
M  V30 42 1 39 41
M  V30 43 1 42 41
M  V30 44 1 42 43 CFG=3
M  V30 45 1 43 44
M  V30 46 1 44 45
M  V30 47 1 45 46
M  V30 48 2 46 47
M  V30 49 1 47 48
M  V30 50 2 48 49
M  V30 51 1 49 50
M  V30 52 2 50 51
M  V30 53 1 51 52
M  V30 54 2 44 52
M  V30 55 1 47 52
M  V30 56 1 42 53
M  V30 57 2 53 54
M  V30 58 1 53 55
M  V30 59 1 56 55
M  V30 60 1 56 57 CFG=1
M  V30 61 1 57 58
M  V30 62 1 58 59
M  V30 63 1 59 60
M  V30 64 1 60 61
M  V30 65 1 56 62
M  V30 66 2 62 63
M  V30 67 1 62 64
M  V30 68 1 64 65 CFG=1
M  V30 69 1 66 65 CFG=3
M  V30 70 1 66 67
M  V30 71 1 66 68 CFG=3
M  V30 72 1 65 69
M  V30 73 2 69 70
M  V30 74 1 69 71
M  V30 75 1 71 10 CFG=3
M  V30 76 1 72 42
M  V30 77 1 73 56
M  V30 78 1 74 64
M  V30 79 1 75 66
M  V30 80 1 76 71
M  V30 81 1 77 2
M  V30 82 1 78 4
M  V30 83 1 79 15
M  V30 84 1 80 19
M  V30 85 1 81 30
M  V30 86 1 82 32
M  V30 87 1 83 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
13

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Octreotide Acetate

>  <Synonyms>
SMS 201-995 (acetate);Sandostatin;Longastatin;SMS 201995

>  <CAS>
79517-01-4

>  <Formula>
C51H70N10O12S2

>  <MolWt>
1079

>  <Pathways>
GPCR/G Protein

>  <Target>
Somatostatin

>  <Receptor>
Somatostatin Receptor

>  <Bioactivity>
"Octreotide acetate is a potent, long-acting synthetic somatostatin octapeptide analog that inhibits secretion of growth hormone."

>  <Reference>
"Kim S, et al. Treatment of Gastrin-Secreting Tumor With Sustained-Release Octreotide Acetate in a Dog. J Am Anim Hosp Assoc. 2015 Nov-Dec;51(6):407-12.;Wang M, et al. Pharmacokinetic and pharmacodynamic study of a phospholipid-based phase separation gel for once a month administration of octreotide. J Control Release. 2016 May 28;230:45-56."

>  <ID<1>>
T4119

$$$$
StarDrop ID 14
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -3.5724 -2.8875 0.0000 0
M  V30 2 C -2.8579 -2.4750 0.0000 0
M  V30 3 N -2.1434 -2.8875 0.0000 0
M  V30 4 C -2.1434 -3.7125 0.0000 0
M  V30 5 C -2.8579 -4.1250 0.0000 0
M  V30 6 C -1.4289 -2.4750 0.0000 0
M  V30 7 C -0.7145 -2.8875 0.0000 0
M  V30 8 C 0.0000 -2.4750 0.0000 0
M  V30 9 C 0.7145 -2.8875 0.0000 0
M  V30 10 N 1.4289 -2.4750 0.0000 0
M  V30 11 C 1.4289 -1.6500 0.0000 0
M  V30 12 C 0.7145 -1.2375 0.0000 0
M  V30 13 C 0.7145 -0.4125 0.0000 0
M  V30 14 N 1.4289 0.0000 0.0000 0
M  V30 15 C 2.1434 -0.4125 0.0000 0
M  V30 16 C 2.8579 0.0000 0.0000 0
M  V30 17 C 3.5724 -0.4125 0.0000 0
M  V30 18 Cl 4.2868 -0.0000 0.0000 0
M  V30 19 C 3.5724 -1.2375 0.0000 0
M  V30 20 C 2.8579 -1.6500 0.0000 0
M  V30 21 C 2.1434 -1.2375 0.0000 0
M  V30 22 C 0.7145 -3.7125 0.0000 0
M  V30 23 C 0.0000 -4.1250 0.0000 0
M  V30 24 C -0.7145 -3.7125 0.0000 0
M  V30 25 O -1.4289 -4.1250 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 17 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 11 21
M  V30 22 1 15 21
M  V30 23 2 9 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 7 24
M  V30 27 1 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
14

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Amodiaquine

>  <Synonyms>
N/A

>  <CAS>
86-42-0

>  <Formula>
C20H22ClN3O

>  <MolWt>
355.9

>  <Pathways>
Microbiology/Virology;Others;Chromatin/Epigenetic

>  <Target>
Others;Parasite;Histone Methyltransferase

>  <Receptor>
 Nurr1-LBD (ligand binding domain):20 ??M (EC50)

>  <Bioactivity>
"Amodiaquine is a synthetic aminoquinoline, used to treat malaria."

>  <Reference>
"Yasuteru Sakurai , Norikazu Sakakibara , Masaaki Toyama,et al.Novel Amodiaquine Derivatives Potently Inhibit Ebola Virus Infection.Antiviral Res. 2018 Dec;160:175-182.;Keita, Kinoshita, Kosei,et al. A Nurr1 agonist amodiaquine attenuates inflammatory events and neurological deficits in a mouse model of intracerebral hemorrhage.[J]. Journal of Neuroimmunology, 2019."

>  <ID<1>>
T8381

$$$$
StarDrop ID 15
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 122 127 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 14.8999 5.5393 0.0000 0
M  V30 2 C 14.8428 4.7163 0.0000 0
M  V30 3 N 15.5271 4.2554 0.0000 0
M  V30 4 C 15.4701 3.4324 0.0000 0
M  V30 5 N 14.7288 3.0702 0.0000 0
M  V30 6 C 14.6718 2.2472 0.0000 0
M  V30 7 C 13.9305 1.8851 0.0000 0
M  V30 8 N 16.1543 2.9715 0.0000 0
M  V30 9 C 16.0973 2.1484 0.0000 0
M  V30 10 C 16.7815 1.6875 0.0000 0
M  V30 11 C 16.7245 0.8645 0.0000 0
M  V30 12 C 17.4088 0.4036 0.0000 0
M  V30 13 C 17.3518 -0.4194 0.0000 0 CFG=1
M  V30 14 N 16.6105 -0.7815 0.0000 0
M  V30 15 C 15.9262 -0.3206 0.0000 0
M  V30 16 O 15.9833 0.5024 0.0000 0
M  V30 17 C 15.1850 -0.6828 0.0000 0 CFG=2
M  V30 18 C 15.1279 -1.5058 0.0000 0
M  V30 19 C 15.8122 -1.9667 0.0000 0
M  V30 20 C 16.5535 -1.6046 0.0000 0
M  V30 21 C 17.2377 -2.0655 0.0000 0
M  V30 22 C 17.1807 -2.8885 0.0000 0
M  V30 23 O 17.8649 -3.3494 0.0000 0
M  V30 24 C 16.4394 -3.2506 0.0000 0
M  V30 25 C 15.7552 -2.7897 0.0000 0
M  V30 26 N 14.5007 -0.2219 0.0000 0
M  V30 27 C 13.7594 -0.5840 0.0000 0
M  V30 28 O 13.7024 -1.4070 0.0000 0
M  V30 29 C 13.0752 -0.1231 0.0000 0 CFG=2
M  V30 30 C 13.1322 0.6999 0.0000 0
M  V30 31 O 13.8735 1.0620 0.0000 0
M  V30 32 N 12.3339 -0.4852 0.0000 0
M  V30 33 C 11.6497 -0.0244 0.0000 0
M  V30 34 O 11.7067 0.7987 0.0000 0
M  V30 35 C 10.9084 -0.3865 0.0000 0 CFG=1
M  V30 36 C 10.8514 -1.2095 0.0000 0
M  V30 37 C 11.5356 -1.6704 0.0000 0
M  V30 38 C 12.2769 -1.3083 0.0000 0
M  V30 39 C 12.9611 -1.7692 0.0000 0
M  V30 40 C 12.9041 -2.5922 0.0000 0
M  V30 41 N 12.1628 -2.9543 0.0000 0
M  V30 42 C 11.4786 -2.4934 0.0000 0
M  V30 43 N 10.2241 0.0744 0.0000 0
M  V30 44 C 9.4829 -0.2877 0.0000 0
M  V30 45 O 9.4258 -1.1107 0.0000 0
M  V30 46 C 8.7986 0.1732 0.0000 0 CFG=1
M  V30 47 C 8.8556 0.9962 0.0000 0
M  V30 48 C 9.5969 1.3583 0.0000 0
M  V30 49 C 9.6539 2.1814 0.0000 0
M  V30 50 C 10.3952 2.5435 0.0000 0
M  V30 51 C 11.0794 2.0826 0.0000 0
M  V30 52 Cl 11.8207 2.4447 0.0000 0
M  V30 53 C 11.0224 1.2596 0.0000 0
M  V30 54 C 10.2812 0.8974 0.0000 0
M  V30 55 N 8.0573 -0.1890 0.0000 0
M  V30 56 C 7.3731 0.2719 0.0000 0
M  V30 57 O 7.4301 1.0950 0.0000 0
M  V30 58 C 6.6318 -0.0902 0.0000 0 CFG=1
M  V30 59 C 5.9476 0.3707 0.0000 0
M  V30 60 C 5.2063 0.0086 0.0000 0
M  V30 61 C 5.1493 -0.8145 0.0000 0
M  V30 62 C 4.4080 -1.1766 0.0000 0
M  V30 63 C 3.7237 -0.7157 0.0000 0
M  V30 64 C 2.9825 -1.0778 0.0000 0
M  V30 65 C 2.2982 -0.6169 0.0000 0
M  V30 66 C 2.3552 0.2061 0.0000 0
M  V30 67 C 3.0965 0.5682 0.0000 0
M  V30 68 C 3.7808 0.1073 0.0000 0
M  V30 69 C 4.5220 0.4695 0.0000 0
M  V30 70 N 6.5748 -0.9132 0.0000 0
M  V30 71 C 7.2590 -1.3741 0.0000 0
M  V30 72 C 7.2020 -2.1971 0.0000 0
M  V30 73 O 8.0003 -1.0120 0.0000 0
M  V30 74 C 18.0360 -0.8803 0.0000 0
M  V30 75 O 17.9790 -1.7033 0.0000 0
M  V30 76 N 18.7773 -0.5182 0.0000 0
M  V30 77 C 19.4615 -0.9791 0.0000 0 CFG=1
M  V30 78 C 19.4045 -1.8021 0.0000 0
M  V30 79 C 20.0888 -2.2630 0.0000 0
M  V30 80 C 20.8300 -1.9009 0.0000 0
M  V30 81 C 20.0317 -3.0860 0.0000 0
M  V30 82 C 20.2028 -0.6169 0.0000 0
M  V30 83 O 20.2598 0.2061 0.0000 0
M  V30 84 N 20.8871 -1.0778 0.0000 0
M  V30 85 C 21.6283 -0.7157 0.0000 0 CFG=1
M  V30 86 C 22.3126 -1.1766 0.0000 0
M  V30 87 C 23.0539 -0.8145 0.0000 0
M  V30 88 C 23.7381 -1.2754 0.0000 0
M  V30 89 C 24.4794 -0.9132 0.0000 0
M  V30 90 N 25.1636 -1.3741 0.0000 0
M  V30 91 C 25.9049 -1.0120 0.0000 0
M  V30 92 N 25.9619 -0.1890 0.0000 0
M  V30 93 C 26.7032 0.1732 0.0000 0
M  V30 94 C 26.7602 0.9962 0.0000 0
M  V30 95 N 26.5892 -1.4729 0.0000 0
M  V30 96 C 27.3304 -1.1107 0.0000 0
M  V30 97 C 28.0147 -1.5716 0.0000 0
M  V30 98 C 21.6854 0.1073 0.0000 0
M  V30 99 O 21.0011 0.5682 0.0000 0
M  V30 100 N 22.4266 0.4695 0.0000 0
M  V30 101 C 23.1553 0.0826 0.0000 0
M  V30 102 C 23.7484 0.6561 0.0000 0
M  V30 103 C 23.3863 1.3974 0.0000 0
M  V30 104 C 22.5694 1.2820 0.0000 0 CFG=1
M  V30 105 C 21.9959 1.8751 0.0000 0
M  V30 106 O 22.2228 2.6683 0.0000 0
M  V30 107 N 21.1955 1.6750 0.0000 0
M  V30 108 C 20.6220 2.2681 0.0000 0 CFG=2
M  V30 109 C 20.8489 3.0613 0.0000 0
M  V30 110 C 19.8217 2.0680 0.0000 0
M  V30 111 N 19.5948 1.2748 0.0000 0
M  V30 112 O 19.2482 2.6611 0.0000 0
M  V30 113 H 21.6132 0.9891 0.0000 0
M  V30 114 H 19.9269 2.9870 0.0000 0
M  V30 115 H 16.5224 0.1392 0.0000 0
M  V30 116 H 14.2864 -1.1217 0.0000 0
M  V30 117 H 12.2458 0.4355 0.0000 0
M  V30 118 H 10.0099 -0.8254 0.0000 0
M  V30 119 H 7.9691 0.7318 0.0000 0
M  V30 120 H 7.4612 -0.6488 0.0000 0
M  V30 121 H 18.5630 -1.4181 0.0000 0
M  V30 122 H 20.7990 -0.1569 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 4 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=3
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 17 15
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 1 22 24
M  V30 24 2 24 25
M  V30 25 1 19 25
M  V30 26 1 17 26 CFG=3
M  V30 27 1 26 27
M  V30 28 2 27 28
M  V30 29 1 29 27
M  V30 30 1 29 30
M  V30 31 1 30 31
M  V30 32 1 29 32 CFG=1
M  V30 33 1 32 33
M  V30 34 2 33 34
M  V30 35 1 35 33
M  V30 36 1 35 36
M  V30 37 1 36 37
M  V30 38 2 37 38
M  V30 39 1 38 39
M  V30 40 2 39 40
M  V30 41 1 40 41
M  V30 42 2 41 42
M  V30 43 1 37 42
M  V30 44 1 35 43 CFG=1
M  V30 45 1 43 44
M  V30 46 2 44 45
M  V30 47 1 46 44
M  V30 48 1 46 47
M  V30 49 1 47 48
M  V30 50 2 48 49
M  V30 51 1 49 50
M  V30 52 2 50 51
M  V30 53 1 51 52
M  V30 54 1 51 53
M  V30 55 2 53 54
M  V30 56 1 48 54
M  V30 57 1 46 55 CFG=3
M  V30 58 1 55 56
M  V30 59 2 56 57
M  V30 60 1 58 56
M  V30 61 1 58 59
M  V30 62 1 59 60
M  V30 63 2 60 61
M  V30 64 1 61 62
M  V30 65 2 62 63
M  V30 66 1 63 64
M  V30 67 2 64 65
M  V30 68 1 65 66
M  V30 69 2 66 67
M  V30 70 1 67 68
M  V30 71 1 63 68
M  V30 72 2 68 69
M  V30 73 1 60 69
M  V30 74 1 58 70 CFG=3
M  V30 75 1 70 71
M  V30 76 1 71 72
M  V30 77 2 71 73
M  V30 78 1 13 74
M  V30 79 2 74 75
M  V30 80 1 74 76
M  V30 81 1 77 76 CFG=3
M  V30 82 1 77 78
M  V30 83 1 78 79
M  V30 84 1 79 80
M  V30 85 1 79 81
M  V30 86 1 77 82
M  V30 87 2 82 83
M  V30 88 1 82 84
M  V30 89 1 85 84 CFG=3
M  V30 90 1 85 86
M  V30 91 1 86 87
M  V30 92 1 87 88
M  V30 93 1 88 89
M  V30 94 1 89 90
M  V30 95 2 90 91
M  V30 96 1 91 92
M  V30 97 1 92 93
M  V30 98 1 93 94
M  V30 99 1 91 95
M  V30 100 1 95 96
M  V30 101 1 96 97
M  V30 102 1 85 98
M  V30 103 2 98 99
M  V30 104 1 98 100
M  V30 105 1 100 101
M  V30 106 1 101 102
M  V30 107 1 102 103
M  V30 108 1 104 103
M  V30 109 1 104 100
M  V30 110 1 104 105 CFG=3
M  V30 111 2 105 106
M  V30 112 1 105 107
M  V30 113 1 108 107
M  V30 114 1 108 109 CFG=1
M  V30 115 1 108 110
M  V30 116 1 110 111
M  V30 117 2 110 112
M  V30 118 1 113 104
M  V30 119 1 114 108
M  V30 120 1 115 13
M  V30 121 1 116 17
M  V30 122 1 117 29
M  V30 123 1 118 35
M  V30 124 1 119 46
M  V30 125 1 120 58
M  V30 126 1 121 77
M  V30 127 1 122 85
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
15

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ganirelix Acetate

>  <Synonyms>
N/A

>  <CAS>
123246-29-7

>  <Formula>
C82H117ClN18O15

>  <MolWt>
1630

>  <Pathways>
GPCR/G Protein

>  <Target>
GNRH Receptor

>  <Receptor>
GnRHR

>  <Bioactivity>
Ganirelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist

>  <Reference>
"Rabasseda X ,  Leeson P , J Casta?er. Ganirelix acetate.[J]. Drugs of the Future, 1999, 24(4)."

>  <ID<1>>
TP2337

$$$$
StarDrop ID 16
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 43 47 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.2203 -2.7899 0.0000 0
M  V30 2 C 7.4338 -1.9930 0.0000 0
M  V30 3 O 6.8505 -1.4096 0.0000 0
M  V30 4 N 7.0640 -0.6127 0.0000 0
M  V30 5 C 6.4806 -0.0294 0.0000 0
M  V30 6 C 6.6942 0.7675 0.0000 0
M  V30 7 O 6.1108 1.3509 0.0000 0
M  V30 8 N 7.4911 0.9810 0.0000 0
M  V30 9 C 8.0744 0.3977 0.0000 0
M  V30 10 C 8.8994 0.3977 0.0000 0
M  V30 11 S 9.6139 0.8102 0.0000 0
M  V30 12 C 10.3284 0.3977 0.0000 0
M  V30 13 C 10.3284 -0.4273 0.0000 0
M  V30 14 S 11.0428 -0.8398 0.0000 0
M  V30 15 C 11.7573 -0.4273 0.0000 0
M  V30 16 N 11.8435 0.3932 0.0000 0
M  V30 17 C 12.6505 0.5647 0.0000 0
M  V30 18 C 13.0630 -0.1498 0.0000 0
M  V30 19 S 12.5110 -0.7629 0.0000 0
M  V30 20 C 12.9861 1.3184 0.0000 0
M  V30 21 C 12.5012 1.9858 0.0000 0
M  V30 22 C 12.8367 2.7395 0.0000 0
M  V30 23 N 13.6572 2.8257 0.0000 0 CHG=1
M  V30 24 C 13.9927 3.5794 0.0000 0
M  V30 25 C 14.1421 2.1583 0.0000 0
M  V30 26 C 13.8066 1.4046 0.0000 0
M  V30 27 C 9.6139 -0.8398 0.0000 0
M  V30 28 N 8.8994 -0.4273 0.0000 0
M  V30 29 C 8.0744 -0.4273 0.0000 0
M  V30 30 O 7.4911 -1.0107 0.0000 0
M  V30 31 C 9.6139 -1.6648 0.0000 0
M  V30 32 O 8.8994 -2.0773 0.0000 0
M  V30 33 O 10.3284 -2.0773 0.0000 0
M  V30 34 C 5.6838 -0.2429 0.0000 0
M  V30 35 N 5.3881 -1.0131 0.0000 0
M  V30 36 S 4.5642 -0.9699 0.0000 0
M  V30 37 C 4.3507 -0.1730 0.0000 0
M  V30 38 N 3.5805 0.1226 0.0000 0
M  V30 39 P 2.9394 -0.3966 0.0000 0
M  V30 40 O 2.2982 -0.9158 0.0000 0
M  V30 41 O 2.4202 0.2446 0.0000 0
M  V30 42 O 3.4585 -1.0377 0.0000 0
M  V30 43 N 5.0426 0.2763 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 1 15 19
M  V30 20 1 17 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 1 23 25
M  V30 26 2 25 26
M  V30 27 1 20 26
M  V30 28 2 13 27
M  V30 29 1 27 28
M  V30 30 1 10 28
M  V30 31 1 28 29
M  V30 32 1 9 29
M  V30 33 2 29 30
M  V30 34 1 27 31
M  V30 35 1 31 32
M  V30 36 2 31 33
M  V30 37 1 5 34
M  V30 38 2 34 35
M  V30 39 1 35 36
M  V30 40 1 36 37
M  V30 41 1 37 38
M  V30 42 1 38 39
M  V30 43 1 39 40
M  V30 44 1 39 41
M  V30 45 2 39 42
M  V30 46 2 37 43
M  V30 47 1 34 43
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
16

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ceftaroline fosamil

>  <Synonyms>
TAK-599;PPI0903

>  <CAS>
400827-46-5

>  <Formula>
C24H25N8O10PS4

>  <MolWt>
744.7

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
"Ceftaroline fosamil is a cephalosporin, with activity against Gram-positive pathogens."

>  <Reference>
"So W, et al. Comparison of in vivo and in vitro pharmacodynamics of a humanized regimen of 600 milligrams of Ceftaroline Fosamil every 12 hours against Staphylococcus aureus at initial inocula of 106 and 108 CFU per milliliter. Antimicrob Agents Chemother. 2014 Nov;58(11):6931-3.;Zhong, Nan Shan, Sun, Tieying, Zhuo, Chao,et,al. Ceftaroline fosamil versus ceftriaxone for the treatment of Asian patients with community-acquired pneumonia: a randomised, controlled, double-blind, phase 3, non-inferiority with nested superiority trial[J]. Lancet Infectious Diseases, 2015, 15(2):161-171."

>  <ID<1>>
T7387

$$$$
StarDrop ID 17
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 119 119 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -5.1303 9.5204 0.0000 0
M  V30 2 C -4.4159 9.9329 0.0000 0
M  V30 3 C -3.7014 9.5204 0.0000 0 CFG=2
M  V30 4 C -3.7014 8.6954 0.0000 0
M  V30 5 C -2.9869 9.9329 0.0000 0
M  V30 6 C -2.2724 9.5204 0.0000 0
M  V30 7 C -1.5580 9.9329 0.0000 0
M  V30 8 C -0.8435 9.5204 0.0000 0
M  V30 9 C -0.1290 9.9329 0.0000 0
M  V30 10 O -0.1290 10.7579 0.0000 0
M  V30 11 N 0.5854 9.5204 0.0000 0
M  V30 12 C 1.2999 9.9329 0.0000 0 CFG=1
M  V30 13 C 1.2999 10.7579 0.0000 0
M  V30 14 C 2.0144 11.1704 0.0000 0
M  V30 15 N 2.0144 11.9954 0.0000 0
M  V30 16 C 1.2999 12.4079 0.0000 0
M  V30 17 S 1.2999 13.2329 0.0000 0
M  V30 18 O 2.1249 13.2329 0.0000 0
M  V30 19 O 0.4749 13.2329 0.0000 0
M  V30 20 O 1.2999 14.0579 0.0000 0
M  V30 21 C 2.0144 9.5204 0.0000 0
M  V30 22 O 2.0144 8.6954 0.0000 0
M  V30 23 N 2.7289 9.9329 0.0000 0
M  V30 24 C 3.4433 9.5204 0.0000 0 CFG=1
M  V30 25 C 3.4433 8.6954 0.0000 0 CFG=1
M  V30 26 C 2.7289 8.2829 0.0000 0
M  V30 27 O 4.1578 8.2829 0.0000 0
M  V30 28 C 4.1578 9.9329 0.0000 0
M  V30 29 O 4.1578 10.7579 0.0000 0
M  V30 30 N 4.8723 9.5204 0.0000 0
M  V30 31 C 5.5867 9.9329 0.0000 0 CFG=1
M  V30 32 C 5.5867 10.7579 0.0000 0
M  V30 33 C 4.8723 11.1704 0.0000 0
M  V30 34 N 4.8723 11.9954 0.0000 0
M  V30 35 C 4.1578 12.4079 0.0000 0
M  V30 36 S 3.4433 11.9954 0.0000 0
M  V30 37 O 3.8558 11.2809 0.0000 0
M  V30 38 O 2.7289 11.5829 0.0000 0
M  V30 39 O 3.0308 12.7099 0.0000 0
M  V30 40 C 6.3012 9.5204 0.0000 0
M  V30 41 O 6.3012 8.6954 0.0000 0
M  V30 42 N 7.0157 9.9329 0.0000 0
M  V30 43 C 7.0157 10.7579 0.0000 0
M  V30 44 C 6.2392 10.4790 0.0000 0
M  V30 45 C 5.7341 11.1313 0.0000 0
M  V30 46 N 6.1984 11.8133 0.0000 0
M  V30 47 C 6.1155 12.7123 0.0000 0
M  V30 48 O 5.3588 13.0411 0.0000 0
M  V30 49 C 6.7678 13.2174 0.0000 0
M  V30 50 N 6.6564 14.0349 0.0000 0
M  V30 51 C 7.3087 14.5400 0.0000 0
M  V30 52 O 8.0723 14.2277 0.0000 0
M  V30 53 C 7.1974 15.3575 0.0000 0 CFG=2
M  V30 54 C 6.4338 15.6698 0.0000 0
M  V30 55 C 6.3224 16.4872 0.0000 0
M  V30 56 N 5.5588 16.7995 0.0000 0
M  V30 57 C 5.4475 17.6170 0.0000 0
M  V30 58 S 4.6839 17.9293 0.0000 0
M  V30 59 O 4.9962 18.6929 0.0000 0
M  V30 60 O 4.3716 17.1657 0.0000 0
M  V30 61 O 3.9203 18.2416 0.0000 0
M  V30 62 N 7.8496 15.8626 0.0000 0
M  V30 63 C 7.7383 16.6800 0.0000 0
M  V30 64 O 6.9747 16.9924 0.0000 0
M  V30 65 C 8.3906 17.1852 0.0000 0 CFG=2
M  V30 66 C 8.2792 18.0026 0.0000 0
M  V30 67 C 8.9315 18.5078 0.0000 0
M  V30 68 N 8.8202 19.3252 0.0000 0
M  V30 69 N 9.1542 16.8729 0.0000 0
M  V30 70 C 9.2655 16.0554 0.0000 0
M  V30 71 O 8.6132 15.5503 0.0000 0
M  V30 72 C 10.0291 15.7431 0.0000 0 CFG=2
M  V30 73 C 10.6814 16.2483 0.0000 0
M  V30 74 C 11.4450 15.9359 0.0000 0
M  V30 75 C 12.0973 16.4411 0.0000 0
M  V30 76 C 11.5563 15.1185 0.0000 0
M  V30 77 N 10.1404 14.9257 0.0000 0
M  V30 78 C 9.4882 14.4205 0.0000 0
M  V30 79 O 8.7246 14.7328 0.0000 0
M  V30 80 C 9.5995 13.6031 0.0000 0 CFG=1
M  V30 81 C 10.3631 13.2907 0.0000 0
M  V30 82 C 11.0154 13.7959 0.0000 0
M  V30 83 C 10.9040 14.6133 0.0000 0
M  V30 84 C 11.7790 13.4836 0.0000 0
M  V30 85 N 8.9472 13.0979 0.0000 0
M  V30 86 C 9.0586 12.2805 0.0000 0
M  V30 87 O 9.8222 11.9682 0.0000 0
M  V30 88 C 8.4063 11.7753 0.0000 0
M  V30 89 C 9.1699 11.4630 0.0000 0
M  V30 90 C 9.2812 10.6456 0.0000 0
M  V30 91 N 10.0448 10.3332 0.0000 0
M  V30 92 C 10.1561 9.5158 0.0000 0
M  V30 93 S 10.9197 9.2035 0.0000 0
M  V30 94 O 11.2321 9.9671 0.0000 0
M  V30 95 O 11.6833 8.8912 0.0000 0
M  V30 96 O 10.6074 8.4399 0.0000 0
M  V30 97 N 8.5176 10.9579 0.0000 0
M  V30 98 C 7.8653 10.4527 0.0000 0
M  V30 99 O 7.9944 9.6379 0.0000 0
M  V30 100 C 6.0042 13.5297 0.0000 0 CFG=1
M  V30 101 C 5.1795 13.5044 0.0000 0
M  V30 102 O 5.8928 14.3472 0.0000 0
M  V30 103 H -2.8354 9.0204 0.0000 0
M  V30 104 H 0.4339 10.4329 0.0000 0
M  V30 105 H 3.4434 10.5204 0.0000 0
M  V30 106 H 3.4434 7.6954 0.0000 0
M  V30 107 H 5.5868 8.9329 0.0000 0
M  V30 108 H 7.4650 17.5636 0.0000 0
M  V30 109 H 10.9547 15.3647 0.0000 0
M  V30 110 H 10.3902 14.2153 0.0000 0
M  V30 111 H 0.0000 0.0000 0.0000 0
M  V30 112 H 0.0000 0.0000 0.0000 0
M  V30 113 H 0.0000 0.0000 0.0000 0
M  V30 114 H 5.2409 14.1757 0.0000 0
M  V30 115 H 0.0000 0.0000 0.0000 0
M  V30 116 H 0.0000 0.0000 0.0000 0
M  V30 117 H 0.0000 0.0000 0.0000 0
M  V30 118 H 0.0000 0.0000 0.0000 0
M  V30 119 H 7.0624 16.3483 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=1
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 12 11 CFG=1
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 17 19
M  V30 19 2 17 20
M  V30 20 1 12 21
M  V30 21 2 21 22
M  V30 22 1 21 23
M  V30 23 1 24 23 CFG=3
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 1 25 27 CFG=3
M  V30 27 1 24 28
M  V30 28 2 28 29
M  V30 29 1 28 30
M  V30 30 1 31 30 CFG=1
M  V30 31 1 31 32
M  V30 32 1 32 33
M  V30 33 1 33 34
M  V30 34 1 34 35
M  V30 35 1 35 36
M  V30 36 1 36 37
M  V30 37 2 36 38
M  V30 38 2 36 39
M  V30 39 1 31 40
M  V30 40 2 40 41
M  V30 41 1 40 42
M  V30 42 1 42 43 CFG=3
M  V30 43 1 44 43 CFG=1
M  V30 44 1 44 45
M  V30 45 1 45 46
M  V30 46 1 46 47
M  V30 47 2 47 48
M  V30 48 1 49 47
M  V30 49 1 50 49 CFG=3
M  V30 50 1 50 51
M  V30 51 2 51 52
M  V30 52 1 53 51
M  V30 53 1 53 54 CFG=3
M  V30 54 1 54 55
M  V30 55 1 55 56
M  V30 56 1 56 57
M  V30 57 1 57 58
M  V30 58 1 58 59
M  V30 59 2 58 60
M  V30 60 2 58 61
M  V30 61 1 53 62
M  V30 62 1 62 63
M  V30 63 2 63 64
M  V30 64 1 65 63
M  V30 65 1 65 66 CFG=3
M  V30 66 1 66 67
M  V30 67 1 67 68
M  V30 68 1 65 69
M  V30 69 1 69 70
M  V30 70 2 70 71
M  V30 71 1 72 70
M  V30 72 1 72 73 CFG=3
M  V30 73 1 73 74
M  V30 74 1 74 75
M  V30 75 1 74 76
M  V30 76 1 72 77
M  V30 77 1 77 78
M  V30 78 2 78 79
M  V30 79 1 80 78
M  V30 80 1 80 81 CFG=1
M  V30 81 1 81 82
M  V30 82 1 82 83
M  V30 83 1 82 84
M  V30 84 1 80 85
M  V30 85 1 85 86
M  V30 86 2 86 87
M  V30 87 1 88 86
M  V30 88 1 89 88 CFG=1
M  V30 89 1 89 90
M  V30 90 1 90 91
M  V30 91 1 91 92
M  V30 92 1 92 93
M  V30 93 1 93 94
M  V30 94 2 93 95
M  V30 95 2 93 96
M  V30 96 1 97 88 CFG=3
M  V30 97 1 97 98
M  V30 98 1 43 98
M  V30 99 2 98 99
M  V30 100 1 100 49 CFG=1
M  V30 101 1 100 101
M  V30 102 1 100 102 CFG=1
M  V30 103 1 103 3
M  V30 104 1 104 12
M  V30 105 1 105 24
M  V30 106 1 106 25
M  V30 107 1 107 31
M  V30 108 1 108 65
M  V30 109 1 109 72
M  V30 110 1 110 80
M  V30 111 1 111 89
M  V30 112 1 112 89
M  V30 113 1 113 97
M  V30 114 1 114 100
M  V30 115 1 115 42
M  V30 116 1 116 44
M  V30 117 1 117 44
M  V30 118 1 118 50
M  V30 119 1 119 53
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
17

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Colistimethate Sodium

>  <Synonyms>
Colistin-1,3,5,9-tetramethanesulfonic A acid

>  <CAS>
30387-39-4

>  <Formula>
C57H108N16O25S4

>  <MolWt>
1546

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Colistimethate Sodium is used for the treatment of serious infections due to selected aerobic Gram-negative pathogens in patients with limited treatment options.

>  <Reference>
"Wilkinson RE, et al. Outcome analysis of colistin-treated burn center patients. Burns. 2017 Apr 11."

>  <ID<1>>
T3501

$$$$
StarDrop ID 18
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -1.0396 -1.0396 0.0000 0
M  V30 2 C -0.7846 -0.2549 0.0000 0
M  V30 3 C -0.0000 -0.0000 0.0000 0 CFG=1
M  V30 4 C 0.0000 0.8250 0.0000 0 CFG=2
M  V30 5 C 0.7145 1.2375 0.0000 0 CFG=2
M  V30 6 C 1.4289 0.8250 0.0000 0 CFG=2
M  V30 7 C 1.4289 -0.0000 0.0000 0 CFG=2
M  V30 8 C 0.7145 -0.4125 0.0000 0 CFG=1
M  V30 9 C 0.8520 0.1375 0.0000 0
M  V30 10 C 0.8520 0.6875 0.0000 0
M  V30 11 H 1.1081 -1.1375 0.0000 0
M  V30 12 C 2.1434 0.4125 0.0000 0
M  V30 13 H 1.1081 1.9625 0.0000 0
M  V30 14 C -0.7846 1.0799 0.0000 0
M  V30 15 O -1.0396 1.8646 0.0000 0
M  V30 16 N -1.2695 0.4125 0.0000 0
M  V30 17 N -2.0945 0.4125 0.0000 0
M  V30 18 C -2.5070 -0.3020 0.0000 0
M  V30 19 O -2.0945 -1.0164 0.0000 0
M  V30 20 C -3.3320 -0.3020 0.0000 0
M  V30 21 C -3.7445 -1.0164 0.0000 0
M  V30 22 C -4.5695 -1.0164 0.0000 0
M  V30 23 C -4.9820 -0.3020 0.0000 0
M  V30 24 C -5.8070 -0.3020 0.0000 0
M  V30 25 F -6.6320 -0.3020 0.0000 0
M  V30 26 F -5.8070 0.5230 0.0000 0
M  V30 27 F -5.8070 -1.1270 0.0000 0
M  V30 28 C -4.5695 0.4125 0.0000 0
M  V30 29 C -3.7445 0.4125 0.0000 0
M  V30 30 H -0.0862 1.6455 0.0000 0
M  V30 31 H -0.0862 -0.8205 0.0000 0
M  V30 32 H 2.4289 0.8247 0.0000 0
M  V30 33 H 2.4289 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 8 7
M  V30 8 1 3 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 5 10
M  V30 12 1 8 11 CFG=1
M  V30 13 1 7 12 CFG=1
M  V30 14 1 6 12 CFG=1
M  V30 15 1 5 13 CFG=1
M  V30 16 1 4 14
M  V30 17 2 14 15
M  V30 18 1 14 16
M  V30 19 1 2 16
M  V30 20 1 16 17
M  V30 21 1 17 18
M  V30 22 2 18 19
M  V30 23 1 18 20
M  V30 24 2 20 21
M  V30 25 1 21 22
M  V30 26 2 22 23
M  V30 27 1 23 24
M  V30 28 1 24 25
M  V30 29 1 24 26
M  V30 30 1 24 27
M  V30 31 1 23 28
M  V30 32 2 28 29
M  V30 33 1 20 29
M  V30 34 1 4 30 CFG=3
M  V30 35 1 3 31 CFG=3
M  V30 36 1 32 6
M  V30 37 1 33 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
18

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tecovirimat

>  <Synonyms>
ST-246

>  <CAS>
869572-92-9

>  <Formula>
C19H15F3N2O3

>  <MolWt>
376.3

>  <Pathways>
Proteases/Proteasome

>  <Target>
Cysteine Protease

>  <Receptor>
Cysteine protease

>  <Bioactivity>
Tecovirimat is a core protein cysteine protease inhibitor potentially for treatment of smallpox infection.Tecovirimat is a novel antiviral potent and selective activity against multiple orthopoxviruses (EC50: about 10 nM). that inhibits the egress of orthopoxviruses by targeting viral p37 protein orthologs.Tecovirimat has shown efficacy in all small animal and nonhuman primate prophylaxis and therapeutic efficacy models of poxvirus-induced disease tested to date.

>  <Reference>
"Yang G, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J Virol. 2005 Oct;79(20):13139-49. ;Quenelle DC, et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother. 2007 Feb;51(2):689-95."

>  <ID<1>>
T17026

$$$$
StarDrop ID 19
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 133 134 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -3.2493 -0.7536 0.0000 0
M  V30 2 C -2.4284 -0.6714 0.0000 0
M  V30 3 C -2.0892 0.0806 0.0000 0
M  V30 4 C -1.9468 -1.3412 0.0000 0
M  V30 5 C -1.1259 -1.2590 0.0000 0 CFG=2
M  V30 6 N -0.6443 -1.9289 0.0000 0
M  V30 7 C 0.1766 -1.8467 0.0000 0
M  V30 8 O 0.6582 -2.5165 0.0000 0
M  V30 9 C 0.5159 -1.0947 0.0000 0 CFG=2
M  V30 10 C -0.1124 -0.4889 0.0000 0
M  V30 11 S 0.0801 0.3504 0.0000 0
M  V30 12 S 1.0146 0.5575 0.0000 0
M  V30 13 C 1.6520 -0.0070 0.0000 0
M  V30 14 C 1.0851 -0.6589 0.0000 0 CFG=2
M  V30 15 N 0.6678 0.1092 0.0000 0
M  V30 16 C 0.5561 1.0427 0.0000 0
M  V30 17 O -0.2389 1.2632 0.0000 0
M  V30 18 C 1.0814 1.7191 0.0000 0 CFG=2
M  V30 19 C 0.6232 2.4051 0.0000 0
M  V30 20 C 0.9881 3.1450 0.0000 0
M  V30 21 C 0.5299 3.8310 0.0000 0
M  V30 22 C 1.8114 3.1988 0.0000 0
M  V30 23 N 1.9022 1.9439 0.0000 0
M  V30 24 C 2.7416 1.8091 0.0000 0
M  V30 25 O 2.9019 2.6184 0.0000 0
M  V30 26 C 3.5543 1.6172 0.0000 0
M  V30 27 C 3.6747 2.4334 0.0000 0
M  V30 28 C 4.4418 2.7372 0.0000 0
M  V30 29 C 4.5622 3.5533 0.0000 0
M  V30 30 O 3.9156 4.0657 0.0000 0
M  V30 31 O 5.3292 3.8571 0.0000 0
M  V30 32 N 4.3623 1.5678 0.0000 0
M  V30 33 C 5.1641 1.8082 0.0000 0 CFG=1
M  V30 34 O 5.0266 2.6217 0.0000 0
M  V30 35 C 5.9930 1.8442 0.0000 0
M  V30 36 C 6.7874 2.1224 0.0000 0
M  V30 37 S 7.6083 2.2424 0.0000 0
M  V30 38 S 8.2439 1.7134 0.0000 0
M  V30 39 C 8.3089 0.8727 0.0000 0
M  V30 40 C 8.0978 0.0632 0.0000 0 CFG=2
M  V30 41 N 8.8254 -0.3448 0.0000 0
M  V30 42 C 9.4124 -0.9320 0.0000 0
M  V30 43 O 10.1920 -0.6621 0.0000 0
M  V30 44 C 9.3142 -1.7542 0.0000 0 CFG=2
M  V30 45 C 10.0612 -2.1043 0.0000 0
M  V30 46 N 8.7302 -2.3713 0.0000 0
M  V30 47 C 7.8828 -2.4658 0.0000 0
M  V30 48 O 7.7869 -1.6464 0.0000 0
M  V30 49 C 7.0563 -2.5672 0.0000 0
M  V30 50 N 6.2293 -2.6941 0.0000 0
M  V30 51 C 5.3963 -2.8446 0.0000 0
M  V30 52 O 5.5184 -3.6605 0.0000 0
M  V30 53 C 4.5557 -2.9447 0.0000 0
M  V30 54 C 4.6738 -3.7612 0.0000 0
M  V30 55 C 4.0257 -4.2717 0.0000 0
M  V30 56 N 4.1437 -5.0882 0.0000 0
M  V30 57 O 3.2595 -3.9657 0.0000 0
M  V30 58 N 3.7222 -3.0867 0.0000 0
M  V30 59 C 2.8716 -3.1157 0.0000 0
M  V30 60 O 2.7838 -3.9361 0.0000 0
M  V30 61 C 2.0376 -2.9050 0.0000 0 CFG=1
M  V30 62 N 1.3437 -2.4245 0.0000 0
M  V30 63 C 1.0151 -1.6316 0.0000 0
M  V30 64 O 1.6005 -2.2130 0.0000 0
M  V30 65 C 1.6962 -3.6561 0.0000 0
M  V30 66 C 0.8751 -3.7360 0.0000 0
M  V30 67 C 2.1760 -4.3272 0.0000 0
M  V30 68 C 7.1692 -3.3845 0.0000 0 CFG=2
M  V30 69 C 6.5178 -3.8908 0.0000 0
M  V30 70 C 7.9333 -3.6954 0.0000 0
M  V30 71 C 7.2688 -0.1950 0.0000 0
M  V30 72 O 7.4724 -0.9945 0.0000 0
M  V30 73 N 6.4434 -0.3595 0.0000 0
M  V30 74 C 5.6227 -0.4936 0.0000 0
M  V30 75 C 5.7254 -1.3121 0.0000 0 CFG=1
M  V30 76 C 5.0679 -1.8104 0.0000 0
M  V30 77 O 6.4857 -1.6325 0.0000 0
M  V30 78 C 4.7846 -0.5673 0.0000 0
M  V30 79 O 4.7006 0.2534 0.0000 0
M  V30 80 N 3.9483 -0.6649 0.0000 0
M  V30 81 C 3.1206 -0.8189 0.0000 0
M  V30 82 C 2.3330 -1.1271 0.0000 0
M  V30 83 O 2.5072 -1.9335 0.0000 0
M  V30 84 N 1.4760 -1.1720 0.0000 0
M  V30 85 N 5.8371 2.6543 0.0000 0
M  V30 86 C 6.4608 3.1944 0.0000 0
M  V30 87 O 7.2403 2.9244 0.0000 0
M  V30 88 C 6.3049 4.0046 0.0000 0 CFG=2
M  V30 89 C 5.5253 4.2746 0.0000 0
M  V30 90 C 5.3694 5.0847 0.0000 0
M  V30 91 C 4.5898 5.3548 0.0000 0
M  V30 92 O 3.9662 4.8147 0.0000 0
M  V30 93 O 4.4339 6.1649 0.0000 0
M  V30 94 N 6.9285 4.5446 0.0000 0
M  V30 95 C 7.7081 4.2746 0.0000 0
M  V30 96 O 7.8640 3.4645 0.0000 0
M  V30 97 C 8.3317 4.8147 0.0000 0 CFG=2
M  V30 98 C 8.1758 5.6248 0.0000 0
M  V30 99 C 7.3962 5.8949 0.0000 0
M  V30 100 O 6.7726 5.3548 0.0000 0
M  V30 101 O 7.2403 6.7050 0.0000 0
M  V30 102 N 9.1112 4.5446 0.0000 0
M  V30 103 C 9.7349 5.0847 0.0000 0
M  V30 104 O 9.5790 5.8949 0.0000 0
M  V30 105 C 10.5144 4.8147 0.0000 0 CFG=1
M  V30 106 N 10.6703 4.0046 0.0000 0
M  V30 107 C 11.1381 5.3548 0.0000 0
M  V30 108 C 11.9176 5.0847 0.0000 0
M  V30 109 N 12.5413 5.6248 0.0000 0
M  V30 110 O 12.0735 4.2746 0.0000 0
M  V30 111 C -0.7867 -0.5070 0.0000 0
M  V30 112 O -1.2683 0.1628 0.0000 0
M  V30 113 O -0.1708 0.0420 0.0000 0
M  V30 114 H -1.5371 -2.1705 0.0000 0
M  V30 115 H -0.4729 -1.2441 0.0000 0
M  V30 116 H 1.1899 0.3356 0.0000 0
M  V30 117 H 1.4513 2.6482 0.0000 0
M  V30 118 H 0.0000 0.0000 0.0000 0
M  V30 119 H 0.0000 0.0000 0.0000 0
M  V30 120 H 0.0000 0.0000 0.0000 0
M  V30 121 H 6.2429 -3.0076 0.0000 0
M  V30 122 H 5.8500 -2.3043 0.0000 0
M  V30 123 H 0.0000 0.0000 0.0000 0
M  V30 124 H 7.2497 3.6771 0.0000 0
M  V30 125 H 9.0172 0.4565 0.0000 0
M  V30 126 H 10.1872 -1.2665 0.0000 0
M  V30 127 H 0.0000 0.0000 0.0000 0
M  V30 128 H 0.0000 0.0000 0.0000 0
M  V30 129 H 0.0000 0.0000 0.0000 0
M  V30 130 H 0.0000 0.0000 0.0000 0
M  V30 131 H 1.0701 -3.1579 0.0000 0
M  V30 132 H 8.5207 3.8327 0.0000 0
M  V30 133 H 9.7585 4.1600 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=1
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 9 7 CFG=3
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 14 13
M  V30 14 1 14 15 CFG=1
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 18 16
M  V30 18 1 18 19 CFG=3
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 20 22
M  V30 22 1 18 23
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 26 24
M  V30 26 1 27 26 CFG=1
M  V30 27 1 27 28
M  V30 28 1 28 29
M  V30 29 1 29 30
M  V30 30 2 29 31
M  V30 31 1 32 26 CFG=3
M  V30 32 1 32 33
M  V30 33 2 33 34
M  V30 34 1 33 35 CFG=1
M  V30 35 1 35 36
M  V30 36 1 36 37
M  V30 37 1 37 38
M  V30 38 1 38 39
M  V30 39 1 40 39
M  V30 40 1 40 41 CFG=3
M  V30 41 1 41 42
M  V30 42 2 42 43
M  V30 43 1 44 42
M  V30 44 1 44 45 CFG=3
M  V30 45 1 44 46
M  V30 46 1 46 47
M  V30 47 2 47 48
M  V30 48 1 49 47
M  V30 49 1 50 49 CFG=3
M  V30 50 1 50 51
M  V30 51 2 51 52
M  V30 52 1 53 51
M  V30 53 1 54 53 CFG=1
M  V30 54 1 54 55
M  V30 55 1 55 56
M  V30 56 2 55 57
M  V30 57 1 58 53 CFG=3
M  V30 58 1 58 59
M  V30 59 2 59 60
M  V30 60 1 61 59
M  V30 61 1 61 62
M  V30 62 1 62 63
M  V30 63 1 14 63
M  V30 64 2 63 64
M  V30 65 1 61 65 CFG=3
M  V30 66 1 65 66
M  V30 67 1 65 67
M  V30 68 1 68 49 CFG=1
M  V30 69 1 68 69
M  V30 70 1 68 70
M  V30 71 1 40 71
M  V30 72 2 71 72
M  V30 73 1 71 73
M  V30 74 1 73 74
M  V30 75 1 75 74
M  V30 76 1 75 76
M  V30 77 1 75 77 CFG=3
M  V30 78 1 74 78
M  V30 79 2 78 79
M  V30 80 1 78 80
M  V30 81 1 80 81
M  V30 82 1 81 82
M  V30 83 2 82 83
M  V30 84 1 82 84
M  V30 85 1 9 84
M  V30 86 1 85 35 CFG=3
M  V30 87 1 85 86
M  V30 88 2 86 87
M  V30 89 1 88 86
M  V30 90 1 88 89
M  V30 91 1 89 90
M  V30 92 1 90 91
M  V30 93 1 91 92
M  V30 94 2 91 93
M  V30 95 1 88 94 CFG=3
M  V30 96 1 94 95
M  V30 97 2 95 96
M  V30 98 1 97 95
M  V30 99 1 97 98
M  V30 100 1 98 99
M  V30 101 1 99 100
M  V30 102 2 99 101
M  V30 103 1 97 102 CFG=3
M  V30 104 1 102 103
M  V30 105 2 103 104
M  V30 106 1 105 103
M  V30 107 1 105 106 CFG=3
M  V30 108 1 105 107
M  V30 109 1 107 108
M  V30 110 1 108 109
M  V30 111 2 108 110
M  V30 112 1 5 111
M  V30 113 1 111 112
M  V30 114 2 111 113
M  V30 115 1 114 5
M  V30 116 1 115 9
M  V30 117 1 116 14
M  V30 118 1 117 18
M  V30 119 1 118 27
M  V30 120 1 119 27
M  V30 121 1 120 32
M  V30 122 1 121 68
M  V30 123 1 122 75
M  V30 124 1 123 85
M  V30 125 1 124 88
M  V30 126 1 125 40
M  V30 127 1 126 44
M  V30 128 1 127 50
M  V30 129 1 128 54
M  V30 130 1 129 54
M  V30 131 1 130 58
M  V30 132 1 131 61
M  V30 133 1 132 97
M  V30 134 1 133 105
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
19

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Plecanatide

>  <Synonyms>
N/A

>  <CAS>
467426-54-6

>  <Formula>
C65H104N18O26S4

>  <MolWt>
1682

>  <Pathways>
GPCR/G Protein

>  <Target>
Guanylate cyclase

>  <Receptor>
 guanylate cyclase-C:190 nM (EC50)

>  <Bioactivity>
Plecanatide acetate is an analogue of Uroguanylin. It is an orally active guanylate cyclase-C (GC-C) receptor agonist.

>  <Reference>
"https://pubmed.ncbi.nlm.nih.gov/26558155/;Rao SSC. Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol. 2018 Jun 8;11:1756284818777945.;Yang J Y , Pharmacy D O . Plecanatide: a new guanylate cyclase C agonist for treatment of chronic idiopathic constipation[J]. Chinese Journal of New Drugs and Clinical Remedies, 2018."

>  <ID<1>>
T9080

$$$$
StarDrop ID 20
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 38 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -0.2942 -2.9846 0.0000 0
M  V30 2 C 0.4203 -2.5721 0.0000 0
M  V30 3 C 0.4203 -1.7471 0.0000 0 CFG=2
M  V30 4 C -0.2942 -1.3346 0.0000 0
M  V30 5 C -1.0087 -1.7471 0.0000 0
M  V30 6 C -1.7231 -1.3346 0.0000 0
M  V30 7 C -1.7231 -0.5096 0.0000 0
M  V30 8 C -1.0087 -0.0971 0.0000 0
M  V30 9 C -0.2942 -0.5096 0.0000 0
M  V30 10 C -2.4376 -0.0971 0.0000 0
M  V30 11 O -2.4376 0.7279 0.0000 0
M  V30 12 C -3.1521 1.1404 0.0000 0
M  V30 13 C -3.1521 1.9654 0.0000 0
M  V30 14 C -3.8665 2.3779 0.0000 0
M  V30 15 C -3.8665 3.2029 0.0000 0
M  V30 16 C -3.1521 3.6154 0.0000 0
M  V30 17 C -2.4376 3.2029 0.0000 0
M  V30 18 C -2.4376 2.3779 0.0000 0
M  V30 19 C -3.1521 4.4404 0.0000 0
M  V30 20 C -4.5810 1.9654 0.0000 0
M  V30 21 O -3.8665 0.7279 0.0000 0
M  V30 22 C 1.1347 -1.3346 0.0000 0
M  V30 23 N 1.8492 -1.7471 0.0000 0
M  V30 24 C 2.5637 -1.3346 0.0000 0
M  V30 25 C 3.2782 -1.7471 0.0000 0
M  V30 26 C 3.9926 -1.3346 0.0000 0
M  V30 27 C 3.9926 -0.5096 0.0000 0
M  V30 28 C 4.7071 -0.0971 0.0000 0
M  V30 29 N 5.4216 -0.5096 0.0000 0
M  V30 30 C 5.4216 -1.3346 0.0000 0
M  V30 31 C 4.7071 -1.7471 0.0000 0
M  V30 32 C 3.2782 -0.0971 0.0000 0
M  V30 33 C 2.5637 -0.5096 0.0000 0
M  V30 34 O 1.1347 -0.5096 0.0000 0
M  V30 35 H 1.2863 -2.2471 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 4 9
M  V30 10 1 7 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 13 18
M  V30 20 1 16 19
M  V30 21 1 14 20
M  V30 22 2 12 21
M  V30 23 1 3 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 26 31
M  V30 34 1 27 32
M  V30 35 2 32 33
M  V30 36 1 24 33
M  V30 37 2 22 34
M  V30 38 1 35 3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
20

>  <Plate>
PHD136328

>  <Row>
a

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Netarsudil Dihydrochloride

>  <Synonyms>
AR-13324 Dihydrochloride

>  <CAS>
1253952-02-1

>  <Formula>
C28H29Cl2N3O3

>  <MolWt>
526.5

>  <Pathways>
Cytoskeletal Signaling;Stem Cells;Cell Cycle/Checkpoint

>  <Target>
ROCK

>  <Receptor>
ROCK

>  <Bioactivity>
Netarsudil Dihydrochloride is an inhibitor of Rho-associated protein kinase (ROCK) and norepinephrine transporter (NET) with effective in intraocular pressure (IOP) reduction.

>  <Reference>
"Kiel JW, et al. Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits. J Ocul Pharmacol Ther. 2015 Apr;31(3):146-151.;Wang RF, et al. Effect of 0.04% AR-13324, a ROCK, and norepinephrine transporter inhibitor, on aqueous humor dynamics in normotensive monkey eyes. J Glaucoma. 2015 Jan;24(1):51-54."

>  <ID<1>>
T10358

$$$$
StarDrop ID 21
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -3.0603 -1.6500 0.0000 0
M  V30 2 C -2.7247 -2.4037 0.0000 0
M  V30 3 C -1.9042 -2.4899 0.0000 0
M  V30 4 C -1.5687 -3.2436 0.0000 0 CFG=2
M  V30 5 C -0.7617 -3.4151 0.0000 0
M  V30 6 C -0.6755 -4.2356 0.0000 0 CFG=2
M  V30 7 N -1.4291 -4.5712 0.0000 0
M  V30 8 C -1.6007 -5.3781 0.0000 0
M  V30 9 C -1.9812 -3.9581 0.0000 0
M  V30 10 C 0.0390 -4.6481 0.0000 0
M  V30 11 O 0.7535 -4.2356 0.0000 0
M  V30 12 N 0.0390 -5.4731 0.0000 0
M  V30 13 C 0.7535 -5.8856 0.0000 0 CFG=2
M  V30 14 C 1.4679 -5.4731 0.0000 0 CFG=1
M  V30 15 C 1.4679 -4.6481 0.0000 0
M  V30 16 O 2.1824 -5.8856 0.0000 0
M  V30 17 C 0.7535 -6.7106 0.0000 0 CFG=1
M  V30 18 O 1.4679 -7.1231 0.0000 0
M  V30 19 C 1.4679 -7.9481 0.0000 0 CFG=2
M  V30 20 S 2.1824 -8.3606 0.0000 0
M  V30 21 C 2.8969 -7.9481 0.0000 0
M  V30 22 C 0.7535 -8.3606 0.0000 0 CFG=2
M  V30 23 O 0.7535 -9.1856 0.0000 0
M  V30 24 C 0.0390 -7.9481 0.0000 0 CFG=1
M  V30 25 O -0.6755 -8.3606 0.0000 0
M  V30 26 C 0.0390 -7.1231 0.0000 0 CFG=1
M  V30 27 O -0.6755 -6.7106 0.0000 0
M  V30 28 H -0.9393 -2.4665 0.0000 0
M  V30 29 H -0.7277 -5.2342 0.0000 0
M  V30 30 H 0.7534 -4.8856 0.0000 0
M  V30 31 H 1.4680 -6.4731 0.0000 0
M  V30 32 H 0.7534 -7.7106 0.0000 0
M  V30 33 H 1.4680 -8.9481 0.0000 0
M  V30 34 H 1.6195 -8.8606 0.0000 0
M  V30 35 H -0.8270 -7.4481 0.0000 0
M  V30 36 H -0.8270 -7.6231 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=3
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 4 9
M  V30 10 1 6 10 CFG=1
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 13 12 CFG=3
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 14 16 CFG=1
M  V30 17 1 13 17
M  V30 18 1 17 18 CFG=1
M  V30 19 1 19 18
M  V30 20 1 19 20 CFG=3
M  V30 21 1 20 21
M  V30 22 1 22 19
M  V30 23 1 22 23 CFG=3
M  V30 24 1 24 22
M  V30 25 1 24 25 CFG=1
M  V30 26 1 26 24
M  V30 27 1 17 26
M  V30 28 1 26 27 CFG=1
M  V30 29 1 28 4
M  V30 30 1 29 6
M  V30 31 1 30 13
M  V30 32 1 31 14
M  V30 33 1 32 17
M  V30 34 1 33 19
M  V30 35 1 34 22
M  V30 36 1 35 24
M  V30 37 1 36 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
21

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lincomycin hydrochloride monohydrate

>  <Synonyms>
Lincomycin hydrochloride hydrate

>  <CAS>
7179-49-9

>  <Formula>
C18H37ClN2O7S

>  <MolWt>
461

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial;ribosome;Antibiotic

>  <Receptor>
50S ribosome; Antibiotic; Bacterial

>  <Bioactivity>
"Lincomycin hydrochloride is an antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections."

>  <Reference>
"Odom OW, Hardesty B. J Biol Chem. 1992 Sep 25;267(27):19117-22."

>  <ID<1>>
T1235

$$$$
StarDrop ID 22
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 40 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 1.4769 0.6459 0.0000 0
M  V30 2 C 1.6905 -0.1510 0.0000 0 CFG=1
M  V30 3 S 2.4049 0.2615 0.0000 0
M  V30 4 C 3.1194 -0.1510 0.0000 0
M  V30 5 C 3.1194 -0.9760 0.0000 0
M  V30 6 C 3.8339 -1.3885 0.0000 0
M  V30 7 S 3.8339 -2.2135 0.0000 0
M  V30 8 C 4.5483 -2.6260 0.0000 0
M  V30 9 N 5.3020 -2.2904 0.0000 0
M  V30 10 N 5.8540 -2.9035 0.0000 0
M  V30 11 N 5.4415 -3.6180 0.0000 0
M  V30 12 N 4.6346 -3.4465 0.0000 0
M  V30 13 C 4.0215 -3.9985 0.0000 0
M  V30 14 C 4.1930 -4.8055 0.0000 0
M  V30 15 O 3.5799 -5.3575 0.0000 0
M  V30 16 O 4.9776 -5.0604 0.0000 0
M  V30 17 C 2.4049 -1.3885 0.0000 0
M  V30 18 N 1.6905 -0.9760 0.0000 0
M  V30 19 C 0.8655 -0.9760 0.0000 0
M  V30 20 O 0.2821 -1.5593 0.0000 0
M  V30 21 C 0.8655 -0.1510 0.0000 0 CFG=1
M  V30 22 N 0.2821 0.4324 0.0000 0
M  V30 23 C 0.4956 1.2293 0.0000 0
M  V30 24 O 1.2925 1.4428 0.0000 0
M  V30 25 C -0.0877 1.8126 0.0000 0
M  V30 26 C -0.8846 1.5991 0.0000 0
M  V30 27 C -1.0982 0.8022 0.0000 0
M  V30 28 C -1.8950 0.5887 0.0000 0
M  V30 29 C -2.4784 1.1721 0.0000 0
M  V30 30 C -2.2649 1.9689 0.0000 0
M  V30 31 C -1.4680 2.1825 0.0000 0
M  V30 32 C -1.2545 2.9794 0.0000 0
M  V30 33 N -0.4576 3.1929 0.0000 0
M  V30 34 C 2.4049 -2.2135 0.0000 0
M  V30 35 O 1.6905 -2.6260 0.0000 0
M  V30 36 O 3.1194 -2.6260 0.0000 0
M  V30 37 H 1.2481 0.7729 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 8 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 2 5 17
M  V30 18 1 17 18
M  V30 19 1 2 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 21 19
M  V30 23 1 2 21
M  V30 24 1 21 22 CFG=1
M  V30 25 1 22 23
M  V30 26 2 23 24
M  V30 27 1 23 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 1 26 31
M  V30 35 1 31 32
M  V30 36 1 32 33
M  V30 37 1 17 34
M  V30 38 1 34 35
M  V30 39 2 34 36
M  V30 40 1 37 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
22

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ceforanide

>  <Synonyms>
N/A

>  <CAS>
60925-61-3

>  <Formula>
C20H21N7O6S2

>  <MolWt>
519.5

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial; PBPs

>  <Bioactivity>
Ceforanide is a second-generation cephalosporin antibiotic with bactericidal activity. Ceforanide causes inhibition of bacterial cell wall synthesis by inactivating penicillin binding proteins (PBPs) thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of the cell wall.

>  <Reference>
"Sifakis S, et al. Chemoprophylactic and bactericidal efficacy of 80 mg gentamicin in a single and once-daily dosing. Arch Gynecol Obstet. 2005 Sep;272(3):201-6."

>  <ID<1>>
T5022

$$$$
StarDrop ID 23
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.5600 0.7927 0.0000 0
M  V30 2 C 1.9469 1.3448 0.0000 0 CFG=1
M  V30 3 C 2.5600 1.8968 0.0000 0
M  V30 4 C 1.4620 0.6773 0.0000 0 CFG=2
M  V30 5 C 1.7169 -0.1073 0.0000 0
M  V30 6 O 1.1649 -0.7204 0.0000 0
M  V30 7 O 2.5239 -0.2788 0.0000 0
M  V30 8 N 0.6773 0.9323 0.0000 0
M  V30 9 C 0.6773 1.7573 0.0000 0 CFG=2
M  V30 10 S 1.4620 2.0122 0.0000 0
M  V30 11 O 1.2989 2.8209 0.0000 0
M  V30 12 O 2.0692 2.5706 0.0000 0
M  V30 13 C -0.1477 1.7573 0.0000 0
M  V30 14 C -0.1477 0.9323 0.0000 0
M  V30 15 O -0.7310 0.3489 0.0000 0
M  V30 16 H 0.5483 2.5721 0.0000 0
M  V30 17 N 3.3446 1.0477 0.0000 0
M  V30 18 C 3.5995 1.8323 0.0000 0
M  V30 19 C 4.4245 1.8323 0.0000 0
M  V30 20 N 4.6795 1.0477 0.0000 0
M  V30 21 N 4.0120 0.5628 0.0000 0
M  V30 22 H 2.4497 0.5210 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3 CFG=3
M  V30 3 1 2 4
M  V30 4 1 4 5 CFG=3
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 4 8
M  V30 8 1 9 8
M  V30 9 1 9 10
M  V30 10 1 2 10
M  V30 11 2 10 11
M  V30 12 2 10 12
M  V30 13 1 9 13
M  V30 14 1 13 14
M  V30 15 1 8 14
M  V30 16 2 14 15
M  V30 17 1 9 16 CFG=3
M  V30 18 1 1 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 17 21
M  V30 24 1 22 4
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
23

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tazobactam

>  <Synonyms>
CL-298741;Tazobactam acid;YTR-830H;Tazobactamum

>  <CAS>
89786-04-9

>  <Formula>
C10H12N4O5S

>  <MolWt>
300.3

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial; ??-Lactamase

>  <Bioactivity>
Tazobactam is an antibacterial penicillin derivative which inhibits the action of bacterial beta-lactamases.

>  <Reference>
"Overington JP, et al. Nat Rev Drug Discov. 2006 Dec;5(12):993-6."

>  <ID<1>>
T1262

$$$$
StarDrop ID 24
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.4677 2.8399 0.0000 0
M  V30 2 C 3.1821 2.4274 0.0000 0
M  V30 3 C 3.8966 2.8399 0.0000 0
M  V30 4 N 3.1821 1.6024 0.0000 0 CHG=1
M  V30 5 C 2.3571 1.6024 0.0000 0
M  V30 6 C 3.1821 0.7774 0.0000 0
M  V30 7 C 3.8966 0.3649 0.0000 0
M  V30 8 C 3.8966 -0.4601 0.0000 0
M  V30 9 C 3.0716 -0.4601 0.0000 0
M  V30 10 N 2.6591 -1.1746 0.0000 0
M  V30 11 O 2.6591 0.2544 0.0000 0
M  V30 12 C 3.8966 -1.2851 0.0000 0
M  V30 13 C 4.6111 -1.6976 0.0000 0
M  V30 14 C 4.6111 -2.5226 0.0000 0
M  V30 15 C 3.8966 -2.9351 0.0000 0
M  V30 16 C 3.1821 -2.5226 0.0000 0
M  V30 17 C 3.1821 -1.6976 0.0000 0
M  V30 18 C 4.7216 -0.4601 0.0000 0
M  V30 19 C 5.1341 0.2544 0.0000 0
M  V30 20 C 5.9591 0.2544 0.0000 0
M  V30 21 C 6.3716 -0.4601 0.0000 0
M  V30 22 C 5.9591 -1.1746 0.0000 0
M  V30 23 C 5.1341 -1.1746 0.0000 0
M  V30 24 C 4.0071 1.6024 0.0000 0
M  V30 25 C 4.4196 0.8879 0.0000 0
M  V30 26 C 4.4196 2.3169 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 8 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 12 17
M  V30 18 1 8 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 18 23
M  V30 25 1 4 24
M  V30 26 1 24 25
M  V30 27 1 24 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
24

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Isopropamide Iodide

>  <Synonyms>
N/A

>  <CAS>
71-81-8

>  <Formula>
C23H33IN2O

>  <MolWt>
480.4

>  <Pathways>
Neuroscience

>  <Target>
AChR

>  <Receptor>
muscarinic receptor

>  <Bioactivity>
Isopropamide iodide is a long-acting anticholinergic drug. It is used in the treatment of peptic ulcers and other gastrointestinal disorders. It also acts as a muscarinic receptor antagonist which can be applied to the treatment of diseases affecting cognition including Alzheimer's disease.

>  <Reference>
"Fisher A, et al. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. J Mol Neurosci. 2002 Aug-Oct;19(1-2):145-53."

>  <ID<1>>
T5051

$$$$
StarDrop ID 25
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.3584 1.5197 0.0000 0
M  V30 2 C 7.3584 0.6947 0.0000 0
M  V30 3 C 8.0729 0.2822 0.0000 0
M  V30 4 C 8.0729 -0.5428 0.0000 0
M  V30 5 C 8.7874 -0.9553 0.0000 0
M  V30 6 N 7.3584 -0.9553 0.0000 0
M  V30 7 C 6.6440 -0.5428 0.0000 0
M  V30 8 N 5.9295 -0.9553 0.0000 0
M  V30 9 S 5.2150 -0.5428 0.0000 0
M  V30 10 O 5.6275 0.1717 0.0000 0
M  V30 11 O 4.8025 -1.2572 0.0000 0
M  V30 12 C 4.5006 -0.1303 0.0000 0
M  V30 13 C 3.7861 -0.5428 0.0000 0
M  V30 14 C 3.0716 -0.1303 0.0000 0
M  V30 15 C 3.0716 0.6947 0.0000 0
M  V30 16 N 2.3571 1.1072 0.0000 0
M  V30 17 C 3.7861 1.1072 0.0000 0
M  V30 18 C 4.5006 0.6947 0.0000 0
M  V30 19 N 6.6440 0.2822 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 2 9 11
M  V30 11 1 9 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 2 17 18
M  V30 18 1 12 18
M  V30 19 2 7 19
M  V30 20 1 2 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
25

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Sulfamethazine sodium

>  <Synonyms>
Sulfadimethyldiazine Sodium Salt;Sulfamethazine sodium salt

>  <CAS>
1981-58-4

>  <Formula>
C12H13N4NaO2S

>  <MolWt>
300.3

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial;Antibiotic

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
"Sulfamethazine Sodium is a sodium salt form of sulfamethazine, a sulfonamide antibiotic used in the livestock industry."

>  <Reference>
"Fukahori S, et al. J Environ Manage. 2015 Jul 1;157:103-10."

>  <ID<1>>
T2184L

$$$$
StarDrop ID 26
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.0400 -0.8735 0.0000 0
M  V30 2 C 5.3256 -0.4610 0.0000 0
M  V30 3 C 5.3256 0.3640 0.0000 0
M  V30 4 N 4.6111 0.7765 0.0000 0
M  V30 5 C 3.8966 0.3640 0.0000 0
M  V30 6 C 3.1821 0.7765 0.0000 0
M  V30 7 C 3.8966 -0.4610 0.0000 0
M  V30 8 C 6.0400 0.7765 0.0000 0
M  V30 9 O 6.0400 1.6015 0.0000 0
M  V30 10 C 6.7545 0.3640 0.0000 0
M  V30 11 C 7.4690 0.7765 0.0000 0
M  V30 12 C 8.1834 0.3640 0.0000 0
M  V30 13 C 8.1834 -0.4610 0.0000 0
M  V30 14 O 8.8979 -0.8735 0.0000 0
M  V30 15 C 7.4690 -0.8735 0.0000 0
M  V30 16 O 7.4690 -1.6985 0.0000 0
M  V30 17 C 6.7545 -0.4610 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 3 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 2 15 17
M  V30 17 1 10 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
26

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Isoetharine mesylate salt

>  <Synonyms>
Isoetarine mesilate

>  <CAS>
7279-75-6

>  <Formula>
C14H25NO6S

>  <MolWt>
335.4

>  <Pathways>
Others;Neuroscience;GPCR/G Protein

>  <Target>
Adrenergic Receptor;Others

>  <Receptor>
PXR; ??-adrenergic receptor

>  <Bioactivity>
Isoetharine Mesylate Salt is a ??-adrenergic receptor agonist. it also is pregnane X receptor (PXR) activator capable of upregulating CYP450 expression.

>  <Reference>
"Ratajewski M, et al. Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202."

>  <ID<1>>
T4983

$$$$
StarDrop ID 27
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 3.8697 1.4850 0.0000 0
M  V30 2 C 3.8697 0.6600 0.0000 0
M  V30 3 N 4.5842 0.2475 0.0000 0
M  V30 4 C 4.5842 -0.5775 0.0000 0
M  V30 5 N 3.8697 -0.9900 0.0000 0
M  V30 6 C 3.1553 -0.5775 0.0000 0
M  V30 7 N 2.3706 -0.8324 0.0000 0
M  V30 8 C 1.8857 -0.1650 0.0000 0
M  V30 9 N 2.3706 0.5024 0.0000 0
M  V30 10 C 3.1553 0.2475 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 2 10
M  V30 11 1 6 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
27

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
6-Mercaptopurine hydrate

>  <Synonyms>
6-Mercaptopurine (6-MP) Monohydrate;6-Mercaptopurine monohydrate

>  <CAS>
6112-76-1

>  <Formula>
C5H6N4OS

>  <MolWt>
170.2

>  <Pathways>
Cell Cycle/Checkpoint;DNA Damage/DNA Repair;Others

>  <Target>
Others;DNA/RNA Synthesis;Nucleoside Antimetabolite/Analog

>  <Receptor>
DNA synthesis; Nucleoside Antimetabolite/Analog; PRPP Amidotransferase

>  <Bioactivity>
"6-Mercaptopurine anhydrous is a Nucleoside Metabolic Inhibitor. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia."

>  <Reference>
"Sahasranaman S, et al. Eur J Clin Pharmacol, 2008, 64(8), 753-767.;Weinshilboum RM, et al. Am J Hum Genet, 1980, 32(5), 651-662.;Fu Y H, Xu Z X, Jiang N, et al. High-throughput screening of active compounds against human respiratory syncytial virus. Virology. 2019."

>  <ID<1>>
T2201

$$$$
StarDrop ID 28
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 48 52 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.6876 -6.6016 0.0000 0
M  V30 2 C -1.6876 -5.7766 0.0000 0
M  V30 3 O -2.4021 -5.3641 0.0000 0
M  V30 4 C -3.1165 -5.7766 0.0000 0
M  V30 5 O -3.1165 -6.6016 0.0000 0
M  V30 6 O -3.8310 -5.3641 0.0000 0
M  V30 7 C -4.5455 -5.7766 0.0000 0
M  V30 8 C -4.5455 -6.6016 0.0000 0
M  V30 9 C -5.2600 -7.0141 0.0000 0
M  V30 10 C -5.9744 -6.6016 0.0000 0
M  V30 11 C -5.9744 -5.7766 0.0000 0
M  V30 12 C -5.2600 -5.3641 0.0000 0
M  V30 13 O -0.9731 -5.3641 0.0000 0
M  V30 14 C -0.2587 -5.7766 0.0000 0
M  V30 15 O -0.2587 -6.6016 0.0000 0
M  V30 16 C 0.4558 -5.3641 0.0000 0
M  V30 17 C 0.4558 -4.5391 0.0000 0
M  V30 18 C -0.2587 -4.1266 0.0000 0
M  V30 19 S -0.9731 -4.5391 0.0000 0
M  V30 20 C -1.6876 -4.1266 0.0000 0
M  V30 21 N -2.4413 -4.4621 0.0000 0
M  V30 22 N -2.9933 -3.8490 0.0000 0
M  V30 23 N -2.5808 -3.1346 0.0000 0
M  V30 24 N -1.7738 -3.3061 0.0000 0
M  V30 25 C -1.1607 -2.7541 0.0000 0
M  V30 26 C -0.3761 -3.0090 0.0000 0
M  V30 27 N 0.2370 -2.4570 0.0000 0
M  V30 28 C 0.0654 -1.6500 0.0000 0
M  V30 29 C 1.0216 -2.7119 0.0000 0
M  V30 30 C 1.1703 -4.1266 0.0000 0
M  V30 31 S 1.8848 -4.5391 0.0000 0
M  V30 32 C 1.8848 -5.3641 0.0000 0 CFG=2
M  V30 33 C 2.2973 -6.0785 0.0000 0 CFG=2
M  V30 34 N 3.0941 -6.2921 0.0000 0
M  V30 35 C 3.6775 -5.7087 0.0000 0
M  V30 36 O 3.4640 -4.9118 0.0000 0
M  V30 37 C 4.4744 -5.9222 0.0000 0
M  V30 38 C 5.0578 -5.3389 0.0000 0
M  V30 39 C 4.9287 -4.5240 0.0000 0
M  V30 40 S 5.6638 -4.1495 0.0000 0
M  V30 41 C 6.2471 -4.7329 0.0000 0
M  V30 42 N 7.0620 -4.6038 0.0000 0
M  V30 43 N 5.8726 -5.4679 0.0000 0
M  V30 44 C 1.5828 -6.4910 0.0000 0
M  V30 45 O 1.3693 -7.2879 0.0000 0
M  V30 46 N 1.1703 -5.7766 0.0000 0
M  V30 47 H 2.4276 -7.0700 0.0000 0
M  V30 48 H 1.6259 -6.3300 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 12
M  V30 13 1 2 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 1 20 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 27 29
M  V30 31 1 17 30
M  V30 32 1 30 31
M  V30 33 1 32 31
M  V30 34 1 32 33
M  V30 35 1 33 34 CFG=3
M  V30 36 1 34 35
M  V30 37 2 35 36
M  V30 38 1 35 37
M  V30 39 1 37 38
M  V30 40 2 38 39
M  V30 41 1 39 40
M  V30 42 1 40 41
M  V30 43 1 41 42
M  V30 44 2 41 43
M  V30 45 1 38 43
M  V30 46 1 33 44
M  V30 47 2 44 45
M  V30 48 1 44 46
M  V30 49 1 16 46
M  V30 50 1 32 46 CFG=3
M  V30 51 1 47 33
M  V30 52 1 48 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
28

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cefotiam Hexetil Hydrochloride

>  <Synonyms>
N/A

>  <CAS>
95789-30-3

>  <Formula>
C27H39Cl2N9O7S3

>  <MolWt>
768.8

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial; PBPs

>  <Bioactivity>
"Cefotiam Hydrochloride is the hydrochloride salt form of cefotiam, a third-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity. Cefotiam binds to penicillin-binding proteins (PBPs), transpeptidases that are responsible for crosslinking of peptidoglycan. By preventing crosslinking of peptidoglycan, cell wall integrity is lost and cell wall synthesis is halted."

>  <Reference>
"Matsuda K, et al. Antimicrob Agents ChemOthers. 1995 Dec;39(12):2631-4."

>  <ID<1>>
T5024

$$$$
StarDrop ID 29
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 11 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6591 2.0135 0.0000 0
M  V30 2 N 3.0716 1.2990 0.0000 0 CHG=1
M  V30 3 C 2.3571 0.8865 0.0000 0
M  V30 4 C 3.7861 1.7115 0.0000 0
M  V30 5 C 3.4841 0.5846 0.0000 0
M  V30 6 C 3.0716 -0.1299 0.0000 0 CFG=1
M  V30 7 O 2.2466 -0.1299 0.0000 0
M  V30 8 C 3.4841 -0.8444 0.0000 0
M  V30 9 C 3.0716 -1.5588 0.0000 0
M  V30 10 O 3.4841 -2.2733 0.0000 0
M  V30 11 O 2.2466 -1.5588 0.0000 0
M  V30 12 H 2.5716 0.7361 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 12 6
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
29

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
D-Carnitine hydrochloride

>  <Synonyms>
L-Carnitine hydrochloride

>  <CAS>
10017-44-4

>  <Formula>
C7H16ClNO3

>  <MolWt>
197.7

>  <Pathways>
Others;Metabolism

>  <Target>
Others;Endogenous Metabolite

>  <Receptor>
CRAT; Endogenous Metabolite

>  <Bioactivity>
The l-carnitine hydrochloride is a constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.

>  <Reference>
"Guo Y, Suo N, Cui X, et al. Vitamin C promotes oligodendrocytes generation and remyelination[J]. Glia. 2018 Jul;66(7):1302-1316.;Merra G, et al. World J Gastroenterol. 2012 Sep 28;18(36):5065-71."

>  <ID<1>>
T2203

$$$$
StarDrop ID 30
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 39 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.4614 -3.1732 0.0000 0
M  V30 2 O 5.2479 -2.3763 0.0000 0
M  V30 3 N 5.8313 -1.7930 0.0000 0
M  V30 4 C 5.6177 -0.9961 0.0000 0
M  V30 5 C 6.2011 -0.4127 0.0000 0
M  V30 6 O 5.9876 0.3842 0.0000 0
M  V30 7 N 6.9980 -0.6263 0.0000 0
M  V30 8 C 7.5814 -0.0429 0.0000 0
M  V30 9 C 8.4064 -0.0429 0.0000 0
M  V30 10 S 9.1208 -0.4554 0.0000 0
M  V30 11 C 9.8353 -0.0429 0.0000 0
M  V30 12 C 9.8353 0.7821 0.0000 0
M  V30 13 C 10.5498 1.1946 0.0000 0
M  V30 14 N 11.2642 0.7821 0.0000 0 CHG=1
M  V30 15 C 11.9787 1.1946 0.0000 0
M  V30 16 C 12.6932 0.7821 0.0000 0
M  V30 17 C 12.6932 -0.0429 0.0000 0
M  V30 18 C 11.9787 -0.4554 0.0000 0
M  V30 19 C 11.8072 -1.2624 0.0000 0
M  V30 20 C 10.9867 -1.3486 0.0000 0
M  V30 21 C 10.6511 -0.5949 0.0000 0
M  V30 22 C 11.2642 -0.0429 0.0000 0
M  V30 23 C 9.1208 1.1946 0.0000 0
M  V30 24 N 8.4064 0.7821 0.0000 0
M  V30 25 C 7.5814 0.7821 0.0000 0
M  V30 26 O 6.9980 1.3655 0.0000 0
M  V30 27 C 9.1208 2.0196 0.0000 0
M  V30 28 O 9.8353 2.4321 0.0000 0
M  V30 29 O 8.4064 2.4321 0.0000 0
M  V30 30 C 4.8209 -0.7826 0.0000 0
M  V30 31 C 4.1797 -1.3018 0.0000 0
M  V30 32 S 3.4878 -0.8524 0.0000 0
M  V30 33 C 3.7013 -0.0555 0.0000 0
M  V30 34 N 3.1821 0.5856 0.0000 0
M  V30 35 N 4.5252 -0.0124 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 14 22
M  V30 23 2 18 22
M  V30 24 2 12 23
M  V30 25 1 23 24
M  V30 26 1 9 24
M  V30 27 1 24 25
M  V30 28 1 8 25
M  V30 29 2 25 26
M  V30 30 1 23 27
M  V30 31 1 27 28
M  V30 32 2 27 29
M  V30 33 1 4 30
M  V30 34 2 30 31
M  V30 35 1 31 32
M  V30 36 1 32 33
M  V30 37 1 33 34
M  V30 38 2 33 35
M  V30 39 1 30 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
30

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cefpirome sulfate

>  <Synonyms>
HR-810 sulfate

>  <CAS>
98753-19-6

>  <Formula>
C22H24N6O9S3

>  <MolWt>
612.7

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
Cefpirome Sulfate is a fourth generation cephalosporin antibiotic.

>  <Reference>
"Matsuda K, et al. Antimicrob Agents ChemOthers. 1995 Dec;39(12):2631-4."

>  <ID<1>>
T4995

$$$$
StarDrop ID 31
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.7603 -0.8815 0.0000 0
M  V30 2 C 6.1283 -1.4118 0.0000 0
M  V30 3 C 5.4963 -0.8815 0.0000 0
M  V30 4 C 6.5408 -2.1263 0.0000 0
M  V30 5 C 7.2552 -2.5388 0.0000 0
M  V30 6 C 7.2552 -3.3638 0.0000 0
M  V30 7 Cl 7.9697 -3.7763 0.0000 0
M  V30 8 Cl 6.5408 -3.7763 0.0000 0
M  V30 9 C 5.7158 -2.1263 0.0000 0
M  V30 10 C 5.0013 -2.5388 0.0000 0
M  V30 11 O 4.2868 -2.1263 0.0000 0
M  V30 12 O 5.0013 -3.3638 0.0000 0
M  V30 13 C 4.2868 -3.7763 0.0000 0
M  V30 14 C 4.2868 -4.6013 0.0000 0
M  V30 15 C 5.0013 -5.0138 0.0000 0
M  V30 16 C 5.0013 -5.8388 0.0000 0
M  V30 17 C 4.2868 -6.2513 0.0000 0
M  V30 18 C 3.5724 -5.8388 0.0000 0
M  V30 19 O 2.8579 -6.2513 0.0000 0
M  V30 20 C 2.1434 -5.8388 0.0000 0
M  V30 21 C 1.4289 -6.2513 0.0000 0
M  V30 22 C 0.7145 -5.8388 0.0000 0
M  V30 23 C 0.7145 -5.0138 0.0000 0
M  V30 24 C 1.4289 -4.6013 0.0000 0
M  V30 25 C 2.1434 -5.0138 0.0000 0
M  V30 26 C 3.5724 -5.0138 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 4 9
M  V30 9 1 2 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 20 25
M  V30 27 2 18 26
M  V30 28 1 14 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
31

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Permethrin

>  <Synonyms>
NRDC-143;Pounce;Transpermethrin;Ambush

>  <CAS>
52645-53-1

>  <Formula>
C21H20Cl2O3

>  <MolWt>
391.3

>  <Pathways>
Membrane transporter/Ion channel;Microbiology/Virology

>  <Target>
Sodium Channel;Parasite

>  <Receptor>
Parasite; Sodium Channel

>  <Bioactivity>
Permethrin is a pyrethroid insecticide commonly used in the treatment of LICE INFESTATIONS and SCABIES.

>  <Reference>
"Cao Z, et al. J Pharmacol Exp Ther. 2011, 336(1):197-205."

>  <ID<1>>
T1332

$$$$
StarDrop ID 32
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0291 3.4805 0.0000 0
M  V30 2 O 4.7436 3.0680 0.0000 0
M  V30 3 C 4.7436 2.2430 0.0000 0
M  V30 4 C 5.4581 1.8305 0.0000 0
M  V30 5 C 5.4581 1.0055 0.0000 0
M  V30 6 C 4.7436 0.5930 0.0000 0
M  V30 7 N 4.7436 -0.2320 0.0000 0
M  V30 8 C 5.4581 -0.6445 0.0000 0
M  V30 9 O 6.1725 -0.2320 0.0000 0
M  V30 10 C 5.4581 -1.4695 0.0000 0
M  V30 11 C 6.1725 -1.8820 0.0000 0
M  V30 12 C 6.1725 -2.7070 0.0000 0
M  V30 13 C 5.4581 -3.1195 0.0000 0
M  V30 14 C 4.7436 -2.7070 0.0000 0
M  V30 15 C 4.7436 -1.8820 0.0000 0
M  V30 16 C 5.4581 -3.9445 0.0000 0
M  V30 17 N 6.1725 -4.3570 0.0000 0
M  V30 18 N 4.7436 -4.3570 0.0000 0
M  V30 19 C 4.7436 -5.1820 0.0000 0
M  V30 20 C 4.0291 -3.9445 0.0000 0
M  V30 21 C 4.0291 1.0055 0.0000 0
M  V30 22 C 4.0291 1.8305 0.0000 0
M  V30 23 C 3.3147 0.5930 0.0000 0
M  V30 24 O 3.3147 -0.2320 0.0000 0
M  V30 25 N 2.6002 1.0055 0.0000 0
M  V30 26 C 2.6002 1.8305 0.0000 0
M  V30 27 C 1.8857 2.2430 0.0000 0
M  V30 28 C 1.8857 3.0680 0.0000 0
M  V30 29 C 2.6002 3.4805 0.0000 0
M  V30 30 Cl 2.6002 4.3055 0.0000 0
M  V30 31 C 3.3147 3.0680 0.0000 0
M  V30 32 N 3.3147 2.2430 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 10 15
M  V30 16 1 13 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 6 21
M  V30 22 2 21 22
M  V30 23 1 3 22
M  V30 24 1 21 23
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 1 29 31
M  V30 33 2 31 32
M  V30 34 1 26 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
32

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Betrixaban hydrochloride(330942-05-7(free base))

>  <Synonyms>
PRT054021 hydrochloride

>  <CAS>
T4690

>  <Formula>
C23H23Cl2N5O3

>  <MolWt>
488.4

>  <Pathways>
Metabolism

>  <Target>
Factor Xa

>  <Receptor>
 fXa:1.5 nM

>  <Bioactivity>
"Betrixaban is a potent, selective, and orally efficacious factor Xa (fXa) inhibitor (IC50: 1.5 nM)."

>  <Reference>
"Zhang P, et al. Discovery of Betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenzamide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2179-85.;Lu G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013 Apr;19(4):446-51."

>  <ID<1>>
T4690

$$$$
StarDrop ID 33
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -4.4116 3.2167 0.0000 0
M  V30 2 C -3.5878 3.1735 0.0000 0
M  V30 3 S -2.7729 3.3026 0.0000 0
M  V30 4 C -2.3984 2.5675 0.0000 0 CFG=2
M  V30 5 C -1.8150 1.9842 0.0000 0 CFG=2
M  V30 6 C -2.3984 1.4008 0.0000 0
M  V30 7 N -2.9817 1.9842 0.0000 0
M  V30 8 C -3.7168 2.3587 0.0000 0 CFG=2
M  V30 9 C -4.4519 1.9842 0.0000 0
M  V30 10 O -4.4951 1.1603 0.0000 0
M  V30 11 O -5.1438 2.4335 0.0000 0
M  V30 12 O -2.3984 0.5758 0.0000 0
M  V30 13 N -0.9900 1.9842 0.0000 0
M  V30 14 C -0.5775 1.2697 0.0000 0
M  V30 15 C 0.2475 1.2697 0.0000 0
M  V30 16 C 0.6600 0.5552 0.0000 0
M  V30 17 C 1.4805 0.4690 0.0000 0
M  V30 18 S 1.6520 -0.3380 0.0000 0
M  V30 19 C 0.9375 -0.7505 0.0000 0
M  V30 20 C 0.3244 -0.1985 0.0000 0
M  V30 21 C 0.6600 1.9842 0.0000 0
M  V30 22 O 1.4850 1.9842 0.0000 0
M  V30 23 O 0.2475 2.6986 0.0000 0
M  V30 24 O -0.9900 0.5552 0.0000 0
M  V30 25 C -3.6309 3.9974 0.0000 0
M  V30 26 H -2.3983 1.5675 0.0000 0
M  V30 27 H -1.4323 2.9081 0.0000 0
M  V30 28 H -4.5259 2.9464 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 4 7 CFG=3
M  V30 8 1 8 7
M  V30 9 1 8 2
M  V30 10 1 8 9 CFG=3
M  V30 11 1 9 10
M  V30 12 2 9 11
M  V30 13 2 6 12
M  V30 14 1 5 13 CFG=1
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 16 20
M  V30 23 1 15 21
M  V30 24 1 21 22
M  V30 25 2 21 23
M  V30 26 2 14 24
M  V30 27 1 2 25
M  V30 28 1 26 4
M  V30 29 1 27 5
M  V30 30 1 28 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
33

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ticarcillin disodium

>  <Synonyms>
Ticarcillin disodium salt;Ticarpen

>  <CAS>
4697-14-7

>  <Formula>
C15H14N2Na2O6S2

>  <MolWt>
428.4

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial;Antibiotic

>  <Receptor>
Antibacterial; Antibiotic; Bacterial

>  <Bioactivity>
"Ticarcillin Disodium is the disodium salt form of ticarcillin, a broad-spectrum, semi-synthetic penicillin antibiotic with bactericidal and beta-lactamase resistant activity. Similar to carbenicillin in action, ticarcillin inactivates the penicillin-sensitive transpeptidase C-terminal domain by opening the lactam ring. This inactivation prevents the cross-linkage of peptidoglycan strands, thereby inhibiting the third and last stage of bacterial cell wall synthesis. This leads to incomplete bacterial cell wall synthesis and eventually causes cell lysis."

>  <Reference>
"Webb D, et al. Arch Intern Med. 1978 Nov;138(11):1618-20."

>  <ID<1>>
T1063

$$$$
StarDrop ID 34
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.4990 1.1104 0.0000 0
M  V30 2 O 2.7845 0.6979 0.0000 0
M  V30 3 C 2.0701 1.1104 0.0000 0
M  V30 4 C 1.3556 0.6979 0.0000 0
M  V30 5 C 0.6411 1.1104 0.0000 0
M  V30 6 C -0.1435 0.8555 0.0000 0
M  V30 7 C -0.6284 1.5229 0.0000 0
M  V30 8 C -1.4534 1.5229 0.0000 0
M  V30 9 C -1.8659 2.2374 0.0000 0
M  V30 10 C -2.6909 2.2374 0.0000 0
M  V30 11 C -3.1034 2.9519 0.0000 0
M  V30 12 N -2.6909 3.6664 0.0000 0
M  V30 13 C -3.1034 4.3808 0.0000 0
M  V30 14 C -2.6909 5.0953 0.0000 0
M  V30 15 C -3.1034 5.8098 0.0000 0
M  V30 16 C -2.6909 6.5242 0.0000 0
M  V30 17 C -1.8659 6.5242 0.0000 0
M  V30 18 C -1.4534 5.8098 0.0000 0
M  V30 19 C -1.8659 5.0953 0.0000 0
M  V30 20 C -1.8659 3.6664 0.0000 0
M  V30 21 C -1.4534 2.9519 0.0000 0
M  V30 22 C -0.1435 2.1904 0.0000 0
M  V30 23 O -0.3984 2.9750 0.0000 0
M  V30 24 C 0.6411 1.9354 0.0000 0
M  V30 25 C 1.3556 2.3479 0.0000 0
M  V30 26 C 2.0701 1.9354 0.0000 0
M  V30 27 O 2.7845 2.3479 0.0000 0
M  V30 28 C 3.4990 1.9354 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 14 19
M  V30 20 1 12 20
M  V30 21 1 20 21
M  V30 22 1 9 21
M  V30 23 1 7 22
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 2 5 24
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 1 3 26
M  V30 30 1 26 27
M  V30 31 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
34

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Donepezil

>  <Synonyms>
E2020;Aricept;Donepezilo

>  <CAS>
120014-06-4

>  <Formula>
C24H29NO3

>  <MolWt>
379.5

>  <Pathways>
Neuroscience

>  <Target>
AChE

>  <Receptor>
" hAChE:11.6 nM, bAChE:8.12 nM"

>  <Bioactivity>
"Donepezil is a piperidine-based, potent, specific, and reversible inhibitor of acetylcholinesterase (AChE). It can be used for the treatment of mild to moderate dementia of the Alzheimer's type."

>  <Reference>
"Jiang Q, Lu C, Sun T, et al. Alterations of the Brain Proteome and Gut Microbiota in d-Galactose-Induced Brain-Aging Mice with Krill Oil Supplementation[J]. Journal of agricultural and food chemistry. 2019, 67(35): 9820-9830.;Cacabelos R. Donepezil in Alzheimer??s disease: From conventional trials to pharmacogenetics[J]. Neuropsychiatric Disease & Treatment, 2007, 3(3):303-333.;Miki A, et al. Protective effect of donepezil on retinal ganglion cells in vitro and in vivo[J]. Current Eye Research, 2006, 31(1):69-77."

>  <ID<1>>
T7041

$$$$
StarDrop ID 35
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 1 0 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
35

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Sodium montmorillonite

>  <Synonyms>
Montmorillonite;Bentolite;Gelwhite L

>  <CAS>
1318-93-0

>  <Formula>
Al2H2O12Si4

>  <MolWt>
360.3

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Sodium montmorillonite can catalyze reactions of the 5'-phosphorimidazolide of adenosine used as a model generated RNA type oligomers.

>  <Reference>
"Joshi PC, Aldersley MF. J Mol Evol. 2013 Jun;76(6):371-9"

>  <ID<1>>
T1397

$$$$
StarDrop ID 36
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.0716 3.1604 0.0000 0
M  V30 2 C 3.0716 2.3354 0.0000 0
M  V30 3 C 3.7861 1.9229 0.0000 0
M  V30 4 C 3.7861 1.0979 0.0000 0
M  V30 5 C 3.0716 0.6854 0.0000 0
M  V30 6 C 3.0716 -0.1396 0.0000 0
M  V30 7 C 2.3571 -0.5521 0.0000 0
M  V30 8 C 4.5006 0.6854 0.0000 0
M  V30 9 O 5.2150 1.0979 0.0000 0
M  V30 10 O 4.5006 -0.1396 0.0000 0
M  V30 11 C 5.2150 -0.5521 0.0000 0 CFG=2
M  V30 12 C 5.1534 -1.3748 0.0000 0
M  V30 13 C 5.7581 -1.9360 0.0000 0 CFG=2
M  V30 14 C 6.5739 -1.8130 0.0000 0
M  V30 15 C 6.9864 -1.0985 0.0000 0
M  V30 16 C 6.6850 -0.3306 0.0000 0 CFG=2
M  V30 17 C 5.8967 -0.0874 0.0000 0
M  V30 18 N 6.4223 -1.2491 0.0000 0 CHG=1
M  V30 19 C 5.8673 -0.6387 0.0000 0
M  V30 20 C 5.6161 -1.0737 0.0000 0
M  V30 21 H 5.1777 0.4472 0.0000 0
M  V30 22 H 4.9423 -2.0590 0.0000 0
M  V30 23 H 6.3836 0.4373 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 4 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 11 10 CFG=1
M  V30 11 1 11 12
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=1
M  V30 14 1 14 15
M  V30 15 1 16 15 CFG=1
M  V30 16 1 16 17
M  V30 17 1 11 17
M  V30 18 1 16 18
M  V30 19 1 13 18
M  V30 20 1 18 19
M  V30 21 1 18 20
M  V30 22 1 21 11
M  V30 23 1 22 13
M  V30 24 1 23 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
36

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Anisotropine Methylbromide

>  <Synonyms>
N/A

>  <CAS>
80-50-2

>  <Formula>
C17H32BrNO2

>  <MolWt>
362.4

>  <Pathways>
GPCR/G Protein;Neuroscience;Immunology/Inflammation

>  <Target>
AChR;Prostaglandin Receptor

>  <Receptor>
" DP1:0.6 nM (EC50), IP:1.9 nM (EC50), EP3:68.9 nM (EC50), EP2:6.2 nM (EC50)"

>  <Bioactivity>
Anisotropine Methylbromide is an anticholinergic agent and has been used for relief of gastrointestinal spasm and for the suppression of gastric acid secretion.

>  <Reference>
"Freston JW, et al. A double-blind evaluation of the nocturnal antisecretory effects of anisotropine methylbromide in man. Dose response and duration of action studies. J Clin Pharmacol. 1977 Jan;17(1):29-36."

>  <ID<1>>
T4981

$$$$
StarDrop ID 37
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.4289 -4.9500 0.0000 0
M  V30 2 C 2.1434 -5.3625 0.0000 0
M  V30 3 C 2.8579 -4.9500 0.0000 0
M  V30 4 C 3.5724 -5.3625 0.0000 0
M  V30 5 C 4.2868 -4.9500 0.0000 0
M  V30 6 C 5.0013 -5.3625 0.0000 0
M  V30 7 C 5.7158 -4.9500 0.0000 0
M  V30 8 C 6.4302 -5.3625 0.0000 0
M  V30 9 C 7.1447 -4.9500 0.0000 0
M  V30 10 C 7.8592 -5.3625 0.0000 0
M  V30 11 C 8.5737 -4.9500 0.0000 0
M  V30 12 C 9.2881 -5.3625 0.0000 0
M  V30 13 C 9.2881 -6.1875 0.0000 0
M  V30 14 O 10.0026 -6.6000 0.0000 0
M  V30 15 C 10.7171 -6.1875 0.0000 0
M  V30 16 C 11.4315 -6.6000 0.0000 0
M  V30 17 O 12.1460 -6.1875 0.0000 0
M  V30 18 C 8.5737 -6.6000 0.0000 0
M  V30 19 C 7.8592 -6.1875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 13 18
M  V30 18 2 18 19
M  V30 19 1 10 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
37

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
4-Nonylphenol polyethoxylate

>  <Synonyms>
Nonoxinol-9;Nonoxynol

>  <CAS>
26027-38-3

>  <Formula>
C17H28O2

>  <MolWt>
264.4

>  <Pathways>
Neuroscience;Immunology/Inflammation

>  <Target>
COX

>  <Receptor>
COX

>  <Bioactivity>
"Nonoxynol-9 (N-9) is a typical surfactant used as a vaginal spermicide. Spermicides are locally acting non-hormonal contraceptives. When present in the vagina during intercourse, they immobilize/inactivate/damage and/or kill sperms without eliciting systemic effects. N-9 has been in use for more than 30 years as an over-the-counter (OTC) drug in creams, gels, foams and condom lubricants. It is the most commonly used spermicidal contraceptive in the UK and the USA. In several European countries, spermicides are no longer on the market."

>  <Reference>
"Zalenskaya IA, et al. Am J Reprod Immunol. 2011, 65(6):569-77."

>  <ID<1>>
T0824

$$$$
StarDrop ID 38
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -6.9260 -3.3552 0.0000 0
M  V30 2 C -6.2116 -2.9427 0.0000 0
M  V30 3 C -5.4971 -3.3552 0.0000 0
M  V30 4 C -4.7826 -2.9427 0.0000 0
M  V30 5 C -4.0681 -3.3552 0.0000 0
M  V30 6 C -3.3537 -2.9427 0.0000 0
M  V30 7 O -3.3537 -2.1177 0.0000 0
M  V30 8 C -2.6392 -3.3552 0.0000 0
M  V30 9 C -1.9247 -2.9427 0.0000 0
M  V30 10 C -1.2103 -3.3552 0.0000 0
M  V30 11 C -1.1240 -4.1757 0.0000 0
M  V30 12 O -1.7371 -4.7277 0.0000 0
M  V30 13 C -0.3170 -4.3472 0.0000 0
M  V30 14 C 0.0955 -3.6327 0.0000 0
M  V30 15 C 0.9024 -3.4612 0.0000 0
M  V30 16 C 1.1574 -2.6766 0.0000 0
M  V30 17 C 0.6053 -2.0635 0.0000 0
M  V30 18 C -0.2016 -2.2350 0.0000 0
M  V30 19 C -0.4566 -3.0196 0.0000 0
M  V30 20 C 0.8603 -1.2789 0.0000 0
M  V30 21 C 1.6672 -1.1074 0.0000 0
M  V30 22 C 2.2193 -1.7204 0.0000 0
M  V30 23 C 1.9643 -2.5051 0.0000 0
M  V30 24 O 2.5164 -3.1182 0.0000 0
M  V30 25 C 3.3233 -2.9466 0.0000 0
M  V30 26 C 3.8754 -3.5597 0.0000 0
M  V30 27 O 4.6823 -3.3882 0.0000 0
M  V30 28 O 3.6204 -4.3444 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 10 19
M  V30 20 1 14 19
M  V30 21 1 17 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 16 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 2 26 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
38

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Treprostinil Sodium

>  <Synonyms>
UT-15

>  <CAS>
289480-64-4

>  <Formula>
C23H33NaO5

>  <MolWt>
412.5

>  <Pathways>
GPCR/G Protein;Immunology/Inflammation;Tyrosine Kinase/Adaptors;Angiogenesis;Apoptosis

>  <Target>
Prostaglandin Receptor;VEGFR;c-RET

>  <Receptor>
" VEGFR2:1 nM (Cell-free), RET:13 nM (Cell-free)"

>  <Bioactivity>
"Treprostinil is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM)."

>  <Reference>
"Whittle BJ, et al. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012 Jul 1;84(1):68-75.;Nikam VS, et al. Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J. 2010 Dec;36(6):1302-14.;Kazemi Z, et al. Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation. Mol Pharmacol. 2016 Jun;89(6):630-44.;Smadja DM, et al. Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells. Thromb Haemost. 2015 Oct;114(4):735-47.;Ghonem N, et al. Treprostinil, a prostacyclin analog, ameliorates ischemia-reperfusion injury in rat orthotopic liver transplantation."

>  <ID<1>>
T5171

$$$$
StarDrop ID 39
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 -2.4750 0.0000 0
M  V30 2 O 0.0000 -1.6500 0.0000 0
M  V30 3 C 0.7145 -1.2375 0.0000 0
M  V30 4 C 0.7145 -0.4125 0.0000 0
M  V30 5 C 1.4289 0.0000 0.0000 0
M  V30 6 C 2.1434 -0.4125 0.0000 0
M  V30 7 C 2.8579 0.0000 0.0000 0
M  V30 8 C 3.5724 -0.4125 0.0000 0
M  V30 9 C 3.5724 -1.2375 0.0000 0
M  V30 10 C 2.8579 -1.6500 0.0000 0
M  V30 11 C 2.1434 -1.2375 0.0000 0
M  V30 12 C 1.4289 -1.6500 0.0000 0
M  V30 13 C 4.2868 -0.0000 0.0000 0 CFG=1
M  V30 14 C 4.2868 0.8250 0.0000 0
M  V30 15 C 5.0013 -0.4125 0.0000 0
M  V30 16 O 5.7158 -0.0000 0.0000 0
M  V30 17 O 5.0013 -1.2375 0.0000 0
M  V30 18 H 3.4208 0.5000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 6 11
M  V30 12 2 11 12
M  V30 13 1 3 12
M  V30 14 1 13 8
M  V30 15 1 13 14 CFG=1
M  V30 16 1 13 15
M  V30 17 1 15 16
M  V30 18 2 15 17
M  V30 19 1 18 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
39

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
(R)-Naproxen

>  <Synonyms>
N/A

>  <CAS>
23979-41-1

>  <Formula>
C14H14O3

>  <MolWt>
230.3

>  <Pathways>
Neuroscience;Immunology/Inflammation

>  <Target>
COX

>  <Receptor>
COX

>  <Bioactivity>
"(R)-Naproxen, an anti-inflammatory agent, has antipyretic and analgesic properties. Both the acid and its sodium salt are used in the therapy of acute gout or dysmenorrhea, musculoskeletal disorders, rheumatoid arthritis and other rheumatic."

>  <Reference>
"Zhao, Ming, et al. GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid protein. Nature Communications . 12.1 (2021): 1-14.;Liu Y, Liu Y, Liu Z, et al. Chiral Molecularly Imprinted Polymeric Stir Bar Sorptive Extraction for Naproxen Enantiomer Detection in PPCPs[J]. Journal of Hazardous Materials. 2020: 122251.;Albertini R, et al. Inflamm Res. 2007, 56(6):228-9."

>  <ID<1>>
T0855

$$$$
StarDrop ID 40
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.5414 1.1020 0.0000 0
M  V30 2 P 0.8739 0.6171 0.0000 0
M  V30 3 O 0.8739 1.4421 0.0000 0
M  V30 4 O 0.0489 0.6171 0.0000 0
M  V30 5 O 0.8739 -0.2079 0.0000 0
M  V30 6 C 1.5884 -0.6204 0.0000 0
M  V30 7 C 2.3029 -1.0329 0.0000 0
M  V30 8 N 2.3029 -1.8579 0.0000 0
M  V30 9 C 2.9703 -2.3429 0.0000 0
M  V30 10 N 2.7154 -3.1275 0.0000 0
M  V30 11 C 1.8904 -3.1275 0.0000 0
M  V30 12 N 1.6354 -2.3429 0.0000 0
M  V30 13 C 1.1759 -1.3349 0.0000 0
M  V30 14 N 0.3509 -1.3349 0.0000 0
M  V30 15 C -0.1340 -0.6675 0.0000 0
M  V30 16 N -0.9187 -0.9224 0.0000 0
M  V30 17 C -0.9187 -1.7474 0.0000 0
M  V30 18 N -0.1340 -2.0024 0.0000 0
M  V30 19 C 2.0009 0.0940 0.0000 0
M  V30 20 C 1.5884 0.8085 0.0000 0
M  V30 21 C 2.0009 1.5230 0.0000 0
M  V30 22 C 2.8259 1.5230 0.0000 0
M  V30 23 F 3.2384 2.2374 0.0000 0
M  V30 24 C 3.2384 0.8085 0.0000 0
M  V30 25 C 2.8259 0.0940 0.0000 0
M  V30 26 F 3.2384 -0.6204 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 8 12
M  V30 13 1 6 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 14 18
M  V30 20 1 6 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 22 24
M  V30 26 2 24 25
M  V30 27 1 19 25
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
40

>  <Plate>
PHD136328

>  <Row>
b

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fosfluconazole

>  <Synonyms>
N/A

>  <CAS>
194798-83-9

>  <Formula>
C13H13F2N6O4P

>  <MolWt>
386.3

>  <Pathways>
Microbiology/Virology

>  <Target>
Antifungal

>  <Receptor>
Antifungal; Fungal

>  <Bioactivity>
Fosfluconazole is water-soluble phosphate prodrug of fluconazole. Fluconazole is an antifungal drug.

>  <Reference>
"Aoyama T, et al. Pharmacokinetics of fluconazole and Fosfluconazole after intraperitoneal administration to peritoneal dialysis rats. Drug Metab Pharmacokinet. 2005 Dec;20(6):485-90.;Yuan H, et al. Evaluation of in vitro models for screening alkaline phosphatase-mediated bioconversion of phosphate ester prodrugs. Drug Metab Dispos. 2009 Jul;37(7):1443-7."

>  <ID<1>>
T5328

$$$$
StarDrop ID 41
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 111 116 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 14.5761 1.2729 0.0000 0
M  V30 2 C 13.9605 0.7236 0.0000 0 CFG=1
M  V30 3 N 13.1771 0.9821 0.0000 0
M  V30 4 C 12.5615 0.4329 0.0000 0
M  V30 5 C 11.7780 0.6913 0.0000 0 CFG=1
M  V30 6 N 11.1624 0.1421 0.0000 0
M  V30 7 C 10.3790 0.4005 0.0000 0
M  V30 8 C 9.7634 -0.1487 0.0000 0 CFG=2
M  V30 9 N 8.9799 0.1098 0.0000 0
M  V30 10 C 8.3644 -0.4395 0.0000 0
M  V30 11 C 7.5809 -0.1810 0.0000 0 CFG=2
M  V30 12 C 7.4130 0.6267 0.0000 0
M  V30 13 C 8.0286 1.1760 0.0000 0
M  V30 14 C 7.8607 1.9837 0.0000 0
M  V30 15 C 8.4763 2.5330 0.0000 0
M  V30 16 C 9.2597 2.2745 0.0000 0
M  V30 17 O 9.8753 2.8238 0.0000 0
M  V30 18 C 9.4276 1.4668 0.0000 0
M  V30 19 C 8.8120 0.9175 0.0000 0
M  V30 20 N 6.9653 -0.7303 0.0000 0
M  V30 21 C 6.1818 -0.4718 0.0000 0
M  V30 22 C 5.5663 -1.0211 0.0000 0 CFG=1
M  V30 23 N 4.7828 -0.7626 0.0000 0
M  V30 24 C 4.1672 -1.3119 0.0000 0
M  V30 25 C 3.3838 -1.0534 0.0000 0 CFG=1
M  V30 26 C 3.2159 -0.2456 0.0000 0
M  V30 27 C 3.8315 0.3036 0.0000 0
M  V30 28 C 3.6636 1.1114 0.0000 0
M  V30 29 C 4.2791 1.6606 0.0000 0
M  V30 30 C 5.0626 1.4021 0.0000 0
M  V30 31 N 5.2305 0.5944 0.0000 0
M  V30 32 C 4.6149 0.0451 0.0000 0
M  V30 33 N 2.7682 -1.6026 0.0000 0
M  V30 34 C 1.9847 -1.3442 0.0000 0
M  V30 35 C 1.3691 -1.8934 0.0000 0 CFG=1
M  V30 36 C 1.5370 -2.7012 0.0000 0
M  V30 37 C 2.3205 -2.9596 0.0000 0
M  V30 38 C 2.9361 -2.4104 0.0000 0
M  V30 39 C 3.7195 -2.6689 0.0000 0
M  V30 40 C 3.8874 -3.4766 0.0000 0
M  V30 41 Cl 4.6709 -3.7351 0.0000 0
M  V30 42 C 3.2718 -4.0259 0.0000 0
M  V30 43 C 2.4884 -3.7674 0.0000 0
M  V30 44 N 0.5857 -1.6350 0.0000 0
M  V30 45 C -0.0299 -2.1842 0.0000 0
M  V30 46 C -0.8134 -1.9257 0.0000 0 CFG=1
M  V30 47 C -0.9812 -1.1180 0.0000 0
M  V30 48 C -1.7647 -0.8595 0.0000 0
M  V30 49 C -1.9326 -0.0518 0.0000 0
M  V30 50 C -2.7161 0.2067 0.0000 0
M  V30 51 C -3.3316 -0.3426 0.0000 0
M  V30 52 C -3.1638 -1.1503 0.0000 0
M  V30 53 C -2.3803 -1.4088 0.0000 0
M  V30 54 C -4.1151 -0.0841 0.0000 0
M  V30 55 C -4.2830 0.7236 0.0000 0
M  V30 56 C -3.6674 1.2729 0.0000 0
M  V30 57 C -2.8839 1.0144 0.0000 0
M  V30 58 N -1.4289 -2.4750 0.0000 0
M  V30 59 C -1.2611 -3.2827 0.0000 0
M  V30 60 C -1.8766 -3.8320 0.0000 0
M  V30 61 O -0.4776 -3.5412 0.0000 0
M  V30 62 O 0.1380 -2.9920 0.0000 0
M  V30 63 O 1.8168 -0.5364 0.0000 0
M  V30 64 O 4.3351 -2.1196 0.0000 0
M  V30 65 C 5.7342 -1.8288 0.0000 0
M  V30 66 O 5.1186 -2.3781 0.0000 0
M  V30 67 O 6.0140 0.3359 0.0000 0
M  V30 68 C 7.1332 -1.5380 0.0000 0
M  V30 69 O 8.5322 -1.2472 0.0000 0
M  V30 70 C 9.9313 -0.9565 0.0000 0
M  V30 71 C 10.7147 -1.2149 0.0000 0
M  V30 72 N 11.3303 -0.6657 0.0000 0
M  V30 73 O 10.8826 -2.0227 0.0000 0
M  V30 74 O 10.2111 1.2083 0.0000 0
M  V30 75 C 11.6101 1.4991 0.0000 0
M  V30 76 C 12.2257 2.0483 0.0000 0
M  V30 77 C 12.0578 2.8561 0.0000 0
M  V30 78 C 13.0092 1.7899 0.0000 0
M  V30 79 O 12.7294 -0.3749 0.0000 0
M  V30 80 C 14.1284 -0.0841 0.0000 0
M  V30 81 C 14.9119 -0.3426 0.0000 0
M  V30 82 C 15.0798 -1.1503 0.0000 0
M  V30 83 C 15.8632 -1.4088 0.0000 0
M  V30 84 N 16.0311 -2.2165 0.0000 0
M  V30 85 C 16.8146 -2.4750 0.0000 0
M  V30 86 C 17.4301 -1.9257 0.0000 0
M  V30 87 C 16.9825 -3.2827 0.0000 0
M  V30 88 O 15.3596 1.0144 0.0000 0
M  V30 89 N 14.4082 2.0806 0.0000 0
M  V30 90 C 14.9630 2.6912 0.0000 0 CFG=2
M  V30 91 C 15.7831 2.6013 0.0000 0
M  V30 92 N 16.1152 1.8461 0.0000 0
M  V30 93 C 16.9353 1.7562 0.0000 0 CFG=1
M  V30 94 C 17.2675 1.0010 0.0000 0
M  V30 95 N 18.0876 0.9111 0.0000 0
M  V30 96 O 16.7796 0.3358 0.0000 0
M  V30 97 C 17.4233 2.4214 0.0000 0
M  V30 98 O 16.2710 3.2665 0.0000 0
M  V30 99 C 14.5537 3.4076 0.0000 0
M  V30 100 C 13.7460 3.2397 0.0000 0
M  V30 101 C 13.6561 2.4196 0.0000 0
M  V30 102 H 13.2143 0.0578 0.0000 0
M  V30 103 H 10.8284 1.0047 0.0000 0
M  V30 104 H 9.5599 0.8304 0.0000 0
M  V30 105 H 6.6312 0.1322 0.0000 0
M  V30 106 H 5.3627 -0.0420 0.0000 0
M  V30 107 H 3.5872 -2.0325 0.0000 0
M  V30 108 H 0.6231 -2.5593 0.0000 0
M  V30 109 H -0.6098 -2.9048 0.0000 0
M  V30 110 H 15.3172 1.7560 0.0000 0
M  V30 111 H 17.9293 1.6471 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3 CFG=3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=1
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=1
M  V30 9 1 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 2 18 19
M  V30 19 1 13 19
M  V30 20 1 11 20 CFG=1
M  V30 21 1 20 21
M  V30 22 1 22 21
M  V30 23 1 22 23 CFG=3
M  V30 24 1 23 24
M  V30 25 1 25 24
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 2 28 29
M  V30 30 1 29 30
M  V30 31 2 30 31
M  V30 32 1 31 32
M  V30 33 2 27 32
M  V30 34 1 25 33 CFG=3
M  V30 35 1 33 34
M  V30 36 1 35 34
M  V30 37 1 35 36
M  V30 38 1 36 37
M  V30 39 2 37 38
M  V30 40 1 38 39
M  V30 41 2 39 40
M  V30 42 1 40 41
M  V30 43 1 40 42
M  V30 44 2 42 43
M  V30 45 1 37 43
M  V30 46 1 35 44 CFG=1
M  V30 47 1 44 45
M  V30 48 1 46 45
M  V30 49 1 46 47
M  V30 50 1 47 48
M  V30 51 2 48 49
M  V30 52 1 49 50
M  V30 53 2 50 51
M  V30 54 1 51 52
M  V30 55 2 52 53
M  V30 56 1 48 53
M  V30 57 1 51 54
M  V30 58 2 54 55
M  V30 59 1 55 56
M  V30 60 2 56 57
M  V30 61 1 50 57
M  V30 62 1 46 58 CFG=3
M  V30 63 1 58 59
M  V30 64 1 59 60
M  V30 65 2 59 61
M  V30 66 2 45 62
M  V30 67 2 34 63
M  V30 68 2 24 64
M  V30 69 1 22 65
M  V30 70 1 65 66
M  V30 71 2 21 67
M  V30 72 1 20 68
M  V30 73 2 10 69
M  V30 74 1 8 70
M  V30 75 1 70 71
M  V30 76 1 71 72
M  V30 77 2 71 73
M  V30 78 2 7 74
M  V30 79 1 5 75
M  V30 80 1 75 76
M  V30 81 1 76 77
M  V30 82 1 76 78
M  V30 83 2 4 79
M  V30 84 1 2 80
M  V30 85 1 80 81
M  V30 86 1 81 82
M  V30 87 1 82 83
M  V30 88 1 83 84
M  V30 89 1 84 85
M  V30 90 1 85 86
M  V30 91 1 85 87
M  V30 92 2 1 88
M  V30 93 1 1 89
M  V30 94 1 90 89
M  V30 95 1 90 91 CFG=1
M  V30 96 1 91 92
M  V30 97 1 93 92
M  V30 98 1 93 94
M  V30 99 1 94 95
M  V30 100 2 94 96
M  V30 101 1 93 97 CFG=3
M  V30 102 2 91 98
M  V30 103 1 90 99
M  V30 104 1 99 100
M  V30 105 1 100 101
M  V30 106 1 89 101
M  V30 107 1 102 2
M  V30 108 1 103 5
M  V30 109 1 104 8
M  V30 110 1 105 11
M  V30 111 1 106 22
M  V30 112 1 107 25
M  V30 113 1 108 35
M  V30 114 1 109 46
M  V30 115 1 110 90
M  V30 116 1 111 93
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
41

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Abarelix

>  <Synonyms>
R3827;PPI 149

>  <CAS>
183552-38-7

>  <Formula>
C72H95ClN14O14

>  <MolWt>
1416

>  <Pathways>
GPCR/G Protein

>  <Target>
GNRH Receptor

>  <Receptor>
GnRHR

>  <Bioactivity>
"Abarelix is a potent gonadotrophin-releasing hormone (GnRH) antagonist, which is used for prostate cancer treatment."

>  <Reference>
"Koechling W, et al. A novel GnRH antagonist, causes minimal histamine release compared with abarelix in an ex vivo model of human skin samples. Br J Clin Pharmacol. 2010 Oct;70(4):580-7.;Debruyne F, et al. Abarelix for injectable suspension: first-in-class releasing hormone antagonist for prostate cancer. Future Oncol. 2006 Dec;2(6):677-96.;Kirby RS, et al. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int. 2009 Dec;104(11):1580-4."

>  <ID<1>>
T10217L

$$$$
StarDrop ID 42
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 39 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.1434 -6.1875 0.0000 0
M  V30 2 C -1.4289 -5.7750 0.0000 0 CFG=2
M  V30 3 O -0.7145 -6.1875 0.0000 0
M  V30 4 C 0.0000 -5.7750 0.0000 0
M  V30 5 P 0.7145 -6.1875 0.0000 0
M  V30 6 O 1.4289 -6.6000 0.0000 0
M  V30 7 C 2.1434 -6.1875 0.0000 0
M  V30 8 C 2.8579 -6.6000 0.0000 0
M  V30 9 C 3.5724 -6.1875 0.0000 0
M  V30 10 O 4.2868 -6.6000 0.0000 0
M  V30 11 C 5.0013 -6.1875 0.0000 0
M  V30 12 C 5.7158 -6.6000 0.0000 0
M  V30 13 C 6.4302 -6.1875 0.0000 0
M  V30 14 C 7.1447 -6.6000 0.0000 0
M  V30 15 C 7.8592 -6.1875 0.0000 0
M  V30 16 C 8.5737 -6.6000 0.0000 0
M  V30 17 C 9.2881 -6.1875 0.0000 0
M  V30 18 C 10.0026 -6.6000 0.0000 0
M  V30 19 C 10.7171 -6.1875 0.0000 0
M  V30 20 C 11.4315 -6.6000 0.0000 0
M  V30 21 C 12.1460 -6.1875 0.0000 0
M  V30 22 C 12.8605 -6.6000 0.0000 0
M  V30 23 C 13.5749 -6.1875 0.0000 0
M  V30 24 C 14.2894 -6.6000 0.0000 0
M  V30 25 C 15.0039 -6.1875 0.0000 0
M  V30 26 C 15.7184 -6.6000 0.0000 0
M  V30 27 O 1.1270 -5.4730 0.0000 0
M  V30 28 O 0.3020 -6.9020 0.0000 0
M  V30 29 C -1.4289 -4.9500 0.0000 0
M  V30 30 O -0.7145 -4.5375 0.0000 0
M  V30 31 N -2.8579 -5.7750 0.0000 0
M  V30 32 C -3.5724 -6.1875 0.0000 0
M  V30 33 O -3.5724 -7.0125 0.0000 0
M  V30 34 N -4.2868 -5.7750 0.0000 0
M  V30 35 C -4.2868 -4.9500 0.0000 0
M  V30 36 N -5.0013 -4.5375 0.0000 0
M  V30 37 C -3.5724 -4.5375 0.0000 0
M  V30 38 C -2.8579 -4.9500 0.0000 0
M  V30 39 H -1.4290 -6.7750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3 CFG=1
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 2 5 27
M  V30 27 1 5 28
M  V30 28 1 2 29
M  V30 29 1 29 30
M  V30 30 1 1 31
M  V30 31 1 31 32
M  V30 32 2 32 33
M  V30 33 1 32 34
M  V30 34 2 34 35
M  V30 35 1 35 36
M  V30 36 1 35 37
M  V30 37 2 37 38
M  V30 38 1 31 38
M  V30 39 1 39 2
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
42

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Brincidofovir

>  <Synonyms>
HDP-CDV;CMX001

>  <CAS>
444805-28-1

>  <Formula>
C27H52N3O7P

>  <MolWt>
561.7

>  <Pathways>
Others;Immunology/Inflammation;Microbiology/Virology

>  <Target>
Others;Antiviral;HSV

>  <Receptor>
" anti-CMV, in PDA at 7 dpi:5.5 nM (EC50)"

>  <Bioactivity>
"Brincidofovir is an orally active, lipophilic form of cidofovir. It has enhanced activity compared to CDV against certain adenoviruses, herpesviruses, and orthopoxviruses."

>  <Reference>
"Marty FM, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013 Sep 26;369(13):1227-36."

>  <ID<1>>
TQ0095

$$$$
StarDrop ID 43
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 39 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 20.6171 6.9533 0.0000 0
M  V30 2 C 20.6171 6.1283 0.0000 0
M  V30 3 C 19.9026 5.7158 0.0000 0
M  V30 4 C 19.1881 6.1283 0.0000 0
M  V30 5 C 18.4737 5.7158 0.0000 0
M  V30 6 O 18.4737 4.8908 0.0000 0
M  V30 7 N 17.7592 6.1283 0.0000 0
M  V30 8 C 17.0447 5.7158 0.0000 0
M  V30 9 C 16.3302 6.1283 0.0000 0
M  V30 10 S 15.6158 5.7158 0.0000 0
M  V30 11 S 14.9013 6.1283 0.0000 0
M  V30 12 C 14.1868 5.7158 0.0000 0
M  V30 13 C 13.4724 6.1283 0.0000 0
M  V30 14 N 12.7579 5.7158 0.0000 0
M  V30 15 C 12.0434 6.1283 0.0000 0
M  V30 16 O 12.0434 6.9533 0.0000 0
M  V30 17 C 11.3289 5.7158 0.0000 0
M  V30 18 C 10.6145 6.1283 0.0000 0
M  V30 19 C 9.9000 5.7158 0.0000 0
M  V30 20 N 9.9000 4.8908 0.0000 0
M  V30 21 C 9.1855 6.1283 0.0000 0
M  V30 22 O 8.4711 5.7158 0.0000 0
M  V30 23 O 9.1855 6.9533 0.0000 0
M  V30 24 C 13.4724 6.9533 0.0000 0
M  V30 25 O 14.1868 7.3658 0.0000 0
M  V30 26 N 12.7579 7.3658 0.0000 0
M  V30 27 C 12.7579 8.1908 0.0000 0
M  V30 28 C 12.0434 8.6033 0.0000 0
M  V30 29 O 11.3289 8.1908 0.0000 0
M  V30 30 O 12.0434 9.4283 0.0000 0
M  V30 31 C 17.0447 4.8908 0.0000 0
M  V30 32 O 16.3302 4.4783 0.0000 0
M  V30 33 N 17.7592 4.4783 0.0000 0
M  V30 34 C 17.7592 3.6533 0.0000 0
M  V30 35 C 18.4737 3.2408 0.0000 0
M  V30 36 O 19.1881 3.6533 0.0000 0
M  V30 37 O 18.4737 2.4158 0.0000 0
M  V30 38 C 21.3315 5.7158 0.0000 0
M  V30 39 O 22.0460 6.1283 0.0000 0
M  V30 40 O 21.3315 4.8908 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 19 21
M  V30 21 1 21 22
M  V30 22 2 21 23
M  V30 23 1 13 24
M  V30 24 2 24 25
M  V30 25 1 24 26
M  V30 26 1 26 27
M  V30 27 1 27 28
M  V30 28 1 28 29
M  V30 29 2 28 30
M  V30 30 1 8 31
M  V30 31 2 31 32
M  V30 32 1 31 33
M  V30 33 1 33 34
M  V30 34 1 34 35
M  V30 35 1 35 36
M  V30 36 2 35 37
M  V30 37 1 2 38
M  V30 38 1 38 39
M  V30 39 2 38 40
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
43

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Glutathione oxidized

>  <Synonyms>
L(-)-Glutathione;GSSG;Oxidized glutathione;Glutathione disulfide;Bi(glutathion-S-yl);L-Glutathione oxidized

>  <CAS>
27025-41-8

>  <Formula>
C20H32N6O12S2

>  <MolWt>
612.6

>  <Pathways>
oxidation-reduction;NF-??b;Immunology/Inflammation;Metabolism

>  <Target>
Glutathione reductase;Reactive Oxygen Species;Endogenous Metabolite

>  <Receptor>
Endogenous Metabolite; Glutathione reductase; Reactive Oxygen Species

>  <Bioactivity>
A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.

>  <Reference>
"Hall MN, et al. Environ Health Perspect. 2013 Sep;121(9):1068-74."

>  <ID<1>>
T1085L

$$$$
StarDrop ID 44
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 0.8250 0.0000 0
M  V30 2 C 0.0000 -0.0000 0.0000 0
M  V30 3 N -0.7145 -0.4125 0.0000 0
M  V30 4 C -1.4289 -0.0000 0.0000 0
M  V30 5 C -2.1434 -0.4125 0.0000 0
M  V30 6 C -2.8579 -0.0000 0.0000 0
M  V30 7 C -2.8579 0.8250 0.0000 0
M  V30 8 C -2.1434 1.2375 0.0000 0
M  V30 9 C -1.4289 0.8250 0.0000 0
M  V30 10 C -0.7145 -1.2375 0.0000 0
M  V30 11 C -1.4289 -1.6500 0.0000 0 CFG=1
M  V30 12 N -1.4289 -2.4750 0.0000 0
M  V30 13 C -2.1434 -2.8875 0.0000 0
M  V30 14 C -2.1434 -3.7125 0.0000 0
M  V30 15 N -1.5303 -4.2645 0.0000 0
M  V30 16 C -1.8659 -5.0182 0.0000 0
M  V30 17 N -2.6864 -4.9320 0.0000 0
M  V30 18 C -2.8579 -4.1250 0.0000 0
M  V30 19 N -3.5724 -3.7125 0.0000 0
M  V30 20 C -3.5724 -2.8875 0.0000 0
M  V30 21 N -2.8579 -2.4750 0.0000 0
M  V30 22 C -2.1434 -1.2375 0.0000 0
M  V30 23 N 0.0000 -1.6500 0.0000 0
M  V30 24 C 0.7145 -1.2375 0.0000 0
M  V30 25 C 0.7145 -0.4125 0.0000 0
M  V30 26 C 1.4289 -0.0000 0.0000 0
M  V30 27 F 1.4289 0.8250 0.0000 0
M  V30 28 C 2.1434 -0.4125 0.0000 0
M  V30 29 C 2.1434 -1.2375 0.0000 0
M  V30 30 C 1.4289 -1.6500 0.0000 0
M  V30 31 H -1.4290 -0.6500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 4 9
M  V30 10 1 3 10
M  V30 11 1 11 10
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 14 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 13 21
M  V30 24 1 11 22 CFG=1
M  V30 25 2 10 23
M  V30 26 1 23 24
M  V30 27 2 24 25
M  V30 28 1 2 25
M  V30 29 1 25 26
M  V30 30 1 26 27
M  V30 31 2 26 28
M  V30 32 1 28 29
M  V30 33 2 29 30
M  V30 34 1 24 30
M  V30 35 1 31 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
44

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
CAL-101

>  <Synonyms>
GS-1101;Idelalisib

>  <CAS>
1146702-54-6

>  <Formula>
C22H18FN7O

>  <MolWt>
415.4

>  <Pathways>
PI3K/Akt/mTOR signaling

>  <Target>
PI3K

>  <Receptor>
" p110??(Cell-free assay):2.5 nM , p110??(Cell-free assay):89 nM"

>  <Bioactivity>
"CAL-101 is a selective inhibitor of p110??(IC50 : 2.5 nM; in cell-free assays); shown to have 40- to 300-fold greater selectivity for p110?? than p110??/??/??, and 400- to 4000-fold more selectivity to p110?? than C2??, hVPS34, DNA-PK and mTOR."

>  <Reference>
"Brian J Lannutti, Sarah A Meadows, Sarah E M Herman,et al.CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.Blood. 2011 Jan 13;117(2):591-4.;Sarah E M Herman , Amber L Gordon, Amy J Wagner,et al.Phosphatidylinositol 3-kinase-?? inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.Blood. 2010 Sep 23;116(12):2078-88."

>  <ID<1>>
T8651

$$$$
StarDrop ID 45
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 58 60 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 11.0364 -4.9050 0.0000 0
M  V30 2 S 10.2168 -4.9997 0.0000 0
M  V30 3 C 9.7251 -4.3372 0.0000 0
M  V30 4 C 8.9055 -4.4319 0.0000 0
M  V30 5 C 8.4138 -3.7694 0.0000 0 CFG=2
M  V30 6 N 7.5942 -3.8640 0.0000 0
M  V30 7 C 7.2664 -4.6211 0.0000 0
M  V30 8 O 7.7582 -5.2836 0.0000 0
M  V30 9 C 6.4469 -4.7158 0.0000 0 CFG=2
M  V30 10 C 6.1190 -5.4728 0.0000 0
M  V30 11 C 6.6108 -6.1353 0.0000 0
M  V30 12 C 7.4357 -6.1268 0.0000 0
M  V30 13 N 7.6987 -6.9088 0.0000 0
M  V30 14 C 7.0363 -7.4005 0.0000 0
M  V30 15 C 6.9584 -8.2218 0.0000 0
M  V30 16 C 6.2082 -8.5651 0.0000 0
M  V30 17 C 5.5359 -8.0870 0.0000 0
M  V30 18 C 5.6137 -7.2657 0.0000 0
M  V30 19 C 6.3639 -6.9225 0.0000 0
M  V30 20 N 5.9551 -4.0533 0.0000 0
M  V30 21 C 6.2830 -3.2962 0.0000 0
M  V30 22 O 7.1025 -3.2016 0.0000 0
M  V30 23 C 5.7912 -2.6338 0.0000 0
M  V30 24 C 6.1190 -1.8767 0.0000 0
M  V30 25 N 5.6273 -1.2143 0.0000 0
M  V30 26 C 4.8078 -1.3089 0.0000 0
M  V30 27 O 4.3160 -0.6465 0.0000 0
M  V30 28 O 4.4799 -2.0660 0.0000 0
M  V30 29 C 3.6604 -2.1606 0.0000 0
M  V30 30 C 2.8408 -2.2553 0.0000 0
M  V30 31 C 3.7550 -2.9802 0.0000 0
M  V30 32 C 3.5658 -1.3411 0.0000 0
M  V30 33 C 8.7416 -3.0123 0.0000 0
M  V30 34 O 8.2499 -2.3499 0.0000 0
M  V30 35 N 9.5612 -2.9177 0.0000 0
M  V30 36 C 9.8890 -2.1606 0.0000 0 CFG=1
M  V30 37 C 9.3973 -1.4982 0.0000 0
M  V30 38 C 9.7251 -0.7411 0.0000 0
M  V30 39 O 9.2334 -0.0787 0.0000 0
M  V30 40 O 10.5446 -0.6465 0.0000 0
M  V30 41 C 10.7086 -2.0660 0.0000 0
M  V30 42 O 11.2003 -2.7284 0.0000 0
M  V30 43 N 11.0364 -1.3089 0.0000 0
M  V30 44 C 11.8559 -1.2143 0.0000 0 CFG=1
M  V30 45 C 12.1838 -0.4572 0.0000 0
M  V30 46 C 13.0033 -0.3626 0.0000 0
M  V30 47 C 13.3311 0.3945 0.0000 0
M  V30 48 C 14.1507 0.4891 0.0000 0
M  V30 49 C 14.6424 -0.1733 0.0000 0
M  V30 50 C 14.3146 -0.9304 0.0000 0
M  V30 51 C 13.4950 -1.0250 0.0000 0
M  V30 52 C 12.3477 -1.8767 0.0000 0
M  V30 53 N 12.0198 -2.6338 0.0000 0
M  V30 54 O 13.1672 -1.7821 0.0000 0
M  V30 55 H 7.8177 -2.9665 0.0000 0
M  V30 56 H 5.4535 -4.8303 0.0000 0
M  V30 57 H 8.8956 -2.2754 0.0000 0
M  V30 58 H 11.4586 -2.1320 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 9 7
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 11 19
M  V30 20 1 14 19
M  V30 21 1 9 20 CFG=3
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 29 31
M  V30 33 1 29 32
M  V30 34 1 5 33
M  V30 35 2 33 34
M  V30 36 1 33 35
M  V30 37 1 36 35 CFG=1
M  V30 38 1 36 37
M  V30 39 1 37 38
M  V30 40 1 38 39
M  V30 41 2 38 40
M  V30 42 1 36 41
M  V30 43 2 41 42
M  V30 44 1 41 43
M  V30 45 1 44 43 CFG=1
M  V30 46 1 44 45
M  V30 47 1 45 46
M  V30 48 2 46 47
M  V30 49 1 47 48
M  V30 50 2 48 49
M  V30 51 1 49 50
M  V30 52 2 50 51
M  V30 53 1 46 51
M  V30 54 1 44 52
M  V30 55 1 52 53
M  V30 56 2 52 54
M  V30 57 1 55 5
M  V30 58 1 56 9
M  V30 59 1 57 36
M  V30 60 1 58 44
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
45

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pentagastrin

>  <Synonyms>
ICI-50123

>  <CAS>
5534-95-2

>  <Formula>
C37H49N7O9S

>  <MolWt>
767.9

>  <Pathways>
GPCR/G Protein;Others

>  <Target>
Others;cholecystokinin

>  <Receptor>
 CCKBreceptor:11 nM (IC50)

>  <Bioactivity>
"pentagastrin is a synthetic polypeptide that has effects like gastrin when given parenterally, which can cause the secretion and synthesis of salivary proteins."

>  <Reference>
"Abdel-Salam O.etal.Gastric acid inhibitory and gastric protective effects of Cannabis and cannabinoids. Asian Pac J Trop Med. 2016 May;9(5):413-9.;Czekaj R,etal.Role of curcumin in protection of gastric mucosa against stress-induced gastric mucosal damage. Involvement of hypoacidity, vasoactive mediators and sensory neuropeptides.J Physiol Pharmacol. 2016 Apr;67(2):261-75.;Loy F,etal.Ultrastructural evidence of a secretory role for melatonin in the human parotid gland.J Physiol Pharmacol. 2015 Dec;66(6):847-53."

>  <ID<1>>
T4579

$$$$
StarDrop ID 46
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 52 56 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.3492 4.3988 0.0000 0
M  V30 2 N 4.0637 3.9863 0.0000 0
M  V30 3 C 4.7782 4.3988 0.0000 0
M  V30 4 C 5.4926 3.9863 0.0000 0
M  V30 5 O 5.4926 3.1613 0.0000 0
M  V30 6 O 6.2071 4.3988 0.0000 0
M  V30 7 C 6.9216 3.9863 0.0000 0
M  V30 8 C 7.6360 4.3988 0.0000 0
M  V30 9 C 7.6360 5.2238 0.0000 0
M  V30 10 C 8.3505 5.6363 0.0000 0
M  V30 11 C 9.0650 5.2238 0.0000 0
M  V30 12 N 9.0650 4.3988 0.0000 0
M  V30 13 C 8.3505 3.9863 0.0000 0
M  V30 14 N 8.3505 3.1613 0.0000 0
M  V30 15 C 9.0650 2.7488 0.0000 0
M  V30 16 C 7.6360 2.7488 0.0000 0
M  V30 17 O 6.9216 3.1613 0.0000 0
M  V30 18 O 7.6360 1.9238 0.0000 0
M  V30 19 C 6.9216 1.5113 0.0000 0
M  V30 20 C 6.2071 1.9238 0.0000 0
M  V30 21 N 6.9216 0.6863 0.0000 0 CHG=1
M  V30 22 C 7.5890 0.2014 0.0000 0
M  V30 23 N 7.3341 -0.5832 0.0000 0
M  V30 24 N 6.5091 -0.5832 0.0000 0
M  V30 25 C 6.0241 -1.2507 0.0000 0
M  V30 26 C 5.2037 -1.1644 0.0000 0 CFG=1
M  V30 27 O 5.2899 -0.3439 0.0000 0
M  V30 28 C 5.1174 -1.9849 0.0000 0 CFG=1
M  V30 29 C 4.3638 -2.3205 0.0000 0
M  V30 30 C 5.7849 -2.4698 0.0000 0
M  V30 31 N 5.7849 -3.2948 0.0000 0
M  V30 32 C 6.5695 -3.5498 0.0000 0
M  V30 33 C 7.0544 -2.8823 0.0000 0
M  V30 34 S 6.5695 -2.2149 0.0000 0
M  V30 35 C 6.8244 -4.3344 0.0000 0
M  V30 36 C 7.6314 -4.5059 0.0000 0
M  V30 37 C 7.8863 -5.2905 0.0000 0
M  V30 38 C 7.3343 -5.9036 0.0000 0
M  V30 39 C 6.5273 -5.7321 0.0000 0
M  V30 40 C 6.2724 -4.9475 0.0000 0
M  V30 41 C 7.5892 -6.6882 0.0000 0
M  V30 42 N 7.8442 -7.4729 0.0000 0
M  V30 43 C 4.3832 -1.0782 0.0000 0
M  V30 44 C 3.8983 -1.7456 0.0000 0
M  V30 45 C 3.0778 -1.6594 0.0000 0
M  V30 46 F 2.5929 -2.3268 0.0000 0
M  V30 47 C 2.7422 -0.9057 0.0000 0
M  V30 48 C 3.2271 -0.2383 0.0000 0
M  V30 49 C 4.0476 -0.3245 0.0000 0
M  V30 50 F 4.5325 0.3429 0.0000 0
M  V30 51 C 6.2541 0.2014 0.0000 0
M  V30 52 H 5.0130 -2.9794 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 8 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 26 25 CFG=1
M  V30 27 1 26 27 CFG=3
M  V30 28 1 26 28
M  V30 29 1 28 29 CFG=3
M  V30 30 1 28 30
M  V30 31 2 30 31
M  V30 32 1 31 32
M  V30 33 2 32 33
M  V30 34 1 33 34
M  V30 35 1 30 34
M  V30 36 1 32 35
M  V30 37 2 35 36
M  V30 38 1 36 37
M  V30 39 2 37 38
M  V30 40 1 38 39
M  V30 41 2 39 40
M  V30 42 1 35 40
M  V30 43 1 38 41
M  V30 44 3 41 42
M  V30 45 1 26 43
M  V30 46 2 43 44
M  V30 47 1 44 45
M  V30 48 1 45 46
M  V30 49 2 45 47
M  V30 50 1 47 48
M  V30 51 2 48 49
M  V30 52 1 43 49
M  V30 53 1 49 50
M  V30 54 1 24 51
M  V30 55 2 21 51
M  V30 56 1 52 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
46

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Isavuconazonium sulfate

>  <Synonyms>
N/A

>  <CAS>
946075-13-4

>  <Formula>
C35H36F2N8O9S2

>  <MolWt>
814.8

>  <Pathways>
Microbiology/Virology

>  <Target>
Antifungal

>  <Receptor>
antifungal; Fungal

>  <Bioactivity>
"Isavuconazonium sulfate is hydrolyzed by plasma esterases to yield the active moiety isavuconazole. Isavuconazole binds to and inhibits the fungal cytochrome P450 family enzyme lanosterol 14-alpha-demethylase (CYP51), which catalyzes the demethylation of lanosterol to yield ergosterol, an important component of the fungal cell membrane. Isavuconazonium Sulfate is a prodrug of the triazole antifungal agent isavuconazole, with broad-spectrum antifungal activity. Inhibition of CYP51 leads to a decrease in fungal ergosterol production and disrupts the synthesis of the fungal cell membrane, which decreases membrane integrity, increases cell membrane permeability and promotes the loss of essential intracellular elements. This results in fungal cell lysis and death."

>  <Reference>
"Kovanda LL, et al. Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response. Clin Infect Dis. 2017 May 2."

>  <ID<1>>
T3934

$$$$
StarDrop ID 47
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 140 152 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.7129 -3.8417 0.0000 0
M  V30 2 N 3.5156 -3.0407 0.0000 0
M  V30 3 C 4.1108 -2.4693 0.0000 0 CFG=1
M  V30 4 C 4.7813 -2.9927 0.0000 0
M  V30 5 C 4.7974 -3.8324 0.0000 0
M  V30 6 C 5.5149 -4.2549 0.0000 0
M  V30 7 C 6.2357 -3.8379 0.0000 0
M  V30 8 O 6.9455 -4.2585 0.0000 0
M  V30 9 C 6.2555 -2.9989 0.0000 0
M  V30 10 O 6.9107 -2.4558 0.0000 0
M  V30 11 C 7.1379 -1.6357 0.0000 0
M  V30 12 C 7.8805 -1.2450 0.0000 0
M  V30 13 C 7.9352 -0.4158 0.0000 0
M  V30 14 O 8.6746 -0.0500 0.0000 0
M  V30 15 C 7.2445 0.0428 0.0000 0
M  V30 16 Cl 7.3035 0.8657 0.0000 0
M  V30 17 C 6.4863 -0.3171 0.0000 0
M  V30 18 C 6.4530 -1.1530 0.0000 0
M  V30 19 C 5.7375 0.0964 0.0000 0 CFG=2
M  V30 20 N 4.8974 -0.0069 0.0000 0
M  V30 21 C 4.0589 -0.0488 0.0000 0
M  V30 22 O 3.9526 0.7693 0.0000 0
M  V30 23 C 3.2273 -0.2248 0.0000 0 CFG=1
M  V30 24 C 2.5637 0.3137 0.0000 0
M  V30 25 C 2.3566 1.1375 0.0000 0
M  V30 26 C 1.7676 1.7370 0.0000 0
M  V30 27 C 1.9926 2.5447 0.0000 0
M  V30 28 C 2.8028 2.7816 0.0000 0
M  V30 29 O 3.3083 3.4734 0.0000 0
M  V30 30 C 4.1133 3.7688 0.0000 0
M  V30 31 C 4.6702 3.1403 0.0000 0
M  V30 32 C 5.5023 3.2505 0.0000 0
M  V30 33 C 5.7615 4.0478 0.0000 0
M  V30 34 C 5.2544 4.7171 0.0000 0
M  V30 35 O 5.6969 5.4489 0.0000 0
M  V30 36 C 6.5058 5.7357 0.0000 0
M  V30 37 C 6.9270 5.0118 0.0000 0
M  V30 38 C 7.7527 4.9810 0.0000 0
M  V30 39 C 8.2137 5.6782 0.0000 0
M  V30 40 C 7.8002 6.4130 0.0000 0
M  V30 41 C 6.9641 6.4421 0.0000 0
M  V30 42 Cl 6.5830 7.1738 0.0000 0
M  V30 43 C 9.0046 5.3661 0.0000 0 CFG=1
M  V30 44 O 9.5205 6.0099 0.0000 0
M  V30 45 C 9.4805 4.6637 0.0000 0 CFG=2
M  V30 46 N 9.1156 3.9038 0.0000 0
M  V30 47 C 8.7866 3.1388 0.0000 0
M  V30 48 O 8.0067 3.4081 0.0000 0
M  V30 49 C 8.5720 2.3287 0.0000 0 CFG=2
M  V30 50 N 7.7260 2.3375 0.0000 0
M  V30 51 C 6.9040 2.5041 0.0000 0
M  V30 52 O 7.0276 3.3198 0.0000 0
M  V30 53 C 6.0534 2.5901 0.0000 0 CFG=2
M  V30 54 N 5.8010 1.7816 0.0000 0
M  V30 55 C 5.7275 0.9402 0.0000 0
M  V30 56 O 4.9030 0.9713 0.0000 0
M  V30 57 C 9.1534 1.6937 0.0000 0
M  V30 58 C 9.0198 0.8677 0.0000 0
M  V30 59 C 9.6409 0.3111 0.0000 0
M  V30 60 C 10.4254 0.5783 0.0000 0
M  V30 61 O 11.0442 0.0327 0.0000 0
M  V30 62 C 10.5939 1.3972 0.0000 0
M  V30 63 C 9.9533 1.9383 0.0000 0
M  V30 64 C 11.3143 1.8393 0.0000 0
M  V30 65 C 11.8251 1.1914 0.0000 0
M  V30 66 O 11.5194 0.4251 0.0000 0
M  V30 67 C 12.0301 -0.2228 0.0000 0 CFG=1
M  V30 68 O 12.8466 -0.1044 0.0000 0
M  V30 69 C 13.3573 -0.7523 0.0000 0 CFG=2
M  V30 70 C 14.1738 -0.6339 0.0000 0
M  V30 71 O 14.6845 -1.2818 0.0000 0
M  V30 72 C 13.0516 -1.5185 0.0000 0 CFG=1
M  V30 73 O 13.5623 -2.1664 0.0000 0
M  V30 74 C 12.2351 -1.6369 0.0000 0 CFG=2
M  V30 75 O 11.9294 -2.4032 0.0000 0
M  V30 76 C 11.7244 -0.9890 0.0000 0 CFG=2
M  V30 77 O 10.9079 -1.1074 0.0000 0
M  V30 78 C 12.6416 1.3098 0.0000 0
M  V30 79 C 12.9473 2.0760 0.0000 0
M  V30 80 O 13.7637 2.1944 0.0000 0
M  V30 81 C 12.4365 2.7239 0.0000 0
M  V30 82 C 11.6201 2.6056 0.0000 0
M  V30 83 C 11.5050 3.4537 0.0000 0 CFG=2
M  V30 84 N 11.0429 4.1605 0.0000 0
M  V30 85 C 10.3252 4.5997 0.0000 0
M  V30 86 O 10.5787 5.3847 0.0000 0
M  V30 87 C 12.2780 3.7419 0.0000 0
M  V30 88 O 12.4149 4.5555 0.0000 0
M  V30 89 O 12.9142 3.2166 0.0000 0
M  V30 90 C 4.4266 4.5456 0.0000 0
M  V30 91 O 3.8978 5.1788 0.0000 0
M  V30 92 C 3.0850 5.0375 0.0000 0 CFG=2
M  V30 93 O 2.8010 4.2629 0.0000 0
M  V30 94 C 1.9882 4.1215 0.0000 0 CFG=1
M  V30 95 C 1.4594 4.7548 0.0000 0 CFG=1
M  V30 96 O 0.6466 4.6134 0.0000 0
M  V30 97 C 1.7434 5.5294 0.0000 0 CFG=2
M  V30 98 O 1.2145 6.1626 0.0000 0
M  V30 99 C 2.5562 5.6707 0.0000 0 CFG=1
M  V30 100 N 2.8401 6.4453 0.0000 0
M  V30 101 C 2.3113 7.0785 0.0000 0
M  V30 102 O 1.4985 6.9372 0.0000 0
M  V30 103 C 2.5953 7.8531 0.0000 0
M  V30 104 C 2.0665 8.4863 0.0000 0
M  V30 105 C 2.3504 9.2609 0.0000 0
M  V30 106 C 1.8216 9.8941 0.0000 0
M  V30 107 C 2.1056 10.6687 0.0000 0
M  V30 108 C 1.5768 11.3019 0.0000 0
M  V30 109 C 1.8608 12.0765 0.0000 0
M  V30 110 C 1.3319 12.7098 0.0000 0
M  V30 111 C 1.6159 13.4843 0.0000 0
M  V30 112 C 1.0871 14.1176 0.0000 0
M  V30 113 C 2.4287 13.6257 0.0000 0
M  V30 114 C 1.7042 3.3470 0.0000 0
M  V30 115 O 0.8914 3.2056 0.0000 0
M  V30 116 O 1.5028 2.5469 0.0000 0
M  V30 117 C 3.3740 2.1703 0.0000 0
M  V30 118 C 3.1584 1.3748 0.0000 0
M  V30 119 N 3.1844 -1.0690 0.0000 0
M  V30 120 C 3.6224 -1.7880 0.0000 0
M  V30 121 O 2.9344 -2.2433 0.0000 0
M  V30 122 C 5.5187 -2.5955 0.0000 0
M  V30 123 H 11.0404 -0.3662 0.0000 0
M  V30 124 H 13.7279 0.1765 0.0000 0
M  V30 125 H 14.0413 -1.3751 0.0000 0
M  V30 126 H 11.2455 -1.7804 0.0000 0
M  V30 127 H 11.3538 -1.9178 0.0000 0
M  V30 128 H 11.8032 4.4082 0.0000 0
M  V30 129 H 3.7259 4.2699 0.0000 0
M  V30 130 H 1.0030 3.9503 0.0000 0
M  V30 131 H 1.1152 3.8159 0.0000 0
M  V30 132 H 10.0029 5.3071 0.0000 0
M  V30 133 H 9.9837 3.7996 0.0000 0
M  V30 134 H 9.5486 2.5435 0.0000 0
M  V30 135 H 5.0700 2.4088 0.0000 0
M  V30 136 H 3.1159 -2.3684 0.0000 0
M  V30 137 H 6.6016 0.5997 0.0000 0
M  V30 138 H 3.9903 -0.8712 0.0000 0
M  V30 139 H 0.7582 5.3580 0.0000 0
M  V30 140 H 1.9152 6.4382 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 2 17 18
M  V30 18 1 11 18
M  V30 19 1 19 17 CFG=3
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 23 21
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 2 27 28
M  V30 29 1 28 29
M  V30 30 1 29 30
M  V30 31 2 30 31
M  V30 32 1 31 32
M  V30 33 2 32 33
M  V30 34 1 33 34
M  V30 35 1 34 35
M  V30 36 1 35 36
M  V30 37 2 36 37
M  V30 38 1 37 38
M  V30 39 2 38 39
M  V30 40 1 39 40
M  V30 41 2 40 41
M  V30 42 1 36 41
M  V30 43 1 41 42
M  V30 44 1 43 39
M  V30 45 1 43 44 CFG=1
M  V30 46 1 43 45
M  V30 47 1 45 46 CFG=1
M  V30 48 1 46 47
M  V30 49 2 47 48
M  V30 50 1 49 47
M  V30 51 1 49 50
M  V30 52 1 50 51
M  V30 53 2 51 52
M  V30 54 1 53 51
M  V30 55 1 53 32 CFG=3
M  V30 56 1 53 54
M  V30 57 1 54 55
M  V30 58 1 19 55
M  V30 59 2 55 56
M  V30 60 1 49 57 CFG=1
M  V30 61 2 57 58
M  V30 62 1 58 59
M  V30 63 2 59 60
M  V30 64 1 60 61
M  V30 65 1 60 62
M  V30 66 2 62 63
M  V30 67 1 57 63
M  V30 68 1 62 64
M  V30 69 2 64 65
M  V30 70 1 65 66
M  V30 71 1 67 66 CFG=1
M  V30 72 1 67 68
M  V30 73 1 69 68
M  V30 74 1 69 70 CFG=3
M  V30 75 1 70 71
M  V30 76 1 72 69
M  V30 77 1 72 73 CFG=1
M  V30 78 1 72 74
M  V30 79 1 74 75 CFG=3
M  V30 80 1 74 76
M  V30 81 1 76 67
M  V30 82 1 76 77 CFG=3
M  V30 83 1 65 78
M  V30 84 2 78 79
M  V30 85 1 79 80
M  V30 86 1 79 81
M  V30 87 2 81 82
M  V30 88 1 64 82
M  V30 89 1 83 82
M  V30 90 1 83 84
M  V30 91 1 84 85
M  V30 92 1 45 85
M  V30 93 2 85 86
M  V30 94 1 83 87 CFG=3
M  V30 95 1 87 88
M  V30 96 2 87 89
M  V30 97 2 34 90
M  V30 98 1 30 90
M  V30 99 1 90 91
M  V30 100 1 92 91 CFG=3
M  V30 101 1 92 93
M  V30 102 1 94 93
M  V30 103 1 95 94
M  V30 104 1 95 96 CFG=1
M  V30 105 1 95 97
M  V30 106 1 97 98 CFG=3
M  V30 107 1 97 99
M  V30 108 1 99 92
M  V30 109 1 99 100 CFG=1
M  V30 110 1 100 101
M  V30 111 2 101 102
M  V30 112 1 101 103
M  V30 113 1 103 104
M  V30 114 1 104 105
M  V30 115 1 105 106
M  V30 116 1 106 107
M  V30 117 1 107 108
M  V30 118 1 108 109
M  V30 119 1 109 110
M  V30 120 1 110 111
M  V30 121 1 111 112
M  V30 122 1 111 113
M  V30 123 1 94 114 CFG=3
M  V30 124 1 114 115
M  V30 125 2 114 116
M  V30 126 1 28 117
M  V30 127 2 117 118
M  V30 128 1 25 118
M  V30 129 1 23 119 CFG=3
M  V30 130 1 119 120
M  V30 131 1 3 120
M  V30 132 2 120 121
M  V30 133 2 9 122
M  V30 134 1 4 122
M  V30 135 1 123 67
M  V30 136 1 124 69
M  V30 137 1 125 72
M  V30 138 1 126 74
M  V30 139 1 127 76
M  V30 140 1 128 83
M  V30 141 1 129 92
M  V30 142 1 130 94
M  V30 143 1 131 95
M  V30 144 1 132 43
M  V30 145 1 133 45
M  V30 146 1 134 49
M  V30 147 1 135 53
M  V30 148 1 136 3
M  V30 149 1 137 19
M  V30 150 1 138 23
M  V30 151 1 139 97
M  V30 152 1 140 99
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
47

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
A40926

>  <Synonyms>
Dalbavancin Impurity

>  <CAS>
102961-72-8

>  <Formula>
C83H88Cl2N8O29

>  <MolWt>
1733

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial

>  <Receptor>
antibacterial; Bacterial

>  <Bioactivity>
Dalbavancin Impurity is effective against Gram positive bacteria.

>  <Reference>
"Smith JR, Roberts KD, Rybak MJ. Infect Dis Ther. 2015 Sep;4(3):245-58."

>  <ID<1>>
T2692

$$$$
StarDrop ID 48
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.2446 0.3362 0.0000 0
M  V30 2 C 4.8321 -0.3782 0.0000 0
M  V30 3 N 4.0071 -0.3782 0.0000 0
M  V30 4 C 3.5946 0.3362 0.0000 0
M  V30 5 C 2.7696 0.3362 0.0000 0
M  V30 6 C 2.3571 1.0507 0.0000 0
M  V30 7 C 2.7696 1.7652 0.0000 0
M  V30 8 C 3.5946 1.7652 0.0000 0
M  V30 9 C 4.0071 1.0507 0.0000 0
M  V30 10 C 4.8321 1.0507 0.0000 0
M  V30 11 C 2.3571 -0.3782 0.0000 0
M  V30 12 C 5.2446 -1.0927 0.0000 0
M  V30 13 N 6.0696 -1.0927 0.0000 0
M  V30 14 C 6.4821 -1.8072 0.0000 0
M  V30 15 C 7.3071 -1.8072 0.0000 0
M  V30 16 C 6.4821 -0.3782 0.0000 0
M  V30 17 C 7.3071 -0.3782 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 4 9
M  V30 10 1 9 10
M  V30 11 1 5 11
M  V30 12 1 2 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 13 16
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
48

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lidocaine hydrochloride

>  <Synonyms>
Xyloneural;Lidocaine HCL;Lidothesin;Lignocaine hydrochloride

>  <CAS>
73-78-9

>  <Formula>
C14H23ClN2O

>  <MolWt>
270.8

>  <Pathways>
MAPK;Membrane transporter/Ion channel;Apoptosis;NF-??b

>  <Target>
Apoptosis;NF-??B;Sodium Channel;ERK;MEK

>  <Receptor>
Apoptosis; ERK; MEK; NF-??B; Sodium Channel

>  <Bioactivity>
Lidocaine hydrochloride is a local anesthetic and cardiac depressant used as an antiarrhythmic agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.

>  <Reference>
"Sakaguchi M, et al. Anesth Analg. 2006, 102(4):1103-7.;Huang Z, Wei P, Gan L, et al. Protective effects of different anti?inflammatory drugs on tracheal stenosis following injury and potential mechanisms[J]. Molecular Medicine Reports. 2021, 23(5): 1-11.;Kurabe M, et al. Sci Rep. 2016, 6:26253.;Yu HZ, et al. Basic Clin Pharmacol Toxicol. 2014, 114(4):352-9."

>  <ID<1>>
T1144

$$$$
StarDrop ID 49
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 150 157 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 41.6403 -13.8795 0.0000 0
M  V30 2 C 41.7081 -13.0572 0.0000 0
M  V30 3 C 42.4541 -12.7049 0.0000 0
M  V30 4 C 41.0300 -12.5874 0.0000 0
M  V30 5 C 41.0978 -11.7652 0.0000 0 CFG=1
M  V30 6 N 40.4197 -11.2954 0.0000 0
M  V30 7 C 39.6737 -11.6477 0.0000 0
M  V30 8 O 39.6059 -12.4700 0.0000 0
M  V30 9 C 38.9956 -11.1779 0.0000 0 CFG=2
M  V30 10 C 39.0634 -10.3557 0.0000 0
M  V30 11 N 38.2496 -11.5303 0.0000 0
M  V30 12 C 37.5715 -11.0605 0.0000 0
M  V30 13 O 37.6393 -10.2382 0.0000 0
M  V30 14 C 36.8255 -11.4128 0.0000 0
M  V30 15 N 36.1474 -10.9430 0.0000 0
M  V30 16 C 35.4014 -11.2954 0.0000 0
M  V30 17 O 35.3336 -12.1176 0.0000 0
M  V30 18 C 34.7232 -10.8255 0.0000 0 CFG=1
M  V30 19 N 33.9773 -11.1779 0.0000 0
M  V30 20 C 33.2991 -10.7081 0.0000 0
M  V30 21 O 32.5532 -11.0605 0.0000 0
M  V30 22 C 34.7911 -10.0033 0.0000 0
M  V30 23 C 34.1129 -9.5335 0.0000 0
M  V30 24 C 35.5370 -9.6510 0.0000 0
M  V30 25 C 41.8438 -11.4128 0.0000 0
M  V30 26 O 41.9116 -10.5906 0.0000 0
M  V30 27 N 42.5219 -11.8827 0.0000 0
M  V30 28 C 43.2679 -11.5303 0.0000 0 CFG=1
M  V30 29 C 43.3357 -10.7081 0.0000 0
M  V30 30 C 43.9460 -12.0001 0.0000 0
M  V30 31 O 43.8782 -12.8223 0.0000 0
M  V30 32 N 44.6920 -11.6477 0.0000 0
M  V30 33 C 45.3701 -12.1176 0.0000 0 CFG=2
M  V30 34 C 45.3023 -12.9398 0.0000 0
M  V30 35 C 45.9805 -13.4096 0.0000 0
M  V30 36 C 44.5564 -13.2922 0.0000 0
M  V30 37 C 46.1161 -11.7652 0.0000 0
M  V30 38 O 46.1839 -10.9430 0.0000 0
M  V30 39 N 46.7942 -12.2350 0.0000 0
M  V30 40 C 47.5402 -11.8827 0.0000 0 CFG=1
M  V30 41 C 47.6080 -11.0605 0.0000 0
M  V30 42 C 48.3540 -10.7081 0.0000 0
M  V30 43 C 46.9299 -10.5906 0.0000 0
M  V30 44 C 48.2183 -12.3525 0.0000 0
M  V30 45 O 48.1505 -13.1747 0.0000 0
M  V30 46 N 48.9643 -12.0001 0.0000 0
M  V30 47 C 49.6425 -12.4700 0.0000 0 CFG=1
M  V30 48 C 49.5746 -13.2922 0.0000 0
M  V30 49 C 50.2528 -13.7620 0.0000 0
M  V30 50 C 48.8287 -13.6445 0.0000 0
M  V30 51 C 50.3884 -12.1176 0.0000 0
M  V30 52 O 50.4562 -11.2954 0.0000 0
M  V30 53 N 51.0666 -12.5874 0.0000 0
M  V30 54 C 51.8125 -12.2350 0.0000 0 CFG=1
M  V30 55 C 51.8803 -11.4128 0.0000 0
M  V30 56 C 52.6263 -11.0605 0.0000 0
M  V30 57 C 53.3498 -11.4568 0.0000 0
M  V30 58 N 53.9504 -10.8912 0.0000 0
M  V30 59 C 53.5980 -10.1452 0.0000 0
M  V30 60 C 53.9166 -9.3842 0.0000 0
M  V30 61 C 53.4168 -8.7278 0.0000 0
M  V30 62 C 52.5985 -8.8324 0.0000 0
M  V30 63 C 52.2799 -9.5934 0.0000 0
M  V30 64 C 52.7797 -10.2498 0.0000 0
M  V30 65 C 52.4907 -12.7049 0.0000 0
M  V30 66 O 52.4229 -13.5271 0.0000 0
M  V30 67 N 53.2366 -12.3525 0.0000 0
M  V30 68 C 53.9148 -12.8223 0.0000 0 CFG=2
M  V30 69 C 53.8470 -13.6445 0.0000 0
M  V30 70 C 54.5251 -14.1144 0.0000 0
M  V30 71 C 55.2711 -13.7620 0.0000 0
M  V30 72 C 54.4573 -14.9366 0.0000 0
M  V30 73 C 54.6607 -12.4700 0.0000 0
M  V30 74 O 54.7285 -11.6477 0.0000 0
M  V30 75 N 55.3389 -12.9398 0.0000 0
M  V30 76 C 56.0848 -12.5874 0.0000 0 CFG=1
M  V30 77 C 56.1527 -11.7652 0.0000 0
M  V30 78 C 56.8986 -11.4128 0.0000 0
M  V30 79 C 57.6222 -11.8092 0.0000 0
M  V30 80 N 58.2227 -11.2436 0.0000 0
M  V30 81 C 57.8703 -10.4976 0.0000 0
M  V30 82 C 58.1889 -9.7366 0.0000 0
M  V30 83 C 57.6891 -9.0802 0.0000 0
M  V30 84 C 56.8708 -9.1848 0.0000 0
M  V30 85 C 56.5522 -9.9458 0.0000 0
M  V30 86 C 57.0520 -10.6022 0.0000 0
M  V30 87 C 56.7630 -13.0572 0.0000 0
M  V30 88 O 56.6952 -13.8795 0.0000 0
M  V30 89 N 57.5089 -12.7049 0.0000 0
M  V30 90 C 58.1871 -13.1747 0.0000 0 CFG=2
M  V30 91 C 58.1193 -13.9969 0.0000 0
M  V30 92 C 58.7974 -14.4667 0.0000 0
M  V30 93 C 59.5434 -14.1144 0.0000 0
M  V30 94 C 58.7296 -15.2890 0.0000 0
M  V30 95 C 58.9331 -12.8223 0.0000 0
M  V30 96 O 59.0009 -12.0001 0.0000 0
M  V30 97 N 59.6112 -13.2922 0.0000 0
M  V30 98 C 60.3572 -12.9398 0.0000 0 CFG=1
M  V30 99 C 60.4250 -12.1176 0.0000 0
M  V30 100 C 61.1709 -11.7652 0.0000 0
M  V30 101 C 61.8945 -12.1616 0.0000 0
M  V30 102 N 62.4950 -11.5959 0.0000 0
M  V30 103 C 62.1427 -10.8500 0.0000 0
M  V30 104 C 62.4612 -10.0890 0.0000 0
M  V30 105 C 61.9615 -9.4326 0.0000 0
M  V30 106 C 61.1431 -9.5372 0.0000 0
M  V30 107 C 60.8246 -10.2982 0.0000 0
M  V30 108 C 61.3243 -10.9546 0.0000 0
M  V30 109 C 61.0353 -13.4096 0.0000 0
M  V30 110 O 60.9675 -14.2318 0.0000 0
M  V30 111 N 61.7813 -13.0572 0.0000 0
M  V30 112 C 62.4594 -13.5271 0.0000 0 CFG=2
M  V30 113 C 62.3916 -14.3493 0.0000 0
M  V30 114 C 63.0697 -14.8191 0.0000 0
M  V30 115 C 63.8157 -14.4667 0.0000 0
M  V30 116 C 63.0019 -15.6413 0.0000 0
M  V30 117 C 63.2054 -13.1747 0.0000 0
M  V30 118 O 63.2732 -12.3525 0.0000 0
M  V30 119 N 63.8835 -13.6445 0.0000 0
M  V30 120 C 64.6295 -13.2922 0.0000 0 CFG=1
M  V30 121 C 65.3076 -13.7620 0.0000 0
M  V30 122 C 66.0536 -13.4096 0.0000 0
M  V30 123 C 66.2070 -12.5990 0.0000 0
M  V30 124 N 67.0253 -12.4944 0.0000 0
M  V30 125 C 67.3777 -13.2404 0.0000 0
M  V30 126 C 68.1678 -13.4776 0.0000 0
M  V30 127 C 68.3574 -14.2806 0.0000 0
M  V30 128 C 67.7568 -14.8462 0.0000 0
M  V30 129 C 66.9667 -14.6089 0.0000 0
M  V30 130 C 66.7771 -13.8060 0.0000 0
M  V30 131 C 64.6973 -12.4700 0.0000 0
M  V30 132 O 65.4433 -12.1176 0.0000 0
M  V30 133 N 64.0191 -12.0001 0.0000 0
M  V30 134 C 64.0870 -11.1779 0.0000 0
M  V30 135 C 63.4088 -10.7081 0.0000 0
M  V30 136 O 63.4766 -9.8859 0.0000 0
M  V30 137 H 40.1936 -12.1924 0.0000 0
M  V30 138 H 39.8998 -10.7507 0.0000 0
M  V30 139 H 34.6411 -11.8221 0.0000 0
M  V30 140 H 44.1721 -11.1031 0.0000 0
M  V30 141 H 53.0106 -13.2494 0.0000 0
M  V30 142 H 56.0027 -13.5840 0.0000 0
M  V30 143 H 57.2829 -13.6018 0.0000 0
M  V30 144 H 45.4524 -11.1210 0.0000 0
M  V30 145 H 46.7182 -11.3132 0.0000 0
M  V30 146 H 49.7245 -11.4734 0.0000 0
M  V30 147 H 50.9905 -11.6655 0.0000 0
M  V30 148 H 60.2749 -13.9364 0.0000 0
M  V30 149 H 62.5417 -12.5305 0.0000 0
M  V30 150 H 63.8075 -12.7227 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=1
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 9 7
M  V30 9 1 9 10 CFG=1
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 18 16
M  V30 18 1 18 19 CFG=1
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 18 22
M  V30 22 1 22 23
M  V30 23 1 22 24
M  V30 24 1 5 25
M  V30 25 2 25 26
M  V30 26 1 25 27
M  V30 27 1 28 27
M  V30 28 1 28 29 CFG=1
M  V30 29 1 28 30
M  V30 30 2 30 31
M  V30 31 1 30 32
M  V30 32 1 33 32 CFG=1
M  V30 33 1 33 34
M  V30 34 1 34 35
M  V30 35 1 34 36
M  V30 36 1 33 37
M  V30 37 2 37 38
M  V30 38 1 37 39
M  V30 39 1 40 39 CFG=1
M  V30 40 1 40 41
M  V30 41 1 41 42
M  V30 42 1 41 43
M  V30 43 1 40 44
M  V30 44 2 44 45
M  V30 45 1 44 46
M  V30 46 1 47 46 CFG=3
M  V30 47 1 47 48
M  V30 48 1 48 49
M  V30 49 1 48 50
M  V30 50 1 47 51
M  V30 51 2 51 52
M  V30 52 1 51 53
M  V30 53 1 54 53 CFG=1
M  V30 54 1 54 55
M  V30 55 1 55 56
M  V30 56 1 56 57
M  V30 57 1 57 58
M  V30 58 2 58 59
M  V30 59 1 59 60
M  V30 60 2 60 61
M  V30 61 1 61 62
M  V30 62 2 62 63
M  V30 63 1 63 64
M  V30 64 2 56 64
M  V30 65 1 59 64
M  V30 66 1 54 65
M  V30 67 2 65 66
M  V30 68 1 65 67
M  V30 69 1 68 67 CFG=1
M  V30 70 1 68 69
M  V30 71 1 69 70
M  V30 72 1 70 71
M  V30 73 1 70 72
M  V30 74 1 68 73
M  V30 75 2 73 74
M  V30 76 1 73 75
M  V30 77 1 76 75 CFG=1
M  V30 78 1 76 77
M  V30 79 1 77 78
M  V30 80 1 78 79
M  V30 81 1 79 80
M  V30 82 2 80 81
M  V30 83 1 81 82
M  V30 84 2 82 83
M  V30 85 1 83 84
M  V30 86 2 84 85
M  V30 87 1 85 86
M  V30 88 2 78 86
M  V30 89 1 81 86
M  V30 90 1 76 87
M  V30 91 2 87 88
M  V30 92 1 87 89
M  V30 93 1 90 89 CFG=1
M  V30 94 1 90 91
M  V30 95 1 91 92
M  V30 96 1 92 93
M  V30 97 1 92 94
M  V30 98 1 90 95
M  V30 99 2 95 96
M  V30 100 1 95 97
M  V30 101 1 98 97 CFG=1
M  V30 102 1 98 99
M  V30 103 1 99 100
M  V30 104 1 100 101
M  V30 105 1 101 102
M  V30 106 2 102 103
M  V30 107 1 103 104
M  V30 108 2 104 105
M  V30 109 1 105 106
M  V30 110 2 106 107
M  V30 111 1 107 108
M  V30 112 2 100 108
M  V30 113 1 103 108
M  V30 114 1 98 109
M  V30 115 2 109 110
M  V30 116 1 109 111
M  V30 117 1 112 111 CFG=1
M  V30 118 1 112 113
M  V30 119 1 113 114
M  V30 120 1 114 115
M  V30 121 1 114 116
M  V30 122 1 112 117
M  V30 123 2 117 118
M  V30 124 1 117 119
M  V30 125 1 120 119 CFG=3
M  V30 126 1 120 121
M  V30 127 1 121 122
M  V30 128 1 122 123
M  V30 129 1 123 124
M  V30 130 2 124 125
M  V30 131 1 125 126
M  V30 132 2 126 127
M  V30 133 1 127 128
M  V30 134 2 128 129
M  V30 135 1 129 130
M  V30 136 2 122 130
M  V30 137 1 125 130
M  V30 138 1 120 131
M  V30 139 2 131 132
M  V30 140 1 131 133
M  V30 141 1 133 134
M  V30 142 1 134 135
M  V30 143 1 135 136
M  V30 144 1 137 5
M  V30 145 1 138 9
M  V30 146 1 139 18
M  V30 147 1 140 28
M  V30 148 1 141 68
M  V30 149 1 142 76
M  V30 150 1 143 90
M  V30 151 1 144 33
M  V30 152 1 145 40
M  V30 153 1 146 47
M  V30 154 1 147 54
M  V30 155 1 148 98
M  V30 156 1 149 112
M  V30 157 1 150 120
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
49

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Gramicidin

>  <Synonyms>
Gramicidine;Gramicidina;Gramicidinum

>  <CAS>
1405-97-6

>  <Formula>
C99H140N20O17

>  <MolWt>
1882

>  <Pathways>
Microbiology/Virology;Immunology/Inflammation

>  <Target>
MRP;Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial; MRP1

>  <Bioactivity>
"A group of peptide antibiotics from BACILLUS brevis. Gramicidin C or S is a cyclic, ten-amino acid polypeptide and gramicidins A, B, D are linear. Gramicidin is one of the two principal components of TYROTHRICIN."

>  <Reference>
"Wang J, Zhu Y, Chen J, et al. Identification of a novel PAK1 inhibitor to treat pancreatic cancer[J]. Acta Pharmaceutica Sinica B. 2020, 10(4): 603-614.;Nagy H, et al. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9."

>  <ID<1>>
T1130

$$$$
StarDrop ID 50
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.2466 0.4313 0.0000 0
M  V30 2 C 3.0716 0.4313 0.0000 0
M  V30 3 C 3.0716 -0.3937 0.0000 0
M  V30 4 C 3.7861 -0.8062 0.0000 0
M  V30 5 N 3.7861 -1.6312 0.0000 0
M  V30 6 C 4.5006 -2.0438 0.0000 0
M  V30 7 C 4.5006 -2.8688 0.0000 0
M  V30 8 C 3.7861 -3.2813 0.0000 0
M  V30 9 C 3.0716 -2.8688 0.0000 0
M  V30 10 C 3.0716 -2.0438 0.0000 0
M  V30 11 C 3.0716 1.2563 0.0000 0
M  V30 12 C 2.3571 1.6688 0.0000 0
M  V30 13 C 2.3571 2.4938 0.0000 0
M  V30 14 C 3.0716 2.9063 0.0000 0
M  V30 15 C 3.7861 2.4938 0.0000 0
M  V30 16 C 3.7861 1.6688 0.0000 0
M  V30 17 C 3.8966 0.4312 0.0000 0
M  V30 18 C 4.3091 1.1457 0.0000 0
M  V30 19 C 5.1341 1.1457 0.0000 0
M  V30 20 C 5.5466 0.4312 0.0000 0
M  V30 21 C 5.1341 -0.2832 0.0000 0
M  V30 22 C 4.3091 -0.2832 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 5 10
M  V30 11 1 2 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 11 16
M  V30 18 1 2 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
50

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
DL-trihexyphenidyl hydrochloride

>  <Synonyms>
Trihexyphenidyl HCl;Artane;Tremin

>  <CAS>
58947-95-8

>  <Formula>
C20H32ClNO

>  <MolWt>
337.9

>  <Pathways>
Neuroscience

>  <Target>
AChR

>  <Receptor>
mAChR

>  <Bioactivity>
DL-trihexyphenidyl hydrochloride is a muscarinic antagonist.

>  <Reference>
"Bognar IT, et al. Naunyn Schmiedebergs Arch Pharmacol. 1992 Jun;345(6):611-8."

>  <ID<1>>
T1328

$$$$
StarDrop ID 51
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 100 105 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 12.5381 -3.2666 0.0000 0
M  V30 2 C 12.9411 -2.5467 0.0000 0
M  V30 3 C 13.7660 -2.5357 0.0000 0
M  V30 4 C 12.5191 -1.8378 0.0000 0
M  V30 5 C 12.9220 -1.1179 0.0000 0 CFG=2
M  V30 6 N 12.5000 -0.4090 0.0000 0
M  V30 7 C 11.6751 -0.4200 0.0000 0
M  V30 8 O 11.2722 -1.1399 0.0000 0
M  V30 9 C 11.2531 0.2889 0.0000 0 CFG=1
M  V30 10 C 11.6560 1.0088 0.0000 0
M  V30 11 O 12.4809 1.0199 0.0000 0
M  V30 12 C 12.8839 1.7398 0.0000 0
M  V30 13 C 13.6038 1.3368 0.0000 0
M  V30 14 C 12.1640 2.1427 0.0000 0
M  V30 15 C 13.2868 2.4597 0.0000 0
M  V30 16 N 10.4282 0.2779 0.0000 0
M  V30 17 C 10.0062 0.9868 0.0000 0
M  V30 18 O 10.4091 1.7067 0.0000 0
M  V30 19 C 9.1812 0.9758 0.0000 0 CFG=2
M  V30 20 C 8.7783 0.2559 0.0000 0
M  V30 21 C 9.2003 -0.4530 0.0000 0
M  V30 22 C 10.0252 -0.4420 0.0000 0
M  V30 23 C 10.4472 -1.1509 0.0000 0
M  V30 24 C 10.0443 -1.8708 0.0000 0
M  V30 25 O 10.4663 -2.5797 0.0000 0
M  V30 26 C 9.2194 -1.8818 0.0000 0
M  V30 27 C 8.7974 -1.1729 0.0000 0
M  V30 28 N 8.7592 1.6847 0.0000 0
M  V30 29 C 7.9343 1.6737 0.0000 0
M  V30 30 O 7.5314 0.9538 0.0000 0
M  V30 31 C 7.5123 2.3826 0.0000 0 CFG=2
M  V30 32 C 7.9153 3.1025 0.0000 0
M  V30 33 O 8.7402 3.1135 0.0000 0
M  V30 34 N 6.6874 2.3716 0.0000 0
M  V30 35 C 6.2654 3.0805 0.0000 0
M  V30 36 O 6.6683 3.8004 0.0000 0
M  V30 37 C 5.4405 3.0695 0.0000 0 CFG=2
M  V30 38 C 5.0185 3.7784 0.0000 0
M  V30 39 C 4.1936 3.7674 0.0000 0
M  V30 40 C 3.7176 3.0936 0.0000 0
M  V30 41 N 2.9296 3.3380 0.0000 0
M  V30 42 C 2.9186 4.1629 0.0000 0
M  V30 43 C 2.2982 4.7067 0.0000 0
M  V30 44 C 2.4590 5.5159 0.0000 0
M  V30 45 C 3.2401 5.7813 0.0000 0
M  V30 46 C 3.8605 5.2375 0.0000 0
M  V30 47 C 3.6998 4.4283 0.0000 0
M  V30 48 N 5.0375 2.3496 0.0000 0
M  V30 49 C 5.4595 1.6407 0.0000 0
M  V30 50 O 6.2845 1.6517 0.0000 0
M  V30 51 C 5.0566 0.9208 0.0000 0 CFG=2
M  V30 52 C 4.2755 0.6554 0.0000 0
M  V30 53 C 3.6551 1.1992 0.0000 0
M  V30 54 C 2.8504 1.0169 0.0000 0
M  V30 55 N 2.4284 1.7258 0.0000 0
M  V30 56 C 2.9723 2.3462 0.0000 0
M  V30 57 N 3.7303 2.0208 0.0000 0
M  V30 58 N 5.6770 0.3770 0.0000 0
M  V30 59 C 5.5163 -0.4322 0.0000 0
M  V30 60 O 4.7351 -0.6976 0.0000 0
M  V30 61 C 6.1367 -0.9760 0.0000 0 CFG=2
M  V30 62 C 6.0614 -1.7976 0.0000 0
M  V30 63 C 6.8195 -2.1230 0.0000 0
M  V30 64 C 7.3633 -1.5026 0.0000 0
M  V30 65 O 8.1848 -1.5779 0.0000 0
M  V30 66 N 6.9413 -0.7937 0.0000 0
M  V30 67 C 13.7469 -1.1069 0.0000 0
M  V30 68 O 14.1499 -0.3869 0.0000 0
M  V30 69 N 14.1689 -1.8158 0.0000 0
M  V30 70 C 14.9939 -1.8048 0.0000 0 CFG=1
M  V30 71 C 15.3968 -1.0848 0.0000 0
M  V30 72 C 16.2217 -1.0738 0.0000 0
M  V30 73 C 16.6246 -0.3539 0.0000 0
M  V30 74 N 17.4496 -0.3429 0.0000 0
M  V30 75 C 17.8525 0.3770 0.0000 0
M  V30 76 N 17.4305 1.0859 0.0000 0
M  V30 77 N 18.6774 0.3880 0.0000 0
M  V30 78 C 15.4159 -2.5137 0.0000 0
M  V30 79 O 16.2408 -2.5027 0.0000 0
M  V30 80 N 15.0129 -3.2336 0.0000 0
M  V30 81 C 14.1937 -3.3307 0.0000 0
M  V30 82 C 14.0329 -4.1399 0.0000 0
M  V30 83 C 14.7528 -4.5429 0.0000 0
M  V30 84 C 15.3585 -3.9827 0.0000 0 CFG=1
M  V30 85 C 16.1677 -4.1434 0.0000 0
M  V30 86 O 16.7115 -3.5230 0.0000 0
M  V30 87 N 16.4331 -4.9246 0.0000 0
M  V30 88 N 17.2423 -5.0853 0.0000 0
M  V30 89 C 17.5076 -5.8665 0.0000 0
M  V30 90 N 18.3168 -6.0272 0.0000 0
M  V30 91 O 16.9638 -6.4869 0.0000 0
M  V30 92 H 14.5054 -2.6774 0.0000 0
M  V30 93 H 15.9774 -3.1972 0.0000 0
M  V30 94 H 13.4104 -0.2453 0.0000 0
M  V30 95 H 10.7416 1.1482 0.0000 0
M  V30 96 H 8.1813 0.9625 0.0000 0
M  V30 97 H 7.0239 1.5100 0.0000 0
M  V30 98 H 4.4406 3.0562 0.0000 0
M  V30 99 H 6.0421 1.0904 0.0000 0
M  V30 100 H 6.3826 -0.0067 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 9 7
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 15 1 9 16 CFG=3
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 19 17
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 2 24 26
M  V30 26 1 26 27
M  V30 27 2 21 27
M  V30 28 1 19 28 CFG=3
M  V30 29 1 28 29
M  V30 30 2 29 30
M  V30 31 1 31 29
M  V30 32 1 31 32
M  V30 33 1 32 33
M  V30 34 1 31 34 CFG=1
M  V30 35 1 34 35
M  V30 36 2 35 36
M  V30 37 1 37 35
M  V30 38 1 37 38
M  V30 39 1 38 39
M  V30 40 1 39 40
M  V30 41 1 40 41
M  V30 42 2 41 42
M  V30 43 1 42 43
M  V30 44 2 43 44
M  V30 45 1 44 45
M  V30 46 2 45 46
M  V30 47 1 46 47
M  V30 48 2 39 47
M  V30 49 1 42 47
M  V30 50 1 37 48 CFG=1
M  V30 51 1 48 49
M  V30 52 2 49 50
M  V30 53 1 51 49
M  V30 54 1 51 52
M  V30 55 1 52 53
M  V30 56 1 53 54
M  V30 57 1 54 55
M  V30 58 2 55 56
M  V30 59 1 56 57
M  V30 60 2 53 57
M  V30 61 1 51 58 CFG=1
M  V30 62 1 58 59
M  V30 63 2 59 60
M  V30 64 1 61 59 CFG=1
M  V30 65 1 61 62
M  V30 66 1 62 63
M  V30 67 1 63 64
M  V30 68 2 64 65
M  V30 69 1 64 66
M  V30 70 1 61 66
M  V30 71 1 5 67
M  V30 72 2 67 68
M  V30 73 1 67 69
M  V30 74 1 70 69 CFG=1
M  V30 75 1 70 71
M  V30 76 1 71 72
M  V30 77 1 72 73
M  V30 78 1 73 74
M  V30 79 1 74 75
M  V30 80 1 75 76
M  V30 81 2 75 77
M  V30 82 1 70 78
M  V30 83 2 78 79
M  V30 84 1 78 80
M  V30 85 1 80 81
M  V30 86 1 81 82
M  V30 87 1 82 83
M  V30 88 1 84 83
M  V30 89 1 84 80
M  V30 90 1 84 85 CFG=3
M  V30 91 2 85 86
M  V30 92 1 85 87
M  V30 93 1 87 88
M  V30 94 1 88 89
M  V30 95 1 89 90
M  V30 96 2 89 91
M  V30 97 1 92 70
M  V30 98 1 93 84
M  V30 99 1 94 5
M  V30 100 1 95 9
M  V30 101 1 96 19
M  V30 102 1 97 31
M  V30 103 1 98 37
M  V30 104 1 99 51
M  V30 105 1 100 61
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
51

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Goserelin acetate

>  <Synonyms>
ICI-118630 acetate;Fertilan;Zoladex

>  <CAS>
145781-92-6

>  <Formula>
C61H88N18O16

>  <MolWt>
1329

>  <Pathways>
GPCR/G Protein;Apoptosis

>  <Target>
Apoptosis;GNRH Receptor

>  <Receptor>
Apoptosis; GnRHR

>  <Bioactivity>
"Goserelin acetate is a synthetic long-acting agonist of gonadotropin-releasing hormone, used in treatments of cancer."

>  <Reference>
I.K. Morton; Judith M. Hall (6 December 2012).?Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp.?136?C.

>  <ID<1>>
T4102

$$$$
StarDrop ID 52
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.7679 0.1261 0.0000 0
M  V30 2 C 2.5929 0.1261 0.0000 0
M  V30 3 O 3.0054 0.8406 0.0000 0
M  V30 4 C 3.8304 0.8406 0.0000 0
M  V30 5 C 4.2429 1.5550 0.0000 0
M  V30 6 N 5.0679 1.5550 0.0000 0
M  V30 7 C 5.4804 2.2695 0.0000 0
M  V30 8 C 6.3054 2.2695 0.0000 0
M  V30 9 C 5.4804 0.8406 0.0000 0
M  V30 10 C 5.0679 0.1261 0.0000 0
M  V30 11 C 3.0054 -0.5884 0.0000 0
M  V30 12 C 3.8304 -0.5884 0.0000 0
M  V30 13 C 4.2429 -1.3029 0.0000 0
M  V30 14 C 3.8304 -2.0173 0.0000 0
M  V30 15 N 4.2429 -2.7318 0.0000 0
M  V30 16 C 3.0054 -2.0173 0.0000 0
M  V30 17 C 2.5929 -1.3029 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 6 9
M  V30 9 1 9 10
M  V30 10 1 2 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 2 16 17
M  V30 17 1 11 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
52

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Procaine hydrochloride

>  <Synonyms>
Novocaine HCl;Procaine HCl

>  <CAS>
51-05-8

>  <Formula>
C13H21ClN2O2

>  <MolWt>
272.8

>  <Pathways>
DNA Damage/DNA Repair;GPCR/G Protein;Membrane transporter/Ion channel;Cell Cycle/Checkpoint;Neuroscience;Chromatin/Epigenetic

>  <Target>
AChR;DNA/RNA Synthesis;Histone Demethylase;Sodium Channel;5-HT Receptor;NMDAR

>  <Receptor>
" sodium channel:60 ??M, NMDA Receptor:0.296 mM, 5-HT3:1.7 ??M(Kd), nAChR:45.5 ??M"

>  <Bioactivity>
"Procaine Hydrochloride is the hydrochloride salt form of procaine, a benzoic acid derivative with local anesthetic and antiarrhythmic properties. Procaine binds to and inhibits voltage-gated sodiumchannels, thereby inhibiting the ionic flux required for the initiation and conduction of impulses. In addition, this agent increases electrical excitation threshold, reduces rate of rise of action potential and slows nerve impulse propagation thereby causing loss of sensation."

>  <Reference>
"Fan P, et al. Neuropharmacology, 1994, 33(12), 1573-1579.;Zahradn??kov?? A, et al. Biophys J. 1993 Apr;64(4):1991-12003.;Wang H, et al. Eur J Pharmacol, 2010, 630(1-3), 29-33.;Br?u ME ME, et al. Anesth Analg, 1998, 87(4), 885-889.;Hahnenkamp K, et al. Br J Anaesth, 2006, 96(1), 77-87."

>  <ID<1>>
T0802

$$$$
StarDrop ID 53
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 87 87 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -0.8657 2.7433 0.0000 0
M  V30 2 C -0.4876 2.0100 0.0000 0
M  V30 3 C 0.3364 1.9708 0.0000 0
M  V30 4 N 0.7145 1.2375 0.0000 0
M  V30 5 C 0.0000 0.8250 0.0000 0
M  V30 6 O -0.7145 1.2375 0.0000 0
M  V30 7 C 0.0000 0.0000 0.0000 0
M  V30 8 C -0.7145 -0.4125 0.0000 0 CFG=2
M  V30 9 O -0.7145 -1.2375 0.0000 0
M  V30 10 C -1.4289 0.0000 0.0000 0 CFG=2
M  V30 11 C -2.1434 -0.4125 0.0000 0
M  V30 12 C -1.4289 0.8250 0.0000 0
M  V30 13 C -2.1434 1.2375 0.0000 0
M  V30 14 C -2.1434 2.0625 0.0000 0
M  V30 15 C -2.8579 2.4750 0.0000 0
M  V30 16 N 0.7145 -0.4125 0.0000 0
M  V30 17 C 1.5061 -0.1801 0.0000 0
M  V30 18 C 0.3364 -1.1458 0.0000 0
M  V30 19 O -0.4352 -1.4378 0.0000 0
M  V30 20 C 0.7825 -1.8398 0.0000 0
M  V30 21 C 0.4044 -2.5731 0.0000 0
M  V30 22 C 0.8505 -3.2671 0.0000 0
M  V30 23 C -0.4196 -2.6124 0.0000 0
M  V30 24 N 1.6065 -1.8006 0.0000 0
M  V30 25 C 2.1468 -1.1771 0.0000 0
M  V30 26 C 1.6849 -2.6218 0.0000 0
M  V30 27 O 1.1937 -3.2846 0.0000 0
M  V30 28 C 2.4354 -2.9646 0.0000 0
M  V30 29 C 2.5138 -3.7858 0.0000 0
M  V30 30 C 1.8418 -4.2644 0.0000 0
M  V30 31 C 1.9202 -5.0856 0.0000 0
M  V30 32 C 1.0913 -3.9216 0.0000 0
M  V30 33 N 3.1074 -2.4860 0.0000 0
M  V30 34 C 3.2248 -1.6694 0.0000 0
M  V30 35 C 3.6174 -3.1345 0.0000 0
M  V30 36 O 3.3108 -3.9004 0.0000 0
M  V30 37 C 4.4340 -3.0171 0.0000 0
M  V30 38 C 4.9440 -3.6656 0.0000 0
M  V30 39 C 4.6374 -4.4315 0.0000 0
M  V30 40 C 5.1473 -5.0800 0.0000 0
M  V30 41 C 3.8208 -4.5489 0.0000 0
M  V30 42 N 4.7406 -2.2512 0.0000 0
M  V30 43 C 4.3979 -1.5007 0.0000 0
M  V30 44 C 5.5203 -2.5210 0.0000 0
M  V30 45 O 5.6764 -3.3311 0.0000 0
M  V30 46 C 6.1437 -1.9808 0.0000 0
M  V30 47 C 6.9234 -2.2506 0.0000 0
M  V30 48 N 5.9876 -1.1707 0.0000 0
M  V30 49 C 6.7894 -0.9762 0.0000 0
M  V30 50 O 7.3587 -1.5732 0.0000 0
M  V30 51 C 7.0218 -0.1846 0.0000 0
M  V30 52 C 7.8235 0.0099 0.0000 0
M  V30 53 N 6.4525 0.4125 0.0000 0
M  V30 54 C 7.0218 1.0096 0.0000 0
M  V30 55 O 7.8235 0.8151 0.0000 0
M  V30 56 C 6.7894 1.8012 0.0000 0
M  V30 57 C 7.3587 2.3982 0.0000 0
M  V30 58 C 8.1604 2.2037 0.0000 0
M  V30 59 C 8.7297 2.8008 0.0000 0
M  V30 60 C 8.3928 1.4122 0.0000 0
M  V30 61 N 5.9876 1.9957 0.0000 0
M  V30 62 C 5.2936 1.5496 0.0000 0
M  V30 63 C 6.1437 2.8058 0.0000 0
M  V30 64 O 6.9234 3.0756 0.0000 0
M  V30 65 C 5.5203 3.3460 0.0000 0
M  V30 66 N 4.7406 3.0762 0.0000 0
M  V30 67 C 4.4340 3.8421 0.0000 0
M  V30 68 O 4.9440 4.4906 0.0000 0
M  V30 69 C 3.6174 3.9595 0.0000 0
M  V30 70 C 3.3108 4.7254 0.0000 0
M  V30 71 C 3.8208 5.3739 0.0000 0
M  V30 72 C 3.5141 6.1398 0.0000 0
M  V30 73 C 4.6374 5.2565 0.0000 0
M  V30 74 N 3.1074 3.3110 0.0000 0
M  V30 75 C 3.2248 2.4944 0.0000 0
M  V30 76 C 2.4354 3.7896 0.0000 0
M  V30 77 O 2.5138 4.6108 0.0000 0
M  V30 78 C 1.6849 3.4468 0.0000 0
M  V30 79 N 1.6065 2.6256 0.0000 0
M  V30 80 C 2.1468 2.0021 0.0000 0
M  V30 81 C 0.7825 2.6648 0.0000 0
M  V30 82 O 0.4044 3.3981 0.0000 0
M  V30 83 C 5.6764 4.1561 0.0000 0
M  V30 84 C 5.2504 4.8626 0.0000 0
M  V30 85 C 6.4560 4.4259 0.0000 0
M  V30 86 H -1.5805 -0.9125 0.0000 0
M  V30 87 H -1.4290 -1.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=3
M  V30 9 1 8 10
M  V30 10 1 10 11 CFG=3
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 7 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 21 23
M  V30 23 1 20 24
M  V30 24 1 24 25
M  V30 25 1 24 26
M  V30 26 2 26 27
M  V30 27 1 26 28
M  V30 28 1 28 29
M  V30 29 1 29 30
M  V30 30 1 30 31
M  V30 31 1 30 32
M  V30 32 1 28 33
M  V30 33 1 33 34
M  V30 34 1 33 35
M  V30 35 2 35 36
M  V30 36 1 35 37
M  V30 37 1 37 38
M  V30 38 1 38 39
M  V30 39 1 39 40
M  V30 40 1 39 41
M  V30 41 1 37 42
M  V30 42 1 42 43
M  V30 43 1 42 44
M  V30 44 2 44 45
M  V30 45 1 44 46
M  V30 46 1 46 47
M  V30 47 1 46 48
M  V30 48 1 48 49
M  V30 49 2 49 50
M  V30 50 1 49 51
M  V30 51 1 51 52
M  V30 52 1 51 53
M  V30 53 1 53 54
M  V30 54 2 54 55
M  V30 55 1 54 56
M  V30 56 1 56 57
M  V30 57 1 57 58
M  V30 58 1 58 59
M  V30 59 1 58 60
M  V30 60 1 56 61
M  V30 61 1 61 62
M  V30 62 1 61 63
M  V30 63 2 63 64
M  V30 64 1 63 65
M  V30 65 1 65 66
M  V30 66 1 66 67
M  V30 67 2 67 68
M  V30 68 1 67 69
M  V30 69 1 69 70
M  V30 70 1 70 71
M  V30 71 1 71 72
M  V30 72 1 71 73
M  V30 73 1 69 74
M  V30 74 1 74 75
M  V30 75 1 74 76
M  V30 76 2 76 77
M  V30 77 1 76 78
M  V30 78 1 78 79
M  V30 79 1 79 80
M  V30 80 1 79 81
M  V30 81 1 3 81
M  V30 82 2 81 82
M  V30 83 1 65 83
M  V30 84 1 83 84
M  V30 85 1 83 85
M  V30 86 1 86 8
M  V30 87 1 87 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
53

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cyclosporine

>  <Synonyms>
N/A

>  <CAS>
79217-60-0

>  <Formula>
C62H111N11O12

>  <MolWt>
1203

>  <Pathways>
Metabolism

>  <Target>
Phosphatase

>  <Receptor>
calcineurin phosphatase

>  <Bioactivity>
"Cyclosporine is a calcineurin phosphatase pathway inhibitor, used as an immunosuppressant drug to prevent rejection in organ transplantation."

>  <Reference>
"Hojo M, et al. Nature, 1999, 397(6719), 530-534.;Lang E, et al. Pain, 1996, 68(1), 151-155.;Hesselink DA, et al. Am J Transplant, 2005, 5(5), 1987-1994.;Abbott KL, et al. Mol Biol Cell, 1998, 9(10), 2905-2916.;Matsuda S, et al. Immunopharmacology, 2000, 47(2-3), 119-125."

>  <ID<1>>
T6459

$$$$
StarDrop ID 54
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.2867 -0.5304 0.0000 0
M  V30 2 C 6.2867 0.2946 0.0000 0
M  V30 3 C 5.5723 0.7071 0.0000 0
M  V30 4 N 4.8578 0.2946 0.0000 0
M  V30 5 C 4.1433 0.7071 0.0000 0
M  V30 6 C 4.8578 -0.5304 0.0000 0
M  V30 7 C 7.0012 0.7071 0.0000 0
M  V30 8 N 7.7157 0.2946 0.0000 0
M  V30 9 C 8.4301 0.7071 0.0000 0
M  V30 10 C 8.4301 1.5321 0.0000 0
M  V30 11 C 9.1446 1.9446 0.0000 0
M  V30 12 C 9.8591 1.5321 0.0000 0
M  V30 13 C 9.8591 0.7071 0.0000 0
M  V30 14 C 9.1446 0.2946 0.0000 0
M  V30 15 S 9.1446 -0.5304 0.0000 0
M  V30 16 C 8.4301 -0.9429 0.0000 0
M  V30 17 C 8.4301 -1.7679 0.0000 0
M  V30 18 C 7.7157 -2.1804 0.0000 0
M  V30 19 C 7.0012 -1.7679 0.0000 0
M  V30 20 C 7.0012 -0.9429 0.0000 0
M  V30 21 C 7.7157 -0.5304 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 2 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 9 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 8 21
M  V30 23 1 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
54

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Alimemazine hemitartrate

>  <Synonyms>
Trimeprazine hemitartrate;Alimemazine Tartrate;Trimeprazine tartrate;Methylpromazine Tartrate

>  <CAS>
4330-99-8

>  <Formula>
C40H50N4O6S2

>  <MolWt>
747

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Trimeprazine tartrate is aphenothiazine derivative that is used as an antipruritic. It also acts as a sedative, hypnotic, and antiemetic for prevention of motion sickness."

>  <Reference>
Hu OY et al. The Journal of Pharmacy and Pharmacology. 38 (3): 172?C6.

>  <ID<1>>
T3282

$$$$
StarDrop ID 55
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 87 90 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 12.7275 0.5866 0.0000 0
M  V30 2 C 11.9206 0.7581 0.0000 0
M  V30 3 O 11.6656 1.5427 0.0000 0
M  V30 4 C 11.3685 0.1450 0.0000 0
M  V30 5 C 10.5616 0.3165 0.0000 0
M  V30 6 C 10.0095 -0.2966 0.0000 0
M  V30 7 N 10.8165 -0.4681 0.0000 0
M  V30 8 C 11.0714 -1.2527 0.0000 0
M  V30 9 O 11.8784 -1.4242 0.0000 0
M  V30 10 C 10.5194 -1.8658 0.0000 0 CFG=2
M  V30 11 C 10.7743 -2.6504 0.0000 0
M  V30 12 C 11.5813 -2.8220 0.0000 0
M  V30 13 C 12.1334 -2.2089 0.0000 0
M  V30 14 C 12.9403 -2.3804 0.0000 0
M  V30 15 C 13.1953 -3.1650 0.0000 0
M  V30 16 C 12.6432 -3.7781 0.0000 0
M  V30 17 C 11.8363 -3.6066 0.0000 0
M  V30 18 N 9.7124 -1.6943 0.0000 0
M  V30 19 C 9.1604 -2.3074 0.0000 0
M  V30 20 O 9.4153 -3.0920 0.0000 0
M  V30 21 C 8.3534 -2.1359 0.0000 0
M  V30 22 C 8.6084 -2.9205 0.0000 0
M  V30 23 C 8.0563 -3.5336 0.0000 0
M  V30 24 C 8.3113 -4.3182 0.0000 0
M  V30 25 C 7.7592 -4.9313 0.0000 0
M  V30 26 C 6.9523 -4.7598 0.0000 0
M  V30 27 O 6.4002 -5.3729 0.0000 0
M  V30 28 C 6.6973 -3.9751 0.0000 0
M  V30 29 C 7.2494 -3.3620 0.0000 0
M  V30 30 N 7.8014 -2.7490 0.0000 0
M  V30 31 C 6.9944 -2.5774 0.0000 0
M  V30 32 O 6.7395 -1.7928 0.0000 0
M  V30 33 C 6.4424 -3.1905 0.0000 0
M  V30 34 C 5.6354 -3.0190 0.0000 0
M  V30 35 S 5.3805 -2.2344 0.0000 0
M  V30 36 S 5.9325 -1.6213 0.0000 0
M  V30 37 C 5.6776 -0.8367 0.0000 0
M  V30 38 C 6.2296 -0.2236 0.0000 0 CFG=2
M  V30 39 N 7.0366 -0.3951 0.0000 0
M  V30 40 C 7.5886 0.2180 0.0000 0
M  V30 41 O 7.3337 1.0026 0.0000 0
M  V30 42 C 8.3956 0.0465 0.0000 0
M  V30 43 C 8.1406 0.8311 0.0000 0
M  V30 44 C 8.6927 1.4442 0.0000 0
M  V30 45 N 9.4997 1.2727 0.0000 0
M  V30 46 O 8.4377 2.2288 0.0000 0
M  V30 47 N 8.9476 0.6596 0.0000 0
M  V30 48 C 9.7546 0.4880 0.0000 0
M  V30 49 O 10.3066 1.1011 0.0000 0
M  V30 50 C 5.9747 0.5611 0.0000 0
M  V30 51 O 6.5267 1.1742 0.0000 0
M  V30 52 N 5.1677 0.7326 0.0000 0
M  V30 53 C 4.5546 0.1806 0.0000 0
M  V30 54 C 3.8401 0.5931 0.0000 0
M  V30 55 C 4.0117 1.4000 0.0000 0
M  V30 56 C 4.8321 1.4863 0.0000 0 CFG=1
M  V30 57 C 5.2446 2.2007 0.0000 0
M  V30 58 O 4.8321 2.9152 0.0000 0
M  V30 59 N 6.0696 2.2007 0.0000 0
M  V30 60 C 6.4821 2.9152 0.0000 0 CFG=1
M  V30 61 C 6.0696 3.6297 0.0000 0
M  V30 62 C 5.2446 3.6297 0.0000 0
M  V30 63 C 4.8321 4.3441 0.0000 0
M  V30 64 N 4.0071 4.3441 0.0000 0
M  V30 65 C 3.5946 5.0586 0.0000 0
M  V30 66 N 2.7696 5.0586 0.0000 0
M  V30 67 N 4.0071 5.7731 0.0000 0
M  V30 68 C 7.3071 2.9152 0.0000 0
M  V30 69 O 7.7196 2.2007 0.0000 0
M  V30 70 N 7.7196 3.6297 0.0000 0
M  V30 71 C 8.5446 3.6297 0.0000 0
M  V30 72 C 8.9571 4.3441 0.0000 0
M  V30 73 N 8.5446 5.0586 0.0000 0
M  V30 74 O 9.7821 4.3441 0.0000 0
M  V30 75 H 0.0000 0.0000 0.0000 0
M  V30 76 H 0.0000 0.0000 0.0000 0
M  V30 77 H 0.0000 0.0000 0.0000 0
M  V30 78 H 9.8502 -2.6089 0.0000 0
M  V30 79 H 0.0000 0.0000 0.0000 0
M  V30 80 H 0.0000 0.0000 0.0000 0
M  V30 81 H 0.0000 0.0000 0.0000 0
M  V30 82 H 6.8987 0.5196 0.0000 0
M  V30 83 H 0.0000 0.0000 0.0000 0
M  V30 84 H 0.0000 0.0000 0.0000 0
M  V30 85 H 0.0000 0.0000 0.0000 0
M  V30 86 H 4.2875 2.3250 0.0000 0
M  V30 87 H 6.9821 2.0492 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6 CFG=1
M  V30 6 1 7 6 CFG=3
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 10 8
M  V30 10 1 10 11 CFG=3
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 12 17
M  V30 18 1 10 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 21 19
M  V30 22 1 22 21 CFG=1
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 1 26 28
M  V30 29 2 28 29
M  V30 30 1 23 29
M  V30 31 1 30 21 CFG=3
M  V30 32 1 30 31
M  V30 33 2 31 32
M  V30 34 1 31 33
M  V30 35 1 33 34
M  V30 36 1 34 35
M  V30 37 1 35 36
M  V30 38 1 36 37
M  V30 39 1 38 37
M  V30 40 1 38 39
M  V30 41 1 39 40
M  V30 42 2 40 41
M  V30 43 1 42 40
M  V30 44 1 43 42 CFG=1
M  V30 45 1 43 44
M  V30 46 1 44 45
M  V30 47 2 44 46
M  V30 48 1 47 42 CFG=3
M  V30 49 1 47 48
M  V30 50 1 6 48
M  V30 51 2 48 49
M  V30 52 1 38 50 CFG=1
M  V30 53 2 50 51
M  V30 54 1 50 52
M  V30 55 1 52 53
M  V30 56 1 53 54
M  V30 57 1 54 55
M  V30 58 1 56 55
M  V30 59 1 56 52
M  V30 60 1 56 57 CFG=1
M  V30 61 2 57 58
M  V30 62 1 57 59
M  V30 63 1 60 59 CFG=1
M  V30 64 1 60 61
M  V30 65 1 61 62
M  V30 66 1 62 63
M  V30 67 1 63 64
M  V30 68 1 64 65
M  V30 69 1 65 66
M  V30 70 2 65 67
M  V30 71 1 60 68
M  V30 72 2 68 69
M  V30 73 1 68 70
M  V30 74 1 70 71
M  V30 75 1 71 72
M  V30 76 1 72 73
M  V30 77 2 72 74
M  V30 78 1 75 5
M  V30 79 1 76 5
M  V30 80 1 77 7
M  V30 81 1 78 10
M  V30 82 1 79 22
M  V30 83 1 80 22
M  V30 84 1 81 30
M  V30 85 1 82 38
M  V30 86 1 83 43
M  V30 87 1 84 43
M  V30 88 1 85 47
M  V30 89 1 86 56
M  V30 90 1 87 60
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
55

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Desmopressin acetate (16679-58-6 free base)

>  <Synonyms>
DDAVP;Desmopressin acetate

>  <CAS>
62288-83-9

>  <Formula>
C48H68N14O14S2

>  <MolWt>
1129

>  <Pathways>
GPCR/G Protein

>  <Target>
Vasopressin Receptor

>  <Receptor>
Vasopressin receptor 1; vasopressin receptor 1a; Vasopressin receptor 2

>  <Bioactivity>
"Desmopressin is the synthetic analog of the antidiuretic hormone arginine vasopressin. Vasopressin Receptor The antidiuretic properties of desmopressin have led to its use in polyuric conditions including primary nocturnal enuresis, nocturia, and diabetes insipidus. Desmopressin works by limiting the amount of water that is eliminated in the urine. Desmopressin binds to V2 receptors in renal collecting ducts, increasing water reabsorption. It also stimulates the release of von Willebrand factor from endothelial cells by acting on the V2 receptor."

>  <Reference>
"Kaufmann JE, et al. Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling. J Thromb Haemost. 2003 Apr;1(4):821-8.;Tsukamoto I. Recent patenting activities in the discovery and development of vasopressin V2 receptor agonists. Expert Opin Ther Pat. 2012 Jun;22(6):579-86."

>  <ID<1>>
T5144

$$$$
StarDrop ID 56
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.5724 -2.0625 0.0000 0
M  V30 2 C 3.5724 -1.2375 0.0000 0 CFG=1
M  V30 3 N 2.8579 -0.8250 0.0000 0
M  V30 4 C 2.1434 -1.2375 0.0000 0 CFG=1
M  V30 5 C 1.4289 -0.8250 0.0000 0
M  V30 6 C 0.7145 -1.2375 0.0000 0
M  V30 7 C 0.0000 -0.8250 0.0000 0
M  V30 8 C -0.7145 -1.2375 0.0000 0
M  V30 9 C -1.4289 -0.8250 0.0000 0
M  V30 10 C -1.4289 -0.0000 0.0000 0
M  V30 11 C -0.7145 0.4125 0.0000 0
M  V30 12 C 0.0000 -0.0000 0.0000 0
M  V30 13 C 2.1434 -2.0625 0.0000 0
M  V30 14 O 1.4289 -2.4750 0.0000 0
M  V30 15 O 2.8579 -2.4750 0.0000 0
M  V30 16 C 4.2868 -0.8250 0.0000 0
M  V30 17 C 5.0013 -1.2375 0.0000 0
M  V30 18 C 5.7158 -0.8250 0.0000 0
M  V30 19 C 6.4302 -1.2375 0.0000 0
M  V30 20 N 7.1447 -0.8250 0.0000 0
M  V30 21 O 3.2368 -2.8162 0.0000 0
M  V30 22 N 4.2868 -2.4750 0.0000 0
M  V30 23 C 4.3731 -3.2955 0.0000 0 CFG=2
M  V30 24 C 3.7600 -3.8475 0.0000 0
M  V30 25 O 2.9753 -3.5926 0.0000 0
M  V30 26 O 3.9315 -4.6545 0.0000 0
M  V30 27 C 5.1800 -3.4670 0.0000 0
M  V30 28 C 5.5925 -2.7525 0.0000 0
M  V30 29 C 5.0405 -2.1394 0.0000 0
M  V30 30 H 3.5723 -0.2375 0.0000 0
M  V30 31 H 3.0094 -1.7375 0.0000 0
M  V30 32 H 4.6318 -4.2614 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3 CFG=1
M  V30 3 1 4 3 CFG=3
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 7 12
M  V30 13 1 4 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 2 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 1 21
M  V30 22 1 1 22
M  V30 23 1 23 22
M  V30 24 1 23 24 CFG=1
M  V30 25 1 24 25
M  V30 26 2 24 26
M  V30 27 1 23 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 1 22 29
M  V30 31 1 30 2
M  V30 32 1 31 4
M  V30 33 1 32 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
56

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lisinopril

>  <Synonyms>
Prinivil;Zestril;Linopril;Lisipril

>  <CAS>
76547-98-3

>  <Formula>
C21H31N3O5

>  <MolWt>
405.5

>  <Pathways>
Endocrinology/Hormones

>  <Target>
RAAS

>  <Receptor>
ACE

>  <Bioactivity>
"Lisinopril, the angiotensin-converting enzyme (ACE) inhibitor, is used primarily in the treatment of high heart failure, blood pressure, and heart attacks. It is also used for preventing eye and kidney complications in people with diabetes."

>  <Reference>
"Jiang M, Huang CR, Wang Q, et al. Combined spectroscopies and molecular docking approach to characterizing the binding interaction between lisinopril and bovine serum albumin. Luminescence. 2016 Mar;31(2):468-77. doi: 10.1002/bio.2984. Epub 2015 Aug 24. PubMed PMID: 26300521.;Akintunde JK, Bolarin OE, Akintunde DG. Garlic capsule and selenium-vitamins ACE combination therapy modulate key antioxidant proteins and cellular adenosine triphosphate in lisinopril-induced lung damage in rats. Drug Metabol Personal Ther. 2016 Mar 1;31(1):47-54. doi: 10.1515/dmpt-2015-0035. PubMed PMID: 26943616.;Simonyi G, Ferenci T. [Ramipril plus amlodipine and lisinopril plus amlodipine fixed dose combinations and patient's adherence]. Orv Hetil. 2016 Jan 3;157(1):30-4. doi: 10.1556/650.2016.30344. Hungarian. PubMed PMID: 26708684.;Cinelli E, Bongianni F, Pantaleo T, Mutolo D. The cough reflex is upregulated by lisinopril microinjected into the caudal nucleus tractus solitarii of the rabbit. Respir Physiol Neurobiol. 2015 Dec;219:9-17. doi: 10.1016/j.resp.2015.07.013. Epub 2015 Jul 30. PubMed PMID: 26234277."

>  <ID<1>>
T21418

$$$$
StarDrop ID 57
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 80 82 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.6770 -0.3279 0.0000 0
M  V30 2 C 4.9319 -1.1126 0.0000 0
M  V30 3 C 5.7389 -1.2841 0.0000 0 CFG=2
M  V30 4 C 5.9938 -2.0687 0.0000 0
M  V30 5 C 6.2909 -0.6710 0.0000 0 CFG=2
M  V30 6 N 5.4839 -0.4995 0.0000 0
M  V30 7 C 5.2290 0.2852 0.0000 0
M  V30 8 O 4.4220 0.4567 0.0000 0
M  V30 9 C 5.7810 0.8982 0.0000 0 CFG=2
M  V30 10 C 5.5261 1.6829 0.0000 0
M  V30 11 C 4.7191 1.8544 0.0000 0
M  V30 12 C 4.1671 1.2413 0.0000 0
M  V30 13 C 3.3601 1.4128 0.0000 0
M  V30 14 C 3.1052 2.1975 0.0000 0
M  V30 15 O 2.2982 2.3690 0.0000 0
M  V30 16 C 3.6572 2.8105 0.0000 0
M  V30 17 C 4.4642 2.6390 0.0000 0
M  V30 18 N 6.5880 0.7267 0.0000 0
M  V30 19 C 7.1400 1.3398 0.0000 0
M  V30 20 O 6.8851 2.1244 0.0000 0
M  V30 21 C 7.9470 1.1683 0.0000 0 CFG=1
M  V30 22 N 8.2020 0.3837 0.0000 0
M  V30 23 C 8.4990 1.7814 0.0000 0
M  V30 24 S 9.3060 1.6099 0.0000 0
M  V30 25 S 9.8581 2.2229 0.0000 0
M  V30 26 C 10.6650 2.0514 0.0000 0
M  V30 27 C 10.9200 1.2668 0.0000 0 CFG=2
M  V30 28 N 10.3679 0.6537 0.0000 0
M  V30 29 C 10.6229 -0.1309 0.0000 0
M  V30 30 O 11.4298 -0.3024 0.0000 0
M  V30 31 C 10.0708 -0.7440 0.0000 0 CFG=2
M  V30 32 C 10.3258 -1.5286 0.0000 0
M  V30 33 C 11.1327 -1.7002 0.0000 0
M  V30 34 N 11.6848 -1.0871 0.0000 0
M  V30 35 O 11.3877 -2.4848 0.0000 0
M  V30 36 N 9.2639 -0.5725 0.0000 0
M  V30 37 C 8.7118 -1.1856 0.0000 0
M  V30 38 O 8.9668 -1.9702 0.0000 0
M  V30 39 C 7.9049 -1.0141 0.0000 0
M  V30 40 C 8.1598 -1.7987 0.0000 0
M  V30 41 C 7.6078 -2.4118 0.0000 0
M  V30 42 C 7.8627 -3.1964 0.0000 0
M  V30 43 N 8.6697 -3.3679 0.0000 0
M  V30 44 O 7.3107 -3.8095 0.0000 0
M  V30 45 N 7.3528 -1.6271 0.0000 0
M  V30 46 C 6.5459 -1.4556 0.0000 0
M  V30 47 O 6.4596 -2.2761 0.0000 0
M  V30 48 C 11.7269 1.0953 0.0000 0
M  V30 49 O 11.9819 0.3107 0.0000 0
M  V30 50 N 12.2790 1.7084 0.0000 0
M  V30 51 C 12.1074 2.5153 0.0000 0
M  V30 52 C 12.8219 2.9278 0.0000 0
M  V30 53 C 13.4350 2.3758 0.0000 0
M  V30 54 C 13.0994 1.6221 0.0000 0 CFG=1
M  V30 55 C 13.5119 0.9077 0.0000 0
M  V30 56 O 13.0994 0.1932 0.0000 0
M  V30 57 N 14.3369 0.9077 0.0000 0
M  V30 58 C 14.7494 0.1932 0.0000 0 CFG=1
M  V30 59 C 14.3369 -0.5213 0.0000 0
M  V30 60 C 14.7494 -1.2358 0.0000 0
M  V30 61 C 15.5744 -1.2358 0.0000 0
M  V30 62 C 14.3369 -1.9502 0.0000 0
M  V30 63 C 15.5744 0.1932 0.0000 0
M  V30 64 O 15.9869 0.9077 0.0000 0
M  V30 65 N 15.9869 -0.5213 0.0000 0
M  V30 66 C 16.8119 -0.5213 0.0000 0
M  V30 67 C 17.2244 -1.2358 0.0000 0
M  V30 68 N 18.0494 -1.2358 0.0000 0
M  V30 69 O 16.8119 -1.9502 0.0000 0
M  V30 70 H 0.0000 0.0000 0.0000 0
M  V30 71 H 0.0000 0.0000 0.0000 0
M  V30 72 H 0.0000 0.0000 0.0000 0
M  V30 73 H 12.5548 0.7834 0.0000 0
M  V30 74 H 15.2494 1.0592 0.0000 0
M  V30 75 H 5.0697 -2.0272 0.0000 0
M  V30 76 H 6.0359 0.1136 0.0000 0
M  V30 77 H 4.8029 1.1063 0.0000 0
M  V30 78 H 8.9252 0.9604 0.0000 0
M  V30 79 H 11.5890 2.0100 0.0000 0
M  V30 80 H 9.4018 -1.4872 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=1
M  V30 4 1 3 5
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 9 7
M  V30 9 1 9 10 CFG=3
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 2 16 17
M  V30 17 1 11 17
M  V30 18 1 9 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 21 19
M  V30 22 1 21 22 CFG=3
M  V30 23 1 21 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 27 26
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 2 29 30
M  V30 31 1 31 29
M  V30 32 1 31 32 CFG=3
M  V30 33 1 32 33
M  V30 34 1 33 34
M  V30 35 2 33 35
M  V30 36 1 31 36
M  V30 37 1 36 37
M  V30 38 2 37 38
M  V30 39 1 39 37
M  V30 40 1 40 39 CFG=1
M  V30 41 1 40 41
M  V30 42 1 41 42
M  V30 43 1 42 43
M  V30 44 2 42 44
M  V30 45 1 45 39 CFG=3
M  V30 46 1 45 46
M  V30 47 1 5 46 CFG=3
M  V30 48 2 46 47
M  V30 49 1 27 48 CFG=1
M  V30 50 2 48 49
M  V30 51 1 48 50
M  V30 52 1 50 51
M  V30 53 1 51 52
M  V30 54 1 52 53
M  V30 55 1 54 53
M  V30 56 1 54 50
M  V30 57 1 54 55 CFG=1
M  V30 58 2 55 56
M  V30 59 1 55 57
M  V30 60 1 58 57 CFG=3
M  V30 61 1 58 59
M  V30 62 1 59 60
M  V30 63 1 60 61
M  V30 64 1 60 62
M  V30 65 1 58 63
M  V30 66 2 63 64
M  V30 67 1 63 65
M  V30 68 1 65 66
M  V30 69 1 66 67
M  V30 70 1 67 68
M  V30 71 2 67 69
M  V30 72 1 70 40
M  V30 73 1 71 40
M  V30 74 1 72 45
M  V30 75 1 73 54
M  V30 76 1 74 58
M  V30 77 1 75 3
M  V30 78 1 76 5
M  V30 79 1 77 9
M  V30 80 1 78 21
M  V30 81 1 79 27
M  V30 82 1 80 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
57

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Oxytocin acetate

>  <Synonyms>
??-Hypophamine acetate;Oxytocic hormone acetate;Oxytocin acetate (50-56-6 free base)

>  <CAS>
6233-83-6

>  <Formula>
C45H70N12O14S2

>  <MolWt>
1067

>  <Pathways>
GPCR/G Protein;Endocrinology/Hormones

>  <Target>
Oxytocin Receptor

>  <Receptor>
Oxytocin Receptor

>  <Bioactivity>
"Oxytocin is a mammalian neurohypophysial hormone, a ligand of oxytocin receptor."

>  <Reference>
"Oxytocin, From Wikipedia"

>  <ID<1>>
T5145

$$$$
StarDrop ID 58
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.2868 0.8250 0.0000 0
M  V30 2 O -3.5724 1.2375 0.0000 0
M  V30 3 C -2.8579 0.8250 0.0000 0
M  V30 4 C -2.1434 1.2375 0.0000 0
M  V30 5 C -1.4289 0.8250 0.0000 0
M  V30 6 C -0.7145 1.2375 0.0000 0
M  V30 7 N 0.0000 0.8250 0.0000 0
M  V30 8 C 0.7145 1.2375 0.0000 0
M  V30 9 O 0.7145 2.0625 0.0000 0
M  V30 10 C 1.4289 0.8250 0.0000 0
M  V30 11 C 2.1434 1.2375 0.0000 0
M  V30 12 C 2.8579 0.8250 0.0000 0
M  V30 13 C 3.5724 1.2375 0.0000 0
M  V30 14 C 4.2868 0.8250 0.0000 0
M  V30 15 C 5.0013 1.2375 0.0000 0
M  V30 16 C 5.0013 2.0625 0.0000 0
M  V30 17 C 4.2868 2.4750 0.0000 0
M  V30 18 C 5.7158 2.4750 0.0000 0
M  V30 19 C -1.4289 -0.0000 0.0000 0
M  V30 20 C -2.1434 -0.4125 0.0000 0
M  V30 21 C -2.8579 -0.0000 0.0000 0
M  V30 22 O -3.5724 -0.4125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 2 5 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 3 21
M  V30 22 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
58

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
(Z)-Capsaicin

>  <Synonyms>
Zucapsaicin;cis-Capsaicin;Civamide

>  <CAS>
25775-90-0

>  <Formula>
C18H27NO3

>  <MolWt>
305.4

>  <Pathways>
Membrane transporter/Ion channel;Microbiology/Virology

>  <Target>
HSV;TRP/TRPV Channel

>  <Receptor>
HSV; hTRPV1; TRP Channel

>  <Bioactivity>
Zucapsaicin is a medication used to treat osteoarthritis of the knee and Others neuropathic pain.Zucapsaicin is a synthetic cis isomer of natural capsaicin that has shown therapeutic efficacy in pain accompanying osteoarthritis of the knee.

>  <Reference>
"Sa?at K, et al. Expert Opin Investig Drugs. 2014 Oct;23(10):1433-40."

>  <ID<1>>
T1109

$$$$
StarDrop ID 59
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 85 89 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.7696 -2.2282 0.0000 0
M  V30 2 C 3.4841 -2.6407 0.0000 0
M  V30 3 C 4.1986 -2.2282 0.0000 0
M  V30 4 C 4.9131 -2.6407 0.0000 0
M  V30 5 C 5.6275 -2.2282 0.0000 0 CFG=2
M  V30 6 N 5.6275 -1.4032 0.0000 0
M  V30 7 C 6.3420 -0.9907 0.0000 0
M  V30 8 C 6.3420 -0.1657 0.0000 0
M  V30 9 O 7.0565 -1.4032 0.0000 0
M  V30 10 C 6.3420 -2.6407 0.0000 0
M  V30 11 O 6.3420 -3.4657 0.0000 0
M  V30 12 N 7.0565 -2.2282 0.0000 0
M  V30 13 C 7.5414 -1.5608 0.0000 0
M  V30 14 C 6.7493 -1.3300 0.0000 0
M  V30 15 C 6.7241 -0.5054 0.0000 0
M  V30 16 O 6.0421 -0.0411 0.0000 0
M  V30 17 N 7.5005 -0.2265 0.0000 0
M  V30 18 C 7.9619 0.5495 0.0000 0
M  V30 19 C 8.7865 0.5747 0.0000 0
M  V30 20 C 9.1769 1.3015 0.0000 0
M  V30 21 C 10.0015 1.3268 0.0000 0
M  V30 22 C 10.3919 2.0536 0.0000 0 CFG=2
M  V30 23 N 11.2165 2.0788 0.0000 0
M  V30 24 C 11.6070 2.8056 0.0000 0
M  V30 25 O 11.1728 3.5071 0.0000 0
M  V30 26 C 12.4316 2.8309 0.0000 0 CFG=2
M  V30 27 C 12.8220 3.5577 0.0000 0
M  V30 28 C 13.6466 3.5829 0.0000 0
M  V30 29 C 14.1517 2.9307 0.0000 0
M  V30 30 N 14.9282 3.2095 0.0000 0
M  V30 31 C 14.9029 4.0341 0.0000 0
M  V30 32 C 15.4988 4.6047 0.0000 0
M  V30 33 C 15.3026 5.4060 0.0000 0
M  V30 34 C 14.5106 5.6368 0.0000 0
M  V30 35 C 13.9147 5.0662 0.0000 0
M  V30 36 C 14.1109 4.2649 0.0000 0
M  V30 37 N 12.8658 2.1294 0.0000 0
M  V30 38 C 12.4753 1.4026 0.0000 0
M  V30 39 O 11.6507 1.3773 0.0000 0
M  V30 40 C 12.9095 0.7011 0.0000 0 CFG=2
M  V30 41 C 13.7342 0.7264 0.0000 0
M  V30 42 C 14.1683 0.0249 0.0000 0
M  V30 43 C 14.9930 0.0502 0.0000 0
M  V30 44 N 15.4272 -0.6513 0.0000 0
M  V30 45 C 16.2518 -0.6261 0.0000 0
M  V30 46 N 16.6422 0.1007 0.0000 0
M  V30 47 N 16.6860 -1.3276 0.0000 0
M  V30 48 N 12.5191 -0.0257 0.0000 0
M  V30 49 C 11.6945 -0.0509 0.0000 0
M  V30 50 O 11.2603 0.6506 0.0000 0
M  V30 51 C 11.3041 -0.7777 0.0000 0 CFG=1
M  V30 52 C 11.7383 -1.4792 0.0000 0
M  V30 53 C 12.5629 -1.4539 0.0000 0
M  V30 54 C 12.9533 -0.7272 0.0000 0
M  V30 55 C 13.7779 -0.7019 0.0000 0
M  V30 56 C 14.2121 -1.4034 0.0000 0
M  V30 57 C 13.8217 -2.1302 0.0000 0
M  V30 58 C 12.9971 -2.1554 0.0000 0
M  V30 59 N 10.4795 -0.8030 0.0000 0
M  V30 60 C 10.0891 -1.5298 0.0000 0
M  V30 61 O 10.5232 -2.2313 0.0000 0
M  V30 62 C 9.2644 -1.5550 0.0000 0
M  V30 63 C 9.6986 -2.2565 0.0000 0
M  V30 64 C 9.3082 -2.9833 0.0000 0
M  V30 65 C 9.6667 -3.7263 0.0000 0
M  V30 66 N 9.0708 -4.2969 0.0000 0
M  V30 67 C 8.3440 -3.9065 0.0000 0
M  V30 68 N 8.4908 -3.0946 0.0000 0
M  V30 69 N 8.8740 -2.2818 0.0000 0
M  V30 70 C 8.0494 -2.3071 0.0000 0
M  V30 71 O 7.6749 -3.0421 0.0000 0
M  V30 72 C 9.9577 2.7551 0.0000 0
M  V30 73 O 10.3482 3.4818 0.0000 0
M  V30 74 O 9.1331 2.7298 0.0000 0
M  V30 75 H 4.7615 -1.7282 0.0000 0
M  V30 76 H 0.0000 0.0000 0.0000 0
M  V30 77 H 0.0000 0.0000 0.0000 0
M  V30 78 H 0.0000 0.0000 0.0000 0
M  V30 79 H 9.3924 2.0229 0.0000 0
M  V30 80 H 11.9053 3.6812 0.0000 0
M  V30 81 H 13.3828 1.5820 0.0000 0
M  V30 82 H 10.8309 -1.6587 0.0000 0
M  V30 83 H 0.0000 0.0000 0.0000 0
M  V30 84 H 0.0000 0.0000 0.0000 0
M  V30 85 H 0.0000 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 5 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13 CFG=3
M  V30 13 1 14 13 CFG=1
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 22 21
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 26 24
M  V30 26 1 26 27 CFG=3
M  V30 27 1 27 28
M  V30 28 1 28 29
M  V30 29 1 29 30
M  V30 30 2 30 31
M  V30 31 1 31 32
M  V30 32 2 32 33
M  V30 33 1 33 34
M  V30 34 2 34 35
M  V30 35 1 35 36
M  V30 36 2 28 36
M  V30 37 1 31 36
M  V30 38 1 26 37
M  V30 39 1 37 38
M  V30 40 2 38 39
M  V30 41 1 40 38
M  V30 42 1 40 41 CFG=3
M  V30 43 1 41 42
M  V30 44 1 42 43
M  V30 45 1 43 44
M  V30 46 1 44 45
M  V30 47 1 45 46
M  V30 48 2 45 47
M  V30 49 1 40 48
M  V30 50 1 48 49
M  V30 51 2 49 50
M  V30 52 1 51 49
M  V30 53 1 51 52 CFG=1
M  V30 54 1 52 53
M  V30 55 2 53 54
M  V30 56 1 54 55
M  V30 57 2 55 56
M  V30 58 1 56 57
M  V30 59 2 57 58
M  V30 60 1 53 58
M  V30 61 1 51 59
M  V30 62 1 59 60
M  V30 63 2 60 61
M  V30 64 1 62 60
M  V30 65 1 63 62 CFG=1
M  V30 66 1 63 64
M  V30 67 1 64 65
M  V30 68 1 65 66
M  V30 69 2 66 67
M  V30 70 1 67 68
M  V30 71 2 64 68
M  V30 72 1 69 62 CFG=3
M  V30 73 1 69 70
M  V30 74 1 13 70
M  V30 75 2 70 71
M  V30 76 1 22 72 CFG=1
M  V30 77 1 72 73
M  V30 78 2 72 74
M  V30 79 1 75 5
M  V30 80 1 76 12
M  V30 81 1 77 14
M  V30 82 1 78 14
M  V30 83 1 79 22
M  V30 84 1 80 26
M  V30 85 1 81 40
M  V30 86 1 82 51
M  V30 87 1 83 63
M  V30 88 1 84 63
M  V30 89 1 85 69
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
59

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Bremelanotide Acetate

>  <Synonyms>
bremelanotide;PT-141 Acetate

>  <CAS>
1607799-13-2

>  <Formula>
C52H72N14O12

>  <MolWt>
1085

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Melanocortin Receptor

>  <Receptor>
Melanocortin Receptor

>  <Bioactivity>
Bremelanotide is an agonist of melanocortin receptor (MCR) .

>  <Reference>
"Clayton AH, Althof SE, Kingsberg S,et al.Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial[J].Womens Health (Lond). 2016 Jun;12(3):325-37.;Pfaus JG, Shadiack A, Van Soest T,et al.Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist[J].Proc Natl Acad Sci U S A. 2004 Jul 6;101(27)"

>  <ID<1>>
T7608

$$$$
StarDrop ID 60
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 2.5702 0.0000 0
M  V30 2 N 3.0716 2.1577 0.0000 0
M  V30 3 C 3.0716 1.3327 0.0000 0
M  V30 4 C 3.7861 0.9202 0.0000 0
M  V30 5 O 4.5006 1.3327 0.0000 0
M  V30 6 C 3.7861 0.0952 0.0000 0
M  V30 7 C 4.5006 -0.3173 0.0000 0
M  V30 8 C 4.5006 -1.1423 0.0000 0
M  V30 9 C 3.7861 -1.5548 0.0000 0
M  V30 10 O 3.7861 -2.3798 0.0000 0
M  V30 11 C 3.0716 -1.1423 0.0000 0
M  V30 12 O 2.3571 -1.5548 0.0000 0
M  V30 13 C 3.0716 -0.3173 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 1 6 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
60

>  <Plate>
PHD136328

>  <Row>
c

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
DL-Adrenaline Hydrochloride

>  <Synonyms>
N/A

>  <CAS>
329-63-5

>  <Formula>
C9H14ClNO3

>  <MolWt>
219.7

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor

>  <Bioactivity>
"DL-Adrenaline Hydrochloride is the hydrochloride salt of the naturally occurring sympathomimetic amine with vasoconstricting, intraocular pressure-reducing activities."

>  <Reference>
"Chen Y, Chen L, Wu Y, et al. Highly sensitive determination of dopamine based on the aggregation of small-sized gold nanoparticles[J]. Microchemical Journal. 2019, 147: 955-961.;Xu H R, Yang Q, Xiang S Y, et al. Rosuvastatin Enhances Alveolar Fluid Clearance in Lipopolysaccharide-Induced Acute Lung Injury by Activating the Expression of Sodium Channel and Na, K-ATPase via the PI3K/AKT/Nedd4-2 Pathway[J]. Journal of Inflammation Research. 2021, 14: 1537;Han M, Kang F, Yang C, et al. Comparison of Adrenaline and Dexmedetomidine in Improving the Cutaneous Analgesia of Mexiletine in Response to Skin Pinpricks in Rats[J]. Pharmacology. 2020: 1-7.;Leineweber K, et al. Naunyn Schmiedebergs Arch Pharmacol. 2007 Jul;375(5):303-9."

>  <ID<1>>
T1071L

$$$$
StarDrop ID 61
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -0.5359 -2.6813 0.0000 0
M  V30 2 C -0.5359 -3.5063 0.0000 0
M  V30 3 C 0.1786 -3.9188 0.0000 0 CFG=2
M  V30 4 O 0.8931 -3.5063 0.0000 0
M  V30 5 C 0.1786 -4.7438 0.0000 0
M  V30 6 C 0.8931 -5.1563 0.0000 0
M  V30 7 C 0.8931 -5.9813 0.0000 0
M  V30 8 C 0.1786 -6.3938 0.0000 0
M  V30 9 O 0.1786 -7.2188 0.0000 0
M  V30 10 C -0.5359 -5.9813 0.0000 0
M  V30 11 O -1.2503 -6.3937 0.0000 0
M  V30 12 C -0.5359 -5.1563 0.0000 0
M  V30 13 H 1.0446 -4.4188 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=3
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 5 12
M  V30 13 1 13 3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
61

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Noradrenaline bitartrate

>  <Synonyms>
N/A

>  <CAS>
69815-49-2

>  <Formula>
C12H19NO10

>  <MolWt>
337.3

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor

>  <Bioactivity>
"Norepinephrine bitartrate acts directly on the ??- and ??-adrenergic receptors. Norepinephrine Bitartrate is a bitartrate salt of norepinephrine, a synthetic phenylethylamine that mimics the sympathomimetic actions of the endogenous norepinephrine. Clinically, norepinephrine is used as a peripheral vasoconstrictor that causes constriction of arterial and venous beds via its alpha-adrenergic action. It is also used as a potent inotropic and chronotropic stimulator of the heart mediated through its beta-1 adrenergic action."

>  <Reference>
"Han M, Kang F, Yang C, et al. A comparative study of serotonin and norepinephrine as adjuncts to improve cutaneous antinociception of mexiletine in response to skin pinpricks in rats[J]. International Journal of Immunopathology and Pharmacology. 2021, 35: 20587384211016129.;Lachnit WG, et al. Br J Pharmacol. 1997 Mar;120(5):819-26.;Gao J, Xi B, Chen K, et al. The stress hormone norepinephrine increases the growth and virulence of Aeromonas hydrophila[J]. MicrobiologyOpen. 2019, 8(4): e00664."

>  <ID<1>>
T0871

$$$$
StarDrop ID 62
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.5045 -4.5982 0.0000 0
M  V30 2 C 2.4450 -3.7753 0.0000 0
M  V30 3 O 1.7026 -3.4155 0.0000 0
M  V30 4 O 3.1278 -3.3123 0.0000 0
M  V30 5 C 3.0683 -2.4895 0.0000 0 CFG=2
M  V30 6 C 2.2561 -2.6347 0.0000 0
M  V30 7 C 1.7243 -2.0040 0.0000 0
M  V30 8 O 1.5733 -3.0977 0.0000 0
M  V30 9 C 2.8390 -1.6970 0.0000 0
M  V30 10 C 2.0630 -1.4167 0.0000 0
M  V30 11 C 3.5218 -1.2340 0.0000 0
M  V30 12 C 4.1731 -1.7404 0.0000 0 CFG=1
M  V30 13 C 4.9853 -1.5952 0.0000 0 CFG=2
M  V30 14 C 5.2655 -0.8192 0.0000 0
M  V30 15 C 6.0777 -0.6740 0.0000 0
M  V30 16 C 6.6095 -1.3047 0.0000 0
M  V30 17 C 7.4216 -1.1595 0.0000 0
M  V30 18 C 7.9534 -1.7902 0.0000 0
M  V30 19 O 8.7655 -1.6450 0.0000 0
M  V30 20 C 7.6731 -2.5662 0.0000 0
M  V30 21 C 6.8610 -2.7114 0.0000 0
M  V30 22 C 6.3292 -2.0807 0.0000 0 CFG=2
M  V30 23 C 5.5171 -2.2259 0.0000 0 CFG=1
M  V30 24 C 5.2368 -3.0018 0.0000 0
M  V30 25 C 4.4247 -3.1470 0.0000 0
M  V30 26 C 3.8928 -2.5163 0.0000 0 CFG=2
M  V30 27 C 3.5330 -3.2587 0.0000 0
M  V30 28 H 3.2125 -2.0183 0.0000 0
M  V30 29 H 4.3406 -0.8308 0.0000 0
M  V30 30 H 5.9894 -3.0212 0.0000 0
M  V30 31 H 6.1617 -2.9904 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4 CFG=3
M  V30 5 1 5 6 CFG=1
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 5 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 12 11 CFG=1
M  V30 12 1 12 13
M  V30 13 1 13 14 CFG=3
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 1 20 21
M  V30 21 1 22 21 CFG=3
M  V30 22 1 22 16
M  V30 23 1 23 22
M  V30 24 1 13 23
M  V30 25 1 23 24 CFG=1
M  V30 26 1 24 25
M  V30 27 1 26 25
M  V30 28 1 26 5
M  V30 29 1 12 26
M  V30 30 1 26 27 CFG=1
M  V30 31 1 28 12
M  V30 32 1 29 13
M  V30 33 1 30 22
M  V30 34 1 31 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
62

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Nestoron

>  <Synonyms>
Nestorone;ST-1435;Elcometrine;Segesterone Acetate

>  <CAS>
7759-35-5

>  <Formula>
C23H30O4

>  <MolWt>
370.5

>  <Pathways>
Others;Endocrinology/Hormones

>  <Target>
Estrogen/progestogen Receptor;Progesterone Receptor

>  <Receptor>
 PR:10.3 nM

>  <Bioactivity>
"Nestoron, a synthetic progestin, is a high-affinity agonist of the progesterone receptor (EC50: 10.3 nM)."

>  <Reference>
"Kumar N, et al. Nestorone: a progestin with a unique pharmacological profile. Steroids. 2000 Oct-Nov;65(10-11):629-36.;Chen S, et al. Therapeutic progestin segesterone acetate promotes neurogenesis: implications for sustaining regeneration in female brain. Menopause. 2018 Oct;25(10):1138-1151."

>  <ID<1>>
T5174

$$$$
StarDrop ID 63
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 0.7145 -1.2375 0.0000 0
M  V30 2 C 0.7145 -0.4125 0.0000 0
M  V30 3 C 0.0000 0.0000 0.0000 0
M  V30 4 C 0.0000 0.8250 0.0000 0
M  V30 5 C 0.7145 1.2375 0.0000 0
M  V30 6 C 1.4289 0.8250 0.0000 0
M  V30 7 Cl 2.1434 1.2375 0.0000 0
M  V30 8 C 1.4289 0.0000 0.0000 0
M  V30 9 N 2.1434 -0.4125 0.0000 0
M  V30 10 C 2.1434 -1.2375 0.0000 0
M  V30 11 N 2.8109 -1.7224 0.0000 0
M  V30 12 C 2.5559 -2.5070 0.0000 0
M  V30 13 C 1.7309 -2.5070 0.0000 0
M  V30 14 N 1.4760 -1.7224 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 2 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 10 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
63

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Clonidine

>  <Synonyms>
Catapres;Kapvay;Nexiclon

>  <CAS>
4205-90-7

>  <Formula>
C9H9Cl2N3

>  <MolWt>
230.1

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor; ??2 adrenergic receptor

>  <Bioactivity>
"Clonidine is a centrally active alpha-adrenergic agonist used predominantly as an antihypertensive agent, usually in combination with other agents. Despite wide-scale use for many years, clonidine has not been linked definitively to either serum aminotransferase elevations or clinically apparent liver injury."

>  <Reference>
"Bugajski J, et al. The involvement of central alpha-adrenergic and histamine H2-receptors in the hypothermia induced by clonidine in the rat. Neuropharmacology. 1980 Jan;19(1):9-15.;Nassar N, et al. Brainstem adenosine A1 receptor signaling masks phosphorylated extracellular signal-regulated kinase 1/2-dependent hypotensive action of clonidine in conscious normotensive rats. J Pharmacol Exp Ther. 2009 Jan;328(1):83-9.;Jentsch JD, et al. Clonidine and guanfacine attenuate phencyclidine-induced dopamine overflow in rat prefrontal cortex: mediating influence of the alpha-2A adrenoceptor subtype. Brain Res. 2008 Dec 30;1246:41-6.;Zhang YM, et al. Clonidine induces calcitonin gene-related peptide expression via nitric oxide pathway in endothelial cells. Peptides. 2009 Sep;30(9):1746-52."

>  <ID<1>>
T7045

$$$$
StarDrop ID 64
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.7145 -3.7125 0.0000 0
M  V30 2 C 1.4289 -3.3000 0.0000 0
M  V30 3 O 2.1434 -3.7125 0.0000 0
M  V30 4 N 1.4289 -2.4750 0.0000 0
M  V30 5 C 2.1434 -2.0625 0.0000 0 CFG=1
M  V30 6 C 2.1434 -1.2375 0.0000 0
M  V30 7 C 2.8579 -0.8250 0.0000 0
M  V30 8 C 2.8579 0.0000 0.0000 0
M  V30 9 C 3.5724 0.4125 0.0000 0
M  V30 10 C 4.2868 0.0000 0.0000 0
M  V30 11 O 5.0013 0.4125 0.0000 0
M  V30 12 C 4.2868 -0.8250 0.0000 0
M  V30 13 C 3.5724 -1.2375 0.0000 0
M  V30 14 C 2.8579 -2.4750 0.0000 0
M  V30 15 O 3.5724 -2.0625 0.0000 0
M  V30 16 O 2.8579 -3.3000 0.0000 0
M  V30 17 H 1.2774 -1.5625 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 7 13
M  V30 14 1 5 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 17 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
64

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
N-Acetyl-L-tyrosine

>  <Synonyms>
Ac-Tyr-OH

>  <CAS>
537-55-3

>  <Formula>
C11H13NO4

>  <MolWt>
223.2

>  <Pathways>
Others;Metabolism

>  <Target>
Others;Endogenous Metabolite

>  <Receptor>
Endogenous Metabolite

>  <Bioactivity>
Acetyltyrosine is a side chain reaction of tyrosine. It converts to tyrosine and then can be used in neurotransmitter treatment as a precursor of cathecholamine.

>  <Reference>
"Rao NR, et al. Estimation of serum alpha 2-macroglobulin based on the esterolytic activity of bound alpha-chymotrypsin. Biochem Med. 1984 Dec;32(3):357-63."

>  <ID<1>>
T5292

$$$$
StarDrop ID 65
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 1.1101 -3.1499 0.0000 0
M  V30 2 C 0.2897 -3.2361 0.0000 0
M  V30 3 C -0.1953 -2.5687 0.0000 0 CFG=1
M  V30 4 O 0.0597 -1.7840 0.0000 0
M  V30 5 C -0.6078 -1.2991 0.0000 0
M  V30 6 O -0.0557 -0.6860 0.0000 0
M  V30 7 C -1.1598 -0.6860 0.0000 0
M  V30 8 O -0.9049 0.0986 0.0000 0
M  V30 9 C -1.2752 -1.7840 0.0000 0 CFG=1
M  V30 10 O -2.0598 -1.5291 0.0000 0
M  V30 11 C -1.0203 -2.5687 0.0000 0 CFG=2
M  V30 12 O -1.5052 -3.2361 0.0000 0
M  V30 13 C -1.1696 -3.9898 0.0000 0 CFG=2
M  V30 14 O -0.3491 -4.0760 0.0000 0
M  V30 15 C -0.0136 -4.8297 0.0000 0 CFG=2
M  V30 16 C 0.8069 -4.9159 0.0000 0
M  V30 17 O 1.2918 -4.2485 0.0000 0
M  V30 18 C -0.4985 -5.4971 0.0000 0 CFG=2
M  V30 19 O -0.1630 -6.2508 0.0000 0
M  V30 20 C -1.3190 -5.4109 0.0000 0 CFG=2
M  V30 21 O -1.8039 -6.0783 0.0000 0
M  V30 22 C -1.6546 -4.6572 0.0000 0 CFG=1
M  V30 23 O -2.4750 -4.5710 0.0000 0
M  V30 24 H 0.7924 -2.4121 0.0000 0
M  V30 25 H -1.4317 -0.7963 0.0000 0
M  V30 26 H -0.5663 -3.4597 0.0000 0
M  V30 27 H -2.1641 -3.8852 0.0000 0
M  V30 28 H 0.5742 -4.0207 0.0000 0
M  V30 29 H -1.0863 -6.3061 0.0000 0
M  V30 30 H -2.3135 -5.3063 0.0000 0
M  V30 31 H -2.2423 -5.4663 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 9 5
M  V30 9 1 9 10 CFG=3
M  V30 10 1 11 9
M  V30 11 1 11 3
M  V30 12 1 11 12 CFG=1
M  V30 13 1 13 12 CFG=3
M  V30 14 1 13 14
M  V30 15 1 15 14
M  V30 16 1 15 16 CFG=3
M  V30 17 1 16 17
M  V30 18 1 18 15
M  V30 19 1 18 19 CFG=3
M  V30 20 1 18 20
M  V30 21 1 20 21 CFG=3
M  V30 22 1 20 22
M  V30 23 1 22 13
M  V30 24 1 22 23 CFG=1
M  V30 25 1 24 3
M  V30 26 1 25 9
M  V30 27 1 26 11
M  V30 28 1 27 13
M  V30 29 1 28 15
M  V30 30 1 29 18
M  V30 31 1 30 20
M  V30 32 1 31 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
65

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lactulose

>  <Synonyms>
4-O-??-D-Galactopyranosyl-D-fructose;D-Lactulose;Lactulosum;Duphalac

>  <CAS>
4618-18-2

>  <Formula>
C12H22O11

>  <MolWt>
342.3

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
??-gal

>  <Bioactivity>
"Lactulose , a synthetic disaccharide , is used in the treatment of constipation and hepatic encephalopathy."

>  <Reference>
"Algieri F, et al. J Agric Food Chem. 2014 May 14; 62(19):4285-97."

>  <ID<1>>
T0799

$$$$
StarDrop ID 66
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 -0.6337 0.0000 0
M  V30 2 C 3.1673 -0.7896 0.0000 0
M  V30 3 C 3.4373 -1.5691 0.0000 0
M  V30 4 C 3.7074 -0.1659 0.0000 0
M  V30 5 O 4.5175 -0.3218 0.0000 0
M  V30 6 C 5.0576 0.3018 0.0000 0
M  V30 7 C 5.8677 0.1459 0.0000 0
M  V30 8 C 6.4078 0.7695 0.0000 0
M  V30 9 N 7.2179 0.6136 0.0000 0
M  V30 10 C 7.4880 -0.1659 0.0000 0
M  V30 11 C 8.2981 -0.3218 0.0000 0
M  V30 12 C 8.8382 0.3018 0.0000 0
M  V30 13 C 9.6483 0.1459 0.0000 0
M  V30 14 C 9.9184 -0.6337 0.0000 0
M  V30 15 C 9.3783 -1.2573 0.0000 0
M  V30 16 C 8.5682 -1.1014 0.0000 0
M  V30 17 C 7.7580 1.2373 0.0000 0
M  V30 18 C 7.4880 2.0168 0.0000 0
M  V30 19 C 8.0281 2.6405 0.0000 0
M  V30 20 C 8.8382 2.4846 0.0000 0
M  V30 21 C 9.1083 1.7050 0.0000 0
M  V30 22 C 8.5682 1.0814 0.0000 0
M  V30 23 N 6.1378 -0.6337 0.0000 0
M  V30 24 C 6.9272 -0.8734 0.0000 0
M  V30 25 C 6.9431 -1.6982 0.0000 0
M  V30 26 C 6.1635 -1.9683 0.0000 0
M  V30 27 C 5.6658 -1.3103 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 11 16
M  V30 17 1 9 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 17 22
M  V30 24 1 7 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 23 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
66

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Bepridil hydrochloride

>  <Synonyms>
CERM 1978

>  <CAS>
68099-86-5

>  <Formula>
C24H35ClN2O

>  <MolWt>
403

>  <Pathways>
Metabolism;Membrane transporter/Ion channel

>  <Target>
Calcium Channel

>  <Receptor>
Calcium Channel

>  <Bioactivity>
"Bepridil is a calcium channel blocker and also inhibits Na+/Ca2+ exchange (NCX), sodium channels and cardiac sarcolemmal KATP channels."

>  <Reference>
"Qiu M, Li Z, Chen Y, et al. Tolcapone Potently Inhibits Seminal Amyloid Fibrils Formation and Blocks Entry of Ebola Pseudoviruses. Frontiers in Microbiology. 2020, 11: 504.;Li Y, et al. Bepridil blunts the shortening of action potential duration caused by metabolic inhibition via blockade of ATP-sensitive K(+) channels and Na(+)-activated K(+) channels. J Pharmacol Exp Ther. 1999 Nov;291(2):562-8.;Flaim SF, et al. Effects of bepridil hydrochloride on cardiocirculatory dynamics, coronary vascular resistance, and cardiac output distribution in normal, conscious rats. J Cardiovasc Pharmacol. 1988 Mar;11(3):363-72."

>  <ID<1>>
T5391

$$$$
StarDrop ID 67
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.5330 -3.2587 0.0000 0
M  V30 2 C 3.8928 -2.5163 0.0000 0 CFG=2
M  V30 3 C 4.4247 -3.1470 0.0000 0
M  V30 4 C 5.2368 -3.0018 0.0000 0
M  V30 5 O 5.7686 -3.6325 0.0000 0
M  V30 6 C 5.5171 -2.2259 0.0000 0 CFG=1
M  V30 7 C 4.9853 -1.5952 0.0000 0 CFG=1
M  V30 8 C 5.2655 -0.8192 0.0000 0
M  V30 9 C 6.0777 -0.6740 0.0000 0
M  V30 10 C 6.6095 -1.3047 0.0000 0
M  V30 11 C 7.4216 -1.1595 0.0000 0
M  V30 12 C 7.9534 -1.7902 0.0000 0
M  V30 13 O 8.7655 -1.6450 0.0000 0
M  V30 14 C 7.6731 -2.5662 0.0000 0
M  V30 15 C 6.8610 -2.7114 0.0000 0
M  V30 16 C 6.3292 -2.0807 0.0000 0 CFG=2
M  V30 17 C 6.0489 -2.8566 0.0000 0
M  V30 18 C 4.1731 -1.7404 0.0000 0 CFG=2
M  V30 19 C 3.5218 -1.2340 0.0000 0
M  V30 20 C 2.8390 -1.6970 0.0000 0
M  V30 21 C 3.0683 -2.4895 0.0000 0
M  V30 22 O 2.5619 -3.1408 0.0000 0
M  V30 23 H 6.1617 -2.9904 0.0000 0
M  V30 24 H 4.3406 -0.8308 0.0000 0
M  V30 25 H 3.2125 -2.0183 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 6 4 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 8 CFG=3
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 16 15
M  V30 16 1 6 16
M  V30 17 1 16 10
M  V30 18 1 16 17 CFG=1
M  V30 19 1 7 18
M  V30 20 1 18 2
M  V30 21 1 18 19 CFG=1
M  V30 22 1 19 20
M  V30 23 1 20 21
M  V30 24 1 2 21
M  V30 25 2 21 22
M  V30 26 1 23 6
M  V30 27 1 24 7
M  V30 28 1 25 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
67

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Adrenosterone

>  <Synonyms>
11-oxoandrostenedione;11-ketoandrostenedione;Reichstein's substance G

>  <CAS>
382-45-6

>  <Formula>
C19H24O3

>  <MolWt>
300.4

>  <Pathways>
Endocrinology/Hormones;Metabolism

>  <Target>
Endogenous Metabolite;Androgen Receptor

>  <Receptor>
Androgen Receptor; Endogenous Metabolite

>  <Bioactivity>
Adrenosterone is a steroid hormone isolated from the adrenal cortex.

>  <Reference>
"Blasco M, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 May 15;877(14-15):1509-15."

>  <ID<1>>
T2207

$$$$
StarDrop ID 68
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.5423 -4.7445 0.0000 0
M  V30 2 P 0.6286 -3.9240 0.0000 0
M  V30 3 O 1.4491 -4.0102 0.0000 0
M  V30 4 O 0.7148 -3.1035 0.0000 0
M  V30 5 O -0.1919 -3.8378 0.0000 0
M  V30 6 C -0.5275 -3.0841 0.0000 0
M  V30 7 N -0.0425 -2.4167 0.0000 0
M  V30 8 C 0.7825 -2.4167 0.0000 0
M  V30 9 O 1.2674 -3.0841 0.0000 0
M  V30 10 N 1.0374 -1.6320 0.0000 0
M  V30 11 C 0.3700 -1.1471 0.0000 0
M  V30 12 C -0.2975 -1.6320 0.0000 0
M  V30 13 O -1.0821 -1.3771 0.0000 0
M  V30 14 C 0.9772 -0.5887 0.0000 0
M  V30 15 C 0.7973 0.2164 0.0000 0
M  V30 16 C 1.4046 0.7749 0.0000 0
M  V30 17 C 2.1918 0.5281 0.0000 0
M  V30 18 C 2.3718 -0.2770 0.0000 0
M  V30 19 C 1.7645 -0.8354 0.0000 0
M  V30 20 C -0.0350 -0.4284 0.0000 0
M  V30 21 C -0.8600 -0.4197 0.0000 0
M  V30 22 C -1.2650 0.2990 0.0000 0
M  V30 23 C -0.8450 1.0091 0.0000 0
M  V30 24 C -0.0201 1.0005 0.0000 0
M  V30 25 C 0.3849 0.2817 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 12
M  V30 13 2 12 13
M  V30 14 1 11 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 14 19
M  V30 21 1 11 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 20 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
68

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fosphenytoin disodium

>  <Synonyms>
ACC-9653;Fosphenytoin sodium

>  <CAS>
92134-98-0

>  <Formula>
C16H13N2Na2O6P

>  <MolWt>
406.2

>  <Pathways>
Membrane transporter/Ion channel

>  <Target>
Sodium Channel

>  <Receptor>
Sodium Channel

>  <Bioactivity>
"Fosphenytoin is a prodrug of phenytoin that is rapidly converted to phenytoin, a voltage-gated sodium channel blocker"

>  <Reference>
"Smith R D , Brown B S , Maher R W , et al. Pharmacology of ACC?9653 (Phenytoin Prodrug)[J]. Epilepsia, 2010, 30(s2):S15-S21."

>  <ID<1>>
T7066

$$$$
StarDrop ID 69
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 0.6806 0.0000 0
M  V30 2 N 3.0716 0.2681 0.0000 0
M  V30 3 C 3.0716 -0.5569 0.0000 0
M  V30 4 C 3.7861 0.6806 0.0000 0
M  V30 5 C 4.5006 0.2681 0.0000 0
M  V30 6 C 5.2150 0.6806 0.0000 0
M  V30 7 N 5.9295 0.2681 0.0000 0
M  V30 8 C 6.6440 0.6806 0.0000 0
M  V30 9 C 6.6440 1.5056 0.0000 0
M  V30 10 C 7.3584 1.9181 0.0000 0
M  V30 11 C 8.0729 1.5056 0.0000 0
M  V30 12 C 8.0729 0.6806 0.0000 0
M  V30 13 C 7.3584 0.2681 0.0000 0
M  V30 14 S 7.3584 -0.5569 0.0000 0
M  V30 15 C 6.6440 -0.9694 0.0000 0
M  V30 16 C 6.6440 -1.7944 0.0000 0
M  V30 17 C 5.9295 -2.2069 0.0000 0
M  V30 18 C 5.2150 -1.7944 0.0000 0
M  V30 19 C 5.2150 -0.9694 0.0000 0
M  V30 20 C 5.9295 -0.5569 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 8 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 7 20
M  V30 22 1 15 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
69

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Promazine hydrochloride

>  <Synonyms>
Sinophenin hydrochloride;Romtiazin hydrochloride

>  <CAS>
53-60-1

>  <Formula>
C17H21ClN2S

>  <MolWt>
320.9

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
AChR;Adrenergic Receptor;5-HT Receptor;Dopamine Receptor

>  <Receptor>
5-HT; Adrenergic Receptor; Dopamine; mAChR

>  <Bioactivity>
Promazine hydrochloride is a phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.

>  <Reference>
"VLAVIANOS G, FINK L. Dis Nerv Syst. 1960 Sep;21:515-7."

>  <ID<1>>
T0766

$$$$
StarDrop ID 70
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 3.1508 0.8481 0.0000 0
M  V30 2 C 3.6826 0.2174 0.0000 0 CFG=2
M  V30 3 C 4.3340 -0.2889 0.0000 0
M  V30 4 C 5.0168 0.1741 0.0000 0
M  V30 5 C 4.7875 0.9666 0.0000 0 CFG=2
M  V30 6 O 4.7280 1.7894 0.0000 0
M  V30 7 C 5.4108 2.2524 0.0000 0
M  V30 8 C 5.3513 3.0752 0.0000 0
M  V30 9 O 6.1532 1.8925 0.0000 0
M  V30 10 C 5.5996 1.1118 0.0000 0
M  V30 11 C 6.1315 0.4811 0.0000 0
M  V30 12 O 6.2825 1.5747 0.0000 0
M  V30 13 C 3.9629 0.9934 0.0000 0 CFG=2
M  V30 14 C 4.3228 1.7357 0.0000 0
M  V30 15 C 3.4311 1.6241 0.0000 0
M  V30 16 C 2.6190 1.4789 0.0000 0 CFG=2
M  V30 17 O 2.0872 2.1096 0.0000 0
M  V30 18 C 2.3387 0.7029 0.0000 0 CFG=1
M  V30 19 F 1.8069 1.3336 0.0000 0
M  V30 20 C 2.8705 0.0722 0.0000 0 CFG=1
M  V30 21 H 3.4023 -0.5585 0.0000 0
M  V30 22 C 2.5902 -0.7037 0.0000 0
M  V30 23 C 1.7781 -0.8489 0.0000 0 CFG=2
M  V30 24 C 1.4978 -1.6248 0.0000 0
M  V30 25 C 1.2463 -0.2182 0.0000 0
M  V30 26 C 0.4342 -0.3634 0.0000 0
M  V30 27 C -0.0976 0.2673 0.0000 0
M  V30 28 O -0.9098 0.1221 0.0000 0
M  V30 29 C 0.1827 1.0432 0.0000 0
M  V30 30 C 0.9948 1.1884 0.0000 0
M  V30 31 C 1.5266 0.5577 0.0000 0 CFG=2
M  V30 32 C 1.2973 1.3502 0.0000 0
M  V30 33 H 2.9588 2.4194 0.0000 0
M  V30 34 H 2.4227 -1.6134 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 5 10 CFG=1
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 13 5
M  V30 13 1 2 13
M  V30 14 1 13 14 CFG=1
M  V30 15 1 13 15
M  V30 16 1 16 15
M  V30 17 1 16 17 CFG=1
M  V30 18 1 18 16
M  V30 19 1 18 19 CFG=3
M  V30 20 1 18 20
M  V30 21 1 20 2
M  V30 22 1 20 21 CFG=1
M  V30 23 1 20 22
M  V30 24 1 23 22
M  V30 25 1 23 24 CFG=3
M  V30 26 1 23 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 27 29
M  V30 31 2 29 30
M  V30 32 1 31 30
M  V30 33 1 18 31
M  V30 34 1 31 25
M  V30 35 1 31 32 CFG=1
M  V30 36 1 33 16
M  V30 37 1 34 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
70

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fluorometholone Acetate

>  <Synonyms>
Oxylone acetate;Eflone;Flarex;NSC 47438

>  <CAS>
3801-06-7

>  <Formula>
C24H31FO5

>  <MolWt>
418.5

>  <Pathways>
Endocrinology/Hormones;Metabolism

>  <Target>
Glucocorticoid Receptor;Carbonic Anhydrase

>  <Receptor>
" human carbonic anhydrase (hCA)-I:2.18 ??M (IC50), hCA-II:17.5 ??M (IC50), hCA-II:9.98 ??M (Ki), hCA-I:1.044 ??M (Ki)"

>  <Bioactivity>
"Fluorometholone Acetate is a synthetic corticosteroid, used in the treatment of steroid responsive inflammatory conditions of the eye."

>  <Reference>
"Kupferman A, et al. Arch Ophthalmol, 1982, 100(4), 640-641."

>  <ID<1>>
T6503

$$$$
StarDrop ID 71
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -0.4304 -0.4390 0.0000 0
M  V30 2 C -0.4304 0.3860 0.0000 0 CFG=1
M  V30 3 C -1.2554 0.3860 0.0000 0 CFG=1
M  V30 4 C -1.2554 -0.4390 0.0000 0
M  V30 5 O -1.8388 -1.0224 0.0000 0
M  V30 6 N -1.8388 0.9693 0.0000 0
M  V30 7 C -2.6356 0.7558 0.0000 0
M  V30 8 O -2.8492 -0.0411 0.0000 0
M  V30 9 C -3.2190 1.3392 0.0000 0
M  V30 10 C -4.0159 1.1256 0.0000 0
M  V30 11 N -4.3115 0.3554 0.0000 0
M  V30 12 C -5.1354 0.3986 0.0000 0
M  V30 13 S -5.3489 1.1955 0.0000 0
M  V30 14 C -4.6570 1.6448 0.0000 0
M  V30 15 N -5.6546 -0.2425 0.0000 0
M  V30 16 S 0.2841 0.7985 0.0000 0
M  V30 17 C 0.9986 0.3860 0.0000 0
M  V30 18 C 0.9986 -0.4390 0.0000 0
M  V30 19 C 0.2841 -0.8515 0.0000 0
M  V30 20 C 0.2841 -1.6765 0.0000 0
M  V30 21 O -0.4304 -2.0890 0.0000 0
M  V30 22 O 0.9986 -2.0890 0.0000 0
M  V30 23 C 1.7130 -0.8515 0.0000 0
M  V30 24 S 2.4275 -0.4390 0.0000 0
M  V30 25 C 3.1420 -0.8515 0.0000 0
M  V30 26 N 3.8956 -0.5160 0.0000 0
M  V30 27 N 4.4477 -1.1291 0.0000 0
M  V30 28 N 4.0352 -1.8435 0.0000 0
M  V30 29 N 3.2282 -1.6720 0.0000 0
M  V30 30 C 4.0672 0.2910 0.0000 0
M  V30 31 C 3.4541 0.8430 0.0000 0
M  V30 32 N 3.6256 1.6500 0.0000 0
M  V30 33 C 4.4102 1.9049 0.0000 0
M  V30 34 C 3.0125 2.2020 0.0000 0
M  V30 35 H -1.1375 -0.3211 0.0000 0
M  V30 36 H -2.1793 0.0033 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 1 4
M  V30 5 2 4 5
M  V30 6 1 3 6 CFG=1
M  V30 7 1 6 7
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 10 14
M  V30 16 1 12 15
M  V30 17 1 2 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 1 19
M  V30 22 1 19 20
M  V30 23 2 20 21
M  V30 24 1 20 22
M  V30 25 1 18 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 2 27 28
M  V30 31 1 28 29
M  V30 32 2 25 29
M  V30 33 1 26 30
M  V30 34 1 30 31
M  V30 35 1 31 32
M  V30 36 1 32 33
M  V30 37 1 32 34
M  V30 38 1 35 2
M  V30 39 1 36 3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
71

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cefotiam hydrochloride

>  <Synonyms>
SCE-963 hydrochloride;Pansporin;Pansporine;Halospor;Cefotiam dihydrochloride

>  <CAS>
66309-69-1

>  <Formula>
C18H23N9O4S3.2HCl

>  <MolWt>
598.6

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial;Antibiotic

>  <Receptor>
Antibiotic; Bacterial; PBPs

>  <Bioactivity>
"Cefotiam Hydrochloride is the hydrochloride salt form of cefotiam, a third-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity. Cefotiam binds to penicillin-binding proteins (PBPs), transpeptidases that are responsible for crosslinking of peptidoglycan. By preventing crosslinking of peptidoglycan, cell wall integrity is lost and cell wall synthesis is halted."

>  <Reference>
"Matsuda K, et al. Antimicrob Agents ChemOthers. 1995 Dec;39(12):2631-4."

>  <ID<1>>
T1616

$$$$
StarDrop ID 72
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.7459 -3.6020 0.0000 0
M  V30 2 C 0.3334 -2.8875 0.0000 0 CFG=2
M  V30 3 N -0.0791 -2.1730 0.0000 0
M  V30 4 C -0.3811 -3.3000 0.0000 0
M  V30 5 C -0.3811 -4.1250 0.0000 0
M  V30 6 C 0.3334 -4.5375 0.0000 0
M  V30 7 C 0.3334 -5.3625 0.0000 0
M  V30 8 C -0.3811 -5.7750 0.0000 0
M  V30 9 O -0.3811 -6.6000 0.0000 0
M  V30 10 C -1.0955 -5.3625 0.0000 0
M  V30 11 O -1.8100 -5.7750 0.0000 0
M  V30 12 C -1.0955 -4.5375 0.0000 0
M  V30 13 C 1.0479 -2.4750 0.0000 0
M  V30 14 O 1.0479 -1.6500 0.0000 0
M  V30 15 O 1.7624 -2.8875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3 CFG=1
M  V30 3 1 2 4 CFG=3
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 5 12
M  V30 13 1 2 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
72

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Methyldopa hydrate

>  <Synonyms>
L-(-)-??-Methyldopa hydrate;Methyldopa Sesquihydrate;MK-351 hydrate;Alpha-Methyldopa Sesquihydrate

>  <CAS>
41372-08-1

>  <Formula>
C20H32N2O11

>  <MolWt>
476.5

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor;Dopamine Receptor

>  <Receptor>
Adrenergic Receptor; DOPA decarboxylase

>  <Bioactivity>
"Alpha-Methyldopa Sesquihydrate is a DOPA decarboxylase inhibitor and indirect ??2-adrenergic receptor agonist used to treat hypertension. It inhibits the sympathetic nervous system, decreases production of dopamine, norepinephrine, and epinephrine, and exhibits NO-dependent sedative activity."

>  <Reference>
"Baila M R , Cintas J A . [The use of the combination of L-alpha-methyldopa and dichlorothiazide in the treatment of arterial hypertension][J]. El D??a M??dico, 1962, 34:2422.;Program N T . NTP Toxicology and Carcinogenesis Studies of alpha-Methyldopa Sesquihydrate (CAS No. 41372-08-1) in F344/N Rats and B6C3F1 Mice (Feed Studies).[J]. National Toxicology Program Technical Report, 1989, 348."

>  <ID<1>>
T5954

$$$$
StarDrop ID 73
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0071 -0.5569 0.0000 0
M  V30 2 N 4.7216 -0.1444 0.0000 0
M  V30 3 C 4.7216 0.6806 0.0000 0
M  V30 4 C 5.4361 -0.5569 0.0000 0
M  V30 5 C 6.1506 -0.1444 0.0000 0
M  V30 6 O 6.8650 -0.5569 0.0000 0
M  V30 7 C 7.5795 -0.1444 0.0000 0
M  V30 8 C 8.2940 -0.5569 0.0000 0
M  V30 9 C 9.0084 -0.1444 0.0000 0
M  V30 10 C 9.7229 -0.5569 0.0000 0
M  V30 11 C 9.7229 -1.3819 0.0000 0
M  V30 12 Cl 10.4374 -1.7944 0.0000 0
M  V30 13 C 9.0084 -1.7944 0.0000 0
M  V30 14 C 8.2940 -1.3819 0.0000 0
M  V30 15 C 7.5795 0.6806 0.0000 0
M  V30 16 C 6.8650 1.0931 0.0000 0
M  V30 17 C 6.8650 1.9181 0.0000 0
M  V30 18 C 7.5795 2.3306 0.0000 0
M  V30 19 C 8.2940 1.9181 0.0000 0
M  V30 20 N 8.2940 1.0931 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 2 13 14
M  V30 14 1 8 14
M  V30 15 1 7 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 15 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
73

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Carbinoxamine Maleate Salt

>  <Synonyms>
CarbinoxaMine Maleate;Lergefin

>  <CAS>
3505-38-2

>  <Formula>
C20H23ClN2O5

>  <MolWt>
406.9

>  <Pathways>
Immunology/Inflammation;Neuroscience;GPCR/G Protein

>  <Target>
Histamine Receptor

>  <Receptor>
H1 receptor; Histamine Receptor

>  <Bioactivity>
Carbinoxamine Maleate is an ethanolamine class of H1 antihistamines with mild antimuscarinic and sedative properties.

>  <Reference>
"Oishi R, et al. Naunyn Schmiedebergs Arch Pharmacol. 1994 Feb;349(2):140-4."

>  <ID<1>>
T2222

$$$$
StarDrop ID 74
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.9296 -4.1250 0.0000 0
M  V30 2 N 3.9296 -3.3000 0.0000 0
M  V30 3 C 3.2151 -2.8875 0.0000 0
M  V30 4 C 2.5006 -3.3000 0.0000 0
M  V30 5 C 1.7862 -2.8875 0.0000 0
M  V30 6 C 1.0717 -3.3000 0.0000 0
M  V30 7 C 0.3572 -2.8875 0.0000 0
M  V30 8 C -0.3572 -3.3000 0.0000 0
M  V30 9 C -1.0717 -2.8875 0.0000 0
M  V30 10 C -1.7862 -3.3000 0.0000 0
M  V30 11 C -2.5006 -2.8875 0.0000 0
M  V30 12 C -3.2151 -3.3000 0.0000 0
M  V30 13 N -3.9296 -2.8875 0.0000 0
M  V30 14 C -3.9296 -2.0625 0.0000 0
M  V30 15 C -4.6441 -3.3000 0.0000 0
M  V30 16 O -4.6441 -4.1250 0.0000 0
M  V30 17 O -5.3585 -2.8875 0.0000 0
M  V30 18 C -6.0730 -3.3000 0.0000 0
M  V30 19 C -6.0730 -4.1250 0.0000 0
M  V30 20 C -6.7875 -4.5375 0.0000 0
M  V30 21 C -7.5019 -4.1250 0.0000 0
M  V30 22 C -7.5019 -3.3000 0.0000 0
M  V30 23 C -6.7875 -2.8875 0.0000 0
M  V30 24 N -8.2164 -2.8875 0.0000 0 CHG=1
M  V30 25 C -8.9309 -2.4750 0.0000 0
M  V30 26 C -8.6289 -3.6020 0.0000 0
M  V30 27 C -7.8039 -2.1730 0.0000 0
M  V30 28 C 4.6441 -2.8875 0.0000 0
M  V30 29 O 4.6441 -2.0625 0.0000 0
M  V30 30 O 5.3585 -3.3000 0.0000 0
M  V30 31 C 6.0730 -2.8875 0.0000 0
M  V30 32 C 6.0730 -2.0625 0.0000 0
M  V30 33 C 6.7875 -1.6500 0.0000 0
M  V30 34 C 7.5019 -2.0625 0.0000 0
M  V30 35 C 7.5019 -2.8875 0.0000 0
M  V30 36 C 6.7875 -3.3000 0.0000 0
M  V30 37 N 8.2164 -3.3000 0.0000 0 CHG=1
M  V30 38 C 8.9309 -3.7125 0.0000 0
M  V30 39 C 7.8039 -4.0145 0.0000 0
M  V30 40 C 8.6289 -2.5855 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 18 23
M  V30 24 1 22 24
M  V30 25 1 24 25
M  V30 26 1 24 26
M  V30 27 1 24 27
M  V30 28 1 2 28
M  V30 29 2 28 29
M  V30 30 1 28 30
M  V30 31 1 30 31
M  V30 32 2 31 32
M  V30 33 1 32 33
M  V30 34 2 33 34
M  V30 35 1 34 35
M  V30 36 2 35 36
M  V30 37 1 31 36
M  V30 38 1 35 37
M  V30 39 1 37 38
M  V30 40 1 37 39
M  V30 41 1 37 40
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
74

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Demecarium bromide

>  <Synonyms>
BC-48

>  <CAS>
56-94-0

>  <Formula>
C32H52Br2N4O4

>  <MolWt>
716.6

>  <Pathways>
Neuroscience

>  <Target>
AChE

>  <Receptor>
 cholinesterase:0.15 ??M (Kiapp)

>  <Bioactivity>
"Demecarium bromide is a potent cholinesterase inhibitor,and is treatment glaucoma agent."

>  <Reference>
"Terner I S , Linn J G , Goldstrohm R . Clinical Experiences with Demecarium Bromide (BC-48) in the Treatment of Glaucoma*[J]. American Journal of Ophthalmology, 1961, 52(4):553-560.;Deutsch A R , Rowlett W M . Demecarium bromide: analysis of its action in selected group of glaucomas.[J]. Journal of the Tennessee State Medical Association Tennessee State Medical Association, 1963, 56(56):5."

>  <ID<1>>
T7213

$$$$
StarDrop ID 75
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.1434 -2.8875 0.0000 0
M  V30 2 C 1.4289 -2.4750 0.0000 0
M  V30 3 N 1.4289 -1.6500 0.0000 0
M  V30 4 C 0.7145 -1.2375 0.0000 0
M  V30 5 C 0.7145 -0.4125 0.0000 0
M  V30 6 C 0.0000 0.0000 0.0000 0
M  V30 7 O 0.0000 0.8250 0.0000 0
M  V30 8 O -0.7145 -0.4125 0.0000 0
M  V30 9 C 1.4289 0.0000 0.0000 0
M  V30 10 O 1.4289 0.8250 0.0000 0
M  V30 11 C 2.1434 -0.4125 0.0000 0
M  V30 12 C 2.8579 0.0000 0.0000 0
M  V30 13 C 3.5724 -0.4125 0.0000 0
M  V30 14 F 4.2868 -0.0000 0.0000 0
M  V30 15 C 3.5724 -1.2375 0.0000 0
M  V30 16 N 4.2868 -1.6500 0.0000 0
M  V30 17 C 5.0013 -1.2375 0.0000 0
M  V30 18 C 5.7158 -1.6500 0.0000 0
M  V30 19 N 5.7158 -2.4750 0.0000 0
M  V30 20 C 5.0013 -2.8875 0.0000 0
M  V30 21 C 5.0013 -3.7125 0.0000 0
M  V30 22 C 4.2868 -2.4750 0.0000 0
M  V30 23 C 2.8579 -1.6500 0.0000 0
M  V30 24 F 2.8579 -2.4750 0.0000 0
M  V30 25 C 2.1434 -1.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 5 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 20 22
M  V30 22 1 16 22
M  V30 23 1 15 23
M  V30 24 1 23 24
M  V30 25 2 23 25
M  V30 26 1 3 25
M  V30 27 1 11 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
75

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lomefloxacin

>  <Synonyms>
SC47111A

>  <CAS>
98079-51-7

>  <Formula>
C17H19F2N3O3

>  <MolWt>
351.4

>  <Pathways>
DNA Damage/DNA Repair;Microbiology/Virology

>  <Target>
Topoisomerase;Antibacterial;Antibiotic

>  <Receptor>
Antibiotic; Bacterial; Topo II; Topo IV

>  <Bioactivity>
Lomefloxacin is a synthetic broad-spectrum fluoroquinolone with antibacterial activity.

>  <Reference>
"Takenouchi T, et al. Antimicrob Agents ChemOthers. 1995 Jul;39(7):1414-8"

>  <ID<1>>
T1444

$$$$
StarDrop ID 76
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.1434 -1.2375 0.0000 0
M  V30 2 C 1.4289 -1.6500 0.0000 0
M  V30 3 O 0.7145 -1.2375 0.0000 0
M  V30 4 C 0.7145 -0.4125 0.0000 0
M  V30 5 C 0.0000 0.0000 0.0000 0
M  V30 6 Cl -0.7145 -0.4125 0.0000 0
M  V30 7 C 0.0000 0.8250 0.0000 0
M  V30 8 C 0.7145 1.2375 0.0000 0
M  V30 9 C 1.4289 0.8250 0.0000 0
M  V30 10 C 1.4289 0.0000 0.0000 0
M  V30 11 Cl 2.1434 -0.4125 0.0000 0
M  V30 12 C 1.4289 -2.4750 0.0000 0
M  V30 13 N 2.0964 -2.9599 0.0000 0
M  V30 14 C 1.8414 -3.7445 0.0000 0
M  V30 15 C 1.0164 -3.7445 0.0000 0
M  V30 16 N 0.7615 -2.9599 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 4 10
M  V30 11 1 10 11
M  V30 12 1 2 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 12 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
76

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lofexidine

>  <Synonyms>
N/A

>  <CAS>
31036-80-3

>  <Formula>
C11H12Cl2N2O

>  <MolWt>
259.1

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor; ??2 receptor

>  <Bioactivity>
"Lofexidine is a selective ??2-receptor agonist, Lofexidine reduces narcotic withdrawal symptoms."

>  <Reference>
"Gorodetzky CW, Walsh SL, Martin PR,et al.A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal[J].Drug Alcohol Depend. 2017 Jul 1;176:79-88.;Pergolizzi J V , Annabi H , Gharibo C , et al. The Role of Lofexidine in Management of Opioid Withdrawal[J]. Pain and Therapy, 2018."

>  <ID<1>>
T7160

$$$$
StarDrop ID 77
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 0.9043 0.0000 0
M  V30 2 C 3.0716 0.4918 0.0000 0 CFG=1
M  V30 3 C 3.0716 -0.3332 0.0000 0
M  V30 4 O 3.7861 -0.7457 0.0000 0
M  V30 5 C 4.5006 -0.3332 0.0000 0
M  V30 6 C 5.2150 -0.7457 0.0000 0
M  V30 7 N 5.2150 -1.5707 0.0000 0
M  V30 8 C 5.9295 -1.9832 0.0000 0
M  V30 9 C 5.9295 -2.8082 0.0000 0
M  V30 10 N 5.2150 -3.2207 0.0000 0
M  V30 11 C 5.2150 -4.0457 0.0000 0
M  V30 12 C 4.5006 -2.8082 0.0000 0
M  V30 13 C 4.5006 -1.9832 0.0000 0
M  V30 14 C 5.9295 -0.3332 0.0000 0
M  V30 15 F 6.6440 -0.7457 0.0000 0
M  V30 16 C 5.9295 0.4918 0.0000 0
M  V30 17 C 5.2150 0.9043 0.0000 0
M  V30 18 C 4.5006 0.4918 0.0000 0
M  V30 19 N 3.7861 0.9043 0.0000 0
M  V30 20 C 3.7861 1.7293 0.0000 0
M  V30 21 C 4.5006 2.1418 0.0000 0
M  V30 22 C 4.5006 2.9668 0.0000 0
M  V30 23 O 3.7861 3.3793 0.0000 0
M  V30 24 O 5.2150 3.3793 0.0000 0
M  V30 25 C 5.2150 1.7293 0.0000 0
M  V30 26 O 5.9295 2.1418 0.0000 0
M  V30 27 H 2.2056 -0.0082 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 7 13
M  V30 14 1 6 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 5 18
M  V30 20 1 18 19
M  V30 21 1 2 19
M  V30 22 1 19 20
M  V30 23 2 20 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 2 22 24
M  V30 27 1 21 25
M  V30 28 1 17 25
M  V30 29 2 25 26
M  V30 30 1 27 2
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
77

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Levofloxacin hydrate

>  <Synonyms>
Levofloxacin Hemihydrate;Tavanic hydrate;Cravit hydrate;Iquix hydrate;Quixin hydrate;Levaquin hydrate

>  <CAS>
138199-71-0

>  <Formula>
C18H20FN3O4??1/2H2O

>  <MolWt>
370.4

>  <Pathways>
DNA Damage/DNA Repair;Microbiology/Virology

>  <Target>
DNA gyrase;Topoisomerase;Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial; DNA gyrase; Topo II; Topo IV

>  <Bioactivity>
"Levofloxacin is a broad-spectrum, third-generation fluoroquinolone antibiotic and optically active L-isomer of ofloxacin with antibacterial activity. Levofloxacin diffuses through the bacterial cell wall and acts by inhibiting DNA gyrase (bacterial topoisomerase II), an enzyme required for DNA replication, RNA transcription, and repair of bacterial DNA. Inhibition of DNA gyrase activity leads to blockage of bacterial cell growth."

>  <Reference>
"Schmitz FJ, et al. J Antimicrob ChemOthers. 1998 Apr;41(4):481-4."

>  <ID<1>>
T1451

$$$$
StarDrop ID 78
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 4.2868 4.1250 0.0000 0
M  V30 2 C 4.2868 3.3000 0.0000 0 CFG=1
M  V30 3 C 4.2868 2.4750 0.0000 0
M  V30 4 C 3.5724 2.0625 0.0000 0 CFG=1
M  V30 5 O 3.5724 1.2375 0.0000 0
M  V30 6 C 4.2868 0.8250 0.0000 0
M  V30 7 O 4.2868 0.0000 0.0000 0
M  V30 8 C 5.0013 1.2375 0.0000 0 CFG=1
M  V30 9 N 5.0013 2.0625 0.0000 0
M  V30 10 C 5.7158 0.8250 0.0000 0
M  V30 11 C 6.4302 1.2375 0.0000 0
M  V30 12 C 5.7158 0.0000 0.0000 0
M  V30 13 C 2.8579 2.4750 0.0000 0 CFG=2
M  V30 14 C 2.1434 2.0625 0.0000 0
M  V30 15 C 2.1434 1.2375 0.0000 0
M  V30 16 C 2.8579 0.8250 0.0000 0
M  V30 17 C 1.4289 0.8250 0.0000 0
M  V30 18 C 2.8579 3.3000 0.0000 0
M  V30 19 N 3.5724 3.7125 0.0000 0
M  V30 20 C 3.5724 4.5375 0.0000 0
M  V30 21 C 4.2868 4.9500 0.0000 0
M  V30 22 C 5.0013 4.5375 0.0000 0
M  V30 23 C 5.7158 4.9500 0.0000 0
M  V30 24 C 6.4302 4.5375 0.0000 0
M  V30 25 O 7.1447 4.9500 0.0000 0
M  V30 26 C 7.1447 5.7750 0.0000 0
M  V30 27 C 6.4302 3.7125 0.0000 0
M  V30 28 O 7.1447 3.3000 0.0000 0
M  V30 29 C 7.1447 2.4750 0.0000 0
M  V30 30 C 5.7158 3.3000 0.0000 0
M  V30 31 C 5.0013 3.7125 0.0000 0
M  V30 32 H 4.4384 1.5625 0.0000 0
M  V30 33 H 4.1353 1.7375 0.0000 0
M  V30 34 H 1.9919 2.9750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5 CFG=1
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 8 6
M  V30 8 1 8 9 CFG=1
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 4 13
M  V30 13 1 13 14 CFG=3
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 1 13 18
M  V30 18 1 18 19
M  V30 19 1 2 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 2 24 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 1 27 30
M  V30 31 2 30 31
M  V30 32 1 2 31
M  V30 33 1 22 31
M  V30 34 1 32 4
M  V30 35 1 33 8
M  V30 36 1 34 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
78

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Valbenazine

>  <Synonyms>
NBI-98854

>  <CAS>
1025504-45-3

>  <Formula>
C24H38N2O4

>  <MolWt>
418.6

>  <Pathways>
Membrane transporter/Ion channel

>  <Target>
Monoamine Transporter

>  <Receptor>
Monoamine Transporter; VMAT2

>  <Bioactivity>
"Valbenazine, a highly selective vesicular monoamine transporter 2(VMAT2) inhibitor, is approved for the treatment of tardive dyskinesia."

>  <Reference>
"Factor S A , Remington G , Comella C L , et al. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study[J]. The Journal of Clinical Psychiatry, 2017, 78(9).;Josiassen R C , Kane J M , Liang G S , et al. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder[J]. Psychopharmacology bulletin, 2017, 47(3):61-68."

>  <ID<1>>
T7147

$$$$
StarDrop ID 79
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 40 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 5.1841 0.0000 0
M  V30 2 C 3.1821 5.1841 0.0000 0
M  V30 3 C 4.0071 5.1841 0.0000 0
M  V30 4 C 3.1821 6.0091 0.0000 0
M  V30 5 O 2.4677 6.4216 0.0000 0
M  V30 6 O 3.8966 6.4216 0.0000 0
M  V30 7 C 3.1821 4.3591 0.0000 0
M  V30 8 C 3.8966 3.9466 0.0000 0
M  V30 9 C 3.8966 3.1216 0.0000 0
M  V30 10 C 3.1821 2.7091 0.0000 0
M  V30 11 C 2.4677 3.1216 0.0000 0
M  V30 12 C 2.4677 3.9466 0.0000 0
M  V30 13 C 3.1821 1.8841 0.0000 0
M  V30 14 O 2.4677 1.4716 0.0000 0
M  V30 15 C 3.8966 1.4716 0.0000 0
M  V30 16 C 3.8966 0.6466 0.0000 0
M  V30 17 C 4.6111 0.2341 0.0000 0
M  V30 18 N 4.6111 -0.5909 0.0000 0
M  V30 19 C 5.3256 -1.0034 0.0000 0
M  V30 20 C 5.3256 -1.8284 0.0000 0
M  V30 21 C 4.6111 -2.2409 0.0000 0
M  V30 22 C 3.8966 -1.8284 0.0000 0
M  V30 23 C 3.8966 -1.0034 0.0000 0
M  V30 24 C 4.6111 -3.0659 0.0000 0
M  V30 25 O 3.7861 -3.0659 0.0000 0
M  V30 26 C 4.6111 -3.8909 0.0000 0
M  V30 27 C 5.3256 -4.3034 0.0000 0
M  V30 28 C 5.3256 -5.1284 0.0000 0
M  V30 29 C 4.6111 -5.5409 0.0000 0
M  V30 30 C 3.8966 -5.1284 0.0000 0
M  V30 31 C 3.8966 -4.3034 0.0000 0
M  V30 32 C 5.4361 -3.0659 0.0000 0
M  V30 33 C 5.8486 -2.3514 0.0000 0
M  V30 34 C 6.6736 -2.3514 0.0000 0
M  V30 35 C 7.0861 -3.0659 0.0000 0
M  V30 36 C 6.6736 -3.7803 0.0000 0
M  V30 37 C 5.8486 -3.7803 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 2 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 7 12
M  V30 13 1 10 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 18 23
M  V30 25 1 21 24
M  V30 26 1 24 25
M  V30 27 1 24 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 26 31
M  V30 34 1 24 32
M  V30 35 2 32 33
M  V30 36 1 33 34
M  V30 37 2 34 35
M  V30 38 1 35 36
M  V30 39 2 36 37
M  V30 40 1 32 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
79

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fexofenadine hydrochloride

>  <Synonyms>
N/A

>  <CAS>
138452-21-8

>  <Formula>
C32H4OClNO4

>  <MolWt>
538.1

>  <Pathways>
Immunology/Inflammation;Neuroscience;GPCR/G Protein

>  <Target>
Histamine Receptor

>  <Receptor>
H1 receptor

>  <Bioactivity>
"Fexofenadine Hydrochloride is a carboxylated metabolic derivative of terfenadine and long-lasting selective histamine H1 receptor antagonist, with antihistaminic activity."

>  <Reference>
"Abbas MN, et al. Anal Sci. 2004 Aug;20(8):1137-42."

>  <ID<1>>
T1470L

$$$$
StarDrop ID 80
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.9532 -2.0138 0.0000 0
M  V30 2 C -2.1282 -2.0138 0.0000 0
M  V30 3 C -1.7157 -1.2994 0.0000 0
M  V30 4 O -1.7157 -2.7283 0.0000 0
M  V30 5 C -0.8907 -2.7283 0.0000 0
M  V30 6 O -0.4782 -2.0138 0.0000 0
M  V30 7 O -0.4782 -3.4428 0.0000 0
M  V30 8 C 0.3468 -3.4428 0.0000 0
M  V30 9 O 0.7593 -4.1572 0.0000 0
M  V30 10 P 1.5843 -4.1572 0.0000 0
M  V30 11 O 1.5843 -4.9822 0.0000 0
M  V30 12 C 2.4093 -4.1572 0.0000 0
M  V30 13 O 2.8218 -4.8717 0.0000 0
M  V30 14 C 3.6468 -4.8717 0.0000 0
M  V30 15 C 4.0593 -4.1572 0.0000 0
M  V30 16 C 4.0593 -5.5862 0.0000 0
M  V30 17 N 4.8843 -5.5862 0.0000 0
M  V30 18 C 5.3692 -4.9187 0.0000 0
M  V30 19 N 6.1539 -5.1737 0.0000 0
M  V30 20 C 6.1539 -5.9987 0.0000 0
M  V30 21 C 6.7670 -6.5507 0.0000 0
M  V30 22 N 7.5516 -6.2958 0.0000 0
M  V30 23 N 6.5954 -7.3577 0.0000 0
M  V30 24 C 5.8108 -7.6126 0.0000 0
M  V30 25 N 5.1977 -7.0606 0.0000 0
M  V30 26 C 5.3692 -6.2536 0.0000 0
M  V30 27 O 1.5843 -3.3322 0.0000 0
M  V30 28 C 2.2988 -2.9197 0.0000 0
M  V30 29 O 3.0133 -3.3322 0.0000 0
M  V30 30 C 3.7277 -2.9197 0.0000 0
M  V30 31 O 3.7277 -2.0947 0.0000 0
M  V30 32 O 4.4422 -3.3322 0.0000 0
M  V30 33 C 5.1567 -2.9197 0.0000 0
M  V30 34 C 5.1567 -2.0947 0.0000 0
M  V30 35 C 5.8711 -3.3322 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 1 21 23
M  V30 23 2 23 24
M  V30 24 1 24 25
M  V30 25 2 25 26
M  V30 26 1 17 26
M  V30 27 1 20 26
M  V30 28 1 10 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 30 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 1 33 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
80

>  <Plate>
PHD136328

>  <Row>
d

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tenofovir Disoproxil

>  <Synonyms>
GS 4331;Bis(POC)-PMPA

>  <CAS>
201341-05-1

>  <Formula>
C19H30N5O10P

>  <MolWt>
519.4

>  <Pathways>
Proteases/Proteasome;Microbiology/Virology

>  <Target>
HBV;HIV Protease;Reverse Transcriptase

>  <Receptor>
HBV; HIV; Reverse Transcriptase

>  <Bioactivity>
Tenofovir Disoproxil is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.

>  <Reference>
"Rachel M , Reagan S , Brooke P , et al. Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity[J]. International Journal of Molecular Sciences, 2017, 18(3):531-.;Thieulent C, Hue E, Sutton G, et al. Identification of antiviral compounds against equid herpesvirus-1 using real-time cell assay screening: efficacy of decitabine and valganciclovir alone or in combination[J]. Antiviral Research. 2020: 104931;Fical L. Vyvoj UHPLC-MS/MS metody pro analyzu vybranych antivirotik v HILIC a RP m??du[J]. 2020;Menne S , Cote P J , Korba B E , et al. Antiviral Effect of Oral Administration of Tenofovir Disoproxil Fumarate in Woodchucks with Chronic Woodchuck Hepatitis Virus Infection[J]. Antimicrobial Agents and Chemotherapy, 2005, 49(7):2720-2728.;Fical L, Khalikova M, Ko?ov?? Vl?kov?? H, et al. Determination of Antiviral Drugs and Their Metabolites Using Micro-Solid Phase Extraction and UHPLC-MS/MS in Reversed-Phase and Hydrophilic Interaction Chromatography Modes[J]. Molecules. 2021, 26(8): 2123."

>  <ID<1>>
T7111

$$$$
StarDrop ID 81
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 130 135 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.0996 -13.5745 0.0000 0
M  V30 2 C -0.4237 -12.9366 0.0000 0
M  V30 3 C -0.1330 -12.1646 0.0000 0
M  V30 4 C -0.6563 -11.5268 0.0000 0
M  V30 5 C -0.3655 -10.7547 0.0000 0 CFG=2
M  V30 6 N -0.8888 -10.1169 0.0000 0
M  V30 7 C -1.7028 -10.2511 0.0000 0
M  V30 8 O -1.9935 -11.0232 0.0000 0
M  V30 9 C -2.2261 -9.6133 0.0000 0 CFG=2
M  V30 10 C -1.9354 -8.8413 0.0000 0
M  V30 11 O -1.1214 -8.7070 0.0000 0
M  V30 12 N -3.0401 -9.7476 0.0000 0
M  V30 13 C -3.5634 -9.1098 0.0000 0
M  V30 14 O -3.2727 -8.3377 0.0000 0
M  V30 15 C -4.3774 -9.2441 0.0000 0 CFG=2
M  V30 16 C -4.9007 -8.6063 0.0000 0
M  V30 17 C -5.7147 -8.7405 0.0000 0
M  V30 18 C -6.0054 -9.5126 0.0000 0
M  V30 19 C -6.8194 -9.6469 0.0000 0
M  V30 20 C -7.3427 -9.0091 0.0000 0
M  V30 21 O -8.1567 -9.1434 0.0000 0
M  V30 22 C -7.0520 -8.2370 0.0000 0
M  V30 23 C -6.2380 -8.1027 0.0000 0
M  V30 24 N -4.6681 -10.0162 0.0000 0
M  V30 25 C -4.1448 -10.6540 0.0000 0
M  V30 26 O -3.3308 -10.5197 0.0000 0
M  V30 27 C -4.4355 -11.4261 0.0000 0 CFG=2
M  V30 28 C -5.2495 -11.5603 0.0000 0
M  V30 29 O -5.7728 -10.9225 0.0000 0
M  V30 30 N -3.9123 -12.0639 0.0000 0
M  V30 31 C -4.2030 -12.8359 0.0000 0
M  V30 32 C -3.6797 -13.4737 0.0000 0
M  V30 33 O -5.0170 -12.9702 0.0000 0
M  V30 34 C 0.4485 -10.6204 0.0000 0
M  V30 35 O 0.7392 -9.8483 0.0000 0
M  V30 36 N 0.9717 -11.2582 0.0000 0
M  V30 37 C 1.7857 -11.1239 0.0000 0 CFG=1
M  V30 38 C 2.0765 -10.3518 0.0000 0
M  V30 39 C 2.8905 -10.2176 0.0000 0
M  V30 40 C 3.1812 -9.4455 0.0000 0
M  V30 41 O 2.6579 -8.8077 0.0000 0
M  V30 42 O 3.9952 -9.3112 0.0000 0
M  V30 43 C 2.3090 -11.7617 0.0000 0
M  V30 44 O 2.0183 -12.5338 0.0000 0
M  V30 45 N 3.1230 -11.6275 0.0000 0
M  V30 46 C 3.6463 -12.2653 0.0000 0 CFG=1
M  V30 47 C 3.3556 -13.0374 0.0000 0
M  V30 48 C 3.8789 -13.6752 0.0000 0
M  V30 49 C 4.7025 -13.6267 0.0000 0
M  V30 50 N 5.0030 -14.3950 0.0000 0
M  V30 51 C 4.3652 -14.9183 0.0000 0
M  V30 52 N 3.6705 -14.4734 0.0000 0
M  V30 53 C 4.4603 -12.1310 0.0000 0
M  V30 54 O 4.7510 -11.3589 0.0000 0
M  V30 55 N 4.9836 -12.7688 0.0000 0
M  V30 56 C 5.7976 -12.6345 0.0000 0 CFG=2
M  V30 57 C 5.8355 -11.8104 0.0000 0
M  V30 58 C 6.5682 -11.4312 0.0000 0
M  V30 59 C 6.6061 -10.6070 0.0000 0
M  V30 60 C 7.3387 -10.2278 0.0000 0
M  V30 61 C 8.0335 -10.6727 0.0000 0
M  V30 62 C 7.9956 -11.4968 0.0000 0
M  V30 63 C 7.2629 -11.8760 0.0000 0
M  V30 64 C 6.3209 -13.2723 0.0000 0
M  V30 65 O 6.0302 -14.0444 0.0000 0
M  V30 66 N 7.1349 -13.1381 0.0000 0
M  V30 67 C 7.6582 -13.7759 0.0000 0 CFG=1
M  V30 68 C 7.3675 -14.5479 0.0000 0
M  V30 69 C 6.5535 -14.6822 0.0000 0
M  V30 70 C 6.2627 -15.4543 0.0000 0
M  V30 71 N 5.4487 -15.5886 0.0000 0
M  V30 72 C 5.1580 -16.3607 0.0000 0
M  V30 73 N 5.6813 -16.9985 0.0000 0
M  V30 74 N 4.3440 -16.4949 0.0000 0
M  V30 75 C 8.4722 -13.6416 0.0000 0
M  V30 76 O 8.2535 -12.8461 0.0000 0
M  V30 77 N 8.9955 -14.2794 0.0000 0
M  V30 78 C 9.8095 -14.1451 0.0000 0 CFG=1
M  V30 79 C 10.1002 -13.3730 0.0000 0
M  V30 80 C 9.5769 -12.7352 0.0000 0
M  V30 81 C 8.7533 -12.7837 0.0000 0
M  V30 82 N 8.4527 -12.0154 0.0000 0
M  V30 83 C 9.0905 -11.4921 0.0000 0
M  V30 84 C 9.1284 -10.6680 0.0000 0
M  V30 85 C 9.8611 -10.2887 0.0000 0
M  V30 86 C 10.5559 -10.7336 0.0000 0
M  V30 87 C 10.5180 -11.5577 0.0000 0
M  V30 88 C 9.7853 -11.9370 0.0000 0
M  V30 89 C 10.3327 -14.7829 0.0000 0
M  V30 90 O 10.0420 -15.5550 0.0000 0
M  V30 91 N 11.1467 -14.6487 0.0000 0
M  V30 92 C 11.6700 -15.2865 0.0000 0
M  V30 93 C 12.4840 -15.1522 0.0000 0
M  V30 94 O 12.7747 -14.3801 0.0000 0
M  V30 95 N 13.0073 -15.7900 0.0000 0
M  V30 96 C 13.8213 -15.6557 0.0000 0 CFG=1
M  V30 97 C 14.1120 -14.8836 0.0000 0
M  V30 98 C 13.5887 -14.2458 0.0000 0
M  V30 99 C 13.8795 -13.4737 0.0000 0
M  V30 100 C 13.3562 -12.8359 0.0000 0
M  V30 101 N 13.6469 -12.0639 0.0000 0
M  V30 102 C 14.3446 -16.2935 0.0000 0
M  V30 103 O 14.0539 -17.0656 0.0000 0
M  V30 104 N 15.1586 -16.1592 0.0000 0
M  V30 105 C 15.5284 -15.4218 0.0000 0
M  V30 106 C 16.3441 -15.5456 0.0000 0
M  V30 107 C 16.4783 -16.3596 0.0000 0
M  V30 108 C 15.7457 -16.7389 0.0000 0 CFG=1
M  V30 109 C 15.6218 -17.5545 0.0000 0
M  V30 110 O 16.2663 -18.0696 0.0000 0
M  V30 111 N 14.8536 -17.8551 0.0000 0
M  V30 112 C 14.7297 -18.6707 0.0000 0 CFG=1
M  V30 113 C 13.9614 -18.9713 0.0000 0
M  V30 114 C 13.8376 -19.7870 0.0000 0
M  V30 115 C 13.3170 -18.4563 0.0000 0
M  V30 116 C 15.3742 -19.1858 0.0000 0
M  V30 117 N 16.1425 -18.8852 0.0000 0
M  V30 118 O 15.2503 -20.0015 0.0000 0
M  V30 119 H 1.4333 -12.0598 0.0000 0
M  V30 120 H 3.9987 -11.3294 0.0000 0
M  V30 121 H 5.0502 -11.9702 0.0000 0
M  V30 122 H 6.6715 -13.9386 0.0000 0
M  V30 123 H 9.4570 -15.0809 0.0000 0
M  V30 124 H 13.4689 -16.5916 0.0000 0
M  V30 125 H -1.3522 -10.9175 0.0000 0
M  V30 126 H -2.8605 -8.8403 0.0000 0
M  V30 127 H -5.3641 -9.4069 0.0000 0
M  V30 128 H -4.7880 -12.3619 0.0000 0
M  V30 129 H 16.5585 -17.3215 0.0000 0
M  V30 130 H 15.6610 -18.3065 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 9 7
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 9 12 CFG=1
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 15 13
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 20 22
M  V30 22 1 22 23
M  V30 23 2 17 23
M  V30 24 1 15 24 CFG=1
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 27 25
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 1 27 30 CFG=1
M  V30 31 1 30 31
M  V30 32 1 31 32
M  V30 33 2 31 33
M  V30 34 1 5 34
M  V30 35 2 34 35
M  V30 36 1 34 36
M  V30 37 1 37 36 CFG=1
M  V30 38 1 37 38
M  V30 39 1 38 39
M  V30 40 1 39 40
M  V30 41 1 40 41
M  V30 42 2 40 42
M  V30 43 1 37 43
M  V30 44 2 43 44
M  V30 45 1 43 45
M  V30 46 1 46 45 CFG=3
M  V30 47 1 46 47
M  V30 48 1 47 48
M  V30 49 1 48 49
M  V30 50 1 49 50
M  V30 51 2 50 51
M  V30 52 1 51 52
M  V30 53 2 48 52
M  V30 54 1 46 53
M  V30 55 2 53 54
M  V30 56 1 53 55
M  V30 57 1 56 55 CFG=3
M  V30 58 1 56 57
M  V30 59 1 57 58
M  V30 60 2 58 59
M  V30 61 1 59 60
M  V30 62 2 60 61
M  V30 63 1 61 62
M  V30 64 2 62 63
M  V30 65 1 58 63
M  V30 66 1 56 64
M  V30 67 2 64 65
M  V30 68 1 64 66
M  V30 69 1 67 66 CFG=3
M  V30 70 1 67 68
M  V30 71 1 68 69
M  V30 72 1 69 70
M  V30 73 1 70 71
M  V30 74 1 71 72
M  V30 75 1 72 73
M  V30 76 2 72 74
M  V30 77 1 67 75
M  V30 78 2 75 76
M  V30 79 1 75 77
M  V30 80 1 78 77 CFG=1
M  V30 81 1 78 79
M  V30 82 1 79 80
M  V30 83 1 80 81
M  V30 84 1 81 82
M  V30 85 2 82 83
M  V30 86 1 83 84
M  V30 87 2 84 85
M  V30 88 1 85 86
M  V30 89 2 86 87
M  V30 90 1 87 88
M  V30 91 2 80 88
M  V30 92 1 83 88
M  V30 93 1 78 89
M  V30 94 2 89 90
M  V30 95 1 89 91
M  V30 96 1 91 92
M  V30 97 1 92 93
M  V30 98 2 93 94
M  V30 99 1 93 95
M  V30 100 1 96 95 CFG=1
M  V30 101 1 96 97
M  V30 102 1 97 98
M  V30 103 1 98 99
M  V30 104 1 99 100
M  V30 105 1 100 101
M  V30 106 1 96 102
M  V30 107 2 102 103
M  V30 108 1 102 104
M  V30 109 1 104 105
M  V30 110 1 105 106
M  V30 111 1 106 107
M  V30 112 1 108 107
M  V30 113 1 108 104
M  V30 114 1 108 109 CFG=1
M  V30 115 2 109 110
M  V30 116 1 109 111
M  V30 117 1 112 111 CFG=3
M  V30 118 1 112 113
M  V30 119 1 113 114
M  V30 120 1 113 115
M  V30 121 1 112 116
M  V30 122 1 116 117
M  V30 123 2 116 118
M  V30 124 1 119 37
M  V30 125 1 120 46
M  V30 126 1 121 56
M  V30 127 1 122 67
M  V30 128 1 123 78
M  V30 129 1 124 96
M  V30 130 1 125 5
M  V30 131 1 126 9
M  V30 132 1 127 15
M  V30 133 1 128 27
M  V30 134 1 129 108
M  V30 135 1 130 112
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
81

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Melanotan I

>  <Synonyms>
[Nle4,D-Phe7]-??-MSH;MT-I;Afamelanotide

>  <CAS>
75921-69-6

>  <Formula>
C78H111N21O19

>  <MolWt>
1647

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Melanotan-I has the amino acid sequence of Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val and a molecular weight of 1647.4 Dalton.

>  <Reference>
"Langan EA, et al. Melanotropic peptides: more than just 'Barbie drugs' and 'sun-tan jabs'? Br J Dermatol. 2010 Sep;163(3):451-5."

>  <ID<1>>
TP1097

$$$$
StarDrop ID 82
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -3.4656 -0.4741 0.0000 0
M  V30 2 N -3.4656 -1.2991 0.0000 0
M  V30 3 C -2.7982 -1.7840 0.0000 0
M  V30 4 C -2.0136 -1.5291 0.0000 0
M  V30 5 N -1.4005 -2.0811 0.0000 0
M  V30 6 C -1.5720 -2.8881 0.0000 0
M  V30 7 C -0.9589 -3.4401 0.0000 0
M  V30 8 C -0.1743 -3.1852 0.0000 0
M  V30 9 C -0.0028 -2.3782 0.0000 0
M  V30 10 O 0.7818 -2.1233 0.0000 0
M  V30 11 C 0.9534 -1.3163 0.0000 0
M  V30 12 C 0.3403 -0.7643 0.0000 0
M  V30 13 C 0.5118 0.0427 0.0000 0
M  V30 14 Cl -0.1013 0.5947 0.0000 0
M  V30 15 C 1.2964 0.2976 0.0000 0
M  V30 16 C 1.9095 -0.2544 0.0000 0
M  V30 17 C 1.7380 -1.0614 0.0000 0
M  V30 18 C 2.6941 0.0005 0.0000 0
M  V30 19 N 3.4788 0.2555 0.0000 0
M  V30 20 C -0.6159 -1.8262 0.0000 0
M  V30 21 O -0.4443 -1.0192 0.0000 0
M  V30 22 C 0.4388 -3.7372 0.0000 0
M  V30 23 F 1.0519 -4.2893 0.0000 0
M  V30 24 F -0.1132 -4.3503 0.0000 0
M  V30 25 F 0.9908 -3.1241 0.0000 0
M  V30 26 N -3.0531 -2.5687 0.0000 0
M  V30 27 N -3.8781 -2.5687 0.0000 0
M  V30 28 C -4.1331 -1.7840 0.0000 0
M  V30 29 O -4.9177 -1.5291 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 11 17
M  V30 18 1 16 18
M  V30 19 3 18 19
M  V30 20 1 9 20
M  V30 21 1 5 20
M  V30 22 2 20 21
M  V30 23 1 8 22
M  V30 24 1 22 23
M  V30 25 1 22 24
M  V30 26 1 22 25
M  V30 27 1 3 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 1 2 28
M  V30 31 2 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
82

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Doravirine

>  <Synonyms>
MK-1439

>  <CAS>
1338225-97-0

>  <Formula>
C17H11ClF3N5O3

>  <MolWt>
425.8

>  <Pathways>
Microbiology/Virology;Proteases/Proteasome

>  <Target>
HIV Protease;Reverse Transcriptase

>  <Receptor>
" K103N/Y181C:33 nM, wild-type virus:12nM, Y181C:31nM, K103N:21nM"

>  <Bioactivity>
"Doravirine is a non-nucleoside reverse transcriptase inhibitor, used in the treatment of HIV/AIDS."

>  <Reference>
"Anderson MS, et al. Antivir Ther. 2015;20(4):397-405.;Fical L. Vyvoj UHPLC-MS/MS metody pro analyzu vybranych antivirotik v HILIC a RP m??du[J]. 2020;Lai MT, et al. Antimicrob Agents Chemother. 2014;58(3):1652-63.;Fical L, Khalikova M, Ko?ov?? Vl?kov?? H, et al. Determination of Antiviral Drugs and Their Metabolites Using Micro-Solid Phase Extraction and UHPLC-MS/MS in Reversed-Phase and Hydrophilic Interaction Chromatography Modes[J]. Molecules. 2021, 26(8): 2123."

>  <ID<1>>
T3632

$$$$
StarDrop ID 83
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 85 88 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.1793 6.9268 0.0000 0
M  V30 2 S 3.9812 6.1259 0.0000 0
M  V30 3 C 3.1886 5.8971 0.0000 0
M  V30 4 C 2.9904 5.0963 0.0000 0
M  V30 5 C 2.1978 4.8675 0.0000 0 CFG=2
M  V30 6 N 1.6033 5.4395 0.0000 0
M  V30 7 C 1.8014 6.2404 0.0000 0
M  V30 8 O 2.5941 6.4692 0.0000 0
M  V30 9 C 1.2070 6.8124 0.0000 0 CFG=2
M  V30 10 C 1.4051 7.6132 0.0000 0
M  V30 11 C 0.8106 8.1853 0.0000 0
M  V30 12 C 0.0180 7.9565 0.0000 0
M  V30 13 C -0.5765 8.5285 0.0000 0
M  V30 14 C -0.3783 9.3293 0.0000 0
M  V30 15 O -0.9728 9.9014 0.0000 0
M  V30 16 S -0.7746 10.7022 0.0000 0
M  V30 17 O -0.5765 11.5031 0.0000 0
M  V30 18 O -1.5755 10.9004 0.0000 0
M  V30 19 O 0.0262 10.5041 0.0000 0
M  V30 20 C 0.4143 9.5582 0.0000 0
M  V30 21 C 1.0088 8.9861 0.0000 0
M  V30 22 N 0.4143 6.5836 0.0000 0
M  V30 23 C 0.2162 5.7827 0.0000 0
M  V30 24 O 0.8106 5.2107 0.0000 0
M  V30 25 C -0.5765 5.5539 0.0000 0 CFG=1
M  V30 26 N -1.1709 6.1259 0.0000 0
M  V30 27 C -0.7746 4.7531 0.0000 0
M  V30 28 C -1.5673 4.5243 0.0000 0
M  V30 29 O -1.7654 3.7234 0.0000 0
M  V30 30 O -2.1617 5.0963 0.0000 0
M  V30 31 C 1.9996 4.0666 0.0000 0
M  V30 32 O 1.2070 3.8378 0.0000 0
M  V30 33 N 2.5941 3.4946 0.0000 0
M  V30 34 C 2.3959 2.6937 0.0000 0
M  V30 35 C 2.9904 2.1217 0.0000 0
M  V30 36 O 3.7830 2.3505 0.0000 0
M  V30 37 N 2.7922 1.3209 0.0000 0
M  V30 38 C 3.3867 0.7488 0.0000 0 CFG=1
M  V30 39 C 3.1886 -0.0520 0.0000 0
M  V30 40 C 2.3959 -0.2808 0.0000 0
M  V30 41 C 2.1151 -1.0566 0.0000 0
M  V30 42 N 1.2906 -1.0293 0.0000 0
M  V30 43 C 1.0618 -0.2366 0.0000 0
M  V30 44 C 0.3196 0.1237 0.0000 0
M  V30 45 C 0.2606 0.9466 0.0000 0
M  V30 46 C 0.9437 1.4091 0.0000 0
M  V30 47 C 1.6859 1.0488 0.0000 0
M  V30 48 C 1.7449 0.2259 0.0000 0
M  V30 49 C 4.1793 0.9776 0.0000 0
M  V30 50 O 4.7738 0.4056 0.0000 0
M  V30 51 N 4.3775 1.7785 0.0000 0
M  V30 52 C 5.1701 2.0073 0.0000 0 CFG=1
M  V30 53 C 5.7646 1.4353 0.0000 0
M  V30 54 C 5.5665 0.6344 0.0000 0
M  V30 55 S 6.1609 0.0624 0.0000 0
M  V30 56 C 5.9628 -0.7385 0.0000 0
M  V30 57 C 5.3683 2.8081 0.0000 0
M  V30 58 O 4.7738 3.3802 0.0000 0
M  V30 59 N 6.1609 3.0370 0.0000 0
M  V30 60 C 6.3591 3.8378 0.0000 0 CFG=1
M  V30 61 C 5.7646 4.4098 0.0000 0
M  V30 62 C 5.9628 5.2107 0.0000 0
M  V30 63 O 5.3683 5.7827 0.0000 0
M  V30 64 O 6.7554 5.4395 0.0000 0
M  V30 65 C 7.1517 4.0666 0.0000 0
M  V30 66 O 7.7462 3.4946 0.0000 0
M  V30 67 N 7.3499 4.8675 0.0000 0
M  V30 68 C 8.1425 5.0963 0.0000 0 CFG=1
M  V30 69 C 8.3407 5.8971 0.0000 0
M  V30 70 C 9.1333 6.1259 0.0000 0
M  V30 71 C 9.3315 6.9268 0.0000 0
M  V30 72 C 10.1241 7.1556 0.0000 0
M  V30 73 C 10.7186 6.5836 0.0000 0
M  V30 74 C 10.5204 5.7827 0.0000 0
M  V30 75 C 9.7278 5.5539 0.0000 0
M  V30 76 C 8.7370 4.5243 0.0000 0
M  V30 77 N 9.5296 4.7531 0.0000 0
M  V30 78 O 8.5388 3.7234 0.0000 0
M  V30 79 H 2.4379 5.8382 0.0000 0
M  V30 80 H 0.4863 7.5057 0.0000 0
M  V30 81 H -1.5373 5.2765 0.0000 0
M  V30 82 H 3.6268 1.7195 0.0000 0
M  V30 83 H 4.4495 2.7007 0.0000 0
M  V30 84 H 5.3983 3.5605 0.0000 0
M  V30 85 H 7.4219 5.7897 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=1
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 9 7
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 16 18
M  V30 18 2 16 19
M  V30 19 2 14 20
M  V30 20 1 20 21
M  V30 21 2 11 21
M  V30 22 1 9 22 CFG=1
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 25 23
M  V30 26 1 25 26 CFG=3
M  V30 27 1 25 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 2 28 30
M  V30 31 1 5 31
M  V30 32 2 31 32
M  V30 33 1 31 33
M  V30 34 1 33 34
M  V30 35 1 34 35
M  V30 36 2 35 36
M  V30 37 1 35 37
M  V30 38 1 38 37 CFG=3
M  V30 39 1 38 39
M  V30 40 1 39 40
M  V30 41 1 40 41
M  V30 42 1 41 42
M  V30 43 2 42 43
M  V30 44 1 43 44
M  V30 45 2 44 45
M  V30 46 1 45 46
M  V30 47 2 46 47
M  V30 48 1 47 48
M  V30 49 2 40 48
M  V30 50 1 43 48
M  V30 51 1 38 49
M  V30 52 2 49 50
M  V30 53 1 49 51
M  V30 54 1 52 51 CFG=3
M  V30 55 1 52 53
M  V30 56 1 53 54
M  V30 57 1 54 55
M  V30 58 1 55 56
M  V30 59 1 52 57
M  V30 60 2 57 58
M  V30 61 1 57 59
M  V30 62 1 60 59 CFG=1
M  V30 63 1 60 61
M  V30 64 1 61 62
M  V30 65 1 62 63
M  V30 66 2 62 64
M  V30 67 1 60 65
M  V30 68 2 65 66
M  V30 69 1 65 67
M  V30 70 1 68 67 CFG=1
M  V30 71 1 68 69
M  V30 72 1 69 70
M  V30 73 2 70 71
M  V30 74 1 71 72
M  V30 75 2 72 73
M  V30 76 1 73 74
M  V30 77 2 74 75
M  V30 78 1 70 75
M  V30 79 1 68 76
M  V30 80 1 76 77
M  V30 81 2 76 78
M  V30 82 1 79 5
M  V30 83 1 80 9
M  V30 84 1 81 25
M  V30 85 1 82 38
M  V30 86 1 83 52
M  V30 87 1 84 60
M  V30 88 1 85 68
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
83

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Sincalide

>  <Synonyms>
CCK-8;Cholecystokinin octapeptide;SQ19844

>  <CAS>
25126-32-3

>  <Formula>
C49H62N10O16S3

>  <MolWt>
1143

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Sincalide (INN) is a cholecystokinetic drug administered by injection to aid in diagnosing disorders of the gallbladder and pancreas. It is the 8-amino acid C-terminal fragment of cholecystokinin, and also known as CCK-8."

>  <Reference>
Maher KA et al. Kinevac (sincalide for injection)/Squibb Diagnostics. Gastroenterol Nurs. 1991 Oct;14(2):98-100.

>  <ID<1>>
TP1197

$$$$
StarDrop ID 84
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F -3.6188 5.3633 0.0000 0
M  V30 2 C -2.8118 5.1918 0.0000 0
M  V30 3 F -2.9834 4.3848 0.0000 0
M  V30 4 F -2.6403 5.9988 0.0000 0
M  V30 5 C -2.0049 5.0203 0.0000 0
M  V30 6 C -1.4528 5.6334 0.0000 0
M  V30 7 C -0.6459 5.4618 0.0000 0
M  V30 8 C -0.3909 4.6772 0.0000 0
M  V30 9 C -0.9429 4.0641 0.0000 0
M  V30 10 C -1.7499 4.2357 0.0000 0
M  V30 11 N -0.6880 3.2795 0.0000 0
M  V30 12 C 0.1190 3.1080 0.0000 0
M  V30 13 C 0.3739 2.3234 0.0000 0
M  V30 14 N -0.1781 1.7103 0.0000 0
M  V30 15 C 0.0768 0.9256 0.0000 0
M  V30 16 C 0.8838 0.7541 0.0000 0
M  V30 17 N 1.1387 -0.0305 0.0000 0
M  V30 18 C 1.9233 -0.2854 0.0000 0
M  V30 19 C 2.6378 0.1271 0.0000 0
M  V30 20 C 3.3523 -0.2854 0.0000 0
M  V30 21 C 3.3523 -1.1104 0.0000 0
M  V30 22 C 2.6378 -1.5229 0.0000 0
M  V30 23 C 1.9233 -1.1104 0.0000 0
M  V30 24 N 1.1387 -1.3654 0.0000 0
M  V30 25 C 0.6538 -0.6979 0.0000 0
M  V30 26 O -0.1712 -0.6979 0.0000 0
M  V30 27 C -0.9851 1.8818 0.0000 0
M  V30 28 C -1.2400 2.6664 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 18 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 17 25
M  V30 28 2 25 26
M  V30 29 1 14 27
M  V30 30 1 27 28
M  V30 31 1 11 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
84

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Flibanserin

>  <Synonyms>
BIMT-17;BIMT-17BS;Girosa

>  <CAS>
167933-07-5

>  <Formula>
C20H21F3N4O

>  <MolWt>
390.4

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
5-HT Receptor;Dopamine Receptor

>  <Receptor>
" D4 Receptor:4-24 nM(Ki), 5-HT2A:49 nM(Ki), 5-HT1A:1 nM(Ki)"

>  <Bioactivity>
Flibanserin is a serotonergic antidepressant used to treat hypoactive sexual desire disorder. Flibanserin has been associated with a low rate of minor serum aminotransferase elevations during treatment but has not been linked to instances of clinically apparent acute liver injury.

>  <Reference>
"Invernizzi RW, ey al. Br J Pharmacol. 2003, 139(7):1281-8.;Clayton AH, et al. Womens Health (Lond). 2010, 6(5):639-53."

>  <ID<1>>
T4297

$$$$
StarDrop ID 85
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 114 119 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 11.5175 -0.2825 0.0000 0
M  V30 2 C 11.0354 -0.9520 0.0000 0
M  V30 3 N 11.5968 -1.5930 0.0000 0
M  V30 4 C 11.7339 -2.4065 0.0000 0 CFG=1
M  V30 5 C 12.5499 -2.5275 0.0000 0
M  V30 6 C 12.9172 -1.7888 0.0000 0
M  V30 7 C 12.3282 -1.2112 0.0000 0
M  V30 8 C 11.3001 -3.2945 0.0000 0
M  V30 9 O 11.9766 -3.7667 0.0000 0
M  V30 10 N 10.7082 -3.9115 0.0000 0
M  V30 11 C 9.9472 -4.2673 0.0000 0 CFG=1
M  V30 12 C 9.9480 -5.0923 0.0000 0
M  V30 13 C 9.1932 -3.9167 0.0000 0
M  V30 14 O 8.4038 -4.1566 0.0000 0
M  V30 15 N 9.6282 -3.1997 0.0000 0
M  V30 16 C 10.2600 -2.6352 0.0000 0 CFG=2
M  V30 17 C 11.1269 -2.7324 0.0000 0
M  V30 18 O 11.4054 -1.9559 0.0000 0
M  V30 19 N 11.9341 -3.2578 0.0000 0
M  V30 20 C 12.1824 -4.0997 0.0000 0
M  V30 21 C 13.0058 -4.1511 0.0000 0 CFG=1
M  V30 22 C 13.4620 -3.4637 0.0000 0
M  V30 23 O 13.3730 -4.8899 0.0000 0
M  V30 24 C 11.8356 -4.8946 0.0000 0
M  V30 25 O 12.5122 -5.3666 0.0000 0
M  V30 26 N 11.2061 -5.4975 0.0000 0
M  V30 27 C 10.4191 -5.8625 0.0000 0
M  V30 28 C 9.5813 -6.0878 0.0000 0
M  V30 29 O 9.7533 -6.8947 0.0000 0
M  V30 30 N 8.7294 -6.2230 0.0000 0
M  V30 31 C 7.9261 -6.5231 0.0000 0 CFG=2
M  V30 32 C 8.1447 -7.3186 0.0000 0
M  V30 33 N 8.9429 -7.5270 0.0000 0
M  V30 34 C 9.1615 -8.3225 0.0000 0 CFG=1
M  V30 35 C 9.9598 -8.5309 0.0000 0
M  V30 36 C 10.1784 -9.3264 0.0000 0
M  V30 37 C 10.9767 -9.5348 0.0000 0
M  V30 38 C 11.1953 -10.3303 0.0000 0
M  V30 39 C 10.6157 -10.9174 0.0000 0
M  V30 40 O 10.8343 -11.7129 0.0000 0
M  V30 41 C 9.8174 -10.7090 0.0000 0
M  V30 42 C 9.5988 -9.9135 0.0000 0
M  V30 43 C 8.5819 -8.9096 0.0000 0
M  V30 44 O 8.8006 -9.7051 0.0000 0
M  V30 45 O 7.7837 -8.7012 0.0000 0
M  V30 46 O 7.5651 -7.9057 0.0000 0
M  V30 47 C 7.0882 -6.6746 0.0000 0
M  V30 48 S 6.3704 -6.2356 0.0000 0
M  V30 49 S 6.4718 -5.3991 0.0000 0
M  V30 50 C 6.8212 -4.6263 0.0000 0
M  V30 51 C 6.7116 -3.7746 0.0000 0 CFG=1
M  V30 52 C 7.1579 -3.0205 0.0000 0
M  V30 53 O 7.8993 -3.3825 0.0000 0
M  V30 54 N 7.4824 -2.1939 0.0000 0
M  V30 55 C 7.8247 -1.2574 0.0000 0 CFG=2
M  V30 56 C 8.5704 -0.7588 0.0000 0
M  V30 57 O 8.2220 -0.0110 0.0000 0
M  V30 58 N 9.3969 -0.5188 0.0000 0
M  V30 59 C 10.2460 -0.6213 0.0000 0 CFG=1
M  V30 60 C 10.4569 0.1763 0.0000 0
M  V30 61 C 9.8716 0.7577 0.0000 0
M  V30 62 N 9.0754 0.5415 0.0000 0
M  V30 63 O 10.0824 1.5553 0.0000 0
M  V30 64 C 7.4926 -0.4619 0.0000 0
M  V30 65 S 7.1040 0.2849 0.0000 0
M  V30 66 S 6.3850 0.7172 0.0000 0
M  V30 67 C 5.5540 0.8231 0.0000 0
M  V30 68 C 4.8943 0.3082 0.0000 0 CFG=2
M  V30 69 N 4.1277 0.6132 0.0000 0
M  V30 70 C 5.0196 -0.5170 0.0000 0
M  V30 71 O 4.2958 -0.9129 0.0000 0
M  V30 72 N 5.6503 -1.0707 0.0000 0
M  V30 73 C 6.1997 -1.7153 0.0000 0 CFG=1
M  V30 74 C 7.0825 -1.6513 0.0000 0
M  V30 75 S 8.0026 -1.8939 0.0000 0
M  V30 76 S 8.7884 -2.2059 0.0000 0
M  V30 77 C 9.6143 -2.1003 0.0000 0
M  V30 78 C 5.4609 -2.1616 0.0000 0
M  V30 79 O 5.7393 -2.9382 0.0000 0
M  V30 80 N 4.6145 -2.2854 0.0000 0
M  V30 81 C 3.7703 -2.3816 0.0000 0 CFG=2
M  V30 82 C 3.3565 -1.6679 0.0000 0
M  V30 83 C 2.5315 -1.6693 0.0000 0
M  V30 84 C 2.1178 -0.9556 0.0000 0
M  V30 85 O 2.5290 -0.2404 0.0000 0
M  V30 86 O 1.2928 -0.9571 0.0000 0
M  V30 87 C 3.2731 -3.0584 0.0000 0
M  V30 88 O 2.4616 -2.9100 0.0000 0
M  V30 89 N 3.4995 -3.8704 0.0000 0
M  V30 90 C 4.2254 -4.3033 0.0000 0 CFG=1
M  V30 91 C 4.0367 -5.1064 0.0000 0
M  V30 92 C 3.2468 -5.3445 0.0000 0
M  V30 93 C 3.0581 -6.1477 0.0000 0
M  V30 94 C 2.2682 -6.3858 0.0000 0
M  V30 95 C 1.6670 -5.8208 0.0000 0
M  V30 96 O 0.8771 -6.0589 0.0000 0
M  V30 97 C 1.8558 -5.0176 0.0000 0
M  V30 98 C 2.6457 -4.7795 0.0000 0
M  V30 99 C 5.0686 -4.2390 0.0000 0
M  V30 100 O 5.2513 -5.0435 0.0000 0
M  V30 101 N 5.8635 -3.9303 0.0000 0
M  V30 102 H 6.4497 -2.5015 0.0000 0
M  V30 103 H 8.5984 -1.5438 0.0000 0
M  V30 104 H 7.5196 -3.9411 0.0000 0
M  V30 105 H 10.5826 -1.8759 0.0000 0
M  V30 106 H 12.3115 -1.8174 0.0000 0
M  V30 107 H 9.8641 -7.6109 0.0000 0
M  V30 108 H 9.6676 0.1945 0.0000 0
M  V30 109 H 9.1010 -4.8002 0.0000 0
M  V30 110 H 12.4528 -4.9843 0.0000 0
M  V30 111 H 7.3788 -7.3600 0.0000 0
M  V30 112 H 4.1177 -0.3218 0.0000 0
M  V30 113 H 2.7711 -2.3411 0.0000 0
M  V30 114 H 3.2985 -4.6785 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 3 7
M  V30 8 1 4 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 11 10
M  V30 12 1 11 12 CFG=1
M  V30 13 1 11 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 16 15
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 19 20
M  V30 21 1 21 20
M  V30 22 1 21 22
M  V30 23 1 21 23 CFG=1
M  V30 24 1 20 24
M  V30 25 2 24 25
M  V30 26 1 24 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 2 28 29
M  V30 30 1 28 30
M  V30 31 1 31 30
M  V30 32 1 31 32 CFG=3
M  V30 33 1 32 33
M  V30 34 1 34 33 CFG=1
M  V30 35 1 34 35
M  V30 36 1 35 36
M  V30 37 2 36 37
M  V30 38 1 37 38
M  V30 39 2 38 39
M  V30 40 1 39 40
M  V30 41 1 39 41
M  V30 42 2 41 42
M  V30 43 1 36 42
M  V30 44 1 34 43
M  V30 45 1 43 44
M  V30 46 2 43 45
M  V30 47 2 32 46
M  V30 48 1 31 47
M  V30 49 1 47 48
M  V30 50 1 48 49
M  V30 51 1 49 50
M  V30 52 1 51 50
M  V30 53 1 51 52
M  V30 54 2 52 53
M  V30 55 1 52 54
M  V30 56 1 55 54
M  V30 57 1 55 56
M  V30 58 2 56 57
M  V30 59 1 56 58
M  V30 60 1 59 58
M  V30 61 1 59 2
M  V30 62 1 59 60 CFG=1
M  V30 63 1 60 61
M  V30 64 1 61 62
M  V30 65 2 61 63
M  V30 66 1 55 64
M  V30 67 1 64 65
M  V30 68 1 65 66
M  V30 69 1 66 67
M  V30 70 1 68 67
M  V30 71 1 68 69 CFG=1
M  V30 72 1 68 70
M  V30 73 2 70 71
M  V30 74 1 70 72
M  V30 75 1 73 72
M  V30 76 1 73 74
M  V30 77 1 74 75
M  V30 78 1 75 76
M  V30 79 1 76 77
M  V30 80 1 16 77
M  V30 81 1 73 78
M  V30 82 2 78 79
M  V30 83 1 78 80
M  V30 84 1 81 80
M  V30 85 1 81 82 CFG=1
M  V30 86 1 82 83
M  V30 87 1 83 84
M  V30 88 1 84 85
M  V30 89 2 84 86
M  V30 90 1 81 87
M  V30 91 2 87 88
M  V30 92 1 87 89
M  V30 93 1 90 89
M  V30 94 1 90 91 CFG=3
M  V30 95 1 91 92
M  V30 96 2 92 93
M  V30 97 1 93 94
M  V30 98 2 94 95
M  V30 99 1 95 96
M  V30 100 1 95 97
M  V30 101 2 97 98
M  V30 102 1 92 98
M  V30 103 1 90 99
M  V30 104 2 99 100
M  V30 105 1 99 101
M  V30 106 1 51 101
M  V30 107 1 73 102 CFG=3
M  V30 108 1 55 103 CFG=3
M  V30 109 1 51 104 CFG=1
M  V30 110 1 16 105 CFG=3
M  V30 111 1 4 106 CFG=3
M  V30 112 1 107 34
M  V30 113 1 108 59
M  V30 114 1 109 11
M  V30 115 1 110 21
M  V30 116 1 111 31
M  V30 117 1 112 68
M  V30 118 1 113 81
M  V30 119 1 114 90
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
85

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Linaclotide

>  <Synonyms>
N/A

>  <CAS>
851199-59-2

>  <Formula>
C59H79N15O21S6

>  <MolWt>
1527

>  <Pathways>
GPCR/G Protein

>  <Target>
Guanylate cyclase

>  <Receptor>
Guanylate cyclase

>  <Bioactivity>
"Linaclotide developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation, and is a potent and selective guanylate cyclase C agonist."

>  <Reference>
"Love BL, et al. Linaclotide: a novel agent for chronic constipation and irritable bowel syndrome. Am J Health Syst Pharm. 2014 Jul 1;71(13):1081-91.;Bryant AP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 2010 May 8;86(19-20):760-5."

>  <ID<1>>
T11852

$$$$
StarDrop ID 86
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -4.2358 -1.6500 0.0000 0
M  V30 2 C -3.5213 -2.0625 0.0000 0
M  V30 3 C -2.8069 -1.6500 0.0000 0
M  V30 4 C -2.0924 -2.0625 0.0000 0
M  V30 5 C -2.0924 -2.8875 0.0000 0
M  V30 6 C -2.8069 -3.3000 0.0000 0
M  V30 7 C -3.5213 -2.8875 0.0000 0
M  V30 8 C -4.2358 -3.3000 0.0000 0
M  V30 9 O -4.9503 -2.8875 0.0000 0
M  V30 10 O -4.2358 -4.1250 0.0000 0
M  V30 11 N -1.3779 -3.3000 0.0000 0
M  V30 12 N -0.6634 -2.8875 0.0000 0
M  V30 13 C 0.0510 -3.3000 0.0000 0
M  V30 14 C 0.7655 -2.8875 0.0000 0
M  V30 15 C 1.4800 -3.3000 0.0000 0
M  V30 16 C 1.4800 -4.1250 0.0000 0
M  V30 17 C 0.7655 -4.5375 0.0000 0
M  V30 18 C 0.0510 -4.1250 0.0000 0
M  V30 19 C 2.1944 -4.5375 0.0000 0
M  V30 20 O 2.1944 -5.3625 0.0000 0
M  V30 21 N 2.9089 -4.1250 0.0000 0
M  V30 22 C 3.6234 -4.5375 0.0000 0
M  V30 23 C 4.3379 -4.1250 0.0000 0
M  V30 24 C 5.0523 -4.5375 0.0000 0
M  V30 25 O 5.7668 -4.1250 0.0000 0
M  V30 26 O 5.0523 -5.3625 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 5 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 13 18
M  V30 20 1 16 19
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 2 24 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
86

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Balsalazide sodium hydrate

>  <Synonyms>
Balsalazide disodium salt dihydrate;Balsalazide disodium;Balsalazide disodium dihydrate

>  <CAS>
150399-21-6

>  <Formula>
C17H17N3Na2O8

>  <MolWt>
437.3

>  <Pathways>
Immunology/Inflammation;JAK/STAT signaling;Stem Cells

>  <Target>
Interleukin;STAT

>  <Receptor>
Interleukin; STAT

>  <Bioactivity>
"Balsalazide is an anti-inflammatory compound used in the treatment of Inflammatory Bowel Disease.Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug. High dose balsalazide (3.0 g twice daily) was superior in maintaining remission in patients with ulcerative colitis compared with a low dose (1.5 g twice daily) or a standard dose of mesalazine (0.5 g three times daily). All three treatments were safe and well tolerated [1]. Balsalazide is approved for the treatment of mild-to-moderate active UC. It is efficacious for the induction of remission in mild to moderate UC and has a favorable safety profile, with the added advantages of greater efficacy of remission induction and rapidity of onset [2]."

>  <Reference>
"Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49(6): p. 783-789.;Wiggins JB, et al. Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis. Expert Opin Drug Metab Toxicol, 2009. 5(10): p. 1279-1284."

>  <ID<1>>
T4615

$$$$
StarDrop ID 87
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 71 79 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -3.3549 -1.5723 0.0000 0
M  V30 2 O -2.5300 -1.5598 0.0000 0
M  V30 3 C -2.1284 -0.8391 0.0000 0
M  V30 4 C -1.3035 -0.8266 0.0000 0 CFG=1
M  V30 5 C -0.8085 -1.4866 0.0000 0
M  V30 6 C -0.0279 -1.2197 0.0000 0 CFG=2
M  V30 7 N -0.0404 -0.3948 0.0000 0
M  V30 8 C -0.8288 -0.1519 0.0000 0
M  V30 9 C 0.6196 0.1002 0.0000 0
M  V30 10 O 1.3783 -0.2239 0.0000 0
M  V30 11 C 0.5209 0.9193 0.0000 0 CFG=2
M  V30 12 N 1.1809 1.4143 0.0000 0
M  V30 13 C 1.9396 1.0902 0.0000 0
M  V30 14 O 2.0383 0.2711 0.0000 0
M  V30 15 O 2.5995 1.5852 0.0000 0
M  V30 16 C 3.3582 1.2612 0.0000 0
M  V30 17 C -0.2378 1.2433 0.0000 0
M  V30 18 C -0.8978 0.7483 0.0000 0
M  V30 19 C -1.6565 1.0724 0.0000 0
M  V30 20 C -1.7552 1.8914 0.0000 0
M  V30 21 C -1.0952 2.3865 0.0000 0
M  V30 22 C -0.3365 2.0624 0.0000 0
M  V30 23 C 0.6469 -1.6944 0.0000 0
M  V30 24 N 0.6594 -2.5194 0.0000 0
M  V30 25 C 1.4478 -2.7623 0.0000 0
M  V30 26 C 1.9225 -2.0876 0.0000 0
M  V30 27 N 1.4275 -1.4276 0.0000 0
M  V30 28 C 2.7475 -2.0750 0.0000 0
M  V30 29 C 3.1708 -2.7832 0.0000 0
M  V30 30 C 3.9957 -2.7706 0.0000 0
M  V30 31 C 4.3973 -2.0500 0.0000 0
M  V30 32 C 3.9739 -1.3418 0.0000 0
M  V30 33 C 4.3755 -0.6212 0.0000 0
M  V30 34 O 5.2004 -0.6086 0.0000 0
M  V30 35 C 5.6238 -1.3167 0.0000 0
M  V30 36 C 6.4487 -1.3042 0.0000 0
M  V30 37 C 6.8720 -2.0123 0.0000 0
M  V30 38 C 7.6969 -1.9998 0.0000 0
M  V30 39 N 8.2395 -1.3783 0.0000 0
M  V30 40 C 8.9982 -1.7024 0.0000 0
M  V30 41 N 8.9245 -2.5241 0.0000 0
M  V30 42 C 8.1202 -2.7079 0.0000 0
M  V30 43 C 7.7186 -3.4285 0.0000 0
M  V30 44 C 6.8937 -3.4411 0.0000 0
M  V30 45 C 6.4704 -2.7330 0.0000 0
M  V30 46 C 5.6455 -2.7455 0.0000 0
M  V30 47 C 5.2222 -2.0374 0.0000 0
M  V30 48 C 9.7063 -1.2791 0.0000 0 CFG=2
M  V30 49 C 10.4650 -1.6031 0.0000 0
M  V30 50 C 11.0077 -0.9817 0.0000 0
M  V30 51 C 10.5843 -0.2736 0.0000 0 CFG=2
M  V30 52 C 10.9084 0.4851 0.0000 0
M  V30 53 N 9.7801 -0.4574 0.0000 0
M  V30 54 C 9.1587 0.0853 0.0000 0
M  V30 55 O 8.3780 -0.1816 0.0000 0
M  V30 56 C 9.3179 0.8947 0.0000 0 CFG=1
M  V30 57 N 10.0985 1.1616 0.0000 0
M  V30 58 C 10.2578 1.9711 0.0000 0
M  V30 59 O 9.6364 2.5137 0.0000 0
M  V30 60 O 11.0384 2.2379 0.0000 0
M  V30 61 C 11.1977 3.0474 0.0000 0
M  V30 62 C 8.6965 1.4374 0.0000 0
M  V30 63 C 7.9158 1.1705 0.0000 0
M  V30 64 C 8.8557 2.2469 0.0000 0
M  V30 65 C 3.1490 -1.3544 0.0000 0
M  V30 66 H -1.7710 0.0574 0.0000 0
M  V30 67 H 0.8561 -0.7523 0.0000 0
M  V30 68 H 1.4405 0.5265 0.0000 0
M  V30 69 H 9.7739 -2.2768 0.0000 0
M  V30 70 H 11.5820 -0.2061 0.0000 0
M  V30 71 H 10.0712 0.2370 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=3
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 4 8
M  V30 9 1 7 9
M  V30 10 2 9 10
M  V30 11 1 11 9
M  V30 12 1 11 12 CFG=1
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 11 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 17 22
M  V30 24 1 6 23 CFG=3
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 23 27
M  V30 30 1 26 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 1 31 32
M  V30 35 1 32 33
M  V30 36 1 33 34
M  V30 37 1 34 35
M  V30 38 1 35 36
M  V30 39 2 36 37
M  V30 40 1 37 38
M  V30 41 1 38 39
M  V30 42 1 39 40
M  V30 43 2 40 41
M  V30 44 1 41 42
M  V30 45 2 38 42
M  V30 46 1 42 43
M  V30 47 2 43 44
M  V30 48 1 44 45
M  V30 49 1 37 45
M  V30 50 2 45 46
M  V30 51 1 46 47
M  V30 52 1 31 47
M  V30 53 2 35 47
M  V30 54 1 48 40 CFG=1
M  V30 55 1 48 49
M  V30 56 1 49 50
M  V30 57 1 51 50
M  V30 58 1 51 52 CFG=1
M  V30 59 1 51 53
M  V30 60 1 48 53
M  V30 61 1 53 54
M  V30 62 2 54 55
M  V30 63 1 56 54
M  V30 64 1 56 57 CFG=3
M  V30 65 1 57 58
M  V30 66 2 58 59
M  V30 67 1 58 60
M  V30 68 1 60 61
M  V30 69 1 56 62
M  V30 70 1 62 63
M  V30 71 1 62 64
M  V30 72 2 32 65
M  V30 73 1 28 65
M  V30 74 1 66 4
M  V30 75 1 67 6
M  V30 76 1 68 11
M  V30 77 1 69 48
M  V30 78 1 70 51
M  V30 79 1 71 56
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
87

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Velpatasvir

>  <Synonyms>
GS-5816

>  <CAS>
1377049-84-7

>  <Formula>
C49H54N8O8

>  <MolWt>
883

>  <Pathways>
Proteases/Proteasome;Microbiology/Virology

>  <Target>
HCV Protease;SARS-CoV

>  <Receptor>
HCV; HCV NS5A; SARS-CoV

>  <Bioactivity>
"Velpatasvir, also known as GS-5816, is a potent and selective Hepatitis C virus NS5A inhibitor. GS-5816 has demonstrated pan-genotypic activity and a high barrier to resistance in HCV replicon assays. GS-5816 demonstrated pangenotypic antiviral activity in patients with genotype 1-4 HCV infection. It will be further evaluated in combination with other pangenotypic direct-acting antivirals to achieve the goal of developing a well-tolerated, highly effective treatment for all HCV genotypes."

>  <Reference>
Kanda T. Hepatol Int. 2016 Jun 9. [Epub ahead of print]

>  <ID<1>>
T3334

$$$$
StarDrop ID 88
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 3.1508 0.8481 0.0000 0
M  V30 2 C 3.6826 0.2174 0.0000 0 CFG=2
M  V30 3 C 4.3340 -0.2889 0.0000 0
M  V30 4 C 5.0168 0.1741 0.0000 0 CFG=1
M  V30 5 C 5.7927 -0.1062 0.0000 0
M  V30 6 C 4.7875 0.9666 0.0000 0 CFG=2
M  V30 7 C 5.2939 1.6179 0.0000 0
M  V30 8 O 4.9830 2.3821 0.0000 0
M  V30 9 C 6.1111 1.5050 0.0000 0
M  V30 10 O 6.6175 2.1564 0.0000 0
M  V30 11 C 3.9629 0.9934 0.0000 0 CFG=2
M  V30 12 C 4.3228 1.7357 0.0000 0
M  V30 13 C 3.4311 1.6241 0.0000 0
M  V30 14 C 2.6190 1.4789 0.0000 0 CFG=2
M  V30 15 O 2.0872 2.1096 0.0000 0
M  V30 16 C 2.3387 0.7029 0.0000 0 CFG=1
M  V30 17 F 1.8069 1.3336 0.0000 0
M  V30 18 C 2.8705 0.0722 0.0000 0 CFG=1
M  V30 19 H 3.4023 -0.5585 0.0000 0
M  V30 20 C 2.5902 -0.7037 0.0000 0
M  V30 21 C 1.7781 -0.8489 0.0000 0
M  V30 22 C 1.2463 -0.2182 0.0000 0
M  V30 23 C 0.4342 -0.3634 0.0000 0
M  V30 24 C -0.0976 0.2673 0.0000 0
M  V30 25 O -0.9098 0.1221 0.0000 0
M  V30 26 C 0.1827 1.0432 0.0000 0
M  V30 27 C 0.9948 1.1884 0.0000 0
M  V30 28 C 1.5266 0.5577 0.0000 0 CFG=2
M  V30 29 C 1.2973 1.3502 0.0000 0
M  V30 30 H 5.1411 -0.8181 0.0000 0
M  V30 31 H 5.7696 0.7781 0.0000 0
M  V30 32 H 2.9588 2.4194 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5 CFG=3
M  V30 5 1 6 4
M  V30 6 1 6 7 CFG=1
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 11 6
M  V30 11 1 2 11
M  V30 12 1 11 12 CFG=1
M  V30 13 1 11 13
M  V30 14 1 14 13
M  V30 15 1 14 15 CFG=1
M  V30 16 1 16 14
M  V30 17 1 16 17 CFG=3
M  V30 18 1 16 18
M  V30 19 1 18 2
M  V30 20 1 18 19 CFG=1
M  V30 21 1 18 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 24 26
M  V30 28 2 26 27
M  V30 29 1 28 27
M  V30 30 1 16 28
M  V30 31 1 28 22
M  V30 32 1 28 29 CFG=1
M  V30 33 1 30 4
M  V30 34 1 31 6
M  V30 35 1 32 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
88

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Desoximetasone

>  <Synonyms>
Desoximetasonum;Desoximetasona;Topicort;Desoxymethasone

>  <CAS>
382-67-2

>  <Formula>
C22H29FO4

>  <MolWt>
376.5

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Desoximetasone(Topicort) is a medication belonging to the family of medications known as topical corticosteroids; is used for the relief of various skin conditions, including rashes."

>  <Reference>
"Lange K, Kleuser B, Gysler A, Bader M, Maia C, Scheidereit C, Korting HC, Schafer-Korting M: Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticoids. Skin Pharmacol Appl Skin Physiol. 2000 Mar-Apr;13(2):93-103."

>  <ID<1>>
T4572

$$$$
StarDrop ID 89
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 127 137 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -4.2868 3.3000 0.0000 0
M  V30 2 C -4.2868 2.4750 0.0000 0
M  V30 3 C -3.5724 2.0625 0.0000 0
M  V30 4 C -3.5724 1.2375 0.0000 0
M  V30 5 C -4.2868 0.8250 0.0000 0
M  V30 6 C -5.0013 1.2375 0.0000 0
M  V30 7 O -5.7158 0.8250 0.0000 0
M  V30 8 C -5.0013 2.0625 0.0000 0
M  V30 9 O -5.7158 2.4750 0.0000 0
M  V30 10 C -2.8579 0.8250 0.0000 0
M  V30 11 O -2.8579 0.0000 0.0000 0
M  V30 12 O -2.1434 1.2375 0.0000 0
M  V30 13 C -1.4289 0.8250 0.0000 0
M  V30 14 C -0.7145 1.2375 0.0000 0
M  V30 15 C 0.0000 0.8250 0.0000 0
M  V30 16 C 0.0000 0.0000 0.0000 0
M  V30 17 C -0.7145 -0.4125 0.0000 0
M  V30 18 O -0.7145 -1.2375 0.0000 0
M  V30 19 C -1.4289 -0.0000 0.0000 0
M  V30 20 O -2.1434 -0.4125 0.0000 0
M  V30 21 C 0.7145 1.2375 0.0000 0
M  V30 22 O 0.7145 2.0625 0.0000 0
M  V30 23 O 1.4289 0.8250 0.0000 0
M  V30 24 C 2.1434 1.2375 0.0000 0
M  V30 25 C 2.8579 0.8250 0.0000 0 CFG=1
M  V30 26 O 2.8579 0.0000 0.0000 0
M  V30 27 C 3.5724 -0.4125 0.0000 0 CFG=1
M  V30 28 O 3.5724 -1.2375 0.0000 0
M  V30 29 C 2.8579 -1.6500 0.0000 0
M  V30 30 O 2.1434 -1.2375 0.0000 0
M  V30 31 C 2.8579 -2.4750 0.0000 0
M  V30 32 C 2.1434 -2.8875 0.0000 0
M  V30 33 C 2.1434 -3.7125 0.0000 0
M  V30 34 O 1.4289 -4.1250 0.0000 0
M  V30 35 C 2.8579 -4.1250 0.0000 0
M  V30 36 O 2.3730 -4.7924 0.0000 0
M  V30 37 C 3.5724 -3.7125 0.0000 0
M  V30 38 O 4.2868 -4.1250 0.0000 0
M  V30 39 C 4.2868 -4.9500 0.0000 0
M  V30 40 O 5.0013 -5.3625 0.0000 0
M  V30 41 C 3.5724 -5.3625 0.0000 0
M  V30 42 C 3.5724 -6.1875 0.0000 0
M  V30 43 C 2.8579 -6.6000 0.0000 0
M  V30 44 O 2.8579 -7.4250 0.0000 0
M  V30 45 C 2.1434 -6.1875 0.0000 0
M  V30 46 O 1.4289 -6.6000 0.0000 0
M  V30 47 C 2.1434 -5.3625 0.0000 0
M  V30 48 O 1.4289 -4.9500 0.0000 0
M  V30 49 C 2.8579 -4.9500 0.0000 0
M  V30 50 C 3.5724 -2.8875 0.0000 0
M  V30 51 C 4.2868 0.0000 0.0000 0 CFG=2
M  V30 52 O 5.0013 -0.4125 0.0000 0
M  V30 53 C 5.0013 -1.2375 0.0000 0
M  V30 54 O 4.2868 -1.6500 0.0000 0
M  V30 55 C 5.7158 -1.6500 0.0000 0
M  V30 56 C 6.4302 -1.2375 0.0000 0
M  V30 57 C 7.1447 -1.6500 0.0000 0
M  V30 58 O 7.8592 -1.2375 0.0000 0
M  V30 59 C 7.1447 -2.4750 0.0000 0
M  V30 60 O 7.8592 -2.8875 0.0000 0
M  V30 61 C 6.4302 -2.8875 0.0000 0
M  V30 62 O 6.4302 -3.7125 0.0000 0
M  V30 63 C 7.1447 -4.1250 0.0000 0
M  V30 64 O 7.8592 -3.7125 0.0000 0
M  V30 65 C 7.1447 -4.9500 0.0000 0
M  V30 66 C 7.8592 -5.3625 0.0000 0
M  V30 67 C 7.8592 -6.1875 0.0000 0
M  V30 68 O 8.5737 -6.6000 0.0000 0
M  V30 69 C 7.1447 -6.6000 0.0000 0
M  V30 70 O 7.1447 -7.4250 0.0000 0
M  V30 71 C 6.4302 -6.1875 0.0000 0
M  V30 72 O 5.7158 -6.6000 0.0000 0
M  V30 73 C 6.4302 -5.3625 0.0000 0
M  V30 74 C 5.7158 -2.4750 0.0000 0
M  V30 75 C 4.2868 0.8250 0.0000 0 CFG=1
M  V30 76 O 5.0013 1.2375 0.0000 0
M  V30 77 C 5.7158 0.8250 0.0000 0
M  V30 78 O 5.7158 0.0000 0.0000 0
M  V30 79 C 6.4302 1.2375 0.0000 0
M  V30 80 C 7.1447 0.8250 0.0000 0
M  V30 81 C 7.8592 1.2375 0.0000 0
M  V30 82 O 8.5737 0.8250 0.0000 0
M  V30 83 C 7.8592 2.0625 0.0000 0
M  V30 84 O 8.5737 2.4750 0.0000 0
M  V30 85 C 7.1447 2.4750 0.0000 0
M  V30 86 O 7.1447 3.3000 0.0000 0
M  V30 87 C 7.8592 3.7125 0.0000 0
M  V30 88 O 8.5737 3.3000 0.0000 0
M  V30 89 C 7.8592 4.5375 0.0000 0
M  V30 90 C 7.1447 4.9500 0.0000 0
M  V30 91 C 7.1447 5.7750 0.0000 0
M  V30 92 O 6.4302 6.1875 0.0000 0
M  V30 93 C 7.8592 6.1875 0.0000 0
M  V30 94 O 7.8592 7.0125 0.0000 0
M  V30 95 C 8.5737 5.7750 0.0000 0
M  V30 96 O 9.2881 6.1875 0.0000 0
M  V30 97 C 8.5737 4.9500 0.0000 0
M  V30 98 C 6.4302 2.0625 0.0000 0
M  V30 99 C 3.5724 1.2375 0.0000 0 CFG=2
M  V30 100 O 3.5724 2.0625 0.0000 0
M  V30 101 C 2.8579 2.4750 0.0000 0
M  V30 102 O 2.1434 2.0625 0.0000 0
M  V30 103 C 2.8579 3.3000 0.0000 0
M  V30 104 C 3.5724 3.7125 0.0000 0
M  V30 105 C 3.5724 4.5375 0.0000 0
M  V30 106 O 4.2868 4.9500 0.0000 0
M  V30 107 C 2.8579 4.9500 0.0000 0
M  V30 108 O 2.8579 5.7750 0.0000 0
M  V30 109 C 2.1434 4.5375 0.0000 0
M  V30 110 O 1.4289 4.9500 0.0000 0
M  V30 111 C 0.7145 4.5375 0.0000 0
M  V30 112 O 0.7145 3.7125 0.0000 0
M  V30 113 C -0.0000 4.9500 0.0000 0
M  V30 114 C -0.7145 4.5375 0.0000 0
M  V30 115 C -1.4289 4.9500 0.0000 0
M  V30 116 O -2.1434 4.5375 0.0000 0
M  V30 117 C -1.4289 5.7750 0.0000 0
M  V30 118 O -2.1434 6.1875 0.0000 0
M  V30 119 C -0.7145 6.1875 0.0000 0
M  V30 120 O -0.7145 7.0125 0.0000 0
M  V30 121 C -0.0000 5.7750 0.0000 0
M  V30 122 C 2.1434 3.7125 0.0000 0
M  V30 123 H 1.9919 0.3250 0.0000 0
M  V30 124 H 4.4384 -0.9125 0.0000 0
M  V30 125 H 4.2869 -1.0000 0.0000 0
M  V30 126 H 4.2869 1.8250 0.0000 0
M  V30 127 H 4.4384 1.7375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 2 8
M  V30 9 1 8 9
M  V30 10 1 4 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 17 19
M  V30 20 1 13 19
M  V30 21 1 19 20
M  V30 22 1 15 21
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 23 24
M  V30 26 1 25 24 CFG=3
M  V30 27 1 25 26
M  V30 28 1 27 26
M  V30 29 1 27 28 CFG=3
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 29 31
M  V30 33 2 31 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 2 33 35
M  V30 37 1 35 36
M  V30 38 1 35 37
M  V30 39 1 37 38
M  V30 40 1 38 39
M  V30 41 2 39 40
M  V30 42 1 39 41
M  V30 43 2 41 42
M  V30 44 1 42 43
M  V30 45 1 43 44
M  V30 46 2 43 45
M  V30 47 1 45 46
M  V30 48 1 45 47
M  V30 49 1 47 48
M  V30 50 2 47 49
M  V30 51 1 41 49
M  V30 52 2 37 50
M  V30 53 1 31 50
M  V30 54 1 51 27
M  V30 55 1 51 52 CFG=1
M  V30 56 1 52 53
M  V30 57 2 53 54
M  V30 58 1 53 55
M  V30 59 2 55 56
M  V30 60 1 56 57
M  V30 61 1 57 58
M  V30 62 2 57 59
M  V30 63 1 59 60
M  V30 64 1 59 61
M  V30 65 1 61 62
M  V30 66 1 62 63
M  V30 67 2 63 64
M  V30 68 1 63 65
M  V30 69 2 65 66
M  V30 70 1 66 67
M  V30 71 1 67 68
M  V30 72 2 67 69
M  V30 73 1 69 70
M  V30 74 1 69 71
M  V30 75 1 71 72
M  V30 76 2 71 73
M  V30 77 1 65 73
M  V30 78 2 61 74
M  V30 79 1 55 74
M  V30 80 1 51 75
M  V30 81 1 75 76 CFG=3
M  V30 82 1 76 77
M  V30 83 2 77 78
M  V30 84 1 77 79
M  V30 85 2 79 80
M  V30 86 1 80 81
M  V30 87 1 81 82
M  V30 88 2 81 83
M  V30 89 1 83 84
M  V30 90 1 83 85
M  V30 91 1 85 86
M  V30 92 1 86 87
M  V30 93 2 87 88
M  V30 94 1 87 89
M  V30 95 2 89 90
M  V30 96 1 90 91
M  V30 97 1 91 92
M  V30 98 2 91 93
M  V30 99 1 93 94
M  V30 100 1 93 95
M  V30 101 1 95 96
M  V30 102 2 95 97
M  V30 103 1 89 97
M  V30 104 2 85 98
M  V30 105 1 79 98
M  V30 106 1 75 99
M  V30 107 1 99 25
M  V30 108 1 99 100 CFG=1
M  V30 109 1 100 101
M  V30 110 2 101 102
M  V30 111 1 101 103
M  V30 112 2 103 104
M  V30 113 1 104 105
M  V30 114 1 105 106
M  V30 115 2 105 107
M  V30 116 1 107 108
M  V30 117 1 107 109
M  V30 118 1 109 110
M  V30 119 1 110 111
M  V30 120 2 111 112
M  V30 121 1 111 113
M  V30 122 2 113 114
M  V30 123 1 114 115
M  V30 124 1 115 116
M  V30 125 2 115 117
M  V30 126 1 117 118
M  V30 127 1 117 119
M  V30 128 1 119 120
M  V30 129 2 119 121
M  V30 130 1 113 121
M  V30 131 2 109 122
M  V30 132 1 103 122
M  V30 133 1 123 25
M  V30 134 1 124 27
M  V30 135 1 125 51
M  V30 136 1 126 75
M  V30 137 1 127 99
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
89

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tannic acid

>  <Synonyms>
Gallotannic acid

>  <CAS>
1401-55-4

>  <Formula>
C76H52O46

>  <MolWt>
1701

>  <Pathways>
Autophagy;Membrane transporter/Ion channel;GPCR/G Protein;Tyrosine Kinase/Adaptors;Immunology/Inflammation;JAK/STAT signaling;Angiogenesis

>  <Target>
CXCR;HER;Potassium Channel

>  <Receptor>
 hERG channel:3.4 ??M

>  <Bioactivity>
Tannic acid is a novel hERG channel blocker.

>  <Reference>
"JENKINS JT. Am J Surg. 1947 Oct;74(4):428-30.;Yang Y, Zhao J, Gao H, et al. Tannic Acid Alleviates Lipopolysaccharide-Induced H9C2 Cell Apoptosis by Suppressing ROS-Mediated ER Stress[J]. Molecular Medicine Reports . 24.1 (2021): 1-11."

>  <ID<1>>
T0801

$$$$
StarDrop ID 90
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 71 76 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.9280 -1.9115 0.0000 0
M  V30 2 O 6.2135 -2.3240 0.0000 0
M  V30 3 C 6.2135 -3.1490 0.0000 0
M  V30 4 O 6.9280 -3.5615 0.0000 0
M  V30 5 N 5.4990 -3.5615 0.0000 0
M  V30 6 C 5.4990 -4.3865 0.0000 0 CFG=1
M  V30 7 C 6.2135 -4.7990 0.0000 0
M  V30 8 C 6.2135 -5.6240 0.0000 0
M  V30 9 C 6.9280 -4.3865 0.0000 0
M  V30 10 C 4.7846 -4.7990 0.0000 0
M  V30 11 O 4.0701 -4.3865 0.0000 0
M  V30 12 N 4.7846 -5.6240 0.0000 0
M  V30 13 C 5.4520 -6.1089 0.0000 0
M  V30 14 C 5.1971 -6.8935 0.0000 0
M  V30 15 C 4.3721 -6.8935 0.0000 0
M  V30 16 C 4.1171 -6.1089 0.0000 0 CFG=1
M  V30 17 C 3.3325 -5.8540 0.0000 0
M  V30 18 O 3.1610 -5.0470 0.0000 0
M  V30 19 N 2.7194 -6.4060 0.0000 0
M  V30 20 C 1.9348 -6.1511 0.0000 0
M  V30 21 C 1.3217 -6.7031 0.0000 0
M  V30 22 C 0.5371 -6.4481 0.0000 0
M  V30 23 C 0.3655 -5.6412 0.0000 0
M  V30 24 C 0.9786 -5.0891 0.0000 0
M  V30 25 C 1.7633 -5.3441 0.0000 0
M  V30 26 C -0.4191 -5.3862 0.0000 0 CFG=2
M  V30 27 C -1.0865 -5.8712 0.0000 0
M  V30 28 C -1.7540 -5.3862 0.0000 0
M  V30 29 C -1.4990 -4.6016 0.0000 0 CFG=2
M  V30 30 N -0.6740 -4.6016 0.0000 0
M  V30 31 C -0.1891 -3.9342 0.0000 0
M  V30 32 C -0.5246 -3.1805 0.0000 0
M  V30 33 C -0.0397 -2.5131 0.0000 0
M  V30 34 C 0.7808 -2.5993 0.0000 0
M  V30 35 C 1.1163 -3.3530 0.0000 0
M  V30 36 C 0.6314 -4.0204 0.0000 0
M  V30 37 C 1.2657 -1.9319 0.0000 0
M  V30 38 C 1.7506 -1.2644 0.0000 0
M  V30 39 C 1.9331 -2.4168 0.0000 0
M  V30 40 C 0.5982 -1.4469 0.0000 0
M  V30 41 C -1.9839 -3.9342 0.0000 0
M  V30 42 C -2.8044 -4.0204 0.0000 0
M  V30 43 C -3.2893 -3.3530 0.0000 0
M  V30 44 C -2.9538 -2.5993 0.0000 0
M  V30 45 N -3.4387 -1.9319 0.0000 0
M  V30 46 C -4.2592 -2.0181 0.0000 0
M  V30 47 O -4.7441 -1.3507 0.0000 0
M  V30 48 C -4.5947 -2.7718 0.0000 0 CFG=2
M  V30 49 C -4.1822 -3.4862 0.0000 0
M  V30 50 C -4.7343 -4.0993 0.0000 0
M  V30 51 C -5.4880 -3.7638 0.0000 0
M  V30 52 N -5.4017 -2.9433 0.0000 0
M  V30 53 C -6.0148 -2.3913 0.0000 0
M  V30 54 O -5.8433 -1.5843 0.0000 0
M  V30 55 C -6.7994 -2.6462 0.0000 0 CFG=1
M  V30 56 N -7.4125 -2.0942 0.0000 0
M  V30 57 C -8.1971 -2.3491 0.0000 0
M  V30 58 O -8.3687 -3.1561 0.0000 0
M  V30 59 O -8.8102 -1.7971 0.0000 0
M  V30 60 C -9.5949 -2.0520 0.0000 0
M  V30 61 C -6.9710 -3.4532 0.0000 0
M  V30 62 C -6.3579 -4.0052 0.0000 0
M  V30 63 C -7.7556 -3.7081 0.0000 0
M  V30 64 C -2.1333 -2.5131 0.0000 0
M  V30 65 C -1.6484 -3.1805 0.0000 0
M  V30 66 H -3.5961 -2.7193 0.0000 0
M  V30 67 H -7.7504 -2.9553 0.0000 0
M  V30 68 H 4.6330 -3.8865 0.0000 0
M  V30 69 H 3.4101 -6.8161 0.0000 0
M  V30 70 H -0.2627 -6.3739 0.0000 0
M  V30 71 H -2.4867 -4.7580 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 6 5 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 6 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 16 15
M  V30 16 1 16 12
M  V30 17 1 16 17 CFG=1
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 20 25
M  V30 27 1 26 23 CFG=3
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 29 28
M  V30 31 1 29 30
M  V30 32 1 26 30
M  V30 33 1 30 31
M  V30 34 2 31 32
M  V30 35 1 32 33
M  V30 36 2 33 34
M  V30 37 1 34 35
M  V30 38 2 35 36
M  V30 39 1 31 36
M  V30 40 1 34 37
M  V30 41 1 37 38
M  V30 42 1 37 39
M  V30 43 1 37 40
M  V30 44 1 29 41 CFG=1
M  V30 45 2 41 42
M  V30 46 1 42 43
M  V30 47 2 43 44
M  V30 48 1 44 45
M  V30 49 1 45 46
M  V30 50 2 46 47
M  V30 51 1 48 46 CFG=3
M  V30 52 1 48 49
M  V30 53 1 49 50
M  V30 54 1 50 51
M  V30 55 1 51 52
M  V30 56 1 48 52
M  V30 57 1 52 53
M  V30 58 2 53 54
M  V30 59 1 55 53
M  V30 60 1 55 56 CFG=3
M  V30 61 1 56 57
M  V30 62 2 57 58
M  V30 63 1 57 59
M  V30 64 1 59 60
M  V30 65 1 55 61
M  V30 66 1 61 62
M  V30 67 1 61 63
M  V30 68 1 44 64
M  V30 69 2 64 65
M  V30 70 1 41 65
M  V30 71 1 66 48
M  V30 72 1 67 55
M  V30 73 1 68 6
M  V30 74 1 69 16
M  V30 75 1 70 26
M  V30 76 1 71 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
90

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ombitasvir

>  <Synonyms>
ABT-267

>  <CAS>
1258226-87-7

>  <Formula>
C50H67N7O8

>  <MolWt>
894.1

>  <Pathways>
Microbiology/Virology;Proteases/Proteasome

>  <Target>
HCV Protease

>  <Receptor>
" HCV genotype 6a:366 pM(EC50), HCV genotypes 1 to 5:0.82 pM-19.3 pM(EC50) "

>  <Bioactivity>
"Ombitasvir is an orally bioavailable and potent inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A).with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a"

>  <Reference>
"Krishnan P, Beyer J, Mistry N,et al.in vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis c virus ns5a[J].Antimicrob Agents Chemother. 2015 Feb;59(2):979-87.;Keating, Gillian M . Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection[J]. Drugs, 2016, 76(12):1203-1211."

>  <ID<1>>
T7158

$$$$
StarDrop ID 91
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 40 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.5760 -0.4155 0.0000 0
M  V30 2 O 8.3211 -1.2001 0.0000 0
M  V30 3 C 7.5141 -1.3716 0.0000 0
M  V30 4 C 7.2592 -2.1563 0.0000 0
M  V30 5 C 6.4522 -2.3278 0.0000 0
M  V30 6 N 6.1972 -3.1124 0.0000 0
M  V30 7 C 6.7493 -3.7255 0.0000 0
M  V30 8 C 5.3903 -3.2839 0.0000 0
M  V30 9 C 5.1353 -4.0686 0.0000 0
M  V30 10 N 4.3284 -4.2401 0.0000 0
M  V30 11 C 4.0734 -5.0247 0.0000 0
M  V30 12 C 3.7763 -3.6270 0.0000 0
M  V30 13 C 5.9002 -1.7147 0.0000 0
M  V30 14 N 5.0932 -1.8862 0.0000 0
M  V30 15 C 4.5411 -1.2731 0.0000 0
M  V30 16 O 4.7961 -0.4885 0.0000 0
M  V30 17 C 3.7342 -1.4447 0.0000 0
M  V30 18 C 3.1821 -0.8316 0.0000 0
M  V30 19 C 6.1551 -0.9301 0.0000 0
M  V30 20 C 6.9621 -0.7586 0.0000 0
M  V30 21 N 7.2170 0.0261 0.0000 0
M  V30 22 C 6.6650 0.6392 0.0000 0
M  V30 23 N 5.8580 0.4676 0.0000 0
M  V30 24 C 5.3060 1.0807 0.0000 0
M  V30 25 C 5.5609 1.8654 0.0000 0
M  V30 26 C 6.3679 2.0369 0.0000 0
M  V30 27 N 6.9199 1.4238 0.0000 0
M  V30 28 C 6.6228 2.8215 0.0000 0
M  V30 29 C 6.1379 3.4889 0.0000 0
M  V30 30 N 6.6228 4.1564 0.0000 0
M  V30 31 C 6.3679 4.9410 0.0000 0
M  V30 32 C 7.4074 3.9014 0.0000 0
M  V30 33 C 8.1219 4.3139 0.0000 0
M  V30 34 C 8.8364 3.9014 0.0000 0
M  V30 35 C 8.8364 3.0764 0.0000 0
M  V30 36 C 8.1219 2.6639 0.0000 0
M  V30 37 C 7.4074 3.0764 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 5 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 2 17 18
M  V30 18 1 13 19
M  V30 19 2 19 20
M  V30 20 1 3 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 22 27
M  V30 29 1 26 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 1 30 31
M  V30 33 1 30 32
M  V30 34 2 32 33
M  V30 35 1 33 34
M  V30 36 2 34 35
M  V30 37 1 35 36
M  V30 38 2 36 37
M  V30 39 1 28 37
M  V30 40 1 32 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
91

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Osimertinib mesylate

>  <Synonyms>
Mereletinib mesylate;AZD-9291 mesylate

>  <CAS>
1421373-66-1

>  <Formula>
C29H37N7O5S

>  <MolWt>
595.7

>  <Pathways>
Tyrosine Kinase/Adaptors;Angiogenesis;JAK/STAT signaling

>  <Target>
EGFR

>  <Receptor>
" EGFR L858R:12 nM (cell free), EGFR L858R/T790M:1 nM (cell free)"

>  <Bioactivity>
Osimertinib (AZD-9291) is an irreversible and mutant selective EGFR inhibitor (IC50s: 12/1 nM for EGFR(L858R) and EGFR(L858R/T790M)).

>  <Reference>
"Cross DA, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.;Chen Z, et al. Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo, and Ex Vivo. Mol Cancer Ther. 2016 Aug;15(8):1845-58.;Finlay MR, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistancemutations that spares the wild type form of the receptor. J Med Chem. 2014 Oct 23;57(20):8249-67."

>  <ID<1>>
T3634

$$$$
StarDrop ID 92
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.3228 1.7357 0.0000 0
M  V30 2 C 3.8598 2.4186 0.0000 0
M  V30 3 C 3.9629 0.9934 0.0000 0 CFG=1
M  V30 4 C 3.6826 0.2174 0.0000 0 CFG=2
M  V30 5 C 2.8705 0.0722 0.0000 0 CFG=1
M  V30 6 C 2.3387 0.7029 0.0000 0 CFG=2
M  V30 7 C 2.6190 1.4789 0.0000 0
M  V30 8 C 3.4311 1.6241 0.0000 0
M  V30 9 C 1.5266 0.5577 0.0000 0 CFG=2
M  V30 10 C 1.2463 -0.2182 0.0000 0
M  V30 11 C 1.7781 -0.8489 0.0000 0
M  V30 12 C 2.5902 -0.7037 0.0000 0
M  V30 13 C 0.4342 -0.3634 0.0000 0
M  V30 14 C -0.0976 0.2673 0.0000 0
M  V30 15 O -0.9098 0.1221 0.0000 0
M  V30 16 C 0.1827 1.0432 0.0000 0
M  V30 17 C 0.9948 1.1884 0.0000 0
M  V30 18 H 0.7145 0.4125 0.0000 0
M  V30 19 H 1.8069 1.3336 0.0000 0
M  V30 20 H 2.0584 -0.0730 0.0000 0
M  V30 21 C 4.3340 -0.2889 0.0000 0
M  V30 22 C 5.0168 0.1741 0.0000 0
M  V30 23 C 4.7875 0.9666 0.0000 0 CFG=1
M  V30 24 C 4.9089 1.7826 0.0000 0
M  V30 25 C 5.0303 2.5986 0.0000 0
M  V30 26 O 5.5484 1.2854 0.0000 0
M  V30 27 H 3.1508 0.8481 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 1 CFG=1
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 3 8
M  V30 9 1 6 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 5 12
M  V30 14 2 10 13
M  V30 15 1 13 14
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 18 1 16 17
M  V30 19 1 9 17
M  V30 20 1 9 18 CFG=1
M  V30 21 1 6 19 CFG=3
M  V30 22 1 5 20 CFG=1
M  V30 23 1 4 21
M  V30 24 1 21 22
M  V30 25 1 23 22
M  V30 26 1 3 23
M  V30 27 1 23 24 CFG=3
M  V30 28 3 24 25
M  V30 29 1 23 26 CFG=1
M  V30 30 1 4 27 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
92

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Norgestrel

>  <Synonyms>
SH-850;WY-3707;SH-70850;FH 122-A

>  <CAS>
6533-00-2

>  <Formula>
C21H28O2

>  <MolWt>
624.9

>  <Pathways>
Immunology/Inflammation;NF-??b;Endocrinology/Hormones;Metabolism

>  <Target>
Reactive Oxygen Species;Estrogen/progestogen Receptor

>  <Receptor>
ER; Reactive Oxygen Species

>  <Bioactivity>
"Norgestrel is a synthetic progestin commonly used alone or in combination with an estrogen for contraception. Norgestrel suppresses the secretion of luteinizing and follicle-stimulating hormones (LH and FSH), thickens cervical mucus, and slows the transit of ova through the fallopian tubes."

>  <Reference>
"Maruo T, et al. Co ntraception. 2007 Jun; 75(6 Suppl):S99-103."

>  <ID<1>>
T2597

$$$$
StarDrop ID 93
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -5.7158 -7.4250 0.0000 0
M  V30 2 C -5.0013 -7.0125 0.0000 0
M  V30 3 C -5.0013 -6.1875 0.0000 0
M  V30 4 N -4.2868 -5.7750 0.0000 0
M  V30 5 C -4.2868 -4.9500 0.0000 0
M  V30 6 C -3.5724 -4.5375 0.0000 0
M  V30 7 N -3.5724 -3.7125 0.0000 0
M  V30 8 C -2.8579 -3.3000 0.0000 0
M  V30 9 C -2.8579 -2.4750 0.0000 0
M  V30 10 C -2.1434 -2.0625 0.0000 0
M  V30 11 C -1.4289 -2.4750 0.0000 0
M  V30 12 N -0.7145 -2.0625 0.0000 0
M  V30 13 C 0.0000 -2.4750 0.0000 0
M  V30 14 C 0.7145 -2.0625 0.0000 0
M  V30 15 N 1.4289 -2.4750 0.0000 0
M  V30 16 C 2.1434 -2.0625 0.0000 0
M  V30 17 C 2.8579 -2.4750 0.0000 0
M  V30 18 O 3.5724 -2.0625 0.0000 0
M  V30 19 C -1.4289 -3.3000 0.0000 0
M  V30 20 C -0.7145 -3.7125 0.0000 0
M  V30 21 O 0.0000 -3.3000 0.0000 0
M  V30 22 C -0.7145 -4.5375 0.0000 0
M  V30 23 C 0.0000 -4.9500 0.0000 0
M  V30 24 O 0.7145 -4.5375 0.0000 0
M  V30 25 C 0.0000 -5.7750 0.0000 0
M  V30 26 C -0.7145 -6.1875 0.0000 0
M  V30 27 C -1.4289 -5.7750 0.0000 0
M  V30 28 O -2.1434 -6.1875 0.0000 0
M  V30 29 C -1.4289 -4.9500 0.0000 0
M  V30 30 C -2.1434 -4.5375 0.0000 0
M  V30 31 O -2.8579 -4.9500 0.0000 0
M  V30 32 C -2.1434 -3.7125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 11 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 20 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 1 23 25
M  V30 25 2 25 26
M  V30 26 1 26 27
M  V30 27 1 27 28
M  V30 28 2 27 29
M  V30 29 1 22 29
M  V30 30 1 29 30
M  V30 31 2 30 31
M  V30 32 1 30 32
M  V30 33 1 8 32
M  V30 34 2 19 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
93

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Mitoxantrone

>  <Synonyms>
mitozantrone

>  <CAS>
65271-80-9

>  <Formula>
C22H28N4O6

>  <MolWt>
444.5

>  <Pathways>
DNA Damage/DNA Repair;Chromatin/Epigenetic;Cytoskeletal Signaling

>  <Target>
PKC;Topoisomerase

>  <Receptor>
 PKC:8.5 ??M.

>  <Bioactivity>
"Mitoxantrone is an anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair. Mitoxantrone is less cardiotoxic compared to doxorubicin."

>  <Reference>
"Boland MP, et al. J Biol Chem, 2000, 275(33), 25231-25238.;Oudard S, et al. J Urol, 2003, 169(5), 1729-1734.;Zeng X, Zhu S, Lu W, et al. Target identification among known drugs by deep learning from heterogeneous networks[J]. Chemical Science. 2020, 11(7): 1775-1797.;Herman EH, et al. J Mol Cell Cardiol, 1997, 29(9), 2415-2430.;Dong L, Shen S, Chen W, et al. Discovery of Novel Inhibitors Targeting Human O-GlcNAcase: Docking-Based Virtual Screening, Biological Evaluation, Structural Modification, and Molecular Dynamics Simulation[J]. Journal of chemical information and modeling. 2019, 59(10): 4374-4382.;Neuhaus O, et al. J Neuroimmunol, 2005, 168(1-2), 128-137.;Bellosillo B, et al. Br J Haematol, 1998, 100(1), 142-146."

>  <ID<1>>
T6588

$$$$
StarDrop ID 94
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.7139 3.2991 0.0000 0
M  V30 2 O 5.0494 2.5454 0.0000 0
M  V30 3 N 4.5645 1.8779 0.0000 0
M  V30 4 C 4.9000 1.1243 0.0000 0
M  V30 5 C 5.7070 0.9527 0.0000 0
M  V30 6 N 5.7933 0.1323 0.0000 0
M  V30 7 C 5.0396 -0.2033 0.0000 0
M  V30 8 C 4.4875 0.4098 0.0000 0
M  V30 9 C 3.6671 0.3236 0.0000 0
M  V30 10 N 3.1821 0.9910 0.0000 0
M  V30 11 C 6.5077 -0.2802 0.0000 0
M  V30 12 N 7.2222 0.1323 0.0000 0
M  V30 13 C 7.9367 -0.2802 0.0000 0
M  V30 14 N 8.6511 0.1323 0.0000 0
M  V30 15 C 9.3656 -0.2802 0.0000 0
M  V30 16 C 9.3656 -1.1052 0.0000 0
M  V30 17 C 10.0801 -1.5177 0.0000 0
M  V30 18 O 10.7946 -1.1052 0.0000 0
M  V30 19 O 10.0801 -2.3427 0.0000 0
M  V30 20 C 8.6511 -1.5177 0.0000 0
M  V30 21 O 8.6511 -2.3427 0.0000 0
M  V30 22 C 7.9367 -1.1052 0.0000 0
M  V30 23 C 7.2222 -1.5177 0.0000 0
M  V30 24 C 6.5077 -1.1052 0.0000 0
M  V30 25 F 5.7933 -1.5177 0.0000 0
M  V30 26 C 8.6511 0.9573 0.0000 0
M  V30 27 C 8.2386 1.6717 0.0000 0
M  V30 28 C 9.0636 1.6717 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 4 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 6 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 17 19
M  V30 20 1 16 20
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 2 13 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 11 24
M  V30 27 1 24 25
M  V30 28 1 14 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 26 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
94

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Gemifloxacin mesylate

>  <Synonyms>
SB-265805S;Gemifloxacin?mesylate;LB-20304a

>  <CAS>
210353-53-0

>  <Formula>
C19H24FN5O7S

>  <MolWt>
485.5

>  <Pathways>
DNA Damage/DNA Repair;Microbiology/Virology

>  <Target>
Antibacterial;Topoisomerase;DNA gyrase

>  <Receptor>
Bacterial; DNA gyrase; Topo II

>  <Bioactivity>
"Gemifloxacin mesylate inhibits activities of DNA gyrase and topoisomerase IV, thereby inhibiting DNA replication and eventually bacterial growth. Gemifloxacin Mesylate is the mesylate salt form of gemifloxacin, a synthetic broad-spectrum fluoroquinolone with antibacterial activity. This fluoroquinolone exerts an enhanced spectrum of activity against gram-positive bacteria such as Streptococcus pneumonia and Staphylococcus aureus, in addition to its activity against gram-negative bacteria."

>  <Reference>
"Ruiz J, et al. Int J Antimicrob Agents. 2003 Jul;22(1):73-6."

>  <ID<1>>
T1492

$$$$
StarDrop ID 95
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 41 45 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 -2.4750 0.0000 0
M  V30 2 C 0.7145 -2.8875 0.0000 0
M  V30 3 C 0.7145 -3.7125 0.0000 0
M  V30 4 N 1.4289 -4.1250 0.0000 0
M  V30 5 C 1.4289 -4.9500 0.0000 0
M  V30 6 C 0.7145 -5.3625 0.0000 0
M  V30 7 C 0.7145 -6.1875 0.0000 0
M  V30 8 O 2.1434 -5.3625 0.0000 0
M  V30 9 C 2.1434 -3.7125 0.0000 0
M  V30 10 C 2.1434 -2.8875 0.0000 0
M  V30 11 N 1.4289 -2.4750 0.0000 0
M  V30 12 C 1.4289 -1.6500 0.0000 0
M  V30 13 N 0.7145 -1.2375 0.0000 0
M  V30 14 C 0.7145 -0.4125 0.0000 0
M  V30 15 N 1.4289 0.0000 0.0000 0
M  V30 16 C 1.4289 0.8250 0.0000 0
M  V30 17 C 2.1434 1.2375 0.0000 0
M  V30 18 C 2.8579 0.8250 0.0000 0
M  V30 19 C 2.1434 2.0625 0.0000 0
M  V30 20 C 1.4289 2.4750 0.0000 0
M  V30 21 N 0.7145 2.0625 0.0000 0
M  V30 22 C 0.7145 1.2375 0.0000 0
M  V30 23 C 0.0000 0.8250 0.0000 0
M  V30 24 C -0.7145 1.2375 0.0000 0
M  V30 25 C 0.0000 0.0000 0.0000 0
M  V30 26 C 2.1434 -0.4125 0.0000 0
M  V30 27 N 2.8579 0.0000 0.0000 0
M  V30 28 C 3.5724 -0.4125 0.0000 0
M  V30 29 C 4.2868 -0.0000 0.0000 0
M  V30 30 C 4.2868 0.8250 0.0000 0
M  V30 31 O 3.5724 1.2375 0.0000 0
M  V30 32 C 5.0013 1.2375 0.0000 0
M  V30 33 C 5.7158 0.8250 0.0000 0
M  V30 34 C 5.7158 -0.0000 0.0000 0
M  V30 35 C 5.0013 -0.4125 0.0000 0
M  V30 36 F 5.0013 -1.2375 0.0000 0
M  V30 37 C 3.5724 -1.2375 0.0000 0
M  V30 38 F 4.2868 -1.6500 0.0000 0
M  V30 39 C 2.8579 -1.6500 0.0000 0
M  V30 40 C 2.1434 -1.2375 0.0000 0
M  V30 41 O -0.1060 -0.4987 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 2 5 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 2 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 16 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 1 23 25
M  V30 27 1 15 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 30 31
M  V30 33 1 30 32
M  V30 34 2 32 33
M  V30 35 1 33 34
M  V30 36 2 34 35
M  V30 37 1 29 35
M  V30 38 1 35 36
M  V30 39 2 28 37
M  V30 40 1 37 38
M  V30 41 1 37 39
M  V30 42 2 39 40
M  V30 43 1 26 40
M  V30 44 1 12 40
M  V30 45 2 14 41
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
95

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Sotorasib

>  <Synonyms>
AMG-510

>  <CAS>
2296729-00-3

>  <Formula>
C30H30F2N6O3

>  <MolWt>
560.6

>  <Pathways>
MAPK;GPCR/G Protein

>  <Target>
Ras

>  <Receptor>
KRAS G12C; Ras

>  <Bioactivity>
AMG-510 is a selective and orally bioavailable KRAS G12C covalent inhibitor.

>  <Reference>
"Marwan Fakih, et al, Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12Cinhibitor, in advanced solid tumors. Journal of Clinical Oncology.;Karen Rex, et al. Abstract 3090: In vivo characterization of AMG 510 - a potent and selective KRASG12Ccovalent small molecule inhibitor in preclinical KRASG12Ccancer models. Experimental and Molecular Therapeutics."

>  <ID<1>>
T8684

$$$$
StarDrop ID 96
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.4978 2.4498 0.0000 0
M  V30 2 C 1.7781 1.6739 0.0000 0 CFG=1
M  V30 3 C 2.5902 1.5287 0.0000 0
M  V30 4 C 2.8705 0.7528 0.0000 0 CFG=1
M  V30 5 C 3.6826 0.6076 0.0000 0 CFG=2
M  V30 6 C 4.3340 1.1139 0.0000 0
M  V30 7 C 5.0168 0.6509 0.0000 0
M  V30 8 C 4.7875 -0.1416 0.0000 0 CFG=2
M  V30 9 C 5.2939 -0.7929 0.0000 0
M  V30 10 C 6.1111 -0.6800 0.0000 0
M  V30 11 O 4.9830 -1.5571 0.0000 0
M  V30 12 C 3.9629 -0.1684 0.0000 0 CFG=2
M  V30 13 C 4.3228 -0.9107 0.0000 0
M  V30 14 C 3.4311 -0.7991 0.0000 0
M  V30 15 C 2.6190 -0.6539 0.0000 0 CFG=2
M  V30 16 O 2.0872 -1.2846 0.0000 0
M  V30 17 C 2.3387 0.1221 0.0000 0 CFG=2
M  V30 18 C 1.5266 0.2673 0.0000 0 CFG=1
M  V30 19 C 1.8069 -0.5086 0.0000 0
M  V30 20 C 0.9948 -0.3634 0.0000 0
M  V30 21 C 0.1827 -0.2182 0.0000 0
M  V30 22 C -0.0976 0.5577 0.0000 0
M  V30 23 O -0.9098 0.7029 0.0000 0
M  V30 24 C 0.4342 1.1884 0.0000 0
M  V30 25 C 1.2463 1.0432 0.0000 0
M  V30 26 H 2.4227 2.4384 0.0000 0
M  V30 27 H 3.5151 1.5173 0.0000 0
M  V30 28 H 4.6432 0.3295 0.0000 0
M  V30 29 H 5.7696 0.0469 0.0000 0
M  V30 30 H 2.9588 -1.5944 0.0000 0
M  V30 31 H 1.6941 -0.6425 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=3
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 12 8
M  V30 12 1 5 12
M  V30 13 1 12 13 CFG=3
M  V30 14 1 12 14
M  V30 15 1 15 14
M  V30 16 1 15 16 CFG=3
M  V30 17 1 17 15 CFG=3
M  V30 18 1 17 4
M  V30 19 1 17 18
M  V30 20 1 18 19 CFG=3
M  V30 21 1 18 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 2 24 25
M  V30 27 1 2 25
M  V30 28 1 18 25
M  V30 29 1 26 2
M  V30 30 1 27 4
M  V30 31 1 28 5
M  V30 32 1 29 8
M  V30 33 1 30 15
M  V30 34 1 31 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
96

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Medrysone

>  <Synonyms>
Gimeracil;6??-Methyl-11??-hydroxyprogesterone

>  <CAS>
2668-66-8

>  <Formula>
C22H32O3

>  <MolWt>
344.5

>  <Pathways>
Others;Endocrinology/Hormones

>  <Target>
Others;Glucocorticoid Receptor

>  <Receptor>
Corticosteroid-binding globulin; Glucocorticoid Receptor

>  <Bioactivity>
"Medrysone is a topical, synthetic glucocorticoid with metabolic, anti-inflammatory and anti-allergic properties. Medrysone exerts its effect by interacting with specific intracellular glucocorticoid receptors and subsequently binds to DNA to modify gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions is accomplished."

>  <Reference>
"Southren AL, et al. Invest Ophthalmol Vis Sci. 1983 Feb;24(2):147-52."

>  <ID<1>>
T0977

$$$$
StarDrop ID 97
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 71 78 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0723 4.4872 0.0000 0
M  V30 2 C 4.3526 5.2631 0.0000 0 CFG=2
M  V30 3 C 3.8208 5.8938 0.0000 0 CFG=2
M  V30 4 C 4.1011 6.6697 0.0000 0 CFG=2
M  V30 5 C 4.9132 6.8149 0.0000 0
M  V30 6 C 5.4450 6.1842 0.0000 0 CFG=1
M  V30 7 O 5.1647 5.4083 0.0000 0
M  V30 8 O 6.2572 6.3295 0.0000 0
M  V30 9 C 6.7890 5.6987 0.0000 0 CFG=2
M  V30 10 C 7.6011 5.8440 0.0000 0 CFG=2
M  V30 11 O 8.1329 5.2133 0.0000 0
M  V30 12 C 7.8526 4.4373 0.0000 0 CFG=2
M  V30 13 C 7.0405 4.2921 0.0000 0
M  V30 14 C 6.5087 4.9228 0.0000 0 CFG=2
M  V30 15 O 5.6966 4.7776 0.0000 0
M  V30 16 O 8.3844 3.8066 0.0000 0
M  V30 17 C 8.1041 3.0307 0.0000 0 CFG=2
M  V30 18 C 8.6360 2.4000 0.0000 0 CFG=2
M  V30 19 O 8.3557 1.6241 0.0000 0
M  V30 20 C 7.5435 1.4789 0.0000 0 CFG=2
M  V30 21 C 7.0117 2.1096 0.0000 0
M  V30 22 C 7.2920 2.8855 0.0000 0 CFG=2
M  V30 23 O 6.7602 3.5162 0.0000 0
M  V30 24 O 7.2632 0.7029 0.0000 0
M  V30 25 C 6.4511 0.5577 0.0000 0 CFG=1
M  V30 26 C 6.1708 -0.2182 0.0000 0
M  V30 27 C 5.3587 -0.3634 0.0000 0
M  V30 28 C 4.8269 0.2673 0.0000 0 CFG=1
M  V30 29 C 5.1072 1.0432 0.0000 0 CFG=1
M  V30 30 C 5.9193 1.1884 0.0000 0
M  V30 31 C 4.5754 1.6739 0.0000 0
M  V30 32 C 3.7633 1.5287 0.0000 0
M  V30 33 C 3.4830 0.7528 0.0000 0 CFG=2
M  V30 34 C 4.0148 0.1221 0.0000 0 CFG=2
M  V30 35 C 3.7345 -0.6539 0.0000 0
M  V30 36 C 2.9224 -0.7991 0.0000 0
M  V30 37 C 2.3905 -0.1684 0.0000 0 CFG=1
M  V30 38 C 2.6708 0.6076 0.0000 0 CFG=2
M  V30 39 C 2.0195 1.1139 0.0000 0
M  V30 40 C 1.3367 0.6509 0.0000 0
M  V30 41 C 1.5660 -0.1416 0.0000 0 CFG=2
M  V30 42 C 1.0596 -0.7929 0.0000 0
M  V30 43 C 1.2889 -1.5854 0.0000 0
M  V30 44 C 0.6061 -2.0484 0.0000 0
M  V30 45 O 0.5793 -2.8729 0.0000 0
M  V30 46 O -0.0452 -1.5420 0.0000 0
M  V30 47 C 0.2351 -0.7661 0.0000 0
M  V30 48 O 2.8685 1.4085 0.0000 0
M  V30 49 C 2.0307 -0.9107 0.0000 0
M  V30 50 C 4.5466 -0.5086 0.0000 0
M  V30 51 C 9.4481 2.5452 0.0000 0
M  V30 52 C 7.8814 6.6199 0.0000 0
M  V30 53 O 3.5693 7.3004 0.0000 0
M  V30 54 O 3.0087 5.7486 0.0000 0
M  V30 55 H 4.4674 0.9288 0.0000 0
M  V30 56 H 4.6594 -0.6425 0.0000 0
M  V30 57 H 1.9907 -1.0469 0.0000 0
M  V30 58 H 4.9972 4.4986 0.0000 0
M  V30 59 H 3.1762 6.6583 0.0000 0
M  V30 60 H 3.1167 6.4937 0.0000 0
M  V30 61 H 5.7848 7.1247 0.0000 0
M  V30 62 H 7.1287 6.6392 0.0000 0
M  V30 63 H 8.5855 6.0200 0.0000 0
M  V30 64 H 7.5128 3.4968 0.0000 0
M  V30 65 H 5.8641 5.6873 0.0000 0
M  V30 66 H 7.4595 3.7952 0.0000 0
M  V30 67 H 9.2806 1.6355 0.0000 0
M  V30 68 H 6.5591 1.3028 0.0000 0
M  V30 69 H 6.3076 2.7095 0.0000 0
M  V30 70 H 7.0957 -0.2068 0.0000 0
M  V30 71 H 5.7518 0.2787 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 3 2
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 6 8 CFG=3
M  V30 9 1 9 8 CFG=3
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 12 11
M  V30 13 1 12 13
M  V30 14 1 14 13
M  V30 15 1 9 14
M  V30 16 1 14 15 CFG=3
M  V30 17 1 12 16 CFG=1
M  V30 18 1 17 16 CFG=3
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 20 19
M  V30 22 1 20 21
M  V30 23 1 22 21
M  V30 24 1 17 22
M  V30 25 1 22 23 CFG=3
M  V30 26 1 20 24 CFG=1
M  V30 27 1 25 24 CFG=1
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 28 27
M  V30 31 1 28 29
M  V30 32 1 29 30 CFG=3
M  V30 33 1 25 30
M  V30 34 1 29 31
M  V30 35 1 31 32
M  V30 36 1 33 32 CFG=3
M  V30 37 1 34 33
M  V30 38 1 28 34
M  V30 39 1 34 35 CFG=1
M  V30 40 1 35 36
M  V30 41 1 37 36
M  V30 42 1 38 37
M  V30 43 1 33 38
M  V30 44 1 38 39
M  V30 45 1 39 40
M  V30 46 1 41 40
M  V30 47 1 37 41
M  V30 48 1 41 42 CFG=1
M  V30 49 2 42 43
M  V30 50 1 43 44
M  V30 51 2 44 45
M  V30 52 1 44 46
M  V30 53 1 46 47
M  V30 54 1 42 47
M  V30 55 1 38 48 CFG=1
M  V30 56 1 37 49 CFG=1
M  V30 57 1 28 50 CFG=1
M  V30 58 1 18 51 CFG=1
M  V30 59 1 10 52 CFG=1
M  V30 60 1 4 53 CFG=1
M  V30 61 1 3 54 CFG=1
M  V30 62 1 55 33
M  V30 63 1 56 34
M  V30 64 1 57 41
M  V30 65 1 58 2
M  V30 66 1 59 3
M  V30 67 1 60 4
M  V30 68 1 61 6
M  V30 69 1 62 9
M  V30 70 1 63 10
M  V30 71 1 64 12
M  V30 72 1 65 14
M  V30 73 1 66 17
M  V30 74 1 67 18
M  V30 75 1 68 20
M  V30 76 1 69 22
M  V30 77 1 70 25
M  V30 78 1 71 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
97

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Digitoxin

>  <Synonyms>
Digitoxinum;Digitoxoside;Unidigin

>  <CAS>
71-63-6

>  <Formula>
C41H64O13

>  <MolWt>
764.9

>  <Pathways>
Membrane transporter/Ion channel;Others

>  <Target>
ATPase;Others

>  <Receptor>
 Na+/K+-ATPase:0.78 ??M(EC50)

>  <Bioactivity>
Digitoxin is an effective Na+/K+-ATPase inhibitor (EC50 value: 0.78 ??M).

>  <Reference>
"Bossuyt X, et al. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6."

>  <ID<1>>
T0295

$$$$
StarDrop ID 98
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.4780 -4.9454 0.0000 0
M  V30 2 C 0.6710 -5.1170 0.0000 0
M  V30 3 O 0.4161 -5.9016 0.0000 0
M  V30 4 C 0.9681 -6.5147 0.0000 0
M  V30 5 N 0.1190 -4.5039 0.0000 0
M  V30 6 C 0.3739 -3.7192 0.0000 0
M  V30 7 C -0.1781 -3.1062 0.0000 0
M  V30 8 N 0.0768 -2.3215 0.0000 0
M  V30 9 C 0.8838 -2.1500 0.0000 0
M  V30 10 N 1.4358 -2.7631 0.0000 0
M  V30 11 C 1.1809 -3.5477 0.0000 0
M  V30 12 N 1.7329 -4.1608 0.0000 0
M  V30 13 C 1.1387 -1.3654 0.0000 0
M  V30 14 N 0.6538 -0.6979 0.0000 0
M  V30 15 N 1.1387 -0.0305 0.0000 0
M  V30 16 C 1.9233 -0.2854 0.0000 0
M  V30 17 N 2.6378 0.1271 0.0000 0
M  V30 18 C 3.3523 -0.2854 0.0000 0
M  V30 19 C 3.3523 -1.1104 0.0000 0
M  V30 20 F 4.0668 -1.5229 0.0000 0
M  V30 21 C 2.6378 -1.5229 0.0000 0
M  V30 22 C 1.9233 -1.1104 0.0000 0
M  V30 23 C 0.8838 0.7541 0.0000 0
M  V30 24 C 1.4358 1.3672 0.0000 0
M  V30 25 C 2.2428 1.1957 0.0000 0
M  V30 26 C 2.7948 1.8088 0.0000 0
M  V30 27 C 2.5399 2.5934 0.0000 0
M  V30 28 C 1.7329 2.7649 0.0000 0
M  V30 29 C 1.1809 2.1518 0.0000 0
M  V30 30 F 0.3739 2.3234 0.0000 0
M  V30 31 N -0.9851 -3.2777 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 11 12
M  V30 13 1 9 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 19 21
M  V30 22 1 21 22
M  V30 23 1 13 22
M  V30 24 2 16 22
M  V30 25 1 15 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 1 26 27
M  V30 30 2 27 28
M  V30 31 1 28 29
M  V30 32 2 24 29
M  V30 33 1 29 30
M  V30 34 1 7 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
98

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Vericiguat

>  <Synonyms>
BAY1021189

>  <CAS>
1350653-20-1

>  <Formula>
C19H16F2N8O2

>  <MolWt>
426.4

>  <Pathways>
GPCR/G Protein

>  <Target>
Guanylate cyclase

>  <Receptor>
guanylate cyclase

>  <Bioactivity>
Vericiguat is a potent and orally available guanylate cyclase stimulator.

>  <Reference>
"Follmann M, et al. Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure. J Med Chem. 2017 Jun 22;60(12):5146-5161."

>  <ID<1>>
T17226

$$$$
StarDrop ID 99
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 44 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.8579 -0.0000 0.0000 0
M  V30 2 C 2.1434 -0.4125 0.0000 0
M  V30 3 C 2.1434 -1.2375 0.0000 0
M  V30 4 N 2.8579 -1.6500 0.0000 0
M  V30 5 C 2.8579 -2.4750 0.0000 0
M  V30 6 C 3.5724 -2.8875 0.0000 0
M  V30 7 N 4.2868 -2.4750 0.0000 0
M  V30 8 O 3.5724 -3.7125 0.0000 0
M  V30 9 C 2.1434 -2.8875 0.0000 0
M  V30 10 N 2.1434 -3.7125 0.0000 0
M  V30 11 C 1.4289 -4.1250 0.0000 0
M  V30 12 C 1.4289 -4.9500 0.0000 0
M  V30 13 C 0.7145 -5.3625 0.0000 0
M  V30 14 C -0.0000 -4.9500 0.0000 0
M  V30 15 N -0.7145 -5.3625 0.0000 0
M  V30 16 C -0.7145 -6.1875 0.0000 0
M  V30 17 C -1.4289 -6.6000 0.0000 0
M  V30 18 C -2.1434 -6.1875 0.0000 0
M  V30 19 C -2.1434 -5.3625 0.0000 0
M  V30 20 C -1.4289 -4.9500 0.0000 0
M  V30 21 N -2.8579 -6.6000 0.0000 0
M  V30 22 C -2.8579 -7.4250 0.0000 0
M  V30 23 C -3.5724 -7.8375 0.0000 0
M  V30 24 N -4.2868 -7.4250 0.0000 0
M  V30 25 C -5.0013 -7.8375 0.0000 0
M  V30 26 C -4.2868 -6.6000 0.0000 0
M  V30 27 C -3.5724 -6.1875 0.0000 0
M  V30 28 C -0.0000 -4.1250 0.0000 0
M  V30 29 O -0.7145 -3.7125 0.0000 0
M  V30 30 C -0.7145 -2.8875 0.0000 0
M  V30 31 C 0.7145 -3.7125 0.0000 0
M  V30 32 N 1.4289 -2.4750 0.0000 0
M  V30 33 C 1.4289 -1.6500 0.0000 0
M  V30 34 N 0.7145 -1.2375 0.0000 0
M  V30 35 C 0.7145 -0.4125 0.0000 0
M  V30 36 C 0.0000 0.0000 0.0000 0
M  V30 37 C 0.0000 0.8250 0.0000 0
M  V30 38 O 0.7145 1.2375 0.0000 0
M  V30 39 C 1.4289 0.8250 0.0000 0
M  V30 40 C 1.4289 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 2 5 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 15 20
M  V30 21 1 18 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 24 26
M  V30 27 1 26 27
M  V30 28 1 21 27
M  V30 29 1 14 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 2 28 31
M  V30 33 1 11 31
M  V30 34 1 9 32
M  V30 35 2 32 33
M  V30 36 1 3 33
M  V30 37 1 33 34
M  V30 38 1 34 35
M  V30 39 1 35 36
M  V30 40 1 36 37
M  V30 41 1 37 38
M  V30 42 1 38 39
M  V30 43 1 39 40
M  V30 44 1 35 40
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
99

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Gilteritinib

>  <Synonyms>
ASP2215

>  <CAS>
1254053-43-4

>  <Formula>
C29H44N8O3

>  <MolWt>
552.7

>  <Pathways>
Angiogenesis;Tyrosine Kinase/Adaptors

>  <Target>
FLT;c-Kit;TAM Receptor

>  <Receptor>
" Axl:0.73 nM, FLT3:0.29 nM, LTK:0.35 nM, c-Kit:230 nM, EML4-ALK:1.2 nM"

>  <Bioactivity>
"Gilteritinib is a potent inhibitor at the FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectively). In preClinicalal studies, gilteritinib showed strong antileukemic and antitumor effects. Gilteritinib is currently in several Phase 3 Clinicalal trials for acute myeloid leukemia."

>  <Reference>
"Mori M,etal.Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.Invest New Drugs. 2017 Oct;35(5):556-565.;Lee LY,etal.PreClinicalal studies of gilteritinib, a next-generation FLT3 inhibitor.Blood. 2017 Jan 12;129(2):257-260."

>  <ID<1>>
T4409

$$$$
StarDrop ID 100
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 67 73 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 2.1042 -1.9856 0.0000 0
M  V30 2 C 2.8579 -1.6500 0.0000 0 CFG=1
M  V30 3 C 3.5724 -1.2375 0.0000 0
M  V30 4 N 3.5724 -0.4125 0.0000 0
M  V30 5 C 2.5803 -0.3443 0.0000 0 CFG=1
M  V30 6 C 2.2448 -1.0980 0.0000 0 CFG=2
M  V30 7 C 1.4378 -1.2695 0.0000 0
M  V30 8 C 0.8858 -0.6564 0.0000 0
M  V30 9 C 2.1550 0.3626 0.0000 0
M  V30 10 O 1.3302 0.3477 0.0000 0
M  V30 11 N 2.5546 1.0844 0.0000 0
M  V30 12 C 2.1293 1.7913 0.0000 0 CFG=2
M  V30 13 C 1.9714 2.6011 0.0000 0
M  V30 14 C 2.7516 2.3329 0.0000 0 CFG=1
M  V30 15 C 3.5613 2.4908 0.0000 0
M  V30 16 F 4.1029 1.8685 0.0000 0
M  V30 17 F 3.8295 3.2710 0.0000 0
M  V30 18 C 1.3592 1.4952 0.0000 0
M  V30 19 O 1.2306 0.6803 0.0000 0
M  V30 20 N 0.7178 2.0140 0.0000 0
M  V30 21 S -0.0523 1.7179 0.0000 0
M  V30 22 O 0.2439 0.9479 0.0000 0
M  V30 23 O -0.3484 2.4880 0.0000 0
M  V30 24 C -0.8223 1.4218 0.0000 0
M  V30 25 C -1.2476 2.1288 0.0000 0
M  V30 26 C -0.6644 0.6121 0.0000 0
M  V30 27 C -1.4446 0.8802 0.0000 0
M  V30 28 C 4.2868 -0.0000 0.0000 0
M  V30 29 O 4.2868 0.8250 0.0000 0
M  V30 30 C 5.0013 -0.4125 0.0000 0 CFG=1
M  V30 31 N 5.0013 -1.2375 0.0000 0
M  V30 32 C 5.7158 -1.6500 0.0000 0
M  V30 33 O 6.4302 -1.2375 0.0000 0
M  V30 34 O 5.7158 -2.4750 0.0000 0
M  V30 35 C 6.4302 -2.8875 0.0000 0 CFG=2
M  V30 36 C 7.1447 -3.3000 0.0000 0
M  V30 37 C 6.4302 -3.7125 0.0000 0 CFG=1
M  V30 38 C 5.7158 -4.1250 0.0000 0
M  V30 39 C 5.7158 -4.9500 0.0000 0
M  V30 40 C 5.0013 -5.3625 0.0000 0
M  V30 41 C 4.2868 -4.9500 0.0000 0
M  V30 42 C 4.2868 -4.1250 0.0000 0
M  V30 43 F 3.7565 -4.7570 0.0000 0
M  V30 44 F 3.4744 -4.2683 0.0000 0
M  V30 45 C 3.5724 -3.7125 0.0000 0
M  V30 46 N 2.8579 -4.1250 0.0000 0
M  V30 47 C 2.1434 -3.7125 0.0000 0
M  V30 48 C 1.4289 -4.1250 0.0000 0
M  V30 49 C 0.7145 -3.7125 0.0000 0
M  V30 50 C 0.7145 -2.8875 0.0000 0
M  V30 51 O -0.0000 -2.4750 0.0000 0
M  V30 52 C -0.7145 -2.8875 0.0000 0
M  V30 53 C 1.4289 -2.4750 0.0000 0
M  V30 54 C 2.1434 -2.8875 0.0000 0
M  V30 55 N 2.9485 -2.1369 0.0000 0
M  V30 56 C 3.5724 -2.8875 0.0000 0
M  V30 57 O 2.8579 -2.4750 0.0000 0
M  V30 58 C 5.7158 -0.0000 0.0000 0
M  V30 59 C 6.4302 0.4125 0.0000 0
M  V30 60 C 6.1283 -0.7145 0.0000 0
M  V30 61 C 5.3033 0.7145 0.0000 0
M  V30 62 H 6.9302 -3.7535 0.0000 0
M  V30 63 H 5.7157 -4.1250 0.0000 0
M  V30 64 H 1.5822 -0.4057 0.0000 0
M  V30 65 H 1.6154 -0.3209 0.0000 0
M  V30 66 H 3.1905 1.4343 0.0000 0
M  V30 67 H 5.8673 -0.9125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 6 5
M  V30 6 1 6 2
M  V30 7 1 6 7 CFG=1
M  V30 8 1 7 8
M  V30 9 1 5 9 CFG=1
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 12 11 CFG=3
M  V30 13 1 12 13
M  V30 14 1 14 13
M  V30 15 1 12 14
M  V30 16 1 14 15 CFG=1
M  V30 17 1 15 16
M  V30 18 1 15 17
M  V30 19 1 12 18 CFG=1
M  V30 20 2 18 19
M  V30 21 1 18 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 2 21 23
M  V30 25 1 21 24
M  V30 26 1 24 25
M  V30 27 1 24 26
M  V30 28 1 26 27
M  V30 29 1 24 27
M  V30 30 1 4 28
M  V30 31 2 28 29
M  V30 32 1 30 28
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 2 32 33
M  V30 36 1 32 34
M  V30 37 1 35 34
M  V30 38 1 35 36 CFG=3
M  V30 39 1 37 36 CFG=1
M  V30 40 1 35 37
M  V30 41 1 37 38
M  V30 42 1 38 39
M  V30 43 1 39 40
M  V30 44 1 40 41
M  V30 45 1 41 42
M  V30 46 1 42 43
M  V30 47 1 42 44
M  V30 48 1 42 45
M  V30 49 2 45 46
M  V30 50 1 46 47
M  V30 51 2 47 48
M  V30 52 1 48 49
M  V30 53 2 49 50
M  V30 54 1 50 51
M  V30 55 1 51 52
M  V30 56 1 50 53
M  V30 57 2 53 54
M  V30 58 1 47 54
M  V30 59 1 54 55
M  V30 60 2 55 56
M  V30 61 1 45 56
M  V30 62 1 56 57
M  V30 63 1 2 57
M  V30 64 1 30 58 CFG=3
M  V30 65 1 58 59
M  V30 66 1 58 60
M  V30 67 1 58 61
M  V30 68 1 62 35
M  V30 69 1 63 37
M  V30 70 1 64 5
M  V30 71 1 65 6
M  V30 72 1 66 14
M  V30 73 1 67 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
100

>  <Plate>
PHD136328

>  <Row>
e

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Voxilaprevir

>  <Synonyms>
N/A

>  <CAS>
1535212-07-7

>  <Formula>
C40H52F4N6O9S

>  <MolWt>
868.9

>  <Pathways>
Proteases/Proteasome;Microbiology/Virology

>  <Target>
HCV Protease

>  <Receptor>
HCV

>  <Bioactivity>
Voxilaprevir is an inhibitor of hepatitis C virus (HCV) nonstructural (NS) protein 3/4A protease.

>  <Reference>
"Bourli??re, Marc, Gordon S C , Flamm S L , et al. Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.[J]. N Engl J Med, 2017, 376(22):2134-2146."

>  <ID<1>>
T19862

$$$$
StarDrop ID 101
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.7069 0.5635 0.0000 0
M  V30 2 C 1.9924 0.9760 0.0000 0
M  V30 3 C 1.2780 0.5635 0.0000 0
M  V30 4 N 0.5635 0.9760 0.0000 0
M  V30 5 C 0.5635 1.8010 0.0000 0 CFG=2
M  V30 6 S 1.2780 2.2135 0.0000 0
M  V30 7 C 1.9924 1.8010 0.0000 0
M  V30 8 C -0.2615 1.8010 0.0000 0 CFG=2
M  V30 9 N -0.8449 2.3843 0.0000 0
M  V30 10 C -0.6314 3.1812 0.0000 0
M  V30 11 O 0.1655 3.3948 0.0000 0
M  V30 12 C -1.2147 3.7646 0.0000 0 CFG=2
M  V30 13 N -2.0116 3.5511 0.0000 0
M  V30 14 C -1.0012 4.5615 0.0000 0
M  V30 15 C -1.5846 5.1449 0.0000 0
M  V30 16 C -1.3710 5.9417 0.0000 0
M  V30 17 C -0.5741 6.1553 0.0000 0
M  V30 18 O -0.3606 6.9522 0.0000 0
M  V30 19 C 0.0092 5.5719 0.0000 0
M  V30 20 C -0.2043 4.7750 0.0000 0
M  V30 21 C -0.2615 0.9760 0.0000 0
M  V30 22 O -0.8449 0.3926 0.0000 0
M  V30 23 C 1.2780 -0.2615 0.0000 0
M  V30 24 O 0.5635 -0.6740 0.0000 0
M  V30 25 O 1.9924 -0.6740 0.0000 0
M  V30 26 H -0.1436 1.0939 0.0000 0
M  V30 27 H -1.1854 1.4183 0.0000 0
M  V30 28 H -1.4736 2.7987 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 1 8 9 CFG=1
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 12 10
M  V30 13 1 12 13 CFG=3
M  V30 14 1 12 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 2 19 20
M  V30 21 1 14 20
M  V30 22 1 8 21
M  V30 23 1 4 21
M  V30 24 2 21 22
M  V30 25 1 3 23
M  V30 26 1 23 24
M  V30 27 2 23 25
M  V30 28 1 26 5
M  V30 29 1 27 8
M  V30 30 1 28 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
101

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cefadroxil

>  <Synonyms>
BL-S 578

>  <CAS>
50370-12-2

>  <Formula>
C16H17N3O5S

>  <MolWt>
363.4

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial; PBPs

>  <Bioactivity>
Cefadroxil is a Cephalosporin Antibacterial. The chemical classification of cefadroxil anhydrous is Cephalosporins.

>  <Reference>
"Williamson R, et al. Antimicrob Agents ChemOthers. 1980 Oct;18(4):629-37."

>  <ID<1>>
T0366

$$$$
StarDrop ID 102
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 39 41 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 -1.5851 0.0000 0
M  V30 2 C 3.1673 -1.7410 0.0000 0
M  V30 3 O 3.7074 -1.1174 0.0000 0
M  V30 4 C 4.5175 -1.2733 0.0000 0
M  V30 5 O 4.7875 -2.0528 0.0000 0
M  V30 6 C 5.0576 -0.6496 0.0000 0 CFG=2
M  V30 7 C 4.7875 0.1299 0.0000 0
M  V30 8 C 3.9774 0.2858 0.0000 0
M  V30 9 C 3.7074 1.0654 0.0000 0
M  V30 10 C 2.8972 1.2213 0.0000 0
M  V30 11 C 2.6272 2.0008 0.0000 0
M  V30 12 C 3.1673 2.6245 0.0000 0
M  V30 13 C 3.9774 2.4686 0.0000 0
M  V30 14 C 4.2475 1.6890 0.0000 0
M  V30 15 N 5.8677 -0.8055 0.0000 0
M  V30 16 C 6.1378 -1.5851 0.0000 0 CFG=1
M  V30 17 C 5.5977 -2.2087 0.0000 0
M  V30 18 C 6.9479 -1.7410 0.0000 0
M  V30 19 O 7.2179 -2.5206 0.0000 0
M  V30 20 N 7.4880 -1.1174 0.0000 0
M  V30 21 C 7.2179 -0.3378 0.0000 0
M  V30 22 C 7.7580 0.2858 0.0000 0
M  V30 23 C 7.4880 1.0654 0.0000 0
M  V30 24 C 8.0281 1.6890 0.0000 0
M  V30 25 O 7.7580 2.4686 0.0000 0
M  V30 26 C 8.2981 3.0922 0.0000 0
M  V30 27 C 8.8382 1.5331 0.0000 0
M  V30 28 O 9.3783 2.1568 0.0000 0
M  V30 29 C 9.1083 2.9363 0.0000 0
M  V30 30 C 9.1083 0.7536 0.0000 0
M  V30 31 C 8.5682 0.1299 0.0000 0
M  V30 32 C 8.8382 -0.6496 0.0000 0
M  V30 33 C 8.2981 -1.2733 0.0000 0 CFG=1
M  V30 34 C 8.5682 -2.0528 0.0000 0
M  V30 35 O 8.0281 -2.6765 0.0000 0
M  V30 36 O 9.3783 -2.2087 0.0000 0
M  V30 37 H 5.7122 0.1064 0.0000 0
M  V30 38 H 6.4651 -2.5300 0.0000 0
M  V30 39 H 7.6435 -2.0293 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 6 4
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 9 14
M  V30 15 1 6 15 CFG=3
M  V30 16 1 16 15
M  V30 17 1 16 17 CFG=3
M  V30 18 1 16 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 2 24 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 1 27 30
M  V30 31 2 30 31
M  V30 32 1 22 31
M  V30 33 1 31 32
M  V30 34 1 33 32
M  V30 35 1 33 20
M  V30 36 1 33 34 CFG=1
M  V30 37 1 34 35
M  V30 38 2 34 36
M  V30 39 1 37 6
M  V30 40 1 38 16
M  V30 41 1 39 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
102

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Moexipril hydrochloride

>  <Synonyms>
CI-925;SPM 925;RS-10085;Moexipril HCl

>  <CAS>
82586-52-5

>  <Formula>
C27H34N2O7??HCl

>  <MolWt>
535

>  <Pathways>
Apoptosis;Endocrinology/Hormones

>  <Target>
RAAS;Apoptosis

>  <Receptor>
 ACE:0.041 ??M

>  <Bioactivity>
"Moexipril HCl is a potent orally active nonsulfhydrylangiotensin converting enzyme (ACE)inhibitor, used for the treatment of hypertension and congestive heart failure."

>  <Reference>
"Ravati A, et al. Eur J Pharmacol,1999, 373(1), 21-33.;Edling O, et al. J Pharmacol Exp Ther,1995, 275(2), 854-863.;Ma YF, et al. J Endocrinol,1997, 154(3), 467-474."

>  <ID<1>>
T6595

$$$$
StarDrop ID 103
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 39 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.4289 -0.0000 0.0000 0
M  V30 2 O 0.7145 -0.4125 0.0000 0
M  V30 3 C 0.7145 -1.2375 0.0000 0
M  V30 4 C 1.4289 -1.6500 0.0000 0
M  V30 5 C 1.4289 -2.4750 0.0000 0
M  V30 6 C 0.7145 -2.8875 0.0000 0
M  V30 7 C 0.0000 -2.4750 0.0000 0
M  V30 8 C 0.0000 -1.6500 0.0000 0
M  V30 9 N -0.7145 -1.2375 0.0000 0
M  V30 10 C -0.7145 -0.4125 0.0000 0
M  V30 11 N 0.0000 0.0000 0.0000 0
M  V30 12 C 0.0000 0.8250 0.0000 0
M  V30 13 C -0.7145 1.2375 0.0000 0
M  V30 14 Cl -0.7145 2.0625 0.0000 0
M  V30 15 C -1.4289 0.8250 0.0000 0
M  V30 16 N -2.1434 1.2375 0.0000 0
M  V30 17 C -2.8579 0.8250 0.0000 0
M  V30 18 C -2.8579 0.0000 0.0000 0
M  V30 19 C -3.5724 -0.4125 0.0000 0
M  V30 20 C -4.2868 0.0000 0.0000 0
M  V30 21 C -4.2868 0.8250 0.0000 0
M  V30 22 C -3.5724 1.2375 0.0000 0
M  V30 23 P -3.5724 2.0625 0.0000 0
M  V30 24 C -3.5724 2.8875 0.0000 0
M  V30 25 C -2.7474 2.0625 0.0000 0
M  V30 26 O -4.3974 2.0625 0.0000 0
M  V30 27 N -1.4289 0.0000 0.0000 0
M  V30 28 N 2.1434 -2.8875 0.0000 0
M  V30 29 C 2.8579 -2.4750 0.0000 0
M  V30 30 C 3.5724 -2.8875 0.0000 0
M  V30 31 C 3.5724 -3.7125 0.0000 0
M  V30 32 C 2.8579 -4.1250 0.0000 0
M  V30 33 C 2.1434 -3.7125 0.0000 0
M  V30 34 N 4.2868 -4.1250 0.0000 0
M  V30 35 C 5.0013 -3.7125 0.0000 0
M  V30 36 C 4.2868 -4.9500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 3 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 17 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 1 23 25
M  V30 27 2 23 26
M  V30 28 2 15 27
M  V30 29 1 10 27
M  V30 30 1 5 28
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 1 32 33
M  V30 36 1 28 33
M  V30 37 1 31 34
M  V30 38 1 34 35
M  V30 39 1 34 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
103

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
ALK-IN-1

>  <Synonyms>
AP26113;AP26113-analog;Brigatinib

>  <CAS>
1197958-12-5

>  <Formula>
C26H34ClN6O2P

>  <MolWt>
529

>  <Pathways>
Angiogenesis;Tyrosine Kinase/Adaptors;JAK/STAT signaling

>  <Target>
IGF-1R;EGFR;ALK

>  <Receptor>
 ALK:0.62 nM

>  <Bioactivity>
"AP26113 is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2."

>  <Reference>
"Uchibori K, et al. Nat Commun. 2017, 8:14768.;Wei-Sheng Huang, et al. J Med Chem, 2016, 59(10):4948-4964."

>  <ID<1>>
T3059

$$$$
StarDrop ID 104
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 -0.8021 0.0000 0
M  V30 2 C 3.0716 -1.2146 0.0000 0
M  V30 3 N 3.7861 -0.8021 0.0000 0
M  V30 4 C 3.7861 0.0229 0.0000 0
M  V30 5 C 4.5006 0.4354 0.0000 0
M  V30 6 C 4.5006 -1.2146 0.0000 0
M  V30 7 C 5.2150 -0.8021 0.0000 0
M  V30 8 O 5.9295 -1.2146 0.0000 0
M  V30 9 C 6.6440 -0.8021 0.0000 0
M  V30 10 O 7.3584 -1.2146 0.0000 0
M  V30 11 C 6.6440 0.0229 0.0000 0
M  V30 12 C 5.9295 0.4354 0.0000 0
M  V30 13 C 5.9295 1.2604 0.0000 0
M  V30 14 C 6.6440 1.6729 0.0000 0
M  V30 15 N 6.6440 2.4979 0.0000 0
M  V30 16 C 7.3584 1.2604 0.0000 0
M  V30 17 C 7.3584 0.4354 0.0000 0
M  V30 18 Cl 8.0729 0.0229 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 2 16 17
M  V30 17 1 11 17
M  V30 18 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
104

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Chloroprocaine hydrochloride

>  <Synonyms>
Chloroprocaine HCl

>  <CAS>
3858-89-7

>  <Formula>
C13H20Cl2N2O2

>  <MolWt>
307.2

>  <Pathways>
Others;Membrane transporter/Ion channel

>  <Target>
ATPase;Others

>  <Receptor>
" Na,K-ATPase:13 mM (IC50)"

>  <Bioactivity>
Chloroprocaine HCl is a local anesthetic during surgical procedures.

>  <Reference>
"Dolle FA, Dobbs EC.J Am Dent Soc Anesthesiol. 1962 Sep;9(7):156-8."

>  <ID<1>>
T6443

$$$$
StarDrop ID 105
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.6947 1.2964 0.0000 0
M  V30 2 O 5.4092 1.7089 0.0000 0
M  V30 3 C 6.1237 1.2964 0.0000 0
M  V30 4 O 6.8381 1.7089 0.0000 0
M  V30 5 C 6.1237 0.4714 0.0000 0
M  V30 6 N 5.4092 0.0589 0.0000 0
M  V30 7 C 5.4092 -0.7661 0.0000 0
M  V30 8 C 4.6947 -1.1786 0.0000 0
M  V30 9 C 3.9803 -0.7661 0.0000 0
M  V30 10 S 3.1956 -1.0210 0.0000 0
M  V30 11 C 2.7107 -0.3536 0.0000 0
M  V30 12 C 3.1956 0.3139 0.0000 0
M  V30 13 C 3.9803 0.0589 0.0000 0
M  V30 14 C 4.6947 0.4714 0.0000 0
M  V30 15 C 6.8381 0.0589 0.0000 0
M  V30 16 C 7.5526 0.4714 0.0000 0
M  V30 17 C 8.2671 0.0589 0.0000 0
M  V30 18 C 8.2671 -0.7661 0.0000 0
M  V30 19 C 7.5526 -1.1786 0.0000 0
M  V30 20 C 6.8381 -0.7661 0.0000 0
M  V30 21 Cl 6.1237 -1.1786 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 9 13
M  V30 14 1 13 14
M  V30 15 1 6 14
M  V30 16 1 5 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 15 20
M  V30 23 1 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
105

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
(??) Clopidogrel hydrogen sulfate

>  <Synonyms>
Iscover;Plavix;Clopidogrel hydrogen sulfate

>  <CAS>
135046-48-9

>  <Formula>
C16H18ClNO6S2

>  <MolWt>
419.9

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
P2Y Receptor

>  <Receptor>
P2Y12

>  <Bioactivity>
"Clopidogrel, an antiplatelet agent pharmacologically and structurally analogous to ticlopidine, is used to inhibit blood clots in various conditions such as cerebrovascular disease, peripheral vascular disease, and coronary artery disease."

>  <Reference>
"Dorsam RT, et al. Hematology. 2003 Dec;8(6):359-65."

>  <ID<1>>
T0182L2

$$$$
StarDrop ID 106
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 -4.9500 0.0000 0
M  V30 2 N 0.0000 -5.7750 0.0000 0
M  V30 3 C 0.7145 -6.1875 0.0000 0 CFG=1
M  V30 4 C 1.4289 -5.7750 0.0000 0
M  V30 5 N 2.1434 -6.1875 0.0000 0
M  V30 6 C 2.8579 -5.7750 0.0000 0
M  V30 7 C 2.8579 -4.9500 0.0000 0
M  V30 8 C 3.5724 -4.5375 0.0000 0
M  V30 9 C 4.2868 -4.9500 0.0000 0
M  V30 10 C 4.2868 -5.7750 0.0000 0
M  V30 11 C 3.5724 -6.1875 0.0000 0
M  V30 12 C 5.0013 -4.5375 0.0000 0
M  V30 13 O 5.0013 -3.7125 0.0000 0
M  V30 14 N 5.7158 -4.9500 0.0000 0
M  V30 15 C 6.4302 -4.5375 0.0000 0 CFG=1
M  V30 16 C 7.1447 -4.9500 0.0000 0
M  V30 17 C 7.8592 -4.5375 0.0000 0
M  V30 18 C 8.5737 -4.9500 0.0000 0
M  V30 19 O 9.2881 -4.5375 0.0000 0
M  V30 20 O 8.5737 -5.7750 0.0000 0
M  V30 21 C 6.4302 -3.7125 0.0000 0
M  V30 22 O 7.1447 -3.3000 0.0000 0
M  V30 23 O 5.7158 -3.3000 0.0000 0
M  V30 24 C 0.7145 -7.0125 0.0000 0
M  V30 25 N 0.0000 -7.4250 0.0000 0
M  V30 26 C -0.7145 -7.0125 0.0000 0
M  V30 27 N -1.4289 -7.4250 0.0000 0
M  V30 28 C -2.1434 -7.0125 0.0000 0
M  V30 29 N -2.8579 -7.4250 0.0000 0
M  V30 30 N -2.1434 -6.1875 0.0000 0
M  V30 31 C -1.4289 -5.7750 0.0000 0
M  V30 32 O -1.4289 -4.9500 0.0000 0
M  V30 33 C -0.7145 -6.1875 0.0000 0
M  V30 34 H 0.7144 -5.1875 0.0000 0
M  V30 35 H 6.4303 -5.5375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 9 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 15 14 CFG=3
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 18 20
M  V30 21 1 15 21
M  V30 22 1 21 22
M  V30 23 2 21 23
M  V30 24 1 3 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 2 27 28
M  V30 29 1 28 29
M  V30 30 1 28 30
M  V30 31 1 30 31
M  V30 32 2 31 32
M  V30 33 1 31 33
M  V30 34 1 2 33
M  V30 35 2 26 33
M  V30 36 1 34 3
M  V30 37 1 35 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
106

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Levomefolic Acid

>  <Synonyms>
5-MTHF

>  <CAS>
31690-09-2

>  <Formula>
C20H25N7O6

>  <MolWt>
459.5

>  <Pathways>
Metabolism;NF-??b;Immunology/Inflammation

>  <Target>
Reactive Oxygen Species;Endogenous Metabolite

>  <Receptor>
Endogenous Metabolite; Human Endogenous Metabolite; Reactive Oxygen Species

>  <Bioactivity>
"Levomefolinic acid is a natural, active form of folic acid used at the cellular level for DNA reproduction, the cysteine cycle and the regulation of homocysteine among other functions. Levomefolinic acid is used as a treatment and to prevent Folate Deficiency"

>  <Reference>
"Rezk B M , Haenen G R M M , Vijgh W J F V D , et al. Tetrahydrofolate and 5-methyltetrahydrofolate are folates with high antioxidant activity. Identification of the antioxidant pharmacophore[J]. FEBS Letters, 2003, 555(3):0-605.;Thermal oxidation studies on reduced folate, L-5-methyltetrahydrofolic acid (L-5-MTHF) and strategies for stabilization using food matrices.;Scaglione F , Panzavolta G . Folate, folic acid and 5-methyltetrahydrofolate are not the same thing[J]. Xenobiotica, 2014, 44(5):480-488."

>  <ID<1>>
T7094

$$$$
StarDrop ID 107
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.1434 -2.8875 0.0000 0
M  V30 2 C 1.4289 -2.4750 0.0000 0
M  V30 3 N 1.4289 -1.6500 0.0000 0
M  V30 4 C 0.7145 -1.2375 0.0000 0
M  V30 5 C 0.7145 -0.4125 0.0000 0
M  V30 6 C 0.0000 0.0000 0.0000 0
M  V30 7 O 0.0000 0.8250 0.0000 0
M  V30 8 O -0.7145 -0.4125 0.0000 0
M  V30 9 C 1.4289 0.0000 0.0000 0
M  V30 10 O 1.4289 0.8250 0.0000 0
M  V30 11 C 2.1434 -0.4125 0.0000 0
M  V30 12 C 2.8579 0.0000 0.0000 0
M  V30 13 C 3.5724 -0.4125 0.0000 0
M  V30 14 C 3.5724 -1.2375 0.0000 0
M  V30 15 C 4.2868 -1.6500 0.0000 0
M  V30 16 N 2.8579 -1.6500 0.0000 0
M  V30 17 C 2.1434 -1.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 5 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 2 16 17
M  V30 17 1 3 17
M  V30 18 1 11 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
107

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Nalidixic acid sodium salt

>  <Synonyms>
Baktogram;Sodium nalidixate

>  <CAS>
3374-05-8

>  <Formula>
C12H11N2NaO3

>  <MolWt>
254.2

>  <Pathways>
DNA Damage/DNA Repair;Microbiology/Virology

>  <Target>
Topoisomerase;Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial; Topo II; Topoisomerase

>  <Bioactivity>
Nalidixic acid sodium salt is an antimicrobial agent with a limited bacteriocidal spectrum.

>  <Reference>
"Jain A, Rajeswari MR. J Biomol Struct Dyn. 2002 Oct;20(2):291-9."

>  <ID<1>>
T0909L

$$$$
StarDrop ID 108
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.1801 -0.1848 0.0000 0
M  V30 2 C 3.4656 -0.5973 0.0000 0
M  V30 3 C 2.7512 -0.1848 0.0000 0
M  V30 4 N 3.4656 -1.4223 0.0000 0
M  V30 5 N 2.7982 -1.9072 0.0000 0
M  V30 6 C 3.0531 -2.6919 0.0000 0
M  V30 7 C 3.8781 -2.6919 0.0000 0
M  V30 8 C 4.1331 -1.9072 0.0000 0
M  V30 9 C 4.9177 -1.6523 0.0000 0
M  V30 10 N 5.0892 -0.8453 0.0000 0
M  V30 11 C 5.8739 -0.5904 0.0000 0
M  V30 12 C 6.4870 -1.1424 0.0000 0
M  V30 13 C 6.3154 -1.9494 0.0000 0
M  V30 14 C 5.5308 -2.2043 0.0000 0
M  V30 15 C 5.3593 -3.0113 0.0000 0
M  V30 16 O 5.9724 -3.5633 0.0000 0
M  V30 17 C 5.8008 -4.3703 0.0000 0
M  V30 18 C 6.4139 -4.9223 0.0000 0
M  V30 19 C 6.2424 -5.7293 0.0000 0
M  V30 20 C 5.4578 -5.9843 0.0000 0
M  V30 21 C 4.8447 -5.4322 0.0000 0
M  V30 22 O 4.0601 -5.6872 0.0000 0
M  V30 23 C 5.0162 -4.6253 0.0000 0
M  V30 24 C 4.4031 -4.0732 0.0000 0
M  V30 25 O 4.5747 -3.2662 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 4 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 9 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 21 23
M  V30 25 1 17 23
M  V30 26 1 23 24
M  V30 27 2 24 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
108

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
voxelotor

>  <Synonyms>
GBT 440

>  <CAS>
1446321-46-5

>  <Formula>
C19H19N3O3

>  <MolWt>
337.4

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
sickle hemoglobin (HbS)

>  <Bioactivity>
voxelotor is an inhibitor of sickle hemoglobin (HbS)

>  <Reference>
"Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease[J]. Hematology Reports, 2018, 10(2).;Hutchaleelaha A , Patel M , Washington C , et al. Pharmacokinetics and Pharmacodynamics of Voxelotor (GBT440) in Healthy Adults and Patients With Sickle Cell Disease[J]. British Journal of Clinical Pharmacology, 2019."

>  <ID<1>>
T7581

$$$$
StarDrop ID 109
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.4102 -5.5334 0.0000 0
M  V30 2 C -2.4102 -6.3584 0.0000 0
M  V30 3 C -1.6957 -6.7709 0.0000 0
M  V30 4 N -0.9812 -6.3584 0.0000 0
M  V30 5 C -0.3979 -6.9417 0.0000 0
M  V30 6 C 0.4271 -6.9417 0.0000 0 CFG=1
M  V30 7 C -0.2343 -6.0490 0.0000 0
M  V30 8 C -0.3979 -4.9500 0.0000 0 CFG=2
M  V30 9 C 0.4271 -4.9500 0.0000 0
M  V30 10 N 1.0105 -5.5334 0.0000 0
M  V30 11 C 1.7250 -5.1209 0.0000 0
M  V30 12 C 2.4395 -5.5334 0.0000 0
M  V30 13 C 2.4395 -6.3584 0.0000 0
M  V30 14 C 1.7250 -6.7709 0.0000 0
M  V30 15 C 1.0105 -6.3584 0.0000 0 CFG=2
M  V30 16 C -0.9812 -5.5334 0.0000 0 CFG=2
M  V30 17 C -1.6957 -5.1209 0.0000 0
M  V30 18 H 1.0885 -7.8344 0.0000 0
M  V30 19 H -0.5615 -3.8510 0.0000 0
M  V30 20 H 1.8765 -5.8584 0.0000 0
M  V30 21 H -1.8472 -6.0334 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 8 7 CFG=3
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 15 14
M  V30 15 1 6 15
M  V30 16 1 15 10 CFG=3
M  V30 17 1 8 16
M  V30 18 1 16 4 CFG=1
M  V30 19 1 16 17
M  V30 20 1 1 17
M  V30 21 1 18 6
M  V30 22 1 19 8
M  V30 23 1 20 15
M  V30 24 1 21 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
109

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
(-)-Sparteine sulfate pentahydrate

>  <Synonyms>
(-)-Sparteine Sulfate;sulfate pentahydrate;Lupinidine sulfate pentahydrate;(-)-Sparteine sulfate salt

>  <CAS>
6160-12-9

>  <Formula>
C15H38N2O9S

>  <MolWt>
422.5

>  <Pathways>
Membrane transporter/Ion channel

>  <Target>
Sodium Channel

>  <Receptor>
Sodium Channel

>  <Bioactivity>
Sparteine sulfate pentahydrate is a class 1a antiarrhythmic agent and a sodium channel blocker. It can chelate the bivalents calcium and magnesium.

>  <Reference>
"Preissner S, et al. Nucleic Acids Res. 2010 Jan; 38(Database issue):D237-43.;Gawali VS, et al. C2-Modified Sparteine Derivatives Are a New Class of Potentially Long-Acting Sodium Channel Blockers. ChemMedChem. 2017 Nov 22;12(22):1819-1822."

>  <ID<1>>
T0792

$$$$
StarDrop ID 110
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.4440 -2.7799 0.0000 0
M  V30 2 C 2.2561 -2.6347 0.0000 0
M  V30 3 C 3.0683 -2.4895 0.0000 0 CFG=2
M  V30 4 O 3.1278 -3.3123 0.0000 0
M  V30 5 C 2.4450 -3.7753 0.0000 0
M  V30 6 C 1.7026 -3.4155 0.0000 0
M  V30 7 O 2.5045 -4.5982 0.0000 0
M  V30 8 C 2.8390 -1.6970 0.0000 0
M  V30 9 C 3.5218 -1.2340 0.0000 0
M  V30 10 C 4.1731 -1.7404 0.0000 0 CFG=1
M  V30 11 C 4.9853 -1.5952 0.0000 0 CFG=2
M  V30 12 C 5.2655 -0.8192 0.0000 0
M  V30 13 C 6.0777 -0.6740 0.0000 0
M  V30 14 C 6.6095 -1.3047 0.0000 0
M  V30 15 C 7.4216 -1.1595 0.0000 0
M  V30 16 C 7.9534 -1.7902 0.0000 0
M  V30 17 N 8.7655 -1.6450 0.0000 0
M  V30 18 O 9.2974 -2.2757 0.0000 0
M  V30 19 C 7.6731 -2.5662 0.0000 0
M  V30 20 C 6.8610 -2.7114 0.0000 0
M  V30 21 C 6.3292 -2.0807 0.0000 0 CFG=2
M  V30 22 C 5.5171 -2.2259 0.0000 0 CFG=1
M  V30 23 C 5.2368 -3.0018 0.0000 0
M  V30 24 C 4.4247 -3.1470 0.0000 0
M  V30 25 C 3.8928 -2.5163 0.0000 0 CFG=2
M  V30 26 C 3.5330 -3.2587 0.0000 0
M  V30 27 C 3.9959 -3.9415 0.0000 0
M  V30 28 H 3.2125 -2.0183 0.0000 0
M  V30 29 H 4.3406 -0.8308 0.0000 0
M  V30 30 H 5.9894 -3.0212 0.0000 0
M  V30 31 H 6.1617 -2.9904 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 3 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 3 8
M  V30 8 1 8 9
M  V30 9 1 10 9 CFG=1
M  V30 10 1 10 11
M  V30 11 1 11 12 CFG=3
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 16 19
M  V30 19 1 19 20
M  V30 20 1 21 20 CFG=3
M  V30 21 1 21 14
M  V30 22 1 22 21
M  V30 23 1 11 22
M  V30 24 1 22 23 CFG=1
M  V30 25 1 23 24
M  V30 26 1 25 24
M  V30 27 1 10 25
M  V30 28 1 25 3
M  V30 29 1 25 26 CFG=1
M  V30 30 1 26 27
M  V30 31 1 28 10
M  V30 32 1 29 11
M  V30 33 1 30 21
M  V30 34 1 31 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
110

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Norgestimate

>  <Synonyms>
N/A

>  <CAS>
35189-28-7

>  <Formula>
C23H31NO3

>  <MolWt>
369.5

>  <Pathways>
Others

>  <Target>
Progesterone Receptor

>  <Receptor>
Progesterone Receptor

>  <Bioactivity>
Norgestimate is an acetylated progestinused in combination with ethinyl estradiol as an oral contraceptive.

>  <Reference>
"Yoshii Y , Okuda K I , Yamada S , et al. Norgestimate inhibits staphylococcal biofilm formation and resensitizes methicillin-resistant Staphylococcus aureus to ??-lactam antibiotics[J]. npj Biofilms and Microbiomes, 2017, 3(1):18."

>  <ID<1>>
T7537

$$$$
StarDrop ID 111
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.2093 -1.6500 0.0000 0
M  V30 2 N 6.2093 -2.4750 0.0000 0
M  V30 3 C 6.9238 -2.8875 0.0000 0
M  V30 4 C 6.9238 -3.7125 0.0000 0
M  V30 5 C 6.2093 -4.1250 0.0000 0
M  V30 6 C 5.4948 -3.7125 0.0000 0
M  V30 7 C 5.4948 -2.8875 0.0000 0
M  V30 8 C 6.2093 -4.9500 0.0000 0
M  V30 9 C 6.9526 -5.3080 0.0000 0
M  V30 10 C 7.5573 -4.7468 0.0000 0
M  V30 11 C 8.3457 -4.9900 0.0000 0
M  V30 12 C 8.5293 -5.7943 0.0000 0
M  V30 13 C 7.9245 -6.3554 0.0000 0
M  V30 14 C 7.1362 -6.1123 0.0000 0
M  V30 15 C 6.6218 -6.7573 0.0000 0
M  V30 16 C 5.7968 -6.7573 0.0000 0
M  V30 17 C 5.2824 -6.1123 0.0000 0
M  V30 18 C 4.4941 -6.3554 0.0000 0
M  V30 19 C 3.8893 -5.7943 0.0000 0
M  V30 20 C 4.0729 -4.9900 0.0000 0
M  V30 21 C 4.8612 -4.7468 0.0000 0
M  V30 22 C 5.4660 -5.3080 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 2 5 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 9 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 8 22
M  V30 25 1 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
111

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cyproheptadine hydrochloride sesquihydrate

>  <Synonyms>
Peritol;Cyproheptadine hydrochloride;Periactin hydrochloride

>  <CAS>
41354-29-4

>  <Formula>
C42H50Cl2N2O3

>  <MolWt>
701.8

>  <Pathways>
Immunology/Inflammation;Chromatin/Epigenetic;GPCR/G Protein;Neuroscience

>  <Target>
Histone Methyltransferase;Histamine Receptor;5-HT Receptor

>  <Receptor>
" 5-HT2:0.6 nM, SETD7/9:1 ??M"

>  <Bioactivity>
"Cyproheptadine hydrochloride sesquihydrate, an antihistamine, is an antagonist of serotonin and histamine2."

>  <Reference>
"Rashid M, et al. Jpn J Pharmacol. 2002 Aug;89(4):405-12."

>  <ID<1>>
T0174

$$$$
StarDrop ID 112
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 11.2361 0.2681 0.0000 0
M  V30 2 C 10.5216 0.6806 0.0000 0
M  V30 3 O 10.5216 1.5056 0.0000 0
M  V30 4 C 9.8072 0.2681 0.0000 0
M  V30 5 C 9.8072 -0.5569 0.0000 0
M  V30 6 C 9.0927 -0.9694 0.0000 0
M  V30 7 C 8.3782 -0.5569 0.0000 0
M  V30 8 N 7.5936 -0.8118 0.0000 0
M  V30 9 C 7.1087 -0.1444 0.0000 0
M  V30 10 O 7.5936 0.5231 0.0000 0
M  V30 11 C 8.3782 0.2681 0.0000 0
M  V30 12 C 9.0927 0.6806 0.0000 0
M  V30 13 C 6.2837 -0.1444 0.0000 0
M  V30 14 C 5.8712 -0.8588 0.0000 0
M  V30 15 C 5.0462 -0.8588 0.0000 0
M  V30 16 Cl 4.6337 -1.5733 0.0000 0
M  V30 17 C 4.6337 -0.1444 0.0000 0
M  V30 18 C 5.0462 0.5701 0.0000 0
M  V30 19 Cl 4.6337 1.2846 0.0000 0
M  V30 20 C 5.8712 0.5701 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 7 11
M  V30 12 2 11 12
M  V30 13 1 4 12
M  V30 14 1 9 13
M  V30 15 2 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 15 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 2 18 20
M  V30 22 1 13 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
112

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
tafamidis meglumine

>  <Synonyms>
Fx-1006A

>  <CAS>
951395-08-7

>  <Formula>
C21H24Cl2N2O8

>  <MolWt>
503.3

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
 TTR:2.7-3.2 ??M (EC50)

>  <Bioactivity>
Tafamidis meglumine is a Potent and Selective Transthyretin Kinetic Stabilizer That Inhibits the Amyloid Cascade

>  <Reference>
"Bulawa C E , Connelly S , Devit M , et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade[J]. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109(24):p.9629-9634.;Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.[J]. The New England journal of medicine, 2018."

>  <ID<1>>
T7582

$$$$
StarDrop ID 113
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 -0.2025 0.0000 0
M  V30 2 O 3.0716 0.2100 0.0000 0
M  V30 3 C 3.7861 -0.2025 0.0000 0
M  V30 4 C 4.5006 0.2100 0.0000 0
M  V30 5 C 5.2150 -0.2025 0.0000 0
M  V30 6 N 5.9295 0.2100 0.0000 0
M  V30 7 C 6.6440 -0.2025 0.0000 0
M  V30 8 N 6.6440 -1.0275 0.0000 0
M  V30 9 C 5.9295 -1.4400 0.0000 0
M  V30 10 N 5.9295 -2.2650 0.0000 0
M  V30 11 C 5.2150 -1.0275 0.0000 0
M  V30 12 C 4.5006 -1.4400 0.0000 0
M  V30 13 C 3.7861 -1.0275 0.0000 0
M  V30 14 O 3.0716 -1.4400 0.0000 0
M  V30 15 C 2.3571 -1.0275 0.0000 0
M  V30 16 N 7.3584 0.2100 0.0000 0
M  V30 17 C 7.3584 1.0350 0.0000 0
M  V30 18 C 8.0729 1.4475 0.0000 0
M  V30 19 N 8.7874 1.0350 0.0000 0
M  V30 20 C 8.7874 0.2100 0.0000 0
M  V30 21 C 8.0729 -0.2025 0.0000 0
M  V30 22 C 9.5019 1.4475 0.0000 0
M  V30 23 O 9.5019 2.2725 0.0000 0
M  V30 24 C 10.2163 1.0350 0.0000 0
M  V30 25 C 10.9700 1.3705 0.0000 0
M  V30 26 C 11.5220 0.7574 0.0000 0
M  V30 27 C 11.1095 0.0430 0.0000 0
M  V30 28 O 10.3026 0.2145 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 5 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 3 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 7 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 16 21
M  V30 24 1 19 22
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 24 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
113

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Terazosin hydrochloride

>  <Synonyms>
Terazosine;Blavin;Fosfomic;Hytrin;Terazosin HCl;Zayasel

>  <CAS>
63074-08-8

>  <Formula>
C19H26ClN5O4

>  <MolWt>
423.9

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor; ??-adrenergic receptor

>  <Bioactivity>
"Terazosin, a selective alpha1-antagonist, can treat the benign prostatic hyperplasia (BPH). It also can lower blood pressure, so it is a drug of choice for patients with prostate enlargement and hypertension. It works on the smooth muscle of the bladder and the blood vessel walls by blocking the function of adrenaline."

>  <Reference>
"Stone EA, et al. Neuroscience. 1999, 94(4):1245-52.;Pan SL, et al. J Urol. 2003, 169(2):724-9.;Robert Papay, et al. Journal of Neurochemistry. 2002, 83:623-634."

>  <ID<1>>
T0197

$$$$
StarDrop ID 114
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.8503 0.9760 0.0000 0
M  V30 2 C 4.1358 0.5635 0.0000 0
M  V30 3 O 4.1358 -0.2615 0.0000 0
M  V30 4 O 3.4214 0.9760 0.0000 0
M  V30 5 C 2.7069 0.5635 0.0000 0
M  V30 6 C 1.9924 0.9760 0.0000 0
M  V30 7 C 1.2780 0.5635 0.0000 0
M  V30 8 N 0.5635 0.9760 0.0000 0
M  V30 9 C 0.5635 1.8010 0.0000 0 CFG=2
M  V30 10 S 1.2780 2.2135 0.0000 0
M  V30 11 C 1.9924 1.8010 0.0000 0
M  V30 12 C -0.2615 1.8010 0.0000 0 CFG=2
M  V30 13 N -0.8449 2.3843 0.0000 0
M  V30 14 C -0.6314 3.1812 0.0000 0
M  V30 15 O 0.1655 3.3948 0.0000 0
M  V30 16 C -1.2147 3.7646 0.0000 0
M  V30 17 C -1.0012 4.5615 0.0000 0
M  V30 18 C -1.5204 5.2026 0.0000 0
M  V30 19 C -1.0711 5.8945 0.0000 0
M  V30 20 C -0.2742 5.6810 0.0000 0
M  V30 21 S -0.2310 4.8571 0.0000 0
M  V30 22 C -0.2615 0.9760 0.0000 0
M  V30 23 O -0.8449 0.3926 0.0000 0
M  V30 24 C 1.2780 -0.2615 0.0000 0
M  V30 25 O 0.5635 -0.6740 0.0000 0
M  V30 26 O 1.9924 -0.6740 0.0000 0
M  V30 27 H -0.1436 1.0939 0.0000 0
M  V30 28 H -1.1854 1.4183 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 9 8 CFG=1
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 6 11
M  V30 12 1 9 12
M  V30 13 1 12 13 CFG=1
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 1 17 21
M  V30 23 1 12 22
M  V30 24 1 8 22
M  V30 25 2 22 23
M  V30 26 1 7 24
M  V30 27 1 24 25
M  V30 28 2 24 26
M  V30 29 1 27 9
M  V30 30 1 28 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
114

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cephalothin

>  <Synonyms>
Cephalotin acid

>  <CAS>
153-61-7

>  <Formula>
C16H16N2O6S2

>  <MolWt>
396.4

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
 ??-lactamase AmpC:0.32 ??M (Ki)

>  <Bioactivity>
"Cephalotin acid is a beta-lactam antibiotic, inhibits class C ??-lactamase AmpC (Ki: 0.32 ??M)."

>  <Reference>
"Morandi S, et al. Structure-based optimization of cephalothin-analogue boronic acids as beta-lactamase inhibitors. Bioorg Med Chem. 2008 Feb 1;16(3):1195-205. Epub 2007 Nov 7."

>  <ID<1>>
T5570

$$$$
StarDrop ID 115
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.5330 -3.2587 0.0000 0
M  V30 2 C 3.8928 -2.5163 0.0000 0
M  V30 3 C 4.4247 -3.1470 0.0000 0
M  V30 4 C 5.2368 -3.0018 0.0000 0
M  V30 5 O 5.7686 -3.6325 0.0000 0
M  V30 6 C 5.5171 -2.2259 0.0000 0
M  V30 7 C 4.9853 -1.5952 0.0000 0
M  V30 8 C 5.2655 -0.8192 0.0000 0
M  V30 9 C 6.0777 -0.6740 0.0000 0
M  V30 10 C 6.6095 -1.3047 0.0000 0
M  V30 11 C 7.4216 -1.1595 0.0000 0
M  V30 12 C 7.9534 -1.7902 0.0000 0
M  V30 13 O 8.7655 -1.6450 0.0000 0
M  V30 14 C 7.6731 -2.5662 0.0000 0
M  V30 15 C 6.8610 -2.7114 0.0000 0
M  V30 16 C 6.3292 -2.0807 0.0000 0
M  V30 17 C 6.0489 -2.8566 0.0000 0
M  V30 18 C 4.1731 -1.7404 0.0000 0
M  V30 19 C 3.5218 -1.2340 0.0000 0
M  V30 20 C 2.8390 -1.6970 0.0000 0
M  V30 21 C 3.0683 -2.4895 0.0000 0
M  V30 22 O 2.3074 -2.8084 0.0000 0
M  V30 23 C 2.9469 -3.3055 0.0000 0
M  V30 24 O 2.1795 -3.6084 0.0000 0
M  V30 25 C 3.5929 -3.8187 0.0000 0
M  V30 26 O 3.4715 -4.6347 0.0000 0
M  V30 27 P 4.1174 -5.1478 0.0000 0
M  V30 28 O 4.7634 -5.6610 0.0000 0
M  V30 29 O 4.6306 -4.5018 0.0000 0
M  V30 30 O 3.6043 -5.7938 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 6 16
M  V30 17 1 10 16
M  V30 18 1 16 17
M  V30 19 1 7 18
M  V30 20 1 2 18
M  V30 21 1 18 19
M  V30 22 1 19 20
M  V30 23 1 20 21
M  V30 24 1 2 21
M  V30 25 1 21 22
M  V30 26 1 21 23
M  V30 27 2 23 24
M  V30 28 1 23 25
M  V30 29 1 25 26
M  V30 30 1 26 27
M  V30 31 1 27 28
M  V30 32 1 27 29
M  V30 33 2 27 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
115

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Prednisolone disodium phosphate

>  <Synonyms>
Prednisolone phosphate sodium;Prednisolone 21-phosphate disodium

>  <CAS>
125-02-0

>  <Formula>
C21H27Na2O8P

>  <MolWt>
484.4

>  <Pathways>
Endocrinology/Hormones

>  <Target>
Glucocorticoid Receptor

>  <Receptor>
Glucocorticoid Receptor

>  <Bioactivity>
"Prednisolone disodium phosphate, a synthetic glucocorticoid, has immunomodulating and anti-inflammatory properties."

>  <Reference>
"Ikonomidis I, et al. Heart. 2009 Sep;95(18):1502-7."

>  <ID<1>>
T0208

$$$$
StarDrop ID 116
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7145 -0.4125 0.0000 0
M  V30 2 C 0.7145 -1.2375 0.0000 0
M  V30 3 C 1.4289 -1.6500 0.0000 0
M  V30 4 C 1.4289 -2.4750 0.0000 0
M  V30 5 C 0.7145 -2.8875 0.0000 0
M  V30 6 N 0.0000 -2.4750 0.0000 0
M  V30 7 C 0.0000 -1.6500 0.0000 0
M  V30 8 C 0.7145 -3.7125 0.0000 0
M  V30 9 C 1.4289 -4.1250 0.0000 0
M  V30 10 C 1.4289 -4.9500 0.0000 0
M  V30 11 C 0.7145 -5.3625 0.0000 0
M  V30 12 C 0.7145 -6.1875 0.0000 0
M  V30 13 C -0.0000 -4.9500 0.0000 0
M  V30 14 N 0.0000 -4.1250 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 13 14
M  V30 15 1 8 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
116

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Abametapir

>  <Synonyms>
HA-44;BRN 0123183

>  <CAS>
1762-34-1

>  <Formula>
C12H12N2

>  <MolWt>
184.2

>  <Pathways>
Microbiology/Virology;Others;Proteases/Proteasome

>  <Target>
Others;MMP;Parasite

>  <Receptor>
metalloproteinase; MMP; Parasite

>  <Bioactivity>
"Abametapir, a metalloproteinase inhibitor, is able to target metalloproteinases critical to egg hatching and louse development."

>  <Reference>
"Bowles VM, Hanegraaf S, Ahveninen T.et al.Effect of a New Head Lice Treatment, Abametapir Lotion, 0.74%, on Louse Eggs: A Randomized, Double-Blind Study.Glob Pediatr Health. 2019 Feb 22.;Bowles, Vernon, M, et al. Clinical studies evaluating abametapir lotion, 0.74%, for the treatment of head louse infestation[J]. Pediatric dermatology, 2018."

>  <ID<1>>
T7459

$$$$
StarDrop ID 117
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.4652 -0.8227 0.0000 0
M  V30 2 N 0.9803 -0.1553 0.0000 0
M  V30 3 C 0.1553 -0.1553 0.0000 0
M  V30 4 O -0.3297 -0.8227 0.0000 0
M  V30 5 O -0.0997 0.6294 0.0000 0
M  V30 6 C 0.5678 1.1143 0.0000 0
M  V30 7 C 0.0157 1.7274 0.0000 0
M  V30 8 C 1.1198 1.7274 0.0000 0
M  V30 9 C 1.2352 0.6294 0.0000 0
M  V30 10 O 2.0198 0.8843 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 6 9
M  V30 9 1 2 9
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
117

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Trimethadione

>  <Synonyms>
3,5,5,-Trimethyloxazolidine-2,4-dione

>  <CAS>
127-48-0

>  <Formula>
C6H9NO3

>  <MolWt>
143.1

>  <Pathways>
Metabolism;Membrane transporter/Ion channel

>  <Target>
Calcium Channel

>  <Receptor>
Calcium Channel

>  <Bioactivity>
Trimethadione is a dione-type anticonvulsant with antiepileptic activity.

>  <Reference>
"Shen H, et al. Hear Res. 2007 Apr;226(1-2):52-60."

>  <ID<1>>
T0283

$$$$
StarDrop ID 118
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.3376 -1.1894 0.0000 0
M  V30 2 C 1.5623 -0.9073 0.0000 0
M  V30 3 N 1.4191 -0.0948 0.0000 0
M  V30 4 C 2.0510 0.4355 0.0000 0
M  V30 5 C 1.9078 1.2480 0.0000 0
M  V30 6 C 0.6438 0.1874 0.0000 0
M  V30 7 O 0.5006 0.9998 0.0000 0
M  V30 8 C 0.0118 -0.3429 0.0000 0 CFG=1
M  V30 9 C -0.6202 0.1874 0.0000 0
M  V30 10 C -1.3954 -0.0948 0.0000 0
M  V30 11 C -2.0274 0.4355 0.0000 0
M  V30 12 C -1.8841 1.2480 0.0000 0
M  V30 13 C -1.1089 1.5301 0.0000 0
M  V30 14 C -0.4769 0.9998 0.0000 0
M  V30 15 C 0.4243 -1.0574 0.0000 0
M  V30 16 C -0.4007 -1.0574 0.0000 0 CFG=1
M  V30 17 C -1.1151 -1.4699 0.0000 0
M  V30 18 N -1.8296 -1.0574 0.0000 0
M  V30 19 H -0.1417 -2.0233 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 2 6 7
M  V30 7 1 8 6 CFG=1
M  V30 8 1 8 9 CFG=3
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 9 14
M  V30 15 1 8 15
M  V30 16 1 16 15
M  V30 17 1 8 16
M  V30 18 1 16 17 CFG=1
M  V30 19 1 17 18
M  V30 20 1 19 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
118

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Milnacipran ((1S-cis) hydrochloride)

>  <Synonyms>
Levomilnacipran Hydrochloride

>  <CAS>
175131-60-9

>  <Formula>
C15H23ClN2O

>  <MolWt>
282.8

>  <Pathways>
Neuroscience

>  <Target>
Serotonin Transporter

>  <Receptor>
serotonin; Serotonin Transporter

>  <Bioactivity>
"Milnacipran ((1S-cis) hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI),  treatment of fibromyalgia."

>  <Reference>
"Keks N A , Judy H , Simone K , et al. Milnacipran: serotonin-noradrenaline reuptake inhibitor approved for fibromyalgia may be a useful antidepressant[J]. Australasian Psychiatry, 2018:103985621879487-."

>  <ID<1>>
T7940

$$$$
StarDrop ID 119
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.1270 -3.6020 0.0000 0
M  V30 2 C 1.8414 -3.1895 0.0000 0
M  V30 3 C 2.5559 -3.6020 0.0000 0
M  V30 4 O 2.5559 -4.4270 0.0000 0
M  V30 5 N 3.2704 -3.1895 0.0000 0
M  V30 6 C 3.9849 -3.6020 0.0000 0
M  V30 7 C 4.6993 -3.1895 0.0000 0 CFG=2
M  V30 8 C 5.1118 -2.4750 0.0000 0
M  V30 9 C 5.5243 -3.1895 0.0000 0 CFG=1
M  V30 10 C 6.2388 -3.6020 0.0000 0
M  V30 11 C 6.9533 -3.1895 0.0000 0
M  V30 12 C 7.6677 -3.6020 0.0000 0
M  V30 13 C 7.6677 -4.4270 0.0000 0
M  V30 14 C 6.9533 -4.8395 0.0000 0
M  V30 15 O 6.7817 -5.6464 0.0000 0
M  V30 16 C 5.9613 -5.7327 0.0000 0
M  V30 17 C 5.6257 -4.9790 0.0000 0
M  V30 18 C 6.2388 -4.4270 0.0000 0
M  V30 19 H 4.9583 -4.1554 0.0000 0
M  V30 20 H 5.2655 -4.1554 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=3
M  V30 7 1 7 8
M  V30 8 1 9 8
M  V30 9 1 7 9
M  V30 10 1 9 10 CFG=1
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 10 18
M  V30 20 2 14 18
M  V30 21 1 19 7
M  V30 22 1 20 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
119

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tasimelteon

>  <Synonyms>
VEC-162;BMS-214778

>  <CAS>
609799-22-6

>  <Formula>
C15H19NO2

>  <MolWt>
245.3

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Melatonin Receptor;MT Receptor

>  <Receptor>
" MT1 receptor:9.45(pKi), MT2 receptor:9.8(pKi)"

>  <Bioactivity>
Tasimelteon is a melatonin receptor agonist that is used for the treatment of non-24 hour sleep-wake disorder in blind individuals.

>  <Reference>
"Keating GM, et al. Tasimelteon: A Review in Non-24-Hour Sleep-Wake Disorder in Totally Blind Individuals. CNS Drugs. 2016 Mar 22.;Leger D, et al. Safety profile of tasimelteon, a melatonin MT1 and MT2 receptor agonist: pooled safety analyses from six clinical studies. Expert Opin Drug Saf. 2015;14(11):1673-85."

>  <ID<1>>
T3495

$$$$
StarDrop ID 120
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -6.1702 -1.8853 0.0000 0
M  V30 2 C -5.4557 -2.2978 0.0000 0
M  V30 3 O -4.7413 -1.8853 0.0000 0
M  V30 4 C -5.4557 -3.1228 0.0000 0
M  V30 5 C -6.1702 -3.5353 0.0000 0
M  V30 6 C -4.7413 -3.5353 0.0000 0
M  V30 7 O -3.9163 -3.5353 0.0000 0
M  V30 8 C -4.3288 -4.2497 0.0000 0
M  V30 9 C -4.3288 -5.0747 0.0000 0
M  V30 10 C -3.6143 -5.4872 0.0000 0
M  V30 11 C -2.8998 -5.0747 0.0000 0
M  V30 12 O -2.1854 -5.4872 0.0000 0
M  V30 13 C -2.1854 -6.3122 0.0000 0
M  V30 14 C -1.4709 -6.7247 0.0000 0
M  V30 15 C -0.7564 -6.3122 0.0000 0
M  V30 16 C -0.7564 -5.4872 0.0000 0
M  V30 17 C -0.0419 -6.7247 0.0000 0
M  V30 18 C 0.6725 -6.3122 0.0000 0
M  V30 19 O 0.6725 -5.4872 0.0000 0
M  V30 20 O 1.3870 -6.7247 0.0000 0
M  V30 21 C 2.1015 -6.3122 0.0000 0
M  V30 22 C 2.8159 -6.7247 0.0000 0
M  V30 23 C 3.5304 -6.3122 0.0000 0
M  V30 24 C 4.2449 -6.7247 0.0000 0
M  V30 25 C 4.9594 -6.3122 0.0000 0
M  V30 26 C 5.6738 -6.7247 0.0000 0
M  V30 27 C 6.3883 -6.3122 0.0000 0
M  V30 28 C 7.1028 -6.7247 0.0000 0
M  V30 29 C 7.8172 -6.3122 0.0000 0
M  V30 30 O 8.5317 -6.7247 0.0000 0
M  V30 31 O 7.8172 -5.4872 0.0000 0
M  V30 32 C -2.8998 -6.7247 0.0000 0
M  V30 33 O -2.8998 -7.5497 0.0000 0
M  V30 34 C -3.6143 -6.3122 0.0000 0
M  V30 35 O -4.3288 -6.7247 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 15 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 1 29 30
M  V30 31 2 29 31
M  V30 32 1 13 32
M  V30 33 1 32 33
M  V30 34 1 32 34
M  V30 35 1 10 34
M  V30 36 1 34 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
120

>  <Plate>
PHD136328

>  <Row>
f

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Mupirocin calcium hydrate

>  <Synonyms>
Mupirocin calcium

>  <CAS>
115074-43-6

>  <Formula>
C52H90CaO20

>  <MolWt>
1075

>  <Pathways>
Others;Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial;Others

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
"Mupirocin calcium is an antibiotic produced by Pseudomonas fluorescens, showed a high level of activity against staphylococci and streptococci and against certain gram-negative bacteria"

>  <Reference>
"Parenti M A , Hatfield S M , Leyden J J . Mupirocin: A topical antibiotic with a unique structure and mechanism of action[J]. Clinical pharmacy, 1987, 6(10):761-770.;Sutherland R, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985 Apr;27(4):495-8."

>  <ID<1>>
T8148

$$$$
StarDrop ID 121
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -9.8876 4.0982 0.0000 0
M  V30 2 C -9.0806 3.9267 0.0000 0
M  V30 3 N -8.5286 4.5397 0.0000 0
M  V30 4 C -7.7216 4.3682 0.0000 0
M  V30 5 O -7.1696 4.9813 0.0000 0
M  V30 6 C -7.4667 3.5836 0.0000 0
M  V30 7 C -8.0187 2.9705 0.0000 0
M  V30 8 N -7.6062 2.2560 0.0000 0
M  V30 9 C -6.7993 2.4276 0.0000 0
M  V30 10 C -6.7130 3.2480 0.0000 0
M  V30 11 C -5.9986 3.6605 0.0000 0
M  V30 12 C -5.9986 4.4855 0.0000 0
M  V30 13 C -5.2841 4.8980 0.0000 0
M  V30 14 C -5.2841 5.7230 0.0000 0
M  V30 15 C -4.5696 6.1355 0.0000 0
M  V30 16 C -3.8551 5.7230 0.0000 0
M  V30 17 C -3.8551 4.8980 0.0000 0
M  V30 18 C -4.5696 4.4855 0.0000 0
M  V30 19 C -3.1407 6.1355 0.0000 0
M  V30 20 O -3.1407 6.9605 0.0000 0
M  V30 21 N -2.4262 5.7230 0.0000 0
M  V30 22 C -1.7117 6.1355 0.0000 0 CFG=1
M  V30 23 C -0.9973 5.7230 0.0000 0
M  V30 24 C -0.2828 6.1355 0.0000 0
M  V30 25 C 0.4317 5.7230 0.0000 0
M  V30 26 O 1.1462 6.1355 0.0000 0
M  V30 27 O 0.4317 4.8980 0.0000 0
M  V30 28 C -1.7117 6.9605 0.0000 0
M  V30 29 O -0.9973 7.3730 0.0000 0
M  V30 30 O -2.4262 7.3730 0.0000 0
M  V30 31 N -8.8257 3.1420 0.0000 0
M  V30 32 H -1.7118 5.1355 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 6 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 13 18
M  V30 20 1 16 19
M  V30 21 2 19 20
M  V30 22 1 19 21
M  V30 23 1 22 21 CFG=3
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 22 28
M  V30 30 2 28 29
M  V30 31 1 28 30
M  V30 32 2 7 31
M  V30 33 1 2 31
M  V30 34 1 32 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
121

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pemetrexed

>  <Synonyms>
LY231514;Pemetrexed acid;LY-231514 Disodium Hydrate

>  <CAS>
137281-23-3

>  <Formula>
C20H21N5O6

>  <MolWt>
427.4

>  <Pathways>
Autophagy;Cell Cycle/Checkpoint;Metabolism;DNA Damage/DNA Repair

>  <Target>
DHFR;DNA/RNA Synthesis;Antifolate;Autophagy

>  <Receptor>
" glycinamide ribonucleotide formyltransferase (GARFT),:65 nM(ki), dihydrofolate reductase (DHFR):7.2 nM(ki), thymidylate synthase (TS):1.3 nM(ki)"

>  <Bioactivity>
"Pemetrexed, a guanine-derived antineoplastic agent, binds to and inhibits the enzyme thymidylate synthase (TS)."

>  <Reference>
"Shih C, et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 1997 Mar 15;57(6):1116-23.;Anraku M, et al. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignantmesothelioma. J Immunol. 2010 Jul 15;185(2):956-66."

>  <ID<1>>
T0189

$$$$
StarDrop ID 122
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.7519 1.4850 0.0000 0
M  V30 2 C 3.7519 0.6600 0.0000 0
M  V30 3 N 4.4663 0.2475 0.0000 0
M  V30 4 C 4.4663 -0.5775 0.0000 0
M  V30 5 N 3.7519 -0.9900 0.0000 0
M  V30 6 C 3.0374 -0.5775 0.0000 0
M  V30 7 N 2.2528 -0.8324 0.0000 0
M  V30 8 N 1.7679 -0.1650 0.0000 0
M  V30 9 C 2.2528 0.5024 0.0000 0
M  V30 10 C 3.0374 0.2475 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 2 10
M  V30 11 1 6 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
122

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Allopurinol Sodium

>  <Synonyms>
Allopurinol sodium salt;Sodium allopurinol

>  <CAS>
17795-21-0

>  <Formula>
C5H4N4NaO

>  <MolWt>
159.1

>  <Pathways>
Immunology/Inflammation

>  <Target>
ROS

>  <Receptor>
 xanthine oxidase:7.82??0.12 ??M.

>  <Bioactivity>
Allopurinol Sodium is a xanthine oxidase inhibitor with an IC50 of 7.82??0.12 ??M.

>  <Reference>
"Mitsuboshi S, et al. J Pharm Health Care Sci. 2015 Oct 6;1:28."

>  <ID<1>>
T6376

$$$$
StarDrop ID 123
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.9179 1.9161 0.0000 0
M  V30 2 C 3.6324 1.5036 0.0000 0
M  V30 3 C 3.6324 0.6786 0.0000 0 CFG=1
M  V30 4 C 4.2999 0.1937 0.0000 0 CFG=1
M  V30 5 C 5.0845 0.4486 0.0000 0
M  V30 6 C 5.6976 -0.1034 0.0000 0
M  V30 7 C 6.5045 0.0681 0.0000 0
M  V30 8 N 6.9170 -0.6463 0.0000 0
M  V30 9 C 6.3650 -1.2594 0.0000 0
M  V30 10 N 5.6113 -0.9239 0.0000 0
M  V30 11 C 4.8969 -1.3364 0.0000 0
M  V30 12 C 4.0449 -0.5909 0.0000 0
M  V30 13 O 3.2199 -0.5909 0.0000 0
M  V30 14 C 2.9650 0.1937 0.0000 0
M  V30 15 O 2.1804 0.4486 0.0000 0
M  V30 16 H 2.7414 1.1326 0.0000 0
M  V30 17 H 5.0069 -0.5135 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 4 5 CFG=1
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 6 10
M  V30 11 1 10 11
M  V30 12 1 4 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 3 14
M  V30 16 2 14 15
M  V30 17 1 16 3
M  V30 18 1 17 4
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
123

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pilocarpine nitrate

>  <Synonyms>
Pilofrin;Pilagan

>  <CAS>
148-72-1

>  <Formula>
C11H17N3O5

>  <MolWt>
271.3

>  <Pathways>
Neuroscience

>  <Target>
AChR

>  <Receptor>
mAChR

>  <Bioactivity>
Pilocarpine nitrate is a slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.

>  <Reference>
"Sykes DA, et al. Mol Pharmacol. 2009 Sep;76(3):543-51.;Xingqi Wang, Yong Zhang, Jie Huang, Mengqiu Xia, Liu Liu, Chunling Tian, Rongfeng Hu, Shuangying Gui, and Xiaoqin Chu. Self-assembled hexagonal liquid crystalline gels as novel ocular formulation with enhanced topical delivery of pilocarpine nitrate [J]. International Journal of Pharmaceutics. 2019 May 1;562:31-41.;Wang, Xingqi, et al. A Novel Phytantriol-Based Lyotropic Liquid Crystalline Gel for Efficient Ophthalmic Delivery of Pilocarpine Nitrate [J]. AAPS PharmSciTech. 2019 Jan 2;20(1):32."

>  <ID<1>>
T1231

$$$$
StarDrop ID 124
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 -2.4750 0.0000 0
M  V30 2 C 0.0000 -1.6500 0.0000 0
M  V30 3 O -0.7145 -1.2375 0.0000 0
M  V30 4 C 0.7145 -1.2375 0.0000 0
M  V30 5 C 0.7145 -0.4125 0.0000 0
M  V30 6 N 1.4289 0.0000 0.0000 0
M  V30 7 C 2.1434 -0.4125 0.0000 0
M  V30 8 C 2.8579 0.0000 0.0000 0
M  V30 9 C 3.5724 -0.4125 0.0000 0
M  V30 10 C 3.5724 -1.2375 0.0000 0
M  V30 11 F 4.2868 -1.6500 0.0000 0
M  V30 12 C 2.8579 -1.6500 0.0000 0
M  V30 13 C 2.1434 -1.2375 0.0000 0
M  V30 14 C 1.4289 -1.6500 0.0000 0
M  V30 15 O 1.4289 -2.4750 0.0000 0
M  V30 16 N 4.2868 -0.0000 0.0000 0
M  V30 17 C 4.2868 0.8250 0.0000 0
M  V30 18 C 5.0013 1.2375 0.0000 0
M  V30 19 N 5.7158 0.8250 0.0000 0
M  V30 20 C 5.7158 -0.0000 0.0000 0
M  V30 21 C 5.0013 -0.4125 0.0000 0
M  V30 22 C 1.4289 0.8250 0.0000 0
M  V30 23 C 2.1434 1.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 7 13
M  V30 14 1 13 14
M  V30 15 1 4 14
M  V30 16 2 14 15
M  V30 17 1 9 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 16 21
M  V30 24 1 6 22
M  V30 25 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
124

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Norfloxacin

>  <Synonyms>
MK-0366

>  <CAS>
70458-96-7

>  <Formula>
C16H18FN3O3

>  <MolWt>
319.3

>  <Pathways>
Metabolism;DNA Damage/DNA Repair;Microbiology/Virology

>  <Target>
Antibiotic;DNA gyrase;Topoisomerase;Endogenous Metabolite;Antibacterial

>  <Receptor>
Antibiotic; Bacterial; DNA gyrase; Endogenous Metabolite; Topo II

>  <Bioactivity>
Norfloxacin(Norxacin) is a broad-spectrum antibiotic that is active against both Gram-positive and Gram-negative bacteria.

>  <Reference>
"Khan K Y, Ali B, Zhang S, et al. Effects of antibiotics stress on growth variables, ultrastructure, and metabolite pattern of Brassica rapa ssp. Chinensis[J]. Science of The Total Environment. 2021: 146333.;Preissner S, et al. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43."

>  <ID<1>>
T1306

$$$$
StarDrop ID 125
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 61 64 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.2933 1.7735 0.0000 0 CFG=2
M  V30 2 O -0.4212 1.3610 0.0000 0
M  V30 3 C -0.4212 0.5360 0.0000 0 CFG=2
M  V30 4 O 0.2463 0.0511 0.0000 0
M  V30 5 C -0.0087 -0.7335 0.0000 0 CFG=2
M  V30 6 C 0.4763 -1.4010 0.0000 0
M  V30 7 O 0.1407 -2.1546 0.0000 0
M  V30 8 C -0.8337 -0.7335 0.0000 0 CFG=1
M  V30 9 O -1.3186 -1.4010 0.0000 0
M  V30 10 C -2.1391 -1.3147 0.0000 0 CFG=1
M  V30 11 O -2.4746 -0.5610 0.0000 0
M  V30 12 C -3.2951 -0.4748 0.0000 0 CFG=1
M  V30 13 C -3.6307 0.2789 0.0000 0
M  V30 14 N -3.1457 0.9463 0.0000 0
M  V30 15 C -3.7800 -1.1422 0.0000 0 CFG=2
M  V30 16 C -3.4445 -1.8959 0.0000 0 CFG=1
M  V30 17 C -2.6240 -1.9822 0.0000 0 CFG=1
M  V30 18 N -2.2884 -2.7358 0.0000 0
M  V30 19 O -3.9294 -2.5634 0.0000 0
M  V30 20 O -4.6005 -1.0560 0.0000 0
M  V30 21 C -1.0886 0.0511 0.0000 0 CFG=1
M  V30 22 O -1.8732 0.3060 0.0000 0
M  V30 23 C 0.2933 2.5985 0.0000 0 CFG=2
M  V30 24 C 1.0078 3.0110 0.0000 0 CFG=2
M  V30 25 N 1.0078 3.8360 0.0000 0
M  V30 26 C 1.7222 2.5985 0.0000 0
M  V30 27 C 1.7222 1.7735 0.0000 0 CFG=1
M  V30 28 C 1.0078 1.3610 0.0000 0 CFG=1
M  V30 29 O 1.0078 0.5360 0.0000 0
M  V30 30 C 1.7222 0.1235 0.0000 0 CFG=1
M  V30 31 O 2.4367 0.5360 0.0000 0
M  V30 32 C 3.1512 0.1235 0.0000 0 CFG=1
M  V30 33 C 3.1512 -0.7015 0.0000 0 CFG=1
M  V30 34 O 3.8657 -1.1140 0.0000 0
M  V30 35 C 2.4367 -1.1140 0.0000 0 CFG=1
M  V30 36 C 1.7222 -0.7015 0.0000 0 CFG=1
M  V30 37 N 1.0078 -1.1140 0.0000 0
M  V30 38 O 2.4367 -1.9390 0.0000 0
M  V30 39 C 3.8657 0.5360 0.0000 0
M  V30 40 N 4.5801 0.1235 0.0000 0
M  V30 41 N 2.4367 1.3610 0.0000 0
M  V30 42 O -0.4212 3.0110 0.0000 0
M  V30 43 H -0.5727 2.2735 0.0000 0
M  V30 44 H -1.3122 0.9900 0.0000 0
M  V30 45 H 0.9790 -0.5772 0.0000 0
M  V30 46 H -0.3797 -1.6245 0.0000 0
M  V30 47 H -1.7324 -2.2283 0.0000 0
M  V30 48 H -4.2896 -0.3702 0.0000 0
M  V30 49 H -4.3678 -1.9512 0.0000 0
M  V30 50 H -3.0378 -2.8095 0.0000 0
M  V30 51 H -1.6295 -2.0866 0.0000 0
M  V30 52 H -1.7957 -0.6560 0.0000 0
M  V30 53 H -0.5727 2.0985 0.0000 0
M  V30 54 H 1.8738 3.5110 0.0000 0
M  V30 55 H 1.7223 0.7735 0.0000 0
M  V30 56 H 1.8738 0.8610 0.0000 0
M  V30 57 H 1.7223 1.1235 0.0000 0
M  V30 58 H 4.0172 -0.3765 0.0000 0
M  V30 59 H 4.0172 -0.2015 0.0000 0
M  V30 60 H 1.5707 -1.6140 0.0000 0
M  V30 61 H 1.7223 -1.7015 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2 CFG=3
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 1 8 5
M  V30 8 1 8 9 CFG=1
M  V30 9 1 10 9 CFG=3
M  V30 10 1 10 11
M  V30 11 1 12 11
M  V30 12 1 12 13 CFG=3
M  V30 13 1 13 14
M  V30 14 1 15 12
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 10
M  V30 18 1 17 18 CFG=3
M  V30 19 1 16 19 CFG=1
M  V30 20 1 15 20 CFG=3
M  V30 21 1 8 21
M  V30 22 1 21 3
M  V30 23 1 21 22 CFG=1
M  V30 24 1 1 23
M  V30 25 1 23 24
M  V30 26 1 24 25 CFG=3
M  V30 27 1 24 26
M  V30 28 1 27 26
M  V30 29 1 28 27
M  V30 30 1 1 28
M  V30 31 1 28 29 CFG=1
M  V30 32 1 30 29 CFG=1
M  V30 33 1 30 31
M  V30 34 1 32 31
M  V30 35 1 33 32
M  V30 36 1 33 34 CFG=1
M  V30 37 1 33 35
M  V30 38 1 35 36
M  V30 39 1 36 30
M  V30 40 1 36 37 CFG=1
M  V30 41 1 35 38 CFG=3
M  V30 42 1 32 39 CFG=3
M  V30 43 1 39 40
M  V30 44 1 27 41 CFG=3
M  V30 45 1 23 42 CFG=1
M  V30 46 1 43 1
M  V30 47 1 44 3
M  V30 48 1 45 5
M  V30 49 1 46 8
M  V30 50 1 47 10
M  V30 51 1 48 12
M  V30 52 1 49 15
M  V30 53 1 50 16
M  V30 54 1 51 17
M  V30 55 1 52 21
M  V30 56 1 53 23
M  V30 57 1 54 24
M  V30 58 1 55 27
M  V30 59 1 56 28
M  V30 60 1 57 30
M  V30 61 1 58 32
M  V30 62 1 59 33
M  V30 63 1 60 35
M  V30 64 1 61 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
125

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Framycetin sulfate

>  <Synonyms>
Framycetin sulphate;Neomycin Sulphate B

>  <CAS>
4146-30-9

>  <Formula>
C23H48N6O17S

>  <MolWt>
712.2

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
" hammerhead ribozyme:13.5 ??M (Ki), RNase P cleavage activity:35 ??M (Ki)"

>  <Bioactivity>
Neomycin Sulphate B belongs to aminoglycoside class of antibiotics that contain two or more aminosugars connected by glycosidic bonds.

>  <Reference>
"Li J, Fan Y Y, Wang M, et al. A Light-Up Strategy with Aggregation-Induced Emission for Identification of HIV-?? RNA-Binding Small Molecules[J]. Analytical Chemistry. 2020;Quader, S., Boyd, S., Jenkins, I., & Houston, T. (2007). Multisite Modification of Neomycin B:? Combined Mitsunobu and Click Chemistry Approach.?The Journal Of Organic Chemistry,?72(6), 1962-1979. doi: 10.1021/jo0620967"

>  <ID<1>>
T2096

$$$$
StarDrop ID 126
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6052 -0.6036 0.0000 0
M  V30 2 C 3.4121 -0.4320 0.0000 0
M  V30 3 C 3.6671 0.3526 0.0000 0
M  V30 4 C 3.1821 1.0200 0.0000 0
M  V30 5 C 2.3571 1.0200 0.0000 0
M  V30 6 N 3.6671 1.6875 0.0000 0
M  V30 7 C 4.4517 1.4325 0.0000 0
M  V30 8 C 5.1662 1.8450 0.0000 0
M  V30 9 C 5.8806 1.4325 0.0000 0
M  V30 10 C 5.8806 0.6075 0.0000 0
M  V30 11 C 6.5951 0.1950 0.0000 0
M  V30 12 N 6.5951 -0.6300 0.0000 0
M  V30 13 C 7.3096 -1.0425 0.0000 0
M  V30 14 C 7.3096 -1.8675 0.0000 0
M  V30 15 O 6.5951 -2.2800 0.0000 0
M  V30 16 C 5.8806 -1.8675 0.0000 0
M  V30 17 C 5.8806 -1.0425 0.0000 0
M  V30 18 C 5.1662 0.1950 0.0000 0
M  V30 19 O 5.1662 -0.6300 0.0000 0
M  V30 20 C 4.4517 0.6075 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 12 17
M  V30 18 1 10 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 2 3 20
M  V30 22 1 7 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
126

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Molindone hydrochloride

>  <Synonyms>
EN-1733A

>  <CAS>
15622-65-8

>  <Formula>
C16H25ClN2O2

>  <MolWt>
312.8

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
5-HT Receptor;AChR;Dopamine Receptor

>  <Receptor>
5-HT; Dopamine; mAChR

>  <Bioactivity>
Molindone hydrochloride is an indole derivative effective in schizophrenia and other psychoses by blocking the effects of dopamine in the brain.

>  <Reference>
"Nguyen TV, Juorio AV. Naunyn Schmiedebergs Arch Pharmacol. 1989 Oct;340(4):366-71."

>  <ID<1>>
T0716

$$$$
StarDrop ID 127
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.4289 -2.4750 0.0000 0
M  V30 2 C 1.4289 -1.6500 0.0000 0
M  V30 3 N 0.7145 -1.2375 0.0000 0
M  V30 4 C 0.0000 -1.6500 0.0000 0
M  V30 5 C -0.7145 -1.2375 0.0000 0
M  V30 6 O 0.0000 -2.4750 0.0000 0
M  V30 7 C 0.7145 -0.4125 0.0000 0
M  V30 8 O 0.0000 0.0000 0.0000 0
M  V30 9 C 1.4289 0.0000 0.0000 0
M  V30 10 C 1.4289 0.8250 0.0000 0
M  V30 11 C 0.7615 1.3099 0.0000 0
M  V30 12 C 1.0164 2.0945 0.0000 0
M  V30 13 C 1.8414 2.0945 0.0000 0
M  V30 14 C 2.0964 1.3099 0.0000 0
M  V30 15 C 2.1434 -0.4125 0.0000 0
M  V30 16 N 2.8579 0.0000 0.0000 0
M  V30 17 C 3.5724 -0.4125 0.0000 0
M  V30 18 N 4.2868 -0.0000 0.0000 0
M  V30 19 C 5.0013 -0.4125 0.0000 0
M  V30 20 C 5.7158 -0.0000 0.0000 0
M  V30 21 C 6.4302 -0.4125 0.0000 0
M  V30 22 C 6.4302 -1.2375 0.0000 0
M  V30 23 C 5.7158 -1.6500 0.0000 0
M  V30 24 N 5.0013 -1.2375 0.0000 0
M  V30 25 N 7.1447 -1.6500 0.0000 0
M  V30 26 C 7.8592 -1.2375 0.0000 0
M  V30 27 C 8.5737 -1.6500 0.0000 0
M  V30 28 N 8.5737 -2.4750 0.0000 0
M  V30 29 C 7.8592 -2.8875 0.0000 0
M  V30 30 C 7.1447 -2.4750 0.0000 0
M  V30 31 C 3.5724 -1.2375 0.0000 0
M  V30 32 C 2.8579 -1.6500 0.0000 0
M  V30 33 C 2.1434 -1.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 3 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 10 14
M  V30 15 1 9 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 19 24
M  V30 26 1 22 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 25 30
M  V30 33 2 17 31
M  V30 34 1 31 32
M  V30 35 2 32 33
M  V30 36 1 2 33
M  V30 37 1 15 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
127

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Palbociclib

>  <Synonyms>
PD 0332991

>  <CAS>
571190-30-2

>  <Formula>
C25H32N6O2

>  <MolWt>
448.6

>  <Pathways>
Cell Cycle/Checkpoint

>  <Target>
CDK

>  <Receptor>
" CDK6:16 nM, CDK4:11 nM"

>  <Bioactivity>
"Palbociclib is an orally available cyclin-dependent kinase (CDK) inhibitor with potential antineoplastic activity. Palbociclib selectively inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), thereby inhibiting retinoblastoma (Rb) protein phosphorylation early in the G1 phase leading to cell cycle arrest. This suppresses DNA replication and decreases tumor cell proliferation."

>  <Reference>
"Katsumi Y, et al. Sensitivity of malignant rhabdoid tumor cell lines to PD 03321991 is inversely correlated with p16 expression. Biochem Biophys Res Commun, 2011, 413(1), 62-68.;Fry DW, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3(11):1427-38.;Qin Z, Hu H, Sun W, et al. miR-224-5p Contained in Urinary Extracellular Vesicles Regulates PD-L1 Expression by Inhibiting Cyclin D1 in Renal Cell Carcinoma Cells. Cancers . 2021, 13, 618[J]. 2021."

>  <ID<1>>
T1785

$$$$
StarDrop ID 128
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.8579 -1.6500 0.0000 0
M  V30 2 C 3.5724 -2.0625 0.0000 0
M  V30 3 O 4.2868 -1.6500 0.0000 0
M  V30 4 C 3.5724 -2.8875 0.0000 0
M  V30 5 C 4.2868 -3.3000 0.0000 0
M  V30 6 C 4.2868 -4.1250 0.0000 0
M  V30 7 C 3.5724 -4.5375 0.0000 0
M  V30 8 C 2.8579 -4.1250 0.0000 0
M  V30 9 C 2.8579 -3.3000 0.0000 0
M  V30 10 S 3.5724 -5.3625 0.0000 0
M  V30 11 O 2.7474 -5.3625 0.0000 0
M  V30 12 O 4.3974 -5.3625 0.0000 0
M  V30 13 N 3.5724 -6.1875 0.0000 0
M  V30 14 C 2.8579 -6.6000 0.0000 0
M  V30 15 O 2.1434 -6.1875 0.0000 0
M  V30 16 N 2.8579 -7.4250 0.0000 0
M  V30 17 C 2.1434 -7.8375 0.0000 0
M  V30 18 C 2.1434 -8.6625 0.0000 0
M  V30 19 C 1.4289 -9.0750 0.0000 0
M  V30 20 C 0.7145 -8.6625 0.0000 0
M  V30 21 C 0.7145 -7.8375 0.0000 0
M  V30 22 C 1.4289 -7.4250 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 4 9
M  V30 10 1 7 10
M  V30 11 2 10 11
M  V30 12 2 10 12
M  V30 13 1 10 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
128

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Acetohexamide

>  <Synonyms>
Dymelor;Acetohexamid;Gamadiabet

>  <CAS>
968-81-0

>  <Formula>
C15H20N2O4S

>  <MolWt>
324.4

>  <Pathways>
Metabolism;Membrane transporter/Ion channel

>  <Target>
NADPH;Potassium Channel

>  <Receptor>
" KIR6.2:14.2 ??M(Ki), SUR1:22.9 ??M(Ki)"

>  <Bioactivity>
"Acetohexamide is an intermediate-acting, first-generation sulfonylurea with hypoglycemic activity. It inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (KIR6.2) with Ki values of 22.9 and 14.2 ??M in HEK293 cells transfected with the human receptor and in rat brain, respectively. Acetohexamide is metabolized in the liver to its active metabolite hydroxyhexamide."

>  <Reference>
"Aldawsari H, et al. Int J Pharm. 2013 Sep 10;453(2):315-21.;McMahon RE, et al. The nature of the metabolites of acetohexamide in the rat and in the human. J Pharmacol Exp Ther. 1965 Aug;149(2):272-9.;Imamura Y, et al. Hypoglycemic effect of S(-)-hydroxyhexamide, a major metabolite of acetohexamide, and its enantiomer R(+)-hydroxyhexamide. Life Sci. 2001 Sep 7;69(16):1947-55.;Gopalakrishnan M, et al. Pharmacology of human sulphonylurea receptor SUR1 and inward rectifier K(+) channel Kir6.2 combination expressed in HEK-293 cells. Br J Pharmacol. 2000 Apr;129(7):1323-32."

>  <ID<1>>
T0816

$$$$
StarDrop ID 129
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -0.8612 2.7643 0.0000 0
M  V30 2 C -0.1467 2.3518 0.0000 0
M  V30 3 C 0.5678 1.9393 0.0000 0
M  V30 4 N 0.5678 1.1143 0.0000 0
M  V30 5 C 1.2352 0.6294 0.0000 0
M  V30 6 C 0.9803 -0.1553 0.0000 0
M  V30 7 N 0.1553 -0.1553 0.0000 0
M  V30 8 C -0.0997 0.6294 0.0000 0
M  V30 9 P 0.2658 3.0663 0.0000 0
M  V30 10 O 0.6783 3.7807 0.0000 0
M  V30 11 O 0.9803 2.6538 0.0000 0
M  V30 12 O -0.4487 3.4788 0.0000 0
M  V30 13 P -0.5592 1.6373 0.0000 0
M  V30 14 O 0.1553 1.2248 0.0000 0
M  V30 15 O -0.9717 0.9228 0.0000 0
M  V30 16 O -1.2737 2.0498 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 4 8
M  V30 9 1 2 9
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 2 9 12
M  V30 13 1 2 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 2 13 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
129

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Zoledronic Acid

>  <Synonyms>
Zoledronate;Zometa;ZOL 446;CGP42446A;CGP-4244;CGP 42446

>  <CAS>
118072-93-8

>  <Formula>
C5H10N2O7P2

>  <MolWt>
272.1

>  <Pathways>
Cell Cycle/Checkpoint;Apoptosis;Autophagy

>  <Target>
Rho;Autophagy;Apoptosis

>  <Receptor>
Apoptosis; Autophagy; Rho

>  <Bioactivity>
"Zoledronate is a bisphosphonate. Zometa is used to prevent skeletal fractures in patients with cancers such as multiple myeloma and prostate cancer. It can also be used to treat hypercalcemia of malignancy and can be helpful for treating pain from bone metastases. An annual dose of Zoledronate may also prevent recurring fractures in patients with a previous hip fracture. Zoledronate is a single 5 mg infusion for the treatment of Paget's disease of bone. In 2007, the FDA also approved Reclast for the treatment of postmenopausal osteoporosis."

>  <Reference>
"Croucher PI, et al. J Bone Miner Res, 2003, 18(3), 482-492.;Jagdev SP, et al. Br J Cancer, 2001, 84(8), 1126-1134.;Viereck V, et al. Biochem Biophys Res Commun, 2002, 291(3), 680-686."

>  <ID<1>>
T6739

$$$$
StarDrop ID 130
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.1433 -1.4615 0.0000 0
M  V30 2 C 4.1433 -0.6365 0.0000 0
M  V30 3 C 4.8578 -0.2240 0.0000 0
M  V30 4 C 5.5723 -0.6365 0.0000 0
M  V30 5 C 6.2867 -0.2240 0.0000 0
M  V30 6 C 7.0012 -0.6365 0.0000 0
M  V30 7 C 7.7157 -0.2240 0.0000 0
M  V30 8 C 8.4301 -0.6365 0.0000 0
M  V30 9 O 8.4301 -1.4615 0.0000 0
M  V30 10 N 9.1446 -0.2240 0.0000 0
M  V30 11 C 9.8591 -0.6365 0.0000 0 CFG=2
M  V30 12 C 9.8591 -1.4615 0.0000 0
M  V30 13 N 10.5736 -1.8740 0.0000 0
M  V30 14 C 11.3272 -1.5384 0.0000 0
M  V30 15 C 11.8793 -2.1515 0.0000 0
M  V30 16 C 11.4668 -2.8660 0.0000 0
M  V30 17 C 10.6598 -2.6945 0.0000 0
M  V30 18 C 10.5736 -0.2240 0.0000 0 CFG=1
M  V30 19 O 11.2880 -0.6365 0.0000 0
M  V30 20 C 10.5736 0.6010 0.0000 0
M  V30 21 C 9.8591 1.0135 0.0000 0
M  V30 22 C 9.8591 1.8385 0.0000 0
M  V30 23 C 10.5736 2.2510 0.0000 0
M  V30 24 O 10.5736 3.0760 0.0000 0
M  V30 25 C 11.2880 3.4885 0.0000 0
M  V30 26 C 12.0025 3.0760 0.0000 0
M  V30 27 O 12.0025 2.2510 0.0000 0
M  V30 28 C 11.2880 1.8385 0.0000 0
M  V30 29 C 11.2880 1.0135 0.0000 0
M  V30 30 H 8.9931 -1.1365 0.0000 0
M  V30 31 H 10.5735 -1.2240 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 11 10 CFG=1
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 13 17
M  V30 18 1 11 18
M  V30 19 1 18 19 CFG=3
M  V30 20 1 18 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 1 23 28
M  V30 30 2 28 29
M  V30 31 1 20 29
M  V30 32 1 30 11
M  V30 33 1 31 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
130

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Eliglustat hemitartrate

>  <Synonyms>
Genz-112638;Eliglustat tartrate

>  <CAS>
928659-70-5

>  <Formula>
C27H42N2O10

>  <MolWt>
554.6

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
 glucocerebroside synthase:24 nM 

>  <Bioactivity>
"Eliglustat Hemitartrate, with an IC50 of 24 nM, is a specific, potent, oral active glucocerebral glycosidase inhibitor."

>  <Reference>
"McEachern KA, et al. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy ofGaucher disease. Mol Genet Metab. 2007 Jul;91(3):259-67."

>  <ID<1>>
T11176

$$$$
StarDrop ID 131
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 9.7492 2.4134 0.0000 0
M  V30 2 N 9.0347 2.0009 0.0000 0
M  V30 3 C 9.0347 1.1759 0.0000 0
M  V30 4 O 9.7492 0.7634 0.0000 0
M  V30 5 C 8.3202 0.7634 0.0000 0
M  V30 6 C 8.3202 -0.0616 0.0000 0
M  V30 7 C 7.6058 -0.4741 0.0000 0
M  V30 8 C 6.8913 -0.0616 0.0000 0
M  V30 9 C 6.8913 0.7634 0.0000 0
M  V30 10 C 7.6058 1.1759 0.0000 0
M  V30 11 F 7.6058 2.0009 0.0000 0
M  V30 12 C 6.1768 -0.4741 0.0000 0
M  V30 13 C 6.1768 -1.2991 0.0000 0
M  V30 14 N 5.4623 -1.7116 0.0000 0
M  V30 15 C 4.7479 -1.2991 0.0000 0
M  V30 16 N 3.9633 -1.5540 0.0000 0
M  V30 17 C 3.4783 -0.8866 0.0000 0
M  V30 18 C 3.9633 -0.2192 0.0000 0
M  V30 19 C 3.7083 0.5655 0.0000 0
M  V30 20 C 4.2603 1.1785 0.0000 0
M  V30 21 C 4.0054 1.9632 0.0000 0
M  V30 22 C 4.5574 2.5763 0.0000 0
M  V30 23 C 5.3644 2.4047 0.0000 0
M  V30 24 N 5.9164 3.0178 0.0000 0
M  V30 25 C 6.7234 2.8463 0.0000 0
M  V30 26 C 6.9784 2.0617 0.0000 0
M  V30 27 C 6.4263 1.4486 0.0000 0
M  V30 28 C 5.6194 1.6201 0.0000 0
M  V30 29 C 5.0673 1.0070 0.0000 0
M  V30 30 N 4.7479 -0.4741 0.0000 0
M  V30 31 N 5.4623 -0.0616 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 5 10
M  V30 11 1 10 11
M  V30 12 1 8 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 1 23 28
M  V30 30 2 28 29
M  V30 31 1 20 29
M  V30 32 1 18 30
M  V30 33 1 15 30
M  V30 34 1 30 31
M  V30 35 2 12 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
131

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Capmatinib

>  <Synonyms>
INCB28060;NVP-INC280;INC-280

>  <CAS>
1029712-80-8

>  <Formula>
C23H17FN6O

>  <MolWt>
412.4

>  <Pathways>
Tyrosine Kinase/Adaptors;Apoptosis

>  <Target>
Apoptosis;c-Met/HGFR

>  <Receptor>
 c-Met:0.13 nM

>  <Bioactivity>
Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.

>  <Reference>
"Cao Shangtao, Shengyong Yu, Dongwei Li, Jing Ye, Xuejie Yang, Chen Li, Xiaoshan Wang et al. Chromatin accessibility dynamics during chemical induction of pluripotency[J]. Cell stem cell. 2018 Apr 22(4): 529-542. e5.;Liu X, et al, Clin Cancer Res, 2011, 17(227). 7127-7138."

>  <ID<1>>
T1963

$$$$
StarDrop ID 132
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -2.8579 -0.1768 0.0000 0
M  V30 2 C -2.1434 0.2357 0.0000 0
M  V30 3 C -1.4289 -0.1768 0.0000 0
M  V30 4 O -1.4289 -1.0018 0.0000 0
M  V30 5 C -0.7145 0.2357 0.0000 0
M  V30 6 O -0.7145 1.0607 0.0000 0
M  V30 7 C 0.0000 -0.1768 0.0000 0
M  V30 8 O 0.0000 -1.0018 0.0000 0
M  V30 9 C 0.7145 0.2357 0.0000 0
M  V30 10 O 0.7145 1.0607 0.0000 0
M  V30 11 C 1.4289 -0.1768 0.0000 0
M  V30 12 O 2.1434 0.2357 0.0000 0
M  V30 13 O 1.4289 -1.0018 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
132

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Gluconate Calcium

>  <Synonyms>
Calcium D-gluconate;Calcium gluconate;Gluconic acid hemicalcium salt

>  <CAS>
299-28-5

>  <Formula>
C12H22CaO14

>  <MolWt>
430.4

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Calcium gluconate is the calcium salt of gluconic acid, used as a calcium replenisher in hypocalcemic states."

>  <Reference>
"Drop LJ, Cullen DJ. Br J Anaesth. 1980 May;52(5):501-5."

>  <ID<1>>
T0411

$$$$
StarDrop ID 133
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 38 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7158 -4.9500 0.0000 0
M  V30 2 C 6.4302 -5.3625 0.0000 0
M  V30 3 N 6.4302 -6.1875 0.0000 0
M  V30 4 C 7.1447 -6.6000 0.0000 0
M  V30 5 C 7.1447 -7.4250 0.0000 0
M  V30 6 N 6.4302 -7.8375 0.0000 0
M  V30 7 C 5.7158 -7.4250 0.0000 0
M  V30 8 C 5.7158 -6.6000 0.0000 0
M  V30 9 C 6.4302 -8.6625 0.0000 0
M  V30 10 C 7.1447 -9.0750 0.0000 0
M  V30 11 C 7.1447 -9.9000 0.0000 0
M  V30 12 C 6.4302 -10.3125 0.0000 0
M  V30 13 N 6.4302 -11.1375 0.0000 0
M  V30 14 C 5.7158 -11.5500 0.0000 0
M  V30 15 C 5.7158 -12.3750 0.0000 0
M  V30 16 C 5.0013 -12.7875 0.0000 0
M  V30 17 N 4.2868 -12.3750 0.0000 0
M  V30 18 C 4.2868 -11.5500 0.0000 0
M  V30 19 N 5.0013 -11.1375 0.0000 0
M  V30 20 N 5.0013 -13.6125 0.0000 0
M  V30 21 C 5.7158 -14.0250 0.0000 0
M  V30 22 C 4.2868 -14.0250 0.0000 0
M  V30 23 O 3.5724 -13.6125 0.0000 0
M  V30 24 N 4.2868 -14.8500 0.0000 0
M  V30 25 C 3.5724 -15.2625 0.0000 0
M  V30 26 C 3.5724 -16.0875 0.0000 0
M  V30 27 Cl 4.2868 -16.5000 0.0000 0
M  V30 28 C 2.8579 -16.5000 0.0000 0
M  V30 29 O 2.8579 -17.3250 0.0000 0
M  V30 30 C 3.5724 -17.7375 0.0000 0
M  V30 31 C 2.1434 -16.0875 0.0000 0
M  V30 32 C 2.1434 -15.2625 0.0000 0
M  V30 33 O 1.4289 -14.8500 0.0000 0
M  V30 34 C 1.4289 -14.0250 0.0000 0
M  V30 35 C 2.8579 -14.8500 0.0000 0
M  V30 36 Cl 2.8579 -14.0250 0.0000 0
M  V30 37 C 5.7158 -9.9000 0.0000 0
M  V30 38 C 5.7158 -9.0750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 3 8
M  V30 9 1 6 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 14 19
M  V30 21 1 16 20
M  V30 22 1 20 21
M  V30 23 1 20 22
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 1 26 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 2 28 31
M  V30 33 1 31 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 2 32 35
M  V30 37 1 25 35
M  V30 38 1 35 36
M  V30 39 1 12 37
M  V30 40 2 37 38
M  V30 41 1 9 38
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
133

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Infigratinib

>  <Synonyms>
BGJ-398;NVP-BGJ398

>  <CAS>
872511-34-7

>  <Formula>
C26H31Cl2N7O3

>  <MolWt>
560.5

>  <Pathways>
Apoptosis;Angiogenesis;Tyrosine Kinase/Adaptors

>  <Target>
Apoptosis;FGFR

>  <Receptor>
" FGFR3 (K650E):4.9 nM (cell free), FGFR4:60 nM (cell free), FGFR1:0.2 nM (cell free), FGFR3:1.0 nM (cell free), FGFR2:1.4 nM (cell free)"

>  <Bioactivity>
"Infigratinib (BGJ398) is an orally bioavailable pan FGFR inhibitor (IC50: 0.9/1.4/1 nM for FGFR1/2/3), >40-fold selective for FGFR versus FGFR4 and VEGFR2."

>  <Reference>
"Lin H, Lu P, Zhou M, et al. Purification of recombinant human fibroblast growth factor 13 in E. coli and its molecular mechanism of mitogenesis[J]. Applied microbiology and biotechnology. 2019: 1-11.;Pu X, Ye Q, Cai J, et al. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas[J]. Cell death & disease. 2021, 12(3): 1-14.;Guagnano V, et al. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J Med Chem. 2011 Oct 27;54(20):7066-83.;Konecny GE, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013 May;12(5):632-42.;Guagnano V, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012 Dec;2(12):1118-33."

>  <ID<1>>
T1975

$$$$
StarDrop ID 134
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 -2.8875 0.0000 0
M  V30 2 N 3.0716 -3.3000 0.0000 0
M  V30 3 C 3.0716 -4.1250 0.0000 0
M  V30 4 C 3.7861 -2.8875 0.0000 0
M  V30 5 C 3.7861 -2.0625 0.0000 0
M  V30 6 C 4.5006 -1.6500 0.0000 0
M  V30 7 C 5.2150 -2.0625 0.0000 0
M  V30 8 N 5.9295 -1.6500 0.0000 0
M  V30 9 C 6.6440 -2.0625 0.0000 0
M  V30 10 C 7.3584 -1.6500 0.0000 0
M  V30 11 C 8.0729 -2.0625 0.0000 0
M  V30 12 C 8.0729 -2.8875 0.0000 0
M  V30 13 C 7.3584 -3.3000 0.0000 0
M  V30 14 C 6.6440 -2.8875 0.0000 0
M  V30 15 S 5.9295 -3.3000 0.0000 0 CHG=1
M  V30 16 C 5.2150 -2.8875 0.0000 0
M  V30 17 C 4.5006 -3.3000 0.0000 0
M  V30 18 N 8.7874 -3.3000 0.0000 0
M  V30 19 C 9.5019 -2.8875 0.0000 0
M  V30 20 C 8.7874 -4.1250 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 9 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 7 16
M  V30 18 2 16 17
M  V30 19 1 4 17
M  V30 20 1 12 18
M  V30 21 1 18 19
M  V30 22 1 18 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
134

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Methylene Blue trihydrate

>  <Synonyms>
Methylene Blue;Methylthionine chloride;Basic blue 9

>  <CAS>
7220-79-3

>  <Formula>
C16H24ClN3O3S

>  <MolWt>
373.9

>  <Pathways>
Microbiology/Virology;GPCR/G Protein;Neuroscience;Cytoskeletal Signaling;Immunology/Inflammation

>  <Target>
Monoamine Oxidase;Parasite;NO Synthase;Microtubule Associated;Guanylate cyclase

>  <Receptor>
 tau filament:1.9??M

>  <Bioactivity>
"Methylene blue is a compound consisting of dark green crystals or crystalline powder, having a bronze-like luster. Solutions in water or alcohol have a deep blue color. Methylene blue is used as a bacteriologic stain and as an indicator. It inhibits soluble guanylyl cyclase and has been used to treat cyanide poisoning and to lower levels of methemoglobin. It also inhibits tau filament formation (IC50: 1.9??M)."

>  <Reference>
"Rager T, et al. Phys Chem Chem Phys. 2012 Jun 14;14(22):8074-82."

>  <ID<1>>
T0006

$$$$
StarDrop ID 135
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 1.2640 -1.3384 0.0000 0
M  V30 2 C 0.9483 -0.5762 0.0000 0 CFG=2
M  V30 3 N 0.3649 -1.1595 0.0000 0
M  V30 4 C 0.5785 -1.9564 0.0000 0
M  V30 5 O 1.3754 -2.1700 0.0000 0
M  V30 6 C -0.0049 -2.5398 0.0000 0 CFG=2
M  V30 7 N -0.8018 -2.3263 0.0000 0
M  V30 8 C 0.2086 -3.3367 0.0000 0
M  V30 9 C 1.0055 -3.5502 0.0000 0
M  V30 10 C 1.2190 -4.3471 0.0000 0
M  V30 11 C 0.6357 -4.9305 0.0000 0
M  V30 12 C -0.1612 -4.7169 0.0000 0
M  V30 13 C -0.3747 -3.9200 0.0000 0
M  V30 14 C 0.9483 0.2488 0.0000 0
M  V30 15 O 0.3649 0.8322 0.0000 0
M  V30 16 N 1.7733 0.2488 0.0000 0
M  V30 17 C 2.5579 0.5038 0.0000 0 CFG=1
M  V30 18 C 2.8129 1.2884 0.0000 0
M  V30 19 O 2.2608 1.9015 0.0000 0
M  V30 20 O 3.6198 1.4599 0.0000 0
M  V30 21 C 3.0428 -0.1637 0.0000 0
M  V30 22 C 3.6559 0.3884 0.0000 0
M  V30 23 C 3.6559 -0.7157 0.0000 0
M  V30 24 S 2.5579 -0.8311 0.0000 0
M  V30 25 C 1.7733 -0.5762 0.0000 0 CFG=2
M  V30 26 H 2.0436 -1.3556 0.0000 0
M  V30 27 H -0.7120 -3.2469 0.0000 0
M  V30 28 H 3.5456 0.6601 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3 CFG=3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 6 4
M  V30 6 1 6 7 CFG=1
M  V30 7 1 6 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 8 13
M  V30 14 1 2 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 17 16
M  V30 18 1 17 18 CFG=1
M  V30 19 1 18 19
M  V30 20 2 18 20
M  V30 21 1 17 21
M  V30 22 1 21 22
M  V30 23 1 21 23
M  V30 24 1 21 24
M  V30 25 1 25 24
M  V30 26 1 2 25
M  V30 27 1 25 16
M  V30 28 1 25 26 CFG=1
M  V30 29 1 27 6
M  V30 30 1 28 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
135

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ampicillin

>  <Synonyms>
Aminobenzylpenicillin;D-(-)-??-Aminobenzylpenicillin;Amcill;Ampicillin acid

>  <CAS>
69-53-4

>  <Formula>
C16H19N3O4S

>  <MolWt>
349.4

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial;Antibiotic

>  <Receptor>
Antibiotic; Bacterial; PBPs

>  <Bioactivity>
"Ampicillin is a broad-spectrum, semi-synthetic, beta-lactam penicillin antibiotic with bactericidal activity."

>  <Reference>
"Lee KE, et al. The neuroprotective mechanism of ampicillin in a mouse model of transient forebrain ischemia. Korean J Physiol Pharmacol. 2016 Mar;20(2):185-92.;Chopra SL, et al. Effect of Ampicillin on E. Coli of Swine Origin. Can J Comp Med Vet Sci. 1963 Sep;27(9):223-7.;Lund B, et al. Ampicillin in portal and peripheral blood and bile after oral administration of ampicillin andpivampicillin. Eur J Clin Pharmacol. 1974;7(2):133-5."

>  <ID<1>>
T0814L

$$$$
StarDrop ID 136
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.5946 0.7145 0.0000 0
M  V30 2 C 3.1821 -0.0000 0.0000 0
M  V30 3 O 3.5946 -0.7145 0.0000 0
M  V30 4 C 2.3571 -0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
136

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Sodium acetate

>  <Synonyms>
N/A

>  <CAS>
127-09-3

>  <Formula>
C2H4NaO2

>  <MolWt>
83.04

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Sodium acetate is Commonly used laboratory reagent

>  <Reference>
N/A

>  <ID<1>>
T23377

$$$$
StarDrop ID 137
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 40 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 4.2868 1.6500 0.0000 0
M  V30 2 C 4.2868 0.8250 0.0000 0 CFG=2
M  V30 3 C 4.2868 -0.0000 0.0000 0 CFG=2
M  V30 4 C 5.0013 -0.4125 0.0000 0 CFG=2
M  V30 5 N 5.0013 -1.2375 0.0000 0
M  V30 6 C 5.7158 -1.6500 0.0000 0
M  V30 7 C 4.2868 -1.6500 0.0000 0
M  V30 8 C 5.7158 0.0000 0.0000 0
M  V30 9 O 6.4302 -0.4125 0.0000 0
M  V30 10 C 5.7158 0.8250 0.0000 0
M  V30 11 C 6.4302 1.2375 0.0000 0
M  V30 12 N 6.4302 2.0625 0.0000 0
M  V30 13 O 7.1447 0.8250 0.0000 0
M  V30 14 C 5.0013 1.2375 0.0000 0
M  V30 15 O 5.0013 2.0625 0.0000 0
M  V30 16 C 3.5724 -0.4125 0.0000 0 CFG=1
M  V30 17 O 3.5724 -1.2375 0.0000 0
M  V30 18 C 2.8579 -0.0000 0.0000 0 CFG=1
M  V30 19 C 2.8579 0.8250 0.0000 0
M  V30 20 C 3.5724 1.2375 0.0000 0
M  V30 21 O 3.5724 2.0625 0.0000 0
M  V30 22 C 2.1434 1.2375 0.0000 0
M  V30 23 O 2.1434 2.0625 0.0000 0
M  V30 24 C 1.4289 0.8250 0.0000 0
M  V30 25 C 1.4289 0.0000 0.0000 0
M  V30 26 C 2.1434 -0.4125 0.0000 0 CFG=2
M  V30 27 C 2.1434 -1.2375 0.0000 0
M  V30 28 C 0.7145 -0.4125 0.0000 0
M  V30 29 C 0.0000 -0.0000 0.0000 0
M  V30 30 C 0.0000 0.8250 0.0000 0
M  V30 31 C 0.7145 1.2375 0.0000 0
M  V30 32 O 0.7145 2.0625 0.0000 0
M  V30 33 H 2.1434 0.4125 0.0000 0
M  V30 34 H 3.5724 0.4125 0.0000 0
M  V30 35 H 4.1353 -0.9125 0.0000 0
M  V30 36 H 4.4384 -0.9125 0.0000 0
M  V30 37 H 3.0094 -0.9125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 3 2
M  V30 3 1 3 4
M  V30 4 1 4 5 CFG=1
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 4 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 1 10 14
M  V30 14 1 2 14
M  V30 15 2 14 15
M  V30 16 1 3 16
M  V30 17 1 16 17 CFG=1
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 2 20
M  V30 22 1 20 21
M  V30 23 1 19 22
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 24 25
M  V30 27 1 26 25
M  V30 28 1 18 26
M  V30 29 1 26 27 CFG=1
M  V30 30 2 25 28
M  V30 31 1 28 29
M  V30 32 2 29 30
M  V30 33 1 30 31
M  V30 34 2 24 31
M  V30 35 1 31 32
M  V30 36 1 18 33 CFG=1
M  V30 37 1 3 34 CFG=1
M  V30 38 1 35 4
M  V30 39 1 36 16
M  V30 40 1 37 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
137

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Doxycycline

>  <Synonyms>
Doxytetracycline;Doxiciclina;Doxycyclinum;Vibramycin

>  <CAS>
564-25-0

>  <Formula>
C22H24N2O8

>  <MolWt>
444.4

>  <Pathways>
Microbiology/Virology;Proteases/Proteasome

>  <Target>
Parasite;Antibiotic;MMP;ribosome;Antibacterial

>  <Receptor>
16S ribosome; 30S ribosome; Antibiotic; Bacterial; MMP; Parasite

>  <Bioactivity>
Doxycycline is a synthetic tetracycline derivative with similar antimicrobial activity.

>  <Reference>
"Griffin MO, et al. Am J Physiol Cell Physiol. 2010 Sep;299(3):C539-48.;Lu J, Lu Z, Liu L, et al. Identification of crocin as a new hIAPP amyloid inhibitor via a simple yet highly biospecific screening system[J]. Chemistry & Biodiversity. 2021;Xin Y, Chen X, Tang X, et al. Mechanics and actomyosin-dependent survival and chemoresistance of suspended tumor cells in shear flow[J]. Biophysical Journal. 2019 May 21;116(10):1803-1814."

>  <ID<1>>
T1687

$$$$
StarDrop ID 138
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.2375 0.7145 0.0000 0
M  V30 2 Al 0.8250 0.0000 0.0000 0
M  V30 3 O 1.2375 -0.7145 0.0000 0
M  V30 4 O 0.0000 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
138

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Aluminum Hydroxide

>  <Synonyms>
N/A

>  <CAS>
21645-51-2

>  <Formula>
AlH3O3

>  <MolWt>
78

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Aluminum Hydroxide is an orally active main form of aluminum used as an adjuvant. Aluminum hydroxide-based adjuvant researches including the repository effect, pro-phagocytic effect, and activation of the pro-inflammatory NLRP3 pathway."

>  <Reference>
"Ohtawa M, et al. Effect of aluminum ingestion on lipid peroxidation in rats. Chem Pharm Bull (Tokyo). 1983 Apr;31(4):1415-8.;He P, et al. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Hum Vaccin Immunother. 2015;11(2):477-88.;Amini Y, et al. Aluminum hydroxide nanoparticles show strong activity to stimulate Th-1 immune response against tuberculosis. Artif Cells Nanomed Biotechnol. 2017 Nov;45(7):1331-1335."

>  <ID<1>>
T13545

$$$$
StarDrop ID 139
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 2.7845 0.6979 0.0000 0
M  V30 2 C 2.0701 1.1104 0.0000 0
M  V30 3 N 1.3556 0.6979 0.0000 0
M  V30 4 C 0.6411 1.1104 0.0000 0
M  V30 5 N -0.1435 0.8555 0.0000 0
M  V30 6 C -0.6284 1.5229 0.0000 0
M  V30 7 N -0.1435 2.1904 0.0000 0
M  V30 8 C 0.6411 1.9354 0.0000 0
M  V30 9 C 1.3556 2.3479 0.0000 0
M  V30 10 O 1.3556 3.1729 0.0000 0
M  V30 11 N 2.0701 1.9354 0.0000 0
M  V30 12 C -0.3984 0.0709 0.0000 0 CFG=1
M  V30 13 C 0.0865 -0.5966 0.0000 0
M  V30 14 C -0.3984 -1.2640 0.0000 0 CFG=2
M  V30 15 O -0.1435 -2.0486 0.0000 0
M  V30 16 C -1.1831 -1.0091 0.0000 0 CFG=1
M  V30 17 C -1.8505 -1.4940 0.0000 0
M  V30 18 O -1.7643 -2.3145 0.0000 0
M  V30 19 C -1.1831 -0.1841 0.0000 0
M  V30 20 C -1.8505 0.3009 0.0000 0
M  V30 21 H 0.5893 0.2272 0.0000 0
M  V30 22 H 0.5893 -1.4205 0.0000 0
M  V30 23 H -2.0741 -0.5551 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 4 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 2 2 11
M  V30 13 1 12 5 CFG=1
M  V30 14 1 12 13
M  V30 15 1 14 13
M  V30 16 1 14 15 CFG=3
M  V30 17 1 14 16
M  V30 18 1 16 17 CFG=1
M  V30 19 1 17 18
M  V30 20 1 16 19
M  V30 21 1 12 19
M  V30 22 2 19 20
M  V30 23 1 21 12
M  V30 24 1 22 14
M  V30 25 1 23 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
139

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Entecavir

>  <Synonyms>
SQ34676;BMS200475

>  <CAS>
142217-69-4

>  <Formula>
C12H15N5O3

>  <MolWt>
277.3

>  <Pathways>
Microbiology/Virology

>  <Target>
HBV

>  <Receptor>
 HBV(in HepG2 cell):3.75 nM(ec50)

>  <Bioactivity>
"Entecavir is a guanosine nucleoside analogue used in the treatment of chronic hepatitis B virus (HBV) infection. Entecavir therapy can be associated with flares of the underlying hepatitis B during or after therapy, but has not been linked to cases of clinically apparent liver injury."

>  <Reference>
"Sham, H., Kempf, D., Molla, A., Marsh, K., Kumar, G., & Chen, C. et al. (1998). ABT-378, a Highly Potent Inhibitor of the Human Immunodeficiency Virus Protease.?Antimicrobial Agents And Chemotherapy,?42(12), 3218-3224. doi: 10.1128/aac.42.12.3218;Xie B, Sun D, Du Y, et al. A two-step lineage reprogramming strategy to generate functionally competent human hepatocytes from fibroblasts[J]. Cell research. 2019: 1."

>  <ID<1>>
T0085L

$$$$
StarDrop ID 140
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 145 157 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.2192 -3.9385 0.0000 0
M  V30 2 N 2.1313 -3.1182 0.0000 0
M  V30 3 C 2.7977 -2.6319 0.0000 0 CFG=2
M  V30 4 C 3.5192 -3.0933 0.0000 0
M  V30 5 C 3.9690 -2.3902 0.0000 0
M  V30 6 C 4.7930 -2.3934 0.0000 0
M  V30 7 C 5.2126 -3.1173 0.0000 0
M  V30 8 O 5.9850 -2.7669 0.0000 0
M  V30 9 C 6.4911 -2.0548 0.0000 0
M  V30 10 C 7.3198 -1.9047 0.0000 0
M  V30 11 C 7.6213 -1.1274 0.0000 0
M  V30 12 O 8.4364 -1.0001 0.0000 0
M  V30 13 C 7.0972 -0.4794 0.0000 0
M  V30 14 Cl 7.4070 0.2852 0.0000 0
M  V30 15 C 6.2640 -0.5807 0.0000 0
M  V30 16 C 5.6528 0.0265 0.0000 0 CFG=2
M  V30 17 N 4.8125 0.1228 0.0000 0
M  V30 18 C 3.9760 -0.0128 0.0000 0
M  V30 19 C 3.1664 -0.2421 0.0000 0 CFG=1
M  V30 20 C 2.5093 0.2997 0.0000 0
M  V30 21 C 2.3003 1.1321 0.0000 0
M  V30 22 C 3.1133 1.3236 0.0000 0
M  V30 23 C 3.3934 2.0962 0.0000 0
M  V30 24 C 2.8518 2.7388 0.0000 0
M  V30 25 O 3.4567 3.3449 0.0000 0
M  V30 26 C 4.2397 3.7480 0.0000 0
M  V30 27 C 4.6143 4.5078 0.0000 0
M  V30 28 O 4.1307 5.1761 0.0000 0
M  V30 29 C 3.3100 5.0915 0.0000 0 CFG=2
M  V30 30 O 2.9730 4.3384 0.0000 0
M  V30 31 C 2.1524 4.2538 0.0000 0 CFG=1
M  V30 32 C 1.6687 4.9221 0.0000 0 CFG=1
M  V30 33 O 0.8481 4.8374 0.0000 0
M  V30 34 C 2.0057 5.6751 0.0000 0 CFG=2
M  V30 35 O 1.5221 6.3435 0.0000 0
M  V30 36 C 2.8264 5.7598 0.0000 0 CFG=1
M  V30 37 N 3.1634 6.5129 0.0000 0
M  V30 38 C 2.6797 7.1812 0.0000 0
M  V30 39 C 3.0167 7.9343 0.0000 0
M  V30 40 C 3.8373 8.0189 0.0000 0
M  V30 41 C 4.3210 7.3506 0.0000 0
M  V30 42 C 5.1416 7.4352 0.0000 0
M  V30 43 C 5.6253 6.7669 0.0000 0
M  V30 44 C 6.4459 6.8516 0.0000 0
M  V30 45 C 6.9296 6.1832 0.0000 0
M  V30 46 C 7.7502 6.2679 0.0000 0
M  V30 47 C 8.2339 5.5995 0.0000 0
M  V30 48 C 9.0545 5.6842 0.0000 0
M  V30 49 C 7.8276 4.7526 0.0000 0
M  V30 50 O 1.8591 7.0965 0.0000 0
M  V30 51 C 1.8154 3.5007 0.0000 0
M  V30 52 O 2.2991 2.8324 0.0000 0
M  V30 53 O 0.9948 3.4160 0.0000 0
M  V30 54 C 5.4553 4.6264 0.0000 0
M  V30 55 C 5.9160 3.9281 0.0000 0
M  V30 56 C 5.5933 3.1565 0.0000 0
M  V30 57 C 6.0844 2.4635 0.0000 0 CFG=1
M  V30 58 N 5.8776 1.6458 0.0000 0
M  V30 59 C 5.9615 0.8150 0.0000 0
M  V30 60 O 6.7788 0.7029 0.0000 0
M  V30 61 C 6.9192 2.3616 0.0000 0
M  V30 62 N 7.6765 2.0152 0.0000 0
M  V30 63 C 8.4977 2.1775 0.0000 0 CFG=2
M  V30 64 C 9.1273 1.6037 0.0000 0
M  V30 65 C 9.0243 0.7732 0.0000 0
M  V30 66 C 9.6708 0.2512 0.0000 0
M  V30 67 C 10.4435 0.5606 0.0000 0
M  V30 68 O 11.0857 0.0428 0.0000 0
M  V30 69 C 10.5826 1.3861 0.0000 0
M  V30 70 C 11.3341 1.7703 0.0000 0
M  V30 71 C 11.5897 2.5547 0.0000 0 CFG=1
M  V30 72 C 12.3969 2.7255 0.0000 0
M  V30 73 C 12.9484 2.1120 0.0000 0
M  V30 74 O 13.7555 2.2828 0.0000 0
M  V30 75 C 12.6927 1.3276 0.0000 0
M  V30 76 C 11.8856 1.1567 0.0000 0
M  V30 77 O 11.6300 0.3723 0.0000 0
M  V30 78 C 12.1815 -0.2412 0.0000 0 CFG=1
M  V30 79 O 12.9886 -0.0704 0.0000 0
M  V30 80 C 13.5401 -0.6840 0.0000 0 CFG=2
M  V30 81 C 14.3472 -0.5132 0.0000 0
M  V30 82 O 14.8987 -1.1267 0.0000 0
M  V30 83 C 13.2845 -1.4684 0.0000 0 CFG=1
M  V30 84 O 13.8360 -2.0820 0.0000 0
M  V30 85 C 12.4774 -1.6392 0.0000 0 CFG=2
M  V30 86 O 12.2218 -2.4236 0.0000 0
M  V30 87 C 11.9259 -1.0256 0.0000 0 CFG=2
M  V30 88 O 11.1188 -1.1965 0.0000 0
M  V30 89 C 11.1360 3.2597 0.0000 0
M  V30 90 N 11.0730 4.0855 0.0000 0
M  V30 91 C 10.3746 4.5306 0.0000 0
M  V30 92 C 9.5483 4.3957 0.0000 0 CFG=1
M  V30 93 N 9.1544 3.6474 0.0000 0
M  V30 94 C 8.6169 3.0101 0.0000 0
M  V30 95 O 7.8641 3.3475 0.0000 0
M  V30 96 C 9.2599 5.1949 0.0000 0 CFG=2
M  V30 97 O 9.9009 5.7142 0.0000 0
M  V30 98 C 8.5359 5.6440 0.0000 0
M  V30 99 C 8.0987 6.3684 0.0000 0
M  V30 100 C 7.2611 6.3772 0.0000 0
M  V30 101 Cl 6.8512 7.0931 0.0000 0
M  V30 102 C 6.8376 5.6380 0.0000 0
M  V30 103 O 6.0739 5.2513 0.0000 0
M  V30 104 C 7.2749 4.9218 0.0000 0
M  V30 105 C 8.0968 4.9334 0.0000 0
M  V30 106 O 10.5407 5.3387 0.0000 0
M  V30 107 C 11.9181 3.5223 0.0000 0 CFG=1
M  V30 108 N 12.0816 4.3310 0.0000 0
M  V30 109 C 12.8637 4.5936 0.0000 0
M  V30 110 C 13.0273 5.4022 0.0000 0
M  V30 111 C 13.8094 5.6649 0.0000 0
M  V30 112 N 13.9729 6.4735 0.0000 0
M  V30 113 C 13.3544 7.0195 0.0000 0
M  V30 114 C 14.7550 6.7362 0.0000 0
M  V30 115 O 12.5366 2.9764 0.0000 0
M  V30 116 C 9.9119 1.8907 0.0000 0
M  V30 117 O 7.1434 3.1555 0.0000 0
M  V30 118 C 4.7597 3.0923 0.0000 0
M  V30 119 C 2.0164 2.5776 0.0000 0
M  V30 120 C 1.7598 1.7786 0.0000 0
M  V30 121 N 2.8211 -1.0164 0.0000 0
M  V30 122 C 2.5812 -1.8149 0.0000 0
M  V30 123 O 1.7563 -1.8013 0.0000 0
M  V30 124 O 3.7974 0.7926 0.0000 0
M  V30 125 C 5.9925 -1.3827 0.0000 0
M  V30 126 C 4.7766 -3.8489 0.0000 0
M  V30 127 O 5.1729 -4.5724 0.0000 0
M  V30 128 C 3.9398 -3.8229 0.0000 0
M  V30 129 H 1.8612 -2.2811 0.0000 0
M  V30 130 H 6.6339 0.2199 0.0000 0
M  V30 131 H 2.1923 -0.4680 0.0000 0
M  V30 132 H 3.7186 6.0042 0.0000 0
M  V30 133 H 2.7385 3.4436 0.0000 0
M  V30 134 H 1.0825 5.7322 0.0000 0
M  V30 135 H 1.0110 5.5725 0.0000 0
M  V30 136 H 3.8211 5.8626 0.0000 0
M  V30 137 H 5.1000 2.2876 0.0000 0
M  V30 138 H 9.4428 2.5042 0.0000 0
M  V30 139 H 11.2032 -0.4484 0.0000 0
M  V30 140 H 14.2086 -1.4277 0.0000 0
M  V30 141 H 12.9747 -2.4192 0.0000 0
M  V30 142 H 13.1459 -2.3829 0.0000 0
M  V30 143 H 11.6161 -1.9764 0.0000 0
M  V30 144 H 10.1245 3.5784 0.0000 0
M  V30 145 H 10.2174 4.9065 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 16 15 CFG=3
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 19 18
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 27 28
M  V30 28 1 29 28 CFG=3
M  V30 29 1 29 30
M  V30 30 1 31 30
M  V30 31 1 32 31
M  V30 32 1 32 33 CFG=1
M  V30 33 1 32 34
M  V30 34 1 34 35 CFG=3
M  V30 35 1 34 36
M  V30 36 1 36 29
M  V30 37 1 36 37 CFG=1
M  V30 38 1 37 38
M  V30 39 1 38 39
M  V30 40 1 39 40
M  V30 41 1 40 41
M  V30 42 1 41 42
M  V30 43 1 42 43
M  V30 44 1 43 44
M  V30 45 1 44 45
M  V30 46 1 45 46
M  V30 47 1 46 47
M  V30 48 1 47 48
M  V30 49 1 47 49
M  V30 50 2 38 50
M  V30 51 1 31 51 CFG=3
M  V30 52 1 51 52
M  V30 53 2 51 53
M  V30 54 1 27 54
M  V30 55 2 54 55
M  V30 56 1 55 56
M  V30 57 1 57 56 CFG=3
M  V30 58 1 57 58
M  V30 59 1 58 59
M  V30 60 1 16 59
M  V30 61 2 59 60
M  V30 62 1 57 61
M  V30 63 1 61 62
M  V30 64 1 63 62
M  V30 65 1 63 64 CFG=1
M  V30 66 2 64 65
M  V30 67 1 65 66
M  V30 68 2 66 67
M  V30 69 1 67 68
M  V30 70 1 67 69
M  V30 71 1 69 70
M  V30 72 2 70 71
M  V30 73 1 71 72
M  V30 74 2 72 73
M  V30 75 1 73 74
M  V30 76 1 73 75
M  V30 77 2 75 76
M  V30 78 1 70 76
M  V30 79 1 76 77
M  V30 80 1 78 77 CFG=1
M  V30 81 1 78 79
M  V30 82 1 80 79
M  V30 83 1 80 81 CFG=3
M  V30 84 1 81 82
M  V30 85 1 83 80
M  V30 86 1 83 84 CFG=1
M  V30 87 1 83 85
M  V30 88 1 85 86 CFG=3
M  V30 89 1 85 87
M  V30 90 1 87 78
M  V30 91 1 87 88 CFG=3
M  V30 92 1 71 89 CFG=3
M  V30 93 1 89 90
M  V30 94 1 90 91
M  V30 95 1 92 91
M  V30 96 1 92 93 CFG=1
M  V30 97 1 93 94
M  V30 98 1 63 94
M  V30 99 2 94 95
M  V30 100 1 92 96
M  V30 101 1 96 97 CFG=1
M  V30 102 1 96 98
M  V30 103 2 98 99
M  V30 104 1 99 100
M  V30 105 1 100 101
M  V30 106 2 100 102
M  V30 107 1 102 103
M  V30 108 1 54 103
M  V30 109 1 102 104
M  V30 110 2 104 105
M  V30 111 1 98 105
M  V30 112 2 91 106
M  V30 113 1 107 89 CFG=1
M  V30 114 1 107 108
M  V30 115 1 108 109
M  V30 116 1 109 110
M  V30 117 1 110 111
M  V30 118 1 111 112
M  V30 119 1 112 113
M  V30 120 1 112 114
M  V30 121 2 107 115
M  V30 122 2 69 116
M  V30 123 1 64 116
M  V30 124 2 61 117
M  V30 125 2 56 118
M  V30 126 1 26 118
M  V30 127 1 24 119
M  V30 128 2 119 120
M  V30 129 1 21 120
M  V30 130 1 19 121 CFG=3
M  V30 131 1 121 122
M  V30 132 1 3 122
M  V30 133 2 122 123
M  V30 134 2 18 124
M  V30 135 2 15 125
M  V30 136 1 9 125
M  V30 137 1 7 126
M  V30 138 1 126 127
M  V30 139 2 126 128
M  V30 140 1 4 128
M  V30 141 1 129 3
M  V30 142 1 130 16
M  V30 143 1 131 19
M  V30 144 1 132 29
M  V30 145 1 133 31
M  V30 146 1 134 32
M  V30 147 1 135 34
M  V30 148 1 136 36
M  V30 149 1 137 57
M  V30 150 1 138 63
M  V30 151 1 139 78
M  V30 152 1 140 80
M  V30 153 1 141 83
M  V30 154 1 142 85
M  V30 155 1 143 87
M  V30 156 1 144 92
M  V30 157 1 145 96
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
140

>  <Plate>
PHD136328

>  <Row>
g

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dalbavancin

>  <Synonyms>
VER 001;BI-397;A-A 1;VER-001;Dalbavancin HCl;BI397;BI 397

>  <CAS>
171500-79-1

>  <Formula>
C88H100Cl2N10O28

>  <MolWt>
1817

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial;Antibiotic

>  <Receptor>
" Staphylococcus aureus:0.06 ??g/mL (MIC90), Bacillus anthracis:0.25 ??g/mL (MIC90)"

>  <Bioactivity>
"Dalbavancin, a novel second-generation lipoglycopeptide antibiotic, possesses in vitro activity against a variety of Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE),Dalbavancin hydrochloride inhibits Staphylococcus aureus and Bacillus anthracis with MIC90s of 0.06 ??g/mL and 0.25 ??g/mL, respectively"

>  <Reference>
"Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS, Jones RN. Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13). J Antimicrob Chemother. 2015 Oct 7. pii: dkv303. [Epub ahead of print] PubMed PMID: 26451012.;Koeth LM, DiFranco-Fisher JM, McCurdy S. A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically. J Vis Exp. 2015 Sep 9;(103). doi: 10.3791/53028. PubMed PMID: 26381422.;Lepak A, Marchillo K, VanHecker J, Andes D. Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target. Antimicrob Agents Chemother. 2015 Sep 21. pii: AAC.01717-15. [Epub ahead of print] PubMed PMID: 26392492.;Scoble PJ, Owens RC Jr, Puttagunta S, Yen M, Dunne MW. Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects. Clin Drug Investig. 2015 Oct 12. [Epub ahead of print] PubMed PMID: 26458939."

>  <ID<1>>
T21358

$$$$
StarDrop ID 141
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.4118 7.8321 0.0000 0
M  V30 2 C 0.5954 7.0278 0.0000 0
M  V30 3 O 1.3838 6.7846 0.0000 0
M  V30 4 C 1.5673 5.9803 0.0000 0
M  V30 5 C 2.3557 5.7371 0.0000 0
M  V30 6 C 2.5393 4.9328 0.0000 0
M  V30 7 C 1.9345 4.3716 0.0000 0
M  V30 8 C 2.1181 3.5673 0.0000 0
M  V30 9 C 1.5133 3.0062 0.0000 0
M  V30 10 C 1.6969 2.2019 0.0000 0
M  V30 11 C 1.0921 1.6407 0.0000 0
M  V30 12 C 0.3038 1.8839 0.0000 0
M  V30 13 C 0.1202 2.6882 0.0000 0
M  V30 14 C 0.7250 3.2494 0.0000 0
M  V30 15 Cl 0.5414 4.0537 0.0000 0
M  V30 16 C 1.2757 0.8364 0.0000 0 CFG=2
M  V30 17 O 0.6307 0.3220 0.0000 0
M  V30 18 C 0.6307 -0.5030 0.0000 0
M  V30 19 C 1.2757 -1.0173 0.0000 0 CFG=2
M  V30 20 C 1.0921 -1.8217 0.0000 0
M  V30 21 O 1.6969 -2.3828 0.0000 0
M  V30 22 O 1.0440 -0.0905 0.0000 0
M  V30 23 C 2.0800 -0.8338 0.0000 0 CFG=1
M  V30 24 O 2.5944 -1.4788 0.0000 0
M  V30 25 C 2.4380 -0.0905 0.0000 0 CFG=2
M  V30 26 O 3.2630 -0.0905 0.0000 0
M  V30 27 C 2.0800 0.6528 0.0000 0 CFG=1
M  V30 28 O 2.5944 1.2978 0.0000 0
M  V30 29 C 1.1462 4.6148 0.0000 0
M  V30 30 C 0.9626 5.4191 0.0000 0
M  V30 31 H 3.0737 -0.7218 0.0000 0
M  V30 32 H 2.9700 -0.9372 0.0000 0
M  V30 33 H 3.0737 0.5408 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 9 14
M  V30 15 1 14 15
M  V30 16 1 16 11 CFG=1
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 19 18
M  V30 20 1 19 20 CFG=1
M  V30 21 1 20 21
M  V30 22 1 19 22
M  V30 23 1 16 22
M  V30 24 1 23 19
M  V30 25 1 23 24 CFG=3
M  V30 26 1 23 25
M  V30 27 1 25 26 CFG=1
M  V30 28 1 25 27
M  V30 29 1 27 16
M  V30 30 1 27 28 CFG=3
M  V30 31 1 7 29
M  V30 32 2 29 30
M  V30 33 1 4 30
M  V30 34 1 31 23
M  V30 35 1 32 25
M  V30 36 1 33 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
141

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ertugliflozin

>  <Synonyms>
PF-04971729;MK-8835

>  <CAS>
1210344-57-2

>  <Formula>
C22H25ClO7

>  <MolWt>
436.9

>  <Pathways>
GPCR/G Protein

>  <Target>
SGLT

>  <Receptor>
 hSGLT2:0.877 nM

>  <Bioactivity>
PF-04971729 (Ertugliflozin) is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2).

>  <Reference>
"Miao Z, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects. Drug Metab Dispos. 2013 Feb;41(2):445-56.;Mascitti V, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodium-dependent glucose cotransporter 2 inhibitors. J Med Chem. 2011 Apr 28;54(8):2952-60.;Kalgutkar AS, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos. 2011 Sep;39(9):16"

>  <ID<1>>
T4999

$$$$
StarDrop ID 142
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -5.0013 3.7125 0.0000 0
M  V30 2 C -4.2868 4.1250 0.0000 0
M  V30 3 C -3.5724 3.7125 0.0000 0
M  V30 4 N -3.9849 2.9980 0.0000 0
M  V30 5 C -3.1599 4.4270 0.0000 0
M  V30 6 O -2.3349 4.4270 0.0000 0
M  V30 7 C -2.8579 3.3000 0.0000 0
M  V30 8 C -2.1434 3.7125 0.0000 0
M  V30 9 C -1.4289 3.3000 0.0000 0
M  V30 10 C -0.7145 3.7125 0.0000 0
M  V30 11 C 0.0000 3.3000 0.0000 0
M  V30 12 C 0.0000 2.4750 0.0000 0
M  V30 13 C -0.7145 2.0625 0.0000 0
M  V30 14 C -1.4289 2.4750 0.0000 0
M  V30 15 C 0.7145 2.0625 0.0000 0
M  V30 16 C 1.4289 2.4750 0.0000 0
M  V30 17 C 2.1434 2.0625 0.0000 0
M  V30 18 C 2.8579 2.4750 0.0000 0
M  V30 19 C 3.5724 2.0625 0.0000 0
M  V30 20 C 4.2868 2.4750 0.0000 0
M  V30 21 C 5.0013 2.0625 0.0000 0
M  V30 22 C 5.7158 2.4750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 3 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 9 14
M  V30 15 1 12 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
142

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fingolimod

>  <Synonyms>
FTY-720A;FTY-720

>  <CAS>
162359-55-9

>  <Formula>
C19H33NO2

>  <MolWt>
307.5

>  <Pathways>
Cytoskeletal Signaling;GPCR/G Protein

>  <Target>
PAK;S1P Receptor;LPL Receptor

>  <Receptor>
 sphingosine 1-phosphate (S1P):0.033 nM

>  <Bioactivity>
Fingolimod is an antagonist of sphingosine 1-phosphate (S1P) (IC50 of 0.033 nM in K562 and NK cells).

>  <Reference>
"Amelioration of colitis through blocking lymphocytes entry to Peyer's patches by sphingosine??phosphate lyase inhibitor[J]. Journal of Gastroenterology & Hepatology, 2018, 33(9).;Szepanowski, Fabian, Derksen, Angelika, Steiner, Irina,et al. Fingolimod promotes peripheral nerve regeneration via modulation of lysophospholipid signaling[J]. Journal of Neuroinflammation, 13(1):143."

>  <ID<1>>
T7939

$$$$
StarDrop ID 143
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.6002 2.7991 0.0000 0
M  V30 2 C 2.6002 1.9741 0.0000 0
M  V30 3 N 1.8857 1.5616 0.0000 0
M  V30 4 N 3.3147 1.5616 0.0000 0
M  V30 5 N 3.3147 0.7366 0.0000 0
M  V30 6 C 4.0291 0.3241 0.0000 0
M  V30 7 C 4.0291 -0.5009 0.0000 0
M  V30 8 C 4.7436 -0.9134 0.0000 0
M  V30 9 Cl 5.4581 -0.5009 0.0000 0
M  V30 10 C 4.7436 -1.7384 0.0000 0
M  V30 11 C 4.0291 -2.1509 0.0000 0
M  V30 12 C 3.3147 -1.7384 0.0000 0
M  V30 13 C 3.3147 -0.9134 0.0000 0
M  V30 14 Cl 2.6002 -0.5009 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 7 13
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
143

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Guanabenz hydrochloride

>  <Synonyms>
NE56490

>  <CAS>
23113-43-1

>  <Formula>
C8H9Cl3N4

>  <MolWt>
267.5

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
??2-adrenoceptor

>  <Bioactivity>
Guanabenz hydrochloride is an orally active ??2-adrenoceptor agonist with hypotensive effects.

>  <Reference>
"Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Guanabenz. A review of its pharmacodynamic properties and therapeutic efficacy in hypertension. Drugs. 1983 Sep;26(3):212-29. d"

>  <ID<1>>
T21957

$$$$
StarDrop ID 144
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.2868 0.8250 0.0000 0
M  V30 2 N -3.5724 1.2375 0.0000 0
M  V30 3 C -2.8579 0.8250 0.0000 0
M  V30 4 N -2.1434 1.2375 0.0000 0
M  V30 5 C -1.4289 0.8250 0.0000 0
M  V30 6 C -1.4289 0.0000 0.0000 0
M  V30 7 C -2.1434 -0.4125 0.0000 0
M  V30 8 C -2.8579 0.0000 0.0000 0
M  V30 9 C -3.5724 -0.4125 0.0000 0
M  V30 10 C -0.7145 -0.4125 0.0000 0
M  V30 11 C -0.7145 -1.2375 0.0000 0
M  V30 12 C 0.0000 -1.6500 0.0000 0
M  V30 13 C 0.7145 -1.2375 0.0000 0
M  V30 14 C 0.7145 -0.4125 0.0000 0
M  V30 15 C 0.0000 -0.0000 0.0000 0
M  V30 16 C 0.0000 0.8250 0.0000 0
M  V30 17 N 1.4289 -0.0000 0.0000 0
M  V30 18 C 2.1434 -0.4125 0.0000 0
M  V30 19 C 2.1434 -1.2375 0.0000 0
M  V30 20 C 2.8579 -1.6500 0.0000 0
M  V30 21 O 3.5724 -1.2375 0.0000 0
M  V30 22 O 2.8579 -2.4750 0.0000 0
M  V30 23 C 1.4289 -1.6500 0.0000 0
M  V30 24 O 1.4289 -2.4750 0.0000 0
M  V30 25 C 1.4289 0.8250 0.0000 0
M  V30 26 C 1.0164 1.5395 0.0000 0
M  V30 27 C 1.8414 1.5395 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 3 8
M  V30 9 1 8 9
M  V30 10 1 6 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 10 15
M  V30 17 1 15 16
M  V30 18 1 14 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 20 22
M  V30 24 1 19 23
M  V30 25 1 13 23
M  V30 26 2 23 24
M  V30 27 1 17 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 25 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
144

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ozenoxacin

>  <Synonyms>
T-3912

>  <CAS>
245765-41-7

>  <Formula>
C21H21N3O3

>  <MolWt>
363.4

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial

>  <Receptor>
Bacterial

>  <Bioactivity>
Ozenoxacin is a quinolone antibacterial. It shows potent activities against the main microorganisms isolated from soft tissue and skin infections.

>  <Reference>
"L??pez Y, et al. In vitro selection of mutants resistant to ozenoxacin compared with levofloxacin and ciprofloxacin in Gram-positive cocci. J Antimicrob Chemother. 2015 Jan;70(1):57-61;L??pez Y, et al. In vitro activity of Ozenoxacin against quinolone-susceptible and quinolone-resistant gram-positive bacteria. Antimicrob Agents Chemother. 2013 Dec;57(12):6389-92."

>  <ID<1>>
T7902

$$$$
StarDrop ID 145
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.6017 2.0350 0.0000 0
M  V30 2 P 0.1892 1.3205 0.0000 0
M  V30 3 O -0.5252 1.7330 0.0000 0
M  V30 4 O 0.9037 0.9080 0.0000 0
M  V30 5 C -0.2233 0.6060 0.0000 0
M  V30 6 O -0.9377 1.0185 0.0000 0
M  V30 7 C 0.4912 0.1935 0.0000 0
M  V30 8 N 0.4912 -0.6315 0.0000 0
M  V30 9 C 1.1586 -1.1164 0.0000 0
M  V30 10 N 0.9037 -1.9010 0.0000 0
M  V30 11 C 0.0787 -1.9010 0.0000 0
M  V30 12 C -0.1762 -1.1164 0.0000 0
M  V30 13 P -0.6358 -0.1084 0.0000 0
M  V30 14 O -1.3502 0.3041 0.0000 0
M  V30 15 O 0.0787 -0.5209 0.0000 0
M  V30 16 O -1.0483 -0.8229 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 8 12
M  V30 13 1 5 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 13 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
145

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Zoledronic acid monohydrate

>  <Synonyms>
Zoledronic acid hydrate;zoledronate;CGP42446A;ZOL 446;CGP 42446

>  <CAS>
165800-06-6

>  <Formula>
C5H12N2O8P2

>  <MolWt>
290.1

>  <Pathways>
Autophagy;Others;Apoptosis

>  <Target>
Autophagy;Others;Apoptosis

>  <Receptor>
Apoptosis; Autophagy

>  <Bioactivity>
Zoledronic acid hydrate is a synthetic imidazole bisphosphonate analog with anti-bone-resorption activity.

>  <Reference>
"Huang WW, Huang C, Liu J, Zheng HY, Lin L. Zoledronic acid as an adjuvant therapy in patients with breast cancer: a systematic review and meta-analysis. PLoS One. 2012;7(7):e4078doi: 10.1371/journal.pone.004078Epub 2012 Jul 26. Review. PubMed PMID: 22844410; PubMed Central PMCID: PMC3406041.;Hadji P, Coleman R, Gnant M, Green J. The impact of menopause on bone, zoledronic acid, and implications for breast cancer growth and metastasis. Ann Oncol. 2012 Nov;23(11):2782-90. doi: 10.1093/annonc/mds169. Epub 2012 Jun 2Review. PubMed PMID: 22730099; PubMed Central PMCID: PMC3477882.;Albani-Campanario M , G Buend??a-D??az,  Flores-Islas M , et al. [Zoledronic acid-based uveitis: a case report and a bibliography review][J]. Ginecolog??a Y Obstetricia De M??xico, 2012, 80(5):355-9.;Zhang J, Wang R, Zhao YL, Sun XH, Zhao HX, Tan L, Chen DC, Hai-Bin X. Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: a meta-analysis. Asian Pac J Trop Med. 2012 Sep;5(9):743-8. doi: 10.1016/S1995-7645(12)60118-7. Review. PubMed PMID: 22805729."

>  <ID<1>>
T21299

$$$$
StarDrop ID 146
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.5600 0.7927 0.0000 0
M  V30 2 C 1.9469 1.3448 0.0000 0
M  V30 3 C 2.5600 1.8968 0.0000 0
M  V30 4 S 1.4620 0.6773 0.0000 0
M  V30 5 C 0.6773 0.9323 0.0000 0
M  V30 6 C -0.1477 0.9323 0.0000 0
M  V30 7 N -0.7310 0.3489 0.0000 0
M  V30 8 C -1.5279 0.5624 0.0000 0
M  V30 9 O -1.7414 1.3593 0.0000 0
M  V30 10 C -2.1113 -0.0209 0.0000 0
M  V30 11 N -1.8977 -0.8178 0.0000 0
M  V30 12 C -2.9082 0.1926 0.0000 0
M  V30 13 C -3.4915 -0.3908 0.0000 0
M  V30 14 C -4.2884 -0.1772 0.0000 0
M  V30 15 C -4.5019 0.6197 0.0000 0
M  V30 16 O -5.2988 0.8332 0.0000 0
M  V30 17 C -3.9186 1.2030 0.0000 0
M  V30 18 C -3.1217 0.9895 0.0000 0
M  V30 19 C -0.1477 1.7573 0.0000 0
M  V30 20 O -0.7310 2.3406 0.0000 0
M  V30 21 N 0.6773 1.7573 0.0000 0
M  V30 22 C 1.4620 2.0122 0.0000 0
M  V30 23 C 1.7169 2.7968 0.0000 0
M  V30 24 O 2.5239 2.9684 0.0000 0
M  V30 25 O 1.1649 3.4099 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 2 17 18
M  V30 18 1 12 18
M  V30 19 1 6 19
M  V30 20 2 19 20
M  V30 21 1 19 21
M  V30 22 1 5 21
M  V30 23 1 21 22
M  V30 24 1 2 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 2 23 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
146

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Amoxicillin Sodium

>  <Synonyms>
N/A

>  <CAS>
34642-77-8

>  <Formula>
C16H18N3NaO5S

>  <MolWt>
387.4

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
antibiotic; Bacterial

>  <Bioactivity>
"Amoxicillin Sodium is a moderate- spectrum, bacteriolytic, ??-lactam antibiotic."

>  <Reference>
"Rajapakse NS, et al.Paediatr Child Health. 2016 Mar;21(2):65-6.;Bystrzycka W, et al.Cent Eur J Immunol. 2016;41(1):1-5."

>  <ID<1>>
T6385

$$$$
StarDrop ID 147
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 4.3830 -3.9584 0.0000 0
M  V30 2 C 3.6685 -3.5459 0.0000 0
M  V30 3 O 3.6685 -2.7209 0.0000 0
M  V30 4 C 4.3830 -2.3084 0.0000 0 CFG=1
M  V30 5 C 4.3830 -1.4834 0.0000 0
M  V30 6 N 5.0975 -1.0709 0.0000 0
M  V30 7 C 5.8119 -1.4834 0.0000 0
M  V30 8 C 5.8119 -2.3084 0.0000 0
M  V30 9 C 5.0975 -2.7209 0.0000 0
M  V30 10 C 5.2350 -2.1709 0.0000 0
M  V30 11 C 5.2350 -1.6209 0.0000 0
M  V30 12 N 2.9540 -3.9584 0.0000 0
M  V30 13 C 2.9540 -4.7834 0.0000 0
M  V30 14 C 2.2396 -5.1959 0.0000 0
M  V30 15 C 1.5251 -4.7834 0.0000 0
M  V30 16 C 0.8106 -5.1959 0.0000 0
M  V30 17 C 0.0962 -4.7834 0.0000 0
M  V30 18 C 0.0962 -3.9584 0.0000 0
M  V30 19 C 0.8106 -3.5459 0.0000 0
M  V30 20 C 1.5251 -3.9584 0.0000 0
M  V30 21 C 2.2396 -3.5459 0.0000 0 CFG=2
M  V30 22 C 2.2396 -2.7209 0.0000 0
M  V30 23 C 1.5251 -2.3084 0.0000 0
M  V30 24 C 1.5251 -1.4834 0.0000 0
M  V30 25 C 2.2396 -1.0709 0.0000 0
M  V30 26 C 2.9540 -1.4834 0.0000 0
M  V30 27 C 2.9540 -2.3084 0.0000 0
M  V30 28 H 3.5170 -1.8084 0.0000 0
M  V30 29 H 3.1056 -3.0459 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 4 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 6 11
M  V30 13 1 2 12
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 15 20
M  V30 23 1 21 20
M  V30 24 1 21 12
M  V30 25 1 21 22 CFG=3
M  V30 26 2 22 23
M  V30 27 1 23 24
M  V30 28 2 24 25
M  V30 29 1 25 26
M  V30 30 2 26 27
M  V30 31 1 22 27
M  V30 32 1 28 4
M  V30 33 1 29 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
147

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Solifenacin

>  <Synonyms>
YM905 free base

>  <CAS>
242478-37-1

>  <Formula>
C23H26N2O2

>  <MolWt>
362.5

>  <Pathways>
Neuroscience

>  <Target>
AChR

>  <Receptor>
" M2 receptor:6.9 (ki), M1 receptor:7.6 (ki), M3 receptor:8 (ki)"

>  <Bioactivity>
"Solifenacin (YM905 free base) is a novel muscarinic receptor antagonist, its pKis for M1, M2 and M3 receptors is of 7.6, 6.9 and 8.0, respectively."

>  <Reference>
"Ikeda K, et al. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol. 2002 Aug;366(2):97-103."

>  <ID<1>>
T8147

$$$$
StarDrop ID 148
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 4 3 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.2375 -0.7145 0.0000 0
M  V30 2 C 0.8250 0.0000 0.0000 0
M  V30 3 O 1.2375 0.7145 0.0000 0
M  V30 4 O 0.0000 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 2 4
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
148

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Potassium acetate

>  <Synonyms>
Diuretic salt;Potassium ethanoate

>  <CAS>
127-08-2

>  <Formula>
C2H3KO2

>  <MolWt>
98.14

>  <Pathways>
Microbiology/Virology

>  <Target>
Antifungal

>  <Receptor>
Antifungal

>  <Bioactivity>
Potassium acetate with antibacterial and antifungal properties.

>  <Reference>
"Liato, Viacheslav, Labrie, Steve, A?der, Mohammed. Electro-activation of potassium acetate, potassium citrate and calcium lactate: impact on solution acidity, Redox potential, vibrational properties of Raman spectra and antibacterial activity on E. coli O157:H7 at ambient temperature[J]. Springerplus, 5(1):1760."

>  <ID<1>>
T8129

$$$$
StarDrop ID 149
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -2.8579 -2.4750 0.0000 0
M  V30 2 C -2.1434 -2.8875 0.0000 0
M  V30 3 C -2.1434 -3.7125 0.0000 0
M  V30 4 O -1.4760 -4.1974 0.0000 0
M  V30 5 C -1.7309 -4.9820 0.0000 0
M  V30 6 C -2.5559 -4.9820 0.0000 0
M  V30 7 C -2.8109 -4.1974 0.0000 0
M  V30 8 N -1.4289 -2.4750 0.0000 0
M  V30 9 C -1.4289 -1.6500 0.0000 0
M  V30 10 C -0.7145 -1.2375 0.0000 0
M  V30 11 N 0.0000 -1.6500 0.0000 0
M  V30 12 C 0.7145 -1.2375 0.0000 0
M  V30 13 N 0.7145 -0.4125 0.0000 0
M  V30 14 C 1.4289 0.0000 0.0000 0
M  V30 15 N 1.4289 0.8250 0.0000 0
M  V30 16 C 2.1434 -0.4125 0.0000 0
M  V30 17 C 2.8579 0.0000 0.0000 0
M  V30 18 C 3.5724 -0.4125 0.0000 0
M  V30 19 O 4.2868 -0.0000 0.0000 0
M  V30 20 C 4.2868 0.8250 0.0000 0
M  V30 21 C 3.5724 -1.2375 0.0000 0
M  V30 22 O 4.2868 -1.6500 0.0000 0
M  V30 23 C 4.2868 -2.4750 0.0000 0
M  V30 24 C 2.8579 -1.6500 0.0000 0
M  V30 25 C 2.1434 -1.2375 0.0000 0
M  V30 26 N 1.4289 -1.6500 0.0000 0
M  V30 27 C 0.0000 -2.4750 0.0000 0
M  V30 28 C -0.7145 -2.8875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 3 7
M  V30 8 1 2 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 18 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 2 21 24
M  V30 25 1 24 25
M  V30 26 2 16 25
M  V30 27 1 25 26
M  V30 28 2 12 26
M  V30 29 1 11 27
M  V30 30 1 27 28
M  V30 31 1 8 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
149

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Prazosin

>  <Synonyms>
Prazocin;Prazosine;Furazosin

>  <CAS>
19216-56-9

>  <Formula>
C19H21N5O4

>  <MolWt>
383.4

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor; ??1-adrenergic receptor

>  <Bioactivity>
"Prazosin, an ??1-blocker, acts as an inverse agonist at alpha-1 adrenergic receptors and is used to treat hypertension."

>  <Reference>
"Mindi Zhao, et al. PLoS One. 2016, 11(10): e0164796."

>  <ID<1>>
T22406

$$$$
StarDrop ID 150
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3106 -6.1875 0.0000 0
M  V30 2 O 1.5961 -5.7750 0.0000 0
M  V30 3 C 0.8816 -6.1875 0.0000 0
M  V30 4 C 0.8816 -7.0125 0.0000 0
M  V30 5 C 0.1672 -7.4250 0.0000 0
M  V30 6 C -0.5473 -7.0125 0.0000 0
M  V30 7 N -1.2618 -7.4250 0.0000 0
M  V30 8 C -1.9763 -7.0125 0.0000 0
M  V30 9 C -1.9763 -6.1875 0.0000 0
M  V30 10 C -1.2618 -5.7750 0.0000 0
M  V30 11 C -1.2618 -4.9500 0.0000 0
M  V30 12 O -1.9763 -4.5375 0.0000 0
M  V30 13 C -0.5473 -4.5375 0.0000 0
M  V30 14 C -0.5473 -3.7125 0.0000 0
M  V30 15 C 0.1672 -3.3000 0.0000 0
M  V30 16 C 0.3047 -3.8500 0.0000 0
M  V30 17 C 0.3047 -4.4000 0.0000 0
M  V30 18 N 0.1672 -4.9500 0.0000 0
M  V30 19 C 0.8816 -4.5375 0.0000 0
M  V30 20 C 0.8816 -3.7125 0.0000 0
M  V30 21 C 1.5961 -3.3000 0.0000 0
M  V30 22 C 1.5961 -2.4750 0.0000 0
M  V30 23 C -0.5473 -6.1875 0.0000 0
M  V30 24 C 0.1672 -5.7750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 13 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 15 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 10 23
M  V30 25 1 6 23
M  V30 26 2 23 24
M  V30 27 1 3 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
150

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Quinidine sulfate dihydrate

>  <Synonyms>
??-quinine Sodium;Quinidine sulfate;Pitayine Sodium;Chinidin Sodium

>  <CAS>
6591-63-5

>  <Formula>
C40H54N4O10S

>  <MolWt>
783

>  <Pathways>
Metabolism

>  <Target>
P450

>  <Receptor>
CYP450; Cytochrome P450

>  <Bioactivity>
Quinidine sulfate dihydrate is a potent and selective cytochrome P450db  inhibitor

>  <Reference>
"Tsuruo T , Iida H , Kitatani Y , et al. Effects of Quinidine and Related Compounds on Cytotoxicity and Cellular Accumulation of Vincristine and Adriamycin in Drugresistant Tumor Cells[J]. Cancer Research, 1984, 44(10):4303-4307.;Hanna G M , Lau-Cam C A . Application of ^-Nuclear Magnetic Resonance Spectroscopic Method for Quinidine to Simultaneous Determination of Quinidine and Dihydroquinidine in Quinidine Sulfate Tablets[J]. Journal of the Association of Official Analytical Chemists(6):6."

>  <ID<1>>
T8125

$$$$
StarDrop ID 151
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.5737 1.6500 0.0000 0
M  V30 2 C 7.8592 1.2375 0.0000 0
M  V30 3 N 7.8592 0.4125 0.0000 0
M  V30 4 C 7.1447 0.0000 0.0000 0
M  V30 5 C 6.4302 0.4125 0.0000 0
M  V30 6 O 5.7158 0.0000 0.0000 0
M  V30 7 C 8.5737 0.0000 0.0000 0
M  V30 8 C 9.2881 0.4125 0.0000 0
M  V30 9 C 10.0026 0.0000 0.0000 0
M  V30 10 C 10.7171 0.4125 0.0000 0
M  V30 11 C 10.7171 1.2375 0.0000 0
M  V30 12 N 11.4315 0.0000 0.0000 0
M  V30 13 C 12.1460 0.4125 0.0000 0
M  V30 14 C 12.1460 1.2375 0.0000 0
M  V30 15 C 12.8605 1.6500 0.0000 0
M  V30 16 N 13.5749 1.2375 0.0000 0
M  V30 17 C 13.5749 0.4125 0.0000 0
M  V30 18 C 14.2894 0.0000 0.0000 0
M  V30 19 C 14.2894 -0.8250 0.0000 0
M  V30 20 Cl 15.0039 -1.2375 0.0000 0
M  V30 21 C 13.5749 -1.2375 0.0000 0
M  V30 22 C 12.8605 -0.8250 0.0000 0
M  V30 23 C 12.8605 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 3 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 2 19 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 13 23
M  V30 24 1 17 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
151

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Hydroxychloroquine

>  <Synonyms>
2-[[4-[(7-Chloroquinolin-4-yl)amino]pentyl](ethyl)amino]ethanol

>  <CAS>
118-42-3

>  <Formula>
C18H26ClN3O

>  <MolWt>
335.9

>  <Pathways>
Immunology/Inflammation;Autophagy;Microbiology/Virology

>  <Target>
Autophagy;Parasite;SARS-CoV;TLR

>  <Receptor>
Autophagy; Parasite; SARS-CoV; TLR; TLR7; TLR9

>  <Bioactivity>
"Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR7/9. It is a medication used to prevent and treat malaria, and it's also being studied as an experimental treatment for COVID-19."

>  <Reference>
"Ponticelli C, Moroni G. Hydroxychloroquine in systemic lupus erythematosus (SLE). Expert Opin Drug Saf. 2017 Mar;16(3):411-419."

>  <ID<1>>
T9287

$$$$
StarDrop ID 152
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.1725 -0.8813 0.0000 0
M  V30 2 C 6.1725 -0.0562 0.0000 0
M  V30 3 C 5.4581 0.3563 0.0000 0
M  V30 4 C 4.7436 -0.0562 0.0000 0
M  V30 5 C 4.0291 0.3562 0.0000 0
M  V30 6 C 3.3147 -0.0563 0.0000 0
M  V30 7 C 2.6002 0.3562 0.0000 0
M  V30 8 C 2.6002 1.1812 0.0000 0
M  V30 9 O 1.8857 1.5937 0.0000 0
M  V30 10 C 3.3147 1.5938 0.0000 0
M  V30 11 C 4.0291 1.1812 0.0000 0
M  V30 12 N 6.8870 0.3563 0.0000 0
M  V30 13 C 7.6015 -0.0562 0.0000 0
M  V30 14 C 8.3160 0.3563 0.0000 0
M  V30 15 C 9.0304 -0.0562 0.0000 0
M  V30 16 C 9.7449 0.3563 0.0000 0
M  V30 17 C 10.4594 -0.0562 0.0000 0
M  V30 18 C 10.4594 -0.8812 0.0000 0
M  V30 19 O 11.1738 -1.2937 0.0000 0
M  V30 20 C 9.7449 -1.2937 0.0000 0
M  V30 21 O 9.7449 -2.1187 0.0000 0
M  V30 22 C 9.0304 -0.8812 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 10 11
M  V30 11 1 5 11
M  V30 12 1 2 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 2 20 22
M  V30 23 1 15 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
152

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dobutamine hydrochloride

>  <Synonyms>
Dobutamine (hydrochloride)

>  <CAS>
49745-95-1

>  <Formula>
C18H24ClNO3

>  <MolWt>
337.8

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor

>  <Bioactivity>
Dobutamine (hydrochloride) is a catecholamine that acts as a ??-adrenergic receptor agonist with potent positive inotropic effects.

>  <Reference>
"Vallet B, et al. Dobutamine: mechanisms of action and use in acute cardiovascular pathology. Ann Cardiol Angeiol (Paris). 1991 Jun;40(6):397-402.;Tyrankiewicz U , et al. Characterization of the cardiac response to a low and high dose of dobutamine in the mouse model of dilated cardiomyopathy by MRI in vivo. J Magn Reson Imaging. 2013 Mar;37(3):669-77."

>  <ID<1>>
T8149

$$$$
StarDrop ID 153
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 45 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 10.2627 -4.8430 0.0000 0
M  V30 2 C 9.6495 -5.2536 0.0000 0
M  V30 3 O 9.7859 -6.0673 0.0000 0
M  V30 4 O 8.8767 -4.9650 0.0000 0
M  V30 5 C 8.7402 -4.1513 0.0000 0
M  V30 6 C 7.8531 -3.8394 0.0000 0
M  V30 7 O 7.3310 -4.3876 0.0000 0
M  V30 8 C 7.8310 -3.0490 0.0000 0 CFG=1
M  V30 9 O 7.0993 -3.4302 0.0000 0
M  V30 10 C 6.5107 -2.8521 0.0000 0
M  V30 11 C 6.1428 -3.5906 0.0000 0
M  V30 12 C 5.3268 -3.4689 0.0000 0
M  V30 13 C 5.1904 -2.6552 0.0000 0
M  V30 14 C 5.9221 -2.2741 0.0000 0
M  V30 15 O 6.8786 -2.1137 0.0000 0
M  V30 16 C 7.6946 -2.2354 0.0000 0 CFG=2
M  V30 17 C 8.4262 -1.8542 0.0000 0
M  V30 18 C 9.0148 -2.4323 0.0000 0 CFG=1
M  V30 19 C 9.8383 -2.3816 0.0000 0 CFG=2
M  V30 20 C 10.2062 -1.6432 0.0000 0
M  V30 21 C 11.0296 -1.5926 0.0000 0
M  V30 22 C 11.4852 -2.2804 0.0000 0
M  V30 23 C 12.3086 -2.2297 0.0000 0
M  V30 24 C 12.7642 -2.9176 0.0000 0
M  V30 25 O 13.5876 -2.8669 0.0000 0
M  V30 26 C 12.3963 -3.6560 0.0000 0
M  V30 27 C 11.5729 -3.7066 0.0000 0
M  V30 28 C 11.1173 -3.0188 0.0000 0 CFG=1
M  V30 29 C 10.4064 -3.6876 0.0000 0
M  V30 30 C 10.2938 -3.0694 0.0000 0 CFG=2
M  V30 31 F 10.7494 -3.7573 0.0000 0
M  V30 32 C 9.9260 -3.8079 0.0000 0 CFG=1
M  V30 33 O 10.3815 -4.4957 0.0000 0
M  V30 34 C 9.1025 -3.8585 0.0000 0
M  V30 35 C 8.6470 -3.1707 0.0000 0 CFG=2
M  V30 36 C 8.2039 -3.8666 0.0000 0
M  V30 37 H 6.9939 -2.9488 0.0000 0
M  V30 38 H 8.0286 -2.5976 0.0000 0
M  V30 39 H 10.8364 -2.3203 0.0000 0
M  V30 40 H 9.4800 -4.7029 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 8 6 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 10 14
M  V30 15 1 10 15
M  V30 16 1 16 15 CFG=3
M  V30 17 1 8 16
M  V30 18 1 16 17
M  V30 19 1 18 17 CFG=1
M  V30 20 1 19 18
M  V30 21 1 19 20 CFG=3
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 24 26
M  V30 28 2 26 27
M  V30 29 1 28 27
M  V30 30 1 28 22
M  V30 31 1 28 29 CFG=1
M  V30 32 1 30 28
M  V30 33 1 30 19
M  V30 34 1 30 31 CFG=3
M  V30 35 1 30 32
M  V30 36 1 32 33 CFG=1
M  V30 37 1 32 34
M  V30 38 1 35 34
M  V30 39 1 35 8
M  V30 40 1 18 35
M  V30 41 1 35 36 CFG=1
M  V30 42 1 37 16
M  V30 43 1 38 18
M  V30 44 1 39 19
M  V30 45 1 40 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
153

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Amcinonide

>  <Synonyms>
CL-34699

>  <CAS>
51022-69-6

>  <Formula>
C28H35FO7

>  <MolWt>
502.6

>  <Pathways>
GPCR/G Protein;Endocrinology/Hormones

>  <Target>
Glucocorticoid Receptor;Annexin A

>  <Receptor>
 NO release:3.38 nM

>  <Bioactivity>
Amcinonide is a Corticosteroid. The mechanism of action of amcinonide is as a Corticosteroid Hormone Receptor Agonist.

>  <Reference>
"Grossman R, et al. Ann N Y Acad Sci. 2006 Jul;1071:410-21.;Zeng X, Zhu S, Lu W, et al. Target identification among known drugs by deep learning from heterogeneous networks[J]. Chemical Science. 2020, 11(7): 1775-1797."

>  <ID<1>>
T0261

$$$$
StarDrop ID 154
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 52 56 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.9260 1.0650 0.0000 0
M  V30 2 C 3.6404 0.6525 0.0000 0
M  V30 3 C 4.3549 1.0650 0.0000 0
M  V30 4 C 5.0694 0.6525 0.0000 0
M  V30 5 C 5.7838 1.0650 0.0000 0
M  V30 6 O 5.7838 1.8900 0.0000 0
M  V30 7 O 6.4983 0.6525 0.0000 0
M  V30 8 C 7.2128 1.0650 0.0000 0
M  V30 9 C 7.9272 0.6525 0.0000 0
M  V30 10 O 8.6417 1.0650 0.0000 0
M  V30 11 C 7.9272 -0.1725 0.0000 0 CFG=1
M  V30 12 O 8.7397 -0.0293 0.0000 0
M  V30 13 C 8.2094 -0.9478 0.0000 0
M  V30 14 C 7.6791 -1.5798 0.0000 0 CFG=2
M  V30 15 O 7.9613 -2.3550 0.0000 0
M  V30 16 C 8.7737 -2.4983 0.0000 0
M  V30 17 C 9.3040 -1.8663 0.0000 0
M  V30 18 C 10.1165 -2.0096 0.0000 0
M  V30 19 N 10.6468 -1.3776 0.0000 0
M  V30 20 C 11.4593 -1.5208 0.0000 0
M  V30 21 O 11.7414 -2.2961 0.0000 0
M  V30 22 C 11.9896 -0.8888 0.0000 0
M  V30 23 F 12.5199 -0.2569 0.0000 0
M  V30 24 F 12.6216 -1.4191 0.0000 0
M  V30 25 F 11.3576 -0.3585 0.0000 0
M  V30 26 C 10.3987 -2.7848 0.0000 0
M  V30 27 O 11.2111 -2.9281 0.0000 0
M  V30 28 C 9.8684 -3.4168 0.0000 0
M  V30 29 C 10.1505 -4.1920 0.0000 0
M  V30 30 O 9.0559 -3.2735 0.0000 0
M  V30 31 C 6.8666 -1.4365 0.0000 0
M  V30 32 C 6.3363 -2.0685 0.0000 0
M  V30 33 O 6.6185 -2.8437 0.0000 0
M  V30 34 C 5.5239 -1.9252 0.0000 0
M  V30 35 C 4.9936 -2.5572 0.0000 0
M  V30 36 O 5.2757 -3.3325 0.0000 0
M  V30 37 C 4.1811 -2.4140 0.0000 0
M  V30 38 C 3.6508 -3.0460 0.0000 0
M  V30 39 O 3.9330 -3.8212 0.0000 0
M  V30 40 C 3.4027 -4.4532 0.0000 0
M  V30 41 C 2.8383 -2.9027 0.0000 0
M  V30 42 C 2.5562 -2.1274 0.0000 0
M  V30 43 C 3.0865 -1.4955 0.0000 0
M  V30 44 C 3.8989 -1.6387 0.0000 0
M  V30 45 C 4.4292 -1.0067 0.0000 0
M  V30 46 O 4.1471 -0.2315 0.0000 0
M  V30 47 C 5.2417 -1.1500 0.0000 0
M  V30 48 C 5.7720 -0.5180 0.0000 0
M  V30 49 O 5.4898 0.2572 0.0000 0
M  V30 50 C 6.5845 -0.6613 0.0000 0
M  V30 51 C 7.1148 -0.0293 0.0000 0
M  V30 52 H 8.6639 -1.7534 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 11 9 CFG=1
M  V30 11 1 11 12 CFG=3
M  V30 12 1 11 13
M  V30 13 1 14 13
M  V30 14 1 14 15 CFG=3
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 20 22
M  V30 22 1 22 23
M  V30 23 1 22 24
M  V30 24 1 22 25
M  V30 25 1 18 26
M  V30 26 1 26 27
M  V30 27 1 26 28
M  V30 28 1 28 29
M  V30 29 1 28 30
M  V30 30 1 16 30
M  V30 31 1 14 31
M  V30 32 2 31 32
M  V30 33 1 32 33
M  V30 34 1 32 34
M  V30 35 1 34 35
M  V30 36 2 35 36
M  V30 37 1 35 37
M  V30 38 2 37 38
M  V30 39 1 38 39
M  V30 40 1 39 40
M  V30 41 1 38 41
M  V30 42 2 41 42
M  V30 43 1 42 43
M  V30 44 2 43 44
M  V30 45 1 37 44
M  V30 46 1 44 45
M  V30 47 2 45 46
M  V30 48 1 45 47
M  V30 49 2 34 47
M  V30 50 1 47 48
M  V30 51 1 48 49
M  V30 52 2 48 50
M  V30 53 1 31 50
M  V30 54 1 50 51
M  V30 55 1 11 51
M  V30 56 1 52 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
154

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Valrubicin

>  <Synonyms>
AD-32

>  <CAS>
56124-62-0

>  <Formula>
C34H36F3NO13

>  <MolWt>
723.7

>  <Pathways>
Cytoskeletal Signaling;Microbiology/Virology;Chromatin/Epigenetic

>  <Target>
PKC;Antibiotic

>  <Receptor>
" PDBu-activated PKC:1.25 ??M, TPA-activated PKC:0.85 ??M"

>  <Bioactivity>
Valrubicin (AD 32) inhibits TPA- and PDBu-induced PKC activation (IC50s: 0.85 and 1.25 ??M) and has antitumor and anti-inflammatory activity.

>  <Reference>
"Chuang LF, et al. Activation of human leukemia protein kinase C by tumor promoters and its inhibition by N-trifluoroacetyladriamycin-14-valerate (AD 32). Biochem Pharmacol. 1992 Feb 18;43(4):865-72.;Wani MK, et al. Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck. Laryngoscope. 2000 Dec;110(12):2026-32.;Hauge E, et al. Topical valrubicin application reduces skin inflammation in murine models. Br J Dermatol. 2012 Aug;167(2):288-95."

>  <ID<1>>
T7604

$$$$
StarDrop ID 155
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.1801 -0.0616 0.0000 0
M  V30 2 C 4.8946 -0.4741 0.0000 0 CFG=2
M  V30 3 O 4.8946 -1.2991 0.0000 0
M  V30 4 C 4.1801 -1.7116 0.0000 0
M  V30 5 C 4.1801 -2.5366 0.0000 0
M  V30 6 C 3.4656 -2.9491 0.0000 0
M  V30 7 C 2.7512 -2.5366 0.0000 0
M  V30 8 N 2.7512 -1.7116 0.0000 0
M  V30 9 C 3.4656 -1.2991 0.0000 0
M  V30 10 N 3.4656 -0.4741 0.0000 0
M  V30 11 C 3.4656 -3.7741 0.0000 0
M  V30 12 C 4.1331 -4.2590 0.0000 0
M  V30 13 N 3.8781 -5.0437 0.0000 0
M  V30 14 N 3.0531 -5.0437 0.0000 0
M  V30 15 C 2.7982 -4.2590 0.0000 0
M  V30 16 C 2.5682 -5.7111 0.0000 0
M  V30 17 C 2.9038 -6.4648 0.0000 0
M  V30 18 C 2.4189 -7.1322 0.0000 0
M  V30 19 N 1.5984 -7.0460 0.0000 0
M  V30 20 C 1.2628 -6.2923 0.0000 0
M  V30 21 C 1.7477 -5.6249 0.0000 0
M  V30 22 C 5.6091 -0.0616 0.0000 0
M  V30 23 C 5.6091 0.7634 0.0000 0
M  V30 24 Cl 4.8946 1.1759 0.0000 0
M  V30 25 C 6.3235 1.1759 0.0000 0
M  V30 26 C 7.0380 0.7634 0.0000 0
M  V30 27 C 7.0380 -0.0616 0.0000 0
M  V30 28 F 7.7525 -0.4741 0.0000 0
M  V30 29 C 6.3235 -0.4741 0.0000 0
M  V30 30 Cl 6.3235 -1.2991 0.0000 0
M  V30 31 H 4.0286 -0.9741 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 4 9
M  V30 10 1 9 10
M  V30 11 1 6 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 11 15
M  V30 17 1 14 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 16 21
M  V30 24 1 2 22
M  V30 25 2 22 23
M  V30 26 1 23 24
M  V30 27 1 23 25
M  V30 28 2 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 2 27 29
M  V30 32 1 22 29
M  V30 33 1 29 30
M  V30 34 1 31 2
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
155

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
(S)-crizotinib

>  <Synonyms>
ent-crizotinib

>  <CAS>
1374356-45-2

>  <Formula>
C21H22Cl2FN5O

>  <MolWt>
450.3

>  <Pathways>
Apoptosis;DNA Damage/DNA Repair;Cell Cycle/Checkpoint

>  <Target>
Apoptosis;DNA/RNA Synthesis;MTH1

>  <Receptor>
 MTH1:72 nM

>  <Bioactivity>
"(S)-crizotinib??IC50 of 72 nM??, an effective MTH1 (NUDT1) inhibitor, is the (S)-enantiomer of crizotinib."

>  <Reference>
"Huber KV, et al. Nature. 2014 , 508(7495), 222-227."

>  <ID<1>>
T6357

$$$$
StarDrop ID 156
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.8069 -2.9836 0.0000 0
M  V30 2 C 1.5266 -2.2077 0.0000 0 CFG=1
M  V30 3 C 2.3387 -2.3529 0.0000 0 CFG=2
M  V30 4 C 2.8705 -1.7222 0.0000 0 CFG=2
M  V30 5 C 3.6826 -1.8674 0.0000 0 CFG=1
M  V30 6 C 3.9629 -2.6434 0.0000 0 CFG=2
M  V30 7 C 4.3228 -3.3857 0.0000 0
M  V30 8 C 3.4311 -3.2741 0.0000 0
M  V30 9 C 2.6190 -3.1289 0.0000 0
M  V30 10 C 4.7875 -2.6166 0.0000 0 CFG=1
M  V30 11 O 5.2939 -3.2679 0.0000 0
M  V30 12 C 6.1111 -3.1550 0.0000 0
M  V30 13 C 6.6175 -3.8064 0.0000 0
M  V30 14 O 6.4220 -2.3909 0.0000 0
M  V30 15 C 5.0168 -1.8241 0.0000 0
M  V30 16 C 4.3340 -1.3611 0.0000 0
M  V30 17 H 3.1508 -2.4981 0.0000 0
M  V30 18 C 2.5902 -0.9463 0.0000 0
M  V30 19 C 1.7781 -0.8011 0.0000 0
M  V30 20 C 1.2463 -1.4318 0.0000 0
M  V30 21 C 0.4342 -1.2866 0.0000 0
M  V30 22 C -0.0976 -1.9173 0.0000 0
M  V30 23 O -0.9098 -1.7721 0.0000 0
M  V30 24 C 0.1827 -2.6932 0.0000 0
M  V30 25 C 0.9948 -2.8384 0.0000 0
M  V30 26 H 3.4023 -1.0915 0.0000 0
M  V30 27 H 2.0584 -1.5770 0.0000 0
M  V30 28 H 5.7696 -2.4281 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 3 2
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7 CFG=3
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 3 9
M  V30 10 1 6 10
M  V30 11 1 10 11 CFG=3
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 10 15
M  V30 16 1 15 16
M  V30 17 1 5 16
M  V30 18 1 5 17 CFG=1
M  V30 19 1 4 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 2 20
M  V30 23 2 20 21
M  V30 24 1 21 22
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 1 24 25
M  V30 28 1 2 25
M  V30 29 1 4 26 CFG=3
M  V30 30 1 3 27 CFG=1
M  V30 31 1 28 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
156

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Testosterone acetate

>  <Synonyms>
NSC523836;NSC 523836;NSC-523836

>  <CAS>
1045-69-8

>  <Formula>
C21H30O3

>  <MolWt>
330.5

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Testosterone acetate is a hormone with in vitro antitumor activity.

>  <Reference>
"Couture JF, de J??sus-Tran KP, Roy AM, Cantin L, C?t?? PL, Legrand P, Luu-The V, Labrie F, Breton R. Comparison of crystal structures of human type 3 3alpha-hydroxysteroid dehydrogenase reveals an ""induced-fit"" mechanism and a conserved basic motif involved in the binding of androgen. Protein Sci. 2005 Jun;14(6):1485-97. PubMed PMID: 15929998; PubMed Central PMCID: PMC2253370.;Mohamed ZH, El-Koussi NA, Mahfouz NM, Youssef AF, Abdel Jaleel GA, Shouman SA. Cu (I) catalyzed alkyne-azide 1,3-dipolar cycloaddition (CuAAC): Synthesis of 17??-[1-(substituted phenyl)-1,2,3-triazol-4-yl]-19-nor-testosterone-17??-yl acetates targeting progestational and antipro-liferative activities. Eur J Med Chem. 2015 Jun 5;97:75-82. doi: 10.1016/j.ejmech.2015.04.045. Epub 2015 Apr 28. PubMed PMID: 25942354.;Murugkar A, Unnikrishnan B, Padhye S, Bhonde R, Teat S, Triantafillou E, Sinn E. Hormone anchored metal complexes. 1. Synthesis, structure, spectroscopy and in vitro antitumor activity of testosterone acetate thiosemicarbazone and its metal complexes. Met Based Drugs. 1999;6(3):177-82. doi: 10.1155/MBD.1999.177. PubMed PMID: 18472909; PubMed Central PMCID: PMC2366831.;Dallagi T, Top S, Masi S, Jaouen G, Saidi M. Synthesis and biodistribution of [99mTc]-N-[4-nitro-3-trifluoromethyl-phenyl] cyclopentadienyltricarbonyltechnetium carboxamide, a nonsteroidal antiandrogen flutamide derivative. Metallomics. 2010 Apr;2(4):289-93. doi: 10.1039/b925224j. Epub 2010 Feb 12. PubMed PMID: 21069171."

>  <ID<1>>
TC0025

$$$$
StarDrop ID 157
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.8011 0.4760 0.0000 0
M  V30 2 C 3.5155 0.0635 0.0000 0
M  V30 3 O 3.5155 -0.7615 0.0000 0
M  V30 4 C 4.2300 0.4760 0.0000 0
M  V30 5 N 4.9445 0.0635 0.0000 0
M  V30 6 C 5.6590 0.4760 0.0000 0
M  V30 7 O 5.6590 1.3010 0.0000 0
M  V30 8 C 6.3734 0.0635 0.0000 0
M  V30 9 C 7.0879 0.4760 0.0000 0
M  V30 10 C 7.8024 0.0635 0.0000 0
M  V30 11 C 7.8024 -0.7615 0.0000 0
M  V30 12 C 7.0879 -1.1740 0.0000 0
M  V30 13 C 6.3734 -0.7615 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 8 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
157

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Methenamine Hippurate

>  <Synonyms>
N/A

>  <CAS>
5714-73-8

>  <Formula>
C15H21N5O3

>  <MolWt>
319.4

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial

>  <Receptor>
Bacterial

>  <Bioactivity>
"Methenamine Hippurate is a component of Hiprex, with antibacterial activity."

>  <Reference>
"Lee B S , Bhuta T , Craig J C , et al. Methenamine hippurate for preventing urinary tract infections[J]. Cochrane database of systematic reviews (Online), 2002, 10(1):CD003265.;Lo T S , Hammer K D , Zegarra M , et al. Methenamine: a forgotten drug for preventing recurrent urinary tract infection in a multidrug resistance era[J]. Expert Review of Anti Infective Therapy, 2014, 12(5):549-554."

>  <ID<1>>
T8365

$$$$
StarDrop ID 158
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.0713 -4.4770 0.0000 0
M  V30 2 C 0.8834 -4.3318 0.0000 0
M  V30 3 O 1.4153 -4.9625 0.0000 0
M  V30 4 O 1.1637 -3.5559 0.0000 0
M  V30 5 C 1.9758 -3.4106 0.0000 0
M  V30 6 C 2.2561 -2.6347 0.0000 0
M  V30 7 O 1.7243 -2.0040 0.0000 0
M  V30 8 C 3.0683 -2.4895 0.0000 0 CFG=1
M  V30 9 O 3.1278 -3.3123 0.0000 0
M  V30 10 C 2.8390 -1.6970 0.0000 0
M  V30 11 C 3.5218 -1.2340 0.0000 0
M  V30 12 C 4.1731 -1.7404 0.0000 0 CFG=1
M  V30 13 C 4.9853 -1.5952 0.0000 0 CFG=2
M  V30 14 C 5.2655 -0.8192 0.0000 0
M  V30 15 C 6.0777 -0.6740 0.0000 0
M  V30 16 C 6.6095 -1.3047 0.0000 0
M  V30 17 C 7.4216 -1.1595 0.0000 0
M  V30 18 C 7.9534 -1.7902 0.0000 0
M  V30 19 O 8.7655 -1.6450 0.0000 0
M  V30 20 C 7.6731 -2.5662 0.0000 0
M  V30 21 C 6.8610 -2.7114 0.0000 0
M  V30 22 C 6.3292 -2.0807 0.0000 0 CFG=1
M  V30 23 C 6.0489 -2.8566 0.0000 0
M  V30 24 C 5.5171 -2.2259 0.0000 0 CFG=1
M  V30 25 C 5.2368 -3.0018 0.0000 0
M  V30 26 O 5.7686 -3.6325 0.0000 0
M  V30 27 C 4.4247 -3.1470 0.0000 0
M  V30 28 C 3.8928 -2.5163 0.0000 0 CFG=2
M  V30 29 C 3.5330 -3.2587 0.0000 0
M  V30 30 H 3.2125 -2.0183 0.0000 0
M  V30 31 H 4.3406 -0.8308 0.0000 0
M  V30 32 H 6.1617 -2.9904 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 8 6 CFG=1
M  V30 8 1 8 9 CFG=3
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 12 11 CFG=1
M  V30 12 1 12 13
M  V30 13 1 13 14 CFG=3
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 2 20 21
M  V30 21 1 22 21
M  V30 22 1 22 16
M  V30 23 1 22 23 CFG=1
M  V30 24 1 24 22
M  V30 25 1 13 24
M  V30 26 1 24 25 CFG=1
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 28 27
M  V30 30 1 28 8
M  V30 31 1 12 28
M  V30 32 1 28 29 CFG=1
M  V30 33 1 30 12
M  V30 34 1 31 13
M  V30 35 1 32 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
158

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Prednisone acetate

>  <Synonyms>
Prednisone 21-acetate

>  <CAS>
125-10-0

>  <Formula>
C23H28O6

>  <MolWt>
400.5

>  <Pathways>
Endocrinology/Hormones

>  <Target>
Glucocorticoid Receptor

>  <Receptor>
Glucocorticoid Receptor

>  <Bioactivity>
Prednisone acetate is a glucocorticoid receptor agonist with immunomodulating properties and anti-inflammatory.

>  <Reference>
"Williams J R , Moore R H , Li R , et al. ChemInform Abstract: STRUCTURE AND PHOTOCHEMISTRY OF LUMIPREDNISONE AND LUMIPREDNISONE ACETATE[J]. Chemischer Informationsdienst, 1979, 10(47)."

>  <ID<1>>
T8396

$$$$
StarDrop ID 159
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -0.0000 -2.4750 0.0000 0
M  V30 2 F -0.0000 -3.3000 0.0000 0
M  V30 3 F 0.8250 -2.4750 0.0000 0
M  V30 4 F -0.8250 -2.4750 0.0000 0
M  V30 5 C -0.0000 -1.6500 0.0000 0
M  V30 6 C 0.7145 -1.2375 0.0000 0
M  V30 7 C 0.7145 -0.4125 0.0000 0
M  V30 8 C 1.4289 -0.0000 0.0000 0
M  V30 9 C 1.4289 0.8250 0.0000 0 CFG=2
M  V30 10 O 0.7145 1.2375 0.0000 0
M  V30 11 C 2.1434 1.2375 0.0000 0 CFG=1
M  V30 12 C 2.1434 2.0625 0.0000 0
M  V30 13 C 2.8579 2.4750 0.0000 0
M  V30 14 C 3.5724 2.0625 0.0000 0
M  V30 15 C 3.5724 1.2375 0.0000 0
M  V30 16 N 2.8579 0.8250 0.0000 0
M  V30 17 H 2.1434 0.4125 0.0000 0
M  V30 18 C 2.1434 -0.4125 0.0000 0
M  V30 19 C 2.1434 -1.2375 0.0000 0
M  V30 20 C 2.8579 -1.6500 0.0000 0
M  V30 21 F 3.5724 -2.0625 0.0000 0
M  V30 22 F 2.4454 -2.3645 0.0000 0
M  V30 23 F 3.2704 -0.9355 0.0000 0
M  V30 24 N 1.4289 -1.6500 0.0000 0
M  V30 25 C 0.0000 -0.0000 0.0000 0
M  V30 26 C -0.7145 -0.4125 0.0000 0
M  V30 27 C -0.7145 -1.2375 0.0000 0
M  V30 28 H 1.4290 1.8250 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 9 8
M  V30 9 1 9 10 CFG=3
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 11 16
M  V30 17 1 11 17 CFG=3
M  V30 18 2 8 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 20 22
M  V30 23 1 20 23
M  V30 24 2 19 24
M  V30 25 1 6 24
M  V30 26 1 7 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 5 27
M  V30 30 1 28 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
159

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Mefloquine

>  <Synonyms>
Ro215998;Ro-215998;Ro 215998;WR 142490;Lariam

>  <CAS>
53230-10-7

>  <Formula>
C17H16F6N2O

>  <MolWt>
378.3

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Mefloquine, a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 ??M. Mefloquine can be used for malaria, systemic lupus erythematosus, and cancer research."

>  <Reference>
"Tao Y, Xue J, Jiang B, Zhang HB, Xiao SH. Significance of higher drug concentration in erythrocytes of mice infected with Schistosoma japonicum and treated orally with mefloquine at single doses. Parasitol Res. 2015 Dec;114(12):4521-30. doi: 10.1007/s00436-015-4696-4. Epub 2015 Sep 4. PubMed PMID: 26341799.;Janowsky A, Eshleman AJ, Johnson RA, Wolfrum KM, Hinrichs DJ, Yang J, Zabriskie TM, Smilkstein MJ, Riscoe MK. Mefloquine and psychotomimetics share neurotransmitter receptor and transporter interactions in vitro. Psychopharmacology (Berl). 2014 Jul;231(14):2771-83. doi: 10.1007/s00213-014-3446-0. Epub 2014 Feb 2. PubMed PMID: 24488404; PubMed Central PMCID: PMC4097020.;Maaswinkel H, Zhu L, Weng W. A small-fish model for behavioral-toxicological screening of new antimalarial drugs: a comparison between erythro- and threo-mefloquine. BMC Res Notes. 2015 Apr 2;8:122. doi: 10.1186/s13104-015-1088-x. PubMed PMID: 25886204; PubMed Central PMCID: PMC4386100.;Kang J, et al. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK andHERG. J Pharmacol Exp Ther. 2001 Oct;299(1):290-6."

>  <ID<1>>
T0860L

$$$$
StarDrop ID 160
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.2466 0.4313 0.0000 0
M  V30 2 C 3.0716 0.4313 0.0000 0
M  V30 3 C 3.0716 -0.3937 0.0000 0
M  V30 4 C 3.7861 -0.8062 0.0000 0
M  V30 5 N 3.7861 -1.6312 0.0000 0
M  V30 6 C 4.5006 -2.0438 0.0000 0
M  V30 7 C 4.5006 -2.8688 0.0000 0
M  V30 8 C 3.7861 -3.2813 0.0000 0
M  V30 9 C 3.0716 -2.8688 0.0000 0
M  V30 10 C 3.0716 -2.0438 0.0000 0
M  V30 11 C 3.0716 1.2563 0.0000 0
M  V30 12 C 2.3571 1.6688 0.0000 0
M  V30 13 C 2.3571 2.4938 0.0000 0
M  V30 14 C 3.0716 2.9063 0.0000 0
M  V30 15 C 3.7861 2.4938 0.0000 0
M  V30 16 C 3.7861 1.6688 0.0000 0
M  V30 17 C 3.8966 0.4312 0.0000 0
M  V30 18 C 4.3091 1.1457 0.0000 0
M  V30 19 C 5.1341 1.1457 0.0000 0
M  V30 20 C 5.5466 0.4312 0.0000 0
M  V30 21 C 5.1341 -0.2832 0.0000 0
M  V30 22 C 4.3091 -0.2832 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 5 10
M  V30 11 1 2 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 11 16
M  V30 18 1 2 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
160

>  <Plate>
PHD136328

>  <Row>
h

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Trihexyphenidyl hydrochloride

>  <Synonyms>
Benzhexol hydrochloride;Artane hydrochloride;Tremin;Triesifenidile

>  <CAS>
52-49-3

>  <Formula>
C20H31NO??HCl

>  <MolWt>
337.9

>  <Pathways>
Neuroscience

>  <Target>
AChR

>  <Receptor>
AChR; mAChR

>  <Bioactivity>
Trihexyphenidyl hydrochloride is an antiparkinsonian agent of the antimuscarinic class.

>  <Reference>
"Amal M. Moustafa, et al. The Egyptian Journal of Histology. 2011, 34:687-696.;Huang Y, et al. J Neuroinflammation. 2016, 13(1):175."

>  <ID<1>>
T7002

$$$$
StarDrop ID 161
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 39 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.5597 -2.2275 0.0000 0
M  V30 2 C 0.9943 -1.5262 0.0000 0
M  V30 3 N 0.6043 -0.7992 0.0000 0
M  V30 4 C -0.2203 -0.7735 0.0000 0
M  V30 5 C -0.6549 -1.4747 0.0000 0
M  V30 6 F -0.2649 -2.2017 0.0000 0
M  V30 7 C -1.4795 -1.4490 0.0000 0
M  V30 8 O -1.9141 -2.1502 0.0000 0
M  V30 9 C -2.7387 -2.1244 0.0000 0
M  V30 10 C -1.8694 -0.7219 0.0000 0
M  V30 11 C -1.4348 -0.0207 0.0000 0
M  V30 12 O -1.8248 0.7063 0.0000 0
M  V30 13 C -1.3902 1.4075 0.0000 0
M  V30 14 C -0.6102 -0.0465 0.0000 0
M  V30 15 F -0.1756 0.6548 0.0000 0
M  V30 16 C 1.0390 -0.0980 0.0000 0
M  V30 17 C 1.8636 -0.1238 0.0000 0
M  V30 18 C 2.2982 0.5775 0.0000 0
M  V30 19 N 3.1228 0.5517 0.0000 0
M  V30 20 C 3.5127 -0.1753 0.0000 0
M  V30 21 N 4.3140 -0.3719 0.0000 0
M  V30 22 C 4.3745 -1.1947 0.0000 0
M  V30 23 C 3.6108 -1.5066 0.0000 0
M  V30 24 C 3.0781 -0.8765 0.0000 0
M  V30 25 C 2.2535 -0.8508 0.0000 0
M  V30 26 N 1.8189 -1.5520 0.0000 0
M  V30 27 C 2.2089 -2.2790 0.0000 0
M  V30 28 C 1.7743 -2.9802 0.0000 0
M  V30 29 C 5.0758 -1.6293 0.0000 0
M  V30 30 N 5.0500 -2.4539 0.0000 0
M  V30 31 C 5.7513 -2.8885 0.0000 0
M  V30 32 C 5.7255 -3.7131 0.0000 0
M  V30 33 O 4.9985 -4.1031 0.0000 0
M  V30 34 C 4.2973 -3.6685 0.0000 0
M  V30 35 C 4.3230 -2.8439 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 7 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 11 14
M  V30 14 2 4 14
M  V30 15 1 14 15
M  V30 16 1 3 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 1 20 24
M  V30 26 2 24 25
M  V30 27 1 17 25
M  V30 28 1 25 26
M  V30 29 1 2 26
M  V30 30 1 26 27
M  V30 31 1 27 28
M  V30 32 1 22 29
M  V30 33 1 29 30
M  V30 34 1 30 31
M  V30 35 1 31 32
M  V30 36 1 32 33
M  V30 37 1 33 34
M  V30 38 1 34 35
M  V30 39 1 30 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
161

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pemigatinib

>  <Synonyms>
INCB054828

>  <CAS>
1513857-77-6

>  <Formula>
C24H27F2N5O4

>  <MolWt>
487.5

>  <Pathways>
Angiogenesis;Tyrosine Kinase/Adaptors

>  <Target>
FGFR

>  <Receptor>
" FGFR4:30 nM, FGFR1:0.4 nM, FGFR2:0.5 nM, FGFR3:1.2 nM"

>  <Bioactivity>
"Pemigatinib is an orally active, selective inhibitor of FGFR(IC50s of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively)."

>  <Reference>
"Arudra K, et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. J Cutan Pathol. 2018 Oct;45(10):786-790.;Roskoski R Jr, et al. The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder. Pharmacol Res. 2020 Jan;151:104567.;Krook MA, et al. Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy. Cold Spring Harb Mol Case Stud. 2019 Aug 1;5(4)."

>  <ID<1>>
T12401

$$$$
StarDrop ID 162
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 1.5395 -4.3164 0.0000 0
M  V30 2 C 1.9520 -3.6020 0.0000 0 CFG=1
M  V30 3 C 1.5395 -2.8875 0.0000 0 CFG=1
M  V30 4 C 0.7145 -2.8875 0.0000 0 CFG=2
M  V30 5 C 0.3020 -2.1730 0.0000 0
M  V30 6 O -0.5230 -2.1730 0.0000 0
M  V30 7 O 0.3020 -3.6020 0.0000 0
M  V30 8 O 1.9520 -2.1730 0.0000 0
M  V30 9 C 2.7770 -3.6020 0.0000 0 CFG=1
M  V30 10 C 3.1895 -2.8875 0.0000 0
M  V30 11 O 4.0145 -2.8875 0.0000 0
M  V30 12 O 3.1895 -4.3164 0.0000 0
M  V30 13 C 1.9520 -5.0309 0.0000 0 CFG=2
M  V30 14 O 2.7770 -5.0309 0.0000 0
M  V30 15 C 3.1895 -5.7454 0.0000 0 CFG=2
M  V30 16 C 4.0145 -5.7454 0.0000 0
M  V30 17 O 4.4270 -5.0309 0.0000 0
M  V30 18 C 2.7770 -6.4599 0.0000 0 CFG=2
M  V30 19 O 3.1895 -7.1743 0.0000 0
M  V30 20 C 1.9520 -6.4599 0.0000 0 CFG=2
M  V30 21 O 1.5395 -7.1743 0.0000 0
M  V30 22 C 1.5395 -5.7454 0.0000 0 CFG=1
M  V30 23 O 0.7145 -5.7454 0.0000 0
M  V30 24 H 0.9520 -3.6019 0.0000 0
M  V30 25 H 1.0395 -2.0215 0.0000 0
M  V30 26 H 1.2145 -3.7535 0.0000 0
M  V30 27 H 3.7770 -3.6019 0.0000 0
M  V30 28 H 2.4520 -4.1649 0.0000 0
M  V30 29 H 3.6895 -4.8794 0.0000 0
M  V30 30 H 3.7770 -6.4598 0.0000 0
M  V30 31 H 0.9520 -6.4598 0.0000 0
M  V30 32 H 1.0395 -4.8794 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 4 7 CFG=1
M  V30 7 1 3 8 CFG=1
M  V30 8 1 2 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 9 12 CFG=1
M  V30 12 1 13 1 CFG=3
M  V30 13 1 13 14
M  V30 14 1 15 14
M  V30 15 1 15 16 CFG=3
M  V30 16 1 16 17
M  V30 17 1 18 15
M  V30 18 1 18 19 CFG=3
M  V30 19 1 18 20
M  V30 20 1 20 21 CFG=3
M  V30 21 1 20 22
M  V30 22 1 22 13
M  V30 23 1 22 23 CFG=1
M  V30 24 1 24 2
M  V30 25 1 25 3
M  V30 26 1 26 4
M  V30 27 1 27 9
M  V30 28 1 28 13
M  V30 29 1 29 15
M  V30 30 1 30 18
M  V30 31 1 31 20
M  V30 32 1 32 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
162

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lactitol

>  <Synonyms>
Lactit;NSC231323;D-Lactitol;Lactosit Miruhen;NSC 231323;NSC-231323

>  <CAS>
585-86-4

>  <Formula>
C12H24O11

>  <MolWt>
344.3

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Lactitol is a agent that acts on the gastrointestinal tract.

>  <Reference>
"Morimoto K, Shimonishi T, Miyake S, Takata G, Izumori K. Preparation of D-gulose from disaccharide lactitol using microbial and chemical methods. Biosci Biotechnol Biochem. 2013;77(2):253-8. Epub 2013 Feb 7. PubMed PMID: 23391912.;Gluud LL, Vilstrup H, Morgan MY. Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2016 May 6;(5):CD003044. doi: 10.1002/14651858.CD003044.pub4. Review. PubMed PMID: 27153247.;Miller LE, Tennil? J, Ouwehand AC. Efficacy and tolerance of lactitol supplementation for adult constipation: a systematic review and meta-analysis. Clin Exp Gastroenterol. 2014 Jul 12;7:241-8. doi: 10.2147/CEG.S58952. eCollection 2014. Review. PubMed PMID: 25050074.;Olli K, Saarinen MT, Forssten SD,et al. Independent and Combined Effects of Lactitol, Polydextrose, and Bacteroides thetaiotaomicron on Postprandial Metabolism and Body Weight in Rats Fed a High-Fat Diet. Front Nutr. 2016 Jun 8;3:15. doi: 10.3389/fnut.2016.00015. eCollection 2016. PubMed PMID: 27376068."

>  <ID<1>>
T20576

$$$$
StarDrop ID 163
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 0.0000 3.3000 0.0000 0
M  V30 2 C 0.0000 2.4750 0.0000 0
M  V30 3 C 0.7145 2.0625 0.0000 0 CFG=2
M  V30 4 O 1.4289 2.4750 0.0000 0
M  V30 5 C 0.7145 1.2375 0.0000 0
M  V30 6 C 1.4289 0.8250 0.0000 0
M  V30 7 C 1.4289 -0.0000 0.0000 0
M  V30 8 C 0.7145 -0.4125 0.0000 0
M  V30 9 O 0.7145 -1.2375 0.0000 0
M  V30 10 C 0.0000 0.0000 0.0000 0
M  V30 11 O -0.7145 -0.4125 0.0000 0
M  V30 12 C 0.0000 0.8250 0.0000 0
M  V30 13 H 0.7144 3.0625 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=3
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 5 12
M  V30 13 1 13 3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
163

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Norepinephrine

>  <Synonyms>
Levophed;Levonoradrenaline;Nor-Epirenan;Arterenol;Aktamin;Levonor

>  <CAS>
51-41-2

>  <Formula>
C8H11NO3

>  <MolWt>
169.2

>  <Pathways>
GPCR/G Protein;Neuroscience;Proteases/Proteasome;Autophagy;Metabolism

>  <Target>
Endogenous Metabolite;MMP;Autophagy;Adrenergic Receptor

>  <Receptor>
" ??1 adrenoceptor:740 nM(Ki), ??2A adrenoceptor:56 nM(Ki), ??1 adrenoceptor:330 nM(Ki)"

>  <Bioactivity>
"Norepinephrine can stimulate apoptosis in adult rat ventricular myocytes by activation of the ??-adrenergic pathway. It can up-regulate the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumour cells."

>  <Reference>
"Gu Y, Zhang M, Liu X, et al. Impact of bilateral sympathetic stellate ganglionectomy on TGF-??1 signaling pathway in rats with chronic volume overload[J]. Frontiers in Physiology. 2020, 11: 375.;Mansley M K, et al. Norepinephrine stimulates the epithelial sodium channel (ENaC) in cortical collecting duct cells via ??2-adrenoceptors[J]. Am J Physiol Renal Physiol, 2015, 308(5):F450.;Communal C, et al. Norepinephrine Stimulates Apoptosis in Adult Rat Ventricular Myocytes by Activation of the ??-Adrenergic Pathway[J]. Circulation, 1998, 98(13):1329-1334.;Ngan Kee W D, et al. Randomized double-blinded comparison of norepinephrine and phenylephrine for maintenance of blood pressure during spinal anesthesia for cesarean delivery.[J]. Anesthesiology, 2015, 122(4):736-745."

>  <ID<1>>
T7044

$$$$
StarDrop ID 164
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7145 1.2375 0.0000 0
M  V30 2 C 0.0000 0.8250 0.0000 0
M  V30 3 C 0.0000 0.0000 0.0000 0
M  V30 4 C -0.7145 -0.4125 0.0000 0
M  V30 5 C -0.7145 -1.2375 0.0000 0
M  V30 6 C -1.4289 -1.6500 0.0000 0
M  V30 7 C -2.1434 -1.2375 0.0000 0
M  V30 8 C -2.1434 -0.4125 0.0000 0
M  V30 9 C -1.4289 0.0000 0.0000 0
M  V30 10 C 0.7145 -0.4125 0.0000 0
M  V30 11 C 1.4289 0.0000 0.0000 0
M  V30 12 O 1.4289 0.8250 0.0000 0
M  V30 13 C 2.1434 -0.4125 0.0000 0
M  V30 14 C 2.8579 0.0000 0.0000 0
M  V30 15 C 3.5724 -0.4125 0.0000 0
M  V30 16 C 3.5724 -1.2375 0.0000 0
M  V30 17 C 2.8579 -1.6500 0.0000 0
M  V30 18 C 2.1434 -1.2375 0.0000 0
M  V30 19 O 1.4289 -1.6500 0.0000 0
M  V30 20 C 0.7145 -1.2375 0.0000 0
M  V30 21 O 0.0000 -1.6500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 4 9
M  V30 10 1 3 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 13 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 10 20
M  V30 23 2 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
164

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Phenprocoumon

>  <Synonyms>
N/A

>  <CAS>
435-97-2

>  <Formula>
C18H16O3

>  <MolWt>
280.3

>  <Pathways>


>  <Target>


>  <Receptor>
 vitamin K:1 ??M

>  <Bioactivity>
Phenprocoumon is an antagonist of vitamin K(IC50:1 ??M).

>  <Reference>
"Martin, M??ller, Fabian, et al. Characteristics, treatment and outcome of bleeding after tooth extraction in patients on DOAC and phenprocoumon compared to non-anticoagulated patients-a retrospective study of emergency department consultations.[J]. Clinical oral investigations, 2018.;Trenk D , Beermann D , Oesch F , et al. Age-dependent differences in the effect of phenprocoumon on the vitamin K1-epoxide cycle in rats[J]. Journal of Pharmacy and Pharmacology, 1981, 32(12):828-832."

>  <ID<1>>
T7636

$$$$
StarDrop ID 165
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 1.4289 -4.1250 0.0000 0
M  V30 2 C 1.4289 -4.9500 0.0000 0 CFG=2
M  V30 3 C 2.0964 -5.4349 0.0000 0
M  V30 4 C 1.8414 -6.2195 0.0000 0
M  V30 5 N 1.0164 -6.2195 0.0000 0
M  V30 6 C 0.7615 -5.4349 0.0000 0
M  V30 7 C 0.5315 -6.8870 0.0000 0
M  V30 8 N 0.8671 -7.6407 0.0000 0
M  V30 9 C 0.3822 -8.3081 0.0000 0
M  V30 10 C -0.4383 -8.2219 0.0000 0
M  V30 11 C -0.7739 -7.4682 0.0000 0
M  V30 12 C -0.2890 -6.8007 0.0000 0
M  V30 13 C -0.6245 -6.0471 0.0000 0
M  V30 14 C -1.4315 -5.8755 0.0000 0
M  V30 15 C -1.5177 -5.0551 0.0000 0
M  V30 16 N -0.7641 -4.7195 0.0000 0
M  V30 17 N -0.2120 -5.3326 0.0000 0
M  V30 18 C -0.9232 -8.8893 0.0000 0
M  V30 19 O -1.7437 -8.8031 0.0000 0
M  V30 20 N -0.5877 -9.6430 0.0000 0
M  V30 21 C -1.0726 -10.3104 0.0000 0
M  V30 22 C -0.7371 -11.0641 0.0000 0
M  V30 23 C -1.2220 -11.7315 0.0000 0
M  V30 24 C -2.0425 -11.6453 0.0000 0
M  V30 25 O -2.5274 -12.3127 0.0000 0
M  V30 26 C -2.1918 -13.0664 0.0000 0
M  V30 27 F -1.8563 -13.8201 0.0000 0
M  V30 28 F -2.9455 -13.4020 0.0000 0
M  V30 29 Cl -1.4382 -12.7308 0.0000 0
M  V30 30 C -2.3780 -10.8916 0.0000 0
M  V30 31 C -1.8931 -10.2242 0.0000 0
M  V30 32 H 0.5379 -4.4960 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 2 6
M  V30 7 1 5 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 7 12
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 13 17
M  V30 20 1 10 18
M  V30 21 2 18 19
M  V30 22 1 18 20
M  V30 23 1 20 21
M  V30 24 2 21 22
M  V30 25 1 22 23
M  V30 26 2 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 26 28
M  V30 31 1 26 29
M  V30 32 1 24 30
M  V30 33 2 30 31
M  V30 34 1 21 31
M  V30 35 1 32 2
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
165

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Asciminib

>  <Synonyms>
ABL001

>  <CAS>
1492952-76-7

>  <Formula>
C20H18ClF2N5O3

>  <MolWt>
449.8

>  <Pathways>
Angiogenesis;Cytoskeletal Signaling;Tyrosine Kinase/Adaptors

>  <Target>
Bcr-Abl

>  <Receptor>
 Abl1:0.45 nM

>  <Bioactivity>
Asciminib (ABL001) is a potent and selective Bcr-Abl inhibitor (Kd: 0.5?C0.8nM).

>  <Reference>
"Wylie AA, et al. The allosteric inhibitor ABL2001 enables dual targeting of BCR-ABL1. Nature. 2017 Mar 30;543(7647):733-737.;Eadie LN, et al. The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro. Oncotarget. 2018 Feb 3;9(17):13423-13437."

>  <ID<1>>
T5177

$$$$
StarDrop ID 166
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.1467 3.1768 0.0000 0
M  V30 2 C -0.1467 2.3518 0.0000 0
M  V30 3 C 0.5678 1.9393 0.0000 0
M  V30 4 C 1.2822 2.3518 0.0000 0
M  V30 5 N 0.5678 1.1143 0.0000 0
M  V30 6 C 1.2352 0.6294 0.0000 0
M  V30 7 C 0.9803 -0.1553 0.0000 0
M  V30 8 C 0.1553 -0.1553 0.0000 0
M  V30 9 C -0.0997 0.6294 0.0000 0
M  V30 10 O -0.8843 0.8843 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 5 9
M  V30 10 2 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
166

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Povidone iodine

>  <Synonyms>
Betadine;PVP-I;PVP iodine;iodopovidone;Povidone-iodine;Isodine

>  <CAS>
25655-41-8

>  <Formula>
C8H15NO

>  <MolWt>
141.2

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial;Antibiotic

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
"Povidone-Iodine is an iodophor solution containing a water-soluble complex of iodine and polyvinylpyrrolidone (PVP) with broad microbicidal activity. Free iodine, slowly liberated from the polyvinylpyrrolidone iodine (PVPI) complex in solution, kills eukaryotic or prokaryotic cells through iodination of lipids and oxidation of cytoplasmic and membrane compounds. This agent exhibits a broad range of microbicidal activity against bacteria, fungi, protozoa, and viruses. Slow release of iodine from the PVPI complex in solution minimizes iodine toxicity towards mammalian cells."

>  <Reference>
"Wang Y, Yang T, Liu Y, et al. Decrease of miR-195 promotes chondrocytes proliferation and maintenance of chondrogenic phenotype via targeting FGF-18 pathway[J]. International journal of molecular sciences. 2017 May 4;18(5).;Sato S, et al. Drug Chem Toxicol. 2014, 37(3):268-75.;Akcay E, et al. Childs Nerv Syst. 2012, 28(12):2071-5."

>  <ID<1>>
T3114

$$$$
StarDrop ID 167
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 117 126 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -1.5529 -2.4922 0.0000 0
M  V30 2 C -1.0878 -1.8108 0.0000 0
M  V30 3 C -0.2602 -1.8783 0.0000 0
M  V30 4 C 0.1955 -1.1745 0.0000 0
M  V30 5 C -0.1214 -0.4052 0.0000 0
M  V30 6 C -0.9542 -0.3820 0.0000 0
M  V30 7 C -1.4538 -1.0611 0.0000 0
M  V30 8 O -2.2477 -0.7676 0.0000 0
M  V30 9 C -2.8557 -0.1775 0.0000 0
M  V30 10 C -2.2552 0.4061 0.0000 0
M  V30 11 Cl -1.4652 0.1683 0.0000 0
M  V30 12 C -2.4313 1.2128 0.0000 0
M  V30 13 C -3.2095 1.5193 0.0000 0
M  V30 14 C -3.8191 0.8969 0.0000 0
M  V30 15 C -3.6529 0.0744 0.0000 0
M  V30 16 C -2.9712 2.3876 0.0000 0 CFG=1
M  V30 17 O -3.6699 2.8263 0.0000 0
M  V30 18 C -2.3197 2.9559 0.0000 0 CFG=1
M  V30 19 N -2.7291 3.6721 0.0000 0
M  V30 20 C -2.3137 4.3848 0.0000 0
M  V30 21 C -2.7231 5.1010 0.0000 0 CFG=1
M  V30 22 C -2.3077 5.8137 0.0000 0
M  V30 23 C -2.7171 6.5299 0.0000 0
M  V30 24 C -3.5421 6.5334 0.0000 0
M  V30 25 C -2.3017 7.2427 0.0000 0
M  V30 26 N -3.5481 5.1045 0.0000 0
M  V30 27 C -3.9636 4.3917 0.0000 0
M  V30 28 O -1.4887 4.3814 0.0000 0
M  V30 29 C -1.5281 3.2196 0.0000 0
M  V30 30 O -1.6004 4.0414 0.0000 0
M  V30 31 N -0.7138 3.0997 0.0000 0
M  V30 32 C -0.0098 2.6853 0.0000 0 CFG=1
M  V30 33 C 0.6061 3.2342 0.0000 0
M  V30 34 C 0.4387 4.0421 0.0000 0
M  V30 35 N -0.3446 4.3010 0.0000 0
M  V30 36 O 1.0546 4.5910 0.0000 0
M  V30 37 C 0.3206 1.9396 0.0000 0
M  V30 38 O 1.1341 2.0767 0.0000 0
M  V30 39 N 0.2529 1.1268 0.0000 0
M  V30 40 C 0.3653 0.3010 0.0000 0 CFG=1
M  V30 41 C 1.2166 0.3474 0.0000 0
M  V30 42 O 1.4259 -0.4506 0.0000 0
M  V30 43 N 1.9767 0.7226 0.0000 0
M  V30 44 C 2.8039 0.5294 0.0000 0 CFG=2
M  V30 45 C 3.4605 1.0825 0.0000 0
M  V30 46 C 4.2350 0.7667 0.0000 0
M  V30 47 C 4.9173 1.2516 0.0000 0
M  V30 48 C 5.6375 0.8163 0.0000 0
M  V30 49 C 5.9027 0.0351 0.0000 0 CFG=2
M  V30 50 C 5.4540 -0.6821 0.0000 0
M  V30 51 C 6.2295 -0.9636 0.0000 0 CFG=1
M  V30 52 O 6.3734 -1.7760 0.0000 0
M  V30 53 O 6.8611 -0.4328 0.0000 0
M  V30 54 N 5.3395 -1.5094 0.0000 0
M  V30 55 C 4.6216 -1.9314 0.0000 0
M  V30 56 O 4.7579 -2.7451 0.0000 0
M  V30 57 C 3.7921 -1.7637 0.0000 0 CFG=2
M  V30 58 C 3.4784 -2.5586 0.0000 0 CFG=2
M  V30 59 O 4.0982 -3.1030 0.0000 0
M  V30 60 C 2.7337 -2.9704 0.0000 0
M  V30 61 C 2.2888 -3.6816 0.0000 0
M  V30 62 C 1.4543 -3.6664 0.0000 0
M  V30 63 Cl 1.0366 -4.3778 0.0000 0
M  V30 64 C 1.0246 -2.9281 0.0000 0
M  V30 65 O 0.2362 -2.5655 0.0000 0
M  V30 66 C 1.4847 -2.2285 0.0000 0
M  V30 67 C 2.3080 -2.2504 0.0000 0
M  V30 68 N 3.3817 -1.0058 0.0000 0
M  V30 69 C 2.8742 -0.3198 0.0000 0
M  V30 70 O 2.1020 -0.6103 0.0000 0
M  V30 71 H 2.9686 -1.8133 0.0000 0
M  V30 72 C 6.7118 -0.1259 0.0000 0
M  V30 73 C 7.2558 0.4944 0.0000 0
M  V30 74 O 8.0650 0.3334 0.0000 0
M  V30 75 C 6.9906 1.2756 0.0000 0
M  V30 76 C 6.1815 1.4365 0.0000 0
M  V30 77 O 5.9163 2.2178 0.0000 0
M  V30 78 C 4.8199 2.0820 0.0000 0
M  V30 79 O 5.4841 2.5714 0.0000 0
M  V30 80 C 4.0607 2.4189 0.0000 0
M  V30 81 C 3.3939 1.9201 0.0000 0
M  V30 82 H 2.6115 1.3317 0.0000 0
M  V30 83 H -0.4372 0.4923 0.0000 0
M  V30 84 C -2.3756 -2.4300 0.0000 0 CFG=1
M  V30 85 C -2.8407 -3.1114 0.0000 0 CFG=2
M  V30 86 O -2.4832 -3.8549 0.0000 0
M  V30 87 C -2.9484 -4.5363 0.0000 0 CFG=1
M  V30 88 C -2.5909 -5.2798 0.0000 0
M  V30 89 C -3.0561 -5.9611 0.0000 0 CFG=2
M  V30 90 C -2.3043 -6.3009 0.0000 0
M  V30 91 N -3.2601 -6.7605 0.0000 0
M  V30 92 C -3.8787 -5.8990 0.0000 0 CFG=2
M  V30 93 O -4.3439 -6.5803 0.0000 0
M  V30 94 C -4.2362 -5.1555 0.0000 0 CFG=2
M  V30 95 C -5.0589 -5.0933 0.0000 0
M  V30 96 O -3.7711 -4.4741 0.0000 0
M  V30 97 C -3.6634 -3.0492 0.0000 0 CFG=1
M  V30 98 O -4.1286 -3.7306 0.0000 0
M  V30 99 C -4.0209 -2.3057 0.0000 0 CFG=2
M  V30 100 O -4.8436 -2.2435 0.0000 0
M  V30 101 C -3.5557 -1.6243 0.0000 0 CFG=1
M  V30 102 C -3.9132 -0.8808 0.0000 0
M  V30 103 O -4.7359 -0.8187 0.0000 0
M  V30 104 O -2.7331 -1.6865 0.0000 0
M  V30 105 H -3.0180 3.3865 0.0000 0
M  V30 106 H -1.9563 3.8875 0.0000 0
M  V30 107 H -3.2196 5.9691 0.0000 0
M  V30 108 H 0.9693 2.4817 0.0000 0
M  V30 109 H -1.9422 -3.3312 0.0000 0
M  V30 110 H -1.8435 -3.1867 0.0000 0
M  V30 111 H -1.9512 -4.6116 0.0000 0
M  V30 112 H -4.8759 -5.8236 0.0000 0
M  V30 113 H -4.6696 -4.2543 0.0000 0
M  V30 114 H 3.3489 -3.5502 0.0000 0
M  V30 115 H -4.6606 -2.9739 0.0000 0
M  V30 116 H -4.5848 -3.1315 0.0000 0
M  V30 117 H -2.9919 -0.7984 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 9 15
M  V30 17 1 16 13
M  V30 18 1 16 17 CFG=1
M  V30 19 1 16 18
M  V30 20 1 18 19 CFG=1
M  V30 21 1 19 20
M  V30 22 1 21 20
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 1 23 25
M  V30 27 1 21 26 CFG=3
M  V30 28 1 26 27
M  V30 29 2 20 28
M  V30 30 1 18 29
M  V30 31 2 29 30
M  V30 32 1 29 31
M  V30 33 1 32 31
M  V30 34 1 32 33 CFG=1
M  V30 35 1 33 34
M  V30 36 1 34 35
M  V30 37 2 34 36
M  V30 38 1 32 37
M  V30 39 2 37 38
M  V30 40 1 37 39
M  V30 41 1 40 39
M  V30 42 1 40 5
M  V30 43 1 40 41
M  V30 44 2 41 42
M  V30 45 1 41 43
M  V30 46 1 44 43
M  V30 47 1 44 45
M  V30 48 1 45 46
M  V30 49 2 46 47
M  V30 50 1 47 48
M  V30 51 1 48 49
M  V30 52 1 49 50 CFG=1
M  V30 53 1 51 50 CFG=3
M  V30 54 1 51 52
M  V30 55 2 51 53
M  V30 56 1 50 54
M  V30 57 1 54 55
M  V30 58 2 55 56
M  V30 59 1 57 55
M  V30 60 1 57 58
M  V30 61 1 58 59 CFG=3
M  V30 62 1 58 60
M  V30 63 1 60 61
M  V30 64 2 61 62
M  V30 65 1 62 63
M  V30 66 1 62 64
M  V30 67 1 64 65
M  V30 68 1 3 65
M  V30 69 2 64 66
M  V30 70 1 66 67
M  V30 71 2 60 67
M  V30 72 1 57 68
M  V30 73 1 68 69
M  V30 74 1 44 69
M  V30 75 2 69 70
M  V30 76 1 57 71 CFG=1
M  V30 77 2 49 72
M  V30 78 1 72 73
M  V30 79 1 73 74
M  V30 80 2 73 75
M  V30 81 1 75 76
M  V30 82 2 48 76
M  V30 83 1 76 77
M  V30 84 1 47 78
M  V30 85 1 78 79
M  V30 86 2 78 80
M  V30 87 1 80 81
M  V30 88 2 45 81
M  V30 89 1 44 82 CFG=1
M  V30 90 1 40 83 CFG=3
M  V30 91 1 84 1 CFG=1
M  V30 92 1 85 84
M  V30 93 1 85 86 CFG=3
M  V30 94 1 87 86 CFG=1
M  V30 95 1 87 88
M  V30 96 1 89 88
M  V30 97 1 89 90 CFG=1
M  V30 98 1 89 91 CFG=3
M  V30 99 1 92 89
M  V30 100 1 92 93 CFG=3
M  V30 101 1 92 94
M  V30 102 1 94 95 CFG=3
M  V30 103 1 94 96
M  V30 104 1 87 96
M  V30 105 1 85 97
M  V30 106 1 97 98 CFG=1
M  V30 107 1 97 99
M  V30 108 1 99 100 CFG=3
M  V30 109 1 99 101
M  V30 110 1 101 102 CFG=1
M  V30 111 1 102 103
M  V30 112 1 101 104
M  V30 113 1 84 104
M  V30 114 1 105 16
M  V30 115 1 106 18
M  V30 116 1 107 21
M  V30 117 1 108 32
M  V30 118 1 109 84
M  V30 119 1 110 85
M  V30 120 1 111 87
M  V30 121 1 112 92
M  V30 122 1 113 94
M  V30 123 1 114 58
M  V30 124 1 115 97
M  V30 125 1 116 99
M  V30 126 1 117 101
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
167

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Vancomycin

>  <Synonyms>
N/A

>  <CAS>
1404-90-6

>  <Formula>
C66H75Cl2N9O24

>  <MolWt>
1449

>  <Pathways>
Microbiology/Virology;Autophagy

>  <Target>
Antibiotic;Autophagy;Antibacterial

>  <Receptor>
antibiotic; Autophagy; Bacterial

>  <Bioactivity>
Vancomycin is an antibiotic used to treat serious bacterial infections by stopping the growth of bacteria.

>  <Reference>
"Reardon J , Lau T T Y , Ensom M H H . Vancomycin loading doses: a systematic review.[J]. The Annals of pharmacotherapy, 2015, 49(5):557."

>  <ID<1>>
T8641

$$$$
StarDrop ID 168
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.1044 1.4764 0.0000 0
M  V30 2 O -1.1044 2.3014 0.0000 0
M  V30 3 C -0.3899 1.0639 0.0000 0 CFG=1
M  V30 4 C 0.3245 0.6514 0.0000 0
M  V30 5 C 0.3245 -0.1736 0.0000 0
M  V30 6 C 1.0390 -0.5861 0.0000 0
M  V30 7 C 1.0390 -1.4111 0.0000 0
M  V30 8 C 0.3245 -1.8236 0.0000 0
M  V30 9 C -0.3899 -1.4111 0.0000 0
M  V30 10 C -0.3899 -0.5861 0.0000 0
M  V30 11 O 0.3245 -2.6486 0.0000 0
M  V30 12 O 1.7535 -1.8236 0.0000 0
M  V30 13 C -0.8024 0.3495 0.0000 0
M  V30 14 N 0.0226 1.7784 0.0000 0
M  V30 15 N 0.8476 1.7784 0.0000 0
M  V30 16 O -1.8189 1.0639 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 3 1 CFG=1
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 5 10
M  V30 11 1 8 11
M  V30 12 1 7 12
M  V30 13 1 3 13 CFG=3
M  V30 14 1 3 14
M  V30 15 1 14 15
M  V30 16 1 1 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
168

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Carbidopa monohydrate

>  <Synonyms>
S(-)-Carbidopa;Carbidopa Hydrate

>  <CAS>
38821-49-7

>  <Formula>
C10H16N2O5

>  <MolWt>
244.2

>  <Pathways>
Immunology/Inflammation;Others;Metabolism

>  <Target>
Aryl Hydrocarbon Receptor;Decarboxylase

>  <Receptor>
aromatic-L-amino-acid decarboxylase; Aryl Hydrocarbon Receptor

>  <Bioactivity>
"Carbidopa Hydrate is an inhibitor of DOPA decarboxylase, preventing the conversion of levodopa to dopamine."

>  <Reference>
"Orlefors H, et al. Eur J Nucl Med Mol Imaging. 2006 Jan;33(1):60-5."

>  <ID<1>>
T2148

$$$$
StarDrop ID 169
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.3091 2.0001 0.0000 0
M  V30 2 O 5.0236 2.4126 0.0000 0
M  V30 3 C 5.7381 2.0001 0.0000 0
M  V30 4 C 6.4525 2.4126 0.0000 0
M  V30 5 C 7.1670 2.0001 0.0000 0
M  V30 6 N 7.8815 2.4126 0.0000 0
M  V30 7 C 8.5959 2.0001 0.0000 0
M  V30 8 C 8.5959 1.1751 0.0000 0
M  V30 9 C 7.8815 0.7626 0.0000 0
M  V30 10 O 7.8815 -0.0624 0.0000 0
M  V30 11 C 7.1670 -0.4749 0.0000 0
M  V30 12 C 6.4525 -0.0624 0.0000 0
M  V30 13 C 5.7381 -0.4749 0.0000 0
M  V30 14 C 5.7381 -1.2999 0.0000 0
M  V30 15 N 5.0236 -1.7124 0.0000 0
M  V30 16 C 4.3091 -1.2999 0.0000 0
M  V30 17 O 4.3091 -0.4749 0.0000 0
M  V30 18 N 3.5946 -1.7124 0.0000 0
M  V30 19 C 3.5946 -2.5374 0.0000 0
M  V30 20 C 4.0071 -3.2518 0.0000 0
M  V30 21 C 3.1821 -3.2518 0.0000 0
M  V30 22 C 6.4525 -1.7124 0.0000 0
M  V30 23 Cl 6.4525 -2.5374 0.0000 0
M  V30 24 C 7.1670 -1.2999 0.0000 0
M  V30 25 C 7.1670 1.1751 0.0000 0
M  V30 26 C 6.4525 0.7626 0.0000 0
M  V30 27 C 5.7381 1.1751 0.0000 0
M  V30 28 C 5.0236 0.7626 0.0000 0
M  V30 29 N 4.3091 1.1751 0.0000 0
M  V30 30 O 5.0236 -0.0624 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 19 21
M  V30 22 1 14 22
M  V30 23 1 22 23
M  V30 24 2 22 24
M  V30 25 1 11 24
M  V30 26 2 9 25
M  V30 27 1 5 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 3 27
M  V30 31 1 27 28
M  V30 32 1 28 29
M  V30 33 2 28 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
169

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lenvatinib mesylate

>  <Synonyms>
E7080 (mesylate)

>  <CAS>
857890-39-2

>  <Formula>
C22H23ClN4O7S

>  <MolWt>
523

>  <Pathways>
Tyrosine Kinase/Adaptors;Apoptosis;Angiogenesis

>  <Target>
c-RET;VEGFR;c-Kit;FGFR;PDGFR

>  <Receptor>
" VEGFR3:5.2 nM, PDGFR??:39 nM, PDGFR??:51 nM, c-Kit:100 nM, VEGFR2:4 nM, VEGFR1:22 nM, FGFR1:46 nM"

>  <Bioactivity>
"Lenvatinib mesylate is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities."

>  <Reference>
"Kudo M, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellularcarcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173.;Matsui J, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res. 2008, 14(17),545.;Suyama K, et al. Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers. Cancer Control. 2018 Jan-Dec;25(1):1073274818789361."

>  <ID<1>>
T8541

$$$$
StarDrop ID 170
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.7351 -0.5711 0.0000 0
M  V30 2 C -0.9599 -0.2889 0.0000 0
M  V30 3 N -0.3279 -0.8192 0.0000 0
M  V30 4 C -0.4711 -1.6317 0.0000 0
M  V30 5 C -1.2464 -1.9139 0.0000 0
M  V30 6 C 0.4474 -0.5371 0.0000 0
M  V30 7 O 0.5906 0.2754 0.0000 0
M  V30 8 C 1.0793 -1.0674 0.0000 0
M  V30 9 C 1.4918 -1.7818 0.0000 0
M  V30 10 C 0.6668 -1.7818 0.0000 0
M  V30 11 C -0.0476 -2.1943 0.0000 0
M  V30 12 N -0.0476 -3.0193 0.0000 0
M  V30 13 C 1.7113 -0.5371 0.0000 0
M  V30 14 C 1.5681 0.2754 0.0000 0
M  V30 15 C 2.2001 0.8057 0.0000 0
M  V30 16 C 2.9753 0.5235 0.0000 0
M  V30 17 C 3.1186 -0.2889 0.0000 0
M  V30 18 C 2.4866 -0.8192 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 8 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 13 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
170

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dextromilnacipran

>  <Synonyms>
Levomilnacipran

>  <CAS>
96847-55-1

>  <Formula>
C15H22N2O

>  <MolWt>
246.4

>  <Pathways>
Neuroscience

>  <Target>
Norepinephrine;Serotonin Transporter

>  <Receptor>
 alpha-adrenergic receptor:3.4 ??M (IC50)

>  <Bioactivity>
Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor.

>  <Reference>
"Leo RJ, Brooks VL. Curr Opin Investig Drugs. 2006 Jul;7(7):637-42."

>  <ID<1>>
T2594

$$$$
StarDrop ID 171
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.9246 2.3479 0.0000 0
M  V30 2 N 6.2102 2.7604 0.0000 0
M  V30 3 S 5.4957 2.3479 0.0000 0
M  V30 4 O 5.0832 3.0624 0.0000 0
M  V30 5 O 5.9082 1.6335 0.0000 0
M  V30 6 C 4.7812 1.9354 0.0000 0
M  V30 7 C 4.0668 2.3479 0.0000 0
M  V30 8 C 3.3523 1.9354 0.0000 0
M  V30 9 C 3.3523 1.1104 0.0000 0
M  V30 10 C 2.6378 0.6979 0.0000 0
M  V30 11 C 1.9233 1.1104 0.0000 0
M  V30 12 N 1.1387 0.8555 0.0000 0
M  V30 13 C 0.6538 1.5229 0.0000 0
M  V30 14 C 1.1387 2.1904 0.0000 0
M  V30 15 C 0.8838 2.9750 0.0000 0
M  V30 16 C 0.0768 3.1465 0.0000 0
M  V30 17 C -0.1781 3.9312 0.0000 0
M  V30 18 N 0.3739 4.5442 0.0000 0
M  V30 19 C 0.1190 5.3289 0.0000 0
M  V30 20 C 1.1809 4.3727 0.0000 0
M  V30 21 C 1.4358 3.5881 0.0000 0
M  V30 22 C 1.9233 1.9354 0.0000 0
M  V30 23 C 2.6378 2.3479 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 2 3 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 18 20
M  V30 20 1 20 21
M  V30 21 1 15 21
M  V30 22 1 14 22
M  V30 23 2 11 22
M  V30 24 1 22 23
M  V30 25 2 8 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
171

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Naratriptan

>  <Synonyms>
N/A

>  <CAS>
121679-13-8

>  <Formula>
C17H25N3O2S

>  <MolWt>
335.5

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
5-HT Receptor

>  <Receptor>
5-HT Receptor; 5-HT1

>  <Bioactivity>
Naratriptan is a selective agonist of 5-HT1 receptor and is is used for the treatment of migraine headaches.

>  <Reference>
"Ito Y , Mitsufuji T , Asano Y , et al. Naratriptan in the Prophylactic Treatment of Cluster Headache[J]. Intern Med, 2017, 56(19).;Connor HE, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia. 1997 May;17(3):145-52."

>  <ID<1>>
T8666

$$$$
StarDrop ID 172
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 8.9995 -3.3843 0.0000 0
M  V30 2 C 9.7140 -2.9718 0.0000 0
M  V30 3 C 10.4284 -3.3843 0.0000 0
M  V30 4 C 11.1429 -2.9718 0.0000 0
M  V30 5 C 11.8574 -3.3843 0.0000 0
M  V30 6 C 12.5719 -2.9718 0.0000 0
M  V30 7 C 13.2863 -3.3843 0.0000 0
M  V30 8 C 14.0008 -2.9718 0.0000 0
M  V30 9 C 14.7153 -3.3843 0.0000 0
M  V30 10 C 15.4297 -2.9718 0.0000 0
M  V30 11 O 15.4297 -2.1468 0.0000 0
M  V30 12 O 16.1442 -3.3843 0.0000 0
M  V30 13 C 16.8587 -2.9718 0.0000 0 CFG=1
M  V30 14 C 16.9449 -2.1513 0.0000 0
M  V30 15 C 17.7519 -1.9798 0.0000 0
M  V30 16 C 18.1644 -2.6942 0.0000 0 CFG=1
M  V30 17 C 18.9714 -2.8658 0.0000 0 CFG=2
M  V30 18 C 19.5234 -2.2527 0.0000 0
M  V30 19 C 20.3304 -2.4242 0.0000 0
M  V30 20 C 20.5853 -3.2088 0.0000 0
M  V30 21 C 21.3923 -3.3803 0.0000 0
M  V30 22 C 21.6472 -4.1650 0.0000 0
M  V30 23 O 22.4542 -4.3365 0.0000 0
M  V30 24 C 21.0952 -4.7781 0.0000 0
M  V30 25 C 20.2882 -4.6065 0.0000 0
M  V30 26 C 20.0333 -3.8219 0.0000 0 CFG=2
M  V30 27 C 19.2263 -3.6504 0.0000 0 CFG=1
M  V30 28 C 18.6743 -4.2635 0.0000 0
M  V30 29 C 17.8673 -4.0920 0.0000 0
M  V30 30 C 17.6124 -3.3073 0.0000 0 CFG=2
M  V30 31 C 16.9993 -3.8594 0.0000 0
M  V30 32 H 16.0200 -2.4272 0.0000 0
M  V30 33 H 17.1699 -2.5897 0.0000 0
M  V30 34 H 18.6623 -1.9148 0.0000 0
M  V30 35 H 19.3641 -4.5650 0.0000 0
M  V30 36 H 18.2481 -3.4425 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 13 12 CFG=1
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 16 15 CFG=1
M  V30 16 1 16 17
M  V30 17 1 17 18 CFG=3
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 24 25
M  V30 25 1 26 25 CFG=3
M  V30 26 1 26 20
M  V30 27 1 27 26
M  V30 28 1 17 27
M  V30 29 1 27 28 CFG=1
M  V30 30 1 28 29
M  V30 31 1 30 29
M  V30 32 1 30 13
M  V30 33 1 16 30
M  V30 34 1 30 31 CFG=1
M  V30 35 1 32 13
M  V30 36 1 33 16
M  V30 37 1 34 17
M  V30 38 1 35 26
M  V30 39 1 36 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
172

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Nandrolone decanoate

>  <Synonyms>
19-Nortestosterone decanoate

>  <CAS>
360-70-3

>  <Formula>
C28H44O3

>  <MolWt>
428.7

>  <Pathways>
Others;Microbiology/Virology;Proteases/Proteasome

>  <Target>
HIV Protease;Others

>  <Receptor>
HIV

>  <Bioactivity>
"Nandrolone Decanoate is the decanoate salt form of nandrolone, an anabolic steroid analog of testosterone with androgenic, anabolic, and erythropoietin stimulating effects. Nandrolone enters the cell and binds to and activates specific nuclear androgen receptors in responsive tissue, including the prostate, seminal vesicles, scrotum, penis, larynx, hair follicles, muscle, and bone."

>  <Reference>
"Frankenfeld SP, et al. J Endocrinol. 2014, 220(2):143-153.;Beatriz Guimaraes Ribeiro, et al. Fisioter Pesq. 2014, 21(1):16-20."

>  <ID<1>>
T2556

$$$$
StarDrop ID 173
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.6762 -3.6799 0.0000 0
M  V30 2 C 2.4795 -2.8787 0.0000 0
M  V30 3 C 1.6873 -2.6484 0.0000 0
M  V30 4 C 3.0751 -2.3078 0.0000 0
M  V30 5 N 2.8784 -1.5066 0.0000 0
M  V30 6 C 2.1147 -1.1947 0.0000 0
M  V30 7 N 2.1752 -0.3719 0.0000 0
M  V30 8 C 2.9765 -0.1753 0.0000 0
M  V30 9 C 3.3664 0.5517 0.0000 0
M  V30 10 N 2.9318 1.2530 0.0000 0
M  V30 11 N 4.1910 0.5775 0.0000 0
M  V30 12 C 4.6256 -0.1238 0.0000 0
M  V30 13 C 5.4502 -0.0980 0.0000 0
M  V30 14 C 5.8849 -0.7992 0.0000 0
M  V30 15 C 5.4949 -1.5262 0.0000 0
M  V30 16 C 4.6703 -1.5520 0.0000 0
M  V30 17 C 4.2357 -0.8508 0.0000 0
M  V30 18 C 3.4111 -0.8765 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 12 17
M  V30 18 2 17 18
M  V30 19 1 5 18
M  V30 20 1 8 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
173

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Imiquimod

>  <Synonyms>
R 837;S-26308

>  <CAS>
99011-02-6

>  <Formula>
C14H16N4

>  <MolWt>
240.3

>  <Pathways>
Immunology/Inflammation;Microbiology/Virology;Autophagy

>  <Target>
Autophagy;HSV;SARS-CoV;TLR

>  <Receptor>
Autophagy; HSV; SARS-CoV; TLR; TLR7; TLR8

>  <Bioactivity>
Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist.

>  <Reference>
"Gibson SJ, et al. Cell Immunol. 2002 Jul-Aug;218(1-2):74-86."

>  <ID<1>>
T0134

$$$$
StarDrop ID 174
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 11 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.9520 1.1270 0.0000 0 CFG=2
M  V30 2 C 1.2375 0.7145 0.0000 0 CFG=1
M  V30 3 C 0.5230 1.1270 0.0000 0
M  V30 4 O -0.1914 0.7145 0.0000 0
M  V30 5 O 0.5230 1.9520 0.0000 0
M  V30 6 S 1.2375 -0.1105 0.0000 0
M  V30 7 C 2.6664 0.7145 0.0000 0
M  V30 8 O 3.3809 1.1270 0.0000 0
M  V30 9 O 2.6664 -0.1105 0.0000 0
M  V30 10 S 1.9520 1.9520 0.0000 0
M  V30 11 H 2.8180 1.6270 0.0000 0
M  V30 12 H 0.3715 0.2145 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 2 6 CFG=3
M  V30 6 1 1 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 1 10 CFG=1
M  V30 10 1 11 1
M  V30 11 1 12 2
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
174

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Succimer

>  <Synonyms>
Dimercaptosuccinic acid;meso-2,3-dimercaptosuccinic acid;DMSA

>  <CAS>
304-55-2

>  <Formula>
C4H6O4S2

>  <MolWt>
182.2

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Lead; Mercury

>  <Bioactivity>
Succimer is a Lead Chelator. The mechanism of action of succimer is as a Lead Chelating Activity.

>  <Reference>
"Blanusa M, et al. Curr Med Chem. 2005;12(23):2771-94."

>  <ID<1>>
T2552

$$$$
StarDrop ID 175
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 -2.4750 0.0000 0
M  V30 2 C 0.0000 -1.6500 0.0000 0
M  V30 3 O -0.7145 -1.2375 0.0000 0
M  V30 4 C 0.7145 -1.2375 0.0000 0
M  V30 5 C 0.7145 -0.4125 0.0000 0
M  V30 6 N 1.4289 0.0000 0.0000 0
M  V30 7 C 1.4289 0.8250 0.0000 0
M  V30 8 C 1.0164 1.5395 0.0000 0
M  V30 9 C 1.8414 1.5395 0.0000 0
M  V30 10 C 2.1434 -0.4125 0.0000 0
M  V30 11 C 2.8579 0.0000 0.0000 0
M  V30 12 C 3.5724 -0.4125 0.0000 0
M  V30 13 N 4.2868 -0.0000 0.0000 0
M  V30 14 C 4.2868 0.8250 0.0000 0
M  V30 15 C 5.0013 1.2375 0.0000 0
M  V30 16 N 5.7158 0.8250 0.0000 0
M  V30 17 C 5.7158 -0.0000 0.0000 0
M  V30 18 C 5.0013 -0.4125 0.0000 0
M  V30 19 C 3.5724 -1.2375 0.0000 0
M  V30 20 F 4.2868 -1.6500 0.0000 0
M  V30 21 C 2.8579 -1.6500 0.0000 0
M  V30 22 C 2.1434 -1.2375 0.0000 0
M  V30 23 C 1.4289 -1.6500 0.0000 0
M  V30 24 O 1.4289 -2.4750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 7 9
M  V30 10 1 6 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 13 18
M  V30 20 2 12 19
M  V30 21 1 19 20
M  V30 22 1 19 21
M  V30 23 2 21 22
M  V30 24 1 10 22
M  V30 25 1 22 23
M  V30 26 1 4 23
M  V30 27 2 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
175

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ciprofloxacin

>  <Synonyms>
Ciprobay;Ciproxan;Bay-09867;Bay o 9867

>  <CAS>
85721-33-1

>  <Formula>
C17H18FN3O3

>  <MolWt>
331.3

>  <Pathways>
DNA Damage/DNA Repair;Microbiology/Virology

>  <Target>
Topoisomerase;Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial; Topo II; Topo IV

>  <Bioactivity>
"Ciprofloxacin, a synthetic broad spectrum fluoroquinolone antibiotic, inhibits bacterial DNA gyrase. It is more active against Gram-negative bacteria than Gram-positive bacteria."

>  <Reference>
"Wise R, et al. Antimicrob Agents Chemother, 1983, 23(4), 559-564.;Hamblin KA, et al. Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague. Front Microbiol. 2017 Feb 6;8:91.;Peltzer PM, et al. Ecotoxicity of veterinary enrofloxacin and ciprofloxacin antibiotics on anuran amphibian larvae. Environ Toxicol Pharmacol. 2017 Feb 4.  pii: S1382-6689(17)320029-7.;Steenbergen J, et al. In Vitro and In Vivo Activity of Omadacycline Against Two Biothreat Pathogens: Bacillus anthracis and Yersinia pestis. Antimicrob Agents Chemother. 2017 Feb 21.;Lacy MK, et al. Antimicrob Agents Chemother, 1999, 43(3), 672-677.;Pan XS, et al. Antimicrob Agents Chemother, 1996, 40(10), 2321-2326."

>  <ID<1>>
T1640

$$$$
StarDrop ID 176
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -0.7145 2.0625 0.0000 0
M  V30 2 C 0.0000 2.4750 0.0000 0 CFG=1
M  V30 3 C 0.7145 2.0625 0.0000 0 CFG=2
M  V30 4 O 1.4289 2.4750 0.0000 0
M  V30 5 C 0.7145 1.2375 0.0000 0
M  V30 6 C 1.4289 0.8250 0.0000 0
M  V30 7 C 1.4289 -0.0000 0.0000 0
M  V30 8 C 0.7145 -0.4125 0.0000 0
M  V30 9 O 0.7145 -1.2375 0.0000 0
M  V30 10 C 0.0000 0.0000 0.0000 0
M  V30 11 O -0.7145 -0.4125 0.0000 0
M  V30 12 C 0.0000 0.8250 0.0000 0
M  V30 13 C 0.0000 3.3000 0.0000 0
M  V30 14 O -0.7145 3.7125 0.0000 0
M  V30 15 O 0.7145 3.7125 0.0000 0
M  V30 16 H -0.8660 2.9750 0.0000 0
M  V30 17 H 0.7144 3.0625 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4 CFG=3
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 5 12
M  V30 13 1 2 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 16 2
M  V30 17 1 17 3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
176

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Droxidopa

>  <Synonyms>
DOPS;SM5688;L-DOPS

>  <CAS>
23651-95-8

>  <Formula>
C9H11NO5

>  <MolWt>
213.2

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor

>  <Bioactivity>
Droxidopa is an orally available prodrug of norepinephrine that is used in the treatment of symptomatic orthostatic hypotension due to neurogenic causes of autonomic failure.

>  <Reference>
"Mathias CJ, et al. Clin Auton Res, 2001, 11(4), 235-242.;Goldstein DS. Cardiovasc Drug Rev, 2006, 24(3-4), 189-203.;Mathias CJ. Clin Auton Res, 2008, 18 Suppl 1, 25-29.;Kaufmann H. Clin Auton Res, 2008, 18 Suppl 1, 19-24."

>  <ID<1>>
T2547

$$$$
StarDrop ID 177
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.1434 3.7125 0.0000 0
M  V30 2 C -2.1434 2.8875 0.0000 0
M  V30 3 C -2.8579 2.4750 0.0000 0
M  V30 4 C -2.8579 1.6500 0.0000 0
M  V30 5 N -3.5724 1.2375 0.0000 0
M  V30 6 C -3.5724 0.4125 0.0000 0
M  V30 7 C -2.8579 -0.0000 0.0000 0
M  V30 8 N -2.8579 -0.8250 0.0000 0
M  V30 9 C -3.5724 -1.2375 0.0000 0
M  V30 10 O -3.5724 -2.0625 0.0000 0
M  V30 11 N -4.2868 -0.8250 0.0000 0
M  V30 12 C -4.2868 -0.0000 0.0000 0
M  V30 13 O -5.0013 0.4125 0.0000 0
M  V30 14 N -2.1434 0.4125 0.0000 0
M  V30 15 C -1.4289 -0.0000 0.0000 0
M  V30 16 C -0.7145 0.4125 0.0000 0 CFG=2
M  V30 17 O -0.7145 1.2375 0.0000 0
M  V30 18 C 0.0000 -0.0000 0.0000 0 CFG=2
M  V30 19 O 0.0000 -0.8250 0.0000 0
M  V30 20 C 0.7145 0.4125 0.0000 0 CFG=2
M  V30 21 O 0.7145 1.2375 0.0000 0
M  V30 22 C 1.4289 -0.0000 0.0000 0
M  V30 23 O 2.1434 0.4125 0.0000 0
M  V30 24 C -2.1434 1.2375 0.0000 0
M  V30 25 C -1.4289 1.6500 0.0000 0
M  V30 26 C -1.4289 2.4750 0.0000 0
M  V30 27 C -0.7145 2.8875 0.0000 0
M  V30 28 H -1.5805 0.9125 0.0000 0
M  V30 29 H -0.8660 -0.5000 0.0000 0
M  V30 30 H 1.5805 0.9125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 1 6 12
M  V30 13 2 12 13
M  V30 14 1 7 14
M  V30 15 1 14 15
M  V30 16 1 16 15
M  V30 17 1 16 17 CFG=3
M  V30 18 1 18 16
M  V30 19 1 18 19 CFG=1
M  V30 20 1 18 20
M  V30 21 1 20 21 CFG=3
M  V30 22 1 20 22
M  V30 23 1 22 23
M  V30 24 1 14 24
M  V30 25 2 4 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 2 26
M  V30 29 1 26 27
M  V30 30 1 28 16
M  V30 31 1 29 18
M  V30 32 1 30 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
177

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Riboflavin

>  <Synonyms>
Vitamin B2;E101

>  <CAS>
83-88-5

>  <Formula>
C17H20N4O6

>  <MolWt>
376.4

>  <Pathways>
Metabolism

>  <Target>
Endogenous Metabolite

>  <Receptor>
Endogenous Metabolite; VB2

>  <Bioactivity>
"Riboflavin is a micronutrient that occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms in tissues and cells are as flavin mononucleotide and flavin-adenine dinucleotide."

>  <Reference>
"Solovieva IM, et al. FEMS Microbiol Lett. 2005 Feb 1;243(1):51-8."

>  <ID<1>>
T0937

$$$$
StarDrop ID 178
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.4289 0.0000 0.0000 0
M  V30 2 C 0.7145 -0.4125 0.0000 0
M  V30 3 C 0.7145 -1.2375 0.0000 0
M  V30 4 C 0.0000 -1.6500 0.0000 0
M  V30 5 N 0.0000 -2.4750 0.0000 0
M  V30 6 C -0.7145 -2.8875 0.0000 0
M  V30 7 C -0.7145 -3.7125 0.0000 0
M  V30 8 C 0.0000 -4.1250 0.0000 0
M  V30 9 C 0.7145 -3.7125 0.0000 0
M  V30 10 C 0.7145 -2.8875 0.0000 0 CFG=1
M  V30 11 C 1.4289 -2.4750 0.0000 0
M  V30 12 N 2.1434 -2.8875 0.0000 0
M  V30 13 C 2.8579 -2.4750 0.0000 0
M  V30 14 C 2.8579 -1.6500 0.0000 0
M  V30 15 C 2.1434 -1.2375 0.0000 0
M  V30 16 C 3.5724 -1.2375 0.0000 0
M  V30 17 C 4.2868 -1.6500 0.0000 0
M  V30 18 C 4.2868 -2.4750 0.0000 0
M  V30 19 C 3.5724 -2.8875 0.0000 0
M  V30 20 C 3.5724 -3.7125 0.0000 0
M  V30 21 O 1.4289 -1.6500 0.0000 0
M  V30 22 H 0.7144 -1.8875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 10 9
M  V30 10 1 10 5
M  V30 11 1 10 11 CFG=3
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 13 19
M  V30 21 1 19 20
M  V30 22 2 11 21
M  V30 23 1 22 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
178

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Levobupivacaine

>  <Synonyms>
N/A

>  <CAS>
27262-47-1

>  <Formula>
C18H28N2O

>  <MolWt>
288.4

>  <Pathways>
Membrane transporter/Ion channel

>  <Target>
Sodium Channel

>  <Receptor>
Sodium Channel

>  <Bioactivity>
"Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. Compared to bupivacaine, levobupivacaine is associated with less vasodilation and has a longer duration of action. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children. Adverse drug reactions (ADRs) are rare when it is administered correctly. Most ADRs relate to administration technique (resulting in systemic exposure) or pharmacological effects of anesthesia, however allergic reactions can rarely occur."

>  <Reference>
"Ueta K, et al. Reg Anesth Pain Med. 2006 Jan-Feb;31(1):19-25."

>  <ID<1>>
T1787

$$$$
StarDrop ID 179
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.4957 2.3479 0.0000 0
M  V30 2 C 4.7812 1.9354 0.0000 0
M  V30 3 O 4.0668 2.3479 0.0000 0
M  V30 4 C 3.3523 1.9354 0.0000 0
M  V30 5 C 3.3523 1.1104 0.0000 0
M  V30 6 C 2.6378 0.6979 0.0000 0
M  V30 7 C 1.9233 1.1104 0.0000 0
M  V30 8 N 1.1387 0.8555 0.0000 0
M  V30 9 C 0.6538 1.5229 0.0000 0
M  V30 10 S 1.1387 2.1904 0.0000 0
M  V30 11 C 1.9233 1.9354 0.0000 0
M  V30 12 C 2.6378 2.3479 0.0000 0
M  V30 13 S -0.1712 1.5229 0.0000 0
M  V30 14 N -0.9962 1.5229 0.0000 0
M  V30 15 O -0.1712 2.3479 0.0000 0
M  V30 16 O -0.1712 0.6979 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 7 11
M  V30 12 2 11 12
M  V30 13 1 4 12
M  V30 14 1 9 13
M  V30 15 1 13 14
M  V30 16 2 13 15
M  V30 17 2 13 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
179

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ethoxzolamide

>  <Synonyms>
Redupresin;PNU-4191;L-643786

>  <CAS>
452-35-7

>  <Formula>
C9H10N2O3S2

>  <MolWt>
258.3

>  <Pathways>
Microbiology/Virology;Metabolism

>  <Target>
Carbonic Anhydrase;Antibacterial

>  <Receptor>
 Carbonic anhydrase:1nM(Ki??

>  <Bioactivity>
Ethoxzolamide is a carbonic anhydrase inhibitor.

>  <Reference>
"Song Gao, et al. Development and validation of an UPLC-MS/MS method for the quantification of ethoxzolamide in plasma and bioequivalent buffers: Applications to absorption, brain distribution, and pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Apr 1; 0: 54?C59.;Maren TH, et al. Relations among IOP reduction, ocular disposition and pharmacology of the carbonic anhydrase inhibitor ethoxzolamide. Exp Eye Res. 1992 Jul;55(1):73-9.;Benjamin K. Johnson, et al. The Carbonic Anhydrase Inhibitor Ethoxzolamide Inhibits theMycobacterium tuberculosis PhoPR Regulon and Esx-1 Secretion and Attenuates Virulence. Antimicrob Agents Chemother. 2015 Aug; 59(8): 4436?C4445."

>  <ID<1>>
T5012

$$$$
StarDrop ID 180
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8966 3.5145 0.0000 0
M  V30 2 N 4.6111 3.1020 0.0000 0
M  V30 3 C 4.6111 2.2770 0.0000 0
M  V30 4 C 5.3256 1.8645 0.0000 0
M  V30 5 O 6.0400 2.2770 0.0000 0
M  V30 6 C 5.3256 1.0395 0.0000 0
M  V30 7 C 6.0400 0.6270 0.0000 0
M  V30 8 C 6.0400 -0.1980 0.0000 0
M  V30 9 C 5.3256 -0.6105 0.0000 0
M  V30 10 O 5.3256 -1.4355 0.0000 0
M  V30 11 C 4.6111 -1.8480 0.0000 0
M  V30 12 O 3.8966 -1.4355 0.0000 0
M  V30 13 C 4.6111 -2.6730 0.0000 0
M  V30 14 C 4.6111 -3.4980 0.0000 0
M  V30 15 C 3.7861 -2.6730 0.0000 0
M  V30 16 C 5.4361 -2.6730 0.0000 0
M  V30 17 C 4.6111 -0.1980 0.0000 0
M  V30 18 O 3.8966 -0.6105 0.0000 0
M  V30 19 C 3.1821 -0.1980 0.0000 0
M  V30 20 O 2.4677 -0.6105 0.0000 0
M  V30 21 C 3.1821 0.6270 0.0000 0
M  V30 22 C 4.0071 0.6270 0.0000 0
M  V30 23 C 2.3571 0.6270 0.0000 0
M  V30 24 C 3.1821 1.4520 0.0000 0
M  V30 25 C 4.6111 0.6270 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 1 13 16
M  V30 16 1 9 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 19 21
M  V30 21 1 21 22
M  V30 22 1 21 23
M  V30 23 1 21 24
M  V30 24 2 17 25
M  V30 25 1 6 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
180

>  <Plate>
PHD136328

>  <Row>
i

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dipivefrin hydrochloride

>  <Synonyms>
Dipivefrin HCL

>  <CAS>
64019-93-8

>  <Formula>
C19H30ClNO5

>  <MolWt>
387.9

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor;AChR

>  <Receptor>
AChR; Adrenergic Receptor

>  <Bioactivity>
"Dipivefrin that is available as an ophthalmic solution is a prodrug of adrenaline, which is used to treat glaucoma."

>  <Reference>
"Nakamura M, et al. Ophthalmic Res. 1993;25(1):46-51."

>  <ID<1>>
T0103

$$$$
StarDrop ID 181
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 1.0970 2.9228 0.0000 0
M  V30 2 C 1.5095 2.2084 0.0000 0
M  V30 3 C 1.0970 1.4939 0.0000 0
M  V30 4 C 1.5095 0.7794 0.0000 0
M  V30 5 C 1.0970 0.0650 0.0000 0
M  V30 6 C 0.2720 0.0650 0.0000 0 CFG=1
M  V30 7 N -0.1405 -0.6495 0.0000 0
M  V30 8 C -0.9655 -0.6495 0.0000 0
M  V30 9 C -1.3780 -1.3640 0.0000 0
M  V30 10 C -2.2030 -1.3640 0.0000 0
M  V30 11 C -2.6879 -2.0314 0.0000 0
M  V30 12 C -3.4725 -1.7765 0.0000 0
M  V30 13 C -3.4725 -0.9515 0.0000 0
M  V30 14 S -2.6879 -0.6966 0.0000 0
M  V30 15 C 0.2720 -1.3640 0.0000 0
M  V30 16 C 1.0970 -1.3640 0.0000 0
M  V30 17 C 1.5095 -2.0785 0.0000 0
M  V30 18 C -0.1405 0.7794 0.0000 0
M  V30 19 C 0.2720 1.4939 0.0000 0
M  V30 20 C 2.3345 0.7794 0.0000 0
M  V30 21 C 2.7470 1.4939 0.0000 0
M  V30 22 C 2.3345 2.2084 0.0000 0
M  V30 23 H -0.7280 0.0649 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=1
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 10 14
M  V30 15 1 7 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 6 18
M  V30 19 1 18 19
M  V30 20 1 3 19
M  V30 21 2 4 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 2 22
M  V30 25 1 23 6
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
181

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Rotigotine Hydrochloride

>  <Synonyms>
N-0924;N-0923;Rotigotine HCl;Rotigotine (Hydrochloride);N 0923

>  <CAS>
125572-93-2

>  <Formula>
C19H26ClNOS

>  <MolWt>
351.9

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor;5-HT Receptor;Dopamine Receptor

>  <Receptor>
" D 2 Receptor:4-15 nM (Ki), ??2A:338 nM (Ki), D 3 Receptor:0.71 nM (Ki), ??1B:273 nM (Ki), 5-HT 1A Receptor:30 nM (Ki), D 5 Receptor:4-15 nM (Ki), 5-HT 7 Receptor:86 nM (Ki), D 1 Receptor:83 nM (Ki), ??2B:27 nM (Ki), D 4 Receptor:4-15 nM (Ki), ??1A:176 nM (Ki)"

>  <Bioactivity>
"Rotigotine Hydrochloride, a dopamine receptor agonist prefering for D3 receptors over D1 and D2, has effective activity of anti-Parkinsonian. Racemic rotigotine hydrochloride is about 50 times as potent as quinpirole, the gold standard D2 agonist."

>  <Reference>
"Cannas A, Meloni M, Mascia MM,et al. Priapism and Hypersexuality Associated With Rotigotine in an Elderly Parkinsonian Patient: A Case Report. Clin Neuropharmacol. 2016 Apr 4. [Epub ahead of print] PubMed PMID: 27046660.;Giladi N, Asgharnejad M, Bauer L, Grieger F, Boroojerdi B. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis. J Parkinsons Dis. 2016 Apr 2. [Epub ahead of print] PubMed PMID: 27061066.;LeWitt PA, Poewe W, Elmer LW, et al. The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis. Clin Neuropharmacol. 2016 Mar-Apr;39(2):88-93.;Dauvilliers Y, Benes H, Partinen M, Rauta V, Rifkin D, Dohin E, Goldammer N, Schollmayer E, Schr?der H, Winkelman JW. Rotigotine in Hemodialysis-Associated Restless Legs Syndrome: A Randomized Controlled Trial. Am J Kidney Dis. 2016 Feb 2. pii: S0272-6386(16)00018-4."

>  <ID<1>>
T21446

$$$$
StarDrop ID 182
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -3.3937 -4.9500 0.0000 0
M  V30 2 C -2.6793 -5.3625 0.0000 0
M  V30 3 N -1.9648 -4.9500 0.0000 0
M  V30 4 C -1.9648 -4.1250 0.0000 0
M  V30 5 C -1.2503 -3.7125 0.0000 0
M  V30 6 C -1.2503 -5.3625 0.0000 0
M  V30 7 C -0.5359 -4.9500 0.0000 0
M  V30 8 N 0.1786 -5.3625 0.0000 0
M  V30 9 C 0.8931 -4.9500 0.0000 0
M  V30 10 O 1.6076 -5.3625 0.0000 0
M  V30 11 C 0.8931 -4.1250 0.0000 0
M  V30 12 C 0.1786 -3.7125 0.0000 0
M  V30 13 C 0.1786 -2.8875 0.0000 0
M  V30 14 Cl -0.5359 -2.4750 0.0000 0
M  V30 15 C 0.8931 -2.4750 0.0000 0
M  V30 16 N 0.8931 -1.6500 0.0000 0
M  V30 17 C 1.6076 -2.8875 0.0000 0
M  V30 18 C 1.6076 -3.7125 0.0000 0
M  V30 19 O 2.3220 -4.1250 0.0000 0
M  V30 20 C 2.3220 -4.9500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 2 17 18
M  V30 18 1 11 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
182

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Metoclopramide hydrochloride hydrate

>  <Synonyms>
Metoclopramide monohydrochloride monohydrate

>  <CAS>
54143-57-6

>  <Formula>
C14H25Cl2N3O3

>  <MolWt>
354.3

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Dopamine Receptor;5-HT Receptor

>  <Receptor>
" D 2 Receptor:483 nM (IC50), 5-HT 3 Receptor:308 nM (IC50)"

>  <Bioactivity>
Metoclopramide hydrochloride hydrate is a dopamine D2 antagonist that is a drug used for digestive dysfunction. It acts as an anti-emetic

>  <Reference>
"Ahmed Madisch , Bettina R Vinson.et al.Modulation of Gastrointestinal Motility Beyond Metoclopramide and Domperidone : Pharmacological and Clinical Evidence for Phytotherapy in Functional Gastrointestinal Disorders.Wien Med Wochenschr. 2017 May;167(7-8):160-168.;Shakhatreh M , Jehangir A , Malik Z , et al. Metoclopramide for the treatment of diabetic gastroparesis[J]. Expert Review of Gastroenterology and Hepatology, 2019, 13(8)."

>  <ID<1>>
T8385

$$$$
StarDrop ID 183
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 39 42 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.3393 -3.2516 0.0000 0
M  V30 2 C -0.4695 -3.4146 0.0000 0 CFG=1
M  V30 3 C -1.2567 -3.6613 0.0000 0 CFG=2
M  V30 4 C -1.8640 -3.1029 0.0000 0 CFG=1
M  V30 5 C -1.6840 -2.2978 0.0000 0 CFG=1
M  V30 6 C -2.2913 -1.7394 0.0000 0 CFG=2
M  V30 7 C -1.5041 -1.4926 0.0000 0
M  V30 8 C -3.0786 -1.9861 0.0000 0
M  V30 9 C -3.2585 -2.7912 0.0000 0 CFG=1
M  V30 10 C -4.0458 -3.0379 0.0000 0
M  V30 11 C -2.6512 -3.3496 0.0000 0
M  V30 12 C -3.6858 -1.4276 0.0000 0
M  V30 13 C -3.5059 -0.6225 0.0000 0
M  V30 14 O -4.1131 -0.0641 0.0000 0
M  V30 15 C -2.7186 -0.3758 0.0000 0
M  V30 16 C -2.1113 -0.9342 0.0000 0
M  V30 17 C -0.8968 -2.0511 0.0000 0 CFG=1
M  V30 18 O -0.7168 -1.2459 0.0000 0
M  V30 19 C -0.2895 -2.6095 0.0000 0
M  V30 20 H -1.1256 -1.6905 0.0000 0
M  V30 21 H -2.4713 -2.5445 0.0000 0
M  V30 22 C -1.2654 -4.4863 0.0000 0
M  V30 23 C -0.4834 -4.7494 0.0000 0
M  V30 24 C 0.0084 -4.0871 0.0000 0 CFG=2
M  V30 25 C 0.7229 -4.4996 0.0000 0
M  V30 26 C 1.4374 -4.0871 0.0000 0
M  V30 27 O 2.1519 -4.4996 0.0000 0
M  V30 28 C 2.8663 -4.0871 0.0000 0
M  V30 29 C 3.5808 -4.4996 0.0000 0
M  V30 30 C 4.2953 -4.0871 0.0000 0
M  V30 31 C 5.0097 -4.4996 0.0000 0
M  V30 32 O 5.7242 -4.0871 0.0000 0
M  V30 33 O 5.0097 -5.3246 0.0000 0
M  V30 34 O 2.8663 -3.2621 0.0000 0
M  V30 35 O 0.7229 -5.3246 0.0000 0
M  V30 36 O 0.7314 -3.6897 0.0000 0
M  V30 37 H -1.0767 -2.8562 0.0000 0
M  V30 38 H -3.9947 -2.1144 0.0000 0
M  V30 39 H -1.6328 -1.3741 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 3 2
M  V30 3 1 4 3
M  V30 4 1 5 4
M  V30 5 1 5 6
M  V30 6 1 6 7 CFG=1
M  V30 7 1 6 8
M  V30 8 1 9 8
M  V30 9 1 9 10 CFG=3
M  V30 10 1 9 11
M  V30 11 1 4 11
M  V30 12 2 8 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 2 15 16
M  V30 17 1 6 16
M  V30 18 1 5 17
M  V30 19 1 17 18 CFG=1
M  V30 20 1 17 19
M  V30 21 1 2 19
M  V30 22 1 5 20 CFG=3
M  V30 23 1 4 21 CFG=1
M  V30 24 1 3 22
M  V30 25 1 22 23
M  V30 26 1 24 23
M  V30 27 1 2 24
M  V30 28 1 24 25 CFG=1
M  V30 29 1 25 26
M  V30 30 1 26 27
M  V30 31 1 27 28
M  V30 32 1 28 29
M  V30 33 1 29 30
M  V30 34 1 30 31
M  V30 35 1 31 32
M  V30 36 2 31 33
M  V30 37 2 28 34
M  V30 38 2 25 35
M  V30 39 1 24 36 CFG=3
M  V30 40 1 3 37 CFG=3
M  V30 41 1 38 9
M  V30 42 1 39 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
183

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Methylprednisolone succinate

>  <Synonyms>
Methylprednisolone hydrogen succinate;Methylprednisolone hemisuccinate

>  <CAS>
2921-57-5

>  <Formula>
C26H34O8

>  <MolWt>
474.5

>  <Pathways>
Endocrinology/Hormones

>  <Target>
Glucocorticoid Receptor

>  <Receptor>
Glucocorticoid Receptor

>  <Bioactivity>
Methylprednisolone succinate is a synthetic glucocorticoid and is widely used as an anti-inflammatory agent.

>  <Reference>
N/A

>  <ID<1>>
T22367

$$$$
StarDrop ID 184
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -0.0000 7.1786 0.0000 0
M  V30 2 N 0.7145 6.7661 0.0000 0
M  V30 3 O 1.4289 7.1786 0.0000 0
M  V30 4 C 0.7145 5.9411 0.0000 0
M  V30 5 C 1.4289 5.5286 0.0000 0
M  V30 6 C 1.4289 4.7036 0.0000 0
M  V30 7 C 0.7145 4.2911 0.0000 0
M  V30 8 C 0.0000 4.7036 0.0000 0
M  V30 9 C -0.0000 5.5286 0.0000 0
M  V30 10 C 0.7145 3.4661 0.0000 0
M  V30 11 C 1.3819 2.9812 0.0000 0
M  V30 12 C 1.1270 2.1965 0.0000 0
M  V30 13 C 0.3020 2.1965 0.0000 0
M  V30 14 C -0.1830 1.5291 0.0000 0
M  V30 15 N 0.1526 0.7754 0.0000 0
M  V30 16 N -0.3323 0.1080 0.0000 0
M  V30 17 C -0.0774 -0.6766 0.0000 0
M  V30 18 C -0.7448 -1.1616 0.0000 0
M  V30 19 O -0.7448 -1.9866 0.0000 0
M  V30 20 N -1.4123 -0.6766 0.0000 0
M  V30 21 C -1.1573 0.1080 0.0000 0
M  V30 22 O -1.6422 0.7754 0.0000 0
M  V30 23 O 0.0470 2.9812 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 4 9
M  V30 10 1 7 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 14 13
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 1 16 21
M  V30 23 2 21 22
M  V30 24 1 13 23
M  V30 25 1 10 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
184

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dantrolene

>  <Synonyms>
N/A

>  <CAS>
7261-97-4

>  <Formula>
C14H10N4O5

>  <MolWt>
314.3

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Ryanodine receptor

>  <Bioactivity>
Dantrolene is a postsynaptic muscle relaxant by inhibiting Ca2+ ions release from sarcoplasmic reticulum stores by antagonizing ryanodine receptors.

>  <Reference>
"Diszhazi G , Magyar Z E , Motyan J A , et al. Dantrolene Requires Mg2+ and ATP To Inhibit the Ryanodine Receptor[J]. Molecular Pharmacology, 2019, 96(3):mol.119.116475."

>  <ID<1>>
T8452

$$$$
StarDrop ID 185
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.1433 0.6930 0.0000 0
M  V30 2 O 4.8578 1.1055 0.0000 0
M  V30 3 C 5.5723 0.6930 0.0000 0
M  V30 4 C 6.2867 1.1055 0.0000 0
M  V30 5 C 7.0012 0.6930 0.0000 0
M  V30 6 C 7.0012 -0.1320 0.0000 0
M  V30 7 C 7.7157 -0.5445 0.0000 0
M  V30 8 C 8.4301 -0.1320 0.0000 0 CFG=1
M  V30 9 C 8.4301 0.6930 0.0000 0
M  V30 10 N 9.1446 -0.5445 0.0000 0
M  V30 11 C 9.8591 -0.1320 0.0000 0
M  V30 12 C 10.5736 -0.5445 0.0000 0 CFG=2
M  V30 13 O 10.5736 -1.3695 0.0000 0
M  V30 14 C 11.2880 -0.1320 0.0000 0
M  V30 15 C 11.2880 0.6930 0.0000 0
M  V30 16 C 12.0025 1.1055 0.0000 0
M  V30 17 C 12.7170 0.6930 0.0000 0
M  V30 18 O 13.4314 1.1055 0.0000 0
M  V30 19 C 12.7170 -0.1320 0.0000 0
M  V30 20 N 13.4314 -0.5445 0.0000 0
M  V30 21 C 13.4314 -1.3695 0.0000 0
M  V30 22 O 14.1459 -1.7820 0.0000 0
M  V30 23 C 12.0025 -0.5445 0.0000 0
M  V30 24 C 6.2867 -0.5445 0.0000 0
M  V30 25 C 5.5723 -0.1320 0.0000 0
M  V30 26 H 7.5641 0.3680 0.0000 0
M  V30 27 H 11.4396 -1.0445 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=1
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 12 11
M  V30 12 1 12 13 CFG=1
M  V30 13 1 12 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 17 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 2 19 23
M  V30 23 1 14 23
M  V30 24 1 6 24
M  V30 25 2 24 25
M  V30 26 1 3 25
M  V30 27 1 26 8
M  V30 28 1 27 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
185

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Arformoterol Tartrate

>  <Synonyms>
(R,R)-Formoterol tartrate

>  <CAS>
200815-49-2

>  <Formula>
C23H30N2O10

>  <MolWt>
494.5

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
 Beta-2 adrenergic receptor:2.9 nM (Kd)

>  <Bioactivity>
Arformoterol Tartrate is the tartrate salt of arformoterol. Arformoterol is a long-acting beta-2 adrenergic agonist with bronchodilator activity[2].

>  <Reference>
"Song W, et al. Postexposure administration of a {beta}2-agonist decreases chlorine-induced airway hyperreactivity in mice. Am J Respir Cell Mol Biol. 2011 Jul;45(1):88-94.;Pahwa R ,  Soni V ,  Sharma P C , et al. Arformoterol Tartrate: A Review of Pharmacology, Analysis and Clinical Studies[J]. Tropical Journal of Pharmaceutical Research, 2011, 9(6)."

>  <ID<1>>
T22245

$$$$
StarDrop ID 186
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 39 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 11.4315 -9.9000 0.0000 0
M  V30 2 C 11.4315 -9.0750 0.0000 0
M  V30 3 O 10.7171 -8.6625 0.0000 0
M  V30 4 C 10.0026 -9.0750 0.0000 0
M  V30 5 C 9.2881 -8.6625 0.0000 0
M  V30 6 O 9.2881 -7.8375 0.0000 0
M  V30 7 C 10.0026 -7.4250 0.0000 0
M  V30 8 O 10.7171 -7.8375 0.0000 0
M  V30 9 C 10.0026 -6.6000 0.0000 0
M  V30 10 C 10.7171 -6.1875 0.0000 0
M  V30 11 C 10.7171 -5.3625 0.0000 0
M  V30 12 C 11.4315 -4.9500 0.0000 0
M  V30 13 C 11.4315 -4.1250 0.0000 0
M  V30 14 C 12.1460 -3.7125 0.0000 0
M  V30 15 C 12.8605 -4.1250 0.0000 0
M  V30 16 C 12.8605 -4.9500 0.0000 0
M  V30 17 C 12.1460 -5.3625 0.0000 0
M  V30 18 C 8.5737 -9.0750 0.0000 0
M  V30 19 O 7.8592 -8.6625 0.0000 0
M  V30 20 C 7.1447 -9.0750 0.0000 0
M  V30 21 O 7.1447 -9.9000 0.0000 0
M  V30 22 C 6.4302 -8.6625 0.0000 0
M  V30 23 C 5.7158 -9.0750 0.0000 0
M  V30 24 C 5.0013 -8.6625 0.0000 0
M  V30 25 C 4.2868 -9.0750 0.0000 0
M  V30 26 C 4.2868 -9.9000 0.0000 0
M  V30 27 C 3.5724 -10.3125 0.0000 0
M  V30 28 C 2.8579 -9.9000 0.0000 0
M  V30 29 C 2.8579 -9.0750 0.0000 0
M  V30 30 C 3.5724 -8.6625 0.0000 0
M  V30 31 C 12.1460 -8.6625 0.0000 0
M  V30 32 C 12.8605 -9.0750 0.0000 0
M  V30 33 C 13.5749 -8.6625 0.0000 0
M  V30 34 C 14.2894 -9.0750 0.0000 0
M  V30 35 C 15.0039 -8.6625 0.0000 0
M  V30 36 C 15.7184 -9.0750 0.0000 0
M  V30 37 C 15.7184 -9.9000 0.0000 0
M  V30 38 C 15.0039 -10.3125 0.0000 0
M  V30 39 C 14.2894 -9.9000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 12 17
M  V30 18 1 5 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 2 28 29
M  V30 30 1 29 30
M  V30 31 2 25 30
M  V30 32 1 2 31
M  V30 33 1 31 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 1 34 35
M  V30 37 2 35 36
M  V30 38 1 36 37
M  V30 39 2 37 38
M  V30 40 1 38 39
M  V30 41 2 34 39
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
186

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Glycerol phenylbutyrate

>  <Synonyms>
HPN-100

>  <CAS>
611168-24-2

>  <Formula>
C33H38O6

>  <MolWt>
530.7

>  <Pathways>
GPCR/G Protein

>  <Target>
Sigma receptor

>  <Receptor>
 ??2:pKi: 8.02

>  <Bioactivity>
Glycerol phenylbutyrate (GPB) is a new generation ammonia scavenger drug and it also is a sigma-2 (??2) receptor ligand (pKi: 8.02).

>  <Reference>
"Rescifina A, et al. Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis. Eur J Pharm Sci. 2017 Aug 30;106:94-101.;Oishi K, et al. Glycerol phenylbutyrate for the chronic management of urea cycle disorders. Expert Rev Endocrinol Metab. 2014 Sep;9(5):427-434."

>  <ID<1>>
T15393

$$$$
StarDrop ID 187
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 43 46 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 4.9260 1.4455 0.0000 0
M  V30 2 C 4.1272 1.2396 0.0000 0 CFG=2
M  V30 3 C 3.4631 0.7501 0.0000 0
M  V30 4 O 3.6097 -0.2163 0.0000 0
M  V30 5 C 2.7923 1.2304 0.0000 0
M  V30 6 C 3.0419 2.0167 0.0000 0
M  V30 7 C 3.8668 2.0224 0.0000 0 CFG=2
M  V30 8 C 3.0440 1.7010 0.0000 0
M  V30 9 C 2.7696 0.8895 0.0000 0
M  V30 10 C 3.4022 0.3119 0.0000 0 CFG=1
M  V30 11 C 2.8003 -0.3631 0.0000 0
M  V30 12 C 4.2644 0.5008 0.0000 0 CFG=2
M  V30 13 C 4.4450 -0.3519 0.0000 0
M  V30 14 C 5.1373 0.4117 0.0000 0 CFG=1
M  V30 15 C 5.8517 0.8923 0.0000 0
M  V30 16 C 5.9823 1.7179 0.0000 0 CFG=1
M  V30 17 C 6.5244 2.3906 0.0000 0
M  V30 18 C 6.8469 1.4554 0.0000 0
M  V30 19 C 7.6410 1.7990 0.0000 0
M  V30 20 C 5.4688 2.3774 0.0000 0 CFG=1
M  V30 21 O 5.7154 3.2009 0.0000 0
M  V30 22 C 4.6111 2.4527 0.0000 0 CFG=2
M  V30 23 C 4.3946 3.2837 0.0000 0
M  V30 24 O 5.5618 -0.3605 0.0000 0
M  V30 25 C 6.2617 -0.8587 0.0000 0
M  V30 26 O 6.8941 -0.3290 0.0000 0
M  V30 27 C 6.4075 -1.6899 0.0000 0
M  V30 28 S 7.2734 -1.6804 0.0000 0
M  V30 29 C 7.6937 -2.3903 0.0000 0 CFG=2
M  V30 30 C 8.5187 -2.3812 0.0000 0
M  V30 31 C 8.9390 -3.0911 0.0000 0
M  V30 32 C 8.5343 -3.8101 0.0000 0 CFG=1
M  V30 33 N 8.9546 -4.5200 0.0000 0
M  V30 34 C 7.7094 -3.8191 0.0000 0
M  V30 35 C 7.2891 -3.1092 0.0000 0 CFG=1
M  V30 36 O 6.4641 -3.1183 0.0000 0
M  V30 37 H 2.4053 0.2332 0.0000 0
M  V30 38 H 6.1061 0.1637 0.0000 0
M  V30 39 H 4.9065 3.2044 0.0000 0
M  V30 40 H 3.6881 2.8376 0.0000 0
M  V30 41 H 6.6938 -2.4012 0.0000 0
M  V30 42 H 8.0438 -4.6816 0.0000 0
M  V30 43 H 6.7986 -3.9806 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=1
M  V30 7 1 2 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 10 9
M  V30 11 1 10 11 CFG=3
M  V30 12 1 12 10
M  V30 13 1 12 2
M  V30 14 1 12 13 CFG=1
M  V30 15 1 12 14
M  V30 16 1 14 15
M  V30 17 1 16 15
M  V30 18 1 16 17 CFG=1
M  V30 19 1 16 18 CFG=3
M  V30 20 2 18 19
M  V30 21 1 20 16
M  V30 22 1 20 21 CFG=3
M  V30 23 1 22 20
M  V30 24 1 7 22
M  V30 25 1 22 23 CFG=1
M  V30 26 1 14 24 CFG=1
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 1 25 27
M  V30 30 1 27 28
M  V30 31 1 29 28 CFG=3
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 32 31
M  V30 35 1 32 33 CFG=1
M  V30 36 1 32 34
M  V30 37 1 35 34
M  V30 38 1 29 35
M  V30 39 1 35 36 CFG=1
M  V30 40 1 37 10
M  V30 41 1 38 14
M  V30 42 1 39 20
M  V30 43 1 40 22
M  V30 44 1 41 29
M  V30 45 1 42 32
M  V30 46 1 43 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
187

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lefamulin acetate

>  <Synonyms>
BC-3781 acetate

>  <CAS>
1350636-82-6

>  <Formula>
C30H49NO7S

>  <MolWt>
567.8

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial;ribosome

>  <Receptor>
50S ribosome; Antibiotic; Bacterial

>  <Bioactivity>
"Lefamulin acetate (formally BC-3781 acetate) is a novel pleuromutilin antibiotic and is the first to be used for the systemic treatment of bacterial infections in humans. Lefamulin acetate (BC-3781 acetate) inhibits protein synthesis by binding to the peptidyl transferase center of the 50S bacterial ribosome, preventing the binding of transfer RNA for peptide transfer.?Lefamulin acetate (BC-3781 acetate) is an orally active antibiotic for community-acquired bacterial pneumonia (CABP) treatment."

>  <Reference>
"Veve MP, et al. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic. Pharmacotherapy. 2018 Sep;38(9):935-946. doi: 10.1002/phar.2166. Epub 2018 Aug 20."

>  <ID<1>>
T11836

$$$$
StarDrop ID 188
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.7565 -5.0895 0.0000 0
M  V30 2 C 3.4710 -4.6770 0.0000 0
M  V30 3 C 4.1854 -5.0895 0.0000 0
M  V30 4 C 4.8999 -4.6770 0.0000 0
M  V30 5 C 5.6144 -5.0895 0.0000 0
M  V30 6 O 5.6144 -5.9145 0.0000 0
M  V30 7 O 6.3289 -4.6770 0.0000 0
M  V30 8 C 6.3289 -3.8520 0.0000 0 CFG=2
M  V30 9 C 5.5084 -3.9383 0.0000 0
M  V30 10 C 5.1728 -3.1846 0.0000 0
M  V30 11 C 5.7859 -2.6326 0.0000 0 CFG=1
M  V30 12 C 5.7859 -1.8076 0.0000 0 CFG=2
M  V30 13 C 5.0714 -1.3951 0.0000 0
M  V30 14 C 5.0714 -0.5701 0.0000 0
M  V30 15 C 5.7859 -0.1576 0.0000 0
M  V30 16 C 5.7859 0.6674 0.0000 0
M  V30 17 C 6.5004 1.0799 0.0000 0
M  V30 18 O 6.5004 1.9049 0.0000 0
M  V30 19 C 7.2149 0.6674 0.0000 0
M  V30 20 C 7.2149 -0.1576 0.0000 0
M  V30 21 C 6.5004 -0.5701 0.0000 0 CFG=1
M  V30 22 C 7.2149 -0.9826 0.0000 0
M  V30 23 C 6.5004 -1.3951 0.0000 0 CFG=1
M  V30 24 C 7.2149 -1.8076 0.0000 0 CFG=1
M  V30 25 O 7.9293 -1.3951 0.0000 0
M  V30 26 C 7.2149 -2.6326 0.0000 0
M  V30 27 C 6.5004 -3.0451 0.0000 0 CFG=2
M  V30 28 C 7.1678 -3.5300 0.0000 0
M  V30 29 C 7.1493 -3.9383 0.0000 0
M  V30 30 O 7.6343 -3.2708 0.0000 0
M  V30 31 C 7.4849 -4.6919 0.0000 0
M  V30 32 O 7.0000 -5.3594 0.0000 0
M  V30 33 H 5.8905 -3.6271 0.0000 0
M  V30 34 H 4.9199 -2.3076 0.0000 0
M  V30 35 H 5.6344 -0.8951 0.0000 0
M  V30 36 H 7.2148 -0.8076 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 8 7 CFG=3
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10 CFG=1
M  V30 11 1 12 11
M  V30 12 1 12 13 CFG=3
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 19 20
M  V30 20 1 21 20
M  V30 21 1 21 15
M  V30 22 1 21 22 CFG=1
M  V30 23 1 23 21 CFG=1
M  V30 24 1 23 12
M  V30 25 1 23 24
M  V30 26 1 24 25 CFG=1
M  V30 27 1 24 26
M  V30 28 1 27 26
M  V30 29 1 27 8
M  V30 30 1 11 27
M  V30 31 1 27 28 CFG=1
M  V30 32 1 8 29 CFG=1
M  V30 33 2 29 30
M  V30 34 1 29 31
M  V30 35 1 31 32
M  V30 36 1 33 11
M  V30 37 1 34 12
M  V30 38 1 35 23
M  V30 39 1 36 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
188

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Hydrocortisone Valerate

>  <Synonyms>
Westcort

>  <CAS>
57524-89-7

>  <Formula>
C26H38O6

>  <MolWt>
446.6

>  <Pathways>
Endocrinology/Hormones

>  <Target>
Glucocorticoid Receptor

>  <Receptor>
Glucocorticoid Receptor

>  <Bioactivity>
"Hydrocortisone Valerate has anti-inflammatory, antipruritic and vasoconstrictive properties."

>  <Reference>
"Suzuki G, et al. Sci Total Environ. 2015 May 9;527-528C:328-334."

>  <ID<1>>
T0276

$$$$
cExt:v:28:3
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Gd 1.8241 -1.5925 0.0000 0 CHG=3
M  V30 2 N 1.2486 -2.3864 0.0000 0
M  V30 3 C 0.8024 -3.1404 0.0000 0
M  V30 4 C 1.5219 -3.2343 0.0000 0
M  V30 5 N 1.8674 -2.1628 0.0000 0
M  V30 6 C 2.0015 -1.0342 0.0000 0
M  V30 7 C 2.8561 -0.6416 0.0000 0
M  V30 8 N 2.6982 -1.1641 0.0000 0
M  V30 9 C 3.5205 -1.4004 0.0000 0
M  V30 10 C 3.4721 -2.1899 0.0000 0
M  V30 11 N 2.6490 -2.1670 0.0000 0
M  V30 12 C 2.8747 -2.9913 0.0000 0
M  V30 13 C 2.0202 -3.1881 0.0000 0
M  V30 14 C 2.4028 -2.8469 0.0000 0
M  V30 15 C 1.6141 -2.7531 0.0000 0
M  V30 16 O 1.2444 -1.9358 0.0000 0 CHG=-1
M  V30 17 O 1.1266 -3.4187 0.0000 0
M  V30 18 C 2.5385 -0.2263 0.0000 0
M  V30 19 C 1.7900 0.0177 0.0000 0
M  V30 20 O 1.4786 -0.7126 0.0000 0 CHG=-1
M  V30 21 O 1.4488 0.7689 0.0000 0
M  V30 22 C 0.8433 -2.5285 0.0000 0
M  V30 23 C 0.4348 -1.8102 0.0000 0
M  V30 24 O 1.0349 -1.3688 0.0000 0 CHG=-1
M  V30 25 O -0.3721 -1.6385 0.0000 0
M  V30 26 C 0.2992 -2.2655 0.0000 0
M  V30 27 C 0.1967 -1.3335 0.0000 0
M  V30 28 C -0.5303 -0.9435 0.0000 0
M  V30 29 O 0.9670 -0.9359 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 1 5
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 1 8
M  V30 10 1 8 9
M  V30 11 1 9 10
M  V30 12 1 10 11
M  V30 13 1 1 11
M  V30 14 1 11 12
M  V30 15 1 12 13
M  V30 16 1 2 13
M  V30 17 1 11 14
M  V30 18 1 14 15
M  V30 19 1 15 16
M  V30 20 1 1 16
M  V30 21 2 15 17
M  V30 22 1 8 18
M  V30 23 1 18 19
M  V30 24 1 19 20
M  V30 25 1 1 20
M  V30 26 2 19 21
M  V30 27 1 5 22
M  V30 28 1 22 23
M  V30 29 1 23 24
M  V30 30 1 1 24
M  V30 31 2 23 25
M  V30 32 1 2 26
M  V30 33 1 26 27
M  V30 34 1 27 28
M  V30 35 1 27 29
M  V30 36 1 1 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
189

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Gadoteridol

>  <Synonyms>
ProHance;SQ-32692;Gd-HP-DO3A

>  <CAS>
120066-54-8

>  <Formula>
C17H29GdN4O7

>  <MolWt>
558.7

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Gadoteridolused in the imaging of the central nervous system that is used for a gadolinium-based MRI contrast agent.

>  <Reference>
"Krishan Kumar et al.Gadoteridol. Analytical Profiles of Drug Substances and Excipients, Academic Press, Volume 24,1996,Pages 209-241,"

>  <ID<1>>
T19333

$$$$
StarDrop ID 190
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.6091 -3.3616 0.0000 0
M  V30 2 C -4.8946 -2.9491 0.0000 0
M  V30 3 C -4.4821 -3.6636 0.0000 0
M  V30 4 C -5.3071 -2.2346 0.0000 0
M  V30 5 C -4.1801 -2.5366 0.0000 0
M  V30 6 C -4.1801 -1.7116 0.0000 0
M  V30 7 C -3.4656 -1.2991 0.0000 0
M  V30 8 C -2.7512 -1.7116 0.0000 0
M  V30 9 C -2.7512 -2.5366 0.0000 0
M  V30 10 C -3.4656 -2.9491 0.0000 0
M  V30 11 N -3.4656 -3.7741 0.0000 0
M  V30 12 C -2.7982 -4.2590 0.0000 0
M  V30 13 C -3.0531 -5.0437 0.0000 0
M  V30 14 C -3.8781 -5.0437 0.0000 0
M  V30 15 C -4.1331 -4.2590 0.0000 0
M  V30 16 C -3.4656 -0.4741 0.0000 0
M  V30 17 C -4.1801 -0.0616 0.0000 0
M  V30 18 C -4.1801 0.7634 0.0000 0
M  V30 19 C -3.4656 1.1759 0.0000 0
M  V30 20 C -2.7512 0.7634 0.0000 0
M  V30 21 C -2.7512 -0.0616 0.0000 0
M  V30 22 O -2.0367 -0.4741 0.0000 0
M  V30 23 C -2.0367 -1.2991 0.0000 0
M  V30 24 C -1.3222 -1.7116 0.0000 0
M  V30 25 O -1.3222 -2.5366 0.0000 0
M  V30 26 C -4.8946 1.1759 0.0000 0
M  V30 27 C -5.6091 0.7634 0.0000 0
M  V30 28 C -6.3235 1.1759 0.0000 0
M  V30 29 C -6.3235 2.0009 0.0000 0
M  V30 30 C -5.6091 2.4134 0.0000 0
M  V30 31 C -4.8946 2.0009 0.0000 0
M  V30 32 C -7.0380 2.4134 0.0000 0
M  V30 33 O -7.7525 2.0009 0.0000 0
M  V30 34 O -7.0380 3.2384 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 5 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 11 15
M  V30 17 1 7 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 16 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 18 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 1 26 31
M  V30 35 1 29 32
M  V30 36 1 32 33
M  V30 37 2 32 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
190

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
trifarotene

>  <Synonyms>
CD5789

>  <CAS>
895542-09-3

>  <Formula>
C29H33NO4

>  <MolWt>
459.6

>  <Pathways>
Metabolism;Autophagy

>  <Target>
Autophagy;Retinoid Receptor

>  <Receptor>
" RAR??:125 nM (EC50), RAR??:7.7 nM (EC50), RAR??:500 nM (EC50)"

>  <Bioactivity>
trifarotene is a potent and selective RAR?? agonist with 65-fold and 16-fold selectivitiy for the RAR?? (EC50=7.7 nM) over RAR?? (EC50=500 nM) and RAR?? (EC50=125 nM).

>  <Reference>
"Etienne Thoreau, et al. Structure-based design of Trifarotene (CD5789), a potent and selective RAR?? agonist for the treatment of acne. Bioorg Med Chem Lett. 2018 Jun 1;28(10):1736-1741.;J Aubert, et al. Nonclinical and human pharmacology of the potent and selective topical retinoic acid receptor-?? agonist trifarotene. Br J Dermatol. 2018 Aug;179(2):442-456."

>  <ID<1>>
T7586

$$$$
StarDrop ID 191
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 45 48 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.7665 1.8903 0.0000 0
M  V30 2 C 2.3902 1.3502 0.0000 0
M  V30 3 O 2.2342 0.5401 0.0000 0
M  V30 4 C 2.8579 0.0000 0.0000 0
M  V30 5 N 2.7020 -0.8101 0.0000 0
M  V30 6 C 3.3256 -1.3502 0.0000 0
M  V30 7 O 4.1052 -1.0802 0.0000 0
M  V30 8 C 3.1697 -2.1604 0.0000 0
M  V30 9 C 2.3902 -2.4304 0.0000 0
M  V30 10 C 1.7665 -1.8903 0.0000 0
M  V30 11 C 0.9870 -2.1604 0.0000 0
M  V30 12 C 0.3633 -1.6203 0.0000 0
M  V30 13 C 0.5192 -0.8101 0.0000 0
M  V30 14 O -0.1044 -0.2700 0.0000 0
M  V30 15 C -0.8840 -0.5401 0.0000 0
M  V30 16 C -1.5076 -0.0000 0.0000 0
M  V30 17 C -2.2872 -0.2700 0.0000 0
M  V30 18 C -2.9108 0.2700 0.0000 0
M  V30 19 N -3.6904 -0.0000 0.0000 0
M  V30 20 C -3.8463 -0.8101 0.0000 0
M  V30 21 C -4.6258 -1.0802 0.0000 0
M  V30 22 N -5.2495 -0.5401 0.0000 0
M  V30 23 C -6.0290 -0.8101 0.0000 0
M  V30 24 C -6.1849 -1.6203 0.0000 0
M  V30 25 C -6.9645 -1.8903 0.0000 0
M  V30 26 C -7.5881 -1.3502 0.0000 0
M  V30 27 C -7.4322 -0.5401 0.0000 0
M  V30 28 Cl -8.0558 -0.0000 0.0000 0
M  V30 29 C -6.6526 -0.2700 0.0000 0
M  V30 30 Cl -6.4967 0.5401 0.0000 0
M  V30 31 C -5.0935 0.2700 0.0000 0
M  V30 32 C -4.3140 0.5401 0.0000 0
M  V30 33 C 1.2988 -0.5401 0.0000 0
M  V30 34 C 1.9224 -1.0802 0.0000 0
M  V30 35 C 3.1697 1.6203 0.0000 0
M  V30 36 C 3.7933 1.0802 0.0000 0
M  V30 37 C 4.5729 1.3502 0.0000 0
M  V30 38 C 5.1965 0.8101 0.0000 0
M  V30 39 C 5.9761 1.0802 0.0000 0
M  V30 40 C 6.5997 0.5401 0.0000 0
M  V30 41 C 7.3793 0.8101 0.0000 0
M  V30 42 C 8.0029 0.2700 0.0000 0
M  V30 43 C 8.7825 0.5401 0.0000 0
M  V30 44 C 9.4061 0.0000 0.0000 0
M  V30 45 C 10.1857 0.2700 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 27 28
M  V30 28 1 27 29
M  V30 29 2 23 29
M  V30 30 1 29 30
M  V30 31 1 22 31
M  V30 32 1 31 32
M  V30 33 1 19 32
M  V30 34 1 13 33
M  V30 35 2 33 34
M  V30 36 1 10 34
M  V30 37 1 5 34
M  V30 38 1 2 35
M  V30 39 1 35 36
M  V30 40 1 36 37
M  V30 41 1 37 38
M  V30 42 1 38 39
M  V30 43 1 39 40
M  V30 44 1 40 41
M  V30 45 1 41 42
M  V30 46 1 42 43
M  V30 47 1 43 44
M  V30 48 1 44 45
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
191

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Aripiprazole Lauroxil

>  <Synonyms>
N/A

>  <CAS>
1259305-29-7

>  <Formula>
C36H51Cl2N3O4

>  <MolWt>
660.7

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Dopamine Receptor;5-HT Receptor

>  <Receptor>
5-HT1A; 5-HT2A; D2 receptor

>  <Bioactivity>
"Aripiprazole lauroxil, the N-acyloxymethyl prodrug form of aripiprazole, a long-acting injectable (LAI) antipsychotic. Aripiprazole lauroxil is cleaved by esterases in vivo to N-hydroxymethyl aripiprazole (lauric acid), which is then cleaved to aripiprazole, which is non-toxic."

>  <Reference>
"Jann MW, et al. Long-Acting Injectable Second-Generation Antipsychotics:An Update and Comparison Between Agents.CNS Drugs. 2018 Mar;32(3):241-257.;Rohde M, et al. Biological conversion of aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug.Results Pharma Sci. 2014 May 2;4:19-25."

>  <ID<1>>
T14319

$$$$
StarDrop ID 192
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 9.0454 2.7474 0.0000 0
M  V30 2 C 9.0454 3.5724 0.0000 0
M  V30 3 O 8.3309 3.9849 0.0000 0
M  V30 4 C 7.6164 3.5724 0.0000 0
M  V30 5 C 6.9020 3.9849 0.0000 0
M  V30 6 O 6.9020 4.8099 0.0000 0
M  V30 7 C 6.1875 3.5724 0.0000 0
M  V30 8 O 5.4730 3.9849 0.0000 0
M  V30 9 C 9.7599 3.9849 0.0000 0
M  V30 10 C 10.4743 3.5724 0.0000 0
M  V30 11 C 11.1888 3.9849 0.0000 0
M  V30 12 C 11.9033 3.5724 0.0000 0
M  V30 13 C 12.6177 3.9849 0.0000 0
M  V30 14 C 13.3322 3.5724 0.0000 0
M  V30 15 C 14.0467 3.9849 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 2 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
192

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Monoctanoin

>  <Synonyms>
Moctanin;Glyceryl 1-caprylate

>  <CAS>
502-54-5

>  <Formula>
C11H22O4

>  <MolWt>
218.3

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial

>  <Receptor>
E. coli; S. aureus

>  <Bioactivity>
Monoctanoin has antibacterial activity against Staphylococcus aureus and Escherichia coli.

>  <Reference>
"Wang J, et al. In Vitro Antibacterial Activity and Mechanism of Monocaprylin against Escherichia coli and Staphylococcus aureus. J Food Prot. 2018 Dec;81(12):1988-1996.;Smith BF. Dissolution of cholesterol gallstones in vitro. Gallstone matrix content and diameter, not cholesterol content, predict gallstone dissolution in monooctanoin. Gastroenterology. 1987 Jul;93(1):98-105.;Valipe SR, et al. In vitro antimicrobial properties of caprylic acid, monocaprylin, and sodium caprylate against Dermatophilus congolensis. Am J Vet Res. 2011 Mar;72(3):331-5.;Tritapepe R, Di Padova C, Pozzoli M, Rovagnati P, Montorsi W. The treatment of retained biliary stones with monooctanoin: report of 16 patients. Am J Gastroenterol. 1984 Sep;79(9):710-4."

>  <ID<1>>
T33470

$$$$
StarDrop ID 193
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 40 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.4305 4.5060 0.0000 0
M  V30 2 N -5.2309 3.7055 0.0000 0
M  V30 3 C -4.4660 3.3965 0.0000 0
M  V30 4 C -4.5235 2.5735 0.0000 0
M  V30 5 C -5.3240 2.3739 0.0000 0
M  V30 6 N -5.7612 3.0735 0.0000 0
M  V30 7 C -3.8915 2.0432 0.0000 0
M  V30 8 C -3.1163 2.3254 0.0000 0
M  V30 9 C -2.4843 1.7951 0.0000 0
M  V30 10 O -1.7091 2.0772 0.0000 0
M  V30 11 C -1.0771 1.5469 0.0000 0
M  V30 12 C -0.3018 1.8291 0.0000 0
M  V30 13 C 0.3302 1.2988 0.0000 0
M  V30 14 F 1.1054 1.5810 0.0000 0
M  V30 15 C 0.1869 0.4863 0.0000 0
M  V30 16 N 0.8189 -0.0440 0.0000 0
M  V30 17 C 1.5941 0.2382 0.0000 0
M  V30 18 O 1.7374 1.0507 0.0000 0
M  V30 19 C 2.2261 -0.2921 0.0000 0
M  V30 20 C 2.6386 -1.0066 0.0000 0
M  V30 21 C 1.8136 -1.0066 0.0000 0
M  V30 22 C 2.8581 0.2382 0.0000 0
M  V30 23 O 2.7149 1.0507 0.0000 0
M  V30 24 N 3.6334 -0.0440 0.0000 0
M  V30 25 C 3.7766 -0.8564 0.0000 0
M  V30 26 C 4.5519 -1.1386 0.0000 0
M  V30 27 C 4.6951 -1.9511 0.0000 0
M  V30 28 C 4.0631 -2.4814 0.0000 0
M  V30 29 C 3.2879 -2.1992 0.0000 0
M  V30 30 C 3.1446 -1.3867 0.0000 0
M  V30 31 C -0.5883 0.2042 0.0000 0
M  V30 32 C -1.2203 0.7345 0.0000 0
M  V30 33 F -1.9956 0.4523 0.0000 0
M  V30 34 C -2.6276 0.9826 0.0000 0
M  V30 35 C -3.4028 0.7004 0.0000 0
M  V30 36 N -4.0348 1.2307 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 2 6
M  V30 7 1 4 7
M  V30 8 2 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 19 21
M  V30 23 1 19 22
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 25 30
M  V30 33 1 15 31
M  V30 34 2 31 32
M  V30 35 1 11 32
M  V30 36 1 32 33
M  V30 37 2 9 34
M  V30 38 1 34 35
M  V30 39 2 35 36
M  V30 40 1 7 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
193

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
c-Kit-IN-1

>  <Synonyms>
PDGFR inhibitor 1;DCC-2618

>  <CAS>
1225278-16-9

>  <Formula>
C26H21F2N5O3

>  <MolWt>
489.5

>  <Pathways>
Tyrosine Kinase/Adaptors

>  <Target>
c-Kit;c-Met/HGFR

>  <Receptor>
" c-Kit:<200 nM, c-Met:<200 nM"

>  <Bioactivity>
DCC-2618 is an effective inhibitor of c-Met and c-Kit (IC50s<200 nM).

>  <Reference>
"Daniel L. Flynn, et al. Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities. WO 2010051373 A1"

>  <ID<1>>
T4332

$$$$
StarDrop ID 194
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 0.8250 0.0000 0
M  V30 2 C 0.0000 0.0000 0.0000 0
M  V30 3 N -0.7145 -0.4125 0.0000 0
M  V30 4 C -0.7145 -1.2375 0.0000 0
M  V30 5 C -1.4289 -1.6500 0.0000 0
M  V30 6 N -2.1434 -1.2375 0.0000 0
M  V30 7 C -2.8579 -1.6500 0.0000 0
M  V30 8 N -2.8579 -2.4750 0.0000 0
M  V30 9 C -3.5724 -2.8875 0.0000 0
M  V30 10 N -3.5724 -3.7125 0.0000 0
M  V30 11 C -4.2868 -2.4750 0.0000 0
M  V30 12 C -5.0013 -2.8875 0.0000 0
M  V30 13 C -5.7158 -2.4750 0.0000 0
M  V30 14 O -6.4302 -2.8875 0.0000 0
M  V30 15 C -7.1447 -2.4750 0.0000 0
M  V30 16 C -5.7158 -1.6500 0.0000 0
M  V30 17 O -6.4302 -1.2375 0.0000 0
M  V30 18 C -6.4302 -0.4125 0.0000 0
M  V30 19 C -5.0013 -1.2375 0.0000 0
M  V30 20 C -4.2868 -1.6500 0.0000 0
M  V30 21 N -3.5724 -1.2375 0.0000 0
M  V30 22 C -2.1434 -0.4125 0.0000 0
M  V30 23 C -1.4289 0.0000 0.0000 0
M  V30 24 C 0.7145 -0.4125 0.0000 0
M  V30 25 O 1.4289 0.0000 0.0000 0
M  V30 26 C 2.1434 -0.4125 0.0000 0
M  V30 27 C 2.8579 0.0000 0.0000 0
M  V30 28 C 3.5724 -0.4125 0.0000 0
M  V30 29 C 3.5724 -1.2375 0.0000 0
M  V30 30 C 2.8579 -1.6500 0.0000 0
M  V30 31 C 2.1434 -1.2375 0.0000 0
M  V30 32 O 1.4289 -1.6500 0.0000 0
M  V30 33 C 0.7145 -1.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 13 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 16 19
M  V30 19 1 19 20
M  V30 20 2 11 20
M  V30 21 1 20 21
M  V30 22 2 7 21
M  V30 23 1 6 22
M  V30 24 1 22 23
M  V30 25 1 3 23
M  V30 26 1 2 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 2 27 28
M  V30 31 1 28 29
M  V30 32 2 29 30
M  V30 33 1 30 31
M  V30 34 2 26 31
M  V30 35 1 31 32
M  V30 36 1 32 33
M  V30 37 1 24 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
194

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Doxazosin

>  <Synonyms>
UK 33274

>  <CAS>
74191-85-8

>  <Formula>
C23H25N5O5

>  <MolWt>
451.5

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Adrenergic Receptor

>  <Receptor>
??1-adrenergic receptor

>  <Bioactivity>
Doxazosin is a long-lasting inhibitor of ??1-adrenoceptors that is widely used to treat benign prostatic hyperplasia and lower urinary tract symptoms.

>  <Reference>
"D'Eletto, R.D. and N.B. Javitt, Effect of doxazosin on cholesterol synthesis in cell culture. J Cardiovasc Pharmacol, 1989. 13 Suppl 2: p. S1-4; discussion S4.;Miura, Y. and K. Yoshinaga, Doxazosin: a newly developed, selective alpha 1-inhibitor in the management of patients with pheochromocytoma. Am Heart J, 1988. 116(6 Pt 2): p. 1785-9.;Sun, J.A., et al., Stereoselective binding of doxazosin enantiomers to plasma proteins from rats, dogs and humans in vitro. Acta Pharmacol Sin, 2013. 34(12): p. 1568-74."

>  <ID<1>>
T22316

$$$$
StarDrop ID 195
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 1.6139 1.3069 0.0000 0
M  V30 2 C 0.8995 1.7194 0.0000 0
M  V30 3 C 0.1850 1.3069 0.0000 0
M  V30 4 C 1.6139 0.4819 0.0000 0
M  V30 5 C 2.3284 0.0694 0.0000 0
M  V30 6 C 3.0429 0.4819 0.0000 0 CFG=1
M  V30 7 C 3.7574 0.0694 0.0000 0
M  V30 8 C 4.4718 0.4819 0.0000 0
M  V30 9 N 5.1863 0.0694 0.0000 0
M  V30 10 O 4.4718 1.3069 0.0000 0
M  V30 11 C 3.7574 -0.7556 0.0000 0
M  V30 12 C 4.4718 -1.1681 0.0000 0
M  V30 13 N 3.0429 -1.1681 0.0000 0
M  V30 14 C 2.3284 -0.7556 0.0000 0
M  V30 15 C 1.6139 -1.1681 0.0000 0
M  V30 16 C 1.6139 -1.9931 0.0000 0
M  V30 17 C 0.8995 -0.7556 0.0000 0
M  V30 18 N 0.8995 0.0694 0.0000 0
M  V30 19 C 3.2978 1.2666 0.0000 0
M  V30 20 C 2.7458 1.8797 0.0000 0
M  V30 21 O 1.9388 1.7081 0.0000 0
M  V30 22 C 1.3868 2.3212 0.0000 0
M  V30 23 C 3.0007 2.6643 0.0000 0
M  V30 24 C 3.8077 2.8358 0.0000 0
M  V30 25 C 4.0626 3.6204 0.0000 0
M  V30 26 N 4.3176 4.4051 0.0000 0
M  V30 27 C 4.3597 2.2227 0.0000 0
M  V30 28 C 4.1048 1.4381 0.0000 0
M  V30 29 H 3.9765 0.8403 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 1 4
M  V30 4 2 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 2 7 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 5 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 2 17 18
M  V30 19 1 4 18
M  V30 20 1 6 19 CFG=3
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 20 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 3 25 26
M  V30 28 1 24 27
M  V30 29 2 27 28
M  V30 30 1 19 28
M  V30 31 1 29 6
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
195

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Finerenone

>  <Synonyms>
BAY 94-8862;BAY-94-8862;BAY948862;BAY94-8862;BAY-948862;BAY 948862

>  <CAS>
1050477-31-0

>  <Formula>
C21H22N4O3

>  <MolWt>
378.4

>  <Pathways>
Endocrinology/Hormones

>  <Target>
Glucocorticoid Receptor

>  <Receptor>
 Mineralocorticoid Receptor:18 nM

>  <Bioactivity>
"Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist with IC50 of 18 nM for the treatment of chronic heart failure. Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold)."

>  <Reference>
"Bramlage P, Swift SL, Thoenes M, Minguet J, Ferrero C, Schmieder RE. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur J Heart Fail. 2016 Jan;18(1):28-37. doi: 10.1002/ejhf.444. Epub 2015 Dec 3. Review. PubMed PMID: 26634965.;George L Bakris , Rajiv Agarwal ,et al.Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.JAMA. 2015 Sep 1;314(9):884-94. "

>  <ID<1>>
T21395

$$$$
StarDrop ID 196
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.4034 0.6966 0.0000 0
M  V30 2 N 3.1179 1.1091 0.0000 0
M  V30 3 C 3.1179 1.9341 0.0000 0
M  V30 4 C 3.8324 0.6966 0.0000 0
M  V30 5 C 4.5468 1.1091 0.0000 0
M  V30 6 C 5.2613 0.6966 0.0000 0
M  V30 7 C 5.9758 1.1091 0.0000 0 CFG=1
M  V30 8 O 6.5889 1.6611 0.0000 0
M  V30 9 C 7.3033 1.2486 0.0000 0
M  V30 10 C 7.1318 0.4417 0.0000 0
M  V30 11 C 7.6167 -0.2258 0.0000 0
M  V30 12 C 7.2812 -0.9794 0.0000 0
M  V30 13 C 6.4607 -1.0657 0.0000 0
M  V30 14 C 5.9758 -0.3982 0.0000 0
M  V30 15 C 6.3113 0.3554 0.0000 0
M  V30 16 C 7.7661 -1.6469 0.0000 0
M  V30 17 N 8.2510 -2.3143 0.0000 0
M  V30 18 C 5.4909 1.7765 0.0000 0
M  V30 19 C 4.6704 1.6903 0.0000 0
M  V30 20 C 4.1854 2.3578 0.0000 0
M  V30 21 C 4.5210 3.1114 0.0000 0
M  V30 22 F 4.0361 3.7789 0.0000 0
M  V30 23 C 5.3415 3.1977 0.0000 0
M  V30 24 C 5.8264 2.5302 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=1
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 7 15
M  V30 16 1 10 15
M  V30 17 1 12 16
M  V30 18 3 16 17
M  V30 19 1 7 18 CFG=3
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 1 21 23
M  V30 25 2 23 24
M  V30 26 1 18 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
196

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Escitalopram

>  <Synonyms>
Seroplex;S-(+)-Citalopram;(S)-Citalopram

>  <CAS>
128196-01-0

>  <Formula>
C20H21FN2O

>  <MolWt>
324.4

>  <Pathways>
GPCR/G Protein;Immunology/Inflammation;Neuroscience

>  <Target>
Adrenergic Receptor;AChR;Histamine Receptor;5-HT Receptor;Norepinephrine;Dopamine Receptor;Serotonin Transporter

>  <Receptor>
 SSRI:0.89 nM(ki)

>  <Bioactivity>
"Escitalopram is a furancarbonitrile that is one of the SEROTONIN UPTAKE INHIBITORS used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from tardive dyskinesia in preference to tricyclic antidepressants, which aggravate this condition."

>  <Reference>
"Owens JM, et al. Encephale. 2002 Jul-Aug;28(4):350-5."

>  <ID<1>>
T0185

$$$$
StarDrop ID 197
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 42 46 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.7861 -0.2161 0.0000 0
M  V30 2 C 4.5006 -0.6286 0.0000 0
M  V30 3 N 4.5006 -1.4536 0.0000 0
M  V30 4 C 3.7861 -1.8661 0.0000 0
M  V30 5 C 3.7861 -2.6911 0.0000 0
M  V30 6 C 4.5006 -3.1036 0.0000 0
M  V30 7 O 5.2150 -2.6911 0.0000 0
M  V30 8 N 4.5006 -3.9286 0.0000 0
M  V30 9 C 3.7861 -4.3411 0.0000 0
M  V30 10 C 3.0716 -3.9286 0.0000 0
M  V30 11 C 3.0716 -3.1036 0.0000 0
M  V30 12 C 2.3571 -2.6911 0.0000 0
M  V30 13 C 3.7861 -5.1661 0.0000 0
M  V30 14 C 5.2150 -0.2161 0.0000 0
M  V30 15 C 5.2150 0.6089 0.0000 0
M  V30 16 C 5.9295 1.0214 0.0000 0
M  V30 17 C 6.6440 0.6089 0.0000 0
M  V30 18 C 6.6440 -0.2161 0.0000 0
M  V30 19 C 5.9295 -0.6286 0.0000 0
M  V30 20 C 5.9295 -1.4536 0.0000 0
M  V30 21 N 7.3584 -0.6286 0.0000 0
M  V30 22 C 8.0729 -0.2161 0.0000 0
M  V30 23 C 8.7874 -0.6286 0.0000 0
M  V30 24 C 7.3584 -1.4536 0.0000 0
M  V30 25 C 8.0729 -1.8661 0.0000 0
M  V30 26 C 8.0729 -2.6911 0.0000 0
M  V30 27 O 7.3584 -3.1036 0.0000 0
M  V30 28 C 6.6440 -2.6911 0.0000 0
M  V30 29 C 6.6440 -1.8661 0.0000 0
M  V30 30 C 5.9295 1.8464 0.0000 0
M  V30 31 C 5.2150 2.2589 0.0000 0
M  V30 32 C 5.2150 3.0839 0.0000 0
M  V30 33 C 5.9295 3.4964 0.0000 0
M  V30 34 C 6.6440 3.0839 0.0000 0
M  V30 35 C 6.6440 2.2589 0.0000 0
M  V30 36 C 5.9295 4.3214 0.0000 0
M  V30 37 N 6.6440 4.7339 0.0000 0
M  V30 38 C 6.6440 5.5589 0.0000 0
M  V30 39 C 7.3584 5.9714 0.0000 0
M  V30 40 O 8.0729 5.5589 0.0000 0
M  V30 41 C 8.0729 4.7339 0.0000 0
M  V30 42 C 7.3584 4.3214 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 5 11
M  V30 12 1 11 12
M  V30 13 1 9 13
M  V30 14 1 2 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 14 19
M  V30 21 1 19 20
M  V30 22 1 18 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 1 21 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 24 29
M  V30 32 1 16 30
M  V30 33 2 30 31
M  V30 34 1 31 32
M  V30 35 2 32 33
M  V30 36 1 33 34
M  V30 37 2 34 35
M  V30 38 1 30 35
M  V30 39 1 33 36
M  V30 40 1 36 37
M  V30 41 1 37 38
M  V30 42 1 38 39
M  V30 43 1 39 40
M  V30 44 1 40 41
M  V30 45 1 41 42
M  V30 46 1 37 42
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
197

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tazemetostat hydrobromide

>  <Synonyms>
EPZ-6438 hydrobromide;E-7438 hydrobromide

>  <CAS>
1467052-75-0

>  <Formula>
C34H45BrN4O4

>  <MolWt>
653.7

>  <Pathways>
Chromatin/Epigenetic

>  <Target>
Histone Methyltransferase

>  <Receptor>
" EZH1:392 nM, EZH2:11 nM (in peptide assay), EZH2:16 nM (in nucleosome assay), Rat EZH2:4 nM, EZH2 WT:2.5 nM (Ki)"

>  <Bioactivity>
Tazemetostat hydrobromide is a potent and selective EZH2 inhibitor. Tazemetostat hydrobromide inhibits the activity of human polycomb repressive complex 2 (PRC2)-containing wild-type EZH2 (Ki: 2.5 nM). Tazemetostat hydrobromide also inhibits EZH1 (IC50: 392 nM).

>  <Reference>
"Knutson SK, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferaseEZH2. Proc Natl Acad Sci U S A. 2013 May 7;110(19):7922-7."

>  <ID<1>>
T17002

$$$$
StarDrop ID 198
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.4358 -2.7631 0.0000 0
M  V30 2 C 0.8838 -2.1500 0.0000 0
M  V30 3 C 0.0768 -2.3215 0.0000 0
M  V30 4 C -0.4752 -1.7084 0.0000 0
M  V30 5 C -1.2822 -1.8800 0.0000 0
M  V30 6 C -1.5371 -2.6646 0.0000 0
M  V30 7 C -1.8342 -1.2669 0.0000 0
M  V30 8 C -2.3863 -0.6538 0.0000 0
M  V30 9 C -2.4473 -1.8189 0.0000 0
M  V30 10 O -1.2211 -0.7148 0.0000 0
M  V30 11 C 1.1387 -1.3654 0.0000 0
M  V30 12 C 0.6538 -0.6979 0.0000 0
M  V30 13 C 1.1387 -0.0305 0.0000 0
M  V30 14 C 1.9233 -0.2854 0.0000 0
M  V30 15 C 2.6378 0.1271 0.0000 0
M  V30 16 C 3.3523 -0.2854 0.0000 0
M  V30 17 C 3.3523 -1.1104 0.0000 0
M  V30 18 C 2.6378 -1.5229 0.0000 0
M  V30 19 C 1.9233 -1.1104 0.0000 0
M  V30 20 C 1.8371 -1.9309 0.0000 0
M  V30 21 C 2.6378 0.9521 0.0000 0
M  V30 22 C 1.9233 1.3646 0.0000 0
M  V30 23 C 1.9233 2.1896 0.0000 0
M  V30 24 C 1.2089 2.6021 0.0000 0
M  V30 25 C 1.2089 3.4271 0.0000 0
M  V30 26 O 0.4944 3.8396 0.0000 0
M  V30 27 C 1.9233 3.8396 0.0000 0
M  V30 28 C 2.6378 3.4271 0.0000 0
M  V30 29 O 3.3523 3.8396 0.0000 0
M  V30 30 C 2.6378 2.6021 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 2 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 11 19
M  V30 20 1 14 19
M  V30 21 1 19 20
M  V30 22 2 15 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 25 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 28 30
M  V30 32 1 23 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
198

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Paricalcitol

>  <Synonyms>
N/A

>  <CAS>
131918-61-1

>  <Formula>
C27H44O3

>  <MolWt>
416.6

>  <Pathways>


>  <Target>


>  <Receptor>
VD/VDR; vitamin D receptor

>  <Bioactivity>
Paricalcitol is a vitamin D receptor agonist. It is used for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

>  <Reference>
"Martinez-Moreno JM, et al. In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/beta-catenin activation. Am J Physiol Renal Physiol. 2012 Aug 8.;Meems LM, et al. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J Steroid Biochem Mol Biol. 2012 Jul 16;132(3-5):282-289."

>  <ID<1>>
TQ0200

$$$$
StarDrop ID 199
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 41 45 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.9934 2.4750 0.0000 0
M  V30 2 O 3.2789 2.0625 0.0000 0
M  V30 3 C 3.2789 1.2375 0.0000 0
M  V30 4 C 3.9934 0.8250 0.0000 0
M  V30 5 N 3.9934 0.0000 0.0000 0
M  V30 6 C 3.2789 -0.4125 0.0000 0
M  V30 7 N 3.2789 -1.2375 0.0000 0
M  V30 8 C 3.9464 -1.7224 0.0000 0
M  V30 9 N 3.6914 -2.5070 0.0000 0
M  V30 10 C 2.8664 -2.5070 0.0000 0
M  V30 11 C 2.3815 -3.1745 0.0000 0
M  V30 12 N 2.6115 -1.7224 0.0000 0
M  V30 13 C 2.5645 0.0000 0.0000 0
M  V30 14 N 1.7798 -0.2549 0.0000 0
M  V30 15 C 1.5249 -1.0396 0.0000 0
M  V30 16 O 0.7179 -1.2111 0.0000 0
M  V30 17 P 0.1659 -0.5980 0.0000 0
M  V30 18 O 0.7790 -0.0460 0.0000 0
M  V30 19 O -0.4472 -1.1500 0.0000 0
M  V30 20 O -0.3861 0.0151 0.0000 0
M  V30 21 C 1.2949 0.4125 0.0000 0
M  V30 22 C 1.7798 1.0799 0.0000 0
M  V30 23 C 1.5249 1.8646 0.0000 0
M  V30 24 O 2.0769 2.4777 0.0000 0
M  V30 25 C 0.7179 2.0361 0.0000 0
M  V30 26 O 0.1659 1.4230 0.0000 0
M  V30 27 N 0.4630 2.8207 0.0000 0
M  V30 28 C -0.3440 2.9922 0.0000 0
M  V30 29 C -0.5989 3.7769 0.0000 0
M  V30 30 N -0.0469 4.3900 0.0000 0
M  V30 31 C 0.7601 4.2184 0.0000 0
M  V30 32 C 1.0150 3.4338 0.0000 0
M  V30 33 C -0.3018 5.1746 0.0000 0
M  V30 34 O -1.1088 5.3461 0.0000 0
M  V30 35 C 0.2502 5.7877 0.0000 0
M  V30 36 C -0.0047 6.5723 0.0000 0
M  V30 37 C 0.5473 7.1854 0.0000 0
M  V30 38 C 1.3543 7.0139 0.0000 0
M  V30 39 C 1.6092 6.2292 0.0000 0
M  V30 40 C 1.0572 5.6161 0.0000 0
M  V30 41 C 2.5645 0.8250 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 7 12
M  V30 13 1 6 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 2 17 20
M  V30 21 1 14 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 23 25
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 1 29 30
M  V30 31 1 30 31
M  V30 32 1 31 32
M  V30 33 1 27 32
M  V30 34 1 30 33
M  V30 35 2 33 34
M  V30 36 1 33 35
M  V30 37 2 35 36
M  V30 38 1 36 37
M  V30 39 2 37 38
M  V30 40 1 38 39
M  V30 41 2 39 40
M  V30 42 1 35 40
M  V30 43 1 22 41
M  V30 44 1 3 41
M  V30 45 2 13 41
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
199

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fostemsavir

>  <Synonyms>
BMS-663068

>  <CAS>
864953-29-7

>  <Formula>
C25H26N7O8P

>  <MolWt>
583.5

>  <Pathways>
Microbiology/Virology;Proteases/Proteasome

>  <Target>
HIV Protease

>  <Receptor>
HIV; HIV-1

>  <Bioactivity>
BMS-663068 is an HIV-1 attachment inhibitor in development for the treatment of HIV-1 infection.

>  <Reference>
"Nowicka-Sans B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother. 2012 Jul;56(7):3498-507."

>  <ID<1>>
T3523

$$$$
StarDrop ID 200
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.3228 -0.9107 0.0000 0
M  V30 2 C 3.9629 -0.1684 0.0000 0 CFG=2
M  V30 3 C 3.4311 -0.7991 0.0000 0
M  V30 4 C 2.6190 -0.6539 0.0000 0
M  V30 5 C 2.3387 0.1221 0.0000 0 CFG=1
M  V30 6 C 1.5266 0.2673 0.0000 0 CFG=2
M  V30 7 C 1.8069 -0.5086 0.0000 0
M  V30 8 C 0.9948 -0.3634 0.0000 0
M  V30 9 C 0.1827 -0.2182 0.0000 0
M  V30 10 C 3.6826 0.6076 0.0000 0 CFG=1
M  V30 11 C 4.3340 1.1139 0.0000 0
M  V30 12 C 5.0168 0.6509 0.0000 0
M  V30 13 C 2.8705 0.7528 0.0000 0 CFG=2
M  V30 14 C 2.5902 1.5287 0.0000 0
M  V30 15 C 1.7781 1.6739 0.0000 0
M  V30 16 C 1.2463 1.0432 0.0000 0
M  V30 17 C 0.4342 1.1884 0.0000 0
M  V30 18 C -0.0976 0.5577 0.0000 0
M  V30 19 O -0.9098 0.7029 0.0000 0
M  V30 20 C 4.7875 -0.1416 0.0000 0 CFG=2
M  V30 21 C 5.2939 -0.7929 0.0000 0
M  V30 22 C 6.1111 -0.6800 0.0000 0
M  V30 23 O 4.9830 -1.5571 0.0000 0
M  V30 24 H 1.6941 -0.6425 0.0000 0
M  V30 25 H 4.6432 0.3295 0.0000 0
M  V30 26 H 3.5151 1.5173 0.0000 0
M  V30 27 H 5.7696 0.0469 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 6 7 CFG=1
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 2 10
M  V30 10 1 10 11 CFG=3
M  V30 11 1 11 12
M  V30 12 1 10 13
M  V30 13 1 13 5
M  V30 14 1 13 14 CFG=1
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 6 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 1 9 18
M  V30 21 2 18 19
M  V30 22 1 2 20
M  V30 23 1 20 12
M  V30 24 1 20 21 CFG=3
M  V30 25 1 21 22
M  V30 26 2 21 23
M  V30 27 1 24 5
M  V30 28 1 25 10
M  V30 29 1 26 13
M  V30 30 1 27 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
200

>  <Plate>
PHD136328

>  <Row>
j

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dydrogesterone

>  <Synonyms>
N/A

>  <CAS>
152-62-5

>  <Formula>
C21H28O2

>  <MolWt>
312.5

>  <Pathways>
Others

>  <Target>
Progesterone Receptor

>  <Receptor>
progesterone receptor

>  <Bioactivity>
Dydrogesterone is a potent progestogen which can be used in progesterone deficiency studies.

>  <Reference>
"Griesinger G, et al. Dydrogesterone as an oral alternative to vaginal progesterone for IVF luteal phase support: A systematic review and individual participant data meta-analysis. PLoS One. 2020 Nov 4;15(11):e0241044."

>  <ID<1>>
T3036

$$$$
StarDrop ID 201
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.8579 -6.6000 0.0000 0
M  V30 2 C -2.1434 -6.1875 0.0000 0
M  V30 3 C -1.4289 -6.6000 0.0000 0
M  V30 4 N -2.1434 -5.3625 0.0000 0
M  V30 5 C -1.4289 -4.9500 0.0000 0
M  V30 6 O -0.7145 -5.3625 0.0000 0
M  V30 7 C -1.4289 -4.1250 0.0000 0
M  V30 8 O -0.7145 -3.7125 0.0000 0
M  V30 9 C -0.7145 -2.8875 0.0000 0
M  V30 10 C -1.4289 -2.4750 0.0000 0
M  V30 11 C -1.4289 -1.6500 0.0000 0
M  V30 12 C -0.7145 -1.2375 0.0000 0
M  V30 13 C 0.0000 -1.6500 0.0000 0
M  V30 14 C 0.0000 -2.4750 0.0000 0
M  V30 15 C 0.7145 -1.2375 0.0000 0
M  V30 16 N 0.7145 -0.4125 0.0000 0
M  V30 17 C 1.4289 0.0000 0.0000 0
M  V30 18 N 1.4289 0.8250 0.0000 0
M  V30 19 C 2.1434 1.2375 0.0000 0
M  V30 20 C 2.1434 2.0625 0.0000 0
M  V30 21 C 2.8579 2.4750 0.0000 0
M  V30 22 C 3.5724 2.0625 0.0000 0
M  V30 23 N 4.3570 2.3174 0.0000 0
M  V30 24 N 4.8419 1.6500 0.0000 0
M  V30 25 C 4.3570 0.9826 0.0000 0
M  V30 26 C 3.5724 1.2375 0.0000 0
M  V30 27 C 2.8579 0.8250 0.0000 0
M  V30 28 C 2.1434 -0.4125 0.0000 0
M  V30 29 C 2.8579 0.0000 0.0000 0
M  V30 30 C 3.5724 -0.4125 0.0000 0
M  V30 31 C 3.5724 -1.2375 0.0000 0
M  V30 32 C 2.8579 -1.6500 0.0000 0
M  V30 33 C 2.1434 -1.2375 0.0000 0
M  V30 34 N 1.4289 -1.6500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 9 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 22 26
M  V30 28 1 26 27
M  V30 29 2 19 27
M  V30 30 1 17 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 1 31 32
M  V30 35 2 32 33
M  V30 36 1 28 33
M  V30 37 1 33 34
M  V30 38 2 15 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
201

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Belumosudil

>  <Synonyms>
Rezurock;SLx-2119;KD025;ROCK inhibitor

>  <CAS>
911417-87-3

>  <Formula>
C26H24N6O2

>  <MolWt>
452.5

>  <Pathways>
Cytoskeletal Signaling;Stem Cells;Cell Cycle/Checkpoint

>  <Target>
ROCK

>  <Receptor>
" ROCK2:41 nM(Ki), ROCK2:60 nM"

>  <Bioactivity>
"KD025 is an orally available, and specific ROCK2 inhibitor (IC50/Ki: 60/41 nM)."

>  <Reference>
"Zanin-Zhorov A, et al. Proc Natl Acad Sci U S A. 2014, 111(47), 16814-16819.;Flynn R, et al. Blood. 2016. pii: blood-2015-10-678706.;Lee JH, et al. Ann Clin Transl Neurol. 2014, 1(1), 2-14."

>  <ID<1>>
T6867

$$$$
StarDrop ID 202
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.7145 -0.4125 0.0000 0
M  V30 2 C 0.7145 -1.2375 0.0000 0
M  V30 3 C 1.4289 -1.6500 0.0000 0
M  V30 4 C 1.4289 -2.4750 0.0000 0
M  V30 5 C 0.7145 -2.8875 0.0000 0
M  V30 6 N 0.0000 -2.4750 0.0000 0
M  V30 7 C 0.0000 -1.6500 0.0000 0
M  V30 8 O -0.7145 -1.2375 0.0000 0
M  V30 9 C 2.1434 -2.8875 0.0000 0
M  V30 10 C 2.8579 -2.4750 0.0000 0
M  V30 11 C 3.5724 -2.8875 0.0000 0
M  V30 12 N 3.5724 -3.7125 0.0000 0
M  V30 13 C 2.8579 -4.1250 0.0000 0
M  V30 14 C 2.1434 -3.7125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 2 7 8
M  V30 9 1 4 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 9 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
202

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Amrinone

>  <Synonyms>
Wincoram;Inocor;Inamrinone

>  <CAS>
60719-84-8

>  <Formula>
C10H9N3O

>  <MolWt>
187.2

>  <Pathways>
Apoptosis;Metabolism

>  <Target>
PDE;TNF

>  <Receptor>
PDE; phosphodiesterase; TNF-??

>  <Bioactivity>
"Amrinone is a positive inotropic cardiotonic (cardiotonic agent) with vasodilator properties, phosphodiesterase 3 inhibitory activity."

>  <Reference>
"Kobayashi T, et al. J Hepatol. 2002 Jul; 37(1):31-8."

>  <ID<1>>
T1265

$$$$
StarDrop ID 203
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 43 47 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 4.1355 2.9140 0.0000 0
M  V30 2 C 4.2217 2.0936 0.0000 0 CFG=2
M  V30 3 C 4.9362 2.5061 0.0000 0
M  V30 4 C 5.6506 2.0936 0.0000 0 CFG=2
M  V30 5 H 6.3651 1.6811 0.0000 0
M  V30 6 C 6.3651 2.5061 0.0000 0
M  V30 7 C 7.0796 2.0936 0.0000 0 CFG=1
M  V30 8 C 7.0796 1.2686 0.0000 0
M  V30 9 C 6.3651 0.8561 0.0000 0
M  V30 10 C 5.6506 1.2686 0.0000 0 CFG=1
M  V30 11 H 5.6506 0.4436 0.0000 0
M  V30 12 C 4.9362 0.8561 0.0000 0 CFG=2
M  V30 13 C 4.9362 0.0311 0.0000 0
M  V30 14 C 5.6506 -0.3814 0.0000 0
M  V30 15 C 5.6506 -1.2064 0.0000 0
M  V30 16 C 6.3651 -1.6189 0.0000 0
M  V30 17 C 6.3651 -2.4439 0.0000 0
M  V30 18 C 5.6506 -2.8564 0.0000 0
M  V30 19 C 4.9362 -2.4439 0.0000 0
M  V30 20 N 4.9362 -1.6189 0.0000 0
M  V30 21 C 5.6506 -3.6814 0.0000 0
M  V30 22 C 6.3651 -4.0939 0.0000 0
M  V30 23 C 6.3651 -4.9189 0.0000 0
M  V30 24 C 5.6506 -5.3314 0.0000 0
M  V30 25 C 4.9362 -4.9189 0.0000 0
M  V30 26 F 4.2217 -5.3314 0.0000 0
M  V30 27 C 4.9362 -4.0939 0.0000 0
M  V30 28 C 4.2217 1.2686 0.0000 0 CFG=2
M  V30 29 H 4.9362 1.6811 0.0000 0
M  V30 30 C 3.4371 1.0136 0.0000 0 CFG=1
M  V30 31 C 3.1821 0.2290 0.0000 0
M  V30 32 O 2.9522 1.6811 0.0000 0
M  V30 33 C 3.4371 2.3485 0.0000 0
M  V30 34 O 3.1821 3.1331 0.0000 0
M  V30 35 N 7.7941 2.5061 0.0000 0
M  V30 36 C 8.5085 2.0936 0.0000 0
M  V30 37 O 8.5085 1.2686 0.0000 0
M  V30 38 O 9.2230 2.5061 0.0000 0
M  V30 39 C 9.9375 2.0936 0.0000 0
M  V30 40 C 10.6519 2.5061 0.0000 0
M  V30 41 H 7.9456 1.5936 0.0000 0
M  V30 42 H 5.8022 0.3561 0.0000 0
M  V30 43 H 2.4494 0.8573 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5 CFG=1
M  V30 5 1 4 6
M  V30 6 1 7 6
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 10 9
M  V30 10 1 10 4
M  V30 11 1 10 11 CFG=3
M  V30 12 1 12 10
M  V30 13 1 12 13 CFG=3
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 15 20
M  V30 22 1 18 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 2 25 27
M  V30 29 1 21 27
M  V30 30 1 28 12
M  V30 31 1 28 2
M  V30 32 1 28 29 CFG=1
M  V30 33 1 28 30
M  V30 34 1 30 31 CFG=1
M  V30 35 1 30 32
M  V30 36 1 32 33
M  V30 37 1 2 33
M  V30 38 2 33 34
M  V30 39 1 7 35 CFG=3
M  V30 40 1 35 36
M  V30 41 2 36 37
M  V30 42 1 36 38
M  V30 43 1 38 39
M  V30 44 1 39 40
M  V30 45 1 41 7
M  V30 46 1 42 12
M  V30 47 1 43 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
203

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Vorapaxar sulfate

>  <Synonyms>
vorapaxar monosulfate;SCH 530348 sulfate;Zontivity

>  <CAS>
705260-08-8

>  <Formula>
C29H35FN2O8S

>  <MolWt>
590.7

>  <Pathways>
GPCR/G Protein

>  <Target>
Protease-activated Receptor

>  <Receptor>
 PAR-1:8.1 nM (Ki)

>  <Bioactivity>
Vorapaxar sulfate is a potent and orally active thrombin receptor (PAR-1) antagonist.

>  <Reference>
"Chackalamannil S, et al. J Med Chem, 2008, 51(11), 3061-3064."

>  <ID<1>>
T3098

$$$$
StarDrop ID 204
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 53 52 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 15.3730 9.7006 0.0000 0
M  V30 2 C 16.0875 9.2881 0.0000 0
M  V30 3 C 16.8020 9.7006 0.0000 0
M  V30 4 C 17.5164 9.2881 0.0000 0
M  V30 5 C 18.2309 9.7006 0.0000 0
M  V30 6 C 18.9454 9.2881 0.0000 0
M  V30 7 C 19.6599 9.7006 0.0000 0
M  V30 8 C 20.3743 9.2881 0.0000 0
M  V30 9 C 21.0888 9.7006 0.0000 0
M  V30 10 C 21.8033 9.2881 0.0000 0
M  V30 11 C 22.5177 9.7006 0.0000 0
M  V30 12 C 23.2322 9.2881 0.0000 0
M  V30 13 C 23.9467 9.7006 0.0000 0
M  V30 14 C 24.6612 9.2881 0.0000 0
M  V30 15 C 25.3756 9.7006 0.0000 0
M  V30 16 C 26.0901 9.2881 0.0000 0
M  V30 17 O 26.0901 8.4631 0.0000 0
M  V30 18 O 26.8046 9.7006 0.0000 0
M  V30 19 C 27.5190 9.2881 0.0000 0
M  V30 20 C 28.2335 9.7006 0.0000 0 CFG=2
M  V30 21 C 28.2335 10.5256 0.0000 0
M  V30 22 O 28.9480 10.9381 0.0000 0
M  V30 23 P 28.9480 11.7631 0.0000 0
M  V30 24 O 28.1230 11.7631 0.0000 0
M  V30 25 O 29.7730 11.7631 0.0000 0
M  V30 26 O 28.9480 12.5881 0.0000 0
M  V30 27 C 29.6624 13.0006 0.0000 0
M  V30 28 C 29.6624 13.8256 0.0000 0
M  V30 29 N 30.3769 14.2381 0.0000 0 CHG=1
M  V30 30 C 30.7894 13.5237 0.0000 0
M  V30 31 C 29.9644 14.9526 0.0000 0
M  V30 32 C 31.0914 14.6506 0.0000 0
M  V30 33 O 28.9480 9.2881 0.0000 0
M  V30 34 C 29.6624 9.7006 0.0000 0
M  V30 35 O 29.6624 10.5256 0.0000 0
M  V30 36 C 30.3769 9.2881 0.0000 0
M  V30 37 C 31.0914 9.7006 0.0000 0
M  V30 38 C 31.8059 9.2881 0.0000 0
M  V30 39 C 32.5203 9.7006 0.0000 0
M  V30 40 C 33.2348 9.2881 0.0000 0
M  V30 41 C 33.9493 9.7006 0.0000 0
M  V30 42 C 34.6637 9.2881 0.0000 0
M  V30 43 C 35.3782 9.7006 0.0000 0
M  V30 44 C 36.0927 9.2881 0.0000 0
M  V30 45 C 36.8072 9.7006 0.0000 0
M  V30 46 C 36.8072 10.5256 0.0000 0
M  V30 47 C 37.5216 10.9381 0.0000 0
M  V30 48 C 37.5216 11.7631 0.0000 0
M  V30 49 C 38.2361 12.1756 0.0000 0
M  V30 50 C 38.2361 13.0006 0.0000 0
M  V30 51 C 38.9506 13.4131 0.0000 0
M  V30 52 C 38.9506 14.2381 0.0000 0
M  V30 53 H 29.0995 10.2006 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 18 19
M  V30 19 1 20 19
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 2 23 25
M  V30 25 1 23 26
M  V30 26 1 26 27
M  V30 27 1 27 28
M  V30 28 1 28 29
M  V30 29 1 29 30
M  V30 30 1 29 31
M  V30 31 1 29 32
M  V30 32 1 20 33 CFG=3
M  V30 33 1 33 34
M  V30 34 2 34 35
M  V30 35 1 34 36
M  V30 36 1 36 37
M  V30 37 1 37 38
M  V30 38 1 38 39
M  V30 39 1 39 40
M  V30 40 1 40 41
M  V30 41 1 41 42
M  V30 42 1 42 43
M  V30 43 2 43 44
M  V30 44 1 44 45
M  V30 45 1 45 46
M  V30 46 2 46 47
M  V30 47 1 47 48
M  V30 48 1 48 49
M  V30 49 1 49 50
M  V30 50 1 50 51
M  V30 51 1 51 52
M  V30 52 1 53 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
204

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lecithin

>  <Synonyms>
L-??-Phosphatidylcholine;Phosphatidylcholines;Phospholutein

>  <CAS>
8002-43-5

>  <Formula>
C42H80NO8P

>  <MolWt>
758.1

>  <Pathways>
Others;Metabolism

>  <Target>
Others;Endogenous Metabolite

>  <Receptor>
Endogenous Metabolite

>  <Bioactivity>
"Typical lots of egg yolk phosphatidylcholine have fatty acid contents of approximately 33% 16:0 (palmitic), 13% 18:0 (stearic), 31% 18:1(oleic), and 15% 18:2 (linoleic) (other fatty acids being minor contributors), which would give an average molecular weight of approximately 768. Phospholipids are reported to alter the fatty acid composition and microstructure of the membranes in animal cells."

>  <Reference>
"Mansour M, et al. Novel polyglycerol-dioleate based cubosomal dispersion with tailored physical characteristics for controlled delivery of ondansetron. Colloids Surf B Biointerfaces. 2017 Apr 26;156:44-54."

>  <ID<1>>
T3237

$$$$
StarDrop ID 205
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.0000 -0.0000 0.0000 0
M  V30 2 O -0.7145 -0.4125 0.0000 0
M  V30 3 C -0.7145 -1.2375 0.0000 0
M  V30 4 C 0.0000 -1.6500 0.0000 0
M  V30 5 C 0.0000 -2.4750 0.0000 0
M  V30 6 C -0.7145 -2.8875 0.0000 0
M  V30 7 C -1.4289 -2.4750 0.0000 0
M  V30 8 C -1.4289 -1.6500 0.0000 0
M  V30 9 C -2.1434 -1.2375 0.0000 0
M  V30 10 C -2.8579 -0.8250 0.0000 0
M  V30 11 C -1.7309 -0.5230 0.0000 0
M  V30 12 C -2.5559 -1.9520 0.0000 0
M  V30 13 N -0.7145 -3.7125 0.0000 0
M  V30 14 C 0.0000 -4.1250 0.0000 0
M  V30 15 C 0.0000 -4.9500 0.0000 0
M  V30 16 C -0.7145 -5.3625 0.0000 0
M  V30 17 O -0.7145 -6.1875 0.0000 0
M  V30 18 N -1.4289 -4.9500 0.0000 0
M  V30 19 C -1.4289 -4.1250 0.0000 0
M  V30 20 O -2.1434 -3.7125 0.0000 0
M  V30 21 C 0.7145 -1.2375 0.0000 0
M  V30 22 C 0.7145 -0.4125 0.0000 0
M  V30 23 C 1.4289 0.0000 0.0000 0
M  V30 24 C 2.1434 -0.4125 0.0000 0
M  V30 25 C 2.8579 0.0000 0.0000 0
M  V30 26 C 3.5724 -0.4125 0.0000 0
M  V30 27 N 4.2868 -0.0000 0.0000 0
M  V30 28 S 4.2868 0.8250 0.0000 0
M  V30 29 C 4.2868 1.6500 0.0000 0
M  V30 30 O 5.1118 0.8250 0.0000 0
M  V30 31 O 3.4618 0.8250 0.0000 0
M  V30 32 C 3.5724 -1.2375 0.0000 0
M  V30 33 C 2.8579 -1.6500 0.0000 0
M  V30 34 C 2.1434 -1.2375 0.0000 0
M  V30 35 C 1.4289 -1.6500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 3 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 1 9 12
M  V30 13 1 6 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 1 13 19
M  V30 21 2 19 20
M  V30 22 1 4 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 2 28 30
M  V30 32 2 28 31
M  V30 33 1 26 32
M  V30 34 2 32 33
M  V30 35 1 33 34
M  V30 36 1 24 34
M  V30 37 2 34 35
M  V30 38 1 21 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
205

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dasabuvir

>  <Synonyms>
ABT-333

>  <CAS>
1132935-63-7

>  <Formula>
C26H27N3O5S

>  <MolWt>
493.6

>  <Pathways>
Microbiology/Virology;Proteases/Proteasome

>  <Target>
HCV Protease

>  <Receptor>
 GnRH:0.33 nM

>  <Bioactivity>
"Dasabuvir is a non-nucleoside inhibitor of the hepatitis C virus (HCV) non-structural protein 5B (NS5B), an RNA-dependent RNA polymerase, with potential activity against HCV. Upon administration and after intracellular uptake, dasabuvir binds HCV NS5B polymerase and blocks viral RNA synthesis and replication. The HCV NS5B protein is essential for the replication of the HCV RNA genome."

>  <Reference>
"Kati W, et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother. 2015 Mar;59(3):1505-11."

>  <ID<1>>
T3489

$$$$
StarDrop ID 206
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 67 69 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.2154 5.6980 0.0000 0
M  V30 2 C -1.9720 5.3692 0.0000 0
M  V30 3 C -2.0655 4.5495 0.0000 0
M  V30 4 O -1.2625 4.7385 0.0000 0
M  V30 5 C -0.8346 4.0332 0.0000 0
M  V30 6 O -0.0124 3.9647 0.0000 0
M  V30 7 C -1.3732 3.4082 0.0000 0 CFG=2
M  V30 8 C -2.1434 3.7039 0.0000 0
M  V30 9 C -1.3928 2.5056 0.0000 0 CFG=1
M  V30 10 O -0.6783 2.0931 0.0000 0
M  V30 11 C 0.0362 2.5056 0.0000 0 CFG=1
M  V30 12 C 0.0362 3.3306 0.0000 0
M  V30 13 C 0.7506 3.7431 0.0000 0 CFG=1
M  V30 14 C 0.2203 4.3751 0.0000 0
M  V30 15 O 1.2809 4.3751 0.0000 0
M  V30 16 C 0.9988 5.1504 0.0000 0
M  V30 17 C 1.4651 3.3306 0.0000 0 CFG=1
M  V30 18 O 2.1796 3.7431 0.0000 0
M  V30 19 C 1.4651 2.5056 0.0000 0 CFG=2
M  V30 20 C 2.1796 2.0931 0.0000 0
M  V30 21 O 0.7506 2.0931 0.0000 0
M  V30 22 C -2.0981 2.0777 0.0000 0 CFG=2
M  V30 23 C -2.8214 2.4746 0.0000 0
M  V30 24 C -2.0802 1.2529 0.0000 0 CFG=1
M  V30 25 O -1.3570 0.8560 0.0000 0
M  V30 26 C -1.3390 0.0312 0.0000 0 CFG=2
M  V30 27 O -0.6158 -0.3657 0.0000 0
M  V30 28 C -0.5979 -1.1905 0.0000 0 CFG=2
M  V30 29 C 0.1254 -1.5874 0.0000 0
M  V30 30 C -1.3032 -1.6184 0.0000 0
M  V30 31 C -2.0265 -1.2215 0.0000 0 CFG=1
M  V30 32 C -2.0444 -0.3967 0.0000 0 CFG=1
M  V30 33 O -2.7677 0.0002 0.0000 0
M  V30 34 N -2.7318 -1.6494 0.0000 0
M  V30 35 C -2.7139 -2.4742 0.0000 0
M  V30 36 C -3.4551 -1.2525 0.0000 0
M  V30 37 C -2.7856 0.8250 0.0000 0 CFG=2
M  V30 38 C -2.2417 0.2047 0.0000 0
M  V30 39 O -3.3020 0.1816 0.0000 0
M  V30 40 C -3.5088 1.2219 0.0000 0
M  V30 41 C -3.5267 2.0467 0.0000 0 CFG=1
M  V30 42 C -3.2076 2.8075 0.0000 0
M  V30 43 C -4.2500 2.4436 0.0000 0
M  V30 44 N -4.2679 3.2684 0.0000 0
M  V30 45 C -3.5626 3.6963 0.0000 0 CFG=2
M  V30 46 C -2.8393 3.2994 0.0000 0
M  V30 47 C -3.5805 4.5211 0.0000 0 CFG=1
M  V30 48 O -4.3037 4.9180 0.0000 0
M  V30 49 C -2.8751 4.9490 0.0000 0 CFG=1
M  V30 50 C -3.2901 5.6621 0.0000 0
M  V30 51 O -2.5236 5.6954 0.0000 0
M  V30 52 H -3.8563 2.9908 0.0000 0
M  V30 53 H -3.5408 2.6965 0.0000 0
M  V30 54 H -4.4355 4.0024 0.0000 0
M  V30 55 H 0.0000 0.0000 0.0000 0
M  V30 56 H 0.0000 0.0000 0.0000 0
M  V30 57 H -1.6171 4.3780 0.0000 0
M  V30 58 H -1.3819 1.5057 0.0000 0
M  V30 59 H 0.0361 1.5056 0.0000 0
M  V30 60 H 2.3311 2.8306 0.0000 0
M  V30 61 H 2.3311 3.0056 0.0000 0
M  V30 62 H -2.1199 3.0775 0.0000 0
M  V30 63 H -1.2252 1.7716 0.0000 0
M  V30 64 H -2.2157 0.5122 0.0000 0
M  V30 65 H -0.5761 -2.1903 0.0000 0
M  V30 66 H -2.9032 -0.7404 0.0000 0
M  V30 67 H -2.8994 -0.9153 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3 CFG=3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 7 5
M  V30 7 1 7 8 CFG=1
M  V30 8 1 9 7
M  V30 9 1 9 10 CFG=1
M  V30 10 1 11 10 CFG=1
M  V30 11 1 11 12
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=3
M  V30 14 1 13 15 CFG=1
M  V30 15 1 15 16
M  V30 16 1 17 13
M  V30 17 1 17 18 CFG=1
M  V30 18 1 17 19
M  V30 19 1 19 20 CFG=3
M  V30 20 1 19 21
M  V30 21 1 11 21
M  V30 22 1 9 22
M  V30 23 1 22 23 CFG=1
M  V30 24 1 22 24
M  V30 25 1 24 25 CFG=1
M  V30 26 1 26 25 CFG=3
M  V30 27 1 26 27
M  V30 28 1 28 27
M  V30 29 1 28 29 CFG=3
M  V30 30 1 28 30
M  V30 31 1 31 30
M  V30 32 1 32 31
M  V30 33 1 32 26
M  V30 34 1 32 33 CFG=1
M  V30 35 1 31 34 CFG=3
M  V30 36 1 34 35
M  V30 37 1 34 36
M  V30 38 1 24 37
M  V30 39 1 37 38 CFG=1
M  V30 40 1 37 39 CFG=3
M  V30 41 1 37 40
M  V30 42 1 41 40
M  V30 43 1 41 42 CFG=3
M  V30 44 1 41 43
M  V30 45 1 43 44
M  V30 46 1 45 44
M  V30 47 1 45 46 CFG=1
M  V30 48 1 47 45
M  V30 49 1 47 48 CFG=1
M  V30 50 1 47 49
M  V30 51 1 49 3
M  V30 52 1 49 50 CFG=1
M  V30 53 1 49 51 CFG=3
M  V30 54 1 52 41
M  V30 55 1 53 45
M  V30 56 1 54 47
M  V30 57 1 55 2
M  V30 58 1 56 2
M  V30 59 1 57 7
M  V30 60 1 58 9
M  V30 61 1 59 11
M  V30 62 1 60 17
M  V30 63 1 61 19
M  V30 64 1 62 22
M  V30 65 1 63 24
M  V30 66 1 64 26
M  V30 67 1 65 28
M  V30 68 1 66 31
M  V30 69 1 67 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
206

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Azathramycin

>  <Synonyms>
Desmethyl Azithromycin;Azaerythromycin A;Azaerythromycin;6-Demethylazithromycin

>  <CAS>
76801-85-9

>  <Formula>
C37H70N2O12

>  <MolWt>
735

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
"Azithromycin A is an antibiotic derived from erythromycin, binding to the 50S subunit of the bacterial ribosome, and thus inhibits translation of mRNA."

>  <Reference>
"Noedl H, et al. Antimicrob Agents Chemother. 2007 Feb;51(2):651-6."

>  <ID<1>>
T3265

$$$$
StarDrop ID 207
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0071 0.6930 0.0000 0
M  V30 2 O 4.7216 1.1055 0.0000 0
M  V30 3 C 5.4361 0.6930 0.0000 0
M  V30 4 C 6.1506 1.1055 0.0000 0
M  V30 5 C 6.8650 0.6930 0.0000 0
M  V30 6 C 6.8650 -0.1320 0.0000 0
M  V30 7 C 7.5795 -0.5445 0.0000 0
M  V30 8 C 8.2940 -0.1320 0.0000 0 CFG=2
M  V30 9 C 8.2940 0.6930 0.0000 0
M  V30 10 N 9.0084 -0.5445 0.0000 0
M  V30 11 C 9.7229 -0.1320 0.0000 0
M  V30 12 C 10.4374 -0.5445 0.0000 0 CFG=1
M  V30 13 O 10.4374 -1.3695 0.0000 0
M  V30 14 C 11.1519 -0.1320 0.0000 0
M  V30 15 C 11.1519 0.6930 0.0000 0
M  V30 16 C 11.8663 1.1055 0.0000 0
M  V30 17 C 12.5808 0.6930 0.0000 0
M  V30 18 O 13.2953 1.1055 0.0000 0
M  V30 19 C 12.5808 -0.1320 0.0000 0
M  V30 20 N 13.2953 -0.5445 0.0000 0
M  V30 21 C 13.2953 -1.3695 0.0000 0
M  V30 22 O 14.0097 -1.7820 0.0000 0
M  V30 23 C 11.8663 -0.5445 0.0000 0
M  V30 24 C 6.1506 -0.5445 0.0000 0
M  V30 25 C 5.4361 -0.1320 0.0000 0
M  V30 26 H 9.1600 0.3680 0.0000 0
M  V30 27 H 9.5714 -1.0445 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=3
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 12 11
M  V30 12 1 12 13 CFG=3
M  V30 13 1 12 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 17 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 2 19 23
M  V30 23 1 14 23
M  V30 24 1 6 24
M  V30 25 2 24 25
M  V30 26 1 3 25
M  V30 27 1 26 8
M  V30 28 1 27 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
207

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Formoterol fumarate

>  <Synonyms>
Formoterol Hemifumarate;YM 08316;Eformoterol Hemifumarate;Eformoterol;NSC 299587;CGP 25827A

>  <CAS>
43229-80-7

>  <Formula>
C42H52N4O12

>  <MolWt>
804.9

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor; ??2-adrenergic receptor

>  <Bioactivity>
"Formoterol Hemifumarate, an effective, specific and long-acting ??2-adrenoceptor agonist, is utilized in the treatment of chronic obstructive pulmonary disease(COPD) and asthma."

>  <Reference>
"Nials AT, et al. Eur J Pharmacol, 1994, 251(2-3), 127-135.;Anderson GP, et al. Life Sci, 1993, 52(26), 2145-2160.;Whelan CJ, et al. Br J Pharmacol, 1993, 110(2), 613-618."

>  <ID<1>>
T6505

$$$$
StarDrop ID 208
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.9441 -4.4555 0.0000 0
M  V30 2 C 4.9441 -3.6305 0.0000 0
M  V30 3 C 5.6585 -3.2180 0.0000 0
M  V30 4 C 5.6585 -2.3930 0.0000 0
M  V30 5 N 6.3730 -1.9805 0.0000 0
M  V30 6 C 7.0875 -2.3930 0.0000 0
M  V30 7 C 7.0875 -3.2180 0.0000 0
M  V30 8 C 7.8020 -3.6305 0.0000 0
M  V30 9 C 7.8020 -4.4555 0.0000 0
M  V30 10 C 6.3730 -1.1555 0.0000 0
M  V30 11 C 7.0875 -0.7430 0.0000 0
M  V30 12 C 7.0875 0.0820 0.0000 0
M  V30 13 C 7.8020 0.4945 0.0000 0
M  V30 14 C 8.5866 0.2395 0.0000 0
M  V30 15 C 9.0715 0.9070 0.0000 0
M  V30 16 C 9.8920 0.8207 0.0000 0
M  V30 17 C 10.2275 0.0671 0.0000 0
M  V30 18 C 9.7426 -0.6004 0.0000 0
M  V30 19 C 8.9221 -0.5141 0.0000 0
M  V30 20 Cl 11.0480 -0.0192 0.0000 0
M  V30 21 C 8.5866 1.5744 0.0000 0
M  V30 22 C 8.8415 2.3590 0.0000 0
M  V30 23 C 8.2895 2.9721 0.0000 0
M  V30 24 C 7.4825 2.8006 0.0000 0
M  V30 25 C 6.9305 3.4137 0.0000 0
M  V30 26 C 7.1854 4.1983 0.0000 0
M  V30 27 C 7.9924 4.3699 0.0000 0
M  V30 28 C 8.5444 3.7568 0.0000 0
M  V30 29 Cl 6.6334 4.8114 0.0000 0
M  V30 30 C 7.8020 1.3195 0.0000 0
M  V30 31 C 7.0875 1.7320 0.0000 0
M  V30 32 C 6.3730 1.3195 0.0000 0
M  V30 33 C 6.3730 0.4945 0.0000 0
M  V30 34 Cl 5.6585 1.7320 0.0000 0
M  V30 35 O 7.8020 -1.1555 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 5 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 14 19
M  V30 20 1 17 20
M  V30 21 1 15 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 2 27 28
M  V30 29 1 23 28
M  V30 30 1 26 29
M  V30 31 1 21 30
M  V30 32 1 13 30
M  V30 33 2 30 31
M  V30 34 1 31 32
M  V30 35 2 32 33
M  V30 36 1 12 33
M  V30 37 1 32 34
M  V30 38 1 11 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
208

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lumefantrine

>  <Synonyms>
Benflumetol;dl-Benflumelol

>  <CAS>
82186-77-4

>  <Formula>
C30H32Cl3NO

>  <MolWt>
528.9

>  <Pathways>
Microbiology/Virology;Others;Autophagy

>  <Target>
Others;Autophagy;Parasite

>  <Receptor>
Antiparasitic; Autophagy; Parasite

>  <Bioactivity>
"Lumefantrine is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with artemether for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of Plasmodium spp. and may be used to treat infections caused by P. falciparum and unidentified Plasmodium species, including infections acquired in chloroquine-resistant areas."

>  <Reference>
"Ndounga M, et al.Malar J. 2015 Oct 29;14(1):423."

>  <ID<1>>
T3266

$$$$
StarDrop ID 209
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 42 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.1082 0.1995 0.0000 0
M  V30 2 N -1.4407 -0.2854 0.0000 0
M  V30 3 C -0.6561 -0.0305 0.0000 0
M  V30 4 C -0.1712 -0.6979 0.0000 0
M  V30 5 C -0.6561 -1.3654 0.0000 0
M  V30 6 N -1.4407 -1.1104 0.0000 0
M  V30 7 C 0.6538 -0.6979 0.0000 0
M  V30 8 C 1.1387 -0.0305 0.0000 0
M  V30 9 C 1.9233 -0.2854 0.0000 0
M  V30 10 C 2.6378 0.1271 0.0000 0
M  V30 11 N 3.3523 -0.2854 0.0000 0
M  V30 12 C 3.3523 -1.1104 0.0000 0
M  V30 13 N 2.6378 -1.5229 0.0000 0
M  V30 14 N 1.9233 -1.1104 0.0000 0
M  V30 15 C 1.1387 -1.3654 0.0000 0
M  V30 16 N 2.6378 0.9521 0.0000 0
M  V30 17 C 1.9233 1.3646 0.0000 0
M  V30 18 C 1.9233 2.1896 0.0000 0
M  V30 19 N 2.6378 2.6021 0.0000 0
M  V30 20 C 3.3523 2.1896 0.0000 0
M  V30 21 C 3.3523 1.3646 0.0000 0
M  V30 22 C 2.6378 3.4271 0.0000 0
M  V30 23 N 1.9233 3.8396 0.0000 0
M  V30 24 C 1.9233 4.6646 0.0000 0
M  V30 25 C 2.6378 5.0771 0.0000 0
M  V30 26 C 3.3523 4.6646 0.0000 0
M  V30 27 N 3.3523 3.8396 0.0000 0
M  V30 28 C 2.6378 5.9021 0.0000 0 CFG=1
M  V30 29 C 3.4628 5.9021 0.0000 0
M  V30 30 N 1.8128 5.9021 0.0000 0
M  V30 31 C 2.6378 6.7271 0.0000 0
M  V30 32 C 1.9233 7.1396 0.0000 0
M  V30 33 C 1.9233 7.9646 0.0000 0
M  V30 34 C 2.6378 8.3771 0.0000 0
M  V30 35 F 2.6378 9.2021 0.0000 0
M  V30 36 C 3.3523 7.9646 0.0000 0
M  V30 37 C 3.3523 7.1396 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 2 6
M  V30 7 1 4 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 9 14
M  V30 16 1 14 15
M  V30 17 2 7 15
M  V30 18 1 10 16
M  V30 19 1 16 17
M  V30 20 1 17 18
M  V30 21 1 18 19
M  V30 22 1 19 20
M  V30 23 1 20 21
M  V30 24 1 16 21
M  V30 25 1 19 22
M  V30 26 2 22 23
M  V30 27 1 23 24
M  V30 28 2 24 25
M  V30 29 1 25 26
M  V30 30 2 26 27
M  V30 31 1 22 27
M  V30 32 1 28 25 CFG=1
M  V30 33 1 28 29
M  V30 34 1 28 30 CFG=3
M  V30 35 1 28 31
M  V30 36 2 31 32
M  V30 37 1 32 33
M  V30 38 2 33 34
M  V30 39 1 34 35
M  V30 40 1 34 36
M  V30 41 2 36 37
M  V30 42 1 31 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
209

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Avapritinib

>  <Synonyms>
BLU-285

>  <CAS>
1703793-34-3

>  <Formula>
C26H27FN10

>  <MolWt>
498.6

>  <Pathways>
Tyrosine Kinase/Adaptors;Angiogenesis

>  <Target>
PDGFR;c-Kit

>  <Receptor>
" KIT D816V:0.27 nM, PDGFR?? D842V:0.24 nM"

>  <Bioactivity>
"Avapritinib is a dual inhibitor of the mutant KIT receptor (KIT D816V, IC50: 0.27 nM) and PDGFR?? (PDGFR?? D842V, IC50: 0.24 nM)."

>  <Reference>
"Erica Evans, et al. Blu-285, a Potent and Selective Inhibitor for Hematologic Malignancies with KIT Exon 17 Mutations.Blood 2015 126:568."

>  <ID<1>>
T5109

$$$$
StarDrop ID 210
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.5983 -3.3875 0.0000 0
M  V30 2 C 1.8532 -2.6029 0.0000 0 CFG=1
M  V30 3 C 1.3683 -1.9354 0.0000 0
M  V30 4 O 1.8532 -1.2680 0.0000 0
M  V30 5 C 2.6378 -1.5229 0.0000 0 CFG=2
M  V30 6 C 3.3523 -1.1104 0.0000 0
M  V30 7 N 4.0668 -1.5229 0.0000 0
M  V30 8 C 4.7812 -1.1104 0.0000 0
M  V30 9 C 5.4957 -1.5229 0.0000 0
M  V30 10 C 6.2102 -1.1104 0.0000 0
M  V30 11 O 6.2102 -0.2854 0.0000 0
M  V30 12 N 6.9246 -1.5229 0.0000 0
M  V30 13 C 7.6391 -1.1104 0.0000 0
M  V30 14 C 8.3536 -1.5229 0.0000 0
M  V30 15 C 9.0681 -1.1104 0.0000 0
M  V30 16 C 9.7825 -1.5229 0.0000 0
M  V30 17 C 9.7825 -2.3479 0.0000 0
M  V30 18 F 10.4970 -2.7604 0.0000 0
M  V30 19 C 9.0681 -2.7604 0.0000 0
M  V30 20 C 8.3536 -2.3479 0.0000 0
M  V30 21 F 7.6391 -2.7604 0.0000 0
M  V30 22 C 5.4957 -2.3479 0.0000 0
M  V30 23 O 6.2102 -2.7604 0.0000 0
M  V30 24 C 4.7812 -2.7604 0.0000 0
M  V30 25 O 4.7812 -3.5854 0.0000 0
M  V30 26 C 4.0668 -2.3479 0.0000 0
M  V30 27 C 3.3523 -2.7604 0.0000 0
M  V30 28 O 3.3523 -3.5854 0.0000 0
M  V30 29 N 2.6378 -2.3479 0.0000 0
M  V30 30 H 2.5604 -3.3099 0.0000 0
M  V30 31 H 1.8288 -2.1107 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 17 19
M  V30 19 2 19 20
M  V30 20 1 14 20
M  V30 21 1 20 21
M  V30 22 1 9 22
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 24 25
M  V30 26 2 24 26
M  V30 27 1 7 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 27 29
M  V30 31 1 2 29
M  V30 32 1 5 29 CFG=3
M  V30 33 1 30 2
M  V30 34 1 31 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
210

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cabotegravir

>  <Synonyms>
GSK744;GSK-1265744;S/GSK1265744

>  <CAS>
1051375-10-0

>  <Formula>
C19H17F2N3O5

>  <MolWt>
405.4

>  <Pathways>
Microbiology/Virology;Proteases/Proteasome

>  <Target>
HIV Protease

>  <Receptor>
 HIV-1:3.0 nM

>  <Bioactivity>
"Cabotegravir (GSK744, GSK1265744) is a long-acting HIV integrase inhibitor and inhibits the HIV-1 integrase catalyzed strand transfer reaction (IC50: 3.0 nM)."

>  <Reference>
"Andrews CD, et al. Sci Transl Med. 2015, 7(270), 270-274.;Yoshinaga T, et al. Antimicrob Agents Chemother. 2015, 59(1), 397-406."

>  <ID<1>>
T6098

$$$$
StarDrop ID 211
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 39 44 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.7021 -8.5808 0.0000 0
M  V30 2 O -2.1146 -7.8664 0.0000 0
M  V30 3 C -1.7021 -7.1519 0.0000 0
M  V30 4 C -2.1146 -6.4374 0.0000 0
M  V30 5 C -1.7021 -5.7229 0.0000 0
M  V30 6 C -0.8771 -5.7229 0.0000 0
M  V30 7 C -0.4646 -5.0085 0.0000 0
M  V30 8 N 0.3604 -5.0085 0.0000 0
M  V30 9 C 0.7729 -4.2940 0.0000 0
M  V30 10 C 0.9516 -5.0085 0.0000 0
M  V30 11 C 0.7729 -5.7229 0.0000 0
M  V30 12 C 1.5979 -5.7229 0.0000 0
M  V30 13 N 2.0104 -5.0085 0.0000 0
M  V30 14 C 1.5979 -4.2940 0.0000 0
M  V30 15 C 2.8354 -5.0085 0.0000 0
M  V30 16 C 3.2479 -4.2940 0.0000 0
M  V30 17 C 4.0729 -4.2940 0.0000 0
M  V30 18 C 4.4854 -5.0085 0.0000 0
M  V30 19 C 4.0729 -5.7229 0.0000 0
M  V30 20 N 3.2479 -5.7229 0.0000 0
M  V30 21 C 5.3104 -5.0085 0.0000 0
M  V30 22 C 5.7229 -4.2940 0.0000 0
M  V30 23 C 6.5479 -4.2940 0.0000 0
M  V30 24 O 6.9604 -3.5795 0.0000 0
M  V30 25 C 7.7854 -3.5795 0.0000 0
M  V30 26 C 8.1979 -2.8651 0.0000 0
M  V30 27 C 8.6104 -2.1506 0.0000 0
M  V30 28 C 8.9124 -3.2776 0.0000 0
M  V30 29 O 7.4835 -2.4526 0.0000 0
M  V30 30 C 6.9604 -5.0085 0.0000 0
M  V30 31 N 6.5479 -5.7229 0.0000 0
M  V30 32 N 6.8029 -6.5076 0.0000 0
M  V30 33 C 6.1354 -6.9925 0.0000 0
M  V30 34 C 5.4680 -6.5076 0.0000 0
M  V30 35 C 4.6834 -6.7625 0.0000 0
M  V30 36 N 3.8988 -7.0174 0.0000 0
M  V30 37 C 5.7229 -5.7229 0.0000 0
M  V30 38 C -0.4646 -6.4374 0.0000 0
M  V30 39 N -0.8771 -7.1519 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 9 14
M  V30 16 1 13 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 15 20
M  V30 23 1 18 21
M  V30 24 2 21 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 26 28
M  V30 31 1 26 29
M  V30 32 2 23 30
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 2 32 33
M  V30 36 1 33 34
M  V30 37 1 34 35
M  V30 38 3 35 36
M  V30 39 2 34 37
M  V30 40 1 21 37
M  V30 41 1 31 37
M  V30 42 1 6 38
M  V30 43 2 38 39
M  V30 44 1 3 39
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
211

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Selpercatinib

>  <Synonyms>
LOXO-292

>  <CAS>
2152628-33-4

>  <Formula>
C29H31N7O3

>  <MolWt>
525.6

>  <Pathways>
Apoptosis;Tyrosine Kinase/Adaptors

>  <Target>
c-RET

>  <Receptor>
" RET (G810R):530.7 nM, RET (WT):14.0 nM , RET (V804M):24.1 nM "

>  <Bioactivity>
"Selpercatinib is a tyrosine kinase inhibitor with antineoplastic properties(IC50 of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M) , and RET (G810R), respectively)"

>  <Reference>
"Steven W. Andrews, et al. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors. WO2018071447A1."

>  <ID<1>>
T8222

$$$$
StarDrop ID 212
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.9360 -1.6500 0.0000 0
M  V30 2 C 1.9360 -2.4750 0.0000 0
M  V30 3 C 1.1110 -2.4750 0.0000 0
M  V30 4 C 2.7610 -2.4750 0.0000 0
M  V30 5 C 1.9360 -3.3000 0.0000 0
M  V30 6 C 2.6505 -3.7125 0.0000 0
M  V30 7 C 2.6505 -4.5375 0.0000 0
M  V30 8 C 1.9360 -4.9500 0.0000 0
M  V30 9 C 1.9360 -5.7750 0.0000 0
M  V30 10 N 1.2215 -6.1875 0.0000 0
M  V30 11 C 1.2215 -7.0125 0.0000 0
M  V30 12 C 0.5070 -7.4250 0.0000 0
M  V30 13 N -0.2074 -7.0125 0.0000 0
M  V30 14 C -0.2074 -6.1875 0.0000 0
M  V30 15 C 0.5070 -5.7750 0.0000 0
M  V30 16 C -0.9219 -7.4250 0.0000 0
M  V30 17 C -0.9219 -8.2500 0.0000 0
M  V30 18 C -0.2074 -8.6625 0.0000 0
M  V30 19 C -0.2074 -9.4875 0.0000 0
M  V30 20 C -0.9219 -9.9000 0.0000 0
M  V30 21 C -1.6364 -9.4875 0.0000 0
M  V30 22 C -1.6364 -8.6625 0.0000 0
M  V30 23 C -1.6364 -7.0125 0.0000 0
M  V30 24 C -2.3508 -7.4250 0.0000 0
M  V30 25 C -3.0653 -7.0125 0.0000 0
M  V30 26 C -3.0653 -6.1875 0.0000 0
M  V30 27 Cl -3.7798 -5.7750 0.0000 0
M  V30 28 C -2.3508 -5.7750 0.0000 0
M  V30 29 C -1.6364 -6.1875 0.0000 0
M  V30 30 C 1.2215 -4.5375 0.0000 0
M  V30 31 C 1.2215 -3.7125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 10 15
M  V30 16 1 13 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 17 22
M  V30 24 1 16 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 1 26 28
M  V30 30 2 28 29
M  V30 31 1 23 29
M  V30 32 1 8 30
M  V30 33 2 30 31
M  V30 34 1 5 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
212

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Buclizine dihydrochloride

>  <Synonyms>
Buclina;Buclizine HCl;UCB-4445;Longifene

>  <CAS>
129-74-8

>  <Formula>
C28H35Cl3N2

>  <MolWt>
506

>  <Pathways>
Neuroscience;Immunology/Inflammation;GPCR/G Protein

>  <Target>
Histamine Receptor;AChR;5-HT Receptor

>  <Receptor>
Cholinergic; Histamine Receptor; HT

>  <Bioactivity>
"Buclizine HCl is the hydrochloride salt form of buclizine, a piperazine histamine H1 receptor antagonist with primarily antiemetic and antivertigo activities. Buclizine binds to and blocks the histamine H1 receptor, thereby preventing the symptoms that are caused by histamine activity. Buclizine exerts its anti-emetic effect by binding to and blocking the muscarinic and histamine receptors in the vomiting center of the central nervous system (CNS). This may prevent activation of the chemoreceptor trigger zone (CTZ) and may reduce nausea and vomiting."

>  <Reference>
"Mostafa GA, et al. Profiles Drug Subst Excip Relat Methodol, 2011, 36:1-33."

>  <ID<1>>
T6426

$$$$
StarDrop ID 213
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -2.0370 -1.2341 0.0000 0
M  V30 2 C -2.0902 -0.4108 0.0000 0
M  V30 3 C -1.4038 0.0469 0.0000 0
M  V30 4 C -0.6643 -0.3187 0.0000 0
M  V30 5 O -0.6111 -1.1419 0.0000 0
M  V30 6 N 0.0221 0.1390 0.0000 0
M  V30 7 C 0.6990 -0.3327 0.0000 0 CFG=1
M  V30 8 C 1.4898 -0.0976 0.0000 0
M  V30 9 C 1.7991 0.6672 0.0000 0
M  V30 10 C 1.3939 1.3859 0.0000 0 CFG=2
M  V30 11 C 1.2613 0.4397 0.0000 0
M  V30 12 O 0.5795 1.5172 0.0000 0
M  V30 13 C -0.0311 0.9623 0.0000 0 CFG=2
M  V30 14 C -0.7706 1.3279 0.0000 0
M  V30 15 N -1.4570 0.8702 0.0000 0
M  V30 16 C -2.1966 1.2358 0.0000 0
M  V30 17 C -2.8830 0.7781 0.0000 0
M  V30 18 C -3.6226 1.1437 0.0000 0
M  V30 19 O -4.3090 0.6860 0.0000 0
M  V30 20 N -3.6758 1.9669 0.0000 0
M  V30 21 C -4.4153 2.3325 0.0000 0
M  V30 22 C -4.4685 3.1558 0.0000 0
M  V30 23 C -5.2081 3.5214 0.0000 0
M  V30 24 F -5.8945 3.0637 0.0000 0
M  V30 25 C -5.2613 4.3447 0.0000 0
M  V30 26 C -4.5749 4.8024 0.0000 0
M  V30 27 F -4.6281 5.6257 0.0000 0
M  V30 28 C -3.8353 4.4368 0.0000 0
M  V30 29 C -3.7821 3.6135 0.0000 0
M  V30 30 F -3.0426 3.2479 0.0000 0
M  V30 31 C -2.8298 -0.0452 0.0000 0
M  V30 32 O -3.5162 -0.5029 0.0000 0
M  V30 33 H 0.1367 -1.1051 0.0000 0
M  V30 34 H 1.5265 2.3321 0.0000 0
M  V30 35 H -0.8631 0.4075 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 7 6
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 10 9
M  V30 10 1 10 11 CFG=1
M  V30 11 1 7 11 CFG=1
M  V30 12 1 10 12
M  V30 13 1 13 12
M  V30 14 1 13 6 CFG=1
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 3 15
M  V30 18 1 15 16
M  V30 19 2 16 17
M  V30 20 1 17 18
M  V30 21 2 18 19
M  V30 22 1 18 20
M  V30 23 1 20 21
M  V30 24 1 21 22
M  V30 25 2 22 23
M  V30 26 1 23 24
M  V30 27 1 23 25
M  V30 28 2 25 26
M  V30 29 1 26 27
M  V30 30 1 26 28
M  V30 31 2 28 29
M  V30 32 1 22 29
M  V30 33 1 29 30
M  V30 34 1 17 31
M  V30 35 1 2 31
M  V30 36 2 31 32
M  V30 37 1 33 7
M  V30 38 1 34 10
M  V30 39 1 35 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
213

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Bictegravir

>  <Synonyms>
GS-9883

>  <CAS>
1611493-60-7

>  <Formula>
C21H18F3N3O5

>  <MolWt>
449.4

>  <Pathways>
Microbiology/Virology;Proteases/Proteasome

>  <Target>
HIV Protease

>  <Receptor>
 HIV-1 integrase:7.5 nM

>  <Bioactivity>
Bictegravir is a potent inhibitor of HIV-1 integrase (IC50: 7.5 nM).

>  <Reference>
"Tsiang M, et al. Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7086-7097."

>  <ID<1>>
T4493

$$$$
StarDrop ID 214
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 59 66 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -0.7930 -7.2760 0.0000 0
M  V30 2 C -1.2055 -6.5616 0.0000 0
M  V30 3 C -2.0305 -6.5616 0.0000 0
M  V30 4 N -2.4430 -5.8471 0.0000 0
M  V30 5 C -2.0305 -5.1326 0.0000 0
M  V30 6 C -1.2055 -5.1326 0.0000 0
M  V30 7 N -0.7930 -5.8471 0.0000 0
M  V30 8 C -2.4430 -4.4181 0.0000 0
M  V30 9 O -3.2680 -4.4181 0.0000 0
M  V30 10 N -2.0305 -3.7037 0.0000 0
M  V30 11 C -2.4430 -2.9892 0.0000 0 CFG=1
M  V30 12 C -3.2277 -3.2441 0.0000 0
M  V30 13 C -4.0481 -3.1579 0.0000 0
M  V30 14 C -4.7626 -2.7454 0.0000 0
M  V30 15 C -5.2475 -2.0780 0.0000 0
M  V30 16 C -5.4191 -1.2710 0.0000 0
M  V30 17 C -5.2475 -0.4640 0.0000 0
M  V30 18 C -4.7626 0.2034 0.0000 0
M  V30 19 C -4.0481 0.6159 0.0000 0 CFG=2
M  V30 20 C -3.7126 1.3696 0.0000 0
M  V30 21 C -3.2277 0.7022 0.0000 0 CFG=1
M  V30 22 N -2.4430 0.4472 0.0000 0
M  V30 23 C -1.8299 -0.1048 0.0000 0
M  V30 24 O -1.1625 0.3801 0.0000 0
M  V30 25 C -1.4944 -0.8585 0.0000 0 CFG=2
M  V30 26 C -0.7098 -0.6036 0.0000 0
M  V30 27 C -0.2248 -1.2710 0.0000 0 CFG=2
M  V30 28 C -0.7098 -1.9384 0.0000 0
M  V30 29 N -1.4944 -1.6835 0.0000 0
M  V30 30 C -1.8299 -2.4372 0.0000 0
M  V30 31 O -1.1625 -2.9221 0.0000 0
M  V30 32 O 0.6002 -1.2710 0.0000 0
M  V30 33 C 1.0127 -1.9855 0.0000 0
M  V30 34 N 1.8377 -1.9855 0.0000 0
M  V30 35 C 2.2502 -2.6999 0.0000 0
M  V30 36 C 3.0752 -2.6999 0.0000 0
M  V30 37 C 3.4877 -3.4144 0.0000 0
M  V30 38 C 3.0752 -4.1289 0.0000 0
M  V30 39 C 2.2502 -4.1289 0.0000 0
M  V30 40 C 1.8377 -3.4144 0.0000 0
M  V30 41 C 1.0127 -3.4144 0.0000 0
M  V30 42 C 0.6002 -4.1289 0.0000 0
M  V30 43 C -0.2248 -4.1289 0.0000 0
M  V30 44 C -0.6373 -3.4144 0.0000 0
M  V30 45 C -0.2248 -2.6999 0.0000 0
M  V30 46 C 0.6002 -2.6999 0.0000 0
M  V30 47 C -2.7427 1.3696 0.0000 0
M  V30 48 O -1.9223 1.2834 0.0000 0
M  V30 49 N -3.0783 2.1233 0.0000 0
M  V30 50 S -2.5934 2.7907 0.0000 0
M  V30 51 O -1.9259 2.3058 0.0000 0
M  V30 52 O -3.2608 3.2756 0.0000 0
M  V30 53 C -2.1084 3.4581 0.0000 0
M  V30 54 C -2.0222 4.2786 0.0000 0
M  V30 55 C -1.3548 3.7937 0.0000 0
M  V30 56 H -1.4553 -3.1457 0.0000 0
M  V30 57 H -3.2391 1.2038 0.0000 0
M  V30 58 H -0.6854 -1.4463 0.0000 0
M  V30 59 H 0.2291 -0.3800 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 11 10 CFG=1
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 19 18
M  V30 20 1 19 20 CFG=3
M  V30 21 1 21 20
M  V30 22 1 19 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 25 23
M  V30 27 1 25 26
M  V30 28 1 27 26
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 25 29 CFG=3
M  V30 32 1 29 30
M  V30 33 1 11 30
M  V30 34 2 30 31
M  V30 35 1 27 32 CFG=1
M  V30 36 1 32 33
M  V30 37 2 33 34
M  V30 38 1 34 35
M  V30 39 2 35 36
M  V30 40 1 36 37
M  V30 41 2 37 38
M  V30 42 1 38 39
M  V30 43 2 39 40
M  V30 44 1 35 40
M  V30 45 1 40 41
M  V30 46 2 41 42
M  V30 47 1 42 43
M  V30 48 2 43 44
M  V30 49 1 44 45
M  V30 50 2 45 46
M  V30 51 1 33 46
M  V30 52 1 41 46
M  V30 53 1 21 47 CFG=3
M  V30 54 2 47 48
M  V30 55 1 47 49
M  V30 56 1 49 50
M  V30 57 2 50 51
M  V30 58 2 50 52
M  V30 59 1 50 53
M  V30 60 1 53 54
M  V30 61 1 54 55
M  V30 62 1 53 55
M  V30 63 1 56 11
M  V30 64 1 57 19
M  V30 65 1 58 25
M  V30 66 1 59 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
214

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Paritaprevir

>  <Synonyms>
Veruprevir;ABT-450

>  <CAS>
1221573-85-8

>  <Formula>
C40H43N7O7S

>  <MolWt>
765.9

>  <Pathways>
Microbiology/Virology;Proteases/Proteasome

>  <Target>
HCV Protease

>  <Receptor>
HCV NS3/4A

>  <Bioactivity>
"Paritaprevir is an orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and 4A (NS3/NS4A), with potential activity against HCV genotype 1. Upon administration, paritaprevir reversibly binds to the active center and binding site of the HCV NS3/NS4A protease and prevents NS3/NS4A protease-mediated polyprotein maturation. This disrupts both the processing of viral proteins and the formation of the viral replication complex, which inhibits viral replication in HCV genotype 1-infected host cells. NS3, a serine protease, is essential for the proteolytic cleavage of multiple sites within the HCV polyprotein and plays a key role during HCV ribonucleic acid (RNA) replication. NS4A is an activating factor for NS3. HCV is a small, enveloped, single-stranded RNA virus belonging to the Flaviviridae family, and infection is associated with the development of hepatocellular carcinoma (HCC)."

>  <Reference>
"Smith, M., & Lim, A. (2015). Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.?Drug Design, Development And Therapy, 6083. doi: 10.2147/dddt.s80226;Schnell G, et al. Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/ritonavir. Antimicrob Agents Chemother. 2015 Aug 17. pii: AAC.01229-15."

>  <ID<1>>
T3226

$$$$
StarDrop ID 215
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 42 47 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 3.4479 1.4620 0.0000 0
M  V30 2 C 3.6315 0.6577 0.0000 0 CFG=1
M  V30 3 C 4.4358 0.4742 0.0000 0 CFG=1
M  V30 4 C 4.7938 -0.2691 0.0000 0
M  V30 5 C 4.4358 -1.0124 0.0000 0
M  V30 6 C 3.6315 -1.1960 0.0000 0 CFG=1
M  V30 7 O 3.4479 -2.0003 0.0000 0
M  V30 8 C 2.6596 -2.2435 0.0000 0
M  V30 9 O 2.0548 -1.6824 0.0000 0
M  V30 10 N 2.4760 -3.0478 0.0000 0
M  V30 11 C 3.0808 -3.6090 0.0000 0
M  V30 12 C 2.8972 -4.4133 0.0000 0
M  V30 13 C 2.1088 -4.6565 0.0000 0
M  V30 14 C 1.5041 -4.0953 0.0000 0
M  V30 15 C 1.6876 -3.2910 0.0000 0
M  V30 16 N 1.9253 -5.4608 0.0000 0
M  V30 17 C 2.4681 -6.0821 0.0000 0
M  V30 18 C 3.2930 -6.0944 0.0000 0
M  V30 19 C 3.6947 -6.8150 0.0000 0
M  V30 20 C 3.2716 -7.5232 0.0000 0
M  V30 21 N 2.4467 -7.5108 0.0000 0
M  V30 22 C 2.0449 -6.7903 0.0000 0
M  V30 23 N 1.2406 -6.6067 0.0000 0
M  V30 24 C 1.1666 -5.7850 0.0000 0
M  V30 25 O 0.4584 -5.3619 0.0000 0
M  V30 26 C 2.9865 -0.6816 0.0000 0
M  V30 27 N 2.2720 -1.0941 0.0000 0
M  V30 28 C 1.5575 -0.6816 0.0000 0
M  V30 29 C 1.5575 0.1434 0.0000 0
M  V30 30 C 2.2720 0.5559 0.0000 0
M  V30 31 C 2.9865 0.1434 0.0000 0
M  V30 32 C 4.9502 1.1192 0.0000 0
M  V30 33 C 4.6488 1.8871 0.0000 0
M  V30 34 C 5.1632 2.5321 0.0000 0
M  V30 35 C 5.9790 2.4092 0.0000 0
M  V30 36 C 6.2804 1.6412 0.0000 0
M  V30 37 F 7.0961 1.5183 0.0000 0
M  V30 38 C 5.7660 0.9962 0.0000 0
M  V30 39 F 6.0674 0.2282 0.0000 0
M  V30 40 H 2.6876 0.9880 0.0000 0
M  V30 41 H 5.4295 0.3622 0.0000 0
M  V30 42 H 2.6876 -1.5262 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=1
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 10 15
M  V30 16 1 13 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 17 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 1 16 24
M  V30 27 2 24 25
M  V30 28 1 6 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 1 2 31
M  V30 35 1 26 31
M  V30 36 1 3 32 CFG=3
M  V30 37 2 32 33
M  V30 38 1 33 34
M  V30 39 2 34 35
M  V30 40 1 35 36
M  V30 41 1 36 37
M  V30 42 2 36 38
M  V30 43 1 32 38
M  V30 44 1 38 39
M  V30 45 1 40 2
M  V30 46 1 41 3
M  V30 47 1 42 6
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
215

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Rimegepant

>  <Synonyms>
BMS 927711;BMS-927711;BHV-3000;BMS927711

>  <CAS>
1289023-67-1

>  <Formula>
C28H28F2N6O3

>  <MolWt>
534.6

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
CGRP Receptor

>  <Receptor>
 CGRP Receptor:0.14 nM

>  <Bioactivity>
"BMS-927711 is a highly potent, oral calcitonin gene-related peptide (CGRP) receptor antagonist with a Ki value of 0.027 nM."

>  <Reference>
"Zheng N, et al. Improved liquid-liquid extraction with inter-well volume replacement dilution workflow and its application to quantify BMS-927711 in rat dried blood spots by UHPLC-MS/MS. J Pharm Biomed Anal. 2014 Feb;89:240-50.;Luo G, et al. Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) a"

>  <ID<1>>
T4610

$$$$
StarDrop ID 216
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -0.7145 -7.8375 0.0000 0
M  V30 2 C -0.7145 -7.0125 0.0000 0
M  V30 3 C 0.0000 -6.6000 0.0000 0
M  V30 4 C 0.7145 -7.0125 0.0000 0
M  V30 5 C 1.4289 -6.6000 0.0000 0
M  V30 6 C 2.1434 -7.0125 0.0000 0
M  V30 7 C 2.8579 -6.6000 0.0000 0
M  V30 8 C 3.5724 -7.0125 0.0000 0
M  V30 9 O 3.5724 -7.8375 0.0000 0
M  V30 10 N 4.2868 -6.6000 0.0000 0
M  V30 11 C 5.0013 -7.0125 0.0000 0 CFG=2
M  V30 12 C 5.0013 -7.8375 0.0000 0
M  V30 13 N 5.7158 -8.2500 0.0000 0
M  V30 14 C 6.4694 -7.9144 0.0000 0
M  V30 15 C 7.0215 -8.5275 0.0000 0
M  V30 16 C 6.6090 -9.2420 0.0000 0
M  V30 17 C 5.8020 -9.0705 0.0000 0
M  V30 18 C 5.7158 -6.6000 0.0000 0 CFG=2
M  V30 19 O 6.4302 -7.0125 0.0000 0
M  V30 20 C 5.7158 -5.7750 0.0000 0
M  V30 21 C 5.0013 -5.3625 0.0000 0
M  V30 22 C 5.0013 -4.5375 0.0000 0
M  V30 23 C 5.7158 -4.1250 0.0000 0
M  V30 24 O 5.7158 -3.3000 0.0000 0
M  V30 25 C 6.4302 -2.8875 0.0000 0
M  V30 26 C 7.1447 -3.3000 0.0000 0
M  V30 27 O 7.1447 -4.1250 0.0000 0
M  V30 28 C 6.4302 -4.5375 0.0000 0
M  V30 29 C 6.4302 -5.3625 0.0000 0
M  V30 30 H 4.1353 -7.5125 0.0000 0
M  V30 31 H 5.7157 -7.6000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 11 10 CFG=1
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 13 17
M  V30 18 1 11 18
M  V30 19 1 18 19 CFG=1
M  V30 20 1 18 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 1 23 28
M  V30 30 2 28 29
M  V30 31 1 20 29
M  V30 32 1 30 11
M  V30 33 1 31 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
216

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Eliglustat

>  <Synonyms>
GENZ-112638;Genz 99067

>  <CAS>
491833-29-5

>  <Formula>
C23H36N2O4

>  <MolWt>
404.6

>  <Pathways>
Metabolism

>  <Target>
Transferase

>  <Receptor>
 glucosylceramide synthase:20 nM

>  <Bioactivity>
Eliglustat is an oral inhibitor of glucosylceramide synthase which is used in the therapy of type 1 Gaucher disease.

>  <Reference>
"Nelson S. Yew, et al. PLoS One. 2010, 5(6):e11239.;Shayman JA. Drugs Future. 2010, 35(8):613-620."

>  <ID<1>>
T3663

$$$$
StarDrop ID 217
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 10.8306 1.8219 0.0000 0
M  V30 2 C 10.1162 1.4094 0.0000 0
M  V30 3 O 9.4017 1.8219 0.0000 0
M  V30 4 C 10.1162 0.5844 0.0000 0
M  V30 5 C 10.8306 0.1719 0.0000 0
M  V30 6 C 10.8306 -0.6531 0.0000 0
M  V30 7 C 10.1162 -1.0656 0.0000 0
M  V30 8 C 9.4017 -0.6531 0.0000 0
M  V30 9 C 8.6171 -0.9081 0.0000 0
M  V30 10 N 8.1321 -0.2406 0.0000 0
M  V30 11 N 8.6171 0.4268 0.0000 0
M  V30 12 C 9.4017 0.1719 0.0000 0
M  V30 13 C 7.3071 -0.2406 0.0000 0
M  V30 14 C 6.8946 -0.9551 0.0000 0
M  V30 15 C 6.0696 -0.9551 0.0000 0
M  V30 16 C 5.6571 -0.2406 0.0000 0
M  V30 17 C 6.0696 0.4738 0.0000 0
M  V30 18 C 6.8946 0.4738 0.0000 0
M  V30 19 C 4.8321 -0.2406 0.0000 0 CFG=2
M  V30 20 C 4.4196 -0.9551 0.0000 0
M  V30 21 C 3.5946 -0.9551 0.0000 0
M  V30 22 C 3.1821 -0.2406 0.0000 0
M  V30 23 N 3.5946 0.4738 0.0000 0
M  V30 24 C 4.4196 0.4738 0.0000 0
M  V30 25 H 5.3321 0.6254 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 4 12
M  V30 13 1 8 12
M  V30 14 1 10 13
M  V30 15 2 13 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 13 18
M  V30 21 1 19 16 CFG=3
M  V30 22 1 19 20
M  V30 23 1 20 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 1 19 24
M  V30 28 1 25 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
217

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Niraparib tosylate

>  <Synonyms>
Niraparib (MK-4827) tosylate;MK 4827 tosylate;MK-4827 (tosylate)

>  <CAS>
1038915-73-9

>  <Formula>
C26H28N4O4S

>  <MolWt>
492.6

>  <Pathways>
Chromatin/Epigenetic;Apoptosis;DNA Damage/DNA Repair

>  <Target>
Apoptosis;PARP

>  <Receptor>
" PARP1:3.8 nM, PARP2:2.1 nM"

>  <Bioactivity>
MK-4827(Niraparib) tosylate (with IC50 of 3.8 nM/2.1 nM) is a selective PARP1/PARP2 inhibitor.

>  <Reference>
"Patel AG, et al. J Biol Chem. 2012, 287(6):4198-210.;Mueller S, et al. Anticancer Res. 2013, 33(3):755-62.;Wang L, et al. Invest New Drugs. 2012, 30(6):2113-20.;Bridges KA, et al. oncotarget. 2014, 5(13):5076-86.;Jones P, et al. J Med Chem. 2009, 52(22):7170-85."

>  <ID<1>>
T6892

$$$$
StarDrop ID 218
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.8216 -5.0612 0.0000 0
M  V30 2 C 2.5045 -4.5982 0.0000 0
M  V30 3 C 2.4450 -3.7753 0.0000 0
M  V30 4 O 1.7026 -3.4155 0.0000 0
M  V30 5 O 3.1278 -3.3123 0.0000 0
M  V30 6 C 3.0683 -2.4895 0.0000 0 CFG=2
M  V30 7 C 2.8390 -1.6970 0.0000 0
M  V30 8 C 3.5218 -1.2340 0.0000 0
M  V30 9 C 4.1731 -1.7404 0.0000 0 CFG=1
M  V30 10 C 4.9853 -1.5952 0.0000 0 CFG=2
M  V30 11 C 5.2655 -0.8192 0.0000 0
M  V30 12 C 6.0777 -0.6740 0.0000 0
M  V30 13 C 6.6095 -1.3047 0.0000 0
M  V30 14 C 7.4216 -1.1595 0.0000 0
M  V30 15 C 7.9534 -1.7902 0.0000 0
M  V30 16 O 8.7655 -1.6450 0.0000 0
M  V30 17 C 7.6731 -2.5662 0.0000 0
M  V30 18 C 6.8610 -2.7114 0.0000 0
M  V30 19 C 6.3292 -2.0807 0.0000 0 CFG=1
M  V30 20 C 6.0489 -2.8566 0.0000 0
M  V30 21 C 5.5171 -2.2259 0.0000 0 CFG=1
M  V30 22 C 5.2368 -3.0018 0.0000 0
M  V30 23 C 4.4247 -3.1470 0.0000 0
M  V30 24 C 3.8928 -2.5163 0.0000 0 CFG=2
M  V30 25 C 3.5330 -3.2587 0.0000 0
M  V30 26 C 2.2561 -2.6347 0.0000 0
M  V30 27 O 1.5733 -3.0977 0.0000 0
M  V30 28 C 1.7243 -2.0040 0.0000 0
M  V30 29 O 0.9122 -2.1492 0.0000 0
M  V30 30 H 3.2125 -2.0183 0.0000 0
M  V30 31 H 4.3406 -0.8308 0.0000 0
M  V30 32 H 6.1617 -2.9904 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 6 5 CFG=3
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 9 8 CFG=1
M  V30 9 1 9 10
M  V30 10 1 10 11 CFG=3
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 1 19 18
M  V30 19 1 19 13
M  V30 20 1 19 20 CFG=1
M  V30 21 1 21 19
M  V30 22 1 10 21
M  V30 23 1 21 22 CFG=1
M  V30 24 1 22 23
M  V30 25 1 24 23
M  V30 26 1 24 6
M  V30 27 1 9 24
M  V30 28 1 24 25 CFG=1
M  V30 29 1 6 26 CFG=1
M  V30 30 2 26 27
M  V30 31 1 26 28
M  V30 32 1 28 29
M  V30 33 1 30 9
M  V30 34 1 31 10
M  V30 35 1 32 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
218

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Clascoterone

>  <Synonyms>
Cortexolone 17 alpha-propionate;17 alpha-propionate;Cortexolone 17??-propionate;CB-03-01

>  <CAS>
19608-29-8

>  <Formula>
C24H34O5

>  <MolWt>
402.5

>  <Pathways>
Endocrinology/Hormones

>  <Target>
Androgen Receptor

>  <Receptor>
Androgen Receptor

>  <Bioactivity>
17 alpha-propionate is a new topical and peripherally selective androgen antagonist.

>  <Reference>
"Trifu V, et al.. Br J Dermatol. 2011 Jul;165(1):177-83."

>  <ID<1>>
T3357

$$$$
StarDrop ID 219
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.0013 -6.1875 0.0000 0
M  V30 2 C 5.0013 -5.3625 0.0000 0
M  V30 3 O 4.2868 -4.9500 0.0000 0
M  V30 4 C 3.5724 -5.3625 0.0000 0
M  V30 5 C 2.8579 -4.9500 0.0000 0
M  V30 6 N 2.1434 -5.3625 0.0000 0
M  V30 7 C 2.1434 -6.1875 0.0000 0
M  V30 8 C 1.4289 -6.6000 0.0000 0
M  V30 9 O 0.7145 -6.1875 0.0000 0
M  V30 10 C 0.7145 -5.3625 0.0000 0
M  V30 11 C 1.4289 -4.9500 0.0000 0
M  V30 12 C 5.7158 -4.9500 0.0000 0
M  V30 13 C 6.4302 -5.3625 0.0000 0
M  V30 14 C 7.1447 -4.9500 0.0000 0
M  V30 15 C 7.1447 -4.1250 0.0000 0
M  V30 16 C 7.8592 -5.3625 0.0000 0
M  V30 17 C 8.5737 -4.9500 0.0000 0
M  V30 18 C 9.2881 -5.3625 0.0000 0
M  V30 19 C 10.0026 -4.9500 0.0000 0
M  V30 20 O 10.0026 -4.1250 0.0000 0
M  V30 21 C 10.7171 -5.3625 0.0000 0
M  V30 22 C 10.7171 -6.1875 0.0000 0
M  V30 23 C 11.5017 -6.4424 0.0000 0
M  V30 24 O 11.9866 -5.7750 0.0000 0
M  V30 25 C 11.5017 -5.1076 0.0000 0
M  V30 26 O 11.7566 -4.3229 0.0000 0
M  V30 27 C 10.0026 -6.6000 0.0000 0
M  V30 28 C 10.0026 -7.4250 0.0000 0
M  V30 29 C 9.2881 -6.1875 0.0000 0
M  V30 30 O 8.5737 -6.6000 0.0000 0
M  V30 31 C 7.8592 -6.1875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 6 11
M  V30 12 1 2 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 21 25
M  V30 27 2 25 26
M  V30 28 1 22 27
M  V30 29 1 27 28
M  V30 30 2 27 29
M  V30 31 1 18 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
219

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
RS 61443

>  <Synonyms>
TM-MMF;Mycophenolate mofetil;RS61443

>  <CAS>
115007-34-6

>  <Formula>
C23H31NO7

>  <MolWt>
433.5

>  <Pathways>
Metabolism

>  <Target>
Dehydrogenase

>  <Receptor>
IMPDH

>  <Bioactivity>
"RS 61443 is an immunosuppressant, a non-competitive, selective and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH)"

>  <Reference>
"Zwerner J ,  Fiorentino D . Mycophenolate mofetil[J]. Dermatologic Therapy, 2010, 20(4):229-238."

>  <ID<1>>
T0245

$$$$
StarDrop ID 220
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.3055 -2.9519 0.0000 0
M  V30 2 N 1.0200 -3.3644 0.0000 0
M  V30 3 O 1.0200 -4.1894 0.0000 0
M  V30 4 C 1.7344 -2.9519 0.0000 0
M  V30 5 C 2.4489 -3.3644 0.0000 0
M  V30 6 N 2.4489 -4.1894 0.0000 0
M  V30 7 C 3.1634 -4.6019 0.0000 0
M  V30 8 N 3.1634 -2.9519 0.0000 0
M  V30 9 C 3.8779 -3.3644 0.0000 0
M  V30 10 C 4.5923 -2.9519 0.0000 0
M  V30 11 S 5.3068 -3.3644 0.0000 0
M  V30 12 C 6.0213 -2.9519 0.0000 0
M  V30 13 C 6.7357 -3.3644 0.0000 0
M  V30 14 O 7.4894 -3.0288 0.0000 0
M  V30 15 C 8.0414 -3.6419 0.0000 0
M  V30 16 C 7.6289 -4.3564 0.0000 0
M  V30 17 C 6.8220 -4.1848 0.0000 0
M  V30 18 C 8.8619 -3.5557 0.0000 0
M  V30 19 N 9.3468 -4.2231 0.0000 0
M  V30 20 C 10.1673 -4.1369 0.0000 0
M  V30 21 C 9.0113 -4.9768 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 2 3
M  V30 3 1 4 2
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 5 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 13 17
M  V30 18 1 15 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
220

>  <Plate>
PHD136328

>  <Row>
k

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ranitidine

>  <Synonyms>
Ranitidin;HSDB 3925

>  <CAS>
66357-35-5

>  <Formula>
C13H22N4O3S

>  <MolWt>
314.4

>  <Pathways>
GPCR/G Protein;Immunology/Inflammation;Neuroscience;Metabolism;Microbiology/Virology

>  <Target>
Histamine Receptor;P450;Antibacterial

>  <Receptor>
 H 2 Receptor:3.3 ??M (IC50)

>  <Bioactivity>
Ranitidine is a non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.

>  <Reference>
Fedorowicz Z. et al; Cochrane Database Syst Rev. 2012 Mar 14;(3):CD008596.;Tleyjeh IMPLoS One. 2013;8(3):e56498.

>  <ID<1>>
T3610

$$$$
StarDrop ID 221
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.7145 -0.4125 0.0000 0
M  V30 2 C -0.0000 0.0000 0.0000 0
M  V30 3 C 0.0000 0.8250 0.0000 0
M  V30 4 C 0.7145 1.2375 0.0000 0
M  V30 5 C 1.4289 0.8250 0.0000 0
M  V30 6 C 1.4289 -0.0000 0.0000 0
M  V30 7 C 0.7145 2.0625 0.0000 0
M  V30 8 C 0.0000 2.4750 0.0000 0 CFG=1
M  V30 9 C 0.0000 3.3000 0.0000 0
M  V30 10 O -0.7145 3.7125 0.0000 0
M  V30 11 O 0.7145 3.7125 0.0000 0
M  V30 12 N -0.7145 2.0625 0.0000 0
M  V30 13 H -0.8660 2.9750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 1 6
M  V30 7 1 4 7
M  V30 8 1 8 7
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 8 12 CFG=3
M  V30 13 1 13 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
221

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
L-Phenylalanine

>  <Synonyms>
(S)-2-Amino-3-phenylpropionic acid;phenylalanine;3-Phenyl-L-alanine

>  <CAS>
63-91-2

>  <Formula>
C9H11NO2

>  <MolWt>
165.2

>  <Pathways>
Neuroscience;Membrane transporter/Ion channel;Metabolism

>  <Target>
Endogenous Metabolite;Calcium Channel;iGluR

>  <Receptor>
 ??2?? calcium channels:980 nM(ki)

>  <Bioactivity>
"Phenylalanine is an essential amino acid and the precursor of the amino acid tyrosine, acts as an antagonist at ??2?? calcium channels."

>  <Reference>
"Moller, H.E., et al., Brain imaging and proton magnetic resonance spectroscopy in patients with phenylketonuria. Pediatrics, 2003. 112(6 Pt 2): p. 1580-3.;Wu WB, et al. Enhancement of l-phenylalanine production in Escherichia coli by heterologous expression of Vitreoscilla hemoglobin. Biotechnol Appl Biochem. 2018 May;65(3):476-483.;Glushakov, A.V., et al., L-phenylalanine selectively depresses currents at glutamatergic excitatory synapses. J Neurosci Res, 2003. 72(1): p. 116-24;Mortell, K.H., et al., Structure-activity relationships of alpha-amino acid ligands for the alpha2delta subunit of voltage-gated calcium channels. Bioorg Med Chem Lett, 2006. 16(5): p. 1138-41;Glushakov, A.V., et al., Long-term changes in glutamatergic synaptic transmission in phenylketonuria. Brain, 2005. 128(Pt 2): p. 300-7.;Glushakov,A.V.et al. Specific inhibition of N-methyl-D-aspartate receptor function in rat hippocampal neurons by L-phenylalanine at concentrations observed during phenylketonuria. Mol Psychiatry, 2002. 7(4): p. 359-67."

>  <ID<1>>
T3377

$$$$
StarDrop ID 222
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.8155 2.0034 0.0000 0
M  V30 2 C 4.9588 1.1909 0.0000 0 CFG=2
M  V30 3 C 5.7340 0.9088 0.0000 0
M  V30 4 C 6.3660 1.4391 0.0000 0
M  V30 5 C 7.1412 1.1569 0.0000 0
M  V30 6 C 7.2845 0.3444 0.0000 0
M  V30 7 C 6.6525 -0.1859 0.0000 0
M  V30 8 C 5.8773 0.0963 0.0000 0
M  V30 9 C 6.7958 -0.9983 0.0000 0
M  V30 10 F 6.9390 -1.8108 0.0000 0
M  V30 11 F 7.6082 -0.8551 0.0000 0
M  V30 12 F 5.9833 -1.1416 0.0000 0
M  V30 13 C 7.7732 1.6872 0.0000 0
M  V30 14 F 8.4052 2.2175 0.0000 0
M  V30 15 F 8.3035 1.0552 0.0000 0
M  V30 16 F 7.2429 2.3192 0.0000 0
M  V30 17 O 4.3268 0.6606 0.0000 0
M  V30 18 C 3.5515 0.9428 0.0000 0
M  V30 19 C 2.9195 0.4125 0.0000 0 CFG=1
M  V30 20 C 2.5070 -0.3020 0.0000 0
M  V30 21 C 1.6820 -0.3020 0.0000 0
M  V30 22 C 1.2695 0.4125 0.0000 0 CFG=1
M  V30 23 C 0.7846 -0.2549 0.0000 0
M  V30 24 C 0.0000 -0.0000 0.0000 0
M  V30 25 C -0.0000 0.8250 0.0000 0
M  V30 26 O -0.6674 1.3099 0.0000 0
M  V30 27 N 0.7846 1.0799 0.0000 0
M  V30 28 C 1.6820 1.1270 0.0000 0
M  V30 29 N 2.5070 1.1270 0.0000 0
M  V30 30 C 3.5515 -0.1178 0.0000 0
M  V30 31 C 4.3268 0.1644 0.0000 0
M  V30 32 C 4.9588 -0.3659 0.0000 0
M  V30 33 C 4.8155 -1.1784 0.0000 0
M  V30 34 C 4.0403 -1.4606 0.0000 0
M  V30 35 C 3.4083 -0.9303 0.0000 0
M  V30 36 H 5.7247 1.8338 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 3 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 1 9 12
M  V30 13 1 5 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 13 16
M  V30 17 1 2 17
M  V30 18 1 17 18
M  V30 19 1 19 18 CFG=1
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 22 21
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 28 1 22 27 CFG=1
M  V30 29 1 22 28
M  V30 30 1 28 29
M  V30 31 1 19 29
M  V30 32 1 19 30 CFG=3
M  V30 33 2 30 31
M  V30 34 1 31 32
M  V30 35 2 32 33
M  V30 36 1 33 34
M  V30 37 2 34 35
M  V30 38 1 30 35
M  V30 39 1 36 2
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
222

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Rolapitant

>  <Synonyms>
SCH619734

>  <CAS>
552292-08-7

>  <Formula>
C25H26F6N2O2

>  <MolWt>
500.5

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Neurokinin receptor

>  <Receptor>
 NK1:0.66 nM. (Ki)

>  <Bioactivity>
"Rolapitant Hydrochloride is the hydrochloride salt form of rolapitant, an orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor) antagonist with potential antiemetic activity. Upon oral administration, rolapitant competitively binds to and blocks the activity of the NK1-receptor in the central nervous system, thereby inhibiting the binding of the endogenous ligand, substance P (SP). This may prevent both SP-induced emesis and chemotherapy-induced nausea and vomiting (CINV). The interaction of SP with the NK1-receptor plays a key role in the induction of nausea and vomiting caused by emetogenic cancer chemotherapy. Compared to other NK1-receptor antagonists, rolapitant has both a more rapid onset of action and a much longer half-life."

>  <Reference>
"Duffy RA, et al. Rolapitant (SCH 619734): a potent, selective and orally active neurokininNK1 receptor antagonist with centrally-mediated antiemetic effects inferrets. Pharmacol Biochem Behav. 2012 Jul;102(1):95-100."

>  <ID<1>>
T3716

$$$$
StarDrop ID 223
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.0630 -1.4167 0.0000 0
M  V30 2 C 2.8390 -1.6970 0.0000 0 CFG=2
M  V30 3 C 3.5218 -1.2340 0.0000 0
M  V30 4 C 4.1731 -1.7404 0.0000 0 CFG=1
M  V30 5 C 4.9853 -1.5952 0.0000 0 CFG=2
M  V30 6 C 5.2655 -0.8192 0.0000 0
M  V30 7 C 6.0777 -0.6740 0.0000 0
M  V30 8 C 6.6095 -1.3047 0.0000 0
M  V30 9 C 7.4216 -1.1595 0.0000 0
M  V30 10 C 7.9534 -1.7902 0.0000 0
M  V30 11 O 8.7655 -1.6450 0.0000 0
M  V30 12 C 7.6731 -2.5662 0.0000 0
M  V30 13 C 6.8610 -2.7114 0.0000 0
M  V30 14 C 6.3292 -2.0807 0.0000 0 CFG=2
M  V30 15 C 5.5171 -2.2259 0.0000 0 CFG=1
M  V30 16 C 5.2368 -3.0018 0.0000 0 CFG=2
M  V30 17 C 4.4247 -3.1470 0.0000 0
M  V30 18 C 3.8928 -2.5163 0.0000 0 CFG=2
M  V30 19 C 3.0683 -2.4895 0.0000 0 CFG=1
M  V30 20 C 2.3074 -2.8084 0.0000 0
M  V30 21 O 2.2031 -3.6268 0.0000 0
M  V30 22 C 1.6508 -2.3089 0.0000 0
M  V30 23 O 0.8899 -2.6277 0.0000 0
M  V30 24 P 0.7856 -3.4461 0.0000 0
M  V30 25 O 1.6040 -3.5504 0.0000 0
M  V30 26 O -0.0328 -3.3418 0.0000 0
M  V30 27 O 0.6813 -4.2645 0.0000 0
M  V30 28 O 2.9469 -3.3055 0.0000 0
M  V30 29 C 3.5330 -3.2587 0.0000 0
M  V30 30 O 5.7686 -3.6325 0.0000 0
M  V30 31 F 6.0489 -2.8566 0.0000 0
M  V30 32 C 6.5585 -2.8731 0.0000 0
M  V30 33 H 2.7146 -0.7048 0.0000 0
M  V30 34 H 3.2125 -2.0183 0.0000 0
M  V30 35 H 4.3406 -0.8308 0.0000 0
M  V30 36 H 6.2212 -2.8258 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 14 13
M  V30 14 1 14 8
M  V30 15 1 15 14
M  V30 16 1 15 5
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 18 17
M  V30 20 1 4 18
M  V30 21 1 18 19
M  V30 22 1 19 2
M  V30 23 1 19 20 CFG=1
M  V30 24 2 20 21
M  V30 25 1 20 22
M  V30 26 1 22 23
M  V30 27 1 23 24
M  V30 28 2 24 25
M  V30 29 1 24 26
M  V30 30 1 24 27
M  V30 31 1 19 28 CFG=3
M  V30 32 1 18 29 CFG=1
M  V30 33 1 16 30 CFG=1
M  V30 34 1 15 31 CFG=3
M  V30 35 1 14 32 CFG=1
M  V30 36 1 33 2
M  V30 37 1 34 4
M  V30 38 1 35 5
M  V30 39 1 36 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
223

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dexamethasone Sodium Phosphate

>  <Synonyms>
Dexadreson;Dexagro;Dalalone

>  <CAS>
55203-24-2

>  <Formula>
C22H30FO8P??2Na

>  <MolWt>
516.4

>  <Pathways>
Neuroscience;Immunology/Inflammation

>  <Target>
IL Receptor;COX

>  <Receptor>
COX-2; IL receptor

>  <Bioactivity>
"Dexamethasone, an interleukin receptor modulator, has anti-inflammatory and immunosuppressant effects. It belongs to a potent glucocorticoid class of steroid synthetic drugs."

>  <Reference>
"Yamamoto K, et al. FEBS Lett, 2000, 465(2-3), 103-106.;Blanco FJ, et al. J Rheumatol, 1999, 26(6), 1366-1373."

>  <ID<1>>
T6465

$$$$
StarDrop ID 224
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 2.5615 -2.7373 0.0000 0
M  V30 2 C 2.0297 -3.3680 0.0000 0 CFG=2
M  V30 3 C 1.3784 -3.8744 0.0000 0
M  V30 4 C 0.6955 -3.4114 0.0000 0
M  V30 5 C 0.9249 -2.6189 0.0000 0 CFG=2
M  V30 6 O 0.4185 -1.9676 0.0000 0
M  V30 7 C -0.3987 -2.0804 0.0000 0
M  V30 8 C -0.9051 -1.4291 0.0000 0
M  V30 9 O -0.7096 -2.8446 0.0000 0
M  V30 10 C 1.7494 -2.5921 0.0000 0 CFG=2
M  V30 11 C 1.3895 -1.8497 0.0000 0
M  V30 12 C 2.2812 -1.9614 0.0000 0
M  V30 13 C 3.0934 -2.1066 0.0000 0
M  V30 14 C 3.3737 -2.8825 0.0000 0 CFG=2
M  V30 15 H 3.6540 -3.6584 0.0000 0
M  V30 16 C 4.1858 -3.0277 0.0000 0 CFG=1
M  V30 17 H 3.9055 -2.2518 0.0000 0
M  V30 18 C 4.7176 -2.3970 0.0000 0
M  V30 19 C 5.5297 -2.5422 0.0000 0
M  V30 20 C 5.8100 -3.3182 0.0000 0
M  V30 21 O 6.6221 -3.4634 0.0000 0
M  V30 22 C 5.2782 -3.9489 0.0000 0
M  V30 23 C 4.4661 -3.8037 0.0000 0
M  V30 24 C 3.9343 -4.4344 0.0000 0
M  V30 25 C 3.1221 -4.2891 0.0000 0
M  V30 26 C 2.8418 -3.5132 0.0000 0 CFG=1
M  V30 27 H 2.3100 -4.1439 0.0000 0
M  V30 28 H -0.0572 -2.8074 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 10 5
M  V30 10 1 2 10
M  V30 11 1 10 11 CFG=3
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 14 13
M  V30 15 1 14 15 CFG=1
M  V30 16 1 14 16
M  V30 17 1 16 17 CFG=3
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 2 22 23
M  V30 24 1 16 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 26 25
M  V30 28 1 2 26
M  V30 29 1 26 14
M  V30 30 1 26 27 CFG=3
M  V30 31 1 28 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
224

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Nandrolone acetate

>  <Synonyms>
19-Nortestosterone 17??-acetate

>  <CAS>
1425-10-1

>  <Formula>
C20H28O3

>  <MolWt>
316.4

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
" ??5-3-ketosteroid isomerase:7 ??M(Ki, Pseudomonas testosreroni)"

>  <Bioactivity>
Nandrolone acetate is a competitive inhibitor of isomerase with the Ki of 7 ??M for ??5-3-ketosteroid isomerase of Pseudomonas testosreroni.

>  <Reference>
"Martyr RJ, et al. Affinity labeling of the active sites of delta 5 -ketosteroid isomerase using photoexcited natural ligands. Biochemistry. 1973;12(11):2172-2178."

>  <ID<1>>
T38862

$$$$
StarDrop ID 225
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.4906 1.5346 0.0000 0
M  V30 2 C 4.6741 0.7302 0.0000 0 CFG=1
M  V30 3 C 5.4785 0.5467 0.0000 0
M  V30 4 N 5.8364 -0.1966 0.0000 0
M  V30 5 C 5.4785 -0.9399 0.0000 0
M  V30 6 C 4.6741 -1.1235 0.0000 0
M  V30 7 C 4.0291 -0.6091 0.0000 0
M  V30 8 C 3.3147 -1.0216 0.0000 0
M  V30 9 C 2.6002 -0.6091 0.0000 0
M  V30 10 C 2.6002 0.2159 0.0000 0
M  V30 11 Cl 1.8857 0.6284 0.0000 0
M  V30 12 C 3.3147 0.6284 0.0000 0
M  V30 13 C 4.0291 0.2159 0.0000 0
M  V30 14 H 5.3812 1.4373 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 2 13
M  V30 14 1 7 13
M  V30 15 1 14 2
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
225

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lorcaserin HCl

>  <Synonyms>
N/A

>  <CAS>
846589-98-8

>  <Formula>
C11H15Cl2N

>  <MolWt>
232.1

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
5-HT Receptor

>  <Receptor>
5-HT2C (Human); 5-HT2C (Rat)

>  <Bioactivity>
Lorcaserin is a selective serotonin agonist that has been recently approved as a weight loss agent.

>  <Reference>
"Thomsen WJ, et al. J Pharmacol Exp Ther, 2008, 325(2), 577-587.;Levin ED, et al. J Pharmacol Exp Ther, 2011, 338(3), 890-896."

>  <ID<1>>
T6572

$$$$
StarDrop ID 226
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -0.6525 -2.9942 0.0000 0
M  V30 2 C -0.1676 -2.3268 0.0000 0
M  V30 3 N -0.4226 -1.5422 0.0000 0
M  V30 4 C 0.2449 -1.0572 0.0000 0
M  V30 5 C -0.3071 -0.4441 0.0000 0
M  V30 6 C -1.1141 -0.6157 0.0000 0
M  V30 7 C -1.6662 -0.0026 0.0000 0
M  V30 8 C -1.4112 0.7820 0.0000 0
M  V30 9 C -0.6042 0.9536 0.0000 0
M  V30 10 C -0.0522 0.3405 0.0000 0
M  V30 11 C 0.9123 -1.5422 0.0000 0
M  V30 12 O 1.6969 -1.2872 0.0000 0
M  V30 13 N 0.6574 -2.3268 0.0000 0
M  V30 14 C 1.1423 -2.9942 0.0000 0
M  V30 15 C 0.7969 -0.4441 0.0000 0
M  V30 16 C 1.6039 -0.6157 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 4 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 2 13
M  V30 15 1 13 14
M  V30 16 1 4 15
M  V30 17 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
226

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Mephenytoin

>  <Synonyms>
Phenantoin;Methylphenetoin;Methoin;Mesantoin;Insulton

>  <CAS>
50-12-4

>  <Formula>
C12H14N2O2

>  <MolWt>
218.3

>  <Pathways>
Metabolism

>  <Target>
P450

>  <Receptor>
CYP2B6; CYP2C19

>  <Bioactivity>
Mephenytoin is an anticonvulsant and a substrate of CYP2C19 and CYP2B6.

>  <Reference>
"Lee SJ, et al. Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug Metab Dispos. 2009 Nov;37(11):2262-9.;Klaassen T, et al. Assessment of urinary mephenytoin metrics to phenotype for CYP2C19 and CYP2B6 activity. Eur J Clin Pharmacol. 2008 Apr;64(4):387-98. Epub 2007 Dec 11.;Vijayabhaskar V, Srivastava P, Rajagopal S. Breaking the sensitivity limitations of cytochrome P450 oxidation product: dansyl chloride derivatisation of 4-OH mephenytoin, a CYP2C19 metabolite and its application to in vitro CYP inhibition assay. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 May 1;989:27-36.;Wang H, et al. Evaluation of the effects of 20 nonsynonymous single nucleotide polymorphisms of CYP2C19 on S-mephenytoin 4'-hydroxylation and omeprazole 5'-hydroxylation. Drug Metab Dispos. 2011 May;39(5):830-7."

>  <ID<1>>
T21425

$$$$
StarDrop ID 227
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.1270 -2.1730 0.0000 0
M  V30 2 C -0.7145 -2.8875 0.0000 0
M  V30 3 C 0.1105 -2.8875 0.0000 0
M  V30 4 N 0.5230 -3.6020 0.0000 0
M  V30 5 C 1.3480 -3.6020 0.0000 0
M  V30 6 C 1.7605 -2.8875 0.0000 0
M  V30 7 C 2.5855 -2.8875 0.0000 0
M  V30 8 C 3.0705 -2.2201 0.0000 0
M  V30 9 C 3.8551 -2.4750 0.0000 0
M  V30 10 C 3.8551 -3.3000 0.0000 0
M  V30 11 S 3.0705 -3.5549 0.0000 0
M  V30 12 C 0.1105 -4.3164 0.0000 0 CFG=1
M  V30 13 C -0.7145 -4.3164 0.0000 0
M  V30 14 C -1.1270 -5.0309 0.0000 0
M  V30 15 C -0.7145 -5.7454 0.0000 0
M  V30 16 C 0.1105 -5.7454 0.0000 0
M  V30 17 C 0.5230 -5.0309 0.0000 0
M  V30 18 C 0.5230 -6.4599 0.0000 0
M  V30 19 C 0.1105 -7.1743 0.0000 0
M  V30 20 C -0.7145 -7.1743 0.0000 0
M  V30 21 C -1.1270 -6.4599 0.0000 0
M  V30 22 O -1.9520 -6.4599 0.0000 0
M  V30 23 H 1.1105 -4.3165 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 7 11
M  V30 12 1 12 4 CFG=3
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 12 17
M  V30 19 1 16 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 15 21
M  V30 24 1 21 22
M  V30 25 1 23 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
227

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Rotigotine-

>  <Synonyms>
Neupro;N-0923;N-0437;SPM 962

>  <CAS>
99755-59-6

>  <Formula>
C19H25NOS

>  <MolWt>
315.5

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Adrenergic Receptor;Dopamine Receptor;5-HT Receptor

>  <Receptor>
" 5-HT 1A Receptor:30 nM (Ki), D 5 Receptor:4-15 nM (Ki), 5-HT 7 Receptor:86 nM (Ki), D 2 Receptor:4-15 nM (Ki), D 3 Receptor:0.71  nM (Ki), D 1 Receptor:83 nM (Ki), D 4 Receptor:4-15 nM (Ki)"

>  <Bioactivity>
"Rotigotine is a non-ergot dopamine receptor agonist used in the therapy of Parkinson disease and restless leg syndrome. Administered as a once-daily transdermal patch, Rotigotine has not been associated with serum enzyme elevations during treatment or with episodes of clinically apparent liver injury."

>  <Reference>
"Wood M, et al. Rotigotine is a potent agonist at dopamine D1 receptors as well as at dopamine D2 and D3 receptors. Br J Pharmacol. 2015 Feb;172(4):1124-35.;Fenu S, et al. In vivo dopamine agonist properties of rotigotine: Role of D1 and D2 receptors. Eur J Pharmacol. 2016 Oct 5;788:183-91.;Scheller D, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson's disease. Naunyn Schmiedebergs Arch Pharmacol. 2009 Jan;379(1):73-86.;Radad K, Scheller D, et al. Neuroprotective effect of rotigotine against complex I inhibitors, MPP? and rotenone, in primary mesencephalic cell culture. Folia Neuropathol. 2014;52(2):179-86."

>  <ID<1>>
T6647

$$$$
StarDrop ID 228
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 43 48 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 2.2389 -1.7523 0.0000 0
M  V30 2 C 2.7647 -1.1165 0.0000 0
M  V30 3 C 2.5593 -0.3175 0.0000 0 CFG=1
M  V30 4 C 3.2558 0.1248 0.0000 0
M  V30 5 C 3.8916 -0.4010 0.0000 0
M  V30 6 N 3.5881 -1.1681 0.0000 0
M  V30 7 N 4.6648 -0.1132 0.0000 0
M  V30 8 C 4.8022 0.7002 0.0000 0
M  V30 9 C 4.1664 1.2260 0.0000 0
M  V30 10 C 3.3932 0.9382 0.0000 0
M  V30 11 C 2.3540 0.4816 0.0000 0
M  V30 12 C 1.5306 0.5332 0.0000 0
M  V30 13 C 1.2271 -0.2339 0.0000 0
M  V30 14 C 1.8629 -0.7597 0.0000 0
M  V30 15 N 0.4109 -0.3546 0.0000 0
M  V30 16 C -0.1017 0.2918 0.0000 0
M  V30 17 C 0.2019 1.0589 0.0000 0
M  V30 18 C -0.3107 1.7054 0.0000 0
M  V30 19 N -1.1268 1.5847 0.0000 0
M  V30 20 C -1.6394 2.2311 0.0000 0 CFG=1
M  V30 21 C -2.4555 2.1104 0.0000 0
M  V30 22 C -2.9681 2.7568 0.0000 0 CFG=2
M  V30 23 C -2.6646 3.5240 0.0000 0 CFG=1
M  V30 24 C -3.1772 4.1704 0.0000 0
M  V30 25 N -1.8485 3.6447 0.0000 0
M  V30 26 C -1.5449 4.4118 0.0000 0
M  V30 27 C -0.7288 4.5325 0.0000 0
M  V30 28 F -0.6081 3.7164 0.0000 0
M  V30 29 F -0.8495 5.3486 0.0000 0
M  V30 30 F 0.0873 4.6532 0.0000 0
M  V30 31 C -1.3359 2.9982 0.0000 0
M  V30 32 O -0.5198 3.1189 0.0000 0
M  V30 33 C -3.7843 2.6361 0.0000 0
M  V30 34 C -4.0878 1.8690 0.0000 0
M  V30 35 C -4.9039 1.7483 0.0000 0
M  V30 36 C -5.4165 2.3947 0.0000 0
M  V30 37 C -5.1130 3.1619 0.0000 0
M  V30 38 C -4.2968 3.2826 0.0000 0
M  V30 39 H -3.4807 3.4033 0.0000 0
M  V30 40 O -0.0072 2.4725 0.0000 0
M  V30 41 C 1.0180 1.1796 0.0000 0
M  V30 42 H -0.6502 2.3774 0.0000 0
M  V30 43 H -2.2967 4.4539 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 2 6
M  V30 7 2 5 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 2 4 10
M  V30 12 1 3 11
M  V30 13 1 11 12
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 3 14
M  V30 17 2 13 15
M  V30 18 1 15 16
M  V30 19 2 16 17
M  V30 20 1 17 18
M  V30 21 1 18 19
M  V30 22 1 20 19 CFG=1
M  V30 23 1 20 21
M  V30 24 1 22 21
M  V30 25 1 22 23
M  V30 26 1 23 24 CFG=1
M  V30 27 1 23 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 27 29
M  V30 32 1 27 30
M  V30 33 1 25 31
M  V30 34 1 20 31
M  V30 35 2 31 32
M  V30 36 1 22 33
M  V30 37 2 33 34
M  V30 38 1 34 35
M  V30 39 2 35 36
M  V30 40 1 36 37
M  V30 41 2 37 38
M  V30 42 1 33 38
M  V30 43 1 22 39 CFG=3
M  V30 44 2 18 40
M  V30 45 1 17 41
M  V30 46 2 12 41
M  V30 47 1 42 20
M  V30 48 1 43 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
228

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ubrogepant

>  <Synonyms>
MK-1602

>  <CAS>
1374248-77-7

>  <Formula>
C29H26F3N5O3

>  <MolWt>
549.5

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
CGRP Receptor

>  <Receptor>
CGRP

>  <Bioactivity>
Ubrogepant is an antagonist of calcitonin gene-related peptide receptor that can be used in the acute treatment of migraine studies.

>  <Reference>
"Li CC, et al. Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling. J Clin Pharmacol. 2017 Nov 14. doi: 10.1002/jcph.1021."

>  <ID<1>>
T17194

$$$$
StarDrop ID 229
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.7120 1.4905 0.0000 0
M  V30 2 C 6.9975 1.0780 0.0000 0
M  V30 3 O 6.2831 1.4905 0.0000 0
M  V30 4 C 5.5686 1.0780 0.0000 0
M  V30 5 O 4.8541 1.4905 0.0000 0
M  V30 6 C 5.5686 0.2530 0.0000 0
M  V30 7 C 6.2831 -0.1595 0.0000 0
M  V30 8 C 6.9975 0.2530 0.0000 0
M  V30 9 O 7.7120 -0.1595 0.0000 0
M  V30 10 C 8.4265 0.2530 0.0000 0
M  V30 11 C 9.1410 -0.1595 0.0000 0
M  V30 12 N 9.8554 0.2530 0.0000 0
M  V30 13 N 6.2831 -0.9845 0.0000 0
M  V30 14 C 5.5686 -1.3970 0.0000 0
M  V30 15 C 5.5686 -2.2220 0.0000 0
M  V30 16 C 4.8541 -0.9845 0.0000 0
M  V30 17 C 4.8541 -0.1595 0.0000 0 CFG=2
M  V30 18 C 4.1397 0.2530 0.0000 0
M  V30 19 C 3.4252 -0.1595 0.0000 0
M  V30 20 C 2.7107 0.2530 0.0000 0
M  V30 21 C 2.7107 1.0780 0.0000 0
M  V30 22 C 3.4252 1.4905 0.0000 0
M  V30 23 C 4.1397 1.0780 0.0000 0
M  V30 24 Cl 4.4752 1.8317 0.0000 0
M  V30 25 C 4.1397 -1.3970 0.0000 0
M  V30 26 O 3.4252 -0.9845 0.0000 0
M  V30 27 O 4.1397 -2.2220 0.0000 0
M  V30 28 C 3.4252 -2.6345 0.0000 0
M  V30 29 H 4.8542 0.8405 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 17 16
M  V30 17 1 17 6
M  V30 18 1 17 18 CFG=3
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 18 23
M  V30 25 1 23 24
M  V30 26 1 16 25
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 1 27 28
M  V30 30 1 29 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
229

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Levamlodipine besylate

>  <Synonyms>
(S)-Amlodipine Besylate (103129-82-4(free base))

>  <CAS>
150566-71-5

>  <Formula>
C26H31ClN2O8S

>  <MolWt>
567

>  <Pathways>
Metabolism;Membrane transporter/Ion channel

>  <Target>
Calcium Channel

>  <Receptor>
 Calcium channel:

>  <Bioactivity>
"Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of amlodipine, an antihypertensive and anti-anginal medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. The names S-amlodipine and levamlodipine may be used interchangeably as both substances are the same, however, with differing nomenclature. As a racemic mixture, amlodipine contains (R) and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety possesses therapeutic activity."

>  <Reference>
"Liu F,etal.Tolerability and effectiveness of (S)-amlodipine compared with racemic amlodipine in hypertension: a systematic review and meta-analysis.Curr Ther Res Clin Exp. 2010 Feb;71(1):1-29."

>  <ID<1>>
T4284

$$$$
StarDrop ID 230
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.6009 5.1746 0.0000 0
M  V30 2 N -0.3459 4.3900 0.0000 0
M  V30 3 C 0.4610 4.2184 0.0000 0
M  V30 4 O 1.0131 4.8315 0.0000 0
M  V30 5 C 0.7160 3.4338 0.0000 0
M  V30 6 C 1.5229 3.2623 0.0000 0
M  V30 7 C 1.7779 2.4777 0.0000 0
M  V30 8 C 1.2258 1.8646 0.0000 0
M  V30 9 C 0.4189 2.0361 0.0000 0
M  V30 10 C 0.1639 2.8207 0.0000 0
M  V30 11 F -0.6430 2.9922 0.0000 0
M  V30 12 N 1.4808 1.0799 0.0000 0
M  V30 13 C 2.2654 0.8250 0.0000 0
M  V30 14 S 2.9328 1.3099 0.0000 0
M  V30 15 N 2.2654 -0.0000 0.0000 0
M  V30 16 C 1.4808 -0.2549 0.0000 0
M  V30 17 O 1.2258 -1.0396 0.0000 0
M  V30 18 C 0.9959 0.4125 0.0000 0
M  V30 19 C 0.4125 -0.1709 0.0000 0
M  V30 20 C -0.1709 0.4125 0.0000 0
M  V30 21 C 0.4125 0.9959 0.0000 0
M  V30 22 C 2.9328 -0.4849 0.0000 0
M  V30 23 C 3.6865 -0.1494 0.0000 0
M  V30 24 C 4.3540 -0.6343 0.0000 0
M  V30 25 C 4.2677 -1.4548 0.0000 0
M  V30 26 C 4.9352 -1.9397 0.0000 0
M  V30 27 N 5.6026 -2.4246 0.0000 0
M  V30 28 C 3.5140 -1.7903 0.0000 0
M  V30 29 C 2.8466 -1.3054 0.0000 0
M  V30 30 C 3.4278 -2.6108 0.0000 0
M  V30 31 F 3.3416 -3.4313 0.0000 0
M  V30 32 F 2.6073 -2.5246 0.0000 0
M  V30 33 F 4.2483 -2.6970 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 5 10
M  V30 11 1 10 11
M  V30 12 1 8 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 12 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 18 21
M  V30 24 1 15 22
M  V30 25 2 22 23
M  V30 26 1 23 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 3 26 27
M  V30 30 1 25 28
M  V30 31 2 28 29
M  V30 32 1 22 29
M  V30 33 1 28 30
M  V30 34 1 30 31
M  V30 35 1 30 32
M  V30 36 1 30 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
230

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
RD162

>  <Synonyms>
N/A

>  <CAS>
915087-27-3

>  <Formula>
C22H16F4N4O2S

>  <MolWt>
476.5

>  <Pathways>
Endocrinology/Hormones

>  <Target>
Androgen Receptor

>  <Receptor>
Androgen Receptor

>  <Bioactivity>
RD162 is a non-steroidal antiandrogen (NSAA) specifically binding to the androgen receptor (AR).

>  <Reference>
"Chris Tran, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009 May 8;324(5928):787-90."

>  <ID<1>>
T21740

$$$$
StarDrop ID 231
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -0.8666 -2.0033 0.0000 0
M  V30 2 S -0.8050 -1.1806 0.0000 0
M  V30 3 O 0.0177 -1.2423 0.0000 0
M  V30 4 O -1.6276 -1.1190 0.0000 0
M  V30 5 O -0.7433 -0.3580 0.0000 0
M  V30 6 N 0.0000 -0.0000 0.0000 0
M  V30 7 C 0.6450 -0.5144 0.0000 0 CFG=1
M  V30 8 C 0.8767 0.4125 0.0000 0
M  V30 9 N 0.6450 1.3394 0.0000 0
M  V30 10 C 1.4493 1.1558 0.0000 0 CFG=1
M  V30 11 C 1.8073 0.4125 0.0000 0
M  V30 12 C 1.4493 -0.3308 0.0000 0
M  V30 13 C 1.9637 1.8008 0.0000 0
M  V30 14 O 2.7795 1.6779 0.0000 0
M  V30 15 N 1.6623 2.5688 0.0000 0
M  V30 16 C 2.1767 3.2138 0.0000 0
M  V30 17 C 1.8753 3.9818 0.0000 0
M  V30 18 C 2.3897 4.6268 0.0000 0
M  V30 19 N 3.2054 4.5038 0.0000 0
M  V30 20 C 3.5068 3.7358 0.0000 0
M  V30 21 C 2.9925 3.0908 0.0000 0
M  V30 22 C -0.0000 0.8250 0.0000 0
M  V30 23 O -0.7433 1.1830 0.0000 0
M  V30 24 H 1.2900 -1.0288 0.0000 0
M  V30 25 H 2.4430 1.0438 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=1
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 10 9
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 12
M  V30 13 1 10 13 CFG=3
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 16 21
M  V30 23 1 9 22
M  V30 24 1 6 22
M  V30 25 2 22 23
M  V30 26 1 24 7
M  V30 27 1 25 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
231

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Relebactam

>  <Synonyms>
MK-7655

>  <CAS>
1174018-99-5

>  <Formula>
C12H20N4O6S

>  <MolWt>
348.4

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial

>  <Receptor>
Bacterial; ??-lactamase

>  <Bioactivity>
Relebactam is a diazabicyclooctane inhibitor with activity against a wide spectrum of ??-lactamases.

>  <Reference>
"Bush K., et al. A resurgence of ??-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015 Nov;46(5):483-93.;Lapuebla A, et al. Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City. Antimicrob Agents Chemother. 2015 Aug;59(8):5029-31."

>  <ID<1>>
T4017

$$$$
StarDrop ID 232
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 76 81 0 0 1
M  V30 BEGIN ATOM
M  V30 1 Cl 7.8592 -14.4375 0.0000 0
M  V30 2 C 7.8592 -15.2625 0.0000 0
M  V30 3 C 7.1447 -15.6750 0.0000 0
M  V30 4 C 7.1447 -16.5000 0.0000 0
M  V30 5 C 6.4302 -16.9125 0.0000 0 CFG=1
M  V30 6 C 5.7158 -16.5000 0.0000 0
M  V30 7 N 5.7158 -15.6750 0.0000 0
M  V30 8 C 5.0013 -15.2625 0.0000 0
M  V30 9 C 6.4302 -15.2625 0.0000 0
M  V30 10 C 6.4302 -17.7375 0.0000 0
M  V30 11 C 7.1447 -18.1500 0.0000 0
M  V30 12 C 7.1447 -18.9750 0.0000 0
M  V30 13 S 7.8592 -19.3875 0.0000 0
M  V30 14 N 8.5737 -19.8000 0.0000 0
M  V30 15 C 9.2881 -19.3875 0.0000 0
M  V30 16 C 10.0026 -19.8000 0.0000 0
M  V30 17 O 10.7171 -19.3875 0.0000 0
M  V30 18 C 11.4315 -19.8000 0.0000 0
M  V30 19 C 12.1460 -19.3875 0.0000 0
M  V30 20 O 12.8605 -19.8000 0.0000 0
M  V30 21 C 13.5749 -19.3875 0.0000 0
M  V30 22 C 14.2894 -19.8000 0.0000 0
M  V30 23 N 15.0039 -19.3875 0.0000 0
M  V30 24 C 15.7184 -19.8000 0.0000 0
M  V30 25 N 16.4328 -19.3875 0.0000 0
M  V30 26 C 17.1473 -19.8000 0.0000 0
M  V30 27 C 17.8618 -19.3875 0.0000 0
M  V30 28 C 18.5762 -19.8000 0.0000 0
M  V30 29 C 19.2907 -19.3875 0.0000 0
M  V30 30 N 20.0052 -19.8000 0.0000 0
M  V30 31 C 20.7197 -19.3875 0.0000 0
M  V30 32 N 21.4341 -19.8000 0.0000 0
M  V30 33 C 22.1486 -19.3875 0.0000 0
M  V30 34 C 22.8631 -19.8000 0.0000 0
M  V30 35 O 23.5775 -19.3875 0.0000 0
M  V30 36 C 24.2920 -19.8000 0.0000 0
M  V30 37 C 25.0065 -19.3875 0.0000 0
M  V30 38 O 25.7210 -19.8000 0.0000 0
M  V30 39 C 26.4354 -19.3875 0.0000 0
M  V30 40 C 27.1499 -19.8000 0.0000 0
M  V30 41 N 27.8644 -19.3875 0.0000 0
M  V30 42 S 28.5788 -19.8000 0.0000 0
M  V30 43 O 28.1663 -20.5145 0.0000 0
M  V30 44 O 28.9913 -19.0855 0.0000 0
M  V30 45 C 29.2933 -20.2125 0.0000 0
M  V30 46 C 30.0078 -19.8000 0.0000 0
M  V30 47 C 30.7223 -20.2125 0.0000 0
M  V30 48 C 30.7223 -21.0375 0.0000 0
M  V30 49 C 30.0078 -21.4500 0.0000 0
M  V30 50 C 29.2933 -21.0375 0.0000 0
M  V30 51 C 31.4367 -19.8000 0.0000 0 CFG=1
M  V30 52 C 32.1512 -20.2125 0.0000 0
M  V30 53 C 32.8657 -19.8000 0.0000 0
M  V30 54 C 33.5801 -20.2125 0.0000 0
M  V30 55 Cl 34.2946 -19.8000 0.0000 0
M  V30 56 C 33.5801 -21.0375 0.0000 0
M  V30 57 C 32.8657 -21.4500 0.0000 0
M  V30 58 Cl 32.8657 -22.2750 0.0000 0
M  V30 59 C 32.1512 -21.0375 0.0000 0
M  V30 60 C 32.8657 -18.9750 0.0000 0
M  V30 61 N 32.1512 -18.5625 0.0000 0
M  V30 62 C 32.1512 -17.7375 0.0000 0
M  V30 63 C 31.4367 -18.9750 0.0000 0
M  V30 64 O 20.7197 -18.5625 0.0000 0
M  V30 65 O 15.7184 -20.6250 0.0000 0
M  V30 66 O 7.4467 -20.1020 0.0000 0
M  V30 67 O 8.2717 -18.6730 0.0000 0
M  V30 68 C 6.4302 -19.3875 0.0000 0
M  V30 69 C 5.7158 -18.9750 0.0000 0
M  V30 70 C 5.7158 -18.1500 0.0000 0
M  V30 71 C 7.8592 -16.9125 0.0000 0
M  V30 72 C 8.5737 -16.5000 0.0000 0
M  V30 73 Cl 9.2881 -16.9125 0.0000 0
M  V30 74 C 8.5737 -15.6750 0.0000 0
M  V30 75 H 31.4368 -20.8000 0.0000 0
M  V30 76 H 5.5642 -17.4125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 3 9
M  V30 10 1 5 10 CFG=3
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 1 29 30
M  V30 31 1 30 31
M  V30 32 1 31 32
M  V30 33 1 32 33
M  V30 34 1 33 34
M  V30 35 1 34 35
M  V30 36 1 35 36
M  V30 37 1 36 37
M  V30 38 1 37 38
M  V30 39 1 38 39
M  V30 40 1 39 40
M  V30 41 1 40 41
M  V30 42 1 41 42
M  V30 43 2 42 43
M  V30 44 2 42 44
M  V30 45 1 42 45
M  V30 46 2 45 46
M  V30 47 1 46 47
M  V30 48 2 47 48
M  V30 49 1 48 49
M  V30 50 2 49 50
M  V30 51 1 45 50
M  V30 52 1 51 47 CFG=3
M  V30 53 1 51 52
M  V30 54 1 52 53
M  V30 55 2 53 54
M  V30 56 1 54 55
M  V30 57 1 54 56
M  V30 58 2 56 57
M  V30 59 1 57 58
M  V30 60 1 57 59
M  V30 61 2 52 59
M  V30 62 1 53 60
M  V30 63 1 60 61
M  V30 64 1 61 62
M  V30 65 1 61 63
M  V30 66 1 51 63
M  V30 67 2 31 64
M  V30 68 2 24 65
M  V30 69 2 13 66
M  V30 70 2 13 67
M  V30 71 2 12 68
M  V30 72 1 68 69
M  V30 73 2 69 70
M  V30 74 1 10 70
M  V30 75 2 4 71
M  V30 76 1 71 72
M  V30 77 1 72 73
M  V30 78 2 72 74
M  V30 79 1 2 74
M  V30 80 1 75 51
M  V30 81 1 76 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
232

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tenapanor

>  <Synonyms>
AZD-1722;AZD 1722;RDX5791;Tenapanor free base;RDX-5791;RDX 5791;AZD1722

>  <CAS>
1234423-95-0

>  <Formula>
C50H66Cl4N8O10S2

>  <MolWt>
1145

>  <Pathways>
Membrane transporter/Ion channel

>  <Target>
Sodium Channel

>  <Receptor>
" NHE3, human:5 nM (IC50), NHE3, rat:10 nM (IC50)"

>  <Bioactivity>
"Tenapanor is an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3, which plays a prominent role in sodium handling in the gastrointestinal tract and kidney. Tenapanor possesses an excellent preclinical safety profile and, as of now, there are no serious concerns about its side effects."

>  <Reference>
"Johansson SA, Knutsson M, Leonsson-Zachrisson M, Rosenbaum DP. Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study. Clin Pharmacol Drug Dev. 2017 Mar 24. doi: 10.1002/cpdd.341. [Epub ahead of print] PubMed PMID: 28339149.;Carney EF. Dialysis: Efficacy of tenapanor in hyperphosphataemia. Nat Rev Nephrol. 2017 Apr;13(4):194. doi: 10.1038/nrneph.2017.27. PubMed PMID: 28239171.;Chey WD, Lembo AJ, Rosenbaum DP. Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial. Am J Gastroenterol. 2017 Feb 28. doi: 10.1038/ajg.2017.41. [Epub ahead of print] PubMed PMID: 28244495.;Johansson S, Rosenbaum DP, Ahlqvist M, Rollison H, Knutsson M, Stefansson B, Elebring M. Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions. Clin Pharmacol Drug Dev. 2017 Mar 16. doi: 10.1002/cpdd.346. [Epub ahead of print] PubMed PMID: 28301096."

>  <ID<1>>
T7587

$$$$
StarDrop ID 233
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 71 80 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.7696 -5.9868 0.0000 0
M  V30 2 O 3.3217 -6.5998 0.0000 0
M  V30 3 C 4.1286 -6.4283 0.0000 0
M  V30 4 O 4.3836 -5.6437 0.0000 0
M  V30 5 N 4.6807 -7.0414 0.0000 0
M  V30 6 C 5.4877 -6.8699 0.0000 0 CFG=1
M  V30 7 C 6.0397 -7.4830 0.0000 0
M  V30 8 C 6.8467 -7.3115 0.0000 0
M  V30 9 C 5.7847 -8.2676 0.0000 0
M  V30 10 C 5.7426 -6.0853 0.0000 0
M  V30 11 O 5.1906 -5.4722 0.0000 0
M  V30 12 N 6.5496 -5.9137 0.0000 0
M  V30 13 C 7.1627 -6.4658 0.0000 0
M  V30 14 C 7.8771 -6.0533 0.0000 0
M  V30 15 C 8.3621 -6.7207 0.0000 0
M  V30 16 C 8.6976 -5.9670 0.0000 0
M  V30 17 C 7.7056 -5.2463 0.0000 0
M  V30 18 C 6.8851 -5.1601 0.0000 0 CFG=1
M  V30 19 C 6.4726 -4.4456 0.0000 0
M  V30 20 N 5.6521 -4.3594 0.0000 0
M  V30 21 C 5.4806 -3.5524 0.0000 0
M  V30 22 C 6.1951 -3.1399 0.0000 0
M  V30 23 N 6.8082 -3.6919 0.0000 0
M  V30 24 C 6.2813 -2.3194 0.0000 0
M  V30 25 C 5.6139 -1.8345 0.0000 0
M  V30 26 C 5.7001 -1.0140 0.0000 0
M  V30 27 C 6.4538 -0.6784 0.0000 0
M  V30 28 C 6.7087 0.1062 0.0000 0
M  V30 29 C 6.2962 0.8206 0.0000 0
M  V30 30 C 6.7087 1.5351 0.0000 0
M  V30 31 C 7.5337 1.5351 0.0000 0
M  V30 32 C 7.9462 0.8206 0.0000 0
M  V30 33 C 7.5337 0.1062 0.0000 0
M  V30 34 C 7.7887 -0.6784 0.0000 0
M  V30 35 F 8.5423 -0.3429 0.0000 0
M  V30 36 F 8.2012 -1.3929 0.0000 0
M  V30 37 C 7.1212 -1.1634 0.0000 0
M  V30 38 C 7.0350 -1.9838 0.0000 0
M  V30 39 C 7.9462 2.2496 0.0000 0
M  V30 40 C 7.5337 2.9641 0.0000 0
M  V30 41 C 7.9462 3.6785 0.0000 0
M  V30 42 C 8.7712 3.6785 0.0000 0
M  V30 43 N 9.3233 4.2916 0.0000 0
M  V30 44 C 10.0769 3.9561 0.0000 0
M  V30 45 N 9.9907 3.1356 0.0000 0
M  V30 46 C 9.1837 2.9641 0.0000 0
M  V30 47 C 8.7712 2.2496 0.0000 0
M  V30 48 C 10.7914 4.3686 0.0000 0 CFG=2
M  V30 49 C 11.5059 3.9561 0.0000 0 CFG=1
M  V30 50 C 12.2204 4.3686 0.0000 0
M  V30 51 C 12.2204 5.1936 0.0000 0
M  V30 52 C 11.5059 5.6061 0.0000 0 CFG=2
M  V30 53 C 11.2996 4.7811 0.0000 0
M  V30 54 N 10.7914 5.1936 0.0000 0
M  V30 55 C 10.0769 5.6061 0.0000 0
M  V30 56 O 9.3625 5.1936 0.0000 0
M  V30 57 C 10.0769 6.4311 0.0000 0 CFG=1
M  V30 58 N 10.7914 6.8436 0.0000 0
M  V30 59 C 10.7914 7.6686 0.0000 0
M  V30 60 O 10.0769 8.0811 0.0000 0
M  V30 61 O 11.5059 8.0811 0.0000 0
M  V30 62 C 11.5059 8.9061 0.0000 0
M  V30 63 C 9.3625 6.8436 0.0000 0
M  V30 64 C 8.6480 6.4311 0.0000 0
M  V30 65 C 9.3625 7.6686 0.0000 0
M  V30 66 H 9.9254 4.8686 0.0000 0
M  V30 67 H 11.7122 3.1311 0.0000 0
M  V30 68 H 11.7122 6.4311 0.0000 0
M  V30 69 H 10.0770 7.4311 0.0000 0
M  V30 70 H 4.8185 -6.1268 0.0000 0
M  V30 71 H 5.8865 -5.2123 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 6 5 CFG=3
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 6 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 14 16
M  V30 17 1 14 17
M  V30 18 1 18 17
M  V30 19 1 18 12
M  V30 20 1 18 19 CFG=3
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 19 23
M  V30 26 1 22 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 1 31 32
M  V30 35 2 32 33
M  V30 36 1 28 33
M  V30 37 1 33 34
M  V30 38 1 34 35
M  V30 39 1 34 36
M  V30 40 1 34 37
M  V30 41 1 27 37
M  V30 42 2 37 38
M  V30 43 1 24 38
M  V30 44 1 31 39
M  V30 45 1 39 40
M  V30 46 2 40 41
M  V30 47 1 41 42
M  V30 48 1 42 43
M  V30 49 1 43 44
M  V30 50 2 44 45
M  V30 51 1 45 46
M  V30 52 2 42 46
M  V30 53 1 46 47
M  V30 54 2 39 47
M  V30 55 1 48 44 CFG=1
M  V30 56 1 48 49
M  V30 57 1 49 50
M  V30 58 1 50 51
M  V30 59 1 52 51
M  V30 60 1 52 53 CFG=1
M  V30 61 1 49 53 CFG=1
M  V30 62 1 52 54
M  V30 63 1 48 54
M  V30 64 1 54 55
M  V30 65 2 55 56
M  V30 66 1 57 55
M  V30 67 1 57 58 CFG=3
M  V30 68 1 58 59
M  V30 69 2 59 60
M  V30 70 1 59 61
M  V30 71 1 61 62
M  V30 72 1 57 63
M  V30 73 1 63 64
M  V30 74 1 63 65
M  V30 75 1 66 48
M  V30 76 1 67 49
M  V30 77 1 68 52
M  V30 78 1 69 57
M  V30 79 1 70 6
M  V30 80 1 71 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
233

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ledipasvir (acetone)

>  <Synonyms>
GS-5885 acetone;Ledipasvir acetone

>  <CAS>
1441674-54-9

>  <Formula>
C52H60F2N8O7

>  <MolWt>
947.1

>  <Pathways>
Proteases/Proteasome;Microbiology/Virology

>  <Target>
HCV Protease

>  <Receptor>
" GT1b:4 pM(EC50), GT1a:34 pM (EC50)"

>  <Bioactivity>
"Ledipasvir (GS5885) is an HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection."

>  <Reference>
"Smith MA, et al. Ann Pharmacother. 2015 Mar;49(3):343-50."

>  <ID<1>>
T4203

$$$$
StarDrop ID 234
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 104 108 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.3551 0.7756 0.0000 0
M  V30 2 C -2.1139 -0.0133 0.0000 0 CFG=1
M  V30 3 C -2.6766 -0.6167 0.0000 0
M  V30 4 N -2.4355 -1.4056 0.0000 0
M  V30 5 C -2.9982 -2.0090 0.0000 0 CFG=2
M  V30 6 C -2.7570 -2.7979 0.0000 0
M  V30 7 N -3.3197 -3.4013 0.0000 0
M  V30 8 C -3.0785 -4.1902 0.0000 0 CFG=2
M  V30 9 C -3.6412 -4.7936 0.0000 0
M  V30 10 N -3.4001 -5.5825 0.0000 0
M  V30 11 C -3.9628 -6.1859 0.0000 0 CFG=1
M  V30 12 C -3.7216 -6.9748 0.0000 0
M  V30 13 C -4.2843 -7.5782 0.0000 0
M  V30 14 C -4.0432 -8.3671 0.0000 0
M  V30 15 C -4.6058 -8.9704 0.0000 0
M  V30 16 C -5.4097 -8.7848 0.0000 0
M  V30 17 C -5.6508 -7.9958 0.0000 0
M  V30 18 C -5.0881 -7.3925 0.0000 0
M  V30 19 C -4.7666 -6.0002 0.0000 0
M  V30 20 N -5.3293 -6.6035 0.0000 0
M  V30 21 O -5.0078 -5.2112 0.0000 0
M  V30 22 O -4.4451 -4.6079 0.0000 0
M  V30 23 C -2.2747 -4.3759 0.0000 0
M  V30 24 C -2.0335 -5.1648 0.0000 0
M  V30 25 O -1.2297 -5.3505 0.0000 0
M  V30 26 O -2.5962 -5.7682 0.0000 0
M  V30 27 O -1.9532 -2.9836 0.0000 0
M  V30 28 C -3.8020 -1.8233 0.0000 0
M  V30 29 C -4.3647 -2.4267 0.0000 0
M  V30 30 S -4.1235 -3.2156 0.0000 0
M  V30 31 C -4.6862 -3.8190 0.0000 0
M  V30 32 O -3.4805 -0.4310 0.0000 0
M  V30 33 N -1.3101 -0.1990 0.0000 0
M  V30 34 C -1.0689 -0.9879 0.0000 0
M  V30 35 C -0.2651 -1.1736 0.0000 0
M  V30 36 N -0.0239 -1.9626 0.0000 0
M  V30 37 C 0.7799 -2.1482 0.0000 0
M  V30 38 C 1.0211 -2.9372 0.0000 0 CFG=1
M  V30 39 N 1.8249 -3.1228 0.0000 0
M  V30 40 C 2.0661 -3.9118 0.0000 0
M  V30 41 C 2.8699 -4.0974 0.0000 0 CFG=2
M  V30 42 C 3.4326 -3.4941 0.0000 0
M  V30 43 C 3.1914 -2.7051 0.0000 0
M  V30 44 C 2.3876 -2.5195 0.0000 0
M  V30 45 C 2.1464 -1.7305 0.0000 0
M  V30 46 C 2.7091 -1.1272 0.0000 0
M  V30 47 O 2.4680 -0.3382 0.0000 0
M  V30 48 S 3.0307 0.2651 0.0000 0
M  V30 49 O 3.6340 -0.2976 0.0000 0
M  V30 50 O 2.4273 0.8278 0.0000 0
M  V30 51 O 3.5934 0.8684 0.0000 0
M  V30 52 C 3.5130 -1.3128 0.0000 0
M  V30 53 C 3.7541 -2.1018 0.0000 0
M  V30 54 N 3.1110 -4.8864 0.0000 0
M  V30 55 C 3.9149 -5.0720 0.0000 0
M  V30 56 C 4.1560 -5.8610 0.0000 0 CFG=1
M  V30 57 N 4.9599 -6.0466 0.0000 0
M  V30 58 C 5.2010 -6.8356 0.0000 0
M  V30 59 C 6.0049 -7.0212 0.0000 0 CFG=1
M  V30 60 N 6.2460 -7.8102 0.0000 0
M  V30 61 C 7.0499 -7.9958 0.0000 0
M  V30 62 O 7.6126 -7.3925 0.0000 0
M  V30 63 C 7.2910 -8.7848 0.0000 0 CFG=1
M  V30 64 N 8.0711 -9.0535 0.0000 0
M  V30 65 C 8.0566 -9.8783 0.0000 0
M  V30 66 O 8.7154 -10.3749 0.0000 0
M  V30 67 C 7.2676 -10.1195 0.0000 0
M  V30 68 C 6.7945 -9.4436 0.0000 0
M  V30 69 C 6.5676 -6.4179 0.0000 0
M  V30 70 C 7.3714 -6.6035 0.0000 0
M  V30 71 C 7.9341 -6.0002 0.0000 0
M  V30 72 N 7.6930 -5.2112 0.0000 0
M  V30 73 O 8.7379 -6.1859 0.0000 0
M  V30 74 O 4.6383 -7.4389 0.0000 0
M  V30 75 C 3.5934 -6.4643 0.0000 0
M  V30 76 C 2.7895 -6.2787 0.0000 0
M  V30 77 O 2.2268 -6.8820 0.0000 0
M  V30 78 O 2.5484 -5.4897 0.0000 0
M  V30 79 O 4.4776 -4.4687 0.0000 0
M  V30 80 O 1.5034 -4.5151 0.0000 0
M  V30 81 C 0.4584 -3.5405 0.0000 0 CFG=1
M  V30 82 C 0.6995 -4.3295 0.0000 0
M  V30 83 O -0.3455 -3.3549 0.0000 0
M  V30 84 O 1.3426 -1.5449 0.0000 0
M  V30 85 O -1.6316 -1.5913 0.0000 0
M  V30 86 C -3.1589 0.9613 0.0000 0
M  V30 87 C -3.4812 1.7207 0.0000 0
M  V30 88 C -4.3031 1.6489 0.0000 0
M  V30 89 N -4.4887 0.8450 0.0000 0
M  V30 90 C -3.7816 0.4201 0.0000 0
M  V30 91 C -4.7762 2.3247 0.0000 0
M  V30 92 C -4.4275 3.0724 0.0000 0
M  V30 93 C -3.6057 3.1442 0.0000 0
M  V30 94 C -3.1325 2.4684 0.0000 0
M  V30 95 H -0.2237 -4.2718 0.0000 0
M  V30 96 H 1.3134 -3.8935 0.0000 0
M  V30 97 H 2.1879 -4.8287 0.0000 0
M  V30 98 H 4.4485 -6.8173 0.0000 0
M  V30 99 H 5.3228 -7.7525 0.0000 0
M  V30 100 H 6.3062 -8.6110 0.0000 0
M  V30 101 H -1.8217 -0.9697 0.0000 0
M  V30 102 H -3.2904 -1.0526 0.0000 0
M  V30 103 H -4.0529 -3.9654 0.0000 0
M  V30 104 H -4.2550 -5.2295 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=3
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 8 7 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10 CFG=1
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 13 18
M  V30 19 1 11 19
M  V30 20 1 19 20
M  V30 21 2 19 21
M  V30 22 2 9 22
M  V30 23 1 8 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 2 24 26
M  V30 27 2 6 27
M  V30 28 1 5 28
M  V30 29 1 28 29
M  V30 30 1 29 30
M  V30 31 1 30 31
M  V30 32 2 3 32
M  V30 33 1 2 33 CFG=3
M  V30 34 1 33 34
M  V30 35 1 34 35
M  V30 36 1 35 36
M  V30 37 1 36 37
M  V30 38 1 38 37
M  V30 39 1 38 39 CFG=1
M  V30 40 1 39 40
M  V30 41 1 41 40
M  V30 42 1 41 42
M  V30 43 1 42 43
M  V30 44 2 43 44
M  V30 45 1 44 45
M  V30 46 2 45 46
M  V30 47 1 46 47
M  V30 48 1 47 48
M  V30 49 2 48 49
M  V30 50 2 48 50
M  V30 51 1 48 51
M  V30 52 1 46 52
M  V30 53 2 52 53
M  V30 54 1 43 53
M  V30 55 1 41 54 CFG=3
M  V30 56 1 54 55
M  V30 57 1 56 55
M  V30 58 1 56 57 CFG=1
M  V30 59 1 57 58
M  V30 60 1 59 58
M  V30 61 1 59 60 CFG=3
M  V30 62 1 60 61
M  V30 63 2 61 62
M  V30 64 1 63 61 CFG=1
M  V30 65 1 63 64
M  V30 66 1 64 65
M  V30 67 2 65 66
M  V30 68 1 65 67
M  V30 69 1 67 68
M  V30 70 1 63 68
M  V30 71 1 59 69
M  V30 72 1 69 70
M  V30 73 1 70 71
M  V30 74 1 71 72
M  V30 75 2 71 73
M  V30 76 2 58 74
M  V30 77 1 56 75
M  V30 78 1 75 76
M  V30 79 1 76 77
M  V30 80 2 76 78
M  V30 81 2 55 79
M  V30 82 2 40 80
M  V30 83 1 38 81
M  V30 84 1 81 82
M  V30 85 1 81 83 CFG=1
M  V30 86 2 37 84
M  V30 87 2 34 85
M  V30 88 1 1 86
M  V30 89 1 86 87
M  V30 90 1 87 88
M  V30 91 1 88 89
M  V30 92 1 89 90
M  V30 93 2 86 90
M  V30 94 2 88 91
M  V30 95 1 91 92
M  V30 96 2 92 93
M  V30 97 1 93 94
M  V30 98 2 87 94
M  V30 99 1 95 81
M  V30 100 1 96 38
M  V30 101 1 97 41
M  V30 102 1 98 56
M  V30 103 1 99 59
M  V30 104 1 100 63
M  V30 105 1 101 2
M  V30 106 1 102 5
M  V30 107 1 103 8
M  V30 108 1 104 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
234

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ceruletide

>  <Synonyms>
Cerulein;FI-6934;Caerulein

>  <CAS>
17650-98-5

>  <Formula>
C58H73N13O21S2

>  <MolWt>
1352

>  <Pathways>
GPCR/G Protein

>  <Target>
cholecystokinin

>  <Receptor>
Cholecystokinin

>  <Bioactivity>
Ceruletide is a potent agonist of cholecystokinin receptor and it also is a safe and effective cholecystokinetic agent. It has a direct spasmogenic effect on the gallbladder muscle and bile ducts.

>  <Reference>
"Steinle AU, et al. NF-kappaB/Rel activation in cerulein pancreatitis. Gastroenterology. 1999 Feb;116(2):420-30.;Bridger N, et al. Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8.;Vincent ME, et al. Pharmacology, clinical uses, and adverse effects of ceruletide, a cholecystokinetic agent. Pharmacotherapy. 1982 Jul-Aug;2(4):223-34.;Zarrindast MR, et al. Effects of cholecystokinin receptor agonist and antagonists on morphin dependence in mice. Pharmacol Toxicol. 1995 Dec;77(6):360-4."

>  <ID<1>>
T14932

$$$$
StarDrop ID 235
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.3106 -5.3625 0.0000 0
M  V30 2 O 1.5961 -4.9500 0.0000 0
M  V30 3 C 0.8816 -5.3625 0.0000 0
M  V30 4 C 0.8816 -6.1875 0.0000 0
M  V30 5 C 0.1672 -6.6000 0.0000 0
M  V30 6 C -0.5473 -6.1875 0.0000 0
M  V30 7 N -1.2618 -6.6000 0.0000 0
M  V30 8 C -1.9763 -6.1875 0.0000 0
M  V30 9 C -1.9763 -5.3625 0.0000 0
M  V30 10 C -1.2618 -4.9500 0.0000 0
M  V30 11 C -1.2618 -4.1250 0.0000 0 CFG=1
M  V30 12 O -1.9763 -3.7125 0.0000 0
M  V30 13 C -0.5473 -3.7125 0.0000 0 CFG=2
M  V30 14 C -0.5473 -2.8875 0.0000 0
M  V30 15 C 0.1672 -2.4750 0.0000 0 CFG=2
M  V30 16 C 0.3047 -3.0250 0.0000 0
M  V30 17 C 0.3047 -3.5750 0.0000 0
M  V30 18 N 0.1672 -4.1250 0.0000 0
M  V30 19 C 0.8816 -3.7125 0.0000 0
M  V30 20 C 0.8816 -2.8875 0.0000 0 CFG=2
M  V30 21 C 1.5961 -2.4750 0.0000 0
M  V30 22 C 1.5961 -1.6500 0.0000 0
M  V30 23 C -0.5473 -5.3625 0.0000 0
M  V30 24 C 0.1672 -4.9500 0.0000 0
M  V30 25 H -2.1278 -4.6250 0.0000 0
M  V30 26 H 0.3187 -3.2125 0.0000 0
M  V30 27 H 0.8817 -2.0625 0.0000 0
M  V30 28 H 0.8817 -1.8875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=1
M  V30 12 1 11 13
M  V30 13 1 13 14 CFG=3
M  V30 14 1 15 14 CFG=1
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 13 18
M  V30 19 1 18 19
M  V30 20 1 20 19
M  V30 21 1 15 20
M  V30 22 1 20 21 CFG=1
M  V30 23 2 21 22
M  V30 24 1 10 23
M  V30 25 1 6 23
M  V30 26 2 23 24
M  V30 27 1 3 24
M  V30 28 1 25 11
M  V30 29 1 26 13
M  V30 30 1 27 15
M  V30 31 1 28 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
235

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Quinine dihydrochloride

>  <Synonyms>
Quinine bimuriate

>  <CAS>
60-93-5

>  <Formula>
C20H26Cl2N2O2

>  <MolWt>
397.3

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Quinine Dihydrochloride is a primary alkaloid of various species of Cinchona (Rubiaceae). It is also an antimalarial and muscle relaxant (skeletal).

>  <Reference>
"Kharal SA,etal.Quinine is bactericidal.J Pak Med Assoc. 2009 Apr;59(4):208-12.;Achan J,etal.Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria.Malar J. 2011; 10: 144."

>  <ID<1>>
T4333

$$$$
StarDrop ID 236
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 39 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -2.0572 -6.6762 0.0000 0
M  V30 2 C -2.0572 -5.8512 0.0000 0
M  V30 3 O -2.7717 -5.4387 0.0000 0
M  V30 4 C -3.4862 -5.8512 0.0000 0
M  V30 5 C -3.7683 -5.0760 0.0000 0
M  V30 6 C -4.5808 -4.9327 0.0000 0
M  V30 7 C -4.8630 -4.1575 0.0000 0
M  V30 8 C -4.3327 -3.5255 0.0000 0
M  V30 9 Cl -4.6148 -2.7502 0.0000 0
M  V30 10 C -3.5202 -3.6687 0.0000 0
M  V30 11 C -3.2380 -4.4440 0.0000 0
M  V30 12 C -2.9559 -6.4832 0.0000 0
M  V30 13 C -3.2380 -7.2585 0.0000 0
M  V30 14 N -4.0505 -7.4017 0.0000 0
M  V30 15 C -4.3327 -8.1770 0.0000 0
M  V30 16 C -5.1451 -8.3202 0.0000 0
M  V30 17 C -5.4273 -9.0955 0.0000 0
M  V30 18 C -6.2398 -9.2387 0.0000 0
M  V30 19 O -6.7701 -8.6067 0.0000 0
M  V30 20 C -6.5219 -10.0140 0.0000 0
M  V30 21 C -5.9916 -10.6460 0.0000 0
M  V30 22 C -6.2738 -11.4212 0.0000 0
M  V30 23 C -7.0863 -11.5645 0.0000 0
M  V30 24 F -7.3684 -12.3397 0.0000 0
M  V30 25 C -7.6166 -10.9325 0.0000 0
M  V30 26 C -7.3344 -10.1572 0.0000 0
M  V30 27 C -4.5808 -6.7697 0.0000 0
M  V30 28 C -4.2986 -5.9945 0.0000 0
M  V30 29 C -1.3428 -5.4387 0.0000 0
M  V30 30 C -0.6283 -5.8512 0.0000 0
M  V30 31 C 0.0862 -5.4387 0.0000 0
M  V30 32 C 0.8006 -5.8512 0.0000 0
M  V30 33 C 1.5151 -5.4387 0.0000 0
M  V30 34 C 2.2296 -5.8512 0.0000 0
M  V30 35 C 2.9441 -5.4387 0.0000 0
M  V30 36 C 3.6585 -5.8512 0.0000 0
M  V30 37 C 4.3730 -5.4387 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 10 11
M  V30 11 1 5 11
M  V30 12 1 4 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 1 23 25
M  V30 26 2 25 26
M  V30 27 1 20 26
M  V30 28 1 14 27
M  V30 29 1 27 28
M  V30 30 1 4 28
M  V30 31 1 2 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 1 32 33
M  V30 36 1 33 34
M  V30 37 1 34 35
M  V30 38 1 35 36
M  V30 39 1 36 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
236

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Haloperidol decanoate

>  <Synonyms>
KD 136;KD-136;Neoperidole;Haldol;KD 16

>  <CAS>
74050-97-8

>  <Formula>
C31H41ClFNO3

>  <MolWt>
530.1

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Haloperidol decanoate is a typical antipsychotic agent utilized as maintenance treatment for schizophrenia and mood disorders formulated as an ester for intramuscular injection.

>  <Reference>
"Emsley R, Parellada E, Bioque M, Herrera B, Hernando T, Garc??a-Dorado M. Real-world data on paliperidone palmitate for the treatment of schizophrenia and other psychotic disorders: a systematic review of randomized and nonrandomized studies. Int Clin Psychopharmacol. 2018 Jan;33(1):15-33. doi: 10.1097/YIC.0000000000000195. PubMed PMID: 28817397.;Geerts H, Spiros A, Roberts P, Alphs L. A quantitative systems pharmacology study on optimal scenarios for switching to paliperidone palmitate once-monthly. Schizophr Res. 2018 Jan 25. pii: S0920-9964(17)30711-9. doi: 10.1016/j.schres.2017.11.016. [Epub ahead of print] PubMed PMID: 29395607.;Dekkers BGJ, Eck RJ, Ter Maaten JC, Touw DJ. An acute oral intoxication with haloperidol decanoate. Am J Emerg Med. 2017 Sep;35(9):1387.e1-1387.e2. doi: 10.1016/j.ajem.2017.07.013. Epub 2017 Jul 5. PubMed PMID: 28705742.;Jann MW, Penzak SR. Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents. CNS Drugs. 2018 Mar;32(3):241-257. doi: 10.1007/s40263-018-0508-6. Review. Erratum in: CNS Drugs. 2018 Jun 2;:. PubMed PMID: 29569082."

>  <ID<1>>
T25487

$$$$
StarDrop ID 237
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 0.6794 0.0000 0
M  V30 2 C 3.0716 0.2669 0.0000 0
M  V30 3 C 3.0716 -0.5581 0.0000 0
M  V30 4 N 3.7861 0.6794 0.0000 0
M  V30 5 C 4.5006 0.2669 0.0000 0
M  V30 6 N 4.5006 -0.5581 0.0000 0
M  V30 7 N 5.2150 0.6794 0.0000 0
M  V30 8 C 5.9295 0.2669 0.0000 0
M  V30 9 N 5.9295 -0.5581 0.0000 0
M  V30 10 N 6.6440 0.6794 0.0000 0
M  V30 11 C 7.3584 0.2669 0.0000 0
M  V30 12 C 8.0729 0.6794 0.0000 0
M  V30 13 C 8.7874 0.2669 0.0000 0
M  V30 14 C 8.7874 -0.5581 0.0000 0
M  V30 15 Cl 9.5019 -0.9706 0.0000 0
M  V30 16 C 8.0729 -0.9706 0.0000 0
M  V30 17 C 7.3584 -0.5581 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 2 16 17
M  V30 17 1 11 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
237

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Proguanil hydrochloride

>  <Synonyms>
Chlorguanide hydrochloride;Paludrine hydrochloride;Chloroquanil

>  <CAS>
637-32-1

>  <Formula>
C11H17Cl2N5

>  <MolWt>
290.2

>  <Pathways>
DNA Damage/DNA Repair;Microbiology/Virology;Metabolism;Others;Cell Cycle/Checkpoint

>  <Target>
Others;Antifolate;Parasite;Dehydrogenase;DNA/RNA Synthesis

>  <Receptor>
Antifolate; dihydrofolate reductase; NADH dehydrogenase; Parasite; thymidylate synthase

>  <Bioactivity>
"Proguanil Hydrochloride is a biguanide compound which metabolizes in the body to form cycloguanil, an anti-malaria agent.Upon hydrolysis, proguanil is converted to its active cyclic triazine metabolite, cycloguanil, by a cytochrome P450 dependent reaction. Cycloguanil selectively inhibits the bifunctional dihydrofolate reductase-thymidylate synthase of plasmodium parasite, thereby disrupting deoxythymidylate synthesis and ultimately blocking DNA and protein synthesis in the parasite."

>  <Reference>
"Gerlinde F. Pl?ger, etal. Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride[J]. Journal of Pharmaceutical Sciences, 2018, 163(4):1-21."

>  <ID<1>>
T4382

$$$$
StarDrop ID 238
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 40 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -6.6000 0.2211 0.0000 0
M  V30 2 C -5.8855 -0.1914 0.0000 0
M  V30 3 O -5.1711 0.2211 0.0000 0
M  V30 4 C -5.8855 -1.0164 0.0000 0
M  V30 5 C -5.8855 -1.8414 0.0000 0
M  V30 6 C -5.1711 -2.2539 0.0000 0
M  V30 7 C -5.1711 -3.0789 0.0000 0
M  V30 8 C -5.8855 -3.4914 0.0000 0
M  V30 9 C -6.6000 -3.0789 0.0000 0
M  V30 10 C -6.6000 -2.2539 0.0000 0
M  V30 11 C -5.8855 -4.3164 0.0000 0
M  V30 12 O -6.6000 -4.7289 0.0000 0
M  V30 13 C -5.1711 -4.7289 0.0000 0
M  V30 14 C -5.1711 -5.5539 0.0000 0
M  V30 15 C -4.4566 -5.9664 0.0000 0
M  V30 16 N -4.4566 -6.7914 0.0000 0
M  V30 17 C -3.7421 -7.2039 0.0000 0
M  V30 18 C -3.7421 -8.0289 0.0000 0
M  V30 19 C -4.4566 -8.4414 0.0000 0
M  V30 20 C -5.1711 -8.0289 0.0000 0
M  V30 21 C -5.1711 -7.2039 0.0000 0
M  V30 22 C -4.4566 -9.2664 0.0000 0
M  V30 23 O -5.2816 -9.2664 0.0000 0
M  V30 24 C -4.4566 -10.0914 0.0000 0
M  V30 25 C -3.7421 -10.5039 0.0000 0
M  V30 26 C -3.7421 -11.3289 0.0000 0
M  V30 27 C -4.4566 -11.7414 0.0000 0
M  V30 28 C -5.1711 -11.3289 0.0000 0
M  V30 29 C -5.1711 -10.5039 0.0000 0
M  V30 30 C -3.6316 -9.2664 0.0000 0
M  V30 31 C -3.2191 -8.5520 0.0000 0
M  V30 32 C -2.3941 -8.5520 0.0000 0
M  V30 33 C -1.9816 -9.2664 0.0000 0
M  V30 34 C -2.3941 -9.9809 0.0000 0
M  V30 35 C -3.2191 -9.9809 0.0000 0
M  V30 36 C -6.7105 -1.0164 0.0000 0
M  V30 37 C -5.0605 -1.0164 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 5 10
M  V30 11 1 8 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 16 21
M  V30 23 1 19 22
M  V30 24 1 22 23
M  V30 25 1 22 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 2 24 29
M  V30 32 1 22 30
M  V30 33 1 30 31
M  V30 34 2 31 32
M  V30 35 1 32 33
M  V30 36 2 33 34
M  V30 37 1 34 35
M  V30 38 2 30 35
M  V30 39 1 4 36
M  V30 40 1 4 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
238

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fexofenadine

>  <Synonyms>
Carboxyterfenadine;Allegra;Telfast;MDL 16.455

>  <CAS>
83799-24-0

>  <Formula>
C32H39NO4

>  <MolWt>
501.7

>  <Pathways>
Neuroscience;GPCR/G Protein;Immunology/Inflammation

>  <Target>
Histamine Receptor

>  <Receptor>
Histamine Receptor

>  <Bioactivity>
"Fexofenadine, an antihistamine pharmaceutical drug, is used to treat allergy symptoms, such as nasal congestion, hay fever, and urticaria. Compared to first-generation antihistamines, Fexofenadine is less able to pass the blood-brain barrier and cause sedation."

>  <Reference>
"Miura M, Uno T. Clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):69-74.;Compalati E, Baena-Cagnani R, Penagos M, Badellino H, Braido F, G??mez RM, Canonica GW, Baena-Cagnani CE. Systematic review on the efficacy of fexofenadine in seasonal allergic rhinitis: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. Int Arch Allergy Immunol. 2011;156(1):1-15. Review.;Miura M, Uno T. Clinical pharmacokinetics of fexofenadine enantiomers. Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):69-74. doi: 10.1517/17425250903382615. Review. PubMed PMID: 19947891.;Smith SM, Gums JG. Fexofenadine: biochemical, pharmacokinetic and pharmacodynamic properties and its unique role in allergic disorders. Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):813-22."

>  <ID<1>>
T21390

$$$$
StarDrop ID 239
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.8950 0.5887 0.0000 0
M  V30 2 O -1.0982 0.8022 0.0000 0
M  V30 3 N -0.8846 1.5991 0.0000 0
M  V30 4 C -0.0877 1.8126 0.0000 0
M  V30 5 C 0.4956 1.2293 0.0000 0
M  V30 6 O 1.2925 1.4428 0.0000 0
M  V30 7 N 0.2821 0.4324 0.0000 0
M  V30 8 C 0.8655 -0.1510 0.0000 0 CFG=1
M  V30 9 C 1.6905 -0.1510 0.0000 0 CFG=1
M  V30 10 S 2.4049 0.2615 0.0000 0
M  V30 11 C 3.1194 -0.1510 0.0000 0
M  V30 12 C 3.1194 -0.9760 0.0000 0
M  V30 13 C 2.4049 -1.3885 0.0000 0
M  V30 14 N 1.6905 -0.9760 0.0000 0
M  V30 15 C 0.8655 -0.9760 0.0000 0
M  V30 16 O 0.2821 -1.5593 0.0000 0
M  V30 17 C 2.4049 -2.2135 0.0000 0
M  V30 18 O 3.1194 -2.6260 0.0000 0
M  V30 19 O 1.6905 -2.6260 0.0000 0
M  V30 20 C 0.1258 2.6095 0.0000 0
M  V30 21 C -0.3934 3.2507 0.0000 0
M  V30 22 S 0.0559 3.9426 0.0000 0
M  V30 23 C 0.8528 3.7290 0.0000 0
M  V30 24 N 1.4940 4.2482 0.0000 0
M  V30 25 N 0.8960 2.9052 0.0000 0
M  V30 26 H 1.2481 0.7729 0.0000 0
M  V30 27 H 0.9834 -0.8581 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 8 7 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 9 14 CFG=1
M  V30 15 1 14 15
M  V30 16 1 8 15
M  V30 17 2 15 16
M  V30 18 1 13 17
M  V30 19 1 17 18
M  V30 20 2 17 19
M  V30 21 1 4 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 2 23 25
M  V30 27 1 20 25
M  V30 28 1 26 8
M  V30 29 1 27 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
239

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ceftizoxime

>  <Synonyms>
Epocelin

>  <CAS>
68401-81-0

>  <Formula>
C13H13N5O5S2

>  <MolWt>
383.4

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibacterial; Antibiotic; Bacterial

>  <Bioactivity>
"Ceftizoxime is a cephalosporin-based, potent antibacterial agent which can be administered intravenously or by suppository. It is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms."

>  <Reference>
"Zhang J, et al. Toxic effects of cephalosporins with specific functional groups as indicated by zebrafish embryo toxicity testing[J]. Chemical Research in Toxicology, 2013, 26(8):1168-1181.;Ekinci D, et al. Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach[J]. Journal of Enzyme Inhibition & Medicinal Chemistry, 2013, 28(4):824-829."

>  <ID<1>>
T4501

$$$$
StarDrop ID 240
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 68 71 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.0200 -0.7693 0.0000 0
M  V30 2 C 1.3556 -1.5229 0.0000 0 CFG=2
M  V30 3 C 2.0701 -1.1104 0.0000 0
M  V30 4 O 2.0701 -0.2854 0.0000 0
M  V30 5 C 2.7845 0.1271 0.0000 0
M  V30 6 C 3.4990 -0.2854 0.0000 0 CFG=1
M  V30 7 C 3.4990 -1.1104 0.0000 0
M  V30 8 C 4.2135 -1.5229 0.0000 0 CFG=2
M  V30 9 C 4.9279 -1.1104 0.0000 0
M  V30 10 C 4.2135 -2.3479 0.0000 0 CFG=1
M  V30 11 O 4.9279 -2.7604 0.0000 0
M  V30 12 C 5.6424 -2.3479 0.0000 0 CFG=2
M  V30 13 O 5.6424 -1.5229 0.0000 0
M  V30 14 C 6.3569 -1.1104 0.0000 0 CFG=2
M  V30 15 C 6.3569 -0.2854 0.0000 0
M  V30 16 C 7.0714 -1.5229 0.0000 0
M  V30 17 C 7.0714 -2.3479 0.0000 0 CFG=2
M  V30 18 N 7.7858 -2.7604 0.0000 0
M  V30 19 C 8.5003 -2.3479 0.0000 0
M  V30 20 C 7.7858 -3.5854 0.0000 0
M  V30 21 H 5.6424 -3.1729 0.0000 0
M  V30 22 C 6.3569 -2.7604 0.0000 0 CFG=1
M  V30 23 O 6.3569 -3.5854 0.0000 0
M  V30 24 O 4.2135 -0.6979 0.0000 0
M  V30 25 C 4.2135 0.1271 0.0000 0 CFG=2
M  V30 26 O 4.9279 0.5396 0.0000 0
M  V30 27 C 4.9279 1.3646 0.0000 0 CFG=1
M  V30 28 C 5.6424 1.7771 0.0000 0
M  V30 29 C 4.2135 1.7771 0.0000 0 CFG=2
M  V30 30 O 4.2135 2.6021 0.0000 0
M  V30 31 H 4.9279 -0.2854 0.0000 0
M  V30 32 C 3.4990 0.5396 0.0000 0
M  V30 33 C 3.4990 1.3646 0.0000 0 CFG=2
M  V30 34 C 2.6745 1.3933 0.0000 0
M  V30 35 O 3.0618 2.0642 0.0000 0
M  V30 36 C 2.2373 2.0354 0.0000 0
M  V30 37 C 3.8346 0.4682 0.0000 0
M  V30 38 O 2.7845 0.9521 0.0000 0
M  V30 39 C 1.3556 -0.6979 0.0000 0
M  V30 40 C 1.3556 0.1271 0.0000 0
M  V30 41 O 0.5710 -1.2680 0.0000 0
M  V30 42 C 1.3556 -2.3479 0.0000 0 CFG=1
M  V30 43 C 2.0701 -2.7604 0.0000 0 CFG=2
M  V30 44 C 2.0701 -3.5854 0.0000 0
M  V30 45 C 2.7845 -3.9979 0.0000 0 CFG=1
M  V30 46 C 3.4990 -3.5854 0.0000 0
M  V30 47 C 3.4990 -2.7604 0.0000 0 CFG=1
M  V30 48 O 4.0925 -3.3335 0.0000 0
M  V30 49 C 4.2920 -2.9878 0.0000 0
M  V30 50 C 2.7845 -4.8229 0.0000 0
M  V30 51 O 1.3556 -3.9979 0.0000 0
M  V30 52 C 2.7845 -2.3479 0.0000 0
M  V30 53 H 2.0701 -1.9354 0.0000 0
M  V30 54 O 0.5710 -2.6029 0.0000 0
M  V30 55 C 0.0860 -1.9354 0.0000 0
M  V30 56 O -0.7390 -1.9354 0.0000 0
M  V30 57 H 0.0000 0.0000 0.0000 0
M  V30 58 H 0.0000 0.0000 0.0000 0
M  V30 59 H 2.0700 -1.7604 0.0000 0
M  V30 60 H 1.9185 -4.4979 0.0000 0
M  V30 61 H 3.1900 0.6657 0.0000 0
M  V30 62 H 4.2134 -0.5229 0.0000 0
M  V30 63 H 4.2134 -3.3479 0.0000 0
M  V30 64 H 7.2229 -0.6104 0.0000 0
M  V30 65 H 7.0713 -3.3479 0.0000 0
M  V30 66 H 7.2229 -3.2604 0.0000 0
M  V30 67 H 4.9280 2.3646 0.0000 0
M  V30 68 H 5.0795 2.2771 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=1
M  V30 7 1 7 8
M  V30 8 1 8 9 CFG=3
M  V30 9 1 8 10
M  V30 10 1 10 11 CFG=1
M  V30 11 1 12 11
M  V30 12 1 12 13
M  V30 13 1 14 13
M  V30 14 1 14 15 CFG=3
M  V30 15 1 14 16
M  V30 16 1 17 16
M  V30 17 1 17 18 CFG=3
M  V30 18 1 18 19
M  V30 19 1 18 20
M  V30 20 1 12 21 CFG=1
M  V30 21 1 22 12
M  V30 22 1 22 17
M  V30 23 1 22 23 CFG=1
M  V30 24 1 24 7 CFG=3
M  V30 25 1 25 24
M  V30 26 1 25 26
M  V30 27 1 27 26
M  V30 28 1 27 28 CFG=3
M  V30 29 1 29 27
M  V30 30 1 29 30 CFG=1
M  V30 31 1 25 31 CFG=3
M  V30 32 1 25 32
M  V30 33 1 33 32
M  V30 34 1 29 33
M  V30 35 1 33 34 CFG=3
M  V30 36 1 33 35 CFG=1
M  V30 37 1 35 36
M  V30 38 1 6 37 CFG=3
M  V30 39 2 5 38
M  V30 40 1 39 3 CFG=3
M  V30 41 1 39 40
M  V30 42 1 2 41
M  V30 43 1 2 42
M  V30 44 1 42 43
M  V30 45 1 43 44
M  V30 46 1 45 44
M  V30 47 1 45 46
M  V30 48 1 47 46
M  V30 49 1 10 47
M  V30 50 1 47 48 CFG=3
M  V30 51 1 47 49 CFG=1
M  V30 52 1 45 50 CFG=1
M  V30 53 2 44 51
M  V30 54 1 43 52 CFG=1
M  V30 55 1 42 53 CFG=3
M  V30 56 1 42 54
M  V30 57 1 54 55
M  V30 58 1 41 55
M  V30 59 2 55 56
M  V30 60 1 57 39
M  V30 61 1 58 39
M  V30 62 1 59 43
M  V30 63 1 60 45
M  V30 64 1 61 6
M  V30 65 1 62 8
M  V30 66 1 63 10
M  V30 67 1 64 14
M  V30 68 1 65 17
M  V30 69 1 66 22
M  V30 70 1 67 27
M  V30 71 1 68 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
240

>  <Plate>
PHD136328

>  <Row>
l

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Davercin

>  <Synonyms>
Erythromycin Cyclocarbonate

>  <CAS>
55224-05-0

>  <Formula>
C38H65NO14

>  <MolWt>
759.9

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial;Antibiotic

>  <Receptor>
Antibacterial; Antibiotic; Bacterial

>  <Bioactivity>
"Erythromycin Cyclocarbonate, a derivative of Erythromycin, is active against Gram-positive and some Gram-negative microorganisms."

>  <Reference>
"Jelic D, et al. From Erythromycin to Azithromycin and New Potential Ribosome-Binding Antimicrobials. Antibiotics (Basel). 2016 Sep 1;5(3). pii: E29."

>  <ID<1>>
T6492

$$$$
StarDrop ID 241
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.7605 1.0164 0.0000 0
M  V30 2 Se 2.4750 1.4289 0.0000 0
M  V30 3 C 3.1895 1.8414 0.0000 0
M  V30 4 C 3.9039 1.4289 0.0000 0
M  V30 5 C 4.6184 1.8414 0.0000 0
M  V30 6 N 4.6184 2.6664 0.0000 0
M  V30 7 C 5.3329 1.4289 0.0000 0
M  V30 8 O 6.0474 1.8414 0.0000 0
M  V30 9 O 5.3329 0.6039 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
241

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Selenomethionine

>  <Synonyms>
Seleno-DL-methionine;DL-Selenomethionine

>  <CAS>
1464-42-2

>  <Formula>
C5H11NO2Se

>  <MolWt>
196.1

>  <Pathways>
Metabolism;Autophagy

>  <Target>
Amino Acids and Derivatives;Autophagy;Endogenous Metabolite

>  <Receptor>
Amino Acids and Derivatives; Autophagy; Endogenous Metabolite

>  <Bioactivity>
"DL-Selenomethionine is a selenium (Se) analogue of methionine in which sulfur is replaced with the trace element selenium. Selenomethionine (SeMet) can incorporate into proteins in place of methionine with no effects on protein structure and function, providing a mechanism for reversible Se storage in organs and tissues."

>  <Reference>
"Cao J, et al. J Anim Sci Biotechnol. 2014 Oct 2;5(1):46."

>  <ID<1>>
T1658

$$$$
StarDrop ID 242
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.7071 1.9603 0.0000 0
M  V30 2 C 5.4216 1.5478 0.0000 0
M  V30 3 C 5.4216 0.7228 0.0000 0
M  V30 4 N 6.0890 0.2379 0.0000 0
M  V30 5 N 5.8341 -0.5467 0.0000 0
M  V30 6 C 6.3190 -1.2142 0.0000 0
M  V30 7 C 7.1395 -1.1279 0.0000 0
M  V30 8 C 7.6244 -1.7954 0.0000 0
M  V30 9 N 8.4449 -1.7091 0.0000 0
M  V30 10 C 8.7805 -0.9554 0.0000 0
M  V30 11 C 9.6009 -0.8692 0.0000 0
M  V30 12 N 10.0859 -1.5366 0.0000 0
M  V30 13 C 9.7503 -2.2903 0.0000 0
M  V30 14 C 8.9298 -2.3766 0.0000 0
M  V30 15 C 10.9063 -1.4504 0.0000 0
M  V30 16 C 11.2419 -0.6967 0.0000 0
M  V30 17 C 12.0624 -0.6105 0.0000 0
M  V30 18 C 12.5473 -1.2779 0.0000 0
M  V30 19 C 12.2118 -2.0316 0.0000 0
M  V30 20 Cl 12.6967 -2.6991 0.0000 0
M  V30 21 C 11.3913 -2.1179 0.0000 0
M  V30 22 C 5.0091 -0.5467 0.0000 0
M  V30 23 O 4.5242 -1.2142 0.0000 0
M  V30 24 N 4.7542 0.2379 0.0000 0
M  V30 25 C 3.9695 0.4928 0.0000 0
M  V30 26 C 3.7980 1.2998 0.0000 0
M  V30 27 O 3.0134 1.5548 0.0000 0
M  V30 28 C 2.8419 2.3617 0.0000 0
M  V30 29 C 2.0572 2.6167 0.0000 0
M  V30 30 C 1.8857 3.4236 0.0000 0
M  V30 31 C 2.4988 3.9757 0.0000 0
M  V30 32 C 3.2834 3.7207 0.0000 0
M  V30 33 C 3.4550 2.9138 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 9 14
M  V30 15 1 12 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 19 21
M  V30 22 1 15 21
M  V30 23 1 5 22
M  V30 24 2 22 23
M  V30 25 1 22 24
M  V30 26 1 3 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 1 31 32
M  V30 35 2 32 33
M  V30 36 1 28 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
242

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Nefazodone hydrochloride

>  <Synonyms>
MJ-13754-1;Serzone;Dutonin;BMY-13754;BMY-13754-1

>  <CAS>
82752-99-6

>  <Formula>
C25H33Cl2N5O2

>  <MolWt>
506.5

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor;5-HT Receptor

>  <Receptor>
 5-HT 2A Receptor:5.8 nM (Ki)

>  <Bioactivity>
"Nefazodone is a serotoninergic modulating antidepressant that is used in therapy of depression, aggressive behavior and panic disorder."

>  <Reference>
"Bengi Uslu, et al. Analytica Chimica Acta Volume 462, Issue 1, 26 June 2002, Pages 49?C57"

>  <ID<1>>
T3275

$$$$
StarDrop ID 243
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 58 63 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.9627 -7.3998 0.0000 0
M  V30 2 O 4.2483 -7.8123 0.0000 0
M  V30 3 C 4.2483 -8.6373 0.0000 0
M  V30 4 O 4.9627 -9.0498 0.0000 0
M  V30 5 N 3.5338 -9.0498 0.0000 0
M  V30 6 C 3.5338 -9.8748 0.0000 0 CFG=1
M  V30 7 C 4.2483 -10.2873 0.0000 0
M  V30 8 C 4.2483 -11.1123 0.0000 0
M  V30 9 C 4.9627 -9.8748 0.0000 0
M  V30 10 C 2.8193 -10.2873 0.0000 0
M  V30 11 O 2.1049 -9.8748 0.0000 0
M  V30 12 N 2.8193 -11.1123 0.0000 0
M  V30 13 C 3.4868 -11.5972 0.0000 0
M  V30 14 C 3.2318 -12.3818 0.0000 0
M  V30 15 C 2.4068 -12.3818 0.0000 0
M  V30 16 C 2.1519 -11.5972 0.0000 0 CFG=1
M  V30 17 C 1.3673 -11.3423 0.0000 0
M  V30 18 N 0.6998 -11.8272 0.0000 0
M  V30 19 C 0.0324 -11.3423 0.0000 0
M  V30 20 C 0.2873 -10.5576 0.0000 0
M  V30 21 N 1.1123 -10.5576 0.0000 0
M  V30 22 C -0.1976 -9.8902 0.0000 0
M  V30 23 C -1.0181 -9.9764 0.0000 0
M  V30 24 C -1.5030 -9.3090 0.0000 0
M  V30 25 C -1.1674 -8.5553 0.0000 0
M  V30 26 C -0.3470 -8.4691 0.0000 0
M  V30 27 C 0.1380 -9.1365 0.0000 0
M  V30 28 C -1.6524 -7.8879 0.0000 0
M  V30 29 C -2.4728 -7.9741 0.0000 0
M  V30 30 C -2.9578 -7.3067 0.0000 0
M  V30 31 C -2.6222 -6.5530 0.0000 0
M  V30 32 C -1.8017 -6.4668 0.0000 0
M  V30 33 C -1.3168 -7.1342 0.0000 0
M  V30 34 C -3.1071 -5.8856 0.0000 0
M  V30 35 C -3.9321 -5.8856 0.0000 0
M  V30 36 N -4.1871 -5.1009 0.0000 0
M  V30 37 C -3.5196 -4.6160 0.0000 0
M  V30 38 N -2.8522 -5.1009 0.0000 0
M  V30 39 C -3.5196 -3.7910 0.0000 0 CFG=2
M  V30 40 C -4.1871 -3.3061 0.0000 0
M  V30 41 C -3.9321 -2.5215 0.0000 0
M  V30 42 C -3.1071 -2.5215 0.0000 0
M  V30 43 N -2.8522 -3.3061 0.0000 0
M  V30 44 C -2.0676 -3.5610 0.0000 0
M  V30 45 O -1.8960 -4.3680 0.0000 0
M  V30 46 C -1.4545 -3.0090 0.0000 0 CFG=1
M  V30 47 N -0.6699 -3.2639 0.0000 0
M  V30 48 C -0.0568 -2.7119 0.0000 0
M  V30 49 O -0.2283 -1.9049 0.0000 0
M  V30 50 O 0.7279 -2.9668 0.0000 0
M  V30 51 C 1.3410 -2.4148 0.0000 0
M  V30 52 C -1.6260 -2.2020 0.0000 0
M  V30 53 C -2.4106 -1.9471 0.0000 0
M  V30 54 C -1.0129 -1.6500 0.0000 0
M  V30 55 H -2.6286 -4.2450 0.0000 0
M  V30 56 H -0.7114 -2.3398 0.0000 0
M  V30 57 H 2.6678 -9.3748 0.0000 0
M  V30 58 H 1.4448 -12.3043 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 6 5 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 6 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 16 15
M  V30 16 1 16 12
M  V30 17 1 16 17 CFG=1
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 2 17 21
M  V30 23 1 20 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 22 27
M  V30 30 1 25 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 1 31 32
M  V30 35 2 32 33
M  V30 36 1 28 33
M  V30 37 1 31 34
M  V30 38 1 34 35
M  V30 39 1 35 36
M  V30 40 2 36 37
M  V30 41 1 37 38
M  V30 42 2 34 38
M  V30 43 1 39 37 CFG=3
M  V30 44 1 39 40
M  V30 45 1 40 41
M  V30 46 1 41 42
M  V30 47 1 42 43
M  V30 48 1 39 43
M  V30 49 1 43 44
M  V30 50 2 44 45
M  V30 51 1 46 44
M  V30 52 1 46 47 CFG=3
M  V30 53 1 47 48
M  V30 54 2 48 49
M  V30 55 1 48 50
M  V30 56 1 50 51
M  V30 57 1 46 52
M  V30 58 1 52 53
M  V30 59 1 52 54
M  V30 60 1 55 39
M  V30 61 1 56 46
M  V30 62 1 57 6
M  V30 63 1 58 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
243

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Daclatasvir dihydrochloride

>  <Synonyms>
BMS-790052 dihydrochloride

>  <CAS>
1009119-65-6

>  <Formula>
C40H52Cl2N8O6

>  <MolWt>
811.8

>  <Pathways>
Proteases/Proteasome;Microbiology/Virology

>  <Target>
HCV Protease

>  <Receptor>
" NS5A33-202:8 nM (Kd), OATP1B3:3.27 ??M (IC50), HCV replicon genotype 2a:71 pM (EC50), HCV replicon genotype 1a:50 pM (EC50), HCV replicon genotype 5a:33 pM (EC50), HCV replicon genotype 4a:12 pM (EC50), NS5A26-202:210 nM (Kd), HCV replicon genotype 1b:9?pM (EC50), HCV replicon genotype 3a:146 pM (EC50), OATP1B:1.5 ??M (IC50)"

>  <Bioactivity>
"Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and is used in combination with other oral antiviral agents to treat chronic hepatitis C. Elevations in serum enzyme levels during daclatasvir therapy are uncommon, and it has yet to be convincingly implicated in cases of clinically apparent liver injury with jaundice."

>  <Reference>
Fridell RA et al. Antimicrob Agents ChemOthers. 2010 Sep;54(9):3641-50.

>  <ID<1>>
T1786

$$$$
StarDrop ID 244
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 42 45 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.5555 -0.1415 0.0000 0
M  V30 2 C 5.2700 0.2710 0.0000 0
M  V30 3 O 5.9845 -0.1415 0.0000 0
M  V30 4 C 6.6989 0.2710 0.0000 0
M  V30 5 O 6.6989 1.0960 0.0000 0
M  V30 6 C 7.4134 -0.1415 0.0000 0 CFG=1
M  V30 7 N 7.4134 -0.9665 0.0000 0
M  V30 8 C 8.1279 0.2710 0.0000 0
M  V30 9 C 8.8423 -0.1415 0.0000 0
M  V30 10 C 9.5568 0.2710 0.0000 0
M  V30 11 C 10.2713 -0.1415 0.0000 0
M  V30 12 C 10.2713 -0.9665 0.0000 0
M  V30 13 C 9.5568 -1.3790 0.0000 0
M  V30 14 C 8.8423 -0.9665 0.0000 0
M  V30 15 C 10.9858 -1.3790 0.0000 0
M  V30 16 C 11.7002 -0.9665 0.0000 0
M  V30 17 C 12.4147 -1.3790 0.0000 0
M  V30 18 O 13.1292 -0.9665 0.0000 0
M  V30 19 C 13.1292 -0.1415 0.0000 0 CFG=2
M  V30 20 C 12.4147 0.2710 0.0000 0
M  V30 21 C 11.7002 -0.1415 0.0000 0
M  V30 22 C 10.9858 0.2710 0.0000 0
M  V30 23 C 10.9858 1.0960 0.0000 0
M  V30 24 Cl 10.2713 1.5085 0.0000 0
M  V30 25 C 11.7002 1.5085 0.0000 0
M  V30 26 C 12.4147 1.0960 0.0000 0
M  V30 27 N 13.1292 1.5085 0.0000 0
M  V30 28 C 13.2154 2.3290 0.0000 0
M  V30 29 C 14.0224 2.5006 0.0000 0
M  V30 30 C 14.4349 1.7861 0.0000 0
M  V30 31 C 15.2554 1.6998 0.0000 0
M  V30 32 N 13.8828 1.1730 0.0000 0
M  V30 33 C 13.8436 0.2710 0.0000 0
M  V30 34 F 14.5581 0.6835 0.0000 0
M  V30 35 F 13.4311 0.9855 0.0000 0
M  V30 36 F 14.2561 -0.4434 0.0000 0
M  V30 37 N 12.4147 -2.2040 0.0000 0
M  V30 38 C 11.7002 -2.6165 0.0000 0
M  V30 39 N 11.7002 -3.4415 0.0000 0
M  V30 40 N 10.9858 -2.2040 0.0000 0
M  V30 41 H 6.5474 -0.6415 0.0000 0
M  V30 42 H 13.9952 -0.6415 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 6 4
M  V30 6 1 6 7 CFG=3
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 9 14
M  V30 15 1 12 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 19 18 CFG=3
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 1 23 25
M  V30 26 2 25 26
M  V30 27 1 20 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 1 30 31
M  V30 33 2 30 32
M  V30 34 1 27 32
M  V30 35 1 19 33
M  V30 36 1 33 34
M  V30 37 1 33 35
M  V30 38 1 33 36
M  V30 39 2 17 37
M  V30 40 1 37 38
M  V30 41 1 38 39
M  V30 42 2 38 40
M  V30 43 1 15 40
M  V30 44 1 41 6
M  V30 45 1 42 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
244

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Telotristat Etiprate

>  <Synonyms>
LX1606 (Hippurate);LX 1606 Hippurate

>  <CAS>
1137608-69-5

>  <Formula>
C36H35ClF3N7O6

>  <MolWt>
754.2

>  <Pathways>
Metabolism

>  <Target>
Hydroxylase

>  <Receptor>
Tryptophan hydroxylase

>  <Bioactivity>
"Telotristat Etiprate (LX 1606 Hippurate) is an orally bioavailable, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity."

>  <Reference>
"Margolis KG, et al. Gut. 2014, 63(6), 928-937.;Pappas C, et al. J Clin Oncol 27, 2009 (suppl; abstr e14555)."

>  <ID<1>>
T6044

$$$$
StarDrop ID 245
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 6.2847 2.1647 0.0000 0
M  V30 2 C 5.9674 1.4032 0.0000 0
M  V30 3 C 6.4876 0.7472 0.0000 0
M  V30 4 C 6.1761 -0.0184 0.0000 0
M  V30 5 C 5.3514 -0.1047 0.0000 0
M  V30 6 C 5.0523 -0.8534 0.0000 0
M  V30 7 C 4.2341 -0.8639 0.0000 0 CFG=1
M  V30 8 N 3.6903 -1.4520 0.0000 0
M  V30 9 C 3.8279 -2.2654 0.0000 0
M  V30 10 C 3.1923 -2.7914 0.0000 0
M  V30 11 C 3.3300 -3.6048 0.0000 0
M  V30 12 C 2.9690 -1.0679 0.0000 0
M  V30 13 C 3.1117 -0.1806 0.0000 0
M  V30 14 C 3.9566 0.4181 0.0000 0 CFG=1
M  V30 15 C 3.7418 1.2497 0.0000 0 CFG=1
M  V30 16 O 4.4073 1.7525 0.0000 0
M  V30 17 C 5.1190 1.3088 0.0000 0
M  V30 18 C 4.8284 0.5413 0.0000 0
M  V30 19 C 2.9160 1.4100 0.0000 0
M  V30 20 O 2.6606 2.1945 0.0000 0
M  V30 21 C 2.3571 0.8095 0.0000 0
M  V30 22 C 2.6697 0.0685 0.0000 0
M  V30 23 C 3.6435 -0.0785 0.0000 0 CFG=1
M  V30 24 O 3.2208 -0.7869 0.0000 0
M  V30 25 H 3.2489 -0.6925 0.0000 0
M  V30 26 H 4.6786 0.8998 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 8 12
M  V30 12 1 12 13
M  V30 13 1 14 13
M  V30 14 1 14 15
M  V30 15 1 15 16 CFG=3
M  V30 16 1 16 17
M  V30 17 1 2 17
M  V30 18 2 17 18
M  V30 19 1 5 18
M  V30 20 1 14 18 CFG=1
M  V30 21 1 15 19
M  V30 22 2 19 20
M  V30 23 1 19 21
M  V30 24 1 21 22
M  V30 25 1 23 22
M  V30 26 1 23 7
M  V30 27 1 14 23
M  V30 28 1 23 24 CFG=1
M  V30 29 1 25 7
M  V30 30 1 26 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
245

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Naloxone hydrochloride

>  <Synonyms>
Naloxone HCl

>  <CAS>
357-08-4

>  <Formula>
C19H22ClNO4

>  <MolWt>
363.8

>  <Pathways>
Endocrinology/Hormones;Neuroscience;GPCR/G Protein

>  <Target>
Opioid Receptor

>  <Receptor>
Opioid Receptor

>  <Bioactivity>
"Naloxone hydrochloride is a specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors."

>  <Reference>
"Li Y, Shi X, Cai X, et al. microRNA-422a Inhibits DCC Expression in a Manner Dependent on SNP rs12607853[J]. Cytogenetic and Genome Research. 2020, 160(2): 63-71.;Froehlich JC, et al. Pharmacol Biochem Behav, 1990, 35(2), 385-390.;Liu B, et al. J Pharmacol Exp Ther, 2000, 293(2), 607-617.;Liu B, et al. J Pharmacol Exp Ther, 2000, 295(1), 125-132.;Guo H, Xie Q, Cui J, et al. Naloxone reversed cognitive impairments induced by repeated morphine under heavy perceptual load in the 5?choice serial reaction time task[J]. Journal of neuroscience research. 2019 May 12.;Gallate JE, et al. Psychopharmacology (Berl), 1999, 142(3), 302-308."

>  <ID<1>>
T0102

$$$$
StarDrop ID 246
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7954 -1.5395 0.0000 0
M  V30 2 O 1.2079 -0.8250 0.0000 0
M  V30 3 C 2.0329 -0.8250 0.0000 0
M  V30 4 C 2.4454 -0.1105 0.0000 0
M  V30 5 C 3.2704 -0.1105 0.0000 0
M  V30 6 C 3.6829 0.6039 0.0000 0
M  V30 7 C 4.5079 0.6039 0.0000 0
M  V30 8 N 4.9204 -0.1105 0.0000 0
M  V30 9 C 5.7454 -0.1105 0.0000 0
M  V30 10 C 6.1579 -0.8250 0.0000 0
M  V30 11 C 6.9829 -0.8250 0.0000 0
M  V30 12 C 7.3954 -1.5395 0.0000 0
M  V30 13 C 8.2204 -1.5395 0.0000 0
M  V30 14 C 6.9829 -2.2539 0.0000 0
M  V30 15 C 5.7454 -1.5395 0.0000 0
M  V30 16 O 6.1579 -2.2539 0.0000 0
M  V30 17 C 4.9204 -1.5395 0.0000 0
M  V30 18 C 4.5079 -0.8250 0.0000 0
M  V30 19 C 3.6829 -0.8250 0.0000 0
M  V30 20 C 3.2704 -1.5395 0.0000 0
M  V30 21 C 2.4454 -1.5395 0.0000 0
M  V30 22 O 2.0329 -2.2539 0.0000 0
M  V30 23 C 1.2079 -2.2539 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 10 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 1 8 18
M  V30 19 1 18 19
M  V30 20 2 5 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 3 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
246

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tetrabenazine Racemate

>  <Synonyms>
TETRABENAZINE;Nitoman;Ro 1-9569 Racemate;Rubigen

>  <CAS>
718635-93-9

>  <Formula>
C19H27NO3

>  <MolWt>
317.4

>  <Pathways>
Membrane transporter/Ion channel

>  <Target>
Monoamine Transporter

>  <Receptor>
Monoamine Transporter; VMAT-2

>  <Bioactivity>
Tetrabenazine (Racemate) is a selective and reversible inhibitor of vesicular monoamine transporter-2 (VMAT-2). Tetrabenazine blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high-affinity label for the vesicle transport system.

>  <Reference>
"Jankovic, J. and J. Beach, Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology, 1997. 48(2): p. 358-62.;Kenney, C., C. Hunter, and J. Jankovic, Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord, 2007. 22(2): p. 193-7."

>  <ID<1>>
T3534

$$$$
StarDrop ID 247
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 4.0291 0.0243 0.0000 0
M  V30 2 C 4.7436 0.4368 0.0000 0 CFG=1
M  V30 3 C 5.4581 0.8493 0.0000 0
M  V30 4 C 6.1725 0.4368 0.0000 0 CFG=1
M  V30 5 H 6.8870 0.0243 0.0000 0
M  V30 6 C 6.8870 0.8493 0.0000 0 CFG=2
M  V30 7 N 6.8870 1.6743 0.0000 0
M  V30 8 C 7.6015 2.0868 0.0000 0
M  V30 9 C 6.1725 2.0868 0.0000 0
M  V30 10 C 7.6015 0.4368 0.0000 0
M  V30 11 O 8.3160 0.8493 0.0000 0
M  V30 12 C 7.6015 -0.3882 0.0000 0
M  V30 13 C 8.3160 -0.8007 0.0000 0
M  V30 14 N 8.3160 -1.6257 0.0000 0
M  V30 15 O 9.0304 -0.3882 0.0000 0
M  V30 16 C 6.8870 -0.8007 0.0000 0
M  V30 17 O 6.8870 -1.6257 0.0000 0
M  V30 18 C 6.1725 -0.3882 0.0000 0 CFG=2
M  V30 19 O 6.1725 -1.2132 0.0000 0
M  V30 20 C 5.4581 -0.8007 0.0000 0
M  V30 21 O 5.4581 -1.6257 0.0000 0
M  V30 22 C 4.7436 -0.3882 0.0000 0
M  V30 23 C 4.0291 -0.8007 0.0000 0
M  V30 24 O 4.0291 -1.6257 0.0000 0
M  V30 25 C 3.3147 -0.3882 0.0000 0
M  V30 26 C 2.6002 -0.8007 0.0000 0
M  V30 27 O 2.6002 -1.6257 0.0000 0
M  V30 28 C 1.8857 -0.3882 0.0000 0
M  V30 29 C 1.8857 0.4368 0.0000 0
M  V30 30 C 2.6002 0.8493 0.0000 0
M  V30 31 Cl 2.6002 1.6743 0.0000 0
M  V30 32 C 3.3147 0.4368 0.0000 0
M  V30 33 C 4.0291 0.8493 0.0000 0 CFG=1
M  V30 34 O 4.0291 1.6743 0.0000 0
M  V30 35 H 6.0210 1.3493 0.0000 0
M  V30 36 H 3.1631 1.3493 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5 CFG=3
M  V30 5 1 4 6
M  V30 6 1 6 7 CFG=3
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 6 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 12 16
M  V30 16 2 16 17
M  V30 17 1 18 16
M  V30 18 1 4 18
M  V30 19 1 18 19 CFG=3
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 2 20 22
M  V30 23 1 2 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 1 26 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 1 30 31
M  V30 33 2 30 32
M  V30 34 1 25 32
M  V30 35 1 33 32
M  V30 36 1 2 33
M  V30 37 1 33 34 CFG=1
M  V30 38 1 35 6
M  V30 39 1 36 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
247

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Demeclocycline hydrochloride

>  <Synonyms>
Clortetrin;Detravis;Demeclocycline HCl;Declomycin

>  <CAS>
64-73-3

>  <Formula>
C21H22Cl2N2O8

>  <MolWt>
501.3

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial;ribosome

>  <Receptor>
30S ribosome; Antibiotic; Bacterial

>  <Bioactivity>
"Demeclocycline hydrochloride is a TETRACYCLINE analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than TETRACYCLINE, it maintains effective blood levels for longer periods of time."

>  <Reference>
"Imming P, et al. Nat Rev Drug Discov. 2006 Oct;5(10):821-34."

>  <ID<1>>
T1400

$$$$
StarDrop ID 248
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 6.3020 0.4179 0.0000 0
M  V30 2 C 6.3020 -0.4071 0.0000 0
M  V30 3 O 5.5875 -0.8196 0.0000 0
M  V30 4 C 7.0165 -0.8196 0.0000 0
M  V30 5 C 7.0165 -1.6446 0.0000 0
M  V30 6 C 7.7309 -2.0571 0.0000 0
M  V30 7 C 7.7309 -2.8821 0.0000 0
M  V30 8 C 8.4454 -3.2946 0.0000 0
M  V30 9 C 9.1599 -2.8821 0.0000 0
M  V30 10 C 9.1599 -2.0571 0.0000 0
M  V30 11 C 8.4454 -1.6446 0.0000 0
M  V30 12 C 8.4454 -0.8196 0.0000 0
M  V30 13 C 9.1599 -0.4071 0.0000 0
M  V30 14 C 9.1599 0.4179 0.0000 0
M  V30 15 C 8.4454 0.8304 0.0000 0
M  V30 16 O 7.7309 0.4179 0.0000 0
M  V30 17 C 8.4454 1.6554 0.0000 0
M  V30 18 C 9.1599 2.0679 0.0000 0
M  V30 19 C 9.8744 1.6554 0.0000 0
M  V30 20 C 10.5888 2.0679 0.0000 0
M  V30 21 C 11.3033 1.6554 0.0000 0
M  V30 22 C 11.3033 0.8304 0.0000 0
M  V30 23 C 10.5888 0.4179 0.0000 0
M  V30 24 C 9.8744 0.8304 0.0000 0
M  V30 25 C 7.7309 2.0679 0.0000 0
M  V30 26 O 7.7309 2.8929 0.0000 0
M  V30 27 O 7.0165 1.6554 0.0000 0
M  V30 28 C 7.7309 -0.4071 0.0000 0
M  V30 29 O 7.2460 0.2604 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 6 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 14 24
M  V30 26 1 19 24
M  V30 27 1 17 25
M  V30 28 1 25 26
M  V30 29 2 25 27
M  V30 30 2 12 28
M  V30 31 1 4 28
M  V30 32 1 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
248

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Hydroxyzine Pamoate

>  <Synonyms>
Bobsule;Equipose;Hydroxyzine embonate

>  <CAS>
10246-75-0

>  <Formula>
C44H43ClN2O8

>  <MolWt>
763.3

>  <Pathways>
Immunology/Inflammation;Neuroscience;GPCR/G Protein

>  <Target>
Histamine Receptor

>  <Receptor>
H1 receptor; Histamine Receptor

>  <Bioactivity>
"Hydroxyzine pamoate is a histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative."

>  <Reference>
"Spahr L, et al. Am J Gastroenterol. 2007 Apr;102(4):744-53."

>  <ID<1>>
T0053

$$$$
StarDrop ID 249
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.8579 -4.1250 0.0000 0
M  V30 2 C 2.1434 -3.7125 0.0000 0
M  V30 3 C 1.4289 -4.1250 0.0000 0
M  V30 4 N 2.1434 -2.8875 0.0000 0
M  V30 5 C 2.8579 -2.4750 0.0000 0
M  V30 6 C 3.5724 -2.8875 0.0000 0
M  V30 7 C 4.2868 -2.4750 0.0000 0
M  V30 8 C 5.0013 -2.8875 0.0000 0
M  V30 9 O 5.7158 -2.4750 0.0000 0
M  V30 10 C 6.4302 -2.8875 0.0000 0
M  V30 11 C 7.1447 -2.4750 0.0000 0
M  V30 12 O 7.1447 -1.6500 0.0000 0
M  V30 13 N 7.8592 -2.8875 0.0000 0
M  V30 14 S 8.5737 -2.4750 0.0000 0
M  V30 15 C 9.2881 -2.0625 0.0000 0
M  V30 16 O 8.1612 -1.7605 0.0000 0
M  V30 17 O 8.9862 -3.1895 0.0000 0
M  V30 18 C 1.4289 -2.4750 0.0000 0
M  V30 19 C 0.7145 -2.8875 0.0000 0
M  V30 20 N 0.0000 -2.4750 0.0000 0
M  V30 21 C 0.0000 -1.6500 0.0000 0
M  V30 22 C -0.7145 -1.2375 0.0000 0
M  V30 23 C -1.4289 -1.6500 0.0000 0
M  V30 24 C -2.1434 -1.2375 0.0000 0
M  V30 25 C -2.1434 -0.4125 0.0000 0
M  V30 26 C -1.4289 0.0000 0.0000 0
M  V30 27 C -0.7145 -0.4125 0.0000 0
M  V30 28 C 0.7145 -1.2375 0.0000 0
M  V30 29 N 1.4289 -1.6500 0.0000 0
M  V30 30 C 0.7145 -0.4125 0.0000 0
M  V30 31 C 0.0000 0.0000 0.0000 0
M  V30 32 C 0.0000 0.8250 0.0000 0
M  V30 33 C 0.7145 1.2375 0.0000 0
M  V30 34 C 1.4289 0.8250 0.0000 0
M  V30 35 C 1.4289 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 2 14 17
M  V30 17 1 4 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 22 27
M  V30 28 1 21 28
M  V30 29 2 28 29
M  V30 30 1 18 29
M  V30 31 1 28 30
M  V30 32 2 30 31
M  V30 33 1 31 32
M  V30 34 2 32 33
M  V30 35 1 33 34
M  V30 36 2 34 35
M  V30 37 1 30 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
249

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Selexipag

>  <Synonyms>
NS-304;Uptravi;ACT-293987

>  <CAS>
475086-01-2

>  <Formula>
C26H32N4O4S

>  <MolWt>
496.6

>  <Pathways>
Immunology/Inflammation;Others;GPCR/G Protein

>  <Target>
Others;Prostaglandin Receptor

>  <Receptor>
prostacyclin receptor; Prostaglandin Receptor

>  <Bioactivity>
Selexipag(NS-304) is prostacyclin receptor agonist that causes vasodilation in pulmonary vasculature and is used in the therapy of pulmonary arterial hypertension (PAH).

>  <Reference>
"Kuwano K, et al. 2-[4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)amino]butoxy]-N-(methylsulfonyl)acetamide (NS-304), an orally available and long-acting prostacyclin receptor agonist prodrug. J Pharmacol Exp Ther. 2007 Sep;322(3):1181-8."

>  <ID<1>>
T3216

$$$$
StarDrop ID 250
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 9.2368 5.3329 0.0000 0
M  V30 2 C 8.5224 5.7454 0.0000 0
M  V30 3 O 8.5224 6.5704 0.0000 0
M  V30 4 C 7.8079 5.3329 0.0000 0
M  V30 5 N 7.8079 4.5079 0.0000 0
M  V30 6 C 7.0934 4.0954 0.0000 0
M  V30 7 C 6.3789 4.5079 0.0000 0
M  V30 8 N 5.6645 4.0954 0.0000 0
M  V30 9 C 4.9500 4.5079 0.0000 0
M  V30 10 C 4.9500 5.3329 0.0000 0
M  V30 11 O 5.6645 5.7454 0.0000 0
M  V30 12 O 4.2355 5.7454 0.0000 0
M  V30 13 C 5.6645 3.2704 0.0000 0
M  V30 14 C 4.9500 2.8579 0.0000 0
M  V30 15 O 4.2355 3.2704 0.0000 0
M  V30 16 O 4.9500 2.0329 0.0000 0
M  V30 17 C 8.5224 4.0954 0.0000 0
M  V30 18 C 9.2368 4.5079 0.0000 0
M  V30 19 N 9.9513 4.0954 0.0000 0
M  V30 20 C 10.6658 4.5079 0.0000 0
M  V30 21 C 10.6658 5.3329 0.0000 0
M  V30 22 O 9.9513 5.7454 0.0000 0
M  V30 23 O 11.3802 5.7454 0.0000 0
M  V30 24 C 9.9513 3.2704 0.0000 0
M  V30 25 C 10.6658 2.8579 0.0000 0
M  V30 26 O 11.3802 3.2704 0.0000 0
M  V30 27 O 10.6658 2.0329 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 8 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 5 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 2 21 23
M  V30 23 1 19 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 2 25 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
250

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pentetic Acid

>  <Synonyms>
DTPA;Detarex;Detapac;Acidum penteticum;diethylenetriaminepentaacetic acid

>  <CAS>
67-43-6

>  <Formula>
C14H23N3O10

>  <MolWt>
393.3

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
chelating agent

>  <Bioactivity>
Pentetic Acid is an edetate and a chelating agent used in preparing radiopharmaceuticals.

>  <Reference>
"Gi M, et al. Antimicrob Agents ChemOthers. 2014 Dec; 58(12):7205-14."

>  <ID<1>>
T0420

$$$$
StarDrop ID 251
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 44 48 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.1212 -2.1269 0.0000 0
M  V30 2 O -4.2962 -2.1269 0.0000 0
M  V30 3 N -3.8837 -1.4124 0.0000 0
M  V30 4 C -3.0587 -1.4124 0.0000 0
M  V30 5 O -2.6462 -2.1269 0.0000 0
M  V30 6 N -2.6462 -0.6979 0.0000 0
M  V30 7 C -1.8212 -0.6979 0.0000 0
M  V30 8 C -1.4087 0.0165 0.0000 0
M  V30 9 C -0.5837 0.0165 0.0000 0
M  V30 10 C -0.1712 -0.6979 0.0000 0
M  V30 11 C -0.5837 -1.4124 0.0000 0
M  V30 12 C -1.4087 -1.4124 0.0000 0
M  V30 13 C 0.6538 -0.6979 0.0000 0
M  V30 14 S 1.1387 -0.0305 0.0000 0
M  V30 15 C 1.9233 -0.2854 0.0000 0
M  V30 16 N 2.6378 0.1271 0.0000 0
M  V30 17 C 2.6378 0.9521 0.0000 0
M  V30 18 C 3.3523 1.3646 0.0000 0
M  V30 19 C 3.3523 2.1896 0.0000 0
M  V30 20 F 2.6378 2.6021 0.0000 0
M  V30 21 C 4.0668 2.6021 0.0000 0
M  V30 22 C 4.7812 2.1896 0.0000 0
M  V30 23 C 4.7812 1.3646 0.0000 0
M  V30 24 C 4.0668 0.9521 0.0000 0
M  V30 25 F 4.0668 0.1271 0.0000 0
M  V30 26 C 3.3523 -0.2854 0.0000 0
M  V30 27 O 4.1728 -0.3717 0.0000 0
M  V30 28 N 3.3523 -1.1104 0.0000 0
M  V30 29 C 4.0668 -1.5229 0.0000 0
M  V30 30 C 4.7812 -1.1104 0.0000 0
M  V30 31 C 5.4957 -1.5229 0.0000 0
M  V30 32 C 5.4957 -2.3479 0.0000 0
M  V30 33 O 6.2102 -2.7604 0.0000 0
M  V30 34 C 6.2102 -3.5854 0.0000 0
M  V30 35 N 4.7812 -2.7604 0.0000 0
M  V30 36 N 4.0668 -2.3479 0.0000 0
M  V30 37 C 2.6378 -1.5229 0.0000 0
M  V30 38 O 2.6378 -2.3479 0.0000 0
M  V30 39 C 1.9233 -1.1104 0.0000 0
M  V30 40 C 1.1387 -1.3654 0.0000 0
M  V30 41 C 0.8838 -2.1500 0.0000 0
M  V30 42 N 1.4358 -2.7631 0.0000 0
M  V30 43 C 2.2428 -2.5916 0.0000 0
M  V30 44 C 1.1809 -3.5477 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 7 12
M  V30 13 1 10 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 18 24
M  V30 26 1 24 25
M  V30 27 1 16 26
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 30 31
M  V30 33 2 31 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 1 32 35
M  V30 37 2 35 36
M  V30 38 1 29 36
M  V30 39 1 28 37
M  V30 40 2 37 38
M  V30 41 1 37 39
M  V30 42 2 15 39
M  V30 43 1 39 40
M  V30 44 2 13 40
M  V30 45 1 40 41
M  V30 46 1 41 42
M  V30 47 1 42 43
M  V30 48 1 42 44
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
251

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Relugolix

>  <Synonyms>
RVT-601;TAK-385

>  <CAS>
737789-87-6

>  <Formula>
C29H27F2N7O5S

>  <MolWt>
623.6

>  <Pathways>
GPCR/G Protein

>  <Target>
GNRH Receptor

>  <Receptor>
" TNK2(D163E mutations):38nM, TNK2(R806Q mutations):113 nM"

>  <Bioactivity>
"Relugolix is an orally available, non-peptide gonadotropin-releasing hormone (GnRH or luteinizing hormone-releasing hormone (LHRH)) antagonist, with potential antineoplastic activity. Relugolix competitively binds to and blocks the GnRH receptor in the anterior pituitary gland, which both prevents GnRH binding to the GnRH receptor and inhibits the secretion and release of both luteinizing hormone (LH) and follicle stimulating hormone (FSH). In males, the inhibition of LH secretion prevents the release of testosterone from Leydig cells in the testes. Since testosterone is required to sustain prostate growth, reducing testosterone levels may inhibit hormone-dependent prostate cancer cell proliferation."

>  <Reference>
Nakata D et al. Eur J Pharmacol. 2014 Jan 15;723:167-74.;MacLean DB et al. J Clin Endocrinol Metab. 2015 Dec;100(12):4579-87.

>  <ID<1>>
T3630

$$$$
StarDrop ID 252
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.8414 -3.7445 0.0000 0
M  V30 2 C 1.0164 -3.7445 0.0000 0
M  V30 3 N 0.7615 -2.9599 0.0000 0
M  V30 4 C 1.4289 -2.4750 0.0000 0
M  V30 5 N 2.0964 -2.9599 0.0000 0
M  V30 6 C 1.4289 -1.6500 0.0000 0
M  V30 7 C 0.7145 -1.2375 0.0000 0
M  V30 8 C 0.7145 -0.4125 0.0000 0
M  V30 9 C 1.4289 0.0000 0.0000 0
M  V30 10 C 2.1434 -0.4125 0.0000 0
M  V30 11 C 2.8579 0.0000 0.0000 0
M  V30 12 C 3.5724 -0.4125 0.0000 0
M  V30 13 C 3.5724 -1.2375 0.0000 0
M  V30 14 C 2.8579 -1.6500 0.0000 0
M  V30 15 C 2.1434 -1.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 1 5
M  V30 6 1 4 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 6 15
M  V30 17 1 10 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
252

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tetrahydrozoline

>  <Synonyms>
Tetryzolin;Tetryzoline

>  <CAS>
84-22-0

>  <Formula>
C13H16N2

>  <MolWt>
200.3

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor; ??-adrenergic receptor

>  <Bioactivity>
"Tetrahydrozoline, an alpha agonist, have an effect on the constriction of conjunctival blood vessels. This contributes to relieve the redness of the eye resulted from minor ocular irritants."

>  <Reference>
"Dahlstr?m M, et al. J Exp Zool A Comp Exp Biol. 2005 Jul 1;303(7):551-62."

>  <ID<1>>
T0397

$$$$
StarDrop ID 253
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -4.2069 -3.8474 0.0000 0
M  V30 2 C -4.6919 -4.5148 0.0000 0
M  V30 3 C -4.3563 -5.2685 0.0000 0
M  V30 4 N -4.8412 -5.9359 0.0000 0
M  V30 5 C -4.5057 -6.6896 0.0000 0
M  V30 6 S -3.6987 -6.8611 0.0000 0
M  V30 7 C -3.6125 -7.6816 0.0000 0
M  V30 8 C -2.8980 -8.0941 0.0000 0
M  V30 9 C -2.1835 -7.6816 0.0000 0
M  V30 10 C -2.1835 -6.8566 0.0000 0
M  V30 11 C -1.4691 -6.4441 0.0000 0
M  V30 12 C -0.7546 -6.8566 0.0000 0
M  V30 13 O -0.0401 -6.4441 0.0000 0
M  V30 14 C 0.6744 -6.8566 0.0000 0
M  V30 15 C 1.3888 -6.4441 0.0000 0 CFG=2
M  V30 16 O 1.3888 -5.6191 0.0000 0
M  V30 17 C 2.1033 -6.8566 0.0000 0
M  V30 18 O 2.8178 -6.4441 0.0000 0
M  V30 19 C -0.7546 -7.6816 0.0000 0
M  V30 20 Cl -0.0401 -8.0941 0.0000 0
M  V30 21 C -1.4691 -8.0941 0.0000 0
M  V30 22 C -4.3661 -8.0172 0.0000 0
M  V30 23 O -4.5377 -8.8242 0.0000 0
M  V30 24 N -4.9182 -7.4041 0.0000 0
M  V30 25 C -5.7387 -7.4903 0.0000 0
M  V30 26 C -6.0742 -8.2440 0.0000 0
M  V30 27 C -6.8947 -8.3302 0.0000 0
M  V30 28 C -7.3796 -7.6628 0.0000 0
M  V30 29 C -7.0441 -6.9091 0.0000 0
M  V30 30 C -6.2236 -6.8229 0.0000 0
M  V30 31 C -5.8880 -6.0692 0.0000 0
M  V30 32 H 0.5228 -5.9441 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 15 14
M  V30 15 1 15 16 CFG=3
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 1 12 19
M  V30 19 1 19 20
M  V30 20 2 19 21
M  V30 21 1 9 21
M  V30 22 1 7 22
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 5 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 25 30
M  V30 33 1 30 31
M  V30 34 1 32 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
253

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ponesimod

>  <Synonyms>
ACT-128800

>  <CAS>
854107-55-4

>  <Formula>
C23H25ClN2O4S

>  <MolWt>
461

>  <Pathways>
GPCR/G Protein

>  <Target>
S1P Receptor;LPL Receptor

>  <Receptor>
 S1P1 receptor:5.7 nM(EC50)

>  <Bioactivity>
"Ponesimod is an orally available sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) agonist with potential immunomodulating activity."

>  <Reference>
"D'Ambrosio D, et al. Ther Adv Chronic Dis. 2016, 7(1):18-33.;Piali L. et al. J Pharmacol Exp Ther. 2011, 337(2):547-556.;Fauzyah Y, Ono C, Torii S, et al. Ponesimod suppresses hepatitis B virus infection by inhibiting endosome maturation[J]. Antiviral Research. 2020: 104999."

>  <ID<1>>
T3258

$$$$
StarDrop ID 254
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 7 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 1.6500 1.4289 0.0000 0
M  V30 2 C 1.2375 0.7145 0.0000 0
M  V30 3 F 0.5230 1.1270 0.0000 0
M  V30 4 F 1.9520 0.3020 0.0000 0
M  V30 5 C 0.8250 0.0000 0.0000 0
M  V30 6 Cl 1.2375 -0.7145 0.0000 0
M  V30 7 Br 0.0000 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
254

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Halothane

>  <Synonyms>
Anestan;Narcotane

>  <CAS>
151-67-7

>  <Formula>
C2HBrClF3

>  <MolWt>
197.4

>  <Pathways>
Neuroscience;Membrane transporter/Ion channel

>  <Target>
Potassium Channel;Chloride channel;GABA Receptor;NMDAR

>  <Receptor>
GABAR; Glycine receptor; NMDA receptor; Potassium Channel

>  <Bioactivity>
"Halothane is a nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. NITROUS OXIDE is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required."

>  <Reference>
"Namba T, et al. Eur J Pharmacol. 2000 Apr 28;395(2):95-101."

>  <ID<1>>
T0954

$$$$
StarDrop ID 255
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 4.6184 2.6664 0.0000 0
M  V30 2 C 4.6184 1.8414 0.0000 0
M  V30 3 C 3.9039 1.4289 0.0000 0
M  V30 4 C 3.1895 1.8414 0.0000 0
M  V30 5 C 2.4750 1.4289 0.0000 0
M  V30 6 O 1.7605 1.8414 0.0000 0
M  V30 7 O 2.4750 0.6039 0.0000 0
M  V30 8 C 5.3329 1.4289 0.0000 0
M  V30 9 C 6.0474 1.8414 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 2 8
M  V30 8 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
255

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Vigabatrin

>  <Synonyms>
Sabril;Vigabatrine

>  <CAS>
60643-86-9

>  <Formula>
C6H11NO2

>  <MolWt>
129.2

>  <Pathways>
Membrane transporter/Ion channel;Neuroscience

>  <Target>
GABA Receptor;ABC

>  <Receptor>
ABAT; GABA

>  <Bioactivity>
"Vigabatrin, an analogue of gamma-aminobutyric acid, is an irreversible inhibitor of 4-aminobutyrate transaminase responsible for the catabolism of ??-aminobutyric acid. Off-label uses include therapy of cocaine dependence."

>  <Reference>
"Tyacke RJ, et al. Adv Pharmacol. 2010;58:373-96."

>  <ID<1>>
T0128

$$$$
StarDrop ID 256
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.5724 -7.8375 0.0000 0
M  V30 2 C 4.2868 -7.4250 0.0000 0
M  V30 3 C 5.0013 -7.8375 0.0000 0
M  V30 4 C 5.7158 -7.4250 0.0000 0
M  V30 5 O 6.4302 -7.8375 0.0000 0
M  V30 6 C 7.1447 -7.4250 0.0000 0
M  V30 7 C 7.8592 -7.8375 0.0000 0
M  V30 8 O 8.5737 -7.4250 0.0000 0
M  V30 9 C 9.2881 -7.8375 0.0000 0
M  V30 10 C 10.0026 -7.4250 0.0000 0
M  V30 11 O 10.7171 -7.8375 0.0000 0
M  V30 12 C 11.4315 -7.4250 0.0000 0
M  V30 13 C 12.1460 -7.8375 0.0000 0
M  V30 14 C 12.8605 -7.4250 0.0000 0
M  V30 15 C 13.5749 -7.8375 0.0000 0
M  V30 16 O 14.3596 -7.5826 0.0000 0
M  V30 17 C 14.8445 -8.2500 0.0000 0
M  V30 18 O 14.3596 -8.9174 0.0000 0
M  V30 19 C 13.5749 -8.6625 0.0000 0
M  V30 20 C 12.8605 -9.0750 0.0000 0
M  V30 21 C 12.1460 -8.6625 0.0000 0
M  V30 22 C 11.4315 -9.0750 0.0000 0
M  V30 23 C 11.4315 -9.9000 0.0000 0
M  V30 24 C 10.7171 -10.3125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 15 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 13 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
256

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Piperonyl butoxide

>  <Synonyms>
Butacide;Ethanol butoxide;ENT-14250;Pyrenone 606

>  <CAS>
51-03-6

>  <Formula>
C19H30O5

>  <MolWt>
338.4

>  <Pathways>
Others;Microbiology/Virology

>  <Target>
Others;Parasite

>  <Receptor>
MFOs; Parasite

>  <Bioactivity>
"Piperonyl butoxide is an insecticide synergist, particularly for rotenone and pyrethroids."

>  <Reference>
"Casida, J. E. J Agric Food Chem. 1970 Sep-Oct;18(5):753-72."

>  <ID<1>>
T0727

$$$$
StarDrop ID 257
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.2780 2.8555 0.0000 0
M  V30 2 N -3.4710 3.0270 0.0000 0
M  V30 3 C -3.1354 3.7807 0.0000 0
M  V30 4 C -3.5479 4.4952 0.0000 0
M  V30 5 N -4.3729 4.4952 0.0000 0
M  V30 6 C -4.7854 5.2096 0.0000 0
M  V30 7 C -5.6104 5.2096 0.0000 0
M  V30 8 C -6.0229 5.9241 0.0000 0
M  V30 9 C -5.6104 6.6386 0.0000 0
M  V30 10 C -4.7854 6.6386 0.0000 0
M  V30 11 C -4.3729 5.9241 0.0000 0
M  V30 12 C -6.0229 7.3531 0.0000 0
M  V30 13 N -5.6104 8.0675 0.0000 0
M  V30 14 N -6.8479 7.3531 0.0000 0
M  V30 15 N -2.3149 3.6945 0.0000 0
M  V30 16 C -2.1434 2.8875 0.0000 0
M  V30 17 C -1.4289 2.4750 0.0000 0
M  V30 18 C -1.4289 1.6500 0.0000 0
M  V30 19 C -2.1434 1.2375 0.0000 0
M  V30 20 C -2.8579 1.6500 0.0000 0
M  V30 21 C -2.8579 2.4750 0.0000 0
M  V30 22 C -0.7145 1.2375 0.0000 0
M  V30 23 O -0.7145 0.4125 0.0000 0
M  V30 24 N -0.0000 1.6500 0.0000 0
M  V30 25 C 0.7145 1.2375 0.0000 0
M  V30 26 C 1.4289 1.6500 0.0000 0
M  V30 27 C 2.1434 1.2375 0.0000 0
M  V30 28 O 2.8579 1.6500 0.0000 0
M  V30 29 O 2.1434 0.4125 0.0000 0
M  V30 30 C 0.0000 2.4750 0.0000 0
M  V30 31 C -0.7145 2.8875 0.0000 0
M  V30 32 C -0.7145 3.7125 0.0000 0
M  V30 33 C -0.0000 4.1250 0.0000 0
M  V30 34 C 0.7145 3.7125 0.0000 0
M  V30 35 N 0.7145 2.8875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 6 11
M  V30 12 1 9 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 2 3 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 2 21
M  V30 23 1 16 21
M  V30 24 1 18 22
M  V30 25 2 22 23
M  V30 26 1 22 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 2 27 29
M  V30 32 1 24 30
M  V30 33 2 30 31
M  V30 34 1 31 32
M  V30 35 2 32 33
M  V30 36 1 33 34
M  V30 37 2 34 35
M  V30 38 1 30 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
257

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dabigatran

>  <Synonyms>
BIBR 953;BIBR 953ZW

>  <CAS>
211914-51-1

>  <Formula>
C25H25N7O3

>  <MolWt>
471.5

>  <Pathways>
Proteases/Proteasome

>  <Target>
Thrombin

>  <Receptor>
 Thrombin:9.3 nM

>  <Bioactivity>
Dabigatran is a THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation.

>  <Reference>
"Stangier J, et al. Br J Clin Pharmacol. 2007, 64(3), 292-303.;Blech S, et al. Drug Metab Dispos. 2008, 36(2), 386-399.;Alouidor B, Sweeney R E, Tat T, et al. Microfluidic Point-of-Care Ecarin-Based Clotting and Chromogenic Assays for Monitoring Direct Thrombin Inhibitors[J]. The journal of extra-corporeal technology. 2019, 51(1): 29-37.;Hauel NH, et al. J Med Chem. 2002, 45(9), 1757-1766."

>  <ID<1>>
T6295

$$$$
StarDrop ID 258
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 -2.4750 0.0000 0
M  V30 2 C 0.7145 -2.8875 0.0000 0
M  V30 3 C 1.4289 -2.4750 0.0000 0
M  V30 4 C 2.1434 -2.8875 0.0000 0
M  V30 5 C 2.8579 -2.4750 0.0000 0
M  V30 6 O 2.8579 -1.6500 0.0000 0
M  V30 7 C 3.5724 -2.8875 0.0000 0
M  V30 8 C 4.2868 -2.4750 0.0000 0
M  V30 9 C 5.0013 -2.8875 0.0000 0
M  V30 10 C 5.0013 -3.7125 0.0000 0
M  V30 11 C 4.2868 -4.1250 0.0000 0
M  V30 12 C 3.5724 -3.7125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 7 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
258

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fenipentol

>  <Synonyms>
1-Phenylpentanol;1-Phenyl-1-pentanol;Pancoral;1-phenylpentan-1-ol

>  <CAS>
583-03-9

>  <Formula>
C11H16O

>  <MolWt>
164.2

>  <Pathways>
Metabolism

>  <Target>
Lipid

>  <Receptor>
CES1

>  <Bioactivity>
Fenipentol has the properties of Choleretics and Cholagogues.

>  <Reference>
"Chey WY, et al. Gastroenterology. 1983 Jun;84(6):1578-84."

>  <ID<1>>
T0857

$$$$
StarDrop ID 259
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.0164 -3.7934 0.0000 0
M  V30 2 O -0.3020 -3.3809 0.0000 0
M  V30 3 C 0.4125 -3.7934 0.0000 0
M  V30 4 N 0.8250 -3.0789 0.0000 0
M  V30 5 C 0.4125 -2.3645 0.0000 0
M  V30 6 O -0.4125 -2.3645 0.0000 0
M  V30 7 C 0.8250 -1.6500 0.0000 0
M  V30 8 S 1.6500 -1.6500 0.0000 0
M  V30 9 C 2.0625 -2.3645 0.0000 0
M  V30 10 C 2.8875 -2.3645 0.0000 0
M  V30 11 N 3.7125 -2.3645 0.0000 0
M  V30 12 C 1.1270 -4.2059 0.0000 0
M  V30 13 S 1.9520 -4.2059 0.0000 0
M  V30 14 C 2.3645 -4.9204 0.0000 0
M  V30 15 C 1.9520 -5.6349 0.0000 0
M  V30 16 C 2.3645 -6.3493 0.0000 0
M  V30 17 S 3.1895 -6.3493 0.0000 0
M  V30 18 C 3.6020 -7.0638 0.0000 0
M  V30 19 N 4.4225 -7.1500 0.0000 0
M  V30 20 N 4.5940 -7.9570 0.0000 0
M  V30 21 N 3.8795 -8.3695 0.0000 0
M  V30 22 N 3.2664 -7.8175 0.0000 0
M  V30 23 C 2.4594 -7.9890 0.0000 0
M  V30 24 C 1.1270 -5.6349 0.0000 0
M  V30 25 N 0.7145 -4.9204 0.0000 0
M  V30 26 C 0.0000 -4.5079 0.0000 0
M  V30 27 O -0.7969 -4.7214 0.0000 0
M  V30 28 C 0.7145 -6.3493 0.0000 0
M  V30 29 O -0.1105 -6.3493 0.0000 0
M  V30 30 O 1.1270 -7.0638 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 3 10 11
M  V30 11 1 3 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 1 18 22
M  V30 23 1 22 23
M  V30 24 2 15 24
M  V30 25 1 24 25
M  V30 26 1 12 25
M  V30 27 1 25 26
M  V30 28 1 3 26
M  V30 29 2 26 27
M  V30 30 1 24 28
M  V30 31 1 28 29
M  V30 32 2 28 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
259

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cefmetazole sodium

>  <Synonyms>
Sodium cefmetazole

>  <CAS>
56796-39-5

>  <Formula>
C15H16N7NaO5S3

>  <MolWt>
493.5

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibacterial; Antibiotic; Bacterial

>  <Bioactivity>
Cefmetazole sodium is a semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.

>  <Reference>
"Inagaki K, et al. J Parenter Sci Technol. 1993 Jan-Feb;47(1):35-9."

>  <ID<1>>
T1070

$$$$
StarDrop ID 260
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.9980 2.5559 0.0000 0
M  V30 2 C 3.7125 2.1434 0.0000 0
M  V30 3 O 3.7125 1.3184 0.0000 0
M  V30 4 O 4.4270 2.5559 0.0000 0
M  V30 5 C 5.1414 2.1434 0.0000 0
M  V30 6 C 5.8559 2.5559 0.0000 0
M  V30 7 C 6.5704 2.1434 0.0000 0
M  V30 8 O 7.2849 2.5559 0.0000 0
M  V30 9 C 7.9993 2.1434 0.0000 0
M  V30 10 C 8.7138 2.5559 0.0000 0
M  V30 11 O 7.9993 1.3184 0.0000 0
M  V30 12 O 5.8559 3.3809 0.0000 0
M  V30 13 C 5.1414 3.7934 0.0000 0
M  V30 14 C 4.4270 3.3809 0.0000 0
M  V30 15 O 5.1414 4.6184 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 6 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
260

>  <Plate>
PHD136328

>  <Row>
m

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Triacetin

>  <Synonyms>
Glycerin triacetate;1,2,3-Triacetoxypropane;Glycerol triacetate;Glyceryl triacetate

>  <CAS>
102-76-1

>  <Formula>
C9H14O6

>  <MolWt>
218.2

>  <Pathways>
Metabolism;Microbiology/Virology

>  <Target>
Endogenous Metabolite;Antifungal

>  <Receptor>
Antifungal; Endogenous Metabolite; Fungal

>  <Bioactivity>
Triacetin is a triglyceride that is used as an antifungal agent.

>  <Reference>
"Tsen AR, et al. Int J Y. 2014 Mar 15;134(6):1300-10."

>  <ID<1>>
T0730

$$$$
StarDrop ID 261
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.8579 -1.6500 0.0000 0
M  V30 2 C 3.5724 -2.0625 0.0000 0
M  V30 3 O 4.2868 -1.6500 0.0000 0
M  V30 4 C 3.5724 -2.8875 0.0000 0
M  V30 5 C 4.2868 -3.3000 0.0000 0
M  V30 6 C 4.2868 -4.1250 0.0000 0
M  V30 7 C 3.5724 -4.5375 0.0000 0
M  V30 8 C 2.8579 -4.1250 0.0000 0
M  V30 9 C 2.8579 -3.3000 0.0000 0
M  V30 10 S 3.5724 -5.3625 0.0000 0
M  V30 11 O 2.7474 -5.3625 0.0000 0
M  V30 12 O 4.3974 -5.3625 0.0000 0
M  V30 13 N 3.5724 -6.1875 0.0000 0
M  V30 14 C 2.8579 -6.6000 0.0000 0
M  V30 15 O 2.1434 -6.1875 0.0000 0
M  V30 16 N 2.8579 -7.4250 0.0000 0
M  V30 17 C 2.1434 -7.8375 0.0000 0
M  V30 18 C 2.1434 -8.6625 0.0000 0
M  V30 19 C 1.4289 -9.0750 0.0000 0
M  V30 20 C 0.7145 -8.6625 0.0000 0
M  V30 21 C 0.7145 -7.8375 0.0000 0
M  V30 22 C 1.4289 -7.4250 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 4 9
M  V30 10 1 7 10
M  V30 11 2 10 11
M  V30 12 2 10 12
M  V30 13 1 10 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
261

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Hydroxyhexamide

>  <Synonyms>
(??)-Hydroxyhexamid

>  <CAS>
3168-01-2

>  <Formula>
C15H22N2O4S

>  <MolWt>
326.4

>  <Pathways>
Metabolism;Membrane transporter/Ion channel

>  <Target>
Potassium Channel;Drug Metabolite

>  <Receptor>
ATP-sensitive potassium (KATP) channels; Drug Metabolite

>  <Bioactivity>
"Hydroxyhexamide is a pharmacologically active metabolite of Acetohexamide, used as a hypoglycemic agent."

>  <Reference>
"Imamura Y,etal.Hypoglycemic effect of S(-)-hydroxyhexamide, a major metabolite of acetohexamide, and its enantiomer R(+)-hydroxyhexamide.Life Sci. 2001 Sep 7;69(16):1947-55."

>  <ID<1>>
T0150

$$$$
StarDrop ID 262
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.1358 0.5635 0.0000 0
M  V30 2 O 3.4214 0.9760 0.0000 0
M  V30 3 C 2.7069 0.5635 0.0000 0
M  V30 4 C 1.9924 0.9760 0.0000 0
M  V30 5 C 1.2780 0.5635 0.0000 0
M  V30 6 N 0.5635 0.9760 0.0000 0
M  V30 7 C 0.5635 1.8010 0.0000 0 CFG=2
M  V30 8 S 1.2780 2.2135 0.0000 0
M  V30 9 C 1.9924 1.8010 0.0000 0
M  V30 10 C -0.2615 1.8010 0.0000 0 CFG=2
M  V30 11 N -0.8449 2.3843 0.0000 0
M  V30 12 C -1.6418 2.1708 0.0000 0
M  V30 13 O -1.8553 1.3739 0.0000 0
M  V30 14 C -2.2251 2.7542 0.0000 0
M  V30 15 N -2.0116 3.5511 0.0000 0
M  V30 16 O -1.2147 3.7646 0.0000 0
M  V30 17 C -1.0012 4.5615 0.0000 0
M  V30 18 C -3.0220 2.5407 0.0000 0
M  V30 19 C -3.3177 1.7705 0.0000 0
M  V30 20 S -4.1415 1.8136 0.0000 0
M  V30 21 C -4.3551 2.6105 0.0000 0
M  V30 22 N -5.1253 2.9062 0.0000 0
M  V30 23 N -3.6632 3.0598 0.0000 0
M  V30 24 C -0.2615 0.9760 0.0000 0
M  V30 25 O -0.8449 0.3926 0.0000 0
M  V30 26 C 1.2780 -0.2615 0.0000 0
M  V30 27 O 0.5635 -0.6740 0.0000 0
M  V30 28 O 1.9924 -0.6740 0.0000 0
M  V30 29 H -0.1436 1.0939 0.0000 0
M  V30 30 H -1.1854 1.4183 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=1
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 4 9
M  V30 10 1 7 10
M  V30 11 1 10 11 CFG=1
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 14 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 2 21 23
M  V30 24 1 18 23
M  V30 25 1 10 24
M  V30 26 1 6 24
M  V30 27 2 24 25
M  V30 28 1 5 26
M  V30 29 1 26 27
M  V30 30 2 26 28
M  V30 31 1 29 7
M  V30 32 1 30 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
262

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cefpodoxime (free acid)

>  <Synonyms>
N/A

>  <CAS>
80210-62-4

>  <Formula>
C15H17N5O6S2

>  <MolWt>
427.5

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Cefpodoxime (free acid) is an oral, third-generation cephalosporin antibiotic. It is active against most Gram-positive and Gram-negative organisms, except Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis."

>  <Reference>
"Mostafa GAE, Al-Otaibi YH, Al-Badr AA. Cefpodoxime proxetil. Profiles Drug Subst Excip Relat Methodol. 2019;44:1-16;Chocas EC, et al. Cefpodoxime proxetil: a new, broad-spectrum, oral cephalosporin. Ann Pharmacother. 1993 Nov;27(11):1369-77."

>  <ID<1>>
T4998L

$$$$
StarDrop ID 263
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.9058 -2.5769 0.0000 0
M  V30 2 C -1.1375 -1.6500 0.0000 0
M  V30 3 C -1.9418 -1.8336 0.0000 0
M  V30 4 N -2.2998 -2.5769 0.0000 0
M  V30 5 C -1.9418 -3.3202 0.0000 0
M  V30 6 C -1.1375 -3.5038 0.0000 0
M  V30 7 C -0.4925 -2.9894 0.0000 0
M  V30 8 C 0.2220 -3.4019 0.0000 0
M  V30 9 C 0.9364 -2.9894 0.0000 0
M  V30 10 N 1.6509 -3.4019 0.0000 0
M  V30 11 C 2.3654 -2.9894 0.0000 0
M  V30 12 C 2.3654 -2.1644 0.0000 0
M  V30 13 N 1.6509 -1.7519 0.0000 0
M  V30 14 C 0.9364 -2.1644 0.0000 0
M  V30 15 C 0.2220 -1.7519 0.0000 0
M  V30 16 C -0.4925 -2.1644 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 1 6
M  V30 7 1 6 7
M  V30 8 2 7 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 9 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 2 16
M  V30 19 1 7 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
263

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Varenicline

>  <Synonyms>
N/A

>  <CAS>
866823-63-4

>  <Formula>
C13H15Cl2N3

>  <MolWt>
284.2

>  <Pathways>
Neuroscience

>  <Target>
AChR

>  <Receptor>
??4??2 nAChR

>  <Bioactivity>
Varenicline is a Selective ??4??2 nicotinic acetylcholine receptor partial agonist.

>  <Reference>
"Tapper, A., et al.: Science, 306, 1029 (2004);Coe, J., et al.: J. Med. Chem., 48, 3474 (2005);Obach, R., et al.: Drug Metab. Disp., 34, 121 (2006)"

>  <ID<1>>
T4246

$$$$
StarDrop ID 264
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.3106 -5.3625 0.0000 0
M  V30 2 O 1.5961 -4.9500 0.0000 0
M  V30 3 C 0.8816 -5.3625 0.0000 0
M  V30 4 C 0.8816 -6.1875 0.0000 0
M  V30 5 C 0.1672 -6.6000 0.0000 0
M  V30 6 C -0.5473 -6.1875 0.0000 0
M  V30 7 N -1.2618 -6.6000 0.0000 0
M  V30 8 C -1.9763 -6.1875 0.0000 0
M  V30 9 C -1.9763 -5.3625 0.0000 0
M  V30 10 C -1.2618 -4.9500 0.0000 0
M  V30 11 C -1.2618 -4.1250 0.0000 0 CFG=2
M  V30 12 O -1.9763 -3.7125 0.0000 0
M  V30 13 C -0.5473 -3.7125 0.0000 0 CFG=1
M  V30 14 C -0.5473 -2.8875 0.0000 0
M  V30 15 C 0.1672 -2.4750 0.0000 0 CFG=2
M  V30 16 C 0.3047 -3.0250 0.0000 0
M  V30 17 C 0.3047 -3.5750 0.0000 0
M  V30 18 N 0.1672 -4.1250 0.0000 0
M  V30 19 C 0.8816 -3.7125 0.0000 0
M  V30 20 C 0.8816 -2.8875 0.0000 0 CFG=2
M  V30 21 C 1.5961 -2.4750 0.0000 0
M  V30 22 C 1.5961 -1.6500 0.0000 0
M  V30 23 C -0.5473 -5.3625 0.0000 0
M  V30 24 C 0.1672 -4.9500 0.0000 0
M  V30 25 H -2.1278 -4.6250 0.0000 0
M  V30 26 H 0.3187 -3.2125 0.0000 0
M  V30 27 H 0.8817 -2.0625 0.0000 0
M  V30 28 H 0.8817 -1.8875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=3
M  V30 12 1 11 13
M  V30 13 1 13 14 CFG=1
M  V30 14 1 15 14 CFG=1
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 13 18
M  V30 19 1 18 19
M  V30 20 1 20 19
M  V30 21 1 15 20
M  V30 22 1 20 21 CFG=1
M  V30 23 2 21 22
M  V30 24 1 10 23
M  V30 25 1 6 23
M  V30 26 2 23 24
M  V30 27 1 3 24
M  V30 28 1 25 11
M  V30 29 1 26 13
M  V30 30 1 27 15
M  V30 31 1 28 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
264

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Quinidine hydrochloride monohydrate

>  <Synonyms>
Quinidine hydrochloride

>  <CAS>
6151-40-2

>  <Formula>
C20H27ClN2O3

>  <MolWt>
378.9

>  <Pathways>
Membrane transporter/Ion channel;Microbiology/Virology

>  <Target>
Potassium Channel;Sodium Channel;Parasite

>  <Receptor>
 K+ channel:19.9 ??M

>  <Bioactivity>
"Quinidine is an optical isomer of quinine, extracted from the bark of the Cinchona tree and similar plant species. It prolongs cellular action potential and decreases automaticity. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission."

>  <Reference>
"Stokoe KS, et al. J Physiol. 2007 Jan 1;578(Pt 1):69-84."

>  <ID<1>>
T0266

$$$$
StarDrop ID 265
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.5433 -1.9354 0.0000 0
M  V30 2 C 1.3683 -1.9354 0.0000 0
M  V30 3 C 1.8532 -1.2680 0.0000 0
M  V30 4 C 2.6378 -1.5229 0.0000 0
M  V30 5 C 3.3523 -1.1104 0.0000 0
M  V30 6 C 4.0668 -1.5229 0.0000 0
M  V30 7 C 4.7812 -1.1104 0.0000 0
M  V30 8 C 4.7812 -0.2854 0.0000 0
M  V30 9 C 5.4957 -1.5229 0.0000 0
M  V30 10 C 5.4957 -2.3479 0.0000 0
M  V30 11 O 6.2102 -2.7604 0.0000 0
M  V30 12 O 4.7812 -2.7604 0.0000 0
M  V30 13 C 4.0668 -2.3479 0.0000 0
M  V30 14 C 3.3523 -2.7604 0.0000 0
M  V30 15 C 3.3523 -3.5854 0.0000 0
M  V30 16 C 2.6378 -2.3479 0.0000 0
M  V30 17 O 1.8532 -2.6029 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 2 6 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 4 16
M  V30 18 1 16 17
M  V30 19 1 2 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
265

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Trioxsalen

>  <Synonyms>
Trimethylpsoralen;Trioxysalen;Trisoralen

>  <CAS>
3902-71-4

>  <Formula>
C14H12O3

>  <MolWt>
228.2

>  <Pathways>
Cell Cycle/Checkpoint;DNA Damage/DNA Repair;Metabolism

>  <Target>
DHFR;DNA Alkylator/Crosslinker

>  <Receptor>
DHFR; DNA Alkylator/Crosslinker

>  <Bioactivity>
"Trioxsalen is a furanocoumarin and a psoralen derivative, in conjunction with UV-A for phototherapy treatment of vitiligo and hand eczema. After photoactivation it creates interstrand cross-links in DNA, which can cause programmed cell death."

>  <Reference>
"Hadjipavlou-Litina D,etal.Trioxsalen derivatives with lipoxygenase inhibitory activity.J Enzyme Inhib Med Chem. 2009 Dec;24(6):1351-6."

>  <ID<1>>
T4558

$$$$
StarDrop ID 266
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 92 100 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 0.7145 0.4125 0.0000 0
M  V30 2 C 1.2463 1.0432 0.0000 0 CFG=1
M  V30 3 C 1.7781 1.6739 0.0000 0
M  V30 4 C 2.5902 1.5287 0.0000 0
M  V30 5 C 2.8705 0.7528 0.0000 0 CFG=2
M  V30 6 H 3.1508 -0.0231 0.0000 0
M  V30 7 C 2.3387 0.1221 0.0000 0 CFG=2
M  V30 8 H 2.0584 0.8980 0.0000 0
M  V30 9 C 2.6190 -0.6539 0.0000 0
M  V30 10 C 3.4311 -0.7991 0.0000 0 CFG=1
M  V30 11 O 3.7114 -1.5750 0.0000 0
M  V30 12 C 3.9629 -0.1684 0.0000 0 CFG=2
M  V30 13 C 4.3228 -0.9107 0.0000 0
M  V30 14 C 4.7875 -0.1416 0.0000 0 CFG=2
M  V30 15 C 5.0168 0.6509 0.0000 0
M  V30 16 C 4.3340 1.1139 0.0000 0
M  V30 17 C 3.6826 0.6076 0.0000 0 CFG=2
M  V30 18 O 3.4850 1.4085 0.0000 0
M  V30 19 C 5.2939 -0.7929 0.0000 0
M  V30 20 C 6.1184 -0.7661 0.0000 0
M  V30 21 C 6.3987 -1.5420 0.0000 0
M  V30 22 O 7.1912 -1.7713 0.0000 0
M  V30 23 O 5.7474 -2.0484 0.0000 0
M  V30 24 C 5.0646 -1.5854 0.0000 0
M  V30 25 C 1.5266 0.2673 0.0000 0 CFG=2
M  V30 26 C 1.8069 -0.5086 0.0000 0
M  V30 27 C 0.9948 -0.3634 0.0000 0
M  V30 28 C 0.1827 -0.2182 0.0000 0
M  V30 29 C -0.0976 0.5577 0.0000 0 CFG=1
M  V30 30 C 0.4342 1.1884 0.0000 0
M  V30 31 O -0.9098 0.7029 0.0000 0
M  V30 32 C -1.1901 1.4789 0.0000 0 CFG=1
M  V30 33 C -2.0022 1.6241 0.0000 0
M  V30 34 C -2.2825 2.4000 0.0000 0 CFG=2
M  V30 35 O -3.0946 2.5452 0.0000 0
M  V30 36 C -1.7507 3.0307 0.0000 0 CFG=2
M  V30 37 O -2.0310 3.8066 0.0000 0
M  V30 38 C -1.4991 4.4373 0.0000 0 CFG=1
M  V30 39 C -1.7794 5.2133 0.0000 0
M  V30 40 C -1.2476 5.8440 0.0000 0 CFG=2
M  V30 41 O -1.5279 6.6199 0.0000 0
M  V30 42 C -0.4355 5.6987 0.0000 0 CFG=2
M  V30 43 O 0.0963 6.3295 0.0000 0
M  V30 44 C 0.9084 6.1842 0.0000 0 CFG=1
M  V30 45 C 1.4403 6.8149 0.0000 0
M  V30 46 C 2.2524 6.6697 0.0000 0 CFG=2
M  V30 47 O 2.7842 7.3004 0.0000 0
M  V30 48 C 2.5039 8.0764 0.0000 0
M  V30 49 C 1.6918 8.2216 0.0000 0
M  V30 50 O 3.0357 8.7071 0.0000 0
M  V30 51 C 2.5327 5.8938 0.0000 0 CFG=2
M  V30 52 O 3.3448 5.7486 0.0000 0
M  V30 53 C 3.8766 6.3793 0.0000 0 CFG=2
M  V30 54 O 3.5963 7.1552 0.0000 0
M  V30 55 C 4.1281 7.7859 0.0000 0 CFG=2
M  V30 56 C 3.8478 8.5619 0.0000 0
M  V30 57 O 4.3797 9.1926 0.0000 0
M  V30 58 C 4.9402 7.6407 0.0000 0 CFG=1
M  V30 59 O 5.4721 8.2714 0.0000 0
M  V30 60 C 5.2205 6.8648 0.0000 0 CFG=2
M  V30 61 O 6.0327 6.7196 0.0000 0
M  V30 62 C 4.6887 6.2341 0.0000 0 CFG=1
M  V30 63 O 4.9690 5.4582 0.0000 0
M  V30 64 C 2.0009 5.2631 0.0000 0 CFG=1
M  V30 65 C 2.2812 4.4872 0.0000 0
M  V30 66 O 1.1887 5.4083 0.0000 0
M  V30 67 C -0.1552 4.9228 0.0000 0 CFG=1
M  V30 68 C 0.6569 4.7776 0.0000 0
M  V30 69 O -0.6870 4.2921 0.0000 0
M  V30 70 C -0.9385 2.8855 0.0000 0 CFG=1
M  V30 71 C -0.4067 3.5162 0.0000 0
M  V30 72 O -0.6582 2.1096 0.0000 0
M  V30 73 H -2.9271 1.6355 0.0000 0
M  V30 74 H -2.7351 3.2067 0.0000 0
M  V30 75 H -1.1594 3.4968 0.0000 0
M  V30 76 H -2.2320 6.0200 0.0000 0
M  V30 77 H -0.7752 6.6392 0.0000 0
M  V30 78 H 0.2637 5.4197 0.0000 0
M  V30 79 H 3.2368 6.4937 0.0000 0
M  V30 80 H 3.1773 6.6583 0.0000 0
M  V30 81 H 2.8922 6.5553 0.0000 0
M  V30 82 H 4.7727 8.5505 0.0000 0
M  V30 83 H 5.9246 7.4647 0.0000 0
M  V30 84 H 5.8652 7.6292 0.0000 0
M  V30 85 H 4.0441 5.4696 0.0000 0
M  V30 86 H 2.9853 5.0871 0.0000 0
M  V30 87 H 0.4894 5.6873 0.0000 0
M  V30 88 H 0.0459 2.7095 0.0000 0
M  V30 89 H 2.7865 -1.5636 0.0000 0
M  V30 90 H 5.7696 0.0469 0.0000 0
M  V30 91 H -0.7423 -0.2067 0.0000 0
M  V30 92 H -1.8347 0.7143 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 5 7
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 10 9
M  V30 10 1 10 11 CFG=3
M  V30 11 1 12 10
M  V30 12 1 12 13 CFG=3
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 17 16
M  V30 17 1 17 5
M  V30 18 1 12 17
M  V30 19 1 17 18 CFG=3
M  V30 20 1 14 19 CFG=3
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 21 23
M  V30 25 1 23 24
M  V30 26 1 19 24
M  V30 27 1 7 25
M  V30 28 1 25 2
M  V30 29 1 25 26 CFG=3
M  V30 30 1 25 27
M  V30 31 1 27 28
M  V30 32 1 29 28
M  V30 33 1 29 30
M  V30 34 1 2 30
M  V30 35 1 29 31 CFG=3
M  V30 36 1 32 31 CFG=1
M  V30 37 1 32 33
M  V30 38 1 34 33
M  V30 39 1 34 35 CFG=3
M  V30 40 1 36 34
M  V30 41 1 36 37 CFG=3
M  V30 42 1 38 37 CFG=1
M  V30 43 1 38 39
M  V30 44 1 40 39
M  V30 45 1 40 41 CFG=3
M  V30 46 1 42 40
M  V30 47 1 42 43 CFG=3
M  V30 48 1 44 43 CFG=1
M  V30 49 1 44 45
M  V30 50 1 46 45
M  V30 51 1 46 47 CFG=3
M  V30 52 1 47 48
M  V30 53 1 48 49
M  V30 54 2 48 50
M  V30 55 1 51 46
M  V30 56 1 51 52 CFG=3
M  V30 57 1 53 52 CFG=3
M  V30 58 1 53 54
M  V30 59 1 55 54
M  V30 60 1 55 56 CFG=3
M  V30 61 1 56 57
M  V30 62 1 58 55
M  V30 63 1 58 59 CFG=1
M  V30 64 1 58 60
M  V30 65 1 60 61 CFG=3
M  V30 66 1 60 62
M  V30 67 1 62 53
M  V30 68 1 62 63 CFG=1
M  V30 69 1 51 64
M  V30 70 1 64 65 CFG=1
M  V30 71 1 64 66
M  V30 72 1 44 66
M  V30 73 1 42 67
M  V30 74 1 67 68 CFG=1
M  V30 75 1 67 69
M  V30 76 1 38 69
M  V30 77 1 36 70
M  V30 78 1 70 71 CFG=1
M  V30 79 1 70 72
M  V30 80 1 32 72
M  V30 81 1 73 34
M  V30 82 1 74 36
M  V30 83 1 75 38
M  V30 84 1 76 40
M  V30 85 1 77 42
M  V30 86 1 78 44
M  V30 87 1 79 46
M  V30 88 1 80 51
M  V30 89 1 81 53
M  V30 90 1 82 55
M  V30 91 1 83 58
M  V30 92 1 84 60
M  V30 93 1 85 62
M  V30 94 1 86 64
M  V30 95 1 87 67
M  V30 96 1 88 70
M  V30 97 1 89 10
M  V30 98 1 90 14
M  V30 99 1 91 29
M  V30 100 1 92 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
266

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lanatoside C

>  <Synonyms>
Cedilanid;Isolanid;Ceglunate

>  <CAS>
17575-22-3

>  <Formula>
C49H76O20

>  <MolWt>
985.1

>  <Pathways>
Autophagy;Membrane transporter/Ion channel;Microbiology/Virology

>  <Target>
Virus Protease;Autophagy;ATPase

>  <Receptor>
 dengue virus (in HuH-7 cells):0.19 ??M

>  <Bioactivity>
"Lanatoside C is a cardiac glycoside, a type of drug that can be used in the treatment of congestive heart failure and cardiac arrhythmia (irregular heartbeat). Lanatoside C can be used orally or by the intravenous route."

>  <Reference>
"Lypka A, Lazowski J. Wiad Lek. 1979 Sep 15;32(18):1277-81.;Hu Y, Yu K, Wang G, et al. Lanatoside C inhibits cell proliferation and induces apoptosis through attenuating Wnt/??-catenin/c-Myc signaling pathway in human gastric cancer cell[J]. Biochemical pharmacology. 2018 Apr;150:280-292."

>  <ID<1>>
T1670

$$$$
StarDrop ID 267
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 5.8555 0.1406 0.0000 0
M  V30 2 C 5.9846 -0.6742 0.0000 0 CFG=1
M  V30 3 S 6.7692 -0.4193 0.0000 0
M  V30 4 C 7.2541 -1.0867 0.0000 0
M  V30 5 C 7.8672 -0.5347 0.0000 0
M  V30 6 C 7.8672 -1.6387 0.0000 0
M  V30 7 C 6.7692 -1.7541 0.0000 0 CFG=1
M  V30 8 N 5.9846 -1.4992 0.0000 0
M  V30 9 C 5.1596 -1.4992 0.0000 0
M  V30 10 O 4.5762 -2.0826 0.0000 0
M  V30 11 C 5.1596 -0.6742 0.0000 0 CFG=1
M  V30 12 N 4.5762 -0.0908 0.0000 0
M  V30 13 C 4.7897 0.7060 0.0000 0
M  V30 14 O 5.5866 0.9196 0.0000 0
M  V30 15 C 4.2064 1.2894 0.0000 0
M  V30 16 C 4.4199 2.0863 0.0000 0
M  V30 17 C 3.8365 2.6697 0.0000 0
M  V30 18 C 4.0501 3.4665 0.0000 0
M  V30 19 C 4.8469 3.6801 0.0000 0
M  V30 20 C 5.4303 3.0967 0.0000 0
M  V30 21 C 5.2168 2.2998 0.0000 0
M  V30 22 C 7.0241 -2.5388 0.0000 0
M  V30 23 O 7.8311 -2.7103 0.0000 0
M  V30 24 O 6.4721 -3.1519 0.0000 0
M  V30 25 H 6.0622 -2.4613 0.0000 0
M  V30 26 H 4.2357 -1.0568 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 7 4
M  V30 7 1 7 8
M  V30 8 1 2 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 11 9
M  V30 12 1 2 11
M  V30 13 1 11 12 CFG=1
M  V30 14 1 12 13
M  V30 15 2 13 14
M  V30 16 1 13 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 16 21
M  V30 24 1 7 22 CFG=3
M  V30 25 1 22 23
M  V30 26 2 22 24
M  V30 27 1 25 7
M  V30 28 1 26 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
267

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Procaine penicillin G

>  <Synonyms>
Hydracillin;Duphapen;Hostacillin

>  <CAS>
54-35-3

>  <Formula>
C29H38N4O6S

>  <MolWt>
570.7

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic

>  <Receptor>
Antibiotic

>  <Bioactivity>
"Procaine penicillin G (procaine benzylpenicillin) is an antibiotic useful for the treatment of a number of bacterial infections. Specifically, it is used for syphilis, anthrax, mouth infections, pneumonia, diphtheria, cellulitis, and animal bites."

>  <Reference>
"Sahin U, et al. Penicillin resistance in Streptococcus pneumoniae in Isparta. Respirology. 2001 Mar;6(1):23-6. Review. PubMed PMID: 11264759."

>  <ID<1>>
T4553

$$$$
StarDrop ID 268
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.8037 1.1570 0.0000 0
M  V30 2 N 3.0892 1.5695 0.0000 0
M  V30 3 O 4.5181 1.5695 0.0000 0
M  V30 4 N 3.8037 0.3320 0.0000 0
M  V30 5 C 4.5470 -0.0260 0.0000 0
M  V30 6 C 4.7305 -0.8303 0.0000 0
M  V30 7 C 4.2162 -1.4753 0.0000 0 CFG=1
M  V30 8 O 4.5741 -2.2186 0.0000 0
M  V30 9 C 3.3912 -1.4753 0.0000 0
M  V30 10 C 2.8768 -0.8303 0.0000 0
M  V30 11 C 3.0604 -0.0260 0.0000 0
M  V30 12 C 2.4556 0.5352 0.0000 0
M  V30 13 C 1.6673 0.2920 0.0000 0
M  V30 14 C 1.4837 -0.5123 0.0000 0
M  V30 15 C 2.0884 -1.0735 0.0000 0
M  V30 16 C 5.5189 -1.0735 0.0000 0
M  V30 17 C 6.1237 -0.5123 0.0000 0
M  V30 18 C 5.9401 0.2920 0.0000 0
M  V30 19 C 5.1517 0.5352 0.0000 0
M  V30 20 H 3.6841 -2.3220 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 4 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 10 15
M  V30 17 2 6 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 5 19
M  V30 22 1 20 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
268

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Eslicarbazepine

>  <Synonyms>
Pazzul;Stedesa;Erelib;BIA 2-194;EC 810-248-9

>  <CAS>
104746-04-5

>  <Formula>
C15H14N2O2

>  <MolWt>
254.3

>  <Pathways>
Membrane transporter/Ion channel;Neuroscience

>  <Target>
Sodium Channel;Beta-Secretase

>  <Receptor>
Beta-secretase; Voltage-gated sodium channel

>  <Bioactivity>
Eslicarbazepine can be used for adjunctive therapy for adults with partial-onset seizures.

>  <Reference>
"Keating GM. Eslicarbazepine acetate: a review of its use as adjunctive therapy in refractory partial-onset seizures. CNS Drugs. 2014 Jul;28(7):583-600. doi: 10.1007/s40263-014-0182-2. Review. PubMed PMID: 24972948.;Elger C, Bialer M, Falc?o A, Vaz-da-Silva M, Nunes T, Almeida L, Soares-da-Silva P. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. Epilepsia. 2013 Aug;54(8):1453-61. doi: 10.1111/epi.12242. Epub 2013 Jun 12. PubMed PMID: 23758485.;Verrotti A, Loiacono G, Rossi A, Zaccara G. Eslicarbazepine acetate: an update on efficacy and safety in epilepsy. Epilepsy Res. 2014 Jan;108(1):1-10. doi: 10.1016/j.eplepsyres.2013.10.005. Epub 2013 Oct 23. Review. PubMed PMID: 24225327.;Doeser A, Soares-da-Silva P, Beck H, Uebachs M. The effects of eslicarbazepine on persistent Na? current and the role of the Na? channel ?? subunits. Epilepsy Res. 2014 Feb;108(2):202-11. doi: 10.1016/j.eplepsyres.2013.11.022. Epub 2013 Dec 8. PubMed PMID: 24368131."

>  <ID<1>>
T3285L

$$$$
StarDrop ID 269
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.6078 1.1759 0.0000 0
M  V30 2 C 1.3222 0.7634 0.0000 0
M  V30 3 C 2.0367 1.1759 0.0000 0
M  V30 4 C 2.7512 0.7634 0.0000 0
M  V30 5 C 2.7512 -0.0616 0.0000 0
M  V30 6 C 2.0367 -0.4741 0.0000 0
M  V30 7 C 1.3222 -0.0616 0.0000 0
M  V30 8 C 3.4656 -0.4741 0.0000 0
M  V30 9 C 3.4656 -1.2991 0.0000 0
M  V30 10 C 2.7512 -1.7116 0.0000 0
M  V30 11 N 2.7512 -2.5366 0.0000 0
M  V30 12 C 3.4186 -3.0215 0.0000 0
M  V30 13 C 3.1637 -3.8062 0.0000 0
M  V30 14 C 2.3387 -3.8062 0.0000 0
M  V30 15 C 2.0837 -3.0215 0.0000 0
M  V30 16 C 4.1801 -0.0616 0.0000 0
M  V30 17 C 4.1801 0.7634 0.0000 0
M  V30 18 C 4.8946 1.1759 0.0000 0
M  V30 19 C 5.6091 0.7634 0.0000 0
M  V30 20 C 5.6091 -0.0616 0.0000 0
M  V30 21 C 6.3235 -0.4741 0.0000 0
M  V30 22 C 6.3235 -1.2991 0.0000 0
M  V30 23 C 7.0380 -1.7116 0.0000 0
M  V30 24 O 7.7525 -1.2991 0.0000 0
M  V30 25 O 7.0380 -2.5366 0.0000 0
M  V30 26 N 4.8946 -0.4741 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 11 15
M  V30 17 1 8 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 2 23 25
M  V30 27 2 20 26
M  V30 28 1 16 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
269

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Acrivastine

>  <Synonyms>
Acrivastin;Semprex;BW825C

>  <CAS>
87848-99-5

>  <Formula>
C22H24N2O2

>  <MolWt>
348.4

>  <Pathways>
Immunology/Inflammation;Neuroscience;GPCR/G Protein

>  <Target>
Histamine Receptor

>  <Receptor>
H1 receptor; Histamine Receptor

>  <Bioactivity>
Acrivastine is a short-acting histamine 1 receptor antagonist.

>  <Reference>
"Gibbs TG, et al. Acrivastine in two doses compared with placebo in a multicentre, parallel group study for the treatment of seasonal allergic rhinitis. Br J Clin Pract. 1989 Jan;43(1):11-4.;Brogden RN, et al. Acrivastine. A review of its pharmacological properties and therapeutic efficacy in allergic rhinitis, urticaria and related disorders. Drugs. 1991 Jun;41(6):927-40."

>  <ID<1>>
T4551

$$$$
StarDrop ID 270
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.4319 0.6187 0.0000 0
M  V30 2 C 0.3649 0.8322 0.0000 0
M  V30 3 O 0.5785 1.6291 0.0000 0
M  V30 4 C 0.9483 0.2488 0.0000 0
M  V30 5 C 1.7733 0.2488 0.0000 0
M  V30 6 C 2.5579 0.5038 0.0000 0
M  V30 7 C 2.8129 1.2884 0.0000 0
M  V30 8 C 3.0428 -0.1637 0.0000 0
M  V30 9 S 3.8678 -0.1637 0.0000 0
M  V30 10 C 4.2803 0.5508 0.0000 0
M  V30 11 C 3.9448 1.3045 0.0000 0
M  V30 12 N 4.5579 1.8565 0.0000 0
M  V30 13 C 5.2724 1.4440 0.0000 0
M  V30 14 C 5.1008 0.6370 0.0000 0
M  V30 15 C 6.0260 1.7796 0.0000 0
M  V30 16 O 6.6935 1.2946 0.0000 0
M  V30 17 N 6.1123 2.6000 0.0000 0
M  V30 18 C 6.8659 2.9356 0.0000 0
M  V30 19 C 6.9522 3.7561 0.0000 0
M  V30 20 C 7.7059 4.0916 0.0000 0
M  V30 21 C 8.3733 3.6067 0.0000 0
M  V30 22 C 8.2871 2.7862 0.0000 0
M  V30 23 C 7.5334 2.4507 0.0000 0
M  V30 24 C 8.9545 2.3013 0.0000 0
M  V30 25 O 9.7082 2.6369 0.0000 0
M  V30 26 O 8.8683 1.4808 0.0000 0
M  V30 27 C 2.5579 -0.8311 0.0000 0
M  V30 28 N 1.7733 -0.5762 0.0000 0
M  V30 29 C 0.9483 -0.5762 0.0000 0
M  V30 30 O 0.3649 -1.1595 0.0000 0
M  V30 31 C 2.8129 -1.6157 0.0000 0
M  V30 32 O 2.2608 -2.2288 0.0000 0
M  V30 33 O 3.6198 -1.7873 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 10 14
M  V30 15 1 13 15
M  V30 16 2 15 16
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 18 23
M  V30 25 1 22 24
M  V30 26 1 24 25
M  V30 27 2 24 26
M  V30 28 2 8 27
M  V30 29 1 27 28
M  V30 30 1 5 28
M  V30 31 1 28 29
M  V30 32 1 4 29
M  V30 33 2 29 30
M  V30 34 1 27 31
M  V30 35 1 31 32
M  V30 36 2 31 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
270

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ertapenem sodium

>  <Synonyms>
L-749345;MK-826

>  <CAS>
153773-82-1

>  <Formula>
C22H24N3NaO7S

>  <MolWt>
497.5

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
Ertapenem sodium is a new long-acting 1-??-methyl carbapenem antibiotic with a broad antibacterial spectrum including common aerobic and anaerobic bacteria and organisms with extended-spectrum ??-lactamases.

>  <Reference>
"Hoellman DB, et al. In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds. Antimicrob Agents Chemother. 2002 Jan;46(1):220-4."

>  <ID<1>>
T4991

$$$$
StarDrop ID 271
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 41 44 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.8579 0.8250 0.0000 0
M  V30 2 N -2.8579 -0.0000 0.0000 0
M  V30 3 C -2.1434 -0.4125 0.0000 0
M  V30 4 O -1.4289 -0.0000 0.0000 0
M  V30 5 C -2.1434 -1.2375 0.0000 0
M  V30 6 C -1.3184 -1.2375 0.0000 0
M  V30 7 C -2.9684 -1.2375 0.0000 0
M  V30 8 C -2.1434 -2.0625 0.0000 0
M  V30 9 C -1.4289 -2.4750 0.0000 0
M  V30 10 C -1.4289 -3.3000 0.0000 0
M  V30 11 C -2.1434 -3.7125 0.0000 0
M  V30 12 C -2.8579 -3.3000 0.0000 0
M  V30 13 C -2.8579 -2.4750 0.0000 0
M  V30 14 C -3.5724 -3.7125 0.0000 0
M  V30 15 F -4.2868 -4.1250 0.0000 0
M  V30 16 F -3.1599 -4.4270 0.0000 0
M  V30 17 F -3.9849 -2.9980 0.0000 0
M  V30 18 C -0.7145 -3.7125 0.0000 0
M  V30 19 F 0.0000 -4.1250 0.0000 0
M  V30 20 F -1.1270 -4.4270 0.0000 0
M  V30 21 F -0.3020 -2.9980 0.0000 0
M  V30 22 C -3.5724 -0.4125 0.0000 0
M  V30 23 C -3.5724 -1.2375 0.0000 0
M  V30 24 N -4.2868 -1.6500 0.0000 0
M  V30 25 C -5.0013 -1.2375 0.0000 0
M  V30 26 C -5.0013 -0.4125 0.0000 0
M  V30 27 C -4.2868 -0.0000 0.0000 0
M  V30 28 C -4.2868 0.8250 0.0000 0
M  V30 29 C -3.5724 1.2375 0.0000 0
M  V30 30 C -3.5724 2.0625 0.0000 0
M  V30 31 C -4.2868 2.4750 0.0000 0
M  V30 32 C -5.0013 2.0625 0.0000 0
M  V30 33 C -5.0013 1.2375 0.0000 0
M  V30 34 C -5.7158 0.8250 0.0000 0
M  V30 35 N -5.7158 -1.6500 0.0000 0
M  V30 36 C -5.7158 -2.4750 0.0000 0
M  V30 37 C -6.4302 -2.8875 0.0000 0
M  V30 38 N -7.1447 -2.4750 0.0000 0
M  V30 39 C -7.8592 -2.8875 0.0000 0
M  V30 40 C -7.1447 -1.6500 0.0000 0
M  V30 41 C -6.4302 -1.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 8 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 14 17
M  V30 18 1 10 18
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 18 21
M  V30 22 1 2 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 22 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 31 32
M  V30 34 2 32 33
M  V30 35 1 28 33
M  V30 36 1 33 34
M  V30 37 1 25 35
M  V30 38 1 35 36
M  V30 39 1 36 37
M  V30 40 1 37 38
M  V30 41 1 38 39
M  V30 42 1 38 40
M  V30 43 1 40 41
M  V30 44 1 35 41
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
271

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Netupitant

>  <Synonyms>
CID 6451149;Ro 67-31898/000

>  <CAS>
290297-26-6

>  <Formula>
C30H32F6N4O

>  <MolWt>
578.6

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Neurokinin receptor

>  <Receptor>
 NK1:0.95 nM(Ki)

>  <Bioactivity>
Netupitant is a specific neurokinin 1 (NK1) receptor antagonist (Ki: 0.95 nM).

>  <Reference>
"Rizzi A, et al. Peptides. 2012, 37(1):86-97.;Stathis M, et al. Eur J Pharmacol. 2012, 689(1-3):25-30."

>  <ID<1>>
T6905

$$$$
StarDrop ID 272
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 5.0013 0.4125 0.0000 0
M  V30 2 N 5.7158 0.0000 0.0000 0
M  V30 3 C 6.4302 0.4125 0.0000 0
M  V30 4 C 7.1447 0.0000 0.0000 0
M  V30 5 C 7.8592 0.4125 0.0000 0 CFG=2
M  V30 6 O 8.5737 0.0000 0.0000 0
M  V30 7 C 9.2881 0.4125 0.0000 0
M  V30 8 C 9.2881 1.2375 0.0000 0
M  V30 9 C 10.0026 1.6500 0.0000 0
M  V30 10 C 10.7171 1.2375 0.0000 0
M  V30 11 C 10.7171 0.4125 0.0000 0
M  V30 12 C 11.4315 0.0000 0.0000 0
M  V30 13 C 11.4315 -0.8250 0.0000 0
M  V30 14 C 10.7171 -1.2375 0.0000 0
M  V30 15 C 10.0026 -0.8250 0.0000 0
M  V30 16 C 10.0026 0.0000 0.0000 0
M  V30 17 C 7.8592 1.2375 0.0000 0
M  V30 18 C 7.1917 1.7224 0.0000 0
M  V30 19 C 7.4467 2.5070 0.0000 0
M  V30 20 C 8.2717 2.5070 0.0000 0
M  V30 21 S 8.5266 1.7224 0.0000 0
M  V30 22 H 8.7252 0.9125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=1
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 7 16
M  V30 17 1 11 16
M  V30 18 1 5 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 1 17 21
M  V30 24 1 22 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
272

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Duloxetine

>  <Synonyms>
N/A

>  <CAS>
116539-59-4

>  <Formula>
C18H19NOS

>  <MolWt>
297.4

>  <Pathways>
Neuroscience

>  <Target>
Serotonin Transporter

>  <Receptor>
 serotonin-norepinephrine reuptake:4.6 nM(ki)

>  <Bioactivity>
"Duloxetine is an inhibitor of serotonin-norepinephrine reuptake(Ki of 4.6 nM),with treatment of major depressive disorder and generalized anxiety disorder."

>  <Reference>
"Ekram, A, R,et al. Duloxetine in Painful Diabetic Neuropathy: A Systematic Review[J]. Clinical Journal of Pain, 2016.;Wang, S.Y., J. Calderon, and G. Kuo Wang, Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner. Anesthesiology, 2010. 113(3): p. 655-65."

>  <ID<1>>
T7061

$$$$
StarDrop ID 273
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -0.1375 1.4289 0.0000 0
M  V30 2 C 0.2750 0.7145 0.0000 0
M  V30 3 C -0.1375 0.0000 0.0000 0
M  V30 4 O 0.2750 -0.7145 0.0000 0
M  V30 5 O -0.9625 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
273

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ferrous Bisglycinate

>  <Synonyms>
Iron(II) bisglycinate;Bisglycine iron(II) salt

>  <CAS>
20150-34-9

>  <Formula>
C4H8FeN2O4

>  <MolWt>
204

>  <Pathways>
Endocrinology/Hormones

>  <Target>
Estrogen/progestogen Receptor

>  <Receptor>
ER; PR

>  <Bioactivity>
Ferrous Bisglycinate is used in the fortification of infant formulations and foods.

>  <Reference>
"Fox TE,etal.Bioavailability of iron glycine as a fortificant in infant foods.Am J Clin Nutr. 1998 Apr;67(4):664-8.;Heath AL,etal.Can dietary treatment of non-anemic iron deficiency improve iron status?J Am Coll Nutr. 2001 Oct;20(5):477-84."

>  <ID<1>>
T4505

$$$$
StarDrop ID 274
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.6683 -2.7803 0.0000 0
M  V30 2 N -2.4034 -2.4057 0.0000 0
M  V30 3 N -3.1384 -2.7803 0.0000 0
M  V30 4 N -3.7218 -2.1969 0.0000 0
M  V30 5 N -3.3473 -1.4618 0.0000 0
M  V30 6 C -2.5324 -1.5909 0.0000 0
M  V30 7 S -1.9491 -1.0075 0.0000 0
M  V30 8 C -2.1626 -0.2106 0.0000 0
M  V30 9 C -1.5792 0.3727 0.0000 0
M  V30 10 C -1.7928 1.1696 0.0000 0
M  V30 11 N -1.2094 1.7530 0.0000 0
M  V30 12 C -0.4125 1.5395 0.0000 0
M  V30 13 S -0.1990 0.7426 0.0000 0
M  V30 14 C -0.7823 0.1592 0.0000 0
M  V30 15 C -0.1990 2.3364 0.0000 0
M  V30 16 N 0.5155 2.7489 0.0000 0
M  V30 17 C 1.2300 2.3364 0.0000 0
M  V30 18 O 1.2300 1.5114 0.0000 0
M  V30 19 C 1.9444 2.7489 0.0000 0
M  V30 20 O 2.6589 2.3364 0.0000 0
M  V30 21 C 3.3734 2.7489 0.0000 0
M  V30 22 O 4.0879 2.3364 0.0000 0
M  V30 23 C 1.9444 3.5739 0.0000 0
M  V30 24 C 1.2300 3.9864 0.0000 0
M  V30 25 C 1.2300 4.8114 0.0000 0
M  V30 26 C 1.9444 5.2239 0.0000 0
M  V30 27 C 2.6589 4.8114 0.0000 0
M  V30 28 C 2.6589 3.9864 0.0000 0
M  V30 29 C -0.9959 2.5499 0.0000 0
M  V30 30 O -1.4084 3.2644 0.0000 0
M  V30 31 C -2.5896 1.3832 0.0000 0
M  V30 32 O -2.8032 2.1800 0.0000 0
M  V30 33 O -3.1730 0.7998 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 2 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 9 14
M  V30 16 1 12 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 19 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 23 28
M  V30 31 1 15 29
M  V30 32 1 11 29
M  V30 33 2 29 30
M  V30 34 1 10 31
M  V30 35 1 31 32
M  V30 36 2 31 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
274

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cefamandole nafate

>  <Synonyms>
Cefamandole formate sodium;Cephamandole nafate

>  <CAS>
42540-40-9

>  <Formula>
C19H17N6NaO6S2

>  <MolWt>
512.5

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial;Antibiotic

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
Cefamandole nafate is a second-generation broad-spectrum cephalosporin antibiotic.

>  <Reference>
"Taha, M., et al.: Bioorg. Med. Chem., 16, 1218 (2008);Gohil, V., et al.: Nat. Biotechnol., 28, 249 (2010)"

>  <ID<1>>
T4992

$$$$
StarDrop ID 275
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.8299 -3.6748 0.0000 0
M  V30 2 O -2.1154 -3.2623 0.0000 0
M  V30 3 C -1.4009 -3.6748 0.0000 0
M  V30 4 O -1.4009 -4.4998 0.0000 0
M  V30 5 C -0.6865 -3.2623 0.0000 0
M  V30 6 C 0.0280 -3.6748 0.0000 0
M  V30 7 C 0.7425 -3.2623 0.0000 0
M  V30 8 O 1.4569 -3.6748 0.0000 0
M  V30 9 O 0.7425 -2.4373 0.0000 0
M  V30 10 C 1.4569 -2.0248 0.0000 0
M  V30 11 C 2.1714 -2.4373 0.0000 0
M  V30 12 N 2.8859 -2.0248 0.0000 0
M  V30 13 C 2.9721 -1.2043 0.0000 0
M  V30 14 O 2.3590 -0.6523 0.0000 0
M  V30 15 C 3.7791 -1.0328 0.0000 0
M  V30 16 C 4.1916 -1.7472 0.0000 0
M  V30 17 C 3.6396 -2.3603 0.0000 0
M  V30 18 O 3.8111 -3.1673 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 12 17
M  V30 18 2 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
275

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Diroximel fumarate

>  <Synonyms>
Diroximel Fumarete

>  <CAS>
1577222-14-0

>  <Formula>
C11H13NO6

>  <MolWt>
255.2

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Diroximel fumarate, a prodrug of monomethyl fumarate in a controlled-release formulation, rapidly and potently converts to MMF in the body."

>  <Reference>
"Alkermes Announces Positive Clinical Trial Results and Streamlined Registration Pathway for ALKS 8700 for Treatment of Multiple Sclerosis. October 29, 2015 07:00 AM Eastern Daylight Time."

>  <ID<1>>
T4271

$$$$
StarDrop ID 276
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 104 111 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 14.8803 -0.6209 0.0000 0
M  V30 2 C 14.6392 0.1681 0.0000 0 CFG=1
M  V30 3 N 13.8353 0.3537 0.0000 0
M  V30 4 C 13.2726 -0.2496 0.0000 0
M  V30 5 C 12.4688 -0.0640 0.0000 0 CFG=2
M  V30 6 C 12.2276 0.7250 0.0000 0
M  V30 7 C 12.7903 1.3283 0.0000 0
M  V30 8 C 12.5492 2.1173 0.0000 0
M  V30 9 C 13.1119 2.7206 0.0000 0
M  V30 10 C 13.9157 2.5350 0.0000 0
M  V30 11 O 14.4784 3.1383 0.0000 0
M  V30 12 C 14.1569 1.7460 0.0000 0
M  V30 13 C 13.5942 1.1427 0.0000 0
M  V30 14 N 11.9061 -0.6673 0.0000 0
M  V30 15 C 11.1023 -0.4817 0.0000 0
M  V30 16 C 10.5396 -1.0850 0.0000 0 CFG=1
M  V30 17 N 9.7357 -0.8994 0.0000 0
M  V30 18 C 9.1730 -1.5027 0.0000 0
M  V30 19 C 8.3692 -1.3170 0.0000 0 CFG=2
M  V30 20 C 8.1280 -0.5281 0.0000 0
M  V30 21 C 8.6907 0.0753 0.0000 0
M  V30 22 C 8.5334 0.8851 0.0000 0
M  V30 23 C 9.2550 1.2850 0.0000 0
M  V30 24 N 9.8583 0.7223 0.0000 0
M  V30 25 C 9.5096 -0.0253 0.0000 0
M  V30 26 C 9.2694 2.1099 0.0000 0
M  V30 27 C 8.5623 2.5349 0.0000 0
M  V30 28 C 7.8407 2.1349 0.0000 0
M  V30 29 C 7.8262 1.3101 0.0000 0
M  V30 30 N 7.8065 -1.9204 0.0000 0
M  V30 31 C 7.0027 -1.7347 0.0000 0
M  V30 32 C 6.4400 -2.3381 0.0000 0 CFG=2
M  V30 33 C 6.6811 -3.1270 0.0000 0
M  V30 34 C 7.4850 -3.3127 0.0000 0
M  V30 35 C 8.1076 -2.7715 0.0000 0
M  V30 36 N 8.8148 -3.1964 0.0000 0
M  V30 37 C 8.6291 -4.0003 0.0000 0
M  V30 38 N 7.8073 -4.0721 0.0000 0
M  V30 39 N 5.6361 -2.1524 0.0000 0
M  V30 40 C 5.0734 -2.7558 0.0000 0
M  V30 41 O 5.3146 -3.5447 0.0000 0
M  V30 42 C 4.2696 -2.5701 0.0000 0 CFG=1
M  V30 43 N 3.6469 -3.1113 0.0000 0
M  V30 44 C 2.9398 -2.6864 0.0000 0
M  V30 45 O 2.1804 -3.0087 0.0000 0
M  V30 46 C 3.1254 -1.8825 0.0000 0
M  V30 47 C 3.9473 -1.8107 0.0000 0
M  V30 48 O 6.7615 -0.9458 0.0000 0
M  V30 49 O 9.4142 -2.2917 0.0000 0
M  V30 50 C 10.7807 -1.8740 0.0000 0
M  V30 51 O 11.5846 -2.0596 0.0000 0
M  V30 52 O 10.8611 0.3073 0.0000 0
M  V30 53 O 13.5138 -1.0386 0.0000 0
M  V30 54 C 15.2019 0.7714 0.0000 0
M  V30 55 N 16.0057 0.5858 0.0000 0
M  V30 56 C 16.5684 1.1891 0.0000 0 CFG=2
M  V30 57 C 17.3722 1.0034 0.0000 0
M  V30 58 N 17.9349 1.6068 0.0000 0
M  V30 59 C 18.7388 1.4211 0.0000 0 CFG=2
M  V30 60 C 19.3015 2.0245 0.0000 0
M  V30 61 O 19.0603 2.8134 0.0000 0
M  V30 62 N 20.1053 1.8388 0.0000 0
M  V30 63 C 20.7280 2.3800 0.0000 0 CFG=2
M  V30 64 C 20.6561 3.2019 0.0000 0
M  V30 65 N 21.3320 3.6751 0.0000 0
M  V30 66 C 21.2601 4.4969 0.0000 0
M  V30 67 C 21.9359 4.9701 0.0000 0
M  V30 68 N 21.8641 5.7919 0.0000 0
M  V30 69 O 22.6836 4.6214 0.0000 0
M  V30 70 O 19.9084 3.5506 0.0000 0
M  V30 71 C 21.4351 1.9551 0.0000 0
M  V30 72 C 21.2495 1.1512 0.0000 0
M  V30 73 C 20.4276 1.0794 0.0000 0
M  V30 74 C 18.9799 0.6322 0.0000 0
M  V30 75 C 18.4172 0.0288 0.0000 0
M  V30 76 C 18.6584 -0.7601 0.0000 0
M  V30 77 N 18.0957 -1.3635 0.0000 0
M  V30 78 C 18.3368 -2.1524 0.0000 0
M  V30 79 N 19.1407 -2.3381 0.0000 0
M  V30 80 N 17.7742 -2.7558 0.0000 0
M  V30 81 O 17.6134 0.2145 0.0000 0
M  V30 82 C 16.3272 1.9781 0.0000 0
M  V30 83 C 16.8899 2.5814 0.0000 0
M  V30 84 C 16.6488 3.3704 0.0000 0
M  V30 85 C 17.6938 2.3957 0.0000 0
M  V30 86 O 14.9607 1.5604 0.0000 0
M  V30 87 C 15.6842 -0.8065 0.0000 0
M  V30 88 C 16.0065 -1.5660 0.0000 0
M  V30 89 C 16.8283 -1.4941 0.0000 0
M  V30 90 N 17.0140 -0.6903 0.0000 0
M  V30 91 C 16.3068 -0.2653 0.0000 0
M  V30 92 C 17.3015 -2.1700 0.0000 0
M  V30 93 C 16.9528 -2.9176 0.0000 0
M  V30 94 C 16.1309 -2.9895 0.0000 0
M  V30 95 C 15.6578 -2.3137 0.0000 0
M  V30 96 H 4.5114 -3.5404 0.0000 0
M  V30 97 H 16.8606 0.2328 0.0000 0
M  V30 98 H 18.0566 0.6899 0.0000 0
M  V30 99 H 21.5760 2.9100 0.0000 0
M  V30 100 H 13.9571 -0.5632 0.0000 0
M  V30 101 H 12.7611 -1.0203 0.0000 0
M  V30 102 H 9.8575 -1.8163 0.0000 0
M  V30 103 H 8.6614 -2.2734 0.0000 0
M  V30 104 H 5.7578 -3.0693 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3 CFG=1
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 7 13
M  V30 14 1 5 14 CFG=1
M  V30 15 1 14 15
M  V30 16 1 16 15
M  V30 17 1 16 17 CFG=3
M  V30 18 1 17 18
M  V30 19 1 19 18
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 2 21 25
M  V30 27 2 23 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 2 22 29
M  V30 32 1 19 30 CFG=1
M  V30 33 1 30 31
M  V30 34 1 32 31
M  V30 35 1 32 33
M  V30 36 1 33 34
M  V30 37 2 34 35
M  V30 38 1 35 36
M  V30 39 2 36 37
M  V30 40 1 37 38
M  V30 41 1 34 38
M  V30 42 1 32 39 CFG=3
M  V30 43 1 39 40
M  V30 44 2 40 41
M  V30 45 1 42 40 CFG=1
M  V30 46 1 42 43
M  V30 47 1 43 44
M  V30 48 2 44 45
M  V30 49 1 44 46
M  V30 50 1 46 47
M  V30 51 1 42 47
M  V30 52 2 31 48
M  V30 53 2 18 49
M  V30 54 1 16 50
M  V30 55 1 50 51
M  V30 56 2 15 52
M  V30 57 2 4 53
M  V30 58 1 2 54
M  V30 59 1 54 55
M  V30 60 1 56 55 CFG=1
M  V30 61 1 56 57
M  V30 62 1 57 58
M  V30 63 1 59 58 CFG=3
M  V30 64 1 59 60
M  V30 65 2 60 61
M  V30 66 1 60 62
M  V30 67 1 63 62
M  V30 68 1 63 64 CFG=3
M  V30 69 1 64 65
M  V30 70 1 65 66
M  V30 71 1 66 67
M  V30 72 1 67 68
M  V30 73 2 67 69
M  V30 74 2 64 70
M  V30 75 1 63 71
M  V30 76 1 71 72
M  V30 77 1 72 73
M  V30 78 1 62 73
M  V30 79 1 59 74
M  V30 80 1 74 75
M  V30 81 1 75 76
M  V30 82 1 76 77
M  V30 83 1 77 78
M  V30 84 2 78 79
M  V30 85 1 78 80
M  V30 86 2 57 81
M  V30 87 1 56 82
M  V30 88 1 82 83
M  V30 89 1 83 84
M  V30 90 1 83 85
M  V30 91 2 54 86
M  V30 92 1 1 87
M  V30 93 1 87 88
M  V30 94 1 88 89
M  V30 95 1 89 90
M  V30 96 1 90 91
M  V30 97 2 87 91
M  V30 98 2 89 92
M  V30 99 1 92 93
M  V30 100 2 93 94
M  V30 101 1 94 95
M  V30 102 2 88 95
M  V30 103 1 96 42
M  V30 104 1 97 56
M  V30 105 1 98 59
M  V30 106 1 99 63
M  V30 107 1 100 2
M  V30 108 1 101 5
M  V30 109 1 102 16
M  V30 110 1 103 19
M  V30 111 1 104 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
276

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Triptorelin acetate(57773-63-4 free base)

>  <Synonyms>
CL 118,532;Wy 42422;AY 25650;Triptorelin Acetate;BIM 21003;Wy 42462;CL 118532

>  <CAS>
140194-24-7

>  <Formula>
C66H86N18O15

>  <MolWt>
1372

>  <Pathways>
GPCR/G Protein

>  <Target>
GNRH Receptor

>  <Receptor>
GNRHR

>  <Bioactivity>
"Triptorelin Acetate is used as a GnRH agonist. It decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH) by causing constant stimulation of the pituitary. Triptorelin may be used in the treatment of hormone-responsive cancers such as breast cancer or prostate cancer, precocious puberty, estrogen-dependent conditions, and assisted reproduction."

>  <Reference>
"Lambertini M, Boni L, Michelotti A,et al. Ovarian Suppression With Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term Ovarian Function, Pregnancies, and Disease-Free Survival: A Randomized Clinical Trial. JAMA. 2015 Dec 22-29;314(24):2632-40. doi: 10.1001/jama.2015.17291. PubMed PMID: 26720025.;Bellet M, Gray KP, Francis PA,et al. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy. J Clin Oncol. 2016 Jan 4. pii: JCO612259. [Epub ahead of print] PubMed PMID: 26729437.;Meattini I, Saieva C, et al. Impact of age on cytotoxic-induced ovarian failure in breast cancer treated with adjuvant chemotherapy and triptorelin. Future Oncol. 2016 Mar;12(5):625-35. doi: 10.2217/fon.15.357. Epub 2016 Feb 3. PubMed PMID: 26837239.;Klein K, Yang J, Aisenberg J,et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab. 2016 Feb 17. pii: /j/jpem.ahead-of-print/jpem-2015-0376/jpem-2015-0376.xml. doi: 10.1515/jpem-2015-0376. [Epub ahead of print] PubMed PMID: 26887034."

>  <ID<1>>
T21410

$$$$
StarDrop ID 277
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 5 4 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -0.1375 1.4289 0.0000 0
M  V30 2 C 0.2750 0.7145 0.0000 0
M  V30 3 C -0.1375 0.0000 0.0000 0
M  V30 4 O 0.2750 -0.7145 0.0000 0
M  V30 5 O -0.9625 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
277

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Magnesium glycinate

>  <Synonyms>
Magnesium diglycinate;magnesium 2-aminoacetate

>  <CAS>
14783-68-7

>  <Formula>
C4H8MgN2O4

>  <MolWt>
172.4

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Magnesium glycinate is a supplement that boost magnesium levels in people with a deficiency of the mineral. Magnesium is a vital nutrient for regulating many body processes, including muscle and nerve function, blood sugar levels, and blood pressure. This mineral also supports the making of protein, bone, and DNA."

>  <Reference>
"Schwalfenberg GK,etal.The Importance of Magnesium in Clinical Healthcare.Scientifica (Cairo). 2017;2017:4179326."

>  <ID<1>>
T4512

$$$$
StarDrop ID 278
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0768 -2.3215 0.0000 0
M  V30 2 C 0.8838 -2.1500 0.0000 0
M  V30 3 O 1.4358 -2.7631 0.0000 0
M  V30 4 C 1.1387 -1.3654 0.0000 0
M  V30 5 N 0.6538 -0.6979 0.0000 0
M  V30 6 C 1.1387 -0.0305 0.0000 0
M  V30 7 N 1.9233 -0.2854 0.0000 0
M  V30 8 C 2.6378 0.1271 0.0000 0
M  V30 9 O 2.6378 0.9521 0.0000 0
M  V30 10 N 3.3523 -0.2854 0.0000 0
M  V30 11 N 3.3523 -1.1104 0.0000 0
M  V30 12 N 2.6378 -1.5229 0.0000 0
M  V30 13 C 1.9233 -1.1104 0.0000 0
M  V30 14 C 4.0668 0.1271 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 4 13
M  V30 14 1 7 13
M  V30 15 1 10 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
278

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Temozolomide Acid

>  <Synonyms>
TMZA

>  <CAS>
113942-30-6

>  <Formula>
C6H5N5O3

>  <MolWt>
195.1

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Temozolomide Acid is a metabolite of temozolomide (TMZ). Temozolomide processes anticancer activity in vitro. Temozolomide (TMZ) is an oral alkylating agent used to treat glioblastoma multiforme (GBM) and astrocytomas.

>  <Reference>
"Lee S Y . Temozolomide resistance in glioblastoma multiforme[J]. Genes & Diseases, 2016, 3( 3):198-210. ;Karachi A , Dastmalchi F , Mitchell D A , et al. Temozolomide for Immunomodulation in the Treatment of Glioblastoma[J]. Neuro Oncology, 2018, 20(12):1566-1572."

>  <ID<1>>
T21463

$$$$
StarDrop ID 279
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -1.7309 9.3770 0.0000 0
M  V30 2 N -1.0164 8.9645 0.0000 0
M  V30 3 C -0.3020 9.3770 0.0000 0
M  V30 4 C 0.4125 8.9645 0.0000 0
M  V30 5 Cl 1.1270 9.3770 0.0000 0
M  V30 6 C 0.4125 8.1395 0.0000 0
M  V30 7 N 1.1270 7.7270 0.0000 0
M  V30 8 C 1.1270 6.9020 0.0000 0
M  V30 9 O 0.4125 6.4895 0.0000 0
M  V30 10 C 1.8414 6.4895 0.0000 0
M  V30 11 C 2.5559 6.9020 0.0000 0
M  V30 12 C 3.2704 6.4895 0.0000 0
M  V30 13 C 3.2704 5.6645 0.0000 0
M  V30 14 O 3.9849 5.2520 0.0000 0
M  V30 15 C 4.6993 5.6645 0.0000 0
M  V30 16 F 4.6993 6.4895 0.0000 0
M  V30 17 F 5.4138 5.2520 0.0000 0
M  V30 18 C 2.5559 5.2520 0.0000 0
M  V30 19 O 2.5559 4.4270 0.0000 0
M  V30 20 C 3.2704 4.0145 0.0000 0
M  V30 21 C 3.2704 3.1895 0.0000 0
M  V30 22 C 3.6829 2.4750 0.0000 0
M  V30 23 C 2.8579 2.4750 0.0000 0
M  V30 24 C 1.8414 5.6645 0.0000 0
M  V30 25 C -0.3020 7.7270 0.0000 0
M  V30 26 Cl -0.3020 6.9020 0.0000 0
M  V30 27 C -1.0164 8.1395 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 1 13 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 21 23
M  V30 24 2 18 24
M  V30 25 1 10 24
M  V30 26 1 6 25
M  V30 27 1 25 26
M  V30 28 2 25 27
M  V30 29 1 2 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
279

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Roflumilast N-oxide

>  <Synonyms>
N/A

>  <CAS>
292135-78-5

>  <Formula>
C17H14Cl2F2N2O4

>  <MolWt>
419.2

>  <Pathways>
Metabolism

>  <Target>
PDE

>  <Receptor>
 PDE type 4:

>  <Bioactivity>
Roflumilast N-oxide is an inhibitor of PDE type 4.

>  <Reference>
"Victoni T,etal.Roflumilast n-oxide associated with PGE2 prevents the neutrophil elastase-induced production of chemokines by epithelial cells.Int Immunopharmacol. 2016 Jan;30:1-8.;Milara J,etal.Simvastatin Increases the Ability of Roflumilast N-oxide to Inhibit Cigarette Smoke-Induced Epithelial to Mesenchymal Transition in Well-differentiated Human Bronchial Epithelial Cells in vitro.COPD. 2015 Jun;12(3):320-31.;Vollert S,etal.The glucose-lowering effects of the PDE4 inhibitors roflumilast and roflumilast-N-oxide in db/db mice.Diabetologia. 2012 Oct;55(10):2779-2788."

>  <ID<1>>
T4462

$$$$
StarDrop ID 280
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 13 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 1.1049 1.8091 0.0000 0
M  V30 2 C 1.1049 0.9841 0.0000 0 CFG=2
M  V30 3 C 1.5174 0.2696 0.0000 0
M  V30 4 C 0.6924 0.2696 0.0000 0 CFG=1
M  V30 5 C -0.0221 -0.1429 0.0000 0
M  V30 6 C -0.0221 -0.9679 0.0000 0
M  V30 7 C -0.7366 -1.3804 0.0000 0
M  V30 8 C -1.4510 -0.9679 0.0000 0
M  V30 9 C -1.4510 -0.1429 0.0000 0
M  V30 10 C -0.7366 0.2696 0.0000 0
M  V30 11 H 2.0708 1.2429 0.0000 0
M  V30 12 H 0.9512 -0.6963 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 2 4
M  V30 5 1 4 5 CFG=1
M  V30 6 2 5 6
M  V30 7 1 6 7
M  V30 8 2 7 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 5 10
M  V30 12 1 11 2
M  V30 13 1 12 4
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
280

>  <Plate>
PHD136328

>  <Row>
n

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tranylcypromine hemisulfate

>  <Synonyms>
Tranylcypromine Sulfate;Tranylcypromine (hemisulfate)

>  <CAS>
13492-01-8

>  <Formula>
C18H24N2O4S

>  <MolWt>
364.5

>  <Pathways>
Chromatin/Epigenetic;Metabolism;Neuroscience

>  <Target>
MAO;Histone Demethylase;Monoamine Oxidase

>  <Receptor>
Histone Demethylase; LSD1; MAO; Monoamine Oxidase

>  <Bioactivity>
Tranylcypromine is an inhibitor of monoamine oxidase (MAO) and lysine-specific demethylase 1 (LSD1)  with a rapid onset of activity.

>  <Reference>
"Neuroprotective effects of the monoamine oxidase inhibitor tranylcypromine and its amide derivatives against A??(1?C42)-induced toxicity[J]. European Journal of Pharmacology, 2015, 764:256-263.;Takayuki T , Keiichiro I , Hideki H , et al. Potential Neuroprotective Effects of an LSD1 Inhibitor in Retinal Ganglion Cells via p38 MAPK Activity[J]. Investigative Opthalmology & Visual Science, 2016, 57(14):6461-."

>  <ID<1>>
T7942

$$$$
StarDrop ID 281
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7145 -6.1875 0.0000 0
M  V30 2 C 1.4289 -6.6000 0.0000 0
M  V30 3 C 2.1434 -6.1875 0.0000 0
M  V30 4 N 2.8579 -6.6000 0.0000 0
M  V30 5 C 3.5724 -6.1875 0.0000 0
M  V30 6 C 4.2868 -6.6000 0.0000 0
M  V30 7 O 4.2868 -7.4250 0.0000 0
M  V30 8 C 5.0013 -6.1875 0.0000 0
M  V30 9 O 5.7158 -6.6000 0.0000 0
M  V30 10 C 6.4302 -6.1875 0.0000 0
M  V30 11 C 6.4302 -5.3625 0.0000 0
M  V30 12 C 7.1447 -4.9500 0.0000 0
M  V30 13 C 7.8592 -5.3625 0.0000 0
M  V30 14 C 7.8592 -6.1875 0.0000 0
M  V30 15 C 7.1447 -6.6000 0.0000 0
M  V30 16 C 7.1447 -7.4250 0.0000 0
M  V30 17 O 7.8592 -7.8375 0.0000 0
M  V30 18 C 6.4302 -7.8375 0.0000 0
M  V30 19 C 6.4302 -8.6625 0.0000 0
M  V30 20 C 7.1447 -9.0750 0.0000 0
M  V30 21 C 7.8592 -8.6625 0.0000 0
M  V30 22 C 8.5737 -9.0750 0.0000 0
M  V30 23 C 8.5737 -9.9000 0.0000 0
M  V30 24 C 7.8592 -10.3125 0.0000 0
M  V30 25 C 7.1447 -9.9000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 10 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 20 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
281

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Propafenone

>  <Synonyms>
Propafenonum;Rythmol

>  <CAS>
54063-53-5

>  <Formula>
C21H27NO3

>  <MolWt>
341.5

>  <Pathways>
Immunology/Inflammation;Membrane transporter/Ion channel

>  <Target>
Potassium Channel;Sodium Channel;MRP

>  <Receptor>
MRP1; Potassium Channel; Sodium Channel

>  <Bioactivity>
"Propafenone is only found in individuals that have used or taken this drug. It is an antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. The electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy."

>  <Reference>
"Overington JP, et al. Nat Rev Drug Discov. 2006 Dec;5(12):993-6."

>  <ID<1>>
T0866

$$$$
StarDrop ID 282
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7861 2.5300 0.0000 0
M  V30 2 O 4.5006 2.1175 0.0000 0
M  V30 3 C 4.5006 1.2925 0.0000 0
M  V30 4 C 5.2150 0.8800 0.0000 0
M  V30 5 C 5.2150 0.0550 0.0000 0
M  V30 6 C 4.5006 -0.3575 0.0000 0
M  V30 7 O 4.5006 -1.1825 0.0000 0
M  V30 8 C 5.2150 -1.5950 0.0000 0
M  V30 9 C 3.7861 0.0550 0.0000 0
M  V30 10 C 3.7861 0.8800 0.0000 0
M  V30 11 C 3.0716 -0.3575 0.0000 0
M  V30 12 O 2.3571 0.0550 0.0000 0
M  V30 13 C 3.0716 -1.1825 0.0000 0
M  V30 14 C 3.7861 -1.5950 0.0000 0
M  V30 15 N 2.3571 -1.5950 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 6 9
M  V30 9 2 9 10
M  V30 10 1 3 10
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
282

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Methoxamine hydrochloride

>  <Synonyms>
Methoxamine HCl

>  <CAS>
61-16-5

>  <Formula>
C11H17NO3??HCl

>  <MolWt>
247.7

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor

>  <Bioactivity>
An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION.

>  <Reference>
"Satoh M, et al. Eur J Pharmacol. 1994 Nov 24;265(3):133-9."

>  <ID<1>>
T0993

$$$$
StarDrop ID 283
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 27 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 4.8106 6.0880 0.0000 0
M  V30 2 C 4.3257 5.4206 0.0000 0
M  V30 3 C 3.8408 4.7532 0.0000 0
M  V30 4 C 4.1764 3.9995 0.0000 0 CFG=1
M  V30 5 C 4.9968 3.9132 0.0000 0
M  V30 6 C 5.5489 4.5263 0.0000 0
M  V30 7 C 6.3025 4.1908 0.0000 0
M  V30 8 C 6.2163 3.3703 0.0000 0
M  V30 9 C 5.4093 3.1988 0.0000 0
M  V30 10 N 3.6914 3.3320 0.0000 0
M  V30 11 C 3.9464 2.5474 0.0000 0
M  V30 12 C 3.2789 2.0625 0.0000 0
M  V30 13 C 2.6115 2.5474 0.0000 0
M  V30 14 N 2.8664 3.3320 0.0000 0
M  V30 15 C 3.2789 1.2375 0.0000 0
M  V30 16 N 3.9934 0.8250 0.0000 0
M  V30 17 C 3.9934 0.0000 0.0000 0
M  V30 18 N 3.2789 -0.4125 0.0000 0
M  V30 19 C 2.5645 0.0000 0.0000 0
M  V30 20 N 1.7798 -0.2549 0.0000 0
M  V30 21 C 1.2949 0.4125 0.0000 0
M  V30 22 C 1.7798 1.0799 0.0000 0
M  V30 23 C 2.5645 0.8250 0.0000 0
M  V30 24 H 4.7641 4.8086 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 3 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 5 9
M  V30 10 1 4 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 10 14
M  V30 16 1 12 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 15 23
M  V30 26 2 19 23
M  V30 27 1 24 4
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
283

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ruxolitinib (S enantiomer)

>  <Synonyms>
S-Ruxolitinib;INCB018424;INCB18424;Ruxolitinib S enantiomer

>  <CAS>
941685-37-6

>  <Formula>
C17H18N6

>  <MolWt>
306.4

>  <Pathways>
Stem Cells;JAK/STAT signaling;Angiogenesis;Chromatin/Epigenetic;Tyrosine Kinase/Adaptors

>  <Target>
JAK;Tyrosine Kinases

>  <Receptor>
" TYK2(Cell-free assay):19 nM, JAK1(Cell-free assay):3.3 nM, JAK2 (Cell-free assay):2.8 nM"

>  <Bioactivity>
"Ruxolitinib S enantiomer is the S-enantiomer of Ruxolitinib. Ruxolitinib is the first potent, selective JAK1/2 inhibitor."

>  <Reference>
"Quintas-Cardama A, et al. Blood, 2010, 115(15), 3109-3117.;Harrison C, et al. N Engl J Med, 2012, 366(9), 787-798.;Verstovsek S, et al. N Engl J Med, 2012, 366(9), 799-807."

>  <ID<1>>
T6156

$$$$
StarDrop ID 284
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 1.5699 0.5834 0.0000 0
M  V30 2 C 2.3546 0.8384 0.0000 0 CFG=2
M  V30 3 C 2.8395 0.1709 0.0000 0
M  V30 4 S 2.3546 -0.4965 0.0000 0
M  V30 5 C 1.5699 -0.2416 0.0000 0 CFG=2
M  V30 6 C 0.7449 -0.2416 0.0000 0 CFG=1
M  V30 7 C 0.7449 0.5834 0.0000 0
M  V30 8 O 0.1616 1.1668 0.0000 0
M  V30 9 N 0.1616 -0.8249 0.0000 0
M  V30 10 C -0.6353 -0.6114 0.0000 0
M  V30 11 O -0.8488 0.1855 0.0000 0
M  V30 12 C -1.2187 -1.1948 0.0000 0
M  V30 13 C -2.0335 -1.0657 0.0000 0
M  V30 14 N -2.4081 -1.8008 0.0000 0
M  V30 15 O -1.8247 -2.3842 0.0000 0
M  V30 16 C -1.0896 -2.0096 0.0000 0
M  V30 17 C -0.3545 -2.3842 0.0000 0
M  V30 18 C -2.4081 -0.3306 0.0000 0
M  V30 19 C -3.2319 -0.2875 0.0000 0
M  V30 20 C -3.6065 0.4476 0.0000 0
M  V30 21 C -3.1571 1.1395 0.0000 0
M  V30 22 C -2.3333 1.0963 0.0000 0
M  V30 23 C -1.9587 0.3613 0.0000 0
M  V30 24 Cl -1.1349 0.3181 0.0000 0
M  V30 25 Cl -3.6813 -0.9794 0.0000 0
M  V30 26 C 3.5582 -0.2341 0.0000 0
M  V30 27 C 3.5582 0.5759 0.0000 0
M  V30 28 C 2.6095 1.6230 0.0000 0
M  V30 29 O 2.0575 2.2361 0.0000 0
M  V30 30 O 3.4165 1.7945 0.0000 0
M  V30 31 H 3.3423 0.9947 0.0000 0
M  V30 32 H 0.8628 0.4655 0.0000 0
M  V30 33 H -0.1789 0.1412 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 1 CFG=3
M  V30 6 1 5 6
M  V30 7 1 6 7
M  V30 8 1 1 7
M  V30 9 2 7 8
M  V30 10 1 6 9 CFG=3
M  V30 11 1 9 10
M  V30 12 2 10 11
M  V30 13 1 10 12
M  V30 14 1 12 13
M  V30 15 2 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 12 16
M  V30 19 1 16 17
M  V30 20 1 13 18
M  V30 21 2 18 19
M  V30 22 1 19 20
M  V30 23 2 20 21
M  V30 24 1 21 22
M  V30 25 2 22 23
M  V30 26 1 18 23
M  V30 27 1 23 24
M  V30 28 1 19 25
M  V30 29 1 3 26
M  V30 30 1 3 27
M  V30 31 1 2 28 CFG=1
M  V30 32 2 28 29
M  V30 33 1 28 30
M  V30 34 1 31 2
M  V30 35 1 32 5
M  V30 36 1 33 6
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
284

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dicloxacillin Sodium hydrate

>  <Synonyms>
Dicloxacillin sodium salt monohydrate;Dicloxacillin sodium monohydrate

>  <CAS>
13412-64-1

>  <Formula>
C19H18Cl2N3NaO6S

>  <MolWt>
510.3

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial;Antibiotic

>  <Receptor>
Antibacterial; Antibiotic; Bacterial

>  <Bioactivity>
"Dicloxacillin NaOH is a narrow-spectrum ??-Lactam antibiotic of the penicillin class, used to treat infections caused by susceptible Gram-positive bacteria."

>  <Reference>
"Villegas-Guzman P, et al. J Environ Sci Health A Tox Hazard Subst Environ Eng. 2015;50(1):40-8."

>  <ID<1>>
T1001

$$$$
StarDrop ID 285
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 88 97 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.0695 -7.7710 0.0000 0
M  V30 2 O 6.3244 -6.9864 0.0000 0
M  V30 3 C 5.7724 -6.3733 0.0000 0 CFG=2
M  V30 4 C 4.9654 -6.5448 0.0000 0
M  V30 5 C 6.0273 -5.5886 0.0000 0 CFG=2
M  V30 6 N 6.8343 -5.4171 0.0000 0
M  V30 7 C 7.3863 -6.0302 0.0000 0
M  V30 8 O 7.1314 -6.8148 0.0000 0
M  V30 9 O 8.1933 -5.8587 0.0000 0
M  V30 10 C 8.4482 -5.0741 0.0000 0
M  V30 11 C 5.4753 -4.9755 0.0000 0
M  V30 12 O 5.7302 -4.1909 0.0000 0
M  V30 13 N 4.6683 -5.1471 0.0000 0
M  V30 14 C 4.3328 -5.9008 0.0000 0
M  V30 15 C 3.5123 -5.8145 0.0000 0
M  V30 16 C 3.3408 -5.0075 0.0000 0
M  V30 17 C 4.0552 -4.5950 0.0000 0 CFG=1
M  V30 18 C 4.1415 -3.7746 0.0000 0
M  V30 19 N 4.8559 -3.3621 0.0000 0
M  V30 20 C 4.6844 -2.5551 0.0000 0
M  V30 21 C 5.1693 -1.8877 0.0000 0
M  V30 22 C 4.8338 -1.1340 0.0000 0
M  V30 23 F 5.3187 -0.4665 0.0000 0
M  V30 24 C 4.0133 -1.0477 0.0000 0
M  V30 25 C 3.5284 -1.7152 0.0000 0
M  V30 26 C 3.8639 -2.4689 0.0000 0
M  V30 27 N 3.5284 -3.2225 0.0000 0
M  V30 28 C 3.6777 -0.2941 0.0000 0 CFG=1
M  V30 29 C 4.0902 0.4204 0.0000 0
M  V30 30 C 3.5382 1.0335 0.0000 0
M  V30 31 C 2.7845 0.6979 0.0000 0 CFG=1
M  V30 32 N 2.8708 -0.1225 0.0000 0
M  V30 33 C 2.2577 -0.6746 0.0000 0
M  V30 34 C 2.4292 -1.4815 0.0000 0
M  V30 35 C 1.8161 -2.0336 0.0000 0
M  V30 36 F 1.9876 -2.8405 0.0000 0
M  V30 37 C 1.0315 -1.7786 0.0000 0
M  V30 38 N 0.4184 -2.3307 0.0000 0
M  V30 39 C 0.5899 -3.1376 0.0000 0
M  V30 40 C -0.0232 -3.6897 0.0000 0
M  V30 41 C -0.8078 -3.4347 0.0000 0
M  V30 42 C -0.9793 -2.6278 0.0000 0
M  V30 43 C -0.3662 -2.0757 0.0000 0
M  V30 44 C -1.4209 -3.9868 0.0000 0
M  V30 45 C -1.2494 -4.7937 0.0000 0
M  V30 46 C -1.8625 -5.3458 0.0000 0
M  V30 47 C -2.6471 -5.0908 0.0000 0
M  V30 48 F -3.2602 -5.6429 0.0000 0
M  V30 49 C -2.8186 -4.2839 0.0000 0
M  V30 50 C -2.2055 -3.7318 0.0000 0
M  V30 51 C 0.8600 -0.9717 0.0000 0
M  V30 52 F 0.0753 -0.7167 0.0000 0
M  V30 53 C 1.4730 -0.4196 0.0000 0
M  V30 54 C 2.0701 1.1104 0.0000 0
M  V30 55 C 1.3556 0.6979 0.0000 0
M  V30 56 C 0.6411 1.1104 0.0000 0
M  V30 57 N -0.1435 0.8555 0.0000 0
M  V30 58 C -0.6284 1.5229 0.0000 0
M  V30 59 N -0.1435 2.1904 0.0000 0
M  V30 60 C 0.6411 1.9354 0.0000 0
M  V30 61 C 1.3556 2.3479 0.0000 0
M  V30 62 C 2.0701 1.9354 0.0000 0
M  V30 63 F 2.7845 2.3479 0.0000 0
M  V30 64 C -1.4534 1.5229 0.0000 0 CFG=2
M  V30 65 C -1.9384 0.8555 0.0000 0
M  V30 66 C -2.7230 1.1104 0.0000 0
M  V30 67 C -2.7230 1.9354 0.0000 0
M  V30 68 N -1.9384 2.1904 0.0000 0
M  V30 69 C -1.6834 2.9750 0.0000 0
M  V30 70 O -0.8764 3.1465 0.0000 0
M  V30 71 C -2.2354 3.5881 0.0000 0 CFG=1
M  V30 72 N -1.9805 4.3727 0.0000 0
M  V30 73 C -2.5325 4.9858 0.0000 0
M  V30 74 O -3.3395 4.8143 0.0000 0
M  V30 75 O -2.2776 5.7704 0.0000 0
M  V30 76 C -2.8296 6.3835 0.0000 0
M  V30 77 C -3.0424 3.4166 0.0000 0 CFG=1
M  V30 78 C -3.5945 4.0297 0.0000 0
M  V30 79 O -3.2974 2.6319 0.0000 0
M  V30 80 C -4.1043 2.4604 0.0000 0
M  V30 81 H -0.9995 0.6319 0.0000 0
M  V30 82 H -2.9046 4.3312 0.0000 0
M  V30 83 H -4.0205 3.2086 0.0000 0
M  V30 84 H 5.4633 -7.3243 0.0000 0
M  V30 85 H 6.3364 -4.6376 0.0000 0
M  V30 86 H 3.2165 -4.0504 0.0000 0
M  V30 87 H 4.6763 -0.3463 0.0000 0
M  V30 88 H 1.9458 0.1533 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=3
M  V30 4 1 3 5
M  V30 5 1 5 6 CFG=1
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 5 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 17 16
M  V30 17 1 17 13
M  V30 18 1 17 18 CFG=1
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 1 22 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 20 26
M  V30 28 1 26 27
M  V30 29 2 18 27
M  V30 30 1 28 24 CFG=3
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 1 31 30
M  V30 34 1 31 32
M  V30 35 1 28 32
M  V30 36 1 32 33
M  V30 37 2 33 34
M  V30 38 1 34 35
M  V30 39 1 35 36
M  V30 40 2 35 37
M  V30 41 1 37 38
M  V30 42 1 38 39
M  V30 43 1 39 40
M  V30 44 1 40 41
M  V30 45 1 41 42
M  V30 46 1 42 43
M  V30 47 1 38 43
M  V30 48 1 41 44
M  V30 49 2 44 45
M  V30 50 1 45 46
M  V30 51 2 46 47
M  V30 52 1 47 48
M  V30 53 1 47 49
M  V30 54 2 49 50
M  V30 55 1 44 50
M  V30 56 1 37 51
M  V30 57 1 51 52
M  V30 58 2 51 53
M  V30 59 1 33 53
M  V30 60 1 31 54 CFG=1
M  V30 61 1 54 55
M  V30 62 1 55 56
M  V30 63 2 56 57
M  V30 64 1 57 58
M  V30 65 2 58 59
M  V30 66 1 59 60
M  V30 67 2 56 60
M  V30 68 2 60 61
M  V30 69 1 61 62
M  V30 70 2 54 62
M  V30 71 1 62 63
M  V30 72 1 64 58 CFG=3
M  V30 73 1 64 65
M  V30 74 1 65 66
M  V30 75 1 66 67
M  V30 76 1 67 68
M  V30 77 1 64 68
M  V30 78 1 68 69
M  V30 79 2 69 70
M  V30 80 1 71 69
M  V30 81 1 71 72 CFG=3
M  V30 82 1 72 73
M  V30 83 2 73 74
M  V30 84 1 73 75
M  V30 85 1 75 76
M  V30 86 1 71 77
M  V30 87 1 77 78 CFG=3
M  V30 88 1 77 79
M  V30 89 1 79 80
M  V30 90 1 81 64
M  V30 91 1 82 71
M  V30 92 1 83 77
M  V30 93 1 84 3
M  V30 94 1 85 5
M  V30 95 1 86 17
M  V30 96 1 87 28
M  V30 97 1 88 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
285

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
ABT530

>  <Synonyms>
ABT-530;ABT 530;Pibrentasvir

>  <CAS>
1353900-92-1

>  <Formula>
C57H65F5N10O8

>  <MolWt>
1113

>  <Pathways>
Proteases/Proteasome;Microbiology/Virology

>  <Target>
HCV Protease

>  <Receptor>
 HCV NS5A:1.4-5.0 pM(EC50)

>  <Bioactivity>
ABT-530 (Pibrentasvir) is an HCV NS5A inhibitor with EC50s ranging from 1.4-5.0 pM against HCV replicons containing NS5A from genotypes 1-6.

>  <Reference>
"Pham LV, et al. HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models. Gastroenterology. 2018 Jun;154(8):2194-2208.e12.;Ng TI, et al. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir. Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02558-16."

>  <ID<1>>
T5127

$$$$
StarDrop ID 286
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl 2.1434 -8.6625 0.0000 0
M  V30 2 C 2.8579 -9.0750 0.0000 0
M  V30 3 C 3.5724 -8.6625 0.0000 0
M  V30 4 C 4.2868 -9.0750 0.0000 0
M  V30 5 C 4.2868 -9.9000 0.0000 0
M  V30 6 N 5.0013 -10.3125 0.0000 0
M  V30 7 C 5.7158 -9.9000 0.0000 0
M  V30 8 N 5.7158 -9.0750 0.0000 0
M  V30 9 N 6.4302 -10.3125 0.0000 0
M  V30 10 C 7.1447 -9.9000 0.0000 0
M  V30 11 N 7.1447 -9.0750 0.0000 0
M  V30 12 N 7.8592 -10.3125 0.0000 0
M  V30 13 C 8.5737 -9.9000 0.0000 0
M  V30 14 C 9.2881 -10.3125 0.0000 0
M  V30 15 C 10.0026 -9.9000 0.0000 0
M  V30 16 C 10.7171 -10.3125 0.0000 0
M  V30 17 C 11.4315 -9.9000 0.0000 0
M  V30 18 C 12.1460 -10.3125 0.0000 0
M  V30 19 N 12.8605 -9.9000 0.0000 0
M  V30 20 C 13.5749 -10.3125 0.0000 0
M  V30 21 N 13.5749 -11.1375 0.0000 0
M  V30 22 N 14.2894 -9.9000 0.0000 0
M  V30 23 C 15.0039 -10.3125 0.0000 0
M  V30 24 N 15.0039 -11.1375 0.0000 0
M  V30 25 N 15.7184 -9.9000 0.0000 0
M  V30 26 C 16.4328 -10.3125 0.0000 0
M  V30 27 C 17.1473 -9.9000 0.0000 0
M  V30 28 C 17.8618 -10.3125 0.0000 0
M  V30 29 C 17.8618 -11.1375 0.0000 0
M  V30 30 Cl 18.5762 -11.5500 0.0000 0
M  V30 31 C 17.1473 -11.5500 0.0000 0
M  V30 32 C 16.4328 -11.1375 0.0000 0
M  V30 33 C 3.5724 -10.3125 0.0000 0
M  V30 34 C 2.8579 -9.9000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 20 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 23 25
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 27 28
M  V30 28 2 28 29
M  V30 29 1 29 30
M  V30 30 1 29 31
M  V30 31 2 31 32
M  V30 32 1 26 32
M  V30 33 1 5 33
M  V30 34 2 33 34
M  V30 35 1 2 34
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
286

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Chlorhexidine

>  <Synonyms>
Nolvasan;Rotersept;Chlorhexidinum

>  <CAS>
55-56-1

>  <Formula>
C22H30Cl2N10

>  <MolWt>
505.5

>  <Pathways>
Microbiology/Virology;oxidation-reduction

>  <Target>
Antibacterial;Antibiotic;CAT;Antifection

>  <Receptor>
Antibiotic; Bacterial; CAT; HNMT

>  <Bioactivity>
"Chlorhexidine is a biguanide compound used as an antiseptic agent with topical antibacterial activity. Chlorhexidine is positively charged and reacts with the negatively charged microbial cell surface, thereby destroying the integrity of the cell membrane. Subsequently, chlorhexidine penetrates into the cell and causes leakage of intracellular components leading to cell death. Since gram-positive bacteria are more negatively charged, they are more sensitive to this agent."

>  <Reference>
"Solov'eva NN, et al. Antibiotiki. 1979 Jun;24(6):436-40.;Dong L, Shen S, Chen W, et al. Discovery of Novel Inhibitors Targeting Human O-GlcNAcase: Docking-Based Virtual Screening, Biological Evaluation, Structural Modification, and Molecular Dynamics Simulation[J]. Journal of chemical information and modeling. 2019, 59(10): 4374-4382."

>  <ID<1>>
T1000

$$$$
StarDrop ID 287
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 5.6091 -0.8866 0.0000 0
M  V30 2 C 4.8946 -1.2991 0.0000 0
M  V30 3 F 4.4821 -0.5846 0.0000 0
M  V30 4 F 5.3071 -2.0136 0.0000 0
M  V30 5 C 4.1801 -1.7116 0.0000 0
M  V30 6 C 4.1801 -2.5366 0.0000 0
M  V30 7 C 3.4656 -2.9491 0.0000 0
M  V30 8 C 2.7512 -2.5366 0.0000 0
M  V30 9 C 2.7512 -1.7116 0.0000 0
M  V30 10 C 3.4656 -1.2991 0.0000 0
M  V30 11 C 2.0367 -1.2991 0.0000 0
M  V30 12 F 1.3222 -0.8866 0.0000 0
M  V30 13 F 2.4492 -0.5846 0.0000 0
M  V30 14 F 1.6242 -2.0136 0.0000 0
M  V30 15 C 3.4656 -3.7741 0.0000 0
M  V30 16 N 4.1331 -4.2590 0.0000 0
M  V30 17 C 3.8781 -5.0437 0.0000 0
M  V30 18 N 3.0531 -5.0437 0.0000 0
M  V30 19 C 2.5682 -5.7111 0.0000 0
M  V30 20 C 1.7477 -5.6249 0.0000 0
M  V30 21 C 1.2628 -6.2923 0.0000 0
M  V30 22 O 1.5984 -7.0460 0.0000 0
M  V30 23 N 0.4423 -6.2061 0.0000 0
M  V30 24 N -0.0426 -6.8735 0.0000 0
M  V30 25 C -0.8631 -6.7873 0.0000 0
M  V30 26 C -1.3480 -7.4547 0.0000 0
M  V30 27 N -2.1685 -7.3685 0.0000 0
M  V30 28 C -2.5040 -6.6148 0.0000 0
M  V30 29 C -2.0191 -5.9473 0.0000 0
M  V30 30 N -1.1986 -6.0336 0.0000 0
M  V30 31 N 2.7982 -4.2590 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 5 10
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 11 14
M  V30 15 1 7 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 2 27 28
M  V30 29 1 28 29
M  V30 30 2 29 30
M  V30 31 1 25 30
M  V30 32 1 18 31
M  V30 33 2 15 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
287

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
KPT330,(E)-

>  <Synonyms>
KPT-330;KPT330;KPT 330;(E)-RN

>  <CAS>
1421923-86-5

>  <Formula>
C17H11F6N7O

>  <MolWt>
443.3

>  <Pathways>
Others;Membrane transporter/Ion channel

>  <Target>
Others;CRM1

>  <Receptor>
CRM1; XPO1

>  <Bioactivity>
"KPT330,(E)- is a CRM1-selective inhibitor of nuclear export. It inhibits protein trafficking from the nucleus and induces cell cycle arrest and apoptosis in mesothelioma cells."

>  <Reference>
"Tai YT, et al. Leukemia. 2014, 28(1), 155-165.;Etchin J, et al. Br J Haematol. 2013, 161(1), 117-127."

>  <ID<1>>
T1844

$$$$
StarDrop ID 288
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.8697 -1.6500 0.0000 0
M  V30 2 N 3.8697 -0.8250 0.0000 0
M  V30 3 C 3.1553 -0.4125 0.0000 0
M  V30 4 N 2.3706 -0.6674 0.0000 0
M  V30 5 C 1.8857 -0.0000 0.0000 0
M  V30 6 N 2.3706 0.6674 0.0000 0
M  V30 7 C 3.1553 0.4125 0.0000 0
M  V30 8 C 3.8697 0.8250 0.0000 0
M  V30 9 O 3.8697 1.6500 0.0000 0
M  V30 10 N 4.5842 0.4125 0.0000 0
M  V30 11 C 5.2987 0.8250 0.0000 0
M  V30 12 C 4.5842 -0.4125 0.0000 0
M  V30 13 O 5.2987 -0.8250 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 3 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 2 12
M  V30 14 2 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
288

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Theophylline monohydrate

>  <Synonyms>
Quibron

>  <CAS>
5967-84-0

>  <Formula>
C7H10N4O3

>  <MolWt>
198.2

>  <Pathways>
GPCR/G Protein;Neuroscience;Chromatin/Epigenetic;Metabolism;DNA Damage/DNA Repair

>  <Target>
HDAC;PDE;Adenosine Receptor

>  <Receptor>
Adenosine receptor; HDAC2; PDE

>  <Bioactivity>
"Theophylline appears to inhibit phosphodiesterase and prostaglandin production, regulate calcium flux and intracellular calcium distribution, and antagonize adenosine. Theophylline is a natural alkaloid derivative of xanthine isolated from the plants Camellia sinensis and Coffea arabica. Physiologically, this agent relaxes the bronchial smooth muscle, produces vasodilation (except in cerebral vessels), stimulates the CNS, stimulates the cardiac muscle, induces diuresis, and increases gastric acid secretion; it may also suppress inflammation and improve contractility of the diaphragm."

>  <Reference>
"Nantwi KD, et al. J Spinal Cord Med. 2003 Winter;26(4):364-71."

>  <ID<1>>
T1083L

$$$$
StarDrop ID 289
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 44 46 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.4289 -2.4750 0.0000 0
M  V30 2 S -0.7145 -2.0625 0.0000 0
M  V30 3 C 0.0000 -2.4750 0.0000 0
M  V30 4 C 0.7145 -2.0625 0.0000 0
M  V30 5 N 1.4289 -2.4750 0.0000 0
M  V30 6 C 2.1434 -2.0625 0.0000 0
M  V30 7 N 2.1434 -1.2375 0.0000 0
M  V30 8 C 2.8579 -0.8250 0.0000 0
M  V30 9 S 2.8579 -0.0000 0.0000 0
M  V30 10 C 2.1434 0.4125 0.0000 0
M  V30 11 C 2.1434 1.2375 0.0000 0
M  V30 12 C 1.4289 1.6500 0.0000 0
M  V30 13 F 1.8414 2.3645 0.0000 0
M  V30 14 F 1.0164 0.9355 0.0000 0
M  V30 15 F 0.7145 2.0625 0.0000 0
M  V30 16 N 3.5724 -1.2375 0.0000 0
M  V30 17 C 3.5724 -2.0625 0.0000 0
M  V30 18 N 4.1854 -2.6145 0.0000 0
M  V30 19 C 3.8499 -3.3682 0.0000 0
M  V30 20 N 3.0294 -3.2820 0.0000 0
M  V30 21 C 2.8579 -2.4750 0.0000 0
M  V30 22 C 4.9924 -2.4430 0.0000 0
M  V30 23 O 5.3280 -1.6893 0.0000 0
M  V30 24 C 6.1485 -1.7756 0.0000 0
M  V30 25 C 6.7005 -1.1625 0.0000 0
M  V30 26 O 7.5075 -1.3340 0.0000 0
M  V30 27 P 8.0595 -0.7209 0.0000 0
M  V30 28 O 8.6115 -0.1078 0.0000 0
M  V30 29 O 7.4464 -0.1689 0.0000 0
M  V30 30 O 8.6726 -1.2729 0.0000 0
M  V30 31 P 8.5011 -2.0799 0.0000 0
M  V30 32 O 9.3080 -2.2514 0.0000 0
M  V30 33 O 7.6941 -1.9084 0.0000 0
M  V30 34 C 8.3295 -2.8869 0.0000 0
M  V30 35 Cl 9.1365 -3.0584 0.0000 0
M  V30 36 Cl 7.5226 -2.7154 0.0000 0
M  V30 37 P 8.1580 -3.6939 0.0000 0
M  V30 38 O 7.9865 -4.5008 0.0000 0
M  V30 39 O 8.9650 -3.8654 0.0000 0
M  V30 40 O 7.3510 -3.5223 0.0000 0
M  V30 41 C 6.3200 -2.5825 0.0000 0
M  V30 42 O 7.0737 -2.9181 0.0000 0
M  V30 43 C 5.6055 -2.9950 0.0000 0
M  V30 44 O 5.5193 -3.8155 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 15 2 8 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 1 6 21
M  V30 22 2 17 21
M  V30 23 1 18 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 2 27 29
M  V30 31 1 27 30
M  V30 32 1 30 31
M  V30 33 1 31 32
M  V30 34 2 31 33
M  V30 35 1 31 34
M  V30 36 1 34 35
M  V30 37 1 34 36
M  V30 38 1 34 37
M  V30 39 1 37 38
M  V30 40 1 37 39
M  V30 41 2 37 40
M  V30 42 1 24 41
M  V30 43 1 41 42
M  V30 44 1 41 43
M  V30 45 1 22 43
M  V30 46 1 43 44
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
289

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
cangrelor tetrasodium

>  <Synonyms>
N/A

>  <CAS>
163706-36-3

>  <Formula>
C17H21Cl2F3N5Na4O12P3S2

>  <MolWt>
864.3

>  <Pathways>
Endocrinology/Hormones;GPCR/G Protein;Neuroscience

>  <Target>
GPR;P2Y Receptor

>  <Receptor>
GPR17; P2Y

>  <Bioactivity>
"Cangrelor tetrasodium is a reversible and selective antagonist of platelet P2Y12, with prompt and potent antiplatelet effects."

>  <Reference>
"K. Bek?, B. Kov??nyi, F. G?l?ncs??r, et al. Contribution of platelet P2Y12 receptors to chronic Complete Freund's adjuvant-induced inflammatory pain[J]. Journal of Thrombosis and Haemostasis, 2017.;Bhattad VB, , et al. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med. 2019;7(17):408.;Tianwei Zhan, Taofeng Wei.Cangrelor alleviates bleomycin-induced pulmonary fibrosis by inhibiting platelet activation in mice.Mol Immunol. 2020 Apr;120:83-92."

>  <ID<1>>
T5036

$$$$
StarDrop ID 290
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.7145 2.0625 0.0000 0
M  V30 2 C -0.7145 1.2375 0.0000 0
M  V30 3 O -1.4289 0.8250 0.0000 0
M  V30 4 C 0.0000 0.8250 0.0000 0
M  V30 5 C 0.0000 0.0000 0.0000 0
M  V30 6 C -0.7145 -0.4125 0.0000 0
M  V30 7 C -0.7145 -1.2375 0.0000 0
M  V30 8 C -1.4289 -1.6500 0.0000 0
M  V30 9 C -2.1434 -1.2375 0.0000 0
M  V30 10 C -2.1434 -0.4125 0.0000 0
M  V30 11 C -1.4289 0.0000 0.0000 0
M  V30 12 C 0.7145 -0.4125 0.0000 0
M  V30 13 C 1.4289 0.0000 0.0000 0
M  V30 14 O 1.4289 0.8250 0.0000 0
M  V30 15 C 2.1434 -0.4125 0.0000 0
M  V30 16 C 2.8579 0.0000 0.0000 0
M  V30 17 C 3.5724 -0.4125 0.0000 0
M  V30 18 C 3.5724 -1.2375 0.0000 0
M  V30 19 C 2.8579 -1.6500 0.0000 0
M  V30 20 C 2.1434 -1.2375 0.0000 0
M  V30 21 O 1.4289 -1.6500 0.0000 0
M  V30 22 C 0.7145 -1.2375 0.0000 0
M  V30 23 O 0.0000 -1.6500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 6 11
M  V30 12 1 5 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 15 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 12 22
M  V30 25 2 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
290

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Warfarin sodium

>  <Synonyms>
N/A

>  <CAS>
129-06-6

>  <Formula>
C19H15NaO4

>  <MolWt>
330.3

>  <Pathways>


>  <Target>


>  <Receptor>
VKOR complex subunit 1

>  <Bioactivity>
"An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide."

>  <Reference>
Gebauer M. Bioorg Med Chem. 2007 Mar 15;15(6):2414-20.

>  <ID<1>>
T0815L

$$$$
StarDrop ID 291
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.8578 -2.3952 0.0000 0
M  V30 2 C 4.8578 -1.5702 0.0000 0
M  V30 3 C 4.1433 -1.1577 0.0000 0
M  V30 4 C 5.5723 -1.1577 0.0000 0
M  V30 5 O 5.5723 -0.3327 0.0000 0
M  V30 6 C 6.2867 0.0798 0.0000 0
M  V30 7 C 6.2867 0.9048 0.0000 0
M  V30 8 C 7.0012 1.3173 0.0000 0
M  V30 9 C 7.7157 0.9048 0.0000 0
M  V30 10 C 8.4301 1.3173 0.0000 0
M  V30 11 N 9.1446 0.9048 0.0000 0
M  V30 12 C 9.8591 1.3173 0.0000 0
M  V30 13 O 9.8591 2.1423 0.0000 0
M  V30 14 N 10.5736 0.9048 0.0000 0
M  V30 15 C 11.2880 1.3173 0.0000 0
M  V30 16 C 12.0025 0.9048 0.0000 0
M  V30 17 C 12.7170 1.3173 0.0000 0
M  V30 18 C 13.4314 0.9048 0.0000 0
M  V30 19 C 13.4314 0.0798 0.0000 0
M  V30 20 F 14.1459 -0.3327 0.0000 0
M  V30 21 C 12.7170 -0.3327 0.0000 0
M  V30 22 C 12.0025 0.0798 0.0000 0
M  V30 23 C 10.5736 0.0798 0.0000 0
M  V30 24 C 11.2880 -0.3327 0.0000 0
M  V30 25 C 11.2880 -1.1577 0.0000 0
M  V30 26 N 10.5736 -1.5702 0.0000 0
M  V30 27 C 10.5736 -2.3952 0.0000 0
M  V30 28 C 9.8591 -1.1577 0.0000 0
M  V30 29 C 9.8591 -0.3327 0.0000 0
M  V30 30 C 7.7157 0.0798 0.0000 0
M  V30 31 C 7.0012 -0.3327 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 19 21
M  V30 21 2 21 22
M  V30 22 1 16 22
M  V30 23 1 14 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 26 28
M  V30 29 1 28 29
M  V30 30 1 23 29
M  V30 31 1 9 30
M  V30 32 2 30 31
M  V30 33 1 6 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
291

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pimavanserin tartrate

>  <Synonyms>
Nuplazid;ACP-103 tartrate;Pimavanserin;ACP-103

>  <CAS>
706782-28-7

>  <Formula>
C54H74F2N6O10

>  <MolWt>
1005

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
5-HT Receptor

>  <Receptor>
 5-HT2A:8.7(pIC50)

>  <Bioactivity>
"Pimavanserin is an effective and specific serotonin 5-HT2A inverse agonist (pIC50: 8.73), used in the therapy of psychosis associated with Parkinson's disease."

>  <Reference>
"Vanover KE, et al. J Pharmacol Exp Ther. 2006, 317(2), 910-918.;Vanover KE, et al. Pharmacol Biochem Behav. 2008, 90(4), 540-544."

>  <ID<1>>
T6946

$$$$
StarDrop ID 292
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.6449 -1.6500 0.0000 0
M  V30 2 C -1.8199 -1.6500 0.0000 0
M  V30 3 N -1.4074 -2.3645 0.0000 0
M  V30 4 C -1.8199 -3.0789 0.0000 0
M  V30 5 C -2.6449 -3.0789 0.0000 0
M  V30 6 C -0.5824 -2.3645 0.0000 0
M  V30 7 C -0.1699 -3.0789 0.0000 0
M  V30 8 O -0.5824 -3.7934 0.0000 0
M  V30 9 N 0.6551 -3.0789 0.0000 0
M  V30 10 C 1.0676 -3.7934 0.0000 0
M  V30 11 C 1.8926 -3.7934 0.0000 0
M  V30 12 C 2.3051 -3.0789 0.0000 0
M  V30 13 C 2.3051 -4.5079 0.0000 0
M  V30 14 C 1.8926 -5.2224 0.0000 0
M  V30 15 C 1.0676 -5.2224 0.0000 0
M  V30 16 C 0.6551 -4.5079 0.0000 0
M  V30 17 C -0.1699 -4.5079 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 10 16
M  V30 17 1 16 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
292

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lidocaine Hydrochloride hydrate

>  <Synonyms>
N/A

>  <CAS>
6108-05-0

>  <Formula>
C14H25ClN2O2

>  <MolWt>
288.8

>  <Pathways>
Membrane transporter/Ion channel;JAK/STAT signaling;Tyrosine Kinase/Adaptors;Angiogenesis

>  <Target>
Sodium Channel;EGFR

>  <Receptor>
EGFR; Sodium Channel

>  <Bioactivity>
"Lidocaine Hydrochloride hydrate is an amide local anesthetic, has anti-inflammatory property."

>  <Reference>
"Sheets PL, et al. J Physiol. 2007 Jun 15;581(Pt 3):1019-31."

>  <ID<1>>
T1144L

$$$$
StarDrop ID 293
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 70 78 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.1582 -8.3753 0.0000 0
M  V30 2 O 1.1974 -7.5513 0.0000 0
M  V30 3 C 0.5033 -7.1053 0.0000 0
M  V30 4 O -0.2299 -7.4834 0.0000 0
M  V30 5 N 0.5425 -6.2812 0.0000 0
M  V30 6 C -0.1515 -5.8352 0.0000 0 CFG=1
M  V30 7 C -0.8848 -6.2133 0.0000 0
M  V30 8 C -1.5788 -5.7673 0.0000 0
M  V30 9 C -0.9240 -7.0374 0.0000 0
M  V30 10 C -0.1123 -5.0112 0.0000 0
M  V30 11 O 0.6210 -4.6331 0.0000 0
M  V30 12 N -0.8064 -4.5652 0.0000 0
M  V30 13 C -1.5751 -4.8645 0.0000 0
M  V30 14 C -2.0974 -4.2259 0.0000 0
M  V30 15 C -1.6514 -3.5318 0.0000 0
M  V30 16 C -0.8535 -3.7415 0.0000 0 CFG=1
M  V30 17 C -0.2149 -3.2193 0.0000 0
M  V30 18 N -0.2620 -2.3956 0.0000 0
M  V30 19 C 0.5067 -2.0962 0.0000 0
M  V30 20 C 1.0290 -2.7349 0.0000 0
M  V30 21 N 0.5830 -3.4289 0.0000 0
M  V30 22 C 1.8527 -2.6877 0.0000 0
M  V30 23 C 2.2237 -1.9509 0.0000 0
M  V30 24 C 3.0473 -1.9037 0.0000 0
M  V30 25 C 3.5000 -2.5934 0.0000 0
M  V30 26 C 4.3236 -2.5463 0.0000 0
M  V30 27 C 4.8397 -1.9027 0.0000 0
M  V30 28 C 5.6113 -2.1946 0.0000 0
M  V30 29 C 6.3446 -1.8165 0.0000 0
M  V30 30 C 7.0387 -2.2625 0.0000 0
M  V30 31 C 6.9995 -3.0866 0.0000 0
M  V30 32 C 6.2662 -3.4647 0.0000 0
M  V30 33 C 5.5721 -3.0187 0.0000 0
M  V30 34 N 4.7763 -3.2360 0.0000 0
M  V30 35 C 4.4053 -3.9729 0.0000 0 CFG=1
M  V30 36 O 3.5816 -4.0200 0.0000 0
M  V30 37 C 3.1290 -3.3303 0.0000 0
M  V30 38 C 2.3053 -3.3775 0.0000 0
M  V30 39 C 4.8579 -4.6626 0.0000 0
M  V30 40 C 5.6816 -4.6155 0.0000 0
M  V30 41 C 6.1342 -5.3052 0.0000 0
M  V30 42 C 5.7633 -6.0421 0.0000 0
M  V30 43 C 4.9396 -6.0892 0.0000 0
M  V30 44 C 4.4869 -5.3995 0.0000 0
M  V30 45 C 7.7719 -1.8844 0.0000 0
M  V30 46 C 7.8971 -1.0690 0.0000 0
M  V30 47 N 8.7113 -0.9360 0.0000 0
M  V30 48 C 9.0894 -1.6693 0.0000 0
M  V30 49 N 8.5088 -2.2554 0.0000 0
M  V30 50 C 9.9048 -1.7944 0.0000 0 CFG=2
M  V30 51 C 10.4854 -1.2082 0.0000 0
M  V30 52 C 11.2222 -1.5792 0.0000 0
M  V30 53 C 11.0971 -2.3947 0.0000 0
M  V30 54 N 10.2829 -2.5277 0.0000 0
M  V30 55 C 9.9119 -3.2645 0.0000 0
M  V30 56 O 9.0882 -3.3117 0.0000 0
M  V30 57 C 10.3646 -3.9543 0.0000 0 CFG=1
M  V30 58 N 9.9936 -4.6911 0.0000 0
M  V30 59 C 10.4462 -5.3809 0.0000 0
M  V30 60 O 11.2699 -5.3337 0.0000 0
M  V30 61 O 10.0752 -6.1177 0.0000 0
M  V30 62 C 10.5279 -6.8075 0.0000 0
M  V30 63 C 11.1882 -3.9071 0.0000 0
M  V30 64 C 11.5592 -3.1702 0.0000 0
M  V30 65 C 11.6409 -4.5969 0.0000 0
M  V30 66 H 5.4037 -3.9157 0.0000 0
M  V30 67 H 9.3210 -2.6063 0.0000 0
M  V30 68 H 10.9133 -4.7903 0.0000 0
M  V30 69 H 0.7373 -5.3770 0.0000 0
M  V30 70 H -1.0662 -2.7644 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 6 5 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 6 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 16 15
M  V30 16 1 16 12
M  V30 17 1 16 17 CFG=1
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 2 17 21
M  V30 23 1 20 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 31 32
M  V30 34 2 32 33
M  V30 35 1 28 33
M  V30 36 1 33 34
M  V30 37 1 26 34
M  V30 38 1 35 34
M  V30 39 1 35 36
M  V30 40 1 36 37
M  V30 41 1 25 37
M  V30 42 2 37 38
M  V30 43 1 22 38
M  V30 44 1 35 39 CFG=3
M  V30 45 2 39 40
M  V30 46 1 40 41
M  V30 47 2 41 42
M  V30 48 1 42 43
M  V30 49 2 43 44
M  V30 50 1 39 44
M  V30 51 1 30 45
M  V30 52 1 45 46
M  V30 53 1 46 47
M  V30 54 2 47 48
M  V30 55 1 48 49
M  V30 56 2 45 49
M  V30 57 1 50 48 CFG=3
M  V30 58 1 50 51
M  V30 59 1 51 52
M  V30 60 1 52 53
M  V30 61 1 53 54
M  V30 62 1 50 54
M  V30 63 1 54 55
M  V30 64 2 55 56
M  V30 65 1 57 55
M  V30 66 1 57 58 CFG=3
M  V30 67 1 58 59
M  V30 68 2 59 60
M  V30 69 1 59 61
M  V30 70 1 61 62
M  V30 71 1 57 63
M  V30 72 1 63 64
M  V30 73 1 63 65
M  V30 74 1 66 35
M  V30 75 1 67 50
M  V30 76 1 68 57
M  V30 77 1 69 6
M  V30 78 1 70 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
293

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Elbasvir

>  <Synonyms>
MK-8742

>  <CAS>
1370468-36-2

>  <Formula>
C49H55N9O7

>  <MolWt>
882

>  <Pathways>
Proteases/Proteasome;Microbiology/Virology

>  <Target>
HCV Protease

>  <Receptor>
 NS5A:2.2 pM (EC50)

>  <Bioactivity>
Elbasvir is an inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.

>  <Reference>
"McGivern, et al. Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors. Gastroenterology 147(2), 453-462 (2014).;Liu, R., et al. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob. Agents Chemother. 59(11), 6922-6929 (2015).;Lahser, F.C., et al. The combination of grazoprevir, a Hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. Antimicrob. Agents Chemother. 60(5), 2954-2964 (2016).;Lahser FC, et al. The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons. Antimicrob Agents Chemother. 2016 A;Asante-Appiah, et al. Antiviral activity and resistance analysis of NS3/4A protease inhibitor grazoprevir and NS5A inhibitor elbasvir in Hepatitis C virus GT4 replicons. Antimicrob. Agents Chemother. 61(7), e00363-e00417 (2017)."

>  <ID<1>>
T4544

$$$$
StarDrop ID 294
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.8578 2.0969 0.0000 0
M  V30 2 C 4.8578 1.2719 0.0000 0 CFG=2
M  V30 3 N 4.1433 0.8594 0.0000 0
M  V30 4 C 5.5723 0.8594 0.0000 0 CFG=2
M  V30 5 O 6.2867 1.2719 0.0000 0
M  V30 6 C 5.5723 0.0344 0.0000 0
M  V30 7 C 6.2867 -0.3781 0.0000 0
M  V30 8 C 6.2867 -1.2031 0.0000 0
M  V30 9 C 5.5723 -1.6156 0.0000 0
M  V30 10 C 4.8578 -1.2031 0.0000 0
M  V30 11 O 4.1433 -1.6156 0.0000 0
M  V30 12 C 4.8578 -0.3781 0.0000 0
M  V30 13 H 3.9918 1.7719 0.0000 0
M  V30 14 H 5.5722 1.8594 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3 CFG=1
M  V30 3 1 2 4
M  V30 4 1 4 5 CFG=3
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 6 12
M  V30 13 1 13 2
M  V30 14 1 14 4
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
294

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Metaraminol tartrate

>  <Synonyms>
Metaradrine tartrate;Metaraminol bitartrate

>  <CAS>
33402-03-8

>  <Formula>
C13H19NO8

>  <MolWt>
317.3

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor; ??-adrenergic receptor

>  <Bioactivity>
Metaraminol bitartrate is a sympathomimetic agent that acts predominantly at alpha-1 adrenergic receptors. It has been used primarily as a vasoconstrictor in the treatment of HYPOTENSION.

>  <Reference>
"Tatsuta M, et al. Int J Y. 1998 Jul 29;77(3):467-9."

>  <ID<1>>
T0279

$$$$
StarDrop ID 295
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 44 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 10.0873 4.7700 0.0000 0
M  V30 2 O 9.3728 4.3575 0.0000 0
M  V30 3 C 9.3728 3.5325 0.0000 0
M  V30 4 O 10.0873 3.1200 0.0000 0
M  V30 5 C 8.6584 3.1200 0.0000 0
M  V30 6 C 8.6584 2.2950 0.0000 0
M  V30 7 C 7.9439 1.8825 0.0000 0
M  V30 8 C 7.2294 2.2950 0.0000 0
M  V30 9 C 6.4448 2.0400 0.0000 0
M  V30 10 C 6.1899 1.2554 0.0000 0
M  V30 11 N 5.3829 1.0839 0.0000 0
M  V30 12 C 5.1279 0.2993 0.0000 0
M  V30 13 C 5.6800 -0.3138 0.0000 0
M  V30 14 C 5.4250 -1.0985 0.0000 0
M  V30 15 C 4.6181 -1.2700 0.0000 0
M  V30 16 C 4.0660 -0.6569 0.0000 0
M  V30 17 C 4.3210 0.1277 0.0000 0
M  V30 18 N 4.3631 -2.0546 0.0000 0
M  V30 19 C 4.9152 -2.6677 0.0000 0
M  V30 20 C 3.5562 -2.2261 0.0000 0
M  V30 21 O 3.0041 -1.6130 0.0000 0
M  V30 22 C 3.3012 -3.0108 0.0000 0
M  V30 23 N 3.8533 -3.6238 0.0000 0
M  V30 24 C 4.6602 -3.4523 0.0000 0
M  V30 25 C 5.2123 -4.0654 0.0000 0
M  V30 26 N 4.9573 -4.8500 0.0000 0
M  V30 27 C 5.5094 -5.4631 0.0000 0
M  V30 28 C 4.1503 -5.0216 0.0000 0
M  V30 29 C 3.5983 -4.4085 0.0000 0
M  V30 30 C 6.7419 0.6423 0.0000 0
M  V30 31 C 7.5489 0.8138 0.0000 0
M  V30 32 C 8.1009 0.2007 0.0000 0
M  V30 33 C 7.8460 -0.5839 0.0000 0
M  V30 34 C 7.0390 -0.7554 0.0000 0
M  V30 35 C 6.4870 -0.1423 0.0000 0
M  V30 36 C 5.9599 2.7075 0.0000 0
M  V30 37 O 5.1349 2.7075 0.0000 0
M  V30 38 N 6.4448 3.3749 0.0000 0
M  V30 39 C 7.2294 3.1200 0.0000 0
M  V30 40 C 7.9439 3.5325 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 12 17
M  V30 18 1 15 18
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 2 20 21
M  V30 22 1 20 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 26 28
M  V30 29 1 28 29
M  V30 30 1 23 29
M  V30 31 1 10 30
M  V30 32 2 30 31
M  V30 33 1 31 32
M  V30 34 2 32 33
M  V30 35 1 33 34
M  V30 36 2 34 35
M  V30 37 1 30 35
M  V30 38 1 9 36
M  V30 39 2 36 37
M  V30 40 1 36 38
M  V30 41 1 38 39
M  V30 42 1 8 39
M  V30 43 2 39 40
M  V30 44 1 5 40
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
295

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Nintedanib esylate

>  <Synonyms>
Intedanib;BIBF 1120;BIBF 1120 (esylate);Nintedanib Ethanesulfonate Salt

>  <CAS>
656247-18-6

>  <Formula>
C33H39N5O7S

>  <MolWt>
649.8

>  <Pathways>
Tyrosine Kinase/Adaptors;Angiogenesis

>  <Target>
PDGFR;FGFR;VEGFR

>  <Receptor>
" VEGFR2:13 nM, FGFR1:69 nM, VEGFR1:34 nM, VEGFR3:13 nM, PDGFR??:65 nM, FGFR3:108 nM, PDGFR??:59 nM, FGFR2:37 nM"

>  <Bioactivity>
"BIBF 1120 esylate is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFR??/??"

>  <Reference>
"Suzuki N, et al. Effect of a novel oral chemotherapeutic agent containing a combination of trifluridine, tipiracil and the novel triple angiokinase inhibitor nintedanib, on human colorectal cancer xenografts. Oncol Rep. 2016 Dec;36(6):3123-3130.;Roth GJ, et al. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J Med Chem, 2009, 52(14), 4466-4480."

>  <ID<1>>
T5001

$$$$
StarDrop ID 296
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.7604 0.6948 0.0000 0
M  V30 2 C 5.5630 0.1788 0.0000 0
M  V30 3 O 6.4236 0.3820 0.0000 0
M  V30 4 C 5.8080 -0.6632 0.0000 0
M  V30 5 C 5.2559 -1.2763 0.0000 0
M  V30 6 O 4.3864 -1.5528 0.0000 0
M  V30 7 C 5.5109 -2.0609 0.0000 0
M  V30 8 C 6.3178 -2.2324 0.0000 0
M  V30 9 C 6.5728 -3.0170 0.0000 0
M  V30 10 C 7.3797 -3.1886 0.0000 0
M  V30 11 C 7.9318 -2.5755 0.0000 0
M  V30 12 C 7.6768 -1.7909 0.0000 0
M  V30 13 C 6.8699 -1.6193 0.0000 0
M  V30 14 C 6.6149 -0.8347 0.0000 0
M  V30 15 C 7.2587 -0.2638 0.0000 0
M  V30 16 C 7.1670 0.6034 0.0000 0
M  V30 17 C 6.4525 1.0159 0.0000 0
M  V30 18 C 5.5033 1.0155 0.0000 0
M  V30 19 O 4.9591 1.7268 0.0000 0
M  V30 20 O 4.9663 0.2081 0.0000 0
M  V30 21 C 6.4525 1.8409 0.0000 0
M  V30 22 O 5.9652 2.5856 0.0000 0
M  V30 23 C 7.1670 2.2534 0.0000 0
M  V30 24 C 7.8814 1.8409 0.0000 0
M  V30 25 C 8.5959 2.2534 0.0000 0
M  V30 26 C 9.3104 1.8409 0.0000 0
M  V30 27 C 9.3104 1.0159 0.0000 0
M  V30 28 C 8.5959 0.6034 0.0000 0
M  V30 29 C 7.8814 1.0159 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 8 13
M  V30 14 2 13 14
M  V30 15 1 4 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 2 18 20
M  V30 22 1 17 21
M  V30 23 1 21 22
M  V30 24 2 21 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 16 29
M  V30 32 1 24 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
296

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Oxantel Pamoate

>  <Synonyms>
Oxantel embonate

>  <CAS>
68813-55-8

>  <Formula>
C36H32N2O7

>  <MolWt>
604.7

>  <Pathways>
Others;Microbiology/Virology

>  <Target>
Others;Parasite

>  <Receptor>
Antiparasitic; Parasite

>  <Bioactivity>
Oxantel pamoate is used as an Antinematodal agent.

>  <Reference>
"Keiser J, et al. Activity of oxantel pamoate monotherapy and combination chemotherapy against Trichuris muris and hookworms: revival of an old drug. PLoS Negl Trop Dis. 2013;7(3):e2119."

>  <ID<1>>
T0323

$$$$
StarDrop ID 297
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.2659 3.0509 0.0000 0
M  V30 2 O 5.9803 3.4634 0.0000 0
M  V30 3 C 6.6948 3.0509 0.0000 0
M  V30 4 C 7.4093 3.4634 0.0000 0
M  V30 5 C 8.1237 3.0509 0.0000 0
M  V30 6 N 8.8382 3.4634 0.0000 0
M  V30 7 C 9.5527 3.0509 0.0000 0
M  V30 8 C 9.5527 2.2259 0.0000 0
M  V30 9 C 8.8382 1.8134 0.0000 0
M  V30 10 O 8.8382 0.9884 0.0000 0
M  V30 11 C 8.1237 0.5759 0.0000 0
M  V30 12 C 8.1237 -0.2491 0.0000 0
M  V30 13 C 7.4093 -0.6616 0.0000 0
M  V30 14 C 6.6948 -0.2491 0.0000 0
M  V30 15 N 5.9803 -0.6616 0.0000 0
M  V30 16 C 5.9803 -1.4866 0.0000 0
M  V30 17 O 6.6948 -1.8991 0.0000 0
M  V30 18 C 5.2659 -1.8991 0.0000 0
M  V30 19 C 4.4534 -2.0424 0.0000 0
M  V30 20 C 4.7356 -1.2671 0.0000 0
M  V30 21 C 5.5480 -2.6743 0.0000 0
M  V30 22 O 6.3605 -2.8176 0.0000 0
M  V30 23 N 5.0177 -3.3063 0.0000 0
M  V30 24 C 4.2053 -3.1631 0.0000 0
M  V30 25 C 3.6750 -3.7951 0.0000 0
M  V30 26 C 2.8625 -3.6518 0.0000 0
M  V30 27 C 2.5803 -2.8766 0.0000 0
M  V30 28 F 1.7679 -2.7333 0.0000 0
M  V30 29 C 3.1106 -2.2446 0.0000 0
M  V30 30 C 3.9231 -2.3878 0.0000 0
M  V30 31 C 6.6948 0.5759 0.0000 0
M  V30 32 C 7.4093 0.9884 0.0000 0
M  V30 33 C 8.1237 2.2259 0.0000 0
M  V30 34 C 7.4093 1.8134 0.0000 0
M  V30 35 C 6.6948 2.2259 0.0000 0
M  V30 36 O 5.9803 1.8134 0.0000 0
M  V30 37 C 5.2659 2.2259 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 18 20
M  V30 21 1 18 21
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 1 27 29
M  V30 30 2 29 30
M  V30 31 1 24 30
M  V30 32 1 14 31
M  V30 33 2 31 32
M  V30 34 1 11 32
M  V30 35 2 9 33
M  V30 36 1 5 33
M  V30 37 1 33 34
M  V30 38 2 34 35
M  V30 39 1 3 35
M  V30 40 1 35 36
M  V30 41 1 36 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
297

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cabozantinib hydrochloride

>  <Synonyms>
Cabozantinib hydrochloride (849217-68-1(free base));BMS-907351;XL184

>  <CAS>
1817759-42-4

>  <Formula>
C28H25ClFN3O5

>  <MolWt>
538

>  <Pathways>
Tyrosine Kinase/Adaptors;Angiogenesis;Metabolism

>  <Target>
TAM Receptor;ROR;FLT;c-Kit;c-Met/HGFR;VEGFR

>  <Receptor>
" ROR??:172 nM (Ki), ROR??:111 nM (Ki)"

>  <Bioactivity>
"Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6 nM)."

>  <Reference>
"Torres KE, et al. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.Clin Cancer Res. 2011 Jun 15;17(12):3943-55.;You WK, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 2011, 71(14), 4758-4768.;Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011, 10(12), 2298-2308."

>  <ID<1>>
T5164

$$$$
StarDrop ID 298
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -3.4322 -6.1875 0.0000 0
M  V30 2 O -3.4322 -5.3625 0.0000 0
M  V30 3 C -4.1467 -4.9500 0.0000 0
M  V30 4 C -4.8612 -5.3625 0.0000 0
M  V30 5 C -5.5756 -4.9500 0.0000 0
M  V30 6 C -5.5756 -4.1250 0.0000 0
M  V30 7 C -4.8612 -3.7125 0.0000 0
M  V30 8 C -4.1467 -4.1250 0.0000 0
M  V30 9 O -3.4322 -3.7125 0.0000 0
M  V30 10 C -2.7178 -4.1250 0.0000 0
M  V30 11 C -2.0033 -3.7125 0.0000 0
M  V30 12 N -1.2888 -4.1250 0.0000 0
M  V30 13 C -0.5744 -3.7125 0.0000 0
M  V30 14 C 0.1401 -4.1250 0.0000 0
M  V30 15 O 0.1401 -4.9500 0.0000 0
M  V30 16 C 0.8546 -3.7125 0.0000 0
M  V30 17 O 1.5691 -4.1250 0.0000 0
M  V30 18 C 2.2835 -3.7125 0.0000 0
M  V30 19 C 2.2835 -2.8875 0.0000 0
M  V30 20 C 2.9980 -2.4750 0.0000 0
M  V30 21 C 3.7125 -2.8875 0.0000 0
M  V30 22 C 3.7125 -3.7125 0.0000 0
M  V30 23 N 4.3256 -4.2645 0.0000 0
M  V30 24 C 3.9900 -5.0182 0.0000 0
M  V30 25 C 4.3256 -5.7719 0.0000 0
M  V30 26 C 3.8406 -6.4393 0.0000 0
M  V30 27 C 3.0202 -6.3531 0.0000 0
M  V30 28 C 2.6846 -5.5994 0.0000 0
M  V30 29 C 3.1695 -4.9320 0.0000 0
M  V30 30 C 2.9980 -4.1250 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 2 27 28
M  V30 29 1 28 29
M  V30 30 2 24 29
M  V30 31 1 29 30
M  V30 32 2 18 30
M  V30 33 1 22 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
298

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Carvedilol phosphate hemihydrate

>  <Synonyms>
BM 14190 (phosphate hemihydrate);Carvedilol phosphate

>  <CAS>
610309-89-2

>  <Formula>
C48H60N4O17P2

>  <MolWt>
1027

>  <Pathways>
Neuroscience;Membrane transporter/Ion channel;Angiogenesis;Others;Metabolism;Autophagy;Cytoskeletal Signaling;Tyrosine Kinase/Adaptors;GPCR/G Protein

>  <Target>
VEGFR;Integrin;Others;Autophagy;LDL;Adrenergic Receptor;NADPH;Potassium Channel;Gap Junction Protein

>  <Receptor>
 LDL oxidation:3.8 ??M

>  <Bioactivity>
"Carvedilol Phosphate is the phosphate salt form of carvedilol, a racemic mixture and adrenergic blocking agent with antihypertensive activity and devoid of intrinsic sympathomimetic activity."

>  <Reference>
"Nichols AJ, et al. Fundam Clin Pharmacol. 1991;5(1):25-38."

>  <ID<1>>
T0342

$$$$
StarDrop ID 299
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 64 70 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.1227 -1.9626 0.0000 0
M  V30 2 C 2.2821 -1.1532 0.0000 0 CFG=1
M  V30 3 C 3.0916 -1.3126 0.0000 0
M  V30 4 C 1.4727 -0.9938 0.0000 0
M  V30 5 C 2.4415 -0.3437 0.0000 0
M  V30 6 N 1.6608 -0.6104 0.0000 0
M  V30 7 C 1.0395 -0.0676 0.0000 0
M  V30 8 O 0.2588 -0.3343 0.0000 0
M  V30 9 O 1.2068 0.6254 0.0000 0
M  V30 10 C 1.9796 1.0085 0.0000 0 CFG=2
M  V30 11 C 1.1606 0.9100 0.0000 0
M  V30 12 C 0.8137 1.6586 0.0000 0
M  V30 13 C 1.4185 2.2197 0.0000 0
M  V30 14 C 2.1391 1.8180 0.0000 0 CFG=1
M  V30 15 O 2.9198 2.0846 0.0000 0
M  V30 16 C 3.0792 2.8941 0.0000 0
M  V30 17 C 3.8599 3.1607 0.0000 0
M  V30 18 C 4.4812 2.6180 0.0000 0
M  V30 19 C 5.2619 2.8846 0.0000 0
M  V30 20 F 5.9043 3.4022 0.0000 0
M  V30 21 F 4.8637 3.6072 0.0000 0
M  V30 22 C 5.8832 2.3418 0.0000 0
M  V30 23 N 6.6639 2.6085 0.0000 0
M  V30 24 C 7.2852 2.0657 0.0000 0
M  V30 25 C 8.0659 2.3324 0.0000 0
M  V30 26 C 8.6872 1.7896 0.0000 0
M  V30 27 C 8.5278 0.9802 0.0000 0
M  V30 28 C 7.7471 0.7135 0.0000 0
M  V30 29 C 7.1258 1.2563 0.0000 0
M  V30 30 N 6.3451 0.9896 0.0000 0
M  V30 31 C 5.7238 1.5324 0.0000 0
M  V30 32 O 4.9431 1.2657 0.0000 0
M  V30 33 C 4.7837 0.4563 0.0000 0 CFG=2
M  V30 34 C 5.2068 -0.2519 0.0000 0
M  V30 35 C 4.6640 -0.8732 0.0000 0 CFG=2
M  V30 36 N 3.8435 -0.6198 0.0000 0
M  V30 37 C 4.0030 0.1896 0.0000 0
M  V30 38 C 3.0628 -0.8865 0.0000 0
M  V30 39 O 3.4096 -1.6351 0.0000 0
M  V30 40 C 4.8893 -1.6669 0.0000 0
M  V30 41 O 4.3147 -2.2588 0.0000 0
M  V30 42 N 5.6893 -1.8686 0.0000 0
M  V30 43 C 5.9146 -2.6622 0.0000 0 CFG=2
M  V30 44 C 6.3978 -3.3309 0.0000 0
M  V30 45 C 6.7353 -2.5782 0.0000 0 CFG=1
M  V30 46 C 7.4040 -2.0950 0.0000 0
M  V30 47 F 8.1568 -2.4325 0.0000 0
M  V30 48 F 7.3200 -1.2743 0.0000 0
M  V30 49 C 5.1722 -3.0219 0.0000 0
M  V30 50 O 4.4894 -2.5588 0.0000 0
M  V30 51 N 5.1124 -3.8447 0.0000 0
M  V30 52 S 4.3700 -4.2044 0.0000 0
M  V30 53 O 4.0103 -3.4620 0.0000 0
M  V30 54 O 4.7297 -4.9469 0.0000 0
M  V30 55 C 3.6275 -4.5641 0.0000 0
M  V30 56 C 3.1444 -3.8954 0.0000 0
M  V30 57 C 3.8528 -5.3578 0.0000 0
M  V30 58 C 3.0528 -5.1561 0.0000 0
M  V30 59 H 4.4393 -0.4825 0.0000 0
M  V30 60 H 5.6397 -1.0922 0.0000 0
M  V30 61 H 7.5110 -3.2094 0.0000 0
M  V30 62 H 0.0000 0.0000 0.0000 0
M  V30 63 H 2.7986 1.1070 0.0000 0
M  V30 64 H 1.2318 1.3976 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5 CFG=1
M  V30 5 1 6 5 CFG=3
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 10 9
M  V30 10 1 10 11 CFG=1
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 14 13 CFG=1
M  V30 14 1 10 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 17 16
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 22 1 19 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 2 28 29
M  V30 30 1 24 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 22 31
M  V30 34 1 31 32
M  V30 35 1 33 32
M  V30 36 1 33 34 CFG=3
M  V30 37 1 35 34
M  V30 38 1 35 36
M  V30 39 1 36 37
M  V30 40 1 33 37
M  V30 41 1 36 38
M  V30 42 1 5 38
M  V30 43 2 38 39
M  V30 44 1 35 40 CFG=1
M  V30 45 2 40 41
M  V30 46 1 40 42
M  V30 47 1 43 42 CFG=1
M  V30 48 1 43 44
M  V30 49 1 45 44
M  V30 50 1 43 45
M  V30 51 1 45 46 CFG=3
M  V30 52 1 46 47
M  V30 53 1 46 48
M  V30 54 1 43 49 CFG=3
M  V30 55 2 49 50
M  V30 56 1 49 51
M  V30 57 1 51 52
M  V30 58 2 52 53
M  V30 59 2 52 54
M  V30 60 1 52 55
M  V30 61 1 55 56
M  V30 62 1 55 57
M  V30 63 1 57 58
M  V30 64 1 55 58
M  V30 65 1 59 33
M  V30 66 1 60 35
M  V30 67 1 61 45
M  V30 68 1 62 6
M  V30 69 1 63 10
M  V30 70 1 64 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
299

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Glecaprevir

>  <Synonyms>
ABT-493

>  <CAS>
1365970-03-1

>  <Formula>
C38H46F4N6O9S

>  <MolWt>
838.9

>  <Pathways>
Proteases/Proteasome;Microbiology/Virology

>  <Target>
SARS-CoV;HCV Protease

>  <Receptor>
 HCV NS3/4A protease:3.5-11.3 nM

>  <Bioactivity>
"Glecaprevir is an HCV NS3/4A protease inhibitor, (IC50s: 3.5-11.3 nM)."

>  <Reference>
"Lawitz EJ, et al. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection. Antimicrob Agents Chemother. 2015 Dec 28;60(3):1546-55.;Ng TI, et al. In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir. Antimicrob Agents Chemother. 2017 Oct 30. pii: AAC.201620-17."

>  <ID<1>>
T5126

$$$$
StarDrop ID 300
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 38 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 0.8137 0.0000 0
M  V30 2 O 3.1540 1.0272 0.0000 0
M  V30 3 N 3.3676 1.8241 0.0000 0
M  V30 4 C 4.1644 2.0376 0.0000 0
M  V30 5 C 4.7478 1.4543 0.0000 0
M  V30 6 O 5.5447 1.6678 0.0000 0
M  V30 7 N 4.5343 0.6574 0.0000 0
M  V30 8 C 5.1176 0.0740 0.0000 0 CFG=1
M  V30 9 C 5.9426 0.0740 0.0000 0 CFG=1
M  V30 10 S 6.6571 0.4865 0.0000 0
M  V30 11 C 7.3716 0.0740 0.0000 0
M  V30 12 C 7.3716 -0.7510 0.0000 0
M  V30 13 C 8.0861 -1.1635 0.0000 0
M  V30 14 S 8.0861 -1.9885 0.0000 0
M  V30 15 C 8.8005 -2.4010 0.0000 0
M  V30 16 N 9.5542 -2.0654 0.0000 0
M  V30 17 N 10.1062 -2.6785 0.0000 0
M  V30 18 N 9.6937 -3.3930 0.0000 0
M  V30 19 N 8.8868 -3.2215 0.0000 0
M  V30 20 C 8.2737 -3.7735 0.0000 0
M  V30 21 C 6.6571 -1.1635 0.0000 0
M  V30 22 N 5.9426 -0.7510 0.0000 0
M  V30 23 C 5.1176 -0.7510 0.0000 0
M  V30 24 O 4.5343 -1.3343 0.0000 0
M  V30 25 C 6.6571 -1.9885 0.0000 0
M  V30 26 O 5.9426 -2.4010 0.0000 0
M  V30 27 O 7.3716 -2.4010 0.0000 0
M  V30 28 C 4.3780 2.8345 0.0000 0
M  V30 29 C 3.8588 3.4757 0.0000 0
M  V30 30 S 4.3081 4.1676 0.0000 0
M  V30 31 C 5.1050 3.9540 0.0000 0
M  V30 32 N 5.7461 4.4732 0.0000 0
M  V30 33 N 5.1482 3.1302 0.0000 0
M  V30 34 H 5.5003 0.9979 0.0000 0
M  V30 35 H 5.2355 -0.6331 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 8 7 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 1 15 19
M  V30 20 1 19 20
M  V30 21 2 12 21
M  V30 22 1 21 22
M  V30 23 1 9 22 CFG=1
M  V30 24 1 22 23
M  V30 25 1 8 23
M  V30 26 2 23 24
M  V30 27 1 21 25
M  V30 28 1 25 26
M  V30 29 2 25 27
M  V30 30 1 4 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 2 31 33
M  V30 36 1 28 33
M  V30 37 1 34 8
M  V30 38 1 35 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
300

>  <Plate>
PHD136328

>  <Row>
o

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cefmenoxime hydrochloride

>  <Synonyms>
Cefmenoxime hemihydrochloride;SCE-1365 hemihydrochloride

>  <CAS>
75738-58-8

>  <Formula>
C32H35ClN18O10S6

>  <MolWt>
1060

>  <Pathways>
Microbiology/Virology

>  <Target>
Antifection;Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial; Fts1; PBPs

>  <Bioactivity>
"Cefmenoxime hydrochloride is a cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date, no severe side effects have been noted."

>  <Reference>
"Tsuchiya K, et al. Antimicrob Agents ChemOthers. 1981 Jan;19(1):56-65."

>  <ID<1>>
T1190

$$$$
StarDrop ID 301
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 -2.4750 0.0000 0
M  V30 2 C 0.7145 -2.8875 0.0000 0
M  V30 3 C 1.4289 -2.4750 0.0000 0
M  V30 4 O 1.4289 -1.6500 0.0000 0
M  V30 5 C 2.1434 -2.8875 0.0000 0
M  V30 6 O 2.8579 -2.4750 0.0000 0
M  V30 7 C 3.5724 -2.8875 0.0000 0
M  V30 8 C 4.2868 -2.4750 0.0000 0
M  V30 9 C 5.0013 -2.8875 0.0000 0
M  V30 10 C 5.0013 -3.7125 0.0000 0
M  V30 11 Cl 5.7158 -4.1250 0.0000 0
M  V30 12 C 4.2868 -4.1250 0.0000 0
M  V30 13 C 3.5724 -3.7125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 7 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
301

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Chlorphenesin

>  <Synonyms>
Chlorophenesin;Adermykon;Gecophen

>  <CAS>
104-29-0

>  <Formula>
C9H11ClO3

>  <MolWt>
202.6

>  <Pathways>
Immunology/Inflammation;Microbiology/Virology;GPCR/G Protein;Neuroscience

>  <Target>
Histamine Receptor;Antifungal;Antibacterial

>  <Receptor>
Bacterial; Fungal; Histamine relase

>  <Bioactivity>
Chlorphenesin is an antigen-associated immunosuppressant that inhibits IgE-mediated histamine release. It is also used as an antimycotic agent.

>  <Reference>
"Quan J, et al. Synthesis of polymeric prodrugs of chlorphenesin with saccharide branches by chemo-enzymatic regioselective strategy[J]. Polymer, 2007, 48(9):2595-2604.;Collman J P, et al. ChemInform Abstract: A SILICA-SUPPORTED RHODIUM HYDROFORMYLATION CATALYST: EVIDENCE FOR DINUCLEAR ELIMINATION[J]. 1983, 105(12):7288-7294."

>  <ID<1>>
T4507

$$$$
StarDrop ID 302
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.4289 -5.7750 0.0000 0
M  V30 2 C -0.7145 -5.3625 0.0000 0
M  V30 3 C -0.3020 -6.0770 0.0000 0
M  V30 4 C -1.1270 -4.6480 0.0000 0
M  V30 5 N 0.0000 -4.9500 0.0000 0
M  V30 6 C 0.0000 -4.1250 0.0000 0
M  V30 7 C 0.7145 -3.7125 0.0000 0
M  V30 8 O 1.4289 -4.1250 0.0000 0
M  V30 9 C 0.7145 -2.8875 0.0000 0
M  V30 10 O 1.4289 -2.4750 0.0000 0
M  V30 11 C 1.4289 -1.6500 0.0000 0
M  V30 12 C 0.7145 -1.2375 0.0000 0
M  V30 13 C 0.7145 -0.4125 0.0000 0
M  V30 14 C 1.4289 0.0000 0.0000 0
M  V30 15 C 2.1434 -0.4125 0.0000 0
M  V30 16 C 2.8579 0.0000 0.0000 0
M  V30 17 C 3.5724 -0.4125 0.0000 0 CFG=1
M  V30 18 O 4.2868 -0.0000 0.0000 0
M  V30 19 C 3.5724 -1.2375 0.0000 0 CFG=1
M  V30 20 O 4.2868 -1.6500 0.0000 0
M  V30 21 C 2.8579 -1.6500 0.0000 0
M  V30 22 C 2.1434 -1.2375 0.0000 0
M  V30 23 H 3.5723 0.5875 0.0000 0
M  V30 24 H 3.5723 -2.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 17 16
M  V30 17 1 17 18 CFG=1
M  V30 18 1 17 19
M  V30 19 1 19 20 CFG=1
M  V30 20 1 19 21
M  V30 21 1 21 22
M  V30 22 1 11 22
M  V30 23 2 15 22
M  V30 24 1 23 17
M  V30 25 1 24 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
302

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Nadolol

>  <Synonyms>
Anabet;Corgard;Solgol;SQ11725

>  <CAS>
42200-33-9

>  <Formula>
C17H27NO4

>  <MolWt>
309.4

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor; ??-adrenergic receptor

>  <Bioactivity>
"Nadolol is a non-selective beta-adrenergic antagonist with antihypertensive and antiarrhythmic activities. Nadolol competitively blocks beta-1 adrenergic receptors located in the heart and vascular smooth muscle, inhibiting the activities of the catecholamines epinephrine and norepinephrine and producing negative inotropic and chronotropic effects. This agent exhibits antiarrhythmic activity via the impairment of atrioventricular (AV) node conduction and a corresponding reduction in sinus rate. In the kidney, inhibition of the beta-2 receptor within the juxtaglomerular apparatus results in the inhibition of renin production and a subsequent reduction in angiotensin II and aldosterone levels, thus inhibiting angiotensin II-dependent vasoconstriction and aldosterone-dependent water retention."

>  <Reference>
"Wheeldon NM, et al. Br J Clin Pharmacol. 1994 Aug;38(2):103-8."

>  <ID<1>>
T1203

$$$$
StarDrop ID 303
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 1.0461 1.4289 0.0000 0
M  V30 2 C 1.7605 1.8414 0.0000 0
M  V30 3 C 2.4750 1.4289 0.0000 0 CFG=1
M  V30 4 O 2.4750 0.6039 0.0000 0
M  V30 5 C 3.1895 1.8414 0.0000 0 CFG=1
M  V30 6 O 3.1895 2.6664 0.0000 0
M  V30 7 C 3.9039 1.4289 0.0000 0 CFG=2
M  V30 8 O 3.9039 0.6039 0.0000 0
M  V30 9 C 4.6184 1.8414 0.0000 0 CFG=2
M  V30 10 O 4.6184 2.6664 0.0000 0
M  V30 11 C 5.3329 1.4289 0.0000 0
M  V30 12 O 6.0474 1.8414 0.0000 0
M  V30 13 H 1.6090 0.9289 0.0000 0
M  V30 14 H 4.0555 2.3414 0.0000 0
M  V30 15 H 3.0379 0.9289 0.0000 0
M  V30 16 H 5.4844 2.3414 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=3
M  V30 4 1 5 3
M  V30 5 1 5 6 CFG=1
M  V30 6 1 5 7
M  V30 7 1 7 8 CFG=1
M  V30 8 1 7 9
M  V30 9 1 9 10 CFG=3
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 1 13 3
M  V30 13 1 14 5
M  V30 14 1 15 7
M  V30 15 1 16 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
303

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
DL-Mannitol

>  <Synonyms>
Mannitol

>  <CAS>
87-78-5

>  <Formula>
C6H14O6

>  <MolWt>
182.2

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Mannitol is a osmotic diuretic, it may play a role in reducing off-target 68Ga-PSMA renal uptake"

>  <Reference>
"Matteucci F, et al. Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results. Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2189-2194.;Mendelow AD, et al. Effect of mannitol on cerebral blood flow and cerebral perfusion pressure in human head injury. J Neurosurg. 1985 Jul;63(1):43-8."

>  <ID<1>>
T4959

$$$$
StarDrop ID 304
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.8556 -2.5269 0.0000 0
M  V30 2 C 3.1412 -2.1144 0.0000 0
M  V30 3 C 2.4267 -2.5269 0.0000 0 CFG=2
M  V30 4 C 2.3405 -3.3474 0.0000 0
M  V30 5 N 1.5335 -3.5189 0.0000 0
M  V30 6 C 1.1210 -2.8045 0.0000 0
M  V30 7 C 1.6730 -2.1914 0.0000 0 CFG=2
M  V30 8 C 1.5015 -1.3844 0.0000 0
M  V30 9 C 0.7478 -1.0488 0.0000 0
M  V30 10 N 0.8341 -0.2284 0.0000 0
M  V30 11 C 1.6410 -0.0568 0.0000 0
M  V30 12 C 2.0535 0.6576 0.0000 0
M  V30 13 N 2.8785 0.6576 0.0000 0
M  V30 14 C 3.2910 -0.0568 0.0000 0
M  V30 15 N 4.0980 -0.2284 0.0000 0
M  V30 16 C 4.1842 -1.0488 0.0000 0
M  V30 17 C 3.4306 -1.3844 0.0000 0
M  V30 18 C 2.8785 -0.7713 0.0000 0
M  V30 19 N 2.0535 -0.7713 0.0000 0
M  V30 20 C 1.1979 -4.2726 0.0000 0
M  V30 21 O 0.3775 -4.3588 0.0000 0
M  V30 22 N 1.6829 -4.9400 0.0000 0
M  V30 23 C 1.3473 -5.6937 0.0000 0
M  V30 24 C 1.8322 -6.3612 0.0000 0
M  V30 25 F 2.3171 -7.0286 0.0000 0
M  V30 26 F 1.1648 -6.8461 0.0000 0
M  V30 27 F 2.4997 -5.8762 0.0000 0
M  V30 28 H 3.2654 -3.0715 0.0000 0
M  V30 29 H 2.4501 -1.5620 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 3 7
M  V30 8 1 7 8 CFG=3
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 14 18
M  V30 20 1 18 19
M  V30 21 1 8 19
M  V30 22 1 11 19
M  V30 23 1 5 20
M  V30 24 2 20 21
M  V30 25 1 20 22
M  V30 26 1 22 23
M  V30 27 1 23 24
M  V30 28 1 24 25
M  V30 29 1 24 26
M  V30 30 1 24 27
M  V30 31 1 28 3
M  V30 32 1 29 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
304

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Upadacitinib

>  <Synonyms>
ABT-494

>  <CAS>
1310726-60-3

>  <Formula>
C17H19F3N6O

>  <MolWt>
380.4

>  <Pathways>
Angiogenesis;JAK/STAT signaling;Chromatin/Epigenetic;Stem Cells

>  <Target>
JAK

>  <Receptor>
" JAK1:43 nM, JAK2:200 nM"

>  <Bioactivity>
"Upadacitinib (ABT-494) is a selective Janus kinase (JAK) 1 inhibitor, which is being studied for the treatment of several autoimmune disorders in the IC50 of 43 nM."

>  <Reference>
"Kremer JM, et al. A Phase IIb Study of ABT-494, a Selective JAK-1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Therapy. Arthritis Rheumatol. 2016Dec;68(12):2867-2877.;Nakayamada S, et al. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs. 2016 Oct;30(5):407-419."

>  <ID<1>>
T7503

$$$$
StarDrop ID 305
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -1.0392 -3.3000 0.0000 0
M  V30 2 C -0.3248 -2.8875 0.0000 0 CFG=1
M  V30 3 C 0.3897 -3.3000 0.0000 0
M  V30 4 C 0.3897 -4.1250 0.0000 0
M  V30 5 C 1.0572 -4.6099 0.0000 0
M  V30 6 N 0.8022 -5.3945 0.0000 0
M  V30 7 C -0.0228 -5.3945 0.0000 0
M  V30 8 N -0.2777 -4.6099 0.0000 0
M  V30 9 C -0.3248 -2.0625 0.0000 0
M  V30 10 O -1.0392 -1.6500 0.0000 0
M  V30 11 O 0.3897 -1.6500 0.0000 0
M  V30 12 H -0.3247 -3.8875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 4 8
M  V30 9 1 2 9
M  V30 10 1 9 10
M  V30 11 2 9 11
M  V30 12 1 12 2
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
305

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
L-Histidine monohydrochloride monohydrat

>  <Synonyms>
N/A

>  <CAS>
5934-29-2

>  <Formula>
C6H12ClN3O3

>  <MolWt>
209.6

>  <Pathways>
Others;Metabolism

>  <Target>
Endogenous Metabolite;Others

>  <Receptor>
Endogenous Metabolite

>  <Bioactivity>
"Histidine (abbreviated as His or H) is an alpha-amino acid. The L-isomer is one of the 22 proteinogenic amino acids, i.e., the building blocks of proteins. It is classified as a charged, polar because of the hydrophilic nature of the imidazole side chain. L-Histidine is a positively charged (pKa 6.5) aromatic amino acid. Histidine residues are often found in enzyme active sites, where the chemistry of the imidazole ring of histidine makes it a nucleophile and a good acid/base catalyzer. Histidine is special in that its biosynthesis is inherently linked to the pathways of nucleotide formation. In the first step of histidine synthesis, PRPP (5-phosphoribosyl-alpha-pyrophosphate) condenses with ATP to form a purine, N1-5'-phosphoribosyl ATP, in a reaction that is driven by the subsequent hydrolysis of the pyrophosphate that condenses out. Glutamine plays a role as an amino group donor resulting in the formation of 5-aminoamidazole-4-carboximide ribonucleotide (ACAIR), which is an intermediate in purine biosynthesis. Hisitidne is catabolized by the enzyme histidine ammonia-lyase which converts histidine into ammonia and urocanic acid."

>  <Reference>
"De?Sousa, G.P., Freire, P.T.C., Filho, J.M. et al. Braz J Phys (2013) 43: 137. https://doi.org/10.1007/s13538-013-0132-3"

>  <ID<1>>
T4826

$$$$
StarDrop ID 306
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 2.1214 0.0000 0
M  V30 2 C 3.0716 1.7089 0.0000 0
M  V30 3 N 3.7861 2.1214 0.0000 0
M  V30 4 C 3.0716 0.8839 0.0000 0
M  V30 5 O 2.3571 0.4714 0.0000 0
M  V30 6 N 3.7861 0.4714 0.0000 0
M  V30 7 C 3.7861 -0.3536 0.0000 0
M  V30 8 C 4.5006 -0.7661 0.0000 0
M  V30 9 C 5.2150 -0.3536 0.0000 0
M  V30 10 C 4.5006 -1.5911 0.0000 0
M  V30 11 C 3.7861 -2.0036 0.0000 0
M  V30 12 C 3.0716 -1.5911 0.0000 0
M  V30 13 C 3.0716 -0.7661 0.0000 0
M  V30 14 C 2.3571 -0.3536 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 7 13
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
306

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Taquidil

>  <Synonyms>
N/A

>  <CAS>
71395-14-7

>  <Formula>
C11H17ClN2O

>  <MolWt>
228.7

>  <Pathways>


>  <Target>


>  <Receptor>
 sodium channel:

>  <Bioactivity>
"Tocainide hydrochloride is a sodium channel blocker, it blocks the sodium channels in the pain-producing foci in the nerve membranes. Tocainide hydrochloride is an orally effective antiarrhythmic agent, structurally and pharmacologically similar to lidocaine [1] [2]."

>  <Reference>
N/A

>  <ID<1>>
T13177

$$$$
StarDrop ID 307
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.1434 3.7125 0.0000 0
M  V30 2 C 1.4289 3.3000 0.0000 0
M  V30 3 O 0.7145 3.7125 0.0000 0
M  V30 4 C 1.4289 2.4750 0.0000 0
M  V30 5 O 2.1434 2.0625 0.0000 0
M  V30 6 N 0.7145 2.0625 0.0000 0
M  V30 7 C 0.7145 1.2375 0.0000 0
M  V30 8 C 1.4289 0.8250 0.0000 0
M  V30 9 C 1.4289 -0.0000 0.0000 0
M  V30 10 C 0.7145 -0.4125 0.0000 0
M  V30 11 C 0.0000 0.0000 0.0000 0
M  V30 12 N -0.7145 -0.4125 0.0000 0
M  V30 13 C -0.7145 -1.2375 0.0000 0
M  V30 14 O -0.0000 -1.6500 0.0000 0
M  V30 15 C -1.4289 -1.6500 0.0000 0
M  V30 16 O -1.4289 -2.4750 0.0000 0
M  V30 17 O -2.1434 -1.2375 0.0000 0
M  V30 18 C 0.0000 0.8250 0.0000 0
M  V30 19 Cl -0.7145 1.2375 0.0000 0
M  V30 20 C 2.1434 -0.4125 0.0000 0
M  V30 21 N 2.8579 -0.8250 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 2 15 17
M  V30 17 2 11 18
M  V30 18 1 7 18
M  V30 19 1 18 19
M  V30 20 1 9 20
M  V30 21 3 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
307

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lodoxamide

>  <Synonyms>
Lodoxamidum

>  <CAS>
53882-12-5

>  <Formula>
C11H6ClN3O6

>  <MolWt>
311.6

>  <Pathways>
GPCR/G Protein;Neuroscience;Endocrinology/Hormones;Immunology/Inflammation

>  <Target>
GPR;Histamine Receptor

>  <Receptor>
Histamine Receptor

>  <Bioactivity>
Lodoxamide is an antiallergic drug acting as a mast-cell stabilizer. It is effective in the treatment of asthma and allergic conjunctivitis.

>  <Reference>
"Barr ML, et al. Addition of a mast cell stabilizing compound to organ preservation solutions decreases lung reperfusion injury. J Thorac Cardiovasc Surg. 1998 Mar;115(3):631-6; discussion 636-7.;Capron M,et al. Inhibitory effects of lodoxamide on eosinophil activation. Int Arch Allergy Immunol. 1998 Jun;116(2):140-6.;Watt GD, et al. Protective effect opf lodoxamide tromethamine on allergen inhalation challenge. J Allergy Clin Immunol. 1980 Oct;66(4):286-94."

>  <ID<1>>
T4566

$$$$
StarDrop ID 308
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -1.5600 -5.0835 0.0000 0
M  V30 2 C -0.8234 -5.4551 0.0000 0
M  V30 3 O -0.1333 -5.0030 0.0000 0
M  V30 4 C -0.1798 -4.1793 0.0000 0 CFG=1
M  V30 5 C 0.0189 -3.2203 0.0000 0
M  V30 6 C 0.9881 -3.5188 0.0000 0 CFG=1
M  V30 7 C 2.0529 -3.3061 0.0000 0
M  V30 8 C 2.0209 -2.7252 0.0000 0 CFG=2
M  V30 9 C 1.1694 -2.4750 0.0000 0
M  V30 10 C 0.5838 -3.1245 0.0000 0 CFG=1
M  V30 11 C -0.4182 -3.4528 0.0000 0
M  V30 12 N 1.1098 -4.0887 0.0000 0
M  V30 13 C 2.0011 -4.3471 0.0000 0
M  V30 14 C 2.5477 -3.5985 0.0000 0
M  V30 15 O 3.3719 -3.6347 0.0000 0
M  V30 16 C -0.7770 -6.2788 0.0000 0
M  V30 17 C -0.0833 -6.7253 0.0000 0
M  V30 18 N -0.2936 -7.5231 0.0000 0
M  V30 19 C -1.1173 -7.5695 0.0000 0
M  V30 20 C -1.6339 -8.2127 0.0000 0
M  V30 21 C -2.4493 -8.0869 0.0000 0
M  V30 22 C -2.7480 -7.3179 0.0000 0
M  V30 23 C -2.2314 -6.6747 0.0000 0
M  V30 24 C -1.4160 -6.8005 0.0000 0
M  V30 25 H -1.0719 -4.6312 0.0000 0
M  V30 26 H 1.9456 -3.8071 0.0000 0
M  V30 27 H 1.9889 -2.1443 0.0000 0
M  V30 28 H 1.5460 -3.3969 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=3
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7
M  V30 7 1 8 7 CFG=1
M  V30 8 1 8 9
M  V30 9 1 10 9
M  V30 10 1 10 11
M  V30 11 1 4 11
M  V30 12 1 10 12 CFG=3
M  V30 13 1 6 12 CFG=1
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 8 14
M  V30 17 2 14 15
M  V30 18 1 2 16
M  V30 19 1 16 17
M  V30 20 1 17 18
M  V30 21 2 18 19
M  V30 22 1 19 20
M  V30 23 2 20 21
M  V30 24 1 21 22
M  V30 25 2 22 23
M  V30 26 1 23 24
M  V30 27 2 16 24
M  V30 28 1 19 24
M  V30 29 1 25 4
M  V30 30 1 26 6
M  V30 31 1 27 8
M  V30 32 1 28 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
308

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dolasetron Mesylate hydrate

>  <Synonyms>
Dalasetron Mesylate Hydrate

>  <CAS>
878143-33-0

>  <Formula>
C20H26N2O7S

>  <MolWt>
438.5

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
5-HT Receptor

>  <Receptor>
5-HT Receptor; 5-HT3

>  <Bioactivity>
"Dolasetron mesylate, a selective serotonin receptor antagonist, competitively blocks the action of serotonin at 5HT3 receptors, resulting in suppression of chemotherapy- and radiotherapy-induced nausea and vomiting."

>  <Reference>
"Faria C, et al. Am Health Drug Benefits. 2014 Jan;7(1):50-8."

>  <ID<1>>
T2589

$$$$
StarDrop ID 309
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -3.7963 6.3168 0.0000 0
M  V30 2 S -3.0818 5.9043 0.0000 0
M  V30 3 O -3.4943 5.1898 0.0000 0
M  V30 4 O -2.6693 6.6187 0.0000 0
M  V30 5 C -2.3673 5.4918 0.0000 0
M  V30 6 C -2.3673 4.6668 0.0000 0
M  V30 7 C -1.6529 4.2543 0.0000 0
M  V30 8 C -0.9384 4.6668 0.0000 0
M  V30 9 N -0.2239 4.2543 0.0000 0
M  V30 10 C -0.2239 3.4293 0.0000 0
M  V30 11 N -0.9384 3.0168 0.0000 0
M  V30 12 S -1.6529 3.4293 0.0000 0
M  V30 13 O -2.0900 2.7296 0.0000 0
M  V30 14 O -2.4774 3.4005 0.0000 0
M  V30 15 C 0.4906 3.0168 0.0000 0
M  V30 16 C 0.4906 2.1918 0.0000 0
M  V30 17 C 1.2050 1.7793 0.0000 0
M  V30 18 C 0.9988 2.6043 0.0000 0
M  V30 19 C 1.2050 3.4293 0.0000 0
M  V30 20 C 1.9195 3.0168 0.0000 0
M  V30 21 C 1.9195 2.1918 0.0000 0
M  V30 22 C -0.9384 5.4918 0.0000 0
M  V30 23 C -1.6529 5.9043 0.0000 0
M  V30 24 Cl -1.6529 6.7293 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 12
M  V30 13 2 12 13
M  V30 14 2 12 14
M  V30 15 1 10 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 15 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 17 21
M  V30 24 1 8 22
M  V30 25 2 22 23
M  V30 26 1 5 23
M  V30 27 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
309

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cyclothiazide

>  <Synonyms>
N/A

>  <CAS>
2259-96-3

>  <Formula>
C14H16ClN3O4S2

>  <MolWt>
389.9

>  <Pathways>
Neuroscience

>  <Target>
GluR

>  <Receptor>
 AMPA:EC50 = 3.8 M

>  <Bioactivity>
"Cyclothiazide is a benzothiadiazide that acts as a potentiator of AMPA receptorsthat potently inhibits AMPA receptor desensitization, positively modulating its response to glutamic acid (EC50 = 3.8 M)."

>  <Reference>
"Kessler et al (2000) The norbornenyl moiety of cyclothiazide determines the preference for flip-flop variants of AMPA receptor subunits.Neurosci.Lett. 287 161.;Desai et al (1995) Cyclothiazide acts at a site on the ??-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor complex that does not recognise competitive or noncompetitive AMPA receptor antagonists. J.Pharmacol.Exp.Ther. 272 38.;Donevan and Rogawski (1998) Allosteric regulation of a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptors by thiocyanate and cyclothiazide at a common modulatory site distinct from that of 2,3-benzodiazepines. Neuroscience 87 615."

>  <ID<1>>
T4573

$$$$
StarDrop ID 310
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 87 90 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 5.9325 -1.4266 0.0000 0
M  V30 2 C 5.3805 -2.0397 0.0000 0 CFG=1
M  V30 3 C 4.5735 -1.8682 0.0000 0
M  V30 4 S 4.3186 -1.0836 0.0000 0
M  V30 5 S 4.8706 -0.4705 0.0000 0
M  V30 6 C 5.6776 -0.6420 0.0000 0
M  V30 7 C 6.2296 -0.0289 0.0000 0 CFG=2
M  V30 8 N 7.0366 -0.2004 0.0000 0
M  V30 9 C 7.5886 0.4127 0.0000 0
M  V30 10 O 7.3337 1.1973 0.0000 0
M  V30 11 C 8.3956 0.2411 0.0000 0
M  V30 12 C 8.1406 1.0257 0.0000 0
M  V30 13 C 8.6927 1.6388 0.0000 0
M  V30 14 N 8.4377 2.4235 0.0000 0
M  V30 15 O 9.4997 1.4673 0.0000 0
M  V30 16 N 8.9476 0.8542 0.0000 0
M  V30 17 C 9.7546 0.6827 0.0000 0
M  V30 18 O 10.3066 1.2958 0.0000 0
M  V30 19 C 10.0095 -0.1019 0.0000 0 CFG=2
M  V30 20 C 10.8165 -0.2735 0.0000 0
M  V30 21 C 11.3685 0.3396 0.0000 0
M  V30 22 C 12.1755 0.1681 0.0000 0
M  V30 23 N 12.4304 -0.6165 0.0000 0
M  V30 24 O 12.7275 0.7812 0.0000 0
M  V30 25 N 9.4575 -0.7150 0.0000 0
M  V30 26 C 9.7124 -1.4996 0.0000 0
M  V30 27 O 10.5194 -1.6712 0.0000 0
M  V30 28 C 9.1604 -2.1127 0.0000 0 CFG=2
M  V30 29 C 9.4153 -2.8974 0.0000 0
M  V30 30 C 10.2223 -3.0689 0.0000 0
M  V30 31 C 10.7743 -2.4558 0.0000 0
M  V30 32 C 11.5813 -2.6273 0.0000 0
M  V30 33 C 11.8363 -3.4119 0.0000 0
M  V30 34 C 11.2842 -4.0250 0.0000 0
M  V30 35 C 10.4773 -3.8535 0.0000 0
M  V30 36 N 8.3534 -1.9412 0.0000 0
M  V30 37 C 7.8014 -2.5543 0.0000 0
M  V30 38 O 8.0563 -3.3389 0.0000 0
M  V30 39 C 6.9944 -2.3828 0.0000 0
M  V30 40 C 7.2494 -3.1674 0.0000 0
M  V30 41 C 6.6973 -3.7805 0.0000 0
M  V30 42 C 6.9523 -4.5651 0.0000 0
M  V30 43 C 6.4002 -5.1782 0.0000 0
M  V30 44 C 5.5933 -5.0067 0.0000 0
M  V30 45 O 5.0412 -5.6198 0.0000 0
M  V30 46 C 5.3383 -4.2221 0.0000 0
M  V30 47 C 5.8904 -3.6090 0.0000 0
M  V30 48 N 6.4424 -2.9959 0.0000 0
M  V30 49 C 5.6354 -2.8243 0.0000 0
M  V30 50 O 5.0834 -3.4374 0.0000 0
M  V30 51 C 5.9747 0.7557 0.0000 0
M  V30 52 O 6.5267 1.3688 0.0000 0
M  V30 53 N 5.1677 0.9272 0.0000 0
M  V30 54 C 4.5546 0.3752 0.0000 0
M  V30 55 C 3.8401 0.7877 0.0000 0
M  V30 56 C 4.0117 1.5947 0.0000 0
M  V30 57 C 4.8321 1.6809 0.0000 0 CFG=1
M  V30 58 C 5.2446 2.3954 0.0000 0
M  V30 59 O 4.8321 3.1099 0.0000 0
M  V30 60 N 6.0696 2.3954 0.0000 0
M  V30 61 C 6.4821 3.1099 0.0000 0 CFG=1
M  V30 62 C 6.0696 3.8243 0.0000 0
M  V30 63 C 5.2446 3.8243 0.0000 0
M  V30 64 C 4.8321 4.5388 0.0000 0
M  V30 65 N 4.0071 4.5388 0.0000 0
M  V30 66 C 3.5946 5.2533 0.0000 0
M  V30 67 N 2.7696 5.2533 0.0000 0
M  V30 68 N 4.0071 5.9677 0.0000 0
M  V30 69 C 7.3071 3.1099 0.0000 0
M  V30 70 O 7.7196 2.3954 0.0000 0
M  V30 71 N 7.7196 3.8243 0.0000 0
M  V30 72 C 8.5446 3.8243 0.0000 0
M  V30 73 C 8.9571 4.5388 0.0000 0
M  V30 74 N 8.5446 5.2533 0.0000 0
M  V30 75 O 9.7821 4.5388 0.0000 0
M  V30 76 H 6.3587 -2.2476 0.0000 0
M  V30 77 H 6.8988 0.7142 0.0000 0
M  V30 78 H 0.0000 0.0000 0.0000 0
M  V30 79 H 0.0000 0.0000 0.0000 0
M  V30 80 H 0.0000 0.0000 0.0000 0
M  V30 81 H 10.3186 -1.0529 0.0000 0
M  V30 82 H 8.4913 -2.8559 0.0000 0
M  V30 83 H 0.0000 0.0000 0.0000 0
M  V30 84 H 0.0000 0.0000 0.0000 0
M  V30 85 H 0.0000 0.0000 0.0000 0
M  V30 86 H 4.2876 2.5196 0.0000 0
M  V30 87 H 5.4821 3.1098 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 11 9
M  V30 11 1 12 11 CFG=1
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 16 11 CFG=3
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 19 17
M  V30 19 1 19 20 CFG=3
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 2 22 24
M  V30 24 1 19 25
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 28 26
M  V30 28 1 28 29 CFG=3
M  V30 29 1 29 30
M  V30 30 2 30 31
M  V30 31 1 31 32
M  V30 32 2 32 33
M  V30 33 1 33 34
M  V30 34 2 34 35
M  V30 35 1 30 35
M  V30 36 1 28 36
M  V30 37 1 36 37
M  V30 38 2 37 38
M  V30 39 1 39 37
M  V30 40 1 40 39 CFG=1
M  V30 41 1 40 41
M  V30 42 2 41 42
M  V30 43 1 42 43
M  V30 44 2 43 44
M  V30 45 1 44 45
M  V30 46 1 44 46
M  V30 47 2 46 47
M  V30 48 1 41 47
M  V30 49 1 48 39 CFG=3
M  V30 50 1 48 49
M  V30 51 1 2 49
M  V30 52 2 49 50
M  V30 53 1 7 51 CFG=1
M  V30 54 2 51 52
M  V30 55 1 51 53
M  V30 56 1 53 54
M  V30 57 1 54 55
M  V30 58 1 55 56
M  V30 59 1 57 56
M  V30 60 1 57 53
M  V30 61 1 57 58 CFG=1
M  V30 62 2 58 59
M  V30 63 1 58 60
M  V30 64 1 61 60 CFG=1
M  V30 65 1 61 62
M  V30 66 1 62 63
M  V30 67 1 63 64
M  V30 68 1 64 65
M  V30 69 1 65 66
M  V30 70 1 66 67
M  V30 71 2 66 68
M  V30 72 1 61 69
M  V30 73 2 69 70
M  V30 74 1 69 71
M  V30 75 1 71 72
M  V30 76 1 72 73
M  V30 77 1 73 74
M  V30 78 2 73 75
M  V30 79 1 76 2
M  V30 80 1 77 7
M  V30 81 1 78 12
M  V30 82 1 79 12
M  V30 83 1 80 16
M  V30 84 1 81 19
M  V30 85 1 82 28
M  V30 86 1 83 40
M  V30 87 1 84 40
M  V30 88 1 85 48
M  V30 89 1 86 57
M  V30 90 1 87 61
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
310

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Argipressin acetate (113-79-1(free base))

>  <Synonyms>
N/A

>  <CAS>
T7284

>  <Formula>
C48H69N15O14S2

>  <MolWt>
1144

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Vasopressin acetate is a peptide hormone with vasoconstrictive and antidiuretic activities that binds to the vascular arginine vasopressin receptor, V1, with Kd values of 1.31 and 1.44 nM in A7r5 rat aortic smooth muscle cells and neonatal rat cardiomyocytes, respectively"

>  <Reference>
"Xue H , Tang X . Effect of vasopressin on Na+?CK+?C2Cl? cotransporter (NKCC) and the signaling mechanisms on the murine late distal colon[J]. European Journal of Pharmacology, 2016, 771:241-246.;Yao Y , Fu L Y , Zhang X , et al. Vasopressin and oxytocin excite MCH neurons, but not other lateral hypothalamic GABA neurons[J]. AJP Regulatory Integrative and Comparative Physiology, 2012, 302(7):R815-24."

>  <ID<1>>
T7284

$$$$
StarDrop ID 311
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.2466 0.2849 0.0000 0
M  V30 2 C 3.0716 0.2849 0.0000 0
M  V30 3 C 3.0716 -0.5401 0.0000 0
M  V30 4 C 3.7861 -0.9526 0.0000 0
M  V30 5 N 3.7861 -1.7776 0.0000 0
M  V30 6 C 4.4535 -2.2625 0.0000 0
M  V30 7 C 4.1986 -3.0471 0.0000 0
M  V30 8 C 3.3736 -3.0471 0.0000 0
M  V30 9 C 3.1186 -2.2625 0.0000 0
M  V30 10 C 3.0716 1.1099 0.0000 0
M  V30 11 C 2.3571 1.5224 0.0000 0
M  V30 12 C 2.3571 2.3474 0.0000 0
M  V30 13 C 3.0716 2.7599 0.0000 0
M  V30 14 C 3.7861 2.3474 0.0000 0
M  V30 15 C 3.7861 1.5224 0.0000 0
M  V30 16 C 3.8966 0.2849 0.0000 0
M  V30 17 C 4.3091 0.9994 0.0000 0
M  V30 18 C 5.1341 0.9994 0.0000 0
M  V30 19 C 5.5466 0.2849 0.0000 0
M  V30 20 C 5.1341 -0.4295 0.0000 0
M  V30 21 C 4.3091 -0.4295 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 5 9
M  V30 10 1 2 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 10 15
M  V30 17 1 2 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
311

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Procyclidine hydrochloride

>  <Synonyms>
(??)-Procyclidine hydrochlorid

>  <CAS>
1508-76-5

>  <Formula>
C19H30ClNO

>  <MolWt>
323.9

>  <Pathways>
Membrane transporter/Ion channel;Neuroscience

>  <Target>
NMDAR;iGluR

>  <Receptor>
iGluR; NMDA receptor

>  <Bioactivity>
Procyclidine is a potent anticholinergic agent and also have NMDA antagonist properties.

>  <Reference>
"Jevtovic-Todorovic V, et al. Anti-parkinsonian agents procyclidine and ethopropazine alleviate thermal hyperalgesia in neuropathic rats. Neuropharmacology. 2003 May;44(6):739-48."

>  <ID<1>>
T4979

$$$$
StarDrop ID 312
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.0587 0.6430 0.0000 0
M  V30 2 C -1.4712 1.3575 0.0000 0
M  V30 3 C -1.0587 2.0720 0.0000 0
M  V30 4 C -0.2337 2.0720 0.0000 0
M  V30 5 C 0.1788 1.3575 0.0000 0
M  V30 6 C -0.2337 0.6430 0.0000 0
M  V30 7 C 0.1787 -0.0714 0.0000 0 CFG=1
M  V30 8 C -0.2338 -0.7859 0.0000 0
M  V30 9 C 0.1788 -1.5004 0.0000 0
M  V30 10 C -0.2338 -2.2149 0.0000 0
M  V30 11 C -1.0588 -2.2149 0.0000 0
M  V30 12 C -1.4712 -1.5004 0.0000 0
M  V30 13 C -1.0588 -0.7859 0.0000 0
M  V30 14 C 1.0038 -0.0714 0.0000 0
M  V30 15 C 1.4162 -0.7859 0.0000 0
M  V30 16 N 2.2413 -0.7859 0.0000 0
M  V30 17 C 2.6538 -1.5004 0.0000 0
M  V30 18 C 3.4787 -1.5004 0.0000 0
M  V30 19 C 2.2412 -2.2149 0.0000 0
M  V30 20 C 2.6538 -0.0714 0.0000 0
M  V30 21 C 2.2413 0.6430 0.0000 0
M  V30 22 C 3.4787 -0.0714 0.0000 0
M  V30 23 C 0.1788 2.7864 0.0000 0
M  V30 24 O 1.0038 2.7864 0.0000 0
M  V30 25 O -1.4713 -0.0714 0.0000 0
M  V30 26 C -2.2963 -0.0714 0.0000 0
M  V30 27 O -2.7088 -0.7859 0.0000 0
M  V30 28 C -2.7087 0.6430 0.0000 0
M  V30 29 C -2.2962 1.3575 0.0000 0
M  V30 30 C -3.5337 0.6430 0.0000 0
M  V30 31 H 0.6789 0.7945 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 1 6
M  V30 7 1 7 6
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 8 13
M  V30 15 1 7 14 CFG=3
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 17 19
M  V30 21 1 16 20
M  V30 22 1 20 21
M  V30 23 1 20 22
M  V30 24 1 4 23
M  V30 25 1 23 24
M  V30 26 1 1 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 28 29
M  V30 31 1 28 30
M  V30 32 1 31 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
312

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fesoterodine fumarate

>  <Synonyms>
Toviaz;SPM 907

>  <CAS>
286930-03-8

>  <Formula>
C26H37NO3??C4H4O4

>  <MolWt>
527.7

>  <Pathways>
Neuroscience

>  <Target>
AChR

>  <Receptor>
mAChR

>  <Bioactivity>
"Fesoterodine Fumarate is the fumarate salt form of fesoterodine, a competitive muscarinic receptor antagonist with muscle relaxant and urinary antispasmodic properties. Fesoterodine is rapidly hydrolyzed in vivo into its active metabolite 5-hydroxymethyl tolterodine, which binds and inhibits muscarinic receptors on the bladder detrusor muscle, thereby preventing bladder contractions or spasms caused by acetylcholine."

>  <Reference>
"Ney P, et al. BJU Int, 2008, 101(8), 1036-1042.;Malhotra B, et al. Curr Med Chem, 2009, 16(33), 4481-4489.;Vella M, et al. Expert Opin Drug Saf, 2011, 10(5), 805-808."

>  <ID<1>>
T1475

$$$$
StarDrop ID 313
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 43 48 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.1918 1.5237 0.0000 0
M  V30 2 C -1.9369 0.7391 0.0000 0
M  V30 3 C -2.4889 0.1260 0.0000 0
M  V30 4 O -1.1299 0.5675 0.0000 0
M  V30 5 C -0.8750 -0.2171 0.0000 0
M  V30 6 C -0.0680 -0.3886 0.0000 0
M  V30 7 C 0.1869 -1.1732 0.0000 0
M  V30 8 C -0.3651 -1.7863 0.0000 0
M  V30 9 C -1.1721 -1.6148 0.0000 0
M  V30 10 C -1.4270 -0.8302 0.0000 0
M  V30 11 F -2.2340 -0.6587 0.0000 0
M  V30 12 C -0.1102 -2.5710 0.0000 0
M  V30 13 N -0.5951 -3.2384 0.0000 0
M  V30 14 N -0.1102 -3.9058 0.0000 0
M  V30 15 C -0.3651 -4.6905 0.0000 0 CFG=1
M  V30 16 C -1.1721 -4.8620 0.0000 0
M  V30 17 C 0.1869 -5.3035 0.0000 0
M  V30 18 O 0.9939 -5.1320 0.0000 0
M  V30 19 C 1.5459 -5.7451 0.0000 0
M  V30 20 C 2.3529 -5.5736 0.0000 0
M  V30 21 C 2.9049 -6.1867 0.0000 0
M  V30 22 C 2.6500 -6.9713 0.0000 0
M  V30 23 F 3.2020 -7.5844 0.0000 0
M  V30 24 C 1.8430 -7.1428 0.0000 0
M  V30 25 C 1.2910 -6.5297 0.0000 0
M  V30 26 C 0.4840 -6.7013 0.0000 0
M  V30 27 O 0.2291 -7.4859 0.0000 0
M  V30 28 C -0.0680 -6.0882 0.0000 0
M  V30 29 C -0.8750 -6.2597 0.0000 0
M  V30 30 C -1.1299 -7.0443 0.0000 0
M  V30 31 C -1.9369 -7.2158 0.0000 0
M  V30 32 C -2.4889 -6.6028 0.0000 0
M  V30 33 C -2.2340 -5.8181 0.0000 0
M  V30 34 F -2.7860 -5.2050 0.0000 0
M  V30 35 C -1.4270 -5.6466 0.0000 0
M  V30 36 C 0.6745 -3.6509 0.0000 0
M  V30 37 N 1.3889 -4.0634 0.0000 0
M  V30 38 C 2.1034 -3.6509 0.0000 0
M  V30 39 N 2.1034 -2.8259 0.0000 0
M  V30 40 C 1.3889 -2.4134 0.0000 0
M  V30 41 N 1.3889 -1.5884 0.0000 0
M  V30 42 C 0.6745 -2.8259 0.0000 0
M  V30 43 H -0.6742 -5.6415 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 5 10
M  V30 11 1 10 11
M  V30 12 1 8 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 15 14
M  V30 16 1 15 16 CFG=3
M  V30 17 1 15 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 1 22 24
M  V30 25 2 24 25
M  V30 26 1 19 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 2 17 28
M  V30 31 1 28 29
M  V30 32 2 29 30
M  V30 33 1 30 31
M  V30 34 2 31 32
M  V30 35 1 32 33
M  V30 36 1 33 34
M  V30 37 2 33 35
M  V30 38 1 29 35
M  V30 39 1 14 36
M  V30 40 2 36 37
M  V30 41 1 37 38
M  V30 42 2 38 39
M  V30 43 1 39 40
M  V30 44 1 40 41
M  V30 45 2 40 42
M  V30 46 1 12 42
M  V30 47 1 36 42
M  V30 48 1 43 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
313

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Umbralisib

>  <Synonyms>
TGR-1202;TGR1202;RP5264;TGR 1202

>  <CAS>
1532533-67-7

>  <Formula>
C31H24F3N5O3

>  <MolWt>
571.5

>  <Pathways>
PI3K/Akt/mTOR signaling

>  <Target>
PI3K

>  <Receptor>
 PI3K??:22.2 nM

>  <Bioactivity>
TGR-1202 is a PI3K?? inhibitor.

>  <Reference>
"Deng C, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3K?? and CK1?? in hematological malignancies. Blood. 2017 Jan 5;129(1):88-99;Swaroop Vakkalankaa, et al. Inhibition of PI3K?? kinase by a selective, small molecule inhibitor suppresses B-cell proliferation and leukemic cell growth."

>  <ID<1>>
T4976

$$$$
StarDrop ID 314
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.6378 3.1729 0.0000 0
M  V30 2 O 3.3523 3.5854 0.0000 0
M  V30 3 C 4.0668 3.1729 0.0000 0
M  V30 4 O 4.7812 3.5854 0.0000 0
M  V30 5 C 4.0668 2.3479 0.0000 0 CFG=1
M  V30 6 N 3.3523 1.9354 0.0000 0
M  V30 7 C 3.3523 1.1104 0.0000 0
M  V30 8 C 2.6378 0.6979 0.0000 0
M  V30 9 C 1.9233 1.1104 0.0000 0
M  V30 10 C 1.9233 1.9354 0.0000 0
M  V30 11 C 2.6378 2.3479 0.0000 0
M  V30 12 C 1.1387 2.1904 0.0000 0
M  V30 13 C 0.6538 1.5229 0.0000 0
M  V30 14 S 1.1387 0.8555 0.0000 0
M  V30 15 C 4.7812 1.9354 0.0000 0
M  V30 16 C 5.4957 2.3479 0.0000 0
M  V30 17 C 6.2102 1.9354 0.0000 0
M  V30 18 C 6.2102 1.1104 0.0000 0
M  V30 19 C 5.4957 0.6979 0.0000 0
M  V30 20 C 4.7812 1.1104 0.0000 0
M  V30 21 Cl 4.0668 0.6979 0.0000 0
M  V30 22 H 4.9328 2.8479 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 5 3 CFG=3
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 6 11
M  V30 12 1 10 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 9 14
M  V30 16 1 5 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 15 20
M  V30 23 1 20 21
M  V30 24 1 22 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
314

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Clopidogrel

>  <Synonyms>
SR-25990C;(S)-Clopidogrel

>  <CAS>
113665-84-2

>  <Formula>
C16H16ClNO2S

>  <MolWt>
321.8

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
P2Y Receptor

>  <Receptor>
P2Y; P2Y12

>  <Bioactivity>
"Clopidogrel, a P2Y12 receptor antagonist, decreases platelet aggregation."

>  <Reference>
"Dorsam RT, et al. Hematology. 2003 Dec;8(6):359-65."

>  <ID<1>>
T0182

$$$$
StarDrop ID 315
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -1.7098 -3.8725 0.0000 0
M  V30 2 N -0.9252 -3.6175 0.0000 0
M  V30 3 O -0.3121 -4.1696 0.0000 0
M  V30 4 C -0.7537 -2.8106 0.0000 0
M  V30 5 N -1.3057 -2.1975 0.0000 0
M  V30 6 C -0.8932 -1.4830 0.0000 0
M  V30 7 C -0.0862 -1.6545 0.0000 0
M  V30 8 N 0.0000 -2.4750 0.0000 0
M  V30 9 C 0.7145 -2.8875 0.0000 0
M  V30 10 C 1.4289 -2.4750 0.0000 0
M  V30 11 O 1.4289 -1.6500 0.0000 0
M  V30 12 N 2.1434 -2.8875 0.0000 0
M  V30 13 C 2.8579 -2.4750 0.0000 0
M  V30 14 C 3.5724 -2.8875 0.0000 0
M  V30 15 C 4.2868 -2.4750 0.0000 0
M  V30 16 C 5.0013 -2.8875 0.0000 0
M  V30 17 C 5.0013 -3.7125 0.0000 0
M  V30 18 C 4.2868 -4.1250 0.0000 0
M  V30 19 C 3.5724 -3.7125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 4 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 14 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
315

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Benznidazol

>  <Synonyms>
Ro 71051;Ro 07-1051;Benznidazole;Radanil

>  <CAS>
22994-85-0

>  <Formula>
C12H12N4O3

>  <MolWt>
260.3

>  <Pathways>
Microbiology/Virology

>  <Target>
Parasite;Antibiotic

>  <Receptor>
 antiparasitic:20.35 ??M

>  <Bioactivity>
"Benznidazole has an antiprotozoal activity by interfering with parasite protein biosynthesis, influencing cytokines production and stimulating host phagocytosis."

>  <Reference>
"Calvo KL, et al. Benznidazole modulates cell proliferation in acute leukemia cells. Immunopharmacol Immunotoxicol. 2013 Aug;35(4):478-86.;Perin L, et al. Pharmacokinetics and Tissue Distribution of Benznidazole after Oral Administration in Mice. Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02410-16."

>  <ID<1>>
T4982

$$$$
StarDrop ID 316
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 42 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -3.0233 -5.7320 0.0000 0
M  V30 2 C -2.3088 -6.1445 0.0000 0
M  V30 3 C -3.0233 -4.9070 0.0000 0
M  V30 4 C -3.7378 -4.4945 0.0000 0
M  V30 5 C -3.7378 -3.6695 0.0000 0
M  V30 6 C -3.0233 -3.2570 0.0000 0
M  V30 7 C -2.3088 -3.6695 0.0000 0
M  V30 8 C -2.3088 -4.4945 0.0000 0
M  V30 9 C -1.5944 -4.9070 0.0000 0 CFG=1
M  V30 10 O -0.8799 -4.4945 0.0000 0
M  V30 11 C -0.1654 -4.9070 0.0000 0
M  V30 12 C 0.5490 -4.4945 0.0000 0
M  V30 13 C 1.2635 -4.9070 0.0000 0
M  V30 14 C 1.9780 -4.4945 0.0000 0
M  V30 15 C 2.6925 -4.9070 0.0000 0
M  V30 16 C 3.4069 -4.4945 0.0000 0
M  V30 17 C -1.5944 -5.7320 0.0000 0
M  V30 18 C -4.4522 -4.9070 0.0000 0
M  V30 19 N -4.5385 -5.7274 0.0000 0
M  V30 20 C -5.3455 -5.8990 0.0000 0
M  V30 21 N -5.6810 -6.6526 0.0000 0
M  V30 22 C -5.1961 -7.3201 0.0000 0
M  V30 23 O -4.3756 -7.2338 0.0000 0
M  V30 24 C -5.5316 -8.0737 0.0000 0
M  V30 25 C -5.0467 -8.7412 0.0000 0
M  V30 26 C -5.3823 -9.4949 0.0000 0
M  V30 27 Cl -4.8974 -10.1623 0.0000 0
M  V30 28 C -6.2028 -9.5811 0.0000 0
M  V30 29 C -6.5383 -10.3348 0.0000 0
M  V30 30 C -7.3588 -10.4210 0.0000 0
M  V30 31 C -7.6944 -11.1747 0.0000 0
M  V30 32 O -8.5148 -11.2609 0.0000 0
M  V30 33 O -7.2094 -11.8421 0.0000 0
M  V30 34 C -7.8437 -9.7536 0.0000 0
M  V30 35 C -6.6877 -8.9137 0.0000 0
M  V30 36 Cl -7.5082 -8.9999 0.0000 0
M  V30 37 C -6.3521 -8.1600 0.0000 0
M  V30 38 S -5.7580 -5.1845 0.0000 0
M  V30 39 C -5.2059 -4.5714 0.0000 0
M  V30 40 H -2.4604 -5.4070 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 3 8
M  V30 9 1 9 8
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 9 17 CFG=1
M  V30 18 1 4 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 2 26 28
M  V30 29 1 28 29
M  V30 30 2 29 30
M  V30 31 1 30 31
M  V30 32 1 31 32
M  V30 33 2 31 33
M  V30 34 1 30 34
M  V30 35 1 28 35
M  V30 36 1 35 36
M  V30 37 2 35 37
M  V30 38 1 24 37
M  V30 39 1 20 38
M  V30 40 1 38 39
M  V30 41 2 18 39
M  V30 42 1 40 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
316

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lusutrombopag

>  <Synonyms>
S-888711;Mulpleta

>  <CAS>
1110766-97-6

>  <Formula>
C29H32Cl2N2O5S

>  <MolWt>
591.5

>  <Pathways>
Immunology/Inflammation;Proteases/Proteasome

>  <Target>
Thrombin;Thrombopoietin Receptor

>  <Receptor>
Thrombopoietin Receptor; TPO

>  <Bioactivity>
"Lusutrombopag is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery."

>  <Reference>
"Kim ES, et al. Lusutrombopag: First Global Approval. Drugs. 2016 Jan;76(1):155-8."

>  <ID<1>>
TQ0223

$$$$
StarDrop ID 317
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -6.6480 2.8061 0.0000 0
M  V30 2 C -6.0646 3.3894 0.0000 0
M  V30 3 O -6.2781 4.1863 0.0000 0
M  V30 4 O -5.2677 3.1759 0.0000 0
M  V30 5 C -4.6844 3.7593 0.0000 0
M  V30 6 C -3.8875 3.5457 0.0000 0
M  V30 7 C -3.3041 4.1291 0.0000 0
M  V30 8 N -2.5072 3.9156 0.0000 0
M  V30 9 C -2.2937 3.1187 0.0000 0
M  V30 10 S -2.8771 2.5353 0.0000 0
M  V30 11 C -3.6739 2.7489 0.0000 0
M  V30 12 C -1.4968 3.3322 0.0000 0
M  V30 13 N -0.7823 2.9197 0.0000 0
M  V30 14 C -0.0679 3.3322 0.0000 0
M  V30 15 O -0.0679 4.1572 0.0000 0
M  V30 16 C 0.6466 2.9197 0.0000 0
M  V30 17 S 1.3611 3.3322 0.0000 0
M  V30 18 C 2.0755 2.9197 0.0000 0
M  V30 19 C 2.7900 3.3322 0.0000 0
M  V30 20 C 3.5045 2.9197 0.0000 0
M  V30 21 N 3.5045 2.0947 0.0000 0
M  V30 22 C 2.7900 1.6822 0.0000 0
M  V30 23 C 2.0755 2.0947 0.0000 0
M  V30 24 C -1.7103 4.1291 0.0000 0
M  V30 25 O -1.2978 4.8436 0.0000 0
M  V30 26 C -3.5176 4.9260 0.0000 0
M  V30 27 O -2.9343 5.5094 0.0000 0
M  V30 28 O -4.3145 5.1395 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 6 11
M  V30 12 1 9 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 18 23
M  V30 25 1 12 24
M  V30 26 1 8 24
M  V30 27 2 24 25
M  V30 28 1 7 26
M  V30 29 1 26 27
M  V30 30 2 26 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
317

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cephapirin Sodium

>  <Synonyms>
N/A

>  <CAS>
24356-60-3

>  <Formula>
C17H16N3NaO6S2

>  <MolWt>
445.4

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial;Antibiotic

>  <Receptor>
Antibacterial; Antibiotic; Bacterial

>  <Bioactivity>
"Cefapirin sodium is the sodium salt of Cephapirin, an antimicrobial agent."

>  <Reference>
"Tan JS, et al. Bacampicillin, Ampicillin, Cephalothin, and Cephapirin levels in human blood and interstitial fluid. Antimicrob Agents Chemother. 1979 Apr;15(4):510-2."

>  <ID<1>>
T5038

$$$$
StarDrop ID 318
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 F 1.9233 6.0604 0.0000 0
M  V30 2 C 2.6378 5.6479 0.0000 0
M  V30 3 C 3.3523 6.0604 0.0000 0
M  V30 4 C 4.0668 5.6479 0.0000 0
M  V30 5 C 4.0668 4.8229 0.0000 0
M  V30 6 C 3.3523 4.4104 0.0000 0
M  V30 7 C 2.6378 4.8229 0.0000 0
M  V30 8 C 4.7812 4.4104 0.0000 0 CFG=2
M  V30 9 C 5.4957 4.8229 0.0000 0
M  V30 10 C 6.2102 4.4104 0.0000 0
M  V30 11 N 6.2102 3.5854 0.0000 0
M  V30 12 C 5.4957 3.1729 0.0000 0
M  V30 13 C 4.7812 3.5854 0.0000 0 CFG=1
M  V30 14 C 4.0668 3.1729 0.0000 0
M  V30 15 O 4.0668 2.3479 0.0000 0
M  V30 16 C 3.3523 1.9354 0.0000 0
M  V30 17 C 3.3523 1.1104 0.0000 0
M  V30 18 C 2.6378 0.6979 0.0000 0
M  V30 19 C 1.9233 1.1104 0.0000 0
M  V30 20 O 1.1387 0.8555 0.0000 0
M  V30 21 C 0.6538 1.5229 0.0000 0
M  V30 22 O 1.1387 2.1904 0.0000 0
M  V30 23 C 1.9233 1.9354 0.0000 0
M  V30 24 C 2.6378 2.3479 0.0000 0
M  V30 25 H 4.7813 5.4104 0.0000 0
M  V30 26 H 4.7813 2.5854 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 8 5 CFG=3
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 13 12
M  V30 14 1 8 13
M  V30 15 1 13 14 CFG=1
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 1 19 23
M  V30 26 2 23 24
M  V30 27 1 16 24
M  V30 28 1 25 8
M  V30 29 1 26 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
318

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Paroxetine

>  <Synonyms>
N/A

>  <CAS>
61869-08-7

>  <Formula>
C19H20FNO3

>  <MolWt>
329.4

>  <Pathways>
Neuroscience

>  <Target>
Serotonin Transporter

>  <Receptor>
serotonin

>  <Bioactivity>
Paroxetine is a inhibitor of serotonin uptake that is effective in the treatment of depression.

>  <Reference>
"Anick B??rard, Iessa N , Chaabane S , et al. The risk of major cardiac malformations associated with paroxetine use during the first trimester of pregnancy: a systematic review and meta?analysis[J]. Br J Clin Pharmacol, 2016, 81(4).;Cipriani A , Furukawa T A , Veronese A , et al. Paroxetine versus other anti-depressive agents for depression[J]. Cochrane Database of Systematic Reviews, 2007."

>  <ID<1>>
T8708

$$$$
StarDrop ID 319
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 16 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br -0.7145 3.7125 0.0000 0
M  V30 2 C 0.0000 3.3000 0.0000 0
M  V30 3 C 0.0000 2.4750 0.0000 0
M  V30 4 C 0.7145 2.0625 0.0000 0
M  V30 5 O 1.4289 2.4750 0.0000 0
M  V30 6 N 0.7145 1.2375 0.0000 0
M  V30 7 C 1.4289 0.8250 0.0000 0
M  V30 8 C 1.4289 -0.0000 0.0000 0
M  V30 9 N 0.7145 -0.4125 0.0000 0
M  V30 10 C 0.0000 0.0000 0.0000 0
M  V30 11 C 0.0000 0.8250 0.0000 0
M  V30 12 C 0.7145 -1.2375 0.0000 0
M  V30 13 O -0.0000 -1.6500 0.0000 0
M  V30 14 C 1.4289 -1.6500 0.0000 0
M  V30 15 C 1.4289 -2.4750 0.0000 0
M  V30 16 Br 2.1434 -2.8875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 6 11
M  V30 12 1 9 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
319

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pipobroman

>  <Synonyms>
Vercyte;Amedel;A-8103

>  <CAS>
54-91-1

>  <Formula>
C10H16Br2N2O2

>  <MolWt>
356.1

>  <Pathways>
Others;DNA Damage/DNA Repair

>  <Target>
DNA Alkylator/Crosslinker;Others

>  <Receptor>
DNA Alkylator/Crosslinker

>  <Bioactivity>
"Pipobroman is an anti-cancer drug that probably acts as an alkylating agent. Pipobroman has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET). Pipobroman allows, within 3 months, to attain a response in more than 90% of patients, without clinically relevant toxicities. The 10-years risk of thrombosis of patients treated with Pipobroman is about 15%, The anti-proliferative activity of Pipobroman on bone marrow megakaryocytes seems of particular value in lowering the occurrence of post-PV and post-ET MMM, whose risk is the lowest registered with available treatments. The 10-year risk of acute leukemia with Pipobroman is 5% in PVand 3% in ET, which is only slightly higher than that expected as a natural evolution of the disease. In conclusion, the use of Pipobroman is a definite alternative to hydroxyurea in patients with PV and ET at high risk of thrombosis."

>  <Reference>
"Passamonti F, et al. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman. Leuk Lymphoma. 2003 Sep;44(9):1483-1488."

>  <ID<1>>
T4570

$$$$
StarDrop ID 320
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.5224 -2.7859 0.0000 0
M  V30 2 N 7.9704 -2.1728 0.0000 0
M  V30 3 C 7.1634 -2.3444 0.0000 0
M  V30 4 C 8.2253 -1.3882 0.0000 0
M  V30 5 O 9.0323 -1.2167 0.0000 0
M  V30 6 C 7.6733 -0.7751 0.0000 0
M  V30 7 C 7.9282 0.0095 0.0000 0
M  V30 8 C 7.4433 0.6769 0.0000 0
M  V30 9 N 7.9282 1.3444 0.0000 0
M  V30 10 C 8.7129 1.0894 0.0000 0
M  V30 11 C 9.4273 1.5019 0.0000 0
M  V30 12 C 10.1418 1.0894 0.0000 0
M  V30 13 C 10.1418 0.2644 0.0000 0
M  V30 14 C 10.8563 -0.1481 0.0000 0
M  V30 15 C 9.4273 -0.1481 0.0000 0
M  V30 16 N 8.7129 0.2644 0.0000 0
M  V30 17 C 6.6183 0.6769 0.0000 0
M  V30 18 C 6.2058 -0.0375 0.0000 0
M  V30 19 C 5.3808 -0.0375 0.0000 0
M  V30 20 C 4.9683 0.6769 0.0000 0
M  V30 21 C 4.1433 0.6769 0.0000 0
M  V30 22 C 5.3808 1.3914 0.0000 0
M  V30 23 C 6.2058 1.3914 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 15 16
M  V30 16 1 7 16
M  V30 17 1 10 16
M  V30 18 1 8 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 1 20 22
M  V30 24 2 22 23
M  V30 25 1 17 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
320

>  <Plate>
PHD136328

>  <Row>
p

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Zolpidem tartrate

>  <Synonyms>
Zolpidemum;N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide;AMBIEN;Zolpidem

>  <CAS>
103188-50-7

>  <Formula>
C23H27N3O7

>  <MolWt>
457.5

>  <Pathways>
Neuroscience;Membrane transporter/Ion channel;Metabolism

>  <Target>
GABA Receptor;P450

>  <Receptor>
 GABAA:?0.84???M?

>  <Bioactivity>
"Zolpidem is a prescription medication used for the treatment of insomnia, as well as some brain disorders. It is a short-acting nonbenzodiazepine hypnotic of the imidazopyridine class that potentiates gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, by binding to GABAA receptors at the same location as benzodiazepines."

>  <Reference>
"Westermeyer J ,  Carr T M . Zolpidem-Associated Consequences: An Updated Literature Review With Case Reports[J]. The Journal of Nervous and Mental Disease, 2020, 208."

>  <ID<1>>
T9255

$$$$
StarDrop ID 321
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 40 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.7874 -1.6500 0.0000 0
M  V30 2 C 8.7874 -2.4750 0.0000 0
M  V30 3 C 9.5019 -2.8875 0.0000 0
M  V30 4 N 9.5019 -3.7125 0.0000 0
M  V30 5 C 8.7874 -4.1250 0.0000 0
M  V30 6 N 8.7874 -4.9500 0.0000 0
M  V30 7 C 9.5019 -5.3625 0.0000 0
M  V30 8 C 10.2163 -4.9500 0.0000 0
M  V30 9 C 10.9308 -5.3625 0.0000 0
M  V30 10 C 10.9308 -6.1875 0.0000 0
M  V30 11 O 11.6453 -6.6000 0.0000 0
M  V30 12 C 11.6453 -7.4250 0.0000 0
M  V30 13 C 12.3597 -7.8375 0.0000 0
M  V30 14 N 12.3597 -8.6625 0.0000 0
M  V30 15 C 13.0272 -9.1474 0.0000 0
M  V30 16 C 12.7722 -9.9320 0.0000 0
M  V30 17 C 11.9472 -9.9320 0.0000 0
M  V30 18 C 11.6923 -9.1474 0.0000 0
M  V30 19 C 10.2163 -6.6000 0.0000 0
M  V30 20 C 9.5019 -6.1875 0.0000 0
M  V30 21 N 8.0729 -3.7125 0.0000 0
M  V30 22 C 8.0729 -2.8875 0.0000 0
M  V30 23 N 7.3584 -2.4750 0.0000 0
M  V30 24 C 6.6440 -2.8875 0.0000 0
M  V30 25 C 6.6440 -3.7125 0.0000 0
M  V30 26 C 5.9295 -4.1250 0.0000 0
M  V30 27 C 5.2150 -3.7125 0.0000 0
M  V30 28 C 5.2150 -2.8875 0.0000 0
M  V30 29 C 5.9295 -2.4750 0.0000 0
M  V30 30 S 4.5006 -2.4750 0.0000 0
M  V30 31 O 4.9131 -1.7605 0.0000 0
M  V30 32 O 4.0881 -3.1895 0.0000 0
M  V30 33 N 3.7861 -2.0625 0.0000 0
M  V30 34 C 3.0716 -2.4750 0.0000 0
M  V30 35 C 2.3571 -2.8875 0.0000 0
M  V30 36 C 2.6591 -1.7605 0.0000 0
M  V30 37 C 3.4841 -3.1895 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 14 18
M  V30 19 1 10 19
M  V30 20 2 19 20
M  V30 21 1 7 20
M  V30 22 1 5 21
M  V30 23 2 21 22
M  V30 24 1 2 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 24 29
M  V30 33 1 28 30
M  V30 34 2 30 31
M  V30 35 2 30 32
M  V30 36 1 30 33
M  V30 37 1 33 34
M  V30 38 1 34 35
M  V30 39 1 34 36
M  V30 40 1 34 37
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
321

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fedratinib hydrochloride hydrate

>  <Synonyms>
SAR 302503 hydrochloride hydrate;TG-101348 hydrochloride hydrate

>  <CAS>
1374744-69-0

>  <Formula>
C27H40Cl2N6O4S

>  <MolWt>
615.6

>  <Pathways>
JAK/STAT signaling;Angiogenesis;Stem Cells;Apoptosis;Chromatin/Epigenetic

>  <Target>
Apoptosis;JAK

>  <Receptor>
" JAK2(V617F):3 nM, JAK2:3 nM, FLT3:15 nM, RET:48 nM"

>  <Bioactivity>
"Fedratinib hydrochloride hydrate is a potent, selective, ATP-competitive and orally active JAK2 inhibitor."

>  <Reference>
"Wernig G, et al. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell. 2008 Apr;13(4):311-20.;Geron I, et al. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell. 2008 Apr;13(4):321-30."

>  <ID<1>>
T9251

$$$$
StarDrop ID 322
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 -1.6848 0.0000 0
M  V30 2 O 3.1821 -1.6848 0.0000 0
M  V30 3 C 3.5946 -0.9703 0.0000 0
M  V30 4 C 3.1821 -0.2558 0.0000 0
M  V30 5 C 3.5946 0.4587 0.0000 0
M  V30 6 N 4.4196 0.4587 0.0000 0
M  V30 7 C 4.8321 -0.2558 0.0000 0
M  V30 8 C 5.6571 -0.2558 0.0000 0
M  V30 9 S 6.0696 0.4587 0.0000 0
M  V30 10 O 5.6571 1.1731 0.0000 0
M  V30 11 C 6.8946 0.4587 0.0000 0
M  V30 12 N 7.3796 1.1261 0.0000 0
M  V30 13 C 8.1642 0.8712 0.0000 0
M  V30 14 C 8.8787 1.2837 0.0000 0
M  V30 15 C 9.5931 0.8712 0.0000 0
M  V30 16 O 10.3076 1.2837 0.0000 0
M  V30 17 C 11.0221 0.8712 0.0000 0
M  V30 18 F 11.7365 1.2837 0.0000 0
M  V30 19 F 11.0221 0.0462 0.0000 0
M  V30 20 C 9.5931 0.0462 0.0000 0
M  V30 21 C 8.8787 -0.3663 0.0000 0
M  V30 22 C 8.1642 0.0462 0.0000 0
M  V30 23 N 7.3796 -0.2088 0.0000 0 CHG=-1
M  V30 24 C 4.4196 -0.9703 0.0000 0
M  V30 25 O 4.8321 -1.6848 0.0000 0
M  V30 26 C 4.4196 -2.3992 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 17 19
M  V30 19 2 15 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 13 22
M  V30 23 1 22 23
M  V30 24 1 11 23
M  V30 25 2 7 24
M  V30 26 1 3 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
322

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pantoprazole sodium

>  <Synonyms>
BY1023 (sodium);SKF96022 sodium;Pantoloc;BY-1023 sodium;Pantecta;SKF96022 (sodium)

>  <CAS>
138786-67-1

>  <Formula>
C16H14F2N3NaO4S

>  <MolWt>
405.4

>  <Pathways>
Chromatin/Epigenetic;Membrane transporter/Ion channel;Autophagy;Apoptosis;Others;Angiogenesis

>  <Target>
Proton pump;Others;Autophagy;Apoptosis;HIF

>  <Receptor>
Apoptosis; Autophagy; HIF-1??; pronton pump; Proton Pump

>  <Bioactivity>
"Pantoprazole Sodium is the sodium salt form of a substituted benzimidazole with proton pump inhibitor activity. Pantoprazole is a lipophilic, weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulfenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production."

>  <Reference>
"Yeo M, et al. Clin Cancer Res. 2004, 10(24):8687-8696.;Y Wu, et al. Chinese Journal of Gastroenterology. 2010, 15(4):205-208.;Shen Y, et al. Neoplasma. 2012, 59(2):142-149.;Shen Y, et al. Oncol Lett. 2016, 11(1):717-722."

>  <ID<1>>
T6929

$$$$
StarDrop ID 323
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.1164 -2.4234 0.0000 0
M  V30 2 C 0.4019 -2.8359 0.0000 0
M  V30 3 N 0.4019 -3.6609 0.0000 0
M  V30 4 C 1.1164 -4.0734 0.0000 0
M  V30 5 C 1.1164 -4.8984 0.0000 0
M  V30 6 C 1.8308 -5.3109 0.0000 0
M  V30 7 C 1.8308 -6.1359 0.0000 0
M  V30 8 C 1.1164 -6.5484 0.0000 0
M  V30 9 C 0.4019 -6.1359 0.0000 0
M  V30 10 C 0.4019 -5.3109 0.0000 0
M  V30 11 C -0.3126 -2.4234 0.0000 0
M  V30 12 C -0.3126 -1.5984 0.0000 0
M  V30 13 N -1.0271 -1.1859 0.0000 0
M  V30 14 C -1.0271 -0.3609 0.0000 0
M  V30 15 C -0.3126 0.0516 0.0000 0
M  V30 16 C 0.4019 -0.3609 0.0000 0
M  V30 17 C 0.4019 -1.1859 0.0000 0
M  V30 18 C -0.3126 0.8766 0.0000 0
M  V30 19 C -1.0271 1.2891 0.0000 0
M  V30 20 C -1.0271 2.1141 0.0000 0
M  V30 21 C -0.3126 2.5266 0.0000 0
M  V30 22 O -0.3126 3.3516 0.0000 0
M  V30 23 C 0.4019 3.7641 0.0000 0
M  V30 24 C 0.4019 4.5891 0.0000 0
M  V30 25 N -0.3126 5.0016 0.0000 0
M  V30 26 C -1.0271 4.5891 0.0000 0
M  V30 27 C -1.7415 5.0016 0.0000 0
M  V30 28 O -1.7415 5.8266 0.0000 0
M  V30 29 C -1.0271 6.2391 0.0000 0
M  V30 30 C -0.3126 5.8266 0.0000 0
M  V30 31 C 0.4019 2.1141 0.0000 0
M  V30 32 C 0.4019 1.2891 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 2 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 12 17
M  V30 19 1 15 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 25 30
M  V30 33 1 21 31
M  V30 34 2 31 32
M  V30 35 1 18 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
323

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tirbanibulin Mesylate

>  <Synonyms>
KX2-391 Mesylate;KX01 Mesylate

>  <CAS>
1080645-95-9

>  <Formula>
C27H33N3O6S

>  <MolWt>
527.6

>  <Pathways>
Angiogenesis;Cytoskeletal Signaling;Tyrosine Kinase/Adaptors

>  <Target>
Src;Microtubule Associated

>  <Receptor>
" Src:13 nM(in PLC/PRF/5 cells), Src:26 nM(in Hep3B cells), Src:60 nM??in HepG2 cells), Src:9 nM (GI50, in HuH7 cells)"

>  <Bioactivity>
Tirbanibulin Mesylate is an inhibitor of Src that targets the peptide substrate site of Src (GI50: 9-60 nM in cancer cell lines).

>  <Reference>
"Fallah-Tafti A, et al. Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities. Eur J Med Chem, 2011, 46(10), 4853-4858.;Lau GM, et al. Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro. Dig Dis Sci, 2009, 54(7), 1465-1474."

>  <ID<1>>
T15675

$$$$
StarDrop ID 324
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.8579 -7.4250 0.0000 0
M  V30 2 C 2.8579 -6.6000 0.0000 0
M  V30 3 O 2.1434 -6.1875 0.0000 0
M  V30 4 C 1.4289 -6.6000 0.0000 0
M  V30 5 C 0.7145 -6.1875 0.0000 0
M  V30 6 O 1.4289 -7.4250 0.0000 0
M  V30 7 O 3.5724 -6.1875 0.0000 0
M  V30 8 C 4.2868 -6.6000 0.0000 0
M  V30 9 O 4.2868 -7.4250 0.0000 0
M  V30 10 C 5.0013 -6.1875 0.0000 0
M  V30 11 C 5.0013 -5.3625 0.0000 0
M  V30 12 C 5.7158 -6.6000 0.0000 0
M  V30 13 C 6.4302 -6.1875 0.0000 0
M  V30 14 C 7.1447 -6.6000 0.0000 0
M  V30 15 C 7.1447 -7.4250 0.0000 0
M  V30 16 C 6.4302 -7.8375 0.0000 0
M  V30 17 F 6.4302 -8.6625 0.0000 0
M  V30 18 C 5.7158 -7.4250 0.0000 0
M  V30 19 C 7.8592 -7.8375 0.0000 0
M  V30 20 C 8.5737 -7.4250 0.0000 0
M  V30 21 C 9.2881 -7.8375 0.0000 0
M  V30 22 C 9.2881 -8.6625 0.0000 0
M  V30 23 C 8.5737 -9.0750 0.0000 0
M  V30 24 C 7.8592 -8.6625 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 2 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 16 18
M  V30 18 1 12 18
M  V30 19 1 15 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 19 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
324

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Flurbiprofen Axetil

>  <Synonyms>
Ropiopn;Ropion;Lipfen

>  <CAS>
91503-79-6

>  <Formula>
C19H19FO4

>  <MolWt>
330.4

>  <Pathways>
Neuroscience;Immunology/Inflammation

>  <Target>
COX

>  <Receptor>
COX; COX-1; COX-2

>  <Bioactivity>
Flurbiprofen Axetil is an anti-inflammatory used as an analgesic.

>  <Reference>
"Kathleen MK, et al. Defining the COX Inhibitor Selectivity of NSAIDs: Implications for Understanding Toxicity. Expert Rev Clin Pharmacol. 2010;3(6):769-776."

>  <ID<1>>
T3500

$$$$
StarDrop ID 325
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.0716 -3.3643 0.0000 0
M  V30 2 N 3.0716 -2.5393 0.0000 0 CHG=1
M  V30 3 C 2.3571 -2.1268 0.0000 0
M  V30 4 C 2.3571 -1.3018 0.0000 0
M  V30 5 C 3.0716 -0.8893 0.0000 0
M  V30 6 C 3.2091 -1.4393 0.0000 0
M  V30 7 C 3.2091 -1.9893 0.0000 0
M  V30 8 C 3.7861 -1.3018 0.0000 0
M  V30 9 C 3.7861 -2.1268 0.0000 0
M  V30 10 O 4.5006 -0.8893 0.0000 0
M  V30 11 C 4.5006 -0.0643 0.0000 0
M  V30 12 O 3.7861 0.3482 0.0000 0
M  V30 13 C 5.2150 0.3482 0.0000 0
M  V30 14 O 5.6275 -0.3663 0.0000 0
M  V30 15 C 5.9295 0.7607 0.0000 0
M  V30 16 C 5.9295 1.5857 0.0000 0
M  V30 17 C 6.6440 1.9982 0.0000 0
M  V30 18 C 7.3584 1.5857 0.0000 0
M  V30 19 C 7.3584 0.7607 0.0000 0
M  V30 20 C 6.6440 0.3482 0.0000 0
M  V30 21 C 4.8025 1.0627 0.0000 0
M  V30 22 C 3.9775 1.0627 0.0000 0
M  V30 23 C 3.5650 1.7771 0.0000 0
M  V30 24 C 3.9775 2.4916 0.0000 0
M  V30 25 C 4.8025 2.4916 0.0000 0
M  V30 26 C 5.2150 1.7771 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 1 8 9
M  V30 10 1 2 9
M  V30 11 1 8 10
M  V30 12 1 10 11
M  V30 13 2 11 12
M  V30 14 1 11 13
M  V30 15 1 13 14
M  V30 16 1 13 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 15 20
M  V30 23 1 13 21
M  V30 24 2 21 22
M  V30 25 1 22 23
M  V30 26 2 23 24
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 1 21 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
325

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Clidinium bromide

>  <Synonyms>
Ro 2-3773

>  <CAS>
3485-62-9

>  <Formula>
C22H26BrNO3

>  <MolWt>
432.4

>  <Pathways>
Neuroscience

>  <Target>
AChR

>  <Receptor>
mAChR

>  <Bioactivity>
"Clidinium, a synthetic anticholinergic agent, has been shown in experimental and clinical researchers to have a pronounced antisecretory and antispasmodic effect on the gastrointestinal tract. It can inhibit muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve cramps or stomach spasms or abdominal due to colicky abdominal diverticulitis, pain, and irritable bowel syndrome."

>  <Reference>
"Pathak A, et al. J Chromatogr Sci. 2010 Mar;48(3):235-9."

>  <ID<1>>
T0786

$$$$
StarDrop ID 326
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 42 46 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 8.5737 -0.8250 0.0000 0
M  V30 2 S 7.8592 -1.2375 0.0000 0
M  V30 3 O 7.4467 -0.5230 0.0000 0
M  V30 4 O 8.2717 -1.9520 0.0000 0
M  V30 5 C 7.1447 -1.6500 0.0000 0
M  V30 6 C 7.1447 -2.4750 0.0000 0
M  V30 7 C 6.4302 -2.8875 0.0000 0
M  V30 8 C 5.7158 -2.4750 0.0000 0
M  V30 9 C 5.7158 -1.6500 0.0000 0
M  V30 10 C 5.0013 -1.2375 0.0000 0
M  V30 11 C 4.2868 -1.6500 0.0000 0 CFG=2
M  V30 12 N 3.5724 -1.2375 0.0000 0
M  V30 13 C 2.8579 -1.6500 0.0000 0
M  V30 14 O 2.8579 -2.4750 0.0000 0
M  V30 15 C 2.1434 -1.2375 0.0000 0
M  V30 16 C 1.4289 -1.6500 0.0000 0
M  V30 17 Cl 1.4289 -2.4750 0.0000 0
M  V30 18 C 0.7145 -1.2375 0.0000 0
M  V30 19 C 0.7145 -0.4125 0.0000 0
M  V30 20 C -0.0000 -0.0000 0.0000 0
M  V30 21 N 0.0000 0.8250 0.0000 0
M  V30 22 C 0.7145 1.2375 0.0000 0
M  V30 23 C 1.4289 0.8250 0.0000 0
M  V30 24 C 1.4289 -0.0000 0.0000 0
M  V30 25 C 2.1434 -0.4125 0.0000 0
M  V30 26 Cl 2.8579 0.0000 0.0000 0
M  V30 27 C -0.7145 1.2375 0.0000 0
M  V30 28 O -0.7145 2.0625 0.0000 0
M  V30 29 C -1.4289 0.8250 0.0000 0
M  V30 30 C -1.4289 -0.0000 0.0000 0
M  V30 31 C -2.1434 -0.4125 0.0000 0
M  V30 32 C -2.8579 -0.0000 0.0000 0
M  V30 33 C -3.6425 -0.2549 0.0000 0
M  V30 34 C -4.1274 0.4125 0.0000 0
M  V30 35 O -3.6425 1.0799 0.0000 0
M  V30 36 C -2.8579 0.8250 0.0000 0
M  V30 37 C -2.1434 1.2375 0.0000 0
M  V30 38 C 4.2868 -2.4750 0.0000 0
M  V30 39 O 5.0013 -2.8875 0.0000 0
M  V30 40 O 3.5724 -2.8875 0.0000 0
M  V30 41 C 6.4302 -1.2375 0.0000 0
M  V30 42 H 4.2869 -0.6500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=1
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 19 24
M  V30 25 2 24 25
M  V30 26 1 15 25
M  V30 27 1 25 26
M  V30 28 1 21 27
M  V30 29 2 27 28
M  V30 30 1 27 29
M  V30 31 2 29 30
M  V30 32 1 30 31
M  V30 33 2 31 32
M  V30 34 1 32 33
M  V30 35 2 33 34
M  V30 36 1 34 35
M  V30 37 1 35 36
M  V30 38 1 32 36
M  V30 39 2 36 37
M  V30 40 1 29 37
M  V30 41 1 11 38
M  V30 42 1 38 39
M  V30 43 2 38 40
M  V30 44 2 9 41
M  V30 45 1 5 41
M  V30 46 1 42 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
326

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lifitegrast

>  <Synonyms>
SAR 1118;SHP-606

>  <CAS>
1025967-78-5

>  <Formula>
C29H24Cl2N2O7S

>  <MolWt>
615.5

>  <Pathways>
Cytoskeletal Signaling

>  <Target>
Integrin

>  <Receptor>
 LFA-1:2.98 nM.

>  <Bioactivity>
"Lifitegrast is a lymphocyte, function-associated antigen-1 antagonist."

>  <Reference>
"Rao VR, et al. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin(STZ) model of diabetic retinopathy (DR). Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5198-204.;Sun Y, et al. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118). J Ocul Pharmacol Ther. 2013 May;29(4):395-402.;Perez VL, et al. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocul Surf. 2016 Apr;14(2):207-15."

>  <ID<1>>
T3977

$$$$
StarDrop ID 327
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -6.9260 -3.3552 0.0000 0
M  V30 2 C -6.2116 -2.9427 0.0000 0
M  V30 3 C -5.4971 -3.3552 0.0000 0
M  V30 4 C -4.7826 -2.9427 0.0000 0
M  V30 5 C -4.0681 -3.3552 0.0000 0
M  V30 6 C -3.3537 -2.9427 0.0000 0 CFG=2
M  V30 7 O -3.3537 -2.1177 0.0000 0
M  V30 8 C -2.6392 -3.3552 0.0000 0
M  V30 9 C -1.9247 -2.9427 0.0000 0
M  V30 10 C -1.2103 -3.3552 0.0000 0 CFG=1
M  V30 11 C -1.1240 -4.1757 0.0000 0 CFG=2
M  V30 12 O -1.7371 -4.7277 0.0000 0
M  V30 13 C -0.3170 -4.3472 0.0000 0
M  V30 14 C 0.0955 -3.6327 0.0000 0 CFG=2
M  V30 15 C 0.9024 -3.4612 0.0000 0
M  V30 16 C 1.1574 -2.6766 0.0000 0
M  V30 17 C 0.6053 -2.0635 0.0000 0
M  V30 18 C -0.2016 -2.2350 0.0000 0
M  V30 19 C -0.4566 -3.0196 0.0000 0 CFG=2
M  V30 20 C 0.8603 -1.2789 0.0000 0
M  V30 21 C 1.6672 -1.1074 0.0000 0
M  V30 22 C 2.2193 -1.7204 0.0000 0
M  V30 23 C 1.9643 -2.5051 0.0000 0
M  V30 24 O 2.5164 -3.1182 0.0000 0
M  V30 25 C 3.3233 -2.9466 0.0000 0
M  V30 26 C 3.8754 -3.5597 0.0000 0
M  V30 27 O 4.6823 -3.3882 0.0000 0
M  V30 28 O 3.6204 -4.3444 0.0000 0
M  V30 29 H -4.2197 -2.4427 0.0000 0
M  V30 30 H -1.1578 -2.3566 0.0000 0
M  V30 31 H -2.0576 -3.8173 0.0000 0
M  V30 32 H -0.8990 -3.7372 0.0000 0
M  V30 33 H 0.5216 -2.8118 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 10 9 CFG=3
M  V30 10 1 10 11
M  V30 11 1 11 12 CFG=1
M  V30 12 1 11 13
M  V30 13 1 14 13 CFG=1
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 19 18 CFG=1
M  V30 19 1 10 19
M  V30 20 1 19 14
M  V30 21 1 17 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 16 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 2 26 28
M  V30 31 1 29 6
M  V30 32 1 30 10
M  V30 33 1 31 11
M  V30 34 1 32 14
M  V30 35 1 33 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
327

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Treprostinil

>  <Synonyms>
LRX-15;Orenitram;Remodulin

>  <CAS>
81846-19-7

>  <Formula>
C23H34O5

>  <MolWt>
390.5

>  <Pathways>
Immunology/Inflammation;GPCR/G Protein

>  <Target>
Prostaglandin Receptor

>  <Receptor>
" DP1:0.6 nM (EC50), IP:1.9 nM (EC50), EP2:6.2 nM (EC50), EP3:68.9 nM (EC50)"

>  <Bioactivity>
"Treprostinil is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM)."

>  <Reference>
"Whittle BJ, et al. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012 Jul 1;84(1):68-75.;Kazemi Z, et al. Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation. Mol Pharmacol. 2016 Jun;89(6):630-44.;Nikam VS, et al. Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J. 2010 Dec;36(6):1302-14.;Smadja DM, et al. Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells. Thromb Haemost. 2015 Oct;114(4):735-47.;Ghonem N, et al. Treprostinil, a prostacyclin analog, ameliorates ischemia-reperfusion injury in rat orthotopic liver transplantation."

>  <ID<1>>
T5150

$$$$
StarDrop ID 328
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 45 49 0 0 1
M  V30 BEGIN ATOM
M  V30 1 S 0.7145 -0.4125 0.0000 0
M  V30 2 C -0.0000 0.0000 0.0000 0 CFG=1
M  V30 3 N -0.0000 0.8250 0.0000 0
M  V30 4 C -0.8250 0.8250 0.0000 0
M  V30 5 O -1.4084 1.4084 0.0000 0
M  V30 6 C -0.8250 -0.0000 0.0000 0 CFG=1
M  V30 7 N -1.4084 -0.5834 0.0000 0
M  V30 8 C -1.1948 -1.3803 0.0000 0
M  V30 9 O -0.3979 -1.5938 0.0000 0
M  V30 10 C -1.7782 -1.9636 0.0000 0 CFG=2
M  V30 11 N -2.5751 -1.7501 0.0000 0
M  V30 12 C -2.7886 -0.9532 0.0000 0
M  V30 13 O -2.2053 -0.3698 0.0000 0
M  V30 14 C -3.5855 -0.7397 0.0000 0
M  V30 15 C -4.1689 -1.3230 0.0000 0
M  V30 16 O -3.9553 -2.1199 0.0000 0
M  V30 17 C -4.9658 -1.1095 0.0000 0
M  V30 18 C -5.1793 -0.3126 0.0000 0
M  V30 19 N -4.5959 0.2707 0.0000 0
M  V30 20 C -3.7990 0.0572 0.0000 0
M  V30 21 C -5.9762 -0.0991 0.0000 0
M  V30 22 C -1.5647 -2.7605 0.0000 0
M  V30 23 C -0.7678 -2.9740 0.0000 0
M  V30 24 C -0.5543 -3.7709 0.0000 0
M  V30 25 C -1.1376 -4.3543 0.0000 0
M  V30 26 O -0.9241 -5.1512 0.0000 0
M  V30 27 C -1.9345 -4.1408 0.0000 0
M  V30 28 C -2.1480 -3.3439 0.0000 0
M  V30 29 C 0.7145 1.2375 0.0000 0
M  V30 30 C 1.4289 0.8250 0.0000 0
M  V30 31 C 1.4289 0.0000 0.0000 0
M  V30 32 C 2.1434 1.2375 0.0000 0
M  V30 33 S 2.1434 2.0625 0.0000 0
M  V30 34 C 2.8579 2.4750 0.0000 0
M  V30 35 N 2.9441 3.2955 0.0000 0
M  V30 36 N 3.7511 3.4670 0.0000 0
M  V30 37 N 4.1636 2.7525 0.0000 0
M  V30 38 N 3.6116 2.1394 0.0000 0
M  V30 39 C 2.3310 3.8475 0.0000 0
M  V30 40 C 0.7145 2.0625 0.0000 0
M  V30 41 O 1.4289 2.4750 0.0000 0
M  V30 42 O 0.0000 2.4750 0.0000 0
M  V30 43 H -0.7071 0.7071 0.0000 0
M  V30 44 H -1.7489 0.3826 0.0000 0
M  V30 45 H -2.4853 -2.6707 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3 CFG=3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 6 4
M  V30 6 1 2 6
M  V30 7 1 6 7 CFG=3
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 10 8
M  V30 11 1 10 11 CFG=1
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 14 20
M  V30 22 1 18 21
M  V30 23 1 10 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 1 25 27
M  V30 29 2 27 28
M  V30 30 1 22 28
M  V30 31 1 3 29
M  V30 32 2 29 30
M  V30 33 1 30 31
M  V30 34 1 1 31
M  V30 35 1 30 32
M  V30 36 1 32 33
M  V30 37 1 33 34
M  V30 38 1 34 35
M  V30 39 1 35 36
M  V30 40 2 36 37
M  V30 41 1 37 38
M  V30 42 2 34 38
M  V30 43 1 35 39
M  V30 44 1 29 40
M  V30 45 2 40 41
M  V30 46 1 40 42
M  V30 47 1 43 2
M  V30 48 1 44 6
M  V30 49 1 45 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
328

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cefpiramide acid

>  <Synonyms>
Cefpiramidum;Cefpiramido

>  <CAS>
70797-11-4

>  <Formula>
C25H24N8O7S2

>  <MolWt>
612.6

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial

>  <Receptor>
PBPs

>  <Bioactivity>
Cefpiramide is a third-generation cephalosporin antibiotic.

>  <Reference>
"Fass RJ, Helsel VL. Diagn Microbiol Infect Dis. 1986 Jan;4(1):77-81."

>  <ID<1>>
T0138

$$$$
StarDrop ID 329
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 -2.4750 0.0000 0
M  V30 2 C 0.7145 -2.8875 0.0000 0
M  V30 3 O 0.7145 -3.7125 0.0000 0
M  V30 4 C 1.4289 -2.4750 0.0000 0
M  V30 5 C 1.4289 -1.6500 0.0000 0
M  V30 6 C 2.1434 -1.2375 0.0000 0
M  V30 7 C 2.8579 -1.6500 0.0000 0
M  V30 8 S 3.5724 -1.2375 0.0000 0
M  V30 9 C 4.2868 -1.6500 0.0000 0
M  V30 10 C 5.0013 -1.2375 0.0000 0
M  V30 11 C 5.7158 -1.6500 0.0000 0
M  V30 12 C 5.7158 -2.4750 0.0000 0
M  V30 13 C 5.0013 -2.8875 0.0000 0
M  V30 14 C 4.2868 -2.4750 0.0000 0
M  V30 15 N 3.5724 -2.8875 0.0000 0
M  V30 16 C 3.5724 -3.7125 0.0000 0
M  V30 17 C 4.2868 -4.1250 0.0000 0
M  V30 18 C 5.0013 -3.7125 0.0000 0
M  V30 19 N 5.7158 -4.1250 0.0000 0
M  V30 20 C 6.4302 -3.7125 0.0000 0
M  V30 21 C 7.1447 -4.1250 0.0000 0
M  V30 22 C 7.1447 -4.9500 0.0000 0
M  V30 23 C 7.8592 -5.3625 0.0000 0
M  V30 24 C 7.8592 -6.1875 0.0000 0
M  V30 25 O 8.5737 -6.6000 0.0000 0
M  V30 26 C 6.4302 -5.3625 0.0000 0
M  V30 27 C 5.7158 -4.9500 0.0000 0
M  V30 28 C 2.8579 -2.4750 0.0000 0
M  V30 29 C 2.1434 -2.8875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 9 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 22 26
M  V30 27 1 26 27
M  V30 28 1 19 27
M  V30 29 1 15 28
M  V30 30 1 7 28
M  V30 31 2 28 29
M  V30 32 1 4 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
329

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Piperacetazine

>  <Synonyms>
Quide;Piperacetazinum;Psymod

>  <CAS>
3819-00-9

>  <Formula>
C24H30N2O2S

>  <MolWt>
410.6

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
5-HT Receptor;Dopamine Receptor

>  <Receptor>
5-HT; Dopamine

>  <Bioactivity>
"Piperacetazine, an antipsychotic prodrug, is used forschizophrenia."

>  <Reference>
"Gallant DM, Bishop MP. Curr Ther Res Clin Exp. 1970 Jun;12(6):387-9."

>  <ID<1>>
T3085

$$$$
StarDrop ID 330
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.1128 -3.3000 0.0000 0
M  V30 2 C 0.8273 -3.7125 0.0000 0
M  V30 3 C 1.5418 -3.3000 0.0000 0
M  V30 4 O 1.5418 -2.4750 0.0000 0
M  V30 5 O 2.2562 -3.7125 0.0000 0
M  V30 6 C 0.8273 -4.5375 0.0000 0
M  V30 7 C 1.5418 -4.9500 0.0000 0
M  V30 8 C 1.5418 -5.7750 0.0000 0
M  V30 9 C 0.8273 -6.1875 0.0000 0
M  V30 10 C 0.1128 -5.7750 0.0000 0
M  V30 11 O -0.6017 -6.1875 0.0000 0
M  V30 12 C -1.3161 -5.7750 0.0000 0
M  V30 13 C -2.0306 -6.1875 0.0000 0
M  V30 14 C -2.7451 -5.7750 0.0000 0
M  V30 15 C -2.7451 -4.9500 0.0000 0
M  V30 16 C -2.0306 -4.5375 0.0000 0
M  V30 17 C -1.3161 -4.9500 0.0000 0
M  V30 18 C 0.1128 -4.9500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 2 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 12 17
M  V30 18 2 10 18
M  V30 19 1 6 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
330

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fenoprofen calcium dihydrate

>  <Synonyms>
N/A

>  <CAS>
53746-45-5

>  <Formula>
C30H30CaO8

>  <MolWt>
558.6

>  <Pathways>
Neuroscience;Immunology/Inflammation

>  <Target>
COX

>  <Receptor>
COX-1; COX-2

>  <Bioactivity>
Fenoprofen calcium is a propionic acid derivative that is used as a non-steroidal anti-inflammatory agent.

>  <Reference>
"Poggi JC, et al. J Clin Pharmacol. 2006 Nov;46(11):1328-36."

>  <ID<1>>
T0184

$$$$
StarDrop ID 331
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.5724 -6.1875 0.0000 0
M  V30 2 C 3.5724 -7.0125 0.0000 0
M  V30 3 N 4.2398 -7.4974 0.0000 0
M  V30 4 N 3.9849 -8.2820 0.0000 0
M  V30 5 C 3.1599 -8.2820 0.0000 0
M  V30 6 O 2.9049 -7.4974 0.0000 0
M  V30 7 C 2.6749 -8.9495 0.0000 0
M  V30 8 O 1.8545 -8.8632 0.0000 0
M  V30 9 N 3.0105 -9.7032 0.0000 0
M  V30 10 C 2.5256 -10.3706 0.0000 0
M  V30 11 C 1.8581 -9.8857 0.0000 0
M  V30 12 C 3.1930 -10.8555 0.0000 0
M  V30 13 C 2.0406 -11.0380 0.0000 0
M  V30 14 N 2.3762 -11.7917 0.0000 0
M  V30 15 C 1.8913 -12.4592 0.0000 0
M  V30 16 C 2.2268 -13.2128 0.0000 0
M  V30 17 O 3.0473 -13.2991 0.0000 0
M  V30 18 N 1.7419 -13.8803 0.0000 0
M  V30 19 C 2.0775 -14.6339 0.0000 0
M  V30 20 C 1.5925 -15.3014 0.0000 0
M  V30 21 C 1.9281 -16.0551 0.0000 0
M  V30 22 C 1.4432 -16.7225 0.0000 0
M  V30 23 C 0.6227 -16.6363 0.0000 0
M  V30 24 F 0.1378 -17.3037 0.0000 0
M  V30 25 C 0.2871 -15.8826 0.0000 0
M  V30 26 C 0.7721 -15.2151 0.0000 0
M  V30 27 C 1.0708 -12.3729 0.0000 0
M  V30 28 O 0.5859 -13.0404 0.0000 0
M  V30 29 C 0.7352 -11.6192 0.0000 0
M  V30 30 O -0.0852 -11.5330 0.0000 0
M  V30 31 N 1.2202 -10.9518 0.0000 0
M  V30 32 C 0.8846 -10.1981 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 2 6
M  V30 7 1 5 7
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 10 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 1 23 25
M  V30 26 2 25 26
M  V30 27 1 20 26
M  V30 28 2 15 27
M  V30 29 1 27 28
M  V30 30 1 27 29
M  V30 31 2 29 30
M  V30 32 1 29 31
M  V30 33 1 13 31
M  V30 34 1 31 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
331

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Raltegravir potassium

>  <Synonyms>
MK 0518 potassium salt;Raltegravir potassium salt

>  <CAS>
871038-72-1

>  <Formula>
C20H20FKN6O5

>  <MolWt>
482.5

>  <Pathways>
Proteases/Proteasome;Microbiology/Virology

>  <Target>
HIV Protease;Integrase

>  <Receptor>
HIV; HIV Integrase; Integrase (IN)

>  <Bioactivity>
"Raltegravir potassium salt(MK0518 potassium salt) is a potent integrase (IN) inhibitor, used to treat HIV infection."

>  <Reference>
"Hare S, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol. 2011 Oct;80(4):565-72.;Hicks C, et al. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009 Apr 1;48(7):931-9.;Lewis, M.G., et al. Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. Retrovirology, 2010. 7: p. 21.;Hare, S., et al., Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci U S A, 2010. 107(46): p. 20057-62.;Moss DM, et al. Divalent metals and pH alter raltegravir disposition in vitro. Antimicrob Agents Chemother. 2012 Jun;56(6):3020-6."

>  <ID<1>>
T2239

$$$$
StarDrop ID 332
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.7145 -1.2375 0.0000 0
M  V30 2 C 0.0000 -1.6500 0.0000 0
M  V30 3 C 0.7145 -1.2375 0.0000 0
M  V30 4 C 1.4289 -1.6500 0.0000 0
M  V30 5 C 2.1434 -1.2375 0.0000 0
M  V30 6 C 2.8579 -1.6500 0.0000 0
M  V30 7 C 1.4289 -2.4750 0.0000 0
M  V30 8 C 2.1434 -2.8875 0.0000 0
M  V30 9 C 2.1434 -3.7125 0.0000 0
M  V30 10 C 1.4289 -4.1250 0.0000 0
M  V30 11 O 1.4289 -4.9500 0.0000 0
M  V30 12 C 0.7145 -3.7125 0.0000 0
M  V30 13 C 0.7145 -2.8875 0.0000 0
M  V30 14 C 0.7145 -0.4125 0.0000 0
M  V30 15 C 0.0000 0.0000 0.0000 0
M  V30 16 C 0.0000 0.8250 0.0000 0
M  V30 17 C 0.7145 1.2375 0.0000 0
M  V30 18 O 0.7145 2.0625 0.0000 0
M  V30 19 C 1.4289 0.8250 0.0000 0
M  V30 20 C 1.4289 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 4 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 7 13
M  V30 14 1 3 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 2 19 20
M  V30 21 1 14 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
332

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dienestrol

>  <Synonyms>
Restrol;Cycladiene;Dehydrostilbestrol;Dienoestrol

>  <CAS>
84-17-3

>  <Formula>
C18H18O2

>  <MolWt>
266.3

>  <Pathways>
Endocrinology/Hormones

>  <Target>
Estrogen/progestogen Receptor;Estrogen Receptor/ERR

>  <Receptor>
ER; Estrogen Receptor/ERR

>  <Bioactivity>
"Dienestrol is a synthetic and nonsteroidal estrogen, which is an estrogen receptor agonist. Estrogens can increase a normal clear discharge from the vagina and make the vulva and urethra healthy."

>  <Reference>
"Juriansz RL, et al. Y Res. 1988 Jan 1;48(1):14-8."

>  <ID<1>>
T0035

$$$$
StarDrop ID 333
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.4289 9.6536 0.0000 0
M  V30 2 S 2.1434 9.2411 0.0000 0
M  V30 3 C 2.1434 8.4161 0.0000 0
M  V30 4 C 2.8579 8.0036 0.0000 0
M  V30 5 C 2.8579 7.1786 0.0000 0
M  V30 6 C 2.1434 6.7661 0.0000 0
M  V30 7 O 2.1434 5.9411 0.0000 0
M  V30 8 C 1.4289 5.5286 0.0000 0
M  V30 9 C 1.4289 4.7036 0.0000 0
M  V30 10 N 2.0964 4.2187 0.0000 0
M  V30 11 C 1.8414 3.4340 0.0000 0
M  V30 12 C 1.0164 3.4340 0.0000 0
M  V30 13 N 0.7615 4.2187 0.0000 0
M  V30 14 C -0.0231 4.4736 0.0000 0
M  V30 15 N 0.5315 2.7666 0.0000 0
M  V30 16 O 0.8671 2.0129 0.0000 0
M  V30 17 O -0.2890 2.8528 0.0000 0
M  V30 18 C 1.4289 7.1786 0.0000 0
M  V30 19 C 1.4289 8.0036 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 9 13
M  V30 14 1 13 14
M  V30 15 1 12 15
M  V30 16 2 15 16
M  V30 17 2 15 17
M  V30 18 1 6 18
M  V30 19 2 18 19
M  V30 20 1 3 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
333

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fexinidazole

>  <Synonyms>
HOE 239

>  <CAS>
59729-37-2

>  <Formula>
C12H13N3O3S

>  <MolWt>
279.3

>  <Pathways>
Microbiology/Virology;Others

>  <Target>
Parasite;Others

>  <Receptor>
antiparasitic; Parasite

>  <Bioactivity>
"Fexinidazole is an antiparasitic agent. It has activity against Trypanosoma cruzi, Tritrichomonas foetus, Trichomonas vaginalis, Entamoeba histolytica, Trypanosoma brucei, and Leishmania donovani. The biologically relevant active metabolites in vivo are the sulfoxide and sulfone."

>  <Reference>
"Raether W, Seidenath H. Ann Trop Med Parasitol. 1983 Feb;77(1):13-26."

>  <ID<1>>
T2112

$$$$
StarDrop ID 334
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.3300 -2.8681 0.0000 0
M  V30 2 C -0.5031 -2.6195 0.0000 0
M  V30 3 C -0.5060 -1.6500 0.0000 0
M  V30 4 N -1.5794 -2.7848 0.0000 0 CHG=1
M  V30 5 C -0.8839 -3.5991 0.0000 0
M  V30 6 C -1.4501 -1.8382 0.0000 0 CFG=1
M  V30 7 C -2.2401 -2.0761 0.0000 0
M  V30 8 C -2.5467 -2.8420 0.0000 0
M  V30 9 C -2.1390 -3.5592 0.0000 0 CFG=2
M  V30 10 C -1.3241 -3.6877 0.0000 0
M  V30 11 C -0.7155 -3.1307 0.0000 0 CFG=1
M  V30 12 C -0.7716 -2.3076 0.0000 0
M  V30 13 O 0.1472 -3.5086 0.0000 0
M  V30 14 C 0.4863 -4.3417 0.0000 0
M  V30 15 O -0.2983 -4.5966 0.0000 0
M  V30 16 C 1.1164 -4.9090 0.0000 0
M  V30 17 C 1.7741 -4.3417 0.0000 0
M  V30 18 O 2.5531 -4.6132 0.0000 0
M  V30 19 C 1.2707 -5.7194 0.0000 0
M  V30 20 C 2.0498 -5.9910 0.0000 0
M  V30 21 C 2.2041 -6.8014 0.0000 0
M  V30 22 C 1.5794 -7.3403 0.0000 0
M  V30 23 C 0.8004 -7.0688 0.0000 0
M  V30 24 C 0.6461 -6.2583 0.0000 0
M  V30 25 H -0.6601 -1.6003 0.0000 0
M  V30 26 H -1.7313 -4.2764 0.0000 0
M  V30 27 H -0.4532 -4.0957 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 6 4
M  V30 6 1 6 7 CFG=1
M  V30 7 1 7 8
M  V30 8 1 9 8 CFG=1
M  V30 9 1 9 4
M  V30 10 1 9 10
M  V30 11 1 11 10
M  V30 12 1 11 12
M  V30 13 1 6 12
M  V30 14 1 11 13 CFG=1
M  V30 15 1 13 14
M  V30 16 2 14 15
M  V30 17 1 14 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 16 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 19 24
M  V30 27 1 25 6
M  V30 28 1 26 9
M  V30 29 1 27 11
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
334

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ipratropium bromide monohydrate

>  <Synonyms>
Ipratropium bromide hydrate

>  <CAS>
66985-17-9

>  <Formula>
C20H32BrNO4

>  <MolWt>
430.4

>  <Pathways>
Neuroscience

>  <Target>
AChR

>  <Receptor>
mAChR

>  <Bioactivity>
"Ipratropium bromide is a muscarinic antagonist structurally related to ATROPINE but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic."

>  <Reference>
Wellington K. Treat Respir Med. 2005; 4(3):215-20; discussion 221-2.

>  <ID<1>>
T0098

$$$$
StarDrop ID 335
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.0630 -1.4167 0.0000 0
M  V30 2 C 2.8390 -1.6970 0.0000 0 CFG=1
M  V30 3 C 3.5218 -1.2340 0.0000 0
M  V30 4 C 4.1731 -1.7404 0.0000 0 CFG=1
M  V30 5 C 4.9853 -1.5952 0.0000 0 CFG=2
M  V30 6 C 5.2655 -0.8192 0.0000 0
M  V30 7 C 6.0777 -0.6740 0.0000 0 CFG=2
M  V30 8 F 6.3580 0.1019 0.0000 0
M  V30 9 C 6.6095 -1.3047 0.0000 0
M  V30 10 C 7.4216 -1.1595 0.0000 0
M  V30 11 C 7.9534 -1.7902 0.0000 0
M  V30 12 O 8.7655 -1.6450 0.0000 0
M  V30 13 C 7.6731 -2.5662 0.0000 0
M  V30 14 C 6.8610 -2.7114 0.0000 0
M  V30 15 C 6.3292 -2.0807 0.0000 0 CFG=1
M  V30 16 C 6.0489 -2.8566 0.0000 0
M  V30 17 C 5.5171 -2.2259 0.0000 0 CFG=2
M  V30 18 F 5.5766 -3.0487 0.0000 0
M  V30 19 C 5.2368 -3.0018 0.0000 0 CFG=1
M  V30 20 O 5.7686 -3.6325 0.0000 0
M  V30 21 C 4.4247 -3.1470 0.0000 0
M  V30 22 C 3.8928 -2.5163 0.0000 0 CFG=1
M  V30 23 C 3.5330 -3.2587 0.0000 0
M  V30 24 C 3.0683 -2.4895 0.0000 0 CFG=2
M  V30 25 O 2.9469 -3.3055 0.0000 0
M  V30 26 C 2.3074 -2.8084 0.0000 0
M  V30 27 O 2.2031 -3.6268 0.0000 0
M  V30 28 C 1.6508 -2.3089 0.0000 0
M  V30 29 O 0.8899 -2.6277 0.0000 0
M  V30 30 H 2.7146 -0.7048 0.0000 0
M  V30 31 H 3.2125 -2.0183 0.0000 0
M  V30 32 H 4.3406 -0.8308 0.0000 0
M  V30 33 H 7.0621 -0.4980 0.0000 0
M  V30 34 H 6.2212 -2.8258 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=3
M  V30 8 1 7 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 2 13 14
M  V30 14 1 15 14
M  V30 15 1 15 9
M  V30 16 1 15 16 CFG=1
M  V30 17 1 17 15
M  V30 18 1 17 5
M  V30 19 1 17 18 CFG=3
M  V30 20 1 17 19
M  V30 21 1 19 20 CFG=1
M  V30 22 1 19 21
M  V30 23 1 22 21
M  V30 24 1 4 22
M  V30 25 1 22 23 CFG=1
M  V30 26 1 22 24
M  V30 27 1 24 2
M  V30 28 1 24 25 CFG=3
M  V30 29 1 24 26 CFG=1
M  V30 30 2 26 27
M  V30 31 1 26 28
M  V30 32 1 28 29
M  V30 33 1 30 2
M  V30 34 1 31 4
M  V30 35 1 32 5
M  V30 36 1 33 7
M  V30 37 1 34 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
335

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Diflorasone

>  <Synonyms>
N/A

>  <CAS>
2557-49-5

>  <Formula>
C22H28F2O5

>  <MolWt>
410.5

>  <Pathways>
Endocrinology/Hormones

>  <Target>
Glucocorticoid Receptor

>  <Receptor>
Glucocorticoid Receptor

>  <Bioactivity>
"Diflorasone is a synthetic glucocorticoid with anti-inflammatory and immunosuppressive properties. Like other glucocorticoids, diflorasone enters the cell by diffusion across the cell membrane and binds to the glucocorticoid receptor (GR) in the cytoplasm. The receptor complex subsequently translocates to the nucleus and activates or represses genes by interacting with short, palindromic DNA sequences called glucocorticoid response element (GRE). Gene activation leads to the exertion of anti-inflammatory effects, e.g. upregulation of IkappaB, while gene repression inhibits production of pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-2 and IL-6, thereby preventing activation of cytotoxic T-lymphocytes."

>  <Reference>
"Pearce DJ, et al. J Dermatolog Treat. 2004 Jul;15(4):235-8."

>  <ID<1>>
T2548

$$$$
StarDrop ID 336
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.7436 -2.3645 0.0000 0
M  V30 2 N -2.0291 -2.7770 0.0000 0
M  V30 3 C -1.3146 -2.3645 0.0000 0
M  V30 4 C -0.6002 -2.7770 0.0000 0
M  V30 5 N -0.6002 -3.6020 0.0000 0
M  V30 6 C 0.1143 -4.0145 0.0000 0
M  V30 7 C 0.1143 -4.8395 0.0000 0
M  V30 8 C 0.8288 -5.2520 0.0000 0
M  V30 9 N 0.8288 -6.0770 0.0000 0
M  V30 10 C 1.5433 -6.4895 0.0000 0
M  V30 11 C 2.2577 -6.0770 0.0000 0
M  V30 12 C 2.9722 -6.4895 0.0000 0
M  V30 13 C 2.9722 -7.3145 0.0000 0
M  V30 14 C 2.2577 -7.7270 0.0000 0
M  V30 15 C 1.5433 -7.3145 0.0000 0
M  V30 16 S 0.8288 -7.7270 0.0000 0
M  V30 17 C 0.1143 -7.3145 0.0000 0
M  V30 18 C -0.6002 -7.7270 0.0000 0
M  V30 19 C -1.3146 -7.3145 0.0000 0
M  V30 20 C -1.3146 -6.4895 0.0000 0
M  V30 21 Cl -2.0291 -6.0770 0.0000 0
M  V30 22 C -0.6002 -6.0770 0.0000 0
M  V30 23 C 0.1143 -6.4895 0.0000 0
M  V30 24 C -1.3146 -4.0145 0.0000 0
M  V30 25 C -2.0291 -3.6020 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 10 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 1 20 22
M  V30 23 2 22 23
M  V30 24 1 9 23
M  V30 25 1 17 23
M  V30 26 1 5 24
M  V30 27 1 24 25
M  V30 28 1 2 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
336

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Prochlorperazine Maleate

>  <Synonyms>
Prochlorperazin;Compazine;Capazine;Stemetil;Prochlorperazine dimaleate salt

>  <CAS>
84-02-6

>  <Formula>
C28H32ClN3O8S

>  <MolWt>
606.1

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Dopamine Receptor

>  <Receptor>
D2

>  <Bioactivity>
Prochlorperazine maleate is a phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS.

>  <Reference>
"Ghelardini C, et al. Pharmacol Res. 20014, 50(3):351-358.;Huang L, et al. PLoS One. 2011, 6(7):e22274.;Dong L, Shen S, Chen W, et al. Discovery of Novel Inhibitors Targeting Human O-GlcNAcase: Docking-Based Virtual Screening, Biological Evaluation, Structural Modification, and Molecular Dynamics Simulation[J]. Journal of chemical information and modeling. 2019, 59(10): 4374-4382."

>  <ID<1>>
T0385

$$$$
StarDrop ID 337
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.2501 6.0027 0.0000 0
M  V30 2 C 1.5356 5.5902 0.0000 0
M  V30 3 C 1.5356 4.7652 0.0000 0
M  V30 4 C 0.8212 4.3527 0.0000 0
M  V30 5 C 0.1067 4.7652 0.0000 0
M  V30 6 C 0.1067 5.5902 0.0000 0
M  V30 7 C 0.8212 6.0027 0.0000 0
M  V30 8 C -0.6078 4.3527 0.0000 0
M  V30 9 O -1.3222 4.7652 0.0000 0
M  V30 10 C -0.6078 3.5277 0.0000 0
M  V30 11 C 0.0597 3.0428 0.0000 0
M  V30 12 C -0.1953 2.2581 0.0000 0
M  V30 13 C -1.0203 2.2581 0.0000 0
M  V30 14 C -1.5052 1.5907 0.0000 0
M  V30 15 C -2.3257 1.6769 0.0000 0
M  V30 16 O -2.8106 1.0095 0.0000 0
M  V30 17 O -2.6612 2.4306 0.0000 0
M  V30 18 N -1.2752 3.0428 0.0000 0
M  V30 19 C -2.0598 3.2977 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 15 17
M  V30 18 1 13 18
M  V30 19 1 10 18
M  V30 20 1 18 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
337

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tolmetin

>  <Synonyms>
Tolectin

>  <CAS>
26171-23-3

>  <Formula>
C15H15NO3

>  <MolWt>
257.3

>  <Pathways>
Neuroscience;Immunology/Inflammation

>  <Target>
COX

>  <Receptor>
" Human COX-2:0.82 ??M (IC50), Human COX-1:0.35 ??M (IC50)"

>  <Bioactivity>
Tolmetin is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of tolmetin is as a Cyclooxygenase Inhibitor. The chemical classification of tolmetin is Nonsteroidal Anti-inflammatory Compounds.

>  <Reference>
"Burdan F, et al. Pharmacol Res. 2004 Nov;50(5):533-43."

>  <ID<1>>
T2550

$$$$
StarDrop ID 338
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 6 5 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.4750 -1.4289 0.0000 0
M  V30 2 C 2.0625 -0.7145 0.0000 0
M  V30 3 C 1.2375 -0.7145 0.0000 0
M  V30 4 S 0.8250 -1.4289 0.0000 0
M  V30 5 C 0.8250 0.0000 0.0000 0
M  V30 6 S 0.0000 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
338

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dimercaprol

>  <Synonyms>
Dicaptol;Dithiopropanol

>  <CAS>
59-52-9

>  <Formula>
C3H8OS2

>  <MolWt>
124.2

>  <Pathways>
Microbiology/Virology;Others;Proteases/Proteasome

>  <Target>
Others;HIV Protease

>  <Receptor>
HIV; Mercury

>  <Bioactivity>
"An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisonings."

>  <Reference>
"Flora SJ, et al. Int J Environ Res Public Health. 2010, 7(7):2745-88."

>  <ID<1>>
T0781

$$$$
StarDrop ID 339
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 19 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.7512 0.7634 0.0000 0
M  V30 2 C 3.4656 1.1759 0.0000 0
M  V30 3 C 3.4656 2.0009 0.0000 0
M  V30 4 C 4.1801 2.4134 0.0000 0
M  V30 5 C 4.8946 2.0009 0.0000 0
M  V30 6 C 4.8946 1.1759 0.0000 0
M  V30 7 C 4.1801 0.7634 0.0000 0
M  V30 8 C 4.1801 -0.0616 0.0000 0
M  V30 9 O 4.8946 -0.4741 0.0000 0
M  V30 10 N 3.4656 -0.4741 0.0000 0
M  V30 11 C 3.4656 -1.2991 0.0000 0
M  V30 12 N 4.1331 -1.7840 0.0000 0
M  V30 13 C 3.8781 -2.5687 0.0000 0
M  V30 14 C 3.0531 -2.5687 0.0000 0
M  V30 15 S 2.7982 -1.7840 0.0000 0
M  V30 16 N 2.5682 -3.2361 0.0000 0
M  V30 17 O 2.9038 -3.9898 0.0000 0
M  V30 18 O 1.7477 -3.1499 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 11 15
M  V30 17 1 14 16
M  V30 18 2 16 17
M  V30 19 2 16 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
339

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tizoxanide

>  <Synonyms>
Desacetyl-nitazoxanide;TIZ

>  <CAS>
173903-47-4

>  <Formula>
C10H7N3O4S

>  <MolWt>
265.2

>  <Pathways>
Immunology/Inflammation;Microbiology/Virology;Autophagy;Proteases/Proteasome

>  <Target>
HIV Protease;Antiviral;Autophagy;Antibacterial

>  <Receptor>
Antiviral; Autophagy; Bacterial; HIV

>  <Bioactivity>
"Desacetyl-nitazoxanide is a metabolite of lamivudine. Lamivudine (2', 3'-dideoxy-3'-thiacytidine, commonly called 3TC) is a potent nucleoside analog reverse transcriptase inhibitor (nRTI)."

>  <Reference>
"Korba BE, et al. Antiviral Res. 2008 Jan;77(1):56-63.2. Korba BE, et al. Antimicrob Agents ChemOthers. 2008 Nov;52(11):4069-71.;Ivanova L, Rausalu K, Z?usinaite E, et al. 1, 3-Thiazolbenzamide Derivatives as Chikungunya Virus nsP2 Protease Inhibitors[J]. ACS Omega. 2021"

>  <ID<1>>
T2279

$$$$
StarDrop ID 340
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.5177 -1.6500 0.0000 0
M  V30 2 C 1.8032 -2.0625 0.0000 0
M  V30 3 C 1.8032 -2.8875 0.0000 0
M  V30 4 C 1.0887 -3.3000 0.0000 0
M  V30 5 C 0.3742 -2.8875 0.0000 0
M  V30 6 C 0.3742 -2.0625 0.0000 0
M  V30 7 C 1.0887 -1.6500 0.0000 0
M  V30 8 C -0.3402 -3.3000 0.0000 0
M  V30 9 C -0.3402 -4.1250 0.0000 0
M  V30 10 C 0.3742 -4.5375 0.0000 0
M  V30 11 N 0.3742 -5.3625 0.0000 0
M  V30 12 C 1.0417 -5.8474 0.0000 0
M  V30 13 C 0.7867 -6.6320 0.0000 0
M  V30 14 C -0.0383 -6.6320 0.0000 0
M  V30 15 C -0.2932 -5.8474 0.0000 0
M  V30 16 C -1.0547 -2.8875 0.0000 0
M  V30 17 C -1.7692 -3.3000 0.0000 0
M  V30 18 C -2.4836 -2.8875 0.0000 0
M  V30 19 C -2.4836 -2.0625 0.0000 0
M  V30 20 C -1.7692 -1.6500 0.0000 0
M  V30 21 N -1.0547 -2.0625 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 11 15
M  V30 17 1 8 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
340

>  <Plate>
PHD136329

>  <Row>
a

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Triprolidine hydrochloride monohydrate

>  <Synonyms>
Triprolidine hydrochloride

>  <CAS>
6138-79-0

>  <Formula>
C19H25ClN2O

>  <MolWt>
332.9

>  <Pathways>
Neuroscience;GPCR/G Protein;Immunology/Inflammation

>  <Target>
Histamine Receptor

>  <Receptor>
H1 receptor; Histamine Receptor

>  <Bioactivity>
"Triprolidine Hydrochloride is a histamine H1 antagonist used in allergic rhinitis, asthma."

>  <Reference>
"Hansen EB Jr, et al. J Pharm Sci. 1988 Mar;77(3):259-64."

>  <ID<1>>
T1030

$$$$
StarDrop ID 341
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.1943 1.3483 0.0000 0
M  V30 2 C -0.8197 2.0834 0.0000 0
M  V30 3 O -1.1943 2.8185 0.0000 0
M  V30 4 N -0.6109 3.4018 0.0000 0
M  V30 5 C 0.1242 3.0273 0.0000 0
M  V30 6 C -0.0049 2.2124 0.0000 0
M  V30 7 C 0.5785 1.6291 0.0000 0
M  V30 8 O 1.3754 1.8426 0.0000 0
M  V30 9 N 0.3649 0.8322 0.0000 0
M  V30 10 C 0.9483 0.2488 0.0000 0
M  V30 11 C 1.7733 0.2488 0.0000 0
M  V30 12 S 2.5579 0.5038 0.0000 0
M  V30 13 C 3.0428 -0.1637 0.0000 0
M  V30 14 C 3.6559 0.3884 0.0000 0
M  V30 15 C 3.6559 -0.7157 0.0000 0
M  V30 16 C 2.5579 -0.8311 0.0000 0
M  V30 17 N 1.7733 -0.5762 0.0000 0
M  V30 18 C 0.9483 -0.5762 0.0000 0
M  V30 19 O 0.3649 -1.1595 0.0000 0
M  V30 20 C 2.8129 -1.6157 0.0000 0
M  V30 21 O 3.6198 -1.7873 0.0000 0
M  V30 22 O 2.2608 -2.2288 0.0000 0
M  V30 23 C 0.8592 3.4018 0.0000 0
M  V30 24 C 0.9024 4.2257 0.0000 0
M  V30 25 C 1.6375 4.6002 0.0000 0
M  V30 26 C 2.3294 4.1509 0.0000 0
M  V30 27 C 2.2862 3.3270 0.0000 0
M  V30 28 C 1.5511 2.9525 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 2 6
M  V30 7 1 6 7
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 13 16
M  V30 17 1 16 17
M  V30 18 1 11 17
M  V30 19 1 17 18
M  V30 20 1 10 18
M  V30 21 2 18 19
M  V30 22 1 16 20
M  V30 23 1 20 21
M  V30 24 2 20 22
M  V30 25 1 5 23
M  V30 26 2 23 24
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 1 26 27
M  V30 30 2 27 28
M  V30 31 1 23 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
341

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Oxacillin sodium salt

>  <Synonyms>
Oxacillin sodium;Oxabel

>  <CAS>
1173-88-2

>  <Formula>
C19H18N3NaO5S

>  <MolWt>
423.4

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
antibiotic; Bacterial

>  <Bioactivity>
Oxacillin sodium is an antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.

>  <Reference>
"Woods GL, Yam P. Antimicrob Agents ChemOthers. 1988 Nov;32(11):1614-8."

>  <ID<1>>
T0985

$$$$
StarDrop ID 342
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.1434 -2.8875 0.0000 0
M  V30 2 C 1.4289 -2.4750 0.0000 0
M  V30 3 N 1.4289 -1.6500 0.0000 0
M  V30 4 N 0.7145 -1.2375 0.0000 0
M  V30 5 C 0.7145 -0.4125 0.0000 0
M  V30 6 C 0.0000 0.0000 0.0000 0
M  V30 7 O -0.7145 -0.4125 0.0000 0
M  V30 8 O 0.0000 0.8250 0.0000 0
M  V30 9 C 1.4289 0.0000 0.0000 0
M  V30 10 O 1.4289 0.8250 0.0000 0
M  V30 11 C 2.1434 -0.4125 0.0000 0
M  V30 12 C 2.8579 0.0000 0.0000 0
M  V30 13 C 3.5724 -0.4125 0.0000 0
M  V30 14 O 4.3570 -0.1576 0.0000 0
M  V30 15 C 4.8419 -0.8250 0.0000 0
M  V30 16 O 4.3570 -1.4924 0.0000 0
M  V30 17 C 3.5724 -1.2375 0.0000 0
M  V30 18 C 2.8579 -1.6500 0.0000 0
M  V30 19 C 2.1434 -1.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 5 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 13 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 3 19
M  V30 21 1 11 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
342

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cinoxacin

>  <Synonyms>
Compound 64716

>  <CAS>
28657-80-9

>  <Formula>
C12H10N2O5

>  <MolWt>
262.2

>  <Pathways>
DNA Damage/DNA Repair;Microbiology/Virology

>  <Target>
Topoisomerase;Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial; Topo II

>  <Bioactivity>
"Cinoxacin, an older synthetic antimicrobial, was related to the quinolone class of antibiotics. Its activity was similar to oxolinic acid and nalidixic acid."

>  <Reference>
"Jariyawat S, et al. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7."

>  <ID<1>>
T0274

$$$$
StarDrop ID 343
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.3228 1.7357 0.0000 0
M  V30 2 C 3.9629 0.9934 0.0000 0 CFG=1
M  V30 3 C 3.6826 0.2174 0.0000 0 CFG=2
M  V30 4 C 2.8705 0.0722 0.0000 0 CFG=1
M  V30 5 C 2.3387 0.7029 0.0000 0 CFG=1
M  V30 6 C 1.5266 0.5577 0.0000 0
M  V30 7 C 1.2463 -0.2182 0.0000 0
M  V30 8 C 1.7781 -0.8489 0.0000 0
M  V30 9 C 2.5902 -0.7037 0.0000 0
M  V30 10 C 0.4342 -0.3634 0.0000 0
M  V30 11 C -0.0976 0.2673 0.0000 0
M  V30 12 O -0.9098 0.1221 0.0000 0
M  V30 13 C -1.4416 0.7528 0.0000 0
M  V30 14 C -2.2537 0.6076 0.0000 0
M  V30 15 C -2.7855 1.2383 0.0000 0
M  V30 16 O -1.1613 1.5287 0.0000 0
M  V30 17 C 0.1827 1.0432 0.0000 0
M  V30 18 C 0.9948 1.1884 0.0000 0
M  V30 19 C 2.6190 1.4789 0.0000 0
M  V30 20 C 3.4311 1.6241 0.0000 0
M  V30 21 H 1.8069 1.3336 0.0000 0
M  V30 22 H 2.0584 -0.0730 0.0000 0
M  V30 23 C 4.3340 -0.2889 0.0000 0
M  V30 24 C 5.0168 0.1741 0.0000 0
M  V30 25 C 4.7875 0.9666 0.0000 0 CFG=2
M  V30 26 O 5.2939 1.6179 0.0000 0
M  V30 27 C 4.9830 2.3821 0.0000 0
M  V30 28 C 5.4893 3.0334 0.0000 0
M  V30 29 C 6.3066 2.9205 0.0000 0
M  V30 30 O 4.1657 2.4949 0.0000 0
M  V30 31 H 3.1508 0.8481 0.0000 0
M  V30 32 H 5.7696 0.7781 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 4 9
M  V30 10 2 7 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 13 16
M  V30 17 2 11 17
M  V30 18 1 17 18
M  V30 19 2 6 18
M  V30 20 1 5 19
M  V30 21 1 19 20
M  V30 22 1 2 20
M  V30 23 1 5 21 CFG=3
M  V30 24 1 4 22 CFG=1
M  V30 25 1 3 23
M  V30 26 1 23 24
M  V30 27 1 25 24
M  V30 28 1 2 25
M  V30 29 1 25 26 CFG=1
M  V30 30 1 26 27
M  V30 31 1 27 28
M  V30 32 1 28 29
M  V30 33 2 27 30
M  V30 34 1 3 31 CFG=3
M  V30 35 1 32 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
343

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Estradiol dipropionate

>  <Synonyms>
17-Beta-Estradiol-3,17-Dipropionate

>  <CAS>
113-38-2

>  <Formula>
C24H32O4

>  <MolWt>
384.5

>  <Pathways>
Endocrinology/Hormones;Others

>  <Target>
Progesterone Receptor;Estrogen Receptor/ERR;Estrogen/progestogen Receptor

>  <Receptor>
ER; Estrogen Receptor/ERR; Progesterone Receptor

>  <Bioactivity>
"Estradiol dipropionate is a synthetic ester, specifically the 3, 17-dipropanoyl ester, of the natural estrogen, estradiol."

>  <Reference>
"Noguchi M, et al.J Vet Med Sci. 2013; 75(3):343-8."

>  <ID<1>>
T2231

$$$$
StarDrop ID 344
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.1198 1.7274 0.0000 0
M  V30 2 C 0.5678 1.1143 0.0000 0
M  V30 3 C 0.0157 1.7274 0.0000 0
M  V30 4 O 1.2352 0.6294 0.0000 0
M  V30 5 C 0.9803 -0.1553 0.0000 0
M  V30 6 O 1.4652 -0.8227 0.0000 0
M  V30 7 N 0.1553 -0.1553 0.0000 0
M  V30 8 C -0.0997 0.6294 0.0000 0
M  V30 9 O -0.8843 0.8843 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 2 8
M  V30 9 2 8 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
344

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
5,5-Dimethyloxazolidine-2,4-dione

>  <Synonyms>
Dimethyloxazolidinedione;Dimethadion;Dimethadione

>  <CAS>
695-53-4

>  <Formula>
C5H7NO3

>  <MolWt>
129.1

>  <Pathways>
Membrane transporter/Ion channel;Metabolism

>  <Target>
Calcium Channel

>  <Receptor>
Calcium Channel

>  <Bioactivity>
An anticonvulsant that is the active metabolite of TRIMETHADIONE.

>  <Reference>
"Aasa KL, et al. Toxicol Sci. 2014 Dec; 142(2):350-60."

>  <ID<1>>
T1234

$$$$
StarDrop ID 345
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 44 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.1821 -9.4292 0.0000 0
M  V30 2 S 3.5177 -8.6755 0.0000 0
M  V30 3 O 4.2714 -9.0111 0.0000 0
M  V30 4 O 2.7640 -8.3399 0.0000 0
M  V30 5 C 3.8533 -7.9218 0.0000 0
M  V30 6 C 4.6737 -7.8356 0.0000 0
M  V30 7 N 5.0093 -7.0819 0.0000 0
M  V30 8 C 5.8298 -6.9957 0.0000 0
M  V30 9 C 6.1653 -6.2420 0.0000 0
M  V30 10 C 5.7528 -5.5275 0.0000 0
M  V30 11 C 6.3049 -4.9144 0.0000 0
M  V30 12 C 7.0585 -5.2500 0.0000 0
M  V30 13 O 6.9723 -6.0705 0.0000 0
M  V30 14 C 7.7730 -4.8375 0.0000 0
M  V30 15 C 7.7730 -4.0125 0.0000 0
M  V30 16 C 8.4875 -3.6000 0.0000 0
M  V30 17 C 9.2020 -4.0125 0.0000 0
M  V30 18 N 9.9164 -3.6000 0.0000 0
M  V30 19 C 10.6309 -4.0125 0.0000 0
M  V30 20 N 10.6309 -4.8375 0.0000 0
M  V30 21 C 9.9164 -5.2500 0.0000 0
M  V30 22 N 9.9164 -6.0750 0.0000 0
M  V30 23 C 9.2020 -6.4875 0.0000 0
M  V30 24 C 8.4875 -6.0750 0.0000 0
M  V30 25 C 7.7730 -6.4875 0.0000 0
M  V30 26 C 7.7730 -7.3125 0.0000 0
M  V30 27 O 7.0585 -7.7250 0.0000 0
M  V30 28 C 7.0585 -8.5500 0.0000 0
M  V30 29 C 6.3441 -8.9625 0.0000 0
M  V30 30 C 5.6296 -8.5500 0.0000 0
M  V30 31 C 4.9151 -8.9625 0.0000 0
M  V30 32 C 4.9151 -9.7875 0.0000 0
M  V30 33 C 5.6296 -10.2000 0.0000 0
M  V30 34 F 5.6296 -11.0250 0.0000 0
M  V30 35 C 6.3441 -9.7875 0.0000 0
M  V30 36 C 8.4875 -7.7250 0.0000 0
M  V30 37 Cl 8.4875 -8.5500 0.0000 0
M  V30 38 C 9.2020 -7.3125 0.0000 0
M  V30 39 C 9.2020 -4.8375 0.0000 0
M  V30 40 C 8.4875 -5.2500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 9 13
M  V30 14 1 12 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 2 29 30
M  V30 31 1 30 31
M  V30 32 2 31 32
M  V30 33 1 32 33
M  V30 34 1 33 34
M  V30 35 2 33 35
M  V30 36 1 29 35
M  V30 37 1 26 36
M  V30 38 1 36 37
M  V30 39 2 36 38
M  V30 40 1 23 38
M  V30 41 1 21 39
M  V30 42 1 17 39
M  V30 43 2 39 40
M  V30 44 1 14 40
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
345

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lapatinib ditosylate

>  <Synonyms>
Lapatinib tosilate;Lapatinib ditosylate monohydrate;Tyverb;Tykerb;Lapatinib ditoluenesulfonate monohydrate;Lapatinib tosilate hydrate

>  <CAS>
388082-78-8

>  <Formula>
C43H44ClFN4O11S3

>  <MolWt>
943.5

>  <Pathways>
Angiogenesis;JAK/STAT signaling;Apoptosis;Autophagy;Tyrosine Kinase/Adaptors;Cell Cycle/Checkpoint

>  <Target>
Ferroptosis;EGFR;Autophagy

>  <Receptor>
" ErbB2:9.2 nM, ErbB4:367 nM, EGFR:10.8 nM"

>  <Bioactivity>
Lapatinib is a tyrosine kinase receptor inhibitor used in the therapy of advanced breast cancer and other solid tumors. Lapatinib therapy is associated with transient elevations in serum aminotransferase levels and rare instances of clinically apparent acute liver injury.

>  <Reference>
"Rusnak DW, et al. Mol Y Ther, 2001, 1(2), 85-94."

>  <ID<1>>
T0078L

$$$$
StarDrop ID 346
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.1258 2.6095 0.0000 0
M  V30 2 O -0.0877 1.8126 0.0000 0
M  V30 3 N -0.8846 1.5991 0.0000 0
M  V30 4 C -1.0982 0.8022 0.0000 0
M  V30 5 C -0.5148 0.2189 0.0000 0
M  V30 6 O -0.7283 -0.5780 0.0000 0
M  V30 7 N 0.2821 0.4324 0.0000 0
M  V30 8 C 0.8655 -0.1510 0.0000 0
M  V30 9 C 1.6905 -0.1510 0.0000 0
M  V30 10 S 2.4049 0.2615 0.0000 0
M  V30 11 C 3.1194 -0.1510 0.0000 0
M  V30 12 C 3.1194 -0.9760 0.0000 0
M  V30 13 C 3.8339 -1.3885 0.0000 0
M  V30 14 O 4.5483 -0.9760 0.0000 0
M  V30 15 C 5.2628 -1.3885 0.0000 0
M  V30 16 N 5.9773 -0.9760 0.0000 0
M  V30 17 O 5.2628 -2.2135 0.0000 0
M  V30 18 C 2.4049 -1.3885 0.0000 0
M  V30 19 N 1.6905 -0.9760 0.0000 0
M  V30 20 C 0.8655 -0.9760 0.0000 0
M  V30 21 O 0.2821 -1.5593 0.0000 0
M  V30 22 C 2.4049 -2.2135 0.0000 0
M  V30 23 O 1.6905 -2.6260 0.0000 0
M  V30 24 O 3.1194 -2.6260 0.0000 0
M  V30 25 C -1.8950 0.5887 0.0000 0
M  V30 26 C -2.1907 -0.1815 0.0000 0
M  V30 27 C -3.0146 -0.1383 0.0000 0
M  V30 28 C -3.2281 0.6586 0.0000 0
M  V30 29 O -2.5362 1.1079 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 15 17
M  V30 17 2 12 18
M  V30 18 1 18 19
M  V30 19 1 9 19
M  V30 20 1 19 20
M  V30 21 1 8 20
M  V30 22 2 20 21
M  V30 23 1 18 22
M  V30 24 1 22 23
M  V30 25 2 22 24
M  V30 26 1 4 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 1 25 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
346

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cefuroxime sodium

>  <Synonyms>
Cefuroxime sodium salt;Biociclin;Anaptivan

>  <CAS>
56238-63-2

>  <Formula>
C16H15N4NaO8S

>  <MolWt>
446.4

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial;Antibiotic

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
"Cefuroxime Sodium is the sodium salt form of cefuroxime and a semi-synthetic, broad-spectrum, beta-lactamase resistant, second-generation cephalosporin antibiotic with bactericidal activity. Cefuroxime sodium inhibits bacterial cell wall synthesis by inactivating penicillin binding proteins (PBPs) thereby interfering with the final transpeptidation step required for cross-linking of peptidoglycan units which are a component of the cell wall. Lack of cross-linking results in a reduction of cell wall stability and leads to cell lysis."

>  <Reference>
"Capel-Edwards K, et al. Toxicology. 1979, 13(1):1-5."

>  <ID<1>>
T1224

$$$$
StarDrop ID 347
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.1434 -0.4125 0.0000 0
M  V30 2 C 2.1434 -1.2375 0.0000 0
M  V30 3 C 1.4289 -1.6500 0.0000 0
M  V30 4 N 1.4289 -2.4750 0.0000 0
M  V30 5 C 2.1434 -2.8875 0.0000 0
M  V30 6 C 2.1434 -3.7125 0.0000 0
M  V30 7 C 1.4289 -4.1250 0.0000 0
M  V30 8 C 0.7145 -3.7125 0.0000 0
M  V30 9 C 0.7145 -2.8875 0.0000 0 CFG=1
M  V30 10 C 0.0000 -2.4750 0.0000 0
M  V30 11 O 0.0000 -1.6500 0.0000 0
M  V30 12 N -0.7145 -2.8875 0.0000 0
M  V30 13 C -1.4289 -2.4750 0.0000 0
M  V30 14 C -2.1434 -2.8875 0.0000 0
M  V30 15 C -2.1434 -3.7125 0.0000 0
M  V30 16 C -2.8579 -2.4750 0.0000 0
M  V30 17 C -2.8579 -1.6500 0.0000 0
M  V30 18 C -2.1434 -1.2375 0.0000 0
M  V30 19 C -1.4289 -1.6500 0.0000 0
M  V30 20 C -0.7145 -1.2375 0.0000 0
M  V30 21 H 0.7144 -1.8875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 9 8
M  V30 9 1 9 4
M  V30 10 1 9 10 CFG=1
M  V30 11 2 10 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 13 19
M  V30 21 1 19 20
M  V30 22 1 21 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
347

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ropivacaine

>  <Synonyms>
LEA-103 HCl

>  <CAS>
84057-95-4

>  <Formula>
C17H26N2O

>  <MolWt>
274.4

>  <Pathways>
Membrane transporter/Ion channel

>  <Target>
Sodium Channel;Potassium Channel

>  <Receptor>
 TREK-1 in COS-7 cell's membrane:402.7 ??M (IC50)

>  <Bioactivity>
Ropivacaine is a local anaesthetic drug belonging to the amino amide group.

>  <Reference>
"Liu BG, et al. Anesth Analg. 2000 May;90(5):1034-8."

>  <ID<1>>
T0386L

$$$$
StarDrop ID 348
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.0713 -4.4770 0.0000 0
M  V30 2 C 0.8834 -4.3318 0.0000 0
M  V30 3 O 1.4153 -4.9625 0.0000 0
M  V30 4 O 1.1637 -3.5559 0.0000 0
M  V30 5 C 1.9758 -3.4106 0.0000 0
M  V30 6 C 2.2561 -2.6347 0.0000 0
M  V30 7 O 1.7243 -2.0040 0.0000 0
M  V30 8 C 3.0683 -2.4895 0.0000 0 CFG=1
M  V30 9 O 3.1278 -3.3123 0.0000 0
M  V30 10 C 2.8390 -1.6970 0.0000 0
M  V30 11 C 3.5218 -1.2340 0.0000 0
M  V30 12 C 4.1731 -1.7404 0.0000 0 CFG=1
M  V30 13 C 4.9853 -1.5952 0.0000 0 CFG=2
M  V30 14 C 5.2655 -0.8192 0.0000 0
M  V30 15 C 6.0777 -0.6740 0.0000 0
M  V30 16 C 6.6095 -1.3047 0.0000 0
M  V30 17 C 7.4216 -1.1595 0.0000 0
M  V30 18 C 7.9534 -1.7902 0.0000 0
M  V30 19 O 8.7655 -1.6450 0.0000 0
M  V30 20 C 7.6731 -2.5662 0.0000 0
M  V30 21 C 6.8610 -2.7114 0.0000 0
M  V30 22 C 6.3292 -2.0807 0.0000 0 CFG=1
M  V30 23 C 6.0489 -2.8566 0.0000 0
M  V30 24 C 5.5171 -2.2259 0.0000 0 CFG=1
M  V30 25 C 5.2368 -3.0018 0.0000 0 CFG=1
M  V30 26 O 5.7686 -3.6325 0.0000 0
M  V30 27 C 4.4247 -3.1470 0.0000 0
M  V30 28 C 3.8928 -2.5163 0.0000 0 CFG=2
M  V30 29 C 3.5330 -3.2587 0.0000 0
M  V30 30 H 3.2125 -2.0183 0.0000 0
M  V30 31 H 4.3406 -0.8308 0.0000 0
M  V30 32 H 6.1617 -2.9904 0.0000 0
M  V30 33 H 6.2212 -2.8258 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 8 6 CFG=1
M  V30 8 1 8 9 CFG=3
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 12 11 CFG=1
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=3
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 1 20 21
M  V30 21 1 22 21
M  V30 22 1 22 16
M  V30 23 1 22 23 CFG=1
M  V30 24 1 24 22 CFG=1
M  V30 25 1 24 13
M  V30 26 1 24 25
M  V30 27 1 25 26 CFG=1
M  V30 28 1 25 27
M  V30 29 1 28 27
M  V30 30 1 28 8
M  V30 31 1 12 28
M  V30 32 1 28 29 CFG=1
M  V30 33 1 30 12
M  V30 34 1 31 13
M  V30 35 1 32 24
M  V30 36 1 33 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
348

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Hydrocortisone acetate

>  <Synonyms>
Cortisol 21-acetate;Hydrocortisone 21-acetate

>  <CAS>
50-03-3

>  <Formula>
C23H32O6

>  <MolWt>
404.5

>  <Pathways>
GPCR/G Protein;Metabolism;Endocrinology/Hormones

>  <Target>
Glucocorticoid Receptor;Endogenous Metabolite;Annexin A

>  <Receptor>
Annexin A1; Endogenous Metabolite; Glucocorticoid Receptor

>  <Bioactivity>
"Hydrocortisone acetate is the synthetic acetate salt form of hydrocortisone, a corticosteroid with anti-inflammatory and immunosuppressive properties."

>  <Reference>
"Grossman R, et al. Ann N Y Acad Sci. 2006 Jul;1071:410-21."

>  <ID<1>>
T1243

$$$$
StarDrop ID 349
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 38 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.7531 0.1786 0.0000 0
M  V30 2 C 1.4728 -0.5974 0.0000 0
M  V30 3 C 2.0046 -1.2281 0.0000 0
M  V30 4 C 1.7243 -2.0040 0.0000 0
M  V30 5 O 0.9122 -2.1492 0.0000 0
M  V30 6 O 2.2561 -2.6347 0.0000 0
M  V30 7 C 3.0683 -2.4895 0.0000 0 CFG=2
M  V30 8 C 2.8390 -1.6970 0.0000 0
M  V30 9 C 3.5218 -1.2340 0.0000 0
M  V30 10 C 4.1731 -1.7404 0.0000 0 CFG=1
M  V30 11 C 4.9853 -1.5952 0.0000 0 CFG=2
M  V30 12 C 5.2655 -0.8192 0.0000 0
M  V30 13 C 6.0777 -0.6740 0.0000 0
M  V30 14 C 6.6095 -1.3047 0.0000 0
M  V30 15 C 7.4216 -1.1595 0.0000 0
M  V30 16 C 7.9534 -1.7902 0.0000 0
M  V30 17 O 8.7655 -1.6450 0.0000 0
M  V30 18 C 7.6731 -2.5662 0.0000 0
M  V30 19 C 6.8610 -2.7114 0.0000 0
M  V30 20 C 6.3292 -2.0807 0.0000 0 CFG=1
M  V30 21 C 6.0489 -2.8566 0.0000 0
M  V30 22 C 5.5171 -2.2259 0.0000 0 CFG=1
M  V30 23 C 5.2368 -3.0018 0.0000 0 CFG=1
M  V30 24 O 5.7686 -3.6325 0.0000 0
M  V30 25 C 4.4247 -3.1470 0.0000 0
M  V30 26 C 3.8928 -2.5163 0.0000 0 CFG=2
M  V30 27 C 3.5330 -3.2587 0.0000 0
M  V30 28 C 3.1278 -3.3123 0.0000 0
M  V30 29 O 3.8702 -3.6722 0.0000 0
M  V30 30 C 2.4450 -3.7753 0.0000 0
M  V30 31 O 1.7026 -3.4155 0.0000 0
M  V30 32 H 3.2125 -2.0183 0.0000 0
M  V30 33 H 4.3406 -0.8308 0.0000 0
M  V30 34 H 6.1617 -2.9904 0.0000 0
M  V30 35 H 6.2212 -2.8258 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 7 6 CFG=3
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 10 9 CFG=1
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=3
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 1 18 19
M  V30 19 1 20 19
M  V30 20 1 20 14
M  V30 21 1 20 21 CFG=1
M  V30 22 1 22 20 CFG=1
M  V30 23 1 22 11
M  V30 24 1 22 23
M  V30 25 1 23 24 CFG=1
M  V30 26 1 23 25
M  V30 27 1 26 25
M  V30 28 1 26 7
M  V30 29 1 10 26
M  V30 30 1 26 27 CFG=1
M  V30 31 1 7 28 CFG=1
M  V30 32 2 28 29
M  V30 33 1 28 30
M  V30 34 1 30 31
M  V30 35 1 32 10
M  V30 36 1 33 11
M  V30 37 1 34 22
M  V30 38 1 35 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
349

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Hydrocortisone 17-butyrate

>  <Synonyms>
Hydrocortisone butyrate;Cortisol 17-butyrate

>  <CAS>
13609-67-1

>  <Formula>
C25H36O6

>  <MolWt>
432.6

>  <Pathways>
Endocrinology/Hormones;GPCR/G Protein;Neuroscience

>  <Target>
Glucocorticoid Receptor;Adrenergic Receptor;Annexin A

>  <Receptor>
Adrenergic Receptor; Annexin A1; Glucocorticoid Receptor

>  <Bioactivity>
"Hydrocortisone Butyrate is a synthetic glucocorticoid receptor agonist with antiinflammatory, antipruritic and vasoconstrictive effects."

>  <Reference>
"Grossman R, et al. Ann N Y Acad Sci. 2006 Jul;1071:410-21."

>  <ID<1>>
T0270

$$$$
StarDrop ID 350
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.8503 0.9760 0.0000 0
M  V30 2 C 4.1358 0.5635 0.0000 0
M  V30 3 O 4.1358 -0.2615 0.0000 0
M  V30 4 O 3.4214 0.9760 0.0000 0
M  V30 5 C 2.7069 0.5635 0.0000 0
M  V30 6 C 1.9924 0.9760 0.0000 0
M  V30 7 C 1.2780 0.5635 0.0000 0
M  V30 8 N 0.5635 0.9760 0.0000 0
M  V30 9 C 0.5635 1.8010 0.0000 0
M  V30 10 S 1.2780 2.2135 0.0000 0
M  V30 11 C 1.9924 1.8010 0.0000 0
M  V30 12 C -0.2615 1.8010 0.0000 0
M  V30 13 N -0.8449 2.3843 0.0000 0
M  V30 14 C -0.6314 3.1812 0.0000 0
M  V30 15 O 0.1655 3.3948 0.0000 0
M  V30 16 C -1.2147 3.7646 0.0000 0
M  V30 17 C -1.0012 4.5615 0.0000 0
M  V30 18 C -1.5204 5.2026 0.0000 0
M  V30 19 C -1.0711 5.8945 0.0000 0
M  V30 20 C -0.2742 5.6810 0.0000 0
M  V30 21 S -0.2310 4.8571 0.0000 0
M  V30 22 C -0.2615 0.9760 0.0000 0
M  V30 23 O -0.8449 0.3926 0.0000 0
M  V30 24 C 1.2780 -0.2615 0.0000 0
M  V30 25 O 0.5635 -0.6740 0.0000 0
M  V30 26 O 1.9924 -0.6740 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 6 11
M  V30 12 1 9 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 1 17 21
M  V30 23 1 12 22
M  V30 24 1 8 22
M  V30 25 2 22 23
M  V30 26 1 7 24
M  V30 27 1 24 25
M  V30 28 2 24 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
350

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cephalothin sodium

>  <Synonyms>
Cefalotin;Cefalotin sodium;Cephalothin

>  <CAS>
58-71-9

>  <Formula>
C16H15N2NaO6S2

>  <MolWt>
418.4

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial; PBPs

>  <Bioactivity>
"Cephalothin binds to and inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall. Cephalothin Sodium is the sodium salt form of cephalothin, a semisynthetic, beta-lactam, the first-generation cephalosporin antibiotic with bactericidal activity. PBPs participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis."

>  <Reference>
"Williamson R, et al. Antimicrob Agents ChemOthers. 1980 Oct;18(4):629-37."

>  <ID<1>>
T1122

$$$$
StarDrop ID 351
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 40 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 5.6974 -0.0236 0.0000 0
M  V30 2 C 6.4119 0.3889 0.0000 0 CFG=2
M  V30 3 C 7.1264 0.8014 0.0000 0 CFG=1
M  V30 4 O 7.1264 1.6264 0.0000 0
M  V30 5 C 7.8409 0.3889 0.0000 0 CFG=2
M  V30 6 H 8.5553 -0.0236 0.0000 0
M  V30 7 C 8.5553 0.8014 0.0000 0
M  V30 8 C 8.5553 1.6264 0.0000 0
M  V30 9 C 9.2698 0.3889 0.0000 0
M  V30 10 C 9.9843 0.8014 0.0000 0
M  V30 11 Cl 9.9843 1.6264 0.0000 0
M  V30 12 C 10.6987 0.3889 0.0000 0
M  V30 13 C 10.6987 -0.4361 0.0000 0
M  V30 14 C 9.9843 -0.8486 0.0000 0
M  V30 15 O 9.9843 -1.6736 0.0000 0
M  V30 16 C 9.2698 -0.4361 0.0000 0
M  V30 17 C 8.5553 -0.8486 0.0000 0
M  V30 18 O 8.5553 -1.6736 0.0000 0
M  V30 19 C 7.8409 -0.4361 0.0000 0
M  V30 20 C 7.1264 -0.8486 0.0000 0
M  V30 21 O 7.1264 -1.6736 0.0000 0
M  V30 22 C 6.4119 -0.4361 0.0000 0 CFG=1
M  V30 23 O 6.4119 -1.2611 0.0000 0
M  V30 24 C 5.6974 -0.8486 0.0000 0
M  V30 25 O 5.6974 -1.6736 0.0000 0
M  V30 26 C 4.9830 -0.4361 0.0000 0
M  V30 27 C 4.2685 -0.8486 0.0000 0
M  V30 28 N 4.2685 -1.6736 0.0000 0
M  V30 29 O 3.5540 -0.4361 0.0000 0
M  V30 30 C 4.9830 0.3889 0.0000 0
M  V30 31 O 4.2685 0.8014 0.0000 0
M  V30 32 C 5.6974 0.8014 0.0000 0 CFG=1
M  V30 33 N 5.6974 1.6264 0.0000 0
M  V30 34 C 6.4119 2.0389 0.0000 0
M  V30 35 C 4.9830 2.0389 0.0000 0
M  V30 36 H 6.2604 1.3014 0.0000 0
M  V30 37 H 4.8314 1.3014 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4 CFG=1
M  V30 4 1 3 5
M  V30 5 1 5 6 CFG=1
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 14 16
M  V30 16 1 9 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 5 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 1 22 20
M  V30 24 1 2 22
M  V30 25 1 22 23 CFG=1
M  V30 26 1 22 24
M  V30 27 2 24 25
M  V30 28 1 24 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 2 27 29
M  V30 32 2 26 30
M  V30 33 1 30 31
M  V30 34 1 32 30
M  V30 35 1 2 32
M  V30 36 1 32 33 CFG=1
M  V30 37 1 33 34
M  V30 38 1 33 35
M  V30 39 1 36 3
M  V30 40 1 37 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
351

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Meclocycline sulfosalicylate salt

>  <Synonyms>
Mecloderm;Meclan Cream;Meclutin

>  <CAS>
73816-42-9

>  <Formula>
C29H27ClN2O14S

>  <MolWt>
695

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial;Antibiotic

>  <Receptor>
antibiotic; Bacterial

>  <Bioactivity>
"Meclocycline (INN), a tetracycline antibiotic, is used topically (i.e. for skin infections) as it is totally insoluble in water and may damage kidney and liver if given systemically."

>  <Reference>
"Grio R, et al. Minerva Ginecol. 1986 Mar;38(3):163-5."

>  <ID<1>>
T0281

$$$$
StarDrop ID 352
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -2.1434 -2.0625 0.0000 0
M  V30 2 S -1.4289 -1.6500 0.0000 0
M  V30 3 O -1.0164 -2.3645 0.0000 0
M  V30 4 O -1.8414 -0.9355 0.0000 0
M  V30 5 C -0.7145 -1.2375 0.0000 0
M  V30 6 C 0.0000 -1.6500 0.0000 0
M  V30 7 C 0.7145 -1.2375 0.0000 0
M  V30 8 C 0.7145 -0.4125 0.0000 0
M  V30 9 N 1.4289 -0.0000 0.0000 0
M  V30 10 C 2.1434 -0.4125 0.0000 0
M  V30 11 C 2.8579 -0.0000 0.0000 0
M  V30 12 S 3.5724 -0.4125 0.0000 0
M  V30 13 C 4.2868 -0.0000 0.0000 0
M  V30 14 C 5.0013 -0.4125 0.0000 0
M  V30 15 C 5.7158 -0.0000 0.0000 0
M  V30 16 C 6.4302 -0.4125 0.0000 0
M  V30 17 C 6.4302 -1.2375 0.0000 0
M  V30 18 C 5.7158 -1.6500 0.0000 0
M  V30 19 C 5.0013 -1.2375 0.0000 0
M  V30 20 N 2.1434 -1.2375 0.0000 0
M  V30 21 S 1.4289 -1.6500 0.0000 0
M  V30 22 O 1.8163 -2.3784 0.0000 0
M  V30 23 O 1.0416 -2.3784 0.0000 0
M  V30 24 C 0.0000 -0.0000 0.0000 0
M  V30 25 C -0.7145 -0.4125 0.0000 0
M  V30 26 Cl -1.4289 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 2 2 4
M  V30 4 1 2 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 14 19
M  V30 20 2 10 20
M  V30 21 1 20 21
M  V30 22 1 7 21
M  V30 23 2 21 22
M  V30 24 2 21 23
M  V30 25 1 8 24
M  V30 26 2 24 25
M  V30 27 1 5 25
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
352

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Benzthiazide

>  <Synonyms>
Aquatag;Dihydrex;Lemazide

>  <CAS>
91-33-8

>  <Formula>
C15H14ClN3O4S3

>  <MolWt>
431.9

>  <Pathways>
Metabolism

>  <Target>
Carbonic Anhydrase

>  <Receptor>
" CA1:10 nM (Ki), CA9:8.0 nM (Ki), CA2:8.8 nM (Ki)"

>  <Bioactivity>
"Benzthiazide is used in the therapy of edema and hypertension. Like other thiazides, benzthiazide accelerates water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue."

>  <Reference>
"Temperini C, et al. Bioorg Med Chem. 2009 Feb 1;17(3):1214-21."

>  <ID<1>>
T0782

$$$$
StarDrop ID 353
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 1.8857 2.2987 0.0000 0
M  V30 2 C 2.7107 2.2987 0.0000 0
M  V30 3 C 3.1232 1.5843 0.0000 0 CFG=2
M  V30 4 O 2.7107 0.8698 0.0000 0
M  V30 5 C 3.9482 1.5843 0.0000 0 CFG=1
M  V30 6 O 4.3607 2.2987 0.0000 0
M  V30 7 C 4.3607 0.8698 0.0000 0 CFG=2
M  V30 8 O 3.9482 0.1553 0.0000 0
M  V30 9 C 4.3607 -0.5592 0.0000 0 CFG=2
M  V30 10 O 5.1857 -0.5592 0.0000 0
M  V30 11 C 5.5982 -1.2736 0.0000 0 CFG=2
M  V30 12 C 6.4232 -1.2736 0.0000 0
M  V30 13 O 6.8357 -0.5592 0.0000 0
M  V30 14 C 5.1857 -1.9881 0.0000 0 CFG=2
M  V30 15 O 5.5982 -2.7026 0.0000 0
M  V30 16 C 4.3607 -1.9881 0.0000 0 CFG=2
M  V30 17 O 3.9482 -2.7026 0.0000 0
M  V30 18 C 3.9482 -1.2736 0.0000 0 CFG=1
M  V30 19 O 3.1232 -1.2736 0.0000 0
M  V30 20 C 5.1857 0.8698 0.0000 0 CFG=2
M  V30 21 O 5.5982 0.1553 0.0000 0
M  V30 22 C 5.5982 1.5843 0.0000 0
M  V30 23 O 6.4232 1.5843 0.0000 0
M  V30 24 H 2.1232 1.5842 0.0000 0
M  V30 25 H 4.9482 1.5842 0.0000 0
M  V30 26 H 4.8607 0.0038 0.0000 0
M  V30 27 H 3.3607 -0.5591 0.0000 0
M  V30 28 H 6.0982 -0.4076 0.0000 0
M  V30 29 H 4.6857 -2.8541 0.0000 0
M  V30 30 H 4.8607 -2.8541 0.0000 0
M  V30 31 H 3.4482 -0.4076 0.0000 0
M  V30 32 H 4.6857 0.0038 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4 CFG=1
M  V30 4 1 5 3
M  V30 5 1 5 6 CFG=1
M  V30 6 1 5 7
M  V30 7 1 7 8 CFG=1
M  V30 8 1 9 8 CFG=3
M  V30 9 1 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=3
M  V30 12 1 12 13
M  V30 13 1 14 11
M  V30 14 1 14 15 CFG=3
M  V30 15 1 14 16
M  V30 16 1 16 17 CFG=3
M  V30 17 1 16 18
M  V30 18 1 18 9
M  V30 19 1 18 19 CFG=1
M  V30 20 1 7 20
M  V30 21 1 20 21 CFG=1
M  V30 22 1 20 22
M  V30 23 1 22 23
M  V30 24 1 24 3
M  V30 25 1 25 5
M  V30 26 1 26 7
M  V30 27 1 27 9
M  V30 28 1 28 11
M  V30 29 1 29 14
M  V30 30 1 30 16
M  V30 31 1 31 18
M  V30 32 1 32 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
353

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lactitol monohydrate

>  <Synonyms>
D-Lactitol monohydrate

>  <CAS>
81025-04-9

>  <Formula>
C12H26O12

>  <MolWt>
362.3

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Lactitol monohydrate is a disaccharide analog of lactulose. It has been widely used to treat constipation and hepatic encephalopathy.

>  <Reference>
"Kanters JA, et al. Acta Crystallogr C. 1990 Dec 15;46 ( Pt 12):2408-11."

>  <ID<1>>
T0299

$$$$
StarDrop ID 354
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0071 -0.0651 0.0000 0
M  V30 2 N 4.7216 -0.4776 0.0000 0
M  V30 3 C 4.7216 -1.3026 0.0000 0
M  V30 4 C 5.4361 -0.0651 0.0000 0
M  V30 5 C 6.1506 -0.4776 0.0000 0
M  V30 6 C 6.8650 -0.0651 0.0000 0 CFG=1
M  V30 7 C 7.5795 -0.4776 0.0000 0
M  V30 8 C 8.2940 -0.0651 0.0000 0
M  V30 9 C 9.0084 -0.4776 0.0000 0
M  V30 10 C 9.0084 -1.3026 0.0000 0
M  V30 11 Cl 9.7229 -1.7151 0.0000 0
M  V30 12 C 8.2940 -1.7151 0.0000 0
M  V30 13 C 7.5795 -1.3026 0.0000 0
M  V30 14 C 6.8650 0.7599 0.0000 0
M  V30 15 C 6.1506 1.1724 0.0000 0
M  V30 16 C 6.1506 1.9974 0.0000 0
M  V30 17 C 6.8650 2.4099 0.0000 0
M  V30 18 C 7.5795 1.9974 0.0000 0
M  V30 19 N 7.5795 1.1724 0.0000 0
M  V30 20 H 6.8651 -1.0651 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 6 5 CFG=3
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 7 13
M  V30 14 1 6 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 14 19
M  V30 21 1 20 6
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
354

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dexchlorpheniramine Maleate

>  <Synonyms>
S-(+)-Chlorpheniramine maleate salt

>  <CAS>
2438-32-6

>  <Formula>
C20H23ClN2O4

>  <MolWt>
390.9

>  <Pathways>
GPCR/G Protein;Immunology/Inflammation;Neuroscience

>  <Target>
Dopamine Receptor;5-HT Receptor;Norepinephrine;Histamine Receptor

>  <Receptor>
DA transporter; H1 receptor; Histamine Receptor; Noradrenaline transporter (Sodium-dependent); Sert (Sodium-dependent)

>  <Bioactivity>
Dexchlorpheniramine (trade name Polaramine) is an antihistamine with anticholinergic properties used to treat allergic conditions such as hay fever or urticaria. It is the pharmacologically active dextrorotatory isomer of chlorpheniramine.

>  <Reference>
"Tagawa M, et al. Br J Clin Pharmacol. 2001 Nov;52(5):501-9."

>  <ID<1>>
T0785

$$$$
StarDrop ID 355
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 0.6213 0.0000 0
M  V30 2 N 3.0716 0.2088 0.0000 0
M  V30 3 C 3.7861 0.6213 0.0000 0
M  V30 4 C 4.5006 0.2088 0.0000 0
M  V30 5 C 5.2150 0.6213 0.0000 0
M  V30 6 C 5.9295 0.2088 0.0000 0
M  V30 7 C 6.6111 0.6736 0.0000 0
M  V30 8 C 6.4276 1.4779 0.0000 0
M  V30 9 C 7.0323 2.0390 0.0000 0
M  V30 10 C 7.8207 1.7959 0.0000 0
M  V30 11 C 8.0043 0.9915 0.0000 0
M  V30 12 C 7.3995 0.4304 0.0000 0
M  V30 13 C 7.7009 -0.3376 0.0000 0
M  V30 14 C 7.2884 -1.0520 0.0000 0
M  V30 15 C 6.4726 -1.1750 0.0000 0
M  V30 16 C 6.2890 -1.9793 0.0000 0
M  V30 17 C 5.5007 -2.2225 0.0000 0
M  V30 18 C 4.8959 -1.6614 0.0000 0
M  V30 19 C 5.0795 -0.8570 0.0000 0
M  V30 20 C 5.8678 -0.6139 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 7 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 6 20
M  V30 22 1 15 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
355

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Protriptyline hydrochloride

>  <Synonyms>
Protriptyline HCl

>  <CAS>
1225-55-4

>  <Formula>
C19H22ClN

>  <MolWt>
299.8

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
5-HT Receptor;AChE

>  <Receptor>
AChE; Sert (Sodium-dependent)

>  <Bioactivity>
"Protriptyline Hydrochloride is the hydrochloride salt form of protriptyline, a tricyclic secondary amine with an antidepressant property. Protriptyline hydrochloride blocks the re-uptake of norepinephrine and serotonin by nerve terminals, thereby increasing available norepinephrine and serotonin. In addition, this agent exhibits anticholinergic activity."

>  <Reference>
"McDougle CJ, et al. Mol Psychiatry. 1998 May;3(3):270-3."

>  <ID<1>>
T0204

$$$$
StarDrop ID 356
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -0.1712 0.7310 0.0000 0
M  V30 2 C -0.5837 0.0165 0.0000 0
M  V30 3 C -1.4087 0.0165 0.0000 0
M  V30 4 N -0.1712 -0.6979 0.0000 0
M  V30 5 C 0.6538 -0.6979 0.0000 0
M  V30 6 N 1.1387 -0.0305 0.0000 0
M  V30 7 C 1.9233 -0.2854 0.0000 0
M  V30 8 C 2.6378 0.1271 0.0000 0
M  V30 9 C 3.3523 -0.2854 0.0000 0
M  V30 10 Cl 4.0668 0.1271 0.0000 0
M  V30 11 C 3.3523 -1.1104 0.0000 0
M  V30 12 Cl 4.0668 -1.5229 0.0000 0
M  V30 13 C 2.6378 -1.5229 0.0000 0
M  V30 14 C 1.9233 -1.1104 0.0000 0
M  V30 15 N 1.1387 -1.3654 0.0000 0
M  V30 16 C 0.8838 -2.1500 0.0000 0 CFG=1
M  V30 17 O 1.3687 -2.8174 0.0000 0
M  V30 18 C 0.8838 -3.4849 0.0000 0 CFG=1
M  V30 19 C 1.1387 -4.2695 0.0000 0
M  V30 20 O 0.5867 -4.8826 0.0000 0
M  V30 21 C 0.0992 -3.2299 0.0000 0 CFG=2
M  V30 22 O -0.5683 -3.7149 0.0000 0
M  V30 23 C 0.0992 -2.4049 0.0000 0 CFG=2
M  V30 24 O -0.5683 -1.9200 0.0000 0
M  V30 25 H 0.1767 -1.4429 0.0000 0
M  V30 26 H 0.1766 -4.1919 0.0000 0
M  V30 27 H 0.2555 -4.2176 0.0000 0
M  V30 28 H -0.7918 -2.8589 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 2 13 14
M  V30 14 1 7 14
M  V30 15 1 14 15
M  V30 16 1 5 15
M  V30 17 1 16 15 CFG=1
M  V30 18 1 16 17
M  V30 19 1 18 17
M  V30 20 1 18 19 CFG=1
M  V30 21 1 19 20
M  V30 22 1 21 18
M  V30 23 1 21 22 CFG=3
M  V30 24 1 21 23
M  V30 25 1 23 16
M  V30 26 1 23 24 CFG=3
M  V30 27 1 25 16
M  V30 28 1 26 18
M  V30 29 1 27 21
M  V30 30 1 28 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
356

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Maribavir

>  <Synonyms>
BW1263W94;GW257406X;1263W94;Benzimidavir

>  <CAS>
176161-24-3

>  <Formula>
C15H19Cl2N3O4

>  <MolWt>
376.2

>  <Pathways>
Others;Proteases/Proteasome;Microbiology/Virology

>  <Target>
Others;HCV Protease

>  <Receptor>
 histone phosphorylation:3 nM

>  <Bioactivity>
"Maribavir is an orally available benzimidazole riboside compound with activity against cytomegalovirus (CMV). Maribavir is a selective ATP competitor of the viral UL97 kinase, which is involved in viral nuclear maturation events, such as viral DNA assembly and movement of viral capsids from the nucleus of infected cells. Maribavir has activity against strains of CMV that are resistant to standard anti-CMV agents."

>  <Reference>
"Biron KK, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002 Aug;46(8):2365-72.;Shannon-Lowe CD, et al. The effects of Maribavir on the autophosphorylation of ganciclovir resistant mutants of the cytomegalovirus UL97 protein. Herpesviridae. 2010 Dec 7;1(1):4."

>  <ID<1>>
T2162

$$$$
StarDrop ID 357
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 -2.0183 0.0000 0
M  V30 2 C 2.3571 -1.1933 0.0000 0
M  V30 3 O 3.0716 -0.7808 0.0000 0
M  V30 4 C 3.0716 0.0442 0.0000 0
M  V30 5 C 2.3571 0.4567 0.0000 0
M  V30 6 C 2.3571 1.2817 0.0000 0
M  V30 7 C 3.0716 1.6942 0.0000 0
M  V30 8 C 3.7861 1.2817 0.0000 0
M  V30 9 C 3.7861 0.4567 0.0000 0
M  V30 10 O 4.5006 0.0442 0.0000 0
M  V30 11 C 5.2150 0.4567 0.0000 0
M  V30 12 C 5.9295 0.0442 0.0000 0
M  V30 13 N 6.6440 0.4567 0.0000 0
M  V30 14 C 7.3584 0.0442 0.0000 0 CFG=2
M  V30 15 C 7.3584 -0.7808 0.0000 0
M  V30 16 C 8.0729 0.4567 0.0000 0
M  V30 17 C 8.7874 0.0442 0.0000 0
M  V30 18 C 9.5019 0.4567 0.0000 0
M  V30 19 C 10.2163 0.0442 0.0000 0
M  V30 20 C 10.2163 -0.7808 0.0000 0
M  V30 21 O 10.9308 -1.1933 0.0000 0
M  V30 22 C 11.6453 -0.7808 0.0000 0
M  V30 23 C 9.5019 -1.1933 0.0000 0
M  V30 24 C 8.7874 -0.7808 0.0000 0
M  V30 25 S 10.9308 0.4567 0.0000 0
M  V30 26 O 11.6453 0.8692 0.0000 0
M  V30 27 O 11.3433 -0.2578 0.0000 0
M  V30 28 N 10.5183 1.1712 0.0000 0
M  V30 29 H 6.4924 -0.4558 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 4 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 14 13
M  V30 15 1 14 15 CFG=1
M  V30 16 1 14 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 20 23
M  V30 24 2 23 24
M  V30 25 1 17 24
M  V30 26 1 19 25
M  V30 27 2 25 26
M  V30 28 2 25 27
M  V30 29 1 25 28
M  V30 30 1 29 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
357

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tamsulosin hydrochloride

>  <Synonyms>
Flomax hydrochloride;Flomax

>  <CAS>
106463-17-6

>  <Formula>
C20H29ClN2O5S

>  <MolWt>
445

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor; ??1A-adrenergic receptor; ??1B-adrenergic receptor; ??1D-adrenergic receptor

>  <Bioactivity>
"Tamsulosin Hydrochloride is the hydrochloride salt of tamsulosin, a sulfonamide derivative with ??1 adrenergic antagonist activity."

>  <Reference>
"Kuo GH, et al. Bioorg Med Chem. 2000, 8(9):2263-75.;Okutsu H, et al. Urology. 2010, 75(1):235-40.;Franco-Salinas G, et al. Clin Pharmacokinet. 2010, 49(3):177-88."

>  <ID<1>>
T0210

$$$$
StarDrop ID 358
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.0713 -4.4770 0.0000 0
M  V30 2 C 0.8834 -4.3318 0.0000 0
M  V30 3 O 1.4153 -4.9625 0.0000 0
M  V30 4 O 1.1637 -3.5559 0.0000 0
M  V30 5 C 1.9758 -3.4106 0.0000 0
M  V30 6 C 2.2561 -2.6347 0.0000 0
M  V30 7 O 1.7243 -2.0040 0.0000 0
M  V30 8 C 3.0683 -2.4895 0.0000 0 CFG=1
M  V30 9 O 3.1278 -3.3123 0.0000 0
M  V30 10 C 2.8390 -1.6970 0.0000 0
M  V30 11 C 3.5218 -1.2340 0.0000 0
M  V30 12 C 4.1731 -1.7404 0.0000 0 CFG=1
M  V30 13 C 4.9853 -1.5952 0.0000 0 CFG=2
M  V30 14 C 5.2655 -0.8192 0.0000 0
M  V30 15 C 6.0777 -0.6740 0.0000 0
M  V30 16 C 6.6095 -1.3047 0.0000 0
M  V30 17 C 7.4216 -1.1595 0.0000 0
M  V30 18 C 7.9534 -1.7902 0.0000 0
M  V30 19 O 8.7655 -1.6450 0.0000 0
M  V30 20 C 7.6731 -2.5662 0.0000 0
M  V30 21 C 6.8610 -2.7114 0.0000 0
M  V30 22 C 6.3292 -2.0807 0.0000 0 CFG=1
M  V30 23 C 6.0489 -2.8566 0.0000 0
M  V30 24 C 5.5171 -2.2259 0.0000 0 CFG=2
M  V30 25 F 5.5766 -3.0487 0.0000 0
M  V30 26 C 5.2368 -3.0018 0.0000 0 CFG=1
M  V30 27 O 5.7686 -3.6325 0.0000 0
M  V30 28 C 4.4247 -3.1470 0.0000 0
M  V30 29 C 3.8928 -2.5163 0.0000 0 CFG=2
M  V30 30 C 3.5330 -3.2587 0.0000 0
M  V30 31 H 3.2125 -2.0183 0.0000 0
M  V30 32 H 4.3406 -0.8308 0.0000 0
M  V30 33 H 6.2212 -2.8258 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 8 6 CFG=1
M  V30 8 1 8 9 CFG=3
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 12 11 CFG=1
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=3
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 1 20 21
M  V30 21 1 22 21
M  V30 22 1 22 16
M  V30 23 1 22 23 CFG=1
M  V30 24 1 24 22
M  V30 25 1 24 13
M  V30 26 1 24 25 CFG=3
M  V30 27 1 24 26
M  V30 28 1 26 27 CFG=1
M  V30 29 1 26 28
M  V30 30 1 29 28
M  V30 31 1 29 8
M  V30 32 1 12 29
M  V30 33 1 29 30 CFG=1
M  V30 34 1 31 12
M  V30 35 1 32 13
M  V30 36 1 33 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
358

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fludrocortisone acetate

>  <Synonyms>
9??-Fluorcortisol acetate;9??-Fludrocortisone acetate;9??-fluorocortisol acetate

>  <CAS>
514-36-3

>  <Formula>
C23H31FO6

>  <MolWt>
422.5

>  <Pathways>
Autophagy;Endocrinology/Hormones

>  <Target>
Glucocorticoid Receptor;Autophagy

>  <Receptor>
Autophagy; Mineralocorticoid Receptor

>  <Bioactivity>
"Fludrocortisone, a glucocorticoid-receptor agonist, binds to cytoplasmic receptors, translocates to the nucleus, and subsequently initiates the transcription of glucocorticoid-responsive genes such as lipocortins to inhibit phospholipase A2 (PLA2). Fludrocortisone Acetate is the acetate salt of a synthetic fluorinated corticosteroid with anti-inflammatory and antiallergic activities. Inhibition of PLA2 activity prevents the release of arachidonic acid, a precursor of eicosanoids such as prostaglandins and leukotrienes; eicosanoids are important mediators in the pro-inflammatory response mechanism. As a mineralocorticoid-receptor agonist, this agent stimulates Na+ reabsorption and water retention and K+ and H+ secretion in the distal tubules and collecting ducts of the kidney."

>  <Reference>
N/A

>  <ID<1>>
T1666

$$$$
StarDrop ID 359
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.1821 0.5775 0.0000 0
M  V30 2 C 3.8966 0.1650 0.0000 0
M  V30 3 C 3.8966 -0.6600 0.0000 0
M  V30 4 N 4.6111 0.5775 0.0000 0
M  V30 5 C 5.3256 0.1650 0.0000 0
M  V30 6 C 6.0400 0.5775 0.0000 0
M  V30 7 O 6.0400 1.4025 0.0000 0
M  V30 8 C 6.7545 0.1650 0.0000 0
M  V30 9 C 7.4690 0.5775 0.0000 0
M  V30 10 C 8.1834 0.1650 0.0000 0
M  V30 11 O 8.8979 0.5775 0.0000 0
M  V30 12 C 8.1834 -0.6600 0.0000 0
M  V30 13 C 7.4690 -1.0725 0.0000 0
M  V30 14 O 7.4690 -1.8975 0.0000 0
M  V30 15 C 6.7545 -0.6600 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 8 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
359

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Metaproterenol hemisulfate

>  <Synonyms>
Orciprenaline sulfate;Metaproterenol Sulfate

>  <CAS>
5874-97-5

>  <Formula>
C22H36N2O10S

>  <MolWt>
520.6

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Adrenergic Receptor

>  <Receptor>
 ??2-adrenergic receptor:68 nM (IC50)

>  <Bioactivity>
Orciprenaline sulfate is a beta-2 adrenergic agonist used in the treatment of ASTHMA and BRONCHIAL SPASM.

>  <Reference>
"Kimura M, et al. J Pharmacol Exp Ther. 1999 Oct;291(1):171-80."

>  <ID<1>>
T0277

$$$$
StarDrop ID 360
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 6.8513 5.7750 0.0000 0
M  V30 2 C 7.5658 6.1875 0.0000 0
M  V30 3 C 7.5658 7.0125 0.0000 0
M  V30 4 C 8.2802 7.4250 0.0000 0
M  V30 5 N 8.2802 8.2500 0.0000 0
M  V30 6 C 8.9947 8.6625 0.0000 0
M  V30 7 N 8.9947 9.4875 0.0000 0
M  V30 8 C 9.7092 9.9000 0.0000 0
M  V30 9 N 10.4236 9.4875 0.0000 0
M  V30 10 C 10.4236 8.6625 0.0000 0
M  V30 11 C 11.1381 8.2500 0.0000 0
M  V30 12 C 11.1381 7.4250 0.0000 0
M  V30 13 C 10.4236 7.0125 0.0000 0
M  V30 14 N 10.4236 6.1875 0.0000 0
M  V30 15 C 11.1381 5.7750 0.0000 0
M  V30 16 N 11.8918 6.1106 0.0000 0
M  V30 17 C 12.4438 5.4975 0.0000 0
M  V30 18 C 12.9958 6.1106 0.0000 0
M  V30 19 C 13.1113 5.0125 0.0000 0
M  V30 20 C 12.0313 4.7830 0.0000 0
M  V30 21 O 11.2243 4.9545 0.0000 0
M  V30 22 C 9.7092 7.4250 0.0000 0
M  V30 23 C 9.7092 8.2500 0.0000 0
M  V30 24 C 8.9947 7.0125 0.0000 0
M  V30 25 C 8.9947 6.1875 0.0000 0
M  V30 26 C 8.2802 5.7750 0.0000 0
M  V30 27 O 8.2802 4.9500 0.0000 0
M  V30 28 C 7.5658 4.5375 0.0000 0
M  V30 29 C 7.5658 3.7125 0.0000 0
M  V30 30 C 6.8513 3.3000 0.0000 0
M  V30 31 N 6.1368 3.7125 0.0000 0
M  V30 32 N 5.3522 3.4576 0.0000 0
M  V30 33 C 4.8673 4.1250 0.0000 0
M  V30 34 N 5.3522 4.7924 0.0000 0
M  V30 35 C 6.1368 4.5375 0.0000 0
M  V30 36 C 6.8513 4.9500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 17 19
M  V30 19 1 17 20
M  V30 20 1 20 21
M  V30 21 1 15 21
M  V30 22 1 13 22
M  V30 23 2 22 23
M  V30 24 1 6 23
M  V30 25 1 10 23
M  V30 26 2 4 24
M  V30 27 1 24 25
M  V30 28 2 25 26
M  V30 29 1 2 26
M  V30 30 1 26 27
M  V30 31 1 27 28
M  V30 32 1 28 29
M  V30 33 2 29 30
M  V30 34 1 30 31
M  V30 35 1 31 32
M  V30 36 2 32 33
M  V30 37 1 33 34
M  V30 38 2 34 35
M  V30 39 1 31 35
M  V30 40 1 35 36
M  V30 41 2 28 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
360

>  <Plate>
PHD136329

>  <Row>
b

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tucatinib

>  <Synonyms>
ONT-380;ARRY-380;Irbinitinib

>  <CAS>
937263-43-9

>  <Formula>
C26H24N8O2

>  <MolWt>
480.5

>  <Pathways>
JAK/STAT signaling;Angiogenesis;Tyrosine Kinase/Adaptors

>  <Target>
HER;EGFR

>  <Receptor>
 ErbB2:8 nM

>  <Bioactivity>
Irbinitinib(ARRY-380; ONT-380) is a potent and selective HER2 inhibitor (IC50: 8 nM).

>  <Reference>
"P Lee, et al. Cancer Research(Poster Session Abstracts). 2009, 69(24 Suppl):Abstract nr 5104.;SL Moulder, et al. AACR-NCI-EORTC. Nov 12-16, 2011, Abstract#A143."

>  <ID<1>>
T2364

$$$$
StarDrop ID 361
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 7.1795 -4.4656 0.0000 0
M  V30 2 O 7.8940 -4.8781 0.0000 0
M  V30 3 C 8.6084 -4.4656 0.0000 0
M  V30 4 C 9.3229 -4.8781 0.0000 0
M  V30 5 C 10.0374 -4.4656 0.0000 0
M  V30 6 O 10.7519 -4.8781 0.0000 0
M  V30 7 C 11.4663 -4.4656 0.0000 0
M  V30 8 C 11.4663 -3.6406 0.0000 0
M  V30 9 C 12.1808 -3.2281 0.0000 0
M  V30 10 N 12.8953 -3.6406 0.0000 0
M  V30 11 C 12.8953 -4.4656 0.0000 0
M  V30 12 C 13.6097 -4.8781 0.0000 0
M  V30 13 S 14.3242 -4.4656 0.0000 0
M  V30 14 C 15.0387 -4.8781 0.0000 0
M  V30 15 N 15.7924 -4.5425 0.0000 0
M  V30 16 C 16.3444 -5.1556 0.0000 0
M  V30 17 C 17.1694 -5.1556 0.0000 0
M  V30 18 C 17.5819 -5.8701 0.0000 0
M  V30 19 C 17.1694 -6.5845 0.0000 0
M  V30 20 C 16.3444 -6.5845 0.0000 0
M  V30 21 C 15.9319 -5.8701 0.0000 0
M  V30 22 N 15.1249 -5.6985 0.0000 0
M  V30 23 C 12.1808 -4.8781 0.0000 0
M  V30 24 C 12.1808 -5.7031 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 2 16 21
M  V30 22 1 21 22
M  V30 23 2 14 22
M  V30 24 1 11 23
M  V30 25 2 7 23
M  V30 26 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
361

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Rabeprazole Sulfide

>  <Synonyms>
Rabeprazole Related Compound E

>  <CAS>
117977-21-6

>  <Formula>
C18H21N3O2S

>  <MolWt>
343.5

>  <Pathways>
Microbiology/Virology;Membrane transporter/Ion channel

>  <Target>
Proton pump;Antibacterial

>  <Receptor>
Bacterial; Proton pump

>  <Bioactivity>
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors.

>  <Reference>
"Ohara T, et al. Helicobacter. 2001 Jun;6(2):125-9.;Kang D, Pang X, Lian W, et al. Discovery of VEGFR2 inhibitors by integrating na?ve Bayesian classification, molecular docking and drug screening approaches[J]. RSC Advances. 2018 Jan 8(10): 5286-5297."

>  <ID<1>>
T1734

$$$$
StarDrop ID 362
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 40 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.5799 1.0865 0.0000 0
M  V30 2 O 0.8655 0.6740 0.0000 0
M  V30 3 C 0.8655 -0.1510 0.0000 0 CFG=2
M  V30 4 N 0.0405 -0.1510 0.0000 0
M  V30 5 C -0.3720 0.5635 0.0000 0
M  V30 6 O -1.1970 0.5635 0.0000 0
M  V30 7 C 0.0405 1.2780 0.0000 0
M  V30 8 S -0.1731 2.0748 0.0000 0
M  V30 9 C 0.6238 2.2884 0.0000 0
M  V30 10 S 0.8373 1.4915 0.0000 0
M  V30 11 C 1.0363 3.0028 0.0000 0
M  V30 12 C 0.6238 3.7173 0.0000 0
M  V30 13 N 1.0363 4.4318 0.0000 0
M  V30 14 O -0.2012 3.7173 0.0000 0
M  V30 15 C 1.8613 3.0028 0.0000 0
M  V30 16 O 2.2738 3.7173 0.0000 0
M  V30 17 O 2.2738 2.2884 0.0000 0
M  V30 18 C 1.6905 -0.1510 0.0000 0 CFG=1
M  V30 19 S 2.4049 0.2615 0.0000 0
M  V30 20 C 3.1194 -0.1510 0.0000 0
M  V30 21 C 3.1194 -0.9760 0.0000 0
M  V30 22 C 3.8339 -1.3885 0.0000 0
M  V30 23 S 4.5483 -0.9760 0.0000 0
M  V30 24 C 4.5483 -0.1510 0.0000 0
M  V30 25 N 3.8809 0.3339 0.0000 0
M  V30 26 N 4.1358 1.1186 0.0000 0
M  V30 27 N 4.9608 1.1186 0.0000 0
M  V30 28 N 5.2158 0.3339 0.0000 0
M  V30 29 C 6.0004 0.0790 0.0000 0
M  V30 30 C 2.4049 -1.3885 0.0000 0
M  V30 31 N 1.6905 -0.9760 0.0000 0
M  V30 32 C 0.8655 -0.9760 0.0000 0
M  V30 33 O 0.2821 -1.5593 0.0000 0
M  V30 34 C 2.4049 -2.2135 0.0000 0
M  V30 35 O 1.6905 -2.6260 0.0000 0
M  V30 36 O 3.1194 -2.6260 0.0000 0
M  V30 37 H 0.9834 -0.8581 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=3
M  V30 3 1 3 4 CFG=1
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 7 10
M  V30 11 2 9 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 12 14
M  V30 15 1 11 15
M  V30 16 1 15 16
M  V30 17 2 15 17
M  V30 18 1 3 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 1 24 28
M  V30 30 1 28 29
M  V30 31 2 21 30
M  V30 32 1 30 31
M  V30 33 1 18 31 CFG=1
M  V30 34 1 31 32
M  V30 35 1 3 32
M  V30 36 2 32 33
M  V30 37 1 30 34
M  V30 38 1 34 35
M  V30 39 2 34 36
M  V30 40 1 37 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
362

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cefotetan

>  <Synonyms>
Apacef

>  <CAS>
69712-56-7

>  <Formula>
C17H17N7O8S4

>  <MolWt>
575.6

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibacterial; Antibiotic; Bacterial

>  <Bioactivity>
"Cefotetan Sodium (ICI-156834, YM-09330) is a second-generation cephalosporin, cephamycin antibiotic that is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative bacteria. Cefotetan binds to penicillin-binding proteins and disrupts the cell wall synthesis."

>  <Reference>
"Fourches D, et al. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species[J]. Chemical Research in Toxicology, 2010, 23(1):171-183.;Ekinci D, et al. Susceptibility of cord blood antioxidant enzymes glutathione reductase, glutathione peroxidase and glutathione S-transferase to different antibiotics: in vitro approach[J]. Journal of Enzyme Inhibition & Medicinal Chemistry, 2013, 28(4):824-829."

>  <ID<1>>
T7043

$$$$
StarDrop ID 363
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.7812 1.9354 0.0000 0
M  V30 2 O 4.0668 2.3479 0.0000 0
M  V30 3 C 3.3523 1.9354 0.0000 0
M  V30 4 C 3.3523 1.1104 0.0000 0
M  V30 5 C 2.6378 0.6979 0.0000 0
M  V30 6 C 1.9233 1.1104 0.0000 0
M  V30 7 N 1.1387 0.8555 0.0000 0
M  V30 8 C 0.6538 1.5229 0.0000 0
M  V30 9 S -0.1712 1.5229 0.0000 0
M  V30 10 C -0.5837 0.8085 0.0000 0
M  V30 11 C -1.4087 0.8085 0.0000 0
M  V30 12 N -1.8212 0.0940 0.0000 0
M  V30 13 C -2.6462 0.0940 0.0000 0
M  V30 14 C -3.0587 0.8085 0.0000 0
M  V30 15 C -3.8837 0.8085 0.0000 0
M  V30 16 C -2.6462 1.5229 0.0000 0
M  V30 17 O -3.0587 2.2374 0.0000 0
M  V30 18 C -2.6462 2.9519 0.0000 0
M  V30 19 C -1.8212 1.5229 0.0000 0
M  V30 20 C -1.4087 2.2374 0.0000 0
M  V30 21 N 1.1387 2.1904 0.0000 0
M  V30 22 C 1.9233 1.9354 0.0000 0
M  V30 23 C 2.6378 2.3479 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 14 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 16 19
M  V30 19 1 11 19
M  V30 20 1 19 20
M  V30 21 2 8 21
M  V30 22 1 21 22
M  V30 23 2 6 22
M  V30 24 1 22 23
M  V30 25 2 3 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
363

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Omeprazole sulfide

>  <Synonyms>
Omeprazole metabolite Omeprazole sulfide;Ufiprazole

>  <CAS>
73590-85-9

>  <Formula>
C17H19N3O2S

>  <MolWt>
329.4

>  <Pathways>
Metabolism;Membrane transporter/Ion channel

>  <Target>
Drug Metabolite;Proton pump

>  <Receptor>
Drug Metabolite; Proton pump

>  <Bioactivity>
"Omeprazole sulfide is a metabolite of Omeprazole, which is a proton pump inhibitor."

>  <Reference>
"Babiak P, et al. Bioresour Technol. 2011 Sep;102(17):7621-6."

>  <ID<1>>
T2687

$$$$
StarDrop ID 364
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.1434 -2.0625 0.0000 0
M  V30 2 N 2.8579 -1.6500 0.0000 0
M  V30 3 C 3.5724 -2.0625 0.0000 0
M  V30 4 C 4.2868 -1.6500 0.0000 0
M  V30 5 C 5.0013 -2.0625 0.0000 0
M  V30 6 O 5.7158 -1.6500 0.0000 0
M  V30 7 C 6.4302 -2.0625 0.0000 0
M  V30 8 C 7.1447 -1.6500 0.0000 0
M  V30 9 C 7.8592 -2.0625 0.0000 0
M  V30 10 C 7.8592 -2.8875 0.0000 0
M  V30 11 C 7.1447 -3.3000 0.0000 0
M  V30 12 C 6.4302 -2.8875 0.0000 0
M  V30 13 C 8.5737 -3.3000 0.0000 0
M  V30 14 F 9.2881 -3.7125 0.0000 0
M  V30 15 F 8.1612 -4.0145 0.0000 0
M  V30 16 F 8.9862 -2.5855 0.0000 0
M  V30 17 C 5.0013 -2.8875 0.0000 0
M  V30 18 C 5.7158 -3.3000 0.0000 0
M  V30 19 C 5.7158 -4.1250 0.0000 0
M  V30 20 C 5.0013 -4.5375 0.0000 0
M  V30 21 C 4.2868 -4.1250 0.0000 0
M  V30 22 C 4.2868 -3.3000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 7 12
M  V30 13 1 10 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 13 16
M  V30 17 1 5 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
364

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fluoxetine

>  <Synonyms>
LY-110140

>  <CAS>
54910-89-3

>  <Formula>
C17H18F3NO

>  <MolWt>
309.3

>  <Pathways>
Neuroscience;Immunology/Inflammation;Autophagy;GPCR/G Protein

>  <Target>
5-HT Receptor;Autophagy;MRP;Serotonin Transporter

>  <Receptor>
Autophagy; MRP1; Serotonin Transporter; Sert (Sodium-dependent)

>  <Bioactivity>
Fluoxetine is the first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.

>  <Reference>
"Avitsur R1. Increased symptoms of illness following prenatal stress: Can it be prevented by fluoxetine  Behav Brain Res. 2017 Jan 15;317:62-70.;Jinyan Lv, Yemei Liang, Shiqing Zhang, Qunsheng Lan, Ziwei Xu, Xiaoyan Wu, Lijun Kang, Jing Ren, Ying Cao, Ting Wu, Kai Li Lin, Ken Kin Lam Yung, Xiong Cao, Jianxin Pang, and Pingzheng Zhou . DCPIB, an inhibitor of volume-regulated anion channels, distinctly modulates K2P channels [J]. ACS Chemical Neuroscience. 2019 Apr 17.;Zhao J, Zhang Y, Liu Y, et al. Antidepressant-like effects of 1-methylnicotinamide in a chronic unpredictable mild stress model of depression[J]. Neuroscience Letters. 2020: 135535.;Zhang W, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology. 2000 Sep;23(3):250-62.;Jiang Bo, et al. Hippocampal Salt-Inducible Kinase 2 Plays a Role in Depression Via the CREB-Regulated Transcription Coactivator 1-Cyclic AMP Response Element Binding-Brain-Derived Neurotrophic Factor Pathway [J]. Biological psychiatry. 2019 Apr 15;85(8):650-666.;Bymaster FP, et al. Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Psychopharmacology (Berl). 2002 Apr;160(4):353-61.;Malberg JE, et al. Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology. 2003 Sep;28(9):1562-71.;Liu L, Ji C H, Wang Y, et al. Antidepressant-like activity of L-701324 in mice: A behavioral and neurobiological characterization[J]. Behavioural Brain Research. 2020: 113038.;Wang JW, et al. Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci. 2008 Feb 6;28(6):1374-84.;Kodama M, et al. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 2004 Oct 15;56(8):570-80."

>  <ID<1>>
T0450

$$$$
StarDrop ID 365
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 2.3375 0.0000 0
M  V30 2 O 3.0716 1.9250 0.0000 0
M  V30 3 C 3.0716 1.1000 0.0000 0
M  V30 4 C 3.7861 0.6875 0.0000 0
M  V30 5 C 3.7861 -0.1375 0.0000 0
M  V30 6 C 4.5006 -0.5500 0.0000 0
M  V30 7 O 4.5006 -1.3750 0.0000 0
M  V30 8 C 5.2150 -0.1375 0.0000 0
M  V30 9 N 5.9295 -0.5500 0.0000 0
M  V30 10 C 6.6440 -0.1375 0.0000 0
M  V30 11 O 6.6440 0.6875 0.0000 0
M  V30 12 C 7.3584 -0.5500 0.0000 0
M  V30 13 N 8.0729 -0.1375 0.0000 0
M  V30 14 C 3.0716 -0.5500 0.0000 0
M  V30 15 O 3.0716 -1.3750 0.0000 0
M  V30 16 C 2.3571 -1.7875 0.0000 0
M  V30 17 C 2.3571 -0.1375 0.0000 0
M  V30 18 C 2.3571 0.6875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 2 5 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 14 17
M  V30 17 2 17 18
M  V30 18 1 3 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
365

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Midodrine hydrochloride

>  <Synonyms>
Pro-Amatine

>  <CAS>
3092-17-9

>  <Formula>
C12H19ClN2O4

>  <MolWt>
290.7

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
??1-adrenergic receptor

>  <Bioactivity>
"Midodrine is converted to its active metabolite, desglymidodrine by deglycination reaction. Desglymidodrine selectively binds to and activates alpha-1-adrenergic receptors of the arteriolar and venous vasculature. This causes smooth muscle contraction and leads to an elevation of blood pressure. Desglymidodrine diffuses poorly across the blood-brain barrier and is therefore not associated with effects on the central nervous system. Midodrine Hydrochloride is the hydrochloride salt form of midodrine, a direct-acting prodrug and sympathomimetic agent with antihypotensive properties."

>  <Reference>
"Buckner SA, et al. Eur J Pharmacol. 2002 Aug 2;449(1-2):159-65."

>  <ID<1>>
T1577

$$$$
StarDrop ID 366
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.0000 -2.3645 0.0000 0
M  V30 2 N -0.0000 -3.1895 0.0000 0
M  V30 3 C 0.7145 -3.6020 0.0000 0
M  V30 4 C 0.7145 -4.4270 0.0000 0
M  V30 5 C 0.0000 -4.8395 0.0000 0
M  V30 6 C -0.7145 -4.4270 0.0000 0
M  V30 7 C -0.7145 -3.6020 0.0000 0
M  V30 8 C -0.0000 -5.6645 0.0000 0
M  V30 9 C 0.7433 -6.0224 0.0000 0
M  V30 10 C 1.3481 -5.4613 0.0000 0
M  V30 11 C 2.1364 -5.7045 0.0000 0
M  V30 12 C 2.3200 -6.5088 0.0000 0
M  V30 13 C 1.7152 -7.0699 0.0000 0
M  V30 14 C 0.9269 -6.8267 0.0000 0
M  V30 15 C 0.4125 -7.4718 0.0000 0
M  V30 16 C -0.4125 -7.4718 0.0000 0
M  V30 17 C -0.9269 -6.8267 0.0000 0
M  V30 18 C -1.7152 -7.0699 0.0000 0
M  V30 19 C -2.3200 -6.5088 0.0000 0
M  V30 20 C -2.1364 -5.7045 0.0000 0
M  V30 21 N -1.3481 -5.4613 0.0000 0
M  V30 22 C -0.7433 -6.0224 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 2 5 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 9 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 8 22
M  V30 25 1 17 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
366

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Azatadine dimaleate

>  <Synonyms>
Azatadine Maleate;SCH10649

>  <CAS>
3978-86-7

>  <Formula>
C28H30N2O8

>  <MolWt>
522.6

>  <Pathways>
GPCR/G Protein;Immunology/Inflammation;Neuroscience

>  <Target>
5-HT Receptor;AChR;Histamine Receptor

>  <Receptor>
" Histamine receptor:6.5 nM, Cholinergic:10 nM"

>  <Bioactivity>
Azatadine dimaleate is an inhibitor for histamine??IC50=6.5 nM?? and cholinergic??IC50=10 nM??.

>  <Reference>
"Simons FE, et al. Clin Pharmacokinet, 1991, 21(5), 372-393.;Tozzi S, et al. Agents Actions, 1974, 4(4), 264-270.;Katelaris C, et al. Asian Pac J Allergy Immunol, 1990, 8(2), 103-107.;Zhang D, et al. Appl Environ Microbiol, 1996, 62(9), 3477-3479."

>  <ID<1>>
T0236

$$$$
StarDrop ID 367
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.0071 0.3087 0.0000 0
M  V30 2 C 4.7216 -0.1038 0.0000 0
M  V30 3 C 5.4361 0.3087 0.0000 0
M  V30 4 C 6.1506 -0.1038 0.0000 0
M  V30 5 C 6.8650 0.3087 0.0000 0
M  V30 6 N 7.5795 -0.1038 0.0000 0
M  V30 7 C 8.2940 0.3087 0.0000 0
M  V30 8 N 8.2940 1.1337 0.0000 0
M  V30 9 N 9.0084 -0.1038 0.0000 0
M  V30 10 N 9.7229 0.3087 0.0000 0
M  V30 11 C 10.4374 -0.1038 0.0000 0
M  V30 12 C 11.1519 0.3087 0.0000 0
M  V30 13 C 11.2381 1.1292 0.0000 0
M  V30 14 N 12.0451 1.3007 0.0000 0
M  V30 15 C 12.4576 0.5863 0.0000 0
M  V30 16 C 13.2645 0.4147 0.0000 0
M  V30 17 C 13.5195 -0.3699 0.0000 0
M  V30 18 C 12.9674 -0.9830 0.0000 0
M  V30 19 O 13.2224 -1.7676 0.0000 0
M  V30 20 C 14.0293 -1.9391 0.0000 0
M  V30 21 C 12.1605 -0.8115 0.0000 0
M  V30 22 C 11.9055 -0.0268 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 2 18 21
M  V30 21 1 21 22
M  V30 22 2 12 22
M  V30 23 1 15 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
367

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tegaserod maleate

>  <Synonyms>
SDZ-HTF-919;HTF-919

>  <CAS>
189188-57-6

>  <Formula>
C20H27N5O5

>  <MolWt>
417.5

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
5-HT Receptor

>  <Receptor>
5-HT; 5-HT Receptor; Sert (Sodium-dependent)

>  <Bioactivity>
"Tegaserod is a 5-HT4 agonist manufactured by Novartis and used for the management of irritable bowel syndrome and constipation. Its use was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating and constipation associated with irritable bowel syndrome. On March 30, 2007, the U.S. Food and Drug Administration requested that Novartis withdraw Zelnorm from shelves. The FDA alleges a relationship between prescriptions of the drug and increased risks of heart attack or stroke."

>  <Reference>
"Zhang L, Song Q, Zhang X, et al. Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling[J]. Investigational New Drugs. 2019 May 14: 1-10.;Beattie DT, et al. Br J Pharmacol. 2004 Nov;143(5):549-60."

>  <ID<1>>
T1551

$$$$
StarDrop ID 368
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 83 90 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 4.0402 -4.6032 0.0000 0
M  V30 2 C 3.6277 -3.8887 0.0000 0
M  V30 3 N 4.0402 -3.1742 0.0000 0
M  V30 4 C 4.0402 -2.3492 0.0000 0 CFG=2
M  V30 5 C 3.6277 -2.4598 0.0000 0
M  V30 6 O 3.1255 -3.1143 0.0000 0
M  V30 7 N 3.6277 -1.0308 0.0000 0
M  V30 8 C 2.8027 -1.0308 0.0000 0 CFG=2
M  V30 9 C 2.3902 -1.7453 0.0000 0
M  V30 10 O 2.8027 -2.4598 0.0000 0
M  V30 11 O 1.5652 -1.7453 0.0000 0
M  V30 12 C 1.1527 -2.4598 0.0000 0 CFG=2
M  V30 13 C 1.5652 -3.1742 0.0000 0
M  V30 14 C 0.3277 -2.4598 0.0000 0 CFG=2
M  V30 15 N -0.0692 -1.7365 0.0000 0
M  V30 16 C -0.8940 -1.7186 0.0000 0
M  V30 17 O -1.3219 -2.4239 0.0000 0
M  V30 18 C -1.2908 -0.9953 0.0000 0
M  V30 19 C -0.8629 -0.2900 0.0000 0
M  V30 20 O -0.0381 -0.3079 0.0000 0
M  V30 21 C -1.2598 0.4333 0.0000 0
M  V30 22 C -2.0846 0.4512 0.0000 0
M  V30 23 C -2.5125 -0.2542 0.0000 0
M  V30 24 N -2.1157 -0.9774 0.0000 0
M  V30 25 C -0.1572 -3.2213 0.0000 0
M  V30 26 O 0.3480 -3.8735 0.0000 0
M  V30 27 N -0.9418 -3.4762 0.0000 0
M  V30 28 C -0.9418 -4.3012 0.0000 0 CFG=2
M  V30 29 C -1.6092 -4.7861 0.0000 0
M  V30 30 C -2.3629 -4.4506 0.0000 0
M  V30 31 C -0.1572 -4.5561 0.0000 0
M  V30 32 O 0.5248 -4.0919 0.0000 0
M  V30 33 N 0.3277 -5.3176 0.0000 0
M  V30 34 C 1.1527 -5.3176 0.0000 0 CFG=2
M  V30 35 C 1.5652 -4.6032 0.0000 0
M  V30 36 O 1.1527 -3.8887 0.0000 0
M  V30 37 N 2.3902 -4.6032 0.0000 0 CFG=1
M  V30 38 C 2.0547 -5.3568 0.0000 0
M  V30 39 C 2.8027 -3.8887 0.0000 0
M  V30 40 C 3.4158 -4.4407 0.0000 0
M  V30 41 C 3.2443 -5.2477 0.0000 0
M  V30 42 C 3.8574 -5.7997 0.0000 0
M  V30 43 C 3.6859 -6.6067 0.0000 0
M  V30 44 C 2.9013 -6.8616 0.0000 0
M  V30 45 N 2.7297 -7.6686 0.0000 0
M  V30 46 C 3.3428 -8.2206 0.0000 0
M  V30 47 C 1.9451 -7.9236 0.0000 0
M  V30 48 C 2.2882 -6.3096 0.0000 0
M  V30 49 C 2.4597 -5.5026 0.0000 0
M  V30 50 C 1.4077 -6.1023 0.0000 0
M  V30 51 C 0.7402 -6.5872 0.0000 0
M  V30 52 C 0.0728 -6.1023 0.0000 0
M  V30 53 H 0.7402 -4.6032 0.0000 0
M  V30 54 C 2.3902 -0.3163 0.0000 0
M  V30 55 C 1.5652 -0.3163 0.0000 0
M  V30 56 C 1.1527 0.3981 0.0000 0
M  V30 57 C 1.5652 1.1126 0.0000 0
M  V30 58 C 2.3902 1.1126 0.0000 0
M  V30 59 C 2.8027 0.3981 0.0000 0
M  V30 60 H 1.9777 -1.0308 0.0000 0
M  V30 61 C 4.7547 -1.9367 0.0000 0
M  V30 62 C 5.4692 -2.3492 0.0000 0
M  V30 63 O 6.1837 -1.9367 0.0000 0
M  V30 64 C 5.4692 -3.1742 0.0000 0 CFG=2
M  V30 65 C 6.1837 -3.5867 0.0000 0
M  V30 66 S 6.8981 -3.1742 0.0000 0
M  V30 67 C 7.6126 -3.5867 0.0000 0 CFG=1
M  V30 68 C 8.3271 -3.1742 0.0000 0
M  V30 69 C 9.0415 -3.5867 0.0000 0
M  V30 70 C 9.0415 -4.4117 0.0000 0
M  V30 71 N 8.3271 -4.8242 0.0000 0
M  V30 72 C 7.6126 -4.4117 0.0000 0
M  V30 73 C 8.4646 -4.2742 0.0000 0
M  V30 74 C 8.4646 -3.7242 0.0000 0
M  V30 75 C 4.7547 -3.5867 0.0000 0
M  V30 76 H 3.7245 -1.5870 0.0000 0
M  V30 77 H 6.7466 -4.0867 0.0000 0
M  V30 78 H 2.1527 -2.4597 0.0000 0
M  V30 79 H 0.8370 -1.5992 0.0000 0
M  V30 80 H -0.7853 -5.2889 0.0000 0
M  V30 81 H 0.0000 0.0000 0.0000 0
M  V30 82 H 0.0000 0.0000 0.0000 0
M  V30 83 H 6.3352 -2.6742 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 8 7
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 12 11
M  V30 12 1 12 13 CFG=3
M  V30 13 1 12 14
M  V30 14 1 14 15 CFG=1
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 16 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 19 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 18 24
M  V30 25 1 14 25
M  V30 26 2 25 26
M  V30 27 1 25 27
M  V30 28 1 28 27
M  V30 29 1 28 29 CFG=1
M  V30 30 1 29 30
M  V30 31 1 28 31
M  V30 32 2 31 32
M  V30 33 1 31 33
M  V30 34 1 34 33
M  V30 35 1 34 35
M  V30 36 2 35 36
M  V30 37 1 35 37
M  V30 38 1 37 38
M  V30 39 1 37 39 CFG=3
M  V30 40 1 39 2
M  V30 41 1 40 39 CFG=1
M  V30 42 1 40 41
M  V30 43 2 41 42
M  V30 44 1 42 43
M  V30 45 2 43 44
M  V30 46 1 44 45
M  V30 47 1 45 46
M  V30 48 1 45 47
M  V30 49 1 44 48
M  V30 50 2 48 49
M  V30 51 1 41 49
M  V30 52 1 34 50
M  V30 53 1 50 51
M  V30 54 1 51 52
M  V30 55 1 33 52
M  V30 56 1 34 53 CFG=1
M  V30 57 1 8 54
M  V30 58 2 54 55
M  V30 59 1 55 56
M  V30 60 2 56 57
M  V30 61 1 57 58
M  V30 62 2 58 59
M  V30 63 1 54 59
M  V30 64 1 8 60 CFG=1
M  V30 65 1 4 61
M  V30 66 1 61 62
M  V30 67 2 62 63
M  V30 68 1 64 62
M  V30 69 1 64 65 CFG=3
M  V30 70 1 65 66
M  V30 71 1 67 66 CFG=1
M  V30 72 1 67 68
M  V30 73 1 68 69
M  V30 74 1 69 70
M  V30 75 1 70 71
M  V30 76 1 71 72
M  V30 77 1 67 72
M  V30 78 1 71 73
M  V30 79 1 73 74
M  V30 80 1 68 74
M  V30 81 1 64 75
M  V30 82 1 3 75
M  V30 83 1 4 76 CFG=1
M  V30 84 1 77 67
M  V30 85 1 78 12
M  V30 86 1 79 14
M  V30 87 1 80 28
M  V30 88 1 81 40
M  V30 89 1 82 40
M  V30 90 1 83 64
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
368

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Quinupristin

>  <Synonyms>
N/A

>  <CAS>
120138-50-3

>  <Formula>
C53H67N9O10S

>  <MolWt>
1022

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
Quinupristin is a member of the macrolide-lincosamide-streptogramin class of antibiotics. Quinupristin blocks peptide bond synthesis to prevent the extension of polypeptide chains and promote the detachment of incomplete protein chains in the bacterial ribosomal subunits[1] [2].

>  <Reference>
"Gurk-Turner C. Quinupristin/dalfopristin: the first available macrolide-lincosamide-streptogramin antibiotic. Proc (Bayl Univ Med Cent). 2000 Jan;13(1):83-6.;Tantibhedhyangkul W, et al. Anti-Mycoplasma Activity of Daptomycin and Its Use for Mycoplasma Elimination in Cell Cultures of Rickettsiae. Antibiotics (Basel). 2019 Aug 21;8(3)."

>  <ID<1>>
T12607

$$$$
StarDrop ID 369
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 42 46 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.4289 -8.2500 0.0000 0
M  V30 2 C -2.1434 -7.8375 0.0000 0
M  V30 3 C -1.7309 -7.1230 0.0000 0
M  V30 4 O -2.5559 -8.5520 0.0000 0
M  V30 5 C -2.8579 -7.4250 0.0000 0
M  V30 6 C -3.5724 -7.8375 0.0000 0
M  V30 7 C -4.2868 -7.4250 0.0000 0
M  V30 8 C -4.2868 -6.6000 0.0000 0
M  V30 9 C -3.5724 -6.1875 0.0000 0
M  V30 10 C -2.8579 -6.6000 0.0000 0
M  V30 11 C -2.1434 -6.1875 0.0000 0
M  V30 12 C -2.1434 -5.3625 0.0000 0
M  V30 13 C -1.4289 -4.9500 0.0000 0 CFG=1
M  V30 14 S -0.7145 -5.3625 0.0000 0
M  V30 15 C 0.0000 -4.9500 0.0000 0
M  V30 16 C 0.7145 -5.3625 0.0000 0
M  V30 17 C 0.4323 -6.1377 0.0000 0
M  V30 18 C 0.9626 -6.7697 0.0000 0
M  V30 19 O 1.7751 -6.6265 0.0000 0
M  V30 20 O 0.6804 -7.5450 0.0000 0
M  V30 21 C 1.2448 -4.7305 0.0000 0
M  V30 22 C 1.5269 -5.5058 0.0000 0
M  V30 23 C -1.4289 -4.1250 0.0000 0
M  V30 24 C -2.1434 -3.7125 0.0000 0
M  V30 25 C -2.1434 -2.8875 0.0000 0
M  V30 26 C -1.4289 -2.4750 0.0000 0
M  V30 27 C -0.7145 -2.8875 0.0000 0
M  V30 28 C 0.0000 -2.4750 0.0000 0
M  V30 29 C 0.0000 -1.6500 0.0000 0
M  V30 30 C 0.7145 -1.2375 0.0000 0
M  V30 31 C 0.7145 -0.4125 0.0000 0
M  V30 32 C 1.4289 0.0000 0.0000 0
M  V30 33 C 2.1434 -0.4125 0.0000 0
M  V30 34 C 2.8579 0.0000 0.0000 0
M  V30 35 C 3.5724 -0.4125 0.0000 0
M  V30 36 C 3.5724 -1.2375 0.0000 0
M  V30 37 Cl 4.2868 -1.6500 0.0000 0
M  V30 38 C 2.8579 -1.6500 0.0000 0
M  V30 39 C 2.1434 -1.2375 0.0000 0
M  V30 40 N 1.4289 -1.6500 0.0000 0
M  V30 41 C -0.7145 -3.7125 0.0000 0
M  V30 42 H -1.4290 -5.9500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 5 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 13 12
M  V30 14 1 13 14 CFG=3
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 18 20
M  V30 21 1 16 21
M  V30 22 1 21 22
M  V30 23 1 16 22
M  V30 24 1 13 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 31 32
M  V30 34 2 32 33
M  V30 35 1 33 34
M  V30 36 2 34 35
M  V30 37 1 35 36
M  V30 38 1 36 37
M  V30 39 2 36 38
M  V30 40 1 38 39
M  V30 41 1 33 39
M  V30 42 2 39 40
M  V30 43 1 30 40
M  V30 44 2 27 41
M  V30 45 1 23 41
M  V30 46 1 42 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
369

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Montelukast

>  <Synonyms>
Singular

>  <CAS>
158966-92-8

>  <Formula>
C35H36ClNO3S

>  <MolWt>
586.2

>  <Pathways>
GPCR/G Protein;Metabolism;Immunology/Inflammation

>  <Target>
Lipoxygenase;Leukotriene Receptor;LTR

>  <Receptor>
ALOX5; CysLTR1; Leukotriene Receptor

>  <Bioactivity>
Montelukast is an orally available leukotriene receptor antagonist which is widely used for the prophylaxis and chronic treatment of asthma and has been linked to rare cases of clinically apparent liver injury.

>  <Reference>
"Zhang YJ, et al. Acta Pharmacol Sin. 2004 Oct;25(10):1341-6."

>  <ID<1>>
T1677

$$$$
StarDrop ID 370
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 76 81 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 -0.5233 0.0000 0
M  V30 2 O 2.6393 0.2520 0.0000 0
M  V30 3 C 3.4518 0.3952 0.0000 0
M  V30 4 C 3.7339 1.1705 0.0000 0
M  V30 5 C 4.5464 1.3138 0.0000 0
M  V30 6 C 4.8286 2.0890 0.0000 0
M  V30 7 C 5.6410 2.2323 0.0000 0
M  V30 8 N 6.1713 1.6003 0.0000 0 CHG=1
M  V30 9 C 6.7016 2.2323 0.0000 0
M  V30 10 C 6.8858 1.1878 0.0000 0
M  V30 11 C 7.6003 1.6003 0.0000 0
M  V30 12 C 8.3148 1.1878 0.0000 0
M  V30 13 O 9.0292 1.6003 0.0000 0
M  V30 14 C 9.7437 1.1878 0.0000 0
M  V30 15 O 9.7437 0.3628 0.0000 0
M  V30 16 C 10.4582 1.6003 0.0000 0
M  V30 17 C 11.1726 1.1878 0.0000 0
M  V30 18 C 11.8871 1.6003 0.0000 0
M  V30 19 C 12.6016 1.1878 0.0000 0
M  V30 20 C 13.3161 1.6003 0.0000 0
M  V30 21 C 14.0305 1.1878 0.0000 0
M  V30 22 C 14.7450 1.6003 0.0000 0
M  V30 23 O 14.7450 2.4253 0.0000 0
M  V30 24 O 15.4595 1.1878 0.0000 0
M  V30 25 C 16.1739 1.6003 0.0000 0
M  V30 26 C 16.8884 1.1878 0.0000 0
M  V30 27 C 17.6029 1.6003 0.0000 0
M  V30 28 N 18.3173 1.1878 0.0000 0 CHG=1
M  V30 29 C 17.7870 0.5558 0.0000 0
M  V30 30 C 18.5995 1.9630 0.0000 0
M  V30 31 C 19.4120 2.1063 0.0000 0
M  V30 32 C 19.9423 1.4743 0.0000 0
M  V30 33 C 20.7547 1.6176 0.0000 0
M  V30 34 C 21.2850 0.9856 0.0000 0
M  V30 35 O 22.0975 1.1288 0.0000 0
M  V30 36 C 22.3797 1.9041 0.0000 0
M  V30 37 C 21.0029 0.2103 0.0000 0
M  V30 38 O 21.5332 -0.4217 0.0000 0
M  V30 39 C 22.3456 -0.2784 0.0000 0
M  V30 40 C 20.1904 0.0671 0.0000 0
M  V30 41 C 19.6601 0.6990 0.0000 0
M  V30 42 C 18.8476 0.5558 0.0000 0 CFG=1
M  V30 43 C 18.5655 -0.2195 0.0000 0
M  V30 44 C 19.0958 -0.8514 0.0000 0
M  V30 45 C 19.9082 -0.7082 0.0000 0
M  V30 46 C 20.4385 -1.3402 0.0000 0
M  V30 47 O 21.2510 -1.1969 0.0000 0
M  V30 48 C 21.7813 -1.8289 0.0000 0
M  V30 49 C 20.1564 -2.1154 0.0000 0
M  V30 50 O 20.6867 -2.7474 0.0000 0
M  V30 51 C 20.4045 -3.5227 0.0000 0
M  V30 52 C 19.3439 -2.2587 0.0000 0
M  V30 53 O 19.0617 -3.0339 0.0000 0
M  V30 54 C 18.2493 -3.1772 0.0000 0
M  V30 55 C 18.8136 -1.6267 0.0000 0
M  V30 56 C 5.8892 0.8250 0.0000 0 CFG=2
M  V30 57 C 6.4195 0.1930 0.0000 0
M  V30 58 C 6.1373 -0.5822 0.0000 0
M  V30 59 C 6.6676 -1.2142 0.0000 0
M  V30 60 C 6.3854 -1.9894 0.0000 0
M  V30 61 O 6.9157 -2.6214 0.0000 0
M  V30 62 C 6.6336 -3.3967 0.0000 0
M  V30 63 C 5.5730 -2.1327 0.0000 0
M  V30 64 O 5.2908 -2.9079 0.0000 0
M  V30 65 C 4.4783 -3.0512 0.0000 0
M  V30 66 C 5.0427 -1.5007 0.0000 0
M  V30 67 O 4.2302 -1.6440 0.0000 0
M  V30 68 C 3.9480 -2.4192 0.0000 0
M  V30 69 C 5.3248 -0.7255 0.0000 0
M  V30 70 C 5.0767 0.6818 0.0000 0
M  V30 71 C 4.7945 -0.0935 0.0000 0
M  V30 72 C 3.9821 -0.2367 0.0000 0
M  V30 73 O 3.6999 -1.0120 0.0000 0
M  V30 74 C 2.8874 -1.1552 0.0000 0
M  V30 75 H 19.4904 -0.2102 0.0000 0
M  V30 76 H 5.5471 -0.1147 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 1 27 28
M  V30 28 1 28 29
M  V30 29 1 28 30
M  V30 30 1 30 31
M  V30 31 1 31 32
M  V30 32 2 32 33
M  V30 33 1 33 34
M  V30 34 1 34 35
M  V30 35 1 35 36
M  V30 36 2 34 37
M  V30 37 1 37 38
M  V30 38 1 38 39
M  V30 39 1 37 40
M  V30 40 2 40 41
M  V30 41 1 32 41
M  V30 42 1 42 41
M  V30 43 1 42 28
M  V30 44 1 42 43 CFG=1
M  V30 45 1 43 44
M  V30 46 2 44 45
M  V30 47 1 45 46
M  V30 48 1 46 47
M  V30 49 1 47 48
M  V30 50 2 46 49
M  V30 51 1 49 50
M  V30 52 1 50 51
M  V30 53 1 49 52
M  V30 54 1 52 53
M  V30 55 1 53 54
M  V30 56 2 52 55
M  V30 57 1 44 55
M  V30 58 1 56 8
M  V30 59 1 56 57 CFG=3
M  V30 60 1 57 58
M  V30 61 2 58 59
M  V30 62 1 59 60
M  V30 63 1 60 61
M  V30 64 1 61 62
M  V30 65 2 60 63
M  V30 66 1 63 64
M  V30 67 1 64 65
M  V30 68 1 63 66
M  V30 69 1 66 67
M  V30 70 1 67 68
M  V30 71 2 66 69
M  V30 72 1 58 69
M  V30 73 1 56 70
M  V30 74 2 5 70
M  V30 75 1 70 71
M  V30 76 2 71 72
M  V30 77 1 3 72
M  V30 78 1 72 73
M  V30 79 1 73 74
M  V30 80 1 75 42
M  V30 81 1 76 56
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
370

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Mivacurium dichloride

>  <Synonyms>
Mivacurium chloride

>  <CAS>
106861-44-3

>  <Formula>
C58H80ClN2O14

>  <MolWt>
1065

>  <Pathways>
Neuroscience

>  <Target>
AChR

>  <Receptor>
nAChR

>  <Bioactivity>
"Mivacurium chloride is a non-depolarising, rapid neuromuscular blocker of short duration, used therefore as anesthetic, to provide skeletal muscle relaxation in minor surgical operations, in emergency surgical procedures of short to intermediate duration and during intubation of the trachea."

>  <Reference>
"Delu Che, et al. Mivacurium Induce Mast Cell Activation and Pseudo-Allergic Reactions via MAS-related G Protein Coupled receptor-X2. Cell Immunol. 2018 Oct;332:121-128.;J E Caldwell. New Skeletal Muscle Relaxants. Int Anesthesiol Clin. Winter 1995;33(1):39-60."

>  <ID<1>>
T22371

$$$$
StarDrop ID 371
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -0.6955 3.4867 0.0000 0
M  V30 2 C -0.1435 2.8736 0.0000 0
M  V30 3 C -0.3984 2.0890 0.0000 0 CFG=1
M  V30 4 O 0.0865 1.4216 0.0000 0
M  V30 5 C -0.3984 0.7541 0.0000 0 CFG=2
M  V30 6 C -1.1831 1.0091 0.0000 0
M  V30 7 C -1.1831 1.8341 0.0000 0 CFG=2
M  V30 8 O -1.8505 2.3190 0.0000 0
M  V30 9 N -0.1435 -0.0305 0.0000 0
M  V30 10 C -0.6284 -0.6979 0.0000 0
M  V30 11 N -0.1435 -1.3654 0.0000 0
M  V30 12 C 0.6411 -1.1104 0.0000 0
M  V30 13 C 0.6411 -0.2854 0.0000 0
M  V30 14 N 1.3556 0.1271 0.0000 0
M  V30 15 C 2.0701 -0.2854 0.0000 0
M  V30 16 N 2.0701 -1.1104 0.0000 0
M  V30 17 C 1.3556 -1.5229 0.0000 0
M  V30 18 O 1.3556 -2.3479 0.0000 0
M  V30 19 H 0.5893 2.2455 0.0000 0
M  V30 20 H 0.5893 0.5978 0.0000 0
M  V30 21 H -2.0741 1.3801 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 2 CFG=1
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 3 7
M  V30 8 1 7 8 CFG=3
M  V30 9 1 5 9 CFG=1
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 9 13
M  V30 15 2 13 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 1 12 17
M  V30 20 2 17 18
M  V30 21 1 19 3
M  V30 22 1 20 5
M  V30 23 1 21 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
371

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
2'-Deoxyinosine

>  <Synonyms>
Deoxyinosine;Guanine deoxyriboside

>  <CAS>
890-38-0

>  <Formula>
C10H12N4O4

>  <MolWt>
252.2

>  <Pathways>
Others;Metabolism

>  <Target>
Others;Endogenous Metabolite

>  <Receptor>
Endogenous Metabolite

>  <Bioactivity>
2??-deoxyadenosine inhibits the growth of human colon-carcinoma cell lines and is associated with purine nucleoside phosphorylase (PNP) deficiency.

>  <Reference>
"Baumann T, et al. BMC Biotechnol. 2013 Oct 4;13:81."

>  <ID<1>>
T1709

$$$$
StarDrop ID 372
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.0000 -1.6500 0.0000 0
M  V30 2 N 0.7145 -1.2375 0.0000 0
M  V30 3 C 0.7145 -0.4125 0.0000 0
M  V30 4 C 0.0000 0.0000 0.0000 0
M  V30 5 Cl 0.0000 0.8250 0.0000 0
M  V30 6 N 1.4289 0.0000 0.0000 0
M  V30 7 C 2.1434 -0.4125 0.0000 0
M  V30 8 C 2.8579 0.0000 0.0000 0
M  V30 9 C 3.5724 -0.4125 0.0000 0
M  V30 10 Cl 4.2868 -0.0000 0.0000 0
M  V30 11 C 3.5724 -1.2375 0.0000 0
M  V30 12 C 2.8579 -1.6500 0.0000 0
M  V30 13 C 2.1434 -1.2375 0.0000 0
M  V30 14 S 1.4289 -1.6500 0.0000 0
M  V30 15 O 1.8163 -2.3784 0.0000 0
M  V30 16 O 1.0416 -2.3784 0.0000 0
M  V30 17 S 4.2868 -1.6500 0.0000 0
M  V30 18 N 5.0013 -2.0625 0.0000 0
M  V30 19 O 3.8743 -2.3645 0.0000 0
M  V30 20 O 4.6993 -0.9355 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 7 13
M  V30 14 1 13 14
M  V30 15 1 2 14
M  V30 16 2 14 15
M  V30 17 2 14 16
M  V30 18 1 11 17
M  V30 19 1 17 18
M  V30 20 2 17 19
M  V30 21 2 17 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
372

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Methyclothiazide

>  <Synonyms>
Aquatensen;Enduron;Duretic

>  <CAS>
135-07-9

>  <Formula>
C9H11Cl2N3O4S2

>  <MolWt>
360.2

>  <Pathways>
Others;Metabolism

>  <Target>
Others;Carbonic Anhydrase

>  <Receptor>
Carbonic Anhydrase

>  <Bioactivity>
"Methyclothiazide is a substituted benzothiadiazide, used to treat high blood pressure and fluid retention caused by various conditions including heart disease."

>  <Reference>
"Sasaki S, et al. J Cardiovasc Pharmacol, 1983, 5(3), 378-383.;Desaulles E, et al. Br J Pharmacol, 1979, 65(2), 193-196.;Colas B, et al. Fundam Clin Pharmacol, 2000, 14(4), 363-368.;Sasaki S, et al. Jpn Circ J, 1984, 48(11), 1251-1259.;Colas B, et al. Eur J Pharmacol, 2000, 408(1), 63-67."

>  <ID<1>>
T6581

$$$$
StarDrop ID 373
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -4.2868 -5.7750 0.0000 0
M  V30 2 C -3.5724 -5.3625 0.0000 0
M  V30 3 O -3.5724 -4.5375 0.0000 0
M  V30 4 C -2.8579 -5.7750 0.0000 0
M  V30 5 O -2.1434 -5.3625 0.0000 0
M  V30 6 C -1.4289 -5.7750 0.0000 0
M  V30 7 C -0.7145 -5.3625 0.0000 0
M  V30 8 N 0.0000 -5.7750 0.0000 0
M  V30 9 C 0.7145 -5.3625 0.0000 0
M  V30 10 C 1.4289 -5.7750 0.0000 0
M  V30 11 N 1.4289 -6.6000 0.0000 0
M  V30 12 C 0.7145 -7.0125 0.0000 0
M  V30 13 C 0.0000 -6.6000 0.0000 0
M  V30 14 C 2.1434 -7.0125 0.0000 0 CFG=2
M  V30 15 C 2.1434 -7.8375 0.0000 0
M  V30 16 C 2.8579 -8.2500 0.0000 0
M  V30 17 C 2.8579 -9.0750 0.0000 0
M  V30 18 C 2.1434 -9.4875 0.0000 0
M  V30 19 C 1.4289 -9.0750 0.0000 0
M  V30 20 C 1.4289 -8.2500 0.0000 0
M  V30 21 C 2.8579 -6.6000 0.0000 0
M  V30 22 C 2.8579 -5.7750 0.0000 0
M  V30 23 C 3.5724 -5.3625 0.0000 0
M  V30 24 C 4.2868 -5.7750 0.0000 0
M  V30 25 Cl 5.0013 -5.3625 0.0000 0
M  V30 26 C 4.2868 -6.6000 0.0000 0
M  V30 27 C 3.5724 -7.0125 0.0000 0
M  V30 28 H 1.2774 -7.5125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 8 13
M  V30 14 1 14 11 CFG=1
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 15 20
M  V30 22 1 14 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 1 24 26
M  V30 28 2 26 27
M  V30 29 1 21 27
M  V30 30 1 28 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
373

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Levocetirizine

>  <Synonyms>
Levocetirizine HCl

>  <CAS>
130018-77-8

>  <Formula>
C21H25ClN2O3

>  <MolWt>
388.9

>  <Pathways>
Neuroscience;GPCR/G Protein;Immunology/Inflammation

>  <Target>
Histamine Receptor

>  <Receptor>
H1 receptor; Histamine Receptor

>  <Bioactivity>
Levocetirizine is a Histamine-1 Receptor Antagonist. The mechanism of action of levocetirizine is as a Histamine H1 Receptor Antagonist.

>  <Reference>
"Pasquali M, et al. Clin Exp Allergy. 2006 Sep;36(9):1161-7."

>  <ID<1>>
T1469

$$$$
StarDrop ID 374
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl -3.4060 -3.7923 0.0000 0
M  V30 2 C -2.5990 -3.6207 0.0000 0
M  V30 3 C -2.0470 -4.2338 0.0000 0
M  V30 4 C -1.2400 -4.0623 0.0000 0
M  V30 5 C -0.9851 -3.2777 0.0000 0
M  V30 6 C -0.1781 -3.1062 0.0000 0
M  V30 7 C 0.3739 -3.7192 0.0000 0
M  V30 8 N 0.1190 -4.5039 0.0000 0
M  V30 9 C 0.6039 -5.1713 0.0000 0
M  V30 10 C 0.1190 -5.8387 0.0000 0
M  V30 11 N -0.6657 -5.5838 0.0000 0
M  V30 12 C -0.6657 -4.7588 0.0000 0
M  V30 13 O 0.0768 -2.3215 0.0000 0
M  V30 14 C 0.8838 -2.1500 0.0000 0
M  V30 15 C 1.1387 -1.3654 0.0000 0
M  V30 16 C 0.6538 -0.6979 0.0000 0
M  V30 17 S 1.1387 -0.0305 0.0000 0
M  V30 18 C 1.9233 -0.2854 0.0000 0
M  V30 19 C 2.6378 0.1271 0.0000 0
M  V30 20 Cl 2.6378 0.9521 0.0000 0
M  V30 21 C 3.3523 -0.2854 0.0000 0
M  V30 22 C 3.3523 -1.1104 0.0000 0
M  V30 23 C 2.6378 -1.5229 0.0000 0
M  V30 24 C 1.9233 -1.1104 0.0000 0
M  V30 25 C -1.5371 -2.6646 0.0000 0
M  V30 26 Cl -1.2822 -1.8800 0.0000 0
M  V30 27 C -2.3441 -2.8361 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 8 12
M  V30 13 1 6 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 15 24
M  V30 26 1 18 24
M  V30 27 1 5 25
M  V30 28 1 25 26
M  V30 29 2 25 27
M  V30 30 1 2 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
374

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Sertaconazole

>  <Synonyms>
N/A

>  <CAS>
99592-32-2

>  <Formula>
C20H15Cl3N2OS

>  <MolWt>
437.8

>  <Pathways>
Microbiology/Virology

>  <Target>
Antifungal

>  <Receptor>
Antifungal

>  <Bioactivity>
Sertaconazole is a broad-spectrum antifungal.

>  <Reference>
"Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69(3):339-59.;Carrillo-Mu?oz AJ, et al. Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis. Expert Rev Anti Infect Ther. 2013 Apr;11(4):347-58."

>  <ID<1>>
T50005

$$$$
StarDrop ID 375
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 2.3571 1.0977 0.0000 0
M  V30 2 C 3.1540 1.3112 0.0000 0 CFG=1
M  V30 3 C 3.7374 0.7279 0.0000 0
M  V30 4 O 4.5343 0.9414 0.0000 0
M  V30 5 N 3.5239 -0.0690 0.0000 0
M  V30 6 C 4.1072 -0.6524 0.0000 0 CFG=1
M  V30 7 C 4.9322 -0.6524 0.0000 0 CFG=1
M  V30 8 S 5.6467 -0.2399 0.0000 0
M  V30 9 C 6.3612 -0.6524 0.0000 0
M  V30 10 C 6.3612 -1.4774 0.0000 0
M  V30 11 Cl 7.0756 -1.8899 0.0000 0
M  V30 12 C 5.6467 -1.8899 0.0000 0
M  V30 13 N 4.9322 -1.4774 0.0000 0
M  V30 14 C 4.1072 -1.4774 0.0000 0
M  V30 15 O 3.5239 -2.0607 0.0000 0
M  V30 16 C 5.6467 -2.7149 0.0000 0
M  V30 17 O 4.9322 -3.1274 0.0000 0
M  V30 18 O 6.3612 -3.1274 0.0000 0
M  V30 19 C 3.3676 2.1081 0.0000 0
M  V30 20 C 2.7842 2.6915 0.0000 0
M  V30 21 C 2.9977 3.4884 0.0000 0
M  V30 22 C 3.7946 3.7019 0.0000 0
M  V30 23 C 4.3780 3.1185 0.0000 0
M  V30 24 C 4.1644 2.3217 0.0000 0
M  V30 25 H 2.8952 0.3453 0.0000 0
M  V30 26 H 4.4899 0.2715 0.0000 0
M  V30 27 H 4.2251 -1.3595 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 6 5 CFG=1
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 10 12
M  V30 12 1 12 13
M  V30 13 1 7 13 CFG=1
M  V30 14 1 13 14
M  V30 15 1 6 14
M  V30 16 2 14 15
M  V30 17 1 12 16
M  V30 18 1 16 17
M  V30 19 2 16 18
M  V30 20 1 2 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 19 24
M  V30 27 1 25 2
M  V30 28 1 26 6
M  V30 29 1 27 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
375

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cefaclor monohydrate

>  <Synonyms>
Cefaclor;Cefaclorum;Cefachlor

>  <CAS>
70356-03-5

>  <Formula>
C15H16ClN3O5S

>  <MolWt>
385.8

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial; PBPs

>  <Bioactivity>
"Cefaclor monohydrate is a beta-lactam, second-generation cephalosporin antibiotic with bactericidal activity."

>  <Reference>
"Chambers HF, Miick C. Antimicrob Agents ChemOthers. 1992 Mar;36(3):656-61."

>  <ID<1>>
T1495

$$$$
StarDrop ID 376
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3747 3.6320 0.0000 0
M  V30 2 N 2.3747 2.8070 0.0000 0
M  V30 3 C 1.6603 2.3945 0.0000 0
M  V30 4 C 3.0892 2.3945 0.0000 0
M  V30 5 C 3.0892 1.5695 0.0000 0
M  V30 6 C 3.8037 1.1570 0.0000 0
M  V30 7 C 3.8037 0.3320 0.0000 0
M  V30 8 C 4.5470 -0.0260 0.0000 0
M  V30 9 C 4.7305 -0.8303 0.0000 0
M  V30 10 C 4.2162 -1.4753 0.0000 0
M  V30 11 C 3.3912 -1.4753 0.0000 0
M  V30 12 C 5.5189 -1.0735 0.0000 0
M  V30 13 C 6.1237 -0.5123 0.0000 0
M  V30 14 C 5.9401 0.2920 0.0000 0
M  V30 15 C 5.1517 0.5352 0.0000 0
M  V30 16 C 3.0604 -0.0260 0.0000 0
M  V30 17 C 2.8768 -0.8303 0.0000 0
M  V30 18 C 2.0884 -1.0735 0.0000 0
M  V30 19 C 1.4837 -0.5123 0.0000 0
M  V30 20 C 1.6673 0.2920 0.0000 0
M  V30 21 C 2.4556 0.5352 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 9 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 8 15
M  V30 16 1 7 16
M  V30 17 2 16 17
M  V30 18 1 11 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
376

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Amitriptyline

>  <Synonyms>
N/A

>  <CAS>
50-48-6

>  <Formula>
C20H23N

>  <MolWt>
277.4

>  <Pathways>
GPCR/G Protein;Immunology/Inflammation;Neuroscience

>  <Target>
5-HT Receptor;Norepinephrine;Histamine Receptor;Sigma receptor

>  <Receptor>
" 5-HT2:235 nM (ki), histamine receptor H1:0.5 nM (ki), SERT:3.45 nM (ki), sigma 1 receptor:287 nM (ki), histamine receptor H4:7.31 nM (ki), NET:13.3 nM (ki)"

>  <Bioactivity>
"Amitriptyline (MK-230, N-750, Ro41575) is a tricyclic antidepressant (TCA) with analgesic properties. Amitriptyline is widely used to treat depression and neuropathic pain."

>  <Reference>
"Juliano R L ,  Daoud S S . Liposomes as a delivery system for membrane-active antitumor drugs[J]. Journal of Controlled Release, 1990, 11(1-3):225-232."

>  <ID<1>>
T22240

$$$$
StarDrop ID 377
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 89 97 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 9.4481 2.5452 0.0000 0
M  V30 2 C 8.6360 2.4000 0.0000 0 CFG=1
M  V30 3 O 8.3557 1.6241 0.0000 0
M  V30 4 C 7.5435 1.4789 0.0000 0 CFG=2
M  V30 5 C 7.0117 2.1096 0.0000 0
M  V30 6 C 7.2920 2.8855 0.0000 0 CFG=2
M  V30 7 O 6.7602 3.5162 0.0000 0
M  V30 8 C 8.1041 3.0307 0.0000 0 CFG=2
M  V30 9 O 8.3844 3.8066 0.0000 0
M  V30 10 C 7.8526 4.4373 0.0000 0 CFG=1
M  V30 11 C 7.0405 4.2921 0.0000 0
M  V30 12 C 6.5087 4.9228 0.0000 0 CFG=2
M  V30 13 O 5.6966 4.7776 0.0000 0
M  V30 14 C 6.7890 5.6987 0.0000 0 CFG=2
M  V30 15 O 6.2572 6.3295 0.0000 0
M  V30 16 C 6.5375 7.1054 0.0000 0 CFG=1
M  V30 17 C 6.0056 7.7361 0.0000 0
M  V30 18 C 6.2859 8.5120 0.0000 0 CFG=2
M  V30 19 O 5.7541 9.1427 0.0000 0
M  V30 20 C 7.0981 8.6572 0.0000 0 CFG=2
M  V30 21 O 7.3784 9.4332 0.0000 0
M  V30 22 C 8.1905 9.5784 0.0000 0 CFG=2
M  V30 23 O 8.7223 8.9477 0.0000 0
M  V30 24 C 9.5344 9.0929 0.0000 0 CFG=2
M  V30 25 C 10.0662 8.4622 0.0000 0
M  V30 26 O 9.7859 7.6862 0.0000 0
M  V30 27 C 9.8147 9.8688 0.0000 0 CFG=1
M  V30 28 O 10.6268 10.0140 0.0000 0
M  V30 29 C 9.2829 10.4995 0.0000 0 CFG=2
M  V30 30 O 9.5632 11.2754 0.0000 0
M  V30 31 C 8.4708 10.3543 0.0000 0 CFG=1
M  V30 32 O 7.9390 10.9850 0.0000 0
M  V30 33 C 7.6299 8.0265 0.0000 0 CFG=1
M  V30 34 C 8.4420 8.1717 0.0000 0
M  V30 35 O 7.3496 7.2506 0.0000 0
M  V30 36 C 7.6011 5.8440 0.0000 0 CFG=1
M  V30 37 C 7.8814 6.6199 0.0000 0
M  V30 38 O 8.1329 5.2133 0.0000 0
M  V30 39 O 7.2632 0.7029 0.0000 0
M  V30 40 C 6.4511 0.5577 0.0000 0 CFG=1
M  V30 41 C 6.1708 -0.2182 0.0000 0
M  V30 42 C 5.3587 -0.3634 0.0000 0
M  V30 43 C 4.8269 0.2673 0.0000 0 CFG=1
M  V30 44 C 4.5466 -0.5086 0.0000 0
M  V30 45 C 5.1072 1.0432 0.0000 0 CFG=2
M  V30 46 C 4.5754 1.6739 0.0000 0
M  V30 47 C 3.7633 1.5287 0.0000 0
M  V30 48 C 3.4830 0.7528 0.0000 0 CFG=2
M  V30 49 C 4.0148 0.1221 0.0000 0 CFG=2
M  V30 50 C 3.7345 -0.6539 0.0000 0
M  V30 51 C 2.9224 -0.7991 0.0000 0 CFG=1
M  V30 52 O 2.6421 -1.5750 0.0000 0
M  V30 53 C 2.3905 -0.1684 0.0000 0 CFG=2
M  V30 54 C 2.0307 -0.9107 0.0000 0
M  V30 55 C 1.5660 -0.1416 0.0000 0 CFG=2
M  V30 56 C 1.3367 0.6509 0.0000 0
M  V30 57 C 2.0195 1.1139 0.0000 0
M  V30 58 C 2.6708 0.6076 0.0000 0 CFG=2
M  V30 59 O 2.8685 1.4085 0.0000 0
M  V30 60 C 1.0596 -0.7929 0.0000 0
M  V30 61 C 1.2889 -1.5854 0.0000 0
M  V30 62 C 0.6061 -2.0484 0.0000 0
M  V30 63 O 0.5793 -2.8729 0.0000 0
M  V30 64 O -0.0452 -1.5420 0.0000 0
M  V30 65 C 0.2351 -0.7661 0.0000 0
M  V30 66 C 5.9193 1.1884 0.0000 0
M  V30 67 H 8.2745 7.2620 0.0000 0
M  V30 68 H 8.5855 6.0200 0.0000 0
M  V30 69 H 7.0957 -0.2068 0.0000 0
M  V30 70 H 4.1228 0.8672 0.0000 0
M  V30 71 H 4.4674 0.9288 0.0000 0
M  V30 72 H 4.6594 -0.6425 0.0000 0
M  V30 73 H 3.5670 -1.5636 0.0000 0
M  V30 74 H 1.9907 -1.0469 0.0000 0
M  V30 75 H 9.2806 1.6355 0.0000 0
M  V30 76 H 6.5591 1.3028 0.0000 0
M  V30 77 H 6.3076 2.7095 0.0000 0
M  V30 78 H 7.4595 3.7952 0.0000 0
M  V30 79 H 7.5128 3.4968 0.0000 0
M  V30 80 H 5.8641 5.6873 0.0000 0
M  V30 81 H 7.1287 6.6392 0.0000 0
M  V30 82 H 7.1821 6.3409 0.0000 0
M  V30 83 H 5.3015 8.3360 0.0000 0
M  V30 84 H 8.0825 8.8333 0.0000 0
M  V30 85 H 7.5459 10.3429 0.0000 0
M  V30 86 H 10.5188 9.2689 0.0000 0
M  V30 87 H 10.4593 9.1043 0.0000 0
M  V30 88 H 8.6383 11.2640 0.0000 0
M  V30 89 H 7.4864 10.1783 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 8 6
M  V30 8 1 8 2
M  V30 9 1 8 9 CFG=3
M  V30 10 1 10 9 CFG=1
M  V30 11 1 10 11
M  V30 12 1 12 11
M  V30 13 1 12 13 CFG=3
M  V30 14 1 14 12
M  V30 15 1 14 15 CFG=3
M  V30 16 1 16 15 CFG=1
M  V30 17 1 16 17
M  V30 18 1 18 17
M  V30 19 1 18 19 CFG=3
M  V30 20 1 20 18
M  V30 21 1 20 21 CFG=3
M  V30 22 1 22 21 CFG=1
M  V30 23 1 22 23
M  V30 24 1 24 23
M  V30 25 1 24 25 CFG=1
M  V30 26 1 25 26
M  V30 27 1 27 24
M  V30 28 1 27 28 CFG=3
M  V30 29 1 27 29
M  V30 30 1 29 30 CFG=1
M  V30 31 1 29 31
M  V30 32 1 31 22
M  V30 33 1 31 32 CFG=3
M  V30 34 1 20 33
M  V30 35 1 33 34 CFG=1
M  V30 36 1 33 35
M  V30 37 1 16 35
M  V30 38 1 14 36
M  V30 39 1 36 37 CFG=1
M  V30 40 1 36 38
M  V30 41 1 10 38
M  V30 42 1 4 39 CFG=1
M  V30 43 1 40 39 CFG=1
M  V30 44 1 40 41
M  V30 45 1 41 42
M  V30 46 1 43 42
M  V30 47 1 43 44 CFG=1
M  V30 48 1 43 45
M  V30 49 1 45 46 CFG=3
M  V30 50 1 46 47
M  V30 51 1 48 47 CFG=3
M  V30 52 1 48 49
M  V30 53 1 49 43
M  V30 54 1 49 50 CFG=1
M  V30 55 1 51 50
M  V30 56 1 51 52 CFG=1
M  V30 57 1 53 51
M  V30 58 1 53 54 CFG=1
M  V30 59 1 53 55
M  V30 60 1 55 56
M  V30 61 1 56 57
M  V30 62 1 58 57
M  V30 63 1 58 48
M  V30 64 1 53 58
M  V30 65 1 58 59 CFG=1
M  V30 66 1 55 60 CFG=1
M  V30 67 2 60 61
M  V30 68 1 61 62
M  V30 69 2 62 63
M  V30 70 1 62 64
M  V30 71 1 64 65
M  V30 72 1 60 65
M  V30 73 1 45 66
M  V30 74 1 40 66
M  V30 75 1 67 33
M  V30 76 1 68 36
M  V30 77 1 69 40
M  V30 78 1 70 45
M  V30 79 1 71 48
M  V30 80 1 72 49
M  V30 81 1 73 51
M  V30 82 1 74 55
M  V30 83 1 75 2
M  V30 84 1 76 4
M  V30 85 1 77 6
M  V30 86 1 78 8
M  V30 87 1 79 10
M  V30 88 1 80 12
M  V30 89 1 81 14
M  V30 90 1 82 16
M  V30 91 1 83 18
M  V30 92 1 84 20
M  V30 93 1 85 22
M  V30 94 1 86 24
M  V30 95 1 87 27
M  V30 96 1 88 29
M  V30 97 1 89 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
377

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Deslanoside

>  <Synonyms>
Desacetyllanatoside C;Deacetyllanatoside C

>  <CAS>
17598-65-1

>  <Formula>
C47H74O19

>  <MolWt>
943.1

>  <Pathways>
Membrane transporter/Ion channel;Metabolism

>  <Target>
Drug Metabolite;ATPase

>  <Receptor>
Drug Metabolite; Na+/K+ ATPase; Na+/K+-ATPase

>  <Bioactivity>
"Deslanoside is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations."

>  <Reference>
"Hauptman PJ, et al. Digitalis. Circulation. 1999 Mar 9;99(9):1265-70.;Wang L, et al. Ontology-based systematical representation and drug class effect analysis of package insert-reported adverse events associated with cardiovascular drugs used in China. Sci Rep. 2017 Oct 23;7(1):13819.;Klys M, et al. Determination of deslanoside in antemortem and postmortem specimens. Unusual case report. Forensic Sci Int. 1990 Apr;45(3):231-8."

>  <ID<1>>
T8183

$$$$
StarDrop ID 378
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.2288 -0.7293 0.0000 0
M  V30 2 C -0.8932 -1.4830 0.0000 0
M  V30 3 C -0.0862 -1.6545 0.0000 0
M  V30 4 C 0.0000 -2.4750 0.0000 0
M  V30 5 N -0.7537 -2.8106 0.0000 0
M  V30 6 O -1.3057 -2.1975 0.0000 0
M  V30 7 C 0.7145 -2.8875 0.0000 0
M  V30 8 O 0.7145 -3.7125 0.0000 0
M  V30 9 N 1.4289 -2.4750 0.0000 0
M  V30 10 N 2.1434 -2.8875 0.0000 0
M  V30 11 C 2.8579 -2.4750 0.0000 0
M  V30 12 C 3.5724 -2.8875 0.0000 0
M  V30 13 C 4.2868 -2.4750 0.0000 0
M  V30 14 C 5.0013 -2.8875 0.0000 0
M  V30 15 C 5.0013 -3.7125 0.0000 0
M  V30 16 C 4.2868 -4.1250 0.0000 0
M  V30 17 C 3.5724 -3.7125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 2 6
M  V30 7 1 4 7
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 12 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
378

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Isocarboxazid

>  <Synonyms>
N/A

>  <CAS>
59-63-2

>  <Formula>
C12H13N3O2

>  <MolWt>
231.3

>  <Pathways>
Neuroscience

>  <Target>
Monoamine Oxidase

>  <Receptor>
 rat brain monoamine oxidase:4.8 ??M

>  <Bioactivity>
"Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor.[2] It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders."

>  <Reference>
"Kettler R, Da Prada M, Burkard WP: Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats. Acta Psychiatr Scand Suppl. 1990;360:101-2.;Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.;Thase ME, Trivedi MH, Rush AJ: MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995 May;12(3):185-219."

>  <ID<1>>
T4559

$$$$
StarDrop ID 379
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 1.9878 -3.3762 0.0000 0
M  V30 2 C 1.1809 -3.5477 0.0000 0
M  V30 3 C 0.9259 -4.3323 0.0000 0
M  V30 4 C 0.1190 -4.5039 0.0000 0
M  V30 5 N -0.2935 -5.2183 0.0000 0
M  V30 6 N -1.1005 -5.0468 0.0000 0
M  V30 7 C -1.1867 -4.2263 0.0000 0
M  V30 8 C -0.4331 -3.8908 0.0000 0
M  V30 9 C -0.1781 -3.1062 0.0000 0
M  V30 10 C 0.6288 -2.9346 0.0000 0
M  V30 11 C 0.8838 -2.1500 0.0000 0
M  V30 12 F 0.0992 -1.8951 0.0000 0
M  V30 13 F 1.6684 -2.4049 0.0000 0
M  V30 14 C 1.1387 -1.3654 0.0000 0
M  V30 15 N 0.6538 -0.6979 0.0000 0
M  V30 16 N 1.1387 -0.0305 0.0000 0
M  V30 17 C 1.9233 -0.2854 0.0000 0
M  V30 18 C 2.6378 0.1271 0.0000 0
M  V30 19 C 3.3523 -0.2854 0.0000 0
M  V30 20 C 3.3523 -1.1104 0.0000 0
M  V30 21 N 2.6378 -1.5229 0.0000 0
M  V30 22 N 1.9233 -1.1104 0.0000 0
M  V30 23 C 4.0668 -1.5229 0.0000 0
M  V30 24 C 4.8204 -1.1874 0.0000 0
M  V30 25 N 5.3725 -1.8005 0.0000 0
M  V30 26 N 4.9600 -2.5150 0.0000 0
M  V30 27 C 4.1530 -2.3434 0.0000 0
M  V30 28 C 5.2955 -3.2686 0.0000 0
M  V30 29 C 5.9630 -3.7535 0.0000 0
M  V30 30 C 5.2093 -4.0891 0.0000 0
M  V30 31 C -1.7136 -5.5988 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 4 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 2 10
M  V30 12 1 10 11
M  V30 13 1 11 12
M  V30 14 1 11 13
M  V30 15 1 11 14
M  V30 16 2 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 1 17 22
M  V30 25 1 14 22
M  V30 26 1 20 23
M  V30 27 1 23 24
M  V30 28 2 24 25
M  V30 29 1 25 26
M  V30 30 1 26 27
M  V30 31 2 23 27
M  V30 32 1 26 28
M  V30 33 1 28 29
M  V30 34 1 29 30
M  V30 35 1 28 30
M  V30 36 1 6 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
379

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Bozitinib

>  <Synonyms>
CBT-101;PLB-1001

>  <CAS>
1440964-89-5

>  <Formula>
C20H15F3N8

>  <MolWt>
424.4

>  <Pathways>
Tyrosine Kinase/Adaptors

>  <Target>
c-Met/HGFR

>  <Receptor>
c-Met; c-Met/HGFR

>  <Bioactivity>
Bozitinib (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability. Bozitinib binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily.

>  <Reference>
"Hu H, et al. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell. 2018 Nov 29;175(6):1665-1678.e18."

>  <ID<1>>
T10585

$$$$
StarDrop ID 380
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -0.7145 1.2375 0.0000 0
M  V30 2 O 0.0000 0.8250 0.0000 0
M  V30 3 C 0.0000 -0.0000 0.0000 0
M  V30 4 C -0.7145 -0.4125 0.0000 0
M  V30 5 N -1.4289 -0.0000 0.0000 0
M  V30 6 C -2.1826 -0.3356 0.0000 0
M  V30 7 C -2.7346 0.2775 0.0000 0 CFG=1
M  V30 8 N -3.5596 0.2775 0.0000 0
M  V30 9 C -3.9721 0.9920 0.0000 0
M  V30 10 C -3.5596 1.7065 0.0000 0
M  V30 11 C -2.7346 1.7065 0.0000 0
M  V30 12 C -2.3221 0.9920 0.0000 0 CFG=1
M  V30 13 C -1.5152 0.8205 0.0000 0
M  V30 14 C -0.7145 -1.2375 0.0000 0
M  V30 15 C 0.0000 -1.6500 0.0000 0
M  V30 16 C 0.7145 -1.2375 0.0000 0
M  V30 17 F -1.4289 -1.6500 0.0000 0
M  V30 18 C 0.7145 -0.4125 0.0000 0
M  V30 19 N 1.4289 -0.0000 0.0000 0
M  V30 20 C 1.4289 0.8250 0.0000 0
M  V30 21 C 1.0164 1.5395 0.0000 0
M  V30 22 C 1.8414 1.5395 0.0000 0
M  V30 23 C 2.1434 -0.4125 0.0000 0
M  V30 24 C 2.1434 -1.2375 0.0000 0
M  V30 25 C 2.8579 -1.6500 0.0000 0
M  V30 26 O 3.5724 -1.2375 0.0000 0
M  V30 27 O 2.8579 -2.4750 0.0000 0
M  V30 28 C 1.4289 -1.6500 0.0000 0
M  V30 29 O 1.4289 -2.4750 0.0000 0
M  V30 30 H -1.7401 0.3821 0.0000 0
M  V30 31 H -1.9154 0.0784 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=1
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 12 11
M  V30 12 1 7 12
M  V30 13 1 12 13 CFG=1
M  V30 14 1 5 13
M  V30 15 1 4 14
M  V30 16 2 14 15
M  V30 17 1 15 16
M  V30 18 1 14 17
M  V30 19 1 3 18
M  V30 20 2 16 18
M  V30 21 1 18 19
M  V30 22 1 19 20
M  V30 23 1 20 21
M  V30 24 1 21 22
M  V30 25 1 20 22
M  V30 26 1 19 23
M  V30 27 2 23 24
M  V30 28 1 24 25
M  V30 29 1 25 26
M  V30 30 2 25 27
M  V30 31 1 24 28
M  V30 32 1 16 28
M  V30 33 2 28 29
M  V30 34 1 30 7
M  V30 35 1 31 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
380

>  <Plate>
PHD136329

>  <Row>
c

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Moxifloxacin

>  <Synonyms>
Moxeza;Avelox

>  <CAS>
151096-09-2

>  <Formula>
C21H24FN3O4

>  <MolWt>
401.4

>  <Pathways>
Microbiology/Virology;Others

>  <Target>
Others;Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
"Moxifloxacin is a fourth-generation fluoroquinolone that has been shown to be effective against Gram-positive, Gram-negative, and atypical strains, as well as multi-drug resistant Streptococcus pneumoniae."

>  <Reference>
"Miravitlles M ,  Anzueto A . Moxifloxacin: a respiratory fluoroquinolone[J]. Expert Opinion on Pharmacotherapy, 2015, 9(10):1755-72."

>  <ID<1>>
T0331L

$$$$
StarDrop ID 381
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Br 1.8857 1.7944 0.0000 0
M  V30 2 C 2.6002 1.3819 0.0000 0
M  V30 3 C 3.3147 1.7944 0.0000 0
M  V30 4 C 4.0291 1.3819 0.0000 0
M  V30 5 C 4.0291 0.5569 0.0000 0
M  V30 6 C 3.3147 0.1444 0.0000 0
M  V30 7 C 2.6002 0.5569 0.0000 0
M  V30 8 C 4.7436 0.1444 0.0000 0
M  V30 9 O 5.4581 0.5569 0.0000 0
M  V30 10 C 6.1725 0.1444 0.0000 0
M  V30 11 C 6.8870 0.5569 0.0000 0
M  V30 12 N 7.6015 0.1444 0.0000 0
M  V30 13 C 8.3160 0.5569 0.0000 0
M  V30 14 C 7.6015 -0.6806 0.0000 0
M  V30 15 C 4.7436 -0.6806 0.0000 0
M  V30 16 C 5.4581 -1.0931 0.0000 0
M  V30 17 C 5.4581 -1.9181 0.0000 0
M  V30 18 C 4.7436 -2.3306 0.0000 0
M  V30 19 C 4.0291 -1.9181 0.0000 0
M  V30 20 C 4.0291 -1.0931 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 1 8 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 15 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
381

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Bromodiphenhydramine hydrochloride

>  <Synonyms>
N/A

>  <CAS>
1808-12-4

>  <Formula>
C17H21BrClNO

>  <MolWt>
370.7

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Bromodiphenhydramine hydrochloride is a new antihistaminic in the control of cutaneous.

>  <Reference>
"Maclaren W R ,  Bruff W C ,  Eisenberg B C , et al. A clinical comparison of carbinoxamine maleate, tripelennamine hydrochloride, and bromodiphenhydramine hydrochloride in treating allergic symptoms.[J]. Ann Allergy, 1955, 13(13):307-312.;Attwood D, Udeala OK. Aggregation of antihistamines in aqueous solution. The effect of electrolyte on the miscellar properties of some diphenylmethane derivatives. J Pharm Pharmacol. 1975 Jun;27(6):395-9. PubMed PMID: 237086.;Ray S, Chattopadhyay D, Dastidar SG, Chakrabarty AN. Studies on synergism between penicillins and ambodryl (bromodiphenhydramine HCl), an antihistamine with antimicrobial property. Indian J Exp Biol. 1990 Mar;28(3):253-8. PubMed PMID: 1973150.;MOLINA EB. [A new antihistaminic, bromodiphenhydramine hydrochloride, in the control of cutaneous allergies]. Sem Med. 1960 Jul 11;117:151-2. Spanish. PubMed PMID: 13771809."

>  <ID<1>>
T25180

$$$$
StarDrop ID 382
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.5946 -2.2863 0.0000 0
M  V30 2 C 3.1821 -1.5718 0.0000 0
M  V30 3 O 3.5946 -0.8574 0.0000 0
M  V30 4 C 3.1821 -0.1429 0.0000 0
M  V30 5 C 3.5946 0.5716 0.0000 0
M  V30 6 N 3.1821 1.2860 0.0000 0 CHG=1
M  V30 7 C 2.7696 2.0005 0.0000 0
M  V30 8 C 3.8966 1.6985 0.0000 0
M  V30 9 C 2.4677 0.8735 0.0000 0
M  V30 10 C 2.3571 -1.5718 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 6 9
M  V30 9 1 2 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
382

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Acetylcholine bromide

>  <Synonyms>
N/A

>  <CAS>
66-23-9

>  <Formula>
C7H16BrNO2

>  <MolWt>
226.1

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Acetylcholine bromide is the bromide salt of acetylcholine. It is an neurotransmitter found at neuromuscular junctions, autonomic ganglia, parasympathetic effector junctions, a subset of sympathetic effector junctions, and at many sites in the central nervous system."

>  <Reference>
"Masood W, Sitammagari KK. Morvan Syndrome (Morvan Fibrillary Chorea, MFC). 2018 May 24. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2018 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK507887/ PubMed PMID: 29939664.;Leino S, Koski SK, H?nninen R, Tapanainen T, Rannanp?? S, Salminen O. Attenuated dopaminergic neurodegeneration and motor dysfunction in hemiparkinsonian mice lacking the ??5 nicotinic acetylcholine receptor subunit. Neuropharmacology. 2018 Jun 22. pii: S0028-3908(18)30330-7. doi: 10.1016/j.neuropharm.2018.06.028. [Epub ahead of print] PubMed PMID: 29940207.;Xu H, Zhao P, Zhang WJ, Qiu JY, Tan L, Liu XC, Wang Q, Luo X, She YS, Zang DA, Liu BB, Cao L, Zhao XX, Chen YY, Li MY, Shen J, Peng YB, Xue L, Yu MF, Chen W, Ma LQ, Qin G, Liu QH. Generation and Role of Oscillatory Contractions in Mouse Airway Smooth Muscle. Cell Physiol Biochem. 2018 Jun 21;47(4):1546-1555. doi: 10.1159/000490873. [Epub ahead of print] PubMed PMID: 29940574.;Tsetlin VI. Acetylcholine and Acetylcholine Receptors: Textbook Knowledge and New Data. Biomolecules. 2020 Jun 3;10(6):852."

>  <ID<1>>
T20344

$$$$
StarDrop ID 383
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.8838 0.7541 0.0000 0
M  V30 2 C 1.1387 -0.0305 0.0000 0
M  V30 3 N 1.9233 -0.2854 0.0000 0
M  V30 4 C 2.6378 0.1271 0.0000 0
M  V30 5 C 3.3523 -0.2854 0.0000 0
M  V30 6 C 3.3523 -1.1104 0.0000 0
M  V30 7 C 2.6378 -1.5229 0.0000 0
M  V30 8 C 1.9233 -1.1104 0.0000 0
M  V30 9 N 1.1387 -1.3654 0.0000 0
M  V30 10 N 0.6538 -0.6979 0.0000 0
M  V30 11 C -0.1712 -0.6979 0.0000 0
M  V30 12 C -0.5837 0.0165 0.0000 0
M  V30 13 C -1.4087 0.0165 0.0000 0
M  V30 14 N -1.8212 0.7310 0.0000 0
M  V30 15 C -2.6462 0.7310 0.0000 0
M  V30 16 C -3.0587 1.4455 0.0000 0
M  V30 17 N -2.6462 2.1599 0.0000 0
M  V30 18 C -3.0587 2.8744 0.0000 0
M  V30 19 C -3.8837 2.8744 0.0000 0
M  V30 20 C -4.2962 3.5889 0.0000 0
M  V30 21 C -3.8837 4.3034 0.0000 0
M  V30 22 C -3.0587 4.3034 0.0000 0
M  V30 23 Cl -2.6462 5.0178 0.0000 0
M  V30 24 C -2.6462 3.5889 0.0000 0
M  V30 25 C -1.8212 2.1599 0.0000 0
M  V30 26 C -1.4087 1.4455 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 3 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 1 2 10
M  V30 12 1 10 11
M  V30 13 1 11 12
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 22 24
M  V30 26 2 18 24
M  V30 27 1 17 25
M  V30 28 1 25 26
M  V30 29 1 14 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
383

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Trazodone

>  <Synonyms>
AF-1161

>  <CAS>
19794-93-5

>  <Formula>
C19H22ClN5O

>  <MolWt>
371.9

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
5-HT Receptor

>  <Receptor>
serotonin reuptake

>  <Bioactivity>
"Trazodone, a 5-HT 2A/2C receptor antagonist, is used as an antidepressant for treating major anxiety disorders and depressive disorder."

>  <Reference>
"Fagiolini A ,  Comandini A ,  Kasper S . Rediscovering Trazodone for the Treatment of Major Depressive Disorder[J]. Cns Drugs, 2013, 27(8):677-677."

>  <ID<1>>
T22442

$$$$
StarDrop ID 384
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 0.7145 -2.0625 0.0000 0
M  V30 2 C 1.4289 -2.4750 0.0000 0 CFG=2
M  V30 3 C 2.0420 -3.0270 0.0000 0
M  V30 4 C 1.7065 -3.7807 0.0000 0
M  V30 5 C 0.8860 -3.6945 0.0000 0 CFG=2
M  V30 6 O 0.3340 -4.3076 0.0000 0
M  V30 7 C 0.7145 -2.8875 0.0000 0 CFG=2
M  V30 8 C 0.0470 -3.3724 0.0000 0
M  V30 9 C 0.0000 -2.4750 0.0000 0
M  V30 10 C 0.0000 -1.6500 0.0000 0
M  V30 11 C 0.7145 -1.2375 0.0000 0 CFG=2
M  V30 12 H 1.4289 -0.8250 0.0000 0
M  V30 13 C 0.7145 -0.4125 0.0000 0
M  V30 14 C 0.0000 0.0000 0.0000 0
M  V30 15 C 0.0000 0.8250 0.0000 0
M  V30 16 C 0.7145 1.2375 0.0000 0
M  V30 17 O 0.7145 2.0625 0.0000 0
M  V30 18 C -0.0000 2.4750 0.0000 0
M  V30 19 O -0.7145 2.0625 0.0000 0
M  V30 20 N -0.0000 3.3000 0.0000 0
M  V30 21 C -0.7145 3.7125 0.0000 0
M  V30 22 C -0.7145 4.5375 0.0000 0
M  V30 23 Cl -1.4289 4.9500 0.0000 0
M  V30 24 C 0.7145 3.7125 0.0000 0
M  V30 25 C 0.7145 4.5375 0.0000 0
M  V30 26 Cl 1.4289 4.9500 0.0000 0
M  V30 27 C 1.4289 0.8250 0.0000 0
M  V30 28 C 1.4289 0.0000 0.0000 0
M  V30 29 C 2.1434 -0.4125 0.0000 0
M  V30 30 C 2.1434 -1.2375 0.0000 0
M  V30 31 C 1.4289 -1.6500 0.0000 0 CFG=1
M  V30 32 H 2.1434 -2.0625 0.0000 0
M  V30 33 H 1.2444 -4.6281 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 7 5
M  V30 7 1 2 7
M  V30 8 1 7 8 CFG=3
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 11 10
M  V30 12 1 11 12 CFG=1
M  V30 13 1 11 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 20 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 16 27
M  V30 28 2 27 28
M  V30 29 1 13 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 31 30
M  V30 33 1 2 31
M  V30 34 1 31 11
M  V30 35 1 31 32 CFG=3
M  V30 36 1 33 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
384

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Estramustine

>  <Synonyms>
LEO-275;NSC-89201;LEO 275;LEO275;NSC 89201;NSC89201

>  <CAS>
2998-57-4

>  <Formula>
C23H31Cl2NO3

>  <MolWt>
440.4

>  <Pathways>
Cytoskeletal Signaling

>  <Target>
Microtubule Associated

>  <Receptor>
microtubule

>  <Bioactivity>
"Estramustine is a nitrogen mustard linked to estradiol, usually as phosphate. Estramustine has been used to treat prostatic neoplasms; also has radiation protective properties. Estramustine is selectively taken up by prostate cells and exerts antineoplastic effects by interfering with microtubule of dynamics and by reducing plasma levels of testosterone."

>  <Reference>
"Qin Z, Li X, Zhang J, Tang J, Han P, Xu Z, Yu Y, Yang C, Wang C, Xu T, Xu Z, Zou Q. Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2016 Sep;95(39):e4801. doi: 10.1097/MD.0000000000004801. Review. PubMed PMID: 27684806; PubMed Central PMCID: PMC5265899.;Zhang C, Jing T, Wang F, Gao X, Xu C, Sun Y. Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials. Actas Urol Esp. 2014 Apr;38(3):184-91. doi: 10.1016/j.acuro.2013.07.010. Epub 2014 Feb 5. English, Spanish. PubMed PMID: 24507454.;Nakai Y, Nishimura K, Nakayama M, Uemura M, Takayama H, Nonomura N, Tsujimura A; Osaka CRPC Clinical Study Collaboration. Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment. Int J Clin Oncol. 2014 Feb;19(1):165-72. doi: 10.1007/s10147-013-0536-7. Epub 2013 Mar 1. PubMed PMID: 23456140.;Perry CM, McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging. 1995 Jul;7(1):49-74."

>  <ID<1>>
T20681

$$$$
StarDrop ID 385
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.8579 -0.0000 0.0000 0
M  V30 2 C 2.8579 -0.8250 0.0000 0
M  V30 3 N 2.1434 -1.2375 0.0000 0
M  V30 4 C 1.4289 -0.8250 0.0000 0
M  V30 5 C 0.7145 -1.2375 0.0000 0
M  V30 6 O 0.7145 -2.0625 0.0000 0
M  V30 7 C 0.0000 -0.8250 0.0000 0
M  V30 8 C -0.7145 -1.2375 0.0000 0
M  V30 9 C -1.4289 -0.8250 0.0000 0
M  V30 10 O -2.1434 -1.2375 0.0000 0
M  V30 11 C -2.8579 -0.8250 0.0000 0
M  V30 12 C -1.4289 -0.0000 0.0000 0
M  V30 13 C -0.7145 0.4125 0.0000 0
M  V30 14 C 0.0000 -0.0000 0.0000 0
M  V30 15 O 0.7145 0.4125 0.0000 0
M  V30 16 C 1.4289 0.0000 0.0000 0
M  V30 17 C 3.5724 -1.2375 0.0000 0
M  V30 18 N 4.2868 -0.8250 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 9 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 7 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 2 17
M  V30 18 1 17 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
385

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Midodrine

>  <Synonyms>
(??)-Midodrin

>  <CAS>
42794-76-3

>  <Formula>
C12H18N2O4

>  <MolWt>
254.3

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Adrenergic Receptor

>  <Receptor>
??1-adrenoceptor

>  <Bioactivity>
"Midodrine, an adrenergic alpha-1 agonist, belongs to the class of medications known as vasopressors."

>  <Reference>
"Tchen B S ,  Jbsbb B . Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock - ScienceDirect[J]. Journal of Critical Care, 2020, 57:148-156."

>  <ID<1>>
T22369

$$$$
StarDrop ID 386
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 3.5540 3.2375 0.0000 0
M  V30 2 C 4.2685 2.8250 0.0000 0
M  V30 3 F 3.8560 2.1105 0.0000 0
M  V30 4 F 4.6810 3.5395 0.0000 0
M  V30 5 C 4.9830 2.4125 0.0000 0
M  V30 6 C 5.6974 2.8250 0.0000 0
M  V30 7 C 6.4119 2.4125 0.0000 0
M  V30 8 C 6.4119 1.5875 0.0000 0
M  V30 9 C 5.6974 1.1750 0.0000 0
M  V30 10 O 5.6974 0.3500 0.0000 0
M  V30 11 C 6.4119 -0.0625 0.0000 0
M  V30 12 C 7.1264 0.3500 0.0000 0
M  V30 13 O 7.1264 1.1750 0.0000 0
M  V30 14 C 7.8409 1.5875 0.0000 0
M  V30 15 C 7.8409 -0.0625 0.0000 0
M  V30 16 C 7.8409 -0.8875 0.0000 0
M  V30 17 N 8.5553 -1.3000 0.0000 0
M  V30 18 C 9.2698 -0.8875 0.0000 0
M  V30 19 C 9.2698 -0.0625 0.0000 0
M  V30 20 C 9.9843 -1.3000 0.0000 0
M  V30 21 C 10.6987 -0.8875 0.0000 0
M  V30 22 C 11.4132 -1.3000 0.0000 0
M  V30 23 N 11.4132 -2.1250 0.0000 0
M  V30 24 C 7.1264 -1.3000 0.0000 0
M  V30 25 N 7.1264 -2.1250 0.0000 0
M  V30 26 C 6.4119 -2.5375 0.0000 0
M  V30 27 O 6.4119 -3.3625 0.0000 0
M  V30 28 C 5.6974 -3.7750 0.0000 0
M  V30 29 C 5.6974 -2.1250 0.0000 0
M  V30 30 C 5.6974 -1.3000 0.0000 0
M  V30 31 C 6.4119 -0.8875 0.0000 0
M  V30 32 C 4.9830 -0.8875 0.0000 0
M  V30 33 C 4.9830 1.5875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 12 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 18 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 16 24
M  V30 24 2 24 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 1 27 28
M  V30 28 2 26 29
M  V30 29 1 29 30
M  V30 30 2 30 31
M  V30 31 1 24 31
M  V30 32 1 11 31
M  V30 33 1 30 32
M  V30 34 1 9 33
M  V30 35 2 5 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
386

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tafenoquine Succinate

>  <Synonyms>
WR 238605 (Succinate)

>  <CAS>
106635-81-8

>  <Formula>
C28H34F3N3O7

>  <MolWt>
581.6

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
antimalarial

>  <Bioactivity>
Tafenoquine Succinate is an 8-aminoquinoline. and is an agent of anti-malarial prophylactic.

>  <Reference>
"Marcsisin SR, et al. Tafenoquine and NPC-1161B require CYP 2D metabolism for anti-malarial activity: implications for the 8-aminoquinoline class of anti-malarial compounds. Malar J. 2014 Jan 3;13:2."

>  <ID<1>>
T13083L

$$$$
StarDrop ID 387
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 25 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 4.7644 1.1730 0.0000 0
M  V30 2 C 5.5147 0.8299 0.0000 0
M  V30 3 C 4.0921 0.6948 0.0000 0
M  V30 4 C 3.1620 1.1865 0.0000 0
M  V30 5 C 2.6696 0.5596 0.0000 0
M  V30 6 C 2.0337 1.0852 0.0000 0 CFG=2
M  V30 7 C 1.9900 0.2614 0.0000 0 CFG=1
M  V30 8 C 1.4007 -0.9756 0.0000 0 CFG=2
M  V30 9 C 2.2220 -0.8976 0.0000 0
M  V30 10 C 2.9275 -0.4103 0.0000 0
M  V30 11 C 3.4979 -0.6048 0.0000 0
M  V30 12 C 4.1702 -0.1265 0.0000 0
M  V30 13 N 0.7648 -0.4501 0.0000 0
M  V30 14 C 0.0359 -0.8364 0.0000 0
M  V30 15 C 0.6868 0.3712 0.0000 0
M  V30 16 C 1.2124 1.0072 0.0000 0
M  V30 17 H 1.1585 -1.7643 0.0000 0
M  V30 18 C 2.6816 -0.1884 0.0000 0
M  V30 19 C 3.4169 0.1857 0.0000 0
M  V30 20 C 3.4606 1.0095 0.0000 0
M  V30 21 C 2.7690 1.4593 0.0000 0
M  V30 22 H 1.1904 0.4645 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 1 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 6 5 CFG=3
M  V30 6 1 7 6
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 5 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 3 12
M  V30 14 1 8 13
M  V30 15 1 13 14
M  V30 16 1 13 15
M  V30 17 1 15 16
M  V30 18 1 6 16
M  V30 19 1 8 17 CFG=1
M  V30 20 1 7 18
M  V30 21 1 18 19
M  V30 22 1 19 20
M  V30 23 1 20 21
M  V30 24 1 6 21
M  V30 25 1 7 22 CFG=1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
387

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dextromethorphan

>  <Synonyms>
RACEMETHORPHAN;Levomethorphan

>  <CAS>
125-71-3

>  <Formula>
C18H25NO

>  <MolWt>
271.4

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Dextromethorphan is an NMDA receptor antagonist used to treat cases of dry cough.

>  <Reference>
"Alviar MJ, Hale T, Dungca M. Pharmacologic interventions for treating phantom limb pain. Cochrane Database Syst Rev. 2016 Oct 14;10:CD006380. Review. PubMed PMID: 27737513.;Garay RP, Grossberg GT. AVP-786 for the treatment of agitation in dementia of the Alzheimer's type. Expert Opin Investig Drugs. 2017 Jan;26(1):121-132. doi: 10.1080/13543784.2017.1267726. Epub 2016 Dec 11. Review. PubMed PMID: 27936965.;Lener MS, Kadriu B, Zarate CA Jr. Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression. Drugs. 2017 Mar;77(4):381-401. doi: 10.1007/s40265-017-0702-8. Review. PubMed PMID: 28194724; PubMed Central PMCID: PMC5342919.;Porsteinsson AP, Antonsdottir IM. An update on the advancements in the treatment of agitation in Alzheimer's disease. Expert Opin Pharmacother. 2017 Apr;18(6):611-620. doi: 10.1080/14656566.2017.1307340. Epub 2017 Mar 28. Review. PubMed PMID: 28300462."

>  <ID<1>>
T0262L2

$$$$
StarDrop ID 388
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.4760 -6.6724 0.0000 0
M  V30 2 C -2.1434 -6.1875 0.0000 0
M  V30 3 C -1.4289 -5.7750 0.0000 0
M  V30 4 C -1.4289 -4.9500 0.0000 0
M  V30 5 C -2.1434 -4.5375 0.0000 0
M  V30 6 C -2.8579 -4.9500 0.0000 0
M  V30 7 C -3.5724 -4.5375 0.0000 0
M  V30 8 C -3.5724 -3.7125 0.0000 0
M  V30 9 C -2.8579 -3.3000 0.0000 0
M  V30 10 C -2.8579 -2.4750 0.0000 0
M  V30 11 C -2.1434 -2.0625 0.0000 0
M  V30 12 O -2.1434 -1.2375 0.0000 0
M  V30 13 C -2.8579 -0.8250 0.0000 0
M  V30 14 O -3.5724 -1.2375 0.0000 0
M  V30 15 N -2.8579 0.0000 0.0000 0
M  V30 16 C -3.5724 0.4125 0.0000 0
M  V30 17 C -3.5724 1.2375 0.0000 0
M  V30 18 Cl -4.2868 1.6500 0.0000 0
M  V30 19 C -2.1434 0.4125 0.0000 0
M  V30 20 C -2.1434 1.2375 0.0000 0
M  V30 21 Cl -1.4289 1.6500 0.0000 0
M  V30 22 C -1.4289 -2.4750 0.0000 0
M  V30 23 C -1.4289 -3.3000 0.0000 0
M  V30 24 C -2.1434 -3.7125 0.0000 0
M  V30 25 C -2.8579 -5.7750 0.0000 0
M  V30 26 C -3.4710 -6.3270 0.0000 0
M  V30 27 C -3.1354 -7.0807 0.0000 0
M  V30 28 C -2.3149 -6.9945 0.0000 0
M  V30 29 O -1.7629 -7.6076 0.0000 0
M  V30 30 P -2.0178 -8.3922 0.0000 0
M  V30 31 O -2.2728 -9.1768 0.0000 0
M  V30 32 O -1.2332 -8.6471 0.0000 0
M  V30 33 O -2.8025 -8.1372 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 13 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 15 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 11 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 5 24
M  V30 25 1 9 24
M  V30 26 1 6 25
M  V30 27 1 2 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 2 28
M  V30 32 1 28 29
M  V30 33 1 29 30
M  V30 34 1 30 31
M  V30 35 1 30 32
M  V30 36 2 30 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
388

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Estramustine phosphate sodium

>  <Synonyms>
Estramustine phosphate disodium;Ro 21-8837/001

>  <CAS>
52205-73-9

>  <Formula>
C23H30Cl2NNa2O6P

>  <MolWt>
564.3

>  <Pathways>
Apoptosis;Cytoskeletal Signaling

>  <Target>
Microtubule Associated;Apoptosis

>  <Receptor>
Apoptosis; Microtubule/Tubulin

>  <Bioactivity>
Estramustine phosphate sodium is an antimicrotubule chemotherapy agent; arrests prostate cancer cells in the G2/M phase of the cell cycle.

>  <Reference>
"Dene Simpson, et al. Estramustine Phosphate Sodium. American Journal of Cancer 2 (5): 373?C390.;Perry CM,etal.Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.Drugs Aging. 1995 Jul;7(1):49-74.;Bergenheim AT,etal.Pharmacokinetics and pharmacodynamics of estramustine phosphate.Clin Pharmacokinet. 1998 Feb;34(2):163-72."

>  <ID<1>>
T4451

$$$$
StarDrop ID 389
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0145 0.1914 0.0000 0
M  V30 2 C 3.1895 0.1914 0.0000 0
M  V30 3 C 2.7770 0.9059 0.0000 0
M  V30 4 N 2.7770 -0.5230 0.0000 0
M  V30 5 C 1.9520 -0.5230 0.0000 0
M  V30 6 C 1.5395 -1.2375 0.0000 0
M  V30 7 C 0.7145 -1.2375 0.0000 0 CFG=2
M  V30 8 C 0.3020 -0.5230 0.0000 0
M  V30 9 C -0.5230 -0.5230 0.0000 0
M  V30 10 C -0.9355 0.1914 0.0000 0
M  V30 11 C -0.5230 0.9059 0.0000 0
M  V30 12 C 0.3020 0.9059 0.0000 0
M  V30 13 C 0.7145 0.1914 0.0000 0
M  V30 14 C 0.3020 -1.9520 0.0000 0
M  V30 15 C 0.7145 -2.6664 0.0000 0
M  V30 16 C 0.3020 -3.3809 0.0000 0
M  V30 17 C 0.7145 -4.0954 0.0000 0
M  V30 18 O 0.3020 -4.8099 0.0000 0
M  V30 19 C -0.5230 -3.3809 0.0000 0
M  V30 20 C -0.9355 -2.6664 0.0000 0
M  V30 21 C -0.5230 -1.9520 0.0000 0
M  V30 22 O -0.9355 -1.2375 0.0000 0
M  V30 23 C -1.7605 -1.2375 0.0000 0
M  V30 24 O -2.1730 -0.5230 0.0000 0
M  V30 25 C -2.1730 -1.9520 0.0000 0
M  V30 26 C -1.7605 -2.6664 0.0000 0
M  V30 27 C -2.9980 -1.9520 0.0000 0
M  V30 28 C 3.1895 -1.2375 0.0000 0
M  V30 29 C 4.0145 -1.2375 0.0000 0
M  V30 30 C 2.7770 -1.9520 0.0000 0
M  V30 31 H 1.2145 -0.3715 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=1
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 8 13
M  V30 14 1 7 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 16 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 14 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 27 1 25 26
M  V30 28 1 25 27
M  V30 29 1 4 28
M  V30 30 1 28 29
M  V30 31 1 28 30
M  V30 32 1 31 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
389

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fesoterodine

>  <Synonyms>
(R) Fesoterodine

>  <CAS>
286930-02-7

>  <Formula>
C26H37NO3

>  <MolWt>
411.6

>  <Pathways>
Neuroscience

>  <Target>
AChR

>  <Receptor>
" M2 mAChR:7.7(pKi), M1 mAChR:8.0(pKi), M3 mAChR:7.4(pKi)"

>  <Bioactivity>
"Fesoterodine is an orally active, competitive mAChR antagonist with pKi values of 8.0, 7.7, 7.4, 7.3, 7.5 for M1, M2, M3, M4, M5 receptors, respectively. It is used for the overactive bladder (OAB)."

>  <Reference>
"B Malhotra, et al.The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.Curr Med Chem . 2009;16(33):4481-9.;Ney P, et al. Andersson KE. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int. 2008 Apr;101(8):1036-42."

>  <ID<1>>
T9419

$$$$
StarDrop ID 390
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.3066 -2.6738 0.0000 0
M  V30 2 C 3.4997 -2.8453 0.0000 0
M  V30 3 C 3.2447 -3.6299 0.0000 0
M  V30 4 C 2.4377 -3.8015 0.0000 0
M  V30 5 C 1.8857 -3.1884 0.0000 0
M  V30 6 C 2.1407 -2.4037 0.0000 0
M  V30 7 C 2.9476 -2.2322 0.0000 0
M  V30 8 N 3.2026 -1.4476 0.0000 0
M  V30 9 C 2.6505 -0.8345 0.0000 0
M  V30 10 C 2.9055 -0.0499 0.0000 0
M  V30 11 N 3.7124 0.1216 0.0000 0
M  V30 12 C 3.9674 0.9063 0.0000 0
M  V30 13 C 4.7744 1.0778 0.0000 0
M  V30 14 C 5.0293 1.8624 0.0000 0
M  V30 15 N 4.5444 2.5299 0.0000 0
M  V30 16 N 5.0293 3.1973 0.0000 0
M  V30 17 C 5.8139 2.9424 0.0000 0
M  V30 18 C 6.5284 3.3549 0.0000 0
M  V30 19 C 7.2429 2.9424 0.0000 0
M  V30 20 C 7.2429 2.1174 0.0000 0
M  V30 21 C 6.5284 1.7049 0.0000 0
M  V30 22 N 5.8139 2.1174 0.0000 0
M  V30 23 C 4.2645 -0.4915 0.0000 0
M  V30 24 C 4.0095 -1.2761 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 14 22
M  V30 24 1 17 22
M  V30 25 1 11 23
M  V30 26 1 23 24
M  V30 27 1 8 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
390

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dapiprazole Hydrochloride

>  <Synonyms>
Glamidolo Hydrochloride;Reversil Hydrochloride

>  <CAS>
72822-13-0

>  <Formula>
C19H28ClN5

>  <MolWt>
361.9

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor; ??1-adrenergic receptor

>  <Bioactivity>
"Dapiprazole Hydrochloride is an alpha-1-adrenergic antagonist that acts by blocking alpha-adrenergic receptors in the smooth muscle of blood vessels (arteries, arterioles and veins), gastrointestinal tract, and radial smooth muscle of the iris."

>  <Reference>
"Lisciani R., et al. General pharmacological properties of dapiprazole, a potential psychotropic agent. Arzneimittelforschung. 1982;32(6):674-8.;Silvestrini B., et al. Psychopharmacological profile of dapiprazole, a new potential antipsychotic agent. Arzneimittelforschung. 1982;32(6):668-73.;Hogan TS., et al. Dose-response study of dapiprazole HCl in the reversal of mydriasis induced by 2.5% phenylephrine. J Ocul Pharmacol Ther. 1997 Aug;13(4):297-302;Connor CG., et al. The clinical efficacy of Rev-Eyes in reversing the effects of pupillary dilation. J Am Optom Assoc. 1993 Sep;64(9):634-6.;Silvestrini B., et al. Effects of dapiprazole on pupillary size and intraocular pressure in rabbits. Arzneimittelforschung. 1982;32(6):678-81."

>  <ID<1>>
T3996

$$$$
StarDrop ID 391
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 1.6500 2.8579 0.0000 0
M  V30 2 C 1.2375 2.1434 0.0000 0
M  V30 3 F 0.4125 2.1434 0.0000 0
M  V30 4 O 1.6500 1.4289 0.0000 0
M  V30 5 C 1.2375 0.7145 0.0000 0
M  V30 6 F 0.5230 1.1270 0.0000 0
M  V30 7 F 1.9520 0.3020 0.0000 0
M  V30 8 C 0.8250 0.0000 0.0000 0
M  V30 9 F 1.2375 -0.7145 0.0000 0
M  V30 10 Cl 0.0000 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
391

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Enflurane

>  <Synonyms>
NSC 115944;Efrane;NSC-115944;Ethrane;NSC115944

>  <CAS>
13838-16-9

>  <Formula>
C3H2ClF5O

>  <MolWt>
184.5

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Enflurane, a volatile anaesthetic, is a potent inhibitor of high conductance Ca2+-activated K+ channels of Chara australis. Enflurane is an internal standard in monitoring halogenated volatile anaesthetics by headspace gas chromatography-mass spectrometry. It allows rapid adjustments of anesthesia depth with little change in pulse or respiratory rate."

>  <Reference>
"Hung O. From the Journal archives: Early clinical evaluation of enflurane: the cost of progress. Can J Anaesth. 2014 Mar;61(3):269-72. doi: 10.1007/s12630-013-0091-8. Epub 2013 Dec 7. PubMed PMID: 24318728.;Liu H, Weng H. Up-regulation of Alzheimer's disease-associated proteins may cause enflurane anesthesia induced cognitive decline in aged rats. Neurol Sci. 2014 Feb;35(2):185-9. doi: 10.1007/s10072-013-1474-x. Epub 2013 Aug 11. PubMed PMID: 23934553.;Zierkiewicz W, Czarnik-Matusewicz B, Michalska D. Blue shifts and unusual intensity changes in the infrared spectra of the enflurane??????acetone complexes: spectroscopic and theoretical studies. J Phys Chem A. 2011 Oct 20;115(41):11362-8. doi: 10.1021/jp205081r. Epub 2011 Sep 13. PubMed PMID: 21913646.;Andrade LA, Silla JM, Stephens SL, Marat K, da Cunha EF, Ramalho TC, van Wijngaarden J, Freitas MP. Conformational Exploration of Enflurane in Solution and in a Biological Environment. J Phys Chem A. 2015 Oct 29;119(43):10735-42. doi: 10.1021/acs.jpca.5b08087. Epub 2015 Oct 19. PubMed PMID: 26461140."

>  <ID<1>>
T19658

$$$$
StarDrop ID 392
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 29 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.7322 -2.0625 0.0000 0
M  V30 2 C 0.7322 -2.8875 0.0000 0 CFG=2
M  V30 3 N 0.0178 -3.3000 0.0000 0
M  V30 4 C -0.6967 -2.8875 0.0000 0 CFG=1
M  V30 5 C -1.4112 -3.3000 0.0000 0
M  V30 6 C -2.1256 -2.8875 0.0000 0
M  V30 7 C -2.8401 -3.3000 0.0000 0
M  V30 8 C -2.8401 -4.1250 0.0000 0
M  V30 9 C -3.5546 -4.5375 0.0000 0
M  V30 10 C -4.2691 -4.1250 0.0000 0
M  V30 11 C -4.2691 -3.3000 0.0000 0
M  V30 12 C -3.5546 -2.8875 0.0000 0
M  V30 13 C -0.6967 -2.0625 0.0000 0
M  V30 14 O -1.4112 -1.6500 0.0000 0
M  V30 15 O 0.0178 -1.6500 0.0000 0
M  V30 16 C 1.4467 -3.3000 0.0000 0
M  V30 17 O 1.4467 -4.1250 0.0000 0
M  V30 18 N 2.1612 -2.8875 0.0000 0
M  V30 19 C 2.2474 -2.0670 0.0000 0
M  V30 20 C 3.0544 -1.8955 0.0000 0
M  V30 21 C 3.4669 -2.6100 0.0000 0
M  V30 22 C 2.9149 -3.2231 0.0000 0 CFG=1
M  V30 23 C 3.0864 -4.0300 0.0000 0
M  V30 24 O 3.8710 -4.2850 0.0000 0
M  V30 25 O 2.4733 -4.5821 0.0000 0
M  V30 26 H -0.1338 -2.3875 0.0000 0
M  V30 27 H 0.1693 -2.3875 0.0000 0
M  V30 28 H 3.8808 -3.4818 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 7 12
M  V30 13 1 4 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 2 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 22 21
M  V30 23 1 22 18
M  V30 24 1 22 23 CFG=1
M  V30 25 1 23 24
M  V30 26 2 23 25
M  V30 27 1 26 2
M  V30 28 1 27 4
M  V30 29 1 28 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
392

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Enalaprilat Dihydrate

>  <Synonyms>
MK-422 Dihydrate;MK-422

>  <CAS>
84680-54-6

>  <Formula>
C18H28N2O7

>  <MolWt>
384.4

>  <Pathways>
Autophagy;Endocrinology/Hormones

>  <Target>
Autophagy;RAAS

>  <Receptor>
 ACE:1.94 nM

>  <Bioactivity>
Enalaprilat??IC50=1.94 nM?? is a potent angiotensin-converting enzyme (ACE) inhibitor.

>  <Reference>
"Schumacher J, et al. Br J Anaesth, 2006, 96(4), 437-443.;Zou K, et al. J Biol Chem, 2009, 284(46), 31914-31920.;Ceconi C, et al. Eur J Pharmacol, 2007, 577(1-3), 1-6.;Stanisavljevic S, et al. J Pharmacol Exp Ther, 2006, 316(3), 1153-1158.;van Eickels M, et al. Br J Pharmacol, 2000, 131(8), 1592-1596."

>  <ID<1>>
T6340

$$$$
StarDrop ID 393
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3462 -2.3344 0.0000 0
M  V30 2 C 4.7942 -1.7213 0.0000 0
M  V30 3 C 3.9872 -1.8929 0.0000 0
M  V30 4 C 3.7322 -2.6775 0.0000 0
M  V30 5 C 2.9253 -2.8490 0.0000 0
M  V30 6 C 2.6703 -3.6336 0.0000 0
M  V30 7 C 2.4154 -4.4182 0.0000 0
M  V30 8 C 3.4550 -3.8886 0.0000 0
M  V30 9 O 1.8857 -3.3787 0.0000 0
M  V30 10 C 5.0491 -0.9367 0.0000 0
M  V30 11 C 4.5642 -0.2693 0.0000 0
M  V30 12 C 5.0491 0.3982 0.0000 0
M  V30 13 C 5.8337 0.1432 0.0000 0
M  V30 14 C 6.5482 0.5557 0.0000 0
M  V30 15 C 7.2627 0.1432 0.0000 0
M  V30 16 C 7.2627 -0.6818 0.0000 0
M  V30 17 C 6.5482 -1.0943 0.0000 0
M  V30 18 C 5.8337 -0.6818 0.0000 0
M  V30 19 C 5.7475 -1.5022 0.0000 0
M  V30 20 C 6.5482 1.3807 0.0000 0
M  V30 21 C 7.2627 1.7932 0.0000 0
M  V30 22 C 7.2627 2.6182 0.0000 0
M  V30 23 C 6.5482 3.0307 0.0000 0
M  V30 24 C 6.5482 3.8557 0.0000 0
M  V30 25 O 5.8337 4.2682 0.0000 0
M  V30 26 C 7.2627 4.2682 0.0000 0
M  V30 27 C 7.9771 3.8557 0.0000 0
M  V30 28 C 7.9771 3.0307 0.0000 0
M  V30 29 C 8.6916 2.6182 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 6 9
M  V30 9 1 2 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 10 18
M  V30 19 1 13 18
M  V30 20 1 18 19
M  V30 21 2 14 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 24 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 22 28
M  V30 31 2 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
393

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Calcifediol monohydrate

>  <Synonyms>
25-hydroxy Vitamin D3 monohydrate

>  <CAS>
63283-36-3

>  <Formula>
C27H46O3

>  <MolWt>
418.7

>  <Pathways>
Metabolism

>  <Target>
Endogenous Metabolite

>  <Receptor>
Endogenous Metabolite; VD

>  <Bioactivity>
"Calcifediol monohydrate, the main circulating metabolite of vitamin D3, is a potent VDR inhibitor."

>  <Reference>
"Castoldi A, et al. Calcifediol-loaded liposomes for local treatment of pulmonary bacterial infections. Eur J Pharm Biopharm. 2016 Nov 22."

>  <ID<1>>
T6430L

$$$$
StarDrop ID 394
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.7145 -2.8875 0.0000 0
M  V30 2 C 1.4289 -2.4750 0.0000 0
M  V30 3 C 2.1434 -2.8875 0.0000 0
M  V30 4 C 2.1434 -3.7125 0.0000 0
M  V30 5 C 2.8579 -4.1250 0.0000 0
M  V30 6 C 2.8579 -4.9500 0.0000 0
M  V30 7 C 2.1434 -5.3625 0.0000 0
M  V30 8 C 1.4289 -4.9500 0.0000 0
M  V30 9 N 1.4289 -4.1250 0.0000 0
M  V30 10 C 2.1434 -6.1875 0.0000 0
M  V30 11 C 2.8579 -6.6000 0.0000 0
M  V30 12 C 2.8579 -7.4250 0.0000 0
M  V30 13 C 2.1434 -7.8375 0.0000 0
M  V30 14 O 2.1434 -8.6625 0.0000 0
M  V30 15 C 1.4289 -9.0750 0.0000 0
M  V30 16 C 1.4289 -9.9000 0.0000 0
M  V30 17 N 0.7145 -10.3125 0.0000 0
M  V30 18 C 0.7145 -11.1375 0.0000 0
M  V30 19 C -0.0000 -11.5500 0.0000 0
M  V30 20 O -0.7145 -11.1375 0.0000 0
M  V30 21 C -0.7145 -10.3125 0.0000 0
M  V30 22 C -0.0000 -9.9000 0.0000 0
M  V30 23 C 1.4289 -7.4250 0.0000 0
M  V30 24 C 1.4289 -6.6000 0.0000 0
M  V30 25 N 1.4289 -1.6500 0.0000 0
M  V30 26 C 0.7145 -1.2375 0.0000 0
M  V30 27 C 0.7145 -0.4125 0.0000 0
M  V30 28 C 0.0000 0.0000 0.0000 0
M  V30 29 C 0.0000 0.8250 0.0000 0
M  V30 30 C 0.7145 1.2375 0.0000 0
M  V30 31 C 1.4289 0.8250 0.0000 0
M  V30 32 C 1.4289 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 4 9
M  V30 10 1 7 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 17 22
M  V30 24 1 13 23
M  V30 25 2 23 24
M  V30 26 1 10 24
M  V30 27 1 2 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 2 27 28
M  V30 31 1 28 29
M  V30 32 2 29 30
M  V30 33 1 30 31
M  V30 34 2 31 32
M  V30 35 1 27 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
394

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tirbanibulin

>  <Synonyms>
KX2-391;KX-01

>  <CAS>
897016-82-9

>  <Formula>
C26H29N3O3

>  <MolWt>
431.5

>  <Pathways>
Angiogenesis;Tyrosine Kinase/Adaptors;Cytoskeletal Signaling

>  <Target>
Src;Microtubule Associated

>  <Receptor>
" Src (Hep 3B):26 nM(GI50), Src (PLC/PRF/5):13 nM(GI50), Src (HuH7):9 nM(GI50), Src (Hep G2):60 nM(GI50)"

>  <Bioactivity>
"KX2-391 is a highly selective Src kinase inhibitor that has demonstrated efficacy in pre-Clinicalal animal models of colon, pancreatic, prostate and breast cancer. It is a substrate-targeted kinase inhibitor. KX2-391, belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors."

>  <Reference>
"Lau GM, et al, Dig Dis Sci, 2009, 54(7), 1465-1474.;Fallah-Tafti A, et al, Eur J Med Chem, 2011, 46(10), 4853-4858.;Zhang X, Xu H, Bi X, et al. Src acts as the target of matrine to inhibit the proliferation of cancer cells by regulating phosphorylation signaling pathways[J]. 2020"

>  <ID<1>>
T6345

$$$$
StarDrop ID 395
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.4685 1.4354 0.0000 0
M  V30 2 N -2.2136 2.2201 0.0000 0
M  V30 3 C -2.6985 2.8875 0.0000 0
M  V30 4 N -2.2136 3.5549 0.0000 0
M  V30 5 C -1.4289 3.3000 0.0000 0
M  V30 6 C -0.7145 3.7125 0.0000 0
M  V30 7 F -0.7145 4.5375 0.0000 0
M  V30 8 C 0.0000 3.3000 0.0000 0
M  V30 9 N 0.7145 3.7125 0.0000 0
M  V30 10 C 0.7145 4.5375 0.0000 0
M  V30 11 C -0.0000 4.9500 0.0000 0
M  V30 12 C -0.0000 5.7750 0.0000 0
M  V30 13 C 0.7145 6.1875 0.0000 0
M  V30 14 Br 0.7145 7.0125 0.0000 0
M  V30 15 C 1.4289 5.7750 0.0000 0
M  V30 16 C 1.4289 4.9500 0.0000 0
M  V30 17 F 2.1434 4.5375 0.0000 0
M  V30 18 C 0.0000 2.4750 0.0000 0
M  V30 19 C -0.7145 2.0625 0.0000 0
M  V30 20 C -1.4289 2.4750 0.0000 0
M  V30 21 C 0.7145 2.0625 0.0000 0
M  V30 22 O 0.7145 1.2375 0.0000 0
M  V30 23 N 1.4289 2.4750 0.0000 0
M  V30 24 O 2.1434 2.0625 0.0000 0
M  V30 25 C 2.8579 2.4750 0.0000 0
M  V30 26 C 3.5724 2.0625 0.0000 0
M  V30 27 O 4.2868 2.4750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 13 15
M  V30 15 2 15 16
M  V30 16 1 10 16
M  V30 17 1 16 17
M  V30 18 2 8 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 2 20
M  V30 22 1 5 20
M  V30 23 1 18 21
M  V30 24 2 21 22
M  V30 25 1 21 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
395

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Binimetinib

>  <Synonyms>
MEK162;ARRY-162;ARRY-438162

>  <CAS>
606143-89-9

>  <Formula>
C17H15BrF2N4O3

>  <MolWt>
441.2

>  <Pathways>
Autophagy;MAPK

>  <Target>
Autophagy;MEK

>  <Receptor>
 MEK:12 nM

>  <Bioactivity>
"Binimetinib (MEK162, ARRY-162, ARRY-438162) is an orally available inhibitor of MEK1/2 (IC50: 12 nM) in a cell-free assay."

>  <Reference>
"SS Bhagwat, et al. Annu Rep Med Chem, 2007, 42, 265?C278.;Cheng H, et al. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 2016 Jun 9;35(23):2961-70.;Seip K, et al. Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget. 2016 Apr 12;7(15):19997-20015.;D Wright, et al. 2009, Arraybiopharma. Abstract FRI0063.;Serra V, et al. J Clin Invest, 2013, 123(6), 2551-2563.;J Pheneger, et al. 2006, ACR Annual Scientific Meeting. Abst 794."

>  <ID<1>>
T2508

$$$$
StarDrop ID 396
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.0630 -1.4167 0.0000 0
M  V30 2 C 2.8390 -1.6970 0.0000 0 CFG=1
M  V30 3 C 3.5218 -1.2340 0.0000 0
M  V30 4 C 4.1731 -1.7404 0.0000 0 CFG=1
M  V30 5 C 4.9853 -1.5952 0.0000 0 CFG=2
M  V30 6 C 5.2655 -0.8192 0.0000 0
M  V30 7 C 6.0777 -0.6740 0.0000 0
M  V30 8 C 6.6095 -1.3047 0.0000 0
M  V30 9 C 7.4216 -1.1595 0.0000 0
M  V30 10 C 7.9534 -1.7902 0.0000 0
M  V30 11 O 8.7655 -1.6450 0.0000 0
M  V30 12 C 7.6731 -2.5662 0.0000 0
M  V30 13 C 6.8610 -2.7114 0.0000 0
M  V30 14 C 6.3292 -2.0807 0.0000 0 CFG=1
M  V30 15 C 6.0489 -2.8566 0.0000 0
M  V30 16 C 5.5171 -2.2259 0.0000 0 CFG=1
M  V30 17 C 5.2368 -3.0018 0.0000 0
M  V30 18 O 5.7686 -3.6325 0.0000 0
M  V30 19 C 4.4247 -3.1470 0.0000 0
M  V30 20 C 3.8928 -2.5163 0.0000 0 CFG=1
M  V30 21 C 3.5330 -3.2587 0.0000 0
M  V30 22 C 3.0683 -2.4895 0.0000 0 CFG=2
M  V30 23 O 2.9469 -3.3055 0.0000 0
M  V30 24 C 2.3074 -2.8084 0.0000 0
M  V30 25 O 2.2031 -3.6268 0.0000 0
M  V30 26 C 1.6508 -2.3089 0.0000 0
M  V30 27 O 0.8899 -2.6277 0.0000 0
M  V30 28 H 2.7146 -0.7048 0.0000 0
M  V30 29 H 3.2125 -2.0183 0.0000 0
M  V30 30 H 4.3406 -0.8308 0.0000 0
M  V30 31 H 6.1617 -2.9904 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 14 13
M  V30 14 1 14 8
M  V30 15 1 14 15 CFG=1
M  V30 16 1 16 14
M  V30 17 1 5 16
M  V30 18 1 16 17 CFG=1
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 1 20 19
M  V30 22 1 4 20
M  V30 23 1 20 21 CFG=1
M  V30 24 1 20 22
M  V30 25 1 22 2
M  V30 26 1 22 23 CFG=3
M  V30 27 1 22 24 CFG=1
M  V30 28 2 24 25
M  V30 29 1 24 26
M  V30 30 1 26 27
M  V30 31 1 28 2
M  V30 32 1 29 4
M  V30 33 1 30 5
M  V30 34 1 31 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
396

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Meprednisone

>  <Synonyms>
Methylprednisone;NSC 527579;SCH 4358;Betapar;Betanisona

>  <CAS>
1247-42-3

>  <Formula>
C22H28O5

>  <MolWt>
372.5

>  <Pathways>
Autophagy;Endocrinology/Hormones

>  <Target>
Glucocorticoid Receptor;Autophagy

>  <Receptor>
Autophagy; Glucocorticoid Receptor

>  <Bioactivity>
Betapar(Meprednisone) is a glucocorticoid and a methylated derivative of prednisone.

>  <Reference>
"Rubinsztein DC, Bento CF, Deretic V.J Exp Med. 2015 Jun 29;212(7):979-90.;Ma X, He J, Yan J, Wang Q, Li H.Chem Biol Interact. 2016 Mar 25;248:52-9."

>  <ID<1>>
T6580

$$$$
StarDrop ID 397
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.3228 1.7357 0.0000 0
M  V30 2 C 3.9629 0.9934 0.0000 0 CFG=1
M  V30 3 C 3.6826 0.2174 0.0000 0 CFG=2
M  V30 4 C 2.8705 0.0722 0.0000 0 CFG=1
M  V30 5 C 2.3387 0.7029 0.0000 0 CFG=1
M  V30 6 C 1.5266 0.5577 0.0000 0 CFG=2
M  V30 7 C 1.2463 -0.2182 0.0000 0
M  V30 8 C 1.7781 -0.8489 0.0000 0
M  V30 9 C 2.5902 -0.7037 0.0000 0
M  V30 10 C 0.4342 -0.3634 0.0000 0
M  V30 11 C -0.0976 0.2673 0.0000 0
M  V30 12 O -0.9098 0.1221 0.0000 0
M  V30 13 C 0.1827 1.0432 0.0000 0
M  V30 14 C 0.9948 1.1884 0.0000 0
M  V30 15 H 0.7145 0.4125 0.0000 0
M  V30 16 C 2.6190 1.4789 0.0000 0
M  V30 17 C 3.4311 1.6241 0.0000 0
M  V30 18 H 1.8069 1.3336 0.0000 0
M  V30 19 H 2.0584 -0.0730 0.0000 0
M  V30 20 C 4.3340 -0.2889 0.0000 0
M  V30 21 C 5.0168 0.1741 0.0000 0
M  V30 22 C 4.7875 0.9666 0.0000 0 CFG=2
M  V30 23 O 5.2939 1.6179 0.0000 0
M  V30 24 C 4.9830 2.3821 0.0000 0
M  V30 25 C 5.4893 3.0334 0.0000 0
M  V30 26 C 5.1784 3.7976 0.0000 0
M  V30 27 O 4.1657 2.4949 0.0000 0
M  V30 28 H 3.1508 0.8481 0.0000 0
M  V30 29 H 5.7696 0.7781 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 4 9
M  V30 10 2 7 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 6 14
M  V30 16 1 6 15 CFG=1
M  V30 17 1 5 16
M  V30 18 1 16 17
M  V30 19 1 2 17
M  V30 20 1 5 18 CFG=3
M  V30 21 1 4 19 CFG=1
M  V30 22 1 3 20
M  V30 23 1 20 21
M  V30 24 1 22 21
M  V30 25 1 2 22
M  V30 26 1 22 23 CFG=1
M  V30 27 1 23 24
M  V30 28 1 24 25
M  V30 29 1 25 26
M  V30 30 2 24 27
M  V30 31 1 3 28 CFG=3
M  V30 32 1 29 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
397

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Nandrolone propionate

>  <Synonyms>
N/A

>  <CAS>
7207-92-3

>  <Formula>
C21H30O3

>  <MolWt>
330.5

>  <Pathways>
Others;Endocrinology/Hormones

>  <Target>
Others;Androgen Receptor

>  <Receptor>
Androgen Receptor

>  <Bioactivity>
Nandrolone propionate is an anabolic steroid action primarily consisting of androgenic and nitrogen-retentive properties.

>  <Reference>
"Lyd??n E, et al. Effects of nandrolone propionate on experimental tumor growth and cancer cachexia. Metabolism. 1995 Apr;44(4):445-51."

>  <ID<1>>
T19470

$$$$
StarDrop ID 398
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.4820 0.5756 0.0000 0
M  V30 2 C 3.1964 0.1631 0.0000 0
M  V30 3 O 3.9109 0.5756 0.0000 0
M  V30 4 C 4.6254 0.1631 0.0000 0
M  V30 5 C 5.3399 0.5756 0.0000 0
M  V30 6 N 6.0543 0.1631 0.0000 0
M  V30 7 C 6.8080 0.4987 0.0000 0
M  V30 8 N 7.3600 -0.1144 0.0000 0
M  V30 9 C 6.9475 -0.8289 0.0000 0
M  V30 10 C 7.2025 -1.6135 0.0000 0
M  V30 11 C 6.6504 -2.2266 0.0000 0
M  V30 12 C 5.8435 -2.0551 0.0000 0
M  V30 13 C 5.5885 -1.2704 0.0000 0
M  V30 14 C 6.1406 -0.6573 0.0000 0
M  V30 15 N 6.9795 1.3057 0.0000 0
M  V30 16 C 6.3269 1.8103 0.0000 0
M  V30 17 C 6.3146 2.6353 0.0000 0
M  V30 18 C 6.9518 3.1592 0.0000 0
M  V30 19 N 7.7588 2.9877 0.0000 0
M  V30 20 C 8.2634 3.6403 0.0000 0
M  V30 21 C 8.1278 2.2498 0.0000 0
M  V30 22 C 7.7810 1.5013 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 6 14
M  V30 15 1 9 14
M  V30 16 1 7 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 19 21
M  V30 23 1 21 22
M  V30 24 1 15 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
398

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Emedastine

>  <Synonyms>
Emadine;LY188695

>  <CAS>
87233-61-2

>  <Formula>
C17H26N4O

>  <MolWt>
302.4

>  <Pathways>
GPCR/G Protein;Neuroscience;Immunology/Inflammation

>  <Target>
Histamine Receptor

>  <Receptor>
 H1 receptor:1.3 nM(Ki)

>  <Bioactivity>
"Emedastine is a second generation, selective histamine H1 receptor antagonist with anti-allergic activity. Emedastine reversibly and competitively blocks histamine by binding to H1 receptors, thus blocking its downstream activity. As a result this agent interferes with mediator release from mast cells either by inhibiting calcium ion influx across mast cell/basophil plasma membrane or by inhibiting intracellular calcium ion release within the cells. In addition, emedastine may also inhibit the late-phase allergic reaction mediated through leukotrienes or prostaglandins, or by producing an anti-platelet activating factor effect. Upon ocular administration, emedastine causes a dose-dependent inhibition of histamine-stimulated vascular permeability in the conjunctiva. Emedastine does not affect adrenergic, dopamine, or serotonin receptors."

>  <Reference>
"Liu RF., Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle-controlled study.;Dong L, Shen S, Chen W, et al. Discovery of Novel Inhibitors Targeting Human O-GlcNAcase: Docking-Based Virtual Screening, Biological Evaluation, Structural Modification, and Molecular Dynamics Simulation[J]. Journal of chemical information and modeling. 2019, 59(10): 4374-4382.;Murota H., Emedastine difumarate inhibits histamine-induced collagen synthesis in dermal fibroblasts. J Investig Allergol Clin Immunol."

>  <ID<1>>
T3979

$$$$
StarDrop ID 399
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.4957 -7.2979 0.0000 0
M  V30 2 C 5.4957 -6.4729 0.0000 0
M  V30 3 C 4.7812 -6.0604 0.0000 0
M  V30 4 C 4.7812 -5.2354 0.0000 0
M  V30 5 N 5.4957 -4.8229 0.0000 0
M  V30 6 C 6.2102 -5.2354 0.0000 0
M  V30 7 C 6.9246 -4.8229 0.0000 0
M  V30 8 C 7.6391 -5.2354 0.0000 0
M  V30 9 C 7.6391 -6.0604 0.0000 0
M  V30 10 C 6.9246 -6.4729 0.0000 0
M  V30 11 N 6.2102 -6.0604 0.0000 0
M  V30 12 N 8.3536 -6.4729 0.0000 0
M  V30 13 C 9.0681 -6.0604 0.0000 0
M  V30 14 C 9.7825 -6.4729 0.0000 0
M  V30 15 N 9.7825 -7.2979 0.0000 0
M  V30 16 C 9.0681 -7.7104 0.0000 0
M  V30 17 C 8.3536 -7.2979 0.0000 0
M  V30 18 C 9.4806 -8.4249 0.0000 0
M  V30 19 C 8.6556 -8.4249 0.0000 0
M  V30 20 C 4.0668 -4.8229 0.0000 0
M  V30 21 N 3.3523 -5.2354 0.0000 0
M  V30 22 N 2.6378 -4.8229 0.0000 0
M  V30 23 C 1.8532 -5.0779 0.0000 0
M  V30 24 C 1.3683 -4.4104 0.0000 0
M  V30 25 N 1.8532 -3.7430 0.0000 0
M  V30 26 C 2.6378 -3.9979 0.0000 0
M  V30 27 C 3.3523 -3.5854 0.0000 0
M  V30 28 C 4.0668 -3.9979 0.0000 0
M  V30 29 C 3.3523 -2.7604 0.0000 0
M  V30 30 C 0.5433 -4.4104 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 2 11
M  V30 12 1 6 11
M  V30 13 1 9 12
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 12 17
M  V30 20 1 16 18
M  V30 21 1 18 19
M  V30 22 1 16 19
M  V30 23 1 4 20
M  V30 24 2 20 21
M  V30 25 1 21 22
M  V30 26 1 22 23
M  V30 27 2 23 24
M  V30 28 1 24 25
M  V30 29 2 25 26
M  V30 30 1 22 26
M  V30 31 1 26 27
M  V30 32 2 27 28
M  V30 33 1 20 28
M  V30 34 1 27 29
M  V30 35 1 24 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
399

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Risdiplam

>  <Synonyms>
RO7034067;RG7916

>  <CAS>
1825352-65-5

>  <Formula>
C22H23N7O

>  <MolWt>
401.5

>  <Pathways>
DNA Damage/DNA Repair;Cell Cycle/Checkpoint

>  <Target>
DNA/RNA Synthesis

>  <Receptor>
DNA/RNA Synthesis; SMN2

>  <Bioactivity>
Risdiplam (RG7916) is orally administered. Risdiplam is a centrally and peripherally distributed SMN2 pre-mRNA splicing modifier which increases survival motor neuron (SMN) protein levels[1].

>  <Reference>
"Poirier A, et al. Risdiplam distributes and increases SMN protein in both the central nervous system and peripheral organs. Pharmacol Res Perspect. 2018 Nov 29;6(6):e00447."

>  <ID<1>>
T16757

$$$$
StarDrop ID 400
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.4990 -0.5396 0.0000 0
M  V30 2 C 2.7845 -0.1271 0.0000 0
M  V30 3 N 2.7845 0.6979 0.0000 0
M  V30 4 C 3.4990 1.1104 0.0000 0
M  V30 5 C 4.2135 0.6979 0.0000 0
M  V30 6 N 4.2135 -0.1271 0.0000 0
M  V30 7 C 4.9279 -0.5396 0.0000 0
M  V30 8 C 4.9279 -1.3646 0.0000 0
M  V30 9 C 5.6424 -1.7771 0.0000 0
M  V30 10 C 5.6424 -2.6021 0.0000 0
M  V30 11 C 6.3569 -3.0146 0.0000 0
M  V30 12 C 6.4431 -3.8350 0.0000 0
M  V30 13 N 7.2501 -4.0066 0.0000 0
M  V30 14 C 7.6626 -3.2921 0.0000 0
M  V30 15 C 7.1106 -2.6790 0.0000 0
M  V30 16 C 7.3655 -1.8944 0.0000 0
M  V30 17 C 8.1725 -1.7229 0.0000 0
M  V30 18 C 8.7245 -2.3359 0.0000 0
M  V30 19 C 8.4696 -3.1206 0.0000 0
M  V30 20 C 8.4274 -0.9382 0.0000 0
M  V30 21 N 8.6823 -0.1536 0.0000 0
M  V30 22 C 2.0701 1.1104 0.0000 0
M  V30 23 C 1.3556 0.6979 0.0000 0
M  V30 24 C 0.6411 1.1104 0.0000 0
M  V30 25 C 0.6411 1.9354 0.0000 0
M  V30 26 C 1.3556 2.3479 0.0000 0
M  V30 27 C 2.0701 1.9354 0.0000 0
M  V30 28 O -0.1435 2.1904 0.0000 0
M  V30 29 C -0.6284 1.5229 0.0000 0
M  V30 30 C -0.1435 0.8555 0.0000 0
M  V30 31 C -1.4534 1.5229 0.0000 0
M  V30 32 O -1.8659 0.8085 0.0000 0
M  V30 33 N -1.8659 2.2374 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 1 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 11 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 14 19
M  V30 22 1 17 20
M  V30 23 3 20 21
M  V30 24 1 3 22
M  V30 25 2 22 23
M  V30 26 1 23 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 2 26 27
M  V30 30 1 22 27
M  V30 31 1 25 28
M  V30 32 1 28 29
M  V30 33 2 29 30
M  V30 34 1 24 30
M  V30 35 1 29 31
M  V30 36 2 31 32
M  V30 37 1 31 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
400

>  <Plate>
PHD136329

>  <Row>
d

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Vilazodone

>  <Synonyms>
SB659746A;EMD 68843

>  <CAS>
163521-12-8

>  <Formula>
C26H27N5O2

>  <MolWt>
441.5

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Serotonin Transporter;5-HT Receptor

>  <Receptor>
5-HT; 5-HT Receptor; Serotonin Transporter; Sert (Sodium-dependent)

>  <Bioactivity>
"Vilazodone is a selective serotonin (5-HT) reuptake inhibitor (SSRI) and a 5-HT-1A receptor partial agonist, with antidepressant and anti-anxiety activities. Vilazodone inhibits the reuptake of serotonin from the synaptic cleft while stimulating the release of 5-HT into the synaptic cleft. This increases the concentration of 5-HT in the synaptic cleft and potentiates serotonergic neurotransmission in the central nervous system."

>  <Reference>
"Page ME, et al. J Pharmacol Exp Ther. 2002 Sep;302(3):1220-7."

>  <ID<1>>
T1279

$$$$
StarDrop ID 401
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7145 -2.8875 0.0000 0
M  V30 2 C 0.0000 -2.4750 0.0000 0
M  V30 3 C -0.7145 -2.8875 0.0000 0
M  V30 4 C -1.4289 -2.4750 0.0000 0
M  V30 5 C -1.4289 -1.6500 0.0000 0
M  V30 6 C -0.7145 -1.2375 0.0000 0
M  V30 7 C 0.0000 -1.6500 0.0000 0
M  V30 8 N 0.7145 -1.2375 0.0000 0
M  V30 9 C 0.7145 -0.4125 0.0000 0
M  V30 10 C 0.0000 0.0000 0.0000 0
M  V30 11 F 0.0000 0.8250 0.0000 0
M  V30 12 N 1.4289 0.0000 0.0000 0
M  V30 13 C 2.1434 -0.4125 0.0000 0
M  V30 14 C 2.8579 0.0000 0.0000 0
M  V30 15 C 3.5724 -0.4125 0.0000 0
M  V30 16 C 3.5724 -1.2375 0.0000 0
M  V30 17 N 4.2868 -1.6500 0.0000 0
M  V30 18 C 2.8579 -1.6500 0.0000 0
M  V30 19 C 2.1434 -1.2375 0.0000 0
M  V30 20 C 1.4289 -1.6500 0.0000 0
M  V30 21 O 1.4289 -2.4750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 9 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 2 18 19
M  V30 20 1 13 19
M  V30 21 1 19 20
M  V30 22 1 8 20
M  V30 23 2 20 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
401

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Afloqualone

>  <Synonyms>
HQ-495

>  <CAS>
56287-74-2

>  <Formula>
C16H14FN3O

>  <MolWt>
283.3

>  <Pathways>
Neuroscience;Membrane transporter/Ion channel

>  <Target>
GABA Receptor

>  <Receptor>
GABA Receptor; GABAR

>  <Bioactivity>
"Afloqualone is a agonist of GABA receptor . Target: GABA Receptor in vitro: Afloqualone is a quinazolinone family GABAergic drug. Afloqualone is an analogue of methaqualone. It has sedative and muscle-relaxant effects, resulting from its agonist activity at the ?? subtype of the GABAa receptor."

>  <Reference>
"Yamamura M, et al. Effects of afloqualone, a new centrally acting muscle relaxant, on DRL response and CER in rats (author's transl). Nihon Yakurigaku Zasshi. 1981 Oct;78(4):381-92."

>  <ID<1>>
T4993

$$$$
StarDrop ID 402
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 37 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -3.6173 3.5368 0.0000 0
M  V30 2 O -2.7923 3.5368 0.0000 0
M  V30 3 C -2.3798 2.8223 0.0000 0
M  V30 4 O -2.7923 2.1078 0.0000 0
M  V30 5 N -1.5548 2.8223 0.0000 0
M  V30 6 C -1.1423 2.1078 0.0000 0 CFG=1
M  V30 7 C -1.5548 1.3934 0.0000 0
M  V30 8 C -0.3173 2.1078 0.0000 0
M  V30 9 N 0.0952 2.8223 0.0000 0
M  V30 10 C 0.9202 2.8223 0.0000 0
M  V30 11 N 1.3327 2.1078 0.0000 0
M  V30 12 C 2.1577 2.1078 0.0000 0
M  V30 13 C 2.5702 2.8223 0.0000 0
M  V30 14 C 2.1577 3.5368 0.0000 0
M  V30 15 N 1.3327 3.5368 0.0000 0
M  V30 16 C 2.5702 4.2513 0.0000 0
M  V30 17 C 3.3906 4.3375 0.0000 0
M  V30 18 N 3.5622 5.1445 0.0000 0
M  V30 19 N 2.8477 5.5570 0.0000 0
M  V30 20 C 2.2346 5.0049 0.0000 0
M  V30 21 C 1.4276 5.1765 0.0000 0
M  V30 22 C 0.8756 4.5634 0.0000 0
M  V30 23 C 0.0686 4.7349 0.0000 0
M  V30 24 Cl -0.4834 4.1218 0.0000 0
M  V30 25 C -0.1863 5.5195 0.0000 0
M  V30 26 C 0.3657 6.1326 0.0000 0
M  V30 27 N 0.1108 6.9172 0.0000 0
M  V30 28 S -0.6962 7.0888 0.0000 0
M  V30 29 C -0.5247 7.8957 0.0000 0
M  V30 30 O -0.8677 6.2818 0.0000 0
M  V30 31 O -1.5032 7.2603 0.0000 0
M  V30 32 C 1.1727 5.9611 0.0000 0
M  V30 33 F 1.7247 6.5742 0.0000 0
M  V30 34 C 4.3158 5.4800 0.0000 0
M  V30 35 C 4.9833 4.9951 0.0000 0
M  V30 36 C 4.4021 6.3005 0.0000 0
M  V30 37 H -2.1423 2.1079 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 10 15
M  V30 16 1 14 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 16 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 2 23 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 2 28 30
M  V30 32 2 28 31
M  V30 33 2 26 32
M  V30 34 1 21 32
M  V30 35 1 32 33
M  V30 36 1 18 34
M  V30 37 1 34 35
M  V30 38 1 34 36
M  V30 39 1 37 6
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
402

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Encorafenib

>  <Synonyms>
LGX818

>  <CAS>
1269440-17-6

>  <Formula>
C22H27ClFN7O4S

>  <MolWt>
540

>  <Pathways>
MAPK

>  <Target>
Raf

>  <Receptor>
 BRaf V600E:0.3 nM

>  <Bioactivity>
LGX818 is an orally available mutated BRaf V600E inhibitor(IC50=0.3 nM) with potential antineoplastic activity.

>  <Reference>
"Darrin D Stuart, et al. Cancer Res, 2012, 72(8 Supplement): 3790"

>  <ID<1>>
T6487

$$$$
StarDrop ID 403
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 -0.2062 0.0000 0
M  V30 2 O 3.0716 0.2063 0.0000 0
M  V30 3 C 3.7861 -0.2062 0.0000 0
M  V30 4 O 3.7861 -1.0312 0.0000 0
M  V30 5 C 4.5006 0.2063 0.0000 0
M  V30 6 C 5.2150 -0.2063 0.0000 0
M  V30 7 C 5.9295 0.2062 0.0000 0
M  V30 8 O 5.9295 1.0312 0.0000 0
M  V30 9 C 6.6440 -0.2063 0.0000 0
M  V30 10 N 7.3584 0.2062 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
403

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Methyl Aminolevulinate Hydrochloride

>  <Synonyms>
Aminolevulinic acid methyl ester Hydrochloride;Methyl 5-aminolevulinate Hydrochloride;Methyl ??-aminolevulinate hydrochloride;5-Aminolevulinic acid methyl ester

>  <CAS>
79416-27-6

>  <Formula>
C6H12ClNO3

>  <MolWt>
181.6

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Methyl Aminolevulinate Hydrochloride is commonly used in photosentizer reagents for photodynamic therapy to treat conditions such as Acne vulgaris and hypertrophic scarring.

>  <Reference>
"Morrow DI, et al. Hexyl aminolaevulinate is a more effective topical photosensitiser precursor than methyl aminolaevulinate and 5-aminolaevulinic acids when applied in equimolar doses. J Pharm Sci. 2010 Aug;99(8):3486-98."

>  <ID<1>>
T5002

$$$$
StarDrop ID 404
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.7586 3.5724 0.0000 0
M  V30 2 C 5.4730 3.9849 0.0000 0
M  V30 3 C 6.1875 3.5724 0.0000 0
M  V30 4 C 6.9020 3.9849 0.0000 0
M  V30 5 C 7.6164 3.5724 0.0000 0
M  V30 6 C 8.3309 3.9849 0.0000 0
M  V30 7 C 9.0454 3.5724 0.0000 0
M  V30 8 C 9.7599 3.9849 0.0000 0
M  V30 9 C 10.4743 3.5724 0.0000 0
M  V30 10 C 11.1888 3.9849 0.0000 0
M  V30 11 C 11.9033 3.5724 0.0000 0
M  V30 12 C 12.6177 3.9849 0.0000 0
M  V30 13 C 13.3322 3.5724 0.0000 0
M  V30 14 C 14.0467 3.9849 0.0000 0
M  V30 15 O 14.7612 3.5724 0.0000 0
M  V30 16 S 15.4756 3.9849 0.0000 0
M  V30 17 O 16.1901 4.3974 0.0000 0
M  V30 18 O 15.0631 4.6993 0.0000 0
M  V30 19 O 15.8881 3.2704 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 16 18
M  V30 18 2 16 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
404

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Sodium Tetradecyl Sulfate

>  <Synonyms>
N/A

>  <CAS>
1191-50-0

>  <Formula>
C14H29NaO4S

>  <MolWt>
316.4

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Sodium Tetradecyl Sulfate is a detergent sclerosant with antithrombotic effects and commonly used for the treatment of varicose veins.

>  <Reference>
"Tan KT, et al. Percutaneous sodium tetradecyl sulfate sclerotherapy for peripheral venous vascular malformations: a single-center experience. J Vasc Interv Radiol. 2007;18(3):343-351."

>  <ID<1>>
T9620

$$$$
StarDrop ID 405
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 -5.0237 0.0000 0
M  V30 2 O 3.0716 -4.6112 0.0000 0
M  V30 3 C 3.0716 -3.7862 0.0000 0
M  V30 4 C 2.3571 -3.3737 0.0000 0
M  V30 5 C 2.3571 -2.5487 0.0000 0
M  V30 6 C 3.0716 -2.1362 0.0000 0
M  V30 7 C 3.0716 -1.3112 0.0000 0
M  V30 8 C 3.7861 -0.8987 0.0000 0
M  V30 9 C 4.1986 -1.6131 0.0000 0
M  V30 10 C 3.3736 -0.1842 0.0000 0
M  V30 11 N 4.5006 -0.4862 0.0000 0
M  V30 12 C 4.5006 0.3388 0.0000 0
M  V30 13 C 5.2150 0.7513 0.0000 0 CFG=2
M  V30 14 O 5.9295 0.3388 0.0000 0
M  V30 15 C 5.2150 1.5763 0.0000 0
M  V30 16 C 4.5006 1.9888 0.0000 0
M  V30 17 C 4.5006 2.8138 0.0000 0
M  V30 18 O 3.7861 3.2263 0.0000 0
M  V30 19 C 5.2150 3.2263 0.0000 0
M  V30 20 C 5.9295 2.8138 0.0000 0
M  V30 21 N 6.6440 3.2263 0.0000 0
M  V30 22 C 7.3584 2.8138 0.0000 0
M  V30 23 O 8.0729 3.2263 0.0000 0
M  V30 24 C 7.3584 1.9888 0.0000 0
M  V30 25 O 6.6440 1.5763 0.0000 0
M  V30 26 C 5.9295 1.9888 0.0000 0
M  V30 27 C 3.7861 -2.5487 0.0000 0
M  V30 28 C 3.7861 -3.3737 0.0000 0
M  V30 29 H 5.2151 -0.2487 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 1 8 11
M  V30 11 1 11 12
M  V30 12 1 13 12
M  V30 13 1 13 14 CFG=1
M  V30 14 1 13 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 17 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 22 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 1 15 26
M  V30 27 2 20 26
M  V30 28 1 6 27
M  V30 29 2 27 28
M  V30 30 1 3 28
M  V30 31 1 29 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
405

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Olodaterol hydrochloride

>  <Synonyms>
BI 1744 hydrochloride;BI-1744 HCl

>  <CAS>
869477-96-3

>  <Formula>
C21H27ClN2O5

>  <MolWt>
422.9

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
 human ??2-adrenoceptor:97.7 nM(EC50)

>  <Bioactivity>
"Olodaterol is a novel, long-acting ??2-adrenergic agonist (EC50s: 97.7 nM for the human ??2-adrenoceptor) that exerts its pharmacological effect by binding and activating ??2-adrenergic receptors."

>  <Reference>
"Bouyssou T, et al. Pharmacological characterization of olodaterol, a novel inhaled beta2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther. 2010 Jul;334(1):53-62.;Herrmann F E, et al. Olodaterol shows anti?ibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis. Br J Pharmacol, 2017, 174(21):3848.;Bouyssou T, et al. Discovery of olodaterol, a novel inhaled beta2-adrenoceptor agonist with a 24 h bronchodilatory efficacy. Bioorg Med Chem Lett. 2010 Feb 15;20(4):1410-4."

>  <ID<1>>
T5159

$$$$
StarDrop ID 406
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 39 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.5645 5.7750 0.0000 0
M  V30 2 C 2.5645 4.9500 0.0000 0
M  V30 3 C 3.2789 4.5375 0.0000 0
M  V30 4 O 3.9934 4.9500 0.0000 0
M  V30 5 N 3.2789 3.7125 0.0000 0
M  V30 6 C 3.9934 3.3000 0.0000 0
M  V30 7 C 3.9934 2.4750 0.0000 0
M  V30 8 C 3.2789 2.0625 0.0000 0
M  V30 9 C 3.2789 1.2375 0.0000 0
M  V30 10 C 3.9934 0.8250 0.0000 0
M  V30 11 C 3.9934 0.0000 0.0000 0
M  V30 12 N 3.2789 -0.4125 0.0000 0
M  V30 13 C 2.5645 0.0000 0.0000 0
M  V30 14 C 1.7798 -0.2549 0.0000 0
M  V30 15 C 1.5249 -1.0396 0.0000 0
M  V30 16 N 0.7179 -1.2111 0.0000 0
M  V30 17 O 2.0769 -1.6527 0.0000 0
M  V30 18 C 1.2949 0.4125 0.0000 0
M  V30 19 C 0.4699 0.4125 0.0000 0
M  V30 20 C 0.0574 -0.3020 0.0000 0
M  V30 21 C -0.7676 -0.3020 0.0000 0
M  V30 22 C -1.1801 0.4125 0.0000 0
M  V30 23 O -2.0051 0.4125 0.0000 0
M  V30 24 C -2.4176 1.1270 0.0000 0
M  V30 25 C -3.2426 1.1270 0.0000 0
M  V30 26 C -3.6551 1.8414 0.0000 0
M  V30 27 C -3.2426 2.5559 0.0000 0
M  V30 28 C -2.4176 2.5559 0.0000 0
M  V30 29 C -2.0051 1.8414 0.0000 0
M  V30 30 C -0.7676 1.1270 0.0000 0
M  V30 31 C 0.0574 1.1270 0.0000 0
M  V30 32 N 1.7798 1.0799 0.0000 0
M  V30 33 N 2.5645 0.8250 0.0000 0
M  V30 34 C 2.5645 2.4750 0.0000 0
M  V30 35 C 2.5645 3.3000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 15 17
M  V30 17 1 14 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 27 28
M  V30 28 2 28 29
M  V30 29 1 24 29
M  V30 30 1 22 30
M  V30 31 2 30 31
M  V30 32 1 19 31
M  V30 33 2 18 32
M  V30 34 1 32 33
M  V30 35 1 13 33
M  V30 36 1 9 33
M  V30 37 1 8 34
M  V30 38 1 34 35
M  V30 39 1 5 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
406

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
zanubrutinib

>  <Synonyms>
BGB-3111

>  <CAS>
1691249-45-2

>  <Formula>
C27H29N5O3

>  <MolWt>
471.5

>  <Pathways>
Tyrosine Kinase/Adaptors;Angiogenesis

>  <Target>
BTK

>  <Receptor>
BTK

>  <Bioactivity>
Zanubrutinib is an inhibitor of Bruton tyrosine kinase (BTK).

>  <Reference>
"Li N , Sun Z , Liu Y , et al. Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor[J]. Cancer Research, 2015, 75(15 Supplement):2597-2597.;Chiara Tarantelli, Lu Zhang, Elisabetta Curti ,et al.The Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) Demonstrated Synergies With Other Anti-Lymphoma Targeted Agents[J].Haematologica, 104 (7), e307-e309 Jul 2019"

>  <ID<1>>
T7584

$$$$
StarDrop ID 407
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 43 46 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.1434 -1.2375 0.0000 0
M  V30 2 N 2.8579 -1.6500 0.0000 0
M  V30 3 C 3.5724 -1.2375 0.0000 0
M  V30 4 C 2.8579 -2.4750 0.0000 0 CFG=1
M  V30 5 C 3.5724 -2.8875 0.0000 0 CFG=2
M  V30 6 C 4.2868 -2.4750 0.0000 0
M  V30 7 C 5.0013 -2.8875 0.0000 0 CFG=2
M  V30 8 C 5.7158 -2.4750 0.0000 0
M  V30 9 C 6.4302 -2.8875 0.0000 0
M  V30 10 C 7.1447 -2.4750 0.0000 0
M  V30 11 C 7.8592 -2.8875 0.0000 0
M  V30 12 C 7.8592 -3.7125 0.0000 0
M  V30 13 C 8.5737 -4.1250 0.0000 0
M  V30 14 N 9.2881 -3.7125 0.0000 0
M  V30 15 C 10.0026 -4.1250 0.0000 0
M  V30 16 C 10.7171 -3.7125 0.0000 0
M  V30 17 C 11.4315 -3.3000 0.0000 0
M  V30 18 C 11.1296 -4.4270 0.0000 0
M  V30 19 C 10.3046 -2.9980 0.0000 0
M  V30 20 C 7.1447 -4.1250 0.0000 0
M  V30 21 O 7.1447 -4.9500 0.0000 0
M  V30 22 C 6.4302 -3.7125 0.0000 0
M  V30 23 C 5.7158 -4.1250 0.0000 0
M  V30 24 O 5.7158 -4.9500 0.0000 0
M  V30 25 C 5.0013 -3.7125 0.0000 0
M  V30 26 C 4.2868 -4.1250 0.0000 0
M  V30 27 O 4.2868 -4.9500 0.0000 0
M  V30 28 C 3.5724 -3.7125 0.0000 0 CFG=1
M  V30 29 O 3.5724 -4.5375 0.0000 0
M  V30 30 C 2.8579 -4.1250 0.0000 0
M  V30 31 O 2.8579 -4.9500 0.0000 0
M  V30 32 C 2.1434 -3.7125 0.0000 0
M  V30 33 C 1.4289 -4.1250 0.0000 0
M  V30 34 N 0.7145 -3.7125 0.0000 0
M  V30 35 O 1.4289 -4.9500 0.0000 0
M  V30 36 C 2.1434 -2.8875 0.0000 0
M  V30 37 O 1.4289 -2.4750 0.0000 0
M  V30 38 N 7.1447 -1.6500 0.0000 0
M  V30 39 C 7.8592 -1.2375 0.0000 0
M  V30 40 C 6.4302 -1.2375 0.0000 0
M  V30 41 H 3.7239 -1.9750 0.0000 0
M  V30 42 H 3.5723 -1.8875 0.0000 0
M  V30 43 H 4.1353 -3.3875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 2 CFG=1
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 7 6 CFG=3
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 1 16 19
M  V30 19 1 12 20
M  V30 20 1 20 21
M  V30 21 2 20 22
M  V30 22 1 9 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 23 25
M  V30 26 1 7 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 1 28 26
M  V30 30 1 5 28
M  V30 31 1 28 29 CFG=1
M  V30 32 1 28 30
M  V30 33 2 30 31
M  V30 34 1 30 32
M  V30 35 1 32 33
M  V30 36 1 33 34
M  V30 37 2 33 35
M  V30 38 2 32 36
M  V30 39 1 4 36
M  V30 40 1 36 37
M  V30 41 1 10 38
M  V30 42 1 38 39
M  V30 43 1 38 40
M  V30 44 1 41 4
M  V30 45 1 42 5
M  V30 46 1 43 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
407

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Omadacycline

>  <Synonyms>
Amadacycline;PTK 0796

>  <CAS>
389139-89-3

>  <Formula>
C29H40N4O7

>  <MolWt>
556.7

>  <Pathways>
Microbiology/Virology

>  <Target>
ribosome;Antibacterial;Antibiotic

>  <Receptor>
30S ribosome; Antibiotic; Bacterial

>  <Bioactivity>
"Omadacycline, a new tetracycline antibiotic, can inhibit the 30s subunit of bacterial ribosome."

>  <Reference>
"Shoen C, et al. In vitro activities of omadacycline against rapidly growing mycobacteria. Antimicrob Agents Chemother. 2019 Mar 11."

>  <ID<1>>
T5189

$$$$
StarDrop ID 408
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.8236 -3.5925 0.0000 0
M  V30 2 N -1.3589 -2.9109 0.0000 0
M  V30 3 C -1.7714 -2.1964 0.0000 0
M  V30 4 C -1.4700 -1.4284 0.0000 0
M  V30 5 C -0.6816 -1.1853 0.0000 0
M  V30 6 C 0.0000 -1.6500 0.0000 0
M  V30 7 C 0.0617 -2.4727 0.0000 0
M  V30 8 C -0.5431 -3.0338 0.0000 0
M  V30 9 N 0.7145 -1.2375 0.0000 0
M  V30 10 N 0.7145 -0.4125 0.0000 0
M  V30 11 C 1.4289 0.0000 0.0000 0
M  V30 12 C 1.4289 0.8250 0.0000 0
M  V30 13 C 2.1434 1.2375 0.0000 0
M  V30 14 C 2.1434 2.0625 0.0000 0
M  V30 15 C 2.8579 2.4750 0.0000 0
M  V30 16 C 3.5724 2.0625 0.0000 0
M  V30 17 Cl 4.2868 2.4750 0.0000 0
M  V30 18 C 3.5724 1.2375 0.0000 0
M  V30 19 C 2.8579 0.8250 0.0000 0
M  V30 20 C 2.1434 -0.4125 0.0000 0
M  V30 21 C 2.8579 0.0000 0.0000 0
M  V30 22 C 3.5724 -0.4125 0.0000 0
M  V30 23 C 3.5724 -1.2375 0.0000 0
M  V30 24 C 2.8579 -1.6500 0.0000 0
M  V30 25 C 2.1434 -1.2375 0.0000 0
M  V30 26 C 1.4289 -1.6500 0.0000 0
M  V30 27 O 1.4289 -2.4750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 2 8
M  V30 9 1 6 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 2 18 19
M  V30 20 1 13 19
M  V30 21 1 11 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 20 25
M  V30 28 1 25 26
M  V30 29 1 9 26
M  V30 30 2 26 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
408

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Azelastine

>  <Synonyms>
Astelin;Azelastinum;Azelastina

>  <CAS>
58581-89-8

>  <Formula>
C22H24ClN3O

>  <MolWt>
381.9

>  <Pathways>
Microbiology/Virology;Neuroscience;Immunology/Inflammation;GPCR/G Protein

>  <Target>
Histamine Receptor;SARS-CoV

>  <Receptor>
H1 receptor; Histamine Receptor; SARS-CoV

>  <Bioactivity>
"Azelastine is a phthalazine derivative, and is an histamine antagonist and mast cell stabilizer."

>  <Reference>
"Kempuraj D, et al. Int Arch Allergy Immunol,2003, 132(3), 231-239.;Yoneda K, et al. Jpn J Pharmacol,1997, 73(2), 145-153.;Hide I, et al. J Immunol,1997, 159(6), 2932-2940."

>  <ID<1>>
T0211

$$$$
StarDrop ID 409
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0071 3.9984 0.0000 0
M  V30 2 C 4.8141 3.8269 0.0000 0
M  V30 3 C 5.3661 4.4400 0.0000 0
M  V30 4 O 5.0691 3.0423 0.0000 0
M  V30 5 C 5.8760 2.8707 0.0000 0
M  V30 6 C 6.1310 2.0861 0.0000 0 CFG=2
M  V30 7 C 5.5789 1.4730 0.0000 0
M  V30 8 N 6.9379 1.9146 0.0000 0
M  V30 9 P 7.1929 1.1300 0.0000 0
M  V30 10 C 7.4478 0.3453 0.0000 0
M  V30 11 O 8.2548 0.1738 0.0000 0
M  V30 12 C 8.5097 -0.6108 0.0000 0 CFG=2
M  V30 13 C 7.9577 -1.2239 0.0000 0
M  V30 14 C 9.3167 -0.7823 0.0000 0
M  V30 15 N 9.5716 -1.5670 0.0000 0
M  V30 16 C 10.3563 -1.8219 0.0000 0
M  V30 17 N 11.0707 -1.4094 0.0000 0
M  V30 18 C 11.7852 -1.8219 0.0000 0
M  V30 19 N 11.7852 -2.6469 0.0000 0
M  V30 20 C 11.0707 -3.0594 0.0000 0
M  V30 21 N 11.0707 -3.8844 0.0000 0
M  V30 22 C 10.3563 -2.6469 0.0000 0
M  V30 23 N 9.5716 -2.9018 0.0000 0
M  V30 24 C 9.0867 -2.2344 0.0000 0
M  V30 25 O 6.4083 0.8750 0.0000 0
M  V30 26 C 6.2367 0.0680 0.0000 0
M  V30 27 C 6.8498 -0.4840 0.0000 0
M  V30 28 C 6.6783 -1.2910 0.0000 0
M  V30 29 C 5.8937 -1.5459 0.0000 0
M  V30 30 C 5.2806 -0.9939 0.0000 0
M  V30 31 C 5.4521 -0.1869 0.0000 0
M  V30 32 O 7.9775 1.3849 0.0000 0
M  V30 33 O 6.4281 3.4838 0.0000 0
M  V30 34 H 5.1528 2.2939 0.0000 0
M  V30 35 H 7.5315 -0.4029 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=1
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 12 11
M  V30 12 1 12 13 CFG=1
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 20 22
M  V30 22 1 16 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 15 24
M  V30 26 1 9 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 26 31
M  V30 34 2 9 32
M  V30 35 2 5 33
M  V30 36 1 34 6
M  V30 37 1 35 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
409

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tenofovir alafenamide hemifumarate

>  <Synonyms>
Tenofovir alafenamide fumarate;GS-7340 (hemifumarate)

>  <CAS>
1392275-56-7

>  <Formula>
C21H29N6O5P??1/2C4H4O4

>  <MolWt>
534.5

>  <Pathways>
Proteases/Proteasome;Microbiology/Virology

>  <Target>
Reverse Transcriptase;HIV Protease

>  <Receptor>
HIV; HIV-1; Reverse Transcriptase

>  <Bioactivity>
Tenofovir alafenamide fumarate (TAF) is an oral phosphonoamidate prodrug of the HIV reverse transcriptase nucleotide inhibitor tenofovir (TFV)

>  <Reference>
"Birkus G, Bam RA, Willkom M,et al.Intracellular Activation of Tenofovir Alafenamide and the Effect of Viral and Host Protease Inhibitors[J].Antimicrob Agents Chemother. 2015 Oct 26;60(1):316-22.;Callebaut C , Stepan G , Tian Y , et al. In Vitro Virology Profile of Tenofovir Alafenamide, a Novel Oral Prodrug of Tenofovir with Improved Antiviral Activity Compared to Tenofovir Disoproxil Fumarate[J]. Antimicrobial Agents and Chemotherapy, 2015:AAC.01152-15."

>  <ID<1>>
T7282

$$$$
StarDrop ID 410
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.0280 -3.6748 0.0000 0
M  V30 2 C -0.6865 -3.2623 0.0000 0
M  V30 3 C -0.6865 -2.4373 0.0000 0
M  V30 4 C 0.0280 -2.0248 0.0000 0
M  V30 5 C 0.7425 -2.4373 0.0000 0
M  V30 6 C 1.4569 -2.0248 0.0000 0
M  V30 7 C 2.1714 -2.4373 0.0000 0
M  V30 8 O 2.8859 -2.0248 0.0000 0
M  V30 9 O 2.1714 -3.2623 0.0000 0
M  V30 10 C 0.0280 -4.4998 0.0000 0 CFG=2
M  V30 11 C 0.6954 -4.9847 0.0000 0 CFG=1
M  V30 12 C 1.4801 -4.7298 0.0000 0
M  V30 13 C 2.0932 -5.2818 0.0000 0
M  V30 14 C 2.8778 -5.0269 0.0000 0 CFG=1
M  V30 15 C 3.6624 -4.7719 0.0000 0
M  V30 16 C 4.2755 -5.3239 0.0000 0
M  V30 17 C 5.0601 -5.0690 0.0000 0
M  V30 18 C 5.6732 -5.6210 0.0000 0
M  V30 19 C 6.4578 -5.3661 0.0000 0
M  V30 20 C 3.1327 -5.8115 0.0000 0
M  V30 21 O 2.6228 -4.2422 0.0000 0
M  V30 22 C 0.4405 -5.7693 0.0000 0 CFG=2
M  V30 23 O 0.9254 -6.4368 0.0000 0
M  V30 24 C -0.3845 -5.7693 0.0000 0
M  V30 25 C -0.6394 -4.9847 0.0000 0 CFG=2
M  V30 26 O -1.4241 -4.7298 0.0000 0
M  V30 27 H 0.9190 -4.0458 0.0000 0
M  V30 28 H 1.4026 -5.6917 0.0000 0
M  V30 29 H -0.0135 -6.6603 0.0000 0
M  V30 30 H -1.3466 -5.6917 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 10 1 CFG=3
M  V30 10 1 10 11
M  V30 11 1 11 12 CFG=1
M  V30 12 2 12 13
M  V30 13 1 14 13 CFG=1
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 14 20
M  V30 20 1 14 21 CFG=3
M  V30 21 1 11 22
M  V30 22 1 22 23 CFG=3
M  V30 23 1 22 24
M  V30 24 1 25 24
M  V30 25 1 10 25
M  V30 26 1 25 26 CFG=3
M  V30 27 1 27 10
M  V30 28 1 28 11
M  V30 29 1 29 22
M  V30 30 1 30 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
410

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Carboprost

>  <Synonyms>
15-Methyl-PGF2??;15(S)-15-Methyl Prostaglandin F2??

>  <CAS>
35700-23-3

>  <Formula>
C21H36O5

>  <MolWt>
368.5

>  <Pathways>
GPCR/G Protein;Immunology/Inflammation

>  <Target>
Prostaglandin Receptor

>  <Receptor>
prostaglandin F2??

>  <Bioactivity>
Carboprost is a synthetic prostaglandin analogue of PGF2?? which has the effect of oxytocic. Carboprost is commonly used to restore uterine tone.

>  <Reference>
"Vallera C, et al. Uterotonic Medications: Oxytocin, Methylergonovine, Carboprost, Misoprostol. Anesthesiol Clin. 2017 Jun;35(2):207-219.;Carlan SJ, et al. Effect of intramuscular 15-methyl prostaglandin F2 alpha after second-trimester delivery. Obstet Gynecol. 1997 Jan;89(1):5-9.;J W Wilks, et al. Inhibition of the Monkey Corpus Luteum With 15-methyl Prostaglandins. Prostaglandins. 1980 Nov;20(5):793-805."

>  <ID<1>>
T22285

$$$$
StarDrop ID 411
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.7145 -2.8875 0.0000 0
M  V30 2 N 0.7145 -3.7125 0.0000 0
M  V30 3 N 1.3819 -4.1974 0.0000 0
M  V30 4 N 1.1270 -4.9820 0.0000 0
M  V30 5 C 0.3020 -4.9820 0.0000 0
M  V30 6 N 0.0470 -4.1974 0.0000 0
M  V30 7 C -0.1830 -5.6495 0.0000 0
M  V30 8 C 0.1526 -6.4032 0.0000 0
M  V30 9 C -0.3323 -7.0706 0.0000 0
M  V30 10 C -1.1528 -6.9844 0.0000 0
M  V30 11 C -1.4884 -6.2307 0.0000 0
M  V30 12 N -1.0034 -5.5632 0.0000 0
M  V30 13 C -1.6377 -7.6518 0.0000 0
M  V30 14 C -1.3022 -8.4055 0.0000 0
M  V30 15 C -1.7871 -9.0729 0.0000 0
M  V30 16 C -2.6076 -8.9867 0.0000 0
M  V30 17 C -2.9431 -8.2330 0.0000 0
M  V30 18 C -2.4582 -7.5656 0.0000 0
M  V30 19 F -2.7938 -6.8119 0.0000 0
M  V30 20 N -3.0925 -9.6541 0.0000 0
M  V30 21 C -2.8375 -10.4387 0.0000 0
M  V30 22 C -3.5050 -10.9237 0.0000 0 CFG=2
M  V30 23 C -3.5050 -11.7487 0.0000 0
M  V30 24 O -4.2195 -12.1612 0.0000 0
M  V30 25 P -4.2195 -12.9862 0.0000 0
M  V30 26 O -4.2195 -13.8112 0.0000 0
M  V30 27 O -5.0445 -12.9862 0.0000 0
M  V30 28 O -3.3945 -12.9862 0.0000 0
M  V30 29 O -4.1724 -10.4387 0.0000 0
M  V30 30 C -3.9175 -9.6541 0.0000 0
M  V30 31 O -4.4024 -8.9867 0.0000 0
M  V30 32 H -4.3960 -11.3776 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 2 6
M  V30 7 1 5 7
M  V30 8 2 7 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 7 12
M  V30 14 1 10 13
M  V30 15 2 13 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 13 18
M  V30 21 1 18 19
M  V30 22 1 16 20
M  V30 23 1 20 21
M  V30 24 1 22 21
M  V30 25 1 22 23 CFG=3
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 25 27
M  V30 30 2 25 28
M  V30 31 1 22 29
M  V30 32 1 29 30
M  V30 33 1 20 30
M  V30 34 2 30 31
M  V30 35 1 32 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
411

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tedizolid Phosphate

>  <Synonyms>
TR-701FA;Torezolid phosphate

>  <CAS>
856867-55-5

>  <Formula>
C17H16FN6O6P

>  <MolWt>
450.3

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
antibiotic; Bacterial

>  <Bioactivity>
Tedizolid is an oxazolidinone-class antibiotic. Tedizolid phosphate is a phosphate ester prodrug of the active compound tedizolid.

>  <Reference>
"Choi S, et al. Antimicrob Agents Chemother. 2012, 56(9):4713-7.;Prokocimer P, et al. Antimicrob Agents Chemother. 2012, 56(9):4608-13."

>  <ID<1>>
T6998

$$$$
StarDrop ID 412
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.1434 -3.7125 0.0000 0
M  V30 2 N 2.1434 -2.8875 0.0000 0
M  V30 3 C 1.4289 -2.4750 0.0000 0
M  V30 4 C 0.7145 -2.8875 0.0000 0
M  V30 5 C 0.0000 -3.3000 0.0000 0
M  V30 6 C 2.8579 -2.4750 0.0000 0
M  V30 7 C 3.5724 -2.8875 0.0000 0
M  V30 8 C 4.2868 -2.4750 0.0000 0
M  V30 9 C 5.0013 -2.8875 0.0000 0
M  V30 10 C 5.0013 -3.7125 0.0000 0
M  V30 11 C 4.2868 -4.1250 0.0000 0
M  V30 12 C 3.5724 -3.7125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 3 4 5
M  V30 5 1 2 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 7 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
412

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pargyline

>  <Synonyms>
Paragyline;Pargylamine

>  <CAS>
555-57-7

>  <Formula>
C11H13N

>  <MolWt>
159.2

>  <Pathways>
Neuroscience;Metabolism

>  <Target>
Monoamine Oxidase;MAO

>  <Receptor>
" MAO-B:8.2 nM, MAO-A:11.52 nM"

>  <Bioactivity>
Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.

>  <Reference>
"Patkar AA, et al. CNS Spectr. 2006, 11(5):363-75."

>  <ID<1>>
T0300

$$$$
StarDrop ID 413
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -2.4382 -0.8695 0.0000 0
M  V30 2 C -1.6313 -1.0410 0.0000 0 CFG=1
M  V30 3 C -1.0182 -0.4890 0.0000 0
M  V30 4 C -0.3037 -0.9015 0.0000 0
M  V30 5 N -0.4752 -1.7084 0.0000 0
M  V30 6 C -1.2957 -1.7947 0.0000 0
M  V30 7 C 0.0768 -2.3215 0.0000 0
M  V30 8 O -0.1781 -3.1062 0.0000 0
M  V30 9 N 0.8838 -2.1500 0.0000 0
M  V30 10 C 1.1387 -1.3654 0.0000 0
M  V30 11 C 0.6538 -0.6979 0.0000 0
M  V30 12 N 1.1387 -0.0305 0.0000 0
M  V30 13 N 1.9233 -0.2854 0.0000 0
M  V30 14 C 2.6378 0.1271 0.0000 0
M  V30 15 C 3.3523 -0.2854 0.0000 0
M  V30 16 C 3.3523 -1.1104 0.0000 0
M  V30 17 N 2.6378 -1.5229 0.0000 0
M  V30 18 C 1.9233 -1.1104 0.0000 0
M  V30 19 N 4.0668 -1.5229 0.0000 0
M  V30 20 C 4.8204 -1.1874 0.0000 0
M  V30 21 C 5.3725 -1.8005 0.0000 0
M  V30 22 C 4.9600 -2.5150 0.0000 0
M  V30 23 C 4.1530 -2.3434 0.0000 0 CFG=2
M  V30 24 C 3.5399 -2.8955 0.0000 0
M  V30 25 C 2.7553 -2.6405 0.0000 0
M  V30 26 C 2.1422 -3.1925 0.0000 0
M  V30 27 F 1.3576 -2.9376 0.0000 0
M  V30 28 C 2.3137 -3.9995 0.0000 0
M  V30 29 C 3.0983 -4.2545 0.0000 0
M  V30 30 C 3.7114 -3.7024 0.0000 0
M  V30 31 F 4.4960 -3.9574 0.0000 0
M  V30 32 H -1.8900 -0.0751 0.0000 0
M  V30 33 H 4.4118 -3.3093 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 2 6
M  V30 7 1 5 7
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 10 18
M  V30 20 1 13 18
M  V30 21 1 16 19
M  V30 22 1 19 20
M  V30 23 1 20 21
M  V30 24 1 21 22
M  V30 25 1 23 22
M  V30 26 1 23 19
M  V30 27 1 23 24 CFG=3
M  V30 28 2 24 25
M  V30 29 1 25 26
M  V30 30 1 26 27
M  V30 31 2 26 28
M  V30 32 1 28 29
M  V30 33 2 29 30
M  V30 34 1 24 30
M  V30 35 1 30 31
M  V30 36 1 32 2
M  V30 37 1 33 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
413

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Larotrectinib

>  <Synonyms>
LOXO-101;ARRY-470

>  <CAS>
1223403-58-4

>  <Formula>
C21H22F2N6O2

>  <MolWt>
428.4

>  <Pathways>
Apoptosis;Tyrosine Kinase/Adaptors

>  <Target>
Trk receptor;Apoptosis

>  <Receptor>
 TRK:2-20 nM

>  <Bioactivity>
Larotrectinib is an orally administered inhibitor of the TRK kinase and is highly selective only for the TRK family of receptors(IC50s = 2-20 nM).

>  <Reference>
"Laetsch T W , Dubois S G , Mascarenhas L , et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study[J]. The Lancet Oncology, 2018:S1470204518301190.;Doebele R C , Davis L E , Vaishnavi A , et al. An oncogenic NTRK fusion in a soft tissue sarcoma patient with response to the tropomyosin-related kinase (TRK) inhibitor LOXO-101[J]. Cancer Discovery, 2015, 5(10):1049-1057."

>  <ID<1>>
T5995

$$$$
StarDrop ID 414
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.7158 0.8250 0.0000 0
M  V30 2 C 5.0013 1.2375 0.0000 0
M  V30 3 O 5.0013 2.0625 0.0000 0
M  V30 4 C 4.2868 0.8250 0.0000 0
M  V30 5 O 3.5724 1.2375 0.0000 0
M  V30 6 C 2.8579 0.8250 0.0000 0
M  V30 7 C 2.8579 0.0000 0.0000 0
M  V30 8 C 2.1434 -0.4125 0.0000 0
M  V30 9 C 1.4289 -0.0000 0.0000 0
M  V30 10 C 0.7145 -0.4125 0.0000 0
M  V30 11 O 0.7145 -1.2375 0.0000 0
M  V30 12 C -0.0000 0.0000 0.0000 0
M  V30 13 C 0.0000 0.8250 0.0000 0
M  V30 14 C -0.7145 1.2375 0.0000 0
M  V30 15 O -1.4289 0.8250 0.0000 0
M  V30 16 O -0.7145 2.0625 0.0000 0
M  V30 17 N 0.7145 1.2375 0.0000 0
M  V30 18 C 1.4289 0.8250 0.0000 0
M  V30 19 C 2.1434 1.2375 0.0000 0
M  V30 20 C 2.1434 2.0625 0.0000 0
M  V30 21 C 1.4289 2.4750 0.0000 0
M  V30 22 C 1.4289 3.3000 0.0000 0
M  V30 23 C 0.7145 2.0625 0.0000 0
M  V30 24 C 0.0000 2.4750 0.0000 0
M  V30 25 C 3.5724 -0.4125 0.0000 0
M  V30 26 O 3.5724 -1.2375 0.0000 0
M  V30 27 C 4.2868 -0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 13 17
M  V30 17 1 17 18
M  V30 18 1 9 18
M  V30 19 2 18 19
M  V30 20 1 6 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 17 23
M  V30 25 1 23 24
M  V30 26 1 7 25
M  V30 27 2 25 26
M  V30 28 1 25 27
M  V30 29 2 4 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
414

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Nedocromil

>  <Synonyms>
FPL 59002

>  <CAS>
69049-73-6

>  <Formula>
C19H17NO7

>  <MolWt>
371.3

>  <Pathways>
GPCR/G Protein;Neuroscience;Immunology/Inflammation

>  <Target>
Histamine Receptor;Prostaglandin Receptor;Leukotriene Receptor

>  <Receptor>
" PGD2:1.9 ??M(IC30), histamine:2.1 ??M(IC30), LTC4:2.3 ??M(IC30)"

>  <Bioactivity>
"Nedocromil inhibits the action or formation of multiple mediators. Which including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2)."

>  <Reference>
"Myocardial remodeling in diabetic cardiomyopathy associated with cardiac mast cell activation. Huang ZG, et al. PLoS One. 2013;8(3):e60827.;Wells E, et al. Characterization of primate bronchoalveolar mast cells. II. Inhibition of histamine, LTC4, and PGD2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mastcells. J Immunol. 1986 Dec 15;137(12):3941-5."

>  <ID<1>>
T16280

$$$$
StarDrop ID 415
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 45 48 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.8579 -6.6000 0.0000 0
M  V30 2 O -2.1434 -6.1875 0.0000 0
M  V30 3 C -2.1434 -5.3625 0.0000 0
M  V30 4 C -2.8579 -4.9500 0.0000 0
M  V30 5 C -2.8579 -4.1250 0.0000 0
M  V30 6 C -2.1434 -3.7125 0.0000 0
M  V30 7 C -1.4289 -4.1250 0.0000 0
M  V30 8 C -1.4289 -4.9500 0.0000 0
M  V30 9 F -0.7145 -5.3625 0.0000 0
M  V30 10 C -0.7145 -3.7125 0.0000 0
M  V30 11 C 0.0000 -4.1250 0.0000 0
M  V30 12 C 0.0000 -4.9500 0.0000 0
M  V30 13 N 0.7145 -3.7125 0.0000 0
M  V30 14 C 1.4289 -4.1250 0.0000 0
M  V30 15 C 1.4289 -4.9500 0.0000 0
M  V30 16 C 0.7145 -5.3625 0.0000 0
M  V30 17 F -0.1060 -5.4487 0.0000 0
M  V30 18 C 0.7145 -6.1875 0.0000 0
M  V30 19 C 1.4289 -6.6000 0.0000 0
M  V30 20 C 2.1434 -6.1875 0.0000 0
M  V30 21 C 2.1434 -5.3625 0.0000 0
M  V30 22 C 2.8579 -4.9500 0.0000 0
M  V30 23 F 3.5724 -4.5375 0.0000 0
M  V30 24 F 3.2704 -5.6645 0.0000 0
M  V30 25 F 2.4454 -4.2355 0.0000 0
M  V30 26 C 0.7145 -2.8875 0.0000 0
M  V30 27 O 1.4289 -2.4750 0.0000 0
M  V30 28 N 0.0000 -2.4750 0.0000 0
M  V30 29 C 0.0000 -1.6500 0.0000 0
M  V30 30 C 0.7145 -1.2375 0.0000 0
M  V30 31 N 1.4289 -1.6500 0.0000 0
M  V30 32 C 2.1434 -1.2375 0.0000 0
M  V30 33 C 2.8579 -1.6500 0.0000 0
M  V30 34 C 3.5724 -1.2375 0.0000 0
M  V30 35 C 4.2868 -1.6500 0.0000 0
M  V30 36 O 5.0013 -1.2375 0.0000 0
M  V30 37 O 4.2868 -2.4750 0.0000 0
M  V30 38 C 0.7145 -0.4125 0.0000 0
M  V30 39 C 0.0000 0.0000 0.0000 0
M  V30 40 C 0.0000 0.8250 0.0000 0
M  V30 41 C 0.7145 1.2375 0.0000 0
M  V30 42 C 1.4289 0.8250 0.0000 0
M  V30 43 C 1.4289 0.0000 0.0000 0
M  V30 44 C -0.7145 -2.8875 0.0000 0
M  V30 45 O -1.4289 -2.4750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 3 8
M  V30 9 1 8 9
M  V30 10 1 7 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 15 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 1 22 24
M  V30 26 1 22 25
M  V30 27 1 13 26
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 28 29
M  V30 31 1 29 30
M  V30 32 1 30 31
M  V30 33 1 31 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 1 34 35
M  V30 37 1 35 36
M  V30 38 2 35 37
M  V30 39 1 30 38
M  V30 40 2 38 39
M  V30 41 1 39 40
M  V30 42 2 40 41
M  V30 43 1 41 42
M  V30 44 2 42 43
M  V30 45 1 38 43
M  V30 46 1 28 44
M  V30 47 1 10 44
M  V30 48 2 44 45
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
415

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Elagolix sodium

>  <Synonyms>
NBI-56418 sodium

>  <CAS>
832720-36-2

>  <Formula>
C32H29F5N3NaO5

>  <MolWt>
653.6

>  <Pathways>
GPCR/G Protein

>  <Target>
GNRH Receptor

>  <Receptor>
" GnRHR:0.25 nM, GnRHR:3.7 nM"

>  <Bioactivity>
"Elagolix sodium is a GnRH receptor (GnRHR) antagonist ( IC50 and Ki of 0.25 and 3.7 nM, respectively)."

>  <Reference>
"Barra F, Scala C, Ferrero S2.Elagolix sodium for the treatment of women with moderate to severe endometriosis-associated pain.Drugs Today (Barc). 2019 Apr;55(4):237-246.;Elagolix (Orilissa)--an oral GnRH antagonist for endometriosis pain.[J]. The Medical letter on drugs and therapeutics, 2018."

>  <ID<1>>
T5031

$$$$
StarDrop ID 416
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 18 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -0.7145 0.4125 0.0000 0
M  V30 2 C -0.7145 1.2375 0.0000 0
M  V30 3 N -0.7145 2.0625 0.0000 0
M  V30 4 C 0.0000 2.4750 0.0000 0
M  V30 5 N 0.7145 2.0625 0.0000 0
M  V30 6 C 0.7145 1.2375 0.0000 0
M  V30 7 C 1.4289 0.8250 0.0000 0
M  V30 8 C 1.4289 -0.0000 0.0000 0
M  V30 9 N 0.7145 -0.4125 0.0000 0
M  V30 10 C 0.0000 0.0000 0.0000 0
M  V30 11 C 0.0000 0.8250 0.0000 0
M  V30 12 N 0.0000 3.3000 0.0000 0
M  V30 13 C 0.7145 3.7125 0.0000 0
M  V30 14 C 1.4289 3.3000 0.0000 0
M  V30 15 C 0.7145 4.5375 0.0000 0
M  V30 16 C 0.7145 5.3625 0.0000 0
M  V30 17 C 1.5395 4.5375 0.0000 0
M  V30 18 C -0.1105 4.5375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 3 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 6 11
M  V30 12 1 4 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 1 15 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
416

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pinacidil

>  <Synonyms>
P1134;S 1230;P 1134;P-1134;S-1230

>  <CAS>
60560-33-0

>  <Formula>
C13H19N5

>  <MolWt>
245.3

>  <Pathways>
Membrane transporter/Ion channel

>  <Target>
Potassium Channel

>  <Receptor>
Potassium Channel

>  <Bioactivity>
"Pinardil (P-1134, S-1230) is a guanidine that opens potassium channels and directly dilates peripheral blood vessels in small arteries, lowering blood pressure and peripheral resistance and producing fluid retention."

>  <Reference>
"Ahnfelt-R?nne I. Pinacidil. Preclinical investigations. Drugs. 1988;36 Suppl 7:4-9. Review. PubMed PMID: 3076134.;Zushida K, Onodera K, Kamei J. Effect of diabetes on pinacidil-induced antinociception in mice. Eur J Pharmacol. 2002 Oct 25;453(2-3):209-15. PubMed PMID: 12398906.;Cohen ML, Kurz KD. Pinacidil-induced vascular relaxation: comparison to other vasodilators and to classical mechanisms of vasodilation. J Cardiovasc Pharmacol. 1988;12 Suppl 2:S5-9. PubMed PMID: 2466179.;Friedel HA, Brogden RN. Pinacidil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of hypertension. Drugs. 1990 Jun;39(6):929-67. Review. PubMed PMID: 2196168."

>  <ID<1>>
T12478L

$$$$
StarDrop ID 417
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.3222 0.6402 0.0000 0
M  V30 2 N -2.0367 1.0527 0.0000 0
M  V30 3 C -2.0367 1.8777 0.0000 0
M  V30 4 C -1.3222 2.2902 0.0000 0
M  V30 5 C -1.3222 3.1152 0.0000 0
M  V30 6 C -0.6078 3.5277 0.0000 0
M  V30 7 C 0.1067 3.1152 0.0000 0
M  V30 8 C 0.1067 2.2902 0.0000 0
M  V30 9 C -0.6078 1.8777 0.0000 0
M  V30 10 C -2.7512 0.6402 0.0000 0
M  V30 11 C -2.7512 -0.1848 0.0000 0
M  V30 12 C -3.4656 -0.5973 0.0000 0
M  V30 13 C -4.1801 -0.1848 0.0000 0
M  V30 14 C -4.1801 0.6402 0.0000 0
M  V30 15 C -3.4656 1.0527 0.0000 0
M  V30 16 C -1.3222 -0.1848 0.0000 0
M  V30 17 N -0.6548 -0.6697 0.0000 0
M  V30 18 C -0.9097 -1.4544 0.0000 0
M  V30 19 C -1.7347 -1.4544 0.0000 0
M  V30 20 N -1.9897 -0.6697 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 4 9
M  V30 10 1 2 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 10 15
M  V30 17 1 1 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 16 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
417

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Antazoline

>  <Synonyms>
N/A

>  <CAS>
91-75-8

>  <Formula>
C17H19N3

>  <MolWt>
265.4

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Antazoline has antihistamine and anticholinergic effects.It used to treat a variety of arrhythmias.

>  <Reference>
"BJ Bi??kowski,  Makowski M , Kubi??ski, Pawe, et al. Effect of Antazoline on Electrophysiological Properties of Atrial Muscle and Conduction System of the Heart[J]. Cardiovascular Drugs and Therapy, 2018.;Michal M Farkowski , Aleksander Maciag,et al.Intravenous antazoline, a first-generation antihistaminic drug with antiarrhythmic properties, is a suitable agent for pharmacological cardioversion of atrial fibrillation induced during pulmonary vein isolation due to the lack of influence on atrio-venous conduction and high clinical effectiveness (AntaEP Study).Br J Clin Pharmacol. 2019 Jul;85(7):1552-1558. "

>  <ID<1>>
T7477

$$$$
StarDrop ID 418
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -2.9906 2.3882 0.0000 0
M  V30 2 C -3.1622 3.1952 0.0000 0
M  V30 3 C -2.5491 3.7472 0.0000 0
M  V30 4 C -1.7644 3.4923 0.0000 0
M  V30 5 C -1.5929 2.6853 0.0000 0
M  V30 6 C -0.8083 2.4304 0.0000 0
M  V30 7 C -0.6368 1.6234 0.0000 0
M  V30 8 O -1.2499 1.0714 0.0000 0
M  V30 9 O 0.1479 1.3685 0.0000 0
M  V30 10 C -3.6037 1.8362 0.0000 0 CFG=2
M  V30 11 C -3.5175 1.0157 0.0000 0 CFG=1
M  V30 12 C -2.8030 0.6032 0.0000 0
M  V30 13 C -2.8030 -0.2218 0.0000 0
M  V30 14 C -2.0886 -0.6343 0.0000 0 CFG=2
M  V30 15 C -1.3741 -0.2218 0.0000 0
M  V30 16 C -0.6596 -0.6343 0.0000 0
M  V30 17 C 0.0549 -0.2218 0.0000 0
M  V30 18 C 0.7693 -0.6343 0.0000 0
M  V30 19 C 1.4838 -0.2218 0.0000 0
M  V30 20 O -2.0886 -1.4593 0.0000 0
M  V30 21 C -4.2712 0.6802 0.0000 0 CFG=2
M  V30 22 O -4.4427 -0.1268 0.0000 0
M  V30 23 C -4.8232 1.2932 0.0000 0
M  V30 24 C -4.4107 2.0077 0.0000 0 CFG=2
M  V30 25 O -4.7463 2.7614 0.0000 0
M  V30 26 H -2.6701 1.4778 0.0000 0
M  V30 27 H -2.6788 1.5603 0.0000 0
M  V30 28 H -2.9546 -1.1343 0.0000 0
M  V30 29 H -5.2371 0.4212 0.0000 0
M  V30 30 H -5.4093 2.0600 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 10 1 CFG=3
M  V30 10 1 10 11
M  V30 11 1 11 12 CFG=1
M  V30 12 2 12 13
M  V30 13 1 14 13
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 14 20 CFG=3
M  V30 20 1 11 21
M  V30 21 1 21 22 CFG=3
M  V30 22 1 21 23
M  V30 23 1 24 23
M  V30 24 1 10 24
M  V30 25 1 24 25 CFG=3
M  V30 26 1 26 10
M  V30 27 1 27 11
M  V30 28 1 28 14
M  V30 29 1 29 21
M  V30 30 1 30 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
418

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dinoprost

>  <Synonyms>
Prostaglandin F2a;PGF2??

>  <CAS>
551-11-1

>  <Formula>
C20H34O5

>  <MolWt>
354.5

>  <Pathways>
Metabolism

>  <Target>
Endogenous Metabolite

>  <Receptor>
Human Endogenous Metabolite

>  <Bioactivity>
Dinoprost is a naturally occurring prostaglandin. It is used in medicine to induce labor and as an abortifacient.

>  <Reference>
"Coulthard G, et al. Stereocontrolled organocatalytic synthesis of prostaglandin PGF2?? in seven steps. Nature. 2012 Sep 13;489(7415):278-81.;Sharma I, et al. Role of 8-iso-prostaglandin F2alpha and 25-hydroxycholesterol in the pathophysiology of endometriosis. Fertil Steril. 2010 Jun;94(1):63-70."

>  <ID<1>>
T15133

$$$$
StarDrop ID 419
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.3000 -2.2539 0.0000 0
M  V30 2 C 2.8875 -1.5395 0.0000 0
M  V30 3 C 2.0625 -1.5395 0.0000 0
M  V30 4 C 1.6500 -0.8250 0.0000 0
M  V30 5 C 0.8250 -0.8250 0.0000 0
M  V30 6 O 0.0000 -0.8250 0.0000 0
M  V30 7 P 0.8250 -1.6500 0.0000 0
M  V30 8 O 0.0000 -1.6500 0.0000 0
M  V30 9 O 1.6500 -1.6500 0.0000 0
M  V30 10 O 0.8250 -2.4750 0.0000 0
M  V30 11 P 0.8250 0.0000 0.0000 0
M  V30 12 O 0.8250 0.8250 0.0000 0
M  V30 13 O 1.6500 0.0000 0.0000 0
M  V30 14 O 0.0000 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 2 7 10
M  V30 10 1 5 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 2 11 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
419

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Alendronic Acid

>  <Synonyms>
alendronate

>  <CAS>
66376-36-1

>  <Formula>
C4H13NO7P2

>  <MolWt>
249.1

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Alendronic acid is a nonhormonal medication used for osteoporosis, osteogenesis imperfecta, and several other bone diseases."

>  <Reference>
"Parente-Pereira A C , Shmeeda H , Whilding L M , et al. Adoptive Immunotherapy of Epithelial Ovarian Cancer with V?9V?2 T Cells, Potentiated by Liposomal Alendronic Acid[J]. The Journal of Immunology, 2014, 193(11):5557-5566.;Mart??n Siguero A, ??reas Del ??guila VL, Franco Sereno M T , et al. Efficacy and safety of alendronic acid in the treatment of osteoporosis in children.[J]. Farm Hosp, 2015, 39(6):350-354."

>  <ID<1>>
T7469

$$$$
StarDrop ID 420
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -0.0392 -2.5519 0.0000 0
M  V30 2 C 0.7145 -2.8875 0.0000 0
M  V30 3 N 0.6282 -3.7080 0.0000 0
M  V30 4 C -0.1787 -3.8795 0.0000 0
M  V30 5 C -0.5912 -3.1650 0.0000 0
M  V30 6 C 1.4289 -2.4750 0.0000 0
M  V30 7 C 1.4289 -1.6500 0.0000 0
M  V30 8 C 0.7145 -1.2375 0.0000 0
M  V30 9 C 0.7145 -0.4125 0.0000 0
M  V30 10 C 1.4289 0.0000 0.0000 0
M  V30 11 C 2.1434 -0.4125 0.0000 0
M  V30 12 C 2.8579 0.0000 0.0000 0
M  V30 13 C 3.5724 -0.4125 0.0000 0
M  V30 14 C 3.5724 -1.2375 0.0000 0
M  V30 15 C 2.8579 -1.6500 0.0000 0
M  V30 16 C 2.1434 -1.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 1 5
M  V30 6 1 2 6
M  V30 7 1 6 7
M  V30 8 2 7 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 11 16
M  V30 18 1 7 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
420

>  <Plate>
PHD136329

>  <Row>
e

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Naphazoline

>  <Synonyms>
Clear Eyes;Naphcon-a;AK-Con;All Clear

>  <CAS>
835-31-4

>  <Formula>
C14H14N2

>  <MolWt>
210.3

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Adrenergic Receptor

>  <Receptor>
??-adrenergic receptor

>  <Bioactivity>
Naphazoline is a sympathomimetic compound with marked alpha adrenergic activity. Naphazoline can be used as a vasoconstrictor with a rapid action in reducing swelling when applied to mucous membrane.

>  <Reference>
"Hoang VD, Hue NT, Tho NH, Nguyen HM. Simultaneous determination of chloramphenicol, dexamethasone and naphazoline in ternary and quaternary mixtures by RP-HPLC, derivative and wavelet transforms of UV ratio spectra. Spectrochim Acta A Mol Biomol Spectrosc. 2015 Mar 15;139:20-7. doi: 10.1016/j.saa.2014.11.101. Epub 2014 Dec 12. PubMed PMID: 25546493.;Quan L, He H. Treatment with olopatadine and naphazoline hydrochloride reduces allergic conjunctivitis in mice through alterations in inflammation, NGF and VEGF. Mol Med Rep. 2016 Apr;13(4):3319-25. doi: 10.3892/mmr.2016.4937. Epub 2016 Feb 23. PubMed PMID: 26936233.;Liguori C, Garaci F, Romigi A, Mercuri NB, Marciani MG, Placidi F. Bilateral thalamic stroke due to nasal ephedrine and naphazoline use. Neurol Sci. 2015 Jul;36(7):1285-6. doi: 10.1007/s10072-014-2030-z. Epub 2014 Dec 20. PubMed PMID: 25527367.;Oliveira Tda C, Freitas JM, Abarza Munoz RA, Richter EM. A batch injection analysis system with square-wave voltammetric detection for fast and simultaneous determination of naphazoline and zinc. Talanta. 2016 May 15;152:308-13. doi: 10.1016/j.talanta.2016.02.031. Epub 2016 Feb 15. PubMed PMID: 26992525."

>  <ID<1>>
T21445

$$$$
StarDrop ID 421
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7145 1.2375 0.0000 0
M  V30 2 C 1.4289 0.8250 0.0000 0
M  V30 3 N 1.4289 0.0000 0.0000 0
M  V30 4 C 2.1434 -0.4125 0.0000 0
M  V30 5 C 2.8579 0.0000 0.0000 0
M  V30 6 C 3.5724 -0.4125 0.0000 0
M  V30 7 N 4.2868 -0.0000 0.0000 0
M  V30 8 C 5.0013 -0.4125 0.0000 0
M  V30 9 N 3.5724 -1.2375 0.0000 0
M  V30 10 C 2.8579 -1.6500 0.0000 0
M  V30 11 C 2.1434 -1.2375 0.0000 0
M  V30 12 C 1.4289 -1.6500 0.0000 0
M  V30 13 C 0.7145 -1.2375 0.0000 0
M  V30 14 C 0.0000 -1.6500 0.0000 0
M  V30 15 C 0.0000 -2.4750 0.0000 0
M  V30 16 C -0.7145 -2.8875 0.0000 0
M  V30 17 N -0.7145 -3.7125 0.0000 0
M  V30 18 C -1.4289 -4.1250 0.0000 0
M  V30 19 O -2.1434 -3.7125 0.0000 0
M  V30 20 N -1.4289 -4.9500 0.0000 0
M  V30 21 C -2.1434 -5.3625 0.0000 0
M  V30 22 C -2.1434 -6.1875 0.0000 0
M  V30 23 C -2.8579 -6.6000 0.0000 0
M  V30 24 C -3.5724 -6.1875 0.0000 0
M  V30 25 C -3.5724 -5.3625 0.0000 0
M  V30 26 C -2.8579 -4.9500 0.0000 0
M  V30 27 C -1.4289 -2.4750 0.0000 0
M  V30 28 F -2.1434 -2.8875 0.0000 0
M  V30 29 C -1.4289 -1.6500 0.0000 0
M  V30 30 C -0.7145 -1.2375 0.0000 0
M  V30 31 Br -0.7145 -0.4125 0.0000 0
M  V30 32 C 0.7145 -0.4125 0.0000 0
M  V30 33 O 0.0000 -0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 6 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 4 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 21 26
M  V30 28 2 16 27
M  V30 29 1 27 28
M  V30 30 1 27 29
M  V30 31 2 29 30
M  V30 32 1 14 30
M  V30 33 1 30 31
M  V30 34 1 13 32
M  V30 35 1 3 32
M  V30 36 2 32 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
421

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ripretinib

>  <Synonyms>
DCC-2618

>  <CAS>
1442472-39-0

>  <Formula>
C24H21BrFN5O2

>  <MolWt>
510.4

>  <Pathways>
Angiogenesis;Apoptosis;Tyrosine Kinase/Adaptors

>  <Target>
Apoptosis;PDGFR;c-Kit;FLT;VEGFR

>  <Receptor>
Apoptosis; c-Kit; FLT3; Kit; PDGFR; VEGFR

>  <Bioactivity>
Ripretinib is an orally bioavailable inhibitor of KIT and PDGFRA.

>  <Reference>
"Schneeweiss M, et al. The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. Haematologica. 2018 May;103(5):799-809."

>  <ID<1>>
T8482

$$$$
StarDrop ID 422
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 53 55 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 2.8131 -1.0010 0.0000 0
M  V30 2 C 2.7425 -1.8230 0.0000 0 CFG=1
M  V30 3 C 2.5025 -2.6123 0.0000 0 CFG=1
M  V30 4 C 1.6776 -2.6280 0.0000 0
M  V30 5 C 1.4830 -1.9376 0.0000 0
M  V30 6 N 2.0660 -1.3508 0.0000 0
M  V30 7 C 1.3188 -1.7006 0.0000 0
M  V30 8 O 1.2481 -2.5226 0.0000 0
M  V30 9 C 0.6423 -1.2285 0.0000 0
M  V30 10 C 1.3229 -0.7623 0.0000 0
M  V30 11 O 1.0899 0.0291 0.0000 0
M  V30 12 C 0.1829 0.3316 0.0000 0
M  V30 13 C 0.6551 1.0082 0.0000 0
M  V30 14 C 1.4444 0.7681 0.0000 0
M  V30 15 O 1.4853 -0.0558 0.0000 0
M  V30 16 C 2.2779 1.1151 0.0000 0
M  V30 17 C 2.9544 0.6429 0.0000 0 CFG=2
M  V30 18 O 2.8838 -0.1791 0.0000 0
M  V30 19 C 3.7016 0.9927 0.0000 0
M  V30 20 C 4.3781 0.5205 0.0000 0
M  V30 21 C 4.3075 -0.3014 0.0000 0
M  V30 22 C 5.1253 0.8703 0.0000 0
M  V30 23 C 5.8018 0.3982 0.0000 0
M  V30 24 C 6.5490 0.7480 0.0000 0
M  V30 25 N 7.2255 0.2758 0.0000 0
M  V30 26 C 7.1549 -0.5462 0.0000 0
M  V30 27 O 7.8314 -1.0183 0.0000 0
M  V30 28 C 6.4077 -0.8960 0.0000 0
M  V30 29 C 6.3370 -1.7179 0.0000 0
M  V30 30 C 5.5899 -2.0677 0.0000 0 CFG=1
M  V30 31 C 5.5192 -2.8897 0.0000 0
M  V30 32 C 4.9133 -1.5956 0.0000 0
M  V30 33 O 4.1662 -1.9454 0.0000 0
M  V30 34 C 3.4896 -1.4732 0.0000 0
M  V30 35 O 3.5603 -0.6512 0.0000 0
M  V30 36 C 4.8427 -2.4175 0.0000 0 CFG=1
M  V30 37 C 4.0955 -2.7673 0.0000 0
M  V30 38 C 5.1125 -3.1972 0.0000 0
M  V30 39 N 0.6804 -0.3265 0.0000 0
M  V30 40 S 3.0000 -3.2704 0.0000 0
M  V30 41 O 2.3419 -3.7679 0.0000 0
M  V30 42 O 3.6581 -2.7729 0.0000 0
M  V30 43 C 3.4975 -3.9285 0.0000 0
M  V30 44 C 3.1763 -4.6885 0.0000 0
M  V30 45 N 3.6738 -5.3466 0.0000 0
M  V30 46 C 3.3526 -6.1065 0.0000 0
M  V30 47 C 3.8501 -6.7646 0.0000 0
M  V30 48 C 4.4925 -5.2448 0.0000 0
M  V30 49 C 4.9900 -5.9029 0.0000 0
M  V30 50 H 4.0226 -1.8453 0.0000 0
M  V30 51 H 3.4870 -2.4372 0.0000 0
M  V30 52 H 3.7744 0.0706 0.0000 0
M  V30 53 H 4.6843 -2.4917 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 2 6
M  V30 7 1 6 7
M  V30 8 2 7 8
M  V30 9 1 7 9
M  V30 10 2 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 14 16
M  V30 17 1 17 16
M  V30 18 1 17 18 CFG=1
M  V30 19 1 17 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 1 20 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 26 28
M  V30 29 2 28 29
M  V30 30 1 30 29
M  V30 31 1 30 31 CFG=1
M  V30 32 1 30 32
M  V30 33 1 33 32 CFG=1
M  V30 34 1 33 34
M  V30 35 1 2 34
M  V30 36 2 34 35
M  V30 37 1 36 32 CFG=3
M  V30 38 1 36 37
M  V30 39 1 36 38
M  V30 40 2 12 39
M  V30 41 1 9 39
M  V30 42 1 3 40 CFG=3
M  V30 43 2 40 41
M  V30 44 2 40 42
M  V30 45 1 40 43
M  V30 46 1 43 44
M  V30 47 1 44 45
M  V30 48 1 45 46
M  V30 49 1 46 47
M  V30 50 1 45 48
M  V30 51 1 48 49
M  V30 52 1 50 36
M  V30 53 1 51 3
M  V30 54 1 52 17
M  V30 55 1 53 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
422

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dalfopristin

>  <Synonyms>
RP54476

>  <CAS>
112362-50-2

>  <Formula>
C34H50N4O9S

>  <MolWt>
690.8

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
Dalfopristin is a semi-synthetic streptogramin antibiotic. Quinupristin/Dalfopristin (Q/D) is used for the treatment of multi-drug resistant Enterococcus faecium infections.

>  <Reference>
"Wang S, et al. Characteristic of Enterococcus faecium clinical isolates with quinupristin/Dalfopristin resistance in China. BMC Microbiol. 2016 Oct 21;16(1):246."

>  <ID<1>>
TQ0152

$$$$
StarDrop ID 423
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.8578 1.1344 0.0000 0
M  V30 2 C 4.1433 1.5469 0.0000 0
M  V30 3 N 4.1433 2.3719 0.0000 0
M  V30 4 O 5.5723 1.5469 0.0000 0
M  V30 5 C 4.8578 0.3094 0.0000 0
M  V30 6 C 5.5723 -0.1031 0.0000 0
M  V30 7 C 5.5723 -0.9281 0.0000 0
M  V30 8 O 6.2867 -1.3406 0.0000 0
M  V30 9 C 4.8578 -1.3406 0.0000 0
M  V30 10 O 4.8578 -2.1656 0.0000 0
M  V30 11 C 4.1433 -0.9281 0.0000 0
M  V30 12 C 4.1433 -0.1031 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 1 4
M  V30 4 1 1 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 5 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
423

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Norepinephrine bitartrate salt

>  <Synonyms>
N/A

>  <CAS>
3414-63-9

>  <Formula>
C12H17NO9

>  <MolWt>
319.3

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor

>  <Bioactivity>
Norepinephrine bitartrate salt is an adrenergic neurotransmitter.

>  <Reference>
"Haiying Shen, Feng Qu, Yong Xia, et al.Straightforward and Ultrastable Surface Modification of Microfluidic Chips with Norepinephrine Bitartrate Improves Performance in Immunoassays. Anal Chem. 2018 Mar 20;90(6):3697-3702.;Mody V , Patel J , Shah S , et al. Compatibility of Norepinephrine Bitartrate with Levofloxacin and Moxifloxacin During Simulated Y-site Administration[J]. International Journal of Pharmaceutical Compounding, 2016, 20(3):236."

>  <ID<1>>
T21066

$$$$
StarDrop ID 424
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.7145 2.0625 0.0000 0
M  V30 2 C 0.0000 2.4750 0.0000 0 CFG=2
M  V30 3 C -0.7145 2.8875 0.0000 0
M  V30 4 O -0.7145 3.7125 0.0000 0
M  V30 5 O -1.4289 2.4750 0.0000 0
M  V30 6 C -0.4125 1.7605 0.0000 0
M  V30 7 N 0.4125 3.1895 0.0000 0
M  V30 8 C 0.7145 1.2375 0.0000 0
M  V30 9 C 1.4289 0.8250 0.0000 0
M  V30 10 C 1.4289 -0.0000 0.0000 0
M  V30 11 C 0.7145 -0.4125 0.0000 0
M  V30 12 O 0.7145 -1.2375 0.0000 0
M  V30 13 C 0.0000 0.0000 0.0000 0
M  V30 14 C 0.0000 0.8250 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 2 6
M  V30 6 1 2 7 CFG=3
M  V30 7 1 1 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 2 13 14
M  V30 14 1 8 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
424

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Metyrosine

>  <Synonyms>
??-Methyltyrosine

>  <CAS>
672-87-7

>  <Formula>
C10H13NO3

>  <MolWt>
195.2

>  <Pathways>
Immunology/Inflammation;Neuroscience

>  <Target>
COX

>  <Receptor>
COX; COX-2

>  <Bioactivity>
Metyrosine is an antihypertensive drug and could be used as a tyrosine hydroxylase inhibitor.Metyrosine significantly inhibits high COX-2 activity. Metyrosine is a very effective agent for blood pressure control.

>  <Reference>
"Albayrak A, Polat B, Cadirci E, et al. Gastric anti-ulcerative and anti-inflammatory activity of metyrosine in rats. Pharmacol Rep. 2010;62(1):113?	9.;Garg MK, et al. Medical management of pheochromocytoma: Role of the endocrinologist. Indian J Endocrinol Metab. 2011;15 Suppl 4(Suppl4):S329?S336."

>  <ID<1>>
T22368

$$$$
StarDrop ID 425
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 40 43 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.5218 -6.2507 0.0000 0
M  V30 2 C 0.5218 -5.4257 0.0000 0
M  V30 3 N 1.2362 -5.0132 0.0000 0
M  V30 4 C 1.2362 -4.1882 0.0000 0
M  V30 5 C 1.9507 -3.7757 0.0000 0
M  V30 6 N 2.6652 -4.1882 0.0000 0
M  V30 7 C 3.3796 -3.7757 0.0000 0
M  V30 8 O 3.3796 -2.9507 0.0000 0
M  V30 9 N 4.0941 -4.1882 0.0000 0
M  V30 10 C 4.8086 -3.7757 0.0000 0 CFG=1
M  V30 11 C 5.5231 -4.1882 0.0000 0
M  V30 12 O 5.5231 -5.0132 0.0000 0
M  V30 13 N 6.2375 -3.7757 0.0000 0
M  V30 14 C 6.9520 -4.1882 0.0000 0 CFG=1
M  V30 15 C 7.7489 -3.9747 0.0000 0 CFG=1
M  V30 16 S 8.4408 -3.5253 0.0000 0
M  V30 17 C 9.0819 -4.0445 0.0000 0
M  V30 18 C 9.5313 -3.3526 0.0000 0
M  V30 19 C 9.8170 -4.4191 0.0000 0
M  V30 20 C 8.7863 -4.8147 0.0000 0 CFG=1
M  V30 21 N 7.9624 -4.7716 0.0000 0
M  V30 22 C 7.1655 -4.9851 0.0000 0
M  V30 23 O 6.7530 -5.6996 0.0000 0
M  V30 24 C 9.2356 -5.5066 0.0000 0
M  V30 25 O 10.0595 -5.4635 0.0000 0
M  V30 26 O 8.8611 -6.2417 0.0000 0
M  V30 27 C 4.8086 -2.9507 0.0000 0
M  V30 28 C 4.0941 -2.5382 0.0000 0
M  V30 29 C 4.0941 -1.7132 0.0000 0
M  V30 30 C 4.8086 -1.3007 0.0000 0
M  V30 31 C 5.5231 -1.7132 0.0000 0
M  V30 32 C 5.5231 -2.5382 0.0000 0
M  V30 33 C 2.6652 -5.0132 0.0000 0
M  V30 34 O 3.3796 -5.4257 0.0000 0
M  V30 35 C 1.9507 -5.4257 0.0000 0
M  V30 36 O 1.9507 -6.2507 0.0000 0
M  V30 37 H 3.9426 -3.2757 0.0000 0
M  V30 38 H 6.1586 -4.7969 0.0000 0
M  V30 39 H 7.2489 -4.8407 0.0000 0
M  V30 40 H 8.2863 -5.6807 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 10 9 CFG=3
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 14 13 CFG=1
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 17 19
M  V30 19 1 20 17
M  V30 20 1 20 21
M  V30 21 1 15 21 CFG=1
M  V30 22 1 21 22
M  V30 23 1 14 22
M  V30 24 2 22 23
M  V30 25 1 20 24 CFG=3
M  V30 26 1 24 25
M  V30 27 2 24 26
M  V30 28 1 10 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 30 31
M  V30 33 2 31 32
M  V30 34 1 27 32
M  V30 35 1 6 33
M  V30 36 2 33 34
M  V30 37 1 33 35
M  V30 38 1 3 35
M  V30 39 2 35 36
M  V30 40 1 37 10
M  V30 41 1 38 14
M  V30 42 1 39 15
M  V30 43 1 40 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
425

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
piperacillin

>  <Synonyms>
Pipercillin;Pipril;Pipracil

>  <CAS>
61477-96-1

>  <Formula>
C23H27N5O7S

>  <MolWt>
517.6

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial

>  <Receptor>
bacterial

>  <Bioactivity>
Piperacillin is a semisynthetic penicillin with wide spectrum of antimicrobial activity(particularly pseudomonas strains)

>  <Reference>
"Messori A , Tulli G , Caccese E , et al. Piperacillin-Tazobactam: Extended Infusion Versus Continuous Infusion[J]. Critical care medicine, 2018, 46(7):e725."

>  <ID<1>>
T8620

$$$$
StarDrop ID 426
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 25 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.1937 2.6499 0.0000 0
M  V30 2 S 4.7812 1.9354 0.0000 0
M  V30 3 O 4.3687 1.2210 0.0000 0
M  V30 4 N 5.4957 1.5229 0.0000 0
M  V30 5 C 6.2494 1.8585 0.0000 0
M  V30 6 C 6.8014 1.2454 0.0000 0
M  V30 7 C 6.3889 0.5309 0.0000 0
M  V30 8 C 5.5819 0.7025 0.0000 0
M  V30 9 C 4.0668 2.3479 0.0000 0
M  V30 10 C 3.3523 1.9354 0.0000 0
M  V30 11 C 3.3523 1.1104 0.0000 0
M  V30 12 C 2.6378 0.6979 0.0000 0
M  V30 13 C 1.9233 1.1104 0.0000 0
M  V30 14 N 1.1387 0.8555 0.0000 0
M  V30 15 C 0.6538 1.5229 0.0000 0
M  V30 16 C 1.1387 2.1904 0.0000 0
M  V30 17 C 1.9233 1.9354 0.0000 0
M  V30 18 C 2.6378 2.3479 0.0000 0
M  V30 19 C 0.8838 2.9750 0.0000 0
M  V30 20 C 0.0768 3.1465 0.0000 0
M  V30 21 N -0.1781 3.9312 0.0000 0
M  V30 22 C -0.9851 4.1027 0.0000 0
M  V30 23 C 0.3739 4.5442 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 4 8
M  V30 9 1 2 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 13 17
M  V30 19 1 17 18
M  V30 20 2 10 18
M  V30 21 1 16 19
M  V30 22 1 19 20
M  V30 23 1 20 21
M  V30 24 1 21 22
M  V30 25 1 21 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
426

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Almotriptan

>  <Synonyms>
LAS 31416

>  <CAS>
154323-57-6

>  <Formula>
C17H25N3O2S

>  <MolWt>
335.5

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
5-HT Receptor

>  <Receptor>
5-HT Receptor; 5-HT1B/1D

>  <Bioactivity>
Almotriptan is a 5-HT1B/1D-receptor agonist used to treat migraine.Almotriptan is a triptan drug for treatment of migraine headaches.Binding of the drug to the receptor leads to vasoconstriction of the cranial blood vessels and thus affects the redistribution of cranial blood flow. Almotriptan significantly increases cerebral blood flow and reduces blood flow through extracerebral cranial vessels.

>  <Reference>
"Orlandini S, Pasquini B, Stocchero M, Pinzauti S, Furlanetto S. An integrated quality by design and mixture-process variable approach in the development of a capillary electrophoresis method for the analysis of almotriptan and its impurities. J Chromatogr A. 2014 Apr 25;1339:200-9. doi: 10.1016/j.chroma.2014.02.088. Epub 2014 Mar 12. PubMed PMID: 24656544.;Abbas Z, Marihal S. Gellan gum-based mucoadhesive microspheres of almotriptan for nasal administration: Formulation optimization using factorial design, characterization, and in vitro evaluation. J Pharm Bioallied Sci. 2014 Oct;6(4):267-77. doi: 10.4103/0975-7406.142959. PubMed PMID: 25400410; PubMed Central PMCID: PMC4231387.;Castagno E, Lupica M, Viola S, Savino F, Miniero R. Creatin-kinase elevation after accidental ingestion of almotriptan in an 18-month-old girl. Minerva Pediatr. 2014 Feb;66(1):95-7. PubMed PMID: 24608586."

>  <ID<1>>
T21231

$$$$
StarDrop ID 427
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 33 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 0.8974 -1.2234 0.0000 0
M  V30 2 C 0.2242 -0.7465 0.0000 0 CFG=2
M  V30 3 C 0.4180 0.1878 0.0000 0 CFG=1
M  V30 4 C 1.2236 0.0765 0.0000 0
M  V30 5 C 1.6046 0.8305 0.0000 0
M  V30 6 O 0.9385 1.3558 0.0000 0
M  V30 7 C 0.2285 0.8169 0.0000 0 CFG=1
M  V30 8 C -0.5644 0.3699 0.0000 0
M  V30 9 O -1.3860 0.4448 0.0000 0
M  V30 10 C -0.9144 -0.5037 0.0000 0
M  V30 11 C -0.4624 -1.1604 0.0000 0
M  V30 12 H 0.0418 1.6205 0.0000 0
M  V30 13 C 2.4469 0.7922 0.0000 0
M  V30 14 O 2.8926 1.4864 0.0000 0
M  V30 15 C 2.8263 0.0538 0.0000 0
M  V30 16 C 2.3396 -0.6477 0.0000 0
M  V30 17 C 1.4521 -0.7058 0.0000 0
M  V30 18 C 0.6177 -1.1864 0.0000 0
M  V30 19 C -0.3135 -0.6324 0.0000 0 CFG=1
M  V30 20 N -1.1478 -0.0647 0.0000 0 CHG=1
M  V30 21 C -1.9435 0.1532 0.0000 0
M  V30 22 C -2.5301 -0.4269 0.0000 0
M  V30 23 C -2.7480 -1.2226 0.0000 0
M  V30 24 C -3.3282 -0.6360 0.0000 0
M  V30 25 C -1.4935 -0.8138 0.0000 0
M  V30 26 C -1.0650 0.7422 0.0000 0
M  V30 27 C -0.2652 0.9132 0.0000 0
M  V30 28 H 0.0102 0.1264 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4 CFG=1
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 3 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 8 10
M  V30 11 1 10 11
M  V30 12 1 2 11
M  V30 13 1 7 12 CFG=1
M  V30 14 2 5 13
M  V30 15 1 13 14
M  V30 16 1 13 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 4 17
M  V30 20 1 17 18
M  V30 21 1 19 18
M  V30 22 1 2 19
M  V30 23 1 19 20
M  V30 24 1 20 21
M  V30 25 1 21 22
M  V30 26 1 22 23
M  V30 27 1 23 24
M  V30 28 1 22 24
M  V30 29 1 20 25
M  V30 30 1 20 26
M  V30 31 1 26 27
M  V30 32 1 3 27
M  V30 33 1 19 28 CFG=3
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
427

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Methylnaltrexone bromide

>  <Synonyms>
MOA 728;Relistor;Methylnaltrexone;MOA728;MOA-728

>  <CAS>
73232-52-7

>  <Formula>
C21H26BrNO4

>  <MolWt>
436.4

>  <Pathways>
Endocrinology/Hormones;GPCR/G Protein;Neuroscience

>  <Target>
Opioid Receptor

>  <Receptor>
Opioid Receptor; ??-opioid receptor

>  <Bioactivity>
"Methylnaltrexone, used in form of methylnaltrexone bromide, is one of the newer agents of peripherally-acting ??-opioid antagonists. Methylnaltrexone acts to reverse some of the side effects of opioid drugs such as constipation without affecting analgesia or precipitating withdrawals."

>  <Reference>
"Grover M, Camilleri M. Treatment with Methylnaltrexone and IVIG for Paraneoplastic Gastrointestinal Dysmotility. Gastroenterol Hepatol (N Y). 2013 Jan;9(1):51-3. Review. PubMed PMID: 24707236; PubMed Central PMCID: PMC3975980.;Bader S, D??rk T, Becker G. Methylnaltrexone for the treatment of opioid-induced constipation. Expert Rev Gastroenterol Hepatol. 2013 Jan;7(1):13-26. doi: 10.1586/egh.12.63. Review. PubMed PMID: 23265145.;Rauck RL. Treatment of opioid-induced constipation: focus on the peripheral ??-opioid receptor antagonist methylnaltrexone. Drugs. 2013 Aug;73(12):1297-306. doi: 10.1007/s40265-013-0084-5. Review. PubMed PMID: 23881667."

>  <ID<1>>
T21422

$$$$
StarDrop ID 428
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 42 42 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.0013 3.7125 0.0000 0
M  V30 2 C -4.2868 3.3000 0.0000 0
M  V30 3 C -3.5724 3.7125 0.0000 0
M  V30 4 C -2.8579 3.3000 0.0000 0
M  V30 5 N -2.1434 3.7125 0.0000 0
M  V30 6 C -1.4289 3.3000 0.0000 0
M  V30 7 C -0.7145 3.7125 0.0000 0
M  V30 8 C 0.0000 3.3000 0.0000 0
M  V30 9 C 0.0000 2.4750 0.0000 0
M  V30 10 C -0.7145 2.0625 0.0000 0
M  V30 11 C -1.4289 2.4750 0.0000 0
M  V30 12 C 0.7145 2.0625 0.0000 0
M  V30 13 O 0.7145 1.2375 0.0000 0
M  V30 14 O 1.4289 2.4750 0.0000 0
M  V30 15 C 2.1434 2.0625 0.0000 0
M  V30 16 C 2.8579 2.4750 0.0000 0
M  V30 17 O 3.5724 2.0625 0.0000 0
M  V30 18 C 4.2868 2.4750 0.0000 0
M  V30 19 C 5.0013 2.0625 0.0000 0
M  V30 20 O 5.7158 2.4750 0.0000 0
M  V30 21 C 6.4302 2.0625 0.0000 0
M  V30 22 C 7.1447 2.4750 0.0000 0
M  V30 23 O 7.8592 2.0625 0.0000 0
M  V30 24 C 8.5737 2.4750 0.0000 0
M  V30 25 C 9.2881 2.0625 0.0000 0
M  V30 26 O 10.0026 2.4750 0.0000 0
M  V30 27 C 10.7171 2.0625 0.0000 0
M  V30 28 C 11.4315 2.4750 0.0000 0
M  V30 29 O 12.1460 2.0625 0.0000 0
M  V30 30 C 12.8605 2.4750 0.0000 0
M  V30 31 C 13.5749 2.0625 0.0000 0
M  V30 32 O 14.2894 2.4750 0.0000 0
M  V30 33 C 15.0039 2.0625 0.0000 0
M  V30 34 C 15.7184 2.4750 0.0000 0
M  V30 35 O 16.4328 2.0625 0.0000 0
M  V30 36 C 17.1473 2.4750 0.0000 0
M  V30 37 C 17.8618 2.0625 0.0000 0
M  V30 38 O 18.5762 2.4750 0.0000 0
M  V30 39 C 19.2907 2.0625 0.0000 0
M  V30 40 C 20.0052 2.4750 0.0000 0
M  V30 41 O 20.7197 2.0625 0.0000 0
M  V30 42 C 21.4341 2.4750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 6 11
M  V30 12 1 9 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 1 29 30
M  V30 31 1 30 31
M  V30 32 1 31 32
M  V30 33 1 32 33
M  V30 34 1 33 34
M  V30 35 1 34 35
M  V30 36 1 35 36
M  V30 37 1 36 37
M  V30 38 1 37 38
M  V30 39 1 38 39
M  V30 40 1 39 40
M  V30 41 1 40 41
M  V30 42 1 41 42
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
428

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Benzonatate

>  <Synonyms>
N/A

>  <CAS>
104-31-4

>  <Formula>
C30H53NO11

>  <MolWt>
603.8

>  <Pathways>
Membrane transporter/Ion channel

>  <Target>
Sodium Channel

>  <Receptor>
sodium channel

>  <Bioactivity>
Benzonatate is an antagonist of sodium channel protein.

>  <Reference>
"Evans M S , Maglinger G B , Fletcher A M , et al. Benzonatate inhibition of voltage-gated sodium currents[J]. Neuropharmacology, 2016, 101:179."

>  <ID<1>>
T19644

$$$$
StarDrop ID 429
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.1434 2.0625 0.0000 0
M  V30 2 N 2.1434 1.2375 0.0000 0
M  V30 3 O 2.8579 0.8250 0.0000 0
M  V30 4 C 1.4289 0.8250 0.0000 0
M  V30 5 C 1.4289 -0.0000 0.0000 0
M  V30 6 C 0.7145 -0.4125 0.0000 0
M  V30 7 C 0.0000 -0.0000 0.0000 0
M  V30 8 C 0.0000 0.8250 0.0000 0
M  V30 9 O -0.7145 1.2375 0.0000 0
M  V30 10 C 0.7145 1.2375 0.0000 0
M  V30 11 O 0.7145 2.0625 0.0000 0
M  V30 12 C 0.7145 -1.2375 0.0000 0
M  V30 13 N 1.3819 -1.7224 0.0000 0
M  V30 14 C 1.1270 -2.5070 0.0000 0
M  V30 15 N 0.3020 -2.5070 0.0000 0
M  V30 16 O 0.0470 -1.7224 0.0000 0
M  V30 17 C 1.6119 -3.1745 0.0000 0
M  V30 18 C 2.4324 -3.0882 0.0000 0
M  V30 19 Cl 2.7679 -2.3346 0.0000 0
M  V30 20 N 2.9173 -3.7557 0.0000 0
M  V30 21 O 3.7378 -3.6695 0.0000 0
M  V30 22 C 2.5817 -4.5094 0.0000 0
M  V30 23 C 1.7613 -4.5956 0.0000 0
M  V30 24 Cl 1.4257 -5.3493 0.0000 0
M  V30 25 C 1.2763 -3.9282 0.0000 0
M  V30 26 C 0.4559 -4.0144 0.0000 0
M  V30 27 C 3.0667 -5.1768 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 4 10
M  V30 11 1 10 11
M  V30 12 1 6 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 12 16
M  V30 18 1 14 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 2 18 20
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 1 23 25
M  V30 27 2 17 25
M  V30 28 1 25 26
M  V30 29 1 22 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
429

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Opicapone

>  <Synonyms>
BIA 9-1067

>  <CAS>
923287-50-7

>  <Formula>
C15H10Cl2N4O6

>  <MolWt>
413.2

>  <Pathways>
Metabolism

>  <Target>
Transferase

>  <Receptor>
COMT

>  <Bioactivity>
Opicapone reduces the ATP content of the cells (IC50: 98 ??M). Opicapone is an effective third-generation catechol-O-methyltransferase inhibitor for the research of Parkinson's disease and motor fluctuations.

>  <Reference>
"Ferreira JJ, et al. Opicapone as an adjunct to L-DOPA in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016 Feb;15(2):154-165.;Bonif??cio MJ, et al. Pharmacological profile of Opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat. Br J Pharmacol. 2015 Apr;172(7):1739-52."

>  <ID<1>>
T16398

$$$$
StarDrop ID 430
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 42 46 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -1.4289 -1.6500 0.0000 0
M  V30 2 C -0.7145 -1.2375 0.0000 0
M  V30 3 N 0.0000 -1.6500 0.0000 0
M  V30 4 C 0.7145 -1.2375 0.0000 0
M  V30 5 C 0.7145 -0.4125 0.0000 0
M  V30 6 C 0.0000 -0.0000 0.0000 0
M  V30 7 N -0.7145 -0.4125 0.0000 0
M  V30 8 N 0.0000 0.8250 0.0000 0
M  V30 9 C -0.7145 1.2375 0.0000 0 CFG=1
M  V30 10 C -1.4289 0.8250 0.0000 0
M  V30 11 C -0.7145 2.0625 0.0000 0
M  V30 12 N 0.0000 2.4750 0.0000 0
M  V30 13 C 0.0000 3.3000 0.0000 0
M  V30 14 C -0.7145 3.7125 0.0000 0
M  V30 15 C -1.4289 3.3000 0.0000 0
M  V30 16 O 0.7145 3.7125 0.0000 0
M  V30 17 C 0.7145 2.0625 0.0000 0
M  V30 18 C 0.7145 1.2375 0.0000 0
M  V30 19 C 1.4289 -0.0000 0.0000 0
M  V30 20 C 2.1434 -0.4125 0.0000 0
M  V30 21 F 2.8579 -0.0000 0.0000 0
M  V30 22 C 2.1434 -1.2375 0.0000 0
M  V30 23 N 1.4289 -1.6500 0.0000 0
M  V30 24 C 2.8579 -1.6500 0.0000 0
M  V30 25 C 3.5724 -1.2375 0.0000 0
M  V30 26 F 3.5724 -0.4125 0.0000 0
M  V30 27 C 4.2868 -1.6500 0.0000 0
M  V30 28 C 4.2868 -2.4750 0.0000 0
M  V30 29 C 3.5724 -2.8875 0.0000 0
M  V30 30 C 2.8579 -2.4750 0.0000 0
M  V30 31 O 2.1434 -2.8875 0.0000 0
M  V30 32 C 0.0000 -2.4750 0.0000 0
M  V30 33 C 0.7145 -2.8875 0.0000 0
M  V30 34 C 1.4289 -2.4750 0.0000 0
M  V30 35 C 2.2494 -2.3888 0.0000 0
M  V30 36 C 1.9139 -1.8076 0.0000 0
M  V30 37 N 0.7145 -3.7125 0.0000 0
M  V30 38 C 0.0000 -4.1250 0.0000 0
M  V30 39 C -0.7145 -3.7125 0.0000 0
M  V30 40 C -0.7145 -2.8875 0.0000 0
M  V30 41 C -1.4289 -2.4750 0.0000 0
M  V30 42 H -0.7144 0.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 6 8
M  V30 9 1 9 8
M  V30 10 1 9 10 CFG=1
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 2 13 16
M  V30 17 1 12 17
M  V30 18 1 17 18
M  V30 19 1 8 18
M  V30 20 2 5 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 20 22
M  V30 24 1 22 23
M  V30 25 2 4 23
M  V30 26 1 22 24
M  V30 27 2 24 25
M  V30 28 1 25 26
M  V30 29 1 25 27
M  V30 30 2 27 28
M  V30 31 1 28 29
M  V30 32 2 29 30
M  V30 33 1 24 30
M  V30 34 1 30 31
M  V30 35 1 3 32
M  V30 36 2 32 33
M  V30 37 1 33 34
M  V30 38 1 34 35
M  V30 39 1 34 36
M  V30 40 1 33 37
M  V30 41 2 37 38
M  V30 42 1 38 39
M  V30 43 2 39 40
M  V30 44 1 32 40
M  V30 45 1 40 41
M  V30 46 1 42 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
430

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Sotorasib racemate

>  <Synonyms>
AMG-510 racemate

>  <CAS>
2252403-56-6

>  <Formula>
C30H30F2N6O3

>  <MolWt>
560.6

>  <Pathways>
MAPK;GPCR/G Protein

>  <Target>
Ras

>  <Receptor>
KRAS G12C; Ras

>  <Bioactivity>
"AMG-510 racemate is a racemic of AMG-510 which is a potent inhibitor of KRAS G12C covalent, and leading to potential antineoplastic activity."

>  <Reference>
"Canon J , Rex K , Saiki A Y , et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity[J]. Nature, 2019, 575(7781).	"

>  <ID<1>>
T22258

$$$$
StarDrop ID 431
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 7.3584 -1.0450 0.0000 0
M  V30 2 C 7.3584 -0.2200 0.0000 0
M  V30 3 O 6.6440 0.1925 0.0000 0
M  V30 4 C 5.9295 -0.2200 0.0000 0
M  V30 5 C 5.2150 0.1925 0.0000 0
M  V30 6 C 4.5006 -0.2200 0.0000 0
M  V30 7 C 3.7861 0.1925 0.0000 0
M  V30 8 C 3.0716 -0.2200 0.0000 0
M  V30 9 C 2.3571 0.1925 0.0000 0
M  V30 10 C 8.0729 0.1925 0.0000 0
M  V30 11 C 8.7874 -0.2200 0.0000 0
M  V30 12 C 9.5019 0.1925 0.0000 0
M  V30 13 O 9.5019 1.0175 0.0000 0
M  V30 14 C 10.2163 -0.2200 0.0000 0
M  V30 15 N 10.9308 0.1925 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 2 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 12 14
M  V30 14 1 14 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
431

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Hexaminolevulinate hydrochloride

>  <Synonyms>
5-Aminolevulinic acid hexyl ester hydrochloride;P-1206;Hexyl 5-aminolevulinate hydrochloride

>  <CAS>
140898-91-5

>  <Formula>
C11H22ClNO3

>  <MolWt>
251.8

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Hexaminolevulinate hydrochloride has approved for cystoscopic detection of papillary bladder cancer and it also is a fluorescent agent.

>  <Reference>
"Rose JB, et al. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden. BJU Int. 2015 Aug 25. doi: 1"

>  <ID<1>>
T15477

$$$$
StarDrop ID 432
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F -0.6039 -2.4750 0.0000 0
M  V30 2 C 0.1105 -2.0625 0.0000 0
M  V30 3 F 0.8250 -2.4750 0.0000 0
M  V30 4 O 0.1105 -1.2375 0.0000 0
M  V30 5 C 0.8250 -0.8250 0.0000 0
M  V30 6 Cl 1.5395 -1.2375 0.0000 0
M  V30 7 C 0.8250 0.0000 0.0000 0
M  V30 8 F 0.8250 0.8250 0.0000 0
M  V30 9 F 1.6500 -0.0000 0.0000 0
M  V30 10 F 0.0000 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
432

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Isoflurane

>  <Synonyms>
HSDB8057;HSDB-8057;HSDB 8057;Forane;Terrell

>  <CAS>
26675-46-7

>  <Formula>
C3H2ClF5O

>  <MolWt>
184.5

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Isoflurane is a stable, non-explosive inhalation anesthetic that has been reported to induce caspase-3 activation."

>  <Reference>
"Chang PS, Walker SM, Fitzgerald M. Differential Suppression of Spontaneous and Noxious-evoked Somatosensory Cortical Activity by Isoflurane in the Neonatal Rat. Anesthesiology. 2016 Apr;124(4):885-98. doi: 10.1097/ALN.0000000000001017. PubMed PMID: 26808637.;Olutoye OA, Sheikh F, Zamora IJ, Yu L, Akinkuotu AC, Adesina AM, Olutoye OO. Repeated isoflurane exposure and neuroapoptosis in the midgestation fetal sheep brain. Am J Obstet Gynecol. 2016 Apr;214(4):542.e1-8. doi: 10.1016/j.ajog.2015.10.927. Epub 2015 Nov 4. PubMed PMID: 26546852."

>  <ID<1>>
T19651

$$$$
StarDrop ID 433
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 Cl -3.1531 4.6402 0.0000 0
M  V30 2 C -3.3367 3.8358 0.0000 0
M  V30 3 C -4.1251 3.5927 0.0000 0
M  V30 4 C -4.3087 2.7884 0.0000 0
M  V30 5 C -3.7039 2.2272 0.0000 0
M  V30 6 C -2.9155 2.4704 0.0000 0
M  V30 7 C -2.7320 3.2747 0.0000 0
M  V30 8 N -2.2339 2.0056 0.0000 0
M  V30 9 C -2.1722 1.1830 0.0000 0
M  V30 10 C -1.3839 0.9398 0.0000 0
M  V30 11 C -1.2003 0.1355 0.0000 0
M  V30 12 C -1.8051 -0.4257 0.0000 0
M  V30 13 C -2.5934 -0.1825 0.0000 0
M  V30 14 C -2.7770 0.6218 0.0000 0
M  V30 15 C -3.5928 0.7448 0.0000 0
M  V30 16 C -4.0053 1.4592 0.0000 0
M  V30 17 C -1.5194 2.4181 0.0000 0
M  V30 18 C -0.8050 2.0056 0.0000 0
M  V30 19 C -0.0905 2.4181 0.0000 0
M  V30 20 N 0.6240 2.0056 0.0000 0
M  V30 21 C 1.3385 2.4181 0.0000 0
M  V30 22 C 0.6240 1.1806 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 9 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 1 5 16
M  V30 19 1 8 17
M  V30 20 1 17 18
M  V30 21 1 18 19
M  V30 22 1 19 20
M  V30 23 1 20 21
M  V30 24 1 20 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
433

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Clomipramine

>  <Synonyms>
Anafranil (free base);Clomicalm;Clomipramina;Chlorimipramine;Anafranil

>  <CAS>
303-49-1

>  <Formula>
C19H23ClN2

>  <MolWt>
314.9

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
5-HT Receptor

>  <Receptor>
5-HT

>  <Bioactivity>
"Clomipramine is a tricyclic antidepressant (TCA). It is used for the treatment of the panic disorder, obsessive-compulsive disorder, major depressive disorder, and chronic pain. It may decrease the risk of suicide in those over the age of 65. It is similar to Imipramine in that selective inhibition of the serotonin uptake in the brain."

>  <Reference>
"Hatalova H, Radostova D, Pistikova A, Vales K, Stuchlik A. Detrimental effect of clomipramine on hippocampus-dependent learning in an animal model of obsessive-compulsive disorder induced by sensitization with d2/d3 agonist quinpirole. Behav Brain Res. 2017 Jan 15;317:210-217. doi: 10.1016/j.bbr.2016.09.042. Epub 2016 Sep 19. PubMed PMID: 27659555.;Varigonda AL, Jakubovski E, Bloch MH. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder. J Am Acad Child Adolesc Psychiatry. 2016 Oct;55(10):851-859.e2. doi: 10.1016/j.jaac.2016.07.768. Epub 2016 Aug 4. Review. PubMed PMID: 27663940.;Yildirim EA, Hacioglu Yildirim M, Carpar E, Sarac I. Clomipramine trial for treatment-resistant persistent genital arousal disorder: a case series. J Psychosom Obstet Gynaecol. 2017 Dec;38(4):260-267. doi: 10.1080/0167482X.2017.1296427. Epub 2017 Mar 3. PubMed PMID: 28635538.;Brown JT, Schneiderhan M, Eum S, Bishop JR. Serum clomipramine and desmethylclomipramine levels in a CYP2C19 and CYP2D6 intermediate metabolizer. Pharmacogenomics. 2017 May;18(7):601-605. doi: 10.2217/pgs-2017-0015. Epub 2017 May 4. Review. PubMed PMID: 28470111."

>  <ID<1>>
T21013

$$$$
StarDrop ID 434
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 42 45 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.7145 -1.2375 0.0000 0
M  V30 2 N 1.4289 -1.6500 0.0000 0
M  V30 3 S 1.4289 -2.4750 0.0000 0
M  V30 4 O 2.2539 -2.4750 0.0000 0
M  V30 5 O 0.6039 -2.4750 0.0000 0
M  V30 6 C 1.4289 -3.3000 0.0000 0
M  V30 7 C 2.0964 -3.7849 0.0000 0
M  V30 8 N 1.8414 -4.5695 0.0000 0
M  V30 9 C 2.3264 -5.2370 0.0000 0
M  V30 10 N 1.0164 -4.5695 0.0000 0
M  V30 11 C 0.7615 -3.7849 0.0000 0
M  V30 12 C -0.0231 -3.5300 0.0000 0
M  V30 13 O 0.0000 -1.6500 0.0000 0
M  V30 14 C 0.7145 -0.4125 0.0000 0
M  V30 15 C 0.0000 0.0000 0.0000 0
M  V30 16 N 0.0000 0.8250 0.0000 0
M  V30 17 C 0.7145 1.2375 0.0000 0
M  V30 18 C 1.4289 0.8250 0.0000 0
M  V30 19 C 1.4289 0.0000 0.0000 0
M  V30 20 N 0.7145 2.0625 0.0000 0
M  V30 21 N 0.0470 2.5474 0.0000 0
M  V30 22 C 0.3020 3.3320 0.0000 0
M  V30 23 O -0.1830 3.9995 0.0000 0
M  V30 24 C 0.1526 4.7532 0.0000 0
M  V30 25 C -0.3323 5.4206 0.0000 0
M  V30 26 C -0.8172 6.0880 0.0000 0
M  V30 27 F -1.3022 6.7555 0.0000 0
M  V30 28 F -0.1498 6.5730 0.0000 0
M  V30 29 F -1.4847 5.6031 0.0000 0
M  V30 30 C 0.3351 5.9055 0.0000 0
M  V30 31 C -0.9998 4.9357 0.0000 0
M  V30 32 C 1.1270 3.3320 0.0000 0
M  V30 33 C 1.3819 2.5474 0.0000 0
M  V30 34 N -0.7145 -0.4125 0.0000 0
M  V30 35 C -0.8007 -1.2330 0.0000 0
M  V30 36 C -1.6077 -1.4045 0.0000 0 CFG=1
M  V30 37 C -1.9432 -2.1582 0.0000 0
M  V30 38 C -2.0202 -0.6900 0.0000 0
M  V30 39 C -1.4681 -0.0769 0.0000 0
M  V30 40 C -2.0137 0.5419 0.0000 0
M  V30 41 C -1.2214 0.7103 0.0000 0
M  V30 42 H -0.9783 -2.1816 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 2 3 5
M  V30 5 1 3 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 10 11
M  V30 11 1 6 11
M  V30 12 1 11 12
M  V30 13 2 1 13
M  V30 14 1 1 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 14 19
M  V30 21 1 17 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 1 26 28
M  V30 30 1 26 29
M  V30 31 1 25 30
M  V30 32 1 25 31
M  V30 33 1 22 32
M  V30 34 2 32 33
M  V30 35 1 20 33
M  V30 36 1 15 34
M  V30 37 1 34 35
M  V30 38 1 36 35
M  V30 39 1 36 37 CFG=1
M  V30 40 1 36 38
M  V30 41 1 38 39
M  V30 42 1 34 39
M  V30 43 1 39 40
M  V30 44 1 39 41
M  V30 45 1 42 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
434

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Elexacaftor

>  <Synonyms>
VX-445

>  <CAS>
2216712-66-0

>  <Formula>
C26H34F3N7O4S

>  <MolWt>
597.7

>  <Pathways>
Autophagy;Membrane transporter/Ion channel

>  <Target>
CFTR;Autophagy

>  <Receptor>
Autophagy; CFTR

>  <Bioactivity>
Elexacaftor is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR) and it also facilitates the processing and trafficking of CFTR to increase the amount of CFTR at the cell surface.

>  <Reference>
"Keating D, et al. VX-445-Tezacaftor-VX-770 in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med. 2018 Oct 25;379(17):1612-1620.;Alexander Russell Abela, et al. MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR , PHARMACEUTICAL COMPOSITIONS , METHODS OF TREATMENT , AND PROCESS FOR MAKING THE MODULATOR. US 20180162839 A1."

>  <ID<1>>
T14935

$$$$
StarDrop ID 435
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 107 107 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 13.0705 -3.5707 0.0000 0
M  V30 2 C 13.7849 -3.1582 0.0000 0
M  V30 3 C 14.4994 -3.5707 0.0000 0
M  V30 4 C 14.4994 -4.3957 0.0000 0
M  V30 5 C 15.2139 -3.1582 0.0000 0
M  V30 6 C 15.9283 -3.5707 0.0000 0
M  V30 7 C 16.6428 -3.1582 0.0000 0
M  V30 8 C 17.3573 -3.5707 0.0000 0
M  V30 9 C 18.0718 -3.1582 0.0000 0
M  V30 10 O 18.0718 -2.3332 0.0000 0
M  V30 11 N 18.7862 -3.5707 0.0000 0
M  V30 12 C 19.5007 -3.1582 0.0000 0
M  V30 13 C 19.5007 -2.3332 0.0000 0
M  V30 14 C 20.2152 -1.9207 0.0000 0
M  V30 15 N 20.2152 -1.0957 0.0000 0
M  V30 16 C 19.5007 -0.6832 0.0000 0
M  V30 17 S 19.5007 0.1418 0.0000 0
M  V30 18 O 19.5007 0.9668 0.0000 0
M  V30 19 O 20.3257 0.1418 0.0000 0
M  V30 20 O 18.6757 0.1418 0.0000 0
M  V30 21 C 20.2152 -3.5707 0.0000 0
M  V30 22 O 20.2152 -4.3957 0.0000 0
M  V30 23 N 20.9296 -3.1582 0.0000 0
M  V30 24 C 21.6441 -3.5707 0.0000 0
M  V30 25 C 21.6441 -4.3957 0.0000 0
M  V30 26 C 20.9296 -4.8082 0.0000 0
M  V30 27 O 22.3586 -4.8082 0.0000 0
M  V30 28 C 22.3586 -3.1582 0.0000 0
M  V30 29 O 22.3586 -2.3332 0.0000 0
M  V30 30 N 23.0731 -3.5707 0.0000 0
M  V30 31 C 23.7875 -3.1582 0.0000 0
M  V30 32 C 23.7875 -2.3332 0.0000 0
M  V30 33 C 23.0731 -1.9207 0.0000 0
M  V30 34 N 23.0731 -1.0957 0.0000 0
M  V30 35 C 22.3586 -0.6832 0.0000 0
M  V30 36 S 21.6441 -1.0957 0.0000 0
M  V30 37 O 21.2316 -0.3813 0.0000 0
M  V30 38 O 22.0566 -1.8102 0.0000 0
M  V30 39 O 20.9296 -1.5082 0.0000 0
M  V30 40 C 24.5020 -3.5707 0.0000 0
M  V30 41 O 24.5020 -4.3957 0.0000 0
M  V30 42 N 25.2165 -3.1582 0.0000 0
M  V30 43 C 25.2165 -2.3332 0.0000 0
M  V30 44 C 24.4400 -2.6121 0.0000 0
M  V30 45 C 23.9349 -1.9598 0.0000 0
M  V30 46 N 24.3991 -1.2779 0.0000 0
M  V30 47 C 24.3163 -0.3789 0.0000 0
M  V30 48 O 23.5596 -0.0500 0.0000 0
M  V30 49 C 24.9685 0.1263 0.0000 0
M  V30 50 N 24.8572 0.9437 0.0000 0
M  V30 51 C 25.5095 1.4489 0.0000 0
M  V30 52 O 26.2731 1.1366 0.0000 0
M  V30 53 C 25.3982 2.2663 0.0000 0
M  V30 54 C 24.6346 2.5786 0.0000 0
M  V30 55 C 24.5232 3.3961 0.0000 0
M  V30 56 N 23.7596 3.7084 0.0000 0
M  V30 57 C 23.6483 4.5259 0.0000 0
M  V30 58 S 22.8847 4.8382 0.0000 0
M  V30 59 O 22.1211 5.1505 0.0000 0
M  V30 60 O 23.1970 5.6018 0.0000 0
M  V30 61 O 22.5724 4.0746 0.0000 0
M  V30 62 N 26.0504 2.7715 0.0000 0
M  V30 63 C 25.9391 3.5889 0.0000 0
M  V30 64 O 25.1755 3.9012 0.0000 0
M  V30 65 C 26.5914 4.0941 0.0000 0
M  V30 66 C 26.4800 4.9115 0.0000 0
M  V30 67 C 27.1323 5.4167 0.0000 0
M  V30 68 N 27.0210 6.2341 0.0000 0
M  V30 69 C 27.6732 6.7392 0.0000 0
M  V30 70 S 27.5619 7.5567 0.0000 0
M  V30 71 O 27.4506 8.3742 0.0000 0
M  V30 72 O 26.7445 7.4454 0.0000 0
M  V30 73 O 28.3794 7.6680 0.0000 0
M  V30 74 N 27.3550 3.7817 0.0000 0
M  V30 75 C 27.4663 2.9643 0.0000 0
M  V30 76 O 26.8140 2.4592 0.0000 0
M  V30 77 C 28.2299 2.6520 0.0000 0
M  V30 78 C 28.8822 3.1571 0.0000 0
M  V30 79 C 29.6458 2.8448 0.0000 0
M  V30 80 C 30.2980 3.3499 0.0000 0
M  V30 81 C 29.7571 2.0274 0.0000 0
M  V30 82 N 28.3412 1.8345 0.0000 0
M  V30 83 C 27.6890 1.3294 0.0000 0
M  V30 84 O 26.9254 1.6417 0.0000 0
M  V30 85 C 27.8003 0.5119 0.0000 0
M  V30 86 C 28.5639 0.1996 0.0000 0
M  V30 87 C 29.2162 0.7048 0.0000 0
M  V30 88 C 29.1048 1.5222 0.0000 0
M  V30 89 C 29.9798 0.3924 0.0000 0
M  V30 90 N 27.1480 0.0068 0.0000 0
M  V30 91 C 27.2593 -0.8107 0.0000 0
M  V30 92 O 28.0229 -1.1230 0.0000 0
M  V30 93 C 26.6071 -1.3158 0.0000 0
M  V30 94 C 27.3707 -1.6281 0.0000 0
M  V30 95 C 27.4820 -2.4456 0.0000 0
M  V30 96 N 28.2456 -2.7579 0.0000 0
M  V30 97 C 28.3569 -3.5753 0.0000 0
M  V30 98 S 29.1205 -3.8877 0.0000 0
M  V30 99 O 29.8841 -4.2000 0.0000 0
M  V30 100 O 28.8082 -4.6513 0.0000 0
M  V30 101 O 29.4328 -3.1241 0.0000 0
M  V30 102 N 26.7184 -2.1333 0.0000 0
M  V30 103 C 26.0661 -2.6384 0.0000 0
M  V30 104 O 26.1952 -3.4532 0.0000 0
M  V30 105 C 24.2049 0.4386 0.0000 0
M  V30 106 C 23.3803 0.4133 0.0000 0
M  V30 107 O 24.0936 1.2560 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 17 19
M  V30 19 2 17 20
M  V30 20 1 12 21
M  V30 21 2 21 22
M  V30 22 1 21 23
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 1 25 27
M  V30 27 1 24 28
M  V30 28 2 28 29
M  V30 29 1 28 30
M  V30 30 1 30 31
M  V30 31 1 31 32
M  V30 32 1 32 33
M  V30 33 1 33 34
M  V30 34 1 34 35
M  V30 35 1 35 36
M  V30 36 1 36 37
M  V30 37 2 36 38
M  V30 38 2 36 39
M  V30 39 1 31 40
M  V30 40 2 40 41
M  V30 41 1 40 42
M  V30 42 1 42 43
M  V30 43 1 43 44
M  V30 44 1 44 45
M  V30 45 1 45 46
M  V30 46 1 46 47
M  V30 47 2 47 48
M  V30 48 1 47 49
M  V30 49 1 49 50
M  V30 50 1 50 51
M  V30 51 2 51 52
M  V30 52 1 51 53
M  V30 53 1 53 54
M  V30 54 1 54 55
M  V30 55 1 55 56
M  V30 56 1 56 57
M  V30 57 1 57 58
M  V30 58 1 58 59
M  V30 59 2 58 60
M  V30 60 2 58 61
M  V30 61 1 53 62
M  V30 62 1 62 63
M  V30 63 2 63 64
M  V30 64 1 63 65
M  V30 65 1 65 66
M  V30 66 1 66 67
M  V30 67 1 67 68
M  V30 68 1 68 69
M  V30 69 1 69 70
M  V30 70 1 70 71
M  V30 71 2 70 72
M  V30 72 2 70 73
M  V30 73 1 65 74
M  V30 74 1 74 75
M  V30 75 2 75 76
M  V30 76 1 75 77
M  V30 77 1 77 78
M  V30 78 1 78 79
M  V30 79 1 79 80
M  V30 80 1 79 81
M  V30 81 1 77 82
M  V30 82 1 82 83
M  V30 83 2 83 84
M  V30 84 1 83 85
M  V30 85 1 85 86
M  V30 86 1 86 87
M  V30 87 1 87 88
M  V30 88 1 87 89
M  V30 89 1 85 90
M  V30 90 1 90 91
M  V30 91 2 91 92
M  V30 92 1 91 93
M  V30 93 1 93 94
M  V30 94 1 94 95
M  V30 95 1 95 96
M  V30 96 1 96 97
M  V30 97 1 97 98
M  V30 98 1 98 99
M  V30 99 2 98 100
M  V30 100 2 98 101
M  V30 101 1 93 102
M  V30 102 1 102 103
M  V30 103 1 43 103
M  V30 104 2 103 104
M  V30 105 1 49 105
M  V30 106 1 105 106
M  V30 107 1 105 107
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
435

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Colistin methanesulfonate sodium salt

>  <Synonyms>
Colistin Methanesulfonate (sodium salt)

>  <CAS>
8068-28-8

>  <Formula>
C115H208N32Na10O56S10

>  <MolWt>
3486

>  <Pathways>
Immunology/Inflammation;Microbiology/Virology

>  <Target>
Antibacterial;Cell wall

>  <Receptor>
Bacterial; cell wall

>  <Bioactivity>
"Colistin is a cyclic polypeptide antibiotic from Bacillus colistinus,  composed of Polymyxins E1 and E2."

>  <Reference>
"Ozbek B, et al. Chemotherapy, 2010, 56(6), 466-471.;Falagas ME, et al. Clin Infect Dis, 2005, 40(9), 1333-1341.;Evans ME, et al. Ann Pharmacother, 1999, 33(9), 960-967.;Jian Li, et al. In Vitro Pharmacodynamic Properties of Colistin and Colistin Methanesulfonate against Pseudomonas aeruginosa Isolates from Patients with Cystic Fibrosis. Antimicrob Agents Chemother. 2001 Mar; 45(3): 781?C785."

>  <ID<1>>
T21518

$$$$
StarDrop ID 436
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 42 46 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -2.1434 -7.3542 0.0000 0
M  V30 2 C -1.4289 -6.9417 0.0000 0
M  V30 3 C -1.4289 -6.1167 0.0000 0
M  V30 4 N -0.7145 -5.7042 0.0000 0
M  V30 5 C -0.7145 -4.8792 0.0000 0
M  V30 6 C -1.2978 -4.2959 0.0000 0
M  V30 7 C -0.7145 -3.7125 0.0000 0
M  V30 8 F -1.2978 -3.1291 0.0000 0
M  V30 9 F -0.1311 -3.1291 0.0000 0
M  V30 10 C -0.1311 -4.2959 0.0000 0
M  V30 11 O -2.1434 -5.7042 0.0000 0
M  V30 12 C -0.7145 -7.3542 0.0000 0
M  V30 13 C 0.0000 -6.9417 0.0000 0
M  V30 14 Cl 0.0000 -6.1167 0.0000 0
M  V30 15 C 0.7145 -7.3542 0.0000 0
M  V30 16 C 0.7145 -8.1792 0.0000 0
M  V30 17 C 0.0000 -8.5917 0.0000 0
M  V30 18 C -0.7145 -8.1792 0.0000 0
M  V30 19 C -2.8579 -6.9417 0.0000 0
M  V30 20 O -2.8579 -6.1167 0.0000 0
M  V30 21 C -3.5724 -7.3542 0.0000 0 CFG=1
M  V30 22 N -4.3260 -7.0187 0.0000 0
M  V30 23 C -4.8781 -7.6318 0.0000 0
M  V30 24 O -5.6985 -7.5455 0.0000 0
M  V30 25 C -4.4656 -8.3462 0.0000 0
M  V30 26 C -3.6586 -8.1747 0.0000 0
M  V30 27 C -4.4976 -6.2117 0.0000 0
M  V30 28 C -5.2822 -5.9568 0.0000 0
M  V30 29 C -5.4537 -5.1498 0.0000 0
M  V30 30 C -6.2383 -4.8948 0.0000 0
M  V30 31 N -7.0229 -4.6399 0.0000 0
M  V30 32 C -4.8406 -4.5978 0.0000 0
M  V30 33 C -4.0560 -4.8527 0.0000 0
M  V30 34 N -3.8845 -5.6597 0.0000 0
M  V30 35 C -2.1434 -8.1792 0.0000 0
M  V30 36 C -1.4289 -8.5917 0.0000 0
M  V30 37 C -1.4289 -9.4167 0.0000 0
M  V30 38 F -0.7145 -9.8292 0.0000 0
M  V30 39 C -2.1434 -9.8292 0.0000 0
M  V30 40 N -2.8579 -9.4167 0.0000 0
M  V30 41 C -2.8579 -8.5917 0.0000 0
M  V30 42 H -3.6246 -6.3556 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 7 10
M  V30 10 1 5 10
M  V30 11 2 3 11
M  V30 12 1 2 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 12 18
M  V30 20 1 1 19
M  V30 21 2 19 20
M  V30 22 1 21 19 CFG=3
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 27 1 25 26
M  V30 28 1 21 26
M  V30 29 1 22 27
M  V30 30 2 27 28
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 3 30 31
M  V30 34 2 29 32
M  V30 35 1 32 33
M  V30 36 2 33 34
M  V30 37 1 27 34
M  V30 38 1 1 35
M  V30 39 1 35 36
M  V30 40 2 36 37
M  V30 41 1 37 38
M  V30 42 1 37 39
M  V30 43 2 39 40
M  V30 44 1 40 41
M  V30 45 2 35 41
M  V30 46 1 42 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
436

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
AG-120 (racemic)

>  <Synonyms>
N/A

>  <CAS>
1448346-63-1

>  <Formula>
C28H22ClF3N6O3

>  <MolWt>
583

>  <Pathways>
Metabolism

>  <Target>
Dehydrogenase

>  <Receptor>
IDH1

>  <Bioactivity>
"AG-120 (racemic), the racemic mixture of AG-120, is an orally available isocitrate dehydrogenase type 1 (IDH1) inhibitor, and shows potential antineoplastic activity."

>  <Reference>
"M Cecilia Caino, Dario C Altieri. Clin Cancer Res. 2016 Feb 1;22(3):540-5."

>  <ID<1>>
T22253

$$$$
StarDrop ID 437
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.7145 2.0625 0.0000 0
M  V30 2 C 0.0000 2.4750 0.0000 0
M  V30 3 C 0.0000 3.3000 0.0000 0
M  V30 4 C -0.7145 3.7125 0.0000 0
M  V30 5 N 0.7145 1.2375 0.0000 0
M  V30 6 C 1.4289 0.8250 0.0000 0 CFG=2
M  V30 7 C 2.1434 1.2375 0.0000 0
M  V30 8 O 2.8579 0.8250 0.0000 0
M  V30 9 C 1.4289 -0.0000 0.0000 0 CFG=1
M  V30 10 O 2.1434 -0.4125 0.0000 0
M  V30 11 C 0.7145 -0.4125 0.0000 0 CFG=2
M  V30 12 O 0.7145 -1.2375 0.0000 0
M  V30 13 C 0.0000 0.0000 0.0000 0 CFG=1
M  V30 14 O -0.7145 -0.4125 0.0000 0
M  V30 15 C 0.0000 0.8250 0.0000 0
M  V30 16 H 1.4290 1.8250 0.0000 0
M  V30 17 H 1.4290 -1.0000 0.0000 0
M  V30 18 H 1.5805 -0.9125 0.0000 0
M  V30 19 H -0.8660 0.5000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 1 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 7 8
M  V30 8 1 9 6
M  V30 9 1 9 10 CFG=1
M  V30 10 1 9 11
M  V30 11 1 11 12 CFG=3
M  V30 12 1 11 13
M  V30 13 1 13 14 CFG=1
M  V30 14 1 13 15
M  V30 15 1 5 15
M  V30 16 1 16 6
M  V30 17 1 17 9
M  V30 18 1 18 11
M  V30 19 1 19 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
437

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Miglustat

>  <Synonyms>
NB-DNJ;OGT918;N-Butyldeoxynojirimycin

>  <CAS>
72599-27-0

>  <Formula>
C10H21NO4

>  <MolWt>
219.3

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Miglustat is an alkylated product of imino sugar deoxynojirimycin.It is an inhibitor of glucosylceramide synthase, primarily to treat Type I Gaucher disease (GD1)."

>  <Reference>
"van Giersbergen, P.L. and J. Dingemanse, Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase. J Clin Pharmacol, 2007. 47(10): p. 1277-82.;Abian, O., et al., Therapeutic strategies for Gaucher disease: miglustat (NB-DNJ) as a pharmacological chaperone for glucocerebrosidase and the different thermostability of velaglucerase alfa and imiglucerase. Mol Pharm, 2011. 8(6): p. 2390-7."

>  <ID<1>>
T12039

$$$$
StarDrop ID 438
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 39 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -3.0774 -0.5469 0.0000 0
M  V30 2 C -2.6875 -1.2739 0.0000 0
M  V30 3 C -3.1221 -1.9752 0.0000 0
M  V30 4 C -2.7321 -2.7022 0.0000 0
M  V30 5 N -3.1667 -3.4034 0.0000 0
M  V30 6 C -3.9913 -3.3776 0.0000 0
M  V30 7 N -4.4259 -4.0789 0.0000 0
M  V30 8 N -4.3813 -2.6506 0.0000 0
M  V30 9 C -3.9467 -1.9494 0.0000 0
M  V30 10 N -1.8629 -1.2997 0.0000 0
M  V30 11 C -1.4282 -0.5984 0.0000 0
M  V30 12 N -0.6037 -0.6242 0.0000 0
M  V30 13 C -0.1690 0.0770 0.0000 0
M  V30 14 C -0.5590 0.8040 0.0000 0
M  V30 15 C -1.3836 0.8298 0.0000 0
M  V30 16 N -1.9162 1.4598 0.0000 0
M  V30 17 C -2.6800 1.1480 0.0000 0
M  V30 18 C -2.6195 0.3252 0.0000 0
M  V30 19 N -1.8182 0.1286 0.0000 0
M  V30 20 C -0.1244 1.5053 0.0000 0
M  V30 21 C 0.7002 1.4795 0.0000 0
M  V30 22 C 1.0902 0.7525 0.0000 0
M  V30 23 O 1.9148 0.7268 0.0000 0
M  V30 24 C 2.3494 1.4280 0.0000 0
M  V30 25 C 3.1740 1.4022 0.0000 0
M  V30 26 C 3.6086 2.1035 0.0000 0
M  V30 27 N 4.4332 2.0777 0.0000 0
M  V30 28 C 4.8678 2.7789 0.0000 0
M  V30 29 C 5.6924 2.7532 0.0000 0
M  V30 30 O 6.0824 2.0262 0.0000 0
M  V30 31 C 5.6478 1.3249 0.0000 0
M  V30 32 C 4.8232 1.3507 0.0000 0
M  V30 33 C 0.6556 0.0513 0.0000 0
M  V30 34 O 1.0455 -0.6757 0.0000 0
M  V30 35 C 0.6109 -1.3770 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 2 8 9
M  V30 9 1 3 9
M  V30 10 1 2 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 11 19
M  V30 21 1 15 19
M  V30 22 1 14 20
M  V30 23 2 20 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 1 31 32
M  V30 35 1 27 32
M  V30 36 2 22 33
M  V30 37 1 13 33
M  V30 38 1 33 34
M  V30 39 1 34 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
438

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Copanlisib dihydrochloride

>  <Synonyms>
BAY 80-6946 dihydrochloride

>  <CAS>
1402152-13-9

>  <Formula>
C23H30Cl2N8O4

>  <MolWt>
553.5

>  <Pathways>
PI3K/Akt/mTOR signaling;Apoptosis

>  <Target>
PI3K;mTOR;Apoptosis

>  <Receptor>
" PI3K??:0.5 nM, PI3K??:0.7 nM, PI3K??:6.4 nM, PI3K??:3.7 nM, mTOR:45 nM"

>  <Bioactivity>
"Copanlisib dihydrochloride is an ATP-competitive pan-class I PI3K inhibitor (IC50s: 0.5 nM, 0.7 nM, 3.7 nM and 6.4 nM for PI3K??, PI3K??, PI3K?? and PI3K??). Copanlisib dihydrochloride has superior antitumor activity and it also has more than 2,000-fold selectivity against other lipid and protein kinases, except for mTOR."

>  <Reference>
"Elster N, et al. Breast Cancer Res Treat. 2015, 149(2), 373-383.;Liu N, et al. Mol Cancer Ther. 2013, 12(11), 2319-2330."

>  <ID<1>>
T14998

$$$$
StarDrop ID 439
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.7145 -1.2375 0.0000 0
M  V30 2 C 1.4289 -1.6500 0.0000 0
M  V30 3 O 2.1434 -1.2375 0.0000 0
M  V30 4 C 1.4289 -2.4750 0.0000 0
M  V30 5 C 2.1434 -2.8875 0.0000 0
M  V30 6 C 2.1434 -3.7125 0.0000 0
M  V30 7 N 2.8579 -4.1250 0.0000 0
M  V30 8 N 3.5724 -3.7125 0.0000 0
M  V30 9 C 4.2868 -4.1250 0.0000 0
M  V30 10 C 5.0013 -3.7125 0.0000 0
M  V30 11 C 5.7158 -4.1250 0.0000 0
M  V30 12 C 5.7158 -4.9500 0.0000 0
M  V30 13 O 6.4302 -5.3625 0.0000 0
M  V30 14 C 5.0013 -5.3625 0.0000 0
M  V30 15 C 4.2868 -4.9500 0.0000 0
M  V30 16 C 5.0013 -6.1875 0.0000 0
M  V30 17 O 4.2868 -6.6000 0.0000 0
M  V30 18 O 5.7158 -6.6000 0.0000 0
M  V30 19 C 1.4289 -4.1250 0.0000 0
M  V30 20 C 0.7145 -3.7125 0.0000 0
M  V30 21 C 0.7145 -2.8875 0.0000 0
M  V30 22 O 0.0000 -2.4750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 2 14 15
M  V30 15 1 9 15
M  V30 16 1 14 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 2 6 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 4 21
M  V30 23 1 21 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
439

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Olsalazine

>  <Synonyms>
Dipentium;Salicylic acid

>  <CAS>
15722-48-2

>  <Formula>
C14H10N2O6

>  <MolWt>
302.2

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Olsalazine, an anti-inflammatory drug, is used in the treatment of inflammatory bowel disease. It is also a novel DNA hypomethylating agent."

>  <Reference>
"Rao Y, Zheng F. Thrombocytopenia associated with 5-aminosalicylate prodrug, olsalazine: is the devil still there? Int J Clin Pharm. 2013 Aug;35(4):529-31. doi: 10.1007/s11096-013-9778-8. Epub 2013 Apr 27. PubMed PMID: 23625279.;El-Kawy OA, Ibrahim IT, Farah K. Technetium-99?m labeling and evaluation of olsalazine: a novel agent for ulcerative colitis imaging. J Labelled Comp Radiopharm. 2015 Jun 30;58(8):336-41. doi: 10.1002/jlcr.3306. Epub 2015 Jun 1. PubMed PMID: 26031480.;Levine DJ, Run?evski T, Kapelewski MT, Keitz BK, Oktawiec J, Reed DA, Mason JA, Jiang HZ, Colwell KA, Legendre CM, FitzGerald SA, Long JR. Olsalazine-Based Metal-Organic Frameworks as Biocompatible Platforms for H2 Adsorption and Drug Delivery. J Am Chem Soc. 2016 Aug 17;138(32):10143-50. doi: 10.1021/jacs.6b03523. Epub 2016 Aug 3. PubMed PMID: 27486905.;M??ndez-Lucio O, Tran J, Medina-Franco JL, Meurice N, Muller M. Toward drug repurposing in epigenetics: olsalazine as a hypomethylating compound active in a cellular context. ChemMedChem. 2014 Mar;9(3):560-5. doi: 10.1002/cmdc.201300555. Epub 2014 Jan 31. PubMed PMID: 24482360."

>  <ID<1>>
T20615

$$$$
StarDrop ID 440
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 38 40 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.0291 4.1132 0.0000 0
M  V30 2 C 4.0291 3.2882 0.0000 0 CFG=2
M  V30 3 C 4.7436 2.8757 0.0000 0
M  V30 4 C 4.7436 2.0507 0.0000 0
M  V30 5 N 4.0291 1.6382 0.0000 0
M  V30 6 C 3.3147 2.0507 0.0000 0 CFG=2
M  V30 7 C 3.3147 2.8757 0.0000 0
M  V30 8 C 2.6002 1.6382 0.0000 0
M  V30 9 O 1.8857 2.0507 0.0000 0
M  V30 10 O 2.6002 0.8132 0.0000 0
M  V30 11 C 4.0291 0.8132 0.0000 0
M  V30 12 O 3.3147 0.4007 0.0000 0
M  V30 13 C 4.7436 0.4007 0.0000 0 CFG=2
M  V30 14 C 5.4581 0.8132 0.0000 0
M  V30 15 C 6.1725 0.4007 0.0000 0
M  V30 16 C 6.8870 0.8132 0.0000 0
M  V30 17 N 7.6015 0.4007 0.0000 0
M  V30 18 C 8.3160 0.8132 0.0000 0
M  V30 19 N 8.3160 1.6382 0.0000 0
M  V30 20 N 9.0304 0.4007 0.0000 0
M  V30 21 N 4.7436 -0.4243 0.0000 0
M  V30 22 S 5.4581 -0.8368 0.0000 0
M  V30 23 O 5.0456 -1.5513 0.0000 0
M  V30 24 O 5.8706 -0.1223 0.0000 0
M  V30 25 C 6.1725 -1.2493 0.0000 0
M  V30 26 C 6.8870 -0.8368 0.0000 0
M  V30 27 C 7.6015 -1.2493 0.0000 0
M  V30 28 C 7.6015 -2.0743 0.0000 0
M  V30 29 C 6.8870 -2.4868 0.0000 0
M  V30 30 C 6.8870 -3.3118 0.0000 0
M  V30 31 C 6.1725 -3.7243 0.0000 0
M  V30 32 C 6.1725 -4.5493 0.0000 0
M  V30 33 C 5.4581 -3.3118 0.0000 0
M  V30 34 N 5.4581 -2.4868 0.0000 0
M  V30 35 C 6.1725 -2.0743 0.0000 0
M  V30 36 H 3.1631 3.7882 0.0000 0
M  V30 37 H 3.3146 1.0507 0.0000 0
M  V30 38 H 5.6096 -0.0993 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 6 8 CFG=1
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 5 11
M  V30 12 2 11 12
M  V30 13 1 13 11
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 18 20
M  V30 21 1 13 21 CFG=3
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 2 22 24
M  V30 25 1 22 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 2 27 28
M  V30 29 1 28 29
M  V30 30 1 29 30
M  V30 31 1 30 31
M  V30 32 1 31 32
M  V30 33 1 31 33
M  V30 34 1 33 34
M  V30 35 1 34 35
M  V30 36 1 25 35
M  V30 37 2 29 35
M  V30 38 1 36 2
M  V30 39 1 37 6
M  V30 40 1 38 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
440

>  <Plate>
PHD136329

>  <Row>
f

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Argatroban Monohydrate

>  <Synonyms>
N/A

>  <CAS>
141396-28-3

>  <Formula>
C23H38N6O6S

>  <MolWt>
526.7

>  <Pathways>
Proteases/Proteasome

>  <Target>
Thrombin

>  <Receptor>
 Thrombin:5-39 nM(Ki)

>  <Bioactivity>
"Argatroban Monohydrate is a specific thrombin inhibitor, which is a non-heparin anticoagulant, prevents the formation of thrombi."

>  <Reference>
"Berry CN, et al. Br J Pharmacol,1994, 113(4), 1209-1214.;Kawai H, et al. J Pharmacol Exp Ther,1996, 278(2), 780-785.;Yoshinaga M, et al. Eur J Pharmacol,2003, 461(1), 9-17.;Kawai H, et al. Jpn J Pharmacol,1995, 69(2), 143-148."

>  <ID<1>>
T22246

$$$$
StarDrop ID 441
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 43 46 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.0919 -4.6024 0.0000 0
M  V30 2 O 2.8370 -5.3870 0.0000 0
M  V30 3 C 2.0300 -5.5585 0.0000 0
M  V30 4 C 1.7751 -6.3432 0.0000 0
M  V30 5 C 0.9681 -6.5147 0.0000 0
M  V30 6 N 0.7132 -7.2993 0.0000 0
M  V30 7 C 1.2652 -7.9124 0.0000 0
M  V30 8 C -0.0938 -7.4708 0.0000 0
M  V30 9 C -0.3488 -8.2554 0.0000 0
M  V30 10 N -1.1557 -8.4270 0.0000 0
M  V30 11 C -1.4107 -9.2116 0.0000 0
M  V30 12 C -1.7078 -7.8139 0.0000 0
M  V30 13 C 0.4161 -5.9016 0.0000 0
M  V30 14 N -0.3909 -6.0731 0.0000 0
M  V30 15 C -0.9429 -5.4600 0.0000 0
M  V30 16 O -0.6880 -4.6754 0.0000 0
M  V30 17 C -1.7499 -5.6315 0.0000 0
M  V30 18 C -2.3020 -5.0184 0.0000 0
M  V30 19 C 0.6710 -5.1170 0.0000 0
M  V30 20 C 1.4780 -4.9454 0.0000 0
M  V30 21 N 1.7329 -4.1608 0.0000 0
M  V30 22 C 1.1809 -3.5477 0.0000 0
M  V30 23 N 0.3739 -3.7192 0.0000 0
M  V30 24 C -0.1781 -3.1062 0.0000 0
M  V30 25 C 0.0768 -2.3215 0.0000 0
M  V30 26 C -0.4752 -1.7084 0.0000 0
M  V30 27 O -0.2203 -0.9238 0.0000 0
M  V30 28 O -1.2822 -1.8800 0.0000 0
M  V30 29 C -1.5371 -2.6646 0.0000 0
M  V30 30 C -0.9851 -3.2777 0.0000 0
M  V30 31 C -2.3441 -2.8361 0.0000 0
M  V30 32 C 0.8838 -2.1500 0.0000 0
M  V30 33 N 1.4358 -2.7631 0.0000 0
M  V30 34 C 1.1387 -1.3654 0.0000 0
M  V30 35 C 0.6538 -0.6979 0.0000 0
M  V30 36 N 1.1387 -0.0305 0.0000 0
M  V30 37 C 0.8838 0.7541 0.0000 0
M  V30 38 C 1.9233 -0.2854 0.0000 0
M  V30 39 C 2.6378 0.1271 0.0000 0
M  V30 40 C 3.3523 -0.2854 0.0000 0
M  V30 41 C 3.3523 -1.1104 0.0000 0
M  V30 42 C 2.6378 -1.5229 0.0000 0
M  V30 43 C 1.9233 -1.1104 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 5 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 2 17 18
M  V30 18 1 13 19
M  V30 19 2 19 20
M  V30 20 1 3 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 26 28
M  V30 29 1 28 29
M  V30 30 1 29 30
M  V30 31 1 29 31
M  V30 32 1 25 32
M  V30 33 2 32 33
M  V30 34 1 22 33
M  V30 35 1 32 34
M  V30 36 2 34 35
M  V30 37 1 35 36
M  V30 38 1 36 37
M  V30 39 1 36 38
M  V30 40 2 38 39
M  V30 41 1 39 40
M  V30 42 2 40 41
M  V30 43 1 41 42
M  V30 44 2 42 43
M  V30 45 1 34 43
M  V30 46 1 38 43
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
441

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Mobocertinib

>  <Synonyms>
tak788

>  <CAS>
1847461-43-1

>  <Formula>
C32H39N7O4

>  <MolWt>
585.7

>  <Pathways>
Tyrosine Kinase/Adaptors;Angiogenesis;JAK/STAT signaling

>  <Target>
EGFR

>  <Receptor>
 EGFR (wt):35 nM (IC50)

>  <Bioactivity>
Mobocertinib is a potent  inhibitor of epidermal growth factor receptor (EGFR) and an antineoplastic agent

>  <Reference>
"Landon J. DURAK, et al. Pharmaceutical salts of pyrimidine derivatives and method of treating disorders. WO2019222093A1."

>  <ID<1>>
T8151

$$$$
StarDrop ID 442
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -0.0088 0.0019 0.0000 0
M  V30 2 N 0.7981 -0.1696 0.0000 0
M  V30 3 C 1.3502 0.4434 0.0000 0
M  V30 4 C 2.1571 0.2719 0.0000 0
M  V30 5 C 2.8246 0.7568 0.0000 0
M  V30 6 C 3.4920 0.2719 0.0000 0 CFG=1
M  V30 7 C 3.2371 -0.5127 0.0000 0 CFG=1
M  V30 8 N 2.4121 -0.5127 0.0000 0
M  V30 9 C 1.8600 -1.1258 0.0000 0
M  V30 10 C 1.0531 -0.9543 0.0000 0
M  V30 11 C 3.7891 -1.1258 0.0000 0
M  V30 12 C 4.5961 -0.9543 0.0000 0
M  V30 13 N 4.8510 -0.1696 0.0000 0
M  V30 14 C 5.6580 0.0019 0.0000 0
M  V30 15 C 5.9129 0.7865 0.0000 0
M  V30 16 C 6.7199 0.9580 0.0000 0
M  V30 17 C 6.9748 1.7426 0.0000 0
M  V30 18 O 6.4228 2.3557 0.0000 0
M  V30 19 C 7.7818 1.9142 0.0000 0
M  V30 20 C 8.0367 2.6988 0.0000 0
M  V30 21 C 8.8437 2.8703 0.0000 0
M  V30 22 C 9.3958 2.2572 0.0000 0
M  V30 23 F 10.2027 2.4288 0.0000 0
M  V30 24 C 9.1408 1.4726 0.0000 0
M  V30 25 C 8.3338 1.3011 0.0000 0
M  V30 26 C 4.2990 0.4434 0.0000 0
M  V30 27 H 2.9015 -1.2664 0.0000 0
M  V30 28 H 4.0440 -0.3412 0.0000 0
M  V30 29 C 2.7383 1.5773 0.0000 0
M  V30 30 C 1.9847 1.9129 0.0000 0
M  V30 31 C 1.3172 1.4280 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 4 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 2 10
M  V30 12 1 7 11
M  V30 13 1 11 12
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 22 24
M  V30 26 2 24 25
M  V30 27 1 19 25
M  V30 28 1 13 26
M  V30 29 1 6 26
M  V30 30 1 7 27 CFG=1
M  V30 31 1 6 28 CFG=1
M  V30 32 2 5 29
M  V30 33 1 29 30
M  V30 34 2 30 31
M  V30 35 1 3 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
442

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lumateperone

>  <Synonyms>
ITI 722;ITI722;ITI-007;ITI007

>  <CAS>
313368-91-1

>  <Formula>
C24H28FN3O

>  <MolWt>
393.5

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
5-HT Receptor

>  <Receptor>
5-HT Receptor

>  <Bioactivity>
ITI-722 is a 5HT2A receptor antagonist and a dopamine receptor phosphoprotein modulator (DPPM).

>  <Reference>
"Li P, Zhang Q, Robichaud AJ, Lee T, Tomesch J, Yao W, Beard JD, Snyder GL, Zhu H, Peng Y, Hendrick JP, Vanover KE, Davis RE, Mates S, Wennogle LP. Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. J Med Chem. 2014 Mar 27;57(6):2670-82. doi: 10.1021/jm401958n. Epub 2014 Mar 5. PMID: 24559051.;Kumar B, Kuhad A, Kuhad A. Lumateperone: a new treatment approach for neuropsychiatric disorders. Drugs Today (Barc). 2018 Dec;54(12):713-719. doi: 10.1358/dot.2018.54.12.2899443. PubMed PMID: 30596390."

>  <ID<1>>
T21069

$$$$
StarDrop ID 443
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 5.4656 0.0000 0
M  V30 2 N 3.0716 5.0531 0.0000 0
M  V30 3 C 3.7861 5.4656 0.0000 0
M  V30 4 C 3.0716 4.2281 0.0000 0
M  V30 5 O 2.3571 3.8156 0.0000 0
M  V30 6 N 3.7861 3.8156 0.0000 0
M  V30 7 C 3.7861 2.9906 0.0000 0 CFG=1
M  V30 8 C 4.5006 2.5781 0.0000 0
M  V30 9 C 4.5006 1.7531 0.0000 0
M  V30 10 C 3.7861 1.3406 0.0000 0 CFG=2
M  V30 11 C 3.7861 0.5156 0.0000 0
M  V30 12 C 4.5006 0.1031 0.0000 0
M  V30 13 N 4.5006 -0.7219 0.0000 0
M  V30 14 C 5.2150 -1.1344 0.0000 0
M  V30 15 C 5.2150 -1.9594 0.0000 0
M  V30 16 N 4.5006 -2.3719 0.0000 0
M  V30 17 C 3.7861 -1.9594 0.0000 0
M  V30 18 C 3.7861 -1.1344 0.0000 0
M  V30 19 C 4.5006 -3.1969 0.0000 0
M  V30 20 C 5.2150 -3.6094 0.0000 0
M  V30 21 C 5.2150 -4.4344 0.0000 0
M  V30 22 C 4.5006 -4.8469 0.0000 0
M  V30 23 C 3.7861 -4.4344 0.0000 0
M  V30 24 Cl 3.0716 -4.8469 0.0000 0
M  V30 25 C 3.7861 -3.6094 0.0000 0
M  V30 26 Cl 3.0716 -3.1969 0.0000 0
M  V30 27 C 3.0716 1.7531 0.0000 0
M  V30 28 C 3.0716 2.5781 0.0000 0
M  V30 29 H 2.9201 3.4906 0.0000 0
M  V30 30 H 4.6521 0.8406 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 7 6 CFG=1
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 10 9
M  V30 10 1 10 11 CFG=3
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 13 18
M  V30 19 1 16 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 2 23 25
M  V30 26 1 19 25
M  V30 27 1 25 26
M  V30 28 1 10 27
M  V30 29 1 27 28
M  V30 30 1 7 28
M  V30 31 1 29 7
M  V30 32 1 30 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
443

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cariprazine hydrochloride

>  <Synonyms>
RGH188 hydrochloride;Cariprazine HCl

>  <CAS>
1083076-69-0

>  <Formula>
C21H33Cl3N4O

>  <MolWt>
463.9

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
5-HT Receptor;Dopamine Receptor

>  <Receptor>
" D2 receptor:0.49 nM (Ki) , 5-HT1A Receptor:2.6 nM (Ki), D3 receptor:0.085 nM (Ki) "

>  <Bioactivity>
"Cariprazine HCl is an antipsychotic drug, is a D3 and D2 receptor partial agonist((Ki of 0.085 nM and 0.49 nM, respectively)"

>  <Reference>
"Seneca N, et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology (Berl). 2011 Dec;218(3):579-8;B?a?ej, Misiak, Przemys?aw,et al. Cariprazine - a novel antipsychotic drug and its place in the treatment of schizophrenia.[J]. Psychiatria polska, 2018."

>  <ID<1>>
T8382

$$$$
StarDrop ID 444
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.7605 1.8414 0.0000 0
M  V30 2 C 2.4750 1.4289 0.0000 0
M  V30 3 C 3.1895 1.8414 0.0000 0
M  V30 4 C 3.9039 1.4289 0.0000 0
M  V30 5 C 4.6184 1.8414 0.0000 0
M  V30 6 N 5.3329 1.4289 0.0000 0
M  V30 7 C 5.3329 0.6039 0.0000 0
M  V30 8 C 6.0474 1.8414 0.0000 0
M  V30 9 C 6.7618 1.4289 0.0000 0
M  V30 10 C 7.4763 1.8414 0.0000 0
M  V30 11 O 8.1908 2.2539 0.0000 0
M  V30 12 P 7.0638 2.5559 0.0000 0
M  V30 13 O 6.6513 3.2704 0.0000 0
M  V30 14 O 7.7783 2.9684 0.0000 0
M  V30 15 O 6.3493 2.1434 0.0000 0
M  V30 16 P 7.8888 1.1270 0.0000 0
M  V30 17 O 8.6033 1.5395 0.0000 0
M  V30 18 O 8.3013 0.4125 0.0000 0
M  V30 19 O 7.1743 0.7145 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 2 12 15
M  V30 15 1 10 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 2 16 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
444

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ibandronic acid

>  <Synonyms>
Bonviva;Boniva;Bondronat

>  <CAS>
114084-78-5

>  <Formula>
C9H23NO7P2

>  <MolWt>
319.2

>  <Pathways>
Others;Microbiology/Virology

>  <Target>
Others;HBV

>  <Receptor>
FPPS; HAP

>  <Bioactivity>
Ibandronic Acid is a third-generation amino-bisphosphonate with anti-resorptive and anti-hypercalcemic activities.

>  <Reference>
"Dunford JE, et al. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42."

>  <ID<1>>
T1599

$$$$
StarDrop ID 445
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.6468 -1.3109 0.0000 0
M  V30 2 C 6.4286 -1.5745 0.0000 0
M  V30 3 C 7.0477 -1.0293 0.0000 0
M  V30 4 C 7.8295 -1.2929 0.0000 0
M  V30 5 C 8.4486 -0.7476 0.0000 0
M  V30 6 C 9.2304 -1.0112 0.0000 0
M  V30 7 O 9.3930 -1.8200 0.0000 0
M  V30 8 C 9.8495 -0.4660 0.0000 0
M  V30 9 C 9.6869 0.3429 0.0000 0
M  V30 10 N 10.4059 0.7475 0.0000 0
M  V30 11 C 11.0129 0.1887 0.0000 0
M  V30 12 C 11.8342 0.2659 0.0000 0
M  V30 13 C 12.3118 -0.4069 0.0000 0
M  V30 14 C 11.9679 -1.1568 0.0000 0
M  V30 15 C 11.1466 -1.2340 0.0000 0
M  V30 16 C 10.6690 -0.5612 0.0000 0
M  V30 17 C 13.1332 -0.3297 0.0000 0
M  V30 18 N 13.9545 -0.2525 0.0000 0
M  V30 19 C 8.9052 0.6064 0.0000 0
M  V30 20 C 9.3005 1.3306 0.0000 0
M  V30 21 C 8.2607 1.1215 0.0000 0
M  V30 22 C 8.2860 0.0612 0.0000 0
M  V30 23 C 7.5042 0.3248 0.0000 0
M  V30 24 C 6.8851 -0.2205 0.0000 0
M  V30 25 N 6.1033 0.0431 0.0000 0
M  V30 26 C 5.4842 -0.5021 0.0000 0
M  V30 27 C 4.7024 -0.2386 0.0000 0
M  V30 28 C 4.5398 0.5703 0.0000 0
M  V30 29 C 5.1590 1.1155 0.0000 0
M  V30 30 C 5.9407 0.8519 0.0000 0
M  V30 31 N 3.7580 0.8338 0.0000 0
M  V30 32 C 3.1389 0.2886 0.0000 0
M  V30 33 C 2.3571 0.5522 0.0000 0
M  V30 34 O 2.1945 1.3610 0.0000 0
M  V30 35 C 2.8137 1.9062 0.0000 0
M  V30 36 C 3.5954 1.6426 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 8 16
M  V30 17 1 11 16
M  V30 18 1 13 17
M  V30 19 3 17 18
M  V30 20 1 9 19
M  V30 21 1 19 20
M  V30 22 1 19 21
M  V30 23 1 19 22
M  V30 24 1 5 22
M  V30 25 2 22 23
M  V30 26 1 23 24
M  V30 27 2 3 24
M  V30 28 1 24 25
M  V30 29 1 25 26
M  V30 30 1 26 27
M  V30 31 1 27 28
M  V30 32 1 28 29
M  V30 33 1 29 30
M  V30 34 1 25 30
M  V30 35 1 28 31
M  V30 36 1 31 32
M  V30 37 1 32 33
M  V30 38 1 33 34
M  V30 39 1 34 35
M  V30 40 1 35 36
M  V30 41 1 31 36
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
445

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Alectinib hydrochloride

>  <Synonyms>
RO5424802 (Hydrochloride);CH5424802 (Hydrochloride);AF-802 (Hydrochloride)

>  <CAS>
1256589-74-8

>  <Formula>
C30H35ClN4O2

>  <MolWt>
519.1

>  <Pathways>
Tyrosine Kinase/Adaptors;Angiogenesis

>  <Target>
ALK

>  <Receptor>
 ALK:1.9 nM

>  <Bioactivity>
"Alectinib hydrochloride is a selective, and orally available inhibitor of ALK( IC50 : 1.9 nM)"

>  <Reference>
"Sakamoto H, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011, 19(5), 679-690.;Julia P , Sohita D . Alectinib: A Review in Advanced, ALK-Positive NSCLC[J]. Drugs, 2018."

>  <ID<1>>
T8387

$$$$
StarDrop ID 446
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -2.0367 4.3527 0.0000 0
M  V30 2 C -2.0367 3.5277 0.0000 0
M  V30 3 C -1.3222 3.1152 0.0000 0
M  V30 4 C -1.3222 2.2902 0.0000 0
M  V30 5 C -2.0367 1.8777 0.0000 0
M  V30 6 C -2.7512 2.2902 0.0000 0
M  V30 7 C -2.7512 3.1152 0.0000 0
M  V30 8 N -2.0367 1.0527 0.0000 0
M  V30 9 C -1.3222 0.6402 0.0000 0
M  V30 10 C -1.3222 -0.1848 0.0000 0
M  V30 11 N -0.6548 -0.6697 0.0000 0
M  V30 12 C -0.9097 -1.4544 0.0000 0
M  V30 13 C -1.7347 -1.4544 0.0000 0
M  V30 14 N -1.9897 -0.6697 0.0000 0
M  V30 15 C -2.7512 0.6402 0.0000 0
M  V30 16 C -2.7512 -0.1848 0.0000 0
M  V30 17 C -3.4656 -0.5973 0.0000 0
M  V30 18 C -4.1801 -0.1848 0.0000 0
M  V30 19 C -4.1801 0.6402 0.0000 0
M  V30 20 O -4.8946 1.0527 0.0000 0
M  V30 21 C -3.4656 1.0527 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 10 14
M  V30 16 1 8 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 2 19 21
M  V30 23 1 15 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
446

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Phentolamine

>  <Synonyms>
N/A

>  <CAS>
50-60-2

>  <Formula>
C17H19N3O

>  <MolWt>
281.4

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
??1-adrenergic receptor; ??2-adrenergic receptor

>  <Bioactivity>
Phentolamine mesylate is an alpha-1 and alpha-2 selective adrenergic receptor antagonist

>  <Reference>
"Liangli Pan , Chenyang Liu , Yanan Kong,et al,Phentolamine Inhibits Angiogenesis in Vitro: Suppression of Proliferation Migration and Differentiation of Human Endothelial Cells.Clin Hemorheol Microcirc. 2017;65(1):31-41.;Goldstein, I. Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction[J]. international journal of impotence research, 2000, 12:0-0."

>  <ID<1>>
T8348

$$$$
StarDrop ID 447
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.1433 1.4431 0.0000 0
M  V30 2 O 4.8578 1.0306 0.0000 0
M  V30 3 C 5.5723 1.4431 0.0000 0
M  V30 4 C 6.2867 1.0306 0.0000 0
M  V30 5 C 7.0012 1.4431 0.0000 0
M  V30 6 N 7.7157 1.0306 0.0000 0
M  V30 7 C 8.4301 1.4431 0.0000 0
M  V30 8 C 9.1446 1.0306 0.0000 0
M  V30 9 C 9.1446 0.2056 0.0000 0
M  V30 10 C 8.4301 -0.2069 0.0000 0
M  V30 11 C 7.7157 0.2056 0.0000 0
M  V30 12 N 9.8591 -0.2069 0.0000 0
M  V30 13 C 10.5736 0.2056 0.0000 0
M  V30 14 O 10.5736 1.0306 0.0000 0
M  V30 15 C 11.2880 -0.2069 0.0000 0
M  V30 16 C 12.0025 0.2056 0.0000 0
M  V30 17 C 12.7170 -0.2069 0.0000 0
M  V30 18 Cl 13.4314 0.2056 0.0000 0
M  V30 19 C 12.7170 -1.0319 0.0000 0
M  V30 20 N 13.4314 -1.4444 0.0000 0
M  V30 21 C 12.0025 -1.4444 0.0000 0
M  V30 22 C 11.8310 -2.2514 0.0000 0
M  V30 23 C 11.0105 -2.3376 0.0000 0
M  V30 24 O 10.6749 -1.5839 0.0000 0
M  V30 25 C 11.2880 -1.0319 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 6 11
M  V30 12 1 9 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 17 19
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 15 25
M  V30 27 2 21 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
447

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Prucalopride Succinate

>  <Synonyms>
Resolor Succinate;R-108512

>  <CAS>
179474-85-2

>  <Formula>
C22H32ClN3O7

>  <MolWt>
486

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
5-HT Receptor

>  <Receptor>
" 5-HT4B:8 nM(Ki), 5-HT4A:2.5 nM(Ki)"

>  <Bioactivity>
"Prucalopride is a selective, high affinity 5-HT4 receptor agonist, inhibiting human 5-HT(4a) and 5-HT(4b) receptor with Ki value of 2.5 nM and 8 nM, respectively."

>  <Reference>
"Priem E, et al. Neuropharmacology, 2012, 62(5-6), 2126-2135.;Priem EK, et al. Eur J Pharmacol, 2013, 705(1-3), 156-163.;Briejer MR, et al. Eur J Pharmacol, 2001, 423(1), 71-83.;Briejer MR, et al. Neurogastroenterol Motil, 2001, 13(5), 465-472."

>  <ID<1>>
T6958

$$$$
StarDrop ID 448
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 31 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 7.6778 -0.8354 0.0000 0
M  V30 2 C 8.3922 -0.4229 0.0000 0 CFG=1
M  V30 3 N 8.3922 -1.2479 0.0000 0
M  V30 4 C 7.6778 -0.0104 0.0000 0
M  V30 5 C 6.9633 -0.4229 0.0000 0
M  V30 6 O 6.9633 -1.2479 0.0000 0
M  V30 7 N 6.2488 -0.0104 0.0000 0
M  V30 8 C 5.5344 -0.4229 0.0000 0
M  V30 9 C 4.8199 -0.0104 0.0000 0
M  V30 10 N 4.8199 0.8146 0.0000 0
M  V30 11 C 5.5344 1.2271 0.0000 0
M  V30 12 C 6.2488 0.8146 0.0000 0
M  V30 13 N 5.3628 2.0340 0.0000 0
M  V30 14 N 4.5424 2.1203 0.0000 0
M  V30 15 C 4.2068 1.3666 0.0000 0
M  V30 16 C 3.3998 1.1951 0.0000 0
M  V30 17 F 2.5929 1.0235 0.0000 0
M  V30 18 F 3.5714 0.3881 0.0000 0
M  V30 19 F 3.2283 2.0020 0.0000 0
M  V30 20 C 9.1067 -0.0104 0.0000 0
M  V30 21 C 9.8212 -0.4229 0.0000 0
M  V30 22 C 10.5357 -0.0104 0.0000 0
M  V30 23 C 11.2501 -0.4229 0.0000 0
M  V30 24 F 11.9646 -0.0104 0.0000 0
M  V30 25 C 11.2501 -1.2479 0.0000 0
M  V30 26 F 11.9646 -1.6604 0.0000 0
M  V30 27 C 10.5357 -1.6604 0.0000 0
M  V30 28 C 9.8212 -1.2479 0.0000 0
M  V30 29 F 9.1067 -1.6604 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 7 12
M  V30 13 2 11 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 10 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 16 18
M  V30 20 1 16 19
M  V30 21 1 2 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 2 23 25
M  V30 27 1 25 26
M  V30 28 1 25 27
M  V30 29 2 27 28
M  V30 30 1 21 28
M  V30 31 1 28 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
448

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Sitagliptin phosphate

>  <Synonyms>
Januvia;Sitagliptin (phosphate);MK-0431 phosphate

>  <CAS>
654671-78-0

>  <Formula>
C16H18F6N5O5P

>  <MolWt>
505.3

>  <Pathways>
Autophagy;Proteases/Proteasome

>  <Target>
Autophagy;DPP-4

>  <Receptor>
 DPP-4:19 nM

>  <Bioactivity>
Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4) inhibitor.

>  <Reference>
"Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008 Apr;325(1):175-82.;Kim SJ, Nian C, Doudet DJ, McIntosh CH. Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation. Diabetes. 2009 Mar;58(3):641-51."

>  <ID<1>>
T23358

$$$$
StarDrop ID 449
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 21 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 0.0567 0.0000 0
M  V30 2 N 3.0716 -0.3558 0.0000 0
M  V30 3 C 3.0716 -1.1808 0.0000 0
M  V30 4 C 3.7861 0.0567 0.0000 0
M  V30 5 C 4.5006 -0.3558 0.0000 0
M  V30 6 O 5.2150 0.0567 0.0000 0
M  V30 7 C 5.9295 -0.3558 0.0000 0
M  V30 8 O 5.9295 -1.1808 0.0000 0
M  V30 9 C 6.6440 0.0567 0.0000 0
M  V30 10 C 7.3584 -0.3558 0.0000 0
M  V30 11 C 8.0729 0.0567 0.0000 0
M  V30 12 C 8.7874 -0.3558 0.0000 0
M  V30 13 C 8.7874 -1.1808 0.0000 0
M  V30 14 C 8.0729 -1.5933 0.0000 0
M  V30 15 C 7.3584 -1.1808 0.0000 0
M  V30 16 C 6.6440 0.8817 0.0000 0
M  V30 17 O 7.4644 0.7955 0.0000 0
M  V30 18 C 5.8235 0.7955 0.0000 0
M  V30 19 C 5.4879 1.5492 0.0000 0
M  V30 20 C 6.1010 2.1012 0.0000 0
M  V30 21 C 6.8155 1.6887 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 10 15
M  V30 16 1 9 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 16 21
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
449

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cyclopentolate Hydrochloride

>  <Synonyms>
N/A

>  <CAS>
5870-29-1

>  <Formula>
C17H26ClNO3

>  <MolWt>
327.9

>  <Pathways>
Neuroscience

>  <Target>
AChR

>  <Receptor>
" M1:1.62nM , M2:27.5nM , M3:2.63 nM"

>  <Bioactivity>
"Cyclopentolate Hydrochloride is a muscarinic acetylcholine receptors antagonist with Kis of 1.62, 27.5, and 2.63 nM for M1, M2, and M3 receptors, respectively."

>  <Reference>
"Akemi Wakayama.et al.Incidence of Side Effects of Topical Atropine Sulfate and Cyclopentolate Hydrochloride for Cycloplegia in Japanese Children: A Multicenter Study.Multicenter Study  Jpn J Ophthalmol. 2018 Sep;62(5):531-536.;Ishikawa H , Desantis L , Patil P N . Selectivity of Muscarinic Agonists Including (??)-Aceclidine and Antimuscarinics on the Human Intraocular Muscles[J]. Journal of Ocular Pharmacology & Therapeutics, 1998, 14(4):363-373."

>  <ID<1>>
T8383

$$$$
StarDrop ID 450
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7145 2.0625 0.0000 0
M  V30 2 N 0.7145 1.2375 0.0000 0 CHG=1
M  V30 3 C 1.4289 0.8250 0.0000 0
M  V30 4 C 1.4289 -0.0000 0.0000 0
M  V30 5 C 0.7145 -0.4125 0.0000 0
M  V30 6 C 0.0000 0.0000 0.0000 0
M  V30 7 C 0.0000 0.8250 0.0000 0
M  V30 8 O -0.7145 -0.4125 0.0000 0
M  V30 9 C -0.7145 -1.2375 0.0000 0
M  V30 10 O -0.0000 -1.6500 0.0000 0
M  V30 11 N -1.4289 -1.6500 0.0000 0
M  V30 12 C -1.4289 -2.4750 0.0000 0
M  V30 13 C -2.1434 -1.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 13 1 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
450

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
pyridostigmine

>  <Synonyms>
UNII-19QM69HH21;Mestinon-SR;Regonol;PyridostigmineBromine;Pyridostigminum

>  <CAS>
155-97-5

>  <Formula>
C9H13BrN2O2

>  <MolWt>
261.1

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
acetylcholinesterase

>  <Bioactivity>
Pyridostigmine is an acetylcholinesterase inhibitor that can treat myasthenia gravis by increasing acetylcholine at the postsynaptic motor endplate.

>  <Reference>
"Ahuja N K , Mische L , Clarke J O , et al. Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis[J]. Semin Arthritis Rheum, 2018:S0049017217305498.;Byun J I , Moon J , Kim D Y , et al. Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension[J]. Neurology, 2017:10.1212/WNL.0000000000004340."

>  <ID<1>>
T8631

$$$$
StarDrop ID 451
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 44 48 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -1.4289 -7.4250 0.0000 0
M  V30 2 C -1.4289 -6.6000 0.0000 0
M  V30 3 C -2.1434 -6.1875 0.0000 0
M  V30 4 C -2.1434 -5.3625 0.0000 0
M  V30 5 C -1.4289 -4.9500 0.0000 0
M  V30 6 N -1.4289 -4.1250 0.0000 0
M  V30 7 C -0.7145 -3.7125 0.0000 0
M  V30 8 O 0.0000 -4.1250 0.0000 0
M  V30 9 C -0.7145 -2.8875 0.0000 0 CFG=1
M  V30 10 C -1.4289 -2.4750 0.0000 0
M  V30 11 C -1.4289 -1.6500 0.0000 0
M  V30 12 C -0.7145 -1.2375 0.0000 0
M  V30 13 N 0.0000 -1.6500 0.0000 0
M  V30 14 C 0.0000 -2.4750 0.0000 0 CFG=1
M  V30 15 C 0.7145 -2.8875 0.0000 0
M  V30 16 C 1.4289 -2.4750 0.0000 0
M  V30 17 C 2.1434 -2.8875 0.0000 0
M  V30 18 C 2.1434 -3.7125 0.0000 0
M  V30 19 N 2.8579 -4.1250 0.0000 0
M  V30 20 C 2.8579 -4.9500 0.0000 0
M  V30 21 C 3.5253 -5.4349 0.0000 0
M  V30 22 C 3.2704 -6.2195 0.0000 0
M  V30 23 C 2.4454 -6.2195 0.0000 0
M  V30 24 C 2.1904 -5.4349 0.0000 0
M  V30 25 C 1.4289 -4.1250 0.0000 0
M  V30 26 C 0.7145 -3.7125 0.0000 0
M  V30 27 C 0.7145 -1.2375 0.0000 0
M  V30 28 O 1.4289 -1.6500 0.0000 0
M  V30 29 C 0.7145 -0.4125 0.0000 0
M  V30 30 C 0.0000 0.0000 0.0000 0
M  V30 31 C -0.7145 -0.4125 0.0000 0
M  V30 32 C 0.0000 0.8250 0.0000 0
M  V30 33 C 0.7145 1.2375 0.0000 0
M  V30 34 C 1.4289 0.8250 0.0000 0
M  V30 35 C 1.4289 0.0000 0.0000 0
M  V30 36 F 2.1434 -0.4125 0.0000 0
M  V30 37 C -0.7145 -5.3625 0.0000 0
M  V30 38 C -0.7145 -6.1875 0.0000 0
M  V30 39 C 0.0000 -6.6000 0.0000 0
M  V30 40 F 0.7145 -7.0125 0.0000 0
M  V30 41 F -0.4125 -7.3145 0.0000 0
M  V30 42 F 0.4125 -5.8855 0.0000 0
M  V30 43 H -1.5805 -3.3875 0.0000 0
M  V30 44 H 0.8660 -1.9750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 9 7 CFG=1
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 14 13
M  V30 14 1 9 14
M  V30 15 1 14 15 CFG=1
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 20 24
M  V30 26 1 18 25
M  V30 27 2 25 26
M  V30 28 1 15 26
M  V30 29 1 13 27
M  V30 30 2 27 28
M  V30 31 1 27 29
M  V30 32 2 29 30
M  V30 33 1 30 31
M  V30 34 1 30 32
M  V30 35 2 32 33
M  V30 36 1 33 34
M  V30 37 2 34 35
M  V30 38 1 29 35
M  V30 39 1 35 36
M  V30 40 1 5 37
M  V30 41 2 37 38
M  V30 42 1 2 38
M  V30 43 1 38 39
M  V30 44 1 39 40
M  V30 45 1 39 41
M  V30 46 1 39 42
M  V30 47 1 43 9
M  V30 48 1 44 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
451

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Avacopan

>  <Synonyms>
CCX168

>  <CAS>
1346623-17-3

>  <Formula>
C33H35F4N3O2

>  <MolWt>
581.7

>  <Pathways>
Immunology/Inflammation

>  <Target>
Complement System

>  <Receptor>
 C5aR:0.1 nM

>  <Bioactivity>
Avacopan is an orally administered small-molecule C5aR ( IC50 : 0.1 nM.)antagonist that blocks the effects of C5a and prevents the development of GN induced by anti-myeloperoxidase antibodies in a murine model of AAV.

>  <Reference>
"Jayne D R W , Bruchfeld A N , Harper L , et al. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis[J]. Journal of the American Society of Nephrology, 2017:ASN.2016111179.;Bekker P, et al. Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study. PLoS One. 2016 Oct 21;11(10):e0164646."

>  <ID<1>>
T8223

$$$$
StarDrop ID 452
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 15 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 5.4581 -0.6875 0.0000 0
M  V30 2 C 4.7436 -0.2750 0.0000 0 CFG=2
M  V30 3 C 4.7436 -1.1000 0.0000 0
M  V30 4 N 4.0291 -1.5125 0.0000 0
M  V30 5 C 5.4581 0.1375 0.0000 0
M  V30 6 C 6.1725 -0.2750 0.0000 0
M  V30 7 O 6.8870 0.1375 0.0000 0
M  V30 8 O 6.1725 -1.1000 0.0000 0
M  V30 9 C 4.0291 0.1375 0.0000 0
M  V30 10 C 3.3147 -0.2750 0.0000 0
M  V30 11 C 2.6002 0.1375 0.0000 0
M  V30 12 C 2.6002 0.9625 0.0000 0
M  V30 13 Cl 1.8857 1.3750 0.0000 0
M  V30 14 C 3.3147 1.3750 0.0000 0
M  V30 15 C 4.0291 0.9625 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 2 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 2 14 15
M  V30 15 1 9 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
452

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Baclofen hydrochloride

>  <Synonyms>
4-amino-3-(4-chlorophenyl)butanoic acid hydron chloride

>  <CAS>
28311-31-1

>  <Formula>
C10H12Cl2NO2

>  <MolWt>
249.1

>  <Pathways>
Neuroscience;Membrane transporter/Ion channel

>  <Target>
GABA Receptor

>  <Receptor>
GABA

>  <Bioactivity>
"Baclofen hydrochloride is a GAMMA-AMINOBUTYRIC ACID derivative that is a specific GABA-B RECEPTORS agonist. It is used in the treatment of MUSCLE SPASTICITY, especially that due to SPINAL CORD INJURIES. Its therapeutic effects result from actions at spinal and supraspinal sites, generally the reduction of excitatory transmission."

>  <Reference>
"Wendell, Lake, Hamid, et al. Intrathecal Baclofen Infusion for the Treatment of Movement Disorders.[J]. Neurosurgery Clinics of North America, 2019.;Silvia, Minozzi, Rosella, et al. Baclofen for alcohol use disorder.[J]. Cochrane Database of Systematic Reviews, 2018."

>  <ID<1>>
T8630

$$$$
StarDrop ID 453
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 49 53 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.3884 1.0634 0.0000 0
M  V30 2 O 4.1029 0.6509 0.0000 0
M  V30 3 C 4.8173 1.0634 0.0000 0
M  V30 4 C 5.5318 0.6509 0.0000 0
M  V30 5 O 6.2463 1.0634 0.0000 0
M  V30 6 C 6.9607 0.6509 0.0000 0
M  V30 7 C 7.6752 1.0634 0.0000 0
M  V30 8 O 8.3897 0.6509 0.0000 0
M  V30 9 C 9.1042 1.0634 0.0000 0
M  V30 10 C 9.8186 0.6509 0.0000 0
M  V30 11 O 10.5331 1.0634 0.0000 0
M  V30 12 C 11.2476 0.6509 0.0000 0
M  V30 13 C 11.9620 1.0634 0.0000 0
M  V30 14 O 12.6765 0.6509 0.0000 0
M  V30 15 C 13.3910 1.0634 0.0000 0
M  V30 16 C 14.1055 0.6509 0.0000 0
M  V30 17 O 14.8199 1.0634 0.0000 0
M  V30 18 C 15.5344 0.6509 0.0000 0
M  V30 19 C 16.2489 1.0634 0.0000 0
M  V30 20 O 16.9633 0.6509 0.0000 0
M  V30 21 C 17.6778 1.0634 0.0000 0
M  V30 22 C 18.3923 0.6509 0.0000 0
M  V30 23 O 19.1068 1.0634 0.0000 0
M  V30 24 C 19.8212 0.6509 0.0000 0 CFG=1
M  V30 25 C 20.5243 1.0732 0.0000 0
M  V30 26 C 21.1844 0.6134 0.0000 0
M  V30 27 C 21.1264 -0.3698 0.0000 0 CFG=1
M  V30 28 O 21.9071 -0.1031 0.0000 0
M  V30 29 C 21.7723 -1.1101 0.0000 0 CFG=1
M  V30 30 C 21.5920 -1.9086 0.0000 0
M  V30 31 C 20.7976 -2.0455 0.0000 0
M  V30 32 C 20.5425 -2.8345 0.0000 0
M  V30 33 C 19.7290 -2.9806 0.0000 0
M  V30 34 C 19.1950 -2.3358 0.0000 0
M  V30 35 O 18.3843 -2.4884 0.0000 0
M  V30 36 C 19.4631 -1.5252 0.0000 0
M  V30 37 O 19.1769 -0.7370 0.0000 0
M  V30 38 C 19.8067 -0.1902 0.0000 0 CFG=2
M  V30 39 C 20.5761 -0.5727 0.0000 0 CFG=1
M  V30 40 C 21.3370 0.1298 0.0000 0
M  V30 41 C 22.2346 0.0850 0.0000 0
M  V30 42 N 22.4605 -0.7003 0.0000 0
M  V30 43 C 23.2276 -1.0039 0.0000 0
M  V30 44 C 23.8741 -0.4914 0.0000 0
M  V30 45 C 23.7535 0.3247 0.0000 0
M  V30 46 C 20.2743 -1.4001 0.0000 0
M  V30 47 H 19.8077 1.6508 0.0000 0
M  V30 48 H 21.8091 -0.1108 0.0000 0
M  V30 49 H 19.9553 -1.1791 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 24 23 CFG=1
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 1 27 26
M  V30 27 1 27 28 CFG=3
M  V30 28 1 27 29
M  V30 29 1 29 30
M  V30 30 1 30 31
M  V30 31 2 31 32
M  V30 32 1 32 33
M  V30 33 2 33 34
M  V30 34 1 34 35
M  V30 35 1 34 36
M  V30 36 1 36 37
M  V30 37 1 38 37 CFG=1
M  V30 38 1 38 24
M  V30 39 1 39 38
M  V30 40 1 27 39
M  V30 41 1 39 40
M  V30 42 1 40 41
M  V30 43 1 41 42
M  V30 44 1 29 42 CFG=3
M  V30 45 1 42 43
M  V30 46 1 43 44
M  V30 47 2 44 45
M  V30 48 1 39 46 CFG=3
M  V30 49 1 31 46
M  V30 50 2 36 46
M  V30 51 1 47 24
M  V30 52 1 48 29
M  V30 53 1 49 38
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
453

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Naloxegol oxalate

>  <Synonyms>
AZ-13337019 oxalate;NKTR-118;AZ 13337019;NKTR-118 oxalate

>  <CAS>
1354744-91-4

>  <Formula>
C36H55NO15

>  <MolWt>
741.8

>  <Pathways>
Metabolism

>  <Target>
P450

>  <Receptor>
CYP3A

>  <Bioactivity>
Naloxegol oxalate is a peripherally-selective opioid antagonist for the treatment of opioid-induced constipation.

>  <Reference>
"Bui K, et al. J Clin Pharmacol. 2016 Aug;56(8):1019-27."

>  <ID<1>>
T3355

$$$$
StarDrop ID 454
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -0.5359 1.9855 0.0000 0
M  V30 2 C -0.5359 1.1605 0.0000 0
M  V30 3 C 0.1786 0.7480 0.0000 0
M  V30 4 C 0.1786 -0.0770 0.0000 0
M  V30 5 N 0.8461 -0.5619 0.0000 0
M  V30 6 N 0.5911 -1.3466 0.0000 0
M  V30 7 C -0.2339 -1.3466 0.0000 0
M  V30 8 C -0.4888 -0.5619 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 4 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
454

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Betazole dihydrochloride

>  <Synonyms>
Betazole hydrochloride

>  <CAS>
138-92-1

>  <Formula>
C5H11Cl2N3

>  <MolWt>
184.1

>  <Pathways>
Immunology/Inflammation;GPCR/G Protein;Neuroscience

>  <Target>
Histamine Receptor

>  <Receptor>
H2 receptor; Histamine Receptor

>  <Bioactivity>
Betazole hydrochloride is an agonist of H2 receptor.

>  <Reference>
"M D Maples, J W Lea 4th, J P O'LearyEffects of betazole hydrochloride and cimetidine on common bile pressure and duodenal myoelectric activity in the dog.Am Surg. 1981 Dec;47(12):519-21.;Spitz I M , Novis B H , Ebert R , et al. Betazole-induced GIP secretion is not mediated by gastric HCl[J]. Metabolism-clinical & Experimental, 1982, 31(4):380-382."

>  <ID<1>>
T8599

$$$$
>  <Index>


>  <Plate>
 

>  <Row>


>  <Col>


>  <Volume��microliter��>


>  <Concentration��mM��>


>  <Solvent>
 

>  <MOLENAME>
 

>  <Synonyms>
 

>  <CAS>
 

>  <Formula>
 

>  <MolWt>


>  <Pathways>


>  <Target>


>  <Receptor>


>  <Bioactivity>


>  <Reference>


>  <ID<1>>
 

$$$$
StarDrop ID 456
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 2.3571 -0.5547 0.0000 0
M  V30 2 C 3.0716 -0.9672 0.0000 0 CFG=1
M  V30 3 C 3.0716 -0.1422 0.0000 0
M  V30 4 N 3.7861 0.2703 0.0000 0
M  V30 5 C 4.5006 -0.1422 0.0000 0
M  V30 6 O 4.5006 -0.9672 0.0000 0
M  V30 7 C 5.2150 0.2703 0.0000 0
M  V30 8 C 5.2150 1.0953 0.0000 0
M  V30 9 C 5.9295 1.5078 0.0000 0
M  V30 10 O 5.9295 2.3328 0.0000 0
M  V30 11 C 6.6440 2.7453 0.0000 0
M  V30 12 C 6.6440 3.5703 0.0000 0
M  V30 13 F 6.6440 4.3953 0.0000 0
M  V30 14 F 5.8190 3.5703 0.0000 0
M  V30 15 F 7.4690 3.5703 0.0000 0
M  V30 16 C 6.6440 1.0953 0.0000 0
M  V30 17 C 6.6440 0.2703 0.0000 0
M  V30 18 C 5.9295 -0.1422 0.0000 0
M  V30 19 O 5.9295 -0.9672 0.0000 0
M  V30 20 C 5.2150 -1.3797 0.0000 0
M  V30 21 C 5.2150 -2.2047 0.0000 0
M  V30 22 F 4.3900 -2.2047 0.0000 0
M  V30 23 F 6.0400 -2.2047 0.0000 0
M  V30 24 F 5.2150 -3.0297 0.0000 0
M  V30 25 C 3.7861 -1.3797 0.0000 0
M  V30 26 C 3.7861 -2.2047 0.0000 0
M  V30 27 C 3.0716 -2.6172 0.0000 0
M  V30 28 C 2.3571 -2.2047 0.0000 0
M  V30 29 N 2.3571 -1.3797 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 1 12 15
M  V30 15 2 9 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 7 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 21 23
M  V30 24 1 21 24
M  V30 25 1 2 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 1 28 29
M  V30 30 1 2 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
456

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Flecainide hydrochloride

>  <Synonyms>
N/A

>  <CAS>
57415-44-8

>  <Formula>
C17H20ClF6N2O3

>  <MolWt>
449.8

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Flecainide is a medication used to prevent and treat abnormally fast heart rates. This includes ventricular and supraventricular tachycardias.

>  <Reference>
"Markey, Gerard, C, et al. INTRAVENOUS FLECAINIDE FOR EMERGENCY DEPARTMENT MANAGEMENT OF ACUTE ATRIAL FIBRILLATION[J]. Journal of Emergency Medicine, 2018."

>  <ID<1>>
T8581

$$$$
StarDrop ID 457
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.0410 2.1623 0.0000 0
M  V30 2 C 4.8660 2.1623 0.0000 0
M  V30 3 C 5.2785 1.4478 0.0000 0
M  V30 4 C 4.8660 0.7333 0.0000 0
M  V30 5 O 5.1209 -0.0513 0.0000 0
M  V30 6 Fe 4.4535 -1.2380 0.0000 0 CHG=3
M  V30 7 O 3.7595 -2.4094 0.0000 0
M  V30 8 C 2.9525 -2.5809 0.0000 0
M  V30 9 C 2.5400 -3.2954 0.0000 0
M  V30 10 C 1.7150 -3.2954 0.0000 0
M  V30 11 O 1.3025 -2.5809 0.0000 0
M  V30 12 C 1.7150 -1.8664 0.0000 0
M  V30 13 C 2.5400 -1.8664 0.0000 0
M  V30 14 O 3.0921 -1.2533 0.0000 0 CHG=-1
M  V30 15 C 1.3025 -1.1520 0.0000 0
M  V30 16 O 5.8149 -1.2533 0.0000 0
M  V30 17 C 6.3670 -1.8664 0.0000 0
M  V30 18 C 7.1920 -1.8664 0.0000 0
M  V30 19 C 7.6045 -2.5809 0.0000 0
M  V30 20 O 7.1920 -3.2954 0.0000 0
M  V30 21 C 6.3670 -3.2954 0.0000 0
M  V30 22 C 5.9545 -2.5809 0.0000 0
M  V30 23 O 5.1475 -2.4094 0.0000 0 CHG=-1
M  V30 24 C 5.9545 -4.0099 0.0000 0
M  V30 25 O 3.7861 -0.0513 0.0000 0 CHG=-1
M  V30 26 C 4.0410 0.7333 0.0000 0
M  V30 27 C 3.6285 1.4478 0.0000 0
M  V30 28 C 2.8035 1.4478 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 8 13
M  V30 14 1 13 14
M  V30 15 1 6 14
M  V30 16 1 12 15
M  V30 17 1 6 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 17 22
M  V30 25 1 22 23
M  V30 26 1 6 23
M  V30 27 1 21 24
M  V30 28 1 6 25
M  V30 29 1 25 26
M  V30 30 1 4 26
M  V30 31 2 26 27
M  V30 32 1 1 27
M  V30 33 1 27 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
457

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ferric maltol

>  <Synonyms>
Iron(III) 2-methyl-4-oxo-4H-pyran-3-olate

>  <CAS>
33725-54-1

>  <Formula>
C18H15FeO9

>  <MolWt>
431.1

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Ferric maltol is a ferric, non-salt-based oral iron formulation demonstrating improved tolerance in patients with previous intolerance to other iron formulations."

>  <Reference>
"Stallmach A, et al. Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease. Expert Opin Pharmacother. 2015;16(18):2859-67."

>  <ID<1>>
T13692

$$$$
StarDrop ID 458
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 38 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.5418 -1.6500 0.0000 0
M  V30 2 C 1.5418 -2.4750 0.0000 0
M  V30 3 C 0.8273 -2.8875 0.0000 0
M  V30 4 O 2.2562 -2.8875 0.0000 0
M  V30 5 C 2.2562 -3.7125 0.0000 0
M  V30 6 C 2.9707 -4.1250 0.0000 0
M  V30 7 C 2.9707 -4.9500 0.0000 0
M  V30 8 C 3.6852 -5.3625 0.0000 0
M  V30 9 C 4.3996 -4.9500 0.0000 0
M  V30 10 C 5.1141 -5.3625 0.0000 0
M  V30 11 N 5.1141 -6.1875 0.0000 0
M  V30 12 C 4.3996 -6.6000 0.0000 0
M  V30 13 C 3.6852 -6.1875 0.0000 0
M  V30 14 C 2.2562 -5.3625 0.0000 0
M  V30 15 C 2.2562 -6.1875 0.0000 0
M  V30 16 C 1.5418 -4.9500 0.0000 0
M  V30 17 C 1.5418 -4.1250 0.0000 0
M  V30 18 N 0.8273 -3.7125 0.0000 0
M  V30 19 C 0.1128 -4.1250 0.0000 0
M  V30 20 N 0.1128 -4.9500 0.0000 0
M  V30 21 C -0.6017 -5.3625 0.0000 0
M  V30 22 C -1.3161 -4.9500 0.0000 0
M  V30 23 Cl -2.0306 -5.3625 0.0000 0
M  V30 24 C -1.3161 -4.1250 0.0000 0
M  V30 25 N -2.0306 -3.7125 0.0000 0
M  V30 26 C -2.7451 -4.1250 0.0000 0
M  V30 27 C -2.7451 -4.9500 0.0000 0
M  V30 28 C -3.4595 -5.3625 0.0000 0
M  V30 29 C -4.1740 -4.9500 0.0000 0
M  V30 30 C -4.1740 -4.1250 0.0000 0
M  V30 31 C -3.4595 -3.7125 0.0000 0
M  V30 32 S -3.4595 -2.8875 0.0000 0
M  V30 33 O -2.6345 -2.8875 0.0000 0
M  V30 34 O -4.2845 -2.8875 0.0000 0
M  V30 35 C -3.4595 -2.0625 0.0000 0
M  V30 36 C -4.1740 -1.6500 0.0000 0
M  V30 37 C -2.7451 -1.6500 0.0000 0
M  V30 38 N -0.6017 -3.7125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 8 13
M  V30 14 2 7 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 2 16 17
M  V30 18 1 5 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 22 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 2 30 31
M  V30 33 1 26 31
M  V30 34 1 31 32
M  V30 35 2 32 33
M  V30 36 2 32 34
M  V30 37 1 32 35
M  V30 38 1 35 36
M  V30 39 1 35 37
M  V30 40 2 24 38
M  V30 41 1 19 38
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
458

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ceritinib dihydrochloride

>  <Synonyms>
LDK378 dihydrochloride

>  <CAS>
1380575-43-8

>  <Formula>
C28H38Cl3N5O3S

>  <MolWt>
631

>  <Pathways>
Tyrosine Kinase/Adaptors;Angiogenesis

>  <Target>
IGF-1R;ALK

>  <Receptor>
" STK22D:23 nM, IGF-1R:8 nM , InsR:7 nM , ALK:0.2 nM "

>  <Bioactivity>
"Ceritinib dihydrochloride is a selective, orally bioavailable and ATP-competitive inhibitor of ALK tyrosine kinase(IC50 of 200 pM), and also inhibits IGF-1R, InsR, and STK22D (IC50 values of 8, 7, and 23 nM, respectively), shows great antitumor potency"

>  <Reference>
"Hu J , Zhang W , Liu Y , et al. LDK378 inhibits the recruitment of myeloid?derived suppressor cells to spleen via the p38?CGRK2?CCCR2 pathway in mice with sepsis[J]. Immunology and Cell Biology, 2019.;Marsilje TH, et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013, Jun 6."

>  <ID<1>>
T1791L

$$$$
StarDrop ID 459
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -3.0915 -6.4777 0.0000 0
M  V30 2 C -3.8059 -6.0652 0.0000 0
M  V30 3 C -3.8059 -5.2402 0.0000 0
M  V30 4 C -3.0915 -4.8277 0.0000 0
M  V30 5 C -3.0915 -4.0027 0.0000 0
M  V30 6 C -2.3770 -3.5902 0.0000 0
M  V30 7 C -1.6625 -4.0027 0.0000 0
M  V30 8 O -0.9480 -3.5902 0.0000 0
M  V30 9 C -0.2336 -4.0027 0.0000 0
M  V30 10 C 0.4809 -3.5902 0.0000 0
M  V30 11 C -0.2336 -4.8277 0.0000 0
M  V30 12 O -1.6625 -4.8277 0.0000 0
M  V30 13 C -3.0915 -7.3027 0.0000 0 CFG=2
M  V30 14 C -2.4240 -7.7876 0.0000 0 CFG=1
M  V30 15 C -1.6394 -7.5327 0.0000 0
M  V30 16 C -1.0263 -8.0847 0.0000 0
M  V30 17 C -0.2417 -7.8297 0.0000 0
M  V30 18 C 0.5429 -7.5748 0.0000 0
M  V30 19 O 0.7145 -6.7678 0.0000 0
M  V30 20 C 1.4991 -6.5129 0.0000 0
M  V30 21 C 1.6706 -5.7059 0.0000 0
M  V30 22 C 2.4552 -5.4510 0.0000 0
M  V30 23 C 3.0683 -6.0030 0.0000 0
M  V30 24 C 2.8968 -6.8100 0.0000 0
M  V30 25 C 2.1122 -7.0649 0.0000 0
M  V30 26 F 0.0133 -8.6144 0.0000 0
M  V30 27 F -0.4966 -7.0451 0.0000 0
M  V30 28 C -2.6790 -8.5722 0.0000 0 CFG=2
M  V30 29 O -2.1940 -9.2397 0.0000 0
M  V30 30 C -3.5040 -8.5722 0.0000 0
M  V30 31 C -3.7589 -7.7876 0.0000 0 CFG=2
M  V30 32 O -4.5435 -7.5327 0.0000 0
M  V30 33 H -3.9825 -6.8487 0.0000 0
M  V30 34 H -1.7170 -8.4948 0.0000 0
M  V30 35 H -1.6913 -8.4159 0.0000 0
M  V30 36 H -4.4660 -8.4947 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 7 12
M  V30 12 1 13 1 CFG=3
M  V30 13 1 13 14
M  V30 14 1 14 15 CFG=1
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 2 24 25
M  V30 25 1 20 25
M  V30 26 1 17 26
M  V30 27 1 17 27
M  V30 28 1 14 28
M  V30 29 1 28 29 CFG=3
M  V30 30 1 28 30
M  V30 31 1 31 30
M  V30 32 1 13 31
M  V30 33 1 31 32 CFG=3
M  V30 34 1 33 13
M  V30 35 1 34 14
M  V30 36 1 35 28
M  V30 37 1 36 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
459

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tafluprost

>  <Synonyms>
AFP-168;MK2452

>  <CAS>
209860-87-7

>  <Formula>
C25H34F2O5

>  <MolWt>
452.5

>  <Pathways>
GPCR/G Protein;Immunology/Inflammation

>  <Target>
Prostaglandin Receptor

>  <Receptor>
PGF2??

>  <Bioactivity>
"Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2??."

>  <Reference>
"Kuwayama, Y. and A. Nomura, Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther, 2014. 31(4): p. 461-71.;Kumagami, T., et al., Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions. J Ocul Pharmacol Ther, 2014. 30(4): p. 340-5.;Inoue, K., A. Tanaka, and G. Tomita, Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma. Clin Ophthalmol, 2013. 7: p. 1411-6."

>  <ID<1>>
TQ0203

$$$$
StarDrop ID 460
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 24 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -1.0484 -3.8951 0.0000 0
M  V30 2 N -1.6005 -3.2820 0.0000 0
M  V30 3 C -2.4209 -3.3682 0.0000 0
M  V30 4 C -2.8334 -4.0827 0.0000 0
M  V30 5 C -2.4209 -4.7971 0.0000 0
M  V30 6 C -2.8334 -5.5116 0.0000 0
M  V30 7 C -2.4209 -6.2261 0.0000 0
M  V30 8 O -2.8334 -6.9406 0.0000 0
M  V30 9 O -1.5959 -6.2261 0.0000 0
M  V30 10 N -2.7565 -2.6145 0.0000 0
M  V30 11 C -2.1434 -2.0625 0.0000 0
M  V30 12 C -2.1434 -1.2375 0.0000 0
M  V30 13 C -1.4289 -0.8250 0.0000 0
M  V30 14 C -0.7145 -1.2375 0.0000 0
M  V30 15 C -0.7145 -2.0625 0.0000 0
M  V30 16 C -1.4289 -2.4750 0.0000 0
M  V30 17 N -1.4289 0.0000 0.0000 0
M  V30 18 C -2.1434 0.4125 0.0000 0
M  V30 19 C -2.1434 1.2375 0.0000 0
M  V30 20 Cl -2.8579 1.6500 0.0000 0
M  V30 21 C -0.7145 0.4125 0.0000 0
M  V30 22 C -0.7145 1.2375 0.0000 0
M  V30 23 Cl 0.0000 1.6500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 2 3 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 2 16
M  V30 17 1 11 16
M  V30 18 1 13 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 17 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
460

>  <Plate>
PHD136329

>  <Row>
g

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Bendamustine

>  <Synonyms>
SDX105

>  <CAS>
16506-27-7

>  <Formula>
C16H21Cl2N3O2

>  <MolWt>
358.3

>  <Pathways>
Apoptosis;DNA Damage/DNA Repair;Others

>  <Target>
DNA Alkylator/Crosslinker;Apoptosis;Others

>  <Receptor>
Apoptosis; DNA Alkylator/Crosslinker

>  <Bioactivity>
Bendamustine for the treatment of Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

>  <Reference>
"Patekar M B , Milunovi V , Jakobac K M , et al. Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia[J]. Acta Clinica Croatica, 2018, 57(3):542-553.;Gafter-Gvili, Anat, Polliack, et al. Bendamustine associated immune suppression and infections during therapy of hematological malignancies[J]. Leukemia & Lymphoma, 2016."

>  <ID<1>>
T8380

$$$$
StarDrop ID 461
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 8.3980 -2.2544 0.0000 0
M  V30 2 N 7.6835 -2.6669 0.0000 0
M  V30 3 C 7.6835 -3.4919 0.0000 0
M  V30 4 O 8.3980 -3.9044 0.0000 0
M  V30 5 C 6.9691 -3.9044 0.0000 0
M  V30 6 C 6.9691 -4.7294 0.0000 0
M  V30 7 C 6.2546 -5.1419 0.0000 0
M  V30 8 C 5.5401 -4.7294 0.0000 0
M  V30 9 C 5.5401 -3.9044 0.0000 0
M  V30 10 C 6.2546 -3.4919 0.0000 0
M  V30 11 F 6.2546 -2.6669 0.0000 0
M  V30 12 C 4.8256 -5.1419 0.0000 0
M  V30 13 C 4.8256 -5.9669 0.0000 0
M  V30 14 N 4.1112 -6.3794 0.0000 0
M  V30 15 C 3.3967 -5.9669 0.0000 0
M  V30 16 N 2.6121 -6.2219 0.0000 0
M  V30 17 C 2.1272 -5.5544 0.0000 0
M  V30 18 C 2.6121 -4.8870 0.0000 0
M  V30 19 C 2.3571 -4.1024 0.0000 0
M  V30 20 C 2.9092 -3.4893 0.0000 0
M  V30 21 C 2.6542 -2.7047 0.0000 0
M  V30 22 C 3.2063 -2.0916 0.0000 0
M  V30 23 C 4.0132 -2.2631 0.0000 0
M  V30 24 N 4.5653 -1.6500 0.0000 0
M  V30 25 C 5.3722 -1.8215 0.0000 0
M  V30 26 C 5.6272 -2.6061 0.0000 0
M  V30 27 C 5.0752 -3.2192 0.0000 0
M  V30 28 C 4.2682 -3.0477 0.0000 0
M  V30 29 C 3.7161 -3.6608 0.0000 0
M  V30 30 N 3.3967 -5.1419 0.0000 0
M  V30 31 N 4.1112 -4.7294 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 5 10
M  V30 11 1 10 11
M  V30 12 1 8 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 14 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 1 23 28
M  V30 30 2 28 29
M  V30 31 1 20 29
M  V30 32 1 18 30
M  V30 33 1 15 30
M  V30 34 1 30 31
M  V30 35 2 12 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
461

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Capmatinib 2HCl.H2O

>  <Synonyms>
NVP-INC280 2HCl.H2O;INCB28060 2HCl.H2O;INC-280 2HCl.H2O

>  <CAS>
1865733-40-9

>  <Formula>
C23H21Cl2FN6O2

>  <MolWt>
503.4

>  <Pathways>
Tyrosine Kinase/Adaptors

>  <Target>
c-Met/HGFR

>  <Receptor>
c-Met

>  <Bioactivity>
Capmatinib 2HCl.H2O is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.

>  <Reference>
"Baltschukat S, et al. Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation. Clin Cancer Res. 2019 May 15;25(10):3164-3175.;Liu X, et al, Clin Cancer Res, 2011, 17(227). 7127-7138."

>  <ID<1>>
T8825

$$$$
StarDrop ID 462
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.0461 -1.4289 0.0000 0
M  V30 2 C 1.7605 -1.8414 0.0000 0
M  V30 3 O 2.4750 -1.4289 0.0000 0
M  V30 4 C 3.1895 -1.8414 0.0000 0
M  V30 5 O 3.1895 -2.6664 0.0000 0
M  V30 6 C 3.9039 -1.4289 0.0000 0
M  V30 7 C 4.6184 -1.8414 0.0000 0
M  V30 8 C 5.3329 -1.4289 0.0000 0
M  V30 9 C 5.3329 -0.6039 0.0000 0
M  V30 10 C 4.6184 -0.1914 0.0000 0
M  V30 11 C 3.9039 -0.6039 0.0000 0
M  V30 12 C 3.1895 -0.1914 0.0000 0
M  V30 13 C 3.1895 0.6336 0.0000 0
M  V30 14 C 3.9039 1.0461 0.0000 0
M  V30 15 C 4.6184 0.6336 0.0000 0
M  V30 16 C 5.3329 1.0461 0.0000 0
M  V30 17 C 5.3329 1.8711 0.0000 0
M  V30 18 C 6.0474 2.2836 0.0000 0
M  V30 19 C 6.0474 3.1086 0.0000 0
M  V30 20 C 5.3329 3.5211 0.0000 0
M  V30 21 C 5.3329 4.3461 0.0000 0
M  V30 22 C 4.6184 4.7586 0.0000 0
M  V30 23 C 3.9039 4.3461 0.0000 0
M  V30 24 C 3.1895 4.7586 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
462

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Eicosapentaenoic acid ethyl ester

>  <Synonyms>
EPA ethyl ester;Ethyl eicosapentaenoate;Icosapent ethyl

>  <CAS>
86227-47-6

>  <Formula>
C22H34O2

>  <MolWt>
330.5

>  <Pathways>
Others;Metabolism

>  <Target>
Others;Endogenous Metabolite

>  <Receptor>
Endogenous Metabolite

>  <Bioactivity>
Eicosapentaenoic acid ethyl ester is an omega-3 fatty acid.

>  <Reference>
"Jacobson TA. A new pure ??-3 eicosapentaenoic acid ethyl ester (AMR101) for the management of hypertriglyceridemia: the MARINE trial. Expert Rev Cardiovasc Ther. 2012 Jun;10(6):687-695.;Bays H E ,  Braeckman R A ,  Ballantyne C M , et al. Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study).[J]. Journal of Clinical Lipidology, 2012, 6(6):565-572.;Bays HE, et al. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from theMulti-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension[MARINE] trial). Am J Cardiol. 2011 Sep 1;108(5):682-690."

>  <ID<1>>
T7068

$$$$
StarDrop ID 463
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 95 106 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 20.2731 -2.8833 0.0000 0
M  V30 2 C 20.2284 -1.9869 0.0000 0
M  V30 3 O 20.4543 -1.0840 0.0000 0 CHG=-1
M  V30 4 Co 20.1323 -0.1165 0.0000 0 CHG=3
M  V30 5 N 29.7431 0.5726 0.0000 0
M  V30 6 C 29.6191 -0.1549 0.0000 0
M  V30 7 N 28.8898 -0.1247 0.0000 0
M  V30 8 C 28.5044 0.5795 0.0000 0
M  V30 9 C 28.6281 -0.2362 0.0000 0
M  V30 10 C 29.3963 -0.5369 0.0000 0
M  V30 11 C 30.0409 -0.0220 0.0000 0
M  V30 12 C 29.9172 0.7937 0.0000 0
M  V30 13 C 29.1490 1.0944 0.0000 0
M  V30 14 C 30.9466 0.0257 0.0000 0
M  V30 15 C 29.7962 -1.3366 0.0000 0
M  V30 16 C 28.3411 -0.8816 0.0000 0
M  V30 17 O 28.6317 -1.6537 0.0000 0
M  V30 18 C 27.9871 -2.1686 0.0000 0
M  V30 19 C 28.1359 -3.0509 0.0000 0
M  V30 20 O 28.7575 -3.6439 0.0000 0
M  V30 21 C 27.2982 -1.7147 0.0000 0
M  V30 22 O 26.5260 -2.0053 0.0000 0
M  V30 23 P 25.8883 -1.4819 0.0000 0
M  V30 24 O 26.0978 -2.4067 0.0000 0
M  V30 25 O 25.5015 -2.2977 0.0000 0
M  V30 26 O 25.1162 -1.7724 0.0000 0
M  V30 27 C 24.4785 -1.2490 0.0000 0
M  V30 28 C 24.1287 -2.0574 0.0000 0
M  V30 29 C 23.7064 -1.5396 0.0000 0
M  V30 30 N 23.0687 -1.0162 0.0000 0
M  V30 31 C 22.2965 -1.3067 0.0000 0
M  V30 32 O 22.1772 -2.1748 0.0000 0
M  V30 33 C 21.6588 -0.7833 0.0000 0
M  V30 34 C 20.8867 -1.0739 0.0000 0
M  V30 35 C 20.2490 -0.5504 0.0000 0
M  V30 36 C 19.3148 -0.5690 0.0000 0
M  V30 37 C 18.9108 -1.6750 0.0000 0
M  V30 38 C 18.1733 -2.0446 0.0000 0
M  V30 39 N 17.4357 -2.4143 0.0000 0
M  V30 40 C 16.8563 -1.8271 0.0000 0
M  V30 41 C 16.0014 -1.1944 0.0000 0
M  V30 42 C 15.7109 -0.4223 0.0000 0
M  V30 43 N 16.3554 0.0927 0.0000 0
M  V30 44 C 16.0649 0.8648 0.0000 0
M  V30 45 C 16.7835 1.6488 0.0000 0
M  V30 46 C 17.5817 1.8571 0.0000 0
M  V30 47 N 18.1213 1.2302 0.0000 0
M  V30 48 C 18.8248 1.3705 0.0000 0
M  V30 49 C 19.6674 1.4468 0.0000 0
M  V30 50 C 19.5294 0.5739 0.0000 0
M  V30 51 N 19.0059 -0.0638 0.0000 0 CHG=-1
M  V30 52 C 20.2976 0.2731 0.0000 0
M  V30 53 C 21.1642 0.6727 0.0000 0
M  V30 54 C 21.6959 1.3722 0.0000 0
M  V30 55 O 22.4869 1.7610 0.0000 0
M  V30 56 N 21.6585 2.2126 0.0000 0
M  V30 57 C 18.8734 2.1940 0.0000 0
M  V30 58 C 19.7048 2.3507 0.0000 0
M  V30 59 C 19.3226 3.1104 0.0000 0
M  V30 60 C 19.9495 3.8021 0.0000 0
M  V30 61 O 19.9593 4.6646 0.0000 0
M  V30 62 N 20.8208 3.8987 0.0000 0
M  V30 63 C 18.1052 2.4948 0.0000 0
M  V30 64 C 17.7747 3.3509 0.0000 0
M  V30 65 C 17.1737 3.9773 0.0000 0
M  V30 66 C 16.8267 4.7562 0.0000 0
M  V30 67 O 17.4684 5.3150 0.0000 0
M  V30 68 N 16.0011 4.9673 0.0000 0
M  V30 69 C 16.2738 2.3288 0.0000 0
M  V30 70 C 15.2407 0.8271 0.0000 0
M  V30 71 C 15.3317 1.6824 0.0000 0
M  V30 72 C 14.4662 1.3119 0.0000 0
M  V30 73 C 13.8458 1.9571 0.0000 0
M  V30 74 O 12.9919 1.8748 0.0000 0
M  V30 75 N 13.8457 2.8208 0.0000 0
M  V30 76 C 15.0220 0.0316 0.0000 0
M  V30 77 C 14.2634 -0.4274 0.0000 0
M  V30 78 C 13.8412 -1.1883 0.0000 0
M  V30 79 C 12.9959 -1.3492 0.0000 0
M  V30 80 O 12.7357 -2.1522 0.0000 0
M  V30 81 N 12.3716 -0.7702 0.0000 0
M  V30 82 C 17.2356 -1.0945 0.0000 0
M  V30 83 C 16.9131 -0.4236 0.0000 0
M  V30 84 C 16.4201 -0.9901 0.0000 0
M  V30 85 C 18.0496 -1.2290 0.0000 0
M  V30 86 C 17.9972 -0.4920 0.0000 0
M  V30 87 C 18.1959 0.2387 0.0000 0
M  V30 88 C 17.8026 0.8869 0.0000 0
M  V30 89 O 17.2578 1.3649 0.0000 0
M  V30 90 N 18.2158 1.8392 0.0000 0
M  V30 91 C 18.8023 -2.5701 0.0000 0
M  V30 92 C 19.9817 -1.4243 0.0000 0
M  V30 93 C 27.5170 -0.9193 0.0000 0
M  V30 94 O 26.8465 -0.3692 0.0000 0
M  V30 95 C 19.4500 -1.4881 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 8 13
M  V30 14 1 5 13
M  V30 15 1 11 14
M  V30 16 1 10 15
M  V30 17 1 7 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 19 20
M  V30 22 1 18 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 23 25
M  V30 27 1 23 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 27 29
M  V30 31 1 29 30
M  V30 32 1 30 31
M  V30 33 2 31 32
M  V30 34 1 31 33
M  V30 35 1 33 34
M  V30 36 1 34 35
M  V30 37 1 35 36
M  V30 38 2 36 37
M  V30 39 1 37 38
M  V30 40 2 38 39
M  V30 41 1 4 39
M  V30 42 1 39 40
M  V30 43 2 40 41
M  V30 44 1 41 42
M  V30 45 2 42 43
M  V30 46 1 4 43
M  V30 47 1 43 44
M  V30 48 2 44 45
M  V30 49 1 45 46
M  V30 50 2 46 47
M  V30 51 1 4 47
M  V30 52 1 47 48
M  V30 53 1 48 49
M  V30 54 1 48 50
M  V30 55 1 50 51
M  V30 56 1 36 51
M  V30 57 1 4 51
M  V30 58 1 50 52
M  V30 59 1 35 52
M  V30 60 1 52 53
M  V30 61 1 53 54
M  V30 62 2 54 55
M  V30 63 1 54 56
M  V30 64 1 48 57
M  V30 65 1 57 58
M  V30 66 1 57 59
M  V30 67 1 59 60
M  V30 68 2 60 61
M  V30 69 1 60 62
M  V30 70 1 57 63
M  V30 71 1 46 63
M  V30 72 1 63 64
M  V30 73 1 64 65
M  V30 74 1 65 66
M  V30 75 2 66 67
M  V30 76 1 66 68
M  V30 77 1 45 69
M  V30 78 1 44 70
M  V30 79 1 70 71
M  V30 80 1 70 72
M  V30 81 1 72 73
M  V30 82 2 73 74
M  V30 83 1 73 75
M  V30 84 1 70 76
M  V30 85 1 42 76
M  V30 86 1 76 77
M  V30 87 1 77 78
M  V30 88 1 78 79
M  V30 89 2 79 80
M  V30 90 1 79 81
M  V30 91 1 40 82
M  V30 92 1 82 83
M  V30 93 1 82 84
M  V30 94 1 82 85
M  V30 95 1 38 85
M  V30 96 1 85 86
M  V30 97 1 86 87
M  V30 98 1 87 88
M  V30 99 2 88 89
M  V30 100 1 88 90
M  V30 101 1 37 91
M  V30 102 1 35 92
M  V30 103 1 21 93
M  V30 104 1 16 93
M  V30 105 1 93 94
M  V30 106 1 2 95
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
463

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Hydroxocobalamin acetate

>  <Synonyms>
N/A

>  <CAS>
22465-48-1

>  <Formula>
C64H91CoN13O16P

>  <MolWt>
1388

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Hydroxocobalamin acetate is used as a dietary supplement in the treatment of vitamin B12 deficiency including pernicious anemia.?Hydroxocobalamin, an injectable naturally occurring form of vitamin B12 with a favorable adverse effect profile, is approved by the US Food and Drug Administration for the treatment of cyanide toxicity."

>  <Reference>
"Cheungpasitporn W, et al. High-dose hydroxocobalamin for vasoplegic syndrome causing false blood leak alarm. Clin Kidney J. 2017 Jun;10(3):357-362.;Wang H, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev. 2018 Mar 15;3:CD004655.;Greenberg SS, et al. Hydroxocobalamin (vitamin B12a) prevents and reverses endotoxin-induced hypotension and mortality in rodents: role of nitric oxide. J Pharmacol Exp Ther. 1995 Apr;273(1):257-65."

>  <ID<1>>
T13730

$$$$
StarDrop ID 464
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -0.7145 3.7125 0.0000 0
M  V30 2 C 0.0000 3.3000 0.0000 0
M  V30 3 N 0.7145 3.7125 0.0000 0
M  V30 4 C 0.0000 2.4750 0.0000 0
M  V30 5 O -0.7145 2.0625 0.0000 0
M  V30 6 N 0.7145 2.0625 0.0000 0
M  V30 7 C 0.7145 1.2375 0.0000 0
M  V30 8 C 1.4289 0.8250 0.0000 0
M  V30 9 C 2.1434 1.2375 0.0000 0
M  V30 10 C 1.4289 -0.0000 0.0000 0
M  V30 11 C 0.7145 -0.4125 0.0000 0
M  V30 12 C 0.0000 0.0000 0.0000 0
M  V30 13 C 0.0000 0.8250 0.0000 0
M  V30 14 C -0.7145 1.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 1 8 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 7 13
M  V30 14 1 13 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
464

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tocainide

>  <Synonyms>
N/A

>  <CAS>
41708-72-9

>  <Formula>
C11H16N2O

>  <MolWt>
192.3

>  <Pathways>
Membrane transporter/Ion channel

>  <Target>
Sodium Channel

>  <Receptor>
 sodium channel:

>  <Bioactivity>
Tocainide is a blocker of the sodium channel and used for the treatment of tinnitus.

>  <Reference>
"Alpert JS, et al. Chemistry, pharmacology, antiarrhythmic efficacy and adverse effects of tocainide hydrochloride, an orally active structural analog of lidocaine. Pharmacotherapy. 1983 Nov-Dec;3(6):316-23.;De Luca A,et al.Optimal requirements for high affinity and use-dependent block of skeletal muscle sodium channel by N-benzyl analogs of tocainide-like compounds.Mol Pharmacol. 2003 Oct;64(4):932-45."

>  <ID<1>>
T13177L

$$$$
StarDrop ID 465
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.8838 0.7541 0.0000 0
M  V30 2 C 1.1387 -0.0305 0.0000 0
M  V30 3 C 1.9233 -0.2854 0.0000 0
M  V30 4 C 2.6378 0.1271 0.0000 0
M  V30 5 C 3.3523 -0.2854 0.0000 0
M  V30 6 C 3.3523 -1.1104 0.0000 0
M  V30 7 C 2.6378 -1.5229 0.0000 0
M  V30 8 C 1.9233 -1.1104 0.0000 0
M  V30 9 C 1.1387 -1.3654 0.0000 0
M  V30 10 O 0.8838 -2.1500 0.0000 0
M  V30 11 C 0.6538 -0.6979 0.0000 0
M  V30 12 C -0.1712 -0.6979 0.0000 0
M  V30 13 C -0.5837 -1.4124 0.0000 0
M  V30 14 C -1.4087 -1.4124 0.0000 0
M  V30 15 C -1.8212 -0.6979 0.0000 0
M  V30 16 O -2.6462 -0.6979 0.0000 0
M  V30 17 C -3.0587 -1.4124 0.0000 0
M  V30 18 C -1.4087 0.0165 0.0000 0
M  V30 19 C -0.5837 0.0165 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 3 8
M  V30 9 1 8 9
M  V30 10 2 9 10
M  V30 11 1 9 11
M  V30 12 1 2 11
M  V30 13 1 11 12
M  V30 14 2 12 13
M  V30 15 1 13 14
M  V30 16 2 14 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 1 15 18
M  V30 20 2 18 19
M  V30 21 1 12 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
465

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Anisindione

>  <Synonyms>
N/A

>  <CAS>
117-37-3

>  <Formula>
C16H12O3

>  <MolWt>
252.3

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Anisindione is a synthetic anticoagulant and an indanedione derivative. It prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K?Cmediated gamma-carboxylation of precursor proteins."

>  <Reference>
"M, D, Freedman, et al. Clinically significant drug interactions with the oral anticoagulants.[J]. Drug safety, 2018.	"

>  <ID<1>>
T14291

$$$$
StarDrop ID 466
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -2.4465 -0.2375 0.0000 0
M  V30 2 C -2.4465 0.5875 0.0000 0
M  V30 3 C -1.7321 1.0000 0.0000 0
M  V30 4 C -1.7321 1.8250 0.0000 0
M  V30 5 C -1.0176 2.2375 0.0000 0
M  V30 6 C -0.3031 1.8250 0.0000 0
M  V30 7 O 0.4114 2.2375 0.0000 0
M  V30 8 C 0.4114 3.0625 0.0000 0
M  V30 9 C -0.3031 1.0000 0.0000 0
M  V30 10 N 0.4114 0.5875 0.0000 0
M  V30 11 C 1.1258 1.0000 0.0000 0
M  V30 12 C 1.8403 0.5875 0.0000 0
M  V30 13 C 1.8403 -0.2375 0.0000 0
M  V30 14 C 2.5548 -0.6500 0.0000 0
M  V30 15 N 2.5548 -1.4750 0.0000 0
M  V30 16 C 3.2692 -1.8875 0.0000 0
M  V30 17 C 3.2692 -2.7125 0.0000 0
M  V30 18 C 2.5548 -3.1250 0.0000 0
M  V30 19 C 1.8403 -2.7125 0.0000 0
M  V30 20 C 1.8403 -1.8875 0.0000 0
M  V30 21 O 1.1258 1.8250 0.0000 0
M  V30 22 C -1.0176 0.5875 0.0000 0
M  V30 23 N -2.4465 2.2375 0.0000 0
M  V30 24 C -3.1610 1.8250 0.0000 0
M  V30 25 N -3.1610 1.0000 0.0000 0
M  V30 26 C -1.7321 -0.6500 0.0000 0
M  V30 27 C -1.0176 -0.2375 0.0000 0
M  V30 28 C -0.3031 -0.6500 0.0000 0
M  V30 29 Cl 0.4114 -0.2375 0.0000 0
M  V30 30 C -0.3031 -1.4750 0.0000 0
M  V30 31 F 0.4114 -1.8875 0.0000 0
M  V30 32 C -1.0176 -1.8875 0.0000 0
M  V30 33 C -1.7321 -1.4750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 6 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 15 20
M  V30 21 2 11 21
M  V30 22 2 9 22
M  V30 23 1 3 22
M  V30 24 1 4 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 2 25
M  V30 28 1 1 26
M  V30 29 2 26 27
M  V30 30 1 27 28
M  V30 31 1 28 29
M  V30 32 2 28 30
M  V30 33 1 30 31
M  V30 34 1 30 32
M  V30 35 2 32 33
M  V30 36 1 26 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
466

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Dacomitinib hydrate

>  <Synonyms>
PF-00299804;PF299804;PF-299804;PF 299804;PF00299804;PF 00299804

>  <CAS>
1042385-75-0

>  <Formula>
C24H27ClFN5O3

>  <MolWt>
488

>  <Pathways>
Angiogenesis;JAK/STAT signaling;Tyrosine Kinase/Adaptors

>  <Target>
EGFR

>  <Receptor>
EGFR

>  <Bioactivity>
"Dacomitinib hydrate is a highly selective and second-generation small-molecule inhibitor of the pan-epidermal growth factor receptor family of tyrosine kinases. Dacomitinib specifically and irreversibly binds to and inhibits human EGFR subtypes, resulting in inhibition of proliferation and induction of apoptosis in EGFR-expressing tumor cells."

>  <Reference>
"Ramalingam SS, J?nne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O'Connell J, Paz-Ares L. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1369-78. doi: 10.1016/S1470-2045(14)70452-8. Epub 2014 Oct 15. PubMed PMID: 25439691.;Ou SH, Soo RA. Dacomitinib in lung cancer: a ""lost generation"" EGFR tyrosine-kinase inhibitor from a bygone era? Drug Des Devel Ther. 2015 Oct 15;9:5641-53. doi: 10.2147/DDDT.S52787. eCollection 2015. Review. PubMed PMID: 26508839.;Ellis PM, Shepherd FA, Millward M, et al. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2014 Nov;15(12):1379-88. doi: 10.1016/S1470-2045(14)70472-3. Epub 2014 Oct 15. PubMed PMID: 25439692.;Giri N, Masters JC, Plotka A, Liang Y, Boutros T, Pardo P, O'Connell J, Bello C. Investigation of the impact of hepatic impairment on the pharmacokinetics of dacomitinib. Invest New Drugs. 2015 Aug;33(4):931-41. doi: 10.1007/s10637-015-0256-0. Epub 2015 Jun 6. PubMed PMID: 26048096."

>  <ID<1>>
T19965

$$$$
StarDrop ID 467
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.9594 3.9102 0.0000 0
M  V30 2 N 2.3173 3.1669 0.0000 0
M  V30 3 C 3.1400 3.1053 0.0000 0
M  V30 4 C 3.4980 2.3620 0.0000 0
M  V30 5 N 3.0332 1.6803 0.0000 0
M  V30 6 C 2.2105 1.7420 0.0000 0
M  V30 7 C 1.8526 2.4853 0.0000 0
M  V30 8 C 3.3912 0.9370 0.0000 0
M  V30 9 N 4.2162 0.9370 0.0000 0
M  V30 10 C 4.7305 0.2920 0.0000 0
M  V30 11 C 5.5189 0.5352 0.0000 0
M  V30 12 C 6.1237 -0.0260 0.0000 0
M  V30 13 C 5.9401 -0.8303 0.0000 0
M  V30 14 C 5.1517 -1.0735 0.0000 0
M  V30 15 C 4.5470 -0.5123 0.0000 0
M  V30 16 O 3.8037 -0.8703 0.0000 0
M  V30 17 C 3.0604 -0.5123 0.0000 0
M  V30 18 C 2.4556 -1.0735 0.0000 0
M  V30 19 C 1.6673 -0.8303 0.0000 0
M  V30 20 C 1.4837 -0.0260 0.0000 0
M  V30 21 Cl 0.6953 0.2172 0.0000 0
M  V30 22 C 2.0884 0.5352 0.0000 0
M  V30 23 C 2.8768 0.2920 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 10 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 18 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 1 20 22
M  V30 24 2 22 23
M  V30 25 1 8 23
M  V30 26 1 17 23
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
467

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Loxapine

>  <Synonyms>
N/A

>  <CAS>
1977-10-2

>  <Formula>
C18H18ClN3O

>  <MolWt>
327.8

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
5-HT Receptor;Dopamine Receptor

>  <Receptor>
5-HT Receptor; 5-HT2 (bovine); 5-HT2 (human); D2; D4

>  <Bioactivity>
"Loxapine is a D2DR and D4DR inhibitor, serotonergic receptor antagonist and also a dibenzoxazepine anti-psychotic agent,used primarily in the treatment of schizophrenia. The drug is a member of the dibenzoxazepine class and structurally related to clozapine (which belongs to the chemically akin class of dibenzodiazepines)."

>  <Reference>
"Labuzek K, et al. Eur Neuropsychopharmacol, 2005, 15(1), 23-30.;Labuzek K, et al. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur Neuropsychopharmacol. 2005 Jan;15(1):23-30.;Singh AN, et al. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry Neurosci. 1996 Jan;21(1):29-35.;Kalkman HO, et al. Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats. Naunyn Schmiedebergs Arch Pharmacol. 1997 Mar;355(3):361-4.;Berardis D D , Fornaro M , Orsolini L , et al. The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review[J]. International Journal of Molecular ences, 2017, 18(2):349.;Lee T, et al. Psychiatry Res, 1984, 12(4), 277-285."

>  <ID<1>>
T21629

$$$$
StarDrop ID 468
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.3228 1.7357 0.0000 0
M  V30 2 C 3.9629 0.9934 0.0000 0 CFG=1
M  V30 3 C 3.6826 0.2174 0.0000 0 CFG=2
M  V30 4 C 2.8705 0.0722 0.0000 0 CFG=1
M  V30 5 C 2.3387 0.7029 0.0000 0 CFG=1
M  V30 6 C 1.5266 0.5577 0.0000 0 CFG=2
M  V30 7 C 1.8069 1.3336 0.0000 0
M  V30 8 C 1.2463 -0.2182 0.0000 0
M  V30 9 C 1.7781 -0.8489 0.0000 0 CFG=1
M  V30 10 F 1.4978 -1.6248 0.0000 0
M  V30 11 C 2.5902 -0.7037 0.0000 0
M  V30 12 C 0.4342 -0.3634 0.0000 0
M  V30 13 C -0.0976 0.2673 0.0000 0
M  V30 14 O -0.9098 0.1221 0.0000 0
M  V30 15 C 0.1827 1.0432 0.0000 0
M  V30 16 C 0.9948 1.1884 0.0000 0
M  V30 17 C 2.6190 1.4789 0.0000 0 CFG=1
M  V30 18 O 2.0872 2.1096 0.0000 0
M  V30 19 C 3.4311 1.6241 0.0000 0
M  V30 20 H 2.1935 1.5150 0.0000 0
M  V30 21 H 2.0584 -0.0730 0.0000 0
M  V30 22 C 4.3340 -0.2889 0.0000 0
M  V30 23 C 5.0168 0.1741 0.0000 0
M  V30 24 C 4.7875 0.9666 0.0000 0 CFG=2
M  V30 25 C 5.5484 1.2854 0.0000 0
M  V30 26 C 6.2050 0.7859 0.0000 0
M  V30 27 O 6.9659 1.1048 0.0000 0
M  V30 28 O 5.6527 2.1038 0.0000 0
M  V30 29 O 4.9089 1.7826 0.0000 0
M  V30 30 H 3.1508 0.8481 0.0000 0
M  V30 31 H 2.4227 -1.6134 0.0000 0
M  V30 32 H 2.9588 2.4194 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 3 2
M  V30 3 1 4 3
M  V30 4 1 5 4
M  V30 5 1 5 6
M  V30 6 1 6 7 CFG=1
M  V30 7 1 6 8
M  V30 8 1 9 8
M  V30 9 1 9 10 CFG=3
M  V30 10 1 9 11
M  V30 11 1 4 11
M  V30 12 2 8 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 2 15 16
M  V30 17 1 6 16
M  V30 18 1 5 17
M  V30 19 1 17 18 CFG=1
M  V30 20 1 17 19
M  V30 21 1 2 19
M  V30 22 1 5 20 CFG=3
M  V30 23 1 4 21 CFG=1
M  V30 24 1 3 22
M  V30 25 1 22 23
M  V30 26 1 24 23
M  V30 27 1 2 24
M  V30 28 1 24 25 CFG=1
M  V30 29 1 25 26
M  V30 30 1 26 27
M  V30 31 2 25 28
M  V30 32 1 24 29 CFG=3
M  V30 33 1 3 30 CFG=3
M  V30 34 1 31 9
M  V30 35 1 32 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
468

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fluprednisolone

>  <Synonyms>
NSC 47439;NSC47439;NSC-47439

>  <CAS>
53-34-9

>  <Formula>
C21H27FO5

>  <MolWt>
378.4

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Fluprednisolone is a synthetic glucocorticoid that has anti-inflammatory properties.

>  <Reference>
"Wilson ME, Lambert SR, Plager DA, VanderVeen D, Roarty J, O'Halloran H. Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. Eye (Lond). 2017 Mar;31(3):506-507. doi: 10.1038/eye.2016.244. Epub 2016 Nov 4. PubMed PMID: 27813524; PubMed Central PMCID: PMC5350370.;Komori T, Honda T, Irie H, Otsuka A, Kabashima K. Lichen Planus in Irradiated Skin During Nivolumab Treatment. Acta Derm Venereol. 2017 Mar 10;97(3):391-392. doi: 10.2340/00015555-2545. PubMed PMID: 27722767.;Cho SH, Park JA, Zheng W, Abd El-Aty AM, Kim SK, Choi JM, Yi H, Cho SM, Afifi NA, Shim JH, Chang BJ, Kim JS, Shin HC. Quantification of bupivacaine hydrochloride and isoflupredone acetate residues in porcine muscle, beef, milk, egg, shrimp, flatfish, and eel using a simplified extraction method coupled with liquid chromatography-triple quadrupole tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Oct 15;1065-1066:29-34. doi: 10.1016/j.jchromb.2017.09.026. Epub 2017 Sep 19. PubMed PMID: 28946122.;Kaur S, Sukhija J. Difluprednate versus prednisolone acetate for inflammation following cataract surgery in pediatric patients: a randomized safety and efficacy study. Eye (Lond). 2017 Mar;31(3):506. doi: 10.1038/eye.2016.243. Epub 2016 Nov 4. PubMed PMID: 23894096; PubMed Central PMCID: PMC5350369."

>  <ID<1>>
T9047

$$$$
StarDrop ID 469
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 41 47 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -4.2074 -13.7420 0.0000 0
M  V30 2 C -5.0324 -13.7420 0.0000 0
M  V30 3 C -5.5174 -14.4094 0.0000 0 CFG=1
M  V30 4 C -6.3020 -14.1545 0.0000 0 CFG=2
M  V30 5 C -6.9151 -14.7065 0.0000 0 CFG=1
M  V30 6 C -6.0667 -14.7653 0.0000 0
M  V30 7 C -5.3458 -15.2164 0.0000 0 CFG=2
M  V30 8 C -5.9589 -15.7684 0.0000 0
M  V30 9 C -6.7436 -15.5135 0.0000 0
M  V30 10 H -4.7779 -15.8148 0.0000 0
M  V30 11 H -7.7263 -14.8569 0.0000 0
M  V30 12 C -6.3020 -13.3295 0.0000 0
M  V30 13 O -6.9694 -12.8446 0.0000 0
M  V30 14 N -5.5174 -13.0746 0.0000 0
M  V30 15 C -5.2624 -12.2899 0.0000 0
M  V30 16 C -4.4555 -12.1184 0.0000 0 CFG=1
M  V30 17 C -4.2005 -11.3338 0.0000 0 CFG=2
M  V30 18 C -4.7526 -10.7207 0.0000 0
M  V30 19 N -4.4976 -9.9361 0.0000 0
M  V30 20 C -5.0496 -9.3230 0.0000 0
M  V30 21 C -4.7947 -8.5384 0.0000 0
M  V30 22 N -3.9877 -8.3668 0.0000 0
M  V30 23 C -3.4357 -8.9799 0.0000 0
M  V30 24 C -3.6906 -9.7645 0.0000 0
M  V30 25 C -3.7328 -7.5822 0.0000 0
M  V30 26 C -2.9482 -7.3273 0.0000 0
M  V30 27 C -2.9482 -6.5023 0.0000 0
M  V30 28 S -3.7328 -6.2473 0.0000 0
M  V30 29 N -4.2177 -6.9148 0.0000 0
M  V30 30 C -2.2337 -6.0898 0.0000 0
M  V30 31 C -1.5192 -6.5023 0.0000 0
M  V30 32 C -1.5192 -7.3273 0.0000 0
M  V30 33 C -2.2337 -7.7398 0.0000 0
M  V30 34 C -3.3935 -11.1623 0.0000 0
M  V30 35 C -2.8415 -11.7754 0.0000 0
M  V30 36 C -3.0965 -12.5600 0.0000 0
M  V30 37 C -3.9034 -12.7315 0.0000 0
M  V30 38 H -7.0557 -13.8189 0.0000 0
M  V30 39 H -4.7104 -14.5810 0.0000 0
M  V30 40 H -5.1245 -11.3752 0.0000 0
M  V30 41 H -5.1787 -11.5416 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 3 2
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 3 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 5 9
M  V30 11 1 7 10 CFG=3
M  V30 12 1 5 11 CFG=3
M  V30 13 1 4 12
M  V30 14 2 12 13
M  V30 15 1 12 14
M  V30 16 1 2 14
M  V30 17 1 14 15
M  V30 18 1 16 15 CFG=1
M  V30 19 1 16 17
M  V30 20 1 17 18 CFG=3
M  V30 21 1 18 19
M  V30 22 1 19 20
M  V30 23 1 20 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 1 19 24
M  V30 28 1 22 25
M  V30 29 1 25 26
M  V30 30 1 26 27
M  V30 31 1 27 28
M  V30 32 1 28 29
M  V30 33 2 25 29
M  V30 34 2 27 30
M  V30 35 1 30 31
M  V30 36 2 31 32
M  V30 37 1 32 33
M  V30 38 2 26 33
M  V30 39 1 17 34
M  V30 40 1 34 35
M  V30 41 1 35 36
M  V30 42 1 36 37
M  V30 43 1 16 37
M  V30 44 1 4 38 CFG=1
M  V30 45 1 3 39 CFG=1
M  V30 46 1 40 16
M  V30 47 1 41 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
469

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lurasidone

>  <Synonyms>
SM-13496

>  <CAS>
367514-87-2

>  <Formula>
C28H36N4O2S

>  <MolWt>
492.7

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Dopamine Receptor;5-HT Receptor

>  <Receptor>
" D 2 Receptor:1.68 nM (IC50), 5-HT 1A Receptor:6.75 nM (IC50), 5-HT 7 Receptor:0.495 nM (IC50)"

>  <Bioactivity>
"Lurasidone is an antagonist of both dopamine D2 and 5-HT7(IC50=1.68 and 0.495 nM, respectively).It also a partial agonist of 5-HT1A receptor(IC50 : 6.75 nM)."

>  <Reference>
"Greenberg W M , Citrome L . Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature[J]. Clinical Pharmacokinetics, 2016.;Maurizio, Pompili, Claudio,et al. Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders[J]. Expert Opinion on Drug Safety, 2017.;Danek P J, W??jcikowski J, Daniel W A. Asenapine and iloperidone decrease the expression of major cytochrome P450 enzymes CYP1A2 and CYP3A4 in human hepatocytes. A significance for drug-drug interactions during combined therapy[J]. Toxicology and Applied Pharmacology. 2020, 406: 115239."

>  <ID<1>>
T21337

$$$$
StarDrop ID 470
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 8.0882 -2.4167 0.0000 0
M  V30 2 C 7.3737 -2.0042 0.0000 0
M  V30 3 N 7.3737 -1.1792 0.0000 0
M  V30 4 C 6.6592 -0.7667 0.0000 0
M  V30 5 C 5.9448 -1.1792 0.0000 0
M  V30 6 F 5.2303 -0.7667 0.0000 0
M  V30 7 C 5.9448 -2.0042 0.0000 0
M  V30 8 C 6.6592 -2.4167 0.0000 0
M  V30 9 F 6.6592 -3.2417 0.0000 0
M  V30 10 N 6.6592 0.0583 0.0000 0
M  V30 11 C 5.9448 0.4708 0.0000 0
M  V30 12 C 5.9448 1.2958 0.0000 0
M  V30 13 C 5.2303 1.7083 0.0000 0
M  V30 14 O 5.2303 2.5333 0.0000 0
M  V30 15 O 4.5158 1.2958 0.0000 0
M  V30 16 C 6.6592 1.7083 0.0000 0
M  V30 17 O 6.6592 2.5333 0.0000 0
M  V30 18 C 7.3737 1.2958 0.0000 0
M  V30 19 C 8.0882 1.7083 0.0000 0
M  V30 20 C 8.8026 1.2958 0.0000 0
M  V30 21 F 9.5171 1.7083 0.0000 0
M  V30 22 C 8.8026 0.4708 0.0000 0
M  V30 23 N 9.5171 0.0583 0.0000 0
M  V30 24 C 10.3140 0.2719 0.0000 0
M  V30 25 C 10.5275 -0.5250 0.0000 0
M  V30 26 O 11.2420 -0.9375 0.0000 0
M  V30 27 C 9.7306 -0.7386 0.0000 0
M  V30 28 C 8.0882 0.0583 0.0000 0
M  V30 29 Cl 8.0882 -0.7667 0.0000 0
M  V30 30 C 7.3737 0.4708 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 2 8
M  V30 9 1 8 9
M  V30 10 1 4 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 12 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 2 20 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 25 27
M  V30 28 1 23 27
M  V30 29 1 22 28
M  V30 30 1 28 29
M  V30 31 2 28 30
M  V30 32 1 10 30
M  V30 33 1 18 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
470

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Delafloxacin meglumine

>  <Synonyms>
RX-3341 meglumine;WQ-3034 meglumine;ABT492 meglumine

>  <CAS>
352458-37-8

>  <Formula>
C25H29ClF3N5O9

>  <MolWt>
636

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
Delafloxacin meglumine is a broad-spectrum fluoroquinolone antibiotic

>  <Reference>
"2 .Gena K , Kapoor E , Dasgupta A , et al. Delafloxacin meglumine for the treatment of acute bacterial skin and skin structure infections (ABSSSI).[J]. Drugs of Today, 2018, 54:p??gs. 657-666.;Lepak AJ, et al. In Vivo Pharmacodynamic Target Assessment of Delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a Murine Lung Infection Model. Antimicrob Agents Chemother. 2016 Jul 22;60(8):4764-9."

>  <ID<1>>
T8173

$$$$
StarDrop ID 471
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.0630 -1.4167 0.0000 0
M  V30 2 C 2.8390 -1.6970 0.0000 0 CFG=1
M  V30 3 C 3.5218 -1.2340 0.0000 0
M  V30 4 C 4.1731 -1.7404 0.0000 0 CFG=1
M  V30 5 C 4.9853 -1.5952 0.0000 0 CFG=2
M  V30 6 C 5.2655 -0.8192 0.0000 0
M  V30 7 C 6.0777 -0.6740 0.0000 0
M  V30 8 C 6.6095 -1.3047 0.0000 0
M  V30 9 C 7.4216 -1.1595 0.0000 0
M  V30 10 C 7.9534 -1.7902 0.0000 0
M  V30 11 O 8.7655 -1.6450 0.0000 0
M  V30 12 C 7.6731 -2.5662 0.0000 0
M  V30 13 C 6.8610 -2.7114 0.0000 0
M  V30 14 C 6.3292 -2.0807 0.0000 0 CFG=1
M  V30 15 C 6.0489 -2.8566 0.0000 0
M  V30 16 C 5.5171 -2.2259 0.0000 0 CFG=2
M  V30 17 Cl 5.5766 -3.0487 0.0000 0
M  V30 18 C 5.2368 -3.0018 0.0000 0 CFG=1
M  V30 19 O 5.7686 -3.6325 0.0000 0
M  V30 20 C 4.4247 -3.1470 0.0000 0
M  V30 21 C 3.8928 -2.5163 0.0000 0 CFG=1
M  V30 22 C 3.5330 -3.2587 0.0000 0
M  V30 23 C 3.0683 -2.4895 0.0000 0 CFG=2
M  V30 24 O 2.9469 -3.3055 0.0000 0
M  V30 25 C 2.3074 -2.8084 0.0000 0
M  V30 26 O 2.2031 -3.6268 0.0000 0
M  V30 27 C 1.6508 -2.3089 0.0000 0
M  V30 28 O 0.8899 -2.6277 0.0000 0
M  V30 29 H 2.7146 -0.7048 0.0000 0
M  V30 30 H 3.2125 -2.0183 0.0000 0
M  V30 31 H 4.3406 -0.8308 0.0000 0
M  V30 32 H 6.2212 -2.8258 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 4 3 CFG=1
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 14 13
M  V30 14 1 14 8
M  V30 15 1 14 15 CFG=1
M  V30 16 1 16 14
M  V30 17 1 16 5
M  V30 18 1 16 17 CFG=3
M  V30 19 1 16 18
M  V30 20 1 18 19 CFG=1
M  V30 21 1 18 20
M  V30 22 1 21 20
M  V30 23 1 4 21
M  V30 24 1 21 22 CFG=1
M  V30 25 1 21 23
M  V30 26 1 23 2
M  V30 27 1 23 24 CFG=3
M  V30 28 1 23 25 CFG=1
M  V30 29 2 25 26
M  V30 30 1 25 27
M  V30 31 1 27 28
M  V30 32 1 29 2
M  V30 33 1 30 4
M  V30 34 1 31 5
M  V30 35 1 32 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
471

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Beclometasone

>  <Synonyms>
BecloMethasone

>  <CAS>
4419-39-0

>  <Formula>
C22H29ClO5

>  <MolWt>
408.9

>  <Pathways>
Endocrinology/Hormones

>  <Target>
Glucocorticoid Receptor

>  <Receptor>
glucocorticoid receptor

>  <Bioactivity>
BecloMethasone is a prototype glucocorticoid receptor agonist. It is used topically as an anti-inflammatory agent and in aerosol form for the treatment of asthma.

>  <Reference>
"Small, Calvin J , Gillespie, et al. Pharmacokinetics of Beclomethasone Dipropionate Delivered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Subjects[J]. Journal of aerosol medicine and pulmonary drug delivery, 2018.;He S, et al. Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model. J Pathol. 2012 Aug;227(4):431-45."

>  <ID<1>>
T8777

$$$$
StarDrop ID 472
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 I 5.5686 2.2687 0.0000 0
M  V30 2 C 5.5686 1.4437 0.0000 0
M  V30 3 C 6.2831 1.0312 0.0000 0
M  V30 4 C 6.2831 0.2062 0.0000 0
M  V30 5 C 5.5686 -0.2063 0.0000 0
M  V30 6 C 4.8541 0.2062 0.0000 0
M  V30 7 C 4.1397 -0.2062 0.0000 0
M  V30 8 N 4.1397 -1.0312 0.0000 0
M  V30 9 C 3.4252 -1.4437 0.0000 0
M  V30 10 N 3.4252 -2.2687 0.0000 0
M  V30 11 N 2.7107 -1.0312 0.0000 0
M  V30 12 C 4.8541 1.0312 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 9 11
M  V30 11 2 6 12
M  V30 12 1 2 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
472

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Iobenguane sulfate

>  <Synonyms>
MIBG sulfate

>  <CAS>
87862-25-7

>  <Formula>
C16H22I2N6O4S

>  <MolWt>
648.3

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Iobenguane sulfate is a high-affinity substrate for cholera toxin that interferes with cellular mono(ADP-ribosylation). Radioiodinated Iobenguane sulfate is clinically used as a tumor-targeted radiopharmaceutical in the diagnosis and treatment of adrenergic tumors.

>  <Reference>
"Loesberg C, et al. Meta-iodobenzylguanidine (MIBG), a novel high-affinity substrate for cholera toxin that interferes with cellular mono(ADP-ribosylation). Biochim Biophys Acta. 1990 Jan 19;1037(1):92-9."

>  <ID<1>>
T15588

$$$$
StarDrop ID 473
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 41 45 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.9625 -0.8959 0.0000 0
M  V30 2 C 0.4105 -0.2828 0.0000 0
M  V30 3 C -0.3965 -0.4544 0.0000 0
M  V30 4 O -0.9485 0.1587 0.0000 0
M  V30 5 N -0.6514 -1.2390 0.0000 0
M  V30 6 C -0.0994 -1.8521 0.0000 0
M  V30 7 C -0.3543 -2.6367 0.0000 0
M  V30 8 N -1.1613 -2.8082 0.0000 0
M  V30 9 C -1.4162 -3.5928 0.0000 0
M  V30 10 O -0.8642 -4.2059 0.0000 0
M  V30 11 C -2.2232 -3.7644 0.0000 0
M  V30 12 C -2.4781 -4.5490 0.0000 0
M  V30 13 C -3.2851 -4.7205 0.0000 0
M  V30 14 C -3.8371 -4.1074 0.0000 0
M  V30 15 C -3.5822 -3.3228 0.0000 0
M  V30 16 C -2.7752 -3.1513 0.0000 0
M  V30 17 C -1.7133 -2.1951 0.0000 0
M  V30 18 C -1.4584 -1.4105 0.0000 0
M  V30 19 C 0.6655 0.5018 0.0000 0
M  V30 20 C 0.1805 1.1692 0.0000 0
M  V30 21 N 0.6655 1.8367 0.0000 0
M  V30 22 C 1.4501 1.5817 0.0000 0
M  V30 23 C 2.1645 1.9942 0.0000 0
M  V30 24 N 2.8790 1.5817 0.0000 0
M  V30 25 C 2.8790 0.7567 0.0000 0
M  V30 26 C 2.1645 0.3442 0.0000 0
M  V30 27 O 2.1645 -0.4808 0.0000 0
M  V30 28 C 1.4501 -0.8933 0.0000 0
M  V30 29 C 1.4501 0.7567 0.0000 0
M  V30 30 N 2.1645 2.8192 0.0000 0
M  V30 31 N 1.4971 3.3042 0.0000 0
M  V30 32 C 1.7520 4.0888 0.0000 0
M  V30 33 N 2.5770 4.0888 0.0000 0
M  V30 34 C 2.8320 3.3042 0.0000 0
M  V30 35 C 1.2671 4.7562 0.0000 0
M  V30 36 C 0.4105 2.6213 0.0000 0
M  V30 37 O -0.3965 2.7928 0.0000 0
M  V30 38 P -0.9485 2.1797 0.0000 0
M  V30 39 O -0.3354 1.6277 0.0000 0
M  V30 40 O -1.5005 1.5666 0.0000 0
M  V30 41 O -1.5616 2.7318 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 11 16
M  V30 17 1 8 17
M  V30 18 1 17 18
M  V30 19 1 5 18
M  V30 20 1 2 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 1 27 28
M  V30 30 1 26 29
M  V30 31 1 19 29
M  V30 32 2 22 29
M  V30 33 1 23 30
M  V30 34 1 30 31
M  V30 35 2 31 32
M  V30 36 1 32 33
M  V30 37 2 33 34
M  V30 38 1 30 34
M  V30 39 1 32 35
M  V30 40 1 21 36
M  V30 41 1 36 37
M  V30 42 1 37 38
M  V30 43 2 38 39
M  V30 44 1 38 40
M  V30 45 1 38 41
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
473

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fostemsavir Tris

>  <Synonyms>
BMS-663068 Tris

>  <CAS>
864953-39-9

>  <Formula>
C29H37N8O11P

>  <MolWt>
704.6

>  <Pathways>
Microbiology/Virology;Proteases/Proteasome

>  <Target>
HIV Protease

>  <Receptor>
HIV; HIV-1

>  <Bioactivity>
"Fostemsavir Tris is the prodrug of BMS-626529,is a oral, safe and effective inhibitor of HIV-1 attachment. It inhibits human immunodeficiency virus type 1 (HIV-1) infection by binding to gp120 and interfering with the attachment of virus to CD4+ T-cells."

>  <Reference>
"Nowicka-Sans B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother. 2012 Jul;56(7):3498-507."

>  <ID<1>>
T10570

$$$$
StarDrop ID 474
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 13 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.7145 2.0625 0.0000 0 CFG=2
M  V30 2 C 0.0000 2.4750 0.0000 0
M  V30 3 N 0.0000 3.3000 0.0000 0
M  V30 4 C -0.7145 3.7125 0.0000 0
M  V30 5 O 1.4289 2.4750 0.0000 0
M  V30 6 C 0.7145 1.2375 0.0000 0
M  V30 7 C 1.4289 0.8250 0.0000 0
M  V30 8 C 1.4289 -0.0000 0.0000 0
M  V30 9 O 2.1434 -0.4125 0.0000 0
M  V30 10 C 0.7145 -0.4125 0.0000 0
M  V30 11 C 0.0000 0.0000 0.0000 0
M  V30 12 C 0.0000 0.8250 0.0000 0
M  V30 13 H 0.7144 3.0625 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 1 5 CFG=3
M  V30 5 1 1 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 6 12
M  V30 13 1 13 1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
474

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Phenylephrine

>  <Synonyms>
(R)-(-)-Phenylephrine;L-Phenylephrine

>  <CAS>
59-42-7

>  <Formula>
C9H13NO2

>  <MolWt>
167.2

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
" ??1D-adrenergic receptor:5.86 (pKi), ??1B-adrenergic receptor:4.87 (pKi), ??1A-adrenergic receptor:4.70 (pKi)"

>  <Bioactivity>
"Phenylephrine is a selective ??1-adrenoceptor agonist ( pKi: 5.86, 4.87 and 4.70 for ??1D, ??1B, and ??1A receptors respectively)."

>  <Reference>
"Lazou A, et al. Activation of mitogen-activated protein kinases (p38-MAPKs, SAPKs/JNKs and ERKs) by the G-protein-coupled receptor agonist phenylephrine in the perfused rat heart. Biochem J. 1998 Jun 1;332 ( Pt 2):459-65.;Chen F, Xu Y, Wang J, et al. Relaxation Effect of Patchouli Alcohol in Rat Corpus Cavernous and Its Underlying Mechanisms[J]. Evidence-Based Complementary and Alternative Medicine. 2020, 2020.;Ford AP, et al. Pharmacological pleiotropism of the human recombinant alpha1A-adrenoceptor: implications foralpha1-adrenoceptor classification. Br J Pharmacol. 1997 Jul;121(6):1127-35.;Li NJ, et al. Effect of phenylephrine on alveolar fluid clearance in ventilator-induced lung injury. Chin Med Sci J. 2013 Mar;28(1):1-6.;Minneman KP, et al. Selectivity of agonists for cloned alpha 1-adrenergic receptor subtypes. Mol Pharmacol. 1994 Nov;46(5):929-36.;Wang J, et al. Phenylephrine promotes cardiac fibroblast proliferation through calcineurin-NFAT pathway. Front Biosci (Landmark Ed). 2016 Jan 1;21:502-13."

>  <ID<1>>
T17310

$$$$
StarDrop ID 475
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 10 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.1821 2.3100 0.0000 0
M  V30 2 N 3.8966 1.8975 0.0000 0
M  V30 3 C 3.8966 1.0725 0.0000 0
M  V30 4 C 4.6111 0.6600 0.0000 0
M  V30 5 C 4.6111 -0.1650 0.0000 0
M  V30 6 C 5.3256 -0.5775 0.0000 0
M  V30 7 C 5.3256 -1.4025 0.0000 0
M  V30 8 C 4.6111 -1.8150 0.0000 0
M  V30 9 C 3.8966 -1.4025 0.0000 0
M  V30 10 C 3.8966 -0.5775 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
475

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Phenelzine sulfate

>  <Synonyms>
N/A

>  <CAS>
156-51-4

>  <Formula>
C8H14N2O4S

>  <MolWt>
234.3

>  <Pathways>
Neuroscience

>  <Target>
Monoamine Oxidase

>  <Receptor>
monoamine oxidase

>  <Bioactivity>
"Phenelzine sulfate is a non-selective and irreversible inhibitor of monoamine oxidase (MAOI), and with antidepressant and anxiolytic."

>  <Reference>
"A G B , A D M , A M K , et al. Attenuation of the effects of oxidative stress by the MAO-inhibiting antidepressant and carbonyl scavenger phenelzine[J]. Chemico-Biological Interactions, 2019, 304:139-147.	"

>  <ID<1>>
T12441

$$$$
StarDrop ID 476
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 39 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -3.1165 -3.5819 0.0000 0
M  V30 2 C -2.5764 -4.2055 0.0000 0
M  V30 3 C -2.8465 -4.9851 0.0000 0
M  V30 4 N -2.8465 -2.8023 0.0000 0
M  V30 5 C -3.3865 -2.1787 0.0000 0 CFG=1
M  V30 6 C -3.1165 -1.3991 0.0000 0 CFG=1
M  V30 7 C -3.6566 -0.7755 0.0000 0
M  V30 8 C -4.4667 -0.9314 0.0000 0
M  V30 9 C -4.7368 -1.7109 0.0000 0
M  V30 10 C -4.1967 -2.3346 0.0000 0
M  V30 11 C -5.5616 -1.6950 0.0000 0
M  V30 12 N -5.8013 -0.9056 0.0000 0
M  V30 13 C -5.1247 -0.4337 0.0000 0
M  V30 14 C -5.0226 0.3850 0.0000 0
M  V30 15 C -4.2626 0.7059 0.0000 0
M  V30 16 C -3.6046 0.2082 0.0000 0
M  V30 17 C -2.3064 -1.2432 0.0000 0
M  V30 18 C -1.7663 -1.8668 0.0000 0 CFG=1
M  V30 19 C -0.9561 -1.7109 0.0000 0
M  V30 20 N -0.4161 -2.3346 0.0000 0
M  V30 21 C -0.6861 -3.1141 0.0000 0
M  V30 22 N -1.4962 -3.2700 0.0000 0
M  V30 23 C -1.7663 -4.0496 0.0000 0
M  V30 24 C -1.2262 -4.6732 0.0000 0
M  V30 25 O -0.1460 -3.7378 0.0000 0
M  V30 26 C 0.3941 -2.1787 0.0000 0
M  V30 27 C 0.9342 -2.8023 0.0000 0
M  V30 28 C 1.7443 -2.6464 0.0000 0
M  V30 29 N 2.2844 -3.2700 0.0000 0
M  V30 30 C 3.0945 -3.1141 0.0000 0
M  V30 31 C 2.0144 -4.0496 0.0000 0
M  V30 32 O -0.6861 -0.9314 0.0000 0
M  V30 33 C -2.0363 -2.6464 0.0000 0
M  V30 34 H -2.8465 -0.6196 0.0000 0
M  V30 35 H -3.6566 -2.9582 0.0000 0
M  V30 36 H -1.1116 -2.6227 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 1 4
M  V30 4 1 5 4
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 5 10
M  V30 11 2 9 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 2 8 13
M  V30 15 1 13 14
M  V30 16 2 14 15
M  V30 17 1 15 16
M  V30 18 2 7 16
M  V30 19 1 6 17
M  V30 20 1 18 17
M  V30 21 1 18 19 CFG=1
M  V30 22 1 19 20
M  V30 23 1 20 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 2 21 25
M  V30 28 1 20 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 28 29
M  V30 32 1 29 30
M  V30 33 1 29 31
M  V30 34 2 19 32
M  V30 35 1 18 33
M  V30 36 1 4 33
M  V30 37 1 6 34 CFG=3
M  V30 38 1 5 35 CFG=1
M  V30 39 1 36 18
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
476

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cabergoline

>  <Synonyms>
FCE-21336

>  <CAS>
81409-90-7

>  <Formula>
C26H37N5O2

>  <MolWt>
451.6

>  <Pathways>
Neuroscience;GPCR/G Protein;Autophagy

>  <Target>
Dopamine Receptor;Autophagy;5-HT Receptor

>  <Receptor>
5-HT2B; Autophagy; D2; D3; Dopamine

>  <Bioactivity>
"Cabergoline is an ergot derived-dopamine D2-like receptor agonist. It has high affinity for D2, D3, and 5-HT2B receptors (Ki=0.7, 1.5, and 1.2, respectively).Cabergoline permits rapid and effective hormonal and tumor control by normalizing prolactin-producing pituitary adenomas levels."

>  <Reference>
"Jefferson F, et al. A dopamine receptor d2-type agonist attenuates the ability of stress to alter sleep in mice. Endocrinology. 2014 Nov;155(11):4411-21.;Odaka H, et al. Cabergoline, dopamine D2 receptor agonist, prevents neuronal cell death under oxidative stress via reducing excitotoxicity. PLoS One. 2014 Jun 10;9(6):e99271."

>  <ID<1>>
T14853

$$$$
StarDrop ID 477
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 27 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 5.7538 3.1986 0.0000 0
M  V30 2 C 5.9154 2.3895 0.0000 0
M  V30 3 C 5.2566 1.8929 0.0000 0
M  V30 4 C 5.2341 1.0682 0.0000 0
M  V30 5 C 5.8649 0.5365 0.0000 0
M  V30 6 C 5.5541 -0.2277 0.0000 0
M  V30 7 N 4.7312 -0.1683 0.0000 0
M  V30 8 C 4.5335 0.6327 0.0000 0
M  V30 9 C 3.8060 1.0217 0.0000 0
M  V30 10 C 3.7791 1.8462 0.0000 0
M  V30 11 F 3.0515 2.2352 0.0000 0
M  V30 12 C 4.4797 2.2818 0.0000 0
M  V30 13 C 5.9897 -0.9284 0.0000 0
M  V30 14 C 6.8142 -0.9015 0.0000 0
M  V30 15 C 7.2498 -1.6021 0.0000 0
M  V30 16 C 6.8608 -2.3297 0.0000 0
M  V30 17 C 7.2964 -3.0303 0.0000 0
M  V30 18 N 6.9074 -3.7579 0.0000 0
M  V30 19 C 7.3429 -4.4585 0.0000 0
M  V30 20 C 6.0362 -2.3566 0.0000 0
M  V30 21 C 5.6007 -1.6559 0.0000 0
M  V30 22 C 6.6739 0.6981 0.0000 0
M  V30 23 C 7.0520 1.4314 0.0000 0
M  V30 24 N 6.7144 2.1841 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 4 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 1 3 12
M  V30 14 1 6 13
M  V30 15 2 13 14
M  V30 16 1 14 15
M  V30 17 2 15 16
M  V30 18 1 16 17
M  V30 19 1 17 18
M  V30 20 1 18 19
M  V30 21 1 16 20
M  V30 22 2 20 21
M  V30 23 1 13 21
M  V30 24 1 5 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 1 2 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
477

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Rucaparib monocamsylate

>  <Synonyms>
Rucaparib Camsylate

>  <CAS>
1859053-21-6

>  <Formula>
C29H34FN3O5S

>  <MolWt>
555.7

>  <Pathways>
Chromatin/Epigenetic;DNA Damage/DNA Repair

>  <Target>
PARP

>  <Receptor>
 PARP-1:1.4 nM (Ki)

>  <Bioactivity>
"Rucaparib Camsylate is a PARP inhibitor (PARP1,Ki of 1.4 nM). Rucaparib Camsylate also displays binding affinity to eight other PARP domains."

>  <Reference>
"Daniel RA, et al. Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699. Br J Cancer, 2010, 103(10), 1588-1596.;Daniel RA, et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res, 2009, 15(4), 1241-1249.;Thomas HD, et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther, 2007, 6(3), 945-956.;Hunter JE, et al. NF-??B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699. Oncogene, 2012, 31(2), 251-264."

>  <ID<1>>
T16807

$$$$
StarDrop ID 478
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 2.1434 -0.4125 0.0000 0
M  V30 2 C 2.1434 -1.2375 0.0000 0
M  V30 3 C 2.8579 -1.6500 0.0000 0
M  V30 4 C 2.8579 -2.4750 0.0000 0
M  V30 5 I 3.5724 -2.8875 0.0000 0
M  V30 6 C 2.1434 -2.8875 0.0000 0
M  V30 7 O 2.1434 -3.7125 0.0000 0
M  V30 8 C 1.4289 -2.4750 0.0000 0
M  V30 9 I 0.7145 -2.8875 0.0000 0
M  V30 10 C 1.4289 -1.6500 0.0000 0
M  V30 11 C 2.8579 0.0000 0.0000 0
M  V30 12 C 2.8579 0.8250 0.0000 0
M  V30 13 I 2.1434 1.2375 0.0000 0
M  V30 14 C 3.5724 1.2375 0.0000 0
M  V30 15 C 4.2868 0.8250 0.0000 0
M  V30 16 C 5.0013 1.2375 0.0000 0
M  V30 17 C 5.0013 2.0625 0.0000 0 CFG=2
M  V30 18 C 5.7158 2.4750 0.0000 0
M  V30 19 O 5.7158 3.3000 0.0000 0
M  V30 20 O 6.4302 2.0625 0.0000 0
M  V30 21 N 4.2868 2.4750 0.0000 0
M  V30 22 C 4.2868 0.0000 0.0000 0
M  V30 23 C 3.5724 -0.4125 0.0000 0
M  V30 24 I 3.5724 -1.2375 0.0000 0
M  V30 25 H 4.1353 1.5625 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 2 10
M  V30 11 1 1 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 17 16
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 2 18 20
M  V30 21 1 17 21 CFG=1
M  V30 22 1 15 22
M  V30 23 2 22 23
M  V30 24 1 11 23
M  V30 25 1 23 24
M  V30 26 1 25 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
478

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
D-Thyroxine

>  <Synonyms>
Dextroxin;Dextrothyroxine;Biotirmone;Biotirmone;Dextroid;Dextrothyroxine;Debetrol;Dethyrona;Detyroxin

>  <CAS>
51-49-0

>  <Formula>
C15H11I4NO4

>  <MolWt>
776.9

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Dextrothyroxine could lower cholesterol and also increases hepatic lipase which in turn improves utilization of triglycerides, leading to improve apolipoprotein E cholesterol particles."

>  <Reference>
"Hazenberg HJ, Muller CJ, Kerckhoffs HP, Erkelens DW. Dextrothyroxine induced hyperthyroidism in a patient with heterozygous familial hypercholesterolaemia. Neth J Med. 1987 Oct;31(3-4):117-21. PubMed PMID: 3683682.;Hankins JH, Heise CM, Cowan RJ. Iatrogenic hyperthyroidism secondary to dextrothyroxine administration. Clin Nucl Med. 1984 Jan;9(1):17-9. PubMed PMID: 6697613.;Krawczynska H, Wojcik-Musialek K, Illig R. 10 years of successful treatment with dextrothyroxine in a girl with TSH-induced hyperthyroidism. Horm Res. 1991;35(5):213-6. PubMed PMID: 1802825.;Schwartz ID, Bercu BB. Dextrothyroxine in the treatment of generalized thyroid hormone resistance in a boy homozygous for a defect in the T3 receptor. Thyroid. 1992 Spring;2(1):15-9. PubMed PMID: 1525565."

>  <ID<1>>
T21383

$$$$
StarDrop ID 479
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 70 73 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 4.3612 0.0183 0.0000 0
M  V30 2 C 5.1734 -0.1266 0.0000 0
M  V30 3 C 3.8296 -0.6126 0.0000 0 CFG=2
M  V30 4 C 3.0596 -0.4410 0.0000 0 CFG=2
M  V30 5 O 2.5079 -1.1556 0.0000 0
M  V30 6 C 2.5344 -1.9802 0.0000 0 CFG=2
M  V30 7 O 2.6587 -2.7957 0.0000 0
M  V30 8 C 3.6390 -2.0288 0.0000 0 CFG=2
M  V30 9 C 3.9864 -2.7771 0.0000 0
M  V30 10 C 4.1431 -1.3757 0.0000 0
M  V30 11 C 1.7584 -2.2602 0.0000 0
M  V30 12 O 1.5289 -3.0526 0.0000 0
M  V30 13 C 1.2523 -1.6087 0.0000 0
M  V30 14 O 1.6943 -0.9122 0.0000 0
M  V30 15 N 0.3714 -1.4111 0.0000 0
M  V30 16 C 0.0913 -0.6351 0.0000 0 CFG=2
M  V30 17 C -0.6912 -0.8384 0.0000 0
M  V30 18 O -1.5218 -0.6870 0.0000 0
M  V30 19 O -1.0008 0.2864 0.0000 0
M  V30 20 C -1.8129 0.4319 0.0000 0 CFG=2
M  V30 21 C -2.3449 -0.1987 0.0000 0
M  V30 22 C -3.1570 -0.0532 0.0000 0
M  V30 23 C -3.6890 -0.6838 0.0000 0 CFG=1
M  V30 24 C -3.4089 -1.4598 0.0000 0
M  V30 25 C -3.9410 -2.0903 0.0000 0 CFG=1
M  V30 26 O -3.6609 -2.8663 0.0000 0
M  V30 27 C -2.8488 -3.0118 0.0000 0
M  V30 28 C -4.7530 -1.9449 0.0000 0 CFG=2
M  V30 29 O -5.2850 -2.5754 0.0000 0
M  V30 30 C -5.0331 -1.1688 0.0000 0
M  V30 31 C -4.5011 -0.5383 0.0000 0
M  V30 32 C -2.0648 -0.9747 0.0000 0
M  V30 33 C -2.0930 1.2079 0.0000 0 CFG=2
M  V30 34 C -2.9050 1.3533 0.0000 0
M  V30 35 C -1.5609 1.8384 0.0000 0 CFG=1
M  V30 36 O -0.7489 1.6929 0.0000 0
M  V30 37 C -1.8410 2.6144 0.0000 0
M  V30 38 C -1.3090 3.2450 0.0000 0
M  V30 39 O -1.5890 4.0210 0.0000 0
M  V30 40 C -0.4969 3.0995 0.0000 0 CFG=2
M  V30 41 C 0.0351 3.7300 0.0000 0
M  V30 42 C -0.2449 4.5060 0.0000 0
M  V30 43 C 0.2871 5.1366 0.0000 0
M  V30 44 C -0.2168 2.3235 0.0000 0
M  V30 45 C 0.5952 2.1780 0.0000 0
M  V30 46 C 1.1272 2.8086 0.0000 0
M  V30 47 C 0.8753 1.4020 0.0000 0
M  V30 48 C 1.6874 1.2565 0.0000 0 CFG=2
M  V30 49 C 2.2194 1.8871 0.0000 0
M  V30 50 C 1.9674 0.4805 0.0000 0
M  V30 51 C 2.7795 0.3351 0.0000 0 CFG=2
M  V30 52 O 3.3115 0.9656 0.0000 0
M  V30 53 C 4.1236 0.8201 0.0000 0
M  V30 54 C -0.7208 -0.4896 0.0000 0
M  V30 55 C -1.2528 -1.1202 0.0000 0
M  V30 56 C -0.9727 -1.8962 0.0000 0
M  V30 57 C -0.1606 -2.0416 0.0000 0
M  V30 58 H 0.6233 -0.0046 0.0000 0
M  V30 59 H 3.6047 0.1783 0.0000 0
M  V30 60 H -2.7378 0.4435 0.0000 0
M  V30 61 H -1.2216 0.8977 0.0000 0
M  V30 62 H 0.4874 2.9231 0.0000 0
M  V30 63 H 1.3479 2.1971 0.0000 0
M  V30 64 H 2.4399 1.2757 0.0000 0
M  V30 65 H 3.5448 0.3460 0.0000 0
M  V30 66 H 4.6328 -2.1399 0.0000 0
M  V30 67 H -1.4734 -0.5087 0.0000 0
M  V30 68 H -4.0285 0.2568 0.0000 0
M  V30 69 H -4.5858 -2.8547 0.0000 0
M  V30 70 H -4.4136 -2.8855 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 3 1 CFG=1
M  V30 3 1 4 3
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=1
M  V30 7 1 6 8
M  V30 8 1 8 9 CFG=1
M  V30 9 1 8 10
M  V30 10 1 3 10
M  V30 11 1 6 11
M  V30 12 2 11 12
M  V30 13 1 11 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 16 15
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 17 19
M  V30 20 1 20 19
M  V30 21 1 20 21 CFG=3
M  V30 22 2 21 22
M  V30 23 1 23 22 CFG=1
M  V30 24 1 23 24
M  V30 25 1 25 24
M  V30 26 1 25 26 CFG=1
M  V30 27 1 26 27
M  V30 28 1 25 28
M  V30 29 1 28 29 CFG=3
M  V30 30 1 28 30
M  V30 31 1 30 31
M  V30 32 1 23 31
M  V30 33 1 21 32
M  V30 34 1 33 20
M  V30 35 1 33 34 CFG=3
M  V30 36 1 33 35
M  V30 37 1 35 36 CFG=3
M  V30 38 1 35 37
M  V30 39 1 37 38
M  V30 40 2 38 39
M  V30 41 1 40 38
M  V30 42 1 40 41 CFG=3
M  V30 43 1 41 42
M  V30 44 2 42 43
M  V30 45 1 40 44
M  V30 46 2 44 45
M  V30 47 1 45 46
M  V30 48 1 45 47
M  V30 49 1 48 47
M  V30 50 1 48 49 CFG=3
M  V30 51 1 48 50
M  V30 52 1 51 50
M  V30 53 1 4 51
M  V30 54 1 51 52 CFG=3
M  V30 55 1 52 53
M  V30 56 1 16 54
M  V30 57 1 54 55
M  V30 58 1 55 56
M  V30 59 1 56 57
M  V30 60 1 15 57
M  V30 61 1 16 58 CFG=1
M  V30 62 1 4 59 CFG=1
M  V30 63 1 60 33
M  V30 64 1 61 35
M  V30 65 1 62 40
M  V30 66 1 63 48
M  V30 67 1 64 51
M  V30 68 1 65 3
M  V30 69 1 66 8
M  V30 70 1 67 20
M  V30 71 1 68 23
M  V30 72 1 69 25
M  V30 73 1 70 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
479

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tacrolimus monohydrate

>  <Synonyms>
Tacrolimus hydrate;FK-506;LCP-Tacro;Prograf;FK 506;FR900506;FR 900506

>  <CAS>
109581-93-3

>  <Formula>
C44H71NO13

>  <MolWt>
822

>  <Pathways>
Others;Autophagy;Metabolism;Microbiology/Virology

>  <Target>
Antibiotic;Phosphatase;Others;Autophagy;Antibacterial

>  <Receptor>
Antibiotic; Autophagy; BacteriaL; FKBP; Phosphatase

>  <Bioactivity>
"Tacrolimus hydrate is a macrolide from the culture broth of a strain of Streptomyces tsukubaensis, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties. It prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro and has strong immunosuppressive activity in vivo."

>  <Reference>
"Kumar A, Singh N. Calcineurin Inhibition and Protein Kinase A Activation Limits Cognitive Dysfunction and Histopathological Damage in a Model of Dementia of the Alzheimer's Type. Curr Neurovasc Res. 2018 Aug 13. doi: 10.2174/1567202615666180813125125. [Epub ahead of print] PubMed PMID: 30101704.;Liu YJ, Fan H, Zhen WW, Yu X, Chen JT, Wang CD. Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis. Medicine (Baltimore). 2018 Aug;97(32):e11440. doi: 10.1097/MD.0000000000011440. PubMed PMID: 30095612.;Shin MH, Song GW, Lee SG, et al. Once-daily, prolonged-release tacrolimus versus twice-daily, immediate-release tacrolimus in de novo living-donor liver transplantation: a Phase 4, randomized, open-label, comparative, single-center study. Clin Transplant. 2018 Aug 11:e13376. doi: 10.1111/ctr.13376. [Epub ahead of print] PubMed PMID: 30098071.;Dodi PL. Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management. Vet Med (Auckl). 2015 Oct 30;6:341-347. doi: 10.2147/VMRR.S66705. eCollection 2015. Review. PubMed PMID: 30101119; PubMed Central PMCID: PMC6067592."

>  <ID<1>>
T20879

$$$$
StarDrop ID 480
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 3.3147 2.1656 0.0000 0
M  V30 2 C 3.3147 1.3406 0.0000 0
M  V30 3 C 4.0291 0.9281 0.0000 0
M  V30 4 C 4.0291 0.1031 0.0000 0
M  V30 5 C 3.3147 -0.3094 0.0000 0
M  V30 6 C 2.6002 0.1031 0.0000 0
M  V30 7 C 2.6002 0.9281 0.0000 0
M  V30 8 O 1.8857 1.3406 0.0000 0
M  V30 9 C 3.3147 -1.1344 0.0000 0
M  V30 10 O 4.0291 -1.5469 0.0000 0
M  V30 11 C 2.6002 -1.5469 0.0000 0
M  V30 12 N 2.6002 -2.3719 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 7 8
M  V30 9 1 5 9
M  V30 10 1 9 10
M  V30 11 1 9 11
M  V30 12 1 11 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
480

>  <Plate>
PHD136329

>  <Row>
h

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
DL-Norepinephrine hydrochloride

>  <Synonyms>
DL-lysine;Lys

>  <CAS>
55-27-6

>  <Formula>
C8H12ClNO3

>  <MolWt>
205.6

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor; ??1-adrenoceptor; ??1-adrenoceptor

>  <Bioactivity>
DL-Norepinephrine hydrochloride is a high-affinity basic amino acid substrate of amino acid transporter b0 + with a Km value in the range of 100-400 ??M.

>  <Reference>
"Matsuda H, et al. Effects of nitroglycerin, adenosine, noradrenaline, and isoproterenol on the myocardial oxygen tension. Jpn Heart J. 1979 Nov;20(6):867-79."

>  <ID<1>>
T13655

$$$$
StarDrop ID 481
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 46 49 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -3.5724 -1.2375 0.0000 0
M  V30 2 C -2.8579 -1.6500 0.0000 0
M  V30 3 C -2.8579 -2.4750 0.0000 0
M  V30 4 C -2.1434 -2.8875 0.0000 0
M  V30 5 O -2.1434 -3.7125 0.0000 0
M  V30 6 N -1.4289 -2.4750 0.0000 0
M  V30 7 C -0.7145 -2.8875 0.0000 0
M  V30 8 C 0.0000 -2.4750 0.0000 0 CFG=2
M  V30 9 N 0.7145 -2.8875 0.0000 0
M  V30 10 C 1.4289 -2.4750 0.0000 0
M  V30 11 C 2.1434 -2.8875 0.0000 0
M  V30 12 C 2.8579 -2.4750 0.0000 0
M  V30 13 C 3.5724 -2.8875 0.0000 0
M  V30 14 O 3.5724 -3.7125 0.0000 0
M  V30 15 O 4.2868 -2.4750 0.0000 0
M  V30 16 C 0.0000 -1.6500 0.0000 0
M  V30 17 C -0.7145 -1.2375 0.0000 0
M  V30 18 C -0.7145 -0.4125 0.0000 0
M  V30 19 C 0.0000 0.0000 0.0000 0
M  V30 20 C 0.7145 -0.4125 0.0000 0
M  V30 21 C 0.7145 -1.2375 0.0000 0
M  V30 22 C -1.4289 -1.6500 0.0000 0
M  V30 23 O -1.0934 -0.8963 0.0000 0
M  V30 24 N -2.1434 -1.2375 0.0000 0
M  V30 25 C -2.1434 -0.4125 0.0000 0
M  V30 26 C -2.8579 0.0000 0.0000 0
M  V30 27 C -2.8579 0.8250 0.0000 0
M  V30 28 C -2.1434 1.2375 0.0000 0
M  V30 29 F -1.4289 1.6500 0.0000 0
M  V30 30 F -1.7309 0.5230 0.0000 0
M  V30 31 F -2.5559 1.9520 0.0000 0
M  V30 32 C -3.5724 1.2375 0.0000 0
M  V30 33 C -4.2868 0.8250 0.0000 0
M  V30 34 C -4.2868 0.0000 0.0000 0
M  V30 35 C -3.5724 -0.4125 0.0000 0
M  V30 36 F -4.0573 -1.0799 0.0000 0
M  V30 37 C -3.5724 -2.8875 0.0000 0
M  V30 38 C -3.5724 -3.7125 0.0000 0
M  V30 39 F -2.8579 -4.1250 0.0000 0
M  V30 40 C -4.2868 -4.1250 0.0000 0
M  V30 41 O -4.2868 -4.9500 0.0000 0
M  V30 42 C -5.0013 -5.3625 0.0000 0
M  V30 43 C -5.0013 -3.7125 0.0000 0
M  V30 44 C -5.0013 -2.8875 0.0000 0
M  V30 45 C -4.2868 -2.4750 0.0000 0
M  V30 46 H 0.8660 -1.9750 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=1
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 13 15
M  V30 15 1 8 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 16 21
M  V30 22 1 6 22
M  V30 23 2 22 23
M  V30 24 1 22 24
M  V30 25 1 2 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 1 28 30
M  V30 32 1 28 31
M  V30 33 1 27 32
M  V30 34 2 32 33
M  V30 35 1 33 34
M  V30 36 2 34 35
M  V30 37 1 26 35
M  V30 38 1 35 36
M  V30 39 1 3 37
M  V30 40 2 37 38
M  V30 41 1 38 39
M  V30 42 1 38 40
M  V30 43 1 40 41
M  V30 44 1 41 42
M  V30 45 2 40 43
M  V30 46 1 43 44
M  V30 47 2 44 45
M  V30 48 1 37 45
M  V30 49 1 46 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
481

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
(R)-Elagolix

>  <Synonyms>
NBI-56418

>  <CAS>
834153-87-6

>  <Formula>
C32H30F5N3O5

>  <MolWt>
631.6

>  <Pathways>
GPCR/G Protein

>  <Target>
GNRH Receptor

>  <Receptor>
" GnRHR: Ki : 3.7 nM, GnRHR:0.25 nM"

>  <Bioactivity>
"(R)-Elagolix is a short-acting, nonpeptide, GnRH antagonist with an IC50 and Ki of 0.25 and 3.7 nM, respectively. administered orally, that unlike injectable depot GnRH agonists and antagonists, produces a dose-dependent suppression of ovarian estrogen production, that is, from partial suppression at lower doses to full suppression at higher doses."

>  <Reference>
"Carr B, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci. 2014 Nov;21(11):1341-1351."

>  <ID<1>>
T11174

$$$$
StarDrop ID 482
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -1.4341 1.5536 0.0000 0
M  V30 2 C -1.0216 0.8391 0.0000 0
M  V30 3 O -1.4341 0.1246 0.0000 0
M  V30 4 C -0.1966 0.8391 0.0000 0
M  V30 5 C 0.2159 0.1246 0.0000 0
M  V30 6 O -0.4986 -0.2879 0.0000 0
M  V30 7 C 0.9304 0.5371 0.0000 0
M  V30 8 O 1.6448 0.1246 0.0000 0
M  V30 9 O 0.9304 1.3621 0.0000 0
M  V30 10 C 0.6284 -0.5898 0.0000 0
M  V30 11 C 0.2159 -1.3043 0.0000 0
M  V30 12 O 0.6284 -2.0188 0.0000 0
M  V30 13 O -0.6091 -1.3043 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 5 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
482

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Piperazine citrate

>  <Synonyms>
N/A

>  <CAS>
144-29-6

>  <Formula>
C10H18N2O7

>  <MolWt>
278.3

>  <Pathways>
Neuroscience;Membrane transporter/Ion channel

>  <Target>
GABA Receptor

>  <Receptor>
GABA

>  <Bioactivity>
"Piperazine citrate, an organic compound, consists of a six-membered ring, containing two nitrogen atoms at opposite positions in the ring. It used as an Anthelmintic."

>  <Reference>
Ghasi S. Piperazine protects the rat heart against sudden cardiac death from barium chloride-induced ventricular fibrillation. Am J Ther. 2008 Mar-Apr;15(2):119-25.

>  <ID<1>>
T16539

$$$$
StarDrop ID 483
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.3571 -0.2062 0.0000 0
M  V30 2 C 3.0716 0.2063 0.0000 0
M  V30 3 C 3.7861 -0.2062 0.0000 0
M  V30 4 N 4.5006 0.2062 0.0000 0
M  V30 5 C 5.2150 -0.2063 0.0000 0
M  V30 6 C 5.9295 0.2062 0.0000 0
M  V30 7 N 6.6440 -0.2063 0.0000 0
M  V30 8 C 7.3584 0.2062 0.0000 0
M  V30 9 C 8.0729 -0.2063 0.0000 0
M  V30 10 N 8.7874 0.2062 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
483

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Trientine-2HCl

>  <Synonyms>
Trientine;Trientine HCl;TETA;Triethylene tetramine;Triethylenetetramine;Trien

>  <CAS>
38260-01-4

>  <Formula>
C6H18N4

>  <MolWt>
146.2

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Trientine-2HCl, a chelating agent, is used to treat Wilson's disease by binding up and removing copper in the body. Trientine can also be used as a chelating agent for copper in hepatolenticular degeneration, as a stabilizer for epoxy resins, and as ampholyte for isoelectric focusing."

>  <Reference>
"Ala A, Aliu E, Schilsky ML. Prospective Pilot Study of a Single Daily Dosage of Trientine for the Treatment of Wilson Disease. Dig Dis Sci. 2015 Jan 21. [Epub ahead of print] PubMed PMID: 25605552.;Fu S, Hou MM, Wheler J, Hong D, Naing A, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Falchook G, Kuo MT, Kurzrock R. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs. 2014 Jun;32(3):465-72. doi: 10.1007/s10637-013-0051-8. Epub 2013 Dec 5. PubMed PMID: 24306314.;Chandok N, Roberts EA. The trientine crisis in Canada: a call to advocacy. Can J Gastroenterol Hepatol. 2014 Apr;28(4):184. PubMed PMID: 24729990; PubMed Central PMCID: PMC4071922.;Rezaei A, Heidarian E. Co-administration of trientine and flaxseed oil on oxidative stress, serum lipids and heart structure in diabetic rats. Indian J Exp Biol. 2013 Aug;51(8):646-52. PubMed PMID: 24228388."

>  <ID<1>>
T21300

$$$$
StarDrop ID 484
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S 5.0539 0.6420 0.0000 0
M  V30 2 O 5.8789 0.6420 0.0000 0
M  V30 3 O 4.2289 0.6420 0.0000 0
M  V30 4 N 5.0539 -0.1830 0.0000 0
M  V30 5 C 5.7214 -0.6679 0.0000 0
M  V30 6 C 5.4664 -1.4525 0.0000 0
M  V30 7 C 4.6414 -1.4525 0.0000 0
M  V30 8 C 4.1565 -2.1199 0.0000 0
M  V30 9 N 4.4921 -2.8736 0.0000 0
M  V30 10 C 4.0071 -3.5411 0.0000 0
M  V30 11 C 4.3865 -0.6679 0.0000 0
M  V30 12 C 6.5060 -0.4129 0.0000 0
M  V30 13 C 7.1191 -0.9650 0.0000 0
M  V30 14 F 6.9476 -1.7719 0.0000 0
M  V30 15 C 7.9037 -0.7100 0.0000 0
M  V30 16 C 8.0752 0.0969 0.0000 0
M  V30 17 C 7.4621 0.6490 0.0000 0
M  V30 18 C 6.6775 0.3940 0.0000 0
M  V30 19 C 5.0539 1.4670 0.0000 0
M  V30 20 C 4.3395 1.8795 0.0000 0
M  V30 21 C 4.3395 2.7045 0.0000 0
M  V30 22 C 5.0539 3.1170 0.0000 0
M  V30 23 N 5.7684 2.7045 0.0000 0
M  V30 24 C 5.7684 1.8795 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 1 3
M  V30 3 1 1 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 7 11
M  V30 11 1 4 11
M  V30 12 1 5 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 1 13 15
M  V30 16 2 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 12 18
M  V30 20 1 1 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 19 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
484

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Vonoprazan Fumarate

>  <Synonyms>
TAK 438;TAK-438;TAK438;Vonoprazan Fumurate

>  <CAS>
881681-01-2

>  <Formula>
C21H20FN3O6S

>  <MolWt>
461.5

>  <Pathways>
Membrane transporter/Ion channel

>  <Target>
Proton pump

>  <Receptor>
" H+,K+-ATPase:19 nM"

>  <Bioactivity>
"Vonoprazan Fumurate, a novel potassium-competitive acid blocker, inhibits gastric acid secretion. Vonoprazan Fumurate inhibited H+,K+-ATPase activity in porcine gastric microsomes with IC50 value of 19 nM at pH 6.5."

>  <Reference>
"Sugano K. Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Therap Adv Gastroenterol. 2018 Jan 9;11:1756283X17745776.;Hori Y, et al. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther, 2010, 335(1), 231-238.;Masaoka T, et al. Pathophysiology of Potassium-competitive Acid Blocker-refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test. J Neurogastroenterol Motil. 2018 Oct 1;24(4):577-583.;Arikawa Y, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem, 2012, 55(9), 4446-4456."

>  <ID<1>>
T21254

$$$$
StarDrop ID 485
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 105 112 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 8.1638 1.2988 0.0000 0
M  V30 2 C 8.3167 0.4881 0.0000 0 CFG=2
M  V30 3 N 7.6911 -0.0496 0.0000 0
M  V30 4 C 6.9125 0.2233 0.0000 0
M  V30 5 C 6.2869 -0.3145 0.0000 0 CFG=2
M  V30 6 C 6.4398 -1.1252 0.0000 0
M  V30 7 C 7.2184 -1.3981 0.0000 0
M  V30 8 C 7.4552 -2.1884 0.0000 0
M  V30 9 N 8.2800 -2.2074 0.0000 0
M  V30 10 C 8.5529 -1.4288 0.0000 0
M  V30 11 N 7.8968 -0.9287 0.0000 0
M  V30 12 N 5.5084 -0.0416 0.0000 0
M  V30 13 C 4.8827 -0.5793 0.0000 0
M  V30 14 O 5.0356 -1.3900 0.0000 0
M  V30 15 C 4.1042 -0.3064 0.0000 0 CFG=2
M  V30 16 C 3.4257 -0.7758 0.0000 0
M  V30 17 C 2.7696 -0.2757 0.0000 0
M  V30 18 C 3.0426 0.5029 0.0000 0
M  V30 19 O 2.5731 1.1813 0.0000 0
M  V30 20 N 3.8674 0.4839 0.0000 0
M  V30 21 O 6.7596 1.0340 0.0000 0
M  V30 22 C 9.0953 0.2152 0.0000 0
M  V30 23 N 9.7209 0.7530 0.0000 0
M  V30 24 C 10.3021 0.1910 0.0000 0 CFG=2
M  V30 25 C 11.1251 1.0178 0.0000 0
M  V30 26 N 11.9036 0.7449 0.0000 0
M  V30 27 C 12.5293 1.2827 0.0000 0 CFG=1
M  V30 28 C 12.1333 2.0065 0.0000 0
M  V30 29 C 12.5621 2.7113 0.0000 0
M  V30 30 C 12.1662 3.4350 0.0000 0
M  V30 31 C 12.5950 4.1398 0.0000 0
M  V30 32 C 13.4198 4.1208 0.0000 0
M  V30 33 O 13.8486 4.8256 0.0000 0
M  V30 34 C 13.8158 3.3971 0.0000 0
M  V30 35 C 13.3869 2.6923 0.0000 0
M  V30 36 C 13.3078 1.0098 0.0000 0
M  V30 37 N 13.9334 1.5475 0.0000 0
M  V30 38 C 14.7120 1.2746 0.0000 0 CFG=2
M  V30 39 C 15.3376 1.8124 0.0000 0
M  V30 40 C 15.1847 2.6231 0.0000 0
M  V30 41 C 15.8104 3.1609 0.0000 0
M  V30 42 C 15.6574 3.9716 0.0000 0
M  V30 43 C 14.8789 4.2445 0.0000 0
M  V30 44 C 14.2533 3.7067 0.0000 0
M  V30 45 C 14.4062 2.8960 0.0000 0
M  V30 46 C 14.7260 5.0552 0.0000 0
M  V30 47 C 15.3516 5.5930 0.0000 0
M  V30 48 C 16.1302 5.3201 0.0000 0
M  V30 49 C 16.2831 4.5094 0.0000 0
M  V30 50 C 14.8649 0.4639 0.0000 0
M  V30 51 N 14.2393 -0.0739 0.0000 0
M  V30 52 C 14.3922 -0.8846 0.0000 0 CFG=2
M  V30 53 C 13.7665 -1.4224 0.0000 0
M  V30 54 N 13.9195 -2.2331 0.0000 0
M  V30 55 C 13.2938 -2.7708 0.0000 0 CFG=2
M  V30 56 C 13.4467 -3.5815 0.0000 0
M  V30 57 O 14.2253 -3.8545 0.0000 0
M  V30 58 N 12.8211 -4.1193 0.0000 0
M  V30 59 C 12.8884 -4.9416 0.0000 0 CFG=2
M  V30 60 C 13.5932 -5.3704 0.0000 0
M  V30 61 N 13.5742 -6.1952 0.0000 0
M  V30 62 C 14.2790 -6.6240 0.0000 0
M  V30 63 C 14.2600 -7.4488 0.0000 0
M  V30 64 N 14.9648 -7.8776 0.0000 0
M  V30 65 O 13.5363 -7.8447 0.0000 0
M  V30 66 O 14.3170 -4.9745 0.0000 0
M  V30 67 C 12.1272 -5.2597 0.0000 0
M  V30 68 C 11.5895 -4.6341 0.0000 0
M  V30 69 C 12.0183 -3.9293 0.0000 0
M  V30 70 C 12.5153 -2.4979 0.0000 0
M  V30 71 C 12.3624 -1.6872 0.0000 0
M  V30 72 C 11.5838 -1.4143 0.0000 0
M  V30 73 N 11.4309 -0.6036 0.0000 0
M  V30 74 C 10.8497 -0.0416 0.0000 0
M  V30 75 N 10.4994 0.4801 0.0000 0
M  V30 76 N 10.7824 0.7807 0.0000 0
M  V30 77 O 12.9880 -1.1494 0.0000 0
M  V30 78 C 15.1707 -1.1575 0.0000 0
M  V30 79 C 15.3236 -1.9682 0.0000 0
M  V30 80 C 16.1022 -2.2411 0.0000 0
M  V30 81 C 14.6980 -2.5060 0.0000 0
M  V30 82 O 15.6435 0.1910 0.0000 0
M  V30 83 O 13.4607 0.1991 0.0000 0
M  V30 84 O 10.9722 1.8285 0.0000 0
M  V30 85 C 10.6524 -0.3306 0.0000 0
M  V30 86 O 10.0267 -0.8684 0.0000 0
M  V30 87 O 9.2482 -0.5955 0.0000 0
M  V30 88 C 8.7894 1.8366 0.0000 0
M  V30 89 C 8.7221 2.6589 0.0000 0
M  V30 90 C 9.4833 2.9770 0.0000 0
M  V30 91 N 10.0211 2.3514 0.0000 0
M  V30 92 C 9.5923 1.6466 0.0000 0
M  V30 93 C 9.5884 3.7953 0.0000 0
M  V30 94 C 8.9323 4.2954 0.0000 0
M  V30 95 C 8.1711 3.9773 0.0000 0
M  V30 96 C 8.0660 3.1590 0.0000 0
M  V30 97 H 13.9536 0.6228 0.0000 0
M  V30 98 H 15.1505 -0.2327 0.0000 0
M  V30 99 H 14.2375 -3.1017 0.0000 0
M  V30 100 H 13.7393 -4.4163 0.0000 0
M  V30 101 H 7.3730 0.8190 0.0000 0
M  V30 102 H 6.1016 0.6682 0.0000 0
M  V30 103 H 4.8273 0.3843 0.0000 0
M  V30 104 H 9.3171 0.3633 0.0000 0
M  V30 105 H 11.5455 1.4618 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3 CFG=1
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 7 11
M  V30 12 1 5 12 CFG=3
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 15 13 CFG=3
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 15 20
M  V30 22 2 4 21
M  V30 23 1 2 22
M  V30 24 1 22 23
M  V30 25 1 24 23 CFG=3
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 1 27 26 CFG=1
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 30 31
M  V30 33 2 31 32
M  V30 34 1 32 33
M  V30 35 1 32 34
M  V30 36 2 34 35
M  V30 37 1 29 35
M  V30 38 1 27 36
M  V30 39 1 36 37
M  V30 40 1 38 37 CFG=3
M  V30 41 1 38 39
M  V30 42 1 39 40
M  V30 43 2 40 41
M  V30 44 1 41 42
M  V30 45 2 42 43
M  V30 46 1 43 44
M  V30 47 2 44 45
M  V30 48 1 40 45
M  V30 49 1 43 46
M  V30 50 2 46 47
M  V30 51 1 47 48
M  V30 52 2 48 49
M  V30 53 1 42 49
M  V30 54 1 38 50
M  V30 55 1 50 51
M  V30 56 1 52 51 CFG=1
M  V30 57 1 52 53
M  V30 58 1 53 54
M  V30 59 1 55 54 CFG=3
M  V30 60 1 55 56
M  V30 61 2 56 57
M  V30 62 1 56 58
M  V30 63 1 59 58
M  V30 64 1 59 60 CFG=3
M  V30 65 1 60 61
M  V30 66 1 61 62
M  V30 67 1 62 63
M  V30 68 1 63 64
M  V30 69 2 63 65
M  V30 70 2 60 66
M  V30 71 1 59 67
M  V30 72 1 67 68
M  V30 73 1 68 69
M  V30 74 1 58 69
M  V30 75 1 55 70
M  V30 76 1 70 71
M  V30 77 1 71 72
M  V30 78 1 72 73
M  V30 79 1 73 74
M  V30 80 2 74 75
M  V30 81 1 74 76
M  V30 82 2 53 77
M  V30 83 1 52 78
M  V30 84 1 78 79
M  V30 85 1 79 80
M  V30 86 1 79 81
M  V30 87 2 50 82
M  V30 88 2 36 83
M  V30 89 2 25 84
M  V30 90 1 24 85
M  V30 91 1 85 86
M  V30 92 2 22 87
M  V30 93 1 1 88
M  V30 94 1 88 89
M  V30 95 1 89 90
M  V30 96 1 90 91
M  V30 97 1 91 92
M  V30 98 2 88 92
M  V30 99 2 90 93
M  V30 100 1 93 94
M  V30 101 2 94 95
M  V30 102 1 95 96
M  V30 103 2 89 96
M  V30 104 1 97 38
M  V30 105 1 98 52
M  V30 106 1 99 55
M  V30 107 1 100 59
M  V30 108 1 101 2
M  V30 109 1 102 5
M  V30 110 1 103 15
M  V30 111 1 104 24
M  V30 112 1 105 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
485

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Nafarelin acetate(76932-56-4 free base)

>  <Synonyms>
Synarel;Nafarelin acetate hydrate;Nafarelin acetate;RS-94991-298

>  <CAS>
76932-60-0

>  <Formula>
C68H89N17O16

>  <MolWt>
1401

>  <Pathways>
GPCR/G Protein

>  <Target>
GNRH Receptor

>  <Receptor>
GNRHR

>  <Bioactivity>
Nafarelin acetate is a GnRH agonist that acts as an analog of GnRH. Nafarelin causes a decrease in the pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It may be used in the treatment of estrogen-dependent conditions.

>  <Reference>
"Ludwig C, Desmoulins PO, Driancourt MA, Goericke-Pesch S, Hoffmann B. Reversible downregulation of endocrine and germinative testicular function (hormonal castration) in the dog with the GnRH-agonist azagly-nafarelin as a removable implant ""Gonazon""; a preclinical trial. Theriogenology. 2009 Apr 15;71(7):1037-45.;Cheng MH, Yu BK, Chang SP, Wang PH. A randomized, parallel, comparative study of the efficacy and safety of nafarelin versus danazol in the treatment of endometriosis in Taiwan. J Chin Med Assoc. 2005 Jul;68(7):307-14. PubMed PMID: 16038370.;Suh J, Lee E, Hwang S, Yoon S, Yoon BK, Bae D, Choi D. Dose of GnRH agonist (nafarelin acetate) affects intrafollicular PAPP-A expression in controlled ovarian hyperstimulation cycle. Eur J Obstet Gynecol Reprod Biol. 2004 Jan 15;112(1):65-8. PubMed PMID: 14687742.;Raiman J, Koljonen M, Huikko K, Kostiainen R, Hirvonen J. Delivery and stability of LHRH and Nafarelin in human skin: the effect of constant/pulsed iontophoresis. Eur J Pharm Sci. 2004 Feb;21(2-3):371-7. PubMed PMID: 14757511."

>  <ID<1>>
T21309

$$$$
StarDrop ID 486
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 59 64 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 9.7449 5.5443 0.0000 0
M  V30 2 S 9.7449 4.7193 0.0000 0
M  V30 3 O 8.9199 4.7193 0.0000 0
M  V30 4 O 10.5699 4.7193 0.0000 0
M  V30 5 C 9.7449 3.8943 0.0000 0
M  V30 6 C 10.4594 3.4818 0.0000 0
M  V30 7 C 10.4594 2.6568 0.0000 0
M  V30 8 C 9.7449 2.2443 0.0000 0
M  V30 9 C 9.0304 2.6568 0.0000 0
M  V30 10 C 9.0304 3.4818 0.0000 0
M  V30 11 C 8.3160 2.2443 0.0000 0
M  V30 12 N 8.3160 1.4193 0.0000 0
M  V30 13 C 7.6015 1.0068 0.0000 0
M  V30 14 C 7.6015 0.1818 0.0000 0
M  V30 15 C 6.8870 -0.2307 0.0000 0
M  V30 16 C 6.1725 0.1818 0.0000 0
M  V30 17 C 6.1725 1.0068 0.0000 0
M  V30 18 C 6.8870 1.4193 0.0000 0
M  V30 19 C 5.4581 1.4193 0.0000 0
M  V30 20 C 5.4581 -0.2307 0.0000 0
M  V30 21 C 4.7436 0.1818 0.0000 0
M  V30 22 C 4.0291 -0.2307 0.0000 0
M  V30 23 C 3.3147 0.1818 0.0000 0
M  V30 24 C 3.3147 1.0068 0.0000 0
M  V30 25 C 4.0291 1.4193 0.0000 0
M  V30 26 C 4.7436 1.0068 0.0000 0
M  V30 27 N 2.6002 1.4193 0.0000 0
M  V30 28 C 2.6002 2.2443 0.0000 0
M  V30 29 C 1.8857 2.6568 0.0000 0
M  V30 30 C 1.8857 3.4818 0.0000 0
M  V30 31 C 2.6002 3.8943 0.0000 0
M  V30 32 O 2.6002 4.7193 0.0000 0
M  V30 33 C 3.3147 5.1318 0.0000 0
M  V30 34 C 3.3147 5.9568 0.0000 0
M  V30 35 C 3.3147 3.4818 0.0000 0
M  V30 36 C 3.3147 2.6568 0.0000 0
M  V30 37 C 5.4581 -1.0557 0.0000 0
M  V30 38 C 6.1725 -1.4682 0.0000 0
M  V30 39 C 6.1725 -2.2932 0.0000 0
M  V30 40 C 5.4581 -2.7057 0.0000 0
M  V30 41 C 4.7436 -2.2932 0.0000 0
M  V30 42 C 4.7436 -1.4682 0.0000 0
M  V30 43 C 4.0291 -1.0557 0.0000 0
M  V30 44 N 5.4581 -3.5307 0.0000 0
M  V30 45 C 6.1725 -3.9432 0.0000 0
M  V30 46 C 6.1725 -4.7682 0.0000 0
M  V30 47 C 6.8870 -5.1807 0.0000 0
M  V30 48 C 6.8870 -6.0057 0.0000 0
M  V30 49 C 6.1725 -6.4182 0.0000 0
M  V30 50 C 5.4581 -6.0057 0.0000 0
M  V30 51 C 5.4581 -5.1807 0.0000 0
M  V30 52 S 4.7436 -6.4182 0.0000 0
M  V30 53 O 4.0291 -6.8307 0.0000 0
M  V30 54 O 4.3311 -5.7037 0.0000 0
M  V30 55 O 5.1561 -7.1327 0.0000 0
M  V30 56 C 4.7436 -3.9432 0.0000 0
M  V30 57 C 4.0291 -3.5307 0.0000 0
M  V30 58 C 9.0304 1.0068 0.0000 0
M  V30 59 C 9.0304 0.1818 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 2 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 9 11
M  V30 12 1 12 11
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 16 15
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 13 18
M  V30 20 1 17 19
M  V30 21 2 16 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 2 23 24
M  V30 26 1 24 25
M  V30 27 2 25 26
M  V30 28 1 21 26
M  V30 29 1 24 27
M  V30 30 1 27 28
M  V30 31 2 28 29
M  V30 32 1 29 30
M  V30 33 2 30 31
M  V30 34 1 31 32
M  V30 35 1 32 33
M  V30 36 1 33 34
M  V30 37 1 31 35
M  V30 38 2 35 36
M  V30 39 1 28 36
M  V30 40 1 20 37
M  V30 41 2 37 38
M  V30 42 1 38 39
M  V30 43 2 39 40
M  V30 44 1 40 41
M  V30 45 2 41 42
M  V30 46 1 37 42
M  V30 47 1 42 43
M  V30 48 1 40 44
M  V30 49 1 44 45
M  V30 50 1 45 46
M  V30 51 2 46 47
M  V30 52 1 47 48
M  V30 53 2 48 49
M  V30 54 1 49 50
M  V30 55 2 50 51
M  V30 56 1 46 51
M  V30 57 1 50 52
M  V30 58 2 52 53
M  V30 59 2 52 54
M  V30 60 1 52 55
M  V30 61 1 44 56
M  V30 62 1 56 57
M  V30 63 1 12 58
M  V30 64 1 58 59
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
486

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Brilliant blue G-250

>  <Synonyms>
BBG;Brilliant Blue G;Acid blue 90, Coomassie Brilliant Blue G

>  <CAS>
6104-58-1

>  <Formula>
C47H49N3NaO7S2

>  <MolWt>
855

>  <Pathways>
Membrane transporter/Ion channel;Neuroscience

>  <Target>
P2X Receptor

>  <Receptor>
P2X7

>  <Bioactivity>
Brilliant Blue G is an antagonist of the P2X7 purinergic receptor.

>  <Reference>
"Fumagalli M, Lecca D, Abbracchio MP. CNS remyelination as a novel reparative approach to neurodegenerative diseases: The roles of purinergic signaling and the P2Y-like receptor GPR17. Neuropharmacology. 2016 May;104:82-93. doi: 10.1016/j.neuropharm.2015.10.005. Epub 2015 Oct 8. Review. PubMed PMID: 26453964.;Azuma K, Noda Y, Hirasawa K, Ueta T. BRILLIANT BLUE G-ASSISTED INTERNAL LIMITING MEMBRANE PEELING FOR MACULAR HOLE: A Systematic Review of Literature and Meta-Analysis. Retina. 2016 May;36(5):851-8. doi: 10.1097/IAE.0000000000000968. Review. PubMed PMID: 27115851.;Ferreira LG, Faria RX, Ferreira NC, Soares-Bezerra RJ. Brilliant Blue Dyes in Daily Food: How Could Purinergic System Be Affected? Int J Food Sci. 2016;2016:7548498. Epub 2016 Oct 19. Review. PubMed PMID: 27833914; PubMed Central PMCID: PMC5090090.;Burnstock G. An introduction to the roles of purinergic signalling in neurodegeneration, neuroprotection and neuroregeneration. Neuropharmacology. 2016 May;104:4-17. doi: 10.1016/j.neuropharm.2015.05.031. Epub 2015 Jun 6. Review. PubMed PMID: 26056033."

>  <ID<1>>
T20731

$$$$
StarDrop ID 487
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 1.4289 -7.4250 0.0000 0
M  V30 2 C 2.1434 -7.8375 0.0000 0
M  V30 3 C 2.8579 -7.4250 0.0000 0
M  V30 4 C 3.5724 -7.8375 0.0000 0
M  V30 5 C 3.5724 -8.6625 0.0000 0
M  V30 6 C 2.8579 -9.0750 0.0000 0
M  V30 7 C 2.1434 -8.6625 0.0000 0
M  V30 8 C 1.4289 -9.0750 0.0000 0
M  V30 9 O 0.7145 -8.6625 0.0000 0
M  V30 10 C 4.2868 -9.0750 0.0000 0
M  V30 11 O 4.2868 -9.9000 0.0000 0
M  V30 12 C 5.0013 -8.6625 0.0000 0
M  V30 13 N 5.7158 -9.0750 0.0000 0
M  V30 14 C 6.4302 -8.6625 0.0000 0
M  V30 15 C 7.1447 -9.0750 0.0000 0
M  V30 16 C 7.8592 -8.6625 0.0000 0
M  V30 17 C 8.5737 -9.0750 0.0000 0
M  V30 18 C 9.2881 -8.6625 0.0000 0
M  V30 19 C 10.0026 -9.0750 0.0000 0
M  V30 20 O 10.7171 -8.6625 0.0000 0
M  V30 21 C 11.4315 -9.0750 0.0000 0
M  V30 22 C 12.1460 -8.6625 0.0000 0
M  V30 23 C 12.8605 -9.0750 0.0000 0
M  V30 24 C 13.5749 -8.6625 0.0000 0
M  V30 25 C 14.2894 -9.0750 0.0000 0
M  V30 26 C 15.0039 -8.6625 0.0000 0
M  V30 27 C 15.7184 -9.0750 0.0000 0
M  V30 28 C 15.7184 -9.9000 0.0000 0
M  V30 29 C 15.0039 -10.3125 0.0000 0
M  V30 30 C 14.2894 -9.9000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 5 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 2 26 27
M  V30 28 1 27 28
M  V30 29 2 28 29
M  V30 30 1 29 30
M  V30 31 2 25 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
487

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Salmeterol

>  <Synonyms>
GR33343X

>  <CAS>
89365-50-4

>  <Formula>
C25H37NO4

>  <MolWt>
415.6

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
Adrenergic Receptor; ??2-adrenoceptor

>  <Bioactivity>
Salmeterol is a long-acting agonist of beta2-adrenergic receptor (beta 2AR) used for treatment ofasthma.

>  <Reference>
"Rong, Y., et al., Probing the salmeterol binding site on the beta 2-adrenergic receptor using a novel photoaffinity ligand, [(125)I]iodoazidosalmeterol. Biochemistry, 1999. 38(35): p. 11278-86."

>  <ID<1>>
T12829

$$$$
StarDrop ID 488
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 3.0716 -1.6005 0.0000 0
M  V30 2 C 3.0716 -0.7755 0.0000 0
M  V30 3 N 2.3571 -0.3630 0.0000 0
M  V30 4 C 3.7861 -0.3630 0.0000 0
M  V30 5 C 3.7861 0.4620 0.0000 0
M  V30 6 C 4.5006 0.8745 0.0000 0
M  V30 7 C 5.2150 0.4620 0.0000 0
M  V30 8 O 5.9295 0.8745 0.0000 0
M  V30 9 C 6.6440 0.4620 0.0000 0
M  V30 10 C 7.3584 0.8745 0.0000 0
M  V30 11 C 8.0729 0.4620 0.0000 0
M  V30 12 C 8.7874 0.8745 0.0000 0
M  V30 13 C 9.5019 0.4620 0.0000 0
M  V30 14 O 10.2163 0.8745 0.0000 0
M  V30 15 C 10.9308 0.4620 0.0000 0
M  V30 16 C 11.6453 0.8745 0.0000 0
M  V30 17 C 12.3597 0.4620 0.0000 0
M  V30 18 C 12.3597 -0.3630 0.0000 0
M  V30 19 C 11.6453 -0.7755 0.0000 0
M  V30 20 C 10.9308 -0.3630 0.0000 0
M  V30 21 C 13.0742 -0.7755 0.0000 0
M  V30 22 N 13.7887 -0.3630 0.0000 0
M  V30 23 N 13.0742 -1.6005 0.0000 0
M  V30 24 C 5.2150 -0.3630 0.0000 0
M  V30 25 C 4.5006 -0.7755 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 15 20
M  V30 21 1 18 21
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 7 24
M  V30 25 2 24 25
M  V30 26 1 4 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
488

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pentamidine dihydrochloride

>  <Synonyms>
MP-601205 dihydrochloride

>  <CAS>
50357-45-4

>  <Formula>
C19H25ClN4O2

>  <MolWt>
376.9

>  <Pathways>
Metabolism;Microbiology/Virology

>  <Target>
Antifungal;Antibacterial;Parasite;Phosphatase;Antibiotic

>  <Receptor>
 Leishmania infantum:2.5 ??M

>  <Bioactivity>
"Pentamidine dihydrochloride is an aromatic diamidine agent with activity against a number of microorganisms including protozoa (Trypanosoma brucei, Leishmania spp., and Babesia spp.) and fungi (Pneumocystis jirovecii). Pentamidine dihydrochloride is a potent and selective protein tyrosine phosphatases and phosphatase of regenerating liver inhibitor. Pentamidine dihydrochloride inhibits parasite Leishmania infantum with an IC50 of 2.5 ??M."

>  <Reference>
"Sands M, et al. Pentamidine: a review. Rev Infect Dis. 1985 Sep-Oct;7(5):625-34.;Nguewa, P.A., et al., Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin. Chem Biodivers, 2005. 2(10): p. 1387-400.;David C. Bean, et al. Pentamidine: a drug to consider re-purposing in the targeted treatment of multi-drug resistant bacterial infections? J Lab Precis Med 2017;2:49.;Pathak MK, et al. Pentamidine is an inhibitor of PRL phosphatases with anticancer activity. Mol Cancer Ther. 2002 Dec;1(14):1255-64."

>  <ID<1>>
T23132

$$$$
StarDrop ID 489
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 1.3693 -1.7840 0.0000 0
M  V30 2 C 2.0367 -1.2991 0.0000 0
M  V30 3 N 2.7041 -1.7840 0.0000 0
M  V30 4 C 2.4492 -2.5687 0.0000 0
M  V30 5 C 1.6242 -2.5687 0.0000 0
M  V30 6 C 2.0367 -0.4741 0.0000 0
M  V30 7 C 2.7512 -0.0616 0.0000 0
M  V30 8 C 2.7512 0.7634 0.0000 0
M  V30 9 C 3.4656 1.1759 0.0000 0
M  V30 10 C 4.1801 0.7634 0.0000 0
M  V30 11 C 4.1801 -0.0616 0.0000 0
M  V30 12 C 3.4656 -0.4741 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 1 5
M  V30 6 1 2 6
M  V30 7 1 6 7
M  V30 8 1 7 8
M  V30 9 2 8 9
M  V30 10 1 9 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 7 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
489

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tolazoline

>  <Synonyms>
Benzalolin;Priscol;Divascol;Vasimid;Pridazole;Priscoline

>  <CAS>
59-98-3

>  <Formula>
C10H12N2

>  <MolWt>
160.2

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
??-adrenergic receptor

>  <Bioactivity>
"Tolazoline, a non-selective competitive ??-adrenergic receptor antagonist, is used as a vasodilator to treat spasms of peripheral blood vessels. It has also been used successfully as an antidote to reverse the severe peripheral vasoconstriction as a result of overdose with certain 5-HT2A agonist drugs."

>  <Reference>
"Casbeer HC, Knych HK. Pharmacokinetics and pharmacodynamic effects of tolazoline following intravenous administration to horses. Vet J. 2013 Jun;196(3):504-9.;Contreras CD, Ledesma AE, Zinczuk J, Brand??n SA. Vibrational study of tolazoline hydrochloride by using FTIR-Raman and DFT calculations. Spectrochim Acta A Mol Biomol Spectrosc. 2011 Sep;79(5):1710-4.;Mortenson JA, Robison JA. Tolazoline-induced apnea in mule deer (Odocoileus hemionus). J Zoo Wildl Med. 2011 Mar;42(1):105-7.;Yokota S, Hikasa Y, Shimura I, Kusunose S. Effects of imidazoline and nonimidazoline alpha-adrenergic agents, including xylazine, medetomidine, yohimbine, tolazoline, and atipamezole, on aggregation of bovine and equine platelets. Am J Vet Res. 2013 Mar;74(3):395-402."

>  <ID<1>>
T21447

$$$$
StarDrop ID 490
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 24 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 S -1.4534 -0.6979 0.0000 0
M  V30 2 C -1.8659 0.0165 0.0000 0
M  V30 3 C -2.6909 0.0165 0.0000 0
M  V30 4 C -3.1034 -0.6979 0.0000 0
M  V30 5 C -2.6909 -1.4124 0.0000 0
M  V30 6 C -3.9284 -0.6979 0.0000 0
M  V30 7 O -4.3409 -1.4124 0.0000 0
M  V30 8 C -5.1659 -1.4124 0.0000 0
M  V30 9 C -4.3409 0.0165 0.0000 0
M  V30 10 C -5.1659 0.0165 0.0000 0
M  V30 11 C -3.9284 0.7310 0.0000 0
M  V30 12 N -3.1034 0.7310 0.0000 0
M  V30 13 O -1.8659 -1.4124 0.0000 0
M  V30 14 C -0.6284 -0.6979 0.0000 0
M  V30 15 N -0.1435 -1.3654 0.0000 0
M  V30 16 C 0.6411 -1.1104 0.0000 0
M  V30 17 C 0.6411 -0.2854 0.0000 0
M  V30 18 N -0.1435 -0.0305 0.0000 0
M  V30 19 C 1.3556 0.1271 0.0000 0
M  V30 20 C 2.0701 -0.2854 0.0000 0
M  V30 21 C 2.0701 -1.1104 0.0000 0
M  V30 22 O 2.7845 -1.5229 0.0000 0
M  V30 23 C 3.4990 -1.1104 0.0000 0
M  V30 24 C 1.3556 -1.5229 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 4 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 6 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 3 12
M  V30 13 2 1 13
M  V30 14 1 1 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 14 18
M  V30 20 2 17 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 1 22 23
M  V30 25 1 21 24
M  V30 26 2 16 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
490

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Esomeprazole

>  <Synonyms>
N/A

>  <CAS>
119141-88-7

>  <Formula>
C17H19N3O3S

>  <MolWt>
345.4

>  <Pathways>
Membrane transporter/Ion channel;Proteases/Proteasome

>  <Target>
Cysteine Protease;Proton pump

>  <Receptor>
lysosomal cysteine protease; Proton pump

>  <Bioactivity>
"Esomeprazole is the S-isomer of omeprazole, inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis. Esomeprazole is a proton pump inhibitors (PPI)."

>  <Reference>
"Zhao T, et al. Esomeprazole inhibits the lysosomal cysteine protease legumain to prevent cancer metastasis. Invest New Drugs. 2021 Apr;39(2):337-347.;Jankowski JAZ, et al. Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. Lancet. 2018 Aug 4;392(10145):400-408.;Vachhani R, et al. Esomeprazole: a proton pump inhibitor. Expert Rev Gastroenterol Hepatol. 2009 Feb;3(1):15-27.;Qi Q,et al. Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis. Int J Clin Pharmacol Ther. 2015 Oct;53(10):803-10."

>  <ID<1>>
T20626

$$$$
StarDrop ID 491
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.4843 -2.1229 0.0000 0
M  V30 2 N -4.4843 -1.2979 0.0000 0
M  V30 3 C -5.1987 -0.8854 0.0000 0
M  V30 4 C -3.7698 -0.8854 0.0000 0
M  V30 5 C -3.7698 -0.0604 0.0000 0
M  V30 6 C -3.0553 0.3521 0.0000 0
M  V30 7 C -2.3408 -0.0604 0.0000 0
M  V30 8 N -1.6264 0.3521 0.0000 0 CHG=1
M  V30 9 C -1.6264 1.1771 0.0000 0
M  V30 10 C -0.9119 -0.0604 0.0000 0
M  V30 11 C -0.1974 0.3521 0.0000 0
M  V30 12 C 0.5170 -0.0604 0.0000 0
M  V30 13 C 1.2315 0.3521 0.0000 0
M  V30 14 C 1.3177 1.1726 0.0000 0
M  V30 15 C 2.1247 1.3441 0.0000 0
M  V30 16 C 2.4603 2.0978 0.0000 0
M  V30 17 N 2.5372 0.6297 0.0000 0
M  V30 18 C 1.9852 0.0166 0.0000 0
M  V30 19 C 2.1567 -0.7904 0.0000 0
M  V30 20 C 3.3577 0.5434 0.0000 0
M  V30 21 C 3.8426 1.2109 0.0000 0
M  V30 22 C 4.6631 1.1246 0.0000 0
M  V30 23 C 4.9987 0.3710 0.0000 0
M  V30 24 C 4.5137 -0.2965 0.0000 0
M  V30 25 C 3.6933 -0.2102 0.0000 0
M  V30 26 C -0.9119 -0.8854 0.0000 0
M  V30 27 C -1.6264 -1.2979 0.0000 0
M  V30 28 C -2.3408 -0.8854 0.0000 0
M  V30 29 C -3.0553 -1.2979 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 11 10
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 2 13 18
M  V30 19 1 18 19
M  V30 20 1 17 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 23 24
M  V30 25 2 24 25
M  V30 26 1 20 25
M  V30 27 1 10 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 1 7 28
M  V30 31 2 28 29
M  V30 32 1 4 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
491

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pyrvinium pamoate

>  <Synonyms>
Pyrvinium embonate

>  <CAS>
3546-41-6

>  <Formula>
C75H70N6O6

>  <MolWt>
1151

>  <Pathways>
Cytoskeletal Signaling;Stem Cells

>  <Target>
Wnt/beta-catenin

>  <Receptor>
Wnt

>  <Bioactivity>
"Pyrvinium pamoate is an old anthelminthic medicine for the treatment of enterobiasis , which re-attracts attention as an anti-cancer drug due to its inhibition of Wnt/??-catenin pathway in some types of cancer."

>  <Reference>
"Zheng L , Liu Y , Pan J . Inhibitory effect of pyrvinium pamoate on uveal melanoma cells involves blocking of Wnt/??-catenin pathway[J].2017(49):898.;Xu F , Zhu Y , Lu Y , et al. Anthelmintic pyrvinium pamoate blocks Wnt/??-catenin and induces apoptosis in multiple myeloma cells[J]. Oncology Letters, 2018."

>  <ID<1>>
T7333

$$$$
StarDrop ID 492
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 23 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.3501 -2.4848 0.0000 0
M  V30 2 C 6.1602 -2.6407 0.0000 0
M  V30 3 N 6.7003 -2.0171 0.0000 0
M  V30 4 C 6.4302 -1.2375 0.0000 0
M  V30 5 C 6.9703 -0.6139 0.0000 0
M  V30 6 C 7.5104 -2.1730 0.0000 0
M  V30 7 C 8.0505 -1.5493 0.0000 0
M  V30 8 C 8.8606 -1.7052 0.0000 0
M  V30 9 C 9.4007 -1.0816 0.0000 0
M  V30 10 C 9.1307 -0.3020 0.0000 0
M  V30 11 N 10.2109 -1.2375 0.0000 0
M  V30 12 C 10.7510 -0.6139 0.0000 0
M  V30 13 C 10.4809 0.1657 0.0000 0
M  V30 14 C 11.0210 0.7893 0.0000 0
M  V30 15 N 11.8311 0.6334 0.0000 0
M  V30 16 C 12.1012 -0.1461 0.0000 0
M  V30 17 C 12.9113 -0.3020 0.0000 0
M  V30 18 C 13.1814 -1.0816 0.0000 0
M  V30 19 Cl 13.9915 -1.2375 0.0000 0
M  V30 20 C 12.6413 -1.7052 0.0000 0
M  V30 21 C 11.8311 -1.5493 0.0000 0
M  V30 22 C 11.5611 -0.7698 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 3 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 18 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 12 22
M  V30 23 1 16 22
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
492

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Chloroquine

>  <Synonyms>
N/A

>  <CAS>
54-05-7

>  <Formula>
C18H26ClN3

>  <MolWt>
319.9

>  <Pathways>
Immunology/Inflammation;Autophagy;Proteases/Proteasome;Microbiology/Virology

>  <Target>
SARS-CoV;TLR;HIV Protease;Antibiotic;Autophagy;Parasite

>  <Receptor>
Antibiotic; autophagy; HIV; HIV-1; Parasite; SARS-CoV; SARS-COV-2; TLR

>  <Bioactivity>
Chloroquine is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro with EC50 of 1.13 ??M.

>  <Reference>
"Tuomela J, et al. Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer. Oncol Lett. 2013 Dec;6(6):1665-1672.;Said A, et al. Chloroquine promotes IL-17 production by CD4+ T cells via p38-dependent IL-23 release by monocyte-derived Langerhans-like cells. J Immunol. 2014 Dec 15;193(12):6135-43.;Chen J, Li J, Chen J, et al. Treatment of collagen-induced arthritis rat model by using Notch signalling inhibitor[J]. Journal of Orthopaedic Translation. 2021, 28: 100-107.;Xu C, Zhao W, Huang X, et al. TORC2/3-mediated DUSP1 upregulation is essential for human decidualization[J]. Reproduction. 2021, 1(aop).;Pan X, Li R, Guo H, et al. Dihydropyridine Calcium Channel Blockers Suppress the Transcription of PD-L1 by Inhibiting the Activation of STAT1[J]. Frontiers in Pharmacology. 2021, 11: 2233.;Wang M, Xu Y, Zhang Y, et al. Deciphering the autophagy regulatory network via single-cell transcriptome analysis reveals a requirement for autophagy homeostasis in spermatogenesis[J]. Theranostic. 2021, 11(10): 5010.;Mohamed FE, et al. Effect of toll-like receptor 7 and 9 targeted therapy to prevent the development of hepatocellular carcinoma. Liver Int. 2014 Jul 2. doi: 10.1111/liv.12626.;Su G, Yang W, Wang S, et al. SIRT1-autophagy axis inhibits excess iron-induced ferroptosis of foam cells and subsequently increases IL-1?? and IL-18[J]. Biochemical and Biophysical Research Communications. 2021, 561: 33-39."

>  <ID<1>>
T8689

$$$$
StarDrop ID 493
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 22 22 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.1914 -0.9355 0.0000 0
M  V30 2 C -0.6336 -0.9355 0.0000 0
M  V30 3 C -1.0461 -0.2211 0.0000 0
M  V30 4 C -0.6336 0.4934 0.0000 0
M  V30 5 C 0.1914 0.4934 0.0000 0
M  V30 6 C 0.6039 -0.2211 0.0000 0
M  V30 7 C 1.4289 -0.2211 0.0000 0 CFG=2
M  V30 8 C 1.8414 -0.9355 0.0000 0 CFG=1
M  V30 9 C 1.4289 -1.6500 0.0000 0
M  V30 10 O 0.6039 -1.6500 0.0000 0
M  V30 11 N 2.6664 -0.9355 0.0000 0
M  V30 12 C 3.0789 -1.6500 0.0000 0
M  V30 13 O 2.6664 -2.3645 0.0000 0
M  V30 14 C 3.9039 -1.6500 0.0000 0
M  V30 15 Cl 4.3164 -2.3645 0.0000 0
M  V30 16 Cl 4.3164 -0.9355 0.0000 0
M  V30 17 O 1.8414 0.4934 0.0000 0
M  V30 18 N -1.8711 -0.2211 0.0000 0
M  V30 19 O -2.2836 -0.9355 0.0000 0
M  V30 20 O -2.2836 0.4934 0.0000 0
M  V30 21 H 2.4289 -0.2210 0.0000 0
M  V30 22 H 2.3414 -0.0695 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 1 6
M  V30 7 1 7 6
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 8 11 CFG=3
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 1 7 17 CFG=1
M  V30 18 1 3 18
M  V30 19 2 18 19
M  V30 20 2 18 20
M  V30 21 1 21 7
M  V30 22 1 22 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
493

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Chloramphenicol succinate sodium

>  <Synonyms>
Chloramphenicol sodium succinate

>  <CAS>
982-57-0

>  <Formula>
C15H15Cl2N2NaO8

>  <MolWt>
445.2

>  <Pathways>
Microbiology/Virology;Others

>  <Target>
Antibiotic;Others;Antibacterial

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
Chloramphenicol sodium succinate is broad-spectrum antibiotic with antibacterial activity.

>  <Reference>
"Ambekar C S , Lee J S K , Cheung B M Y , et al. Chloramphenicol succinate, a competitive substrate and inhibitor of succinate dehydrogenase: possible reason for its toxicity[J]. Toxicology in Vitro, 2004, 18(4):0-447.;Ambrose D P J . Clinical Pharmacokinetics of Chloramphenicol and Chloramphenicol Succinate[J]. Clinical Pharmacokinetics, 1984, 9(3):222-238."

>  <ID<1>>
T8258

$$$$
StarDrop ID 494
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N -1.8259 -0.3208 0.0000 0
M  V30 2 C -1.1114 0.0917 0.0000 0
M  V30 3 N -0.3969 -0.3208 0.0000 0
M  V30 4 C 0.3175 0.0917 0.0000 0
M  V30 5 N 1.0320 -0.3208 0.0000 0
M  V30 6 C 1.7465 0.0917 0.0000 0
M  V30 7 C 1.0320 -1.1458 0.0000 0
M  V30 8 N 0.3175 0.9167 0.0000 0
M  V30 9 N -1.1114 0.9167 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 4 8
M  V30 8 1 2 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
494

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Metformin

>  <Synonyms>
1,1-Dimethylbiguanide

>  <CAS>
657-24-9

>  <Formula>
C4H12ClN5

>  <MolWt>
129.2

>  <Pathways>
Autophagy;Chromatin/Epigenetic;PI3K/Akt/mTOR signaling

>  <Target>
Autophagy;Mitophagy;AMPK

>  <Receptor>
AMPK; Autophagy; Mitophagy

>  <Bioactivity>
Metformin is an AMP-activated protein kinase (AMPK) activator that improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose.

>  <Reference>
"Jia Y, Cui R, Wang C, et al. Metformin protects against intestinal ischemia-reperfusion injury and cell pyroptosis via TXNIP-NLRP3-GSDMD pathway[J]. Redox Biology. 2020: 101534.;Soraya H, et al. Acute treatment with metformin improves cardiac function following isoproterenol induced myocardial infarction in rats. Pharmacol Rep. 2012;64(6):1476-84.;Quaile M P , Melich D H , Jordan H L , et al. Toxicity and toxicokinetics of metformin in rats[J]. Toxicology & Applied Pharmacology, 2010, 243(3):340-347.;Xue J, et al. Metformin inhibits growth of eutopic stromal cells from adenomyotic endometrium via AMPK activation and subsequent inhibition of AKT phosphorylation: a possible role in the treatment of adenomyosis. Reproduction. 2013 Aug 21;146(4):397-406.;Chen H, Sa G, He S, et al. In vitro and in vivo synergistic anti-tumor effect of LIN28 inhibitor and metformin in oral squamous cell carcinoma[J]. European Journal of Pharmacology. 2020: 173757."

>  <ID<1>>
T8526

$$$$
StarDrop ID 495
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.8579 -4.1250 0.0000 0
M  V30 2 C 2.1434 -3.7125 0.0000 0
M  V30 3 N 2.1434 -2.8875 0.0000 0
M  V30 4 C 1.4289 -2.4750 0.0000 0
M  V30 5 C 0.7145 -2.8875 0.0000 0
M  V30 6 F 0.0000 -2.4750 0.0000 0
M  V30 7 C 0.7145 -3.7125 0.0000 0
M  V30 8 C 1.4289 -4.1250 0.0000 0
M  V30 9 F 1.4289 -4.9500 0.0000 0
M  V30 10 N 1.4289 -1.6500 0.0000 0
M  V30 11 C 0.7145 -1.2375 0.0000 0
M  V30 12 C 0.7145 -0.4125 0.0000 0
M  V30 13 C 0.0000 0.0000 0.0000 0
M  V30 14 O 0.0000 0.8250 0.0000 0
M  V30 15 O -0.7145 -0.4125 0.0000 0
M  V30 16 C 1.4289 0.0000 0.0000 0
M  V30 17 O 1.4289 0.8250 0.0000 0
M  V30 18 C 2.1434 -0.4125 0.0000 0
M  V30 19 C 2.8579 0.0000 0.0000 0
M  V30 20 C 3.5724 -0.4125 0.0000 0
M  V30 21 F 4.2868 -0.0000 0.0000 0
M  V30 22 C 3.5724 -1.2375 0.0000 0
M  V30 23 N 4.2868 -1.6500 0.0000 0
M  V30 24 C 5.0837 -1.4365 0.0000 0
M  V30 25 C 5.2972 -2.2334 0.0000 0
M  V30 26 O 6.0117 -2.6459 0.0000 0
M  V30 27 C 4.5004 -2.4469 0.0000 0
M  V30 28 C 2.8579 -1.6500 0.0000 0
M  V30 29 Cl 2.8579 -2.4750 0.0000 0
M  V30 30 C 2.1434 -1.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 2 7 8
M  V30 8 1 2 8
M  V30 9 1 8 9
M  V30 10 1 4 10
M  V30 11 1 10 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 13 14
M  V30 15 2 13 15
M  V30 16 1 12 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 20 21
M  V30 22 2 20 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 25 27
M  V30 28 1 23 27
M  V30 29 1 22 28
M  V30 30 1 28 29
M  V30 31 2 28 30
M  V30 32 1 10 30
M  V30 33 1 18 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
495

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Delafloxacin

>  <Synonyms>
RX-3341;WQ-3034;ABT492

>  <CAS>
189279-58-1

>  <Formula>
C18H12ClF3N4O4

>  <MolWt>
440.8

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial;Antibiotic

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
"Delafloxacin (RX-3341, ABT-492) is a fluoroquinolone antibiotic agent. It has potent inhibitory against levofloxacin-resistant Streptococcus pneumoniae strains (MIC: 0.0078-0.125 ??g/ml)."

>  <Reference>
"Gunderson SM, Hayes RA, Quinn JP, In vitro pharmacodynamic activities of ABT-492, a novel quinolone, compared to those of levofloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 2004 Jan;48(1):203-8.;Goldstein EJ, Citron DM, Merriam CV, In vitro activities of ABT-492, a new fluoroquinolone, against 155 aerobic and 171 anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis. Antimicrob Agents Chemother. 2003 Sep;47(9):32008-11.;Nilius AM, Shen LL, Hensey-Rudloff D, In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother. 2003 Oct;47(10):3260-9."

>  <ID<1>>
T4063

$$$$
StarDrop ID 496
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 28 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -4.3825 -4.6184 0.0000 0
M  V30 2 O -3.5575 -4.6184 0.0000 0
M  V30 3 C -3.1450 -3.9039 0.0000 0
M  V30 4 C -3.5575 -3.1895 0.0000 0
M  V30 5 C -3.1450 -2.4750 0.0000 0
M  V30 6 N -2.3200 -2.4750 0.0000 0
M  V30 7 C -1.9075 -3.1895 0.0000 0
M  V30 8 C -1.0825 -3.1895 0.0000 0
M  V30 9 S -0.6700 -2.4750 0.0000 0
M  V30 10 O -1.0825 -1.7605 0.0000 0
M  V30 11 C 0.1550 -2.4750 0.0000 0
M  V30 12 N 0.6399 -1.8076 0.0000 0
M  V30 13 C 1.4245 -2.0625 0.0000 0
M  V30 14 C 2.1390 -1.6500 0.0000 0
M  V30 15 C 2.8534 -2.0625 0.0000 0
M  V30 16 O 3.5679 -1.6500 0.0000 0
M  V30 17 C 4.2824 -2.0625 0.0000 0
M  V30 18 F 4.9969 -1.6500 0.0000 0
M  V30 19 F 4.2824 -2.8875 0.0000 0
M  V30 20 C 2.8534 -2.8875 0.0000 0
M  V30 21 C 2.1390 -3.3000 0.0000 0
M  V30 22 C 1.4245 -2.8875 0.0000 0
M  V30 23 N 0.6399 -3.1424 0.0000 0 CHG=-1
M  V30 24 C -2.3200 -3.9039 0.0000 0
M  V30 25 O -1.9075 -4.6184 0.0000 0
M  V30 26 C -2.3200 -5.3329 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 2 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 17 19
M  V30 19 2 15 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 13 22
M  V30 23 1 22 23
M  V30 24 1 11 23
M  V30 25 2 7 24
M  V30 26 1 3 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
496

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pantoprazole Sodium Hydrate

>  <Synonyms>
SKF96022 sodium hydrate;SKF96022 (sodium hydrate);BY1023 (sodium hydrate)

>  <CAS>
164579-32-2

>  <Formula>
C16H16F2N3NaO5S

>  <MolWt>
423.4

>  <Pathways>
Autophagy;Membrane transporter/Ion channel;Apoptosis

>  <Target>
Autophagy;Apoptosis;Potassium Channel;Proton pump

>  <Receptor>
Apoptosis; Autophagy; Potassium-transporting ATPase; Proton pump

>  <Bioactivity>
"Pantoprazole is a proton pump inhibitor drug, used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease."

>  <Reference>
"Cheer SM, et al. Drugs. 2003; 63(1):101-33."

>  <ID<1>>
T0161

$$$$
StarDrop ID 497
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 26 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 6.2847 -1.6797 0.0000 0
M  V30 2 C 5.9674 -2.4413 0.0000 0
M  V30 3 C 6.4876 -3.0973 0.0000 0
M  V30 4 C 6.1761 -3.8629 0.0000 0
M  V30 5 C 5.3514 -3.9492 0.0000 0
M  V30 6 C 5.0523 -4.6979 0.0000 0
M  V30 7 C 4.2341 -4.7084 0.0000 0 CFG=1
M  V30 8 N 3.6903 -5.2965 0.0000 0
M  V30 9 C 3.8279 -6.1099 0.0000 0
M  V30 10 C 3.1923 -6.6358 0.0000 0
M  V30 11 C 3.3300 -7.4493 0.0000 0
M  V30 12 C 2.9690 -4.9124 0.0000 0
M  V30 13 C 3.1117 -4.0251 0.0000 0
M  V30 14 C 3.9566 -3.4263 0.0000 0 CFG=1
M  V30 15 C 3.7418 -2.5948 0.0000 0 CFG=1
M  V30 16 O 4.4073 -2.0920 0.0000 0
M  V30 17 C 5.1190 -2.5356 0.0000 0
M  V30 18 C 4.8284 -3.3032 0.0000 0
M  V30 19 C 2.9160 -2.4345 0.0000 0
M  V30 20 O 2.6606 -1.6500 0.0000 0
M  V30 21 C 2.3571 -3.0350 0.0000 0
M  V30 22 C 2.6697 -3.7759 0.0000 0
M  V30 23 C 3.6435 -3.9229 0.0000 0 CFG=1
M  V30 24 O 3.2208 -4.6314 0.0000 0
M  V30 25 H 3.2489 -4.5370 0.0000 0
M  V30 26 H 4.6786 -2.9446 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 7 6
M  V30 7 1 7 8 CFG=1
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 8 12
M  V30 12 1 12 13
M  V30 13 1 14 13
M  V30 14 1 14 15
M  V30 15 1 15 16 CFG=3
M  V30 16 1 16 17
M  V30 17 1 2 17
M  V30 18 2 17 18
M  V30 19 1 5 18
M  V30 20 1 14 18 CFG=1
M  V30 21 1 15 19
M  V30 22 2 19 20
M  V30 23 1 19 21
M  V30 24 1 21 22
M  V30 25 1 23 22
M  V30 26 1 23 7
M  V30 27 1 14 23
M  V30 28 1 23 24 CFG=1
M  V30 29 1 25 7
M  V30 30 1 26 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
497

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Naloxone HCl Dihydrate

>  <Synonyms>
Naloxone hydrochloride dihydrate

>  <CAS>
51481-60-8

>  <Formula>
C19H26ClNO6

>  <MolWt>
399.9

>  <Pathways>
GPCR/G Protein;Endocrinology/Hormones;Neuroscience

>  <Target>
Opioid Receptor

>  <Receptor>
Opioid receptor

>  <Bioactivity>
Naloxone HCl Dihydrate is an opioid inverse agonist drug used to counter the effects of opiate overdose.

>  <Reference>
"Codd EE, et al. J Pharmacol Exp Ther.1995, 274(3), 1263-70.;Berrocoso E, et al. Psychopharmacology (Berl).2007, 193(1), 97-105."

>  <ID<1>>
T6902

$$$$
StarDrop ID 498
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.2375 0.7145 0.0000 0
M  V30 2 C 0.8250 0.0000 0.0000 0
M  V30 3 C 0.0000 0.0000 0.0000 0
M  V30 4 C -0.4125 -0.7145 0.0000 0
M  V30 5 O -1.2375 -0.7145 0.0000 0
M  V30 6 O 0.0000 -1.4289 0.0000 0
M  V30 7 O 2.0625 0.7145 0.0000 0
M  V30 8 C 2.4750 1.4289 0.0000 0
M  V30 9 O 0.8250 1.4289 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 4 6
M  V30 6 1 1 7
M  V30 7 1 7 8
M  V30 8 2 1 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
498

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Monomethyl fumarate

>  <Synonyms>
N/A

>  <CAS>
2756-87-8

>  <Formula>
C5H6O4

>  <MolWt>
130.1

>  <Pathways>
GPCR/G Protein;Metabolism;Endocrinology/Hormones

>  <Target>
GPR;Drug Metabolite

>  <Receptor>
Drug Metabolite; GPR109A

>  <Bioactivity>
Monomethyl fumarate is a potent agonist of GPR109A .

>  <Reference>
"Tang H, et al. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun. 2008 Oct 31;375(4):562-5.;Sghaier R, et al. Dimethyl fumarate and monomethyl fumarate attenuate oxidative stress and mitochondrialalterations leading to oxiapoptophagy in 158N murine oligodendrocytes treated with 7??-hydroxycholesterol. J Steroid Biochem Mol Biol. 2019 Nov;194:105432.;Jiang D, et al. Monomethyl Fumarate Protects the Retina From Light-Induced Retinopathy. Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1275-1285."

>  <ID<1>>
T12095

$$$$
StarDrop ID 499
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 0.5230 -0.5230 0.0000 0
M  V30 2 C 1.2375 -0.1105 0.0000 0
M  V30 3 O 1.2375 0.7145 0.0000 0
M  V30 4 C 1.9520 1.1270 0.0000 0
M  V30 5 C 1.9520 1.9520 0.0000 0
M  V30 6 F 1.9520 2.7770 0.0000 0
M  V30 7 F 2.7770 1.9520 0.0000 0
M  V30 8 F 1.1270 1.9520 0.0000 0
M  V30 9 C 2.6664 0.7145 0.0000 0
M  V30 10 F 2.2539 0.0000 0.0000 0
M  V30 11 F 3.0789 1.4289 0.0000 0
M  V30 12 F 3.3809 0.3020 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 5 8
M  V30 8 1 4 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 9 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
499

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Sevoflurane

>  <Synonyms>
Fluoromethyl

>  <CAS>
28523-86-6

>  <Formula>
C4H3F7O

>  <MolWt>
200.1

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
5-HT Receptor

>  <Receptor>
5-HT3

>  <Bioactivity>
"Sevoflurane, a noncompetitive inhibitor of 5-HT3 receptor, acts as a low-soluble inhalation anesthetics."

>  <Reference>
"Sakai EM,et al. Pharmacotherapy. 2005 Dec;25(12):1773-88."

>  <ID<1>>
T22425

$$$$
StarDrop ID 500
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 8 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.2382 1.7138 0.0000 0
M  V30 2 C 0.2382 0.8888 0.0000 0
M  V30 3 O 0.6507 0.1743 0.0000 0
M  V30 4 C -0.1743 0.1743 0.0000 0
M  V30 5 P -0.8888 -0.2382 0.0000 0
M  V30 6 O -1.6033 -0.6507 0.0000 0
M  V30 7 O -0.4763 -0.9526 0.0000 0
M  V30 8 O -1.3013 0.4763 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 2 4
M  V30 5 1 4 5
M  V30 6 1 5 6
M  V30 7 1 5 7
M  V30 8 2 5 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
500

>  <Plate>
PHD136329

>  <Row>
i

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fosfomycin sodium

>  <Synonyms>
Fosfomycin Disodium

>  <CAS>
26016-99-9

>  <Formula>
C3H5Na2O4P

>  <MolWt>
182

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibacterial; Antibiotic; Bacterial

>  <Bioactivity>
"Fosfomycin is a bactericidal, low-molecular weight, broad-spectrum antibiotic, with putative activity against several bacteria, including multidrug-resistant Gram-negative bacteria, by irreversibly inhibiting an early stage in cell wall synthesis."

>  <Reference>
"Dijkmans AC, et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics (Basel). 2017 Oct 31;6(4). pii: E24."

>  <ID<1>>
T8262

$$$$
StarDrop ID 501
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 15 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.8517 -2.4835 0.0000 0
M  V30 2 C 0.8517 -1.6585 0.0000 0
M  V30 3 C 0.1163 -2.0322 0.0000 0
M  V30 4 C 0.5657 -1.2419 0.0000 0
M  V30 5 C 1.3012 -1.6156 0.0000 0
M  V30 6 C 2.0368 -1.2419 0.0000 0
M  V30 7 C 2.8344 -1.4529 0.0000 0
M  V30 8 C 1.5873 -2.0322 0.0000 0
M  V30 9 C 2.0368 -0.4945 0.0000 0
M  V30 10 C 1.3012 -0.1208 0.0000 0
M  V30 11 C 1.3012 0.7042 0.0000 0
M  V30 12 C 0.5657 -0.4945 0.0000 0
M  V30 13 C 0.8517 -0.9111 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 2 8
M  V30 9 1 10 13
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 1 4 12
M  V30 14 1 6 9
M  V30 15 1 2 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
501

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Memantine

>  <Synonyms>
N/A

>  <CAS>
19982-08-2

>  <Formula>
C12H21N

>  <MolWt>
179.3

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Memantine, an amantadine derivative with some dopaminergic effects, has been proposed as an antiparkinson agent and has may be used to treat moderate to severe Alzheimer's disease. It acts on the glutamatergic system by blocking NMDA receptors."

>  <Reference>
"Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease. Drug Des Devel Ther. 2016 Oct 3;10:3267-3279. eCollection 2016. Review. PubMed PMID: 27757016; PubMed Central PMCID: PMC5055113.;Greig SL. Memantine ER/Donepezil: A Review in Alzheimer's Disease. CNS Drugs. 2015 Nov;29(11):963-70. doi: 10.1007/s40263-015-0287-Review. PubMed PMID: 26519339.;Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS One. 2015 Apr 10;10(4):e0123289. doi: 10.1371/journal.pone.0123289. eCollection 201Review. PubMed PMID: 25860130; PubMed Central PMCID: PMC4393306.;Chen R, Chan PT, Chu H, Lin YC, Chang PC, Chen CY, Chou KR. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. PLoS One. 2017 Aug 21;12(8):e0183586."

>  <ID<1>>
T20993

$$$$
StarDrop ID 502
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 36 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C -3.4936 -4.1802 0.0000 0
M  V30 2 C -2.9535 -3.5566 0.0000 0
M  V30 3 C -3.2236 -2.7770 0.0000 0
M  V30 4 C -2.1434 -3.7125 0.0000 0
M  V30 5 C -1.8734 -4.4921 0.0000 0 CFG=2
M  V30 6 N -1.0632 -4.6480 0.0000 0
M  V30 7 C -0.5231 -4.0243 0.0000 0
M  V30 8 O -0.7932 -3.2448 0.0000 0
M  V30 9 C 0.2870 -4.1802 0.0000 0
M  V30 10 N 0.8271 -3.5566 0.0000 0
M  V30 11 C 1.6372 -3.7125 0.0000 0
M  V30 12 O 1.9073 -4.4921 0.0000 0
M  V30 13 C 2.1773 -3.0889 0.0000 0
M  V30 14 C 1.9073 -2.3093 0.0000 0
M  V30 15 C 2.4473 -1.6857 0.0000 0
M  V30 16 Cl 2.1773 -0.9061 0.0000 0
M  V30 17 C 3.2575 -1.8416 0.0000 0
M  V30 18 C 3.5275 -2.6211 0.0000 0
M  V30 19 C 2.9874 -3.2448 0.0000 0
M  V30 20 Cl 3.2575 -4.0243 0.0000 0
M  V30 21 B -2.4135 -5.1157 0.0000 0
M  V30 22 O -3.2355 -5.0453 0.0000 0
M  V30 23 C -3.5564 -5.8053 0.0000 0
M  V30 24 O -4.3599 -5.9924 0.0000 0
M  V30 25 C -2.9327 -6.3454 0.0000 0
M  V30 26 C -3.5351 -6.9092 0.0000 0
M  V30 27 C -3.3480 -7.7127 0.0000 0
M  V30 28 O -2.5586 -7.9524 0.0000 0
M  V30 29 O -3.9503 -8.2765 0.0000 0
M  V30 30 C -2.4350 -7.0034 0.0000 0
M  V30 31 C -1.6164 -6.9013 0.0000 0
M  V30 32 O -1.1186 -7.5593 0.0000 0
M  V30 33 O -1.2954 -6.1413 0.0000 0
M  V30 34 O -2.2264 -5.9192 0.0000 0
M  V30 35 H -1.2187 -3.7362 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=3
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 15 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 13 19
M  V30 20 1 19 20
M  V30 21 1 5 21
M  V30 22 1 21 22
M  V30 23 1 22 23
M  V30 24 2 23 24
M  V30 25 1 23 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 2 27 29
M  V30 30 1 25 30
M  V30 31 1 30 31
M  V30 32 1 31 32
M  V30 33 2 31 33
M  V30 34 1 25 34
M  V30 35 1 21 34
M  V30 36 1 35 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
502

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ixazomib citrate

>  <Synonyms>
MLN9708

>  <CAS>
1239908-20-3

>  <Formula>
C20H23BCl2N2O9

>  <MolWt>
517.1

>  <Pathways>
Autophagy;Proteases/Proteasome;Ubiquitination

>  <Target>
Proteasome;Autophagy

>  <Receptor>
" 20S proteasome ??5:3.4 nM , 20S proteasome ??2:3500 nM, 20S proteasome ??1:31 nM "

>  <Bioactivity>
Ixazomib citrate is a prodrug of Ixazomib (MMLN-2238). MLN9708 is an orally bioavailable second generation proteasome inhibitor (IC50 of 3.4 nM ) with potential antineoplastic activity.

>  <Reference>
"Chauhan D, et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011 Aug 15;17(16):5311-21."

>  <ID<1>>
T8397

$$$$
StarDrop ID 503
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 15 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.1434 -0.4125 0.0000 0
M  V30 2 C 2.8579 -0.0000 0.0000 0
M  V30 3 C 3.5724 -0.4125 0.0000 0
M  V30 4 C 4.2868 0.0000 0.0000 0
M  V30 5 C 4.2868 0.8250 0.0000 0
M  V30 6 C 3.5724 1.2375 0.0000 0
M  V30 7 C 2.8579 0.8250 0.0000 0
M  V30 8 C 2.1434 1.2375 0.0000 0
M  V30 9 N 2.1434 2.0625 0.0000 0
M  V30 10 C 1.4289 0.8250 0.0000 0
M  V30 11 C 1.4289 0.0000 0.0000 0
M  V30 12 C 0.7145 -0.4125 0.0000 0
M  V30 13 C 0.0000 -0.0000 0.0000 0
M  V30 14 C 0.0000 0.8250 0.0000 0
M  V30 15 C 0.7145 1.2375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 10 11
M  V30 12 2 1 11
M  V30 13 1 11 12
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 10 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
503

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Tacrine

>  <Synonyms>
CS 12602;Tetrahydroaminocrine;Tacrinum

>  <CAS>
321-64-2

>  <Formula>
C13H14N2

>  <MolWt>
198.3

>  <Pathways>
Neuroscience

>  <Target>
AChR

>  <Receptor>
Cholinergic

>  <Bioactivity>
Tacrine is an indirect cholinergic agonist and centrally acting anticholinesterase. It is approved for the treatment of Alzheimer's disease.

>  <Reference>
"Minarini A, Milelli A, Simoni E, Rosini M, Bolognesi ML, Marchetti C, Tumiatti V. Multifunctional tacrine derivatives in Alzheimer's disease. Curr Top Med Chem. 2013;13(15):1771-86. Review. PubMed PMID: 23931443.;Kor??be?ny J, Spilovsk?? K, Benek O, Mus??lek K, Soukup O, Ku?a K. [Tacrine and its derivatives in the therapy of Alzheimers disease]. Ceska Slov Farm. 2012 Oct;61(5):210-21. Review. Czech. PubMed PMID: 23256654.;Romero A, Cacabelos R, Oset-Gasque MJ, Samadi A, Marco-Contelles J. Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer's disease. Bioorg Med Chem Lett. 2013 Apr 1;23(7):1916-22. doi: 10.1016/j.bmcl.2013.02.017. Epub 2013 Feb 16. Review. PubMed PMID: 23481643.;Ismaili L, Refouvelet B, Benchekroun M, Brogi S, Brindisi M, Gemma S, Campiani G, Filipic S, Agbaba D, Esteban G, Unzeta M, Nikolic K, Butini S, Marco-Contelles J. Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease. Prog Neurobiol. 2016 Jan 18. pii: S0301-0082(15)00162-8. doi: 10.1016/j.pneurobio.2015.12.003. [Epub ahead of print] Review."

>  <ID<1>>
T21439

$$$$
StarDrop ID 504
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 20 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 -0.1954 0.0000 0
M  V30 2 C 3.0716 0.2171 0.0000 0
M  V30 3 C 3.0716 1.0421 0.0000 0
M  V30 4 N 3.7861 -0.1954 0.0000 0
M  V30 5 C 4.5006 0.2171 0.0000 0
M  V30 6 C 5.2150 -0.1954 0.0000 0
M  V30 7 O 5.2150 -1.0204 0.0000 0
M  V30 8 C 5.9295 0.2171 0.0000 0
M  V30 9 O 6.6440 -0.1954 0.0000 0
M  V30 10 C 7.3584 0.2171 0.0000 0
M  V30 11 C 7.3584 1.0421 0.0000 0
M  V30 12 C 8.0729 1.4546 0.0000 0
M  V30 13 C 8.7874 1.0421 0.0000 0
M  V30 14 C 8.7874 0.2171 0.0000 0
M  V30 15 C 9.5019 -0.1954 0.0000 0
M  V30 16 C 9.5019 -1.0204 0.0000 0
M  V30 17 C 8.7874 -1.4329 0.0000 0
M  V30 18 C 8.0729 -1.0204 0.0000 0
M  V30 19 C 8.0729 -0.1954 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 10 19
M  V30 20 1 14 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
504

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Propranolol HCl

>  <Synonyms>
Propranolol hydrochloride;dl-propranolol hcl

>  <CAS>
3506-09-0

>  <Formula>
C16H22ClNO2

>  <MolWt>
295.8

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Adrenergic Receptor

>  <Receptor>
??1-adrenergic receptor; ??2-adrenergic receptor

>  <Bioactivity>
Propranolol hydrochloride is a blocker of ??1 and ??2 adrenergic receptor

>  <Reference>
"Ling Z , Hai-Wei W , Weien Y , et al. Propranolol therapy for infantile hemangioma: our experience[J]. Drug Design Development & Therapy, 2017, 11:1401-1408.;Abdulrahman A Al-Majed, Ahmed H H Bakheit. Profiles Drug Subst Excip Relat Methodol. 2017;42:287-338.Propranolol."

>  <ID<1>>
T8696

$$$$
StarDrop ID 505
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 17 17 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -0.7145 2.8875 0.0000 0
M  V30 2 C 0.0000 2.4750 0.0000 0
M  V30 3 C 0.7145 2.0625 0.0000 0
M  V30 4 C 0.7145 1.2375 0.0000 0
M  V30 5 C 1.4289 0.8250 0.0000 0
M  V30 6 C 1.4289 -0.0000 0.0000 0
M  V30 7 C 0.7145 -0.4125 0.0000 0
M  V30 8 N 0.0000 0.0000 0.0000 0
M  V30 9 C 0.0000 0.8250 0.0000 0
M  V30 10 P 0.4125 3.1895 0.0000 0
M  V30 11 O 0.8250 3.9039 0.0000 0
M  V30 12 O 1.1270 2.7770 0.0000 0
M  V30 13 O -0.3020 3.6020 0.0000 0
M  V30 14 P -0.4125 1.7605 0.0000 0
M  V30 15 O 0.3020 1.3480 0.0000 0
M  V30 16 O -0.8250 1.0461 0.0000 0
M  V30 17 O -1.1270 2.1730 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 4 9
M  V30 10 1 2 10
M  V30 11 1 10 11
M  V30 12 1 10 12
M  V30 13 2 10 13
M  V30 14 1 2 14
M  V30 15 1 14 15
M  V30 16 1 14 16
M  V30 17 2 14 17
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
505

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Risedronic Acid

>  <Synonyms>
Risedronate

>  <CAS>
105462-24-6

>  <Formula>
C7H11NO7P2

>  <MolWt>
283.1

>  <Pathways>
Metabolism;Others

>  <Target>
Others;Transferase

>  <Receptor>
Farnesyl pyrophosphate synthase; Hydroxylapatite

>  <Bioactivity>
"Risedronic acid (Risedronate ), a pyridinyl biphosphonate, can inhibit osteoclast-mediated bone resorption."

>  <Reference>
"Bergstrom JD, et al. Arch Biochem Biophys. 2000 Jan 1;373(1):231-41."

>  <ID<1>>
T0379

$$$$
StarDrop ID 506
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 112 117 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 21.0423 2.8171 0.0000 0
M  V30 2 C 20.5237 2.1755 0.0000 0 CFG=1
M  V30 3 N 19.7087 2.3038 0.0000 0
M  V30 4 C 19.1901 1.6622 0.0000 0
M  V30 5 C 18.3751 1.7905 0.0000 0 CFG=1
M  V30 6 N 17.8565 1.1489 0.0000 0
M  V30 7 C 17.0416 1.2772 0.0000 0
M  V30 8 C 16.5230 0.6356 0.0000 0 CFG=2
M  V30 9 N 15.7080 0.7639 0.0000 0
M  V30 10 C 15.1894 0.1223 0.0000 0
M  V30 11 C 14.3744 0.2506 0.0000 0 CFG=2
M  V30 12 C 14.0781 1.0206 0.0000 0
M  V30 13 C 14.5967 1.6622 0.0000 0
M  V30 14 C 14.3003 2.4321 0.0000 0
M  V30 15 C 14.8189 3.0737 0.0000 0
M  V30 16 C 15.6339 2.9454 0.0000 0
M  V30 17 O 16.1525 3.5870 0.0000 0
M  V30 18 C 15.9303 2.1755 0.0000 0
M  V30 19 C 15.4116 1.5339 0.0000 0
M  V30 20 N 13.8558 -0.3910 0.0000 0
M  V30 21 C 13.0409 -0.2627 0.0000 0
M  V30 22 C 12.5222 -0.9043 0.0000 0 CFG=1
M  V30 23 N 11.7073 -0.7760 0.0000 0
M  V30 24 C 11.1887 -1.4176 0.0000 0
M  V30 25 C 10.3737 -1.2893 0.0000 0 CFG=1
M  V30 26 C 10.0774 -0.5193 0.0000 0
M  V30 27 C 10.5960 0.1223 0.0000 0
M  V30 28 C 10.2996 0.8922 0.0000 0
M  V30 29 C 10.8182 1.5339 0.0000 0
M  V30 30 C 11.6332 1.4055 0.0000 0
M  V30 31 N 11.9295 0.6356 0.0000 0
M  V30 32 C 11.4109 -0.0060 0.0000 0
M  V30 33 N 9.8551 -1.9309 0.0000 0
M  V30 34 C 9.0401 -1.8025 0.0000 0
M  V30 35 C 8.5215 -2.4442 0.0000 0 CFG=1
M  V30 36 C 8.8179 -3.2141 0.0000 0
M  V30 37 C 9.6328 -3.3424 0.0000 0
M  V30 38 C 10.1515 -2.7008 0.0000 0
M  V30 39 C 10.9664 -2.8291 0.0000 0
M  V30 40 C 11.2628 -3.5991 0.0000 0
M  V30 41 Cl 12.0777 -3.7274 0.0000 0
M  V30 42 C 10.7442 -4.2407 0.0000 0
M  V30 43 C 9.9292 -4.1124 0.0000 0
M  V30 44 N 7.7066 -2.3158 0.0000 0
M  V30 45 C 7.1880 -2.9574 0.0000 0
M  V30 46 C 6.3730 -2.8291 0.0000 0 CFG=1
M  V30 47 C 5.8544 -3.4707 0.0000 0
M  V30 48 C 5.0394 -3.3424 0.0000 0
M  V30 49 C 4.7431 -2.5725 0.0000 0
M  V30 50 C 3.9281 -2.4442 0.0000 0
M  V30 51 C 3.4095 -3.0858 0.0000 0
M  V30 52 C 3.7059 -3.8557 0.0000 0
M  V30 53 C 4.5208 -3.9840 0.0000 0
M  V30 54 C 2.5946 -2.9574 0.0000 0
M  V30 55 C 2.2982 -2.1875 0.0000 0
M  V30 56 C 2.8168 -1.5459 0.0000 0
M  V30 57 C 3.6318 -1.6742 0.0000 0
M  V30 58 N 6.0767 -2.0592 0.0000 0
M  V30 59 C 6.5953 -1.4176 0.0000 0
M  V30 60 C 6.2989 -0.6476 0.0000 0
M  V30 61 O 7.4102 -1.5459 0.0000 0
M  V30 62 O 7.4843 -3.7274 0.0000 0
M  V30 63 O 8.7438 -1.0326 0.0000 0
M  V30 64 O 11.4850 -2.1875 0.0000 0
M  V30 65 C 12.8186 -1.6742 0.0000 0
M  V30 66 O 13.6336 -1.8025 0.0000 0
M  V30 67 O 12.7445 0.5073 0.0000 0
M  V30 68 O 15.4857 -0.6476 0.0000 0
M  V30 69 C 16.8193 -0.1343 0.0000 0
M  V30 70 C 16.3007 -0.7760 0.0000 0
M  V30 71 C 16.5970 -1.5459 0.0000 0
M  V30 72 N 16.0784 -2.1875 0.0000 0
M  V30 73 C 16.3748 -2.9574 0.0000 0
M  V30 74 N 17.1897 -3.0858 0.0000 0
M  V30 75 O 15.8562 -3.5991 0.0000 0
M  V30 76 O 16.7452 2.0471 0.0000 0
M  V30 77 C 18.0788 2.5604 0.0000 0
M  V30 78 C 18.5974 3.2020 0.0000 0
M  V30 79 C 18.3010 3.9720 0.0000 0
M  V30 80 C 19.4124 3.0737 0.0000 0
M  V30 81 O 19.4864 0.8922 0.0000 0
M  V30 82 C 20.8200 1.4055 0.0000 0
M  V30 83 C 20.3014 0.7639 0.0000 0
M  V30 84 C 20.5977 -0.0060 0.0000 0
M  V30 85 N 20.0791 -0.6476 0.0000 0
M  V30 86 C 20.3755 -1.4176 0.0000 0
M  V30 87 N 21.1904 -1.5459 0.0000 0
M  V30 88 N 19.8569 -2.0592 0.0000 0
M  V30 89 O 20.7459 3.5870 0.0000 0
M  V30 90 N 21.8572 2.6888 0.0000 0
M  V30 91 C 22.4401 3.2726 0.0000 0 CFG=2
M  V30 92 C 22.3103 4.0874 0.0000 0
M  V30 93 N 22.9510 4.6071 0.0000 0
M  V30 94 C 22.8212 5.4219 0.0000 0 CFG=1
M  V30 95 C 23.4618 5.9416 0.0000 0
M  V30 96 N 23.3320 6.7564 0.0000 0
M  V30 97 O 24.2323 5.6467 0.0000 0
M  V30 98 C 22.0507 5.7168 0.0000 0
M  V30 99 O 21.5398 4.3823 0.0000 0
M  V30 100 C 23.1755 2.8988 0.0000 0
M  V30 101 C 23.0472 2.0838 0.0000 0
M  V30 102 C 22.2324 1.9540 0.0000 0
M  V30 103 H 23.2485 3.8613 0.0000 0
M  V30 104 H 22.6637 6.4094 0.0000 0
M  V30 105 H 19.8951 1.3978 0.0000 0
M  V30 106 H 17.3873 1.9460 0.0000 0
M  V30 107 H 15.8943 -0.1421 0.0000 0
M  V30 108 H 14.7337 -0.6826 0.0000 0
M  V30 109 H 11.8937 -1.6821 0.0000 0
M  V30 110 H 10.7330 -2.2225 0.0000 0
M  V30 111 H 8.1624 -1.5109 0.0000 0
M  V30 112 H 5.3852 -2.6736 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3 CFG=3
M  V30 3 1 3 4
M  V30 4 1 5 4
M  V30 5 1 5 6 CFG=1
M  V30 6 1 6 7
M  V30 7 1 8 7
M  V30 8 1 8 9 CFG=1
M  V30 9 1 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 2 18 19
M  V30 19 1 13 19
M  V30 20 1 11 20 CFG=1
M  V30 21 1 20 21
M  V30 22 1 22 21
M  V30 23 1 22 23 CFG=3
M  V30 24 1 23 24
M  V30 25 1 25 24
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 27 28
M  V30 29 2 28 29
M  V30 30 1 29 30
M  V30 31 2 30 31
M  V30 32 1 31 32
M  V30 33 2 27 32
M  V30 34 1 25 33 CFG=3
M  V30 35 1 33 34
M  V30 36 1 35 34
M  V30 37 1 35 36
M  V30 38 1 36 37
M  V30 39 2 37 38
M  V30 40 1 38 39
M  V30 41 2 39 40
M  V30 42 1 40 41
M  V30 43 1 40 42
M  V30 44 2 42 43
M  V30 45 1 37 43
M  V30 46 1 35 44 CFG=1
M  V30 47 1 44 45
M  V30 48 1 46 45
M  V30 49 1 46 47
M  V30 50 1 47 48
M  V30 51 2 48 49
M  V30 52 1 49 50
M  V30 53 2 50 51
M  V30 54 1 51 52
M  V30 55 2 52 53
M  V30 56 1 48 53
M  V30 57 1 51 54
M  V30 58 2 54 55
M  V30 59 1 55 56
M  V30 60 2 56 57
M  V30 61 1 50 57
M  V30 62 1 46 58 CFG=1
M  V30 63 1 58 59
M  V30 64 1 59 60
M  V30 65 2 59 61
M  V30 66 2 45 62
M  V30 67 2 34 63
M  V30 68 2 24 64
M  V30 69 1 22 65
M  V30 70 1 65 66
M  V30 71 2 21 67
M  V30 72 2 10 68
M  V30 73 1 8 69
M  V30 74 1 69 70
M  V30 75 1 70 71
M  V30 76 1 71 72
M  V30 77 1 72 73
M  V30 78 1 73 74
M  V30 79 2 73 75
M  V30 80 2 7 76
M  V30 81 1 5 77
M  V30 82 1 77 78
M  V30 83 1 78 79
M  V30 84 1 78 80
M  V30 85 2 4 81
M  V30 86 1 2 82
M  V30 87 1 82 83
M  V30 88 1 83 84
M  V30 89 1 84 85
M  V30 90 1 85 86
M  V30 91 2 86 87
M  V30 92 1 86 88
M  V30 93 2 1 89
M  V30 94 1 1 90
M  V30 95 1 91 90
M  V30 96 1 91 92 CFG=3
M  V30 97 1 92 93
M  V30 98 1 94 93
M  V30 99 1 94 95
M  V30 100 1 95 96
M  V30 101 2 95 97
M  V30 102 1 94 98 CFG=3
M  V30 103 2 92 99
M  V30 104 1 91 100
M  V30 105 1 100 101
M  V30 106 1 101 102
M  V30 107 1 90 102
M  V30 108 1 103 91
M  V30 109 1 104 94
M  V30 110 1 105 2
M  V30 111 1 106 5
M  V30 112 1 107 8
M  V30 113 1 108 11
M  V30 114 1 109 22
M  V30 115 1 110 25
M  V30 116 1 111 35
M  V30 117 1 112 46
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
506

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cetrorelix diacetate

>  <Synonyms>
Cetrorelix acetate;SB-075 diacetate;SB-075 acetate;NS-75A;NS-75A diacetate

>  <CAS>
130143-01-0

>  <Formula>
C72H96ClN17O16

>  <MolWt>
1491

>  <Pathways>
GPCR/G Protein

>  <Target>
GNRH Receptor

>  <Receptor>
GnRHR

>  <Bioactivity>
"Cetrorelix diacetate is is a gonadotropin-releasing hormone antagonist. It works by blocking the action of GnRH upon the pituitary, thus rapidly suppressing the production and action of luteinizing hormone (LH) and follicle-stimulating hormone (FSH)."

>  <Reference>
"Griesinger G, Felberbaum RE, Schultze-Mosgau A, Diedrich K. Gonadotropin-releasing hormone antagonists for assisted reproductive techniques: are there clinical differences between agents? Drugs. 2004;64(6):563-75. Review. PubMed PMID: 15018588.;Finas D, Hornung D, Diedrich K, Schultze-Mosgau A. Cetrorelix in the treatment of female infertility and endometriosis. Expert Opin Pharmacother. 2006 Oct;7(15):2155-68. Review. PubMed PMID: 17020439.;Reissmann T, Schally AV, Bouchard P, Riethmiiller H, Engel J. The LHRH antagonist cetrorelix: a review. Hum Reprod Update. 2000 Jul-Aug;6(4):322-31. Review. PubMed PMID: 10972520.;Tur-Kaspa I, Ezcurra D. GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology. Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1323-36. doi: 10.1517/17425250903279969. Review. PubMed PMID: 19761413."

>  <ID<1>>
T5520L

$$$$
StarDrop ID 507
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 13 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 -1.6500 0.0000 0
M  V30 2 Bi 0.7145 -1.2375 0.0000 0
M  V30 3 O 0.7145 -0.4125 0.0000 0
M  V30 4 C 1.4289 0.0000 0.0000 0
M  V30 5 O 1.4289 0.8250 0.0000 0
M  V30 6 C 2.1434 -0.4125 0.0000 0
M  V30 7 C 2.8579 0.0000 0.0000 0
M  V30 8 C 3.5724 -0.4125 0.0000 0
M  V30 9 C 3.5724 -1.2375 0.0000 0
M  V30 10 C 2.8579 -1.6500 0.0000 0
M  V30 11 C 2.1434 -1.2375 0.0000 0
M  V30 12 O 1.4289 -1.6500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 6 11
M  V30 12 1 11 12
M  V30 13 1 2 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
507

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Bismuth Subsalicylate

>  <Synonyms>
Bismuth(III) salicylate basic;Bismuth oxysalicylate;Bismuth subsalicylat

>  <CAS>
14882-18-9

>  <Formula>
C7H5BiO4

>  <MolWt>
362.1

>  <Pathways>
Immunology/Inflammation;Neuroscience

>  <Target>
COX;PGE Synthase

>  <Receptor>
COX-1; COX-2; PGE synthase

>  <Bioactivity>
"Bismuth subsalicylate is the active ingredient in the popular medication Pepto-Bismol that is used to treat nausea, heartburn, indigestion, upset stomach, diarrhea, and other temporary discomforts of the stomach and gastrointestinal tract."

>  <Reference>
"Sox TE, et al. Antimicrob Agents Chemother, 1989, 33(12), 2075-2082.;Bierer DW. Rev Infect Dis, 1990, 12 Suppl 1:S3-8."

>  <ID<1>>
T0424

$$$$
StarDrop ID 508
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 17.7592 6.9533 0.0000 0
M  V30 2 C 17.7592 6.1283 0.0000 0
M  V30 3 O 17.0447 5.7158 0.0000 0
M  V30 4 C 16.3302 6.1283 0.0000 0
M  V30 5 C 15.6158 5.7158 0.0000 0
M  V30 6 O 15.6158 4.8908 0.0000 0
M  V30 7 C 14.9013 4.4783 0.0000 0
M  V30 8 O 14.1868 4.8908 0.0000 0
M  V30 9 C 14.9013 3.6533 0.0000 0
M  V30 10 C 14.1868 3.2408 0.0000 0
M  V30 11 C 14.1868 2.4158 0.0000 0
M  V30 12 C 13.4724 2.0033 0.0000 0
M  V30 13 C 13.4724 1.1783 0.0000 0
M  V30 14 C 12.7579 0.7658 0.0000 0
M  V30 15 C 14.9013 6.1283 0.0000 0
M  V30 16 O 14.1868 5.7158 0.0000 0
M  V30 17 C 13.4724 6.1283 0.0000 0
M  V30 18 O 13.4724 6.9533 0.0000 0
M  V30 19 C 12.7579 5.7158 0.0000 0
M  V30 20 C 12.0434 6.1283 0.0000 0
M  V30 21 C 11.3289 5.7158 0.0000 0
M  V30 22 C 10.6145 6.1283 0.0000 0
M  V30 23 C 9.9000 5.7158 0.0000 0
M  V30 24 C 9.1855 6.1283 0.0000 0
M  V30 25 C 18.4737 5.7158 0.0000 0
M  V30 26 C 19.1881 6.1283 0.0000 0
M  V30 27 C 19.9026 5.7158 0.0000 0
M  V30 28 C 20.6171 6.1283 0.0000 0
M  V30 29 C 21.3315 5.7158 0.0000 0
M  V30 30 C 22.0460 6.1283 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 5 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 17 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 1 23 24
M  V30 24 1 2 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 1 27 28
M  V30 28 1 28 29
M  V30 29 1 29 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
508

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Triheptanoin

>  <Synonyms>
UX007;UX-007;UX 007;IND106011;IND-106011;IND 106011

>  <CAS>
620-67-7

>  <Formula>
C24H44O6

>  <MolWt>
428.6

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
fatty acid metabolic

>  <Bioactivity>
Triheptanoin is a fatty acid metabolic modulator. It potentially for the treatment of fatty acid oxidation disorders and GLUT1.

>  <Reference>
"Nguyen TD, Shingu Y, Amorim PA, Schwarzer M, Doenst T. Triheptanoin Alleviates Ventricular Hypertrophy and Improves Myocardial Glucose Oxidation in Rats With Pressure Overload. J Card Fail. 2015 Nov;21(11):906-15. doi: 10.1016/j.cardfail.2015.07.009. PubMed PMID: 26209001.;Schwarzkopf TM, Koch K, Klein J. Reduced severity of ischemic stroke and improvement of mitochondrial function after dietary treatment with the anaplerotic substance triheptanoin. Neuroscience. 2015 Aug 6;300:201-9. doi: 10.1016/j.neuroscience.2015.05.014. PubMed PMID: 25982559.;Vockley J, Charrow J, Ganesh J, Eswara M, Diaz GA, McCracken E, Conway R, Enns GM, Starr J, Wang R, Abdenur JE, Sanchez-de-Toledo J, Marsden DL. Triheptanoin treatment in patients with pediatric cardiomyopathy associated with long chain-fatty acid oxidation disorders. Mol Genet Metab. 2016 Nov;119(3):223-231. doi: 10.1016/j.ymgme.2016.08.008. PubMed PMID: 27590926.;Vockley J, Marsden D, McCracken E, DeWard S, Barone A, Hsu K, Kakkis E. Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment--A retrospective chart review. Mol Genet Metab. 2015 Sep-Oct;116(1-2):53-60. doi: 10.1016/j.ymgme.2015.06.006. Review. Erratum in: Mol Genet Metab. 2015 Nov;116(3):221. PubMed PMID: 26116311."

>  <ID<1>>
T19663

$$$$
StarDrop ID 509
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 50 55 0 0 0
M  V30 BEGIN ATOM
M  V30 1 F 12.5484 2.0080 0.0000 0
M  V30 2 C 12.8033 1.2233 0.0000 0
M  V30 3 F 12.0187 0.9684 0.0000 0
M  V30 4 F 13.5879 1.4783 0.0000 0
M  V30 5 C 13.0582 0.4387 0.0000 0
M  V30 6 N 12.5062 -0.1744 0.0000 0
M  V30 7 C 12.7611 -0.9590 0.0000 0
M  V30 8 O 13.5681 -1.1305 0.0000 0
M  V30 9 C 12.2091 -1.5721 0.0000 0
M  V30 10 C 11.6571 -0.9590 0.0000 0
M  V30 11 C 10.8501 -1.1305 0.0000 0
M  V30 12 C 10.2981 -0.5174 0.0000 0
M  V30 13 C 9.4911 -0.6890 0.0000 0
M  V30 14 N 8.9391 -0.0759 0.0000 0
M  V30 15 C 8.1321 -0.2474 0.0000 0
M  V30 16 C 7.5801 0.3657 0.0000 0
M  V30 17 C 7.8350 1.1503 0.0000 0
M  V30 18 C 8.6420 1.3218 0.0000 0
M  V30 19 C 9.1940 0.7088 0.0000 0
M  V30 20 N 7.2830 1.7634 0.0000 0
M  V30 21 C 6.4760 1.5919 0.0000 0
M  V30 22 O 5.9240 2.2050 0.0000 0
M  V30 23 C 6.2211 0.8073 0.0000 0
M  V30 24 C 6.7731 0.1942 0.0000 0
M  V30 25 C 6.5181 -0.5904 0.0000 0
M  V30 26 C 5.7112 -0.7620 0.0000 0
M  V30 27 C 5.1591 -0.1489 0.0000 0
M  V30 28 C 5.4141 0.6357 0.0000 0
M  V30 29 C 4.8620 1.2488 0.0000 0
M  V30 30 C 4.0551 1.0773 0.0000 0
M  V30 31 C 3.5030 1.6904 0.0000 0
M  V30 32 C 3.7580 2.4750 0.0000 0
M  V30 33 C 4.5650 2.6465 0.0000 0
M  V30 34 C 5.1170 2.0335 0.0000 0
M  V30 35 C 3.2060 3.0881 0.0000 0
M  V30 36 F 2.6539 3.7012 0.0000 0
M  V30 37 F 3.8190 3.6401 0.0000 0
M  V30 38 F 2.5929 2.5361 0.0000 0
M  V30 39 C 12.8765 -2.0570 0.0000 0
M  V30 40 C 13.6835 -1.8855 0.0000 0
M  V30 41 C 14.2355 -2.4986 0.0000 0
M  V30 42 C 13.9806 -3.2832 0.0000 0
M  V30 43 C 13.1736 -3.4547 0.0000 0
M  V30 44 C 12.6216 -2.8416 0.0000 0
M  V30 45 C 11.7966 -2.8416 0.0000 0
M  V30 46 C 11.2446 -3.4547 0.0000 0
M  V30 47 C 10.4376 -3.2832 0.0000 0
M  V30 48 C 10.1827 -2.4986 0.0000 0
M  V30 49 C 10.7347 -1.8855 0.0000 0
M  V30 50 C 11.5417 -2.0570 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 14 19
M  V30 20 1 17 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 2 23 24
M  V30 25 1 24 25
M  V30 26 2 25 26
M  V30 27 1 26 27
M  V30 28 2 27 28
M  V30 29 1 23 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 30 31
M  V30 33 2 31 32
M  V30 34 1 32 33
M  V30 35 2 33 34
M  V30 36 1 29 34
M  V30 37 1 32 35
M  V30 38 1 35 36
M  V30 39 1 35 37
M  V30 40 1 35 38
M  V30 41 1 9 39
M  V30 42 2 39 40
M  V30 43 1 40 41
M  V30 44 2 41 42
M  V30 45 1 42 43
M  V30 46 2 43 44
M  V30 47 1 39 44
M  V30 48 1 44 45
M  V30 49 2 45 46
M  V30 50 1 46 47
M  V30 51 2 47 48
M  V30 52 1 48 49
M  V30 53 2 49 50
M  V30 54 1 9 50
M  V30 55 1 45 50
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
509

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Lomitapide Mesylate

>  <Synonyms>
BMS-201038 mesylate;AEGR-733 mesylate

>  <CAS>
202914-84-9

>  <Formula>
C40H41F6N3O5S

>  <MolWt>
789.8

>  <Pathways>
Metabolism

>  <Target>
CETP

>  <Receptor>
 MTP:8 nM

>  <Bioactivity>
"Lomitapide Mesylate is a methanesulfonic acid form of lomitapide, a small molecule inhibitor of microsomal triglyceride transfer protein."

>  <Reference>
"Davis KA, Miyares MA. Am J Health Syst Pharm. 2014 Jun 15;71(12):1001-8."

>  <ID<1>>
T2545

$$$$
StarDrop ID 510
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 22 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.7145 2.0625 0.0000 0
M  V30 2 C 1.4289 2.4750 0.0000 0
M  V30 3 C 2.1434 2.0625 0.0000 0
M  V30 4 N 2.1434 1.2375 0.0000 0
M  V30 5 C 2.8579 0.8250 0.0000 0
M  V30 6 C 3.5724 1.2375 0.0000 0
M  V30 7 C 4.2868 0.8250 0.0000 0
M  V30 8 C 4.2868 -0.0000 0.0000 0
M  V30 9 C 3.5724 -0.4125 0.0000 0
M  V30 10 C 2.8579 0.0000 0.0000 0
M  V30 11 S 2.1434 -0.4125 0.0000 0
M  V30 12 C 1.4289 0.0000 0.0000 0
M  V30 13 C 0.7145 -0.4125 0.0000 0
M  V30 14 C 0.0000 0.0000 0.0000 0
M  V30 15 C 0.0000 0.8250 0.0000 0
M  V30 16 C 0.7145 1.2375 0.0000 0
M  V30 17 C 1.4289 0.8250 0.0000 0
M  V30 18 N 1.4289 3.3000 0.0000 0
M  V30 19 C 0.7145 3.7125 0.0000 0
M  V30 20 C 2.1434 3.7125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 5 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 4 17
M  V30 19 1 12 17
M  V30 20 1 2 18
M  V30 21 1 18 19
M  V30 22 1 18 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
510

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Promethazine

>  <Synonyms>
Proazamine;Diphergan

>  <CAS>
60-87-7

>  <Formula>
C17H20N2S

>  <MolWt>
284.4

>  <Pathways>
GPCR/G Protein;Immunology/Inflammation;Neuroscience

>  <Target>
CaMK;Dopamine Receptor;AChR;Histamine Receptor;Adrenergic Receptor;5-HT Receptor

>  <Receptor>
5-HT; Adrenergic Receptor; CAM; D2; H1 receptor; mAChR

>  <Bioactivity>
Tafluprost(AFP-168) is an analogue of anti-glaucoma prostaglandin (PG) .

>  <Reference>
"Suzuki A, et al. Ther Drug Monit. 2003 Apr; 25(2):192-6."

>  <ID<1>>
T0445

$$$$
StarDrop ID 511
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 28 31 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 5.7158 4.9500 0.0000 0
M  V30 2 N 5.0013 4.5375 0.0000 0
M  V30 3 C 5.0013 3.7125 0.0000 0
M  V30 4 C 4.2868 3.3000 0.0000 0
M  V30 5 N 3.5724 3.7125 0.0000 0
M  V30 6 C 2.8579 3.3000 0.0000 0
M  V30 7 C 2.8579 2.4750 0.0000 0
M  V30 8 C 2.1434 2.0625 0.0000 0
M  V30 9 N 2.1434 1.2375 0.0000 0
M  V30 10 C 2.8579 0.8250 0.0000 0
M  V30 11 C 3.5724 1.2375 0.0000 0
M  V30 12 C 4.2868 0.8250 0.0000 0
M  V30 13 C 4.2868 -0.0000 0.0000 0
M  V30 14 C 3.5724 -0.4125 0.0000 0
M  V30 15 C 2.8579 0.0000 0.0000 0
M  V30 16 S 2.1434 -0.4125 0.0000 0
M  V30 17 C 1.4289 0.0000 0.0000 0
M  V30 18 C 0.7145 -0.4125 0.0000 0
M  V30 19 C 0.0000 0.0000 0.0000 0
M  V30 20 C 0.0000 0.8250 0.0000 0
M  V30 21 C 0.7145 1.2375 0.0000 0
M  V30 22 C 1.4289 0.8250 0.0000 0
M  V30 23 C -0.7145 1.2375 0.0000 0
M  V30 24 F -1.4289 1.6500 0.0000 0
M  V30 25 F -0.3020 1.9520 0.0000 0
M  V30 26 F -1.1270 0.5230 0.0000 0
M  V30 27 C 3.5724 4.5375 0.0000 0
M  V30 28 C 4.2868 4.9500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 10 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 18 19
M  V30 20 2 19 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 9 22
M  V30 24 1 17 22
M  V30 25 1 20 23
M  V30 26 1 23 24
M  V30 27 1 23 25
M  V30 28 1 23 26
M  V30 29 1 5 27
M  V30 30 1 27 28
M  V30 31 1 2 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
511

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Trifluoperazine

>  <Synonyms>
N/A

>  <CAS>
117-89-5

>  <Formula>
C21H24F3N3S

>  <MolWt>
407.5

>  <Pathways>
Autophagy;GPCR/G Protein;Microbiology/Virology;Neuroscience;Membrane transporter/Ion channel

>  <Target>
Dopamine Receptor;Influenza Virus;P-gp;Adrenergic Receptor;Autophagy;CaMK

>  <Receptor>
 D2:1.2 nM

>  <Bioactivity>
"Trifluoperazine is a Dopamine D2 receptor inhibitor(IC50 : 1.2 nM), and Treatment of schizophrenia."

>  <Reference>
"Koch K , Mansi K , Haynes E , et al. Trifluoperazine versus placebo for schizophrenia[J]. Cochrane Database of Systematic Reviews, 2014, 1(1):CD010226.;Lu J, Hou Y, Ge S, et al. Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro[J]. Life Sciences . 2020: 118889.;Magdolna, Tardy, Markus,et al. Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia[J]. Cochrane Database of Systematic Reviews, 2014."

>  <ID<1>>
T8389

$$$$
StarDrop ID 512
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 34 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 6.2620 0.3722 0.0000 0
M  V30 2 C 5.4415 0.2859 0.0000 0
M  V30 3 N 5.0290 -0.4285 0.0000 0
M  V30 4 N 4.2221 -0.2570 0.0000 0
M  V30 5 C 4.1358 0.5635 0.0000 0
M  V30 6 S 3.4214 0.9760 0.0000 0
M  V30 7 C 2.7069 0.5635 0.0000 0
M  V30 8 C 1.9924 0.9760 0.0000 0
M  V30 9 C 1.2780 0.5635 0.0000 0
M  V30 10 N 0.5635 0.9760 0.0000 0
M  V30 11 C 0.5635 1.8010 0.0000 0 CFG=2
M  V30 12 S 1.2780 2.2135 0.0000 0
M  V30 13 C 1.9924 1.8010 0.0000 0
M  V30 14 C -0.2615 1.8010 0.0000 0 CFG=2
M  V30 15 N -0.8449 2.3843 0.0000 0
M  V30 16 C -0.6314 3.1812 0.0000 0
M  V30 17 O 0.1655 3.3948 0.0000 0
M  V30 18 C -1.2147 3.7646 0.0000 0
M  V30 19 N -1.0012 4.5615 0.0000 0
M  V30 20 C -1.5204 5.2026 0.0000 0
M  V30 21 N -1.0711 5.8945 0.0000 0
M  V30 22 N -0.2742 5.6810 0.0000 0
M  V30 23 N -0.2310 4.8571 0.0000 0
M  V30 24 C -0.2615 0.9760 0.0000 0
M  V30 25 O -0.8449 0.3926 0.0000 0
M  V30 26 C 1.2780 -0.2615 0.0000 0
M  V30 27 O 0.5635 -0.6740 0.0000 0
M  V30 28 O 1.9924 -0.6740 0.0000 0
M  V30 29 S 4.8895 0.8990 0.0000 0
M  V30 30 H -0.1436 1.0939 0.0000 0
M  V30 31 H -1.1854 1.4183 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 1 11 10 CFG=1
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 8 13
M  V30 14 1 11 14
M  V30 15 1 14 15 CFG=1
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 2 22 23
M  V30 24 1 19 23
M  V30 25 1 14 24
M  V30 26 1 10 24
M  V30 27 2 24 25
M  V30 28 1 9 26
M  V30 29 1 26 27
M  V30 30 2 26 28
M  V30 31 1 5 29
M  V30 32 1 2 29
M  V30 33 1 30 11
M  V30 34 1 31 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
512

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Cefazolin

>  <Synonyms>
N/A

>  <CAS>
25953-19-9

>  <Formula>
C14H14N8O4S3

>  <MolWt>
454.5

>  <Pathways>
Others;Microbiology/Virology

>  <Target>
Others;Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
Cefazolin is a semi-synthetic cephalosporin that has a broad spectrum of antibacterial activity and inhibits the synthesis of bacterial cell walls.

>  <Reference>
"Gabriela, A, Albarellos,et al. Cefazolin pharmacokinetics in cats under surgical conditions.[J]. Journal of Feline Medicine & Surgery, 2017."

>  <ID<1>>
T8390

$$$$
StarDrop ID 513
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 20 21 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.0680 -4.1250 0.0000 0
M  V30 2 C 0.0680 -4.9500 0.0000 0
M  V30 3 C 0.7825 -5.3625 0.0000 0
M  V30 4 C 1.4970 -4.9500 0.0000 0
M  V30 5 C 2.2115 -5.3625 0.0000 0
M  V30 6 O 2.9259 -4.9500 0.0000 0
M  V30 7 O 2.2115 -6.1875 0.0000 0
M  V30 8 C 0.7825 -6.1875 0.0000 0
M  V30 9 C 0.0680 -6.6000 0.0000 0
M  V30 10 C -0.6464 -6.1875 0.0000 0
M  V30 11 C -0.6464 -5.3625 0.0000 0
M  V30 12 C -1.3609 -4.9500 0.0000 0
M  V30 13 O -2.0754 -5.3625 0.0000 0
M  V30 14 C -1.3609 -4.1250 0.0000 0
M  V30 15 C -2.0754 -3.7125 0.0000 0
M  V30 16 C -2.0754 -2.8875 0.0000 0
M  V30 17 C -1.3609 -2.4750 0.0000 0
M  V30 18 Br -1.3609 -1.6500 0.0000 0
M  V30 19 C -0.6464 -2.8875 0.0000 0
M  V30 20 C -0.6464 -3.7125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 5 7
M  V30 7 1 3 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 2 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 12 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 1 17 19
M  V30 20 2 19 20
M  V30 21 1 14 20
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
513

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Bromfenac sodium hydrate

>  <Synonyms>
Bromfenac monosodium salt sesquihydrate;Bromfenac sodium

>  <CAS>
120638-55-3

>  <Formula>
C30H28Br2N2Na2O9

>  <MolWt>
766.3

>  <Pathways>
Neuroscience;Immunology/Inflammation

>  <Target>
COX

>  <Receptor>
" COX-1:5.56 nM (IC50), COX-2:7.45 nM (IC50)"

>  <Bioactivity>
"Bromfenac Sodium Sesquihydrate is the sodium salt form of bromfenac, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic and anti-inflammatory activities. Upon ophthalmic administration, bromfenac binds to and inhibits the activity of cyclooxygenase II (COX II), an enzyme which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins (PG). By inhibiting PG formation, bromfenac is able to inhibit PG-induced inflammation, thereby preventing vasodilation, leukocytosis, disruption of the blood-aqueous humor barrier, an increase in vascular permeability and an increase in intraocular pressure (IOP)."

>  <Reference>
"Shimura M, Yasuda K. Br J Ophthalmol. 2015 Feb;99(2):215-9."

>  <ID<1>>
T2403

$$$$
StarDrop ID 514
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 34 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.0420 -4.6770 0.0000 0
M  V30 2 C 2.7565 -5.0895 0.0000 0
M  V30 3 C 3.4710 -4.6770 0.0000 0
M  V30 4 C 4.1854 -5.0895 0.0000 0
M  V30 5 C 4.8999 -4.6770 0.0000 0
M  V30 6 C 5.6144 -5.0895 0.0000 0
M  V30 7 O 5.6144 -5.9145 0.0000 0
M  V30 8 O 6.3289 -4.6770 0.0000 0
M  V30 9 C 6.3289 -3.8520 0.0000 0 CFG=2
M  V30 10 C 5.5084 -3.9383 0.0000 0
M  V30 11 C 5.1728 -3.1846 0.0000 0
M  V30 12 C 5.7859 -2.6326 0.0000 0 CFG=1
M  V30 13 C 5.7859 -1.8076 0.0000 0 CFG=2
M  V30 14 C 5.0714 -1.3951 0.0000 0
M  V30 15 C 5.0714 -0.5701 0.0000 0
M  V30 16 C 5.7859 -0.1576 0.0000 0
M  V30 17 C 5.7859 0.6674 0.0000 0
M  V30 18 C 6.5004 1.0799 0.0000 0
M  V30 19 O 6.5004 1.9049 0.0000 0
M  V30 20 C 7.2149 0.6674 0.0000 0
M  V30 21 C 7.2149 -0.1576 0.0000 0
M  V30 22 C 6.5004 -0.5701 0.0000 0 CFG=1
M  V30 23 C 7.2149 -0.9826 0.0000 0
M  V30 24 C 6.5004 -1.3951 0.0000 0 CFG=1
M  V30 25 C 7.2149 -1.8076 0.0000 0
M  V30 26 C 7.2149 -2.6326 0.0000 0
M  V30 27 C 6.5004 -3.0451 0.0000 0 CFG=2
M  V30 28 C 7.1678 -3.5300 0.0000 0
M  V30 29 C 7.1493 -3.9383 0.0000 0
M  V30 30 C 7.6343 -3.2708 0.0000 0
M  V30 31 O 7.4849 -4.6919 0.0000 0
M  V30 32 H 5.8905 -3.6271 0.0000 0
M  V30 33 H 4.9199 -2.3076 0.0000 0
M  V30 34 H 7.3664 -0.8951 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 9 8 CFG=3
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 12 11 CFG=1
M  V30 12 1 12 13
M  V30 13 1 13 14 CFG=3
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 18 20
M  V30 20 1 20 21
M  V30 21 1 22 21
M  V30 22 1 22 16
M  V30 23 1 22 23 CFG=1
M  V30 24 1 24 22
M  V30 25 1 13 24
M  V30 26 1 24 25 CFG=1
M  V30 27 1 25 26
M  V30 28 1 27 26
M  V30 29 1 27 9
M  V30 30 1 12 27
M  V30 31 1 27 28 CFG=1
M  V30 32 1 9 29 CFG=1
M  V30 33 1 29 30
M  V30 34 2 29 31
M  V30 35 1 32 12
M  V30 36 1 33 13
M  V30 37 1 34 24
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
514

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Hydroxyprogesterone caproate

>  <Synonyms>
17??-Hydroxyprogesterone hexanoate;Primolut Depot;17??-Hydroxyprogesterone caproate;Delalutin;Hormofort

>  <CAS>
630-56-8

>  <Formula>
C27H40O4

>  <MolWt>
428.6

>  <Pathways>
Autophagy

>  <Target>
Autophagy

>  <Receptor>
ULK1; ULK2

>  <Bioactivity>
Hydroxyprogesterone Caproate is a synthetic progestational agent. It binds to and activates nuclear progesterone receptors in the reproductive system and inhibits ovulation and an alteration in the cervical mucus and endometrium.

>  <Reference>
"Pushpalatha T, et al. Naturwissenschaften. 2004, 91(5):242-4.;Schardein JL, et al. Birth Defects Res B Dev Reprod Toxicol. 2012, 95(2):160-74."

>  <ID<1>>
T6858

$$$$
StarDrop ID 515
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 35 37 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -5.0013 -2.8875 0.0000 0
M  V30 2 C -5.0013 -2.0625 0.0000 0
M  V30 3 O -5.7158 -1.6500 0.0000 0
M  V30 4 C -5.7158 -0.8250 0.0000 0
M  V30 5 C -4.2868 -1.6500 0.0000 0
M  V30 6 C -4.2868 -0.8250 0.0000 0
M  V30 7 N -3.5724 -0.4125 0.0000 0
M  V30 8 C -2.8579 -0.8250 0.0000 0
M  V30 9 C -2.8579 -1.6500 0.0000 0
M  V30 10 C -2.1434 -2.0625 0.0000 0
M  V30 11 O -2.1434 -2.8875 0.0000 0
M  V30 12 O -1.4289 -1.6500 0.0000 0
M  V30 13 C -0.7145 -2.0625 0.0000 0
M  V30 14 C 0.0000 -1.6500 0.0000 0
M  V30 15 N 0.7145 -2.0625 0.0000 0
M  V30 16 C 0.7145 -2.8875 0.0000 0
M  V30 17 C 1.4289 -1.6500 0.0000 0
M  V30 18 C 2.1434 -2.0625 0.0000 0
M  V30 19 C 2.8579 -1.6500 0.0000 0
M  V30 20 C 3.5724 -2.0625 0.0000 0
M  V30 21 C 3.5724 -2.8875 0.0000 0
M  V30 22 C 2.8579 -3.3000 0.0000 0
M  V30 23 C 2.1434 -2.8875 0.0000 0
M  V30 24 C -3.5724 -2.0625 0.0000 0
M  V30 25 C -3.5724 -2.8875 0.0000 0
M  V30 26 C -2.8579 -3.3000 0.0000 0
M  V30 27 C -2.8579 -4.1250 0.0000 0
M  V30 28 C -3.5724 -4.5375 0.0000 0
M  V30 29 C -4.2868 -4.1250 0.0000 0
M  V30 30 C -4.2868 -3.3000 0.0000 0
M  V30 31 N -5.0013 -4.5375 0.0000 0
M  V30 32 O -5.0013 -5.3625 0.0000 0
M  V30 33 O -5.7158 -4.1250 0.0000 0
M  V30 34 C -2.1434 -0.4125 0.0000 0
M  V30 35 C -5.0013 -0.4125 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 2 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 22 23
M  V30 23 2 18 23
M  V30 24 1 9 24
M  V30 25 1 5 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 27 28
M  V30 30 2 28 29
M  V30 31 1 29 30
M  V30 32 2 25 30
M  V30 33 1 29 31
M  V30 34 2 31 32
M  V30 35 2 31 33
M  V30 36 1 8 34
M  V30 37 1 6 35
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
515

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Nicardipine

>  <Synonyms>
Cardene;Antagonil;Flusemide;Dagan

>  <CAS>
55985-32-5

>  <Formula>
C26H29N3O6

>  <MolWt>
479.5

>  <Pathways>
Metabolism;Membrane transporter/Ion channel

>  <Target>
Calcium Channel

>  <Receptor>
 cardiac calcium channels:1 ??M (IC50)

>  <Bioactivity>
"Nicardipine hydrochloride, a calcium channel blockers belonging to the dihydropyridine class, is a drug used to treat angina and high blood pressure."

>  <Reference>
"Sherrin H. Baky. Nic ardipine Hydrochloride. ;R Stamatiou, et al. The dihydropyridine calcium antagonist nicardipine reduces aortic smooth muscle cell viability, proliferation and migration. Cardiovascular Research, 2018 Apr,114(1):S43. ;Charnet P, et al. Electrophysiological analysis of the action of nifedipine and nicardipine on myocardial fibers. Fundam Clin Pharmacol. 1987;1(6):413-31."

>  <ID<1>>
T21454

$$$$
StarDrop ID 516
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.6554 -2.3645 0.0000 0
M  V30 2 N 3.8304 -2.3645 0.0000 0
M  V30 3 Fe 3.4179 -3.0789 0.0000 0 CHG=-2
M  V30 4 C 3.0054 -3.7934 0.0000 0
M  V30 5 N 2.5929 -4.5079 0.0000 0
M  V30 6 C 3.8304 -3.7934 0.0000 0
M  V30 7 N 4.2429 -4.5079 0.0000 0
M  V30 8 C 4.2429 -3.0789 0.0000 0
M  V30 9 N 5.0679 -3.0789 0.0000 0
M  V30 10 C 3.0054 -2.3645 0.0000 0
M  V30 11 N 2.5929 -1.6500 0.0000 0
M  V30 12 C 2.5929 -3.0789 0.0000 0
M  V30 13 N 1.7679 -3.0789 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 3 4 5
M  V30 5 1 3 6
M  V30 6 3 6 7
M  V30 7 1 3 8
M  V30 8 3 8 9
M  V30 9 1 3 10
M  V30 10 3 10 11
M  V30 11 1 3 12
M  V30 12 3 12 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
516

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Nitroprusside disodium dihydrate

>  <Synonyms>
Sodium Nitroprusside Dihydrate;Sodium Nitroferricyanide(III) Dihydrate

>  <CAS>
13755-38-9

>  <Formula>
C5H4FeN6Na2O3

>  <MolWt>
298

>  <Pathways>
Autophagy;GPCR/G Protein

>  <Target>
Autophagy;Guanylate cyclase

>  <Receptor>
Autophagy; guanylate cyclase

>  <Bioactivity>
Sodium Nitroprusside Dihydrate is a potent vasodilator working through releasing NO spontaneously in blood.

>  <Reference>
"Garg UC, et al. J Clin Invest, 1989, 83(5), 1774-7.;Namazi H. Clinics (Sao Paulo), 2008, 63(3), 405.;Wink DA, et al. Arch Biochem Biophys, 1996, 331(2), 241-8."

>  <ID<1>>
T6991

$$$$
StarDrop ID 517
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 7 6 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 4.7732 -0.2041 0.0000 0
M  V30 2 N 3.9482 -0.2041 0.0000 0 CHG=1
M  V30 3 C 3.9482 0.6209 0.0000 0
M  V30 4 C 3.9482 -1.0291 0.0000 0
M  V30 5 C 3.1232 -0.2041 0.0000 0
M  V30 6 C 2.7107 0.5103 0.0000 0
M  V30 7 O 1.8857 0.5103 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
517

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Choline

>  <Synonyms>
N/A

>  <CAS>
123-41-1

>  <Formula>
C5H15NO2

>  <MolWt>
121.2

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
"Choline is a ubiquitous water soluble nutrient, often associated with the B vitamins"

>  <Reference>
"Wiedeman A , Barr S , Green T , et al. Dietary Choline Intake: Current State of Knowledge Across the Life Cycle[J]. Nutrients, 2018, 10(10).;Hollenbeck C B . An Introduction to the Nutrition and Metabolism of Choline[J]. Central Nervous System Agents in Medicinal Chemistry, 2012, 12(2):-."

>  <ID<1>>
T8734

$$$$
StarDrop ID 518
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 29 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.3513 -1.6500 0.0000 0
M  V30 2 C -0.2898 -2.1692 0.0000 0
M  V30 3 N -0.2467 -2.9931 0.0000 0
M  V30 4 C -1.0169 -3.2887 0.0000 0
M  V30 5 C -1.5361 -2.6476 0.0000 0
M  V30 6 S -1.0867 -1.9557 0.0000 0
M  V30 7 C -1.2304 -4.0856 0.0000 0
M  V30 8 C -2.0273 -4.2991 0.0000 0
M  V30 9 C -2.6107 -3.7158 0.0000 0
M  V30 10 C -3.4075 -3.9293 0.0000 0
M  V30 11 O -3.6211 -4.7262 0.0000 0
M  V30 12 O -3.9909 -3.3459 0.0000 0
M  V30 13 C -0.6470 -4.6690 0.0000 0
M  V30 14 O -0.8606 -5.4659 0.0000 0
M  V30 15 N 0.1499 -4.4554 0.0000 0
M  V30 16 C 0.7332 -5.0388 0.0000 0
M  V30 17 C 1.5582 -5.0388 0.0000 0
M  V30 18 S 2.2727 -4.6263 0.0000 0
M  V30 19 C 2.9872 -5.0388 0.0000 0
M  V30 20 C 2.9872 -5.8638 0.0000 0
M  V30 21 C 2.2727 -6.2763 0.0000 0
M  V30 22 N 1.5582 -5.8638 0.0000 0
M  V30 23 C 0.7332 -5.8638 0.0000 0
M  V30 24 O 0.1499 -6.4472 0.0000 0
M  V30 25 C 2.2727 -7.1013 0.0000 0
M  V30 26 O 2.9872 -7.5138 0.0000 0
M  V30 27 O 1.5582 -7.5138 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 2 6
M  V30 7 1 4 7
M  V30 8 2 7 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 2 10 12
M  V30 13 1 7 13
M  V30 14 2 13 14
M  V30 15 1 13 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 18 19
M  V30 20 1 19 20
M  V30 21 2 20 21
M  V30 22 1 21 22
M  V30 23 1 17 22
M  V30 24 1 22 23
M  V30 25 1 16 23
M  V30 26 2 23 24
M  V30 27 1 21 25
M  V30 28 1 25 26
M  V30 29 2 25 27
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
518

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ceftibuten dihydrate

>  <Synonyms>
Sch-39720 dihydrate

>  <CAS>
118081-34-8

>  <Formula>
C15H18N4O8S2

>  <MolWt>
446.5

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
"Ceftibuten dihydrate is the dihydrate form of ceftibuten, and is a third-generation cephalosporin with antibacterial activity."

>  <Reference>
"Wise R, et al. Ceftibuten--in-vitro activity against respiratory pathogens, beta-lactamase stability and mechanism of action. J Antimicrob Chemother, 1990. 26(2): p. 209-213.;JONES, RONALD N. Ceftibuten: a review of antimicrobial activity, spectrum and other microbiologic features.[J]. Pediatric Infectious Disease Journal, 1995, 14(14):S77-83."

>  <ID<1>>
T4405

$$$$
StarDrop ID 519
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 37 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O 9.7037 1.5852 0.0000 0
M  V30 2 C 9.2912 0.8708 0.0000 0
M  V30 3 C 8.4662 0.8708 0.0000 0
M  V30 4 C 8.0537 0.1563 0.0000 0
M  V30 5 N 8.4662 -0.5582 0.0000 0
M  V30 6 C 9.2912 -0.5582 0.0000 0
M  V30 7 C 9.7037 0.1563 0.0000 0
M  V30 8 C 10.5287 0.1563 0.0000 0
M  V30 9 O 10.9412 0.8708 0.0000 0
M  V30 10 O 10.9412 -0.5582 0.0000 0
M  V30 11 C 8.0537 -1.2727 0.0000 0
M  V30 12 C 8.4662 -1.9871 0.0000 0
M  V30 13 F 9.2912 -1.9871 0.0000 0
M  V30 14 C 8.0537 -2.7016 0.0000 0
M  V30 15 C 7.2287 -2.7016 0.0000 0
M  V30 16 F 6.8162 -3.4161 0.0000 0
M  V30 17 C 6.8162 -1.9871 0.0000 0
M  V30 18 C 7.2287 -1.2727 0.0000 0
M  V30 19 N 7.2287 0.1563 0.0000 0
M  V30 20 C 6.8162 0.8708 0.0000 0
M  V30 21 C 7.2287 1.5852 0.0000 0
M  V30 22 F 6.8162 2.2997 0.0000 0
M  V30 23 C 8.0537 1.5852 0.0000 0
M  V30 24 N 5.9912 0.8708 0.0000 0
M  V30 25 C 5.5062 0.2033 0.0000 0
M  V30 26 C 4.7216 0.4583 0.0000 0 CFG=1
M  V30 27 C 4.7216 1.2833 0.0000 0 CFG=1
M  V30 28 C 5.5062 1.5382 0.0000 0
M  V30 29 C 4.0071 0.8708 0.0000 0 CFG=2
M  V30 30 N 3.1821 0.8708 0.0000 0
M  V30 31 H 4.3861 2.0369 0.0000 0
M  V30 32 H 4.3861 -0.2954 0.0000 0
M  V30 33 H 3.7483 -0.0951 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 2 7
M  V30 8 1 7 8
M  V30 9 1 8 9
M  V30 10 2 8 10
M  V30 11 1 5 11
M  V30 12 2 11 12
M  V30 13 1 12 13
M  V30 14 1 12 14
M  V30 15 2 14 15
M  V30 16 1 15 16
M  V30 17 1 15 17
M  V30 18 2 17 18
M  V30 19 1 11 18
M  V30 20 2 4 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 21 22
M  V30 24 1 21 23
M  V30 25 2 3 23
M  V30 26 1 20 24
M  V30 27 1 24 25
M  V30 28 1 26 25
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 24 28
M  V30 32 1 27 29
M  V30 33 1 26 29
M  V30 34 1 29 30 CFG=1
M  V30 35 1 27 31 CFG=1
M  V30 36 1 26 32 CFG=1
M  V30 37 1 33 29
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
519

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Trovafloxacin mesylate

>  <Synonyms>
N/A

>  <CAS>
147059-75-4

>  <Formula>
C21H19F3N4O6S

>  <MolWt>
512.5

>  <Pathways>
Microbiology/Virology;Others;DNA Damage/DNA Repair;Cell Cycle/Checkpoint

>  <Target>
Others;DNA/RNA Synthesis;Topoisomerase;Antibacterial

>  <Receptor>
 Pannexin 1 channel (PANX1):4 ??M 

>  <Bioactivity>
"Trovafloxacin mesylate is an effective and selective inhibitor of pannexin 1 channel (PANX1, IC50 = 4 ??M). Trovafloxacin mesylate exhibits potent activity against Gram-positive, Gram-negative, and anaerobic organisms. Trovafloxacin mesylate blocks the DNA gyrase and topoisomerase IV activity."

>  <Reference>
"Giustarini G, et al. The hepatotoxic fluoroquinolone trovafloxacin disturbs TNF- and LPS-induced p65 nuclear translocation in vivo and in vitro. Toxicol Appl Pharmacol. 2020 Mar 15;391:114915.;Gootz TD, et al. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother. 1996 Dec;40(12):2691-7.;Poon IK, et al. Unexpected link between an antibiotic, pannexin channels and apoptosis. Nature. 2014 Mar 20;507(7492):329-34."

>  <ID<1>>
T13231L

$$$$
StarDrop ID 520
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 35 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 3.1821 -0.6679 0.0000 0
M  V30 2 N 3.9891 -0.8394 0.0000 0
M  V30 3 C 4.5411 -0.2263 0.0000 0
M  V30 4 C 5.3481 -0.3979 0.0000 0
M  V30 5 C 6.0156 0.0871 0.0000 0
M  V30 6 C 6.6830 -0.3979 0.0000 0 CFG=1
M  V30 7 C 6.4281 -1.1825 0.0000 0 CFG=1
M  V30 8 N 5.6031 -1.1825 0.0000 0
M  V30 9 C 5.0510 -1.7956 0.0000 0
M  V30 10 C 4.2441 -1.6240 0.0000 0
M  V30 11 C 6.9801 -1.7956 0.0000 0
M  V30 12 C 7.7871 -1.6240 0.0000 0
M  V30 13 N 8.0420 -0.8394 0.0000 0
M  V30 14 C 8.8490 -0.6679 0.0000 0
M  V30 15 C 9.1039 0.1167 0.0000 0
M  V30 16 C 9.9109 0.2883 0.0000 0
M  V30 17 C 10.1658 1.0729 0.0000 0
M  V30 18 O 9.6138 1.6860 0.0000 0
M  V30 19 C 10.9728 1.2444 0.0000 0
M  V30 20 C 11.2277 2.0290 0.0000 0
M  V30 21 C 12.0347 2.2006 0.0000 0
M  V30 22 C 12.5867 1.5875 0.0000 0
M  V30 23 F 13.3937 1.7590 0.0000 0
M  V30 24 C 12.3318 0.8028 0.0000 0
M  V30 25 C 11.5248 0.6313 0.0000 0
M  V30 26 C 7.4900 -0.2263 0.0000 0
M  V30 27 H 6.0925 -1.9362 0.0000 0
M  V30 28 H 7.2350 -1.0109 0.0000 0
M  V30 29 C 5.9293 0.9075 0.0000 0
M  V30 30 C 5.1756 1.2431 0.0000 0
M  V30 31 C 4.5082 0.7582 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 4 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 2 10
M  V30 12 1 7 11
M  V30 13 1 11 12
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 1 16 17
M  V30 19 2 17 18
M  V30 20 1 17 19
M  V30 21 2 19 20
M  V30 22 1 20 21
M  V30 23 2 21 22
M  V30 24 1 22 23
M  V30 25 1 22 24
M  V30 26 2 24 25
M  V30 27 1 19 25
M  V30 28 1 13 26
M  V30 29 1 6 26
M  V30 30 1 7 27 CFG=1
M  V30 31 1 6 28 CFG=1
M  V30 32 2 5 29
M  V30 33 1 29 30
M  V30 34 2 30 31
M  V30 35 1 3 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
520

>  <Plate>
PHD136329

>  <Row>
j

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
lumateperone Tosylate

>  <Synonyms>
ITI-007

>  <CAS>
1187020-80-9

>  <Formula>
C31H36FN3O4S

>  <MolWt>
565.7

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Dopamine Receptor;5-HT Receptor

>  <Receptor>
" 5-HT2A Receptor:0.54 nM (Ki), SERT:61 nM (Ki)"

>  <Bioactivity>
"Lumateperone Tosylate is a 5-HT2A receptor antagonist (Ki: 0.54 nM), a SERT blocker (Ki: 61 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki: 32 nM)."

>  <Reference>
"Vyas P, et al. An evaluation of lumateperone tosylate for the treatment of schizophrenia. Expert Opin Pharmacother. 2020 Feb;21(2):139-145."

>  <ID<1>>
TQ0084

$$$$
StarDrop ID 521
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.2665 -0.6244 0.0000 0
M  V30 2 C 0.7145 -1.2375 0.0000 0
M  V30 3 C 0.1624 -0.6244 0.0000 0
M  V30 4 N 1.3819 -1.7224 0.0000 0
M  V30 5 C 1.1270 -2.5070 0.0000 0
M  V30 6 S 1.6119 -3.1745 0.0000 0
M  V30 7 N 0.3020 -2.5070 0.0000 0
M  V30 8 C 0.0470 -1.7224 0.0000 0
M  V30 9 O -0.7376 -1.4675 0.0000 0
M  V30 10 C -0.1830 -3.1745 0.0000 0
M  V30 11 C 0.1526 -3.9282 0.0000 0
M  V30 12 C -0.3323 -4.5956 0.0000 0
M  V30 13 C -1.1528 -4.5094 0.0000 0
M  V30 14 C -1.6377 -5.1768 0.0000 0
M  V30 15 N -2.1226 -5.8442 0.0000 0
M  V30 16 C -1.4884 -3.7557 0.0000 0
M  V30 17 C -1.0034 -3.0882 0.0000 0
M  V30 18 C -2.3088 -3.6695 0.0000 0
M  V30 19 F -3.1293 -3.5832 0.0000 0
M  V30 20 F -2.2226 -2.8490 0.0000 0
M  V30 21 F -2.3951 -4.4899 0.0000 0
M  V30 22 C 2.1665 -1.4675 0.0000 0
M  V30 23 C 2.3381 -0.6605 0.0000 0
M  V30 24 C 3.1227 -0.4056 0.0000 0
M  V30 25 C 3.7358 -0.9576 0.0000 0
M  V30 26 C 4.5204 -0.7027 0.0000 0
M  V30 27 O 4.6919 0.1043 0.0000 0
M  V30 28 O 5.1335 -1.2547 0.0000 0
M  V30 29 C 3.5642 -1.7646 0.0000 0
M  V30 30 F 4.1773 -2.3166 0.0000 0
M  V30 31 C 2.7796 -2.0195 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 2 8
M  V30 9 2 8 9
M  V30 10 1 7 10
M  V30 11 2 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 3 14 15
M  V30 16 1 13 16
M  V30 17 2 16 17
M  V30 18 1 10 17
M  V30 19 1 16 18
M  V30 20 1 18 19
M  V30 21 1 18 20
M  V30 22 1 18 21
M  V30 23 1 4 22
M  V30 24 2 22 23
M  V30 25 1 23 24
M  V30 26 2 24 25
M  V30 27 1 25 26
M  V30 28 1 26 27
M  V30 29 2 26 28
M  V30 30 1 25 29
M  V30 31 1 29 30
M  V30 32 2 29 31
M  V30 33 1 22 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
521

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Enzalutamide carboxylic acid

>  <Synonyms>
N/A

>  <CAS>
1242137-15-0

>  <Formula>
C20H13F4N3O3S

>  <MolWt>
451.4

>  <Pathways>
Endocrinology/Hormones;Metabolism

>  <Target>
Androgen Receptor;Drug Metabolite

>  <Receptor>
Androgen Receptor; Drug Metabolite

>  <Bioactivity>
Enzalutamide carboxylic acid is an antagonist of androgen receptor (AR) .

>  <Reference>
"van Nuland M, et al. Exposure-Response Assessment of Enzalutamide and Its Major Metabolites in a Real-World Cohort of Patients with Metastatic Castration-Resistant Prostate Cancer. Pharmacotherapy. 2019 Dec;39(12):1137-1145."

>  <ID<1>>
T8217

$$$$
StarDrop ID 522
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -3.9159 -5.3615 0.0000 0
M  V30 2 C -3.1089 -5.1900 0.0000 0
M  V30 3 C -2.8540 -4.4054 0.0000 0
M  V30 4 S -2.0470 -4.2338 0.0000 0
M  V30 5 O -1.8755 -5.0408 0.0000 0
M  V30 6 O -2.2185 -3.4269 0.0000 0
M  V30 7 N -1.2400 -4.0623 0.0000 0
M  V30 8 C -0.9851 -3.2777 0.0000 0
M  V30 9 C -1.5371 -2.6646 0.0000 0
M  V30 10 C -1.2822 -1.8800 0.0000 0
M  V30 11 C -0.4752 -1.7084 0.0000 0
M  V30 12 F -0.2203 -0.9238 0.0000 0
M  V30 13 C 0.0768 -2.3215 0.0000 0
M  V30 14 C 0.8838 -2.1500 0.0000 0
M  V30 15 O 1.4358 -2.7631 0.0000 0
M  V30 16 C 1.1387 -1.3654 0.0000 0
M  V30 17 C 0.6538 -0.6979 0.0000 0
M  V30 18 N 1.1387 -0.0305 0.0000 0
M  V30 19 C 1.9233 -0.2854 0.0000 0
M  V30 20 N 2.6378 0.1271 0.0000 0
M  V30 21 C 3.3523 -0.2854 0.0000 0
M  V30 22 C 3.3523 -1.1104 0.0000 0
M  V30 23 C 2.6378 -1.5229 0.0000 0
M  V30 24 C 1.9233 -1.1104 0.0000 0
M  V30 25 C 4.0668 -1.5229 0.0000 0
M  V30 26 C 4.7812 -1.1104 0.0000 0
M  V30 27 C 5.4957 -1.5229 0.0000 0
M  V30 28 C 5.4957 -2.3479 0.0000 0
M  V30 29 Cl 6.2102 -2.7604 0.0000 0
M  V30 30 C 4.7812 -2.7604 0.0000 0
M  V30 31 C 4.0668 -2.3479 0.0000 0
M  V30 32 C -0.1781 -3.1062 0.0000 0
M  V30 33 F 0.3739 -3.7192 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 2 4 6
M  V30 6 1 4 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 14 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 19 20
M  V30 20 2 20 21
M  V30 21 1 21 22
M  V30 22 2 22 23
M  V30 23 1 23 24
M  V30 24 2 16 24
M  V30 25 1 19 24
M  V30 26 1 22 25
M  V30 27 2 25 26
M  V30 28 1 26 27
M  V30 29 2 27 28
M  V30 30 1 28 29
M  V30 31 1 28 30
M  V30 32 2 30 31
M  V30 33 1 25 31
M  V30 34 1 13 32
M  V30 35 2 8 32
M  V30 36 1 32 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
522

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Plx-4032

>  <Synonyms>
Vemurafenib

>  <CAS>
1029872-54-5

>  <Formula>
C23H18ClF2N3O3S

>  <MolWt>
489.9

>  <Pathways>
MAPK

>  <Target>
Raf

>  <Receptor>
B-Raf

>  <Bioactivity>
PLX-4032 is a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.

>  <Reference>
"Chapman, Paul, B, et al. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation.[J]. New England Journal of Medicine, 2011.;Smalley K S M . PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma.[J]. Current Opinion in Investigational Drugs, 2010, 11(6):699-706."

>  <ID<1>>
T8654

$$$$
StarDrop ID 523
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 29 32 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -0.0000 -2.4750 0.0000 0
M  V30 2 C -0.0000 -1.6500 0.0000 0
M  V30 3 C 0.7145 -1.2375 0.0000 0
M  V30 4 C 0.7145 -0.4125 0.0000 0
M  V30 5 N 0.0000 -0.0000 0.0000 0
M  V30 6 C -0.7145 -0.4125 0.0000 0
M  V30 7 N -0.7145 -1.2375 0.0000 0
M  V30 8 N -1.4289 -0.0000 0.0000 0
M  V30 9 C -2.1434 -0.4125 0.0000 0
M  V30 10 C -2.8579 0.0000 0.0000 0
M  V30 11 N -2.8579 0.8250 0.0000 0
M  V30 12 C -3.5724 1.2375 0.0000 0
M  V30 13 O -4.2868 0.8250 0.0000 0
M  V30 14 C -3.5724 2.0625 0.0000 0 CFG=1
M  V30 15 C -4.2398 2.5474 0.0000 0
M  V30 16 C -3.9849 3.3320 0.0000 0
M  V30 17 C -3.1599 3.3320 0.0000 0
M  V30 18 O -2.9049 2.5474 0.0000 0
M  V30 19 C -2.1434 1.2375 0.0000 0
M  V30 20 C -1.4289 0.8250 0.0000 0
M  V30 21 C 1.4289 -0.0000 0.0000 0
M  V30 22 C 2.1434 -0.4125 0.0000 0
M  V30 23 O 2.8579 -0.0000 0.0000 0
M  V30 24 C 3.5724 -0.4125 0.0000 0
M  V30 25 C 2.1434 -1.2375 0.0000 0
M  V30 26 O 2.8579 -1.6500 0.0000 0
M  V30 27 C 3.5724 -1.2375 0.0000 0
M  V30 28 C 1.4289 -1.6500 0.0000 0
M  V30 29 H -4.4634 1.6085 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 2 7
M  V30 8 1 6 8
M  V30 9 1 8 9
M  V30 10 1 9 10
M  V30 11 1 10 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 14 12 CFG=1
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 1 14 18
M  V30 20 1 11 19
M  V30 21 1 19 20
M  V30 22 1 8 20
M  V30 23 1 4 21
M  V30 24 2 21 22
M  V30 25 1 22 23
M  V30 26 1 23 24
M  V30 27 1 22 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 2 25 28
M  V30 31 1 3 28
M  V30 32 1 29 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
523

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
(R)-Terazosin

>  <Synonyms>
N/A

>  <CAS>
109351-34-0

>  <Formula>
C19H25N5O4

>  <MolWt>
387.4

>  <Pathways>
GPCR/G Protein;Neuroscience

>  <Target>
Adrenergic Receptor

>  <Receptor>
" ??1a-adrenoceptor:6.51 nM (Ki), ??1b-adrenoceptor:1.01 nM (Ki), ??1D-adrenoceptor:1.97 nM (Ki)"

>  <Bioactivity>
"(R)-Terazosin is an active R-enantiomer of Terazosin. (R)-Terazosin is a potent antagonist of ??1-adrenoceptor (??1a, ??1b and ??1d-adrenoceptor with Ki values of 6.51 nM, 1.01 nM and 1.97 nM, respectively)."

>  <Reference>
"Hancock AA, et al. Actions of terazosin and its enantiomers at subtypes of alpha 1- and alpha 2-adrenoceptors in vitro. J Recept Signal Transduct Res. 1995 Sep-Dec;15(7-8):863-85."

>  <ID<1>>
T12643

$$$$
StarDrop ID 524
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 4.4206 0.6331 0.0000 0
M  V30 2 C 3.7061 1.0456 0.0000 0
M  V30 3 C 3.7061 1.8706 0.0000 0
M  V30 4 C 4.4206 2.2831 0.0000 0
M  V30 5 C 5.1351 1.8706 0.0000 0
M  V30 6 C 5.8495 2.2831 0.0000 0
M  V30 7 C 6.5640 1.8706 0.0000 0
M  V30 8 O 7.2785 2.2831 0.0000 0
M  V30 9 O 6.5640 1.0456 0.0000 0
M  V30 10 C 4.4206 -0.1919 0.0000 0 CFG=2
M  V30 11 C 5.0880 -0.6769 0.0000 0 CFG=1
M  V30 12 C 5.8726 -0.4219 0.0000 0
M  V30 13 C 6.4857 -0.9739 0.0000 0
M  V30 14 C 7.2704 -0.7190 0.0000 0 CFG=1
M  V30 15 C 8.0550 -0.4641 0.0000 0
M  V30 16 C 8.6681 -1.0161 0.0000 0
M  V30 17 C 9.4527 -0.7612 0.0000 0
M  V30 18 C 10.0658 -1.3132 0.0000 0
M  V30 19 C 10.8504 -1.0583 0.0000 0
M  V30 20 C 7.5253 -1.5036 0.0000 0
M  V30 21 O 7.0154 0.0656 0.0000 0
M  V30 22 C 4.8331 -1.4615 0.0000 0 CFG=2
M  V30 23 O 5.3180 -2.1289 0.0000 0
M  V30 24 C 4.0081 -1.4615 0.0000 0
M  V30 25 C 3.7531 -0.6769 0.0000 0 CFG=2
M  V30 26 O 2.9685 -0.4219 0.0000 0
M  V30 27 H 5.3116 0.2620 0.0000 0
M  V30 28 H 5.2444 0.3108 0.0000 0
M  V30 29 H 5.8208 -1.3050 0.0000 0
M  V30 30 H 3.5968 0.3108 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 9 1 10 1 CFG=3
M  V30 10 1 10 11
M  V30 11 1 11 12 CFG=1
M  V30 12 2 12 13
M  V30 13 1 14 13 CFG=1
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 14 20
M  V30 20 1 14 21 CFG=3
M  V30 21 1 11 22
M  V30 22 1 22 23 CFG=3
M  V30 23 1 22 24
M  V30 24 1 25 24
M  V30 25 1 10 25
M  V30 26 1 25 26 CFG=3
M  V30 27 1 27 10
M  V30 28 1 28 11
M  V30 29 1 29 22
M  V30 30 1 30 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
524

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Carboprost tromethamine

>  <Synonyms>
N/A

>  <CAS>
58551-69-2

>  <Formula>
C25H47NO8

>  <MolWt>
489.6

>  <Pathways>
Immunology/Inflammation;GPCR/G Protein

>  <Target>
Prostaglandin Receptor

>  <Receptor>
prostaglandin F2??; Prostaglandin Receptor

>  <Bioactivity>
Carboprost tromethamine is the synthetic 15-methyl analogue of prostaglandin F2?? and it can effectively promote law contraction of the uterus and significantly reduce the amount of bleeding during and after delivery.

>  <Reference>
"Ling Z, et al. Effect of carboprost tromethamine in prevention of postpartum hemorrhage in cesarean section. Pak J Pharm Sci. 2018 Sep;31(5(Special)):2257-2262.;Bai J, et al. A comparison of oxytocin and carboprost tromethamine in the prevention of postpartum hemorrhage in high-risk patients undergoing cesarean delivery. Exp Ther Med. 2014 Jan;7(1):46-50. Epub 2013 Nov 1."

>  <ID<1>>
T14865

$$$$
StarDrop ID 525
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 25 26 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 0.0000 -7.4250 0.0000 0
M  V30 2 C 0.0000 -6.6000 0.0000 0
M  V30 3 N -0.7145 -6.1875 0.0000 0
M  V30 4 C 0.7145 -6.1875 0.0000 0
M  V30 5 C 0.7145 -5.3625 0.0000 0
M  V30 6 C 1.4289 -4.9500 0.0000 0
M  V30 7 C 2.1434 -5.3625 0.0000 0
M  V30 8 O 2.8579 -4.9500 0.0000 0
M  V30 9 C 3.5724 -5.3625 0.0000 0
M  V30 10 C 4.2868 -4.9500 0.0000 0
M  V30 11 C 5.0013 -5.3625 0.0000 0
M  V30 12 C 5.7158 -4.9500 0.0000 0
M  V30 13 C 6.4302 -5.3625 0.0000 0
M  V30 14 O 7.1447 -4.9500 0.0000 0
M  V30 15 C 7.8592 -5.3625 0.0000 0
M  V30 16 C 8.5737 -4.9500 0.0000 0
M  V30 17 C 9.2881 -5.3625 0.0000 0
M  V30 18 C 9.2881 -6.1875 0.0000 0
M  V30 19 C 8.5737 -6.6000 0.0000 0
M  V30 20 C 7.8592 -6.1875 0.0000 0
M  V30 21 C 10.0026 -6.6000 0.0000 0
M  V30 22 N 10.7171 -6.1875 0.0000 0
M  V30 23 N 10.0026 -7.4250 0.0000 0
M  V30 24 C 2.1434 -6.1875 0.0000 0
M  V30 25 C 1.4289 -6.6000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 16 17
M  V30 17 2 17 18
M  V30 18 1 18 19
M  V30 19 2 19 20
M  V30 20 1 15 20
M  V30 21 1 18 21
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 7 24
M  V30 25 2 24 25
M  V30 26 1 4 25
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
525

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Pentamidine

>  <Synonyms>
N/A

>  <CAS>
100-33-4

>  <Formula>
C19H24N4O2

>  <MolWt>
340.4

>  <Pathways>
Microbiology/Virology;Metabolism

>  <Target>
Parasite;Phosphatase;Antibiotic;Antibacterial;Antifungal

>  <Receptor>
 Leishmania infantum:2.5 ??M (IC50)

>  <Bioactivity>
"Pentamidine is an antifungal and antiprotozoal agent, interacting directly with the pathogen genome by binding to AT-rich regions of duplex DNA and the minor groove of DNA, thereby interfering with DNA replication."

>  <Reference>
"Carton F , Chevalier Y , Nicoletti L , et al. Rationally designed hyaluronic acid-based nano-complexes for pentamidine delivery[J]. International Journal of Pharmaceutics, 2019, 568:118526.;Michael S , Kron M A , Brown R B . Pentamidine: A Review[J]. Reviews of Infectious Diseases(5):625."

>  <ID<1>>
T23133

$$$$
StarDrop ID 526
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 0.0000 4.1250 0.0000 0
M  V30 2 C 0.0000 3.3000 0.0000 0
M  V30 3 N 0.7145 2.8875 0.0000 0
M  V30 4 S 0.7145 2.0625 0.0000 0
M  V30 5 O -0.1105 2.0625 0.0000 0
M  V30 6 O 1.5395 2.0625 0.0000 0
M  V30 7 C 0.7145 1.2375 0.0000 0
M  V30 8 C 1.4289 0.8250 0.0000 0
M  V30 9 C 1.4289 -0.0000 0.0000 0
M  V30 10 C 0.7145 -0.4125 0.0000 0
M  V30 11 N 0.7145 -1.2375 0.0000 0
M  V30 12 C 0.0000 0.0000 0.0000 0
M  V30 13 C 0.0000 0.8250 0.0000 0
M  V30 14 C -0.7145 2.8875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 2 4 6
M  V30 6 1 4 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 2 12 13
M  V30 13 1 7 13
M  V30 14 1 2 14
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
526

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Sulfacetamide

>  <Synonyms>
Sulphacetamide;Acetosulfamine;NSC63871;NSC 63871;Sebizon;Region;NSC-63871

>  <CAS>
144-80-9

>  <Formula>
C8H10N2O3S

>  <MolWt>
214.2

>  <Pathways>
Microbiology/Virology;Others

>  <Target>
Others;Antibiotic;Antibacterial

>  <Receptor>
Antibiotic; Bacterial

>  <Bioactivity>
Sulfacetamide is used to treat blepharitis or conjunctivitis (in eye-drop solution) by limiting the presence of folic acid which bacteria need to survive. sulfacetamide may serve as a treatment for mild forms of hidradenitis suppurativa. It is also used to control acne.

>  <Reference>
"T??z??n Y, Wolf R, Kutlubay Z, Karaku? O, Engin B. Rosacea and rhinophyma. Clin Dermatol. 2014 Jan-Feb;32(1):35-46. doi: 10.1016/j.clindermatol.2013.05.024. Review. PubMed PMID: 24314376.;van Zuuren EJ, Kramer SF, Carter BR, Graber MA, Fedorowicz Z. Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review. Br J Dermatol. 2011 Oct;165(4):760-81. doi: 10.1111/j.1365-2133.2011.10473.x. Epub 2011 Sep 15. Review. PubMed PMID: 21692773.;Bartlett KB, Davis SA, Feldman SR. Tolerability of topical antimicrobials in treatment of acne vulgaris. J Drugs Dermatol. 2014 Jun;13(6):658-62. Review. PubMed PMID: 24918554.;Emer J, Waldorf H, Berson D. Botanicals and anti-inflammatories: natural ingredients for rosacea. Semin Cutan Med Surg. 2011 Sep;30(3):148-55. doi: 10.1016/j.sder.2011.05.007. Review. PubMed PMID: 21925368."

>  <ID<1>>
T21434

$$$$
StarDrop ID 527
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 30 34 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.5330 -3.2587 0.0000 0
M  V30 2 C 3.8928 -2.5163 0.0000 0
M  V30 3 C 4.4247 -3.1470 0.0000 0
M  V30 4 C 5.2368 -3.0018 0.0000 0
M  V30 5 C 5.5171 -2.2259 0.0000 0
M  V30 6 C 4.9853 -1.5952 0.0000 0
M  V30 7 C 5.2655 -0.8192 0.0000 0
M  V30 8 C 6.0777 -0.6740 0.0000 0
M  V30 9 C 6.6095 -1.3047 0.0000 0
M  V30 10 C 7.4216 -1.1595 0.0000 0
M  V30 11 C 7.9534 -1.7902 0.0000 0
M  V30 12 O 8.7655 -1.6450 0.0000 0
M  V30 13 C 7.6731 -2.5662 0.0000 0
M  V30 14 C 6.8610 -2.7114 0.0000 0
M  V30 15 C 6.3292 -2.0807 0.0000 0
M  V30 16 C 4.1731 -1.7404 0.0000 0
M  V30 17 C 3.5218 -1.2340 0.0000 0
M  V30 18 C 2.8390 -1.6970 0.0000 0
M  V30 19 C 3.0683 -2.4895 0.0000 0
M  V30 20 O 2.5619 -3.1408 0.0000 0
M  V30 21 C 2.8728 -3.9050 0.0000 0
M  V30 22 O 3.6900 -4.0179 0.0000 0
M  V30 23 C 2.3665 -4.5563 0.0000 0
M  V30 24 C 2.6773 -5.3205 0.0000 0
M  V30 25 C 2.1710 -5.9718 0.0000 0
M  V30 26 C 2.4819 -6.7360 0.0000 0
M  V30 27 C 1.9755 -7.3874 0.0000 0
M  V30 28 C 1.1583 -7.2745 0.0000 0
M  V30 29 C 0.8474 -6.5103 0.0000 0
M  V30 30 C 1.3537 -5.8590 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 10 11
M  V30 11 2 11 12
M  V30 12 1 11 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 5 15
M  V30 16 1 9 15
M  V30 17 1 6 16
M  V30 18 1 2 16
M  V30 19 1 16 17
M  V30 20 1 17 18
M  V30 21 1 18 19
M  V30 22 1 2 19
M  V30 23 1 19 20
M  V30 24 1 20 21
M  V30 25 2 21 22
M  V30 26 1 21 23
M  V30 27 1 23 24
M  V30 28 1 24 25
M  V30 29 2 25 26
M  V30 30 1 26 27
M  V30 31 2 27 28
M  V30 32 1 28 29
M  V30 33 2 29 30
M  V30 34 1 25 30
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
527

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Nandrolone phenylpropionate

>  <Synonyms>
Nandrolone phenpropionate

>  <CAS>
62-90-8

>  <Formula>
C27H34O3

>  <MolWt>
406.6

>  <Pathways>
Endocrinology/Hormones

>  <Target>
Androgen Receptor

>  <Receptor>
androgen receptor

>  <Bioactivity>
Nandrolone phenpropionate is an androgen receptor agonist. It mainly used to treat women with breast cancer and osteoporosis

>  <Reference>
"Kahn S B , Conroy J F , Brodsky I . Effect of nandrolone phenpropionate on myelopoiesis[J]. Journal of Medicine, 1974, 5(6):303.;J. Elks. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. 14 November 2014: 660?C. ISBN 978-1-4757-2085-3."

>  <ID<1>>
T8709

$$$$
StarDrop ID 528
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 41 44 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 12.8605 -1.6500 0.0000 0
M  V30 2 C 13.5749 -2.0625 0.0000 0
M  V30 3 C 14.2894 -1.6500 0.0000 0
M  V30 4 C 15.0039 -2.0625 0.0000 0
M  V30 5 C 15.7184 -1.6500 0.0000 0
M  V30 6 C 16.4328 -2.0625 0.0000 0
M  V30 7 C 17.1473 -1.6500 0.0000 0
M  V30 8 C 17.8618 -2.0625 0.0000 0
M  V30 9 C 18.5762 -1.6500 0.0000 0
M  V30 10 C 19.2907 -2.0625 0.0000 0
M  V30 11 O 19.2907 -2.8875 0.0000 0
M  V30 12 O 20.0052 -1.6500 0.0000 0
M  V30 13 C 20.7197 -2.0625 0.0000 0
M  V30 14 C 21.4341 -1.6500 0.0000 0
M  V30 15 N 22.1486 -2.0625 0.0000 0
M  V30 16 C 22.8631 -1.6500 0.0000 0
M  V30 17 C 23.5775 -2.0625 0.0000 0
M  V30 18 N 23.5775 -2.8875 0.0000 0
M  V30 19 C 24.2920 -3.3000 0.0000 0
M  V30 20 C 25.0065 -2.8875 0.0000 0
M  V30 21 C 25.7210 -3.3000 0.0000 0
M  V30 22 N 26.4354 -2.8875 0.0000 0
M  V30 23 C 26.4354 -2.0625 0.0000 0
M  V30 24 C 25.7210 -1.6500 0.0000 0
M  V30 25 C 25.7210 -0.8250 0.0000 0
M  V30 26 C 26.4354 -0.4125 0.0000 0
M  V30 27 C 27.1499 -0.8250 0.0000 0
M  V30 28 C 27.1499 -1.6500 0.0000 0
M  V30 29 S 27.8644 -2.0625 0.0000 0
M  V30 30 C 27.8644 -2.8875 0.0000 0
M  V30 31 C 28.5788 -3.3000 0.0000 0
M  V30 32 C 28.5788 -4.1250 0.0000 0
M  V30 33 C 27.8644 -4.5375 0.0000 0
M  V30 34 C 27.1499 -4.1250 0.0000 0
M  V30 35 C 27.1499 -3.3000 0.0000 0
M  V30 36 C 27.8644 -5.3625 0.0000 0
M  V30 37 F 27.8644 -6.1875 0.0000 0
M  V30 38 F 27.0394 -5.3625 0.0000 0
M  V30 39 F 28.6894 -5.3625 0.0000 0
M  V30 40 C 22.8631 -3.3000 0.0000 0
M  V30 41 C 22.1486 -2.8875 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 1 14 15
M  V30 15 1 15 16
M  V30 16 1 16 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 2 23 24
M  V30 24 1 24 25
M  V30 25 2 25 26
M  V30 26 1 26 27
M  V30 27 2 27 28
M  V30 28 1 23 28
M  V30 29 1 28 29
M  V30 30 1 29 30
M  V30 31 2 30 31
M  V30 32 1 31 32
M  V30 33 2 32 33
M  V30 34 1 33 34
M  V30 35 2 34 35
M  V30 36 1 22 35
M  V30 37 1 30 35
M  V30 38 1 33 36
M  V30 39 1 36 37
M  V30 40 1 36 38
M  V30 41 1 36 39
M  V30 42 1 18 40
M  V30 43 1 40 41
M  V30 44 1 15 41
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
528

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Fluphenazine decanoate

>  <Synonyms>
N/A

>  <CAS>
5002-47-1

>  <Formula>
C32H44F3N3O2S

>  <MolWt>
591.8

>  <Pathways>
Neuroscience;GPCR/G Protein

>  <Target>
Dopamine Receptor

>  <Receptor>
D2; Dopamine

>  <Bioactivity>
"Fluphenazine decanoate is dopamine D2 receptor blocke,and is a long-acting phenothiazine neuroleptic that used to treat schizophrenia."

>  <Reference>
"Wagman J D , Wolfe B A , Schook M W . The effect of fluphenazine decanoate on glucocorticoid production, reproductive cyclicity, and the behavioral stress response in the Persian onager ( ,?Equus hemionus onager , )[J]. Zoo Biology, 2015, 34(6):525-534.;Falloon I R , Watt D C , Shepherd M . A Comparative Controlled Trial of Pimozide and Fluphenazine Decanoate in the Continuation Therapy of Schizophrenia[J]. Psychological Medicine, 1978, 8(1):59-70."

>  <ID<1>>
T7943

$$$$
StarDrop ID 529
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 32 36 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 4.9683 -0.6565 0.0000 0
M  V30 2 C 5.3808 0.0579 0.0000 0
M  V30 3 C 6.2058 0.0579 0.0000 0
M  V30 4 C 6.6907 0.7254 0.0000 0
M  V30 5 C 7.4754 0.4704 0.0000 0
M  V30 6 C 8.1898 0.8829 0.0000 0
M  V30 7 N 8.9043 0.4704 0.0000 0
M  V30 8 C 8.9043 -0.3546 0.0000 0
M  V30 9 N 8.1898 -0.7671 0.0000 0
M  V30 10 C 7.4754 -0.3546 0.0000 0
M  V30 11 N 6.6907 -0.6095 0.0000 0
M  V30 12 C 6.4358 -1.3941 0.0000 0
M  V30 13 C 6.9207 -2.0616 0.0000 0
M  V30 14 C 6.4358 -2.7290 0.0000 0
M  V30 15 C 5.6512 -2.4741 0.0000 0
M  V30 16 C 5.6512 -1.6491 0.0000 0
M  V30 17 N 9.6188 -0.7671 0.0000 0
M  V30 18 C 10.3332 -0.3546 0.0000 0
M  V30 19 N 10.3332 0.4704 0.0000 0
M  V30 20 C 11.0477 0.8829 0.0000 0
M  V30 21 C 11.7622 0.4704 0.0000 0
M  V30 22 C 11.7622 -0.3546 0.0000 0
M  V30 23 C 11.0477 -0.7671 0.0000 0
M  V30 24 N 12.4767 0.8829 0.0000 0
M  V30 25 C 12.4767 1.7079 0.0000 0
M  V30 26 C 13.1911 2.1204 0.0000 0
M  V30 27 N 13.9056 1.7079 0.0000 0
M  V30 28 C 13.9056 0.8829 0.0000 0
M  V30 29 C 13.1911 0.4704 0.0000 0
M  V30 30 N 4.9683 0.7724 0.0000 0
M  V30 31 C 4.1433 0.7724 0.0000 0
M  V30 32 C 5.3808 1.4869 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 5 10
M  V30 11 1 10 11
M  V30 12 1 3 11
M  V30 13 1 11 12
M  V30 14 1 12 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 1 12 16
M  V30 19 1 8 17
M  V30 20 1 17 18
M  V30 21 2 18 19
M  V30 22 1 19 20
M  V30 23 2 20 21
M  V30 24 1 21 22
M  V30 25 2 22 23
M  V30 26 1 18 23
M  V30 27 1 21 24
M  V30 28 1 24 25
M  V30 29 1 25 26
M  V30 30 1 26 27
M  V30 31 1 27 28
M  V30 32 1 28 29
M  V30 33 1 24 29
M  V30 34 1 2 30
M  V30 35 1 30 31
M  V30 36 1 30 32
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
529

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
DMSO

>  <MOLENAME>
Ribociclib succinate

>  <Synonyms>
LEE011 succinate

>  <CAS>
1374639-75-4

>  <Formula>
C27H36N8O5

>  <MolWt>
552.6

>  <Pathways>
Cell Cycle/Checkpoint

>  <Target>
CDK

>  <Receptor>
" CDK4:10 nM, CDK6:39 nM"

>  <Bioactivity>
"Ribociclib succinate  is a highly specific CDK4/6 inhibitor (IC50: 10 nM and 39 nM, respectively). It also is over 1,000-fold less potent against the cyclin B/CDK1 complex."

>  <Reference>
"VanArsdale T, et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin Cancer Res. 2015 Jul 1;21(13):2905-10.;Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82."

>  <ID<1>>
T15732

$$$$
StarDrop ID 530
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 319 327 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 58.7426 -8.8828 0.0000 0
M  V30 2 C 58.9975 -8.0982 0.0000 0
M  V30 3 C 58.4455 -7.4851 0.0000 0
M  V30 4 C 57.6385 -7.6566 0.0000 0
M  V30 5 C 58.7004 -6.7004 0.0000 0
M  V30 6 N 59.5074 -6.5289 0.0000 0
M  V30 7 C 60.0594 -7.1420 0.0000 0
M  V30 8 O 59.8045 -7.9266 0.0000 0
M  V30 9 C 60.8664 -6.9705 0.0000 0
M  V30 10 C 61.1213 -6.1859 0.0000 0
M  V30 11 C 60.5693 -5.5728 0.0000 0
M  V30 12 C 59.7623 -5.7443 0.0000 0
M  V30 13 C 60.8243 -4.7881 0.0000 0
M  V30 14 N 61.4184 -7.5836 0.0000 0
M  V30 15 C 62.2254 -7.4120 0.0000 0
M  V30 16 O 62.4804 -6.6274 0.0000 0
M  V30 17 C 62.7774 -8.0251 0.0000 0
M  V30 18 C 62.5225 -8.8098 0.0000 0
M  V30 19 O 63.0745 -9.4229 0.0000 0
M  V30 20 N 63.5844 -7.8536 0.0000 0
M  V30 21 C 64.1364 -8.4667 0.0000 0
M  V30 22 O 63.8815 -9.2513 0.0000 0
M  V30 23 C 64.9434 -8.2952 0.0000 0
M  V30 24 C 65.1984 -7.5106 0.0000 0
M  V30 25 C 66.0053 -7.3390 0.0000 0
M  V30 26 C 66.3409 -6.5854 0.0000 0
M  V30 27 N 67.1614 -6.6716 0.0000 0
M  V30 28 C 67.3329 -7.4786 0.0000 0
M  V30 29 N 66.6184 -7.8911 0.0000 0
M  V30 30 N 65.4955 -8.9083 0.0000 0
M  V30 31 C 66.3024 -8.7367 0.0000 0
M  V30 32 O 66.5574 -7.9521 0.0000 0
M  V30 33 C 66.8545 -9.3498 0.0000 0
M  V30 34 N 67.6614 -9.1783 0.0000 0
M  V30 35 C 68.2135 -9.7914 0.0000 0
M  V30 36 O 67.9585 -10.5760 0.0000 0
M  V30 37 C 69.0204 -9.6199 0.0000 0
M  V30 38 C 69.2754 -8.8353 0.0000 0
M  V30 39 C 68.7233 -8.2222 0.0000 0
M  V30 40 C 67.9164 -8.3937 0.0000 0
M  V30 41 C 68.9783 -7.4375 0.0000 0
M  V30 42 N 69.5725 -10.2330 0.0000 0
M  V30 43 C 70.3794 -10.0614 0.0000 0
M  V30 44 O 70.6344 -9.2768 0.0000 0
M  V30 45 C 70.9315 -10.6745 0.0000 0
M  V30 46 C 70.6765 -11.4592 0.0000 0
M  V30 47 O 71.2286 -12.0723 0.0000 0
M  V30 48 N 71.7384 -10.5030 0.0000 0
M  V30 49 C 72.2905 -11.1161 0.0000 0
M  V30 50 O 72.0355 -11.9007 0.0000 0
M  V30 51 C 73.0974 -10.9446 0.0000 0
M  V30 52 N 73.6495 -11.5577 0.0000 0
M  V30 53 C 74.4565 -11.3861 0.0000 0
M  V30 54 O 74.7114 -10.6015 0.0000 0
M  V30 55 C 75.0085 -11.9992 0.0000 0
M  V30 56 C 75.8155 -11.8277 0.0000 0
M  V30 57 C 76.3675 -12.4408 0.0000 0
M  V30 58 C 77.1745 -12.2693 0.0000 0
M  V30 59 C 77.7265 -12.8824 0.0000 0
M  V30 60 C 77.4716 -13.6670 0.0000 0
M  V30 61 O 78.0236 -14.2801 0.0000 0
M  V30 62 C 76.6646 -13.8385 0.0000 0
M  V30 63 C 76.1126 -13.2254 0.0000 0
M  V30 64 N 74.7535 -12.7839 0.0000 0
M  V30 65 C 73.9466 -12.9554 0.0000 0
M  V30 66 C 73.6916 -13.7400 0.0000 0
M  V30 67 O 73.3945 -12.3423 0.0000 0
M  V30 68 C 73.3524 -10.1600 0.0000 0
M  V30 69 C 74.1594 -9.9884 0.0000 0
M  V30 70 O 72.8004 -9.5469 0.0000 0
M  V30 71 C 66.5995 -10.1345 0.0000 0
M  V30 72 C 65.7925 -10.3060 0.0000 0
M  V30 73 C 67.1516 -10.7476 0.0000 0
M  V30 74 C 66.8966 -11.5322 0.0000 0
M  V30 75 C 58.1484 -6.0873 0.0000 0
M  V30 76 O 58.4033 -5.3027 0.0000 0
M  V30 77 N 57.3414 -6.2589 0.0000 0
M  V30 78 C 56.7894 -5.6458 0.0000 0
M  V30 79 C 57.0443 -4.8612 0.0000 0
M  V30 80 C 56.4923 -4.2481 0.0000 0
M  V30 81 C 55.6853 -4.4196 0.0000 0
M  V30 82 O 55.4304 -5.2042 0.0000 0
M  V30 83 O 55.1333 -3.8065 0.0000 0
M  V30 84 C 55.9824 -5.8173 0.0000 0
M  V30 85 O 55.7275 -6.6019 0.0000 0
M  V30 86 N 55.4304 -5.2042 0.0000 0
M  V30 87 C 54.6234 -5.3757 0.0000 0
M  V30 88 C 54.3685 -6.1604 0.0000 0
M  V30 89 C 53.5615 -6.3319 0.0000 0
M  V30 90 C 53.3066 -7.1165 0.0000 0
M  V30 91 O 53.8586 -7.7296 0.0000 0
M  V30 92 O 52.4996 -7.2880 0.0000 0
M  V30 93 C 54.0714 -4.7626 0.0000 0
M  V30 94 O 54.3263 -3.9780 0.0000 0
M  V30 95 N 53.2644 -4.9342 0.0000 0
M  V30 96 C 52.7124 -4.3211 0.0000 0
M  V30 97 C 52.9673 -3.5365 0.0000 0
M  V30 98 O 52.4153 -2.9234 0.0000 0
M  V30 99 C 51.9054 -4.4926 0.0000 0
M  V30 100 O 51.6505 -5.2772 0.0000 0
M  V30 101 N 51.3534 -3.8795 0.0000 0
M  V30 102 C 50.5464 -4.0510 0.0000 0
M  V30 103 C 50.2915 -4.8357 0.0000 0
M  V30 104 C 49.4845 -5.0072 0.0000 0
M  V30 105 C 49.2296 -5.7918 0.0000 0
M  V30 106 N 49.7816 -6.4049 0.0000 0
M  V30 107 O 48.4226 -5.9633 0.0000 0
M  V30 108 C 49.9944 -3.4379 0.0000 0
M  V30 109 O 50.2493 -2.6533 0.0000 0
M  V30 110 N 49.1874 -3.6095 0.0000 0
M  V30 111 C 48.6354 -2.9964 0.0000 0
M  V30 112 C 48.8903 -2.2117 0.0000 0
M  V30 113 C 48.3383 -1.5987 0.0000 0
M  V30 114 N 47.5313 -1.7702 0.0000 0
M  V30 115 O 48.5932 -0.8140 0.0000 0
M  V30 116 C 47.8284 -3.1679 0.0000 0
M  V30 117 O 47.5735 -3.9525 0.0000 0
M  V30 118 N 47.2764 -2.5548 0.0000 0
M  V30 119 C 46.4694 -2.7263 0.0000 0
M  V30 120 C 46.2145 -3.5110 0.0000 0
M  V30 121 C 45.4075 -3.6825 0.0000 0
M  V30 122 C 45.1525 -4.4671 0.0000 0
M  V30 123 N 45.7046 -5.0802 0.0000 0
M  V30 124 O 44.3456 -4.6386 0.0000 0
M  V30 125 C 45.9174 -2.1132 0.0000 0
M  V30 126 O 46.1723 -1.3286 0.0000 0
M  V30 127 N 45.1104 -2.2848 0.0000 0
M  V30 128 C 44.5584 -1.6717 0.0000 0
M  V30 129 C 44.8133 -0.8870 0.0000 0
M  V30 130 C 44.2613 -0.2740 0.0000 0
M  V30 131 C 44.5162 0.5107 0.0000 0
M  V30 132 N 45.3232 0.6822 0.0000 0
M  V30 133 O 43.9642 1.1238 0.0000 0
M  V30 134 C 43.7514 -1.8432 0.0000 0
M  V30 135 O 43.4964 -2.6278 0.0000 0
M  V30 136 N 43.1993 -1.2301 0.0000 0
M  V30 137 C 42.3924 -1.4016 0.0000 0
M  V30 138 C 42.1374 -2.1862 0.0000 0
M  V30 139 C 41.3305 -2.3578 0.0000 0
M  V30 140 C 41.0755 -3.1424 0.0000 0
M  V30 141 O 41.6276 -3.7555 0.0000 0
M  V30 142 O 40.2686 -3.3139 0.0000 0
M  V30 143 C 41.8403 -0.7885 0.0000 0
M  V30 144 O 42.0953 -0.0039 0.0000 0
M  V30 145 N 41.0334 -0.9601 0.0000 0
M  V30 146 C 40.4813 -0.3470 0.0000 0
M  V30 147 C 40.7363 0.4377 0.0000 0
M  V30 148 C 40.1842 1.0508 0.0000 0
M  V30 149 C 40.4392 1.8354 0.0000 0
M  V30 150 C 39.8872 2.4485 0.0000 0
M  V30 151 N 40.1421 3.2331 0.0000 0
M  V30 152 C 39.6744 -0.5185 0.0000 0
M  V30 153 O 39.4194 -1.3031 0.0000 0
M  V30 154 N 39.1223 0.0946 0.0000 0
M  V30 155 C 38.3154 -0.0769 0.0000 0
M  V30 156 C 38.0604 -0.8615 0.0000 0
M  V30 157 C 38.6125 -1.4746 0.0000 0
M  V30 158 N 39.3661 -1.8102 0.0000 0
M  V30 159 O 38.3575 -2.2593 0.0000 0
M  V30 160 C 37.7633 0.5362 0.0000 0
M  V30 161 O 38.0183 1.3208 0.0000 0
M  V30 162 N 36.9564 0.3646 0.0000 0
M  V30 163 C 36.4043 0.9777 0.0000 0
M  V30 164 C 36.6593 1.7624 0.0000 0
M  V30 165 C 36.1072 2.3755 0.0000 0
M  V30 166 C 36.3622 3.1601 0.0000 0
M  V30 167 O 37.1691 3.3316 0.0000 0
M  V30 168 O 35.8101 3.7732 0.0000 0
M  V30 169 C 35.5974 0.8062 0.0000 0
M  V30 170 O 35.3424 0.0216 0.0000 0
M  V30 171 N 35.0453 1.4193 0.0000 0
M  V30 172 C 34.2384 1.2478 0.0000 0
M  V30 173 C 33.9834 0.4632 0.0000 0
M  V30 174 C 33.1764 0.2916 0.0000 0
M  V30 175 C 32.9215 -0.4930 0.0000 0
M  V30 176 N 33.4735 -1.1061 0.0000 0
M  V30 177 O 32.1145 -0.6645 0.0000 0
M  V30 178 C 33.6863 1.8609 0.0000 0
M  V30 179 O 33.9413 2.6455 0.0000 0
M  V30 180 N 32.8793 1.6893 0.0000 0
M  V30 181 C 32.3273 2.3024 0.0000 0
M  V30 182 C 32.5823 3.0871 0.0000 0
M  V30 183 C 32.0302 3.7002 0.0000 0
M  V30 184 C 32.2852 4.4848 0.0000 0
M  V30 185 O 33.0921 4.6563 0.0000 0
M  V30 186 O 31.7331 5.0979 0.0000 0
M  V30 187 C 31.5203 2.1309 0.0000 0
M  V30 188 O 31.2654 1.3463 0.0000 0
M  V30 189 N 30.9683 2.7440 0.0000 0
M  V30 190 C 30.1613 2.5725 0.0000 0
M  V30 191 C 29.9064 1.7879 0.0000 0
M  V30 192 C 29.0994 1.6163 0.0000 0
M  V30 193 C 28.8445 0.8317 0.0000 0
M  V30 194 C 28.5474 2.2294 0.0000 0
M  V30 195 C 29.6093 3.1856 0.0000 0
M  V30 196 O 29.8642 3.9702 0.0000 0
M  V30 197 N 28.8023 3.0140 0.0000 0
M  V30 198 C 28.2503 3.6271 0.0000 0
M  V30 199 C 28.5052 4.4118 0.0000 0
M  V30 200 C 27.9532 5.0249 0.0000 0
M  V30 201 C 27.1462 4.8533 0.0000 0
M  V30 202 C 28.2081 5.8095 0.0000 0
M  V30 203 C 27.4433 3.4556 0.0000 0
M  V30 204 O 27.1884 2.6710 0.0000 0
M  V30 205 N 26.8913 4.0687 0.0000 0
M  V30 206 C 26.0843 3.8972 0.0000 0
M  V30 207 C 25.8294 3.1126 0.0000 0
M  V30 208 C 25.0224 2.9410 0.0000 0
M  V30 209 C 24.7675 2.1564 0.0000 0
M  V30 210 O 25.3195 1.5433 0.0000 0
M  V30 211 O 23.9605 1.9849 0.0000 0
M  V30 212 C 25.5323 4.5103 0.0000 0
M  V30 213 O 25.7872 5.2949 0.0000 0
M  V30 214 N 24.7253 4.3387 0.0000 0
M  V30 215 C 24.1733 4.9518 0.0000 0
M  V30 216 C 24.4282 5.7365 0.0000 0
M  V30 217 C 23.8762 6.3496 0.0000 0
M  V30 218 C 23.0692 6.1780 0.0000 0
M  V30 219 C 24.1311 7.1342 0.0000 0
M  V30 220 C 23.3663 4.7803 0.0000 0
M  V30 221 O 23.1114 3.9957 0.0000 0
M  V30 222 N 22.8143 5.3934 0.0000 0
M  V30 223 C 22.0073 5.2219 0.0000 0
M  V30 224 C 21.7524 4.4373 0.0000 0
M  V30 225 C 20.9454 4.2657 0.0000 0
M  V30 226 O 20.6905 3.4811 0.0000 0
M  V30 227 O 20.3934 4.8788 0.0000 0
M  V30 228 C 21.4553 5.8350 0.0000 0
M  V30 229 O 21.7102 6.6196 0.0000 0
M  V30 230 N 20.6483 5.6634 0.0000 0
M  V30 231 C 20.0963 6.2765 0.0000 0
M  V30 232 C 20.3512 7.0612 0.0000 0
M  V30 233 C 19.7992 7.6743 0.0000 0
M  V30 234 C 20.0541 8.4589 0.0000 0
M  V30 235 C 19.5021 9.0720 0.0000 0
M  V30 236 N 19.7570 9.8566 0.0000 0
M  V30 237 C 19.2893 6.1050 0.0000 0
M  V30 238 O 19.0344 5.3204 0.0000 0
M  V30 239 N 18.7373 6.7181 0.0000 0
M  V30 240 C 17.9303 6.5466 0.0000 0
M  V30 241 C 17.6754 5.7620 0.0000 0
M  V30 242 C 16.8684 5.5904 0.0000 0
M  V30 243 C 16.2553 6.1425 0.0000 0
M  V30 244 N 15.5408 5.7300 0.0000 0
M  V30 245 C 15.7123 4.9230 0.0000 0
M  V30 246 C 15.2274 4.2556 0.0000 0
M  V30 247 C 15.5630 3.5019 0.0000 0
M  V30 248 C 16.3835 3.4156 0.0000 0
M  V30 249 C 16.8684 4.0831 0.0000 0
M  V30 250 C 16.5328 4.8368 0.0000 0
M  V30 251 C 17.3783 7.1597 0.0000 0
M  V30 252 O 17.6332 7.9443 0.0000 0
M  V30 253 N 16.5713 6.9882 0.0000 0
M  V30 254 C 16.0193 7.6012 0.0000 0
M  V30 255 C 16.2742 8.3859 0.0000 0
M  V30 256 C 15.2123 7.4297 0.0000 0
M  V30 257 O 14.9573 6.6451 0.0000 0
M  V30 258 N 14.6603 8.0428 0.0000 0
M  V30 259 C 13.8533 7.8713 0.0000 0
M  V30 260 C 13.5983 7.0867 0.0000 0
M  V30 261 O 12.7914 6.9151 0.0000 0
M  V30 262 C 13.3012 8.4844 0.0000 0
M  V30 263 O 13.5562 9.2690 0.0000 0
M  V30 264 N 12.4943 8.3129 0.0000 0
M  V30 265 C 11.9422 8.9259 0.0000 0
M  V30 266 C 12.1972 9.7106 0.0000 0
M  V30 267 C 11.6452 10.3237 0.0000 0
M  V30 268 C 10.8382 10.1521 0.0000 0
M  V30 269 C 11.9001 11.1083 0.0000 0
M  V30 270 C 11.1353 8.7544 0.0000 0
M  V30 271 O 10.8803 7.9698 0.0000 0
M  V30 272 N 10.5832 9.3675 0.0000 0
M  V30 273 C 9.7763 9.1960 0.0000 0
M  V30 274 C 9.5213 8.4114 0.0000 0
M  V30 275 C 8.7144 8.2398 0.0000 0
M  V30 276 C 8.1013 8.7919 0.0000 0
M  V30 277 N 7.3868 8.3794 0.0000 0
M  V30 278 C 7.5583 7.5724 0.0000 0
M  V30 279 C 7.0734 6.9050 0.0000 0
M  V30 280 C 7.4090 6.1513 0.0000 0
M  V30 281 C 8.2294 6.0651 0.0000 0
M  V30 282 C 8.7144 6.7325 0.0000 0
M  V30 283 C 8.3788 7.4862 0.0000 0
M  V30 284 C 9.2242 9.8091 0.0000 0
M  V30 285 O 9.4792 10.5937 0.0000 0
M  V30 286 N 8.4173 9.6376 0.0000 0
M  V30 287 C 7.8652 10.2507 0.0000 0
M  V30 288 C 8.1202 11.0353 0.0000 0
M  V30 289 C 7.5681 11.6484 0.0000 0
M  V30 290 N 6.7612 11.4768 0.0000 0
M  V30 291 O 7.8231 12.4330 0.0000 0
M  V30 292 C 7.0583 10.0791 0.0000 0
M  V30 293 O 6.8033 9.2945 0.0000 0
M  V30 294 N 6.5062 10.6922 0.0000 0
M  V30 295 C 5.6993 10.5207 0.0000 0
M  V30 296 C 5.1472 11.1338 0.0000 0
M  V30 297 C 4.3403 10.9623 0.0000 0
M  V30 298 C 4.0047 10.2086 0.0000 0
M  V30 299 N 3.1842 10.2948 0.0000 0
M  V30 300 C 3.0127 11.1018 0.0000 0
M  V30 301 C 2.2982 11.5143 0.0000 0
M  V30 302 C 2.2982 12.3393 0.0000 0
M  V30 303 C 3.0127 12.7518 0.0000 0
M  V30 304 C 3.7272 12.3393 0.0000 0
M  V30 305 C 3.7272 11.5143 0.0000 0
M  V30 306 C 5.4443 9.7361 0.0000 0
M  V30 307 O 4.6373 9.5645 0.0000 0
M  V30 308 N 5.9963 9.1230 0.0000 0
M  V30 309 C 5.7414 8.3384 0.0000 0
M  V30 310 C 6.2934 7.7253 0.0000 0
M  V30 311 C 6.0385 6.9406 0.0000 0
M  V30 312 C 6.5905 6.3275 0.0000 0
M  V30 313 C 6.3356 5.5429 0.0000 0
M  V30 314 C 5.5286 5.3714 0.0000 0
M  V30 315 C 4.9766 5.9845 0.0000 0
M  V30 316 C 5.2315 6.7691 0.0000 0
M  V30 317 C 4.9344 8.1668 0.0000 0
M  V30 318 N 4.6795 7.3822 0.0000 0
M  V30 319 O 4.3824 8.7799 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 11 13
M  V30 13 1 9 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 15 17
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 17 20
M  V30 20 1 20 21
M  V30 21 2 21 22
M  V30 22 1 21 23
M  V30 23 1 23 24
M  V30 24 1 24 25
M  V30 25 1 25 26
M  V30 26 1 26 27
M  V30 27 2 27 28
M  V30 28 1 28 29
M  V30 29 2 25 29
M  V30 30 1 23 30
M  V30 31 1 30 31
M  V30 32 2 31 32
M  V30 33 1 31 33
M  V30 34 1 33 34
M  V30 35 1 34 35
M  V30 36 2 35 36
M  V30 37 1 35 37
M  V30 38 1 37 38
M  V30 39 1 38 39
M  V30 40 1 39 40
M  V30 41 1 39 41
M  V30 42 1 37 42
M  V30 43 1 42 43
M  V30 44 2 43 44
M  V30 45 1 43 45
M  V30 46 1 45 46
M  V30 47 1 46 47
M  V30 48 1 45 48
M  V30 49 1 48 49
M  V30 50 2 49 50
M  V30 51 1 49 51
M  V30 52 1 51 52
M  V30 53 1 52 53
M  V30 54 2 53 54
M  V30 55 1 53 55
M  V30 56 1 55 56
M  V30 57 1 56 57
M  V30 58 2 57 58
M  V30 59 1 58 59
M  V30 60 2 59 60
M  V30 61 1 60 61
M  V30 62 1 60 62
M  V30 63 2 62 63
M  V30 64 1 57 63
M  V30 65 1 55 64
M  V30 66 1 64 65
M  V30 67 1 65 66
M  V30 68 2 65 67
M  V30 69 1 51 68
M  V30 70 1 68 69
M  V30 71 1 68 70
M  V30 72 1 33 71
M  V30 73 1 71 72
M  V30 74 1 71 73
M  V30 75 1 73 74
M  V30 76 1 5 75
M  V30 77 2 75 76
M  V30 78 1 75 77
M  V30 79 1 77 78
M  V30 80 1 78 79
M  V30 81 1 79 80
M  V30 82 1 80 81
M  V30 83 1 81 82
M  V30 84 2 81 83
M  V30 85 1 78 84
M  V30 86 2 84 85
M  V30 87 1 84 86
M  V30 88 1 86 87
M  V30 89 1 87 88
M  V30 90 1 88 89
M  V30 91 1 89 90
M  V30 92 1 90 91
M  V30 93 2 90 92
M  V30 94 1 87 93
M  V30 95 2 93 94
M  V30 96 1 93 95
M  V30 97 1 95 96
M  V30 98 1 96 97
M  V30 99 1 97 98
M  V30 100 1 96 99
M  V30 101 2 99 100
M  V30 102 1 99 101
M  V30 103 1 101 102
M  V30 104 1 102 103
M  V30 105 1 103 104
M  V30 106 1 104 105
M  V30 107 1 105 106
M  V30 108 2 105 107
M  V30 109 1 102 108
M  V30 110 2 108 109
M  V30 111 1 108 110
M  V30 112 1 110 111
M  V30 113 1 111 112
M  V30 114 1 112 113
M  V30 115 1 113 114
M  V30 116 2 113 115
M  V30 117 1 111 116
M  V30 118 2 116 117
M  V30 119 1 116 118
M  V30 120 1 118 119
M  V30 121 1 119 120
M  V30 122 1 120 121
M  V30 123 1 121 122
M  V30 124 1 122 123
M  V30 125 2 122 124
M  V30 126 1 119 125
M  V30 127 2 125 126
M  V30 128 1 125 127
M  V30 129 1 127 128
M  V30 130 1 128 129
M  V30 131 1 129 130
M  V30 132 1 130 131
M  V30 133 1 131 132
M  V30 134 2 131 133
M  V30 135 1 128 134
M  V30 136 2 134 135
M  V30 137 1 134 136
M  V30 138 1 136 137
M  V30 139 1 137 138
M  V30 140 1 138 139
M  V30 141 1 139 140
M  V30 142 1 140 141
M  V30 143 2 140 142
M  V30 144 1 137 143
M  V30 145 2 143 144
M  V30 146 1 143 145
M  V30 147 1 145 146
M  V30 148 1 146 147
M  V30 149 1 147 148
M  V30 150 1 148 149
M  V30 151 1 149 150
M  V30 152 1 150 151
M  V30 153 1 146 152
M  V30 154 2 152 153
M  V30 155 1 152 154
M  V30 156 1 154 155
M  V30 157 1 155 156
M  V30 158 1 156 157
M  V30 159 1 157 158
M  V30 160 2 157 159
M  V30 161 1 155 160
M  V30 162 2 160 161
M  V30 163 1 160 162
M  V30 164 1 162 163
M  V30 165 1 163 164
M  V30 166 1 164 165
M  V30 167 1 165 166
M  V30 168 1 166 167
M  V30 169 2 166 168
M  V30 170 1 163 169
M  V30 171 2 169 170
M  V30 172 1 169 171
M  V30 173 1 171 172
M  V30 174 1 172 173
M  V30 175 1 173 174
M  V30 176 1 174 175
M  V30 177 1 175 176
M  V30 178 2 175 177
M  V30 179 1 172 178
M  V30 180 2 178 179
M  V30 181 1 178 180
M  V30 182 1 180 181
M  V30 183 1 181 182
M  V30 184 1 182 183
M  V30 185 1 183 184
M  V30 186 1 184 185
M  V30 187 2 184 186
M  V30 188 1 181 187
M  V30 189 2 187 188
M  V30 190 1 187 189
M  V30 191 1 189 190
M  V30 192 1 190 191
M  V30 193 1 191 192
M  V30 194 1 192 193
M  V30 195 1 192 194
M  V30 196 1 190 195
M  V30 197 2 195 196
M  V30 198 1 195 197
M  V30 199 1 197 198
M  V30 200 1 198 199
M  V30 201 1 199 200
M  V30 202 1 200 201
M  V30 203 1 200 202
M  V30 204 1 198 203
M  V30 205 2 203 204
M  V30 206 1 203 205
M  V30 207 1 205 206
M  V30 208 1 206 207
M  V30 209 1 207 208
M  V30 210 1 208 209
M  V30 211 1 209 210
M  V30 212 2 209 211
M  V30 213 1 206 212
M  V30 214 2 212 213
M  V30 215 1 212 214
M  V30 216 1 214 215
M  V30 217 1 215 216
M  V30 218 1 216 217
M  V30 219 1 217 218
M  V30 220 1 217 219
M  V30 221 1 215 220
M  V30 222 2 220 221
M  V30 223 1 220 222
M  V30 224 1 222 223
M  V30 225 1 223 224
M  V30 226 1 224 225
M  V30 227 1 225 226
M  V30 228 2 225 227
M  V30 229 1 223 228
M  V30 230 2 228 229
M  V30 231 1 228 230
M  V30 232 1 230 231
M  V30 233 1 231 232
M  V30 234 1 232 233
M  V30 235 1 233 234
M  V30 236 1 234 235
M  V30 237 1 235 236
M  V30 238 1 231 237
M  V30 239 2 237 238
M  V30 240 1 237 239
M  V30 241 1 239 240
M  V30 242 1 240 241
M  V30 243 1 241 242
M  V30 244 1 242 243
M  V30 245 1 243 244
M  V30 246 2 244 245
M  V30 247 1 245 246
M  V30 248 2 246 247
M  V30 249 1 247 248
M  V30 250 2 248 249
M  V30 251 1 249 250
M  V30 252 2 242 250
M  V30 253 1 245 250
M  V30 254 1 240 251
M  V30 255 2 251 252
M  V30 256 1 251 253
M  V30 257 1 253 254
M  V30 258 1 254 255
M  V30 259 1 254 256
M  V30 260 2 256 257
M  V30 261 1 256 258
M  V30 262 1 258 259
M  V30 263 1 259 260
M  V30 264 1 260 261
M  V30 265 1 259 262
M  V30 266 2 262 263
M  V30 267 1 262 264
M  V30 268 1 264 265
M  V30 269 1 265 266
M  V30 270 1 266 267
M  V30 271 1 267 268
M  V30 272 1 267 269
M  V30 273 1 265 270
M  V30 274 2 270 271
M  V30 275 1 270 272
M  V30 276 1 272 273
M  V30 277 1 273 274
M  V30 278 1 274 275
M  V30 279 1 275 276
M  V30 280 1 276 277
M  V30 281 2 277 278
M  V30 282 1 278 279
M  V30 283 2 279 280
M  V30 284 1 280 281
M  V30 285 2 281 282
M  V30 286 1 282 283
M  V30 287 2 275 283
M  V30 288 1 278 283
M  V30 289 1 273 284
M  V30 290 2 284 285
M  V30 291 1 284 286
M  V30 292 1 286 287
M  V30 293 1 287 288
M  V30 294 1 288 289
M  V30 295 1 289 290
M  V30 296 2 289 291
M  V30 297 1 287 292
M  V30 298 2 292 293
M  V30 299 1 292 294
M  V30 300 1 294 295
M  V30 301 1 295 296
M  V30 302 1 296 297
M  V30 303 1 297 298
M  V30 304 1 298 299
M  V30 305 2 299 300
M  V30 306 1 300 301
M  V30 307 2 301 302
M  V30 308 1 302 303
M  V30 309 2 303 304
M  V30 310 1 304 305
M  V30 311 2 297 305
M  V30 312 1 300 305
M  V30 313 1 295 306
M  V30 314 2 306 307
M  V30 315 1 306 308
M  V30 316 1 308 309
M  V30 317 1 309 310
M  V30 318 1 310 311
M  V30 319 2 311 312
M  V30 320 1 312 313
M  V30 321 2 313 314
M  V30 322 1 314 315
M  V30 323 2 315 316
M  V30 324 1 311 316
M  V30 325 1 309 317
M  V30 326 1 317 318
M  V30 327 2 317 319
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
530

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
2.5

>  <Solvent>
DMSO

>  <MOLENAME>
Enfuvirtide acetate

>  <Synonyms>
N/A

>  <CAS>
914454-00-5

>  <Formula>
C206H305N51O66

>  <MolWt>
4552

>  <Pathways>
Microbiology/Virology;Proteases/Proteasome

>  <Target>
HIV Protease

>  <Receptor>
HIV

>  <Bioactivity>
Enfuvirtide acetate salt is a linear synthetic peptide made of 36 amino acids. It has an acetylated N-terminus and a carboxamide C-terminus.

>  <Reference>
"Figueira TN, et al. Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance. Sci Rep. 2017 Mar 30;7:45647."

>  <ID<1>>
TP1432

$$$$
StarDrop ID 531
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 39 41 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 3.7125 1.5395 0.0000 0
M  V30 2 C 3.3000 2.2539 0.0000 0
M  V30 3 C 2.4750 2.2539 0.0000 0
M  V30 4 O 2.0625 2.9684 0.0000 0
M  V30 5 O 2.0625 1.5395 0.0000 0
M  V30 6 C 1.2375 1.5395 0.0000 0
M  V30 7 O 0.8250 0.8250 0.0000 0
M  V30 8 P 0.0000 0.8250 0.0000 0
M  V30 9 O -0.8250 0.8250 0.0000 0
M  V30 10 C 0.0000 1.6500 0.0000 0
M  V30 11 C -0.7145 2.0625 0.0000 0
M  V30 12 C -0.7145 2.8875 0.0000 0
M  V30 13 C -1.4289 3.3000 0.0000 0
M  V30 14 C -1.4289 4.1250 0.0000 0
M  V30 15 C -2.1434 4.5375 0.0000 0
M  V30 16 C -2.1434 5.3625 0.0000 0
M  V30 17 C -1.4289 5.7750 0.0000 0
M  V30 18 C -0.7145 5.3625 0.0000 0
M  V30 19 C -0.7145 4.5375 0.0000 0
M  V30 20 C 0.0000 -0.0000 0.0000 0
M  V30 21 C 0.7145 -0.4125 0.0000 0
M  V30 22 O 1.4289 -0.0000 0.0000 0
M  V30 23 N 0.7145 -1.2375 0.0000 0
M  V30 24 C 1.3819 -1.7224 0.0000 0
M  V30 25 C 1.1270 -2.5070 0.0000 0
M  V30 26 C 0.3020 -2.5070 0.0000 0
M  V30 27 C 0.0470 -1.7224 0.0000 0
M  V30 28 C -0.7376 -1.4675 0.0000 0
M  V30 29 O -0.9091 -0.6605 0.0000 0
M  V30 30 O -1.3507 -2.0195 0.0000 0
M  V30 31 C 1.6119 -3.1745 0.0000 0
M  V30 32 C 2.4324 -3.0882 0.0000 0
M  V30 33 C 2.9173 -3.7557 0.0000 0
M  V30 34 C 2.5817 -4.5094 0.0000 0
M  V30 35 C 1.7613 -4.5956 0.0000 0
M  V30 36 C 1.2763 -3.9282 0.0000 0
M  V30 37 C 0.8250 2.2539 0.0000 0
M  V30 38 C 1.2375 2.9684 0.0000 0
M  V30 39 C 0.0000 2.2539 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 2 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 8 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 1 13 14
M  V30 14 2 14 15
M  V30 15 1 15 16
M  V30 16 2 16 17
M  V30 17 1 17 18
M  V30 18 2 18 19
M  V30 19 1 14 19
M  V30 20 1 8 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 21 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 25 26
M  V30 27 1 26 27
M  V30 28 1 23 27
M  V30 29 1 27 28
M  V30 30 1 28 29
M  V30 31 2 28 30
M  V30 32 1 25 31
M  V30 33 1 31 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 1 34 35
M  V30 37 1 35 36
M  V30 38 1 31 36
M  V30 39 1 6 37
M  V30 40 1 37 38
M  V30 41 1 37 39
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
531

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
2.5

>  <Solvent>
DMSO

>  <MOLENAME>
Fosinopril sodium

>  <Synonyms>
SQ28555

>  <CAS>
88889-14-9

>  <Formula>
C30H45NNaO7P

>  <MolWt>
585.7

>  <Pathways>
Endocrinology/Hormones

>  <Target>
RAAS

>  <Receptor>
ACE

>  <Bioactivity>
Fosinopril sodium is a phosphinic acid-containing angiotensin-converting enzyme inhibitor that is effective in the treatment of hypertension. It is a prodrug that is converted to its active metabolite fosinoprilat.

>  <Reference>
"Sharma S, et al. Fosinopril Hemodynamics Study Group. Am J Ther. 1999 Jul;6(4):181-9."

>  <ID<1>>
T1489

$$$$
StarDrop ID 532
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 23 24 0 0 1
M  V30 BEGIN ATOM
M  V30 1 H 3.9327 0.8557 0.0000 0
M  V30 2 C 4.4519 0.2146 0.0000 0 CFG=1
M  V30 3 C 5.0039 0.8277 0.0000 0
M  V30 4 C 5.7576 0.4921 0.0000 0
M  V30 5 S 6.4720 0.9046 0.0000 0
M  V30 6 C 7.1865 0.4921 0.0000 0
M  V30 7 C 7.9010 0.9046 0.0000 0
M  V30 8 N 8.6155 0.4921 0.0000 0
M  V30 9 C 9.3299 0.9046 0.0000 0
M  V30 10 N 10.0444 0.4921 0.0000 0
M  V30 11 C 5.6713 -0.3283 0.0000 0
M  V30 12 N 4.8644 -0.4999 0.0000 0
M  V30 13 C 4.1499 -0.9124 0.0000 0
M  V30 14 O 3.9364 -1.7093 0.0000 0
M  V30 15 C 3.7374 -0.1979 0.0000 0 CFG=2
M  V30 16 C 2.9405 0.0156 0.0000 0 CFG=1
M  V30 17 C 2.3571 -0.5677 0.0000 0
M  V30 18 O 2.7270 0.8125 0.0000 0
M  V30 19 C 6.2844 -0.8804 0.0000 0
M  V30 20 O 6.1129 -1.6873 0.0000 0
M  V30 21 O 7.0691 -0.6254 0.0000 0
M  V30 22 H 3.1287 -0.9913 0.0000 0
M  V30 23 H 1.9746 0.2745 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 2 4 11
M  V30 11 1 11 12
M  V30 12 1 2 12
M  V30 13 1 12 13
M  V30 14 2 13 14
M  V30 15 1 15 13
M  V30 16 1 15 2
M  V30 17 1 15 16 CFG=3
M  V30 18 1 16 17
M  V30 19 1 16 18 CFG=1
M  V30 20 1 11 19
M  V30 21 1 19 20
M  V30 22 2 19 21
M  V30 23 1 22 15
M  V30 24 1 23 16
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
532

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
14

>  <Volume��microliter��>
180

>  <Concentration��mM��>
5

>  <Solvent>
DMSO

>  <MOLENAME>
Imipenem monohydrate

>  <Synonyms>
N-Formimidoyl thienamycin monohydrate;Imipenem

>  <CAS>
74431-23-5

>  <Formula>
C12H19N3O5S

>  <MolWt>
317.4

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibacterial;Antibiotic

>  <Receptor>
Antibiotic; Bacterial; PBPs; ??-Lactamase

>  <Bioactivity>
"Imipenem monohydrate is a broad-spectrum, semi-synthetic beta-lactam carbapenem derived from thienamycin, produced by Streptomyces cattleya."

>  <Reference>
"Pichardo C, et al. Antimicrob Agents ChemOthers. 2005 Aug;49(8):3311-6."

>  <ID<1>>
T1505

$$$$
StarDrop ID 533
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 27 30 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.3571 0.9043 0.0000 0
M  V30 2 C 3.0716 0.4918 0.0000 0 CFG=1
M  V30 3 C 3.0716 -0.3332 0.0000 0
M  V30 4 O 3.7861 -0.7457 0.0000 0
M  V30 5 C 4.5006 -0.3332 0.0000 0
M  V30 6 C 5.2150 -0.7457 0.0000 0
M  V30 7 N 5.2150 -1.5707 0.0000 0
M  V30 8 C 5.9295 -1.9832 0.0000 0
M  V30 9 C 5.9295 -2.8082 0.0000 0
M  V30 10 N 5.2150 -3.2207 0.0000 0
M  V30 11 C 5.2150 -4.0457 0.0000 0
M  V30 12 C 4.5006 -2.8082 0.0000 0
M  V30 13 C 4.5006 -1.9832 0.0000 0
M  V30 14 C 5.9295 -0.3332 0.0000 0
M  V30 15 F 6.6440 -0.7457 0.0000 0
M  V30 16 C 5.9295 0.4918 0.0000 0
M  V30 17 C 5.2150 0.9043 0.0000 0
M  V30 18 C 4.5006 0.4918 0.0000 0
M  V30 19 N 3.7861 0.9043 0.0000 0
M  V30 20 C 3.7861 1.7293 0.0000 0
M  V30 21 C 4.5006 2.1418 0.0000 0
M  V30 22 C 4.5006 2.9668 0.0000 0
M  V30 23 O 3.7861 3.3793 0.0000 0
M  V30 24 O 5.2150 3.3793 0.0000 0
M  V30 25 C 5.2150 1.7293 0.0000 0
M  V30 26 O 5.9295 2.1418 0.0000 0
M  V30 27 H 2.2056 -0.0082 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 7 13
M  V30 14 1 6 14
M  V30 15 1 14 15
M  V30 16 2 14 16
M  V30 17 1 16 17
M  V30 18 2 17 18
M  V30 19 1 5 18
M  V30 20 1 18 19
M  V30 21 1 2 19
M  V30 22 1 19 20
M  V30 23 2 20 21
M  V30 24 1 21 22
M  V30 25 1 22 23
M  V30 26 2 22 24
M  V30 27 1 21 25
M  V30 28 1 17 25
M  V30 29 2 25 26
M  V30 30 1 27 2
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
533

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
15

>  <Volume��microliter��>
180

>  <Concentration��mM��>
5

>  <Solvent>
DMSO

>  <MOLENAME>
Levofloxacin hydrochloride

>  <Synonyms>
N/A

>  <CAS>
177325-13-2

>  <Formula>
C18H21ClFN3O4

>  <MolWt>
397.8

>  <Pathways>
DNA Damage/DNA Repair

>  <Target>
Topoisomerase;DNA gyrase

>  <Receptor>
DNA gyrase; Topo II; Topo IV

>  <Bioactivity>
"Levofloxacin is a broad-spectrum,  third-generation fluoroquinolone antibiotic and optically active L-isomer of ofloxacin with antibacterial activity. Levofloxacin diffuses through the bacterial cell wall and acts by inhibiting DNA gyrase (bacterial topoisomerase II),  an enzyme required for DNA replication,  RNA transcription,  and repair of bacterial DNA. Inhibition of DNA gyrase activity leads to blockage of bacterial cell growth."

>  <Reference>
"Siva, R., et al., Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial. Int J Chron Obstruct Pulmon Dis, 2014. 9: p. 179-86.;Schmitz FJ, et al. J Antimicrob ChemOthers. 1998 Apr;41(4):481-4.;Pradeep, A.R., et al., Clinical and microbiological effects of levofloxacin in the treatment of chronic periodontitis: a randomized, placebo-controlled clinical trial. J Investig Clin Dent, 2014."

>  <ID<1>>
T8747

$$$$
StarDrop ID 534
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 38 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O -0.4733 -4.0433 0.0000 0
M  V30 2 C -0.1759 -3.2737 0.0000 0
M  V30 3 N 0.6392 -3.1465 0.0000 0
M  V30 4 C 0.9366 -2.3769 0.0000 0
M  V30 5 C 0.4188 -1.7346 0.0000 0
M  V30 6 C -0.0989 -1.0923 0.0000 0
M  V30 7 C 0.1984 -0.3228 0.0000 0
M  V30 8 C 1.0136 -0.1955 0.0000 0
M  V30 9 C 1.5313 -0.8378 0.0000 0
M  V30 10 C 1.2339 -1.6074 0.0000 0
M  V30 11 N -0.3963 -1.8619 0.0000 0
M  V30 12 C -1.0363 -1.3413 0.0000 0
M  V30 13 C -1.7292 -1.7891 0.0000 0
M  V30 14 C -1.5174 -2.5864 0.0000 0
M  V30 15 C -0.6937 -2.6314 0.0000 0
M  V30 16 C -2.4634 -1.4129 0.0000 0
M  V30 17 N -2.5048 -0.5889 0.0000 0
M  V30 18 C -1.8119 -0.1411 0.0000 0
M  V30 19 N -1.8532 0.6828 0.0000 0
M  V30 20 C -1.1603 1.1306 0.0000 0
M  V30 21 N -1.2017 1.9546 0.0000 0
M  V30 22 C -0.5088 2.4024 0.0000 0
M  V30 23 C 0.2255 2.0262 0.0000 0
M  V30 24 N 0.9184 2.4740 0.0000 0
M  V30 25 C 0.8770 3.2979 0.0000 0
M  V30 26 C 1.5699 3.7457 0.0000 0
M  V30 27 N 2.3042 3.3696 0.0000 0
M  V30 28 C 2.3455 2.5456 0.0000 0
M  V30 29 C 1.6526 2.0978 0.0000 0
M  V30 30 C 2.9971 3.8173 0.0000 0
M  V30 31 C 0.2668 1.2022 0.0000 0
M  V30 32 C -0.4261 0.7544 0.0000 0
M  V30 33 N -1.0776 -0.5173 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 5 10
M  V30 11 1 5 11
M  V30 12 1 11 12
M  V30 13 2 12 13
M  V30 14 1 13 14
M  V30 15 2 14 15
M  V30 16 1 2 15
M  V30 17 1 11 15
M  V30 18 1 13 16
M  V30 19 2 16 17
M  V30 20 1 17 18
M  V30 21 1 18 19
M  V30 22 1 19 20
M  V30 23 2 20 21
M  V30 24 1 21 22
M  V30 25 2 22 23
M  V30 26 1 23 24
M  V30 27 1 24 25
M  V30 28 1 25 26
M  V30 29 1 26 27
M  V30 30 1 27 28
M  V30 31 1 28 29
M  V30 32 1 24 29
M  V30 33 1 27 30
M  V30 34 1 23 31
M  V30 35 2 31 32
M  V30 36 1 20 32
M  V30 37 2 18 33
M  V30 38 1 12 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
534

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
16

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
Trilaciclib hydrochloride

>  <Synonyms>
G1T28 hydrochloride

>  <CAS>
1977495-97-8

>  <Formula>
C24H32Cl2N8O

>  <MolWt>
519.5

>  <Pathways>
Cell Cycle/Checkpoint

>  <Target>
CDK

>  <Receptor>
" cdk6/cyclin D3:4 nM, Cdk4/cyclin D1:1 nM"

>  <Bioactivity>
Trilaciclib hydrochloride is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).

>  <Reference>
"Bisi JE, et al. Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression. Mol Cancer Ther. 2016 May;15(5):783-93."

>  <ID<1>>
T13202

$$$$
StarDrop ID 535
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 31 33 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -5.7158 2.4750 0.0000 0
M  V30 2 C -5.0013 2.0625 0.0000 0
M  V30 3 C -5.0013 1.2375 0.0000 0
M  V30 4 C -4.2868 0.8250 0.0000 0
M  V30 5 N -4.2868 -0.0000 0.0000 0
M  V30 6 C -3.5724 -0.4125 0.0000 0
M  V30 7 C -2.8579 -0.0000 0.0000 0
M  V30 8 N -2.1434 -0.4125 0.0000 0
M  V30 9 C -2.1434 -1.2375 0.0000 0
M  V30 10 O -1.4289 -1.6500 0.0000 0
M  V30 11 N -2.8579 -1.6500 0.0000 0
M  V30 12 C -3.5724 -1.2375 0.0000 0
M  V30 13 O -4.2868 -1.6500 0.0000 0
M  V30 14 N -2.8579 0.8250 0.0000 0
M  V30 15 C -2.1434 1.2375 0.0000 0
M  V30 16 C -1.4289 0.8250 0.0000 0
M  V30 17 O -1.4289 -0.0000 0.0000 0
M  V30 18 C -0.7145 1.2375 0.0000 0
M  V30 19 O -0.7145 2.0625 0.0000 0
M  V30 20 C 0.0000 0.8250 0.0000 0
M  V30 21 O 0.0000 -0.0000 0.0000 0
M  V30 22 C 0.7145 1.2375 0.0000 0
M  V30 23 O 1.4289 0.8250 0.0000 0
M  V30 24 P 2.1434 1.2375 0.0000 0
M  V30 25 O 2.5559 0.5230 0.0000 0
M  V30 26 O 2.8579 1.6500 0.0000 0
M  V30 27 O 1.7309 1.9520 0.0000 0
M  V30 28 C -3.5724 1.2375 0.0000 0
M  V30 29 C -3.5724 2.0625 0.0000 0
M  V30 30 C -4.2868 2.4750 0.0000 0
M  V30 31 C -4.2868 3.3000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 6 7
M  V30 7 2 7 8
M  V30 8 1 8 9
M  V30 9 2 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 1 6 12
M  V30 13 2 12 13
M  V30 14 1 7 14
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 16 18
M  V30 19 1 18 19
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 1 20 22
M  V30 23 1 22 23
M  V30 24 1 23 24
M  V30 25 1 24 25
M  V30 26 1 24 26
M  V30 27 2 24 27
M  V30 28 1 14 28
M  V30 29 2 4 28
M  V30 30 1 28 29
M  V30 31 2 29 30
M  V30 32 1 2 30
M  V30 33 1 30 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
535

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
17

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
Riboflavin phosphate sodium

>  <Synonyms>
FMN-Na;FMN;Vitamin B2 Phosphate Sodium Salt;Riboflavin 5'-phosphate sodium;riboflavin-5'-phosphate;Flavin mononucleotide

>  <CAS>
130-40-5

>  <Formula>
C17H20N4NaO9P

>  <MolWt>
478.3

>  <Pathways>
Metabolism

>  <Target>
Endogenous Metabolite

>  <Receptor>
Endogenous Metabolite; VB2

>  <Bioactivity>
"Riboflavin phosphate sodium is a water-soluble, essential micronutrient that is the principal growth-promoting factor in naturally occurring vitamin B complexes."

>  <Reference>
"Shen K, Huang XE. Asian Pac J Y Prev. 2015;16(4):1525-7."

>  <ID<1>>
T1331

$$$$
StarDrop ID 536
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 85 88 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 7.6552 0.3382 0.0000 0
M  V30 2 C 8.3898 0.7139 0.0000 0 CFG=2
M  V30 3 C 8.4317 1.5378 0.0000 0
M  V30 4 C 9.1663 1.9134 0.0000 0
M  V30 5 C 9.9019 1.5399 0.0000 0
M  V30 6 N 10.4844 2.1242 0.0000 0
M  V30 7 C 10.1088 2.8587 0.0000 0
M  V30 8 N 9.2941 2.7284 0.0000 0
M  V30 9 N 9.0823 0.2655 0.0000 0
M  V30 10 C 9.8169 0.6412 0.0000 0
M  V30 11 C 10.5094 0.1929 0.0000 0 CFG=1
M  V30 12 N 11.2440 0.5685 0.0000 0
M  V30 13 C 11.9365 0.1202 0.0000 0
M  V30 14 C 12.6711 0.4958 0.0000 0 CFG=2
M  V30 15 C 12.9656 1.2664 0.0000 0
M  V30 16 C 12.4454 1.9068 0.0000 0
M  V30 17 C 11.6308 1.7765 0.0000 0
M  V30 18 C 11.1107 2.4169 0.0000 0
M  V30 19 C 11.4052 3.1876 0.0000 0
M  V30 20 O 10.8851 3.8279 0.0000 0
M  V30 21 C 12.2198 3.3178 0.0000 0
M  V30 22 C 12.7400 2.6774 0.0000 0
M  V30 23 N 13.1912 -0.1446 0.0000 0
M  V30 24 C 14.0058 -0.0144 0.0000 0
M  V30 25 C 14.5260 -0.6547 0.0000 0 CFG=1
M  V30 26 N 15.3406 -0.5245 0.0000 0
M  V30 27 C 15.8607 -1.1649 0.0000 0
M  V30 28 C 16.6754 -1.0346 0.0000 0 CFG=1
M  V30 29 N 17.1955 -1.6750 0.0000 0
M  V30 30 C 18.0102 -1.5448 0.0000 0
M  V30 31 C 18.5303 -2.1851 0.0000 0 CFG=2
M  V30 32 C 19.3450 -2.0549 0.0000 0
M  V30 33 C 19.8651 -2.6953 0.0000 0
M  V30 34 O 19.5706 -3.4659 0.0000 0
M  V30 35 O 20.6797 -2.5650 0.0000 0
M  V30 36 N 18.2358 -2.9558 0.0000 0
M  V30 37 O 18.3047 -0.7741 0.0000 0
M  V30 38 C 16.9699 -0.2640 0.0000 0
M  V30 39 C 17.7846 -0.1337 0.0000 0
M  V30 40 C 18.0791 0.6369 0.0000 0
M  V30 41 N 18.8937 0.7672 0.0000 0
M  V30 42 C 19.1883 1.5378 0.0000 0
M  V30 43 N 18.6681 2.1782 0.0000 0
M  V30 44 N 20.0029 1.6680 0.0000 0
M  V30 45 O 15.5662 -1.9355 0.0000 0
M  V30 46 C 14.2314 -1.4254 0.0000 0 CFG=1
M  V30 47 C 14.7516 -2.0658 0.0000 0
M  V30 48 C 13.4168 -1.5556 0.0000 0
M  V30 49 O 14.3004 0.7563 0.0000 0
M  V30 50 O 11.8946 -0.7038 0.0000 0
M  V30 51 C 10.4675 -0.6311 0.0000 0 CFG=2
M  V30 52 C 9.7329 -1.0067 0.0000 0
M  V30 53 C 9.6910 -1.8306 0.0000 0
M  V30 54 C 11.1600 -1.0794 0.0000 0
M  V30 55 O 10.3351 1.2831 0.0000 0
M  V30 56 O 6.9627 0.7866 0.0000 0
M  V30 57 N 7.6133 -0.4857 0.0000 0
M  V30 58 C 6.9220 -0.9360 0.0000 0 CFG=2
M  V30 59 C 6.1514 -0.6415 0.0000 0
M  V30 60 N 5.5110 -1.1616 0.0000 0
M  V30 61 C 4.7404 -0.8671 0.0000 0 CFG=1
M  V30 62 C 4.6101 -0.0525 0.0000 0
M  V30 63 C 3.8395 0.2421 0.0000 0
M  V30 64 C 3.1991 -0.2781 0.0000 0
M  V30 65 C 2.4285 0.0165 0.0000 0
M  V30 66 C 2.2982 0.8311 0.0000 0
M  V30 67 C 2.9386 1.3512 0.0000 0
M  V30 68 C 3.7092 1.0567 0.0000 0
M  V30 69 C 4.1000 -1.3872 0.0000 0
M  V30 70 O 4.2302 -2.2019 0.0000 0
M  V30 71 O 3.3294 -1.0927 0.0000 0
M  V30 72 O 6.0211 0.1731 0.0000 0
M  V30 73 C 7.1367 -1.7326 0.0000 0
M  V30 74 C 7.9607 -1.7746 0.0000 0
M  V30 75 C 8.2552 -1.0039 0.0000 0
M  V30 76 H 13.8745 -2.3595 0.0000 0
M  V30 77 H 10.4165 -1.6298 0.0000 0
M  V30 78 H 6.1799 -1.6063 0.0000 0
M  V30 79 H 5.5166 -0.2366 0.0000 0
M  V30 80 H 8.3388 -0.2848 0.0000 0
M  V30 81 H 10.5604 1.1916 0.0000 0
M  V30 82 H 12.4645 -0.4826 0.0000 0
M  V30 83 H 14.8829 0.2794 0.0000 0
M  V30 84 H 17.6629 -0.8768 0.0000 0
M  V30 85 H 17.5429 -2.3432 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 4 8
M  V30 9 1 2 9 CFG=3
M  V30 10 1 9 10
M  V30 11 1 11 10
M  V30 12 1 11 12 CFG=1
M  V30 13 1 12 13
M  V30 14 1 14 13
M  V30 15 1 14 15
M  V30 16 1 15 16
M  V30 17 2 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 19 20
M  V30 21 1 19 21
M  V30 22 2 21 22
M  V30 23 1 16 22
M  V30 24 1 14 23 CFG=3
M  V30 25 1 23 24
M  V30 26 1 25 24
M  V30 27 1 25 26 CFG=1
M  V30 28 1 26 27
M  V30 29 1 28 27
M  V30 30 1 28 29 CFG=3
M  V30 31 1 29 30
M  V30 32 1 31 30
M  V30 33 1 31 32
M  V30 34 1 32 33
M  V30 35 1 33 34
M  V30 36 2 33 35
M  V30 37 1 31 36 CFG=3
M  V30 38 2 30 37
M  V30 39 1 28 38
M  V30 40 1 38 39
M  V30 41 1 39 40
M  V30 42 1 40 41
M  V30 43 1 41 42
M  V30 44 2 42 43
M  V30 45 1 42 44
M  V30 46 2 27 45
M  V30 47 1 25 46
M  V30 48 1 46 47 CFG=1
M  V30 49 1 46 48
M  V30 50 2 24 49
M  V30 51 2 13 50
M  V30 52 1 11 51
M  V30 53 1 51 52
M  V30 54 1 52 53
M  V30 55 1 51 54 CFG=1
M  V30 56 2 10 55
M  V30 57 2 1 56
M  V30 58 1 1 57
M  V30 59 1 58 57
M  V30 60 1 58 59 CFG=1
M  V30 61 1 59 60
M  V30 62 1 61 60 CFG=3
M  V30 63 1 61 62
M  V30 64 1 62 63
M  V30 65 2 63 64
M  V30 66 1 64 65
M  V30 67 2 65 66
M  V30 68 1 66 67
M  V30 69 2 67 68
M  V30 70 1 63 68
M  V30 71 1 61 69
M  V30 72 1 69 70
M  V30 73 2 69 71
M  V30 74 2 59 72
M  V30 75 1 58 73
M  V30 76 1 73 74
M  V30 77 1 74 75
M  V30 78 1 57 75
M  V30 79 1 76 46
M  V30 80 1 77 51
M  V30 81 1 78 58
M  V30 82 1 79 61
M  V30 83 1 80 2
M  V30 84 1 81 11
M  V30 85 1 82 14
M  V30 86 1 83 25
M  V30 87 1 84 28
M  V30 88 1 85 31
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
536

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
18

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
Angiotensin II human acetate

>  <Synonyms>
Ang II acetate;DRVYIHPF acetate;Angiotensin II acetate

>  <CAS>
68521-88-0

>  <Formula>
C52H75N13O14

>  <MolWt>
1106

>  <Pathways>
Endocrinology/Hormones;Apoptosis

>  <Target>
Apoptosis;RAAS

>  <Receptor>
angiotensin AT1?receptor; Angiotensin Receptor; Apoptosis

>  <Bioactivity>
Angiotensin II acetate is a vasoconstrictor that mainly acts on the AT1 receptor.

>  <Reference>
"Fyhrquist F, et al. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens. 1995 Nov;9 Suppl 5:S19-24.;Crowley SD, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17985-90."

>  <ID<1>>
T8560

$$$$
StarDrop ID 537
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 14 14 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 4.4291 -4.3717 0.0000 0
M  V30 2 C 5.1436 -3.9592 0.0000 0 CFG=1
M  V30 3 C 5.8581 -4.3717 0.0000 0
M  V30 4 C 5.8581 -5.1967 0.0000 0
M  V30 5 C 6.5725 -5.6092 0.0000 0
M  V30 6 C 6.5725 -6.4342 0.0000 0
M  V30 7 C 5.8581 -6.8467 0.0000 0
M  V30 8 O 5.8581 -7.6717 0.0000 0
M  V30 9 C 5.1436 -6.4342 0.0000 0
M  V30 10 C 5.1436 -5.6092 0.0000 0
M  V30 11 C 5.1436 -3.1342 0.0000 0
M  V30 12 O 4.4291 -2.7217 0.0000 0
M  V30 13 O 5.8581 -2.7217 0.0000 0
M  V30 14 H 4.2776 -3.4592 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 2 9 10
M  V30 10 1 4 10
M  V30 11 1 2 11
M  V30 12 1 11 12
M  V30 13 2 11 13
M  V30 14 1 14 2
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
537

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
19

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
glatiramer Acetate

>  <Synonyms>
N/A

>  <CAS>
147245-92-9

>  <Formula>
C25H45N5O13

>  <MolWt>
623.7

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
Others

>  <Bioactivity>
Glatiramer acetate (GA) is a synthetic amino acid copolymer that is approved for treatment of relapsing remitting multiple sclerosis (RRMS) and clinically isolated syndrome (CIS).

>  <Reference>
"Corey-Bloom J, et al. Beneficial effects of glatiramer acetate in Huntington's disease mouse models: Evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Res. 2017;1673:102-110.;Arnon R, et al. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc Natl Acad Sci U S A. 2004;101 Suppl 2(Suppl 2):14593-14598.;McKeage K. Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review. CNS Drugs. 2015;29(5):425-432.;Prod'homme T, Zamvil SS. The Evolving Mechanisms of Action of Glatiramer Acetate. Cold Spring Harb Perspect Med. 2019 Feb 1;9(2):a029249. doi: 10.1101/cshperspect.a029249."

>  <ID<1>>
TP2315

$$$$
StarDrop ID 538
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 79 78 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 17.6041 -1.3886 0.0000 0
M  V30 2 C 17.6041 -0.5636 0.0000 0 CFG=1
M  V30 3 N 16.8896 -0.1511 0.0000 0
M  V30 4 C 16.1751 -0.5636 0.0000 0
M  V30 5 O 16.1751 -1.3886 0.0000 0
M  V30 6 C 15.4607 -0.1511 0.0000 0 CFG=1
M  V30 7 C 15.4607 0.6739 0.0000 0
M  V30 8 C 16.1751 1.0864 0.0000 0
M  V30 9 C 16.1751 1.9114 0.0000 0
M  V30 10 N 16.8896 2.3239 0.0000 0
M  V30 11 C 16.8896 3.1489 0.0000 0
M  V30 12 N 16.1751 3.5614 0.0000 0
M  V30 13 N 17.6041 3.5614 0.0000 0
M  V30 14 N 14.7462 -0.5636 0.0000 0
M  V30 15 C 14.0317 -0.1511 0.0000 0
M  V30 16 O 14.0317 0.6739 0.0000 0
M  V30 17 C 13.3172 -0.5636 0.0000 0 CFG=1
M  V30 18 C 13.3172 -1.3886 0.0000 0
M  V30 19 C 12.6028 -1.8011 0.0000 0
M  V30 20 C 12.6028 -2.6261 0.0000 0
M  V30 21 N 11.8883 -3.0386 0.0000 0
M  V30 22 C 11.8883 -3.8636 0.0000 0
M  V30 23 N 12.6028 -4.2761 0.0000 0
M  V30 24 N 11.1738 -4.2761 0.0000 0
M  V30 25 N 12.6028 -0.1511 0.0000 0
M  V30 26 C 11.8883 -0.5636 0.0000 0
M  V30 27 O 11.8883 -1.3886 0.0000 0
M  V30 28 C 11.1738 -0.1511 0.0000 0 CFG=1
M  V30 29 C 11.1738 0.6739 0.0000 0
M  V30 30 C 11.8883 1.0864 0.0000 0
M  V30 31 C 11.8883 1.9114 0.0000 0
M  V30 32 N 12.6028 2.3239 0.0000 0
M  V30 33 C 12.6028 3.1489 0.0000 0
M  V30 34 N 11.8883 3.5614 0.0000 0
M  V30 35 N 13.3172 3.5614 0.0000 0
M  V30 36 N 10.4594 -0.5636 0.0000 0
M  V30 37 C 9.7449 -0.1511 0.0000 0
M  V30 38 O 9.7449 0.6739 0.0000 0
M  V30 39 C 9.0304 -0.5636 0.0000 0 CFG=1
M  V30 40 C 9.0304 -1.3886 0.0000 0
M  V30 41 N 8.3160 -0.1511 0.0000 0
M  V30 42 C 7.6015 -0.5636 0.0000 0
M  V30 43 O 7.6015 -1.3886 0.0000 0
M  V30 44 C 6.8870 -0.1511 0.0000 0 CFG=1
M  V30 45 C 6.1725 -0.5636 0.0000 0
M  V30 46 S 5.4581 -0.1511 0.0000 0
M  V30 47 S 4.7436 -0.5636 0.0000 0
M  V30 48 C 4.0291 -0.1511 0.0000 0
M  V30 49 C 3.3147 -0.5636 0.0000 0 CFG=2
M  V30 50 N 3.3147 -1.3886 0.0000 0
M  V30 51 C 2.6002 -0.1511 0.0000 0
M  V30 52 O 1.8857 -0.5636 0.0000 0
M  V30 53 O 2.6002 0.6739 0.0000 0
M  V30 54 N 6.8870 0.6739 0.0000 0
M  V30 55 C 6.1725 1.0864 0.0000 0
M  V30 56 C 5.4581 0.6739 0.0000 0
M  V30 57 O 6.1725 1.9114 0.0000 0
M  V30 58 C 18.3185 -0.1511 0.0000 0
M  V30 59 O 18.3185 0.6739 0.0000 0
M  V30 60 N 19.0330 -0.5636 0.0000 0
M  V30 61 C 19.7475 -0.1511 0.0000 0 CFG=2
M  V30 62 C 20.4620 -0.5636 0.0000 0
M  V30 63 C 21.1764 -0.1511 0.0000 0
M  V30 64 C 21.8909 -0.5636 0.0000 0
M  V30 65 N 22.6054 -0.1511 0.0000 0
M  V30 66 C 23.3198 -0.5636 0.0000 0
M  V30 67 N 24.0343 -0.1511 0.0000 0
M  V30 68 N 23.3198 -1.3886 0.0000 0
M  V30 69 C 19.7475 0.6739 0.0000 0
M  V30 70 O 20.4620 1.0864 0.0000 0
M  V30 71 O 19.0330 1.0864 0.0000 0
M  V30 72 H 8.1644 -1.0636 0.0000 0
M  V30 73 H 6.0210 0.3489 0.0000 0
M  V30 74 H 4.1807 -1.0636 0.0000 0
M  V30 75 H 18.8815 0.3489 0.0000 0
M  V30 76 H 18.4701 -1.0636 0.0000 0
M  V30 77 H 15.4606 -1.1511 0.0000 0
M  V30 78 H 13.3173 0.4364 0.0000 0
M  V30 79 H 11.1739 -1.1511 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=1
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 6 4
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 13 1 6 14 CFG=3
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 17 15
M  V30 17 1 17 18
M  V30 18 1 18 19
M  V30 19 1 19 20
M  V30 20 1 20 21
M  V30 21 1 21 22
M  V30 22 1 22 23
M  V30 23 2 22 24
M  V30 24 1 17 25 CFG=1
M  V30 25 1 25 26
M  V30 26 2 26 27
M  V30 27 1 28 26
M  V30 28 1 28 29
M  V30 29 1 29 30
M  V30 30 1 30 31
M  V30 31 1 31 32
M  V30 32 1 32 33
M  V30 33 1 33 34
M  V30 34 2 33 35
M  V30 35 1 28 36 CFG=3
M  V30 36 1 36 37
M  V30 37 2 37 38
M  V30 38 1 39 37
M  V30 39 1 39 40 CFG=1
M  V30 40 1 39 41
M  V30 41 1 41 42
M  V30 42 2 42 43
M  V30 43 1 44 42
M  V30 44 1 44 45
M  V30 45 1 45 46
M  V30 46 1 46 47
M  V30 47 1 47 48
M  V30 48 1 49 48
M  V30 49 1 49 50 CFG=3
M  V30 50 1 49 51
M  V30 51 1 51 52
M  V30 52 2 51 53
M  V30 53 1 44 54 CFG=1
M  V30 54 1 54 55
M  V30 55 1 55 56
M  V30 56 2 55 57
M  V30 57 1 2 58
M  V30 58 2 58 59
M  V30 59 1 58 60
M  V30 60 1 61 60 CFG=1
M  V30 61 1 61 62
M  V30 62 1 62 63
M  V30 63 1 63 64
M  V30 64 1 64 65
M  V30 65 1 65 66
M  V30 66 1 66 67
M  V30 67 2 66 68
M  V30 68 1 61 69
M  V30 69 1 69 70
M  V30 70 2 69 71
M  V30 71 1 72 39
M  V30 72 1 73 44
M  V30 73 1 74 49
M  V30 74 1 75 61
M  V30 75 1 76 2
M  V30 76 1 77 6
M  V30 77 1 78 17
M  V30 78 1 79 28
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
538

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
20

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
Etelcalcetide hydrochloride

>  <Synonyms>
KAI-4169 hydrochloride;AMG 416 hydrochloride

>  <CAS>
1334237-71-6

>  <Formula>
C38H73ClN20O11S2

>  <MolWt>
1086

>  <Pathways>
GPCR/G Protein

>  <Target>
CaSR

>  <Receptor>
CaSR

>  <Bioactivity>
Etelcalcetide hydrochloride is a synthetic peptide as an allosteric modulator of the calcium (Ca)-sensing receptor (CaSR). Etelcalcetide hydrochloride is effective in lowering parathyroid hormone (PTH) concentrations in patients receiving dialysis with secondary hyperparathyroidism receiving hemodialysis.

>  <Reference>
"Block GA, et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA. 2017 Jan 10;317(2):156-164."

>  <ID<1>>
TP1236

$$$$
StarDrop ID 539
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 56 58 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 3.1821 1.0828 0.0000 0
M  V30 2 C 3.8966 1.4953 0.0000 0
M  V30 3 C 4.6111 1.0828 0.0000 0
M  V30 4 C 5.3256 1.4953 0.0000 0 CFG=2
M  V30 5 O 5.3256 2.3203 0.0000 0
M  V30 6 C 6.0400 1.0828 0.0000 0
M  V30 7 O 6.0400 0.2578 0.0000 0
M  V30 8 N 6.7545 1.4953 0.0000 0
M  V30 9 C 7.4690 1.0828 0.0000 0 CFG=2
M  V30 10 C 8.1834 1.4953 0.0000 0
M  V30 11 C 8.8979 1.0828 0.0000 0 CFG=2
M  V30 12 N 9.6124 1.4953 0.0000 0
M  V30 13 C 8.8979 0.2578 0.0000 0 CFG=2
M  V30 14 O 9.6124 -0.1547 0.0000 0
M  V30 15 C 10.3269 0.2578 0.0000 0 CFG=1
M  V30 16 O 10.3269 1.0828 0.0000 0
M  V30 17 C 11.0413 1.4953 0.0000 0 CFG=1
M  V30 18 C 11.0413 2.3203 0.0000 0
M  V30 19 N 10.3269 2.7328 0.0000 0
M  V30 20 C 11.7558 1.0828 0.0000 0 CFG=1
M  V30 21 O 12.4703 1.4953 0.0000 0
M  V30 22 C 11.7558 0.2578 0.0000 0 CFG=2
M  V30 23 O 12.4703 -0.1547 0.0000 0
M  V30 24 C 11.0413 -0.1547 0.0000 0 CFG=1
M  V30 25 O 11.0413 -0.9797 0.0000 0
M  V30 26 C 8.1834 -0.1547 0.0000 0 CFG=2
M  V30 27 O 8.1834 -0.9797 0.0000 0
M  V30 28 C 7.4690 0.2578 0.0000 0 CFG=2
M  V30 29 O 6.7545 -0.1547 0.0000 0
M  V30 30 C 6.7545 -0.9797 0.0000 0 CFG=1
M  V30 31 O 7.4690 -1.3922 0.0000 0
M  V30 32 C 7.4690 -2.2172 0.0000 0 CFG=1
M  V30 33 C 8.1834 -2.6297 0.0000 0
M  V30 34 O 8.1834 -3.4547 0.0000 0
M  V30 35 C 6.7545 -2.6297 0.0000 0 CFG=1
M  V30 36 O 6.7545 -3.4547 0.0000 0
M  V30 37 C 6.0400 -2.2172 0.0000 0 CFG=2
M  V30 38 N 5.3256 -2.6297 0.0000 0
M  V30 39 C 6.0400 -1.3922 0.0000 0 CFG=1
M  V30 40 O 5.3256 -0.9797 0.0000 0
M  V30 41 H 6.1916 1.9953 0.0000 0
M  V30 42 H 7.4689 2.0828 0.0000 0
M  V30 43 H 9.7639 0.5828 0.0000 0
M  V30 44 H 9.7639 0.7578 0.0000 0
M  V30 45 H 10.3268 -0.7422 0.0000 0
M  V30 46 H 10.1753 1.9953 0.0000 0
M  V30 47 H 12.6218 0.5828 0.0000 0
M  V30 48 H 12.6218 0.7578 0.0000 0
M  V30 49 H 10.1753 -0.6547 0.0000 0
M  V30 50 H 7.3174 -0.6547 0.0000 0
M  V30 51 H 7.4689 -0.7422 0.0000 0
M  V30 52 H 7.6205 -0.4797 0.0000 0
M  V30 53 H 7.4689 -3.2172 0.0000 0
M  V30 54 H 7.6205 -3.1297 0.0000 0
M  V30 55 H 6.0401 -3.2172 0.0000 0
M  V30 56 H 6.0401 -0.3922 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 4 3
M  V30 4 1 4 5 CFG=3
M  V30 5 1 4 6
M  V30 6 2 6 7
M  V30 7 1 6 8
M  V30 8 1 9 8 CFG=3
M  V30 9 1 9 10
M  V30 10 1 11 10
M  V30 11 1 11 12 CFG=3
M  V30 12 1 13 11
M  V30 13 1 13 14 CFG=3
M  V30 14 1 15 14 CFG=1
M  V30 15 1 15 16
M  V30 16 1 17 16
M  V30 17 1 17 18 CFG=1
M  V30 18 1 18 19
M  V30 19 1 20 17
M  V30 20 1 20 21 CFG=1
M  V30 21 1 20 22
M  V30 22 1 22 23 CFG=3
M  V30 23 1 22 24
M  V30 24 1 24 15
M  V30 25 1 24 25 CFG=1
M  V30 26 1 13 26
M  V30 27 1 26 27 CFG=3
M  V30 28 1 26 28
M  V30 29 1 28 9
M  V30 30 1 28 29 CFG=3
M  V30 31 1 30 29 CFG=1
M  V30 32 1 30 31
M  V30 33 1 32 31
M  V30 34 1 32 33 CFG=1
M  V30 35 1 33 34
M  V30 36 1 35 32
M  V30 37 1 35 36 CFG=1
M  V30 38 1 35 37
M  V30 39 1 37 38 CFG=3
M  V30 40 1 37 39
M  V30 41 1 39 30
M  V30 42 1 39 40 CFG=1
M  V30 43 1 41 4
M  V30 44 1 42 9
M  V30 45 1 43 11
M  V30 46 1 44 13
M  V30 47 1 45 15
M  V30 48 1 46 17
M  V30 49 1 47 20
M  V30 50 1 48 22
M  V30 51 1 49 24
M  V30 52 1 50 26
M  V30 53 1 51 28
M  V30 54 1 52 30
M  V30 55 1 53 32
M  V30 56 1 54 35
M  V30 57 1 55 37
M  V30 58 1 56 39
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
539

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
21

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
Amikacin sulfate

>  <Synonyms>
Amikacin Sulfate Salt

>  <CAS>
149022-22-0

>  <Formula>
C22H45N5O17S

>  <MolWt>
683.7

>  <Pathways>
Microbiology/Virology

>  <Target>
ribosome;Antibacterial;Antibiotic

>  <Receptor>
30S ribosome; Antibiotic; Bacterial

>  <Bioactivity>
Amikacin Sulfate Salt is a broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and ototoxic like the other aminoglycoside antibiotics.

>  <Reference>
Tolmasky ME. Front Biosci. 2000 Jan 1;5:D20-9.

>  <ID<1>>
T3125

$$$$
StarDrop ID 540
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 33 35 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C -3.5724 -7.8375 0.0000 0
M  V30 2 N -3.5724 -8.6625 0.0000 0
M  V30 3 C -4.2868 -9.0750 0.0000 0
M  V30 4 C -4.2868 -9.9000 0.0000 0
M  V30 5 N -5.0013 -10.3125 0.0000 0
M  V30 6 C -5.7158 -9.9000 0.0000 0
M  V30 7 N -6.4302 -10.3125 0.0000 0
M  V30 8 N -5.7158 -9.0750 0.0000 0
M  V30 9 C -5.0013 -8.6625 0.0000 0
M  V30 10 O -5.0013 -7.8375 0.0000 0
M  V30 11 N -3.5724 -10.3125 0.0000 0
M  V30 12 C -2.8579 -9.9000 0.0000 0
M  V30 13 C -2.8579 -9.0750 0.0000 0
M  V30 14 C -2.1434 -8.6625 0.0000 0
M  V30 15 N -2.1434 -7.8375 0.0000 0
M  V30 16 C -1.4289 -7.4250 0.0000 0
M  V30 17 C -1.4289 -6.6000 0.0000 0
M  V30 18 C -0.7145 -6.1875 0.0000 0
M  V30 19 C -0.0000 -6.6000 0.0000 0
M  V30 20 C 0.7145 -6.1875 0.0000 0
M  V30 21 O 0.7145 -5.3625 0.0000 0
M  V30 22 N 1.4289 -6.6000 0.0000 0
M  V30 23 C 2.1434 -6.1875 0.0000 0
M  V30 24 C 2.8579 -6.6000 0.0000 0
M  V30 25 C 3.5724 -6.1875 0.0000 0
M  V30 26 C 4.2868 -6.6000 0.0000 0
M  V30 27 O 4.2868 -7.4250 0.0000 0
M  V30 28 O 5.0013 -6.1875 0.0000 0
M  V30 29 C 2.1434 -5.3625 0.0000 0
M  V30 30 O 2.8579 -4.9500 0.0000 0
M  V30 31 O 1.4289 -4.9500 0.0000 0
M  V30 32 C -0.0000 -7.4250 0.0000 0
M  V30 33 C -0.7145 -7.8375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 8 9
M  V30 9 1 3 9
M  V30 10 2 9 10
M  V30 11 1 4 11
M  V30 12 1 11 12
M  V30 13 1 12 13
M  V30 14 1 2 13
M  V30 15 1 13 14
M  V30 16 1 14 15
M  V30 17 1 15 16
M  V30 18 2 16 17
M  V30 19 1 17 18
M  V30 20 2 18 19
M  V30 21 1 19 20
M  V30 22 2 20 21
M  V30 23 1 20 22
M  V30 24 1 22 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 25 26
M  V30 28 2 26 27
M  V30 29 1 26 28
M  V30 30 1 23 29
M  V30 31 2 29 30
M  V30 32 1 29 31
M  V30 33 1 19 32
M  V30 34 2 32 33
M  V30 35 1 16 33
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
540

>  <Plate>
PHD136329

>  <Row>
k

>  <Col>
22

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
Levomefolate calcium

>  <Synonyms>
N/A

>  <CAS>
151533-22-1

>  <Formula>
C20H23CaN7O6

>  <MolWt>
497.5

>  <Pathways>
Cell Cycle/Checkpoint

>  <Target>
Antifolate

>  <Receptor>
Antifolate

>  <Bioactivity>
Levomefolate calcium is an artificial form of folate. It is a coenzymated form of folic acid and a more bioavailable alternative in dietary supplements.

>  <Reference>
"Wiesinger H , Eydeler U , Richard F , et al. Bioequivalence Evaluation of a Folate-Supplemented Oral Contraceptive Containing Ethinylestradiol/Drospirenone/Levomefolate Calcium versus Ethinylestradiol/Drospirenone and Levomefolate Calcium Alone[J]. Clinical Drug Investigation, 2012, 32(10):673-684.;Blode H , Klipping C , Richard F , et al. Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone[J]. Contraception, 2012, 85(2):0-184."

>  <ID<1>>
T7593

$$$$
StarDrop ID 541
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 11 0 0 0
M  V30 BEGIN ATOM
M  V30 1 N 2.3571 -2.3645 0.0000 0
M  V30 2 C 3.0716 -2.7770 0.0000 0
M  V30 3 C 3.7861 -2.3645 0.0000 0
M  V30 4 C 4.5006 -2.7770 0.0000 0
M  V30 5 N 5.2150 -2.3645 0.0000 0
M  V30 6 C 5.9295 -2.7770 0.0000 0
M  V30 7 C 6.6440 -2.3645 0.0000 0
M  V30 8 S 7.3584 -2.7770 0.0000 0
M  V30 9 P 8.0729 -2.3645 0.0000 0
M  V30 10 O 8.7874 -1.9520 0.0000 0
M  V30 11 O 8.4854 -3.0789 0.0000 0
M  V30 12 O 7.6604 -1.6500 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 2 9 12
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
541

>  <Plate>
PHD136329

>  <Row>
l

>  <Col>
3

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
Amifostine trihydrate

>  <Synonyms>
Ethyol trihydrate;Amifostine;WR2721

>  <CAS>
112901-68-5

>  <Formula>
C5H21N2O6PS

>  <MolWt>
268.3

>  <Pathways>
Metabolism;Others;Chromatin/Epigenetic

>  <Target>
Others;HIF/HIF Prolyl-Hydroxylase

>  <Receptor>
HIF/HIF Prolyl-Hydroxylase; MDM-2/p53

>  <Bioactivity>
"Amifostine is the first approved radioprotective drug, used to decrease the risk of kidney problems caused by treatment with cisplatin."

>  <Reference>
"Yang X, Ding Y, Ji T, Zhao X, Wang H, Zhao X, Zhao R, Wei J, Qi S, Nie G.Biochem Pharmacol. 2016 Mar 2. pii: S202006-2952(16)2020113-1.;Tas S, Ozkul F, Arik MK, Kiraz A, Vural A.Acta Cir Bras. 2016 Mar;31(3):156-60."

>  <ID<1>>
T6381

$$$$
StarDrop ID 542
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 18 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 1.7605 -1.8414 0.0000 0
M  V30 2 C 2.4750 -1.4289 0.0000 0
M  V30 3 C 3.1895 -1.8414 0.0000 0
M  V30 4 C 3.9039 -1.4289 0.0000 0
M  V30 5 C 4.6184 -1.8414 0.0000 0
M  V30 6 N 5.3329 -1.4289 0.0000 0
M  V30 7 C 5.3329 -0.6039 0.0000 0
M  V30 8 C 6.0474 -1.8414 0.0000 0
M  V30 9 C 6.7618 -1.4289 0.0000 0
M  V30 10 C 7.4763 -1.8414 0.0000 0
M  V30 11 O 8.1908 -2.2539 0.0000 0
M  V30 12 P 7.8888 -1.1270 0.0000 0
M  V30 13 O 8.3013 -0.4125 0.0000 0
M  V30 14 O 7.1743 -0.7145 0.0000 0
M  V30 15 O 8.6033 -1.5395 0.0000 0
M  V30 16 P 7.0638 -2.5559 0.0000 0
M  V30 17 O 6.6513 -3.2704 0.0000 0
M  V30 18 O 7.7783 -2.9684 0.0000 0
M  V30 19 O 6.3493 -2.1434 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 1 9 10
M  V30 10 1 10 11
M  V30 11 1 10 12
M  V30 12 1 12 13
M  V30 13 1 12 14
M  V30 14 2 12 15
M  V30 15 1 10 16
M  V30 16 1 16 17
M  V30 17 1 16 18
M  V30 18 2 16 19
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
542

>  <Plate>
PHD136329

>  <Row>
l

>  <Col>
4

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
Ibandronate sodium

>  <Synonyms>
Bondronat;Boniva;Ibandronate sodium salt

>  <CAS>
138844-81-2

>  <Formula>
C9H22NNaO7P2

>  <MolWt>
341.2

>  <Pathways>
Microbiology/Virology;Metabolism

>  <Target>
HBV;Transferase

>  <Receptor>
Farnesyl pyrophosphate synthase; HAP

>  <Bioactivity>
"Ibandronate Sodium is a synthetic nitrogen-containing bisphosphonate, used for the treatment of osteoporosis."

>  <Reference>
"Dunford JE, et al. J Pharmacol Exp Ther. 2001 Feb; 296(2):235-42."

>  <ID<1>>
T1599L

$$$$
StarDrop ID 543
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 12 12 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N -0.8612 1.9393 0.0000 0
M  V30 2 C -0.1467 2.3518 0.0000 0 CFG=1
M  V30 3 C 0.5678 1.9393 0.0000 0
M  V30 4 C 0.5678 1.1143 0.0000 0
M  V30 5 C 1.2352 0.6294 0.0000 0
M  V30 6 N 0.9803 -0.1553 0.0000 0
M  V30 7 C 0.1553 -0.1553 0.0000 0
M  V30 8 N -0.0997 0.6294 0.0000 0
M  V30 9 C -0.1467 3.1768 0.0000 0
M  V30 10 O -0.8612 3.5893 0.0000 0
M  V30 11 O 0.5678 3.5893 0.0000 0
M  V30 12 H -1.0127 2.8518 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 2 1 CFG=3
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 5 6
M  V30 6 2 6 7
M  V30 7 1 7 8
M  V30 8 2 4 8
M  V30 9 1 2 9
M  V30 10 1 9 10
M  V30 11 2 9 11
M  V30 12 1 12 2
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
543

>  <Plate>
PHD136329

>  <Row>
l

>  <Col>
5

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
L-Histidine

>  <Synonyms>
L-(-)-Histidine;Glyoxaline-5-alanine;L-Hisidine;histidine

>  <CAS>
71-00-1

>  <Formula>
C6H9N3O2

>  <MolWt>
155.2

>  <Pathways>
Metabolism

>  <Target>
Endogenous Metabolite;Mitochondrial Metabolism

>  <Receptor>
Endogenous Metabolite; Mitochondrial Metabolism

>  <Bioactivity>
"Histidine is a semi-essential amino acid (children should obtain it from food) needed in humans for growth and tissue repair, Histidine is important for maintenance of myelin sheaths that protect nerve cells and is metabolized to the neurotransmitter histamine. Histamines play many roles in immunity, gastric secretion, and sexual functions. Histidine is also required for blood cell manufacture and protects tissues against damage caused by radiation and heavy metals."

>  <Reference>
"Bou Zeidan M, et al. L-histidine inhibits biofilm formation and FLO11-associated phenotypes in Saccharomyces cerevisiae flor yeasts. PLoS One. 2014 Nov 4;9(11):e112141."

>  <ID<1>>
T2A2532

$$$$
StarDrop ID 544
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 36 38 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.1434 -5.3625 0.0000 0
M  V30 2 O 2.8579 -4.9500 0.0000 0
M  V30 3 C 2.1434 -6.1875 0.0000 0 CFG=1
M  V30 4 N 1.4289 -6.6000 0.0000 0
M  V30 5 C 0.7145 -6.1875 0.0000 0
M  V30 6 O 0.7145 -5.3625 0.0000 0
M  V30 7 C 0.0000 -6.6000 0.0000 0
M  V30 8 C 0.0000 -7.4250 0.0000 0
M  V30 9 C -0.7145 -7.8375 0.0000 0
M  V30 10 C -1.4289 -7.4250 0.0000 0
M  V30 11 C -1.4289 -6.6000 0.0000 0
M  V30 12 C -0.7145 -6.1875 0.0000 0
M  V30 13 N -2.1434 -7.8375 0.0000 0
M  V30 14 C -2.8579 -7.4250 0.0000 0
M  V30 15 C -3.5724 -7.8375 0.0000 0 CFG=2
M  V30 16 N -3.5724 -8.6625 0.0000 0
M  V30 17 C -4.2868 -9.0750 0.0000 0
M  V30 18 C -4.2868 -9.9000 0.0000 0
M  V30 19 O -3.5724 -10.3125 0.0000 0
M  V30 20 N -5.0013 -10.3125 0.0000 0
M  V30 21 C -5.7158 -9.9000 0.0000 0
M  V30 22 N -5.7158 -9.0750 0.0000 0
M  V30 23 C -5.0013 -8.6625 0.0000 0
M  V30 24 N -5.0013 -7.8375 0.0000 0
M  V30 25 C -4.2868 -7.4250 0.0000 0
M  V30 26 N -6.4302 -10.3125 0.0000 0
M  V30 27 C -2.8579 -9.0750 0.0000 0
M  V30 28 O -2.8579 -9.9000 0.0000 0
M  V30 29 C 2.8579 -6.6000 0.0000 0
M  V30 30 C 3.5724 -6.1875 0.0000 0
M  V30 31 C 4.2868 -6.6000 0.0000 0
M  V30 32 O 4.2868 -7.4250 0.0000 0
M  V30 33 O 5.0013 -6.1875 0.0000 0
M  V30 34 O 1.4289 -4.9500 0.0000 0
M  V30 35 H 1.2774 -5.6875 0.0000 0
M  V30 36 H -3.5723 -6.8375 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 3 1
M  V30 3 1 3 4 CFG=3
M  V30 4 1 4 5
M  V30 5 2 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 8 9
M  V30 9 1 9 10
M  V30 10 2 10 11
M  V30 11 1 11 12
M  V30 12 2 7 12
M  V30 13 1 10 13
M  V30 14 1 13 14
M  V30 15 1 15 14 CFG=3
M  V30 16 1 15 16
M  V30 17 1 16 17
M  V30 18 1 17 18
M  V30 19 2 18 19
M  V30 20 1 18 20
M  V30 21 1 20 21
M  V30 22 2 21 22
M  V30 23 1 22 23
M  V30 24 2 17 23
M  V30 25 1 23 24
M  V30 26 1 24 25
M  V30 27 1 15 25
M  V30 28 1 21 26
M  V30 29 1 16 27
M  V30 30 2 27 28
M  V30 31 1 3 29
M  V30 32 1 29 30
M  V30 33 1 30 31
M  V30 34 2 31 32
M  V30 35 1 31 33
M  V30 36 1 1 34
M  V30 37 1 35 3
M  V30 38 1 36 15
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
544

>  <Plate>
PHD136329

>  <Row>
l

>  <Col>
6

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
Levoleucovorin Calcium

>  <Synonyms>
Calcium Levofolinate;CL307782

>  <CAS>
80433-71-2

>  <Formula>
C20H21N7O7??Ca

>  <MolWt>
511.5

>  <Pathways>
Cell Cycle/Checkpoint;Others

>  <Target>
Others;Antifolate

>  <Receptor>
Antifolate

>  <Bioactivity>
"Calcium Levofolinate, a calcium salt of the folinic acid, is used in cancer chemotherapy as an adjuvant."

>  <Reference>
"Lebitasy M, Hecq JD, Athanassopoulos A, Vanbeckbergen D, Jamart J, Galanti L.J Clin Pharm Ther. 2009 Aug;34(4):423-8.;Honma H.Gan To Kagaku Ryoho. 2006 Nov;33(11):1633-6. Japanese."

>  <ID<1>>
T6431

$$$$
StarDrop ID 545
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 13 12 0 0 0
M  V30 BEGIN ATOM
M  V30 1 O 2.9980 -2.5559 0.0000 0
M  V30 2 C 3.7125 -2.1434 0.0000 0
M  V30 3 C 4.4270 -2.5559 0.0000 0
M  V30 4 O 4.4270 -3.3809 0.0000 0
M  V30 5 C 5.1414 -2.1434 0.0000 0
M  V30 6 O 5.1414 -1.3184 0.0000 0
M  V30 7 C 5.8559 -2.5559 0.0000 0
M  V30 8 O 5.8559 -3.3809 0.0000 0
M  V30 9 C 6.5704 -2.1434 0.0000 0
M  V30 10 O 6.5704 -1.3184 0.0000 0
M  V30 11 C 7.2849 -2.5559 0.0000 0
M  V30 12 O 7.9993 -2.1434 0.0000 0
M  V30 13 O 7.2849 -3.3809 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 1 7 9
M  V30 9 1 9 10
M  V30 10 1 9 11
M  V30 11 1 11 12
M  V30 12 2 11 13
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
545

>  <Plate>
PHD136329

>  <Row>
l

>  <Col>
7

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
Gluconate sodium

>  <Synonyms>
Sodium D-gluconate;D-Gluconate sodium salt;D-Gluconic acid sodium salt;Sodium gluconate

>  <CAS>
527-07-1

>  <Formula>
C6H11NaO7

>  <MolWt>
218.1

>  <Pathways>
Metabolism;Others

>  <Target>
Others;Endogenous Metabolite

>  <Receptor>
Endogenous Metabolite

>  <Bioactivity>
Sodium Gluconate is the sodium salt of gluconic acid with a chelating property.

>  <Reference>
"G??nal M. Animal Production Science, 2012, 53(4), 316-321"

>  <ID<1>>
T0416

$$$$
StarDrop ID 546
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 10 0 0 1
M  V30 BEGIN ATOM
M  V30 1 N 1.0461 1.4289 0.0000 0
M  V30 2 C 1.7605 1.8414 0.0000 0
M  V30 3 C 2.4750 1.4289 0.0000 0
M  V30 4 C 3.1895 1.8414 0.0000 0
M  V30 5 C 3.9039 1.4289 0.0000 0
M  V30 6 C 4.6184 1.8414 0.0000 0 CFG=2
M  V30 7 N 4.6184 2.6664 0.0000 0
M  V30 8 C 5.3329 1.4289 0.0000 0
M  V30 9 O 6.0474 1.8414 0.0000 0
M  V30 10 O 5.3329 0.6039 0.0000 0
M  V30 11 H 5.4844 2.3414 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 1 4 5
M  V30 5 1 6 5
M  V30 6 1 6 7 CFG=3
M  V30 7 1 6 8
M  V30 8 1 8 9
M  V30 9 2 8 10
M  V30 10 1 11 6
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
546

>  <Plate>
PHD136329

>  <Row>
l

>  <Col>
8

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
L-Lysine

>  <Synonyms>
lysine;Aminutrin;Lysine Acid

>  <CAS>
56-87-1

>  <Formula>
C6H14N2O2

>  <MolWt>
146.2

>  <Pathways>
Metabolism;Microbiology/Virology

>  <Target>
Virus Protease;Antifection;Endogenous Metabolite

>  <Receptor>
Endogenous Metabolite; herpes simplex virus; Virus Protease

>  <Bioactivity>
"Lysine is one of nine essential amino acids in humans required for growth and tissue repair, Lysine is supplied by many foods, especially red meats, fish, and dairy products. Lysine seems to be active against herpes simplex viruses and present in many forms of diet supplements. The mechanism underlying this effect is based on the viral need for amino acid arginine; lysine competes with arginine for absorption and entry into cells. Lysine inhibits HSV growth by knocking out arginine."

>  <Reference>
"Santos AMD, et al. Transitional metaplasia in intestinal epithelium of rats submitted to intestinal cystoplasty and treatment with L -lysine. Acta Cir Bras. 2017 Apr;32(4):297-306.;Al-Malki AL. Suppression of acute pancreatitis by L-lysine in mice. BMC Complement Altern Med. 2015 Jun 23;15:193."

>  <ID<1>>
T2A2498

$$$$
StarDrop ID 547
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 19 19 0 0 1
M  V30 BEGIN ATOM
M  V30 1 O -0.8732 3.3458 0.0000 0
M  V30 2 P -0.8732 2.5208 0.0000 0
M  V30 3 O -1.6982 2.5208 0.0000 0
M  V30 4 O -0.0482 2.5208 0.0000 0
M  V30 5 C -0.8732 1.6958 0.0000 0
M  V30 6 O -0.1588 1.2833 0.0000 0
M  V30 7 C -0.1588 0.4583 0.0000 0 CFG=2
M  V30 8 C -0.8732 0.0458 0.0000 0
M  V30 9 O -0.8732 -0.7792 0.0000 0
M  V30 10 C 0.5557 0.0458 0.0000 0
M  V30 11 N 0.5557 -0.7792 0.0000 0
M  V30 12 C 1.2702 -1.1917 0.0000 0
M  V30 13 N 1.2702 -2.0167 0.0000 0
M  V30 14 C 0.5557 -2.4292 0.0000 0
M  V30 15 C -0.1588 -2.0167 0.0000 0
M  V30 16 C -0.1588 -1.1917 0.0000 0
M  V30 17 N 0.5557 -3.2542 0.0000 0
M  V30 18 O 1.9846 -0.7792 0.0000 0
M  V30 19 H -1.0248 0.9583 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 7 6 CFG=1
M  V30 7 1 7 8
M  V30 8 1 8 9
M  V30 9 1 7 10
M  V30 10 1 10 11
M  V30 11 1 11 12
M  V30 12 1 12 13
M  V30 13 2 13 14
M  V30 14 1 14 15
M  V30 15 2 15 16
M  V30 16 1 11 16
M  V30 17 1 14 17
M  V30 18 2 12 18
M  V30 19 1 19 7
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
547

>  <Plate>
PHD136329

>  <Row>
l

>  <Col>
9

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
Cidofovir dihydrate

>  <Synonyms>
HPMPC;GS 0504;(S)-HPMPC

>  <CAS>
149394-66-1

>  <Formula>
C8H18N3O8P

>  <MolWt>
315.2

>  <Pathways>
Others

>  <Target>
Others

>  <Receptor>
CMV

>  <Bioactivity>
"Cidofovir is an anti-CMV drug, It can suppress CMV replication by selective inhibition of viral DNA polymerase and therefore prevention of viral replication and transcription. idofovir is an injectable antiviral medication primarily used as a treatment for cytomegalovirus (CMV) retinitis- an infection of the retina of the eye in people with AIDS"

>  <Reference>
"Chatterjee S, et al. Antiviral Res., 1992, 19(3), 181-192.;Redondo P, et al. Br J Dermatol, 2000, 143(4), 741-748.;De Clercq E, et al. Antimicrob Agents Chemother, 1991, 35(4), 701-706.;Li SB, et al. Antiviral Res, 1990, 13(5), 237-252.;Snoeck R, et al, Antimicrob Agents Chemother, 1988, 32(12), 1839-1844."

>  <ID<1>>
T8736

$$$$
StarDrop ID 548
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 11 10 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 0.5230 1.1270 0.0000 0
M  V30 2 O -0.1914 0.7145 0.0000 0
M  V30 3 C 1.2375 0.7145 0.0000 0 CFG=1
M  V30 4 N 1.2375 -0.1105 0.0000 0
M  V30 5 C 1.9520 1.1270 0.0000 0 CFG=2
M  V30 6 C 2.6664 0.7145 0.0000 0
M  V30 7 C 3.3809 1.1270 0.0000 0
M  V30 8 C 1.9520 1.9520 0.0000 0
M  V30 9 O 0.5230 1.9520 0.0000 0
M  V30 10 H 0.3715 0.2145 0.0000 0
M  V30 11 H 2.8180 1.6270 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 2 1 2
M  V30 2 1 3 1
M  V30 3 1 3 4 CFG=3
M  V30 4 1 3 5
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 5 8 CFG=1
M  V30 8 1 1 9
M  V30 9 1 10 3
M  V30 10 1 11 5
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
548

>  <Plate>
PHD136329

>  <Row>
l

>  <Col>
10

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
L-Isoleucine

>  <Synonyms>
isoleucine;Ile

>  <CAS>
73-32-5

>  <Formula>
C6H13NO2

>  <MolWt>
131.2

>  <Pathways>
Metabolism

>  <Target>
Endogenous Metabolite;Amino Acids and Derivatives

>  <Receptor>
Amino Acids and Derivatives; Endogenous Metabolite

>  <Bioactivity>
Isoleucine is an essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of LEUCINE. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.

>  <Reference>
"Korman SH, et al. Clin Chem. 2005 Mar;51(3):610-7."

>  <ID<1>>
T0063

$$$$
StarDrop ID 549
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 16 17 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 2.7069 0.5635 0.0000 0
M  V30 2 C 1.9924 0.9760 0.0000 0
M  V30 3 C 1.2780 0.5635 0.0000 0
M  V30 4 N 0.5635 0.9760 0.0000 0
M  V30 5 C 0.5635 1.8010 0.0000 0 CFG=2
M  V30 6 S 1.2780 2.2135 0.0000 0
M  V30 7 C 1.9924 1.8010 0.0000 0
M  V30 8 C -0.2615 1.8010 0.0000 0 CFG=2
M  V30 9 N -0.8449 2.3843 0.0000 0
M  V30 10 C -0.2615 0.9760 0.0000 0
M  V30 11 O -0.8449 0.3926 0.0000 0
M  V30 12 C 1.2780 -0.2615 0.0000 0
M  V30 13 O 0.5635 -0.6740 0.0000 0
M  V30 14 O 1.9924 -0.6740 0.0000 0
M  V30 15 H -0.1436 1.0939 0.0000 0
M  V30 16 H -1.1854 1.4183 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 2 2 3
M  V30 3 1 3 4
M  V30 4 1 5 4 CFG=1
M  V30 5 1 5 6
M  V30 6 1 6 7
M  V30 7 1 2 7
M  V30 8 1 5 8
M  V30 9 1 8 9 CFG=1
M  V30 10 1 8 10
M  V30 11 1 4 10
M  V30 12 2 10 11
M  V30 13 1 3 12
M  V30 14 1 12 13
M  V30 15 2 12 14
M  V30 16 1 15 5
M  V30 17 1 16 8
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
549

>  <Plate>
PHD136329

>  <Row>
l

>  <Col>
11

>  <Volume��microliter��>
180

>  <Concentration��mM��>
10

>  <Solvent>
Water

>  <MOLENAME>
7-Aminodeacetoxycephalosporanic acid

>  <Synonyms>
7-ADCA;Cefalexine EP IMpurity B;Cephalexin Impurity B;7-Aminodesacetoxycephalosporanic acid;Deacetoxycephalosporanic Acid

>  <CAS>
22252-43-3

>  <Formula>
C8H10N2O3S

>  <MolWt>
214.2

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic

>  <Receptor>
antibiotic

>  <Bioactivity>
Cefalexine EP IMpurity B is used as an antibiotic.

>  <Reference>
"Robin J, et al. Biotechnol Bioeng. 2003 Aug 5;83(3):353-60."

>  <ID<1>>
T1364

$$$$
StarDrop ID 550
  StarDrop          2D                              

  0  0  0  0  1  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 10 9 0 0 1
M  V30 BEGIN ATOM
M  V30 1 C 1.9520 1.1270 0.0000 0 CFG=1
M  V30 2 C 1.2375 0.7145 0.0000 0
M  V30 3 C 0.5230 1.1270 0.0000 0
M  V30 4 O -0.1914 0.7145 0.0000 0
M  V30 5 O 0.5230 1.9520 0.0000 0
M  V30 6 C 2.6664 0.7145 0.0000 0
M  V30 7 O 3.3809 1.1270 0.0000 0
M  V30 8 O 2.6664 -0.1105 0.0000 0
M  V30 9 N 1.9520 1.9520 0.0000 0
M  V30 10 H 2.8180 1.6270 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 3 4
M  V30 4 2 3 5
M  V30 5 1 1 6
M  V30 6 1 6 7
M  V30 7 2 6 8
M  V30 8 1 1 9 CFG=3
M  V30 9 1 10 1
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
550

>  <Plate>
PHD136329

>  <Row>
l

>  <Col>
12

>  <Volume��microliter��>
180

>  <Concentration��mM��>
2.5

>  <Solvent>
Water

>  <MOLENAME>
L-Aspartic acid

>  <Synonyms>
Asparagic acid;Aspatofort

>  <CAS>
56-84-8

>  <Formula>
C4H7NO4

>  <MolWt>
133.1

>  <Pathways>
Metabolism;Others

>  <Target>
Others;Endogenous Metabolite

>  <Receptor>
Endogenous Metabolite

>  <Bioactivity>
"Aspartic Acid is a non-essential amino acid in humans, Aspartic Acid has an overall negative charge and plays an important role in the synthesis of other amino acids and in the citric acid and urea cycles. Asparagine, arginine, lysine, methionine, isoleucine, and some nucleotides are synthesized from aspartic acid. Aspartic acid also serves as a neurotransmitter."

>  <Reference>
"Leopold CS, et al. In vivo pharmacokinetic study for the assessment of poly(L-aspartic acid) as a drug carrier for colon-specific drug delivery. J Pharmacokinet Biopharm. 1995 Aug;23(4):397-406."

>  <ID<1>>
T2O2731

$$$$
StarDrop ID 551
  StarDrop          2D                              

  0  0  0  0  0  0  0  0  0  0999 V3000
M  V30 BEGIN CTAB
M  V30 COUNTS 9 8 0 0 0
M  V30 BEGIN ATOM
M  V30 1 C 0.4125 2.1434 0.0000 0
M  V30 2 C 0.8250 1.4289 0.0000 0
M  V30 3 C 0.1105 1.0164 0.0000 0
M  V30 4 S 1.5395 1.8414 0.0000 0
M  V30 5 C 1.2375 0.7145 0.0000 0
M  V30 6 N 2.0625 0.7145 0.0000 0
M  V30 7 C 0.8250 0.0000 0.0000 0
M  V30 8 O 1.2375 -0.7145 0.0000 0
M  V30 9 O 0.0000 0.0000 0.0000 0
M  V30 END ATOM
M  V30 BEGIN BOND
M  V30 1 1 1 2
M  V30 2 1 2 3
M  V30 3 1 2 4
M  V30 4 1 2 5
M  V30 5 1 5 6
M  V30 6 1 5 7
M  V30 7 1 7 8
M  V30 8 2 7 9
M  V30 END BOND
M  V30 END CTAB
M  END
>  <Index>
551

>  <Plate>
PHD136329

>  <Row>
l

>  <Col>
13

>  <Volume��microliter��>
180

>  <Concentration��mM��>
5

>  <Solvent>
Water

>  <MOLENAME>
DL-Penicillamine

>  <Synonyms>
3-Sulfanylvaline

>  <CAS>
52-66-4

>  <Formula>
C5H11NO2S

>  <MolWt>
149.2

>  <Pathways>
Microbiology/Virology

>  <Target>
Antibiotic

>  <Receptor>
antibiotic

>  <Bioactivity>
"DL-Penicillamine is a chelating agent recommended for the removal of excess copper in patients with Wilson's disease. DL-Penicillamine is only found in individuals that have used or taken this drug. It is the most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. From in vitro studies which indicate that one atom of copper combines with two molecules of DL-penicillamine. DL-Penicillamine also reduces excess cystine excretion in cystinuria. This is done, at least in part, by disulfide interchange between DL-penicillamine and cystine, resulting in the formation of penicillamine-cysteine disulfide, a substance that is much more soluble than cysteine and is excreted readily. DL-Penicillamine interferes with the formation of cross-links between tropocollagen molecules and cleaves them when newly formed. The mechanism of action of DL-penicillamine in rheumatoid arthritis is unknown although it appears to suppress disease activity. Unlike cytotoxic immunosuppressants, DL-penicillamine markedly lowers IgM rheumatoid factor but produces no significant depression in absolute levels of serum immunoglobulins. Also unlike cytotoxic immunosuppressants which act on both, DL-penicillamine in vitro depresses T-cell activity but not B-cell activity."

>  <Reference>
"Brewer GJ. Expert Opin PharmacOthers. 2006, 7(3):317-24"

>  <ID<1>>
T0983L

$$$$
